<SEC-DOCUMENT>0001055726-24-000011.txt : 20240306
<SEC-HEADER>0001055726-24-000011.hdr.sgml : 20240306
<ACCEPTANCE-DATETIME>20240306160149
ACCESSION NUMBER:		0001055726-24-000011
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		103
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240306
DATE AS OF CHANGE:		20240306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		24725781

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ino-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:srt="http://fasb.org/srt/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns="http://www.w3.org/1999/xhtml" xmlns:ino="http://www.inovio.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-33">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-36">0001055726</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-11" decimals="6" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-128">0.083333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-11" decimals="6" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-183">0.083333</ix:nonFraction><ix:nonNumeric contextRef="c-13" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="f-232">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-11" decimals="6" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-288">0.083333</ix:nonFraction><ix:nonNumeric contextRef="c-55" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-447">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-11" decimals="6" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-510">0.083333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-274" decimals="INF" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" scale="-2" id="f-995">50</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-11" decimals="6" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-1235">0.083333</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-24</xbrli:startDate><xbrli:endDate>2024-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ino:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>ino:position</xbrli:measure></xbrli:unit><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:BehestiVKimEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-19</xbrli:startDate><xbrli:endDate>2019-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:FormerPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>ino:lease</xbrli:measure></xbrli:unit><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>ino:agreement</xbrli:measure></xbrli:unit><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:BehestiVKimEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="defendent"><xbrli:measure>ino:defendent</xbrli:measure></xbrli:unit><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:CaliforniaIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:PennsylvaniaStateIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:KoreanStateIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-06</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-117 f-111 f-112 f-110 f-115 f-116 f-113 f-114 f-108 f-109" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-173 f-174 f-171 f-172 f-177 f-178 f-175 f-176 f-179 f-180 f-181 f-182" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-199 f-254 f-255 f-198 f-236 f-237 f-212 f-213 f-208 f-205 f-227 f-209 f-261 f-283 f-240 f-260 f-282 f-265 f-241 f-264 f-269 f-204 f-226 f-268" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="1"></ix:relationship></ix:resources></ix:header></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> FOR THE FISCAL YEAR ENDED <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">DECEMBER 31</ix:nonNumeric>, 2023</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.465%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COMMISSION FILE NO.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-14888</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><img src="ino-20231231_g1.jpg" alt="inoviologosw.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:204px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">Suite 110</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">Plymouth Meeting</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-13">Pennsylvania</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">19462</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">267</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">440-4200</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.965%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.799%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT: NONE</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">&#168;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">x</ix:nonNumeric></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity (which consists solely of shares of Common Stock) held by non-affiliates of the Registrant as of June&#160;30, 2023 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-30">119.7</ix:nonFraction> million based on $5.40 per share, the closing price on that date of the Registrant&#8217;s Common Stock (retroactively giving effect to a 1-for-12 reverse stock split that became effective in January 2024) on the Nasdaq Global Select Market (prior to being transferred to the Nasdaq Capital Market in November 2023).</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">23,370,365</ix:nonFraction> as of March&#160;1, 2024.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#8217;s 2024 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8217;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#8217;s fiscal year ended December&#160;31, 2023.</span></div></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:81.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_10">PART I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_10">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_13">ITEM&#160;1. BUSINESS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_13">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_16">ITEM&#160;1A. RISK FACTORS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_16">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_19">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_19">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_1584">ITEM&#160;1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_1584">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_1584">. </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_1584">CYBERSECURITY</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_19">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_22">ITEM&#160;2. PROPERTIES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_22">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_25">ITEM&#160;3. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_25">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_28">ITEM&#160;4. MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_28">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_31">PART II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_31">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_34">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_34">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_37">ITEM&#160;6. [RESERVED]</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_37">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_40">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_40">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_58">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_58">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_61">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_61">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_64">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_64">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_67">ITEM&#160;9A. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_67">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_73">ITEM 9B. OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_73">7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_76">ITEM 9C.  </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_76">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_76">73</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_79">PART III</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_79">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_82">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_82">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_85">ITEM&#160;11. EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_85">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_88">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_88">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_91">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_91">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_94">ITEM&#160;14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_94">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_97">PART IV</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_97">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_100">ITEM&#160;15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_100">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_103">ITEM 16. FORM 10-K SUMMARY</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_103">71</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_106">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_106">72</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_109">CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_109">1</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K (including the following section regarding Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations), or this Annual Report, contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters, including statements regarding our business, our financial position, the research and development of our products and other statements regarding matters that are not historical are forward-looking statements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading &#8220;Risk Factors&#8221; below, as well as those discussed elsewhere in this Annual Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report includes trademarks and registered trademarks of INOVIO Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Annual Report may be trademarks or registered trademarks of their respective owners. References herein to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;INOVIO&#8221; or the &#8220;Company&#8221; refer to INOVIO Pharmaceuticals, Inc. and its consolidated subsidiaries. References herein to &#8220;DNA medicines&#8221; refers to our product candidates in development for diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Part I, Item 1A., Risk Factors herein. These risk factors include, but are not limited to, the following: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary device technology. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which may prove difficult or costly to obtain. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DNA medicines are a novel approach to treating and preventing disease, and our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delivery devices are a novel approach to administering medicines, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop or our devices could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we and the contract manufacturers upon whom we rely fail to produce our proprietary devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary devices and DNA medicine candidates. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have agreements with government agencies that are subject to termination and uncertain future funding. Termination or cessation of funding would have a negative impact on our ability to develop certain of our pipeline candidates and/or require us to seek alternative funding sources to advance product candidates. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may be harmed if our corporate restructuring plans and cost reduction efforts do not achieve the anticipated results or cause undesirable consequences. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense and increasing competition and steps taken by our competitors, such as the introduction of a new, disruptive technology may impede our ability to develop and commercialize our DNA medicines.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have entered into collaborations with Chinese companies and rely on clinical materials manufactured in China for our development efforts. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure or perceived failure to comply with laws, regulations, contracts, self-regulatory schemes, notices and other obligations related to data privacy and security (including security incidents) could harm our business. Compliance or the actual or perceived failure to comply with such obligations could increase our costs and otherwise negatively affect our operating results and business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Our platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. Our proprietary investigational CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delivery devices help our DNA medicines enter the body&#8217;s cells for optimal effect. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis, or RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. In our completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we announced data from the second cohort of our Phase 1/2 clinical trial, which followed the announcement of data from the first cohort in October 2022. In the second cohort of 11 patients who were administered INO-3107 via an exploratory side port needle, 10 of the 11 patients (91%) saw a reduction in surgical interventions in the year following initial treatment, with the measurement beginning on Day 0, the start of trial therapy. Of these 10 patients, four did not require surgery. There was a statistically significant median decrease of three surgical interventions when comparing the year following treatment to the year prior to treatment. INO-3107 was well tolerated and immunogenic among patients in the second cohort. The safety and efficacy results for the second cohort were consistent with results announced for the first cohort in October 2022. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we received feedback from the U.S. Food and Drug Administration, or FDA, that the data from this completed trial could be used to support the submission of a Biologic License Application, or BLA, for review under the FDA&#8217;s accelerated approval program. As part of submitting our BLA under the accelerated program, we will need to satisfy all FDA filing requirements and initiate a confirmatory clinical trial prior to BLA submission.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our development efforts with INO-3107, we are actively developing or planning to develop DNA medicines for other indications, including HPV-related anal dysplasia and oropharyngeal squamous cell carcinoma, or OPSCC; glioblastoma multiforme, or GBM, a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. We were previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions, or HSIL, but announced in August 2023 that we were ceasing development for this indication in the United States. However, our collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction.  </span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Characteristics of DNA Medicines </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines are optimized DNA plasmids containing a gene encoding for a protein that is expressed once these plasmids are delivered into cells. We can design our plasmids to teach the body&#8217;s cells to produce a wide range of proteins, including antigens to elicit a specific immune response and monoclonal antibodies to fight a specific pathogen. These DNA </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medicines can generate antigen-targeted humoral and cellular immune responses based on the indication, including antigen-specific cytotoxic, or killer, T cell responses that are important for fighting cancer and viral infections. Characteristics of our DNA medicines include:  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">T Cell Responses: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines have demonstrated the ability to generate high levels of T cell (CD4+, CD8+, and memory) response along with antibody response. CD8+ T cell responses are thought to play an important role in clearing tumors or virally infected cells.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Tolerability: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines have been well tolerated by clinical trial participants when evaluated against multiple disease targets. Our DNA medicines have been administered over 15,000 times across more than 5,000 participants to date.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">Ability to Readminister: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines have been used in clinical trials to boost immune response via repeat administration, offering the potential for continued boosting of the immune response through repeat administration.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Versatility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our DNA medicines technology can be utilized to produce in vivo proteins or antigens key to treating or preventing various human diseases, such as cancer, viral infections or protein deficiencies. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">Stability of Product: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines do not require frozen storage or shipping.&#8239;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.17pt">Design and Manufacture: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines can be rapidly designed and scaled, with ease of manufacturing providing a potential cost advantage.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Delivery Mechanism:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our proprietary electroporation devices increase cellular uptake and overcome the barrier posed by cell membranes that can hinder the entry of large molecules, such as DNA plasmids.&#160;</span></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Our DNA Medicines Platform</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA medicines platform consists of DNA plasmids and our CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. These two components combine to create a versatile platform that has the potential to target multiple diseases and conditions. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> - DNA Plasmid Design Technology </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our precisely designed DNA plasmids are circular double-stranded DNA that have been optimized, using our proprietary technology and algorithms, to express a protein. Our plasmids can be designed to enable the body&#8217;s cells to produce a wide range of proteins, including antigens to elicit a specific immune response, monoclonal antibodies to fight a specific pathogen, or therapeutic proteins to replace defective or missing proteins in the body. In the area of HPV-related diseases, for example, the expressed proteins are antigens that elicit antigen-specific T cell responses to fight HPV. We start by identifying one or more antigens that we believe are the best targets for directing the immune system toward HPV and then apply our SynCon design process, which analyzes the genetic make-up of the selected antigens from multiple strains of the virus.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each antigen, we create a new genetic sequence that represents a nucleotide consensus sequence of the targeted antigen. In doing so, we believe we can create a differentiated sequence to help the immune system better recognize the target antigen and potentially variations of the target antigen. We have generated immune responses, including CD4+, CD8+, and memory T cells, with SynCon-designed DNA medicines against various tumor-associated antigens, as well as against different strains of certain infectious diseases in human clinical trials. Because the engineered sequences are substantially similar to the original sequences, without matching them exactly, we believe they are patentable.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a SynCon sequence is designed and synthesized, it is then inserted into a circular DNA plasmid with its own promoter. Promoters serve a vital role in &#8220;promoting&#8221; the expression of the protein once the DNA medicine has entered the cell. Using our technology, our DNA plasmids have been optimized to enable high expression in human cells via our proprietary gene optimization algorithm, which we refer to as GOAL. We believe these design capabilities allow us to better target appropriate immune system mechanisms and produce a higher level of protein expression compared to traditional approaches, potentially enhancing the overall ability to induce the desired immune response.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plasmids are then manufactured in a bacterial fermentation process using scalable manufacturing technology. We have recently developed a high-yield manufacturing process which we anticipate using to manufacture our DNA medicines. The manufactured DNA medicines do not require ultracold or frozen storage or thawing prior to injection and are refrigerator stable at 2 to 8 degrees Celsius, which are key factors for both distribution and administration. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Delivery Technology  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines need a pathway into the cell to work effectively. To help DNA plasmids, which are relatively large molecules, pass through the cell membrane, we use our proprietary CELLECTRA delivery technology. After injecting the DNA medicine either intramuscularly (IM) or intradermally (ID), CELLECTRA devices use electroporation (EP), or brief electrical pulses, to reversibly open small pores in the cell membrane, allowing DNA plasmids to enter. Through this process, the cellular </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uptake of the DNA plasmids can be substantially increased compared to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injection of DNA plasmids alone. This improved cellular uptake has enabled the immune responses and efficacy results observed in our clinical trials to date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CELLECTRA device portfolio currently consists of two models (CELLECTRA 5PSP AND CELLECTRA 3PSP) designed for late-stage clinical use and potentially for eventual commercial use, and one device (CELLECTRA 2000) that we primarily utilize in earlier-stage clinical trials. These devices have been designed to optimize delivery of our DNA medicine candidates depending on the target disease. Our CELLECTRA 5PSP model provides intramuscular EP and is designed to be used with candidates addressing cancers and HPV related pre-cancers. It uses a prefilled drug cartridge, delivers both the DNA medicine and the EP to the patient and is designed for commercial use. CELLECTRA 5PSP was used in our Phase 3 trials (REVEAL1/REVEAL2) for cervical HSIL and will be used in our planned confirmatory trial for INO-3107, our DNA medicines candidate for RRP. Our CELLECTRA 3PSP model was developed with support from the U.S. Department of Defense, the Center for Epidemic Preparedness Innovations, and the Bill &amp; Melinda Gates Foundation for intradermal EP delivery. The small, handheld design is intended for mass administration and commercial use and will mainly be used with candidates addressing infectious disease. CELLECTRA 3PSP only delivers EP, after a separate DNA medicine injection into the skin. The EP is delivered around the intradermal injection site.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CELLECTRA devices are validated and manufactured under Current Good Manufacturing Practices (cGMP). We have used CELLECTRA devices in global human clinical trials. The CELLECTRA 5PSP model has received CE mark certification in the EU.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for administration of our DNA medicines is illustrated in the following graphic.  </span></div><div style="margin-top:5pt"><img src="ino-20231231_g2.jpg" alt="Picture2.jpg" style="height:247px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DNA Medicines and HPV-related Diseases</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV can lead to a persistent viral infection. Approximately 90% of all HPV infections clear naturally and do not result in disease. However, for those not able to clear the virus naturally, persistent infection can lead to cancer and other debilitating, life-threatening diseases affecting quality of life.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, HPV types fall into two groups. Low-risk HPV (e.g., HPV 6 and HPV 11) may lead to benign growths (warts or papillomas) that can develop into conditions such as RRP. High-risk (HR) HPV (e.g., HPV 16 and HPV 18) may lead to cell changes and lesions (i.e., precancerous dysplasia) that can become malignant and lead to cervical cancer. HPV causes nearly all cervical cancers and many cancers of the vagina, vulva, penis, anus, rectum, and oropharynx.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are currently vaccines available to prevent HPV infection, challenges with acceptance, accessibility, and patient compliance have resulted in many vaccine-eligible people remaining unvaccinated and at risk. It is estimated that even in the United States, only 50-60% of the eligible population has been vaccinated against HPV. In addition, current preventive HPV vaccines cannot treat or protect those already infected with the same HPV genotypes. As a result, there is still an urgent need for the development of HPV therapies that can treat existing infections and prevent the development of HPV-related diseases. The current standard of care for many HPV-related diseases, including RRP and many cancers, is surgery. These surgeries can be invasive and may be needed repeatedly because the underlying HPV infection is not eliminated. In addition to surgery, other options are being explored to treat HPV-related diseases, including the usage of immune checkpoint inhibitors and other immunotherapies.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the key characteristics of DNA medicines that we believe are important for the treatment of HPV-related diseases are listed in the following table:  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><img src="ino-20231231_g3.jpg" alt="Picture3.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our DNA Medicines in Development</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chart below provides an overview of our DNA medicines pipeline. In 2023, we reprioritized our pipeline to focus our efforts and resources on those product candidates that we believe have the greatest potential to reach the market. The programs identified in the chart are described in more detail below.  </span></div><div style="margin-top:5pt"><img src="ino-20231231_g4.jpg" alt="Picture4.jpg" style="height:390px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">INO-3107 for HPV-related RRP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRP is a life-long, rare disease characterized by the growth of small tumors, or papillomas, in the respiratory tract primarily caused by HPV-6 and/or HPV-11 genotypes. Although mostly benign, these papillomas can cause severe, sometimes life-threatening airway obstruction and respiratory complications. A distinguishing aspect of RRP is the tendency for the papillomas to recur after surgical procedures to remove them. If RRP develops in the lungs, affected individuals can potentially experience recurrent pneumonia, chronic lung disease (bronchiectasis) and, ultimately, progressive pulmonary failure. In extremely rare cases (approximately 2%), RRP can develop into squamous cell carcinoma. Additional symptoms of RRP can include a hoarse voice, difficulty in sleeping and swallowing, and chronic coughing. RRP symptoms are usually more severe in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">children than in adults. The standard of care for RRP is surgery. The most widely cited U.S. epidemiology data, published in 1995, estimated that there were 14,000 active cases for both adults and juveniles, and about 1.8 new cases per 100,000 adults each year.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing our lead product candidate, INO-3107, for the treatment of HPV-6 and HPV-11-associated RRP. INO-3107 is composed of plasmids encoding for HPV-6 and HPV-11 antigens, as well as human interleukin-12 (IL-12). In May 2023, results from an open-label, multicenter Phase 1/2 trial (NCT:04398433) evaluating the efficacy, safety, tolerability and immunogenicity of our lead product candidate INO-3107 in 32 patients with HPV 6 and/or HPV 11-associated RRP were presented at the American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts. The trial included a first cohort of 21 patients dosed with a standard injection needle and a second cohort of 11 patients dosed with an exploratory side port injection needle. We plan to use the standard needle in our planned confirmatory trial and for delivery of the commercial product, should it be approved. In both cohorts of the trial, our proprietary CELLECTRA 2000 electroporation device was used to deliver the product candidate. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial evaluated the reduction in the number of surgical interventions in the year following initial administration of INO-3107 compared to the year prior to treatment. For this trial, adult patients first underwent surgical removal of their papillomas and then received up to four doses of INO-3107, once every three weeks. The primary endpoint of this trial was safety and tolerability. At the outset of the study (Day 0), patients could have RRP tissue surgically removed, but any surgery performed after Day 0 during the dosing window was counted against the efficacy endpoint.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the trial, 81.3% (26/32) of patients had a decrease in number of surgical interventions in the year after INO-3107 administration compared to the prior year, including 28.1% (9/32) that required no surgical intervention during or after the dosing window. Patients in the trial had a median range of 4 surgeries (overall range of 2-8) in the year prior to dosing. After dosing, there was a statistically significant median decrease of 3 surgical interventions (95% confidence interval: -3 to -2). Treatment with INO-3107 generated a strong immune response in the trial, inducing activated CD4 T cells and activated CD8 T cells with lytic potential. T-cell responses were also observed at Week 52, indicating a persistent cellular memory response. INO-3107 was well tolerated by participants in the trial, resulting in mostly low-grade (Grade 1) treatment-emergent adverse effects such as injection site pain and fatigue. These results were published in a scientific journal, The Laryngoscope, in 2023. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA granted INO-3107 Orphan Drug Designation (ODD) in July 2020 and Breakthrough Therapy Designation in August 2023. The European Commission has also granted INO-3107 Orphan Drug Designation, and our CELLECTRA 5PSP device has received CE marking, a regulatory standard that certifies that a product has met the European Union&#8217;s safety, health and environmental standards ensuring consumer safety.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-3112 is a DNA medicine candidate targeting HPV 16/18 combined with a DNA plasmid encoding for human IL-12 as an immune activator. Results from a Phase 1/2a trial of INO-3112 alone in 22 HPV-positive head and neck squamous cell carcinoma (HNSCC) patients, published in Clinical Cancer Research in 2019, included the observation of T cell responses and&#8239;infiltration of CD8+&#8239;T cells into the head and neck&#8239;tumors. In early 2023, updated results were published in Clinical Cancer Research from a Phase 1b/2a trial of INO-3112 in combination with AstraZeneca&#8217;s PD-L1 immune checkpoint inhibitor, durvalumab, showing an overall response rate, or ORR, of 27.6% (4 complete responses (CR) and 4 partial responses (PR)) in 29 evaluable patients and increased peripheral HPV-specific T cells and tumoral CD8+ T cells. Further, the efficacy of the combination of INO-3112 with durvalumab resulted in a median overall survival, or OS, of more than 29 months. This is an improvement over historical data for immune-checkpoint blockade therapy alone, or in combination with other HPV therapeutic vaccines. Further, this is almost three times that of historical OS data for monotherapy durvalumab in a similar patient population. Objective responses, including CRs, occurred independently of PD-L1 expression, which contrasts with historical data for durvalumab. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. to evaluate the combination of INO-3112 and LOQTORZI&#8482; (toripalimab-tpzi) as a potential treatment for patients with locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma, or OPSCC, a type of head and neck cancer commonly known as throat cancer. Under the terms of the supply agreement, Coherus will provide LOQTORZI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a planned Phase 3 clinical trial to be conducted by INOVIO, pending alignment with the FDA on study design.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGX-3100 for the Treatment of HPV-related Cervical HSIL</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we announced the discontinuance of our U.S. development program of VGX-3100 for the treatment of HPV-related cervical HSIL. This decision followed final analysis of the data from our Phase 3 trial known as REVEAL2. In this trial, statistical significance was not achieved in the investigational biomarker-selected population for the endpoint of lesion regression and viral clearance. However, statistical significance was achieved in the all-participants population for the endpoint of lesion regression and viral clearance. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REVEAL2 was our second Phase 3 trial with VGX-3100. In March 2021, we announced results from our first Phase 3 trial, known as REVEAL1, indicating that VGX-3100 did not meet its primary endpoint. In April 2022, the trial protocol for REVEAL2 was amended to utilize a biomarker-selected population as the primary population, based on prior analysis of REVEAL1 results suggesting that this investigational biomarker had the potential to identify women more likely to respond to treatment with VGX-3100. We announced that this trial would no longer be considered a pivotal trial and would not lead to a BLA filing for a biomarker-selected population, as the FDA had advised us that the results from the biomarker-positive population would not be sufficient to support approval of a potential marketing application for VGX-3100. The FDA recommended using REVEAL2 as an exploratory trial and that conducting one or two additional well-controlled trials in the biomarker-selected population would be more likely to provide evidence to support approval of a potential marketing application. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial participants in REVEAL2 included 203 women, 18 years of age or older, who had histologically confirmed cervical HSIL associated with HPV-16 and/or HPV-18, but who were otherwise healthy. Participants received either VGX-3100 or placebo at 0, 4 and 12 weeks (randomized 2:1). The primary endpoint, as amended, was the percentage of biomarker-selected participants with regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18 in the cervix. A secondary endpoint was the percentage of all participants with regression and virologic clearance. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of participants in the investigational biomarker-selected population meeting the endpoint was 28.6% (6/21) in the treatment group, versus 0% (0/4) in the placebo group (p=0.115; 95% confidence interval: -24.6% to 50.4%), which was not statistically significant. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The result of the all-participants population of 203 participants (134 participants in the treatment group, 69 in the placebo group) was statistically significant, with 27.6% (37/134) of the participants meeting the endpoint in the treatment group, versus 8.7% (6/69) in the placebo group (p=0.001; 95% confidence interval: 7.8% to 28.6%). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, in the all-participants population of REVEAL2, viral clearance was observed in 37.3% (50/134) in the treatment group versus 8.7% (6/69) in the placebo group. Given the importance of viral clearance in removing the underlying cause of the HPV-related diseases, this data may have positive implications in our other HPV-related programs. We plan to submit the data for publication in a peer-reviewed journal. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ad hoc integrated efficacy analysis of the results for both REVEAL1 and REVEAL2 showed statistical significance in the biomarker-selected and all-participants populations for lesion regression and viral clearance. For the combined biomarker-selected population of 92 participants (68 participants in the treatment group, 24 in the placebo group), the percentage of participants meeting the primary endpoint was 54.4% (37/68 in the treatment group, versus 12.5% (3/24) in the placebo group (p=&lt;0.001; 95% confidence interval: 20.4% to 57.0% difference in percentage). For the combined all-participants population of 404 participants (272 participants in the treatment group, 132 in the placebo group), the percentage of participants meeting the primary endpoint was 25.0% (68/272 in the treatment group, versus 9.8% (13/132) in the placebo group (p=&lt;0.001; 95% confidence interval: 7.4% to 22.1% difference in percentage). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both REVEAL1 and REVEAL2, VGX-3100 delivered by the CELLECTRA 5PSP device was well tolerated. There were no treatment-related serious adverse events and most adverse events were considered to be mild to moderate. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This combined data set will be used as supportive data in any future regulatory interactions involving VGX-3100. Our collaborator ApolloBio Corporation is conducting a Phase 3 clinical trial of VGX-3100 for cervical HSIL in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGX-3100 for the Treatment of Anal or Perianal HSIL  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV-16 and HPV-18 can cause precancerous lesions of the anus (anal HSIL). Left untreated, anal HSIL may progress to cancer. Spontaneous regression of anal HSIL is observed in approximately 20% of patients. Persistent infection with one or more high-risk HPV genotypes is responsible for a large portion of anal cancer. In the United States, about 55% to 80% of anal HSIL cases are associated with HPV-16/18, and worldwide about 80% of anal HSIL cases are associated with HPV-16/18. In the United States, over 90% of anal cancer is attributable to HPV, and about 87% of those HPV anal cancers are attributable to HPV-16/18 specifically. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no validated screening tests or a general consensus for screening recommendations for anal HSIL. Treatment usually consists of repeated ablation, most commonly radiofrequency ablation (RFA), resections or laser therapy. However, recurrence rates are high, up to 49% one year after treatment, as ablation does not clear the underlying HPV infection, resulting in an unmet medical need. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted a Phase 2 clinical trial (HPV-203) to evaluate VGX-3100 in participants who were HIV-negative with histologically confirmed anal or perianal HSIL, or anal intraepithelial neoplasia (AIN), associated with HPV-16 and/or HPV-18. This open-label trial enrolled 24 participants who received three doses of VGX-3100 delivered by our CELLECTRA 5PSP device. The primary endpoint of the trial was histologic clearance of the high-grade lesions and virologic clearance of the HPV-16/18 virus in anal/perianal tissue samples. In December 2020, we announced Phase 2 efficacy results from this trial. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One-half of participants treated with VGX-3100 (11/22) showed resolution of HPV-16/18-associated anal HSIL at six months following the start of treatment. VGX-3100 delivered by CELLECTRA-5PSP device was well tolerated in the trial. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Phase 2 anal HSIL trial described above, a separate Phase 2 trial sponsored by the AIDS Malignancy Consortium (AMC-103 study) is evaluating VGX-3100 in participants with histologically confirmed anal or perianal HSIL associated with HPV-16 and/or HPV-18 who are HIV-positive. This open-label single-arm trial plans to enroll approximately 90 participants who will receive up to four doses of VGX-3100 delivered by CELLECTRA 5PSP. The primary endpoint of the trial is histological regression of high-grade anal lesions to low-grade SIL or normal histology. This study is ongoing. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGX-3100 for the Treatment of Vulvar HSIL </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2023, as part of the reprioritization of our pipeline, we discontinued the development of VGX-3100 as a potential treatment for vulvar HSIL. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-5401 for the Treatment of Glioblastoma Multiforme (GBM) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Glioblastoma multiforme, or GBM, is the most common aggressive type of brain cancer. In the United States, the median age at diagnosis is 65 years, and the incidence rate increases thereafter. Prognosis is extremely poor, and a limited number of new therapies have been approved over the last 10 years; average survival for U.S. patients has been reported as low as 8 months with a five-year survival rate of 6.9% for all ages combined. The overall incidence of GBM varies worldwide and is highest in North America, Australia and Northern and Western Europe. In the United States, the average age-adjusted incidence rate of GBM is 3.19 cases per 100,000 persons. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate INO-5401 is an immunotherapy consisting of three DNA plasmids encoding for three tumor-associated antigens: human Telomerase Reverse Transcriptase (hTERT), Wilms Tumor gene-1 (WT1) and Prostate-Specific Membrane Antigen (PSMA). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 1/2 immuno-oncology trial of INO-5401 and INO-9012 (an IL-12 plasmid) in participants with newly diagnosed GBM, in combination with cemiplimab (Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a PD-1 immune checkpoint inhibitor developed by Regeneron Pharmaceuticals. This open-label trial began in 2018 and enrolled 52 newly diagnosed GBM participants. The primary endpoint was safety and tolerability, and the trial also evaluated immunogenicity as well as efficacy based on overall survival, or OS, rates. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we presented OS data at the 2022 American Society of Clinical Oncology (ASCO) from the trial. Median OS duration in patients with an unmethylated MGMT promoter (Cohort A) was 17.9 months, which compared favorably to historical comparisons (between 14.6 and 16 months). Median OS data in patients with an MGMT methylated promoter (Cohort B) was 32.5 months, which also compared favorably to historical comparisons (between 23.2 and 25 months). Overall, administration of INO-5401 + INO-9012 with Libtayo and RT/TMZ (radiation and temozolomide) was well tolerated by newly diagnosed GBM patients. Administration of treatment was also observed to be immunogenic, eliciting antigen-specific T cells that may infiltrate GBM tumors. As of the end of 2023, two GBM patients in the trial remained on drug treatment. We are currently completing the study reports and discussing the further development of INO-5401 with our collaborator Regeneron. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO is partnering with the University of Pennsylvania to conduct a Phase 1b investigator-sponsored trial to evaluate the tolerability and immunogenicity of INO-5401 alone or INO-5401 in combination with INO-9012 delivered with CELLECTRA in adult cancer and non-cancer patients with BRCA1 or BRCA2 mutations. This trial is ongoing. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All humans have BRCA1 and BRCA2 genes, but some people are born with an error, or mutation, in one of these genes. People with a gene mutation in either BRCA1 or BRCA2 are at heightened risk for certain cancers, including breast, ovarian, prostate, and pancreatic cancers. These gene mutations can be passed on to children by either men or women. </span></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Infectious Disease Product Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4800 for COVID-19 </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2/3 Clinical Trial &#8211; SOLIDARITY TRIAL VACCINES (STV) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-4800 is one of two initial COVID-19 vaccine candidates included in the World Health Organization (WHO) sponsored Solidarity Trial Vaccines, or STV, which is designed to evaluate the efficacy and safety of vaccine candidates selected by an independent vaccine prioritization advisory group composed of leading scientists and experts. The conduct of the STV is wholly under the WHO&#8217;s control and any announcement regarding that trial will be made by the WHO.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INO-4800 in China </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaborator Advaccine has completed enrollment of its 200-participant homologous and 267-participant heterologous booster vaccine trials in China. The trials are designed to evaluate safety, tolerability and immunogenicity of INO-4800 as a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">homologous booster where INO-4800 was administered as the primary vaccine and as a heterologous booster where an inactivated vaccine was administered as the primary vaccine.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 DNA-encoded Monoclonal Antibodies (dMAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">)  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our GOAL algorithm technology, we are able to create precisely designed DNA plasmids that encode for specific monoclonal antibodies (mAbs). We refer to these DNA plasmids as our dMAb product candidates to differentiate them from infused recombinant monoclonal antibodies. We deliver the plasmid directly into cells of the body using our CELLECTRA delivery system, enabling the electroporated cells to manufacture those DNA-encoded mAbs in vivo (i.e. by the body itself), unlike conventional recombinant mAb technology that requires manufacture outside of the body. We believe this approach provides potentially significant advantages in terms of design simplicity, rapidity of execution and lower production costs. We expect to design dMAb product candidates not only for new disease targets that are not currently addressable with conventional recombinant mAbs, but also targets of existing, commercially available mAb products.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we, along with a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University, received a $37.6 million grant from the U.S. Defense Advanced Research Projects Agency (DARPA), a research and development agency of the DoD and the JPEO-CBRND, to use our dMAb technology to develop anti-SARS-CoV-2-specific dMAbs that function as both a therapeutic and preventive treatment for COVID-19.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Wistar announced the dosing of the first participant in a Phase 1, open-label, single-center, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic profile of two of our mAb product candidates, administered IM followed immediately by electroporation using our CELLECTRA 2000 device in a 1- and 2-dose regimen (Days 0 and 3) in healthy adults (NCT05293249). The study is ongoing.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4201 for Ebola Virus Disease</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ebola virus causes one of the most virulent viral diseases, with case fatality rates averaging approximately 50% but approaching up to 90% in past outbreaks in areas with no or under-developed health care. Ebola can spread through human-to-human transmission by direct contact with the blood, secretions, organs or bodily fluids of an infected individual and with surfaces or materials that contain the contaminated fluids of an infected person, such as bedding and clothing. It is capable of causing death within 2 to 21 days of exposure. In November 2019, the first conditional approval was issued for a preventive vaccine against Ebola virus. This approval was from the European Medicines Agency (EMA) for the vaccine ERVEBO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. That same month, the WHO pre-qualified that vaccine for use in high-risk countries. In the next month, the FDA approved that vaccine. However, ERVEBO has not been approved for repeat dosing and there are no approved booster vaccines yet available in the United States.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced complete enrollment of a 46-participant Phase 1b trial (NCT04906629) in which our DNA medicine candidate INO-4201 was assessed as a heterologous booster in healthy volunteers previously vaccinated with ERVEBO. In February 2023, we announced results from the Phase 1b trial. INO-4201 was well tolerated and boosted humoral responses in 100% (36 of 36) of treated participants. We and our collaborators plan to publish the data in a peer-reviewed journal and provide updates on the next steps for INO-4201.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-6160 for HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-6160 is a DNA medicine candidate being developed as a prophylactic vaccine against human immunodeficiency virus, or HIV. INO-6160 is composed of one plasmid encoding for an HIV trimer and one encoding for human IL-12.  INO-6160 is being evaluated in a Phase 1 trial that is externally sponsored and funded by the National Institute of Allergy and Infectious Diseases, or NIAID. The trial is a randomized, 20-participant, open-label Phase 1 trial to examine the safety and immunogenicity of INO-6160.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DNA-Launched Nanoparticles (dLNPs) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO and our collaborators at the Wistar Institute are applying our experience in DNA vaccine development toward the development of the next generation of DNA medicine technology, by investigating DNA-launched nanoparticles, or dLNPs, initially targeting infectious diseases vaccines. INO-6172, INOVIO&#8217;s first dLNP to enter clinical trials, is in a Phase 1 trial sponsored and funded by NIAID. INO-6172 contains two plasmids, one encoding for the dLNP and one encoding for human IL-12. The trial is a randomized, 45-participant, open-label Phase 1 trial that is examining the safety and immunogenicity of INO-6172 in adults without HIV. The trial is ongoing, as is additional preclinical work with dLNP technology and additional vaccine candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and Alliances</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our current collaboration with ApolloBio Corporation described below, our other partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences (PLS), Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an Amended and Restated License and Collaboration Agreement with Beijing Apollo Saturn Biological Technology Limited, a corporation organized under the laws of China, or ApolloBio, which was amended on June 14, 2023 (as so amended, the &#8220;License and Collaboration Agreement&#8221;). Under the terms of this License and Collaboration Agreement, we granted to ApolloBio the exclusive right to develop and commercialize VGX-3100, our DNA immunotherapy product candidate designed to treat pre-cancers caused by HPV, within Greater China (defined as China, Hong Kong, Macao and Taiwan). As part of the collaboration, ApolloBio will fund all clinical development costs within the licensed territory.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of VGX-3100 in accordance with the License and Collaboration Agreement. In the event that VGX-3100 is approved for marketing in Greater China, we will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the low- to mid-teens, subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the last-to-expire patent covering the licensed products in the specified territory. After marketing approval in a territory, the License and Collaboration Agreement, will continue in force until ApolloBio has no remaining royalty obligations. In December 2021, ApolloBio dosed its first participant in a separate Phase 3 trial in China (HPV-303CHN).  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we develop and seek to ultimately commercialize our product candidates, we face and will continue to encounter competition with an array of existing or development-stage drug and immunotherapy approaches targeting diseases we are pursuing. We are aware of various established enterprises, including major bio-pharmaceutical companies, broadly engaged in vaccine/immunotherapy research and development. These include AbbVie, AstraZeneca, BioNTech, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceuticals (part of J&amp;J), Merck, Moderna, Novartis, Pfizer, Roche, and Sanofi-Aventis. There are also various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies, including but not limited to Agenus, AIVITA, Barinthus Biotherapeutics (formerly Vaccitech), BL Corp, Entos Pharma, Frantz Viral Therapeutics, Immunocore, Imunon, ImVax, Iovance, Gritstone Bio, Genexine, Hookipa, Mimivax, Nektar, Northwest Therapeutics, Novavax, Nykode, Precigen, and PapiVax. If these companies are successful in developing their technologies, it could materially and adversely affect our business and our future growth prospects. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are also seeking to treat early HPV infections. For RRP, which is caused by HPV subtypes 6 and 11, Precigen is developing a product candidate, PRG-2012, based on a Gorilla adenovirus-based vector. Precigen has publicly stated they expect to file a BLA in 2024 based on their Phase 1/2 trial of PRG-2012 for the treatment of RRP and that no additional randomized, placebo-controlled trial will be required to support their submission of a BLA. Other companies have started to explore RRP as a disease target, including Nykode, Merck and Cytovation. For head and neck cancers, AstraZeneca is developing a bispecific antibody targeting PD-1 and TIGIT for locaregionally advanced head and neck squamous cell carcinoma, while the National Cancer Institute is conducting a Phase 3 study with the immunotherapy nivolumab (Bristol-Myers Squibb&#8217;s Opdivo) in HPV-positive oropharynx cancer. Other companies are pursuing different approaches to pre-cancers and cancers we are targeting. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other delivery technologies such as viral vectors or lipid delivery to induce in vivo generated antigen production and immune responses to prevent or treat various diseases. These competitive technologies have shown promise, but they each also have their own unique obstacles to overcome.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Viral Vector-based Vaccine Delivery </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This technology utilizes a virus as a carrier, or vector, to deliver genetic material into target cells. The method is efficient for delivering immunotherapy antigens and has the advantage of mimicking real viral infection so that the recipient will mount a broad immune response against the immunotherapy. The potential limitation of the technology stems from problems with unwanted immune responses against components of the viral vector itself, making repeated administration difficult. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lipid Nanoparticle DNA/RNA Delivery</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lipid formulations have been developed that increase the effect of DNA/RNA immunotherapies, most notably with COVID-19 mRNA vaccines. These work by either increasing uptake of the DNA/RNA into cells or by acting as an adjuvant, alerting the immune system.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA Immunotherapy Delivery with Electroporation </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are other companies with electroporation intellectual property and devices. We believe we have competitive advantages over other companies focused on electroporation for multiple reasons: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have an extensive history and experience in developing the methods and devices that optimize the use of electroporation in conjunction with DNA medicine. This experience has been validated with multiple sets of data from clinical trials assessing DNA medicine against cancers and infectious disease.  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a broad product line of electroporation instruments designed to enable DNA delivery, including our intradermal and intramuscular devices.  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have been proactive in filing for patents, as well as acquiring and licensing additional patents, to expand our global patent estate.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive or result in treatments or cures superior to ours.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position will be affected by the disease indications addressed by our product candidates versus those of our competitors, the timing of market introduction for these products and the stage of development of other technologies to address these disease indications. For us and our competitors, proprietary technologies, the ability to complete clinical trials on a timely basis and with the desired results, and the ability to obtain timely regulatory approvals to market these product candidates are likely to be significant competitive factors. Other important competitive factors will include efficacy, safety, ease of use, reliability, availability and price of products and the ability to fund operations during the period between technological conception and commercial sales.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies may expand current requirements for public disclosure of DNA-based product development data, which may harm our competitive position with foreign and United States companies developing DNA-based products for similar indications. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization and Manufacturing</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the broad potential applications of our technologies, we intend to develop and commercialize products both on our own and through our collaborators and licensees. We intend to develop and commercialize products in well-defined specialty markets, such as HPV-related diseases, infectious diseases, and cancer. Where appropriate, we intend to rely on strategic marketing and distribution alliances. In 2023, we began accelerating the development of our commercialization plans for INO-3107 in the United States following notice from the FDA that the data from our completed Phase 1/2 trial in patients with RRP could be used to submit a BLA under the accelerated approval program.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our plasmids can be produced in commercial quantities through uniform methods of fermentation and processing that are applicable to all plasmids. We believe we will be able to obtain sufficient supplies of plasmids for all foreseeable clinical investigations.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are essential to our business. We file patent applications to protect our technologies, inventions and improvements to our inventions that we consider important to the development of our business. We file for patent registration extensively in the United States and in key foreign markets. Although our patent filings include claims covering various features of our products and product candidates, including composition, methods of manufacture and use, our patents do not provide us with complete protection, or guarantee, against the development of competing products. In addition, some of our know-how and technology are not patentable. We thus also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position. We also require employees, consultants, advisors and collaborators to enter into confidentiality agreements, but such agreements may provide limited protection for our trade secrets, know-how or other proprietary information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, our patent portfolio included approximately 120 issued U.S. patents and approximately 100 U.S. patent applications as well as approximately 1,100 issued foreign counterpart patents and approximately 800 counterpart foreign patent applications. These are comprised, in part, of: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:13.8pt">one U.S. patent, 4 U.S. patent applications and approximately 40 counterpart foreign patent applications directed to treatment of RRP; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seven issued U.S. patents and four U.S. patent applications, as well as approximately 80 issued foreign counterpart patents and approximately 30 counterpart foreign patent applications, directed to treatment of GBM; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately 100 issued U.S. patents and approximately 80 U.S. patent applications, as well as approximately 850 issued foreign counterpart patents and approximately 590 counterpart foreign patent applications, directed to our other earlier-stage product candidates; and </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">4 issued U.S. patents and 6 U.S. patent applications, as well as approximately 160 issued foreign counterpart patents and approximately 50 counterpart foreign patent applications, directed to our device delivery systems. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending patent applications directed to treatment of RRP, if issued, would expire between about 2040 and 2043. Our issued patents directed to treatment of GBM expire between about 2027 and 2037 and our pending patent applications, if issued, would expire between about 2027 and 2040. Our issued patents directed to our other product candidates expire between about 2027 and 2036 and our pending patent applications, if issued, would expire between about 2027 and 2042. Our issued patents directed to our device delivery systems expire between about 2024 and 2036 and our pending patent applications, if issued, would expire between about 2024 and 2042. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual patent terms extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. In most countries in which we file patent applications, including the United States, the patent term is 20 years from the date of filing of the first non-provisional patent application to which priority is claimed. In some instances, a patent term can be extended under certain circumstances, such as patent term extension or patent term adjustment; alternatively, a patent term may be shortened, for example in the United States, if a patent is terminally disclaimed over an earlier-filed patent. Protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to protect our intellectual property rights adequately our competitors might gain access to our technology and our business would thus be harmed. In addition, defending our intellectual property rights might entail significant expense. Any of our intellectual property rights may be challenged by others or invalidated through administrative processes or litigation through the courts. In addition, our patents, or any other patents that may be issued to us in the future, may not provide us with any competitive advantages, or may be challenged by third parties. Furthermore, legal standards relating to the validity, enforceability and scope of protection of intellectual property rights are uncertain. Effective patent, trademark, copyright and trade secret protection may not be available to us in each country where we operate. The laws of some foreign countries may not be as protective of intellectual property rights as those in the United States, and domestic and international mechanisms for enforcement of intellectual property rights in those countries may be inadequate. Accordingly, despite our efforts, we may be unable to prevent third parties from infringing upon or misappropriating our intellectual property or otherwise gaining access to our technology. We may be required to expend significant resources to monitor and protect our intellectual property rights. We may initiate claims or litigation against third parties for infringement of our proprietary rights or to establish the validity of our proprietary rights. Any such litigation, whether or not it is ultimately resolved in our favor, would result in significant expense to us and divert the efforts of our technical and management personnel. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be rights we are not aware of, including applications that have been filed but not published that, when issued, could be asserted against us. These third parties could bring claims against us, and that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or biologic drug candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose or be required to seek a license from the third party. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also impact our collaborators, which would also impact the success of the collaboration and therefore us. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important legal issues remain to be resolved as to the extent and scope of available patent protection for biologic products, including vaccines, and processes in the United States and other important markets outside the United States, such as Europe and Japan. Foreign markets may not provide the same level of patent protection as provided under the United States patent system. We recognize that litigation or administrative proceedings may be necessary to determine the validity and scope of certain of our and others&#8217; proprietary rights. Any such litigation or proceeding may result in a significant commitment of resources in the future and could force us to interrupt our operations, redesign our products or processes, or negotiate a license agreement, all of which would adversely affect our revenue. Furthermore, changes in, or different interpretations of, patent laws </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States and other countries may result in patent laws that allow others to use our discoveries or develop and commercialize our products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that the patents we obtain or the unpatented technology we hold will afford us significant commercial protection. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States at the federal, state and local level and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products, or biologics, and medical devices, such as our product candidates. Generally, before a new biologic or medical device can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority. These requirements are continually updated by regulatory authorities to address changes in science, manufacturing and potential new threats, such as cybersecurity concerns.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Review and Approval of Combination Products in the United States</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain products may be comprised of components that would normally be regulated under different types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be:  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity;    </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">two or more separate products packaged together in a single package or as a unit and comprised of drug and device products; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device or biological where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any investigational drug, device, or biological packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.   </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products comprising an electroporation device for delivery of a biologic. Under the Federal Food, Drug, and Cosmetic Act, or FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. That determination is based on the &#8220;primary mode of action&#8221; of the combination product, which means the mode of action expected to make the greatest contribution to the overall intended therapeutic effects. Thus, if the primary mode of action of a device-biologic combination product is attributable to the biologic product, that is, if it acts by means of a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, the FDA center responsible for premarket review of the biologic product would have primary jurisdiction for the combination product. We believe that all of our product candidates will have a biologic primary mode of action.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Biological Product Development</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates biologics under FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. Biologics are also subject to other federal, state, and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates must be approved by the FDA through the Biologics License Application, or BLA, process before they may be legally marketed in the United States. The process required by the FDA before a biologic may be marketed in the United States generally involves the following:  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of extensive nonclinical, sometimes referred to as pre-clinical laboratory tests, pre-clinical animal studies and formulation studies in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;   </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations, sometimes referred to as good clinical practices, or GCPs, to establish the safety and efficacy of the proposed product candidate for its proposed indication;  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of a BLA;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product is produced to assess compliance with the FDA&#8217;s current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality, purity and potency;  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential FDA audit of the pre-clinical and/or clinical trial sites that generated the data in support of the BLA; and </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the BLA prior to any commercial marketing or sale of the product in the United States.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data required to support a BLA is generated in two distinct development stages: pre-clinical and clinical. The pre-clinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the pre-clinical studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the pre-clinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical stage of development involves the administration of the product candidate to healthy participants under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCPs, which include the requirement that all research participants provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, participant selection and exclusion criteria, and the parameters to be used to monitor participant safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial participant or his or her legal representative and must monitor the clinical trial until completed.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products, including biologics, are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. The FDA requires sponsors to disclose the results of most, but not all, trials after completion.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are generally conducted in three sequential phases that may overlap, known as Phase 1, Phase 2 and Phase 3 clinical trials. Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a product candidate. The primary purpose of these clinical trials is to assess the action, side effect tolerability and safety of the product candidate and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials typically involve studies in patients to determine the dose required to produce the desired benefits. At the same time, safety and preliminary evaluation of efficacy is assessed. Phase 3 clinical trials generally involve large numbers of patients at multiple sites, in multiple countries (from several hundred to several thousand participants) and are designed to provide the data necessary to demonstrate the efficacy of the product for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. Phase 3 clinical trials may include comparisons with placebo and/or other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may grant conditional approval of a BLA on the sponsor&#8217;s agreement to conduct additional clinical trials, such as these post-approval trials, to further assess the biologic&#8217;s safety and effectiveness after BLA approval.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important rate increase of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research participants are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated intervals based on access to certain data from the trial. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BLA and FDA Review Process</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following trial completion, trial data is analyzed to assess safety and efficacy. The results of pre-clinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling for the product and information about the manufacturing process and facilities that will be used to ensure product quality, results of analytical testing conducted on the chemistry of the product candidate, and other relevant information. The BLA is a request for approval to market the biologic in combination with the device, if applicable, for one or more specified indications and must contain proof of safety, purity, potency and efficacy, which is demonstrated by extensive pre-clinical and clinical testing. The application includes positive findings from pre-clinical and clinical trials as well as ambiguous or negative results. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee, which is adjusted on an annual basis. PDUFA also imposes an annual program fee for approved products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business or a waiver of fee based on orphan drug status.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a BLA has been accepted for filing, which occurs, if at all, 60 days after the BLA&#8217;s submission, the FDA&#8217;s goal is to review BLAs within ten months of the filing date for standard review or six months of the filing date for priority review, if the application is for a product intended for a serious or life-threatening condition and the product, if approved, would provide a significant improvement in safety or effectiveness. The review process is often significantly extended by FDA requests for additional information or clarification. If not accepted for filing, the sponsor must resubmit the BLA and begin the FDA&#8217;s review process again, including the initial 60-day review to determine if the application is sufficiently complete to permit substantive review.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also accept the submission of a BLA under its Accelerated Approval Program, which was instituted to allow for earlier approval of drugs that treat serious conditions and fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but may not it itself be the final measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. Companies are still required to conduct studies to confirm the anticipated clinical benefit. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA would grant provisional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to the removal of the drug from the market.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and effective for its intended use, and whether the product candidate is being manufactured in accordance with cGMP to assure and preserve the product candidate&#8217;s identity, strength, quality, purity and potency. The FDA may refer applications for novel drug product candidates or drug product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of a BLA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and an applicant may not receive a timely approval, if at all.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving a BLA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, pre-clinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that the FDA will ultimately approve a product for marketing in the United States and applicants may encounter significant difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific populations, severities of allergies, and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the BLA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess the product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Marketing Requirements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new product, a manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, also known as off-label use, limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. Moreover, the constituent parts of a combination product retain their regulatory status, for example, as a biologic or device, and as such, we may be subject to additional requirements in the Quality System Regulation, or QSR, applicable to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medical devices, such as design controls, purchasing controls, and corrective and preventive action. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. BLA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require post-approval testing, sometimes referred to as Phase 4 testing, REMS and post-marketing surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage and Reimbursement </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and vaccines. Accordingly, a pharmaceutical company&#8217;s ability to commercialize its products successfully depends in part on the extent to which private health insurers, other third-party payors, and governmental authorities, including Medicare and Medicaid, establish appropriate coverage and reimbursement levels for its product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that products be approved for marketing by the FDA.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are available. The process for obtaining coverage for a product or service is separate from the process to obtain the associated reimbursement. Reimbursement levels can affect the adoption of products and services by physicians and patients. Additionally, products used in connection with medical procedures may not be reimbursed separately, but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for a product or the treatment or procedure in which the product is used may not be available.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for drug products and vaccines can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which may require the provision of scientific and clinical support for the use of the product to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and continue to be, a number of legislative and regulatory changes to the healthcare system that impact the ability to sell pharmaceutical products profitably. In the United States, the federal government enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. The ACA, among other things, increased the minimum level of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid rebates payable by manufacturers of brand name drugs; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, under which they must agree to offer point-of-sale discounts (increased to 70 percent, effective as of January 1, 2019) off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected expanded the types of entities eligible for the 340B drug discount program; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at the Centers for Medicare and Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax, and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and by creating a newly established manufacturer discount program. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect until 2032 unless additional Congressional action is taken. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have increasingly passed legislation and implemented </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Laws</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to the business of a pharmaceutical company. The laws that may affect a pharmaceutical company&#8217;s ability to operate include: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the purchasing, ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities;  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDCA, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples;  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A pharmaceutical company will need to spend substantial time and money to ensure that its business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that its business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If a pharmaceutical company&#8217;s operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to it, it may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm and the curtailment or restructuring of operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Regulations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are subject to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research. The extent of government regulation that might result from any future legislation or administrative action cannot be accurately predicted. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Customers and Research and Development</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, we derived 29% of our revenue from ApolloBio. During the year ended December 31, 2022, we derived 94% of our revenue from the procurement contract with the DoD that we entered into in June 2020. During the year ended December 31, 2021, we derived 43% of our revenue from the procurement contract with the DoD and 14% of our revenue from our collaborator Plumbline Life Sciences, a company of which we are an approximately 19% stockholder. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, virtually all of our activities have consisted of research and development efforts related to developing our electroporation technologies and immunotherapies. Research and development expense consists of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Our research and development expense was $86.7 million in 2023, $187.7 million in 2022 and $249.2 million in 2021. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenue for the years ended December&#160;31, 2023, 2022 and 2021 was earned in the United States. All of our long-lived assets are located in the United States.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462, and our main telephone number is (267) 440-4200. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Internet website address is www.inovio.com. In addition to the information contained in this Annual Report, information about us can be found on our website. Our website and information included in or linked to our website are not part of this Annual Report. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make our annual report on Form&#8239;10-K, quarterly reports on Form&#8239;10-Q, current reports on Form&#8239;8-K and amendments to those reports filed or furnished pursuant to Section&#8239;13(a) or 15(d) of the Securities Exchange Act of 1934, or the Exchange Act, available free of charge on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our corporate governance, including the charters of our audit committee, our nomination and corporate governance committee and our compensation committee, our Code of Business Conduct and Ethics, our Corporate Governance Guidelines, and information for contacting our board of directors is available on our website. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Code of Business Conduct and Ethics includes our Code of Ethics applicable to our Chief Executive Officer and Chief Financial Officer, who also serves as our principal accounting officer. Any amendments to or waivers of the Code of Ethics will be promptly posted on our website or in a report on Form 8-K, as required by applicable law. </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital Resources</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 14, 2024, we employed 122 people on a full-time basis. Of the total, 90 were in product research, which includes research and development, quality assurance, clinical, engineering and manufacturing, and 32 were in general and administrative functions, which includes corporate development, information technology, legal, commercial, investor relations, finance and corporate administration. Approximately one-half of our workforce is comprised of women and approximately one-half is comprised of individuals with ethnically diverse backgrounds. In addition, four of the eight members of our board of directors are women. None of our employees are subject to collective bargaining agreements. We consider our relationship with our employees to be good.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in the highly competitive biotechnology industry. Attracting, developing and retaining talented people in research, quality assurance, clinical, engineering, manufacturing and other positions is crucial to executing our strategy and our ability to compete effectively. Our ability to recruit and retain such talent depends on several factors, including compensation and benefits, talent development and career opportunities, and work environment. To that end, we invest in our employees to be an employer of choice. </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Engagement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we work to make an impact on how healthcare is delivered, we believe it is critical that our employees are informed and engaged. We communicate frequently and transparently with our employees through a variety of communication methods, including video and written communications, town hall meetings, employee surveys and our company intranet, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acknowledge individual contributions to our company&#8217;s success through several rewards and recognition initiatives. We believe these engagement efforts keep employees informed about our strategy, culture and purpose and motivated to do their best work.  </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health, Safety and Wellness</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The physical health, financial well-being, life balance and mental health of our employees is vital to our success. We have a company-wide comprehensive wellness program inclusive of financial, physical, and mental well-being. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our environmental, health and safety team stays abreast of local, regional and global concerns and trends and ensures safety procedures are in place to mitigate workplace injuries and safety risks. Employees are required to complete training in various safety procedures for the laboratories and manufacturing facilities and specialized safety training based on particular job duties. Designated Safety Officers and response teams oversee safety-related initiatives and a safety committee provides input on safety procedures, practices, and policies. Employees are required to wear personal protective equipment relevant for their particular job duties. Occupational injuries at our workplace have historically been very low and are always investigated to determine if any environmental or other changes need to be implemented. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following factors regarding information included in this Annual Report. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks actually occur, our business, financial condition and operating results could be materially adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant operating losses over the last several years. As of December 31, 2023 our accumulated deficit was $1.6 billion. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA medicine candidates or proprietary device technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary device technology.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently generate any revenue from the commercial sale of products. Our ability to generate future revenues depends heavily on our success in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and securing United States and/or foreign regulatory approvals for our DNA medicine candidates, including securing regulatory approval for conducting clinical trials with DNA medicine candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">developing our proprietary device technology; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary device and DNA medicine candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our proprietary device and DNA medicine candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of proprietary devices and DNA medicine products, and we may not be able to continue our operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A small number of licensing partners and government contracts have accounted for a substantial portion of our revenue. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past we have derived a significant portion of our revenue from a limited number of licensing partners and government grants and contracts, and we expect that a significant portion of our revenue will continue to be derived from a limited number of licensing partners and/or government grants and contracts unless and until we are able to commercialize our product candidates. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which may prove difficult or costly to obtain.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our DNA medicine candidates and proprietary device technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of our current and new product development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope and results of our pre-clinical and clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost involved in obtaining regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our DNA medicine candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the related costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility, particularly in light of geopolitical turmoil, inflation and rising interest rates, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through the sale of equity securities, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Rising interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development, Manufacturing and Regulatory Approval</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain FDA approval of our product candidates, we will not be able to commercialize them in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our proprietary device and DNA medicine candidates in the United States. If we fail to obtain FDA approval to market our proprietary device and DNA medicine candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our products as well as the evaluation of our manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our proprietary device and DNA medicine candidates are both safe and effective for each indication for which approval is sought. To the extent that our DNA medicine candidates are manufactured at multiple sites or using different processes, we will also need to demonstrate comparability across the manufacturing batches in order to obtain regulatory approval. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our proprietary device and any of our DNA medicine candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our proprietary device and DNA medicine candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our product candidates or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because our product candidates are combination products comprising an electroporation device for delivery of a biologic, additional time may be required to obtain regulatory approval for our product candidates because of the complexity involved with co-packaging a drug-device combination product. In addition, if the FDA and similar </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory agencies do not approve our delivery devices, then we will not be able to bring to market our DNA medicines that rely on delivery by such a device. Such delays or failure to obtain approval of our devices would result in significant harm to our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we pursue accelerated approval for INO-3107 or any of our other product candidates, it may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We plan to pursue accelerated approval for our product candidate INO-3107 and may in the future decide to pursue accelerated approval for one or more of our other product candidates. Under the FDA&#8217;s accelerated approval program, the FDA may approve a drug or biologic for a serious or life-threatening disease or condition that provides a meaningful advantage over available therapies based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. For drugs or biologics granted accelerated approval, post-marketing confirmatory trials are required to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence, and the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we pursue accelerated approval for INO-3107 for the treatment or RRP, or a future product candidate for another disease or condition, we would do so on the basis that there is no available therapy for that disease or condition or that our product candidate provides a benefit over available therapy. If standard of care were to evolve or if any of our competitors were to receive full approval on the basis of a confirmatory trial for a drug or biologic for a disease or condition for which we are seeking accelerated approval before we receive accelerated approval, the disease or condition would no longer qualify as one for which there is no available therapy, and accelerated approval of our product candidate would not occur without a showing of benefit over available therapy. The treatment landscape can change quickly as the FDA converts accelerated approvals to full approvals on the basis of successful confirmatory trials. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have received feedback from the FDA that data from our completed Phase 1/2 clinical trial of INO-3107 for the treatment of RRP can be used to support the submission of a BLA for review under the accelerated approval program; however, whether any trial is sufficient to receive FDA approval under the accelerated approval pathway will depend on the safety and efficacy results of such trial and will only be determined by the FDA upon review of a submitted BLA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA may withdraw approval of INO-3107 or any future product candidate approved under the accelerated approval pathway if, for example:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the trial or trials required to verify the predicted clinical benefit of our product candidate fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with such product;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">other evidence demonstrates that our product candidate is not shown to be safe or effective under the conditions of use;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">we fail to conduct any required post-approval trial of our product candidate with due diligence; or</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">we disseminate false or misleading promotional materials relating to the relevant product candidate.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA may terminate the accelerated approval program or change the standards under which accelerated approvals are considered and granted in response to public pressure or other concerns regarding the accelerated approval program. Changes to or termination of the accelerated approval program could prevent or limit our ability to obtain accelerated approval of any of our clinical development programs. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States, and the same risk applies for products approved outside the United States, with respect to regulatory approval in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any proprietary device and DNA medicine candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval, and the regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Furthermore, regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our DNA medicine candidates may not be approved for all indications requested, which could limit the uses of our DNA medicine candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and DNA medicine candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to complete the clinical trial process for many reasons, including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our proprietary device or product candidate is safe and effective for any indication; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of clinical or statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our proprietary device or DNA medicine candidates' clinical and other benefits outweigh their safety risks; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our proprietary device or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our DNA medicine candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or that of third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining regulatory approval to commence a clinical trial;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse results from third-party clinical trials involving gene-based therapies and the regulatory response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future bans or stricter standards imposed on clinical trials of gene-based therapy;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manufacturing sufficient quantities of our proprietary device and DNA medicine candidates for use in clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining Internal Review Board, or IRB, approval to conduct a clinical trial at a prospective site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collecting, reviewing and analyzing our clinical trial data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">global unrest, including geopolitical risks emanating from countries such as Russia and China, global pathogen outbreaks or pandemics, terrorist activities, the conflict between Israel and Hamas, bank failures and other economic and other external factors beyond our control.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to clinical trials of product candidates for rare diseases, such as our planned confirmatory trial of INO-3107 for the treatment of recurrent respiratory papillomatosis, or RRP, we may encounter difficulties in recruiting a sufficient number of patients to enroll in the trial due to the small number of patients with the disease. Because RRP is caused by specific HPV types, 6 and 11, and there is currently no standard protocol for diagnostic/screening of RRP patients unless there are symptoms of dysphonia, respiratory distress or other symptoms related to the presence of papillomas, it may be difficult to identify and diagnose patients for whom INO-3107 may be a potential treatment.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unforeseen safety issues; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our proprietary device and our DNA medicine candidates may be harmed and our ability to generate product revenues will be delayed or eliminated altogether. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement, conduct or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our DNA medicines programs are in various stages of research and development, and currently include DNA medicine candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of DNA medicine candidates compared with conventional vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our DNA medicine candidates. The success of our efforts to develop and commercialize our DNA medicine candidates could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our DNA medicine candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We previously expended significant resources on the development of a COVID-19 vaccine candidate. We are now only pursuing development in collaboration with third parties, as both a primary and heterologous booster vaccine, but there can be no assurance that our candidate will ever receive regulatory approval as a primary vaccine or a booster in any country, whether by Emergency Use Authorization or otherwise.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, we expended significant resources on the clinical development of a COVID-19 vaccine candidate, INO-4800. We were previously conducting a Phase 2/3 clinical trial of INO-4800 called INNOVATE. Based on regulatory feedback and the competitive landscape for COVID-19 vaccines, in 2022 we discontinued the INNOVATE trial and pursued a strategy to develop our COVID-19 vaccine as a potential heterologous booster following administration of other primary vaccines. Following an assessment of the current global demand for COVID-19 vaccines, changes in regulatory timelines and requirements, diminishing government financial support, and the overall growing uncertainty related to opportunities for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">heterologous booster vaccines, in the fourth quarter of 2022 we discontinued our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are no longer conducting any active clinical trials of INO-4800 and do not expect that it will ever receive regulatory approval in the United States. Our collaborator Advaccine has completed enrollment of its 200-participant homologous and 267-participant heterologous booster vaccine trials in China. They may seek an Emergency Use Authorization, or EUA, from regulatory authorities in China and other countries in Asia for the use of INO-4800 as a heterologous booster. However, any such decision would be made by Advaccine, and there is no guarantee that Advaccine will apply for an EUA or other similar authorization or, if it does apply, that Advaccine will be able to obtain such authorization. An EUA may not be available if countries are no longer in a state of public health emergency, in which case full approval would need to be sought. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We await the results of our COVID-19 vaccine candidate's participation in the World Health Organization&#8217;s Solidarity Trial Vaccines. Depending on the results of that trial, we could also pursue a strategy of seeking EUA for the vaccine candidate in other countries outside of the United States. Even if an EUA or other authorization is ultimately granted, we will rely on the applicable regulatory authority policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our vaccine candidate. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales of our product could be adversely impacted. Regulatory authorities may also terminate an EUA if safety issues or other concerns about our product arise or if we or Advaccine fail to comply with the conditions of authorization. If we or Advaccine apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our and Advaccine&#8217;s ability to market and sell our COVID-19 vaccine.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">DNA medicines are a novel approach to treating and preventing disease, and our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> delivery devices are a novel approach to administering medicines, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop or our devices could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No DNA medicines have been granted EUA or have been approved to date by the FDA. Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of DNA medicine, or other products that are perceived to be similar to DNA medicines, such as those related to other nucleic acid based vaccines such as mRNA vaccines, gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. Our pipeline of DNA medicine candidates could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole. In addition, responses by U.S., state, or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any investigational medicines or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the novelty of our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delivery devices may make it difficult to demonstrate to physicians and third-party payors that this delivery system is an appropriate approach for DNA medicines and provides advantages compared to the current standards of care. Further, if we or our commercialization and collaboration partners are not successful in conveying to physicians, patients and third-party payors that our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delivery devices provide useful patient outcomes, we or our commercialization and collaboration partners may experience reluctance, or refusal, on the part of physicians to order and use, and third-party payors to cover and provide adequate reimbursement for,our DNA medicines. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and the contract manufacturers upon whom we rely fail to produce our proprietary devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary device and DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture some components of our proprietary devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our DNA medicine candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our DNA medicine candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These problems include difficulties with production costs and yields, quality control, including stability of the equipment and DNA medicine candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our proprietary device to our partners and to supply DNA medicine candidates for clinical trials or to commercially launch a product would be jeopardized. For example, we previously relied on VGXI to manufacture DNA plasmids for our DNA medicine candidates before they became unable to produce the necessary plasmids due to a lack of manufacturing capacity. As a result, we had to engage several additional third-party contract manufacturers. However, there can be no assurance that we will be able to secure adequate additional manufacturing capacity for any of our DNA medicine candidates on commercially reasonable terms. Our inability to secure sufficient manufacturing capacity, or our inability to transfer necessary manufacturing know-how to third parties, would adversely affect our commercialization plans and could also harm our reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any delay or interruption in the supply of clinical trial supplies for our DNA medicine candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the quality system regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our product candidates and investigational medicines.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop and commercialize, our product candidates and investigational medicines. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that may not be interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes, and finished goods exposes us to several risks, including disruptions in supply, price increases, or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials, and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates or investigational medicines could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our product candidates or investigational medicines, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single-source components and materials used in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to supply our investigational medicines.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our reliance on these suppliers, service providers, and manufacturers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays to the development timelines for our development candidates or investigational medicines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a lack of long-term supply arrangements for key components with our suppliers;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">damage to our reputation caused by defective components produced by our suppliers; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if United States regulatory approval is obtained, regulators may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our DNA medicine candidates, or the manufacturing facilities for our DNA medicine candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue Warning Letters or untitled letters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications filed by us; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are developing some of our investigational DNA medicines using new endpoints or methodologies for the treatment of diseases in which there is little clinical experience. As a result, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we currently attempt to address or may address in the future. There has been limited clinical trial experience for the development of pharmaceuticals to treat these rare diseases in general, and we are not aware of a registrational trial that led to approval of a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug to treat these diseases. There have been some historical trials with other agents which may have utilized clinical endpoints that are less applicable to our efforts that address the underlying defect. As a result, the design and conduct of clinical trials of investigational medicines for the treatment of these disorders and other disorders may take longer, be more costly, or be less effective as part of the novelty of development in these diseases. For example, our product candidate INO-3107 is being developed for RRP, a rare condition for which there are no approved non-surgical treatments. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our strategic collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have obtained Orphan Drug Designation for one of our DNA medicine candidates. As part of our business strategy, we may continue to seek Orphan Drug Designation for additional DNA medicine candidates, and we may be unsuccessful in obtaining new designations or may be unable to obtain or maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained Orphan Drug Designation from the FDA for INO-3107 for the treatment of RRP. We have sought and may continue to seek Orphan Drug Designation for one or more of our other DNA medicine candidates, although we may be unsuccessful in doing so. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have obtained Orphan Drug Designation for INO-3107 for the treatment of RRP, and even if we obtain Orphan Drug Designation for our other DNA medicine candidates in specific indications, we may not be the first to obtain marketing approval of these DNA medicine candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our DNA medicine candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our DNA medicine candidates, we may never receive such designations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">A breakthrough therapy designation or fast track designation by the FDA for a drug may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have received breakthrough therapy designation for INO-3107 and may seek this designation for one or more of our other investigational medicines. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the regulatory submission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our investigational medicines meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. Even if we are successful in obtaining accelerated approval in the United States or under comparable pathways in other jurisdictions, we may face requirements and limitations that will adversely affect our prospects. For example, we may be approved only for a very limited indication, we may not successfully complete required post-approval trials, such trials may not confirm the clinical benefit of our drug, or approval of the drug may be withdrawn. In addition, even if one or more of our investigational medicines qualify as breakthrough therapies, the FDA may later decide that the investigational medicine no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our DNA medicine candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to strategically enter into agreements with other organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate, implement and execute a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with government agencies that are subject to termination and uncertain future funding. Termination or cessation of funding would have a negative impact on our ability to develop certain of our pipeline candidates and/or require us to seek alternative funding sources to advance product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with government agencies, such as the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases, DARPA, Medical CBRN Defense Consortium and the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, and we intend to continue entering into these types of agreements with government agencies in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. For example, in 2021 the DoD discontinued funding for the planned Phase 3 trial of our COVID-19 product candidate, which resulted in increased expenditures by us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our proprietary device and DNA medicine candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our DNA medicine candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our DNA medicine candidates. As a result, our financial results and the commercial prospects for our DNA medicine candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enter into various contracts in the normal course of our business in which we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">agree to indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically agree to indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sub licensees&#8217; exercise of rights under the agreement. With respect to our commercial agreements, we have agreed to indemnify our vendors from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we typically agree to indemnify them from claims arising from the good faith performance of their services.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage or not covered by insurance, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator or other third party to indemnify us and the collaborator or other third party is denied insurance coverage or otherwise does not have assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our DNA Medicine Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have only a small marketing organization and no sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, if approved, we may not be able to generate product revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have only a small commercial organization to support pre-commercial activities for our proprietary device and DNA medicine candidates, if approved, and we do not currently have a sales organization. In order to successfully commercialize INO-3107 or any other products that may receive regulatory approval, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of a sales force, either on our own or in conjunction with third parties, will be expensive and time-consuming and could delay any product launch, and we may not be able to successfully develop or acquire this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In the event we are unable to successfully develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our DNA medicine candidates which would negatively impact our ability to generate product revenues. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our proprietary device and DNA medicine candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our DNA medicine candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of administration, including the acceptance and usage of our proprietary device by the medical community; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any actual or perceived adverse side effects; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost effectiveness; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential public perception of new therapies and the reputational challenges that the industry is facing related to drug costs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our proprietary device and DNA medicine candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our DNA medicine candidates may require significant resources and may never be successful. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our DNA medicine candidates, could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our proprietary device and DNA medicine candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our DNA medicine candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors in the United States generally require that drug products and vaccines have been approved for marketing by the FDA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, co-payments may be required that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products. Even if we obtain coverage for our products, the revenue generated may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our DNA medicine candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our DNA medicine candidates or procedures using our DNA medicine candidates, could reduce physician utilization of our products once approved.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for products among third-party payors in the United States. There may be significant </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time-consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee and Operational Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may be harmed if our corporate restructuring plans and cost reduction efforts do not achieve the anticipated results or cause undesirable consequences.</span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between July 2022 and January 2023, we undertook a corporate restructuring that resulted in a total reduction in headcount of more than 25% of our employees and a significant majority of our contractors. In August 2023 we announced a further headcount reduction of approximately 30%. As a result, our full-time employee headcount has declined from more than 300 employees in early 2022 to approximately 122 currently.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring plans may yield unintended consequences, such as attrition beyond our intended reduction in workforce and reduced employee morale, which may cause our employees who were not affected by the reduction in workforce to seek alternate employment. During the second half of 2022, we experienced increased voluntary attrition after conducting the first reduction in force. Additional attrition could impede our ability to meet our operational goals, which could have a material adverse effect on our financial performance. In addition, as a result of the reductions in our workforce, we may face an increased risk of employment litigation. </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, employees whose positions have been or will be eliminated in connection with these restructuring plans may seek future employment with our competitors. Although all our employees are required to sign a confidentiality agreement with us at the time of hire, we cannot be certain that the confidential nature of our proprietary information will be maintained in the course of such future employment. We cannot be certain that any of our restructuring efforts will be successful, or that we will be able to realize the cost savings and other anticipated benefits from our current or any future restructuring plans. In addition, if we continue to reduce our workforce, it may adversely impact our ability to respond rapidly to any new growth or revenue opportunities. Any restructuring activities we undertake may take longer than expected and may require changes to our business that we are unable to implement. If we are unsuccessful in implementing our cost saving initiatives and restructuring plans or if we do not achieve our expected results, our results of operations and cash flows could be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, numerous purported shareholder class action and shareholder derivative complaints were filed against us beginning in 2020, naming us and our directors and executive officers as defendants, alleging that we made materially false and misleading statements in violation of federal securities laws. Although we have resolved these actions, there can be no guarantee that we will not become subject to similar claims in the future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also become party to litigation with third parties as a result of our business activities. In 2020, we filed a lawsuit against one of our contract manufacturers, who then filed a counterclaim against us alleging that we had breached our contract with them, among other claims. There can be no assurance that we will ultimately prevail in the ongoing litigation matters described in this report or in future litigation matters. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our DNA medicine candidates. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and DNA medicine candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, in 2020 a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines were negatively impacted. Similar events could result in future business and manufacturing disruption, or in reduced operations, any of which would materially affect our business, financial condition and results of operations. The COVID-19 pandemic also caused supply chain disruptions and supply shortages globally. As a result, we experienced delays and disruptions in obtaining clinical supplies, manufacturing supplies and components, and had to secure new vendors for certain supplies and components at higher prices. There can be no assurance that we will not encounter similar difficulties in the future.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future health epidemics could adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain participants and principal investigators and site staff who, as healthcare providers, may have heightened exposure if an outbreak occurs in their geography. Trial participants may not be able to or may not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for our clinical trials. Further, future epidemics could also result in delays in our clinical trials due to prioritization of hospital resources toward the disease, restrictions in travel, potential unwillingness of participants to enroll in trials, participants withdrawing from trials following enrollment as a result of contracting disease or other health conditions. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense and increasing competition and steps taken by our competitors such as the introduction of a new, disruptive technology may impede our ability to develop and commercialize our DNA medicines. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates and introduce new, disruptive technology, we may not be able to complete the development of or commercialize our product candidates, and sales of any commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or product candidates obsolete or non-competitive, or result in treatments or cures superior to ours.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors and potential competitors include large pharmaceutical companies broadly engaged in vaccine/immunotherapy research and development, such as Janssen Pharmaceuticals (part of J&amp;J), Sanofi-Aventis, GlaxoSmithKline, Merck, Pfizer, Roche, AbbVie, Novartis, Bristol-Myers Squibb, and AstraZeneca, as well as various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies, such as CureVac, Dynavax, Genexine, Hookipa, Iovance, Nektar, Nykode, Precigen, Zydus, and Vir Biotechnology. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are seeking to treat early HPV infections or low-grade cervical dysplasia. Loop Electrosurgical Excision Procedure, commonly known as LEEP, is a surgical procedure and is the current standard of care for treating high-grade cervical dysplasia. In RRP caused by HPV subtypes 6 and 11, Precigen is developing a potential treatment for RRP based on a gorilla adenovirus vector and has publicly stated its plans to submit a BLA in 2024 based on a completed Phase 1/2 study. As a result, Precigen could receive marketing approval for its RRP product candidate before we can obtain regulatory approval for INO-3107, which could put us at a competitive disadvantage in this indication. Advaxis, Genexine, and Gilead Sciences have therapeutic cervical cancer product candidates under development. Many companies are pursuing different approaches to pre-cancers and cancers we are targeting.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other delivery technologies such as viral vectors or lipid vectors to induce in vivo generated antigen production and immune responses to prevent or treat various diseases. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Small biotechnology companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected acquisition and integration costs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or those of third parties upon which we rely or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to, regulatory </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">investigations and actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue and profits; and other adverse consequences.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential, proprietary or otherwise sensitive information (including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls designed to maintain the confidentiality, availability and integrity of such information as appropriate. A significant breakdown, invasion, corruption, destruction, interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our information and network security. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the compromise of information stored in our or our third-party providers' systems, portable media or storage devices. Cyber-attacks, malicious internet-based activity, online and offline fraud and other similar activities threaten our information and information technology systems and those of third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect and come from a variety of sources such as traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hactivists,&#8221; organized criminal threat actors, personnel (such as through error or malfeasance), sophisticated national states and nation-state support actors (for example, in conjunction with military conflicts). During times of war and other major conflicts, we may be vulnerable to a heightened risk of these attacks. We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to: business interruption, loss of information, theft of information or reputational damage from industrial espionage attacks, malware or other cyber-attacks (including ransomware), social-engineering attacks (including through deep fakes and phishing attacks), malicious code (such as viruses and worms), denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, telecommunications failures, natural disasters, and other similar threats, any of which may compromise our system infrastructure or lead to data compromise. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of data, reputational harm and diversion of funds. Extortion payments may alleviate some of the negative impact of a ransomware attack but we may be unwilling or unable to make such payments. Remote work has also become more common and increased risks to our information technology systems and data. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities as our systems could be negatively affected by vulnerabilities resent in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during diligence of such acquired or integrated entities and it may be difficult to integrate such entities into our programs. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on service providers and third-party technologies to operate critical business systems to process sensitive information in a variety of contexts, including without limitation, cloud-based infrastructure, personnel email, data hosting, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited and these service providers may not have adequate information security measures in place. If our service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our service providers fail to satisfy their privacy or security-related obligations to us, any aware may be insufficient or we may be unable to recover such award.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented measures designed to protect our data and information technology systems, there can be no assurance that our efforts will be effective (including, without limitation prevent service interruptions or security incidents). We take steps designed to detect, mitigate and remediate vulnerabilities in our information systems (such as our hardware and software, including that of third parties upon which we rely). We may not, however, detect and remediate all such vulnerabilities on a timely or effective basis. Vulnerabilities could be exploited and result in a security incident. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific or reasonable security measures.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, regulators, and other stakeholders of security incidents.  Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our proprietary device and DNA medicine candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our DNA medicine candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management's attention from our primary business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably. In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. The ACA, among other things, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, under which they must agree to offer point-of-sale discounts (increased to 70 percent, effective as of January 1, 2019) off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected expanded the types of entities eligible for the 340B drug discount program; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive, judicial, and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage was </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eliminated, along with the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011 included reductions to Medicare payments to providers of 2% per fiscal year, which, due to subsequent legislative amendments to the statute will remain in effect until 2032, unless Congressional action is taken. The American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has also been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, at the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price we believe is fair for our products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely approval of our products. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and related regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDCA, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our DNA medicine candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into collaborations with Chinese companies and rely on clinical materials manufactured in China for our development efforts. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a license and collaboration agreement with a China-based company, ApolloBio, pursuant to which ApolloBio has the exclusive right to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Because Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, China's "zero COVID" policy caused delays in Advaccine&#8217;s conduct of clinical trials for INO-4800 in China under our collaboration with them, which in turn resulted in delays in obtaining clinical data to evaluate the safety and potential efficacy of INO-4800. In addition, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on ApolloBio or Advaccine, which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, including the threat of a trade war between the United States and China, could lead to supply chain disruptions or increased costs for clinical materials manufactured in China that are necessary for our development efforts. These interruptions or failures could then impede commercialization of our DNA medicine candidates and impair our competitive position. We may also be exposed to fluctuations in the value of the local currency in China. These uncertainties may impede our ability to enforce the contracts we have entered into and our ability to continue our research and development activities and could materially and adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, and consultants. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions; provide accurate information to the FDA, the EMA, and other regulatory authorities; comply with healthcare fraud and abuse laws and regulations in the United States and abroad; or report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee litigation and unfavorable publicity could negatively affect our future business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile work place, discrimination, wage and hour disputes, sexual harassment, or other employment issues. In recent years there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our proprietary device and DNA medicine candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications may not result in issued patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governments in the United States or abroad may prevent us from enforcing patents on our vaccines, which could prevent us from excluding competitors from those markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or acquire additional proprietary technologies that are patentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trademarks may be invalid or subject to a third party's prior use; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our DNA medicine candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to an Investment in Our Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Capital Market, we cannot be certain that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price has been and may continue to be highly volatile and has been and may in the future be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indicative of future performance. The following factors, which are not exhaustive, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuating public or scientific interest in the potential for our vaccines or other DNA medicine candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new products or services that we or our competitors offer; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and other countries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceptions of gene-based therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions by executive officers or directors involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">global unrest including geopolitical risks emanating from countries such as Russia and China, terrorist activities, the conflict between Israel and Hamas, bank failures, and other economic and other external factors; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease pandemics. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general can experience relatively large price and volume fluctuations from time to time. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have broad discretion in the use of our cash, cash equivalents, and investments, and may not use them effectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our cash, cash equivalents, and investments, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. For example, our operating expenses increased significantly from 2020 to 2022 due to development and manufacturing activities for our COVID-19 vaccine program, for which we discontinued internal funding in the fourth quarter of 2022. We may not deploy our current capital resources effectively. The failure by our management to apply our funds effectively could result in financial losses that could have a material adverse impact on our business, cause the price of our common stock to decline, and delay the development of our product candidates. Pending their use, we may invest our cash, cash equivalents, and investments in a manner that does not produce income or that loses value.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of cumulative voting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the revised Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity by certain significant shareholders over a rolling three year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our share ownership, some of which would be outside our control. If our ability to use our net operating losses and other tax attributes is limited by ownership changes, we may be unable to utilize a material portion of our net operating losses and other tax attributes to offset our future taxable income. In addition, there is also a risk that due to changes in laws and regulations, such as alternative minimum taxes or suspensions on the use of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our proprietary device, DNA medicine candidates or future development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to corporate transactions, including ones not fully completed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or funding support; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit in which we may become involved; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any legal claims that may be asserted against us or any of our officers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our proprietary device and DNA medicine candidates or those of our competitors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the fair value of our investments, including investments in affiliated entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our DNA medicine candidates receive regulatory approval, the levels of underlying demand for our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, rising interest rates, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, and the availability and cost of credit have in the past and may continue to contribute to increased </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual events involving limited liquidity or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in 2023, several banking institutions were closed or seized by the Federal Deposit Insurance Corporation, leading to significant liquidity concerns in the broader financial services industry. </span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we did not have any deposits at any of the banks impacted by the adverse developments in 2023, we maintain deposits at financial institutions as a part of doing business that could be at risk if another similar event were to occur. Our ongoing cash management strategy is to maintain the majority of our deposit accounts in large financial institutions, but there can be no assurance this strategy will be successful. Increasing concerns regarding the U.S. or international financial systems, including bank failures and bailouts, and their potential broader effects and potential systemic risk on the banking sector generally, may adversely affect our access to capital. Any decline in available funding or access to our cash and liquidity resources could, among other risks, limit our ability to meet our capital needs and fund future growth or fulfill our other obligations, or result in breaches of our financial and/or contractual obligations. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. In 2017, tax legislation commonly known as the Tax Cuts and Jobs Act, or Tax Act, was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The Tax Act, among other things, resulted in significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). It is uncertain if and to what extent various states will conform to the federal tax law. The issuance of additional regulatory or accounting guidance related to the Tax Act, or legislative changes proposed or implemented, could materially affect our tax obligations and effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our research, development candidates, investigational medicines, and the diseases our development candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, participants may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.  Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, and financial information (collectively, sensitive data).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws).  In the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut, and Utah&#8212;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), applies to personal data of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consumers, business representatives, and employees who are California residents, and requires certain businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages.  Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. These developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security.  For example, the European Union&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;), the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal data. For example, under GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows.  Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries.  In particular, the European Economic Area (EEA) and the United Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate.  Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws.  Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.  If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.  Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups.  Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by industry groups.  We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.  We publish privacy policies, marketing materials, and other statements regarding data privacy and security.  If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty.  Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions.  Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations.  Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations.  If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data.  In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands.  Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations.  Any of these events could have a material adverse effect on our reputation, business, or financial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition, including but not limited to: inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.  </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_1584"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1C.&#160;&#160;&#160;&#160;CYBERSECURITY</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk management and strategy</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data (including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data) (collectively, &#8220;Information Systems and Data&#8221;).  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Information Technology department (&#8220;IT Department&#8221;) (including its Senior Director), with support from service providers, helps identify, assess and manage the Company&#8217;s cybersecurity threats and risks. The IT Department identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s risk profile using various methods. For example, the methods include manual and automated tools; subscriptions to reports and services that identify cybersecurity threats; analysis of threat and threat actor reports; threat environment scans; law enforcement coordination; audits; threat assessments; and vulnerability assessments.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: security incident response strategies; tools designed to detect and respond to security incidents; data encryption strategies; access controls; physical security controls; asset management strategies; systems monitoring; personnel training; penetration testing; and cybersecurity insurance.    </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes.  For example, the IT Department works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business and our management evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example: professional services firms (including legal counsel); cybersecurity consultants; cybersecurity software providers; managed cybersecurity service providers; and penetration testing firms.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use service providers to perform a variety of functions throughout our business, such as application providers; hosting providers; and contract research organizations. Depending on the nature of the services provided, in order to analyze the cybersecurity processes of certain vendors we review their internal security assessment reports and certifications, if available.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including in particular under the caption &#8220;if our information technology systems or those of third parties upon which we rely or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to, regulatory investigations and actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue and profits; and other adverse consequences.&#8221;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors addresses our cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of our management, including the Senior Director of the IT Department. This individual has previously held roles as a head of cybersecurity, cybersecurity consultant and information security specialist for other organizations. This individual holds several certifications related to cybersecurity including as a Certified Information Systems Security Professional.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IT Department reports to our Chief Financial Officer (CFO) who is responsible for helping the IT Department hire appropriate personnel, integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. The Senior Director of the IT Department is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CFO.   The Senior Director of IT and the CFO work with our incident response team to help mitigate and remediate cybersecurity incidents of which they </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are notified.  In addition, our incident response and vulnerability management processes include reporting to the audit committee of the board of directors for certain cybersecurity incidents. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As indicated above, the audit committee receives reports from the Senior Director of IT or other designee concerning significant cybersecurity threats and risk and the processes we have implemented to address them. The audit committee also receives various written reports, summaries or presentations related to cybersecurity threats, risk and mitigation. In turn, the audit committee routinely provides reports to the board on cybersecurity matters.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own no real property and have no plans to acquire any real property in the future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">San Diego Leases</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we entered into a lease agreement, or the New San Diego Lease, for research and development space in San Diego, California. The total space under the New San Diego Lease is approximately 5,563 square feet.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the New San Diego Lease commenced on February 10, 2024 and the initial term is 4.3 years.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the New San Diego Lease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent payments under the New San Diego Lease will include base rent with an annual increase of approximately three percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $33,000. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, we entered into a lease, or the First San Diego Lease, for office space in San Diego, California. The initial term of the First San Diego Lease was through November 2023. In June 2015, we amended the First San Diego Lease to increase the total leased space to 31,207 square feet and occupy the entire building. In November 2023, we extended the term of the First San Diego Lease until February 29, 2024.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into an office lease, or the Second San Diego Lease, for a second property in San Diego, California. The total space under the Second San Diego Lease is approximately 51,000 square feet. We are using the facility for office, manufacturing and research and development purposes. The term of the Second San Diego Lease commenced in June 2017 and continues through May 2027.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the Second San Diego Lease. As of December 31, 2023, rent payments under the Second San Diego Lease include base rent with an annual increase of approximately three percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $95,000. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth Meeting Lease </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, we entered into a lease, or the Plymouth Meeting Lease, for our corporate headquarters in Plymouth Meeting, Pennsylvania. We have amended the Plymouth Meeting Lease on multiple occasions to increase the total leased space to 57,361 square feet and extend the lease term through December 31, 2029.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the Plymouth Meeting Lease. As of December 31, 2023, rent payments under the Plymouth Meeting Lease include base rent with an annual increase of approximately two percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid security deposits totaling $124,000. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into four agreements to sublease a total of approximately 25,000 square feet in our Plymouth Meeting headquarters, with one sublease term through March 31, 2025, two terms through December 31, 2026, and one month-to-month. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current and future planned facilities will be adequate to meet our operating needs for the foreseeable future. Should we need additional space, we believe we will be able to secure additional space at commercially reasonable rates.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. The plaintiffs&#8217; complaint was later amended to include certain of the Company&#8217;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, we agreed to pay $30.0&#160;million in cash and $14.0&#160;million in shares of its common stock to settle all outstanding claims. Our insurance carriers paid the $30.0&#160;million cash component of the settlement. During the three months ended March 31, 2023, we issued 760,083 shares of common stock pursuant to the securities class action settlement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserted state and federal claims and was based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accused the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over our management, policies, practices, and internal controls. The plaintiff sought unspecified monetary damages on behalf of the Company as well as governance reforms. Between June 2020 and August 2020, additional shareholder derivative complaints were filed and later consolidated by the court. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, an additional shareholder derivative complaint was filed in the Delaware Court of Chancery, asserting substantially similar claims as those in the consolidated derivative action. In May 2022, the Delaware Court of Chancery entered a stay of the litigation. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the parties submitted a joint status report to the Court of Chancery reporting that the parties agreed to a settlement in principle, which also provided for the resolution of the consolidated derivative action and certain stockholder demands. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the plaintiffs in the consolidated derivative action filed a motion for preliminary approval of settlement with the United States District Court for the Eastern District of Pennsylvania. The proposed settlement provided for resolution of the consolidated derivative action, the derivative action pending in the Delaware Court of Chancery, and certain stockholder demands.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the court entered an order preliminarily approving the proposed settlement of the derivative claims, in accordance with a Stipulation of Settlement. The Stipulation of Settlement contemplated that, following the settlement hearing and the final approval of the settlement by the court, we would implement certain corporate governance reforms described in the Stipulation of Settlement. The preliminary order also approved the form and manner of the notice of the Settlement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Settlement, in July 2023 we paid $1.2 million to plaintiffs&#8217; counsel for their fees and expenses. In October 2023, the court entered an order and final judgment approving the Settlement, which became effective in November 2023. The Company has implemented the corporate governance reforms in response to the provisions of the Stipulation of Settlement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our appeal, in July 2020 VGXI filed counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI. We filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. In October 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against us, alleging that we had breached the CELLECTRA Device License Agreement, or the Agreement, between us and GeneOne. We terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disgorgement of profits, attorneys&#8217; fees, interest, and other relief from us. We filed preliminary objections to the complaint, which were overruled. In September 2021, we filed an answer to the complaint, new matter, and counterclaims. Our counterclaims allege that GeneOne breached the Agreement, and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. On October 18, 2021, GeneOne filed its answer to our counterclaims and new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our counterclaims against GeneOne and to vigorously defend ourselves against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock, par value $0.001 per share, began trading on the Nasdaq Global Select Market on September 15, 2014 under the symbol "INO," having previously traded on the NYSE MKT exchange. On November 2, 2023, the listing of our common stock was transferred to the Nasdaq Capital Market.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2024, we implemented a 1-for-12 reverse stock split of our common stock. As of March 1, 2024, we had approximately 58 common stockholders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing price per share of our common stock on March 1, 2024 was $9.55, as reported on the Nasdaq Capital Market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payment of any dividends on our common stock is within the discretion of our board of directors. We have never paid cash dividends on our common stock and the board of directors does not expect to declare cash dividends on the common stock in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below compares the performance of our common stock with the performance of the NYSE American Index, the S&amp;P SuperCap Biotechnology index and the Nasdaq Composite Index for the five years ended December 31, 2023. The graph assumes a $100 investment on December 31, 2018 in our common stock and in each index, with the reinvestment of all dividends, if any.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><img src="ino-20231231_g5.jpg" alt="1530" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:558px"/></div><div style="padding-left:108pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*$100 invested on 12/31/18 in stock or index, including reinvestment of dividends.<br/>Fiscal year ended December 31.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/23</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc.&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NYSE American</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nasdaq Composite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P SuperCap Biotechnology Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The stock price performance included in this graph is not necessarily indicative of future stock price performance. The performance graph is furnished solely to accompany this Form 10-K annual report and shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Parties </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;RESERVED</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Annual Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes and other financial information appearing elsewhere in this Annual Report. Readers are also urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;I of this Annual Report under the caption &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that pre-clinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our proprietary device technology and DNA medicine candidates may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture our DNA medicine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; and the impact of government healthcare laws and proposals.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_43"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Our platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use proprietary technology to design DNA plasmids which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. Our proprietary investigational CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delivery devices help our DNA medicines enter the body&#8217;s cells for optimal effect.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis, or RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. In our completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP,  81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we announced data from the second cohort of our Phase 1/2 clinical trial, which followed the announcement of the first cohort in October 2022. In the second cohort of 11 patients who were administered INO-3107 via an exploratory side port injection needle, 10 of the 11 patients (91%) saw a reduction in surgical interventions in the year following initial treatment, with the measurement beginning on Day 0, the start of trial therapy. Of these 10 patients, four did not require surgery. There was a statistically significant median decrease of three surgical interventions when comparing the year following treatment to the year prior to treatment. INO-3107 was well-tolerated and immunogenic among patients in the second cohort. The safety and efficacy results for the second cohort were consistent with results announced for the first cohort in October 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we received feedback from the U.S. Food and Drug Administration, or FDA, that the data from this completed trial could be used to support the submission of a Biologic License Application, or BLA, for review under the FDA&#8217;s accelerated approval program. As part of submitting our BLA under the accelerated program, we will need to satisfy all FDA filing requirements and initiate a confirmatory clinical trial prior to BLA submission.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our development efforts with INO-3107, we are actively developing or planning to develop DNA medicines for other indications, including HPV-related anal dysplasia and oropharyngeal squamous cell carcinoma, or OPSCC; glioblastoma multiforme, or GBM, a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. We were previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions, or HSIL, but announced in August 2023 that we were ceasing development for this indication in the United States. However, our collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our DNA medicine candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any material revenues unless and until we obtain marketing approval for and successfully commercialize INO-3107 and our other product candidates. We earn revenue from license fees and milestone revenue and collaborative research and development agreements and contracts. Our DNA medicine candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All DNA medicine candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had an accumulated deficit of $1.6 billion. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC defines critical accounting policies as those that are, in management&#8217;s view, important to the portrayal of our financial condition and results of operations and require management&#8217;s judgment. Our discussion and analysis of our financial condition and results of operations are based on our audited consolidated financial statements, which have been prepared in accordance with U.S.&#160;GAAP. Our significant accounting policies are outlined in Note 2 to the consolidated financial statements included in this report.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. We base our estimates on experience and on various assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. We believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our consolidated financial statements:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and we conclude that our collaboration partner is not a customer, we present such payments as a reduction of research and development expense. If payments from our collaboration partner to us represent consideration from a customer, then we account for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our activities have largely consisted of research and development efforts related to developing proprietary device technologies, DNA medicine candidates and dMABs. For clinical trial expenses, judgments used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to our results of operations. </span></div><div><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding recent accounting pronouncements is contained in Note&#160;2 to the consolidated financial statements, included elsewhere in this report.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial data for the years ended December&#160;31, 2023, 2022 and 2021 is presented in the following table and the results of these periods are used in the discussion thereafter.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:21.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.112%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,  </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)          2023 vs. 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)          2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from collaborative arrangements and other contracts, including affiliated entity<br/></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,262,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,430,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,487,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,676,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,650,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249,240,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100,973,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,589,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,582,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,185,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,752,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,603,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,432,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,772,038&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277,835,788&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302,992,677&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133,063,750)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,156,889)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143,940,028)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(267,573,520)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(301,217,919)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,633,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,644,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,133,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,782,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,351,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,418,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,222,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,253,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,936,447)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,899,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(553,570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,672,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,346,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,850,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,846,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,222,838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,696,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,623,334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,711,596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,861,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(850,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,204,955)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss before share in net loss of Geneos</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(135,117,352)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(277,652,852)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303,224,323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,535,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,571,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,165,213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(434,387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,165,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,730,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(135,117,352)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(279,818,065)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303,658,710)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,700,713&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,840,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Not meaningful</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2023 and 2022 </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue was primarily derived under collaborative arrangements and other contracts, including arrangements with affiliated entities, for the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The $9.4 million decrease in revenue was primarily due to no revenue from our Procurement Contract with the DoD as all performance obligations were satisfied during 2022.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, fees paid to contract research organizations and other consultants, and outside expenses. We utilize a labor reporting system to record employee </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation on a project-by-project basis. Unallocated research and development expenses include engineering and device-related expenses that are not allocable to a specific project, as well as stock-based compensation, other employee-related expenses that are not related to a specific project, and facilities and depreciation expenses.    </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following tables summarize our research and development expense by product candidate for the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-4800 and other Covid-19</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,595)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VGX-3100</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-3107</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-5401 and other Immuno-oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Engineering and device-related </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated expenses (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,974)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.</span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Includes impairment of intangible assets of $2.0 million recorded in the second quarter of 2023.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $101.0 million overall decrease in research and development expenses year over year was primarily the result of:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$61.4 million in lower drug manufacturing, clinical study expenses, outside services and expensed inventory related to INO-4800 after we discontinued this program in the fourth quarter of 2022;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$17.9 million in lower drug manufacturing and clinical study expenses related to other COVID-19 studies that ceased after we discontinued development of INO-4800;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$15.0 million in lower employee and consultant compensation, including stock-based compensation, primarily due to reductions in headcount in 2023;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">$9.4 million in lower expensed inventory and outside services related to our CELLECTRA 3PSP device and array automation project;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$8.4 million in lower immunology, clinical study expenses and outside services related to VGX-3100 as we discontinued development of this product candidate in the third quarter of 2023; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$4.4 million in lower drug manufacturing related to the sub-grant through Wistar for COVID-19 dMAbs</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$17.7 million of lower contra-research and development expense recorded from grant agreements; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$5.8 million of higher other drug manufacturing costs.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $6.8 million and $24.5 million for the years ended December&#160;31, 2023 and 2022, respectively. The decrease year over year was primarily due to decreases of $7.7 million earned under the sub-grant through Wistar primarily for DARPA COVID-19 dMAb, $6.1 million from the DoD 3PSP device development grant and $5.0 million earned under the CEPI Lassa and MERS grants. These decreases were offset by an increase of $2.4 million in reimbursements from Advaccine.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses, which include business development expenses, the amortization of intangible assets and patent expenses, were $47.6 million for the year ended December&#160;31, 2023 as compared to $90.2 million in 2022.  The $42.6 overall decrease year over year was primarily the result of:</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$14.0 million in net expense related to the class action securities litigation settlement, which was accrued in 2022 but paid in 2023;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$11.3 million in lower legal expenses, primarily the result of the conclusion of litigation in 2023;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$6.9 million in one-time severance expenses related to the separation of our former President and Chief Executive Officer in 2022, including $4.2 million of stock-based compensation expense related to equity award modifications, that did not recur in 2023; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$5.9 million in lower employee compensation, including employee and consultant stock-based compensation, as a result of headcount reductions in 2023; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.9 million in lower insurance expenses; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.4 million in lower other outside services related to our discontinued INO-4800 and VGX-3100 programs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Impairment of goodwill  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2023, we concluded that our goodwill was impaired due to a sustained decline in our stock price and related market capitalization, and a general decline in equity values in the biotechnology industry. Based on this analysis, we recognized a non-cash, pre-tax goodwill impairment charge of $10.5 million during the three months ended September 30, 2023. For more information, see Note 8 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">and Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to the consolidated financial statements included in this report.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Stock-based compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee&#8217;s requisite service period. Total employee stock-based compensation cost for the years ended December&#160;31, 2023 and 2022 was $10.4 million and $22.2 million, of which $4.5 million and $8.8 million was included in research and development expenses and $5.9 million and $13.4 million was included in general and administrative expenses, respectively. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $3.4 million increase in interest income for the year ended December&#160;31, 2023 as compared to 2022 was primarily due to higher interest rates earned on our cash balance.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was a $31,000 decrease in interest expense for the year ended December&#160;31, 2023 as compared to 2022. We expect interest expense to decrease materially in 2024 due to the maturity and repayment in full of our convertible senior notes on March 1, 2024. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain (Loss) on Investment in Affiliated Entity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain (loss) on investment in affiliated entity resulted from the change in the fair market value of our investment in PLS of $773,000 and $(1.9) million for the years ended December&#160;31, 2023 and 2022, respectively. We record our investment in PLS at its market value based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the consolidated statements of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Unrealized Gain (Loss) on Available-for-Sale Equity Securities </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gain (loss) on available-for-sale equity securities for the years ended December&#160;31, 2023 and 2022 was $5.9 million and $(7.8) million, respectively, which resulted from a change in the fair market value of the investments.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Expense) Income , net. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net, for the years ended December&#160;31, 2023 and 2022 was $(4.7) million and $(3.9) million, respectively, related primarily to the realized loss on short-term investments sold during the periods.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share in Net Loss of Geneos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share in net loss of Geneos represents our share of Geneos' losses during 2022. As described in Note 15 to the consolidated financial statements in this report, we reduced the carrying value of our investment in Geneos to zero in March 2022 and will not record our share of further net losses of Geneos as we have no obligation to fund its operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred operating losses and accordingly have not recorded a provision for U.S. income taxes for any of the periods presented. Utilization of net operating losses and tax credits are subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code of 1986, as amended, or IRC. As of December&#160;31, 2023, we had net operating loss carry forwards for U.S. federal, California and Pennsylvania income tax purposes of $1,013.3 million, $251.4 million and $102.6 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limitations. We also had U.S. federal and state research and development tax credits of $41.6 million and $6.1 million, respectively, net of the federal research and development credits that will expire due to IRC Section&#160;383 limitations. The net operating losses and credits began to expire during 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2022 and 2021</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a comparison of the years ended December 31, 2022 and 2021, you may refer to Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 1, 2023.</span></div><div><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash are to finance research and development activities, including clinical trial activities for the advancement of our DNA medicine candidates. We have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had cash and short-term investments of $145.3 million and working capital of $110.5 million, as compared to $253.0 million and $218.4 million as of December&#160;31, 2022, respectively. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $124.4 million and $216.2 million for the years ended December&#160;31, 2023 and 2022, respectively. The variance was primarily due to the timing and changes in working capital balances, offset by decreased operating expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $87.4 million and $109.6 million for the years ended December&#160;31, 2023 and 2022, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financing Activities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $5.0 million and $81.8 million for the years ended December&#160;31, 2023 and 2022, respectively. The variance was primarily due to net proceeds of $5.5 million from the sale of common stock under the Sales Agreement (defined below) in 2023 compared to net proceeds of $83.0 million received during 2022.  </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, we entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement, or the Sales Agreement, with outside sale</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s agents, or collectively, the Sales Agents, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock with aggregate gross proceeds of up to $300.0 million, through the Sales Agents.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the common stock by any method permitted by law deemed to be an &#8220;at the market" offering. The Sales Agents will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from us, including any price, time or size limits or other customary parameters or conditions we may impose. We will pay the Sales Agents a commission of up to three percent (3.0%) of the gross sales proceeds of any common stock sold through the Sales Agents under the Sales Agreement, and we have provided the Sales Agents with certain indemnification rights. During</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> the year</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> ended December 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, we sold 875,305 shares of our common stock under the Sales Agreement at a weighted average price of $6.33 per share, resulting in aggregate net proceeds of $5.5&#160;million. During the year ended December 31, 2022, we sold 2,870,478 shares of common stock under the Sales Agreement for aggregate net proceeds of $83.0 million. From January 1, 2024 through the date of this report, we sold an additional 543,620 shares of common stock under the Sales Agreement for net proceeds of $5.2 million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, no stock options were exercised and tax payments of $467,000 were made related to the net sh</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are settlement of RSU awards. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, stock options to purchase 9,891 shares of common stock were exercised for aggregate net proceeds of $283,000, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $1.4 million. During the year ended December 31, 2021, stock options to purchase 109,188 shares of common stock were exercised for aggregate net proceeds of $6.7 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $4.6 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we issued 760,083 shares of common stock pursuant to a securities class action settlement, as described in Note 11 to our consolidated financial statements included in this report.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Requirements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had an accumulated deficit of $1.6 billion and we expect to continue to operate at a loss in the near term. The amount of our accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. Our current cash resources, including amounts that we may be able to obtain through sales of common stock under the S</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ales Agreement, will not be sufficient to complete the clinical development of any of our product candidates, and we anticipate that additional financing will be required in order to complete the development of and to commercialize and generate revenues from the sale of any product candidates that receive regulatory approval. If these activities are successful and if we receive approval from the FDA to market our DNA medicine candidates, then we will need to raise additional funding to market and sell the approved products and equipment. In addition to the potential issuance of equity or debt securities in order to raise capital, we are also evaluating potential collaborations as an additional way to fund our operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months from the date of this report. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we undertook actions to decrease our expenses, including multiple headcount reductions. Taking into account these actions, as well as the changes to our clinical development plan for INO-3107 as a result of FDA feedback, we expect our cash runway to extend into the second quarter of 2025, without giving effect to any further capital raising activities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, future minimum payments due under our contractual obligations are set forth in the table below. We expect to be able to satisfy these obligations, both in the short-term and in the longer-term, with cash on hand.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than<br/>1&#160;year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1&#160;&#8211;&#160;3&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations (2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,665,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,247,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,021,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,265,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing commitments (3)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,489,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,489,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  On March 1, 2024 these Convertible Senior Notes matured and we satisfied the obligation in full from existing cash. See Note 9, Convertible Debt, to the consolidated financial statements in this report for additional information.</span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) We have entered into operating leases for our facilities, which expire from 2024 to 2029, and operating leases for office equipment, which expire in 2024. We have four active subleases for portions of our Plymouth Meeting corporate headquarters facility with periods through March 31, 2025, two through December 31, 2026 and the other month-to-month. As of December&#160;31, 2023, we expect to receive aggregate future minimum lease payments totaling $1.3 million (non-discounted) over the duration of the sublease agreements, which expected payments are not included in the table above.&#160;</span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Purchase obligations from supply agreements with contract manufacturers.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are a party to a variety of agreements pursuant to which we may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by us under these types of agreements have not had a material effect on our business, consolidated results of operations or financial condition.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_58"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in short-term investment-grade securities. During much of 2022 and into the year ended December 31, 2023, there was a pronounced overall increase in prevailing interest rates in the United States compared to the first half of 2022, which contributed to the unrealized loss of $3.9 million in the market value of our investment portfolio as of December 31, 2023.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on our indebtedness at December 31, 2023 was fixed and not subject to fluctuations in interest rates. As of March 1, 2024, we have no indebtedness.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate primarily in the United States and most transactions during the year ended December&#160;31, 2023 were made in United States dollars. Accordingly, we do not have any material exposure to foreign currency rate fluctuations, with the exception of certain cash and cash equivalents held in South Korea that are denominated in South Korean Won and the valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor. Although inflation has increased generally in the United States in recent years, we do not believe that inflation has had a material effect on our business, financial condition or results of operations during the year ended December&#160;31, 2023. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;8 is incorporated by reference to our Consolidated Financial Statements and the Report of Independent Registered Public Accounting Firm beginning at page&#160;F-1 of this report.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation carried out as of the end of the period covered by this Annual Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of December&#160;31, 2023 at the reasonable assurance level.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting and Attestation Report of Registered Public Accounting Firm</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed under the supervision of our Chief Executive Officer and Chief Financial Officer to provide </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with United States generally accepted accounting principles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, management, with the participation of the Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in &#8220;Internal Control&#8212;Integrated Framework,&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the assessment, management determined that we maintained effective internal control over financial reporting as of December&#160;31, 2023.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our registered public accounting firm regarding the effectiveness of internal control over financial reporting as required by Section 404(b) of the Sarbanes-Oxley Act of 2002. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permit smaller reporting companies to provide only management&#8217;s report in this Annual Report.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting that occurred during the fourth quarter of our fiscal year ended December&#160;31, 2023, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. &#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Trading Plans</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fiscal quarter ended December 31, 2023, none of our officers or directors, as defined in Rule 16a-1(f), <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-37"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-38">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-39"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-40">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as those terms are defined in Item 408 of Regulation S-K.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Severance Plan and Participation Agreements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2024, our board of directors approved and adopted the Company&#8217;s Severance Plan and Summary Plan Description (the &#8220;Plan&#8221;), which provides severance benefits to certain eligible of our executives (the &#8220;Covered Executives&#8221;) who become participants in the Plan in the event of termination of a Covered Executive&#8217;s employment with us other than for Cause (as defined in the Plan), or as a result of such Covered Executive&#8217;s resignation for Good Reason (as defined in the Plan) (any such termination, a &#8220;Covered Termination&#8221;).</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer, Jacqueline Shea; our Chief Scientific Officer, Laurent Humeau; and our Chief Medical Officer, Michael Sumner, are participants in the Plan and have entered into Participation Agreements. The terms of the Plan described below will generally supersede any severance and change in control benefits set forth in any pre-existing employment agreement that those officers have with us. Our Chief Financial Officer, Peter Kies, is not a participant in the Plan, and the terms of his existing employment agreement will continue to apply.    </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Plan, in the event of a Covered Termination, a Covered Executive will be eligible to receive as severance: (a) base salary continuation for the applicable number of months set forth in the Covered Executive&#8217;s Participation Agreement (18 months for Dr. Shea and 12 months for Drs. Humeau and Sumner), paid in equal installments on our regular payroll schedule (the &#8220;Severance Period&#8221;); and (b) Company-paid COBRA premiums for the Covered Executive&#8217;s continued coverage under our benefit plans, subject to timely COBRA election, for the number of months set forth in the Covered Executive&#8217;s Participation Agreement (or until the Covered Executive secures employment with similar benefits). </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event such Covered Termination occurs within one (1) year after a Change in Control (as defined in our 2023 Omnibus Incentive Plan), the Covered Executive will be eligible for the following Change in Control severance benefits: (a) base salary continuation for the applicable number of months set forth in the Covered Executive&#8217;s Participation Agreement (24 months for Dr. Shea and 18 months for Drs. Humeau and Sumner), paid in equal installments on the Company&#8217;s regular payroll schedule; (b) an amount equal to the target annual bonus for the year of such Covered Termination multiplied by the applicable bonus multiple set forth in the Covered Executive&#8217;s Participation Agreement (two times for Dr. Shea and 1.5 times for Drs. Humeau and Sumner);  (c) each of the Covered Executive&#8217;s then-outstanding equity awards, other than performance awards, subject to time-based vesting shall accelerate and become vested and exercisable as to the percentage of the unvested shares subject to the equity award set forth in the Covered Executive&#8217;s Participation Agreement (100% for each of Drs. Shea, Humeau and Sumner); and (d) Company-paid COBRA premiums for the Covered Executive&#8217;s continued coverage under the Company benefit plans, subject to timely COBRA election, for the number of months set forth in the Covered Executive&#8217;s Participation Agreement (24 months for Dr. Shea and 18 months for Drs. Humeau and Sumner) (or until the Covered Executive secures employment with similar benefits).</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of the termination of a Covered Executive&#8217;s employment due to Disability (as defined in the Plan), such Covered Executive will be eligible to receive: (a) base salary continuation for the applicable number of months set forth in the Covered Executive&#8217;s Participation Agreement (18 months for Dr. Shea and 12 months for Drs. Humeau and Sumner), paid in equal installments on the Company&#8217;s regular payroll schedule; (b) Company-paid COBRA premiums for the Covered Executive&#8217;s continued coverage under the Company benefit plans, subject to timely COBRA election, for the number of months set forth in the Covered Executive&#8217;s Participation Agreement (18 months for Dr. Shea and 12 months for Drs. Humeau and Sumner) (or until Covered Executive secures employment with similar benefits); and (c) such Covered Executive&#8217;s then-outstanding equity awards, other than performance awards, subject to time-based vesting shall continue to vest on the original vesting dates and any performance awards held by the Covered Executive shall remain outstanding and eligible to vest based on actual performance through the end of the applicable performance period. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of termination of Covered Executive&#8217;s employment due to death, such Covered Executive&#8217;s then-outstanding equity awards, other than performance awards, subject to time-based vesting shall accelerate and become vested and exercisable as to the percentage of the unvested shares subject to the equity award set forth in the Covered Executive&#8217;s Participation Agreement and any performance awards held by the Covered Executive shall remain outstanding and eligible to vest based on the Company&#8217;s actual performance through the end of the applicable performance period.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition to any Covered Executive receiving any severance benefits under the Plan, such Covered Executive must sign, and allow to become effective, a separation agreement containing among other provisions, a release of all claims in favor of us and our subsidiaries and affiliates (the &#8220;Release&#8221;) and the Covered Executive&#8217;s continued compliance with any proprietary information and inventions agreement, and any restrictive covenant agreement between the Covered Executive and us. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits provided under the Plan will generally supersede any other change in control, severance benefit plan, or agreement between us and a Covered Executive. Any prior acceleration rights set forth in existing awards between the Covered Executive and us will not be impacted by participating in the Plan. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Plan is qualified in its entirety by reference to the full text of the Plan, a copy of which is filed as an exhibit to this Annual Report, and the individual Participation Agreements. The Participation Agreements for Drs. Shea, Humeau and Sumner are also filed as exhibits to this Annual Report. </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_76"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.            DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">          </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_79"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;10 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2023 fiscal year, under the captions &#8220;Election of Directors&#8221; and &#8220;Executive Officers and Other Information.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;11 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2023 fiscal year, under the captions &#8220;Executive Compensation&#8221; and &#8220;Director Compensation".</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;12 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2023 fiscal year, under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director independence and other information required by this Item&#160;13 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2023 fiscal year, under the captions &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Election of Directors.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;14 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2023 fiscal year, under the caption &#8220;Ratification of Appointment of Independent Registered Public Accounting Firm.&#8221;</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_100"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statements</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated financial statements required to be filed hereunder begin on Page&#160;F-1 in this report.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules not listed herein have been omitted because the information required to be set forth therein is not applicable or is included in the Financial Statements or notes thereto.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Exhibits</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this annual report on Form&#160;10-K:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.370%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">Certificate of Incorporation with all amendments prior to December 31, 2023 (incorporated by reference to Exhibit&#160;3.1 of the registrant&#8217;s Form S-3 registration statement, filed on July 23, 2014).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312524015380/d736726dex31.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312524015380/d736726dex31.htm">Certificate of Amendment to Certificate of Incorporation, effective as of January 24, 2024 (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s current report on Form 8-K filed on January 25, 2024).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">3.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August&#160;10, 2011 (incorporated by reference to Exhibit&#160;3.2 to the registrant&#8217;s Form&#160;8-K current report filed on August&#160;12, 2011).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">Indenture, dated as of February 19, 2019, by and between the registrant and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on February 20, 2019).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">Form of Note representing the registrant&#8217;s 6.50% Convertible Senior Notes due 2024 (included as Exhibit A to the Indenture filed as Exhibit 4.1).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.9 to the registrant&#8217;s annual report on Form 10-K filed with the SEC on March 12, 2020)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_31.htm">10.1&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_31.htm">R&amp;D Alliance Agreement dated December&#160;19, 2005 by and between Ganial Immunotherapeutics,&#160;Inc. and VGX Pharmaceuticals,&#160;Inc., as amended by Novation and Amendment Agreement by and between VGX Pharmaceuticals, Inc., Ganial Immunotherapeutics, Inc., and Onconox (incorporated by reference to Exhibit&#160;10.31 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_39.htm">10.2&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_39.htm">R&amp;D Collaboration and License Agreement dated December&#160;18, 2006 by and between VGX International,&#160;Inc. and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment dated October&#160;31, 2007 and as amended by Second Amendment dated August&#160;4, 2008 (incorporated by reference to Exhibit&#160;10.39 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_50.htm">10.3&#8224;&#160;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_50.htm">Patent License Agreement dated April&#160;27, 2007 by and between The Trustees of the University of Pennsylvania and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment dated June&#160;12, 2008 (incorporated by reference to Exhibit&#160;10.50 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_34.htm">10.4&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_34.htm">License Agreement dated May&#160;9, 2007 by and between Baylor University and VGX Pharmaceuticals,&#160;Inc. (incorporated by reference to Exhibit&#160;10.34 as filed with the registrant&#8217;s registration statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000062/ino-93021x10xqex101.htm">10.5</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312518175305/d593417d8k.htm">ATM Equity Offering</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312518175305/d593417d8k.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312518175305/d593417d8k.htm"> Sales Agreement dated November 9, 2021 by and among Inovio Pharmaceuticals, Inc., </a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000062/ino-93021x10xqex101.htm">BofA Securities, Inc., RBC Capital Markets, LLC and Oppenheimer &amp; Co. Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrants Form 10-Q quarterly report for the quarter ended September 30, 2021 filed on November 9, 2021).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.370%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312510122273/dex102.htm">10.6&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312510122273/dex102.htm">License and Collaboration Agreement dated March&#160;24, 2010 between Inovio Pharmaceuticals, Inc. and VGX International, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant&#8217;s Form 10-Q quarterly report for the quarter ended March&#160;31, 2010 filed on May&#160;17, 2010).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511298587/d237108dex101.htm">10.7&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511298587/d237108dex101.htm">Collaborative Development and License Agreement dated October 7, 2011 between VGX International, Inc. and Inovio Pharmaceuticals, Inc., as amended by First Amendment dated August 21, 2013, and Second Amendment dated October 7, 2013 (incorporated by reference to Exhibit 10.1 as filed with the registrant&#8217;s Form 10-Q quarterly report for the quarter ended September&#160;30, 2011 filed on November&#160;7, 2011).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016x10qexhibit101.htm">10.8</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016x10qexhibit101.htm">Collaborative Research Agreement dated March 14, 2016 by and between The Wistar Institute of Anatomy and Biology, a Commonwealth of Pennsylvania nonprofit corporation, and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2016 filed on May 9, 2016).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016xexhibit102.htm">10.9</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016xexhibit102.htm">Collaborative Research Agreement dated March 14, 2016 by and between The Wistar Institute of Anatomy and Biology, a Commonwealth of Pennsylvania nonprofit corporation, and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2016 filed on May 9, 2016).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">10.10&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">Amended and Restated License and Collaboration Agreement, dated December 29, 2017, by and between Inovio Pharmaceuticals, Inc. and Beijing Apollo Saturn Biological Technology Limited (incorporated by reference to Exhibit 10.12 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2017 filed on March 14, 2018).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex1011.htm">10.11</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex1011.htm">First Amendment to the Amended and Restated License and Collaboration Agreement, dated June 14, 2023, by and between Inovio Pharmaceuticals, Inc. and Beijing Apollo Saturn Biological Technology Limited (filed herewith).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000003/ino-12312013x10kex1036.htm">10.12</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000067/ino-9302016x10qex101.htm">Office Lease Agreement dated October 10, 2016 by and between 6759 Mesa Ridge Road Holdings, LLC and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2016 filed on November 9, 2016).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex101.htm">10.13</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex102.htm">Sublease dated June 21, 2017 between Accolade, Inc. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2017 filed on August 8, 2017).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm">Employment Agreement dated as of December&#160;27, 2010 between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit 10.5 to the registrant&#8217;s Form 10-K report for the year ended December&#160;31, 2010 filed on March&#160;16, 2011).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm">First Amendment to Employment Agreement dated as of December&#160;31, 2012 between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit&#160;10.42 of the registrant&#8217;s Form 10-K annual report for the year ended December&#160;31, 2012 filed on March&#160;18, 2013).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm">Second Amendment to Employment Agreement dated November 7, 2014 by and between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit 10.2 of the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2014 filed on November 10, 2014).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-123123x10kex1017.htm">10.17+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-123123x10kex1017.htm">Inovio Pharmaceuticals, Inc. Severance Plan and Summary Plan Description (filed herewith).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-123123x10kex1018.htm">10.18+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ino-123123x10kex1018.htm">Participation Agreement under Severance Plan for Jacqueline Shea (filed herewith).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-123123x10kex1019.htm">10.19+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ino-123123x10kex1019.htm">Participation Agreement under Severance Plan for Laurent Humeau (filed herewith). </a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-123123x10kex1020.htm">10.20+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-123123x10kex1020.htm">Participation Agreement under Severance Plan for Michael Sumner (filed herewith).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465909050590/a09-18452_1ex10d1.htm">10.21+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465909050590/a09-18452_1ex10d1.htm">Form of Indemnification Agreement for Directors and Officers of Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit&#160;10.1 to the registrant&#8217;s Form&#160;10-Q quarterly report for the quarterly period ended June&#160;30, 2009, filed on August&#160;19, 2009).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.370%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm">Amended and Restated 2007 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.12 to the registrant's Form 10-K report for the year ended December 31, 2015 filed on March 14, 2016).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">Form of Incentive and Non-Qualified Stock Option Grants under the 2007 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit&#160;4.4 to the registrant&#8217;s Registration Statement on Form&#160;S-8 filed on May&#160;14, 2007).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">Inovio Pharmaceuticals, Inc. 2016 Omnibus Incentive Plan, as amended to date (incorporated by reference to Exhibit 10.1 to the registrant's Form 8-K filed on May 10, 2019).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">Form of Incentive Stock Option Agreement under 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.55 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">Form of Nonqualified Stock Option Agreement under 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.56 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">Form of Restricted Stock Unit Award Agreement under 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.54 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex991.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex991.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex991.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex991.htm">Inovio Pharmaceuticals, Inc. 2022 Inducement Plan (incorporated by reference to Exhibit 99.1 of the registrant&#8217;s Form S-8 registration statement, filed on June 30, 2022).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex992.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex992.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex992.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex992.htm">Form of Option Grant Package under 2022 Inducement Plan (incorporated by reference to Exhibit 99.2 of the registrant&#8217;s Form S-8 registration statement, filed on June 30, 2022).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex993.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex993.htm">30</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex993.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex993.htm">Form of RSU Grant Package under 2022 Inducement Plan (incorporated by reference to Exhibit 99.3 of the registrant&#8217;s Form S-8 registration statement, filed on June 30, 2022).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312523148122/d458280dex101.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312523148122/d458280dex101.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312523148122/d458280dex101.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312523148122/d458280dex101.htm">Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K filed on May 18, 2023).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572623000051/ino-63023x10qex102.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572623000051/ino-63023x10qex102.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572623000051/ino-63023x10qex102.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572623000051/ino-63023x10qex102.htm">Form of Option Grant Package under 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to the registrant&#8217;s quarterly report on Form 10-Q filed on August 9, 2023).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572623000051/ino-63023x10qex103.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572623000051/ino-63023x10qex103.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572623000051/ino-63023x10qex103.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572623000051/ino-63023x10qex103.htm">Form of RSU Grant Package under 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.3 to the registrant&#8217;s quarterly report on Form 10-Q filed on August 9, 2023).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex211.htm">21.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex211.htm">Subsidiaries of the registrant (filed herewith).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex231.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex231.htm">Consent of Independent Registered Public Accounting Firm (filed herewith).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_106">24.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_106">Power of Attorney (included on signature page).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex311.htm">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex312.htm">Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex321.htm">32.1&#x5E;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex312.htm">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex971.htm">97.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312023x10kex971.htm">Incentive Compensation Recoupment Policy, adopted on November 14, 2023 (filed herewith)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.370%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designates management contract, compensatory plan or arrangement.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted for certain portions omitted from this exhibit (indicated by asterisks) pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The confidential portions of this exhibit have been separately filed with the Securities and Exchange Commission.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain confidential portions of this exhibit (indicated by asterisks) were omitted because the identified confidential portions are not material and are of the type that the registrant treats as private or confidential. </span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:4.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#x5E;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March&#160;6, 2024.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JACQUELINE E. SHEA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jacqueline E. Shea<br/>President, Chief Executive Officer and Director                                                                                         (On Behalf of the Registrant)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jacqueline E. Shea and Peter Kies, and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the United States Securities and Exchange Commission in connection with the Annual Report on Form&#160;10-K and any and all amendments hereto, as fully for all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JACQUELINE E. SHEA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jacqueline E. Shea</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;SIMON X. BENITO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Simon X. Benito</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER KIES</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter Kies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/    ROGER D. DANSEY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Roger D. Dansey</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/    ANN C. MILLER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ann C. Miller</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JAY SHEPARD</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jay Shepard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DAVID B. WEINER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">David B. Weiner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;WENDY L. YARNO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wendy L. Yarno</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;LOTA S. ZOTH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lota S. Zoth</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_112"></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_115">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-41">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_115">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_118">Consolidated Balance Sheets </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_118">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_121">Consolidated Statements of Operations </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_121">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_124">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_124">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_127">Consolidated Statements of Stockholders' Equity </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_127">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_130">Consolidated Statements of Cash Flows </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_130">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_133">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icdf8b8d8a6a143b2a034e3544027d42d_133">9</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Shareholders and the Board of Directors of Inovio Pharmaceuticals, Inc. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the consolidated balance sheets of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2023 and 2022, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the three years in the period ended December&#160;31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accrual of Clinical Trial Expenses</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Description of the Matter</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2023, the Company incurred $86.7 million for research and development expenses and as of December 31, 2023 accrued $2.4 million for clinical study costs. A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including clinical research organizations (&#8220;CROs&#8221;). External costs to be paid to CROs are accrued and expensed based upon actual work completed in accordance with signed agreements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing management&#8217;s accounting for accrued clinical study costs is especially challenging because the evaluation is dependent upon a high-volume of data and input exchanged between clinical personnel and third-party service providers, such as the number of sites activated, the number of patients enrolled, and the number of patient visits, which is tracked in spreadsheets and other end user computing programs.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">How We Addressed the Matter in our Audit</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We obtained an understanding of the accounting for accrued clinical trial expenses including management&#8217;s process for measuring estimated accrued clinical study costs such as patient enrollment and total cost incurred to date from third-parties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To test the completeness of the Company&#8217;s accrued clinical trial expenses, we obtained from third-parties confirmation of patient enrollment and direct service cost to date for significant clinical trials. We attended internal clinical trial and project status meetings with accounting personnel and the clinical project manager to understand the status of significant clinical trial activities. To assess the appropriate measurement of accrued clinical trial expenses, we inspected key terms, timelines of completion, activities and costs for a sample of vendor contracts, including amendments, and compared these to management&#8217;s analyses used in tracking the progress of service agreements. We also tested a sample of subsequent payments by agreeing the invoice to the original accrual and the invoice payments to bank statements. </span></div><div><span><br/></span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.220%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-42">Ernst&#160;&amp; Young&#160;LLP</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2002.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-43">San Diego, California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-44">14,310,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-45">46,329,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-46">130,982,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-47">206,669,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="0" id="f-48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-49">1,701,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-50">2,405,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-51">10,036,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-52">5,393,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-53">50,130,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="f-54">20,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="f-55">375,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-56">153,113,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-57">315,242,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-58">4,960,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-59">7,727,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in affiliated entity </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-60">2,780,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-61">2,007,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="f-63">2,129,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="0" id="f-64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="f-65">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-66">9,491,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-67">10,228,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-68">605,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-69">684,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-70">170,951,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-71">348,533,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-72">19,847,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-73">79,686,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-74">1,070,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-75">1,220,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-76">2,365,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-77">10,594,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-78">2,406,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-79">2,803,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-80">87,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-81">2,475,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ino:DeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="f-82">21,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="ino:DeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="f-83">87,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ConvertibleDebtCurrent" format="ixt:num-dot-decimal" scale="0" id="f-84">16,770,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:ConvertibleDebtCurrent" format="ixt:fixed-zero" scale="0" id="f-85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-86">42,570,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-87">96,868,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:fixed-zero" scale="0" id="f-88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-89">16,614,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-90">11,032,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-91">12,655,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:fixed-zero" scale="0" id="f-92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="f-93">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-94">53,602,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-95">126,170,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-96"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-97"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock&#8212;par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-98"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-99">0.001</ix:nonFraction></ix:nonFraction>; Authorized shares: <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-101">10,000,000</ix:nonFraction></ix:nonFraction>, issued and outstanding shares: <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-103"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-104"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-105">9</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> at December&#160;31, 2023 and 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock&#8212;par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-108"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-109">0.001</ix:nonFraction></ix:nonFraction>; Authorized shares: <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-110"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-111">600,000,000</ix:nonFraction></ix:nonFraction> at December 31, 2023 and 2022, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-112"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-113">22,793,075</ix:nonFraction></ix:nonFraction> at December&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-114"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-115">21,090,938</ix:nonFraction></ix:nonFraction> at December&#160;31, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-116">22,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-117">21,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-118">1,740,954,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-119">1,710,888,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-120">1,622,965,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-121">1,487,847,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-122">662,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-123">698,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-124">117,349,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-125">222,362,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-126">170,951,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-127">348,533,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company effected a reverse stock split of its outstanding shares of common stock on January 24, 2024 where every twelve shares of its common stock issued and outstanding was converted into one share of common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any fractional post-split shares as a result of the reverse split were paid in cash. Shareholders of the Company authorized the Board of Directors to approve the reverse stock split at a special meeting of stockholders held on January 12, 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding share amounts have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.</span></div></ix:footnote><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:55.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from collaborative arrangements and other contracts, including affiliated entity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-129">832,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-130">10,262,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-131">1,774,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-132">86,676,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-133">187,650,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-134">249,240,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-135">47,582,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-136">90,185,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-137">53,752,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="0" id="f-138">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-141">144,772,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-142">277,835,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-143">302,992,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-144">143,940,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-145">267,573,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-146">301,217,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="f-147">8,133,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="f-148">4,782,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="f-149">3,363,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="f-150">1,222,789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="f-151">1,253,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="f-152">1,936,447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-153">773,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-154">1,899,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-155">553,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-156">5,850,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-157">7,846,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-158">3,222,838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-159">4,711,596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-160">3,861,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-161">343,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before share in net loss of Geneos</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="f-162">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="f-163">277,652,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="f-164">303,224,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="f-165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="f-166">2,165,213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="f-167">434,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-168">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-169">279,818,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-170">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-171"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-172">6.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-173"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-174">14.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-175"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-176">17.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-177"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-178">22,173,662</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-179"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-180">19,885,182</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-181"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-182">17,402,483</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</span></div></ix:footnote><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-184">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-185">279,818,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-186">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-187">3,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-188">25,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-189">30,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Unrealized (loss) gain on short-term investments, net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-190">40,060</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-191">390,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-192">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-193">135,081,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-194">280,234,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-195">303,684,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_127"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.321%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-196">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-198">15,570,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-199">15,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-200">1,367,578,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-201">906,196,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-202">256,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-203">461,140,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-204">2,275,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-205">2,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-206">209,439,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-207">209,441,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of December 2019 Bonds to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-208">84,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="f-209">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-210">4,377,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-211">4,377,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-212">184,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="f-213">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-214">2,057,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-215">2,057,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-216">26,336,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-217">26,336,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-218">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-219">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-220">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-221">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-222">30,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-223">30,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-224">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-226">18,115,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-227">18,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-228">1,609,789,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-229">1,209,855,522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-230">282,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-231">399,669,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-232">Cumulative adjustment from adoption of ASU 2020-06</span></span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-233">3,294,019</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-234">1,825,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-235">1,468,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-236">2,870,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-237">2,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-238">82,952,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-239">82,955,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-240">105,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="f-241">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-242">1,114,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-243">1,114,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-244">22,555,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-245">22,555,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-246">279,818,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-247">279,818,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-248">390,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-249">390,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-250">25,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-251">25,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-252">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-254">21,090,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-255">21,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-256">1,710,888,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-257">1,487,847,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-258">698,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-259">222,362,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for legal settlement</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-260">760,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="f-261">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-262">13,999,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-263">14,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-264">875,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="f-265">875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-266">5,460,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-267">5,461,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-268">66,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="f-269">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-270">466,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-271">466,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-272">11,072,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-273">11,072,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-274">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-275">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-276">40,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-277">40,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-278">3,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-279">3,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-280">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-282">22,793,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-283">22,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-284">1,740,954,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-285">1,622,965,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-286">662,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-287">117,349,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><ix:footnote id="fn-3" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All share amounts in this column, including appropriate reclassifications between common stock and additional paid-in capital, have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</span></div></ix:footnote><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_130"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-289">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-290">279,818,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-291">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-292">2,621,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-293">3,656,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-294">3,040,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-295">145,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-296">496,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-297">520,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="f-298">736,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="f-299">1,342,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="f-300">1,170,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="0" id="f-301">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="0" id="f-304">1,984,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-307">32,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-310">11,072,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-311">22,555,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-312">26,336,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest on senior convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:NonCashInterestIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-313">155,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="ino:NonCashInterestIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-314">186,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="ino:NonCashInterestIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-315">858,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of (discounts) premiums on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="0" id="f-316">4,686,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="0" id="f-317">1,320,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="0" id="f-318">1,633,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized loss on sales of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="f-319">4,805,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="f-320">4,029,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="f-321">5,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on remeasurement of investment in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:GainLossOnRemeasurementOfEquityMethodInvestment" format="ixt:fixed-zero" scale="0" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="ino:GainLossOnRemeasurementOfEquityMethodInvestment" format="ixt:num-dot-decimal" scale="0" id="f-323">165,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="ino:GainLossOnRemeasurementOfEquityMethodInvestment" format="ixt:fixed-zero" scale="0" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="f-325">317,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="f-326">1,074,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="0" id="f-327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-328">773,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-329">1,899,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-330">553,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share of net loss in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="0" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-332">2,165,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-333">434,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gain) loss on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-334">5,850,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-335">7,846,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-336">3,222,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized transaction (gain) loss on foreign-currency denominated debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-339">176,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-340">9,332,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-341">3,706,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-342">11,031,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets, including from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-343">39,020,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-344">5,336,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-345">6,343,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-346">78,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-347">741,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-348">24,531,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses, including due to affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-349">45,989,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-350">32,606,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-351">26,140,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="f-352">8,228,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="f-353">267,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="f-354">375,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, including from affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="f-356">85,989</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="f-357">39,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="f-358">2,020,971</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="f-359">2,603,956</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="f-360">2,329,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant funding liability, including from affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-361">2,453,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-362">2,034,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-363">2,973,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:fixed-zero" scale="0" id="f-364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-365">14,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-366">42,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-367">124,365,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-368">216,215,421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-369">215,708,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-370">203,475,052</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-371">248,528,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-372">348,953,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-373">284,932,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-374">361,083,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-375">174,839,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of capital assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-376">320,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-377">969,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-378">1,231,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of capital assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-379">6,219,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:fixed-zero" scale="0" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="0" id="f-383">1,999,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:fixed-zero" scale="0" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-385">87,355,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-386">109,585,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-387">175,344,484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-388">5,461,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-389">82,955,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-390">209,441,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:ProceedsfromStockOptionandWarrantExercises" format="ixt:fixed-zero" scale="0" id="f-391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="ino:ProceedsfromStockOptionandWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="f-392">283,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="ino:ProceedsfromStockOptionandWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="f-393">6,668,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="f-394">466,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="f-395">1,397,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="f-396">4,611,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-397">4,995,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-398">81,840,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-399">211,498,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-400">3,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-401">25,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-402">30,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-403">32,018,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-404">24,814,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-405">179,584,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-406">46,329,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-407">71,143,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-408">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-409">14,310,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-410">46,329,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-411">71,143,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts accrued for purchases of fixed assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="0" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="f-413">108,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="f-414">204,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-415">1,066,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-416">1,066,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-417">1,077,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in prepaid expenses and other current assets related to fixed assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" format="ixt:fixed-zero" scale="0" id="f-418">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" format="ixt:num-dot-decimal" scale="0" id="f-419">6,071,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" format="ixt:num-dot-decimal" scale="0" id="f-420">7,709,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock as part of litigation settlement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="0" id="f-421">14,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="0" id="f-422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="0" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_136"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-424" continuedAt="f-424-1" escape="true">The Company</ix:nonNumeric></span></div><ix:continuation id="f-424-1"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA&#174; delivery devices help its DNA medicines enter the body&#8217;s cells for optimal effect. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related anal dysplasia and oropharyngeal squamous cell carcinoma (OPSCC); glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in August 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div id="icdf8b8d8a6a143b2a034e3544027d42d_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-425" continuedAt="f-425-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-426" continuedAt="f-426-1" escape="true"><ix:continuation id="f-425-1" continuedAt="f-425-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-427">135.1</ix:nonFraction> million for the year ended December&#160;31, 2023. The Company had working capital of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ino:WorkingCapital" format="ixt:num-dot-decimal" scale="6" id="f-428">110.5</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="f-429">1.6</ix:nonFraction> billion as of December&#160;31, 2023. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-430">145.3</ix:nonFraction> million as of December 31, 2023 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings, including under At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-431">5.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-432">83.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-433">47.7</ix:nonFraction>&#160;million from equity offerings under Sales Agreements during the years ending December 31, 2023, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-434">162.1</ix:nonFraction>&#160;million from a January 2021 underwritten public offering of common stock. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, </span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-425-2" continuedAt="f-425-3"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-426-1">occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.</ix:continuation> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, as previously amended, to effect a 1-for-12 reverse stock split of our common stock (the &#8220;Reverse Stock Split&#8221;).  As a result of the Reverse Stock Split, every 12 issued and outstanding shares of the Company's common stock were automatically combined into one issued and outstanding share of common stock. The reverse stock split was reflected on the Nasdaq Capital Market beginning with the opening of trading on January 25, 2024. Accordingly, an amount equal to the par value of the decreased shares resulting from the reverse stock split was reclassified from "Additional paid-in capital" to "Common stock" on the balance sheet and statement of changes in stockholders&#8217; equity. Any fractional post-split shares as a result of the reverse stock split were eliminated by the payment of cash for the value of such fractional share. As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding stock options and outstanding shares of Series C Cumulative Convertible Preferred Stock and to the number of shares of common stock issuable under the Company's equity incentive plans. The reverse stock split did not change the par value of the Company's common stock or the authorized number of shares of the Company's common stock. All share amounts and per share amounts disclosed in this Annual Report on Form 10-K have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-435" continuedAt="f-435-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-435-1">The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-436" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-437">one</ix:nonFraction> segment operating primarily within the United States.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-438" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-439" continuedAt="f-439-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-439-1">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-440" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash equivalents, short-term investments, investments in affiliated entity, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes for disclosure purposes only.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-441" continuedAt="f-441-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-425-3" continuedAt="f-425-4"><ix:continuation id="f-441-1"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain mutual funds and U.S. treasury securities at December&#160;31, 2023 and 2022.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-442" continuedAt="f-442-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2023 and 2022. </span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><ix:continuation id="f-442-1" continuedAt="f-442-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-442-2">consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-443" continuedAt="f-443-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-443-1">Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. There was</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="f-444"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="f-445">no</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts for potential credit losses as of December&#160;31, 2023 and 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-446" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets include property and equipment and leasehold improvements. Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:f-447">three</span> to <ix:nonNumeric contextRef="c-56" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-448">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of long-lived assets, which includes fixed assets and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. No impairment losses have been recognized related to long-lived assets for the year ended December 31, 2023 and 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-449" continuedAt="f-449-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goodwill and Intangible Assets</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate the carrying amounts of the assets may not be recoverable. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company&#8217;s stock price. This sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of September 30, 2023. The Company first tested its long-lived assets for impairment. The Company determined that all of its long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, represented one asset group for purposes of its long-lived asset impairment assessment. The Company concluded that the long-lived assets were not impaired, as their carrying values were not in excess of their fair value. Next, the Company determined that the fair value of its reporting unit was less than its carrying value and the Company recorded a loss on impairment of goodwill of $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-450">10.5</ix:nonFraction>&#160;million. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-425-4" continuedAt="f-425-5"><ix:continuation id="f-449-1" continuedAt="f-449-2"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2023, the Company also recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-451">2.0</ix:nonFraction>&#160;million to research and development expense for the remaining book value of intangible assets acquired in 2016 from Bioject Medical Technologies, as the Company had no plans to further develop or utilize this technology. </span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-449-2">Refer to Note 8 for further information regarding Goodwill and Intangible Assets</ix:continuation>.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-452" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-453">327.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-454">299.1</ix:nonFraction> million at December&#160;31, 2023 and 2022, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-456" continuedAt="f-456-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-455" continuedAt="f-455-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-456-1"><ix:continuation id="f-455-1">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;).</ix:continuation></ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="ino:GrantRevenuePolicyTextBlock" id="f-457" continuedAt="f-457-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="f-457-1" continuedAt="f-457-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-457-2">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-research and development expense as opposed to revenue on the consolidated statement of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-458" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="f-459" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-460" continuedAt="f-460-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="f-460-1" continuedAt="f-460-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-460-2"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</ix:continuation>&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-425-5" continuedAt="f-425-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-461" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-462" continuedAt="f-462-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-indent:27pt"><ix:continuation id="f-462-1" continuedAt="f-462-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-462-2">For the years ended December 31, 2023, 2022 and 2021, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes would have been anti-dilutive.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-463" escape="true"><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-464">1,128,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-465">1,018,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-466">874,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-467">274,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-468">212,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-469">204,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-471">9,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-472">55,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-473">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-474">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-475">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-476">254,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-477">254,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-478">254,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-479">1,658,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-480">1,494,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-481">1,387,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-482" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="f-483" continuedAt="f-483-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><ix:continuation id="f-483-1" continuedAt="f-483-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-483-2">The Company recognizes forfeitures as they occur.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-425-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-484" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-485">4.05</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-486">2.05</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-487">0.91</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-488">100</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-489">94</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-490">93</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-74" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-491">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-75" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-492">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-76" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-493">6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-494">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-495">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-496">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-497">3.90</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-498">1.96</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-499">1.45</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-500">89</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-501">87</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-502">87</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-77" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-503">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-78" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-504">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-79" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-505">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-506">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-507">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-508">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-509" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements.  Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2023-07. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the Chief Operating Decision Maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and disclosures.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2023-09. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2023-09 requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_142"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-511" continuedAt="f-511-1" escape="true">Revenue Recognition and Concentration of Credit Risk</ix:nonNumeric></span></div><ix:continuation id="f-511-1" continuedAt="f-511-2"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the years ended December&#160;31, 2023, 2022 and 2021, the Company recognized revenue from various license and other agreements. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-512" continuedAt="f-512-1" escape="true">The following table indicates the percentage of total revenues in excess of 10% with any single customer:</ix:nonNumeric></span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-511-2"><ix:continuation id="f-512-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloBio Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-513">245,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-81" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-514">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc. (affiliated entity)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-521">33,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-89" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-523">245,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-91" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-524">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Defense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-527">9,591,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-95" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-528">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-529">754,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-97" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-530">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-531">586,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-532">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-533">636,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-534">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-535">774,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-536">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-537">832,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-104" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-538">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-539">10,262,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-105" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-540">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-541">1,774,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-106" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-542">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="f-543">No</ix:nonFraction> revenue recognized during the year ended December&#160;31, 2023 was in deferred revenue as of December 31, 2022. During the year ended December 31, 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="0" id="f-544">14,000</ix:nonFraction> that was included in deferred revenue at December 31, 2021. Performance obligations are generally satisfied within 12 months of the initial contract date. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2023, the Company had no accounts receivable balance. As of December&#160;31, 2022, all of the Company's accounts receivable was attributable to the CEPI MERS grant. There is minimal credit risk with the Company's customers based upon the short-term nature of the accounts receivable, collection history, their size and financial condition. Accordingly, the Company does not record an allowance for potential credit losses against its accounts receivable.</span></div></ix:continuation><div><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-545" continuedAt="f-545-1" escape="true">Collaborative Agreements </ix:nonNumeric></span></div><ix:continuation id="f-545-1" continuedAt="f-545-2"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#8217;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. In the fourth quarter of 2022, the Company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine continues to develop INO-4800 with its own resources under the terms of the Advaccine Agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research and development expense on the consolidated statement of operations once earned and collectibility was assured.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023, 2022 and 2021, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-546">3.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-547">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-548">4.5</ix:nonFraction> million, respectively, from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), which was amended on June 14, 2023. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" format="ixt:num-dot-decimal" scale="6" id="f-549">20.0</ix:nonFraction> million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for <ix:nonNumeric contextRef="c-110" name="ino:CollaborationAgreementRoyaltyPeriod" format="ixt-sec:duryear" id="f-550">10</ix:nonNumeric> years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="f-551">245,000</ix:nonFraction> from the ApolloBio Agreement that was recorded as revenue. For the years ended December 31,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">there were <ix:nonFraction unitRef="usd" contextRef="c-111" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-552"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-553">no</ix:nonFraction></ix:nonFraction> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant reimbursable program costs under the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-545-2" continuedAt="f-545-3"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with CEPI, pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS.  As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-554">56</ix:nonFraction>&#160;million of costs over a <ix:nonNumeric contextRef="c-113" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" format="ixt-sec:durwordsen" id="f-555">five-year</ix:nonNumeric> period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023, 2022 and 2021, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-556">1.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-557">6.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-558">10.0</ix:nonFraction> million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December&#160;31, 2023 and 2022, the Company had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:AccountsReceivableNet" scale="0" id="f-559">0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-560">1.7</ix:nonFraction>&#160;million, respectively, on the consolidated balance sheet related to these CEPI grants. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-561">2.2</ix:nonFraction>&#160;million recorded as an accrued liability, and at December 31, 2022, had</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" id="f-562">0</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded as deferred grant funding on the consolidated balance sheet related to these CEPI grants.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-563">9.0</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-564">6.9</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-565">5.0</ix:nonFraction>&#160;million to accelerate development of the Company's next-generation intradermal electroporation device, known as CELLECTRA 3PSP, for the intradermal delivery of INO-4800, and a grant of $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-566">1.3</ix:nonFraction>&#160;million to support large-scale manufacturing of INO-4800. During the years ended December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="f-567">330,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-568">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-569">6.9</ix:nonFraction> million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-570">2.1</ix:nonFraction>&#160;million recorded as an accrued liability, and at December 31, 2022, had</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-571">2.3</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-572">2.2</ix:nonFraction>&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-573">1.1</ix:nonFraction>&#160;million for the project. During the years ended December&#160;31, 2023, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="f-574">70,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="f-575">233,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="f-576">182,000</ix:nonFraction>, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December&#160;31, 2023 and 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-577">87,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-578">153,000</ix:nonFraction>, respectively, recorded as deferred grant funding on the consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. The total amount of funding provided to the Company under the OTA Agreement was $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="f-579">54.5</ix:nonFraction>&#160;million. The Company determined that the OTA Agreement should be considered under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which is outside the scope of Topic 606, as the government agency granting the Company funds was not receiving reciprocal value for their contributions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded contra-research and development expense on the consolidated statement of operations in the same period that the underlying expenses were incurred. During the years ended December&#160;31, 2023, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="ino:GrantProceedsReceived" scale="0" id="f-580">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="f-581">6.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="f-582">27.1</ix:nonFraction> million, respectively, as contra-research and development expense related to the OTA agreement.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><ix:continuation id="f-545-3" continuedAt="f-545-4"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The total purchase price under the Procurement Contract was $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" format="ixt:num-dot-decimal" scale="6" id="f-583">16.8</ix:nonFraction>&#160;million. The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Company determined that the Procurement Contract fell under the scope of ASC Topic 606 as the contract was with a customer and the Company was able to satisfy its obligations under the arrangement. Performance obligations under the Procurement Contract consisted of the delivery of a specified number of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. In 2021, the DoD announced that it would discontinue funding for the Phase 3 segment of the Company's clinical trials for INO-4800 and in January 2022, the total purchase price under the Procurement Contract was reduced to $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" format="ixt:num-dot-decimal" scale="6" id="f-584">10.7</ix:nonFraction>&#160;million. During the year ended December 31, 2022, all performance obligations under the Procurement Contract were satisfied. During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2023, 2022 and 2021</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-545-4">, the Company recorded revenue of $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="ino:CollaborativeArrangementRevenueFromTheProcurementContract" scale="0" id="f-585">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="ino:CollaborativeArrangementRevenueFromTheProcurementContract" format="ixt:num-dot-decimal" scale="6" id="f-586">9.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="ino:CollaborativeArrangementRevenueFromTheProcurementContract" format="ixt:num-dot-decimal" scale="0" id="f-587">755,000</ix:nonFraction>, respectively, from the Procurement Contract.</ix:continuation> </span></div><div style="margin-top:5pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-589" continuedAt="f-589-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-588" continuedAt="f-588-1" escape="true">Short-term Investments and Fair Value Measurements</ix:nonNumeric></ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-590" continuedAt="f-590-1" escape="true"><ix:continuation id="f-589-1" continuedAt="f-589-2"><ix:continuation id="f-588-1" continuedAt="f-588-2"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2023 and 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-589-2" continuedAt="f-589-3"><ix:continuation id="f-588-2" continuedAt="f-588-3"><ix:continuation id="f-590-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-591">55,389,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-592">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-593">3,522,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-594">51,866,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="c-144" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-595">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-596">75,164,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-597">24,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-599">75,189,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="c-146" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-600">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-601">2,978,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-602">11,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="f-603">300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-604">2,990,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-605">1,340,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-606">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-607">403,973</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-608">936,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-609">134,873,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-610">36,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-611">3,927,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-612">130,982,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-613">117,036,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-615">9,373,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-616">107,662,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="c-150" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-617">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-618">95,001,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-619">7,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-620">44,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-621">94,964,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="c-150" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-622">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-623">2,977,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-624">13,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="f-625">320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-626">2,990,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-627">1,435,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-629">384,331</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-630">1,051,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-631">216,450,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-632">21,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-633">9,802,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-634">206,669,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="0" id="f-635">1,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="0" id="f-636">21,000</ix:nonFraction>, respectively, and gross realized loss on investments of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-637">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="6" id="f-638">4.1</ix:nonFraction> million, respectively. During the years ended December&#160;31, 2023 and 2022, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-639">5.9</ix:nonFraction>&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-640">7.8</ix:nonFraction>)&#160;million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2023,&#160;2022&#160;and&#160;2021. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2023, the Company had&#160;<ix:nonFraction unitRef="position" contextRef="c-5" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-641">21</ix:nonFraction>&#160;available-for-sale securities in a gross unrealized loss position, of which <ix:nonFraction unitRef="position" contextRef="c-5" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="f-642">20</ix:nonFraction> with an aggregate total unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="f-643">3.9</ix:nonFraction> million were in such position for longer than 12 months. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2023&#160;were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December&#160;31, 2023, the Company did not record an allowance for credit losses related to its available-for-sale debt securities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-644" continuedAt="f-644-1" escape="true"><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-589-3" continuedAt="f-589-4"><ix:continuation id="f-588-3" continuedAt="f-588-4"><ix:continuation id="f-644-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-645">51,866,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-646">51,866,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-649">75,189,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-650">75,189,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-653">2,990,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-654">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-655">2,990,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-657">936,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-659">936,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-661">130,982,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-662">127,056,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-663">3,926,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" id="f-665">2,780,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" id="f-666">2,780,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" id="f-667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" id="f-668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" id="f-669">133,763,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" id="f-670">129,836,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" id="f-671">3,926,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" id="f-672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-673">107,662,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-674">107,662,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-677">94,964,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-678">94,964,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-680">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-681">2,990,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-683">2,990,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-685">1,051,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-686">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-687">1,051,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-689">206,669,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-690">202,627,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-691">4,042,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="f-693">2,007,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="f-694">2,007,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="f-695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="f-696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-697">208,676,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-698">204,634,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-699">4,042,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2023 and 2022 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in <ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-701"><ix:nonFraction unitRef="shares" contextRef="c-195" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-702">597,808</ix:nonFraction></ix:nonFraction> common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain or loss on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2023 and 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-589-4"><ix:continuation id="f-588-4">There were no Level 3 assets held as of December&#160;31, 2023 or 2022.</ix:continuation></ix:continuation> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentAssetsTextBlock" id="f-703" continuedAt="f-703-1" escape="true">Certain Balance Sheet Items</ix:nonNumeric></span></div><ix:continuation id="f-703-1"><ix:nonNumeric contextRef="c-1" name="ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="f-704" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets at December&#160;31, 2023 and 2022 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance recovery (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:fixed-zero" scale="0" id="f-705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:num-dot-decimal" scale="0" id="f-706">30,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ino:PrepaidManufacturingExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-707">1,486,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="ino:PrepaidManufacturingExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-708">1,401,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-709">3,907,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-710">18,729,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-711">5,393,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-712">50,130,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-713" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2023 and 2022 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-714">3,577,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-715">19,862,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-716">9,837,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-717">12,574,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:LitigationReserveCurrent" format="ixt:fixed-zero" scale="0" id="f-718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="0" id="f-719">44,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses (b) (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-720">6,432,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-721">3,249,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-722">19,847,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-723">79,686,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:24.91pt">In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of class action securities litigation (see Note 11). The final judicial order for the settlement was issued in January 2023. The settlement consisted of $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-724">30.0</ix:nonFraction>&#160;million in cash and $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="ino:LossContingencyEstimateOfPossibleLossValueOfShares" format="ixt:num-dot-decimal" scale="6" id="f-725">14.0</ix:nonFraction>&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="0" id="f-726">252,000</ix:nonFraction> of other expenses on behalf of the Company, which amounts were offset against the insurers' cash commitment as part of the settlement. During the three months ended March 31, 2023, the cash component of the settlement was released from escrow and the Company issued <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="ino:LitigationSettlementAmountAwardedToOtherPartyShares" format="ixt:num-dot-decimal" scale="0" id="f-727">760,083</ix:nonFraction> shares of common stock pursuant to the securities class action settlement.</span></div><div style="padding-left:36pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)        In March 2023, the Company entered into a stipulation of settlement for the proposed settlement of shareholder derivative litigation (see Note 11). In June 2023, the court preliminarily approved the proposed settlement. As part of the settlement, in July 2023, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:LossContingencyDamagesPaidValue" format="ixt:num-dot-decimal" scale="6" id="f-728">1.2</ix:nonFraction>&#160;million to plaintiffs&#8217; counsel for their fees and expenses. This amount was accrued within &#8220;Other accrued expenses&#8221; as of December 31, 2022. On October 12, 2023, the court entered an order and final judgment approving the Settlement, which was effective on November 13, 2023.</span></div><div style="padding-left:36pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)       December 31, 2023 balance includes $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ino:GrantLiability" format="ixt:num-dot-decimal" scale="6" id="f-729">4.3</ix:nonFraction>&#160;million liability for unused grant funding.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-730" continuedAt="f-730-1" escape="true">Fixed Assets</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-731" escape="true"><ix:continuation id="f-730-1" continuedAt="f-730-2"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2023 and 2022 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-732">15,917,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-733">11,753,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-734">4,164,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-735">3,538,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-736">3,078,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-737">460,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-738">2,827,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-739">2,816,577</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-740">10,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-741">3,529,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-742">3,204,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-743">325,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-744">25,812,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-745">20,851,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-746">4,960,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-747">15,803,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-748">10,036,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-749">5,767,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-750">5,300,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-751">4,295,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-752">1,004,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-753">2,827,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-754">2,803,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-755">23,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-756">5,360,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-757">4,428,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-758">932,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-759">29,291,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-760">21,563,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-761">7,727,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-730-2">Depreciation expense for the years ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-762">2.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-763">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-764">3.0</ix:nonFraction> million, respectively. The Company determined that the carrying value of its fixed assets was not impaired during the periods presented. During the year ended December 31, 2023, the Company sold fixed assets with no net book value for a gain of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ino:PropertyPlantAndEquipmentDisposedOfBySale" format="ixt:num-dot-decimal" scale="0" id="f-765">148,000</ix:nonFraction> and disposed of fixed assets with a net book value of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentDisposals" format="ixt:num-dot-decimal" scale="0" id="f-766">466,000</ix:nonFraction>. During the year ended December 31, 2022 the Company sold fixed assets with a net book value of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="ino:PropertyPlantAndEquipmentDisposedOfBySale" format="ixt:num-dot-decimal" scale="6" id="f-767">6.1</ix:nonFraction>&#160;million and disposed of fixed assets with a net book value of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentDisposals" format="ixt:num-dot-decimal" scale="6" id="f-768">1.1</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_157"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-769" continuedAt="f-769-1" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="f-769-1" continuedAt="f-769-2"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended September 30, 2023, as a result of the sustained decline in the Company&#8217;s stock price and related market capitalization, and a general decline in equity values in the biotechnology industry, the Company performed an impairment assessment of its goodwill and long-lived assets.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company operates as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company&#8217;s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company&#8217;s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represented a level 2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a non-cash, pre-tax goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-770">10.5</ix:nonFraction>&#160;million during the three months ended September 30, 2023. As a result, the goodwill was fully impaired as of September 30, 2023.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Before completing the goodwill impairment assessment, the Company first tested its long-lived assets for impairment. The Company held no indefinite-lived intangible assets as of Sep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">tember 30, 2023. The Company determined that all of its long-lived assets, which included property and equipment, leasehold improvements and right-of-use assets, represented one asset group for purposes of its long-lived asset impairment assessment. The Company concluded that the long-lived assets were not impaired, as their carrying values were not in excess of their fair value.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the quarter ended June 30, 2023, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-771">2.0</ix:nonFraction>&#160;million to research and development expense for the remaining book value of intangible assets acquired in 2016 from Bioject Medical Technologies, as the Company had no plans to further develop or utilize this technology. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-772" continuedAt="f-772-1" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-769-2"><ix:continuation id="f-772-1" continuedAt="f-772-2"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.267%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="0" id="f-773">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="0" id="f-774">10,513,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="0" id="f-775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="0" id="f-776">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="f-777">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-208" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-778">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:fixed-zero" scale="0" id="f-779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="0" id="f-780">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-781">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="0" id="f-782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-783">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-784">1,323,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="0" id="f-785">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bioject </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-786">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-787">3,115,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="0" id="f-788">1,984,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="0" id="f-789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-790">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-791">2,988,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-792">2,111,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (a)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-215" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-793">18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-794">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-795">4,050,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-796">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="0" id="f-797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-798">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-799">4,031,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-800">18,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-219" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-801">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-802">9,150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-803">7,165,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="0" id="f-804">1,984,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="0" id="f-805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-806">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-807">8,343,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-808">2,129,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ino:GoodwillAndIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-809">19,663,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-810">7,165,556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="0" id="f-811">12,497,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ino:GoodwillAndIntangibleAssetsNet" format="ixt:fixed-zero" scale="0" id="f-812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="ino:GoodwillAndIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-813">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="f-814">8,343,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="ino:GoodwillAndIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-815">12,643,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><ix:continuation id="f-772-2" continuedAt="f-772-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"><ix:continuation id="f-772-3">Other intangible assets represent the estimated fair value of acquired intellectual property.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to intangible assets was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-816">145,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-817">496,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-818">520,000</ix:nonFraction> for the years ended December&#160;31, 2023, 2022 and 2021, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-819"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-820">no</ix:nonFraction></ix:nonFraction> impairment or impairment indicators present and <ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-821"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-822">no</ix:nonFraction></ix:nonFraction> losses were recorded during the years ended December 31, 2022 and 2021.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_160"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-823" continuedAt="f-823-1" escape="true">Convertible Debt</ix:nonNumeric></span></div><ix:continuation id="f-823-1" continuedAt="f-823-2"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-824"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-825">78.5</ix:nonFraction></ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="c-221" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-826"><ix:nonFraction unitRef="number" contextRef="c-220" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-827">6.50</ix:nonFraction></ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-828">75.7</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Notes were senior unsecured obligations of the Company and accrued interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of <ix:nonFraction unitRef="number" contextRef="c-221" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-829">6.50</ix:nonFraction>% per annum. The Notes matured on March 1, 2024 and the Company paid the then remaining $<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-830">16.9</ix:nonFraction>&#160;million obligation in full, including accrued interest.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="f-831">16.3</ix:nonFraction>&#160;million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-224" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-832">13.1</ix:nonFraction>%. In addition, the Company allocated $<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="0" id="f-833">592,000</ix:nonFraction> of debt issuance costs to the equity component and the remaining debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-834">2.2</ix:nonFraction>&#160;million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, the Company adopted ASU No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;). The ASU eliminated the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, the Company accounted for these securities as a single unit of account, unless the conversion feature met certain criteria. The Company adopted the new standard using the modified retrospective method and recorded a net reduction to accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-835">1.8</ix:nonFraction>&#160;million, a decrease to additional paid-in capital of $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-836">3.3</ix:nonFraction>&#160;million, and an increase to convertible senior notes of $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-837">1.5</ix:nonFraction>&#160;million to reflect the impact of the accounting change. The Notes were subsequently accounted for as a single liability measured at amortized cost, as no other embedded features required bifurcation and recognition as derivatives.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConvertibleDebtTableTextBlock" id="f-838" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December&#160;31, 2023 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="0" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-839">78,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="0" name="ino:DebtInstrumentConvertibleDebtConvertedAmount" format="ixt:num-dot-decimal" scale="0" id="f-840">62,085,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="0" name="us-gaap:DeferredFinanceCostsNet" format="ixt:fixed-zero" scale="0" id="f-841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="0" name="ino:DebtinstrumentAccruedInterest" format="ixt:num-dot-decimal" scale="0" id="f-842">355,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="0" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="f-843">16,770,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-823-2">For the years ended December&#160;31, 2023, 2022 and 2021,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-844">1.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-845">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-846">1.9</ix:nonFraction>&#160;million, respectively, of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="f-847">1.1</ix:nonFraction> million related to the contractual interest coupon in each year.</ix:continuation> </span></div><div><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_166"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-848" continuedAt="f-848-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div style="margin-top:3pt"><span><br/></span></div><ix:continuation id="f-848-1" continuedAt="f-848-2"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-849" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:47.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.313%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $<ix:nonFraction unitRef="usdPerShare" contextRef="c-231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-850"><ix:nonFraction unitRef="usdPerShare" contextRef="c-232" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-851">0.001</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-232" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-852">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-232" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-853">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-232" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-854">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-855">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holder of a share or shares of Series C preferred stock has the right at any time, at such holder&#8217;s option, to convert all or any lesser portion of such holder&#8217;s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2021, the conversion value w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" scale="0" id="f-856">326.40</ix:nonFraction> per share, such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that the outstanding shares of Series C preferred stock were convertible into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-233" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="f-857">275</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="INF" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-858">300.0</ix:nonFraction>&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="c-234" decimals="INF" name="ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage" scale="-2" id="f-859">3.0</ix:nonFraction>% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the years ended December&#160;31, 2023 and 2022, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-235" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-860">875,305</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-236" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-861">2,870,478</ix:nonFraction> shares, respectively, of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-235" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="f-862">6.33</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-236" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="f-863">29.34</ix:nonFraction> per share, respectively, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="f-864">5.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="f-865">83.0</ix:nonFraction>&#160;million, respectively. As of December&#160;31, 2023 there was $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="ino:StockSalesAgreementRemainingAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-866">161.8</ix:nonFraction>&#160;million of remaining capacity under the 2021 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="ino:LitigationSettlementAmountAwardedToOtherPartyShares" format="ixt:num-dot-decimal" scale="0" id="f-867">760,083</ix:nonFraction> shares of common stock pursuant to the securities class action settlement, as described in Note 11.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors adopted the 2023 Omnibus Incentive Plan (the &#8220;2023 Plan&#8221;) on March 24, 2023, pursuant to which the Company may grant stock options, restricted stock awards, RSUs and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Plan was approved by stockholders on May 16, 2023. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2023 Plan will not exceed the sum of <ix:nonFraction unitRef="shares" contextRef="c-238" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-868">1,166,666</ix:nonFraction> shares plus any shares that may return from time to time from the 2016 Omnibus Incentive Plan (as amended, the &#8220;2016 Plan&#8221;) as a result of expirations, terminations or forfeitures of awards outstanding under the 2016 Plan as of May 16, 2023. At December&#160;31, 2023, the Company had <ix:nonFraction unitRef="shares" contextRef="c-239" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-869">1,334,012</ix:nonFraction> shares of common stock available for future grant under the 2023 Plan, <ix:nonFraction unitRef="shares" contextRef="c-239" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-870">1,875</ix:nonFraction> shares underlying outstanding but unvested RSUs and <ix:nonFraction unitRef="shares" contextRef="c-239" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-871">3,150</ix:nonFraction> shares underlying options outstanding to purchase common stock under the 2023 Plan. The awards granted and available for future grant under the 2023 Plan generally vest over <ix:nonNumeric contextRef="c-240" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-872">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="c-240" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="f-873">ten years</ix:nonNumeric>. The 2023 Plan terminates by its terms on March&#160;24, 2033.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company had <ix:nonFraction unitRef="shares" contextRef="c-241" decimals="INF" name="ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" format="ixt:num-dot-decimal" scale="0" id="f-874">262,641</ix:nonFraction> shares underlying outstanding but unvested RSU and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="c-242" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-875">961,499</ix:nonFraction> shares of common stock under the 2016 Plan. The outstanding awards granted under the 2016 Plan generally vest over <ix:nonNumeric contextRef="c-241" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-876">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="c-241" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="f-877">ten years</ix:nonNumeric>. Following adoption of the 2023 Plan, no further awards may be made under the 2016 Plan, but outstanding awards continue to be governed by their existing terms. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2022 Inducement Plan will not exceed <ix:nonFraction unitRef="shares" contextRef="c-243" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-878">166,666</ix:nonFraction> shares. At December&#160;31, 2023 the Company had <ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-879">125,575</ix:nonFraction> shares of common stock available for future grant under the 2022 Inducement Plan, <ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-880">10,278</ix:nonFraction> shares underlying outstanding but unvested RSUs and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-881">27,759</ix:nonFraction> shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-848-2" continuedAt="f-848-3"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2023, the Company had options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="c-245" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-882">136,456</ix:nonFraction> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over <ix:nonNumeric contextRef="c-246" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-883">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="c-246" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="f-884">ten years</ix:nonNumeric>. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-885">10.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-886">22.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-887">25.0</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-888">4.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-889">8.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-890">13.4</ix:nonFraction> million was included in research and development expenses and $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-891">5.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-892">13.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-893">11.6</ix:nonFraction> million was included in general and administrative expenses, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023 and 2022, there was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-894">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-895">10.5</ix:nonFraction> million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-896">1.3</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-12" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-897">1.6</ix:nonNumeric> years, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023 and 2022, there was $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-898">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-899">7.2</ix:nonFraction> million, respectively, of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-255" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-900">1.5</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-256" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-901">1.7</ix:nonNumeric> years, respectively.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the years ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-902">669,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-903">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-904">1.4</ix:nonFraction> million, respectively. As of December&#160;31, 2023, options to purchase <ix:nonFraction unitRef="shares" contextRef="c-260" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-905">61,808</ix:nonFraction> shares of common stock granted to non-employees remained outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="f-906" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:26.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-261" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-907">4.32</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-261" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-908">18.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-262" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-909">283,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-261" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-910">9.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-262" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-911">14.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-262" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-912">66,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-262" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-913">14.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-263" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-914">18.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-263" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-915">39.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-916">264,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-263" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-917">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-264" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-918">35.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-919">141,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-264" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-920">34.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-265" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-921">39.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-265" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-922">52.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-266" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-923">156,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-265" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-924">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-266" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-925">44.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-266" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-926">156,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-266" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-927">44.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-267" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-928">52.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-267" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-929">90.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-268" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-930">129,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-267" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-931">4.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-268" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-932">76.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-268" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-933">121,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-268" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-934">77.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-269" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-935">90.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-269" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-936">130.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-937">136,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-269" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-938">4.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-270" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-939">100.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-940">131,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-270" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-941">100.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-271" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-942">130.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-271" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-943">233.28</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-272" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-944">158,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-271" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-945">5.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-272" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-946">140.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-272" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-947">129,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-272" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-948">141.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-949">1,128,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-950">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-951">58.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-952">746,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-953">72.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the aggregate intrinsic value of options outstanding was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-954">2,000</ix:nonFraction>, the aggregate intrinsic value of options exercisable was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="f-955">1,000</ix:nonFraction>, and the weighted average remaining contractual term of options exercisable was <ix:nonNumeric contextRef="c-1" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="f-956">5.5</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, the aggregate intrinsic value of unvested RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" format="ixt:num-dot-decimal" scale="6" id="f-957">1.7</ix:nonFraction> million and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="f-958">1.3</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, options to purchase <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-959">1,128,864</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-253" decimals="INF" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-960">274,794</ix:nonFraction> RSUs were expected to vest.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-961" escape="true"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2023 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-962">1,018,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-963">75.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-964">339,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-965">14.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-968">228,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-969">66.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-970">1,128,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-971">58.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-972" continuedAt="f-972-1" escape="true"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2023 was as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-848-3"><ix:continuation id="f-972-1"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-254" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-973">212,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-255" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-974">194,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-255" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-975">99,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-255" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-976">33,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-253" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-977">274,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-978">38.86</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-979">9,357</ix:nonFraction> options which expired during the year ended December&#160;31, 2023, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-980">101.64</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-981">6,437</ix:nonFraction> options which expired during the year ended December&#160;31, 2022 and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-982">54.72</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="f-983">583</ix:nonFraction> options which expired during the year ended December&#160;31, 2021.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-984">11.19</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-985">28.08</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-986">91.32</ix:nonFraction> for options granted during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-255" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-987">10.34</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-256" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-988">37.44</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-273" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-989">124.44</ix:nonFraction> per share for RSUs granted during the years ended December&#160;31, 2023, 2022 and 2021, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-990">No</ix:nonFraction> stock options were exercised during the year ended December 31, 2023.  The Company received $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-991">283,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-992">6.7</ix:nonFraction> million in proceeds from the exercise of stock options during the years ended December&#160;31, 2022 and 2021, respectively. The aggregate intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-993">81,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-994">7.0</ix:nonFraction> million during the years ended December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-996" continuedAt="f-996-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-996-1" continuedAt="f-996-2"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="c-275" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-997">56,600</ix:nonFraction> square feet of office, laboratory, and manufacturing space in San Diego, California and <ix:nonFraction unitRef="sqft" contextRef="c-276" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-998">57,360</ix:nonFraction> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December&#160;31, 2023 of <ix:nonNumeric contextRef="c-55" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-999">3.4</ix:nonNumeric> years to <ix:nonNumeric contextRef="c-56" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1000">6.0</ix:nonNumeric> years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company amended <ix:nonFraction unitRef="lease" contextRef="c-277" decimals="INF" name="ino:LesseeOperatingLeaseNumberOfLeasesAmended" format="ixt-sec:numwordsen" scale="0" id="f-1001">one</ix:nonFraction> of its leases representing <ix:nonFraction unitRef="sqft" contextRef="c-277" decimals="0" name="ino:LesseeOperatingLeaseAreaOfLandUnderLeaseAmended" format="ixt:num-dot-decimal" scale="0" id="f-1002">31,207</ix:nonFraction> square feet of office and laboratory space with a lease term expiring in November 2023, to extend the term to February 29, 2024.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company entered into a lease agreement for research and development laboratory space in San Diego, California ("New San Diego Lease"). The total space under the New San Diego Lease is approximately <ix:nonFraction unitRef="sqft" contextRef="c-278" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-1003">5,563</ix:nonFraction> square feet.  The term of the New San Diego Lease commenced on February 10, 2024 and the initial term is <ix:nonNumeric contextRef="c-279" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1004">4.3</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the New San Diego Lease.  Rent payments under the New San Diego Lease will include base rent with an annual increase of approximately <ix:nonFraction unitRef="number" contextRef="c-278" decimals="2" name="ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" format="ixt-sec:numwordsen" scale="-2" id="f-1005">three</ix:nonFraction> percent, and additional monthly fees to cover the Company's share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, the Company has paid a security deposit of $<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:PaymentsForDeposits" format="ixt:num-dot-decimal" scale="0" id="f-1006">33,000</ix:nonFraction>. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1007" continuedAt="f-1007-1" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturities of the Company's operating lease liabilities were as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-996-2" continuedAt="f-996-3"><ix:continuation id="f-1007-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-1008">3,247,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-1009">3,466,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="f-1010">3,555,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="f-1011">2,955,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="0" id="f-1012">2,310,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="0" id="f-1013">2,132,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="f-1014">17,665,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="f-1015">4,226,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-1016">13,439,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-1017">2,407,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-1018">11,032,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1019">5.3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1020">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2023, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-1021">3.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-1022">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-1023">3.4</ix:nonFraction> million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third and fourth quarters of 2023, the Company entered into agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="c-280" decimals="-2" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-1024">4,400</ix:nonFraction> and <ix:nonFraction unitRef="sqft" contextRef="c-281" decimals="-3" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-1025">7,000</ix:nonFraction> square feet, respectively, in its Plymouth Meeting headquarters, in each case with sublease terms through December 31, 2026.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into <ix:nonFraction unitRef="agreement" contextRef="c-282" decimals="INF" name="ino:LesseeOperatingLeaseNumberOfAgreementsToSublease" format="ixt-sec:numwordsen" scale="0" id="f-1026">two</ix:nonFraction> agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="c-283" decimals="-2" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-1027">13,500</ix:nonFraction> square feet in its Plymouth Meeting headquarters, with one sublease term through March 31, 2025 and the other month-to-month.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. The plaintiffs&#8217; complaint was later amended to include certain of the Company&#8217;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, the Company agreed to pay $<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-1028">30.0</ix:nonFraction>&#160;million in cash and $<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="ino:LossContingencyEstimateOfPossibleLossValueOfShares" format="ixt:num-dot-decimal" scale="6" id="f-1029">14.0</ix:nonFraction>&#160;million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers paid the $<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-1030">30.0</ix:nonFraction>&#160;million cash component of the settlement. During the three months ended March 31, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="ino:LitigationSettlementAmountAwardedToOtherPartyShares" format="ixt:num-dot-decimal" scale="0" id="f-1031">760,083</ix:nonFraction> shares of common stock pursuant to the securities class action settlement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming <ix:nonFraction unitRef="defendent" contextRef="c-285" decimals="INF" name="us-gaap:LossContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="f-1032">eight</ix:nonFraction> current and former directors of the Company as defendants. The lawsuit asserted state and federal claims and was based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accused the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff sought unspecified </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-996-3" continuedAt="f-996-4"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monetary damages on behalf of the Company as well as governance reforms. Between June 2020 and August 2020, additional shareholder derivative complaints were filed and later consolidated by the court. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, an additional shareholder derivative complaint was filed in the Delaware Court of Chancery, asserting substantially similar claims as those in the consolidated derivative action. In May 2022, the Delaware Court of Chancery entered a stay of the litigation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the parties submitted a joint status report to the Court of Chancery reporting that the parties agreed to a settlement in principle, which also provided for the resolution of the consolidated derivative action and certain stockholder demands. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the plaintiffs in the consolidated derivative action filed a motion for preliminary approval of settlement with the United States District Court for the Eastern District of Pennsylvania. The proposed settlement provided for resolution of the consolidated derivative action, the derivative action pending in the Delaware Court of Chancery, and certain stockholder demands.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the court entered an order preliminarily approving the proposed settlement of the derivative claims, in accordance with a Stipulation of Settlement. The Stipulation of Settlement contemplated that, following the settlement hearing and the final approval of the settlement by the court, the Company would implement certain corporate governance reforms described in the Stipulation of Settlement. The preliminary order also approved the form and manner of the notice of the Settlement. As part of the Settlement, in July 2023 the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:LossContingencyDamagesPaidValue" format="ixt:num-dot-decimal" scale="6" id="f-1033">1.2</ix:nonFraction>&#160;million to plaintiffs&#8217; counsel for their fees and expenses. In October 2023, the court entered an order and final judgment approving the Settlement, which became effective in November 2023. The Company has implemented the corporate governance reforms in response to the provisions of the Stipulation of Settlement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an appeal by the Company, in July 2020, VGXI filed counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. The Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. In October 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. The Company filed preliminary objections to the complaint, which were overruled by the court. In September 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-996-4"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1034" continuedAt="f-1034-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="f-1034-1" continuedAt="f-1034-2"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-1035" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" id="f-1036">134,979,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" id="f-1037">277,440,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" id="f-1038">302,614,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" id="f-1039">137,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" id="f-1040">211,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" id="f-1041">610,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" id="f-1042">135,117,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" id="f-1043">277,652,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" id="f-1044">303,224,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-1045"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-1046"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-1047">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> provision for or benefit from income taxes for the years ended December 31, 2023, 2022 and 2021. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1048" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2023, 2022 and 2021, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="f-1049">28,375,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="f-1050">58,307,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="f-1051">63,677,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="0" id="f-1052">3,922,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="0" id="f-1053">3,601,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="0" id="f-1054">3,447,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-1055">28,394,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-1056">61,065,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-1057">77,424,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ino:IncomeTaxReconciliationStatuteLimitations" format="ixt:num-dot-decimal" scale="0" id="f-1058">2,139,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="ino:IncomeTaxReconciliationStatuteLimitations" format="ixt:num-dot-decimal" scale="0" id="f-1059">7,534,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="ino:IncomeTaxReconciliationStatuteLimitations" format="ixt:num-dot-decimal" scale="0" id="f-1060">16,523,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-1061">2,099,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-1062">2,913,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-1063">483,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="0" id="f-1064">861,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="0" id="f-1065">2,291,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="0" id="f-1066">6,509,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:num-dot-decimal" scale="0" id="f-1067">1,962,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="0" id="f-1068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="0" id="f-1069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="f-1070">1,352,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="f-1071">1,459,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="f-1072">616,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="f-1073">997,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="f-1074">1,337,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="f-1075">542,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:num-dot-decimal" scale="0" id="f-1076">365,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:num-dot-decimal" scale="0" id="f-1077">187,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="0" id="f-1078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="0" id="f-1079">4,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="0" id="f-1080">8,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="0" id="f-1081">24,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="f-1082">404,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="f-1083">3,246,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="f-1084">819,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ino:ComprehensiveIncomeLossTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-1085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ino:ComprehensiveIncomeLossTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-1086">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ino:ComprehensiveIncomeLossTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-1087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1088" continuedAt="f-1088-1" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are shown below:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1034-2" continuedAt="f-1034-3"><ix:continuation id="f-1088-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-1089">50,143,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-1090">41,252,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-1091">235,624,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-1092">212,768,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-1093">27,734,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-1094">26,442,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="0" id="f-1095">22,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="0" id="f-1096">538,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-1097">3,683,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-1098">3,945,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ino:DeferredTaxAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-1099">907,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ino:DeferredTaxAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-1100">559,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="0" id="f-1101">1,406,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="0" id="f-1102">1,569,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ino:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-1103">2,822,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ino:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-1104">3,247,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-1105">337,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-1106">57,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="f-1107">6,808,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="f-1108">11,062,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-1109">329,486,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-1110">301,439,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-1111">327,493,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-1112">299,124,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-1113">1,993,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-1114">2,315,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:fixed-zero" scale="0" id="f-1115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-1116">199,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-1117">1,993,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-1118">2,148,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-1119">1,993,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-1120">2,347,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="0" id="f-1121">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-1122">32,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company had federal, California and other state tax net operating loss (NOL) carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" format="ixt:num-dot-decimal" scale="6" id="f-1123">1,013.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" format="ixt:num-dot-decimal" scale="6" id="f-1124">251.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" format="ixt:num-dot-decimal" scale="6" id="f-1125">102.6</ix:nonFraction> million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1126">719.3</ix:nonFraction> million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year. The federal NOL carryforward began to expire in 2023, and the California and other state NOL carryforwards will begin and have begun to expire in 2028 and 2023, respectively, unless previously utilized. </span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also had Korean NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" format="ixt:num-dot-decimal" scale="6" id="f-1127">1.1</ix:nonFraction> million as of December 31, 2023. The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2035, unless previously utilized. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2023, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1128">41.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1129">6.1</ix:nonFraction> million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</span></div><ix:nonNumeric contextRef="c-1" name="ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" id="f-1130" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringInNextFiscalYear" scale="6" id="f-1131">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringInNextFiscalYear" scale="6" id="f-1132">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringInNextFiscalYear" format="ixt:fixed-zero" scale="6" id="f-1133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInNextFiscalYear" format="ixt:fixed-zero" scale="6" id="f-1134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInNextFiscalYear" format="ixt:fixed-zero" scale="6" id="f-1135">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" scale="6" id="f-1136">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" scale="6" id="f-1137">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" format="ixt:fixed-zero" scale="6" id="f-1138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinTwoYears" format="ixt:fixed-zero" scale="6" id="f-1139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinTwoYears" format="ixt:fixed-zero" scale="6" id="f-1140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" scale="6" id="f-1141">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" scale="6" id="f-1142">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" format="ixt:fixed-zero" scale="6" id="f-1143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInThreeYears" format="ixt:fixed-zero" scale="6" id="f-1144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInThreeYears" format="ixt:fixed-zero" scale="6" id="f-1145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" scale="6" id="f-1146">249.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" scale="6" id="f-1147">332.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" scale="6" id="f-1148">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInFourYears" scale="6" id="f-1149">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInFourYears" format="ixt:fixed-zero" scale="6" id="f-1150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" scale="6" id="f-1151">719.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" scale="6" id="f-1152">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" format="ixt:fixed-zero" scale="6" id="f-1153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="ino:TaxCreditCarryforwardCarryforwardIndefinitely" format="ixt:fixed-zero" scale="6" id="f-1154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="ino:TaxCreditCarryforwardCarryforwardIndefinitely" scale="6" id="f-1155">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1156">1,013.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1157">354.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1158">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1159">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1160">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;D credit carryforwards as of December&#160;31, 2023. As a result of the analysis, the Company estimates that approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ino:TaxBenefitsExpired" format="ixt:num-dot-decimal" scale="6" id="f-1161">7.3</ix:nonFraction> million of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets accompanied by a corresponding reduction of the valuation </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1034-3"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes, may further limit the ability to use the NOL and R&amp;D carryforwards.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2023, 2022 and 2021, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1162" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="f-1163">21,139,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="f-1164">18,819,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="f-1165">12,210,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="f-1166">1,816,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="f-1167">2,902,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="f-1168">6,602,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="f-1169">841,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="f-1170">582,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="f-1171">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="f-1172">22,114,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="f-1173">21,139,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="f-1174">18,819,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-1175">20.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-1176">19.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-1177">17.4</ix:nonFraction> million as of December&#160;31, 2023, 2022 and 2021, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2020 and state and local income tax examinations before 2019. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not to its knowledge currently under Internal Revenue Service (&#8220;IRS&#8221;), state, local or foreign tax examination.</span></div></ix:continuation><div><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1178" continuedAt="f-1178-1" escape="true">401(k) Plan</ix:nonNumeric></span></div><ix:continuation id="f-1178-1"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-1179">50</ix:nonFraction>% of its employees&#8217; contributions, up to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1180">6</ix:nonFraction>% of their annual compensation. The Company&#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1181">1.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1182">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1183">1.5</ix:nonFraction> million for the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_184"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-1184" continuedAt="f-1184-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-1184-1" continuedAt="f-1184-2"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company owned <ix:nonFraction unitRef="shares" contextRef="c-297" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-1185"><ix:nonFraction unitRef="shares" contextRef="c-298" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-1186">597,808</ix:nonFraction></ix:nonFraction> shares of common stock in PLS as of December 31, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, representing a <ix:nonFraction unitRef="number" contextRef="c-298" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-1187">17.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-297" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-1188">18.7</ix:nonFraction>% ownership interest, respectively. One </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December&#160;31, 2023,  2022 and 2021, the Company recognized revenue from PLS of $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="f-1189">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-1190">34,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-1191">245,000</ix:nonFraction>, respectively. At December 31, 2023 and 2022, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="f-1192">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-1193">59,000</ix:nonFraction>, respectively, related to PLS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1184-2"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-5" name="ino:CollaborativeAgreementExpensesToReimburse" format="ixt:num-dot-decimal" scale="6" id="f-1194">3.1</ix:nonFraction> million during the <ix:nonNumeric contextRef="c-304" name="ino:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="f-1195">five-year</ix:nonNumeric> term of the agreement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the exclusive right to in-license new intellectual property developed under this agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="f-1196">10.7</ix:nonFraction>&#160;million sub-grant through Wistar, which was amended in 2021 to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-5" name="ino:CollaborativeAgreementAmendedAmount" format="ixt:num-dot-decimal" scale="6" id="f-1197">13.6</ix:nonFraction>&#160;million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding extended through August 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The sub-grant also includes an option for an additional $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-5" name="ino:CollaborativeAgreementAwardedOptionAmount" format="ixt:num-dot-decimal" scale="6" id="f-1198">1.6</ix:nonFraction>&#160;million in funding through September 2025. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="f-1199">1.2</ix:nonFraction>&#160;million sub-grant through Wistar with funding through November 2023, with an option for an additional $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="ino:CollaborativeAgreementAwardedOptionAmount" format="ixt:num-dot-decimal" scale="6" id="f-1200">5.4</ix:nonFraction>&#160;million in funding through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched nanoparticles (dLNPs) for vaccination against HIV infection.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2023 and 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="f-1201">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="f-1202">8.7</ix:nonFraction> million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December&#160;31, 2023, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-1203">1.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-1204">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1205">2.9</ix:nonFraction>&#160;million, respectively. At December&#160;31, 2023 and 2022, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-1206">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-1207">9.9</ix:nonFraction> million, respectively, and an accounts payable and accrued liability balance of $<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1208">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1209">1.2</ix:nonFraction> million, respectively, related to Wistar. As of December&#160;31, 2023 and 2022, the Company had a prepaid expense balance of $<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-1210">20,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-1211">375,000</ix:nonFraction>, respectively, and recorded $<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="ino:DeferredGrantFundingFromAffiliate" format="ixt:num-dot-decimal" scale="0" id="f-1212">22,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="ino:DeferredGrantFundingFromAffiliate" format="ixt:num-dot-decimal" scale="0" id="f-1213">88,000</ix:nonFraction>, respectively, as deferred grant funding on its consolidated balance sheet related to Wistar.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-1214" continuedAt="f-1214-1" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><ix:continuation id="f-1214-1" continuedAt="f-1214-2"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a series of financing transactions through June 2020, the Company less than a majority of the outstanding equity of Geneos on an as-converted to common stock basis, which triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance. Accordingly, the Company deconsolidated its investment in Geneos in 2020.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its investment at fair value. The Company determined that its investment in Geneos did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment is marked to fair value.&#160;There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" sign="-" name="ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" format="ixt:num-dot-decimal" scale="6" id="f-1215">1.5</ix:nonFraction>&#160;million; however, only $<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="f-1216">434,000</ix:nonFraction> was recorded, reducing the Company's total investment in Geneos to $<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-1217">0</ix:nonFraction>. Of the total amount, $<ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="f-1218">819,000</ix:nonFraction> was allocated to the equity method investment, reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-1219">0</ix:nonFraction> as of March 31, 2021. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-1220">4.2</ix:nonFraction> million loss was allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-1221">0</ix:nonFraction> as of March 31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1214-2" continuedAt="f-1214-3"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of its Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="c-321" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-1222">35</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-1223">2.0</ix:nonFraction>&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="c-323" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-1224">28</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-2 preferred stock was based on the per share price paid by third-party investors. The Company concluded that its Series A-2 preferred stock investment was a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="f-1225">165,000</ix:nonFraction>.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1226">2.2</ix:nonFraction>&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-1227">0</ix:nonFraction> as of March 31, 2022.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not made any further investment in Geneos subsequent to March 31, 2022. The Company will not reduce its investment below $<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-1228">0</ix:nonFraction> and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, Geneos completed the closing of its Series A-3 preferred stock financing, in which the Company did not participate. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="c-326" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-1229">23</ix:nonFraction>% of the outstanding equity of Geneos on an as-converted to common stock basis. </span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="f-1214-3" continuedAt="f-1214-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1214-4">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</ix:continuation>  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="icdf8b8d8a6a143b2a034e3544027d42d_190"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1230" continuedAt="f-1230-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-1230-1"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2024, the Company implemented the 1-for-12  reverse stock split described in Note 2.  All share information contained within this report, including the accompanying consolidated financial statements and footnotes, have been retroactively adjusted to reflect the effects of the reverse split.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January 1, 2024 through the date of these financial statements, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-327" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1231">543,620</ix:nonFraction> shares of common stock under the 2021 Sales Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1232">5.2</ix:nonFraction>&#160;million.  The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-328" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-1233">9.76</ix:nonFraction> per share.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, the Company's Convertible Senior Notes matured and the Company paid the $<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-1234">16.9</ix:nonFraction>&#160;million obligation in full.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>2
<FILENAME>ino-12312023x10kex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib2849345e7cb41548e15b0a3029fa475_40"></div><div style="min-height:94.32pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:396pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FIRST AMENDMENT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO THE AMENDED AND RESTATED</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LICENSE AND COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This First Amendment to the Amended and Restated License and Collaboration Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), dated as of June 14, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First Amendment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is entered into by and between Beijing Apollo Saturn Biological Technology Limited, a People&#8217;s Republic of China corporation having a principal place of business at B2358 Second Floor, Building 3, No8 Hangfeng Road, Fengtai, Beijing, China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Apollo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Inovio Pharmaceuticals, Inc., a Delaware corporation having a principal place of business at 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, U.S.A.  (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Inovio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Apollo and Inovio may be referred to herein, collectively, as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or, individually, as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties entered into the Amended and Restated License and Collaboration Agreement dated December 29, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties now desire to maintain the Agreement and modify certain rights and obligations under the Agreement by way of this First Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual covenants, agreements and stipulations set forth herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless otherwise defined in this First Amendment, initially capitalized terms used herein shall have the respective meanings given in the Agreement.  </font></div><div style="margin-top:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE II</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT TO THE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1&#160;&#160;&#160;&#160;Section 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Effective as of the First Amendment Date, Section 1.4 of the Agreement is hereby deleted in its entirety and replaced with the following new Section 1.4&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;1.4&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CFDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the National Medical Products Administration (f&#47;k&#47;a China Food and Drug Administration), including without limitation the Center for Drug Evaluation, or any successor entity(ies) thereto performing similar functions.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2&#160;&#160;&#160;&#160;Section 1.17.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective as of the First Amendment Date, Section 1.17 of the Agreement is hereby deleted in its entirety and replaced with the following new Section 1.17&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;1.17 &#8220;Field&#8221; shall mean the diagnosis, treatment and&#47;or prevention of any disease or health condition in humans or animals, including without limitation&#58; (1) pre-dysplastic HPV infections including persistent HPV infections and (2) HPV-driven dysplasias of the genital tract including low grade squamous intraepithelial (LSIL) and high grade squamous intraepithelial (HSIL) of the cervix (previously known as CIN1, CIN2 or CIN3) or vulva, vagina and anus or head and neck&#59; provided that (a) such disease or health condition does not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">involve any HPV driven cancers and (b) excludes any and all combinations of VGX-3100 with other immunostimulants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.4&#160;&#160;&#160;&#160;Section 6.2(a)(2)(b).  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective as of the First Amendment Date, the Section 6.2(a)(2)(b) is hereby added to the Agreement in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;(b) first Marketing Approval, by Apollo, its Affiliates or Sublicensees, of the Product in the indication of cervical dysplasia or other indication within the Field by the CFDA</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the sake of clarity, the Parties agree that cervical dysplasia encompasses cervical high grade squamous intraepithelial neoplasia (HSIL) and cervical intraepithelial neoplasia (CIN) grade 1, 2 or 3&#59; but does not include vulvar or anal intraepithelial neoplasias or persistent infection. For clarity, the maximum total amount payable under Section 6.2(a)(1) is $15,000,000.&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.5&#160;&#160;&#160;&#160;Section 6.3(f). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Effective as of the First Amendment Date, the Section 6.3(f) is hereby added to the Agreement in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.3(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  For purposes of clarity, Apollo shall pay separate Royalties to Inovio, as set forth in this Section 6.3, on the Net Sales of Product in connection with each indication included within the Field.&#8221;</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE III</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GENERAL</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.1&#160;&#160;&#160;&#160;No Other Modifications.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as specifically set forth in this First Amendment, the terms and conditions of the Agreement shall remain in full force and effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.2&#160;&#160;&#160;&#160;Governing Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This First Amendment and any dispute arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the State of New York, without reference to conflicts of laws principles.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.3&#160;&#160;&#160;&#160;Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This First Amendment does not waive or release any rights or interests of either Party under the Agreement. The failure of a Party to assert a right hereunder or under the Agreement or to insist upon compliance with any term or condition of this First Amendment or the Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition. No waiver by a Party of any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.4&#160;&#160;&#160;&#160;Miscellaneous.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This First Amendment may be executed in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.  This First Amendment may be executed by the exchange of signature pages in electronic format (including PDF) or digital signatures.  </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Intentionally left blank&#59; signature page follows&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="ib2849345e7cb41548e15b0a3029fa475_43"></div><hr style="page-break-after:always"><div style="min-height:86.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties have caused this First Amendment to be executed as of the First Amendment Date by their duly authorized representatives.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BEIJING APOLLO SATURN BIOLOGICAL TECHNOLOGY LIMITED</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Li Shu, Ph.D.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;Li Shu, Ph.D.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">19 June 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Jacqueline Shea&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Jacqueline Shea, Ph.D.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">President &#38; CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15 June 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>3
<FILENAME>ino-123123x10kex1017.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i443074c168d647eda1df60c452f2abad_64"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.17</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SEVERANCE PLAN </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SUMMARY PLAN DESCRIPTION</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPROVED BY THE BOARD OF DIRECTORS&#58;  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Introduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The purpose of this Inovio Pharmaceuticals, Inc. Severance Plan (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is to provide specified severance benefits to eligible executives of the Company (as defined below) whose employment is terminated by the Company or a successor under certain circumstances.  This Plan is an &#8220;employee welfare benefit plan,&#8221; as defined in Section&#160;3(1) of ERISA (as defined below).  With the exception of certain definitions set forth below, and subject to Section 6, this Plan shall supersede any individual agreement between the Company and any Covered Employee (as defined below) and any other plan, policy or practice, whether written or unwritten, maintained by the Company with respect to a Covered Employee, in each case to the extent that such agreement, plan, policy or practice provides for equity acceleration or severance benefits upon the Covered Employee&#8217;s separation from the Company.  This document constitutes both the written instrument under which the Plan is maintained and the required summary plan description for the Plan. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For purposes of the Plan, the terms below are defined as follows&#58; </font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Board or Compensation Committee prior to a Change in Control (as defined below)&#59; or, after a Change in Control, one or more members of the successor Board or Compensation Committee or other persons designated by the Company&#8217;s Board or Compensation Committee prior to such Change in Control.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to such Covered Employees that the Company has determined in its sole discretion that the Covered Employee has engaged in any one or more of the following&#58; (i) the Covered Employee&#8217;s commission of a felony&#59; (ii) any act or omission of the Covered Employee constituting dishonesty, fraud, immoral, or disreputable conduct that causes or could reasonably cause material harm to the Company&#59; (iii) the Covered Employee&#8217;s violation of Company policy that causes or could reasonably cause material harm to the Company&#59; (iv) the Covered Employee&#8217;s material breach of any written agreement between the Covered Employee and the Company which, if curable, remains uncured for thirty (30) days after notice&#59; or (v) the Covered Employee&#8217;s breach of fiduciary duty or other statutory or common law duty owed to the Company.  </font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning ascribed to such term in the Stock Plan.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the time period beginning on the date on which a Change in Control becomes effective and ending on the first anniversary of the effective date of such Change in Control (except as otherwise set forth in a Participation Agreement). </font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.8&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Inovio Pharmaceuticals, Inc. and any successor. </font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.9&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Compensation Committee of the Board.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.10&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Covered Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an employee of the Company who (i) is the Company&#8217;s Chief Executive Officer or&#160;has been designated by the Administrator to participate in the Plan, (ii) has executed the Company&#8217;s standard confidentially and inventions assignment agreement, and (iii) has timely and properly executed and delivered a Participation Agreement to the Company.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.11&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Covered Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Covered Employee&#8217;s termination of employment by the Company (or any parent or subsidiary of the Company) without Cause or as a result of a Covered Employee&#8217;s resignation for Good Reason&#59; provided, that, in either case, such termination is not due to the Covered Employee&#8217;s death or disability.</font></div><div style="text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.12&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a termination because a Covered Employee is unable due to a physical or mental condition to perform the essential functions of the Covered Employee&#8217;s position with or without reasonable accommodation for six (6) months in the aggregate during any twelve (12) month period or based on the written certification by two licensed physicians of the likely continuation of such condition for such period.  This definition shall be interpreted and applied consistent with the Americans with Disabilities Act, the Family and Medical Leave Act, and other applicable law. </font></div><div style="padding-left:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.13&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disability Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Covered Employee&#8217;s termination of employment by the Company (or any parent or subsidiary of the Company) due to such Covered Employee&#8217;s Disability.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.14&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the date on which the Plan is approved by the Board.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.15&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Employee Retirement Income Security Act of 1974, as amended. </font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.16&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to such Covered Employee, any of the following conditions or actions taken by the Company without Cause and without such Covered Employee&#8217;s consent&#58; (i) a material breach by the Company of an agreement between a Covered Employee and the Company&#59; (ii) the Company significantly reducing the Covered Employee&#8217;s base salary or the target percentage eligibility established for the Covered Employee&#8217;s annual bonus, other than any Company-wide reduction in compensation of employees&#59; (iii) the Company significantly reducing the Covered Employee&#8217;s duties, authority or responsibilities relative to the Covered Employee&#8217;s duties, authority or responsibilities in effect immediately prior to such reduction&#59; or (iv) the relocation of the Covered Employee&#8217;s principal place of employment by fifty (50) or more miles from the Covered Employee&#8217;s then-current principal place of employment&#59; provided, further, that in each case above, in order for the Covered Employee&#8217;s resignation to be deemed to have been for Good Reason, the Covered Employee must first give the Company written notice of the action or omission giving rise to &#8220;Good Reason&#8221; within thirty (30) days after the first occurrence thereof&#59; the Company must fail to reasonably cure such action or omission within thirty (30) days after receipt of such notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and the Covered Employee&#8217;s resignation must be effective not later than thirty (30) days after the expiration of such Cure Period. </font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.17&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Participation Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an agreement between a Covered Employee and the Company in substantially the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> attached hereto, and which may include such other terms as the Administrator deems necessary or advisable in the administration of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.18&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an equity award that vests only upon satisfaction of performance criteria.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.19&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the compensation and other benefits the Covered Employee will be provided pursuant to Section&#160;4. </font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.20&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Company&#8217;s 2023 Omnibus Incentive Plan, as amended or amended and restated from time to time, or any successor thereto.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.21&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Covered Employee&#8217;s last day of employment with the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Eligibility for Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  An individual is eligible for Severance Benefits under the Plan, in the amounts set forth in Section&#160;4, only if such individual is a Covered Employee on the date </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such individual experiences a Covered Termination, or, as applicable and as described more fully in Section 4, a Disability Termination or such Covered Employee&#8217;s death during their employment.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-indent:86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.1&#160;&#160;&#160;&#160;Covered Termination </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Outside</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> the Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If, at any time outside of the Change in Control Period, a Covered Employee experiences a Covered Termination, then, subject to the Covered Employee&#8217;s compliance with Section&#160;5 and the conditions set forth in this Plan, the Covered Employee shall receive the following Severance Benefits from the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Standard Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#58; </font></div><div style="margin-bottom:12pt;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.1.1&#160;&#160;&#160;&#160;Cash Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Covered Employee shall receive cash severance in an amount equal to the Covered Employee&#8217;s base salary (as in effect immediately prior to any reduction giving rise to Good Reason, if applicable) for the applicable number of months set forth in the Covered Employee&#8217;s Participation Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Standard Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The cash amount shall be paid, less applicable tax withholdings, in equal installments on the Company&#8217;s regular payroll schedule, provided, that no payment shall be made prior to the first payroll date following the effective date of the Release (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  On the Initial Payment Date, the Company shall pay the Covered Employee in a lump sum the cash amount that the Covered Employee would have received on or prior to the Initial Payment Date under the original schedule but for the delay while waiting for the Initial Payment Date in compliance with Section&#160;409A (as defined below) and the effectiveness of the Release (as defined below), with the balance of the cash amount being paid as originally scheduled.  Notwithstanding the foregoing, the Company may pay the cash amount in the form of a lump sum, which amount will be paid on the Initial Payment Date, but such lump sum payment shall be made only if the Company, in consultation with its advisors, determines that such payment will not result in adverse taxation under Section&#160;409A.</font></div><div style="margin-bottom:12pt;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.1.2&#160;&#160;&#160;&#160;COBRA Premiums</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Provided the Covered Employee is eligible for and timely makes the necessary elections for continuation coverage pursuant to COBRA the Company shall pay the applicable premiums (inclusive of premiums for the Covered Employee&#8217;s dependents) for such coverage following the date of the Covered Employee&#8217;s Covered Termination for the Standard Severance Period (such period of months, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Standard COBRA Payment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (but in no event after such time as the Covered Employee is eligible for coverage under a health, dental or vision insurance plan of a subsequent employer or as the Covered Employee and the Covered Employee&#8217;s dependents are no longer eligible for COBRA coverage).  The Covered Employee shall notify the Company immediately if the Covered Employee becomes covered by a health, dental, or vision insurance plan of a subsequent employer or if the Covered Employee&#8217;s dependents are no longer eligible for COBRA coverage.  Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then in lieu of paying COBRA premiums on the Covered Employee&#8217;s behalf, the Company will instead pay such Covered Employee on the last day of each remaining month of the Standard COBRA Payment Period a fully taxable cash payment equal to the COBRA premium for that month, subject to applicable tax withholding (such amount, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Special Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), such Special Severance Payment to be made without regard to the Covered Employee&#8217;s election of COBRA coverage or payment of COBRA premiums and without regard to such Covered Employee&#8217;s continued eligibility for COBRA coverage during the Standard COBRA Payment Period.  Such Special Severance Payment shall end upon expiration of the Standard COBRA Payment Period.</font></div><div style="margin-bottom:12pt;text-indent:85.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.2&#160;&#160;&#160;&#160;Covered Termination During the Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If, at any time during the Change in Control Period, a Covered Employee experiences a Covered Termination, then, subject to the Covered Employee&#8217;s compliance with Section&#160;5 and the conditions set forth in this Plan, the Covered Employee shall receive the following Severance Benefits from the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">CIC Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#58; </font></div><div style="margin-bottom:12pt;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.2.1&#160;&#160;&#160;&#160;Cash Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Covered Employee shall receive cash severance in an amount equal to the Covered Employee&#8217;s base salary (as in effect immediately prior to any reduction giving rise to Good Reason, if applicable) for the applicable number of months set forth in the Covered Employee&#8217;s Participation Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">CIC Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The cash amount shall be paid, less applicable tax withholdings, in equal installments on the Company&#8217;s regular payroll schedule, provided, that no payment shall be made prior to the Initial Payment Date.  On the Initial Payment Date, the Company shall pay the Covered Employee in a lump sum the cash amount that the Covered Employee would have received on or prior to the Initial Payment Date under the original schedule but for the delay while waiting for the Initial Payment Date </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in compliance with Section&#160;409A (as defined below) and the effectiveness of the Release, with the balance of the cash amount being paid as originally scheduled.  Notwithstanding the foregoing, the Company may pay the cash amount in the form of a lump sum, which amount will be paid on the Initial Payment Date, but such lump sum payment shall be made only if the Company, in consultation with its advisors, determines that such payment will not result in adverse taxation under Section&#160;409A.</font></div><div style="margin-bottom:12pt;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.2.2&#160;&#160;&#160;&#160;Target Annual Bonus Entitlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Covered Employee will additionally be eligible to receive a multiple of such Covered Employee&#8217;s target annual bonus, as established by the Board for the year in which the Covered Termination occurs and set forth on the Covered Employee&#8217;s Participation Agreement.  Such payment shall be paid, less applicable tax withholdings, in equal installments on the Company&#8217;s regular payroll schedule, provided, that no payment shall be made prior to the Initial Payment Date.  On the Initial Payment Date, the Company shall pay the Covered Employee in a lump sum the cash amount that the Covered Employee would have received on or prior to the Initial Payment Date under the original schedule but for the delay while waiting for Initial Payment Date in compliance with Section&#160;409A (as defined below) and the effectiveness of the Release, with the balance of the cash amount being paid as originally scheduled.  Notwithstanding the foregoing, the Company may pay the cash amount in the form of a lump sum, which amount will be paid on the Initial Payment Date, but such lump sum payment shall be made only if the Company, in consultation with its advisors, determines that such payment will not result in adverse taxation under Section&#160;409A.</font></div><div style="margin-bottom:12pt;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.2.3&#160;&#160;&#160;&#160;COBRA Premiums</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Provided the Covered Employee is eligible for and timely makes the necessary elections for continuation coverage pursuant to COBRA, the Company shall pay the applicable premiums (inclusive of premiums for the Covered Employee&#8217;s dependents) for such coverage following the date of the Covered Employee&#8217;s Covered Termination for up to the CIC Severance Period (such period of months, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">CIC COBRA Payment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (but in no event after such time as the Covered Employee is eligible for coverage under a health, dental or vision insurance plan of a subsequent employer or as the Covered Employee and the Covered Employee&#8217;s dependents are no longer eligible for COBRA coverage).  The Covered Employee shall notify the Company immediately if the Covered Employee becomes covered by a health, dental, or vision insurance plan of a subsequent employer or if the Covered Employee&#8217;s dependents are no longer eligible for COBRA coverage.  Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then in lieu of paying COBRA premiums on the Covered Employee&#8217;s behalf, the Company will instead pay such Covered Employee on the last day of each remaining month of the CIC COBRA Payment Period a Special Severance Payment to be made without regard to the Covered Employee&#8217;s election of COBRA coverage or payment of COBRA premiums and without regard to such Covered Employee&#8217;s continued eligibility for COBRA coverage during the CIC COBRA Payment Period.  Such Special Severance Payment shall end upon expiration of the CIC COBRA Payment Period.</font></div><div style="margin-bottom:12pt;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.2.4&#160;&#160;&#160;&#160;Equity Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each of the Covered Employee&#8217;s then-outstanding equity awards subject to time-based vesting shall accelerate and become vested and exercisable as to the percentage of the unvested shares subject to the equity award set forth in the Covered Employee&#8217;s Participation Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Acceleration Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), except any award granted after the Effective Date that explicitly overrides this provision in writing.  </font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to Section 5, the accelerated vesting described in this section shall be effective as of the Termination Date.  Notwithstanding anything herein to the contrary, nothing in the Plan shall limit the Company&#8217;s ability to accelerate vesting and&#47;or exercisability of outstanding equity awards pursuant to the terms of the applicable equity incentive plan of the Company.  In order to give effect to the intent of the foregoing provision, notwithstanding anything to the contrary set forth in the applicable equity incentive plan of the Company or the applicable equity award agreements that provide that any then-unvested portion of the Covered Employee&#8217;s award will immediately expire upon such Covered Employee&#8217;s termination of service, such Covered Employee&#8217;s equity awards shall remain outstanding following such Covered Employee&#8217;s Covered Termination to give effect to such acceleration as necessary.</font></div><div style="margin-bottom:12pt;text-indent:85.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.3&#160;&#160;&#160;&#160;Disability Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If, at any time a Covered Employee experiences a Disability Termination, then, subject to the Covered Employee&#8217;s compliance with Section&#160;5 and the conditions set forth in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">this Plan, the Covered Employee shall receive the following Disability Severance Benefits from the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disability Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#58; </font></div><div style="margin-bottom:12pt;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.3.1&#160;&#160;&#160;&#160;Cash Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Covered Employee shall receive cash severance in an amount equal to the Covered Employee&#8217;s base salary (as in effect immediately prior to any reduction giving rise to Good Reason, if applicable) for the applicable number of months set forth in the Covered Employee&#8217;s Participation Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disability Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The cash amount shall be paid, less applicable tax withholdings, in equal installments on the Company&#8217;s regular payroll schedule, provided, that no payment shall be made prior to the Initial Payment Date.  On the Initial Payment Date, the Company shall pay the Covered Employee in a lump sum the cash amount that the Covered Employee would have received on or prior to the Initial Payment Date under the original schedule but for the delay while waiting for the Initial Payment Date in compliance with Section&#160;409A (as defined below) and the effectiveness of the Release, with the balance of the cash amount being paid as originally scheduled.  Notwithstanding the foregoing, the Company may pay the cash amount in the form of a lump sum, which amount will be paid on the Initial Payment Date, but such lump sum payment shall be made only if the Company, in consultation with its advisors, determines that such payment will not result in adverse taxation under Section&#160;409A.</font></div><div style="margin-bottom:12pt;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.3.2&#160;&#160;&#160;&#160;COBRA Premiums</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Provided the Covered Employee is eligible for and timely makes the necessary elections for continuation coverage pursuant to COBRA, the Company shall pay the applicable premiums (inclusive of premiums for the Covered Employee&#8217;s dependents) for such coverage following the date of the Covered Employee&#8217;s Disability Termination for up to the Disability Severance Period (such period of months, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disability COBRA Payment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (but in no event after such time as the Covered Employee is eligible for coverage under a health, dental or vision insurance plan of a subsequent employer or as the Covered Employee and the Covered Employee&#8217;s dependents are no longer eligible for COBRA coverage).  The Covered Employee shall notify the Company immediately if the Covered Employee becomes covered by a health, dental, or vision insurance plan of a subsequent employer or if the Covered Employee&#8217;s dependents are no longer eligible for COBRA coverage.  Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then in lieu of paying COBRA premiums on the Covered Employee&#8217;s behalf, the Company will instead pay such Covered Employee on the last day of each remaining month of the Disability COBRA Payment Period a Special Severance Payment to be made without regard to the Covered Employee&#8217;s election of COBRA coverage or payment of COBRA premiums and without regard to such Covered Employee&#8217;s continued eligibility for COBRA coverage during the Disability COBRA Payment Period.  Such Special Severance Payment shall end upon expiration of the CIC COBRA Payment Period.</font></div><div style="text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.3.3&#160;&#160;&#160;&#160;Equity Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each of the Covered Employee&#8217;s then-outstanding equity awards, other than Performance Awards, shall continue to vest on the original vesting dates notwithstanding such Disability Termination, except any award granted after the Effective Date that explicitly overrides this provision in writing. In addition, Performance Awards held by the Covered Employee shall remain outstanding and eligible to vest based on the Company&#8217;s actual performance through the end of the applicable performance period.</font></div><div style="padding-left:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:85.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.4&#160;&#160;&#160;&#160;Termination due to Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If, at any time a Covered Employee experiences a termination due to such Covered Employee&#8217;s death, then, the Covered Employee&#8217;s estate shall receive the following Death Severance Benefits from the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Death Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#58; </font></div><div style="margin-bottom:12pt;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">4.4.1&#160;&#160;&#160;&#160;Equity Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each of the Covered Employee&#8217;s then-outstanding equity awards, other than Performance Awards, shall accelerate and become vested based on the Equity Acceleration Percentage, except any award granted after the Effective Date that explicitly overrides this provision in writing.  In addition, Performance Awards held by the Covered Employee shall remain outstanding and eligible to vest based on the Company&#8217;s actual performance through the end of the applicable performance period.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Conditions to Receipt of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">5.1&#160;&#160;&#160;&#160;Release Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As a condition to receiving any Severance Benefits described in Section 4 herein, a Covered Employee (or the representative for such Covered Employee&#8217;s estate, as applicable) must sign a separation agreement containing among other provisions, a release of all claims in favor of the Company and its subsidiaries and affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in such form as may be provided by the Company.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Release must become effective in accordance with its terms, which must occur in no event more than sixty (60) days following the date of the applicable Covered Termination, Disability Termination or termination due to such Covered Employee&#8217;s death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In no event shall payment of any benefits under the Plan be made prior to a Covered Employee&#8217;s Termination Date or prior to the effective date of the Release.  If the Company determines that any payments or benefits provided under the Plan constitute &#8220;deferred compensation&#8221; under Section 409A, and the Covered Employee&#8217;s Termination Date occurs at a time during the calendar year when the Release could become effective in the calendar year following the calendar year in which the Covered Employee&#8217;s &#8220;separation from service&#8221; within the meaning of Section&#160;409A of the Code and the final regulations and any guidance promulgated thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) occurs, then regardless of when the Release is returned to the Company and becomes effective, the Release will not be deemed effective any earlier than the latest permitted effective date&#59; provided, that except to the extent that payments may be delayed in accordance with Section , on the first regular payroll date following the effective date of a Covered Employee&#8217;s Release, the Company shall (i) pay the Covered Employee a lump sum amount equal to the sum of the appliable Severance Benefits that the Covered Employee would otherwise have received through such payroll date but for the delay in payment related to the effectiveness of the Release and (ii)&#160;commence paying the balance, if any, of the Severance Benefits in accordance with the applicable payment schedule.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">5.2&#160;&#160;&#160;&#160;Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A Covered Employee&#8217;s receipt of Severance Benefits pursuant to Section&#160;4 will be subject to such Covered Employee&#8217;s continued material compliance with the terms of the Release, the Participation Agreement, the non-disparagement provisions of a separation agreement provided by the Company, and any confidential information agreement, proprietary information and inventions agreement and any other agreement between the Covered Employee and the Company.  Severance Benefits under this Plan shall terminate immediately for a Covered Employee if such Covered Employee is in material violation, at any time, of any legal or contractual obligation owed to the Company. </font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">5.3&#160;&#160;&#160;&#160;Section 280G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any provision of the Plan to the contrary notwithstanding, if any payment or benefit a Covered Employee would receive from the Company and its subsidiaries or an acquiror pursuant to the Plan or otherwise (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii)&#160;but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then such Payment will be equal to the Higher Amount.  The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Higher Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; will be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Covered Employee&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in payments or benefits constituting &#8220;parachute payments&#8221; within the meaning of Section 280G of the Code is necessary so that the Payment equals the Higher Amount, reduction will occur in the manner that results in the greatest economic benefit for a Covered Employee and, to the extent applicable, complies with Section 409A.  In no event will the Company, any subsidiary or any stockholder be liable to any Covered Employee for any amounts not paid as a result of the operation of this Section&#160;5.3.  The Company will use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to a Covered Employee and the Company within fifteen (15) calendar days after the date on which such Covered Employee&#8217;s right to a Payment is triggered (if requested at that time by such Covered Employee or the Company) or such other time as requested by such Covered Employee or the Company.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Non-Duplication of Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Severance Benefits provided to a Covered Employee are intended to be and are exclusive and in lieu of any other change in control severance benefits or payments to which such Covered Employee may otherwise be eligible, either at law, tort, or contract, in equity, or under the Plan, in the event of any termination of such Covered Employee&#8217;s employment.  The Covered Employee will be eligible to no change in control severance benefits or payments upon a termination of employment that constitutes a Covered Termination other than those benefits expressly set forth herein and those benefits required to be provided by applicable law or as negotiated in accordance with applicable law (including any severance benefits that may be included in a severance agreement, employment agreement or similar contract between the Company or a subsidiary of the Company and the Covered Employee).  Notwithstanding the foregoing, if a Covered Employee is eligible to any benefits other than the benefits under the Plan by operation of applicable law or as negotiated in accordance with applicable law, such Covered Employee&#8217;s benefits under the Plan shall be provided only to the extent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">more favorable than such other arrangement.  The Administrator, in its sole discretion, shall have the authority to reduce or otherwise adjust a Covered Employee&#8217;s benefits under the Plan, in whole or in part, by any other severance benefits, pay and benefits in lieu of notice, or other similar benefits payable to such Covered Employee under the Plan that become payable in connection with the Covered Employee&#8217;s termination of employment pursuant to (i) any applicable legal requirement, including the Worker Adjustment and Retraining Notification Act (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">WARN Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), or any other similar state law, or (ii) any policy or practice of the Company providing for the Covered Employee to remain on payroll for a limited period of time after being given notice of termination.  The benefits provided under the Plan are intended to satisfy, in whole or in part, any and all statutory obligations of the Company that may arise out of a Covered Employee&#8217;s termination of employment, and the Administrator shall so construe and implement the terms of the Plan. Notwithstanding anything in this Section 6 to the contrary, to the extent a Covered Employee is a party to a written agreement with the Company, including but not limited to any outstanding equity awards, and such written agreement explicitly provides severance benefits specific to equity acceleration in the event the Company undergoes a Change in Control and&#47;or the Covered Employee is terminated in a Covered Termination, a Disability  Termination or due to death, then the terms of such written agreement shall control with respect to such equity acceleration terms that are more favorable to the Covered Employee than those of this Plan (as determined by the Company in its sole discretion).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Clawback&#59; Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All payments and Severance Benefits provided under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.  In addition, the Administrator may impose such other clawback, recovery or recoupment provisions as the Administrator determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of common stock of the Company or other cash or property upon the occurrence of a termination of employment for Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for Good Reason, constructive termination, or any similar term under any plan of or agreement with the Company.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Plan, no severance payments or benefits will become payable until the Covered Employee has a &#8220;separation from service&#8221; within the meaning of Section&#160;409A.  Further, if some or all of the Covered Employee&#8217;s Severance Benefits are subject to Section&#160;409A and such Covered Employee is a &#8220;specified employee&#8221; within the meaning of Section&#160;409A at the time of such Covered Employee&#8217;s separation from service (other than due to death), then such Severance Benefits otherwise due to such Covered Employee on or within the six-month period following such Covered Employee&#8217;s separation from service will accrue during such six-month period and will become payable in a lump sum payment (less applicable withholding taxes) on the date six months and one day following the date of the Covered Employee&#8217;s separation from service if necessary to avoid adverse taxation under Section 409A.  All subsequent payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.  Notwithstanding anything herein to the contrary, if the Covered Employee dies following such Covered Employee&#8217;s separation from service but prior to the six-month anniversary of such Covered Employee&#8217;s date of separation, then any payments delayed in accordance with this paragraph will be payable in a lump sum (less applicable withholding taxes) to the Covered Employee&#8217;s estate as soon as administratively practicable after the date of such Covered Employee&#8217;s death and all other benefits will be payable in accordance with the payment schedule applicable to each payment or benefit.  Each payment and benefit payable under the Plan is intended to constitute a separate payment for purposes of Section&#160;409A.  It is the intent of this Plan to comply with or be exempt from the requirements of Section&#160;409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section&#160;409A, and any ambiguities herein will be interpreted to so comply. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under the Plan comply with Section&#160;409A, and in no event shall the Company or any of its representatives be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by the Covered Employee on account of non-compliance with Section&#160;409A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company will withhold from any Severance Benefits all federal, state, local and other taxes required to be withheld therefrom and any other required payroll deductions. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Plan will be administered and interpreted by the Administrator (in the Administrator&#8217;s sole discretion).  The Administrator is the &#8220;named fiduciary&#8221; of the Plan for purposes of ERISA and will be subject to the fiduciary standards of ERISA when acting in such capacity.  Any decision made or other action taken by the Administrator with respect to the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related document, will be conclusive and binding on all persons and be given the maximum possible deference allowed by law.  Any decision made or other action taken by the Administrator with respect to the Plan, and any interpretation by the Administrator of any term or condition of the Plan, or any related document that (i)&#160;does not affect the benefits payable under the Plan shall not be subject to review unless found to be arbitrary and capricious or (ii)&#160;does affect the benefits payable under the Plan shall not be subject to review unless found to be unreasonable or not to have been made in good faith.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Amendment or Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company, by action of the Administrator, reserves the right to amend or terminate the Plan at any time, without advance notice to any Covered Employee and without regard to the effect of the amendment or termination on any Covered Employee or on any other individual.  Any amendment or termination of the Plan will be in writing.  Notwithstanding the foregoing, a Covered Employee&#8217;s rights to receive payments and benefits pursuant to this Plan under an effective Participation Agreement may not be adversely affected, without the Covered Employee&#8217;s written consent, by an amendment or termination of this Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Claims Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Claims for benefits under the Plan shall be administered in accordance with Section 503 of ERISA and the Department of Labor Regulations thereunder.  Any employee or other person who believes they are entitled to any payment under the Plan (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">claimant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) may submit a claim in writing to the Administrator within ninety (90)&#160;days of the earlier of (i)&#160;the date the claimant learned the amount of such claimant&#8217;s Severance Benefits under the Plan or (ii)&#160;the date the claimant learned that they will not be eligible to any benefits under the Plan.  In determining claims for benefits, the Administrator or its delegate has the authority to interpret the Plan, to resolve ambiguities, to make factual determinations, and to resolve questions relating to eligibility for and amount of benefits.  If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based.  The notice will also describe any additional information or material that the Administrator needs to complete the review and an explanation of why such information or material is necessary and the Plan&#8217;s procedures for appealing the denial (including a statement of the applicant&#8217;s right to bring a civil action under Section 502(a) of ERISA following a denial on review of the claim, as described below).  The denial notice will be provided within ninety (90)&#160;days after the claim is received.  If special circumstances require an extension of time (up to 90&#160;days), written notice of the extension will be given to the claimant (or representative) within the initial 90-day period.  This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its decision on the claim.  If the extension is provided due to a claimant&#8217;s failure to provide sufficient information, the time frame for rendering the decision will be tolled from the date the notification is sent to the claimant about the failure to the date on which the claimant responds to the request for additional information.  The Administrator has delegated the claims review responsibility to the Company&#8217;s Chief Financial Officer or such other individual designated by the Administrator, except in the case of a claim filed by or on behalf of the Company&#8217;s Chief Financial Officer or such other individual designated by the Administrator, in which case, the claim will be reviewed by the Company&#8217;s Chief Executive Officer. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Appeal Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If the claimant&#8217;s claim is denied, the claimant (or such claimant&#8217;s authorized representative) may apply in writing to an appeals official appointed by the Administrator (which may be a person, committee or other entity) for a review of the decision denying the claim.  Review must be requested within sixty (60)&#160;days following the date the claimant received the written notice of a claim denial or else the claimant will lose the right to such review.  A request for review must set forth all the grounds on which such request is based, all facts in support of the request, and any other matters that the claimant feels are pertinent.  In connection with the request for review, the claimant (or representative) has the right to review and obtain copies of all documents and other information relevant to the claim, upon request and at no charge, and to submit written comments, documents, records and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">other information relating to such claimant&#8217;s claim.  The review shall take into account all comments, documents, records and other information submitted by the claimant (or representative) relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination.  The appeals official will provide written notice of its decision on review within 60&#160;days after it receives a review request.  If special circumstances require an extension of time (up to 60 days), written notice of the extension will be given to the claimant (or representative) within the initial 60-day period.  This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the appeals official expects to render its decision.  If the extension is provided due to a claimant&#8217;s failure to provide sufficient information, the time frame for rendering the decision on review is tolled from the date the notification is sent to the claimant about the failure to the date on which the claimant responds to the request for additional information.  If the claim is denied (in full or in part) upon review, the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based.  The notice shall also include a statement that the claimant will be provided, upon request and free of charge, reasonable access to, and copies of, all documents and other information relevant to the claim and a statement regarding the claimant&#8217;s right to bring an action under Section&#160;502(a) of ERISA.  The Administrator has delegated the appeals review responsibility to the Company&#8217;s Chief Financial Officer, except in the case of an appeal filed by or on behalf of the Company&#8217;s Chief Financial Officer, in which case, the appeal will be reviewed by the Company&#8217;s Chief Executive Officer. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No arbitration proceeding shall be brought to recover benefits under the Plan until the claims procedures described in Sections 12 and 13 have been exhausted and the Plan benefits requested have been denied in whole or in part.  Notwithstanding any other provision of the Plan, to ensure the timely and economical resolution of disputes, all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance or interpretation of this Plan will be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in Philadelphia, Pennsylvania conducted by JAMS, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) under the then-applicable JAMS rules (currently available at the following web address&#58; https&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment).  By agreeing to this arbitration procedure, each Covered Employee and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding.  Covered Employees will have the right to be represented by legal counsel at any arbitration proceeding.  In addition, all claims, disputes, or causes of action under this Section, whether by a Covered Employee or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.  The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding.  To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.  This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law or any claims alleging sexual harassment or a nonconsensual sexual action or sexual contact, to the extent such claims are not permitted by applicable law(s) to be submitted to mandatory arbitration and the applicable law(s) are not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The arbitrator shall&#58;  (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (b) issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award.  The arbitrator shall be authorized to award any or all remedies that a Covered Employee or the Company would be eligible to seek in a court of law.  The Company shall pay all JAMS&#8217; arbitration fees in excess of the amount of court fees that would be required of a Covered Employee if the dispute were decided in a court of law.  Nothing in this paragraph is intended to prevent either a Covered Employee or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.  Any arbitration must be commenced within one year after the Covered Employee&#8217;s receipt of notification that their appeal was denied.  The foregoing provisions shall apply to the extent consistent with and permitted by ERISA.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Source of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All Severance Benefits will be paid in cash from the general funds of the Company&#59; no separate fund will be established under the Plan&#59; and the Plan will have no assets.  No </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">right of any person to receive any payment under the Plan will be any greater than the right of any other general unsecured creditor of the Company. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Inalienability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In no event may any current or former employee of the Company or any of its subsidiaries or affiliates sell, transfer, anticipate, assign or otherwise dispose of any right or interest under the Plan.  At no time will any such right or interest be subject to the claims of creditors nor liable to attachment, execution or other legal process. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">No Enlargement of Employment Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Neither the establishment nor maintenance of the Plan, any amendment of the Plan, nor the making of any benefit payment hereunder, will be construed to confer upon any individual any right to be continued as an employee of the Company.  The Company expressly reserves the right to discharge any of its employees at any time, with or without Cause.  However, as described in the Plan, a Covered Employee may be eligible to benefits under the Plan depending upon the circumstances of such Covered Employee&#8217;s termination of employment. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any successor to the Company of all or substantially all of the Company&#8217;s business or assets (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) will assume the obligations under the Plan and agree expressly to perform the obligations under the Plan in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession.  For all purposes under the Plan, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; will include any successor to the Company&#8217;s business or assets which become bound by the terms of the Plan by operation of law, or otherwise. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The provisions of the Plan will be construed, administered and enforced in accordance with ERISA and, to the extent applicable, the internal substantive laws of the State of Connecticut (except its conflict of laws provisions). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any provision of the Plan is held invalid or unenforceable, its invalidity or unenforceability will not affect any other provision of the Plan, and the Plan will be construed and enforced as if such provision had not been included. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Headings in this Plan document are for purposes of reference only and will not limit or otherwise affect the meaning hereof. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Additional Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:18.73pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.147%"><tr><td style="width:1.0%"></td><td style="width:23.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.640%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Plan Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc. Severance Plan</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Plan Sponsor&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Plan Year&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fiscal year ending December 31</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Plan Administrator&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Administrator of the Inovio Pharmaceuticals, Inc. Severance Plan</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agent for Service of</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Legal Process&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Administrator of the Inovio Pharmaceuticals, Inc. Severance Plan</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Service of process may also be made upon the Administrator.</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Type of Plan&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Severance Plan&#47;Employee Welfare Benefit Plan</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Plan Costs&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The cost of the Plan is paid by the Company.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Statement of ERISA Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;As a Covered Employee under the Plan, you have certain rights and protections under ERISA&#58; </font></div><div style="margin-top:6pt;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;You may examine (without charge) all Plan documents, including any amendments and copies of all documents filed with the U.S. Department of Labor.  These documents are available for your review in the office of the Company&#8217;s Chief Financial Officer. </font></div><div style="margin-top:6pt;text-indent:48.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;You may obtain copies of all Plan documents and other Plan information upon written request to the Administrator.  A reasonable charge may be made for such copies. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In addition to creating rights for Covered Employees, ERISA imposes duties upon the people who are responsible for the operation of the Plan.  The people who operate the Plan (called &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">fiduciaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) have a duty to do so prudently and in the interests of you and the other Covered Employees.  No one, including the Company or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a benefit under the Plan or exercising your rights under ERISA.  If your claim for a severance benefit is denied, in whole or in part, you have a right to know why it was denied, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules.  The claim review procedure is explained in Sections&#160;12 and 13, above. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Under ERISA, there are steps you can take to enforce the above rights.  For instance, if you request a copy of Plan documents and do not receive them within thirty (30)&#160;days, you may file suit in a federal court.  In such a case, the court may require the Administrator to provide the materials and to pay you up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Administrator.  If you have a claim which is denied or ignored, in whole or in part, you may file suit in a federal court.  If it should happen that you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court.  The court will decide who should pay court costs and legal fees.  If you are successful, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the court may order the person you have sued to pay these costs and fees.  If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous.</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;If you have any questions regarding the Plan, please contact the Administrator.  If you have any questions about this statement or about your rights under ERISA, you may contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor (listed in your telephone directory) or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W., Washington, D.C. 20210.  You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration at 1-866-444-3272. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Appendix A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SEVERANCE PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Participation Agreement</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is pleased to inform you, &#91;&#93;, that you have been selected to participate in the Company&#8217;s Severance Plan (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all of the terms and conditions of the Plan. The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In order to become a Covered Employee under the Plan, you must complete and sign this Participation Agreement and return it to &#91;&#93; no later than &#91;&#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Plan describes in detail certain circumstances under which you may become eligible for Severance Benefits and the amount of those benefits. As described more fully in the Plan, you may become eligible for certain Severance Benefits if you experience a Covered Termination. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you become eligible for Standard Severance Benefits under Section 4.1 of the Plan, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="padding-left:58.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.307%"><tr><td style="width:1.0%"></td><td style="width:49.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash Severance Benefits</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;&#160;&#160;&#160;&#160;&#93; months</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Equity Acceleration Percentage</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COBRA Premiums</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;&#160;&#160;&#160;&#160;&#93; months</font></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you become eligible for CIC Severance Benefits under Section 4.2 of the Plan, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="padding-left:58.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.307%"><tr><td style="width:1.0%"></td><td style="width:49.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash Severance Benefits</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;&#160;&#160;&#160;&#160;&#93; months</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Target Annual Bonus Entitlement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;&#160;&#160;&#160;&#160;&#93;x</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity Acceleration Percentage</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COBRA Premiums</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;&#160;&#160;&#160;&#160;&#93; months</font></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you become eligible for Disability Severance Benefits under Section 4.3 of the Plan, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="padding-left:58.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.307%"><tr><td style="width:1.0%"></td><td style="width:49.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash Severance Benefits</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;&#160;&#160;&#160;&#160;&#93; months</font></td></tr><tr><td colspan="6" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continued Equity Vesting</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COBRA Premiums</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;&#160;&#160;&#160;&#160;&#93; months</font></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable, and otherwise comply with the requirements under Section 5 of the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In accordance with Section 6 of the Plan, the benefits, if any, provided under the Plan are intended to be the exclusive benefits for you related to your termination of employment in connection with a change in control of the Company and will supersede and replace, except as provided for in Section 6 of the Plan, any change in control severance benefits to which you otherwise would be eligible to participate in any other Company change in control severance policy, plan, agreement or other arrangement (whether or not subject to ERISA). </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan. Your signature below confirms that&#58; (i) you have received a copy of the Plan&#59; (ii) you have carefully read this Participation Agreement and the Plan and you acknowledge and agree to its terms, including, but not limited to, Section 6 of the Plan&#59; (iii) you agree that this Participation Agreement and the provisions of the Plan supersede any individual agreement between you and the Company and any other plan, policy or practice, whether written or unwritten, maintained by the Company with respect to equity acceleration or severance benefits upon your separation from the Company&#59; and (iv) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors.</font></div><div style="text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC.&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COVERED EMPLOYEE&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attachment&#58;  Inovio Pharmaceuticals, Inc. Severance Plan</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">291493709 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>4
<FILENAME>ino-123123x10kex1018.htm
<DESCRIPTION>EX-10.18
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i107a146b3b874f80b9460f9696540094_64"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.18</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SEVERANCE PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Participation Agreement</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is pleased to inform you, Jacqueline E. Shea, that you have been selected to participate in the Company&#8217;s Severance Plan (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all of the terms and conditions of the Plan and will be effective upon approval of the Plan by the Compensation Committee of the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In order to become a Covered Employee under the Plan, you must complete and sign this Participation Agreement and return it to Robert Crotty, General Counsel and Chief Compliance Officer, within fourteen (14) days of receipt.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Plan describes in detail certain circumstances under which you may become eligible for Severance Benefits and the amount of those benefits. As described more fully in the Plan, you may become eligible for certain Severance Benefits if you experience a Covered Termination. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you become eligible for Standard Severance Benefits under Section 4.1 of the Plan, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="padding-left:58.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.307%"><tr><td style="width:1.0%"></td><td style="width:49.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash Severance Benefits</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18 months</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COBRA Premiums</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18 months</font></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you become eligible for CIC Severance Benefits under Section 4.2 of the Plan, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="padding-left:58.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.307%"><tr><td style="width:1.0%"></td><td style="width:49.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash Severance Benefits</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24 months</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Target Annual Bonus Entitlement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2x</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity Acceleration Percentage</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COBRA Premiums</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24 months</font></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you become eligible for Disability Severance Benefits under Section 4.3 of the Plan, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="padding-left:58.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.307%"><tr><td style="width:1.0%"></td><td style="width:49.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash Severance Benefits</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18 months</font></td></tr><tr><td colspan="6" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continued Equity Vesting</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COBRA Premiums</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18 months</font></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable, and otherwise comply with the requirements under Section 5 of the Plan.</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">283098208 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In accordance with Section 6 of the Plan, the benefits, if any, provided under the Plan are intended to be the exclusive benefits for you related to your termination of employment in connection with a change in control of the Company and will supersede and replace, except as provided for in Section 6 of the Plan, any change in control severance benefits to which you otherwise would be eligible to participate in any other Company change in control severance policy, plan, agreement or other arrangement (whether or not subject to ERISA). </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan. Your signature below confirms that&#58; (i) you have received a copy of the Plan&#59; (ii) you have carefully read this Participation Agreement and the Plan and you acknowledge and agree to its terms, including, but not limited to, Section 6 of the Plan&#59; (iii) you agree that this Participation Agreement and the provisions of the Plan supersede any individual agreement between you and the Company and any other plan, policy or practice, whether written or unwritten, maintained by the Company with respect to equity acceleration or severance benefits upon your separation from the Company&#59; and (iv) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors.</font></div><div style="text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC.&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert Crotty&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Robert Crotty</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; General Counsel and Chief Compliance Officer</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; March 5, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COVERED EMPLOYEE&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jacqueline E. Shea&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Jacqueline E. Shea, Ph.D.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; President &#38; Chief Executive Officer</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; March 5, 2024</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attachment&#58;  Inovio Pharmaceuticals, Inc. Severance Plan</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Inovio Pharmaceuticals, Inc. Severance Plan Participation Agreement&#93;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>5
<FILENAME>ino-123123x10kex1019.htm
<DESCRIPTION>EX-10.19
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7878b96f9ecd455c9a833e815069b70c_64"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.19</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SEVERANCE PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Participation Agreement</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is pleased to inform you, Laurent M. Humeau, that you have been selected to participate in the Company&#8217;s Severance Plan (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all of the terms and conditions of the Plan and will be effective upon approval of the Plan by the Compensation Committee of the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In order to become a Covered Employee under the Plan, you must complete and sign this Participation Agreement and return it to Robert Crotty, General Counsel and Chief Compliance Officer, within fourteen (14) days of receipt.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Plan describes in detail certain circumstances under which you may become eligible for Severance Benefits and the amount of those benefits. As described more fully in the Plan, you may become eligible for certain Severance Benefits if you experience a Covered Termination. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you become eligible for Standard Severance Benefits under Section 4.1 of the Plan, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="padding-left:58.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.307%"><tr><td style="width:1.0%"></td><td style="width:49.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash Severance Benefits</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12 months</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COBRA Premiums</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12 months</font></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you become eligible for CIC Severance Benefits under Section 4.2 of the Plan, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="padding-left:58.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.307%"><tr><td style="width:1.0%"></td><td style="width:49.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash Severance Benefits</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18 months</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Target Annual Bonus Entitlement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5x</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity Acceleration Percentage</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COBRA Premiums</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18 months</font></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you become eligible for Disability Severance Benefits under Section 4.3 of the Plan, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="padding-left:58.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.307%"><tr><td style="width:1.0%"></td><td style="width:49.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash Severance Benefits</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12 months</font></td></tr><tr><td colspan="6" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continued Equity Vesting</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COBRA Premiums</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12 months</font></td></tr></table></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable, and otherwise comply with the requirements under Section 5 of the Plan.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">284274538 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In accordance with Section 6 of the Plan, the benefits, if any, provided under the Plan are intended to be the exclusive benefits for you related to your termination of employment in connection with a change in control of the Company and will supersede and replace, except as provided for in Section 6 of the Plan, any change in control severance benefits to which you otherwise would be eligible to participate in any other Company change in control severance policy, plan, agreement or other arrangement (whether or not subject to ERISA). </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan. Your signature below confirms that&#58; (i) you have received a copy of the Plan&#59; (ii) you have carefully read this Participation Agreement and the Plan and you acknowledge and agree to its terms, including, but not limited to, Section 6 of the Plan&#59; (iii) you agree that this Participation Agreement and the provisions of the Plan supersede any individual agreement between you and the Company and any other plan, policy or practice, whether written or unwritten, maintained by the Company with respect to equity acceleration or severance benefits upon your separation from the Company&#59; and (iv) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors.</font></div><div style="text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC.&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert Crotty&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Robert Crotty</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; General Counsel and Chief Compliance Officer</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; March 5, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COVERED EMPLOYEE&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Laurent M. Humeau&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Laurent M. Humeau, Ph.D.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Chief Scientific Officer</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; March 5, 2024</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attachment&#58;  Inovio Pharmaceuticals, Inc. Severance Plan</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Inovio Pharmaceuticals, Inc. Severance Plan Participation Agreement&#93;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">284274538 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>6
<FILENAME>ino-123123x10kex1020.htm
<DESCRIPTION>EX-10.20
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0b8c03e027514d4bb293ee3b4d3298b9_64"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.20</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SEVERANCE PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Participation Agreement</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is pleased to inform you, Michael Sumner, that you have been selected to participate in the Company&#8217;s Severance Plan (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is subject to all of the terms and conditions of the Plan and will be effective upon approval of the Plan by the Compensation Committee of the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The capitalized terms used but not defined herein will have the meanings ascribed to them in the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In order to become a Covered Employee under the Plan, you must complete and sign this Participation Agreement and return it to Robert Crotty, General Counsel and Chief Compliance Officer, within fourteen (14) days of receipt.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Plan describes in detail certain circumstances under which you may become eligible for Severance Benefits and the amount of those benefits. As described more fully in the Plan, you may become eligible for certain Severance Benefits if you experience a Covered Termination. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you become eligible for Standard Severance Benefits under Section 4.1 of the Plan, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="padding-left:58.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.307%"><tr><td style="width:1.0%"></td><td style="width:49.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash Severance Benefits</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12 months</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COBRA Premiums</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12 months</font></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you become eligible for CIC Severance Benefits under Section 4.2 of the Plan, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="padding-left:58.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.307%"><tr><td style="width:1.0%"></td><td style="width:49.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash Severance Benefits</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18 months</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Target Annual Bonus Entitlement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5x</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity Acceleration Percentage</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COBRA Premiums</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18 months</font></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you become eligible for Disability Severance Benefits under Section 4.3 of the Plan, then subject to the terms and conditions of the Plan, you will receive&#58;</font></div><div style="padding-left:58.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.307%"><tr><td style="width:1.0%"></td><td style="width:49.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash Severance Benefits</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12 months</font></td></tr><tr><td colspan="6" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continued Equity Vesting</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">COBRA Premiums</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12 months</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In order to receive any Severance Benefits for which you otherwise become eligible under the Plan, you must sign and deliver to the Company the Release, which must have become effective and irrevocable, and otherwise comply with the requirements under Section 5 of the Plan.</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">284277249 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In accordance with Section 6 of the Plan, the benefits, if any, provided under the Plan are intended to be the exclusive benefits for you related to your termination of employment in connection with a change in control of the Company and will supersede and replace, except as provided for in Section 6 of the Plan, any change in control severance benefits to which you otherwise would be eligible to participate in any other Company change in control severance policy, plan, agreement or other arrangement (whether or not subject to ERISA). </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By your signature below, you and the Company agree that your participation in the Plan is governed by this Participation Agreement and the provisions of the Plan. Your signature below confirms that&#58; (i) you have received a copy of the Plan&#59; (ii) you have carefully read this Participation Agreement and the Plan and you acknowledge and agree to its terms, including, but not limited to, Section 6 of the Plan&#59; (iii) you agree that this Participation Agreement and the provisions of the Plan supersede any individual agreement between you and the Company and any other plan, policy or practice, whether written or unwritten, maintained by the Company with respect to equity acceleration or severance benefits upon your separation from the Company&#59; and (iv) decisions and determinations by the Administrator under the Plan will be final and binding on you and your successors.</font></div><div style="text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC.&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert Crotty&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Robert Crotty</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; General Counsel and Chief Compliance Officer</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; March 5, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COVERED EMPLOYEE&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael Sumner&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;  Michael Sumner, M.D</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Chief Medical Officer</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; March 5, 2024</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attachment&#58;  Inovio Pharmaceuticals, Inc. Severance Plan</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Inovio Pharmaceuticals, Inc. Severance Plan Participation Agreement&#93;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">284277249 v2</font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>7
<FILENAME>ino-12312023x10kex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8f36aed115a34a7cbca8d1ac4a1c17e2_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Subsidiary Name(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inovio Asia, LLC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>ino-12312023x10kex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i74456bbd30d7475498dc910d392b9849_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3 No. 333-275445) of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 Nos. 333-142938, 333-150769, 333-161559, 333-166906, 333-174353, 333-181532, 333-192318, 333-196325, 333-209155, and 333-216061) pertaining to the 2007 Omnibus Incentive Plan, as amended, of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 Nos. 333-216059, 333-223776, 333-230337, 333-231872, 333-236201, 333-253736, 333-263167 and 333-272047) pertaining to the 2016 Omnibus Incentive Plan, as amended, of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-265944) pertaining to the Inovio Pharmaceuticals, Inc. 2022 Inducement Plan, and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-272045) pertaining to the Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our report dated March&#160;6, 2024, with respect to the consolidated financial statements of Inovio Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Inovio Pharmaceuticals, Inc. for the year ended December 31, 2023.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">March&#160;6, 2024</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>ino-12312023x10kex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i472d3af4ecc444e083a3a7c27d165724_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jacqueline E. Shea, certify that&#58; </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form&#160;10-K of Inovio Pharmaceuticals, Inc.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15(d)-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JACQUELINE E. SHEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jacqueline E. Shea</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>ino-12312023x10kex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i21a13e1f23404decbfae6aee4e2d39ec_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Kies, certify that&#58; </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form&#160;10-K of Inovio Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15(d)-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>ino-12312023x10kex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="icb348477362c424fbb17d791badf1113_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ending December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58; </font></div><div style="margin-top:9pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JACQUELINE E. SHEA</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jacqueline E. Shea</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>12
<FILENAME>ino-12312023x10kex971.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8309f3ba8745406da78625778b0a9788_123"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:360pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 97.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Incentive Compensation Recoupment Policy</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Introduction</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of Inovio Pharmaceuticals, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) providing for the Company&#8217;s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Rule 10D-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Nasdaq Listing Rule 5608 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Listing Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Effective Date</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Incentive Compensation is deemed &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; in the Company&#8217;s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Definitions</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Accounting Restatement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Compensation Committee or, in the absence of such committee, the Board.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Compensation Committee of the Board.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Covered Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each current and former Executive Officer.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Nasdaq Stock Market.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Company&#8217;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">298370802 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#8217;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company.  Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). A measure need not be presented in the Company&#8217;s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Lookback Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#8217;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date. </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Recoverable Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Recoupment</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Applicability of Policy. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv)&#160;during the Lookback Period. </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Recoupment Generally.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#8217;s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">298370802 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Impracticability of Recovery.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Recoupment may be determined to be impracticable if, and only if&#58;</font></div><div style="margin-bottom:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation&#59; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards&#59; or</font></div><div style="margin-bottom:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Sources of Recoupment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date&#58; (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer&#59; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid)&#59; (iii) cancelling or offsetting against any planned future cash or equity-based awards&#59; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A&#59; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">No Indemnification of Covered Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#8217;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Indemnification of Administrator.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">No &#8220;Good Reason&#8221; for Covered Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) &#8220;good reason&#8221; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Administration</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy.  Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">298370802 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Policy. In carrying-out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#8217;s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Severability</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">No Impairment of Other Remedies</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#8217;s obligations to the Company, including, without limitation, termination of employment and&#47;or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SOX 304</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that are applicable to the Company&#8217;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and&#47;or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time&#59; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and&#47;or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">8. &#160;&#160;&#160;&#160;Amendment&#59; Termination</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9. &#160;&#160;&#160;&#160;Successors</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and&#47;or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;Required Filings</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Approved&#58;     November 14, 2023</font></div><div id="i8309f3ba8745406da78625778b0a9788_126"></div><div style="margin-bottom:11pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">298370802 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Incentive Compensation Recoupment Policy</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Form of Executive Acknowledgment</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I, the undersigned, agree and acknowledge that I am bound by, and subject to, the Inovio Pharmaceuticals, Inc.  Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with Inovio Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and&#47;or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreed and Acknowledged&#58;</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">298370802 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>ino-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b4fcd846-7e1f-480b-911d-4744cd39f89e,g:4f8a585f-cb3c-4f96-86ae-b643b290a1f2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.inovio.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.inovio.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsParenthetical" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical">
        <link:definition>0000006 - Statement - Consolidated Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000007 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000008 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000010 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompany" roleURI="http://www.inovio.com/role/TheCompany">
        <link:definition>0000011 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000012 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRisk" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk">
        <link:definition>0000013 - Disclosure - Revenue Recognition and Concentration of Credit Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>0000014 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurements" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements">
        <link:definition>0000015 - Disclosure - Short-term Investments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItems" roleURI="http://www.inovio.com/role/CertainBalanceSheetItems">
        <link:definition>0000016 - Disclosure - Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssets" roleURI="http://www.inovio.com/role/FixedAssets">
        <link:definition>0000017 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000018 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>0000019 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>0000020 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.inovio.com/role/CommitmentsandContingencies">
        <link:definition>0000021 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>0000022 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlan" roleURI="http://www.inovio.com/role/A401kPlan">
        <link:definition>0000023 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>0000024 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>0000025 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.inovio.com/role/SubsequentEvents">
        <link:definition>0000026 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRiskTables" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables">
        <link:definition>9954473 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsTables" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables">
        <link:definition>9954474 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsTables" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsTables">
        <link:definition>9954475 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsTables" roleURI="http://www.inovio.com/role/FixedAssetsTables">
        <link:definition>9954476 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>9954477 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtTables" roleURI="http://www.inovio.com/role/ConvertibleDebtTables">
        <link:definition>9954478 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>9954479 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables">
        <link:definition>9954480 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.inovio.com/role/IncomeTaxesTables">
        <link:definition>9954481 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails">
        <link:definition>9954483 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails">
        <link:definition>9954484 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails">
        <link:definition>9954485 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails">
        <link:definition>9954486 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>9954487 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails">
        <link:definition>9954488 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails">
        <link:definition>9954489 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9954490 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails">
        <link:definition>9954491 - Disclosure - Certain Balance Sheet Items - Schedule of Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails">
        <link:definition>9954492 - Disclosure - Certain Balance Sheet Items - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsDetails" roleURI="http://www.inovio.com/role/FixedAssetsDetails">
        <link:definition>9954493 - Disclosure - Fixed Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>9954494 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails">
        <link:definition>9954495 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill and Intangible Assets By Major Asset Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNarrativeDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails">
        <link:definition>9954496 - Disclosure - Convertible Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtScheduleofConvertibleDebtDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails">
        <link:definition>9954497 - Disclosure - Convertible Debt - Schedule of Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails">
        <link:definition>9954498 - Disclosure - Stockholders' Equity - Schedule of Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9954499 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofStockOptionsOutstandingDetails" roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails">
        <link:definition>9954500 - Disclosure - Stockholders' Equity - Schedule of Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails" roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails">
        <link:definition>9954501 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity Under Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails" roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails">
        <link:definition>9954502 - Disclosure - Stockholders' Equity - Schedule of RSU Activity Under Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>9954503 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails">
        <link:definition>9954504 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1">
        <link:definition>9954504 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofPretaxLossfromOperationsDetails" roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails">
        <link:definition>9954505 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofIncomeTaxesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails">
        <link:definition>9954506 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954507 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9954508 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails">
        <link:definition>9954509 - Disclosure - Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails">
        <link:definition>9954510 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlanDetails" roleURI="http://www.inovio.com/role/A401kPlanDetails">
        <link:definition>9954511 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9954512 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncNarrativeDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails">
        <link:definition>9954513 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.inovio.com/role/SubsequentEventsDetails">
        <link:definition>9954514 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ino_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" abstract="false" name="LesseeOperatingLeaseNumberOfAgreementsToSublease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ino_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_DeferredTaxAssetsIntangibleAssets" abstract="false" name="DeferredTaxAssetsIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" abstract="false" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsIndefinitelyCarryforward" abstract="false" name="OperatingLossCarryforwardsIndefinitelyCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" abstract="false" name="LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_RangeOfExercisePricesFourMember" abstract="true" name="RangeOfExercisePricesFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CollaborativeArrangementRevenueFromTheProcurementContract" abstract="false" name="CollaborativeArrangementRevenueFromTheProcurementContract" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementRoyaltyPeriod" abstract="false" name="CollaborationAgreementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_GrantProceedsReceived" abstract="false" name="GrantProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ApolloBioMember" abstract="true" name="ApolloBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesTwoMember" abstract="true" name="RangeOfExercisePricesTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedAmount" abstract="false" name="CollaborativeAgreementAwardedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSalesAgreementRemainingAuthorizedAmount" abstract="false" name="StockSalesAgreementRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateCurrent" abstract="false" name="DeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DoDMember" abstract="true" name="DoDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CELLECTRA3PSPProprietarySmartDeviceMember" abstract="true" name="CELLECTRA3PSPProprietarySmartDeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_LassaFeverAndMERSVaccineMember" abstract="true" name="LassaFeverAndMERSVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_BiojectMember" abstract="true" name="BiojectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_DebtinstrumentAccruedInterest" abstract="false" name="DebtinstrumentAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" abstract="false" name="IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" abstract="false" name="OperatingLossCarryforwardsExpiringInNextFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_UnderwrittenPublicOfferingMember" abstract="true" name="UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" abstract="false" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsNet" abstract="false" name="GoodwillAndIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LossContingencyEstimateOfPossibleLossValueOfShares" abstract="false" name="LossContingencyEstimateOfPossibleLossValueOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NonCashInterestIncomeExpense" abstract="false" name="NonCashInterestIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesIncMember" abstract="true" name="PlumblineLifeSciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" abstract="true" name="McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" abstract="false" name="OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" abstract="false" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AccountsPayableAndAccruedExpensesLineItems" abstract="true" name="AccountsPayableAndAccruedExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsGross" abstract="false" name="GoodwillAndIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_AccountsPayableAndAccruedExpensesTable" abstract="true" name="AccountsPayableAndAccruedExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ino_PennsylvaniaStateIncomeTaxAuthorityMember" abstract="true" name="PennsylvaniaStateIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringInThreeYears" abstract="false" name="TaxCreditCarryforwardExpiringInThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2023IncentivePlanMember" abstract="true" name="A2023IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" abstract="false" name="ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2021SalesAgreementMember" abstract="true" name="A2021SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_GrantLiability" abstract="false" name="GrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" abstract="false" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DepartmentOfDefenceMember" abstract="true" name="DepartmentOfDefenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_AllOtherCustomersMember" abstract="true" name="AllOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" abstract="false" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_SalesAgreementMember" abstract="true" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" abstract="true" name="AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_INO4800Member" abstract="true" name="INO4800Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LicensewithAffiliatedEntitiesMember" abstract="true" name="LicensewithAffiliatedEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringInFourYears" abstract="false" name="TaxCreditCarryforwardExpiringInFourYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringInNextFiscalYear" abstract="false" name="TaxCreditCarryforwardExpiringInNextFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_RangeOfExercisePricesThreeMember" abstract="true" name="RangeOfExercisePricesThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_PlymouthMeetingPennsylvaniaMember" abstract="true" name="PlymouthMeetingPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" abstract="false" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_BehestiVKimEtAlMember" abstract="true" name="BehestiVKimEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockSaleAgreementWeightedAveragePricePerShare" abstract="false" name="StockSaleAgreementWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="ino_SeriesA2OnePreferredStockMember" abstract="true" name="SeriesA2OnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" abstract="false" name="SaleOfStockSalesProceedsOfAnyCommonStockPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedOptionAmount" abstract="false" name="CollaborativeAgreementAwardedOptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LitigationSettlementAmountAwardedToOtherPartyShares" abstract="false" name="LitigationSettlementAmountAwardedToOtherPartyShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2022InducementPlanMember" abstract="true" name="A2022InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingToBeReceived" abstract="false" name="CollaborativeAgreementFundingToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PropertyPlantAndEquipmentDisposedOfBySale" abstract="false" name="PropertyPlantAndEquipmentDisposedOfBySale" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" abstract="false" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="ino_KoreanStateIncomeTaxAuthorityMember" abstract="true" name="KoreanStateIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" abstract="false" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2007IncentivePlanMember" abstract="true" name="A2007IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2016IncentivePlanMember" abstract="true" name="A2016IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" abstract="false" name="ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="ino_FormerPresidentAndChiefExecutiveOfficerMember" abstract="true" name="FormerPresidentAndChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" abstract="false" name="NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliate" abstract="false" name="DeferredGrantFundingFromAffiliate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GrantRevenuePolicyTextBlock" abstract="false" name="GrantRevenuePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ino_PrepaidManufacturingExpensesCurrent" abstract="false" name="PrepaidManufacturingExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ApolloBioCorporationMember" abstract="true" name="ApolloBioCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingReceived" abstract="false" name="CollaborativeAgreementFundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_ProceedsfromStockOptionandWarrantExercises" abstract="false" name="ProceedsfromStockOptionandWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RangeOfExercisePricesOneMember" abstract="true" name="RangeOfExercisePricesOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" abstract="false" name="ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ComprehensiveIncomeLossTaxExpenseBenefit" abstract="false" name="ComprehensiveIncomeLossTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CoalitionforEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleDebtConvertedAmount" abstract="false" name="DebtInstrumentConvertibleDebtConvertedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxBenefitsExpired" abstract="false" name="TaxBenefitsExpired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" abstract="false" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementExpensesToReimburse" abstract="false" name="CollaborativeAgreementExpensesToReimburse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CertainBalanceSheetItemsAbstract" abstract="true" name="CertainBalanceSheetItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesMember" abstract="true" name="PlumblineLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" abstract="false" name="EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SARSCoV2COVID19VaccineMember" abstract="true" name="SARSCoV2COVID19VaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ino_AdvaccineMember" abstract="true" name="AdvaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" abstract="false" name="EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended" abstract="false" name="LesseeOperatingLeaseAreaOfLandUnderLeaseAmended" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardCarryforwardIndefinitely" abstract="false" name="TaxCreditCarryforwardCarryforwardIndefinitely" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RangeOfExercisePricesSixMember" abstract="true" name="RangeOfExercisePricesSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesFiveMember" abstract="true" name="RangeOfExercisePricesFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinThreeYears" abstract="false" name="OperatingLossCarryforwardsExpiringinThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SanDiegoCaliforniaMember" abstract="true" name="SanDiegoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" abstract="false" name="ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ino_TheWistarInstituteMember" abstract="true" name="TheWistarInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_GainLossOnRemeasurementOfEquityMethodInvestment" abstract="false" name="GainLossOnRemeasurementOfEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A6.50ConvertibleSeniorNotesDue2024Member" abstract="true" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CaliforniaIncomeTaxAuthorityMember" abstract="true" name="CaliforniaIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CollaborativeArrangementFixedPriceContractAmountAwarded" abstract="false" name="CollaborativeArrangementFixedPriceContractAmountAwarded" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseNumberOfLeasesAmended" abstract="false" name="LesseeOperatingLeaseNumberOfLeasesAmended" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" abstract="false" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_SeriesAOnePreferredStockMember" abstract="true" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_GeneosTherapeuticsInc.Member" abstract="true" name="GeneosTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinFourYears" abstract="false" name="OperatingLossCarryforwardsExpiringinFourYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAmendedAmount" abstract="false" name="CollaborativeAgreementAmendedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinTwoYears" abstract="false" name="OperatingLossCarryforwardsExpiringinTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" abstract="true" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringinTwoYears" abstract="false" name="TaxCreditCarryforwardExpiringinTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_IncomeTaxReconciliationStatuteLimitations" abstract="false" name="IncomeTaxReconciliationStatuteLimitations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>ino-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b4fcd846-7e1f-480b-911d-4744cd39f89e,g:4f8a585f-cb3c-4f96-86ae-b643b290a1f2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_43043331-4c8e-4869-be72-0597f465ffef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b284ff66-3aff-4a7a-8bbe-462ca775bdab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_43043331-4c8e-4869-be72-0597f465ffef" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b284ff66-3aff-4a7a-8bbe-462ca775bdab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bc55e1fb-ed8e-49c8-bdd9-d5ae54cd0b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_43043331-4c8e-4869-be72-0597f465ffef" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bc55e1fb-ed8e-49c8-bdd9-d5ae54cd0b67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_513d73d4-2d89-412b-8637-9b09c926406f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_43043331-4c8e-4869-be72-0597f465ffef" xlink:to="loc_us-gaap_ShortTermInvestments_513d73d4-2d89-412b-8637-9b09c926406f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f4da0d81-6742-42da-a82a-cdf813819073" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_43043331-4c8e-4869-be72-0597f465ffef" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f4da0d81-6742-42da-a82a-cdf813819073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_5c663215-74c9-4470-832f-2d5451ac09c5" xlink:href="ino-20231231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_43043331-4c8e-4869-be72-0597f465ffef" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_5c663215-74c9-4470-832f-2d5451ac09c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d85bb9e4-a43a-435e-8d98-80fc850cef18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_516c9c95-ff82-4267-a3e3-84eae913e004" xlink:href="ino-20231231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d85bb9e4-a43a-435e-8d98-80fc850cef18" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_516c9c95-ff82-4267-a3e3-84eae913e004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_16a881c7-a7c7-4ba0-a58f-18ec99a9a39b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d85bb9e4-a43a-435e-8d98-80fc850cef18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_16a881c7-a7c7-4ba0-a58f-18ec99a9a39b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_669d3c65-e41a-4d24-b7ed-a9c3f0858007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d85bb9e4-a43a-435e-8d98-80fc850cef18" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_669d3c65-e41a-4d24-b7ed-a9c3f0858007" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_1ac58e47-9834-4c7e-b59c-c91ddf724f9b" xlink:href="ino-20231231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d85bb9e4-a43a-435e-8d98-80fc850cef18" xlink:to="loc_ino_DeferredGrantFundingCurrent_1ac58e47-9834-4c7e-b59c-c91ddf724f9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_b478b122-5291-4493-87d1-c5215a4f6b47" xlink:href="ino-20231231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d85bb9e4-a43a-435e-8d98-80fc850cef18" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_b478b122-5291-4493-87d1-c5215a4f6b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_bf1652e8-8fe8-4e6a-90fb-5382f89a2742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d85bb9e4-a43a-435e-8d98-80fc850cef18" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_bf1652e8-8fe8-4e6a-90fb-5382f89a2742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_664f6e63-3f2d-4a4f-9693-206af5b1eed2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9aa6bad9-b0b6-4b8c-aad4-c8b8b095bbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_664f6e63-3f2d-4a4f-9693-206af5b1eed2" xlink:to="loc_us-gaap_CommonStockValue_9aa6bad9-b0b6-4b8c-aad4-c8b8b095bbe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_86f341c0-433c-4b96-9c6f-270e493bf066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_664f6e63-3f2d-4a4f-9693-206af5b1eed2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_86f341c0-433c-4b96-9c6f-270e493bf066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3ca43776-1621-4e3d-9409-88b920d72f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_664f6e63-3f2d-4a4f-9693-206af5b1eed2" xlink:to="loc_us-gaap_PreferredStockValue_3ca43776-1621-4e3d-9409-88b920d72f4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e0ba05a-1888-4522-bec8-845b0355efca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_664f6e63-3f2d-4a4f-9693-206af5b1eed2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e0ba05a-1888-4522-bec8-845b0355efca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aecb0a0b-8175-4a44-a9e0-4eb5c5b58ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_664f6e63-3f2d-4a4f-9693-206af5b1eed2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aecb0a0b-8175-4a44-a9e0-4eb5c5b58ca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_345312e9-3720-42db-a57b-dcb7134ae3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0a01ef26-b071-4b83-821e-284dc5b1359b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_345312e9-3720-42db-a57b-dcb7134ae3e2" xlink:to="loc_us-gaap_AssetsCurrent_0a01ef26-b071-4b83-821e-284dc5b1359b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4270deae-6d6d-46ca-8b27-936428f6f439" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_345312e9-3720-42db-a57b-dcb7134ae3e2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4270deae-6d6d-46ca-8b27-936428f6f439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5d1c2f9e-4c8a-4617-9be0-5edfd3764445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_345312e9-3720-42db-a57b-dcb7134ae3e2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5d1c2f9e-4c8a-4617-9be0-5edfd3764445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d6c7c5bf-eaf2-4240-ad37-0d4c8c247376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_345312e9-3720-42db-a57b-dcb7134ae3e2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d6c7c5bf-eaf2-4240-ad37-0d4c8c247376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6fec95bb-a86b-4ea3-911b-fb3810172d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_345312e9-3720-42db-a57b-dcb7134ae3e2" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6fec95bb-a86b-4ea3-911b-fb3810172d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b036c117-cf80-41e8-8202-19b44d90c7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_345312e9-3720-42db-a57b-dcb7134ae3e2" xlink:to="loc_us-gaap_Goodwill_b036c117-cf80-41e8-8202-19b44d90c7f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_69b0f95e-2a52-44f0-a114-be8450000a31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_345312e9-3720-42db-a57b-dcb7134ae3e2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_69b0f95e-2a52-44f0-a114-be8450000a31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8650bd4b-89a7-42f8-a7aa-4ba291888492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dd0941bb-a432-4920-97cc-6cc65d419fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8650bd4b-89a7-42f8-a7aa-4ba291888492" xlink:to="loc_us-gaap_LiabilitiesCurrent_dd0941bb-a432-4920-97cc-6cc65d419fdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ce6dd7e4-33c6-49e3-94d9-88a6e40e0612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8650bd4b-89a7-42f8-a7aa-4ba291888492" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ce6dd7e4-33c6-49e3-94d9-88a6e40e0612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d3a40186-9712-452f-9a7a-7ee98065bf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8650bd4b-89a7-42f8-a7aa-4ba291888492" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d3a40186-9712-452f-9a7a-7ee98065bf5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_8fae254d-7a9f-4a51-9f4c-6155b5cb58db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8650bd4b-89a7-42f8-a7aa-4ba291888492" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_8fae254d-7a9f-4a51-9f4c-6155b5cb58db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7c53e21a-e917-46cf-88cd-16dcbac02e14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e0cf4758-5a4d-403a-8c61-b811300a5d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7c53e21a-e917-46cf-88cd-16dcbac02e14" xlink:to="loc_us-gaap_StockholdersEquity_e0cf4758-5a4d-403a-8c61-b811300a5d2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c2180548-6ea0-4654-9ab7-0e258b1b5738" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7c53e21a-e917-46cf-88cd-16dcbac02e14" xlink:to="loc_us-gaap_Liabilities_c2180548-6ea0-4654-9ab7-0e258b1b5738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a3274cff-02b5-4272-9d97-924c089146be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7c53e21a-e917-46cf-88cd-16dcbac02e14" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a3274cff-02b5-4272-9d97-924c089146be" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ef89f395-abee-420d-a056-d64ccbcd7e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_758f3d0a-18cf-4373-98ea-2fb8d617477f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ef89f395-abee-420d-a056-d64ccbcd7e89" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_758f3d0a-18cf-4373-98ea-2fb8d617477f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_66aba1e4-7a22-4579-892d-ddcb2436705c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ef89f395-abee-420d-a056-d64ccbcd7e89" xlink:to="loc_us-gaap_OperatingExpenses_66aba1e4-7a22-4579-892d-ddcb2436705c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8db7e034-f1ae-46b2-9c7b-3464970c636b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0e5256f2-f6c3-4911-99e7-63401d531a71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8db7e034-f1ae-46b2-9c7b-3464970c636b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0e5256f2-f6c3-4911-99e7-63401d531a71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_58c3efd9-a7bd-4f2f-b99a-913cec0ae414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8db7e034-f1ae-46b2-9c7b-3464970c636b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_58c3efd9-a7bd-4f2f-b99a-913cec0ae414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_92c415bd-28c0-4b09-aae7-6a44bc689d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_46624bfe-f56f-4fcb-b763-aec0ef95a539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_92c415bd-28c0-4b09-aae7-6a44bc689d04" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_46624bfe-f56f-4fcb-b763-aec0ef95a539" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_470482f8-7235-4e83-8fd1-e220461b1d9a" xlink:href="ino-20231231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_92c415bd-28c0-4b09-aae7-6a44bc689d04" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_470482f8-7235-4e83-8fd1-e220461b1d9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_c8a23d05-0a34-4a76-86a8-d18149934075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_92c415bd-28c0-4b09-aae7-6a44bc689d04" xlink:to="loc_us-gaap_InterestIncomeOperating_c8a23d05-0a34-4a76-86a8-d18149934075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bf951323-4ce2-4cd6-9e90-6c24dc723565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_92c415bd-28c0-4b09-aae7-6a44bc689d04" xlink:to="loc_us-gaap_InterestExpense_bf951323-4ce2-4cd6-9e90-6c24dc723565" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3a5c302d-dc6f-41a6-a1a7-7d7b814df975" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_92c415bd-28c0-4b09-aae7-6a44bc689d04" xlink:to="loc_us-gaap_OperatingIncomeLoss_3a5c302d-dc6f-41a6-a1a7-7d7b814df975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_42de8380-c7e4-441e-ac7b-a1f82fee421e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_92c415bd-28c0-4b09-aae7-6a44bc689d04" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_42de8380-c7e4-441e-ac7b-a1f82fee421e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d9e58547-b8d2-418d-b872-a6312c155ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1ccc67b9-3504-48b8-ae47-f0833cadd5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d9e58547-b8d2-418d-b872-a6312c155ee4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1ccc67b9-3504-48b8-ae47-f0833cadd5cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4b9f99b4-4e0d-4c27-b9c1-c58e7ad5bb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d9e58547-b8d2-418d-b872-a6312c155ee4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4b9f99b4-4e0d-4c27-b9c1-c58e7ad5bb0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_189605eb-9e2a-4254-87ab-b24dca4537a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d9e58547-b8d2-418d-b872-a6312c155ee4" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_189605eb-9e2a-4254-87ab-b24dca4537a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_62dc422b-07ce-4095-8336-450b14ffaa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5e255d56-9cd2-40c8-803b-1803636b86d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_62dc422b-07ce-4095-8336-450b14ffaa5e" xlink:to="loc_us-gaap_NetIncomeLoss_5e255d56-9cd2-40c8-803b-1803636b86d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b9f437f3-645f-429f-9b1f-49548c868a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_62dc422b-07ce-4095-8336-450b14ffaa5e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b9f437f3-645f-429f-9b1f-49548c868a5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_67f572f7-c1c7-4b65-bc80-be4c90aba0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_62dc422b-07ce-4095-8336-450b14ffaa5e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_67f572f7-c1c7-4b65-bc80-be4c90aba0ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b29054a7-dd90-4d42-b28b-e702380ec413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ce515d54-6dbf-4b7c-bb3b-c2f02165a558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b29054a7-dd90-4d42-b28b-e702380ec413" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ce515d54-6dbf-4b7c-bb3b-c2f02165a558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_74bfdaf2-3b9c-4d53-8557-f68fc6a5e278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b29054a7-dd90-4d42-b28b-e702380ec413" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_74bfdaf2-3b9c-4d53-8557-f68fc6a5e278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_d9708b5b-b5f8-496c-9fcc-0195cbb2421f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b29054a7-dd90-4d42-b28b-e702380ec413" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_d9708b5b-b5f8-496c-9fcc-0195cbb2421f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1978d654-33ab-48fe-94c9-4178c50fb792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b29054a7-dd90-4d42-b28b-e702380ec413" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1978d654-33ab-48fe-94c9-4178c50fb792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f2e8e115-a0a8-45c6-ab69-5516aab6668b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b29054a7-dd90-4d42-b28b-e702380ec413" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f2e8e115-a0a8-45c6-ab69-5516aab6668b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ad579eed-9c25-4634-ac9c-9f3f3cc160b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e2e666d-3b07-4f22-8bb7-98b134cfecae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ad579eed-9c25-4634-ac9c-9f3f3cc160b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e2e666d-3b07-4f22-8bb7-98b134cfecae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3104f2bd-4312-4d2a-80a7-991275a7d4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ad579eed-9c25-4634-ac9c-9f3f3cc160b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3104f2bd-4312-4d2a-80a7-991275a7d4a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fff9b19-77a5-4d45-a26c-e40a438cd82f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ad579eed-9c25-4634-ac9c-9f3f3cc160b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fff9b19-77a5-4d45-a26c-e40a438cd82f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28d2aa38-2a23-4730-b02b-9188ddb19b65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ad579eed-9c25-4634-ac9c-9f3f3cc160b1" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28d2aa38-2a23-4730-b02b-9188ddb19b65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_8914c866-4c35-4f46-ace6-6bd65cf557dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_8914c866-4c35-4f46-ace6-6bd65cf557dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_de0e03d4-211a-4ab2-a8d7-bdee21f1a156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_Depreciation_de0e03d4-211a-4ab2-a8d7-bdee21f1a156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ab65277f-7884-4cf7-b421-f6465baaffef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ab65277f-7884-4cf7-b421-f6465baaffef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_a291a98a-0198-4a1b-8fff-712c93853157" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_a291a98a-0198-4a1b-8fff-712c93853157" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_79e653b4-0e01-4aba-9647-b407a79e5150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_ShareBasedCompensation_79e653b4-0e01-4aba-9647-b407a79e5150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_5b58a4b8-d4c8-4ce0-8f38-59b4f4d50d0b" xlink:href="ino-20231231.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_5b58a4b8-d4c8-4ce0-8f38-59b4f4d50d0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_de896f5f-5ff7-425c-a4f6-3b49ebeb9626" xlink:href="ino-20231231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_de896f5f-5ff7-425c-a4f6-3b49ebeb9626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c9f631ae-454a-4870-828c-8fed81740a86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c9f631ae-454a-4870-828c-8fed81740a86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_37b32bb1-a7d6-494e-b65c-148d5eaa1dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_37b32bb1-a7d6-494e-b65c-148d5eaa1dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_7bba6c65-5c69-4dab-bd21-4962067aeaee" xlink:href="ino-20231231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_7bba6c65-5c69-4dab-bd21-4962067aeaee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_61b91b0f-4fb1-4519-92a0-92eb4d76ef2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_61b91b0f-4fb1-4519-92a0-92eb4d76ef2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4803cf39-aef8-40bc-9a5f-3fb0fbb3a7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4803cf39-aef8-40bc-9a5f-3fb0fbb3a7fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d5c557cb-e760-40ec-b549-b9227fd0ee15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d5c557cb-e760-40ec-b549-b9227fd0ee15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_93e15a92-f31a-4825-b679-ac9e39e62b2d" xlink:href="ino-20231231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_93e15a92-f31a-4825-b679-ac9e39e62b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c0f2790b-e130-43bd-83f3-85b566fc4f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c0f2790b-e130-43bd-83f3-85b566fc4f07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f134d981-f8e3-4d27-88c0-41acb9ba9db0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_NetIncomeLoss_f134d981-f8e3-4d27-88c0-41acb9ba9db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_56e3f197-8077-4733-8f65-74c22fc350c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_56e3f197-8077-4733-8f65-74c22fc350c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_56cce724-b0e0-4298-b08f-241d202ca772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_56cce724-b0e0-4298-b08f-241d202ca772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0125a2d7-69e8-4622-8579-1241389c7ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0125a2d7-69e8-4622-8579-1241389c7ccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a50578d2-f433-41fb-9bf4-771500ebc9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a50578d2-f433-41fb-9bf4-771500ebc9e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_644c5b46-bca1-4cf1-9e4f-1be613147d7e" xlink:href="ino-20231231.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_ino_NonCashInterestIncomeExpense_644c5b46-bca1-4cf1-9e4f-1be613147d7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_53114e8a-daa3-4b18-9eec-bf6469d0d6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_53114e8a-daa3-4b18-9eec-bf6469d0d6dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c59c8a21-b4a1-4616-ae24-2817e2a94b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c59c8a21-b4a1-4616-ae24-2817e2a94b6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_83bff249-7b5c-45a5-b5b3-c3e5c5c49406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="24" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_83bff249-7b5c-45a5-b5b3-c3e5c5c49406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_6b8cea56-a8f5-45e7-b087-3fd1979efd8c" xlink:href="ino-20231231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:calculationArc order="25" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_6b8cea56-a8f5-45e7-b087-3fd1979efd8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_a3a3fa9d-ab70-459d-b2b6-7145f2e8e3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="26" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_132ebc24-25fe-4743-be30-8f66863c6237" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_a3a3fa9d-ab70-459d-b2b6-7145f2e8e3e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d785eff-5091-4ea0-a464-0d868fa6e4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_57113d9d-d901-475d-92e1-0a82bf7ea6e6" xlink:href="ino-20231231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d785eff-5091-4ea0-a464-0d868fa6e4d4" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_57113d9d-d901-475d-92e1-0a82bf7ea6e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_87e82c79-9722-4811-b32f-4c7f787555a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d785eff-5091-4ea0-a464-0d868fa6e4d4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_87e82c79-9722-4811-b32f-4c7f787555a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_52033333-4ddd-40b2-bebb-36c6f3f6fa15" xlink:href="ino-20231231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d785eff-5091-4ea0-a464-0d868fa6e4d4" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_52033333-4ddd-40b2-bebb-36c6f3f6fa15" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00a63e65-8e9b-4ce9-8612-f52375e7fa93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e36c162a-34e6-47e5-b16d-1de712a8e510" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00a63e65-8e9b-4ce9-8612-f52375e7fa93" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e36c162a-34e6-47e5-b16d-1de712a8e510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4a47cf9e-6f63-43cb-afc8-2b11efb0710d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00a63e65-8e9b-4ce9-8612-f52375e7fa93" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4a47cf9e-6f63-43cb-afc8-2b11efb0710d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_70eb8fbf-3484-49d2-b22b-1218ff5436a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00a63e65-8e9b-4ce9-8612-f52375e7fa93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_70eb8fbf-3484-49d2-b22b-1218ff5436a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c3bc803a-6c79-45c6-83d8-688dc17ae09f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fe4150f0-194b-451b-b372-287b8217e37a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_c3bc803a-6c79-45c6-83d8-688dc17ae09f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fe4150f0-194b-451b-b372-287b8217e37a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_ded1e050-6247-4116-b70d-25005bbc19f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_c3bc803a-6c79-45c6-83d8-688dc17ae09f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_ded1e050-6247-4116-b70d-25005bbc19f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dbbb594d-b57f-4a28-a587-8987ea3a8b25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent_4ebe3e21-5289-4889-81d2-68b819e16626" xlink:href="ino-20231231.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dbbb594d-b57f-4a28-a587-8987ea3a8b25" xlink:to="loc_ino_PrepaidManufacturingExpensesCurrent_4ebe3e21-5289-4889-81d2-68b819e16626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_f389e70c-d9f0-4ce6-8965-181ecfe7b634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dbbb594d-b57f-4a28-a587-8987ea3a8b25" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_f389e70c-d9f0-4ce6-8965-181ecfe7b634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_61bdac18-908b-4d04-8b96-09b0d4e487bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dbbb594d-b57f-4a28-a587-8987ea3a8b25" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_61bdac18-908b-4d04-8b96-09b0d4e487bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3b76bd39-0a85-48d5-b556-f703f447c9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_b5d723ea-e05b-47e3-bed6-6ae9301683a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3b76bd39-0a85-48d5-b556-f703f447c9a4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_b5d723ea-e05b-47e3-bed6-6ae9301683a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_12e9ea9f-6825-432b-831d-d6e929a4280d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3b76bd39-0a85-48d5-b556-f703f447c9a4" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_12e9ea9f-6825-432b-831d-d6e929a4280d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_73f55480-1d4b-4613-a826-1d662a8ed43c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3b76bd39-0a85-48d5-b556-f703f447c9a4" xlink:to="loc_us-gaap_AccruedSalariesCurrent_73f55480-1d4b-4613-a826-1d662a8ed43c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_f0a52a44-b07b-4917-8898-ea3826737a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3b76bd39-0a85-48d5-b556-f703f447c9a4" xlink:to="loc_us-gaap_LitigationReserveCurrent_f0a52a44-b07b-4917-8898-ea3826737a0d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#FixedAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_60f2ed49-1aab-4a94-b3cc-69ee607bf6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4c9022f9-fff1-46b6-b909-2a9f7931ff79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_60f2ed49-1aab-4a94-b3cc-69ee607bf6d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4c9022f9-fff1-46b6-b909-2a9f7931ff79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1dfc6adb-ed94-49e8-8d28-12e6ddae89eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_60f2ed49-1aab-4a94-b3cc-69ee607bf6d5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1dfc6adb-ed94-49e8-8d28-12e6ddae89eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_e55c90a3-7edb-4f51-af15-975bdeaf69d5" xlink:href="ino-20231231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_361399a2-d9f3-492b-8181-9f6d49e5c836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_e55c90a3-7edb-4f51-af15-975bdeaf69d5" xlink:to="loc_us-gaap_GoodwillGross_361399a2-d9f3-492b-8181-9f6d49e5c836" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50572908-f4f5-45c7-99e3-87bfcd66a178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_e55c90a3-7edb-4f51-af15-975bdeaf69d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50572908-f4f5-45c7-99e3-87bfcd66a178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_1ad94bcb-9db8-40a3-8d32-0ddb855d1311" xlink:href="ino-20231231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d13e591e-a466-45fb-9111-f13ebbdfb6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_1ad94bcb-9db8-40a3-8d32-0ddb855d1311" xlink:to="loc_us-gaap_Goodwill_d13e591e-a466-45fb-9111-f13ebbdfb6a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6921b3ec-12f8-4fd6-97a1-77acd18ed410" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_1ad94bcb-9db8-40a3-8d32-0ddb855d1311" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6921b3ec-12f8-4fd6-97a1-77acd18ed410" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ConvertibleDebtScheduleofConvertibleDebtDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1d746b16-b875-441f-842b-ee261a24f0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest_b83eb22f-d8c3-4f23-9e74-9af61a64863b" xlink:href="ino-20231231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1d746b16-b875-441f-842b-ee261a24f0ff" xlink:to="loc_ino_DebtinstrumentAccruedInterest_b83eb22f-d8c3-4f23-9e74-9af61a64863b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_32d33a86-a659-4f4e-be8a-8d4d5af386e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1d746b16-b875-441f-842b-ee261a24f0ff" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_32d33a86-a659-4f4e-be8a-8d4d5af386e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_0f44703c-0b93-44ef-83fd-921de8e4440f" xlink:href="ino-20231231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1d746b16-b875-441f-842b-ee261a24f0ff" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_0f44703c-0b93-44ef-83fd-921de8e4440f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_38dad612-9622-406b-b1df-798984790fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1d746b16-b875-441f-842b-ee261a24f0ff" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_38dad612-9622-406b-b1df-798984790fcb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_640af4c7-881e-4d67-9588-f79f53aef9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_57fbebff-3fad-4b8f-8fe2-115a1923e787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_640af4c7-881e-4d67-9588-f79f53aef9d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_57fbebff-3fad-4b8f-8fe2-115a1923e787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_41111fe6-3f63-4204-b60e-2bb74e8e733f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_640af4c7-881e-4d67-9588-f79f53aef9d2" xlink:to="loc_us-gaap_OperatingLeaseLiability_41111fe6-3f63-4204-b60e-2bb74e8e733f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ea42ab2b-156d-4983-b06a-2e1046569b69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_abb76cd0-46b3-48b4-80be-601bae5008fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ea42ab2b-156d-4983-b06a-2e1046569b69" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_abb76cd0-46b3-48b4-80be-601bae5008fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_72059a53-8407-4766-afb1-4248db652dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ea42ab2b-156d-4983-b06a-2e1046569b69" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_72059a53-8407-4766-afb1-4248db652dc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ino-20231231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c4bcda8-4e71-4d87-86b4-ab0ce3e0cb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_14711934-b256-4be2-b151-c24d5f72ae21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c4bcda8-4e71-4d87-86b4-ab0ce3e0cb6b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_14711934-b256-4be2-b151-c24d5f72ae21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4d1a83b7-f0b2-4439-b123-e48913dd2a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c4bcda8-4e71-4d87-86b4-ab0ce3e0cb6b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4d1a83b7-f0b2-4439-b123-e48913dd2a3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_17f4e3c0-331c-4a41-8cf7-937372886fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c4bcda8-4e71-4d87-86b4-ab0ce3e0cb6b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_17f4e3c0-331c-4a41-8cf7-937372886fb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1d245688-bf6b-4a1f-ba78-3dd9b3482a65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c4bcda8-4e71-4d87-86b4-ab0ce3e0cb6b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1d245688-bf6b-4a1f-ba78-3dd9b3482a65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_421c2804-4d98-4629-b417-79ef94047878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c4bcda8-4e71-4d87-86b4-ab0ce3e0cb6b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_421c2804-4d98-4629-b417-79ef94047878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_294f09f6-c4cf-4dec-8395-65dec15a24b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c4bcda8-4e71-4d87-86b4-ab0ce3e0cb6b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_294f09f6-c4cf-4dec-8395-65dec15a24b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesComponentsofPretaxLossfromOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4547562e-44f4-40cc-be46-0a3144dc82f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ee88fbff-f6df-4279-9f0a-8b045128a9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4547562e-44f4-40cc-be46-0a3144dc82f1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ee88fbff-f6df-4279-9f0a-8b045128a9d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6430d5af-e39f-43cb-b465-c136d0fc3fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4547562e-44f4-40cc-be46-0a3144dc82f1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6430d5af-e39f-43cb-b465-c136d0fc3fc4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesReconciliationofIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:href="ino-20231231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_e5b9bcf4-8774-45f3-a08a-089eab57d75b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_e5b9bcf4-8774-45f3-a08a-089eab57d75b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1140c24b-f670-439f-980a-9723fe5e6c28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1140c24b-f670-439f-980a-9723fe5e6c28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_c3216d3f-5037-4aee-950b-789a329ab5cd" xlink:href="ino-20231231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_c3216d3f-5037-4aee-950b-789a329ab5cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_6f23c15f-5fc2-4e70-a1cb-1d91e1c50c43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_6f23c15f-5fc2-4e70-a1cb-1d91e1c50c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_6a4a1b1a-986f-447e-bd64-fe73e4680c04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_6a4a1b1a-986f-447e-bd64-fe73e4680c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations_48798b10-d7fd-4aa1-ae75-6884e9fc6034" xlink:href="ino-20231231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:to="loc_ino_IncomeTaxReconciliationStatuteLimitations_48798b10-d7fd-4aa1-ae75-6884e9fc6034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ffe6a005-3474-4405-9c7c-52cd271cc579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ffe6a005-3474-4405-9c7c-52cd271cc579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_43765fdc-53ee-4109-8b2b-815bfa738055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_43765fdc-53ee-4109-8b2b-815bfa738055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_bc1de4b9-d709-4b79-911b-833eed28da62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_bc1de4b9-d709-4b79-911b-833eed28da62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_73b582f9-d12e-475b-94a0-69827683e722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_73b582f9-d12e-475b-94a0-69827683e722" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_1b7455f8-8e64-407a-a183-89fce41cbc19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_1b7455f8-8e64-407a-a183-89fce41cbc19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_f59ce6c0-2aca-445b-8aa0-7fd3b22304f8" xlink:href="ino-20231231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c9c4e083-b7f9-4fc4-8b82-069b8d1c76fb" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_f59ce6c0-2aca-445b-8aa0-7fd3b22304f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_bc1cc7d7-02ab-47b1-bc92-82715a3e69c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_15cda631-5cc9-42de-adcb-9bd146b2d5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_bc1cc7d7-02ab-47b1-bc92-82715a3e69c9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_15cda631-5cc9-42de-adcb-9bd146b2d5b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b2dd00c5-ad5c-4c50-9888-2eea28ecc998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_bc1cc7d7-02ab-47b1-bc92-82715a3e69c9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b2dd00c5-ad5c-4c50-9888-2eea28ecc998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0d8b7bb5-578c-457b-a369-fb357af86a94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_edc7efba-1c49-4c0d-94e4-b57b22d8b927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0d8b7bb5-578c-457b-a369-fb357af86a94" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_edc7efba-1c49-4c0d-94e4-b57b22d8b927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_235f97b0-356d-485d-9e07-c49f69f49beb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0d8b7bb5-578c-457b-a369-fb357af86a94" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_235f97b0-356d-485d-9e07-c49f69f49beb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_9ced6c83-64ee-4ea1-9fff-707878494dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0d8b7bb5-578c-457b-a369-fb357af86a94" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_9ced6c83-64ee-4ea1-9fff-707878494dfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_b60fb008-6a25-4706-b76e-66d2a475515c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0d8b7bb5-578c-457b-a369-fb357af86a94" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_b60fb008-6a25-4706-b76e-66d2a475515c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8edf84c4-8513-4a6e-bd88-178a0bcdec64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0d8b7bb5-578c-457b-a369-fb357af86a94" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8edf84c4-8513-4a6e-bd88-178a0bcdec64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_f507f925-b7a1-497f-bb79-2da5b9a3a888" xlink:href="ino-20231231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0d8b7bb5-578c-457b-a369-fb357af86a94" xlink:to="loc_ino_DeferredTaxAssetsIntangibleAssets_f507f925-b7a1-497f-bb79-2da5b9a3a888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_caedad00-a4a9-479c-9569-c32d8c506d98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0d8b7bb5-578c-457b-a369-fb357af86a94" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_caedad00-a4a9-479c-9569-c32d8c506d98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_a2bc60b2-55ff-4f61-8142-c437fc7e661d" xlink:href="ino-20231231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0d8b7bb5-578c-457b-a369-fb357af86a94" xlink:to="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_a2bc60b2-55ff-4f61-8142-c437fc7e661d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1755fa2d-2088-4260-8216-83c7b48d0e58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0d8b7bb5-578c-457b-a369-fb357af86a94" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1755fa2d-2088-4260-8216-83c7b48d0e58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_bd432881-b011-4c16-bc89-7b9d9f00659d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0d8b7bb5-578c-457b-a369-fb357af86a94" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_bd432881-b011-4c16-bc89-7b9d9f00659d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e5edff44-eb60-47ac-8091-b5c23c635ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_40d93672-b31c-4346-9e7c-37c7991af92a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e5edff44-eb60-47ac-8091-b5c23c635ef5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_40d93672-b31c-4346-9e7c-37c7991af92a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_56d52c4a-4036-4e41-aaa9-b951ccc8e8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e5edff44-eb60-47ac-8091-b5c23c635ef5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_56d52c4a-4036-4e41-aaa9-b951ccc8e8ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_55389451-f583-4e5a-9cf9-143ac1ac8b22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ad179499-1f04-40e5-8b56-4257a2544519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_55389451-f583-4e5a-9cf9-143ac1ac8b22" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ad179499-1f04-40e5-8b56-4257a2544519" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_e6caac40-01e5-4b3c-b692-e0e98ab07a4d" xlink:href="ino-20231231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_55389451-f583-4e5a-9cf9-143ac1ac8b22" xlink:to="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_e6caac40-01e5-4b3c-b692-e0e98ab07a4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c97c0c6d-3c2b-4e8c-bfa5-1267fe8011e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_71937662-4e83-48c9-a836-e0e8b46cb63a" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_c97c0c6d-3c2b-4e8c-bfa5-1267fe8011e3" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_71937662-4e83-48c9-a836-e0e8b46cb63a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_1f731828-5239-4afc-9274-b910898fa080" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_c97c0c6d-3c2b-4e8c-bfa5-1267fe8011e3" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_1f731828-5239-4afc-9274-b910898fa080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_b259ba5f-41f5-4323-8c44-aa0bdcd03c02" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_c97c0c6d-3c2b-4e8c-bfa5-1267fe8011e3" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_b259ba5f-41f5-4323-8c44-aa0bdcd03c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_b85005ce-c11e-4c62-8605-8e5b254b2765" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_c97c0c6d-3c2b-4e8c-bfa5-1267fe8011e3" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_b85005ce-c11e-4c62-8605-8e5b254b2765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_f0f07d09-5ca6-4594-a2d0-923b3f975e8a" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringInNextFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_c97c0c6d-3c2b-4e8c-bfa5-1267fe8011e3" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_f0f07d09-5ca6-4594-a2d0-923b3f975e8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_db3bb1cb-5df1-4fab-8be6-0daa73c7d08e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_30d11cec-cbc2-4aa4-9d10-e3a0bc979458" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_db3bb1cb-5df1-4fab-8be6-0daa73c7d08e" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_30d11cec-cbc2-4aa4-9d10-e3a0bc979458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_6f35ef16-065e-44d8-9d17-8681a6153f10" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringInThreeYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_db3bb1cb-5df1-4fab-8be6-0daa73c7d08e" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_6f35ef16-065e-44d8-9d17-8681a6153f10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInFourYears_70462e7f-5033-4cda-88f7-18dc82293a16" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringInFourYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_db3bb1cb-5df1-4fab-8be6-0daa73c7d08e" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInFourYears_70462e7f-5033-4cda-88f7-18dc82293a16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_e547752b-2f8c-4216-8d54-7d82d1705e63" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_db3bb1cb-5df1-4fab-8be6-0daa73c7d08e" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_e547752b-2f8c-4216-8d54-7d82d1705e63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_ac342e64-83b1-41a8-8350-4fa10b384986" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringInNextFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_db3bb1cb-5df1-4fab-8be6-0daa73c7d08e" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_ac342e64-83b1-41a8-8350-4fa10b384986" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>ino-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b4fcd846-7e1f-480b-911d-4744cd39f89e,g:4f8a585f-cb3c-4f96-86ae-b643b290a1f2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0b0564cb-5c13-4bb6-a5b2-337c6d45af67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c3adfda6-bfe2-4c3b-90d9-64b1c34cf5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0b0564cb-5c13-4bb6-a5b2-337c6d45af67" xlink:to="loc_us-gaap_StatementTable_c3adfda6-bfe2-4c3b-90d9-64b1c34cf5a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d9b407f-9302-400b-9afb-81cdd0b20b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c3adfda6-bfe2-4c3b-90d9-64b1c34cf5a7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d9b407f-9302-400b-9afb-81cdd0b20b9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1d9b407f-9302-400b-9afb-81cdd0b20b9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d9b407f-9302-400b-9afb-81cdd0b20b9b" xlink:to="loc_us-gaap_RelatedPartyDomain_1d9b407f-9302-400b-9afb-81cdd0b20b9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a08bba1a-aad3-44a4-9e3c-2913cd965481" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d9b407f-9302-400b-9afb-81cdd0b20b9b" xlink:to="loc_us-gaap_RelatedPartyDomain_a08bba1a-aad3-44a4-9e3c-2913cd965481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_e2b49688-f4a5-477d-9b6b-0ed1a0b44f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a08bba1a-aad3-44a4-9e3c-2913cd965481" xlink:to="loc_us-gaap_NonrelatedPartyMember_e2b49688-f4a5-477d-9b6b-0ed1a0b44f35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_73637f10-8100-42fa-9100-e6c47639722e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a08bba1a-aad3-44a4-9e3c-2913cd965481" xlink:to="loc_us-gaap_RelatedPartyMember_73637f10-8100-42fa-9100-e6c47639722e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0b0564cb-5c13-4bb6-a5b2-337c6d45af67" xlink:to="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8ff1d3a-d784-40a5-9ccd-f27539540103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8ff1d3a-d784-40a5-9ccd-f27539540103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_200e3213-52cc-4034-8f81-84fa1e412a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:to="loc_us-gaap_ShortTermInvestments_200e3213-52cc-4034-8f81-84fa1e412a62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1cd3bb72-1ea1-4548-b608-b1f1985b679b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1cd3bb72-1ea1-4548-b608-b1f1985b679b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c39d738a-d3f7-448e-8db5-176818094df8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c39d738a-d3f7-448e-8db5-176818094df8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_b3d820bb-1dad-4525-b793-8de51f7f44dc" xlink:href="ino-20231231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_b3d820bb-1dad-4525-b793-8de51f7f44dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cde72f21-bc08-4a1a-8c64-0130b8b61601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:to="loc_us-gaap_AssetsCurrent_cde72f21-bc08-4a1a-8c64-0130b8b61601" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2d8adb22-0e20-4241-a70a-2bc7d0c9acf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2d8adb22-0e20-4241-a70a-2bc7d0c9acf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_1f00a2b4-5184-46c9-b529-1c9daa1b5422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_1f00a2b4-5184-46c9-b529-1c9daa1b5422" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d53a076f-77b4-4455-a4e2-636f0b6a62ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d53a076f-77b4-4455-a4e2-636f0b6a62ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_35d21366-7422-44ae-b38e-d1e2927e48b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_Goodwill_35d21366-7422-44ae-b38e-d1e2927e48b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f3dc9ed1-c8d3-4f5b-a1be-007c59bf8991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f3dc9ed1-c8d3-4f5b-a1be-007c59bf8991" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7b1b156b-05e7-4f9d-8be1-2c7081b02fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7b1b156b-05e7-4f9d-8be1-2c7081b02fbf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7bb684d6-02bb-4513-bda9-e694140aae99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_Assets_7bb684d6-02bb-4513-bda9-e694140aae99" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0b0564cb-5c13-4bb6-a5b2-337c6d45af67" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f9ced94b-1250-41bb-b02b-34bf67a1c5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f9ced94b-1250-41bb-b02b-34bf67a1c5f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_1c7264bf-ed99-48b1-a63a-b70f41ead4f7" xlink:href="ino-20231231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_1c7264bf-ed99-48b1-a63a-b70f41ead4f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_82ad1672-d45f-42a3-b385-8f51d191f681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_82ad1672-d45f-42a3-b385-8f51d191f681" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_e1114e43-d59f-4f18-b5bb-47fcf9909109" xlink:href="ino-20231231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_ino_DeferredGrantFundingCurrent_e1114e43-d59f-4f18-b5bb-47fcf9909109" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4c0371e9-6446-4878-83e2-df84138908d7" xlink:href="ino-20231231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4c0371e9-6446-4878-83e2-df84138908d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_6aebe2a6-7155-4c9d-a8b9-66901cc48341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_6aebe2a6-7155-4c9d-a8b9-66901cc48341" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7b20ef8b-6087-48ec-8e7c-f9e2cecb9187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_us-gaap_LiabilitiesCurrent_7b20ef8b-6087-48ec-8e7c-f9e2cecb9187" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_38bdd8db-12f5-42de-b4ff-29459e762e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_38bdd8db-12f5-42de-b4ff-29459e762e1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_985be54c-98e5-49cb-bc64-a1f0dd7435fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_985be54c-98e5-49cb-bc64-a1f0dd7435fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6a73017a-cb8d-435e-8ed7-4b764d67dd87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6a73017a-cb8d-435e-8ed7-4b764d67dd87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_eb19ec3a-2b16-41aa-aa85-e922e2bf597d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_Liabilities_eb19ec3a-2b16-41aa-aa85-e922e2bf597d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6c7b8786-16ed-4e9b-a1d3-8c2f38059507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6c7b8786-16ed-4e9b-a1d3-8c2f38059507" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6fc2d67f-fb9a-4298-a059-c104cca972a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:to="loc_us-gaap_PreferredStockValue_6fc2d67f-fb9a-4298-a059-c104cca972a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2473eadd-64f6-4a08-ae32-d06c384ddf99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:to="loc_us-gaap_CommonStockValue_2473eadd-64f6-4a08-ae32-d06c384ddf99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3c79a2fb-f5f5-401c-a444-706bd711e1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3c79a2fb-f5f5-401c-a444-706bd711e1f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d6908a70-6c4d-4bd3-9c23-0428a6fb3afc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d6908a70-6c4d-4bd3-9c23-0428a6fb3afc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9f122ee9-d6d9-4baf-8cc9-d399c0a078e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9f122ee9-d6d9-4baf-8cc9-d399c0a078e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d5a363d0-a020-42a5-8bea-36be3f6c5d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:to="loc_us-gaap_StockholdersEquity_d5a363d0-a020-42a5-8bea-36be3f6c5d0c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1970614b-24e1-4083-aeb2-13b709c5ecd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1970614b-24e1-4083-aeb2-13b709c5ecd3" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fb4870bb-2318-4865-b881-821a374935fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3710d175-cc9e-4304-ad2e-d46f244af3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fb4870bb-2318-4865-b881-821a374935fa" xlink:to="loc_us-gaap_StatementTable_3710d175-cc9e-4304-ad2e-d46f244af3a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_09c9fe06-3274-4c45-8104-ffa0610be15c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3710d175-cc9e-4304-ad2e-d46f244af3a7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_09c9fe06-3274-4c45-8104-ffa0610be15c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_09c9fe06-3274-4c45-8104-ffa0610be15c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_09c9fe06-3274-4c45-8104-ffa0610be15c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_09c9fe06-3274-4c45-8104-ffa0610be15c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1a352d45-9e41-45e1-a598-cc055e91b3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_09c9fe06-3274-4c45-8104-ffa0610be15c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1a352d45-9e41-45e1-a598-cc055e91b3ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_841fa9d6-9e41-4cbb-80bc-d3b6979d1e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1a352d45-9e41-45e1-a598-cc055e91b3ae" xlink:to="loc_us-gaap_SubsequentEventMember_841fa9d6-9e41-4cbb-80bc-d3b6979d1e1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3e32c3ed-706d-48f3-a4e5-13b9fd361d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fb4870bb-2318-4865-b881-821a374935fa" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3e32c3ed-706d-48f3-a4e5-13b9fd361d5e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedStatementsofOperationsParenthetical"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_14d3b701-d497-495a-a2a4-2c5d23d98984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ed4781e0-72e0-4634-9e75-213f4fb6f2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_14d3b701-d497-495a-a2a4-2c5d23d98984" xlink:to="loc_us-gaap_StatementTable_ed4781e0-72e0-4634-9e75-213f4fb6f2e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a322b629-cf00-483b-b8c2-e045e9842495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ed4781e0-72e0-4634-9e75-213f4fb6f2e8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a322b629-cf00-483b-b8c2-e045e9842495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a322b629-cf00-483b-b8c2-e045e9842495_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a322b629-cf00-483b-b8c2-e045e9842495" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a322b629-cf00-483b-b8c2-e045e9842495_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80f4d591-c20a-4120-9084-bb7b08e11e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a322b629-cf00-483b-b8c2-e045e9842495" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_80f4d591-c20a-4120-9084-bb7b08e11e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f83e0bcd-9f61-4dd1-b0a8-3e3eb0043dda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_80f4d591-c20a-4120-9084-bb7b08e11e89" xlink:to="loc_us-gaap_SubsequentEventMember_f83e0bcd-9f61-4dd1-b0a8-3e3eb0043dda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f80c1ccd-4dda-4b2f-9ff3-604e384376da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_14d3b701-d497-495a-a2a4-2c5d23d98984" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f80c1ccd-4dda-4b2f-9ff3-604e384376da" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6d342973-cdf5-4194-a548-b17930d28e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1a93a1d2-c062-4ee3-afdf-0f9728ea9a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6d342973-cdf5-4194-a548-b17930d28e2e" xlink:to="loc_us-gaap_StatementTable_1a93a1d2-c062-4ee3-afdf-0f9728ea9a35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_75097bce-29f4-4627-855d-577f9a9c581f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1a93a1d2-c062-4ee3-afdf-0f9728ea9a35" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_75097bce-29f4-4627-855d-577f9a9c581f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_75097bce-29f4-4627-855d-577f9a9c581f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_75097bce-29f4-4627-855d-577f9a9c581f" xlink:to="loc_us-gaap_EquityComponentDomain_75097bce-29f4-4627-855d-577f9a9c581f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_75097bce-29f4-4627-855d-577f9a9c581f" xlink:to="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_bd67a7b5-f4c0-4f8f-bb7d-9cd0ab3e9ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:to="loc_us-gaap_PreferredStockMember_bd67a7b5-f4c0-4f8f-bb7d-9cd0ab3e9ef4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ed4fb58f-f65a-4b4a-bba3-1839b38e2ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:to="loc_us-gaap_CommonStockMember_ed4fb58f-f65a-4b4a-bba3-1839b38e2ab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f02f450d-a257-4282-b061-fb5d569ae809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f02f450d-a257-4282-b061-fb5d569ae809" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_539cc2bc-7c5f-44bd-ad29-c3cae0b9babe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:to="loc_us-gaap_RetainedEarningsMember_539cc2bc-7c5f-44bd-ad29-c3cae0b9babe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cdf53ca4-ab0f-42bc-ab76-81f8e57f5bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cdf53ca4-ab0f-42bc-ab76-81f8e57f5bc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7e8db633-228d-4563-a063-fd475b2d070b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1a93a1d2-c062-4ee3-afdf-0f9728ea9a35" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7e8db633-228d-4563-a063-fd475b2d070b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7e8db633-228d-4563-a063-fd475b2d070b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7e8db633-228d-4563-a063-fd475b2d070b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7e8db633-228d-4563-a063-fd475b2d070b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ca437f10-df5a-4962-9bd5-410e78597773" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7e8db633-228d-4563-a063-fd475b2d070b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ca437f10-df5a-4962-9bd5-410e78597773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_35e2764a-08c2-45c9-b3ad-90d838f2cf66" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ca437f10-df5a-4962-9bd5-410e78597773" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_35e2764a-08c2-45c9-b3ad-90d838f2cf66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6d342973-cdf5-4194-a548-b17930d28e2e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_1bcd2b2c-54cd-40bd-8f68-7730f0105e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_SharesIssued_1bcd2b2c-54cd-40bd-8f68-7730f0105e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f81e720c-ab38-4b80-8dd0-25e649879811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockholdersEquity_f81e720c-ab38-4b80-8dd0-25e649879811" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_85758cc2-348c-47b7-8ccd-b49517805809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_85758cc2-348c-47b7-8ccd-b49517805809" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_71fafb5d-4e6b-46ff-b655-c5f597003146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_71fafb5d-4e6b-46ff-b655-c5f597003146" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3bd6e642-f3a5-4420-8e22-cedd747aa370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3bd6e642-f3a5-4420-8e22-cedd747aa370" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1b2386e9-d6ef-47b9-ad9c-d6361156287f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1b2386e9-d6ef-47b9-ad9c-d6361156287f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_12995edd-9cce-4be5-af6e-c0941d674e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_12995edd-9cce-4be5-af6e-c0941d674e86" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5c4f79ca-590d-48cc-89fc-beeccf113aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5c4f79ca-590d-48cc-89fc-beeccf113aa2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_da17277a-ceb5-4f58-a8a7-4647d248f7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_da17277a-ceb5-4f58-a8a7-4647d248f7b9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7c3a781a-1a89-446e-b6c4-0c99ef5e935b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7c3a781a-1a89-446e-b6c4-0c99ef5e935b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_99e0b531-9c03-4d57-aa22-6ff3f5d756c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_99e0b531-9c03-4d57-aa22-6ff3f5d756c6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0409322d-8808-4e14-ac63-f26c69a4705f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_NetIncomeLoss_0409322d-8808-4e14-ac63-f26c69a4705f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7089ed2f-65ba-4a47-b8cc-2790d45b2afa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7089ed2f-65ba-4a47-b8cc-2790d45b2afa" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8e643646-4bfa-4386-a887-c5e916561db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8e643646-4bfa-4386-a887-c5e916561db8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_05202114-49b2-4b8d-8e1e-8b464b361c60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_3592308c-5e46-45a9-abd1-772c2ec3ffff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9737b866-7dc4-4123-91b4-906c0bd4d32d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6e69c686-3097-4348-9720-0a9994e7ff97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9737b866-7dc4-4123-91b4-906c0bd4d32d" xlink:to="loc_us-gaap_StatementTable_6e69c686-3097-4348-9720-0a9994e7ff97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2ec10ca2-39ff-40db-a1f7-df21fd4c014e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6e69c686-3097-4348-9720-0a9994e7ff97" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2ec10ca2-39ff-40db-a1f7-df21fd4c014e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2ec10ca2-39ff-40db-a1f7-df21fd4c014e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2ec10ca2-39ff-40db-a1f7-df21fd4c014e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2ec10ca2-39ff-40db-a1f7-df21fd4c014e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_06631496-364e-4026-a843-64adab1b4bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2ec10ca2-39ff-40db-a1f7-df21fd4c014e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_06631496-364e-4026-a843-64adab1b4bcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e588571c-39db-467e-ba4d-e6cfb5122a13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_06631496-364e-4026-a843-64adab1b4bcd" xlink:to="loc_us-gaap_SubsequentEventMember_e588571c-39db-467e-ba4d-e6cfb5122a13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1230c597-5b58-414a-93e4-313ea9b6e9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9737b866-7dc4-4123-91b4-906c0bd4d32d" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1230c597-5b58-414a-93e4-313ea9b6e9eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_47335047-5a8c-41a9-a7d9-8ca35a914f67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:to="loc_us-gaap_StatementClassOfStockAxis_47335047-5a8c-41a9-a7d9-8ca35a914f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_47335047-5a8c-41a9-a7d9-8ca35a914f67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47335047-5a8c-41a9-a7d9-8ca35a914f67" xlink:to="loc_us-gaap_ClassOfStockDomain_47335047-5a8c-41a9-a7d9-8ca35a914f67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7fe6d15f-21b0-44fd-9ccc-078702d31ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47335047-5a8c-41a9-a7d9-8ca35a914f67" xlink:to="loc_us-gaap_ClassOfStockDomain_7fe6d15f-21b0-44fd-9ccc-078702d31ca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9933f695-5675-4d4e-8dea-ffa356ca18a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7fe6d15f-21b0-44fd-9ccc-078702d31ca7" xlink:to="loc_us-gaap_CommonStockMember_9933f695-5675-4d4e-8dea-ffa356ca18a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1b546d3d-5895-42f2-a460-f2c8f0d3cc35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1b546d3d-5895-42f2-a460-f2c8f0d3cc35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b546d3d-5895-42f2-a460-f2c8f0d3cc35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1b546d3d-5895-42f2-a460-f2c8f0d3cc35" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b546d3d-5895-42f2-a460-f2c8f0d3cc35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65548463-d92f-4ab1-b730-500feae59a25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1b546d3d-5895-42f2-a460-f2c8f0d3cc35" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65548463-d92f-4ab1-b730-500feae59a25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_e6085923-4350-4d13-a689-874d93b0bc13" xlink:href="ino-20231231.xsd#ino_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65548463-d92f-4ab1-b730-500feae59a25" xlink:to="loc_ino_SalesAgreementMember_e6085923-4350-4d13-a689-874d93b0bc13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_278f6aa5-96e1-4ed1-bf87-c01b6a7e1708" xlink:href="ino-20231231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65548463-d92f-4ab1-b730-500feae59a25" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_278f6aa5-96e1-4ed1-bf87-c01b6a7e1708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5f6952c4-4be9-4e98-869a-3a9cd2efe677" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:to="loc_srt_RangeAxis_5f6952c4-4be9-4e98-869a-3a9cd2efe677" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f6952c4-4be9-4e98-869a-3a9cd2efe677_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5f6952c4-4be9-4e98-869a-3a9cd2efe677" xlink:to="loc_srt_RangeMember_5f6952c4-4be9-4e98-869a-3a9cd2efe677_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b34b1cee-b897-48ff-882f-795507b55f37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5f6952c4-4be9-4e98-869a-3a9cd2efe677" xlink:to="loc_srt_RangeMember_b34b1cee-b897-48ff-882f-795507b55f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_73c992f8-cb7d-44ef-bd95-ce0edbb54588" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b34b1cee-b897-48ff-882f-795507b55f37" xlink:to="loc_srt_MinimumMember_73c992f8-cb7d-44ef-bd95-ce0edbb54588" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_53895304-ede0-477d-9fe4-2a8939232ad2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b34b1cee-b897-48ff-882f-795507b55f37" xlink:to="loc_srt_MaximumMember_53895304-ede0-477d-9fe4-2a8939232ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9543ae8e-6e02-415d-9107-816bff813056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9543ae8e-6e02-415d-9107-816bff813056" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9543ae8e-6e02-415d-9107-816bff813056_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9543ae8e-6e02-415d-9107-816bff813056" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9543ae8e-6e02-415d-9107-816bff813056_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_09512fed-ac62-4f04-ab3f-0601e102eabd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9543ae8e-6e02-415d-9107-816bff813056" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_09512fed-ac62-4f04-ab3f-0601e102eabd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6454cef3-c914-4e6d-bd3f-7ead28493df9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_09512fed-ac62-4f04-ab3f-0601e102eabd" xlink:to="loc_us-gaap_SubsequentEventMember_6454cef3-c914-4e6d-bd3f-7ead28493df9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1a32cefd-ee29-4616-a77a-578232742f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1a32cefd-ee29-4616-a77a-578232742f42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a32cefd-ee29-4616-a77a-578232742f42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1a32cefd-ee29-4616-a77a-578232742f42" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a32cefd-ee29-4616-a77a-578232742f42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0e684ba-eb62-44b2-90c4-400ce014fe12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1a32cefd-ee29-4616-a77a-578232742f42" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0e684ba-eb62-44b2-90c4-400ce014fe12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_2f030929-a036-4d7d-9c2a-702e3c328acd" xlink:href="ino-20231231.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0e684ba-eb62-44b2-90c4-400ce014fe12" xlink:to="loc_ino_BiojectMember_2f030929-a036-4d7d-9c2a-702e3c328acd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_60f70b19-6fb6-437d-af3d-b8406452cccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_NetIncomeLoss_60f70b19-6fb6-437d-af3d-b8406452cccc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_79195cac-5a2e-4570-b528-c9c3f53ec9c9" xlink:href="ino-20231231.xsd#ino_WorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_ino_WorkingCapital_79195cac-5a2e-4570-b528-c9c3f53ec9c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77059601-c822-4f89-ab25-07fea8859dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77059601-c822-4f89-ab25-07fea8859dd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_537631ce-851f-4c35-929a-6d66913b4240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_537631ce-851f-4c35-929a-6d66913b4240" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4351d5bc-a303-4633-adeb-e43a791b29ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4351d5bc-a303-4633-adeb-e43a791b29ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_5837555c-0fd7-4703-bff3-89a92b7beebe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_NumberOfOperatingSegments_5837555c-0fd7-4703-bff3-89a92b7beebe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_231c1b0f-cb0d-4f20-9b92-e74def143ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_231c1b0f-cb0d-4f20-9b92-e74def143ab4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_05880153-3a98-48fa-89a0-53592766bdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_05880153-3a98-48fa-89a0-53592766bdd0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b515dc34-6a72-4376-a380-8cda7584b02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b515dc34-6a72-4376-a380-8cda7584b02e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2c77a73e-5889-431c-8160-279d9a518f12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2c77a73e-5889-431c-8160-279d9a518f12" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a75b01d0-9ad8-4e3e-b6c0-0db76d2502fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a75b01d0-9ad8-4e3e-b6c0-0db76d2502fe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_4f32f12a-6d95-4b4d-8617-c0f24a952be2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_4f32f12a-6d95-4b4d-8617-c0f24a952be2" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c11b787b-1d0b-487f-ae44-3ad667f1ad01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0eba1e27-a4b6-4d91-8c16-67b7e116170f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c11b787b-1d0b-487f-ae44-3ad667f1ad01" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0eba1e27-a4b6-4d91-8c16-67b7e116170f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_60adebc1-0865-48ef-9ba9-903a571d77b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0eba1e27-a4b6-4d91-8c16-67b7e116170f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_60adebc1-0865-48ef-9ba9-903a571d77b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60adebc1-0865-48ef-9ba9-903a571d77b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_60adebc1-0865-48ef-9ba9-903a571d77b7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_60adebc1-0865-48ef-9ba9-903a571d77b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_60adebc1-0865-48ef-9ba9-903a571d77b7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fc552a75-ef56-4f83-ba7a-9e2fc7f1dfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fc552a75-ef56-4f83-ba7a-9e2fc7f1dfcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_19855e4a-59aa-49d2-927c-0daea1540ccd" xlink:href="ino-20231231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_19855e4a-59aa-49d2-927c-0daea1540ccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a0465b1b-5262-4f1c-8603-627daa6ee847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a0465b1b-5262-4f1c-8603-627daa6ee847" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_00ff4672-e51e-4a49-b5e3-383b3c5471e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_00ff4672-e51e-4a49-b5e3-383b3c5471e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_78e909f3-dece-4906-8ca5-61847d0871e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_78e909f3-dece-4906-8ca5-61847d0871e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7179d628-4c11-461d-9bb8-8a49145ee49b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0eba1e27-a4b6-4d91-8c16-67b7e116170f" xlink:to="loc_us-gaap_DebtInstrumentAxis_7179d628-4c11-461d-9bb8-8a49145ee49b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7179d628-4c11-461d-9bb8-8a49145ee49b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7179d628-4c11-461d-9bb8-8a49145ee49b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7179d628-4c11-461d-9bb8-8a49145ee49b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52685b3a-1c60-483e-ae4e-2b85992a4667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7179d628-4c11-461d-9bb8-8a49145ee49b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_52685b3a-1c60-483e-ae4e-2b85992a4667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_94882005-b7b8-450a-bd03-0e0e1ebf392c" xlink:href="ino-20231231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52685b3a-1c60-483e-ae4e-2b85992a4667" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_94882005-b7b8-450a-bd03-0e0e1ebf392c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e96df88d-bf89-4f97-b84b-9d9f58bcad48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c11b787b-1d0b-487f-ae44-3ad667f1ad01" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e96df88d-bf89-4f97-b84b-9d9f58bcad48" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb9789-be41-4bcb-b58c-31b6b7325bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2b5097d-1c55-4d6a-a0e6-d421d2931339" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb9789-be41-4bcb-b58c-31b6b7325bf7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2b5097d-1c55-4d6a-a0e6-d421d2931339" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a8612def-6220-4f34-ad52-93a611084c09" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2b5097d-1c55-4d6a-a0e6-d421d2931339" xlink:to="loc_srt_TitleOfIndividualAxis_a8612def-6220-4f34-ad52-93a611084c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a8612def-6220-4f34-ad52-93a611084c09_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_a8612def-6220-4f34-ad52-93a611084c09" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a8612def-6220-4f34-ad52-93a611084c09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_202d88a4-a5b7-4cd2-836e-c186a7d72771" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_a8612def-6220-4f34-ad52-93a611084c09" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_202d88a4-a5b7-4cd2-836e-c186a7d72771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_48c008e1-ca88-42eb-b243-551a9363ab33" xlink:href="ino-20231231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_202d88a4-a5b7-4cd2-836e-c186a7d72771" xlink:to="loc_ino_EmployeesAndDirectorsMember_48c008e1-ca88-42eb-b243-551a9363ab33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_ff6904b6-fd1d-43b7-85d5-546cc3aa451d" xlink:href="ino-20231231.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_202d88a4-a5b7-4cd2-836e-c186a7d72771" xlink:to="loc_ino_NonEmployeeMember_ff6904b6-fd1d-43b7-85d5-546cc3aa451d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_324a88a4-0a3d-4413-b059-b4162470a0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2b5097d-1c55-4d6a-a0e6-d421d2931339" xlink:to="loc_us-gaap_AwardTypeAxis_324a88a4-0a3d-4413-b059-b4162470a0c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_324a88a4-0a3d-4413-b059-b4162470a0c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_324a88a4-0a3d-4413-b059-b4162470a0c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_324a88a4-0a3d-4413-b059-b4162470a0c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0854d02-1b86-48da-8cdd-fd8332f6a6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_324a88a4-0a3d-4413-b059-b4162470a0c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0854d02-1b86-48da-8cdd-fd8332f6a6ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_59843545-fd4a-40a1-b1d2-38503b2eece4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0854d02-1b86-48da-8cdd-fd8332f6a6ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_59843545-fd4a-40a1-b1d2-38503b2eece4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_c0362abf-616f-4398-882f-4f4d00f55c88" xlink:href="ino-20231231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb9789-be41-4bcb-b58c-31b6b7325bf7" xlink:to="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_c0362abf-616f-4398-882f-4f4d00f55c88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8cf8c083-83e3-4303-ab90-d162947e1f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_c0362abf-616f-4398-882f-4f4d00f55c88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8cf8c083-83e3-4303-ab90-d162947e1f4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c262b117-e917-4e01-a9ff-2cb9acb60c16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_c0362abf-616f-4398-882f-4f4d00f55c88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c262b117-e917-4e01-a9ff-2cb9acb60c16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9de0189f-046c-45b5-b50f-a77679ef5843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_c0362abf-616f-4398-882f-4f4d00f55c88" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9de0189f-046c-45b5-b50f-a77679ef5843" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_170fb50a-00c0-4014-bdb4-2340be2233b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_c0362abf-616f-4398-882f-4f4d00f55c88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_170fb50a-00c0-4014-bdb4-2340be2233b1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ecf2d122-4e20-40ca-a83d-e99c3e41a614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7b32ccf8-bae8-4b39-abe0-298d89fdeb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ecf2d122-4e20-40ca-a83d-e99c3e41a614" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7b32ccf8-bae8-4b39-abe0-298d89fdeb3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_11464c9e-4446-48d8-be24-ae3be69746e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b32ccf8-bae8-4b39-abe0-298d89fdeb3d" xlink:to="loc_srt_MajorCustomersAxis_11464c9e-4446-48d8-be24-ae3be69746e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_11464c9e-4446-48d8-be24-ae3be69746e9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_11464c9e-4446-48d8-be24-ae3be69746e9" xlink:to="loc_srt_NameOfMajorCustomerDomain_11464c9e-4446-48d8-be24-ae3be69746e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0fea0970-6cd1-4eff-b3ab-2844385d4949" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_11464c9e-4446-48d8-be24-ae3be69746e9" xlink:to="loc_srt_NameOfMajorCustomerDomain_0fea0970-6cd1-4eff-b3ab-2844385d4949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioCorporationMember_cb83ca38-9cd2-4cc8-acbe-633f911dcddd" xlink:href="ino-20231231.xsd#ino_ApolloBioCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0fea0970-6cd1-4eff-b3ab-2844385d4949" xlink:to="loc_ino_ApolloBioCorporationMember_cb83ca38-9cd2-4cc8-acbe-633f911dcddd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember_5aaa76bb-df63-4723-ad0a-af3cbd21c27e" xlink:href="ino-20231231.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0fea0970-6cd1-4eff-b3ab-2844385d4949" xlink:to="loc_ino_PlumblineLifeSciencesIncMember_5aaa76bb-df63-4723-ad0a-af3cbd21c27e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember_3250a108-af13-4cab-90aa-afb07a071f09" xlink:href="ino-20231231.xsd#ino_DoDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0fea0970-6cd1-4eff-b3ab-2844385d4949" xlink:to="loc_ino_DoDMember_3250a108-af13-4cab-90aa-afb07a071f09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember_9422e395-6b08-42f0-b22b-4348b31b8daf" xlink:href="ino-20231231.xsd#ino_AllOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0fea0970-6cd1-4eff-b3ab-2844385d4949" xlink:to="loc_ino_AllOtherCustomersMember_9422e395-6b08-42f0-b22b-4348b31b8daf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1c8e4dd-fa29-465c-8f37-1bbc9a8e0225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b32ccf8-bae8-4b39-abe0-298d89fdeb3d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1c8e4dd-fa29-465c-8f37-1bbc9a8e0225" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c1c8e4dd-fa29-465c-8f37-1bbc9a8e0225_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1c8e4dd-fa29-465c-8f37-1bbc9a8e0225" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c1c8e4dd-fa29-465c-8f37-1bbc9a8e0225_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2241fa8-0de4-4e1f-a790-8d44f4712653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1c8e4dd-fa29-465c-8f37-1bbc9a8e0225" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2241fa8-0de4-4e1f-a790-8d44f4712653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_80789964-4351-40d9-8bdc-e6379e9312b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2241fa8-0de4-4e1f-a790-8d44f4712653" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_80789964-4351-40d9-8bdc-e6379e9312b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_57fa0586-e23b-4928-8751-254a68501e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b32ccf8-bae8-4b39-abe0-298d89fdeb3d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_57fa0586-e23b-4928-8751-254a68501e93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_57fa0586-e23b-4928-8751-254a68501e93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_57fa0586-e23b-4928-8751-254a68501e93" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_57fa0586-e23b-4928-8751-254a68501e93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5451c609-7932-40c0-b42e-f4aedcbe8e87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_57fa0586-e23b-4928-8751-254a68501e93" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5451c609-7932-40c0-b42e-f4aedcbe8e87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_53faa8b9-a4ab-4d38-9d20-322713a65f60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5451c609-7932-40c0-b42e-f4aedcbe8e87" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_53faa8b9-a4ab-4d38-9d20-322713a65f60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_add4d82a-3dc7-4bf9-8232-8863030cd2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ecf2d122-4e20-40ca-a83d-e99c3e41a614" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_add4d82a-3dc7-4bf9-8232-8863030cd2f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_02171c28-0183-41a2-a6d0-8203cd181b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ecf2d122-4e20-40ca-a83d-e99c3e41a614" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_02171c28-0183-41a2-a6d0-8203cd181b54" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_71d1eb4c-a8ef-4a2a-8b0e-9c29a0bdae33" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:to="loc_srt_CounterpartyNameAxis_71d1eb4c-a8ef-4a2a-8b0e-9c29a0bdae33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71d1eb4c-a8ef-4a2a-8b0e-9c29a0bdae33_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_71d1eb4c-a8ef-4a2a-8b0e-9c29a0bdae33" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71d1eb4c-a8ef-4a2a-8b0e-9c29a0bdae33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_71d1eb4c-a8ef-4a2a-8b0e-9c29a0bdae33" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_50467d8d-267c-44df-a5ad-3f4ead0146f0" xlink:href="ino-20231231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:to="loc_ino_AdvaccineMember_50467d8d-267c-44df-a5ad-3f4ead0146f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_0ae8cb9a-6673-4cd7-9a85-6b266e5571f0" xlink:href="ino-20231231.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:to="loc_ino_ApolloBioMember_0ae8cb9a-6673-4cd7-9a85-6b266e5571f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_e8415cad-0802-4680-bffb-c621c5735679" xlink:href="ino-20231231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_e8415cad-0802-4680-bffb-c621c5735679" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_029f59d6-7b62-4111-9550-1bbaa85e9eb2" xlink:href="ino-20231231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_029f59d6-7b62-4111-9550-1bbaa85e9eb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_4851f524-a831-4e40-8bf9-bcb2cff31529" xlink:href="ino-20231231.xsd#ino_DepartmentOfDefenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:to="loc_ino_DepartmentOfDefenceMember_4851f524-a831-4e40-8bf9-bcb2cff31529" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1467ffec-efd7-4adf-8b5f-d695cde68516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1467ffec-efd7-4adf-8b5f-d695cde68516" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1467ffec-efd7-4adf-8b5f-d695cde68516_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1467ffec-efd7-4adf-8b5f-d695cde68516" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1467ffec-efd7-4adf-8b5f-d695cde68516_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e59e1f7a-8fe7-428d-aa2c-c7aedc696712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1467ffec-efd7-4adf-8b5f-d695cde68516" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e59e1f7a-8fe7-428d-aa2c-c7aedc696712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_7f63d5c7-94c4-4061-95ae-97b3f154a05c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e59e1f7a-8fe7-428d-aa2c-c7aedc696712" xlink:to="loc_us-gaap_CollaborativeArrangementMember_7f63d5c7-94c4-4061-95ae-97b3f154a05c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_872fe268-457b-4660-8887-aa100e332fbe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:to="loc_srt_MajorCustomersAxis_872fe268-457b-4660-8887-aa100e332fbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_872fe268-457b-4660-8887-aa100e332fbe_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_872fe268-457b-4660-8887-aa100e332fbe" xlink:to="loc_srt_NameOfMajorCustomerDomain_872fe268-457b-4660-8887-aa100e332fbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ea14a7a8-f170-457b-920d-343e6af6501e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_872fe268-457b-4660-8887-aa100e332fbe" xlink:to="loc_srt_NameOfMajorCustomerDomain_ea14a7a8-f170-457b-920d-343e6af6501e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_9023d832-05ef-41d0-9498-4b0ae7f63fcf" xlink:href="ino-20231231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ea14a7a8-f170-457b-920d-343e6af6501e" xlink:to="loc_ino_AdvaccineMember_9023d832-05ef-41d0-9498-4b0ae7f63fcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1f10ec3a-0cf4-44f8-889e-e79dde20b861" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:to="loc_srt_ProductOrServiceAxis_1f10ec3a-0cf4-44f8-889e-e79dde20b861" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1f10ec3a-0cf4-44f8-889e-e79dde20b861_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1f10ec3a-0cf4-44f8-889e-e79dde20b861" xlink:to="loc_srt_ProductsAndServicesDomain_1f10ec3a-0cf4-44f8-889e-e79dde20b861_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1f10ec3a-0cf4-44f8-889e-e79dde20b861" xlink:to="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_da095a2f-aa4e-4233-a392-27b8519fe942" xlink:href="ino-20231231.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_da095a2f-aa4e-4233-a392-27b8519fe942" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_7e625efe-6e4a-41f2-87af-90e209322da8" xlink:href="ino-20231231.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_7e625efe-6e4a-41f2-87af-90e209322da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_5ded3f14-86ab-44e4-8c8f-cd6f3f1fdc92" xlink:href="ino-20231231.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_5ded3f14-86ab-44e4-8c8f-cd6f3f1fdc92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_dda590b1-f41d-435f-a0dc-3377f13e998a" xlink:href="ino-20231231.xsd#ino_INO4800Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:to="loc_ino_INO4800Member_dda590b1-f41d-435f-a0dc-3377f13e998a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_ce32b1a7-3569-4d5b-a384-100186680d41" xlink:href="ino-20231231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_ce32b1a7-3569-4d5b-a384-100186680d41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_4ec76d5c-e2d7-416a-a909-d83eae77eafc" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_4ec76d5c-e2d7-416a-a909-d83eae77eafc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_28c295c0-08a5-4e58-bdbe-4790c4988e3b" xlink:href="ino-20231231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_28c295c0-08a5-4e58-bdbe-4790c4988e3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_e5ab2ed5-b64f-4918-81c6-55a708a4c9dd" xlink:href="ino-20231231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_e5ab2ed5-b64f-4918-81c6-55a708a4c9dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_8f3af8ce-7ddc-4e14-bc85-a23c13f10132" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_8f3af8ce-7ddc-4e14-bc85-a23c13f10132" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aeb23078-2dc2-451b-a664-67696461118d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aeb23078-2dc2-451b-a664-67696461118d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_5e231836-4e59-4363-becc-a6b701e85d6b" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_5e231836-4e59-4363-becc-a6b701e85d6b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_eb82f339-93f9-4044-8b46-761842fa01e7" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_eb82f339-93f9-4044-8b46-761842fa01e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_de2ac6a9-f005-4b1f-8740-c6e8095a0347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_us-gaap_AccountsReceivableNet_de2ac6a9-f005-4b1f-8740-c6e8095a0347" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_fbf5bb09-2431-4f3d-bcfb-f6283f2cb999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_fbf5bb09-2431-4f3d-bcfb-f6283f2cb999" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_940bb2c6-b73b-4196-8ca6-502aa99ff6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_us-gaap_GrantsReceivable_940bb2c6-b73b-4196-8ca6-502aa99ff6b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_cbd5ef95-50a2-405d-8a93-a8fc303f1a33" xlink:href="ino-20231231.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_GrantProceedsReceived_cbd5ef95-50a2-405d-8a93-a8fc303f1a33" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_c6efa5b7-f517-4cf1-816d-e0a632731af0" xlink:href="ino-20231231.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_c6efa5b7-f517-4cf1-816d-e0a632731af0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_ada706fa-9009-4a04-a3aa-e51f87268f7a" xlink:href="ino-20231231.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_ada706fa-9009-4a04-a3aa-e51f87268f7a" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8634422b-167c-4bf3-a8e8-aca3ca9449d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bd08181-fc47-43c2-8d20-87e71db59461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8634422b-167c-4bf3-a8e8-aca3ca9449d5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bd08181-fc47-43c2-8d20-87e71db59461" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d96855d9-a076-4f56-90e3-ca5d5997d5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bd08181-fc47-43c2-8d20-87e71db59461" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d96855d9-a076-4f56-90e3-ca5d5997d5c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d96855d9-a076-4f56-90e3-ca5d5997d5c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d96855d9-a076-4f56-90e3-ca5d5997d5c6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d96855d9-a076-4f56-90e3-ca5d5997d5c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d3c648b-76fb-4074-b446-393e2456b392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d96855d9-a076-4f56-90e3-ca5d5997d5c6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d3c648b-76fb-4074-b446-393e2456b392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_8b6e3f4e-f0e2-49ae-b616-58fa7dc055e8" xlink:href="ino-20231231.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d3c648b-76fb-4074-b446-393e2456b392" xlink:to="loc_ino_MutualFundsMember_8b6e3f4e-f0e2-49ae-b616-58fa7dc055e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_5859ba5c-7352-48fb-a005-57cb6b763120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d3c648b-76fb-4074-b446-393e2456b392" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_5859ba5c-7352-48fb-a005-57cb6b763120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_79bc0f70-b5e6-41e3-820c-d2ea06536f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d3c648b-76fb-4074-b446-393e2456b392" xlink:to="loc_us-gaap_CertificatesOfDepositMember_79bc0f70-b5e6-41e3-820c-d2ea06536f2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_0af54d74-caa9-4fdc-8bdf-ffffd41d7fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d3c648b-76fb-4074-b446-393e2456b392" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_0af54d74-caa9-4fdc-8bdf-ffffd41d7fc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2dd73787-d860-41fc-8c61-c7869a8b7bb1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bd08181-fc47-43c2-8d20-87e71db59461" xlink:to="loc_srt_RangeAxis_2dd73787-d860-41fc-8c61-c7869a8b7bb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2dd73787-d860-41fc-8c61-c7869a8b7bb1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2dd73787-d860-41fc-8c61-c7869a8b7bb1" xlink:to="loc_srt_RangeMember_2dd73787-d860-41fc-8c61-c7869a8b7bb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_58087107-7c7d-4a91-be74-22637da9406a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2dd73787-d860-41fc-8c61-c7869a8b7bb1" xlink:to="loc_srt_RangeMember_58087107-7c7d-4a91-be74-22637da9406a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34c5e58e-eb38-4054-9f15-e6f0eb3a2c9c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_58087107-7c7d-4a91-be74-22637da9406a" xlink:to="loc_srt_MaximumMember_34c5e58e-eb38-4054-9f15-e6f0eb3a2c9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_bf03e4ab-fae4-418b-9543-bce60f125346" xlink:href="ino-20231231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8634422b-167c-4bf3-a8e8-aca3ca9449d5" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_bf03e4ab-fae4-418b-9543-bce60f125346" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7d2862a9-0732-4d26-9068-d981f46a646d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8634422b-167c-4bf3-a8e8-aca3ca9449d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7d2862a9-0732-4d26-9068-d981f46a646d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_08d24242-24bd-4635-96b0-72c8dad4e02d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7d2862a9-0732-4d26-9068-d981f46a646d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_08d24242-24bd-4635-96b0-72c8dad4e02d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aa0cb515-25b7-4fc8-b8f4-76ee20148462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7d2862a9-0732-4d26-9068-d981f46a646d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aa0cb515-25b7-4fc8-b8f4-76ee20148462" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_68436a28-d84c-4227-82af-d28796475449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7d2862a9-0732-4d26-9068-d981f46a646d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_68436a28-d84c-4227-82af-d28796475449" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1ebacc1d-ce0a-4f9f-bd72-adf8b5b9d8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7d2862a9-0732-4d26-9068-d981f46a646d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1ebacc1d-ce0a-4f9f-bd72-adf8b5b9d8c6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b7f3f0a4-cb82-4dc7-8ef3-1a36d64ab6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b7f3f0a4-cb82-4dc7-8ef3-1a36d64ab6f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94f45538-d84b-4bcd-885d-dfae8537e0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b7f3f0a4-cb82-4dc7-8ef3-1a36d64ab6f1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94f45538-d84b-4bcd-885d-dfae8537e0e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94f45538-d84b-4bcd-885d-dfae8537e0e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94f45538-d84b-4bcd-885d-dfae8537e0e8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94f45538-d84b-4bcd-885d-dfae8537e0e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_185dbe07-ca2b-458d-81e6-00432f70272b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94f45538-d84b-4bcd-885d-dfae8537e0e8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_185dbe07-ca2b-458d-81e6-00432f70272b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cd35da5d-01eb-4eea-8f26-a9fac4e99a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_185dbe07-ca2b-458d-81e6-00432f70272b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cd35da5d-01eb-4eea-8f26-a9fac4e99a37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_bd557371-6e10-4089-9cd8-c519f7296d28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_bd557371-6e10-4089-9cd8-c519f7296d28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_fa4bbe9d-7489-47fd-b563-cab755763e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_fa4bbe9d-7489-47fd-b563-cab755763e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f9c93b8b-da82-48fa-a341-2306d6347a17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f9c93b8b-da82-48fa-a341-2306d6347a17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8fcfe4f9-7dd5-49df-86c8-b96d851e5af8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8fcfe4f9-7dd5-49df-86c8-b96d851e5af8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_6218fdc5-6215-4705-837b-9b8d74312c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_6218fdc5-6215-4705-837b-9b8d74312c1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_66ebbf05-42d4-47bf-ac64-f7f7281cec4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_66ebbf05-42d4-47bf-ac64-f7f7281cec4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_0830d3fb-efef-42ea-8116-c4230542768f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_0830d3fb-efef-42ea-8116-c4230542768f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3362464a-8d38-48da-b963-b36bd4f1812b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2b5bd279-67e2-4b04-b452-0dbabb4df731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3362464a-8d38-48da-b963-b36bd4f1812b" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2b5bd279-67e2-4b04-b452-0dbabb4df731" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3bea6b06-fccf-472f-964b-74af89392658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2b5bd279-67e2-4b04-b452-0dbabb4df731" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3bea6b06-fccf-472f-964b-74af89392658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3bea6b06-fccf-472f-964b-74af89392658_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3bea6b06-fccf-472f-964b-74af89392658" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3bea6b06-fccf-472f-964b-74af89392658_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b82833fd-4622-411d-9a90-6209136a95bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3bea6b06-fccf-472f-964b-74af89392658" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b82833fd-4622-411d-9a90-6209136a95bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_eb3f7441-e6bd-4744-b1d7-1bad10e72a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b82833fd-4622-411d-9a90-6209136a95bb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_eb3f7441-e6bd-4744-b1d7-1bad10e72a5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6b8d2528-813d-4d72-adeb-e4ba45fa6296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2b5bd279-67e2-4b04-b452-0dbabb4df731" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6b8d2528-813d-4d72-adeb-e4ba45fa6296" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6b8d2528-813d-4d72-adeb-e4ba45fa6296_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6b8d2528-813d-4d72-adeb-e4ba45fa6296" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6b8d2528-813d-4d72-adeb-e4ba45fa6296_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb5b1417-863c-4fcd-8e02-8e9fe1d2b57b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6b8d2528-813d-4d72-adeb-e4ba45fa6296" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb5b1417-863c-4fcd-8e02-8e9fe1d2b57b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_5f6f25f7-5671-4b86-8a73-e229287c0c6e" xlink:href="ino-20231231.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb5b1417-863c-4fcd-8e02-8e9fe1d2b57b" xlink:to="loc_ino_MutualFundsMember_5f6f25f7-5671-4b86-8a73-e229287c0c6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bbf7f6ec-5216-473b-9938-06bdbd0b552b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb5b1417-863c-4fcd-8e02-8e9fe1d2b57b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bbf7f6ec-5216-473b-9938-06bdbd0b552b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6707c453-e078-4d03-ad92-18b95b68fd01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb5b1417-863c-4fcd-8e02-8e9fe1d2b57b" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6707c453-e078-4d03-ad92-18b95b68fd01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_4b7e5020-f311-47c3-8e3c-2e26b004b46b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb5b1417-863c-4fcd-8e02-8e9fe1d2b57b" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_4b7e5020-f311-47c3-8e3c-2e26b004b46b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c601e05a-09aa-493d-b0ae-e354a8f5dc61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2b5bd279-67e2-4b04-b452-0dbabb4df731" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c601e05a-09aa-493d-b0ae-e354a8f5dc61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c601e05a-09aa-493d-b0ae-e354a8f5dc61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c601e05a-09aa-493d-b0ae-e354a8f5dc61" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c601e05a-09aa-493d-b0ae-e354a8f5dc61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d45c350-5894-4994-ae41-8e22f97c6ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c601e05a-09aa-493d-b0ae-e354a8f5dc61" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d45c350-5894-4994-ae41-8e22f97c6ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bbc06896-a70e-4811-86fc-9598e1243681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d45c350-5894-4994-ae41-8e22f97c6ca1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bbc06896-a70e-4811-86fc-9598e1243681" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6d518342-d190-43f6-b507-b9b9095403f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d45c350-5894-4994-ae41-8e22f97c6ca1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6d518342-d190-43f6-b507-b9b9095403f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_60c70001-4170-45b7-bbdc-b0e49dd28fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d45c350-5894-4994-ae41-8e22f97c6ca1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_60c70001-4170-45b7-bbdc-b0e49dd28fef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b7db71a3-5d21-4e30-a887-0849f3e4eb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3362464a-8d38-48da-b963-b36bd4f1812b" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b7db71a3-5d21-4e30-a887-0849f3e4eb7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f552519-ac85-41bf-87c9-811f87dc8cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b7db71a3-5d21-4e30-a887-0849f3e4eb7d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f552519-ac85-41bf-87c9-811f87dc8cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_38b74338-b140-4d71-97f4-51ecf3910cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b7db71a3-5d21-4e30-a887-0849f3e4eb7d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_38b74338-b140-4d71-97f4-51ecf3910cc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_66d18796-81db-4132-911d-3c270d1b5ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b7db71a3-5d21-4e30-a887-0849f3e4eb7d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_66d18796-81db-4132-911d-3c270d1b5ec5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:href="ino-20231231.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable_0117b889-2831-4e62-af68-855303d81b59" xlink:href="ino-20231231.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesTable_0117b889-2831-4e62-af68-855303d81b59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_70a30d7a-bffd-4766-9c80-0dba371c56c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_0117b889-2831-4e62-af68-855303d81b59" xlink:to="loc_srt_LitigationCaseAxis_70a30d7a-bffd-4766-9c80-0dba371c56c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_70a30d7a-bffd-4766-9c80-0dba371c56c3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_70a30d7a-bffd-4766-9c80-0dba371c56c3" xlink:to="loc_srt_LitigationCaseTypeDomain_70a30d7a-bffd-4766-9c80-0dba371c56c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d592f799-4a12-41fa-90aa-3547ff192c9a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_70a30d7a-bffd-4766-9c80-0dba371c56c3" xlink:to="loc_srt_LitigationCaseTypeDomain_d592f799-4a12-41fa-90aa-3547ff192c9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_423e1b10-35b5-420c-9609-31edf9426111" xlink:href="ino-20231231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d592f799-4a12-41fa-90aa-3547ff192c9a" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_423e1b10-35b5-420c-9609-31edf9426111" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BehestiVKimEtAlMember_d2cad6f6-62ff-447e-bf0c-44bad69c40b5" xlink:href="ino-20231231.xsd#ino_BehestiVKimEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d592f799-4a12-41fa-90aa-3547ff192c9a" xlink:to="loc_ino_BehestiVKimEtAlMember_d2cad6f6-62ff-447e-bf0c-44bad69c40b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_17067513-051f-43bd-93cd-581b160b46a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_0117b889-2831-4e62-af68-855303d81b59" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_17067513-051f-43bd-93cd-581b160b46a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_17067513-051f-43bd-93cd-581b160b46a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_17067513-051f-43bd-93cd-581b160b46a5" xlink:to="loc_us-gaap_RelatedPartyDomain_17067513-051f-43bd-93cd-581b160b46a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e0880f87-1f08-4a7f-963b-2ff1a9bb64f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_17067513-051f-43bd-93cd-581b160b46a5" xlink:to="loc_us-gaap_RelatedPartyDomain_e0880f87-1f08-4a7f-963b-2ff1a9bb64f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_ba57ca6f-c8ba-42cd-a532-e74d6a7f91da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e0880f87-1f08-4a7f-963b-2ff1a9bb64f2" xlink:to="loc_us-gaap_NonrelatedPartyMember_ba57ca6f-c8ba-42cd-a532-e74d6a7f91da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_0dd83969-a0b4-4906-85ba-a1fdd3c105bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_0dd83969-a0b4-4906-85ba-a1fdd3c105bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_bea979e9-484a-43f8-b092-75e610a6500e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_AccruedSalariesCurrent_bea979e9-484a-43f8-b092-75e610a6500e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_9c0aa884-2155-406b-a528-bdae3baacb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_LitigationReserveCurrent_9c0aa884-2155-406b-a528-bdae3baacb0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_bb2bdfa9-3c47-43e9-809c-e41535beb9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_bb2bdfa9-3c47-43e9-809c-e41535beb9bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_06440877-98df-49f7-9c4e-21cd7f341248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_06440877-98df-49f7-9c4e-21cd7f341248" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_f7a39d47-36f9-48fd-81c7-4b67e26130f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_f7a39d47-36f9-48fd-81c7-4b67e26130f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_b5cd9328-7f46-4e61-9814-4a0db3be731d" xlink:href="ino-20231231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_b5cd9328-7f46-4e61-9814-4a0db3be731d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e1f98def-fe04-4c3d-8d15-1142d5013a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e1f98def-fe04-4c3d-8d15-1142d5013a77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_c3d8a724-a589-4d0c-8e85-33442efb8bc7" xlink:href="ino-20231231.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_c3d8a724-a589-4d0c-8e85-33442efb8bc7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_4a13d5e6-d087-452c-ac4f-22678adfb286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_4a13d5e6-d087-452c-ac4f-22678adfb286" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantLiability_9317a4f7-6f4d-4388-8301-2f92a353185d" xlink:href="ino-20231231.xsd#ino_GrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_ino_GrantLiability_9317a4f7-6f4d-4388-8301-2f92a353185d" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#FixedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aa6c47c-5d18-4d87-b325-e7e73e9df56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aa6c47c-5d18-4d87-b325-e7e73e9df56c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_38274497-4fa4-43b0-9656-a00b76370bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aa6c47c-5d18-4d87-b325-e7e73e9df56c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_38274497-4fa4-43b0-9656-a00b76370bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_38274497-4fa4-43b0-9656-a00b76370bfc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_38274497-4fa4-43b0-9656-a00b76370bfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_38274497-4fa4-43b0-9656-a00b76370bfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df20eeb-9285-45e0-bb3c-fc63f848b339" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_38274497-4fa4-43b0-9656-a00b76370bfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df20eeb-9285-45e0-bb3c-fc63f848b339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e865a3e6-aaee-484f-955e-b718e499e963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df20eeb-9285-45e0-bb3c-fc63f848b339" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e865a3e6-aaee-484f-955e-b718e499e963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_c06b11ea-4ab4-45af-88c5-5820c3d011e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df20eeb-9285-45e0-bb3c-fc63f848b339" xlink:to="loc_us-gaap_OfficeEquipmentMember_c06b11ea-4ab4-45af-88c5-5820c3d011e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_078935db-93b6-4f54-9848-0c787a637ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df20eeb-9285-45e0-bb3c-fc63f848b339" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_078935db-93b6-4f54-9848-0c787a637ce6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_5cae8e74-9481-4326-84bd-7db78eeb82ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df20eeb-9285-45e0-bb3c-fc63f848b339" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_5cae8e74-9481-4326-84bd-7db78eeb82ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c5210635-1fed-4ea1-a470-ba88a0de993f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c5210635-1fed-4ea1-a470-ba88a0de993f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_52d0388d-4209-4a3b-a7bb-d869f61842b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_52d0388d-4209-4a3b-a7bb-d869f61842b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2848f286-b79d-4881-b425-02ddf8779b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2848f286-b79d-4881-b425-02ddf8779b3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_aa44c7af-cb8a-4aea-ba24-d1a1292b3b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_us-gaap_Depreciation_aa44c7af-cb8a-4aea-ba24-d1a1292b3b15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PropertyPlantAndEquipmentDisposedOfBySale_58ac36d5-493b-49c7-b101-5a38167827e6" xlink:href="ino-20231231.xsd#ino_PropertyPlantAndEquipmentDisposedOfBySale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_ino_PropertyPlantAndEquipmentDisposedOfBySale_58ac36d5-493b-49c7-b101-5a38167827e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_b1e49e72-1e22-4c4f-bc9c-27dfa3ec7461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_b1e49e72-1e22-4c4f-bc9c-27dfa3ec7461" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_11968745-fb8c-4bc9-abe5-a8a9576f602e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_60735bf0-76d9-42d6-8ad2-3c0ce3435c75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_11968745-fb8c-4bc9-abe5-a8a9576f602e" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_60735bf0-76d9-42d6-8ad2-3c0ce3435c75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a634c7c6-d31b-4bcf-a6e9-84e55989ab5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_60735bf0-76d9-42d6-8ad2-3c0ce3435c75" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a634c7c6-d31b-4bcf-a6e9-84e55989ab5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a634c7c6-d31b-4bcf-a6e9-84e55989ab5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a634c7c6-d31b-4bcf-a6e9-84e55989ab5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a634c7c6-d31b-4bcf-a6e9-84e55989ab5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_377309eb-e909-4a0b-be1e-054098639154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a634c7c6-d31b-4bcf-a6e9-84e55989ab5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_377309eb-e909-4a0b-be1e-054098639154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_3d45359a-4cef-4ecb-bc48-712d2b7200f8" xlink:href="ino-20231231.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_377309eb-e909-4a0b-be1e-054098639154" xlink:to="loc_ino_BiojectMember_3d45359a-4cef-4ecb-bc48-712d2b7200f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_9dde90a9-2c86-40be-8600-a0a599ecf6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_11968745-fb8c-4bc9-abe5-a8a9576f602e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_9dde90a9-2c86-40be-8600-a0a599ecf6c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_67d11a37-fe3e-49b3-9786-9449c085486a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_11968745-fb8c-4bc9-abe5-a8a9576f602e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_67d11a37-fe3e-49b3-9786-9449c085486a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_11f5a53d-7b82-4ef6-8fed-9bdf9059d0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_11968745-fb8c-4bc9-abe5-a8a9576f602e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_11f5a53d-7b82-4ef6-8fed-9bdf9059d0f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_61e98f06-cce7-4eb8-9b64-3ac4b40e7097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_11968745-fb8c-4bc9-abe5-a8a9576f602e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_61e98f06-cce7-4eb8-9b64-3ac4b40e7097" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_83fd314b-7457-4629-aaa1-eee285836583" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_2589fcb8-36a4-463f-9e3d-73d58aaa9a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_83fd314b-7457-4629-aaa1-eee285836583" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_2589fcb8-36a4-463f-9e3d-73d58aaa9a3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a41f56a-e79e-4794-96a0-559eb0dc731b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_2589fcb8-36a4-463f-9e3d-73d58aaa9a3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a41f56a-e79e-4794-96a0-559eb0dc731b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a41f56a-e79e-4794-96a0-559eb0dc731b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a41f56a-e79e-4794-96a0-559eb0dc731b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a41f56a-e79e-4794-96a0-559eb0dc731b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_574e2756-b890-4615-b99a-01a6ea0c6d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a41f56a-e79e-4794-96a0-559eb0dc731b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_574e2756-b890-4615-b99a-01a6ea0c6d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_03288405-cfb0-44cd-a03b-f604df58fb51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_574e2756-b890-4615-b99a-01a6ea0c6d54" xlink:to="loc_us-gaap_LicensingAgreementsMember_03288405-cfb0-44cd-a03b-f604df58fb51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_682f2a8c-5cbf-49f0-b20d-f3642f427263" xlink:href="ino-20231231.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_574e2756-b890-4615-b99a-01a6ea0c6d54" xlink:to="loc_ino_BiojectMember_682f2a8c-5cbf-49f0-b20d-f3642f427263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_6b378f1e-8d42-4ddc-b83f-f130abdd1afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_574e2756-b890-4615-b99a-01a6ea0c6d54" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_6b378f1e-8d42-4ddc-b83f-f130abdd1afe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a0843680-4cb2-430e-9a67-a17e0018882c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_2589fcb8-36a4-463f-9e3d-73d58aaa9a3b" xlink:to="loc_srt_RangeAxis_a0843680-4cb2-430e-9a67-a17e0018882c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a0843680-4cb2-430e-9a67-a17e0018882c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a0843680-4cb2-430e-9a67-a17e0018882c" xlink:to="loc_srt_RangeMember_a0843680-4cb2-430e-9a67-a17e0018882c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_172ae783-f0cd-4f22-8e8a-0f0469f8bc4e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a0843680-4cb2-430e-9a67-a17e0018882c" xlink:to="loc_srt_RangeMember_172ae783-f0cd-4f22-8e8a-0f0469f8bc4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_0c56b348-ed60-4a18-95d3-44ca86285cfd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_172ae783-f0cd-4f22-8e8a-0f0469f8bc4e" xlink:to="loc_srt_WeightedAverageMember_0c56b348-ed60-4a18-95d3-44ca86285cfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91f3ab09-9aba-4d97-965b-c0c9a98e3559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_83fd314b-7457-4629-aaa1-eee285836583" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91f3ab09-9aba-4d97-965b-c0c9a98e3559" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_357ce4a5-5714-412c-a4f1-ea97ee6502eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91f3ab09-9aba-4d97-965b-c0c9a98e3559" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_357ce4a5-5714-412c-a4f1-ea97ee6502eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_70cf3694-c161-4466-b29a-c01687cfce64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_357ce4a5-5714-412c-a4f1-ea97ee6502eb" xlink:to="loc_us-gaap_GoodwillGross_70cf3694-c161-4466-b29a-c01687cfce64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a9c3bd61-a6b4-4759-84a3-e31dc876ba62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_357ce4a5-5714-412c-a4f1-ea97ee6502eb" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a9c3bd61-a6b4-4759-84a3-e31dc876ba62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b8da5f18-3f30-466a-a87c-9fd81b254ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_357ce4a5-5714-412c-a4f1-ea97ee6502eb" xlink:to="loc_us-gaap_Goodwill_b8da5f18-3f30-466a-a87c-9fd81b254ac1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91f3ab09-9aba-4d97-965b-c0c9a98e3559" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9b4119d6-b828-44e2-89df-0af250d0e420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9b4119d6-b828-44e2-89df-0af250d0e420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50718209-fdb3-40c1-9cdb-741ce28c93bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50718209-fdb3-40c1-9cdb-741ce28c93bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d893ce9a-0934-4506-9f75-6370d51755ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d893ce9a-0934-4506-9f75-6370d51755ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_606e377b-a81d-4e6f-8a3e-ac59efb69b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_606e377b-a81d-4e6f-8a3e-ac59efb69b4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a4048b7e-0b62-40de-b00a-03b8acaf37a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a4048b7e-0b62-40de-b00a-03b8acaf37a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_efe21c11-ea00-4755-8e6d-189ae4ae79cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_efe21c11-ea00-4755-8e6d-189ae4ae79cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_f3164bfd-0ce1-475f-b93a-cd5af8b0a275" xlink:href="ino-20231231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91f3ab09-9aba-4d97-965b-c0c9a98e3559" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_f3164bfd-0ce1-475f-b93a-cd5af8b0a275" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_ae3bee4e-6fd8-437d-99ec-fde09bf11421" xlink:href="ino-20231231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91f3ab09-9aba-4d97-965b-c0c9a98e3559" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_ae3bee4e-6fd8-437d-99ec-fde09bf11421" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b7381e37-59f0-412d-bcd8-30e0d4cf83e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b7381e37-59f0-412d-bcd8-30e0d4cf83e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b7381e37-59f0-412d-bcd8-30e0d4cf83e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b7381e37-59f0-412d-bcd8-30e0d4cf83e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b7381e37-59f0-412d-bcd8-30e0d4cf83e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3a79cfd9-ccd1-4107-bbdd-4a6324d6fa43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b7381e37-59f0-412d-bcd8-30e0d4cf83e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3a79cfd9-ccd1-4107-bbdd-4a6324d6fa43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_8e69dceb-ca1a-47d9-af36-ec0909eef2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3a79cfd9-ccd1-4107-bbdd-4a6324d6fa43" xlink:to="loc_us-gaap_ConvertibleDebtMember_8e69dceb-ca1a-47d9-af36-ec0909eef2a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_59ca5364-caf0-4fa9-a737-50b6d19d81e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:to="loc_us-gaap_DebtInstrumentAxis_59ca5364-caf0-4fa9-a737-50b6d19d81e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_59ca5364-caf0-4fa9-a737-50b6d19d81e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_59ca5364-caf0-4fa9-a737-50b6d19d81e6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_59ca5364-caf0-4fa9-a737-50b6d19d81e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_888b7a60-75d8-4918-b0f9-a68d241ddefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_59ca5364-caf0-4fa9-a737-50b6d19d81e6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_888b7a60-75d8-4918-b0f9-a68d241ddefc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_67acd3d0-850f-4c55-a5ea-3a27e80c47df" xlink:href="ino-20231231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_888b7a60-75d8-4918-b0f9-a68d241ddefc" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_67acd3d0-850f-4c55-a5ea-3a27e80c47df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44073caf-9ee7-43ed-9853-4d21ea67a9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44073caf-9ee7-43ed-9853-4d21ea67a9b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_44073caf-9ee7-43ed-9853-4d21ea67a9b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44073caf-9ee7-43ed-9853-4d21ea67a9b1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_44073caf-9ee7-43ed-9853-4d21ea67a9b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_b6fa879a-b4b3-4e99-a723-af1a19d313c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44073caf-9ee7-43ed-9853-4d21ea67a9b1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_b6fa879a-b4b3-4e99-a723-af1a19d313c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_0a7ae9ba-8bfd-4448-bf55-f64029a58c10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_b6fa879a-b4b3-4e99-a723-af1a19d313c0" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_0a7ae9ba-8bfd-4448-bf55-f64029a58c10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6ec0b2f9-ac5a-4a61-943c-3bde3de7274a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6ec0b2f9-ac5a-4a61-943c-3bde3de7274a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6ec0b2f9-ac5a-4a61-943c-3bde3de7274a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6ec0b2f9-ac5a-4a61-943c-3bde3de7274a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6ec0b2f9-ac5a-4a61-943c-3bde3de7274a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_caa49bbf-deda-4e9a-8d67-8b85e609b707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6ec0b2f9-ac5a-4a61-943c-3bde3de7274a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_caa49bbf-deda-4e9a-8d67-8b85e609b707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d7a24827-dc4b-4857-bccb-85a48e7edba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_caa49bbf-deda-4e9a-8d67-8b85e609b707" xlink:to="loc_us-gaap_SubsequentEventMember_d7a24827-dc4b-4857-bccb-85a48e7edba7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_85772b90-3f83-4464-a5a8-863640e4c923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_85772b90-3f83-4464-a5a8-863640e4c923" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4aa7128b-7f9b-404e-a86d-0a5b2bace9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4aa7128b-7f9b-404e-a86d-0a5b2bace9ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_884ad500-f1f9-40ec-8b17-9dc4aebea69f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_884ad500-f1f9-40ec-8b17-9dc4aebea69f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_77401d9b-0211-4a41-ab37-94123cb8f408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_77401d9b-0211-4a41-ab37-94123cb8f408" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_118fa4c3-9dd8-4567-a1aa-aad4a3ad67af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_118fa4c3-9dd8-4567-a1aa-aad4a3ad67af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0287148e-1a5c-4e1c-902e-51872bd889e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0287148e-1a5c-4e1c-902e-51872bd889e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_839770fd-6fbf-483e-82fa-acb334f50995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_839770fd-6fbf-483e-82fa-acb334f50995" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d89eec6d-ef79-4dfd-a029-32d6e449e2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d89eec6d-ef79-4dfd-a029-32d6e449e2f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5a0798c6-245e-4bbe-bd7a-76a6c9c3c9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5a0798c6-245e-4bbe-bd7a-76a6c9c3c9f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_2e921f14-25f2-45c7-83a2-07f409c5bdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_ConvertibleDebt_2e921f14-25f2-45c7-83a2-07f409c5bdfc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6313ae23-9f8f-47a9-9cd4-01984b406c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_InterestExpense_6313ae23-9f8f-47a9-9cd4-01984b406c3e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a308781b-daf4-4c9a-8ada-f6fd69ceb035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_InterestExpenseDebt_a308781b-daf4-4c9a-8ada-f6fd69ceb035" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ConvertibleDebtScheduleofConvertibleDebtDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_63ff2816-d572-4f49-ac88-6c34319f670a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:to="loc_us-gaap_DebtInstrumentTable_63ff2816-d572-4f49-ac88-6c34319f670a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fcc16b2d-bcd9-4277-8932-2b0f02e115d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_63ff2816-d572-4f49-ac88-6c34319f670a" xlink:to="loc_us-gaap_DebtInstrumentAxis_fcc16b2d-bcd9-4277-8932-2b0f02e115d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fcc16b2d-bcd9-4277-8932-2b0f02e115d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fcc16b2d-bcd9-4277-8932-2b0f02e115d8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fcc16b2d-bcd9-4277-8932-2b0f02e115d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_68f231cd-3593-477c-98c4-48acb28d3b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fcc16b2d-bcd9-4277-8932-2b0f02e115d8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_68f231cd-3593-477c-98c4-48acb28d3b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c887c3db-e55e-48b1-b72e-75b74edfc7e7" xlink:href="ino-20231231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_68f231cd-3593-477c-98c4-48acb28d3b6b" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c887c3db-e55e-48b1-b72e-75b74edfc7e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5901f12d-2b93-4775-8ac9-e557528ccddc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5901f12d-2b93-4775-8ac9-e557528ccddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_4ec4792a-a142-49c8-83c6-0c7eef0cef5e" xlink:href="ino-20231231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_4ec4792a-a142-49c8-83c6-0c7eef0cef5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_646fc4f1-2528-4ffa-bc85-5b814589bcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_646fc4f1-2528-4ffa-bc85-5b814589bcb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest_3dd1ebd2-6cda-4991-8162-a5e710aed063" xlink:href="ino-20231231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:to="loc_ino_DebtinstrumentAccruedInterest_3dd1ebd2-6cda-4991-8162-a5e710aed063" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6ca65902-c898-493d-a0ba-9c02ccf0044e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:to="loc_us-gaap_LongTermDebt_6ca65902-c898-493d-a0ba-9c02ccf0044e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#StockholdersEquityScheduleofPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d4682da7-a379-420d-800b-3e81bd4d8fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_77fee4f4-b84b-4b50-b76c-394708cef702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d4682da7-a379-420d-800b-3e81bd4d8fc3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_77fee4f4-b84b-4b50-b76c-394708cef702" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9bcf3687-5ef6-4cd4-9e4b-9a99c33b3a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77fee4f4-b84b-4b50-b76c-394708cef702" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9bcf3687-5ef6-4cd4-9e4b-9a99c33b3a62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9bcf3687-5ef6-4cd4-9e4b-9a99c33b3a62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9bcf3687-5ef6-4cd4-9e4b-9a99c33b3a62" xlink:to="loc_us-gaap_ClassOfStockDomain_9bcf3687-5ef6-4cd4-9e4b-9a99c33b3a62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_15f61872-0181-4d83-a68c-788da9995e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9bcf3687-5ef6-4cd4-9e4b-9a99c33b3a62" xlink:to="loc_us-gaap_ClassOfStockDomain_15f61872-0181-4d83-a68c-788da9995e0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_29880e8d-70fd-416f-b103-9980c9829d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_15f61872-0181-4d83-a68c-788da9995e0d" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_29880e8d-70fd-416f-b103-9980c9829d7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f4a2e85a-cdb9-4ca8-9c7a-222dd8b8178b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d4682da7-a379-420d-800b-3e81bd4d8fc3" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f4a2e85a-cdb9-4ca8-9c7a-222dd8b8178b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_914111f5-a5aa-42d3-90a5-9ff0571e6031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f4a2e85a-cdb9-4ca8-9c7a-222dd8b8178b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_914111f5-a5aa-42d3-90a5-9ff0571e6031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_30b078bd-0dfd-427f-a1ba-497365bd28eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f4a2e85a-cdb9-4ca8-9c7a-222dd8b8178b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_30b078bd-0dfd-427f-a1ba-497365bd28eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b773bd4a-b564-485f-9e83-29648b9782a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f4a2e85a-cdb9-4ca8-9c7a-222dd8b8178b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b773bd4a-b564-485f-9e83-29648b9782a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a8897e62-6e5b-43bb-9cfb-e1de97187470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f4a2e85a-cdb9-4ca8-9c7a-222dd8b8178b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a8897e62-6e5b-43bb-9cfb-e1de97187470" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6d24a2cf-fffc-4f8e-b9d4-d0570c9860e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6d24a2cf-fffc-4f8e-b9d4-d0570c9860e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6d24a2cf-fffc-4f8e-b9d4-d0570c9860e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6d24a2cf-fffc-4f8e-b9d4-d0570c9860e5" xlink:to="loc_us-gaap_ClassOfStockDomain_6d24a2cf-fffc-4f8e-b9d4-d0570c9860e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_be5541cf-a1a8-4dc8-99d2-755350b7ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6d24a2cf-fffc-4f8e-b9d4-d0570c9860e5" xlink:to="loc_us-gaap_ClassOfStockDomain_be5541cf-a1a8-4dc8-99d2-755350b7ee48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_c96df47a-68d1-4e52-bbb6-dca8d215233c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_be5541cf-a1a8-4dc8-99d2-755350b7ee48" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_c96df47a-68d1-4e52-bbb6-dca8d215233c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_446d6676-784d-44a9-8719-6ac2a27d8303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_be5541cf-a1a8-4dc8-99d2-755350b7ee48" xlink:to="loc_us-gaap_CommonStockMember_446d6676-784d-44a9-8719-6ac2a27d8303" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_efc633c1-af70-4e86-b406-6a9d7b8379be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_efc633c1-af70-4e86-b406-6a9d7b8379be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_efc633c1-af70-4e86-b406-6a9d7b8379be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_efc633c1-af70-4e86-b406-6a9d7b8379be" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_efc633c1-af70-4e86-b406-6a9d7b8379be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbf1b6d4-80d7-40c6-ba90-f34806a646e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_efc633c1-af70-4e86-b406-6a9d7b8379be" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbf1b6d4-80d7-40c6-ba90-f34806a646e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember_87f983be-4145-439b-9bb1-cda34dc107bd" xlink:href="ino-20231231.xsd#ino_A2021SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbf1b6d4-80d7-40c6-ba90-f34806a646e7" xlink:to="loc_ino_A2021SalesAgreementMember_87f983be-4145-439b-9bb1-cda34dc107bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_f80dedc1-db94-443f-8811-47c3e79cb344" xlink:href="ino-20231231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbf1b6d4-80d7-40c6-ba90-f34806a646e7" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_f80dedc1-db94-443f-8811-47c3e79cb344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7de5e294-fdee-47c0-9221-b49cb1e01818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7de5e294-fdee-47c0-9221-b49cb1e01818" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7de5e294-fdee-47c0-9221-b49cb1e01818_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7de5e294-fdee-47c0-9221-b49cb1e01818" xlink:to="loc_us-gaap_EquityComponentDomain_7de5e294-fdee-47c0-9221-b49cb1e01818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_82fd0d19-b252-4629-b50a-d5f1159dce4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7de5e294-fdee-47c0-9221-b49cb1e01818" xlink:to="loc_us-gaap_EquityComponentDomain_82fd0d19-b252-4629-b50a-d5f1159dce4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8b5a3d33-20da-4ff3-878b-d7f103aec82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_82fd0d19-b252-4629-b50a-d5f1159dce4e" xlink:to="loc_us-gaap_CommonStockMember_8b5a3d33-20da-4ff3-878b-d7f103aec82c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ee876b74-a7f8-45b1-a0c1-a04072757cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_PlanNameAxis_ee876b74-a7f8-45b1-a0c1-a04072757cfe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ee876b74-a7f8-45b1-a0c1-a04072757cfe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ee876b74-a7f8-45b1-a0c1-a04072757cfe" xlink:to="loc_us-gaap_PlanNameDomain_ee876b74-a7f8-45b1-a0c1-a04072757cfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c7f51974-1fc2-4924-b4ed-8e059fc68ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ee876b74-a7f8-45b1-a0c1-a04072757cfe" xlink:to="loc_us-gaap_PlanNameDomain_c7f51974-1fc2-4924-b4ed-8e059fc68ed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_b45da787-32cb-42e9-b065-4d8d3ab2a3ec" xlink:href="ino-20231231.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c7f51974-1fc2-4924-b4ed-8e059fc68ed9" xlink:to="loc_ino_A2016IncentivePlanMember_b45da787-32cb-42e9-b065-4d8d3ab2a3ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember_fc1008a1-4ae0-471e-acd5-f03f9c92d41d" xlink:href="ino-20231231.xsd#ino_A2022InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c7f51974-1fc2-4924-b4ed-8e059fc68ed9" xlink:to="loc_ino_A2022InducementPlanMember_fc1008a1-4ae0-471e-acd5-f03f9c92d41d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_e1dc1117-ea54-400c-b237-9ca9683a8ef5" xlink:href="ino-20231231.xsd#ino_A2007IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c7f51974-1fc2-4924-b4ed-8e059fc68ed9" xlink:to="loc_ino_A2007IncentivePlanMember_e1dc1117-ea54-400c-b237-9ca9683a8ef5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2023IncentivePlanMember_5e878588-025e-4a6e-94f1-3e090532cc4f" xlink:href="ino-20231231.xsd#ino_A2023IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c7f51974-1fc2-4924-b4ed-8e059fc68ed9" xlink:to="loc_ino_A2023IncentivePlanMember_5e878588-025e-4a6e-94f1-3e090532cc4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a3fd8b19-d9ef-42e8-9192-a8504bd663e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_AwardTypeAxis_a3fd8b19-d9ef-42e8-9192-a8504bd663e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3fd8b19-d9ef-42e8-9192-a8504bd663e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a3fd8b19-d9ef-42e8-9192-a8504bd663e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3fd8b19-d9ef-42e8-9192-a8504bd663e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_777dfab5-7fc8-433b-a3e8-efb541471464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a3fd8b19-d9ef-42e8-9192-a8504bd663e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_777dfab5-7fc8-433b-a3e8-efb541471464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_62c1e8d7-f62b-4509-be66-4170efc00b35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_777dfab5-7fc8-433b-a3e8-efb541471464" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_62c1e8d7-f62b-4509-be66-4170efc00b35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0a626089-fced-42c3-b994-46d34a75b4af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0a626089-fced-42c3-b994-46d34a75b4af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0a626089-fced-42c3-b994-46d34a75b4af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0a626089-fced-42c3-b994-46d34a75b4af" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0a626089-fced-42c3-b994-46d34a75b4af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19113b04-521e-4d27-a21d-e3f6ce5a44d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0a626089-fced-42c3-b994-46d34a75b4af" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19113b04-521e-4d27-a21d-e3f6ce5a44d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e756c37-3966-4d2f-83a9-04e15d17aedb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19113b04-521e-4d27-a21d-e3f6ce5a44d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e756c37-3966-4d2f-83a9-04e15d17aedb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8a8240c1-697e-439c-a44a-f668ff09b609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19113b04-521e-4d27-a21d-e3f6ce5a44d1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8a8240c1-697e-439c-a44a-f668ff09b609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0bb53da6-3b1f-460a-b02f-d1b8915de9c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_srt_TitleOfIndividualAxis_0bb53da6-3b1f-460a-b02f-d1b8915de9c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bb53da6-3b1f-460a-b02f-d1b8915de9c0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_0bb53da6-3b1f-460a-b02f-d1b8915de9c0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bb53da6-3b1f-460a-b02f-d1b8915de9c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_028ae6cc-af50-4ba0-96b7-60ac1a28e652" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_0bb53da6-3b1f-460a-b02f-d1b8915de9c0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_028ae6cc-af50-4ba0-96b7-60ac1a28e652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember_f6c09284-bd2c-49ed-931f-e6e65a09d979" xlink:href="ino-20231231.xsd#ino_FormerPresidentAndChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_028ae6cc-af50-4ba0-96b7-60ac1a28e652" xlink:to="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember_f6c09284-bd2c-49ed-931f-e6e65a09d979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_4d35bf91-3b9b-4693-b851-a743f3e53f83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_GranteeStatusAxis_4d35bf91-3b9b-4693-b851-a743f3e53f83" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_4d35bf91-3b9b-4693-b851-a743f3e53f83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_4d35bf91-3b9b-4693-b851-a743f3e53f83" xlink:to="loc_us-gaap_GranteeStatusDomain_4d35bf91-3b9b-4693-b851-a743f3e53f83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_1b2bcc0c-cb65-481d-ad9b-4cd991aab96b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_4d35bf91-3b9b-4693-b851-a743f3e53f83" xlink:to="loc_us-gaap_GranteeStatusDomain_1b2bcc0c-cb65-481d-ad9b-4cd991aab96b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_7fabf147-92c1-456e-88da-952d251dc067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_1b2bcc0c-cb65-481d-ad9b-4cd991aab96b" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_7fabf147-92c1-456e-88da-952d251dc067" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_88cac831-b445-43d7-b024-6f97a3f682d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_srt_LitigationCaseAxis_88cac831-b445-43d7-b024-6f97a3f682d7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_88cac831-b445-43d7-b024-6f97a3f682d7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_88cac831-b445-43d7-b024-6f97a3f682d7" xlink:to="loc_srt_LitigationCaseTypeDomain_88cac831-b445-43d7-b024-6f97a3f682d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7d3aeac0-56cc-4e6f-88d2-dbccc20d6f54" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_88cac831-b445-43d7-b024-6f97a3f682d7" xlink:to="loc_srt_LitigationCaseTypeDomain_7d3aeac0-56cc-4e6f-88d2-dbccc20d6f54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_c907353e-8791-4abd-ba74-cf81f2946371" xlink:href="ino-20231231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7d3aeac0-56cc-4e6f-88d2-dbccc20d6f54" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_c907353e-8791-4abd-ba74-cf81f2946371" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_175d6c27-69c7-48ab-98b3-9ae34dedb1d0" xlink:href="ino-20231231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_175d6c27-69c7-48ab-98b3-9ae34dedb1d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6dc543ff-9f78-44b2-9170-2bd125aae88a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6dc543ff-9f78-44b2-9170-2bd125aae88a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_27d61f20-3323-42da-9340-cb13991cecb0" xlink:href="ino-20231231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_27d61f20-3323-42da-9340-cb13991cecb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_0957ed40-e7b8-4be7-a3bf-0a67acc7a147" xlink:href="ino-20231231.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_0957ed40-e7b8-4be7-a3bf-0a67acc7a147" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_668f8bf9-79c9-4720-9904-c3268573f6be" xlink:href="ino-20231231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_668f8bf9-79c9-4720-9904-c3268573f6be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_bf96de3c-7955-4c3e-a58e-33503202c30a" xlink:href="ino-20231231.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_bf96de3c-7955-4c3e-a58e-33503202c30a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_c475fe7c-27fe-4099-b9af-a9fc33327f14" xlink:href="ino-20231231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_c475fe7c-27fe-4099-b9af-a9fc33327f14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_28420a41-a1c4-422d-b64c-3ee2bd97ca96" xlink:href="ino-20231231.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_28420a41-a1c4-422d-b64c-3ee2bd97ca96" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_16dfff8b-e0f2-4410-acf6-9ae5636ba228" xlink:href="ino-20231231.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_16dfff8b-e0f2-4410-acf6-9ae5636ba228" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c4e47f78-649a-4df1-8004-547147052303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_CommonStockSharesIssued_c4e47f78-649a-4df1-8004-547147052303" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7b3f03d9-1244-45b8-8b4d-622222b0a67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7b3f03d9-1244-45b8-8b4d-622222b0a67e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_48e5eda0-8d9e-4b8b-b0b4-fe63b4e0f7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_48e5eda0-8d9e-4b8b-b0b4-fe63b4e0f7a4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_b2c52eb3-2acd-408e-b6e7-725ee358d894" xlink:href="ino-20231231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_b2c52eb3-2acd-408e-b6e7-725ee358d894" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_1da1f0f7-1ae1-4ea3-af24-60fd978f8217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_1da1f0f7-1ae1-4ea3-af24-60fd978f8217" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00a8bd40-ca9b-48e6-9c12-c89db3ebdd74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00a8bd40-ca9b-48e6-9c12-c89db3ebdd74" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db93f07a-fdfa-427f-b5f1-6f175b337764" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db93f07a-fdfa-427f-b5f1-6f175b337764" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_82e0e1d7-9cf6-4793-9b3f-1be7e0104150" xlink:href="ino-20231231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_82e0e1d7-9cf6-4793-9b3f-1be7e0104150" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2df5a3fc-75dd-44b6-a0f8-8e5898064bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2df5a3fc-75dd-44b6-a0f8-8e5898064bf3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_7d8abfec-a321-4a57-b8db-af49ea417d69" xlink:href="ino-20231231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_7d8abfec-a321-4a57-b8db-af49ea417d69" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_db728d48-b7d7-4f37-a44d-44579f1b03e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_db728d48-b7d7-4f37-a44d-44579f1b03e4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4a17f4f-72e0-4dd4-87b7-5457cb763368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4a17f4f-72e0-4dd4-87b7-5457cb763368" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52c9f615-dce1-449e-9614-083f79fc4191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52c9f615-dce1-449e-9614-083f79fc4191" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_19463c90-b24e-4cdb-8f92-418828227e5a" xlink:href="ino-20231231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_19463c90-b24e-4cdb-8f92-418828227e5a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b728d759-8e78-4cc6-a20a-87caf6c530a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b728d759-8e78-4cc6-a20a-87caf6c530a7" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_2f5f3839-8bb2-4ce3-af01-fb279c3924ae" xlink:href="ino-20231231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_2f5f3839-8bb2-4ce3-af01-fb279c3924ae" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c7a603d4-7ed7-4f26-be27-46326a271f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c7a603d4-7ed7-4f26-be27-46326a271f1e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_30b7de6a-1d21-4b74-9da2-7a6717a1ff12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_30b7de6a-1d21-4b74-9da2-7a6717a1ff12" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_68d2e806-6600-4c7e-9c85-9b39f41ec38b" xlink:href="ino-20231231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_68d2e806-6600-4c7e-9c85-9b39f41ec38b" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_6e86da4a-b991-4f4f-98f7-d50a692d22c5" xlink:href="ino-20231231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_6e86da4a-b991-4f4f-98f7-d50a692d22c5" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_33d4d971-fb28-4a47-a8c0-ab45c1f72780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_33d4d971-fb28-4a47-a8c0-ab45c1f72780" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2ca339a4-7316-49d4-a11a-369e15b2ac6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2ca339a4-7316-49d4-a11a-369e15b2ac6b" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_329961b0-5f8c-4dea-8c97-5d74093599b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_329961b0-5f8c-4dea-8c97-5d74093599b1" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d05bbb08-797f-4627-8377-83a17dc12a73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d05bbb08-797f-4627-8377-83a17dc12a73" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e2e421d4-a486-4f32-baa4-2083c2a7d2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e2e421d4-a486-4f32-baa4-2083c2a7d2aa" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e8c86cda-3577-4a07-823f-cd44f5744f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e8c86cda-3577-4a07-823f-cd44f5744f3b" xlink:type="arc" order="34"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#StockholdersEquityScheduleofStockOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_fca76365-076e-482e-acdf-8c69db9556f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_fca76365-076e-482e-acdf-8c69db9556f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c0a5fe3e-7f93-48ad-b074-1bb2b3a13120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_fca76365-076e-482e-acdf-8c69db9556f7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c0a5fe3e-7f93-48ad-b074-1bb2b3a13120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c0a5fe3e-7f93-48ad-b074-1bb2b3a13120_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c0a5fe3e-7f93-48ad-b074-1bb2b3a13120" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c0a5fe3e-7f93-48ad-b074-1bb2b3a13120_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c0a5fe3e-7f93-48ad-b074-1bb2b3a13120" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember_157d7b9c-fc7d-47c9-bd84-3194bba26d46" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:to="loc_ino_RangeOfExercisePricesOneMember_157d7b9c-fc7d-47c9-bd84-3194bba26d46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_1c92a1d7-6fab-49b4-bc3d-4aae2edd5308" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:to="loc_ino_RangeOfExercisePricesTwoMember_1c92a1d7-6fab-49b4-bc3d-4aae2edd5308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_5c876929-ea5c-42b7-9bd1-58419132303a" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:to="loc_ino_RangeOfExercisePricesThreeMember_5c876929-ea5c-42b7-9bd1-58419132303a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember_63a51e02-8cc8-4493-9c43-bf386a796c0b" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:to="loc_ino_RangeOfExercisePricesFourMember_63a51e02-8cc8-4493-9c43-bf386a796c0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_1ad7389c-dda4-4a13-a8d1-a9805217722c" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:to="loc_ino_RangeOfExercisePricesFiveMember_1ad7389c-dda4-4a13-a8d1-a9805217722c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember_05d314ca-7747-4dbb-b383-4d1d8c72f16e" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:to="loc_ino_RangeOfExercisePricesSixMember_05d314ca-7747-4dbb-b383-4d1d8c72f16e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8c065319-0641-43e9-876f-f614bcc0c378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8c065319-0641-43e9-876f-f614bcc0c378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_dc6fc474-5501-429f-872f-e12746257396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_dc6fc474-5501-429f-872f-e12746257396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_ea4f2606-b906-4a5e-8f05-db9de150102d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_ea4f2606-b906-4a5e-8f05-db9de150102d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_a88a845a-d7ad-4d0a-a5c3-54b1c651f527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_a88a845a-d7ad-4d0a-a5c3-54b1c651f527" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_171d6740-ac87-44be-9f20-50d531b8e55c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_171d6740-ac87-44be-9f20-50d531b8e55c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d29b9dac-9125-4cfe-8be8-cb10e738562e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d29b9dac-9125-4cfe-8be8-cb10e738562e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_bf5b9bbb-aa58-47eb-ab6e-0b6afb89e7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_bf5b9bbb-aa58-47eb-ab6e-0b6afb89e7a7" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36030180-2ae0-44a5-98d2-08b0d4f69016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d30e0104-5c6a-404f-a921-8af8ce161f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36030180-2ae0-44a5-98d2-08b0d4f69016" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d30e0104-5c6a-404f-a921-8af8ce161f80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e94cc68e-20a6-447a-8439-f4f3503c2728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d30e0104-5c6a-404f-a921-8af8ce161f80" xlink:to="loc_us-gaap_AwardTypeAxis_e94cc68e-20a6-447a-8439-f4f3503c2728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e94cc68e-20a6-447a-8439-f4f3503c2728_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e94cc68e-20a6-447a-8439-f4f3503c2728" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e94cc68e-20a6-447a-8439-f4f3503c2728_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b89d2e76-b3f3-47c5-b679-034e64d49ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e94cc68e-20a6-447a-8439-f4f3503c2728" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b89d2e76-b3f3-47c5-b679-034e64d49ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_009e627b-db90-4866-be7c-ffba2428b639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b89d2e76-b3f3-47c5-b679-034e64d49ae2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_009e627b-db90-4866-be7c-ffba2428b639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36030180-2ae0-44a5-98d2-08b0d4f69016" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b17d63ab-1408-4045-a2e6-84a6ac235ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b17d63ab-1408-4045-a2e6-84a6ac235ef8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ca0d4b49-e1c0-443d-8be9-6a8a89a5f931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ca0d4b49-e1c0-443d-8be9-6a8a89a5f931" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e76db63c-fe02-4b30-b19a-b203f44f27c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e76db63c-fe02-4b30-b19a-b203f44f27c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e32d1773-10cc-4804-8974-3dbb4ebeb599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e32d1773-10cc-4804-8974-3dbb4ebeb599" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b7060891-cbc3-4517-a357-9b046bef3bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_056c6240-981c-4d79-94ed-610580efab0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_056c6240-981c-4d79-94ed-610580efab0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d639db8-4287-40a2-a42a-88dc62412345" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_056c6240-981c-4d79-94ed-610580efab0e" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d639db8-4287-40a2-a42a-88dc62412345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2d639db8-4287-40a2-a42a-88dc62412345_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d639db8-4287-40a2-a42a-88dc62412345" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2d639db8-4287-40a2-a42a-88dc62412345_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_db42a96a-3b26-4c3e-8d41-fdecc1861fc3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d639db8-4287-40a2-a42a-88dc62412345" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_db42a96a-3b26-4c3e-8d41-fdecc1861fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_69ae823d-ad34-4ddc-820d-9218b75bbf03" xlink:href="ino-20231231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_db42a96a-3b26-4c3e-8d41-fdecc1861fc3" xlink:to="loc_ino_SanDiegoCaliforniaMember_69ae823d-ad34-4ddc-820d-9218b75bbf03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_d82a1e89-acee-47c3-8b96-a5ca8b4f53c4" xlink:href="ino-20231231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_db42a96a-3b26-4c3e-8d41-fdecc1861fc3" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_d82a1e89-acee-47c3-8b96-a5ca8b4f53c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ace22682-3449-46b0-8730-8823c4664c37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_056c6240-981c-4d79-94ed-610580efab0e" xlink:to="loc_srt_RangeAxis_ace22682-3449-46b0-8730-8823c4664c37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ace22682-3449-46b0-8730-8823c4664c37_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ace22682-3449-46b0-8730-8823c4664c37" xlink:to="loc_srt_RangeMember_ace22682-3449-46b0-8730-8823c4664c37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c19cbc1-f73f-42ba-b87f-2d6da97eeaa1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ace22682-3449-46b0-8730-8823c4664c37" xlink:to="loc_srt_RangeMember_9c19cbc1-f73f-42ba-b87f-2d6da97eeaa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6851b6bd-8499-4054-8612-a6c463aa52d1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9c19cbc1-f73f-42ba-b87f-2d6da97eeaa1" xlink:to="loc_srt_MinimumMember_6851b6bd-8499-4054-8612-a6c463aa52d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4512a367-d85b-49cb-86df-6ae5046e78c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9c19cbc1-f73f-42ba-b87f-2d6da97eeaa1" xlink:to="loc_srt_MaximumMember_4512a367-d85b-49cb-86df-6ae5046e78c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_414310af-63c7-47df-af07-39542c92fe1e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_056c6240-981c-4d79-94ed-610580efab0e" xlink:to="loc_srt_LitigationCaseAxis_414310af-63c7-47df-af07-39542c92fe1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_414310af-63c7-47df-af07-39542c92fe1e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_414310af-63c7-47df-af07-39542c92fe1e" xlink:to="loc_srt_LitigationCaseTypeDomain_414310af-63c7-47df-af07-39542c92fe1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_39395e83-7b18-4346-86c3-94dda100493e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_414310af-63c7-47df-af07-39542c92fe1e" xlink:to="loc_srt_LitigationCaseTypeDomain_39395e83-7b18-4346-86c3-94dda100493e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_6ed31280-573d-4d11-b351-a20f827f9b99" xlink:href="ino-20231231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_39395e83-7b18-4346-86c3-94dda100493e" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_6ed31280-573d-4d11-b351-a20f827f9b99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BehestiVKimEtAlMember_aa66b914-0b64-4831-84ba-b0f29dc3d6ec" xlink:href="ino-20231231.xsd#ino_BehestiVKimEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_39395e83-7b18-4346-86c3-94dda100493e" xlink:to="loc_ino_BehestiVKimEtAlMember_aa66b914-0b64-4831-84ba-b0f29dc3d6ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_19a91cab-7e3e-445c-89bc-2326060ddae2" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_19a91cab-7e3e-445c-89bc-2326060ddae2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfLeasesAmended_2684a6e9-7d1f-4aac-989c-829aa1205eb1" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseNumberOfLeasesAmended"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LesseeOperatingLeaseNumberOfLeasesAmended_2684a6e9-7d1f-4aac-989c-829aa1205eb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended_89f8ba96-2398-45e1-9dd2-0f2adefc80f1" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended_89f8ba96-2398-45e1-9dd2-0f2adefc80f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_6f219721-a330-4d11-ac1a-1ee734a5521a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_6f219721-a330-4d11-ac1a-1ee734a5521a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_27eac4bd-c1ba-41f4-828f-e32bb33c392a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_LeaseCost_27eac4bd-c1ba-41f4-828f-e32bb33c392a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3cdac115-ae32-4648-80f5-96b710dc4341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3cdac115-ae32-4648-80f5-96b710dc4341" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_43567b2b-be3f-4b70-8b0d-5e6796638ea4" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_43567b2b-be3f-4b70-8b0d-5e6796638ea4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDeposits_6ec67c02-5425-420b-90b3-2a6e3db7c60f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_PaymentsForDeposits_6ec67c02-5425-420b-90b3-2a6e3db7c60f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_3bbf75b7-f4c3-4a25-af03-25079b175646" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_3bbf75b7-f4c3-4a25-af03-25079b175646" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_b2e2d066-1f71-428e-80d9-b8f640fc79d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_b2e2d066-1f71-428e-80d9-b8f640fc79d4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_db53f64a-db97-4eef-bb4a-4a4b8c82ae37" xlink:href="ino-20231231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_db53f64a-db97-4eef-bb4a-4a4b8c82ae37" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_38fc8147-483f-4fb1-ab41-571117961bd9" xlink:href="ino-20231231.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_38fc8147-483f-4fb1-ab41-571117961bd9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_5d324cf1-09c6-42db-8c71-b259d498137d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_5d324cf1-09c6-42db-8c71-b259d498137d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_ac861f76-6507-42e4-a0d8-1c0800a56b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_ac861f76-6507-42e4-a0d8-1c0800a56b7c" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_86913ec2-7ee4-413c-90b8-58af0ba6183a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_86913ec2-7ee4-413c-90b8-58af0ba6183a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f12b69f0-d344-4171-86b0-135dcaa5c9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_86913ec2-7ee4-413c-90b8-58af0ba6183a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f12b69f0-d344-4171-86b0-135dcaa5c9c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f12b69f0-d344-4171-86b0-135dcaa5c9c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f12b69f0-d344-4171-86b0-135dcaa5c9c1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f12b69f0-d344-4171-86b0-135dcaa5c9c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f12b69f0-d344-4171-86b0-135dcaa5c9c1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_cf506956-8ecf-46e6-8ac0-641c661ca8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_cf506956-8ecf-46e6-8ac0-641c661ca8c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_38e8837c-c9b6-4bd8-84c4-d54a0b6d4c42" xlink:href="ino-20231231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:to="loc_ino_CaliforniaIncomeTaxAuthorityMember_38e8837c-c9b6-4bd8-84c4-d54a0b6d4c42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_49f1989e-3922-4a70-8d4a-1f5143ab0c37" xlink:href="ino-20231231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:to="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_49f1989e-3922-4a70-8d4a-1f5143ab0c37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_KoreanStateIncomeTaxAuthorityMember_85c41564-a5a3-4f7d-84aa-2abcd5d52d9f" xlink:href="ino-20231231.xsd#ino_KoreanStateIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:to="loc_ino_KoreanStateIncomeTaxAuthorityMember_85c41564-a5a3-4f7d-84aa-2abcd5d52d9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a08b2a3d-473d-411e-a02c-062a919493a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a08b2a3d-473d-411e-a02c-062a919493a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1ab87b9e-bf48-442b-be70-b99abdabaf92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_86913ec2-7ee4-413c-90b8-58af0ba6183a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1ab87b9e-bf48-442b-be70-b99abdabaf92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1ab87b9e-bf48-442b-be70-b99abdabaf92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1ab87b9e-bf48-442b-be70-b99abdabaf92" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1ab87b9e-bf48-442b-be70-b99abdabaf92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_deaf57f2-59ed-41b5-b380-da0502313f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1ab87b9e-bf48-442b-be70-b99abdabaf92" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_deaf57f2-59ed-41b5-b380-da0502313f4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_42a2f793-cd19-404b-bc6d-b89f582a4784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_deaf57f2-59ed-41b5-b380-da0502313f4f" xlink:to="loc_us-gaap_ResearchMember_42a2f793-cd19-404b-bc6d-b89f582a4784" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_47c7b031-2911-425c-8159-d20fc84c0d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_47c7b031-2911-425c-8159-d20fc84c0d8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_d514857c-befb-49e9-a01c-7e72e481b4db" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_d514857c-befb-49e9-a01c-7e72e481b4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_b1d861bb-c796-4277-bc3b-a79b5a9abc22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_b1d861bb-c796-4277-bc3b-a79b5a9abc22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_dbbba8d0-40cc-4ca9-b91c-8070107bdc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_dbbba8d0-40cc-4ca9-b91c-8070107bdc8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired_0e31d6f2-2a0d-4b81-b3b9-4dc8c2deba1e" xlink:href="ino-20231231.xsd#ino_TaxBenefitsExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_ino_TaxBenefitsExpired_0e31d6f2-2a0d-4b81-b3b9-4dc8c2deba1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_36872e05-9bec-4bd7-bfb0-d7ab0660ba1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_36872e05-9bec-4bd7-bfb0-d7ab0660ba1a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_da7f38b7-c2c0-4ebe-97d3-203a9f1857b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_08a2c490-e12d-4bd7-a239-5a93555fa930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da7f38b7-c2c0-4ebe-97d3-203a9f1857b4" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_08a2c490-e12d-4bd7-a239-5a93555fa930" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_ac0370c0-7f3c-4cd0-821e-abcca1a26272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_08a2c490-e12d-4bd7-a239-5a93555fa930" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_ac0370c0-7f3c-4cd0-821e-abcca1a26272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ac0370c0-7f3c-4cd0-821e-abcca1a26272_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ac0370c0-7f3c-4cd0-821e-abcca1a26272" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ac0370c0-7f3c-4cd0-821e-abcca1a26272_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3627c1bd-aee8-40b4-9154-6ac2b9dc07dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ac0370c0-7f3c-4cd0-821e-abcca1a26272" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3627c1bd-aee8-40b4-9154-6ac2b9dc07dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_c0540d13-3863-42d8-b533-0f240fa75290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3627c1bd-aee8-40b4-9154-6ac2b9dc07dc" xlink:to="loc_us-gaap_ResearchMember_c0540d13-3863-42d8-b533-0f240fa75290" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_81fd636e-89fd-4647-8c06-30498cdd8298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_08a2c490-e12d-4bd7-a239-5a93555fa930" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_81fd636e-89fd-4647-8c06-30498cdd8298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_81fd636e-89fd-4647-8c06-30498cdd8298_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_81fd636e-89fd-4647-8c06-30498cdd8298" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_81fd636e-89fd-4647-8c06-30498cdd8298_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_34953c5a-7d04-41ff-9ed4-6587f6d31166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_81fd636e-89fd-4647-8c06-30498cdd8298" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_34953c5a-7d04-41ff-9ed4-6587f6d31166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3543b9b9-824b-4ce8-bab7-a83362731860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_34953c5a-7d04-41ff-9ed4-6587f6d31166" xlink:to="loc_us-gaap_DomesticCountryMember_3543b9b9-824b-4ce8-bab7-a83362731860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_098795f4-8a1c-4e05-bf16-6d58368e0570" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_34953c5a-7d04-41ff-9ed4-6587f6d31166" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_098795f4-8a1c-4e05-bf16-6d58368e0570" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_ceb992bf-dbd7-4ccb-a6fe-787bb8bf0598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_34953c5a-7d04-41ff-9ed4-6587f6d31166" xlink:to="loc_us-gaap_ForeignCountryMember_ceb992bf-dbd7-4ccb-a6fe-787bb8bf0598" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da7f38b7-c2c0-4ebe-97d3-203a9f1857b4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_969e0f09-d959-4d05-a6b5-30fef742bd3b" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringInNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_969e0f09-d959-4d05-a6b5-30fef742bd3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_6d653271-8868-4e48-b882-b80c98c81b76" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_6d653271-8868-4e48-b882-b80c98c81b76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_83c145a8-0c4b-4e6b-ba6f-4f39244dcef9" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_83c145a8-0c4b-4e6b-ba6f-4f39244dcef9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_1ef921db-2c22-4b25-8f8d-db349076ed25" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_1ef921db-2c22-4b25-8f8d-db349076ed25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_d894ea5c-7eb6-499a-85a5-543e4824bbae" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_d894ea5c-7eb6-499a-85a5-543e4824bbae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_021ca779-d75d-49ae-9328-5537beaae1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:to="loc_us-gaap_OperatingLossCarryforwards_021ca779-d75d-49ae-9328-5537beaae1fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da7f38b7-c2c0-4ebe-97d3-203a9f1857b4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_ebf90edc-aa32-4d98-93e6-bdd2a4d7b6ca" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringInNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_ebf90edc-aa32-4d98-93e6-bdd2a4d7b6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_dfbf4b60-6d8c-4708-b185-5e8aecb6eaa7" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_dfbf4b60-6d8c-4708-b185-5e8aecb6eaa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_1bdce53f-cacb-4e78-8263-a4bfe5474214" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringInThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_1bdce53f-cacb-4e78-8263-a4bfe5474214" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInFourYears_bb5dc694-d56f-4c8d-9f95-4fd0f581da57" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringInFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInFourYears_bb5dc694-d56f-4c8d-9f95-4fd0f581da57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_d10bfd09-4e31-4734-985a-d1d43e835cab" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_d10bfd09-4e31-4734-985a-d1d43e835cab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_e6b38260-3eef-4dc9-88ff-4353a7906a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_e6b38260-3eef-4dc9-88ff-4353a7906a07" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_707ead5d-c961-4f7e-9bb1-0ea3da46ad1e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:to="loc_srt_CounterpartyNameAxis_707ead5d-c961-4f7e-9bb1-0ea3da46ad1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_707ead5d-c961-4f7e-9bb1-0ea3da46ad1e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_707ead5d-c961-4f7e-9bb1-0ea3da46ad1e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_707ead5d-c961-4f7e-9bb1-0ea3da46ad1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac9941a7-db34-4b1b-86fb-86c9a1928d88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_707ead5d-c961-4f7e-9bb1-0ea3da46ad1e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac9941a7-db34-4b1b-86fb-86c9a1928d88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_0b00409d-101b-4819-b763-f28747f9a7f6" xlink:href="ino-20231231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac9941a7-db34-4b1b-86fb-86c9a1928d88" xlink:to="loc_ino_PlumblineLifeSciencesMember_0b00409d-101b-4819-b763-f28747f9a7f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_9b48d920-be98-4437-b054-e8d8bce3d855" xlink:href="ino-20231231.xsd#ino_TheWistarInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac9941a7-db34-4b1b-86fb-86c9a1928d88" xlink:to="loc_ino_TheWistarInstituteMember_9b48d920-be98-4437-b054-e8d8bce3d855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91239dc8-3b06-40f6-a126-76635ecb592f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91239dc8-3b06-40f6-a126-76635ecb592f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_91239dc8-3b06-40f6-a126-76635ecb592f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91239dc8-3b06-40f6-a126-76635ecb592f" xlink:to="loc_us-gaap_RelatedPartyDomain_91239dc8-3b06-40f6-a126-76635ecb592f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ec61d0cb-5e42-4840-9b0e-98fdcb135fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91239dc8-3b06-40f6-a126-76635ecb592f" xlink:to="loc_us-gaap_RelatedPartyDomain_ec61d0cb-5e42-4840-9b0e-98fdcb135fa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_8472588a-eec2-4cb6-a538-da391abb0789" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ec61d0cb-5e42-4840-9b0e-98fdcb135fa1" xlink:to="loc_srt_AffiliatedEntityMember_8472588a-eec2-4cb6-a538-da391abb0789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_afa81257-6c8b-4b01-b571-b47b3b529f0b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:to="loc_srt_ProductOrServiceAxis_afa81257-6c8b-4b01-b571-b47b3b529f0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_afa81257-6c8b-4b01-b571-b47b3b529f0b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_afa81257-6c8b-4b01-b571-b47b3b529f0b" xlink:to="loc_srt_ProductsAndServicesDomain_afa81257-6c8b-4b01-b571-b47b3b529f0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c892bbba-6b8a-4d6b-8995-a88c5abdea5c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_afa81257-6c8b-4b01-b571-b47b3b529f0b" xlink:to="loc_srt_ProductsAndServicesDomain_c892bbba-6b8a-4d6b-8995-a88c5abdea5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_c6209655-6518-45a8-bccb-91753e52ec70" xlink:href="ino-20231231.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c892bbba-6b8a-4d6b-8995-a88c5abdea5c" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_c6209655-6518-45a8-bccb-91753e52ec70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5248a0a4-0aeb-4f56-8c4a-127ef6b467fa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:to="loc_srt_OwnershipAxis_5248a0a4-0aeb-4f56-8c4a-127ef6b467fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5248a0a4-0aeb-4f56-8c4a-127ef6b467fa_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_5248a0a4-0aeb-4f56-8c4a-127ef6b467fa" xlink:to="loc_srt_OwnershipDomain_5248a0a4-0aeb-4f56-8c4a-127ef6b467fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fe198437-f148-4a35-a8ab-38a386539459" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_5248a0a4-0aeb-4f56-8c4a-127ef6b467fa" xlink:to="loc_srt_OwnershipDomain_fe198437-f148-4a35-a8ab-38a386539459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_93bd32be-ef56-4b22-b8bd-48b9b9892f35" xlink:href="ino-20231231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_fe198437-f148-4a35-a8ab-38a386539459" xlink:to="loc_ino_PlumblineLifeSciencesMember_93bd32be-ef56-4b22-b8bd-48b9b9892f35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_37021763-d59a-4aef-a365-aa93b2a8d723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_37021763-d59a-4aef-a365-aa93b2a8d723" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_6e8f96d2-f8cc-431b-887d-2ee3fcc19a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_6e8f96d2-f8cc-431b-887d-2ee3fcc19a69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d65e101f-32c0-4e60-b959-bb14de5607e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d65e101f-32c0-4e60-b959-bb14de5607e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_920aef48-4f8b-4a49-a6f3-4c2b19ab39a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_920aef48-4f8b-4a49-a6f3-4c2b19ab39a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_b728ccfc-7a20-44aa-a54d-4954836972a7" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_b728ccfc-7a20-44aa-a54d-4954836972a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_94d3ea4d-49bf-4654-b62b-68eba23e0023" xlink:href="ino-20231231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_CollaborativeArrangementTerm_94d3ea4d-49bf-4654-b62b-68eba23e0023" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_9f867713-88e1-4317-a632-e244c595ae04" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_9f867713-88e1-4317-a632-e244c595ae04" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_ef3276e3-acb2-4e1f-ac87-5362efe7030f" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_ef3276e3-acb2-4e1f-ac87-5362efe7030f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_03a16684-5e8c-4ea4-b313-898bb2fa4a54" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_03a16684-5e8c-4ea4-b313-898bb2fa4a54" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_9845ccbe-582d-46d2-a8fd-165f75d666db" xlink:href="ino-20231231.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_GrantProceedsReceived_9845ccbe-582d-46d2-a8fd-165f75d666db" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9dd05262-51d3-4272-84bd-9d7918cce825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9dd05262-51d3-4272-84bd-9d7918cce825" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_a1e89a4e-f314-4255-aa70-06cf10bb9184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_AccountsReceivableNet_a1e89a4e-f314-4255-aa70-06cf10bb9184" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_93e02962-a7d7-4267-9504-9619a24c1d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_93e02962-a7d7-4267-9504-9619a24c1d9f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_a1403eec-0103-426e-895c-f572514176df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_a1403eec-0103-426e-895c-f572514176df" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_74008b08-dd97-4f8d-8017-7d563980b16b" xlink:href="ino-20231231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_74008b08-dd97-4f8d-8017-7d563980b16b" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_fd5f64ad-02ff-460b-a87d-56a401b021df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_us-gaap_MinorityInterestTable_fd5f64ad-02ff-460b-a87d-56a401b021df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5600f6e3-3b60-479f-9282-48f74c33cc17" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_fd5f64ad-02ff-460b-a87d-56a401b021df" xlink:to="loc_srt_CounterpartyNameAxis_5600f6e3-3b60-479f-9282-48f74c33cc17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5600f6e3-3b60-479f-9282-48f74c33cc17_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5600f6e3-3b60-479f-9282-48f74c33cc17" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5600f6e3-3b60-479f-9282-48f74c33cc17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc01d937-5441-4848-b4a8-177db520e302" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5600f6e3-3b60-479f-9282-48f74c33cc17" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc01d937-5441-4848-b4a8-177db520e302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_051ba087-62bc-4cee-bbde-7307623b826c" xlink:href="ino-20231231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc01d937-5441-4848-b4a8-177db520e302" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_051ba087-62bc-4cee-bbde-7307623b826c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3888b4ec-666e-4604-93e6-13addb4fe050" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_fd5f64ad-02ff-460b-a87d-56a401b021df" xlink:to="loc_srt_OwnershipAxis_3888b4ec-666e-4604-93e6-13addb4fe050" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_3888b4ec-666e-4604-93e6-13addb4fe050_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_3888b4ec-666e-4604-93e6-13addb4fe050" xlink:to="loc_srt_OwnershipDomain_3888b4ec-666e-4604-93e6-13addb4fe050_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6e249bbc-7471-4037-9b14-67f08b0dd3f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_3888b4ec-666e-4604-93e6-13addb4fe050" xlink:to="loc_srt_OwnershipDomain_6e249bbc-7471-4037-9b14-67f08b0dd3f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_250ff8cd-e511-4291-b97f-40e8a30613b9" xlink:href="ino-20231231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_6e249bbc-7471-4037-9b14-67f08b0dd3f9" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_250ff8cd-e511-4291-b97f-40e8a30613b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_92632736-6e3b-4ee0-a7d1-029ea4acaeec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_fd5f64ad-02ff-460b-a87d-56a401b021df" xlink:to="loc_us-gaap_StatementClassOfStockAxis_92632736-6e3b-4ee0-a7d1-029ea4acaeec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_92632736-6e3b-4ee0-a7d1-029ea4acaeec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_92632736-6e3b-4ee0-a7d1-029ea4acaeec" xlink:to="loc_us-gaap_ClassOfStockDomain_92632736-6e3b-4ee0-a7d1-029ea4acaeec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bc929973-018a-4a47-ac8e-bf3718826c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_92632736-6e3b-4ee0-a7d1-029ea4acaeec" xlink:to="loc_us-gaap_ClassOfStockDomain_bc929973-018a-4a47-ac8e-bf3718826c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_214d23de-aebc-44c4-bcc3-84212347fa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bc929973-018a-4a47-ac8e-bf3718826c1e" xlink:to="loc_us-gaap_CommonStockMember_214d23de-aebc-44c4-bcc3-84212347fa8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_51465b4b-2b66-41ec-9f0e-0ca3ecb93649" xlink:href="ino-20231231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bc929973-018a-4a47-ac8e-bf3718826c1e" xlink:to="loc_ino_SeriesAOnePreferredStockMember_51465b4b-2b66-41ec-9f0e-0ca3ecb93649" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_016f7ef5-ff2f-4937-b997-859c7a3c6b33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bc929973-018a-4a47-ac8e-bf3718826c1e" xlink:to="loc_us-gaap_PreferredStockMember_016f7ef5-ff2f-4937-b997-859c7a3c6b33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_46bca4de-248a-4b16-b9bb-a70132dd305f" xlink:href="ino-20231231.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bc929973-018a-4a47-ac8e-bf3718826c1e" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_46bca4de-248a-4b16-b9bb-a70132dd305f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_65d51f1d-5270-4a95-b901-bed17ca07239" xlink:href="ino-20231231.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_65d51f1d-5270-4a95-b901-bed17ca07239" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d0452d11-9f65-4a47-b6cc-452939f934d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d0452d11-9f65-4a47-b6cc-452939f934d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_103db4cb-2d04-42e0-8717-d0055d3e9152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_us-gaap_EquityMethodInvestments_103db4cb-2d04-42e0-8717-d0055d3e9152" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7c971b8d-42d3-4b64-b865-77521aef409a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7c971b8d-42d3-4b64-b865-77521aef409a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_6f2c71ad-f63e-494f-a59b-32d3f693d040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_6f2c71ad-f63e-494f-a59b-32d3f693d040" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_f553581a-4b7d-4f4d-98d1-9352093baf52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_f553581a-4b7d-4f4d-98d1-9352093baf52" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:to="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_43641868-5bcf-4d8f-9691-635a70cf0e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:to="loc_us-gaap_DebtInstrumentAxis_43641868-5bcf-4d8f-9691-635a70cf0e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_43641868-5bcf-4d8f-9691-635a70cf0e8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_43641868-5bcf-4d8f-9691-635a70cf0e8d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_43641868-5bcf-4d8f-9691-635a70cf0e8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_15e27252-1dce-4516-8ed4-09db0407de5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_43641868-5bcf-4d8f-9691-635a70cf0e8d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_15e27252-1dce-4516-8ed4-09db0407de5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_e0a02946-fc7d-41a4-a208-83e4c75d7f9e" xlink:href="ino-20231231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_15e27252-1dce-4516-8ed4-09db0407de5e" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_e0a02946-fc7d-41a4-a208-83e4c75d7f9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a7db1f1e-b0a4-4aba-b09f-51f15a594b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a7db1f1e-b0a4-4aba-b09f-51f15a594b7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a7db1f1e-b0a4-4aba-b09f-51f15a594b7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a7db1f1e-b0a4-4aba-b09f-51f15a594b7f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a7db1f1e-b0a4-4aba-b09f-51f15a594b7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_857483b9-8f61-4ca2-8089-d76c12d5d183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a7db1f1e-b0a4-4aba-b09f-51f15a594b7f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_857483b9-8f61-4ca2-8089-d76c12d5d183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d19f7512-856e-4dfd-a6e7-d73f8d6897dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_857483b9-8f61-4ca2-8089-d76c12d5d183" xlink:to="loc_us-gaap_ConvertibleDebtMember_d19f7512-856e-4dfd-a6e7-d73f8d6897dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_668884d6-603f-452d-b0bb-2d221e1f81e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_668884d6-603f-452d-b0bb-2d221e1f81e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_668884d6-603f-452d-b0bb-2d221e1f81e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_668884d6-603f-452d-b0bb-2d221e1f81e1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_668884d6-603f-452d-b0bb-2d221e1f81e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_935f6ad5-32aa-47a7-9a5c-32013f347563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_668884d6-603f-452d-b0bb-2d221e1f81e1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_935f6ad5-32aa-47a7-9a5c-32013f347563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f50955a6-297e-46d5-a997-6744d1c269ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_935f6ad5-32aa-47a7-9a5c-32013f347563" xlink:to="loc_us-gaap_SubsequentEventMember_f50955a6-297e-46d5-a997-6744d1c269ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_42929f50-8999-4fc9-a4a5-3499b84df5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_42929f50-8999-4fc9-a4a5-3499b84df5d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_42929f50-8999-4fc9-a4a5-3499b84df5d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_42929f50-8999-4fc9-a4a5-3499b84df5d3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_42929f50-8999-4fc9-a4a5-3499b84df5d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2512e787-2fbc-4bbd-a9d6-08febeeb007e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_42929f50-8999-4fc9-a4a5-3499b84df5d3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2512e787-2fbc-4bbd-a9d6-08febeeb007e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember_8cd42c4e-3b4a-4278-b6b9-c984019fe831" xlink:href="ino-20231231.xsd#ino_A2021SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2512e787-2fbc-4bbd-a9d6-08febeeb007e" xlink:to="loc_ino_A2021SalesAgreementMember_8cd42c4e-3b4a-4278-b6b9-c984019fe831" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a0c1687d-6ce4-4225-a035-54e00bbd8034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a0c1687d-6ce4-4225-a035-54e00bbd8034" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0b1363b0-f741-4d22-8033-ac8af2e0d513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0b1363b0-f741-4d22-8033-ac8af2e0d513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d02f9599-0d47-46fb-b2f3-858a094b02a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d02f9599-0d47-46fb-b2f3-858a094b02a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_f4bde965-f017-4de3-b119-a267ffc9004a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_f4bde965-f017-4de3-b119-a267ffc9004a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7213eea4-f47d-46f8-a917-b0f59cbbfcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7213eea4-f47d-46f8-a917-b0f59cbbfcd7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>ino-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b4fcd846-7e1f-480b-911d-4744cd39f89e,g:4f8a585f-cb3c-4f96-86ae-b643b290a1f2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_f288529b-54d9-4aee-a458-a3738ab12338_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_2f1f8973-d020-4636-9bb8-97356ac2febd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Shares Authorized Under Stock Option Plans, By Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0e27e476-0b9a-464c-9cd9-43048318a1d6_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4704c874-e071-43e2-b6cc-053af883a297_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2b13d493-c0ee-454a-954b-63fd07e4a66b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_7c75efa6-d17b-4190-9fff-85bbfabccd7d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_98722e17-5bd9-49e4-a0b1-4bca62306780_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_577a2a82-f4d1-4e83-902c-ee2d151786dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue From External Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc4c79e9-93de-47d6-9281-391aff7e7b5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_63cf3d3c-b636-4c4d-aea9-73d6f82b0477_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ab4a9ba8-4206-4379-913a-1808cd735e3c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_01f20ad9-87fd-43ea-8c40-9e18cdfd604c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of (discounts) premiums on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_94f24edb-a137-478c-b103-5f231ba19ff0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_341e6655-081d-45dd-853d-acc8dbc80342_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$18.01-$39.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Two [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesTwoMember" xlink:to="lab_ino_RangeOfExercisePricesTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_a59fc6db-8b4b-468b-a276-349dc1d894d4_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSU's expected to vest (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:href="ino-20231231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0e6cf876-8787-40dc-b5ec-6fe15a167968_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_28dc5d3a-24f2-441b-9616-2510dcf72243_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5e67dc0b-8f1b-44a6-9e1e-8b3c53a5683f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2007IncentivePlanMember_cdd95280-3c8c-4822-8745-499fb8253cae_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember" xlink:href="ino-20231231.xsd#ino_A2007IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember" xlink:to="lab_ino_A2007IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7eaa3810-8dbd-45de-9ad6-c56ec85bd19d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_677a7204-efaa-40ab-b18f-10d6319e92a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_f2c5e498-5b40-459b-ae6e-9c93d7625733_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b9ca77ad-b5f2-48f5-9bf9-ae27821cc728_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_979835e0-34aa-4f33-ae29-d064b1000ce4_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total goodwill and intangible assets, net book value</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Net</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:href="ino-20231231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:to="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_20b16814-5da3-4c9c-8b56-889f8e75274f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_062aac31-e28d-4a20-8b9b-abbf2645536d_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_e79095eb-0e6e-4ae8-b212-d8e6db82673b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_1ef29c18-4015-4c51-9ec2-1bc787589547_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Two Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_72c33461-42c8-4bab-92d5-cc62731677ee_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December&#160;31, 2023 and 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_e8f5b350-07dc-434f-9d0a-7942501e3c5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in tax rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0b1a8b32-eded-4914-8f69-3be348af7309_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_96e8e03c-08cc-48c7-8618-ead6020bac2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ae0df59c-cd76-4692-8b99-f8e18d827ed5_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_f6053673-dbce-40b9-bd18-094f82a3863d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0cdddda3-796a-4031-a796-decce6427776_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_248bd58d-a485-46f4-b94d-7c27df865b7f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_6a6e9e0a-07a4-4e4c-a348-05895a58b523_verboseLabel_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_label_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Option and Warrant Exercises</link:label>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_documentation_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Option and Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises" xlink:href="ino-20231231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsfromStockOptionandWarrantExercises" xlink:to="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DepartmentOfDefenceMember_5e7cb167-cb1d-4a41-b44a-5b7073555ae5_terseLabel_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Department Of Defence</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_label_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_documentation_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Department Of Defence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember" xlink:href="ino-20231231.xsd#ino_DepartmentOfDefenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DepartmentOfDefenceMember" xlink:to="lab_ino_DepartmentOfDefenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_f6aba42d-8ed7-4fb2-9a70-2e2f1e6bbfd8_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a8259cf8-380d-481c-9990-6a7d6d1916f2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a9a1516e-8947-48ee-8302-7b0a0442cf45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_908cc452-cef6-4cc5-990d-290dec43c38e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MutualFundsMember_993de9d3-116d-49a7-8d7d-563905a8f5e8_terseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_ccd9ee52-ada9-4fd2-bea4-a679500aaaa4_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_label_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_documentation_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember" xlink:href="ino-20231231.xsd#ino_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember" xlink:to="lab_ino_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_fadae1a7-d4a3-4877-b603-50de5abc7ae6_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2b38f781-36e4-447c-a382-60992e4f3123_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5cf94233-4069-493d-846e-78d642522c80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Unrecognized Tax Benefits Rollforward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_4f4d2e16-2d3e-4d35-b3ec-f5e4306c02fb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expirations of Tax Credit Carryforwards [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_73a2ed12-71d1-4888-8c89-78dda0fdd18f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BiojectMember_efffabe2-ab18-4a25-9d61-91af802d23d1_terseLabel_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioject</link:label>
    <link:label id="lab_ino_BiojectMember_label_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioject [Member]</link:label>
    <link:label id="lab_ino_BiojectMember_documentation_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioject [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember" xlink:href="ino-20231231.xsd#ino_BiojectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BiojectMember" xlink:to="lab_ino_BiojectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_92a8ae78-5857-421b-a673-e2de549da096_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8c9cfa3f-c914-42e2-b03c-98be353b222d_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_eff4ee3b-121b-4d71-90c2-b798f8a15fb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_36329503-d936-4541-8fb1-b52b66dbaafd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6d00132d-2e07-4f25-a3a0-0dae411c020d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_c860d9b9-732e-41e3-8670-a5c23ac8dd0e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_d019fab6-e70b-475e-bf3e-7a578db42e59_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_536aad30-f203-4a2e-9161-a854e4ead7c1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2c39ebb3-f3f9-4984-83e6-d1867831b2d4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_4d757dd7-e113-41e1-add3-f17d970228d8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd161597-4b4a-4c11-a7e4-0b22cb21db43_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_918df744-716e-4128-9046-ce6eb675152e_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_cee27e98-882d-4fd5-92fd-b76a0bc81a21_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ae0085a2-a848-433e-a001-9e3beedaee06_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grants under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantLiability_5f43d855-99ca-485a-88b3-537ba7ca4706_terseLabel_en-US" xlink:label="lab_ino_GrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused grant funding</link:label>
    <link:label id="lab_ino_GrantLiability_label_en-US" xlink:label="lab_ino_GrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Liability</link:label>
    <link:label id="lab_ino_GrantLiability_documentation_en-US" xlink:label="lab_ino_GrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantLiability" xlink:href="ino-20231231.xsd#ino_GrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantLiability" xlink:to="lab_ino_GrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26993ab7-9dcd-482f-bf4a-6abf9bc52132_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_62522f07-5641-4ce2-8962-33ca94442b3b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_06ff5876-dd78-48c6-84bb-880fe969f461_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a851fe92-481f-4493-b605-d34dc3d8119e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_15d6e08a-1a02-4e01-a23e-63f69b566620_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:href="ino-20231231.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_8529a3ca-d9b6-4958-9902-c41a2ce9bbd9_terseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service-based restricted stock units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20231231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1c7df7fe-7402-4d10-9d1c-997d3460a33f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e6bc5653-7237-4b5d-8393-b7febe2dc5bd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a5e33d61-9f33-4e5e-964b-cc5ab59929b4_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e14c44d2-0b67-402c-bbf5-635738850bb4_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_672dde1e-bf27-405c-a6ac-910967dbed62_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_63bbf21f-f57a-4432-a033-aa68895ec0db_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember" xlink:href="ino-20231231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_27bd90d1-03f2-4c1e-94e7-c9c02b0271e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_adf3164a-5e5b-49d3-82ed-7373410260be_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_6847eb71-0115-407e-92f5-a6e9a9b10995_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$130.01-$233.28</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Six [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesSixMember" xlink:to="lab_ino_RangeOfExercisePricesSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1fcb9d64-9ade-42e1-b1fb-09181873a84e_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_f323ccaf-8268-42b4-a5fb-c0d04d016274_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock aggregate offering price</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:href="ino-20231231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_KoreanStateIncomeTaxAuthorityMember_a3ab5a70-22cf-4113-a396-5f616f00b4da_terseLabel_en-US" xlink:label="lab_ino_KoreanStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Korean State Income Tax Authority</link:label>
    <link:label id="lab_ino_KoreanStateIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_KoreanStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Korean State Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_KoreanStateIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_KoreanStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Korean State Income Tax Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_KoreanStateIncomeTaxAuthorityMember" xlink:href="ino-20231231.xsd#ino_KoreanStateIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_KoreanStateIncomeTaxAuthorityMember" xlink:to="lab_ino_KoreanStateIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_afd3d0de-5f76-4e6a-9aa0-f67ca24fa2a1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_8a50639b-e0b0-4451-9f41-edfa2eeb2a90_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities (VIE)</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2021SalesAgreementMember_b4fa8b8a-21a9-4796-821f-84f0fe64ce5d_terseLabel_en-US" xlink:label="lab_ino_A2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Sales Agreement</link:label>
    <link:label id="lab_ino_A2021SalesAgreementMember_label_en-US" xlink:label="lab_ino_A2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_A2021SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_A2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember" xlink:href="ino-20231231.xsd#ino_A2021SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2021SalesAgreementMember" xlink:to="lab_ino_A2021SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1d2fc269-868d-483a-9203-331f60182ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_75944a2f-4ac0-4520-a86d-3cd5ac279c90_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Shares That Were Excluded From The Diluted Net Loss Per Share Calculation Because of Their Anti-Dilutive Effect</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_f30ea13b-5c49-4549-b5eb-2ca261bdcd23_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_ccb89691-00bf-48f3-b758-5016c1a555ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_06a83735-b57b-4ff3-92a3-9948e2142abc_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_a8dfb26b-7462-42a5-96df-115c1fc631c7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7ee08e8c-3753-44ac-b4eb-b6be5dae2b1a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_dfce4be4-4bec-4a4e-bf58-6b7ac7fe10ea_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_cc81fa56-74e0-458a-995e-d0f3a22bd04a_verboseLabel_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assumptions used to estimate the fair value of stock options</link:label>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_label_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract]</link:label>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_documentation_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assumptions used in estimation of fair value of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:href="ino-20231231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:to="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2ede98f4-04d2-404b-9001-22ec0233948f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_12e0345c-da21-4c1d-bd76-97634024fe25_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0204b397-b6d0-42a4-8c18-b85fb4a0b788_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_afeb6d8b-722c-4ed5-a8ff-fea99f26771d_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_797917d4-66c2-420d-bb23-4e77ddadc0ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_2b5eb525-d9ad-4236-b1b7-c772a05622f7_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_86f8dae5-a9ad-409e-a3bf-4871644ac4fc_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_d5aef0ae-6192-47c6-84f0-db3c79854d76_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c348a1ec-5c1f-4b36-9248-3d69e2db3d02_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d44a5ba3-81de-4de4-820b-81311a4a2867_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_075ad198-6249-44f7-8b3d-51047403211a_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total goodwill and intangible assets, gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:href="ino-20231231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:to="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7eb5ad4d-af95-430e-a317-9c04de591c34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_77397c43-8da4-4d6e-b33c-0a3bb3fd93ed_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development and other tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other Tax Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_7878e938-fbbd-41b7-8bbc-29607dc03144_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_7ac8d925-3637-48c3-a344-f843b99960c7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8860cc26-c89d-409c-b553-b7a2388ef80f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_03c7525f-a232-4509-bc15-5123aef08537_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember" xlink:href="ino-20231231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember" xlink:to="lab_ino_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7fd43add-e599-4d0e-8b4e-ff3b7c050710_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_a833d351-739f-495b-890a-00be40b0249d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_d8de15bd-b4a4-452c-95cf-e03800ed2462_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net book value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_336c5509-9d54-4df5-b4d4-bb7521c2b1ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e9114d8f-df53-4f75-885a-8c3a7f0e68b7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements - Recently Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_95f22285-dcda-44ea-8382-be9b7f786405_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limited NOLs and credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:href="ino-20231231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_1d06bdf9-e445-4964-9d8e-d8c92893bc94_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:to="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0dd106e3-e034-4093-a1d7-ffb10727f283_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_480488ba-b297-4ac8-a817-bdb24cc7d946_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c0c892af-20ce-4c6f-a574-c4b7e5c27d66_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4a362b81-89ed-44a3-923b-a8ef0110eaed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Components Of Pretax Loss From Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_cfa16106-12f8-48c7-8c6c-8d713f18ee0b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_71d1845c-d786-4a41-b0e5-003165eaeea5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6d3cc222-5282-4892-8f32-c6ce07198b8d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used To Estimate The Fair Value Of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8487d3c7-4daf-43c4-b685-dab0d5a7f676_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_376fa880-a9da-4ca7-83fa-3ed376cf9bc7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities in a gross unrealized loss position for more than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c8fe8ee9-77f4-44ab-b84d-a58e31d3394d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_3ffe4342-55ac-4e35-b1a8-75d7807f18d0_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sale agreement, aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:href="ino-20231231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_77b803f8-b5fb-45a6-b7db-c8ec17b911ae_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1fe80101-a341-4f8d-8a8e-c4a99d374ab3_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_01004cec-e4f0-49c0-bd54-ecd911907da4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_09b8ffbf-660f-4814-8bc4-38fb5d94d5b6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_af875c0b-5205-4ba5-9c1a-c7b006a71603_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e0016a20-5b9a-494e-8f00-054e71e37662_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AdvaccineMember_94c05f30-6e56-435a-9eff-72e950ecec2e_terseLabel_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ApolloBio Corporation</link:label>
    <link:label id="lab_ino_AdvaccineMember_label_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advaccine [Member]</link:label>
    <link:label id="lab_ino_AdvaccineMember_documentation_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember" xlink:href="ino-20231231.xsd#ino_AdvaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AdvaccineMember" xlink:to="lab_ino_AdvaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7b18d980-f9d4-4b8d-a667-79921e2b4f4d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_8d0d4e0b-d1c7-4826-8055-aa4fb44801e2_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awarded option amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_316f31ef-eb23-41cf-aa61-46b82d237953_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred grant funding from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate" xlink:href="ino-20231231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_46153c66-4a05-425a-976e-4fd1458375df_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Three Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_9bed861f-4b20-4267-bdea-473611edd6da_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_04d81233-d961-48fe-abd7-fdeca9fe9dda_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants receivable</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0157ab12-410f-477d-b6f9-2226a064922e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TheWistarInstituteMember_3596b143-3602-4ec7-a0ae-0c2e3e3b1fbb_terseLabel_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Wistar Institute</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_label_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_documentation_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember" xlink:href="ino-20231231.xsd#ino_TheWistarInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TheWistarInstituteMember" xlink:to="lab_ino_TheWistarInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55d45437-c324-47fe-8832-951ffd6b5b02_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Liquidity</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_a34c25ee-75ff-41b2-8f41-3e8861cf9fc4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_70a73511-11d4-41aa-a569-2e774e8a79fa_terseLabel_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="ino-20231231.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b5e7f64e-9941-4dd1-9ac6-b55bfeaecd5c_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_4c83a79a-f06d-45d0-8c0c-ef894fa9277b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Damages paid</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Paid, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:to="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_f7f53648-7ad3-466a-b9a3-cf7e598f43ab_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_a9ae7f41-f6bf-4a37-b06c-7d87b103be55_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:href="ino-20231231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b99a6b83-b6bd-4f07-adc9-787bdfe90bfb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses, including due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3f28cea3-af77-4b10-abf2-669fd9171008_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_dbf7cb91-e2e1-4b5d-bb86-e027ebf52f97_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_7eb2bd2f-50f0-4de0-8260-6371e17d8f0e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_7f164403-b604-47cc-a6c9-98a7532c71f1_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_988a7359-9ef8-4cf2-a284-1b1c7b284b7b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_ee569cd0-7113-407c-951e-f45fac729e31_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_3505947d-0f9f-4dbb-81d9-f68c5a6afa54_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:href="ino-20231231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4799253d-340d-4bdb-b021-1a2d3bffc3ac_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_2179e2b5-47ee-40b3-992f-0224905c762a_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20231231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_e39c9174-e5d7-4527-a81c-8f20a1612238_terseLabel_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COVID19 Vaccine</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_label_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">S A R S Co V2 C O V I D19 Vaccine [Member]</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_documentation_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">S A R S Co V2 C O V I D19 Vaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember" xlink:href="ino-20231231.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SARSCoV2COVID19VaccineMember" xlink:to="lab_ino_SARSCoV2COVID19VaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_d25d939d-5e97-4f19-9e06-b21176c68040_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_46865aa7-3f65-4cad-aa32-73828c802932_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_44bb5590-22e6-490a-92f4-d57cf753cc45_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4e99e9d1-f08c-43e4-85d2-a09282dd059e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_ff28e814-91cd-46b9-bf7f-316e91a4176f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_b560fd95-ec9b-4834-991e-9433a086251e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_de969a8c-d082-4883-b92b-78da0311498d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_f6536fef-5b5d-48c0-896f-2c30c533e189_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonEmployeeMember_0c529163-b569-4cac-a3e7-71e098cf3239_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_label_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember" xlink:href="ino-20231231.xsd#ino_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember" xlink:to="lab_ino_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982b0cec-c364-4394-87d7-3d7db9569207_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_edbe7b46-3cb9-4a89-9c25-20616e5b0a70_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:href="ino-20231231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1b6bb869-9a22-4382-8b42-4a000d83ed4e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_653921eb-b830-4b5d-9632-9ee9e9834eba_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_ad518426-74f6-4031-88cf-22f18726334e_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="ino-20231231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6e12db62-03cf-47ce-a3b6-c2530994576f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_dc281d2b-30a4-4048-87a2-a4890193598f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Deferred Tax Assets And Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_38446b00-eacd-4640-804f-f4c77da1dbc8_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33dbe58d-c53c-49dd-9a85-49fa96158631_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_293d8a29-504e-4bab-8752-02ad38a8ac02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_50e03537-edc0-47c6-8051-968d6db612a9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_0eba9004-c1b1-4ee0-873e-644d08f70c8d_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired NOLs and credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:href="ino-20231231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_b02843fc-7ed9-4d36-873e-26115965953c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimate of cash settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_f35d4643-9713-4b13-b755-bbd09267c30e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_34dd9241-5c11-4528-84bd-5d9b9c71cdd6_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_76eb00fc-bd8e-4ec3-9ec4-c4edaeedafd5_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_56fc177f-95ef-4af3-94cc-1cf912405c11_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_302ffe80-b34c-429e-a2fe-07c3af511809_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_787f5f62-8617-48ab-bda3-bd49d3906f6f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_95540018-c84a-44c8-b93f-da181602cdb0_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3bebab54-96c8-4569-a41f-2c1bbac87c2b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_d7a726fd-c9c5-4181-83ba-26d82c5298ad_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d1ece8db-9a7e-4312-b487-f25afb18facf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b63ab1ef-51fc-4930-af0d-08ec8ff1a2a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioCorporationMember_c8835e72-3ea5-402a-bde2-7f05fa8d6c5f_terseLabel_en-US" xlink:label="lab_ino_ApolloBioCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ApolloBio Corporation</link:label>
    <link:label id="lab_ino_ApolloBioCorporationMember_label_en-US" xlink:label="lab_ino_ApolloBioCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ApolloBio Corporation [Member]</link:label>
    <link:label id="lab_ino_ApolloBioCorporationMember_documentation_en-US" xlink:label="lab_ino_ApolloBioCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ApolloBio Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioCorporationMember" xlink:href="ino-20231231.xsd#ino_ApolloBioCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioCorporationMember" xlink:to="lab_ino_ApolloBioCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f9d8a18e-c112-4079-b165-b2f8310de590_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ad7ba3c5-a02b-4ab2-93a2-7f45859cadf1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_817b56c9-c31d-4d05-a3e7-76f549feade2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bbf3a720-763b-4054-acfe-2c58c8fe3bf5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_4169ed4f-23a4-48db-94a0-cfb4b352ec8a_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share of net loss in Geneos</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_71a7d97d-ecb9-41ea-9170-45dcaf1a3dd5_terseLabel_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember" xlink:href="ino-20231231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesAOnePreferredStockMember" xlink:to="lab_ino_SeriesAOnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_486189bf-9e1b-4e16-9d5e-e1563a2c3e82_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_04c06d7c-4af9-40d1-9e75-8101143ba02d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_c49cf423-106c-43a1-ae0c-419705e2f8dd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_9ff91c1c-6ac5-4bcb-a455-4f1480be4884_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_032ff50b-fd85-4107-b742-865cbc1ab2f0_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_1f267c13-b3fb-4f47-a17d-7c686ff3f68b_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_518c8468-4fe0-4ea9-be0a-8532ad862290_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise&#160;price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_34873f8e-d55b-418d-b080-d317f3caf625_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f8784efb-f30b-4735-9730-101c047dc8a5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_04fa0178-4308-40d8-9d3f-e56843609a6f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_b3e50da8-b5b0-4cec-b03c-90a2de3d61b9_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, remaining contractual term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:href="ino-20231231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_5984f373-3933-4b00-899b-506e0af4c21e_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. agency mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_9e359177-42da-44c7-8f76-bdcb6b329db4_terseLabel_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share)</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_label_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_documentation_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:href="ino-20231231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:to="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapital_ca499185-e857-49ce-88bd-c63f4c1f8fe9_verboseLabel_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_ino_WorkingCapital_label_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_ino_WorkingCapital_documentation_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net amount of current assets and current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital" xlink:href="ino-20231231.xsd#ino_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapital" xlink:to="lab_ino_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_de6c6bce-54e2-47da-b1e0-26068b5a838e_terseLabel_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pennsylvania State Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pennsylvania State Income Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:href="ino-20231231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:to="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23c49bbf-2cf8-4ffc-b956-51814a0a7de3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7f7bf516-a7ce-4674-924a-ae8ec6cce412_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8a982d48-4367-41aa-a5c0-3f4ae1007465_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_379b1927-9848-44a7-a6d4-047ca43e9580_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">%&#160;of&#160;Total Revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_a91726e7-a7de-4d78-93d8-176c8467dd99_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c8d2e8e3-a989-49c6-bb04-5d83133db0ca_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_48dc9ec1-edc3-4f97-bbf1-fef21eb79bf6_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$90.01-$130.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesFiveMember" xlink:to="lab_ino_RangeOfExercisePricesFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_639c0fa7-2191-43d0-8407-f4b7894e69ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, expirations in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_ac39c7b2-a1b3-4cbc-b1ee-0736e74b3342_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_334b95f8-2628-4842-af9d-66bc67afc895_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ec8672ae-81ba-4cd1-bc2a-9f01b1cdb7d6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value for options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_f8362c10-93c3-4e51-919f-f4ae2c1f627b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c73231bf-db31-4707-9dc6-4b0120d0ddf8_totalLabel_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_label_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Tax Expense (Benefit)</link:label>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_documentation_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:href="ino-20231231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:to="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_c80aa32d-d7cf-4a64-8086-585ab73961a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_66886fe3-7278-49e1-9f19-9f3a4110a0c1_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_c870b25a-bacb-4836-bb76-145b516bab48_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Indefinitely Carryforward</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Indefinitely Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:to="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_6a4e068f-53a3-46e9-a9f9-b6dd69155a8a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_e083b793-45ff-426c-87c6-e9420638fa0b_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options expected to vest (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:href="ino-20231231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_257e94c7-0a8d-4320-bfd8-8f49b87edbd6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_57923052-6eda-4616-8d8f-3fd33d084171_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_b75fbe0c-d5f9-4284-8ba1-5cb89fd76142_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_55f26247-4265-4354-90cd-f42fd8596d2d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1d62f83c-273d-442e-88cc-4200d36b3733_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2409fe40-090a-4714-ae73-b7023de1ba24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_006b3097-8303-46e1-bcba-06c1ac7b5626_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_b7c9a96e-4c35-4fe0-9169-a5ab9a3789db_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:href="ino-20231231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_605c302f-c9d2-4fb3-b2e2-101372081898_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e2953232-93de-4f28-a135-6cf817082227_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ac4d2b9c-44fd-47dc-8308-8d1c417ae250_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_4239f1eb-31eb-4037-afd8-d54a0c304593_terseLabel_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">California Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">California Income Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember" xlink:href="ino-20231231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CaliforniaIncomeTaxAuthorityMember" xlink:to="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_27f1f055-4f11-4f28-8b26-3ffd5ee4e27a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_30f07157-288e-4048-b7d1-25160b6546cb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInFourYears_01d153f7-b875-4659-8f12-0127e23b4685_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInFourYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Four Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInFourYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_ccfd37ec-2bd4-4a6d-aa24-5b1e648e3b62_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_456ecdd9-485c-43c5-9879-aab30d9b69d6_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_fbad7770-b332-432f-bf4b-9ce55dc3f4d7_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_7dc8411d-14a8-4801-9483-5dee9fd51b8b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxBenefitsExpired_b8b671cf-f034-4627-ab06-9eee69841352_terseLabel_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefits expired</link:label>
    <link:label id="lab_ino_TaxBenefitsExpired_label_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Benefits Expired</link:label>
    <link:label id="lab_ino_TaxBenefitsExpired_documentation_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Benefits Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired" xlink:href="ino-20231231.xsd#ino_TaxBenefitsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxBenefitsExpired" xlink:to="lab_ino_TaxBenefitsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3747b522-5768-414e-9b42-b85ed3d260b9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_53d41537-bd70-4c6d-b705-4ea335a2f24d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ea02ded7-fe14-4ce2-bbd7-5503322c127a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e26737d1-9edc-4614-ae37-5903db3131ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_6caa9bec-b6ed-4ec8-847b-452812ab8e26_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Carryforward Indefinitely</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Carryforward Indefinitely</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:to="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c82f03aa-bef2-4bc7-8b79-3af99cebabf4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d9635605-9cb6-4d5f-b09f-b057d04f8159_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b176d52a-8fb5-426d-9e69-430c4b7f55f9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Book Value</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_223687be-0cd7-4b5c-81a1-a51579f7ce75_terseLabel_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance recovery</link:label>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:to="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5658aa86-3d6a-4580-841e-6f370253ac2a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6a380427-8587-4efa-899b-aa70c0090545_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1e9e936a-3b61-4a7a-b315-e2d61708307c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized transaction (gain) loss on foreign-currency denominated debt</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_ea72277b-2c95-4855-a332-415d3a31ce4e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_810f625e-4910-4070-8c3c-5c4999b2997a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_4fcf5da3-b690-4808-b39a-e6aa9588ca12_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_abe349e8-47a9-473f-ba00-8bbb618b24f7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_ea83961f-cea8-4a00-a1f7-8ca8e1e6479e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment disposed of</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Disposals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6fdbc988-0762-47fd-b26d-edd7ac6e3f1c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2fb0e908-7d13-4168-8b12-ef949587f651_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c0c6f6e5-885e-407d-b042-cb0f3574c9a4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_19b600b8-673c-4604-a5a6-b3ec950ab447_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_d407c9d8-9fc9-43f2-85c4-5ddbfaa14da9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_ddb0e4bd-019e-44cb-afd2-31dfc78c8cf0_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:href="ino-20231231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b2a4db4a-e77d-4479-bb90-18b13c230de6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInThreeYears_79a058ad-6573-48e9-8e6e-cd68c6861f8a_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInThreeYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Three Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInThreeYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_855c6e84-be6b-4f9b-a403-b4059a4e6bbb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b8a08fd2-bd92-42c5-a5f6-e7e27722dbab_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ab779e64-0fb7-4a65-b461-047772d437f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, exercises in period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_268bb609-a8f3-4e8f-ba75-38a6ecb2ba5e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_d8c46db9-cd21-4209-9232-c80398f04717_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock as part of litigation settlement</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_7c3c656c-509c-4848-ada7-c6171a36157f_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_bfd88269-29fe-4f07-8c02-ac792792af82_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_b3b30e06-0245-49c6-8ea2-9fd410d5dbab_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for legal settlement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8f9fcec1-a168-489b-a1d4-0cacb122aabc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_faddad51-ef46-4e94-81f5-fe8e1a58306a_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_44780349-07f7-4725-9644-ea0e92f02216_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Next Fiscal Year</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringInNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear" xlink:to="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_67b815b2-14f4-4b37-b05e-48e6fccc0ce7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_aba577b9-48ae-4c99-8997-35dff4c4a425_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3c694f82-c443-4868-a4c6-514374053537_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_0c93e83b-6297-4e9e-b2d5-e57bb29fd88a_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent" xlink:href="ino-20231231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent" xlink:to="lab_ino_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_ed1f4053-0fce-48fd-8ebb-a50eadb0a443_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_ab46eceb-b413-444f-9ef3-d5061ec5d7fe_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Next Fiscal Year</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringInNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_88847800-d833-4736-a567-542cf358493c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c44f2ce5-6f29-4b4f-b7d3-c10e84437f1a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e5d58fdc-937c-42fd-afac-b87558d91f16_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1e225649-ee72-40ae-9ddd-742cb0169454_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_e9936947-100f-40c5-8fac-84b210b5b8d3_negatedTerseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal amount converted into common shares</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:href="ino-20231231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:to="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_71fc27aa-ebdd-4b7a-b8c0-c42a5c6edaeb_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_a5161f88-ba8f-44a1-9881-7db4a5a34485_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_16af1d17-b149-48da-832d-de98033ae27f_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_5a557423-400b-4d61-b776-918317bd95d5_terseLabel_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-2 One Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-2 One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A-2 One Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember" xlink:href="ino-20231231.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesA2OnePreferredStockMember" xlink:to="lab_ino_SeriesA2OnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_43fe11f6-9713-4084-bb0f-3c64ffe7bd9f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_add41c89-a323-40c6-ad15-cd2a310f6100_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_f987f361-3abb-48dc-aa26-fee62b8f1b9e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum annual contribution per employee, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_dc3768f9-2427-4e7a-a8db-0aa8f7441e3d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill and Intangible Assets By Major Asset Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_a132d17d-751e-4e97-be9a-96c038e20de0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_93f5ed06-7b98-47e7-8d73-b3ba55c96afb_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_abaf0e72-9d62-46a8-bade-9fcd22c8fa11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized (gain) loss on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_a8480c5a-4862-49a9-99ec-8836af8e1755_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, upper range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_763165b1-c235-4ae8-bac2-05c40600385b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of capital assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_f2844bc5-9252-404c-be57-70c7763dbe19_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7390a448-a482-4a63-ad32-84e41c25f3d9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_34b1b124-8cac-4701-b048-f7fe265f35b8_terseLabel_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from equity method investment, recorded and allocated to investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_label_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_documentation_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:href="ino-20231231.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:to="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_7bb2f2e1-4b93-4437-b8db-d62d7dae59b4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_3db32641-6f0c-4e20-9547-12ff9b13436f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expense</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_204aa4b4-00f6-4ccc-8c6f-f359a47c76fc_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e38db478-5c90-4858-b518-e64499df0de6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_e2068804-a5b6-4336-b0f7-d91449ea266d_verboseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contractual year term of incentive plan</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:href="ino-20231231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_cd7a17cf-92d4-4180-a5c4-ff103d0e884d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_3e72916b-69f2-4ced-99de-b27eb27f1a1c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_cfff6da9-724b-417e-bb2e-6073c076d421_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Realized loss on sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c7afe6fb-1da5-4947-a105-4713f7b2d2bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1296350b-b9e7-416c-baa9-055206d8db96_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_6c8106fd-a331-488a-b4c9-c7fe3876b2f7_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:href="ino-20231231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_31f05859-932d-4933-9cd8-cc599f3e14c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_cfe4bdbd-b7b1-451e-85d1-2f11bb94f6c6_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_c1d9c53b-7819-4557-b397-ec18bed614c4_totalLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForDeposits_bb4e2603-3a72-4265-ae44-2505c173ad39_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposit payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForDeposits_label_en-US" xlink:label="lab_us-gaap_PaymentsForDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDeposits" xlink:to="lab_us-gaap_PaymentsForDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ad8a950-ec3a-4fe4-8ace-136f5cb7b1c5_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_1e6228b8-e625-4f97-b37e-4a68680401bc_terseLabel_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue under collaborative research and development arrangements from affiliated entities</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_label_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_documentation_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:href="ino-20231231.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:to="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_06ab8a33-832b-47f7-bb3f-59c5ce2726c4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_9298141e-25bf-4127-bbe0-598fc90f9aef_terseLabel_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimate of shares settlement</link:label>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_label_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss, Value of Shares</link:label>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_documentation_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss, Value of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:href="ino-20231231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:to="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_f57f8fb6-d2b3-4cca-b2fb-47e293bd1668_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_79255d84-d60b-4149-9839-2a29bd6f76cd_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CertainBalanceSheetItemsAbstract_label_en-US" xlink:label="lab_ino_CertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items [Abstract]</link:label>
    <link:label id="lab_ino_CertainBalanceSheetItemsAbstract_documentation_en-US" xlink:label="lab_ino_CertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract" xlink:href="ino-20231231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract" xlink:to="lab_ino_CertainBalanceSheetItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_b33fcdb2-4a30-4869-a45f-5e07443d226d_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_label_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets" xlink:href="ino-20231231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetsIntangibleAssets" xlink:to="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_f08bab46-a58d-4e7d-8707-0b5a0439deab_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ec566318-204d-4dd0-9643-bf2ff34f05bb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_46ebd9c6-5efc-4180-a5e8-6de7ee4e4e8a_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_133f5b00-d3fa-416e-9f76-0dd9527238c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_654a8129-97bc-4adb-9b5a-c2f7dfda23ba_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_9fe37eef-f12b-4204-bec7-8017428e843a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_281ef32a-2c06-4e1e-b1fc-7b28e82899c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_7d8c6572-fe32-449e-a087-e5ed94de56ca_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_339e80a7-2068-40ca-8fb9-d251cd902f6d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cea038ac-44dc-4904-9e6e-1ea6868894bb_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4a91b303-aa05-4578-b90a-f074fdf1fd9f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_5402ac98-c63c-4355-83f2-79462dbdebb4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DoDMember_5289d265-c564-437d-af2b-2963717fb253_terseLabel_en-US" xlink:label="lab_ino_DoDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Department of Defense</link:label>
    <link:label id="lab_ino_DoDMember_label_en-US" xlink:label="lab_ino_DoDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DoD [Member]</link:label>
    <link:label id="lab_ino_DoDMember_documentation_en-US" xlink:label="lab_ino_DoDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DoD [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember" xlink:href="ino-20231231.xsd#ino_DoDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DoDMember" xlink:to="lab_ino_DoDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_94b87860-81dc-42b5-b7b1-75f3d3255efa_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales made at a weighted average price (in dollars per share)</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Weighted Average Price Per Share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement Weighted Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:href="ino-20231231.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:to="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioMember_0948137e-4d30-467d-ad56-45f9329944dd_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_label_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_documentation_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember" xlink:href="ino-20231231.xsd#ino_ApolloBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember" xlink:to="lab_ino_ApolloBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f05cd969-a92b-451f-9b25-9b96e786dff2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_32531fa5-4a55-4b88-8e58-b0da28d1b715_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a49a52d0-c741-4d6f-86f5-b22e3688bee8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_4e8295d9-3156-4345-be90-08123344a75a_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Resulting in again on memeasurement</link:label>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_ffe64953-f7a1-4820-ac7a-0208925f452f_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_97c800bb-d057-435f-bb38-e54ae8443842_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_ef17e9b4-7d04-494f-be19-0845c8d739fc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e0219e65-47e7-4048-9165-ea2039086bae_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_9d2659d6-c66d-492a-9cbe-d473699b3100_terseLabel_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_label_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt instrument, Accrued Interest</link:label>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_documentation_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest" xlink:href="ino-20231231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtinstrumentAccruedInterest" xlink:to="lab_ino_DebtinstrumentAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_e1fa6b42-55e4-4785-99d1-def450bcad73_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_458c58fa-6c0a-410c-9012-237bdb62c9e6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_bbea86fa-4cef-4b7c-8c88-6119cd75053f_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series&#160;C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_b06a1ad8-b663-48ed-9ecc-5c3e091c7902_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares_320ed475-9318-401c-953c-f58e7c729d39_terseLabel_en-US" xlink:label="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in settlement (in shares)</link:label>
    <link:label id="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares_label_en-US" xlink:label="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party, Shares</link:label>
    <link:label id="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares_documentation_en-US" xlink:label="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:href="ino-20231231.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:to="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5bb83e2-6775-4b1d-887e-22522ea82bc4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fa6f816b-9c0f-4b48-bae1-e4c9c43eeae3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cc92c4d1-9856-4698-82d9-e36cac52bffa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_8c964048-0f13-4e64-800b-56d13cd1d298_terseLabel_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_label_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_documentation_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember" xlink:href="ino-20231231.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LassaFeverAndMERSVaccineMember" xlink:to="lab_ino_LassaFeverAndMERSVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_b7cb376a-7f78-4f54-9634-d5477e4f16c4_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Two Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1e11dd57-3aa8-4109-970e-5a5cb5a6abf5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonemployee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_7f18a91a-f5bc-459b-b806-1c84adffd0f5_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4628fca0-83dd-4619-8d46-53efa6bf2562_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_7d7f2519-33a9-424c-9c5f-b5c8b3f75997_negatedTerseLabel_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest on senior convertible notes</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_label_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_documentation_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense" xlink:href="ino-20231231.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestIncomeExpense" xlink:to="lab_ino_NonCashInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_39ca4ffe-9356-4193-976a-32fded269e53_terseLabel_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_label_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_documentation_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember" xlink:href="ino-20231231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_UnderwrittenPublicOfferingMember" xlink:to="lab_ino_UnderwrittenPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_a7e2709a-599c-4023-93dc-6320e4da1bad_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$52.01-$90.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Four [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesFourMember" xlink:to="lab_ino_RangeOfExercisePricesFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_8eeb4f1d-838b-4d84-96b8-b0ad8563b1e7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_433ad89d-6be5-4bbb-a948-55aebbdf5890_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of unvested restricted stock units and options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b0afd4b6-bd90-48fc-b533-1cdea302f487_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b765a2b6-0385-4bb6-b4b4-7b82f367b03c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_bd34f194-ea25-41b5-ac98-22776f7db30b_verboseLabel_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of vested restricted stock outstanding under the plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_label_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares of Vested Restricted Stock Outstanding Under Plan</link:label>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_documentation_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of vested restricted stock outstanding under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:href="ino-20231231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:to="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_1d157ae1-f38a-4061-acbf-93496af82197_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8c4ab26c-91c7-4b37-a5b3-0a50b5444390_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0bbf5d95-fab2-4eb4-8e01-7c9ed9ca8158_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_03a53897-9a2a-4e48-9b52-673cd18e0ab6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9b3a4bfd-9c73-4378-81d7-19cf70ac6dba_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_31af4247-6ac1-40b9-9496-875715606798_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_643b94ab-1a09-4114-b444-8fdf419e410f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_754aef8e-153a-4edf-ac42-40a31914fa62_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a07ac5ab-32d9-4126-9392-b9bb1af79bfb_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_22849c49-d1e4-449e-bdb9-97923e77d74e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_57833698-f8ae-4251-bf8a-8839bcee2097_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantProceedsReceived_c7e9daa7-8c6e-425b-a48f-a2e1a76fb55e_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant proceeds received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_label_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived" xlink:href="ino-20231231.xsd#ino_GrantProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived" xlink:to="lab_ino_GrantProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_454805bf-28dd-4ff6-b2e8-eaf147a53e48_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_27a93ccc-e3f9-4ced-ae5b-565d0f039514_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, including from affiliated entity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_a53236ca-56de-4d74-a03c-055214b45819_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_63d5c6d5-ef96-453c-afd4-a84c7671169d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5631b049-b1d7-4574-b479-f13ad7f1a214_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d20cf850-1d90-402e-9725-5201f6524e5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e5030c23-eb6d-45bf-9f68-807489aeba5d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_a89b7679-3280-499a-a261-3cd59d22d5ea_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f24dd335-5c93-41d9-b2c7-8853255db37c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of options outstanding to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db637692-8836-482c-aa4d-e98378780ab4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_78483df3-cea6-4d39-ae5c-92422b9f3df5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b2cc53f0-b135-43cd-b2f5-d2500771e475_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, grants in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1757a1af-26b2-4838-8f1e-da9aa43f1e97_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8e800288-df53-4ddf-a4ee-06efa2653d14_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9306dce3-d768-4308-9f11-a193086eaef8_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss from operations</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_fb4b7d13-6a7d-46fc-ae1b-bc673410a801_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a1c22a22-75cc-4c53-9cad-9c1ef71fd273_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_9a4ebf25-09a2-4893-8a2f-72f96053ebc6_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_f360b88a-0787-4bd1-af43-dcd416842b60_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:to="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_697da27d-c580-4437-a520-2af290668299_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_f3c84b2d-47d2-4660-ba09-7dbb4260f309_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a450253-36c3-4f1e-b4a8-8a98c5e6c788_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_2769a9ef-a353-4963-9cfc-f67dd103a984_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of convertible debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO4800Member_5119ef5b-ad9e-478c-b1f9-4275dac43a20_terseLabel_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IN O4800</link:label>
    <link:label id="lab_ino_INO4800Member_label_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">I N O4800 [Member]</link:label>
    <link:label id="lab_ino_INO4800Member_documentation_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">I N O4800</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member" xlink:href="ino-20231231.xsd#ino_INO4800Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO4800Member" xlink:to="lab_ino_INO4800Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_53b6a55d-3971-412b-85d8-5bff2ece8465_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross&#160;Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_940fb3d9-27bd-4c45-9d97-74af042f6bfa_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9a50e7ae-4cf9-480a-be13-872707e053ad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4f8b6345-f452-44da-9aee-ede279da1c75_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_aa970b7e-0d30-415e-96f9-359121d7b1f0_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4159f915-2ab3-479c-a52d-b8f4fcbf64c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting period of incentive plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b3d513f7-8ce9-48ae-b8d1-9fe7b9465b07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_1b82f77c-5e50-4acc-a4da-800f9bbe6720_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_26d04f57-65cb-4138-a596-f5c66a62e4c3_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_cc82b88b-faae-498e-a395-60d2d28eafcf_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4479b080-3f8a-48ac-b6d3-0205c1ad5986_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_12bd62e3-e9ee-4479-8f81-9fd5da1eafa3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_60770e1e-843b-439d-8794-dc5084de6740_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_label_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_documentation_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:href="ino-20231231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:to="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BehestiVKimEtAlMember_342fcdce-c64e-4b96-9cda-e59925a1af8e_terseLabel_en-US" xlink:label="lab_ino_BehestiVKimEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Behesti v. Kim, et al.</link:label>
    <link:label id="lab_ino_BehestiVKimEtAlMember_label_en-US" xlink:label="lab_ino_BehestiVKimEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Behesti v. Kim, et al. [Member]</link:label>
    <link:label id="lab_ino_BehestiVKimEtAlMember_documentation_en-US" xlink:label="lab_ino_BehestiVKimEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Behesti v. Kim, et al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BehestiVKimEtAlMember" xlink:href="ino-20231231.xsd#ino_BehestiVKimEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BehestiVKimEtAlMember" xlink:to="lab_ino_BehestiVKimEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_3c188e22-83d5-4858-92b9-71c7ec434d6b_terseLabel_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_label_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Revenue [Policy Text Block]</link:label>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_documentation_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantRevenuePolicyTextBlock" xlink:href="ino-20231231.xsd#ino_GrantRevenuePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantRevenuePolicyTextBlock" xlink:to="lab_ino_GrantRevenuePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_44be33df-bdbb-4732-8189-430df7a93ea6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f562eb76-3eb7-498d-8d0d-f99569cee8ea_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b6c90733-aa2b-4605-8450-e6b08f200e35_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_92dae218-4d80-4923-8127-5900c604fef1_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d7213cd7-273d-492d-8b85-c6d0267c0a7f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8d772db8-54d5-472b-a9d9-bfaa068115af_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b4990840-cc3c-40a7-9119-b2ce07ca507e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_227a12eb-e338-45e7-b656-bcaa6af7d019_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets and liabilities that are measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_997a7768-f763-475e-a7bd-d0ba005f2292_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Maturities Of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8f2081a0-d74d-4583-b674-15c2950ba625_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_f2b96f5b-7c3f-429f-9bab-78be1bca20a9_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember_c7a90410-d4b8-4e53-8d54-68a67cee9368_terseLabel_en-US" xlink:label="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former President and Chief Executive Officer</link:label>
    <link:label id="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former President and Chief Executive Officer [Member]</link:label>
    <link:label id="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former President and Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:href="ino-20231231.xsd#ino_FormerPresidentAndChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:to="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_67b7f253-c9b8-4d01-8a72-6f521961dde7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SalesAgreementMember_ec99e74e-8a7c-4256-9957-b319f6fd9733_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Agreement</link:label>
    <link:label id="lab_ino_SalesAgreementMember_label_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember" xlink:href="ino-20231231.xsd#ino_SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementMember" xlink:to="lab_ino_SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0826790c-f438-48be-9624-da6b98f77374_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_d7dd9540-2d78-4713-92b8-c286b82ad530_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_f256e4bc-278f-4ec2-842c-575a527c50a1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3449f2b0-2e83-4949-8c8d-cce507105600_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts accrued for purchases of fixed assets</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_777ca7e3-3711-4819-833a-b3825cb80448_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reserved number of shares under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AllOtherCustomersMember_0495e4c8-d410-4594-b37e-ecf83dbfd324_terseLabel_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other, including affiliated entities</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_label_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_documentation_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember" xlink:href="ino-20231231.xsd#ino_AllOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AllOtherCustomersMember" xlink:to="lab_ino_AllOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_86f1851d-8376-4494-b679-95c3c45a64d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_b528eaaf-27c7-40bf-ae08-1427e0262f08_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_b7596bc2-c3ec-4cf9-bbf5-a69ce37bc997_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ed4fbca7-5361-4cf1-9817-01f487fb954f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_c4beac12-6dd3-4422-8b0a-1507a7cccdb7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e69a5fd7-fd29-4262-9ea9-d8c4988658d1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_9e047a3f-d679-4a68-a2d4-33e8b951dccf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fb97f964-7556-49b4-9608-747c7dcab06c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ab78b3c0-f198-4347-99e6-ad0732e4c2b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_8ac5aad3-3c54-4002-8bcc-d8f00af4a048_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_63145a0f-1123-48d9-85c0-10118668bffb_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e2dbcd3c-52e7-4470-94e7-09d7ec342b10_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_8e27468f-7505-45f9-9c72-8ebd48e7f2ee_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_27b39377-c609-429d-816a-8cb6acec0f5d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0adb0f16-edf6-4483-8a26-d9b6821888bc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f0b5af1c-67da-4406-9a81-722a36168451_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_20265c12-b831-49fd-9799-a43dcc92064b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_0e48d6bc-2a75-4eae-976f-b0a813aa7a7d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Preferred Stock Authorized, Issued And Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2c63dfaa-c45b-49be-b2e4-0e13dc381ef3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0e89ee33-c9c2-48cb-89cb-4ed945ed5ff2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_3ae8ec1b-9d93-4b30-9d58-2b04d4e84b90_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_801a63b7-023a-4519-a070-59043424b761_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_281522c7-c780-4487-9c0b-ee6278962df6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_f0c2aba2-b05b-4963-bdc8-7c23cc4e8a66_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investment in affiliated entity</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_807be1f9-84ae-4c54-9952-7cec375bff71_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on equity investment in affiliated entity</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:href="ino-20231231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_8fa41f1c-d290-42df-8d93-23d19700a795_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_c1e295d2-c1db-4d1d-8da6-91f5446bd244_terseLabel_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</link:label>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_label_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim [Member]</link:label>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_documentation_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:href="ino-20231231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:to="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_87320844-0e48-4003-b146-6df1d46e848e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8e98b67a-c073-4c82-a5c8-e8bd191e4a86_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_448b36e1-6aa4-45d5-8316-f8a527017d53_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer matching contribution, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ad593957-f430-4b5f-a983-38fd64648a68_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_09586774-79d7-4c7b-9a79-b80b47c2603e_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences, Inc. (affiliated entity)</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences, Inc. [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember" xlink:href="ino-20231231.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesIncMember" xlink:to="lab_ino_PlumblineLifeSciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_580b5b95-f3cc-4b7d-b78b-0be7239a3668_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_74d07952-c465-4478-a575-728b183bd823_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_d6cbfa89-b6f4-45ec-b7dd-79a0821f2fb2_terseLabel_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Agents will be entitled to compensation</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_label_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_documentation_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:href="ino-20231231.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:to="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_14727475-6b4b-4def-920a-11e4029fad5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_3f257dc8-3351-444b-80ce-2464888ff59c_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_f4415838-9647-4564-ab31-cd8af8ec37d7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_8bcb79b8-cfa4-4cb4-9a51-c7742ec4d89a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d6da39e2-5085-42f7-bc91-8bd4ebd102f3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_67ff042c-20ee-4407-bc9e-c158cfe1e026_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_fcb1dee1-a4ec-4b91-8e9c-497c2cf58cbc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_5df46414-f43b-439b-ad35-c4c262c7a479_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5c1dcec4-e5a7-4248-bbd8-6408b16340bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7eb78f66-f5cc-4bf4-bf18-0f7ca151b433_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_c98c4b7b-1291-458d-ad8f-ca5da6842387_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b7639da3-252f-4cc4-8152-0e301abb526f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_305e461b-83bf-4ff7-8d2a-317003139bc2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_1b2a6289-faae-4b67-9f53-e4cb55d4bee5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_a126252b-4299-4a49-9d22-ad160c51558a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_ec1ee551-d5c4-4cc3-9708-9288f50920ec_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_fc5bec2f-7d2a-44bb-81e1-623efded0ea5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ef86e82d-5a6c-4440-b951-4d7fa69344d9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, net of financing costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_c1ef560c-1d1c-4d66-a8be-2d1c3ad07439_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, gross</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_bb35fad8-ccbe-44f5-ac7b-796049713663_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$39.01-$52.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Three [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesThreeMember" xlink:to="lab_ino_RangeOfExercisePricesThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ec959cc1-264c-4d01-bf66-14fa7149c5a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9547d281-20ea-40db-953e-d44c64137739_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_014e61cb-12a8-4ce8-9cc9-29210def432c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit from income taxes at statutory rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_5092660a-6b82-4337-9366-f6089429f325_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_2c976ab5-35ff-4ec4-b9e8-3349a1c4fcb2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_21999e4e-3b62-4570-8242-7ca91cbda758_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Eligible Item or Group for Fair Value Option [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_b2be7ca9-0c1c-4fee-baaa-6aca8534a313_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_18eab64f-7847-43c7-b140-4b75e5e9cfe5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_49b4427a-13f7-4117-b1e2-1abb6c12bce7_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5fc0e1e3-00a4-49f2-a024-7285cc17c095_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5b1394fb-1d35-44d6-98df-2fd294d35104_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6be8ad5a-c0a2-461b-9530-65e14c660149_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_de639651-cb32-42e0-8d69-3934278b54f7_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_02df6194-aea7-4691-b8b1-779c3e6530ae_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a3f29bc5-369a-4e18-8a95-590e30865fdb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_1634724a-c31e-4e30-92cc-70f6ff5be95f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a1aeff4e-bd1f-476b-ba72-03c8e9337ac9_netLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_cc55472c-ae14-4376-a9ec-2f9978a66f3e_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_84c28195-3351-421c-975d-a5fdce57e810_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4bd1a9ec-65dd-4996-8d7c-96f3fad70d8f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ce358606-5018-4633-b3bf-5a1f7798dd0d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_51d7f89f-a588-4f43-b541-75f8cc4ed8b3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_29c2d0e9-9b67-4b49-a67b-3015e278a0d4_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_5cd3f31b-11c6-4a6b-bd83-04f156151ca7_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f536de1-0c2a-465c-993c-acc190baa32b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_dc6d15e8-d4b0-4130-b971-7f5cadc62cce_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_781ccf0a-da36-4644-843b-56299fa1b56f_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_3633e90c-f113-469f-85e6-8ad8e6de72db_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b80ac772-2d83-47fb-b57b-b5b2dbacbabf_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_13ea99b1-9400-4bd0-822d-62813fcfbabb_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member" xlink:href="ino-20231231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member" xlink:to="lab_ino_GeneosTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0c20d8ea-0488-43bc-9ade-6aca03afb79e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_653931ef-714c-4ab6-b7c9-dfb446cc2cdd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ecd11ea-c36c-4b44-a277-42f07f4be6a2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_32023f07-3b9f-4130-a906-2e2bba9a7157_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_34d21f1c-2652-4b29-8e6e-582bc2f5e6bd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company's contribution to 401(k) plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_2012c9df-e320-428a-887e-3c30d45a6ca3_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_4f4fb6bc-e40d-4529-918f-90e62b1d6e0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8ad5b59b-89ad-435b-9e33-0f5b690ea65a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_c1fbfcad-cc63-4d47-a555-2959317d1aab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9d532e85-766f-43a5-a604-03c7635c8123_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_310262d5-7e19-4edc-821a-8a3a56bade91_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2023 and 2022, issued and outstanding: 22,793,075 at December 31, 2023 and 21,090,938 at December 31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_56a84add-310b-4289-8790-2a52c19d2fbd_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:href="ino-20231231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c122c590-3ce2-4b03-8c57-06d46a614564_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_43395ea1-e4c4-437f-a250-35d06a89ce2c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_2bb85e29-350b-41c6-9ed2-c880c565cd47_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_89d054ff-30cf-4ded-a5de-2d51651d0649_terseLabel_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_label_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_documentation_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember" xlink:href="ino-20231231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoCaliforniaMember" xlink:to="lab_ino_SanDiegoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_472e29d8-ec3f-4b42-8a5c-648e1dba334d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7870e5c7-cb5f-4790-b044-b8300567dd3f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2022InducementPlanMember_e7f9e9b6-756c-4e60-8a98-943ad0282db5_terseLabel_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:label id="lab_ino_A2022InducementPlanMember_label_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan [Member]</link:label>
    <link:label id="lab_ino_A2022InducementPlanMember_documentation_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember" xlink:href="ino-20231231.xsd#ino_A2022InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2022InducementPlanMember" xlink:to="lab_ino_A2022InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_02272126-1322-4e70-b0a3-534dfdc55600_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_219649e1-5e99-4795-a4a1-5bb16fc85fa6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0882c330-f624-4b1c-8f8a-9b19756654af_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_efb5aceb-8a4d-47f0-be7d-c30465239672_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability, including from affiliated entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:href="ino-20231231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e0a24500-0de3-4e90-8ca0-7ab1b3a5e9e4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6c8adc07-9218-476d-b919-901ed1b71986_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c4c50d75-62ce-4e11-8e60-3fbe52e82751_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_d1fdd3fb-7034-4ca1-9677-a26c1dddb067_terseLabel_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Table]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_label_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Table]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_documentation_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable" xlink:href="ino-20231231.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable" xlink:to="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_382cb552-0c7c-4e66-bc34-fa74d4ab20b8_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ed0b9331-5ada-4bf7-9f64-2ebb143dbaff_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_252b77ed-698b-45ed-a1e3-9e3c05ccfd76_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_251979e0-ddf4-4874-b343-8f53e6b58f83_terseLabel_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_label_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation, Statute Limitations</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_documentation_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation, Statute Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations" xlink:href="ino-20231231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeTaxReconciliationStatuteLimitations" xlink:to="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_945c9208-8328-4b84-83e3-658108549eb9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_45bca5f6-1c4e-4789-801b-f86cb7d9db75_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended_5ad83dd4-e423-4df8-90b7-9a6bea842e01_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area under lease amended</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease, Amended</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease, Amended</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended" xlink:to="lab_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_b3c01cbe-4d94-4a35-a5c1-b0b1d4cd0081_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f4a8b17b-01cc-402f-b0a1-75a3e66d790f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_a7882224-51aa-4de1-a3aa-2caecce79179_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, area of land under lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_84a5ff30-9c0e-4816-b146-302f479c0ff0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_fd066637-34e8-4e61-820c-f2318b43ad76_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_076588ea-3e16-47c2-8476-02ca19188bf7_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_4190c136-f770-4634-aae2-4f4865a10e0e_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount paid to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_46151a04-482e-4fd4-9306-bd3c0630fb26_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt interest based on the fixed rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e497e536-0d3a-4f52-9313-b9942aff245d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ec3edee3-ed43-48fc-9831-533881cde6d5_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_4f390b7e-ecdb-4d08-80f0-10b41b8cebf0_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_label_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement , Revenue from the Procurement Contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement , Revenue from the Procurement Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:href="ino-20231231.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:to="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7bcf9d33-c186-4c11-af34-f096de17179b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_cc985c2d-8ac7-4918-98c1-fdc3c3a64f81_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_05ba79ab-ff82-4f66-a143-394bcf1db295_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a8b20144-b0b3-42ca-8a89-c4a8f5ee55ea_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_fc442b9b-5698-4e71-b7c0-13f9c2095d3b_negatedTerseLabel_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="ino-20231231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5c4e6708-439a-40c2-9f34-ac35a7827a1e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ee6ccb2-4dae-4bfd-9570-89c51c21b896_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_86c9a378-fb08-4adb-8877-a48b60644009_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_5a0cc74d-d5e3-42ca-89a8-e15628a83d86_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price, procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_label_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:href="ino-20231231.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:to="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_98c17a29-b88e-42fd-88d5-1bde8b7e8961_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8a5bb607-594a-4073-bc71-c0929a435e08_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a670d332-5d64-4eeb-8577-d5e51ce288c3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_a3e87583-9d10-4618-b5c9-cf5f1cccffa3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_75cc1238-349d-421f-89cc-91fc74309387_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock/senior notes to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_82fa7d19-a309-45db-8c5c-7fcc71bc22b6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Unobservable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_6ccf4a88-5768-4549-9468-4990b5cf0fc6_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$4.32-$18.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices One [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesOneMember" xlink:to="lab_ino_RangeOfExercisePricesOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_14e39fa3-c9d5-4c3a-8908-a01a0416d1c9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_886e5af1-0e31-49ae-b8a9-bc9d38235b77_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sale agreement, aggregate proceeds from issuance of stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:href="ino-20231231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de808f24-7bb0-4901-88e8-64fb30cea07f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e969d815-9a3c-4a54-bfc3-992aa9f58674_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c4567a4d-997b-4c21-a71d-c0968fe1baed_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_1f276226-9691-4807-ac5f-22cf1d181919_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">C E L L E C T R A3 P S P Proprietary Smart Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">C E L L E C T R A3 P S P Proprietary Smart Device</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:href="ino-20231231.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:to="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3928dc75-2794-4918-832b-cb50b9c465c0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0cef287b-311a-49c5-99a3-ff1ffb7adec5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8e2747d9-dec1-4c9f-8338-4a8f4c2f28ac_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4a004978-8ad5-4fe8-8c0c-695f0f781fd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_821638d0-14ed-4b35-8f57-ec8cf46cddff_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Useful Life (Yrs)</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_c67119f5-f2d0-4878-bbe2-1f9a08737f17_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f376f028-1b6e-44ce-b945-4b236fbe3b92_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_2c9f79b4-d691-437d-b6ed-43aa13241801_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_32a8fe69-952b-4d6b-abb8-8199bda77aa9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_ced2d962-71c1-4a17-bba9-cfa64ca428a3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_ec5c6ea6-b87b-4121-a09d-382d1f3a52e7_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_aa910953-0204-4a6f-89b6-6dc46cedf495_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, lower range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5eba3872-dfd7-404f-8155-eebe8ad040d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2288a42b-88c8-4f50-bd3a-9b441976c3f3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7de037ff-ebb4-4e7c-8b48-7e1915cb5d14_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_26250f01-6cf4-422f-90f5-6a0345b7812b_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d641c270-54b0-41b0-ad03-aa91799a181d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c7efb480-48c5-4262-a2d8-de5428aca7c1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ea9422a7-6155-44cd-be16-a517f616c3e1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_b4a322b5-4a3c-4213-9848-75080195ee4d_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bb71e9b8-726c-45e1-9f4a-e417c881029f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_05106092-ebb0-434a-a188-9160b54d8dac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_0d1eaf44-43ad-4c51-b422-53b62dd7daf5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_ba4a706f-2852-4983-8342-96951a0c56d6_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:href="ino-20231231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2753cbce-4961-4593-aff2-0e777676b3d5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_2e321de2-0673-4baf-9692-7f9699f4caa1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_b6186339-6716-44f8-9513-2620be41b03f_terseLabel_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid manufacturing expenses</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_label_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Manufacturing Expenses, Current</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_documentation_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Manufacturing Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent" xlink:href="ino-20231231.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidManufacturingExpensesCurrent" xlink:to="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment_e9cd8392-9fd9-4ee5-a57b-0501db6bc052_negatedTerseLabel_en-US" xlink:label="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on remeasurement of investment in Geneos</link:label>
    <link:label id="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment_label_en-US" xlink:label="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Remeasurement Of Equity Method Investment</link:label>
    <link:label id="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment_documentation_en-US" xlink:label="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Remeasurement Of Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:href="ino-20231231.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:to="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_95330028-81e5-4ba7-bbf1-5b4d08a2703d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d180af93-93d8-4c49-bdae-4e27cd693c83_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_025b5387-af20-4dd5-a89c-ef500945f236_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair&#160;Market&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a81d0d13-b820-498b-b1f4-8ae1eb87519a_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3db2251d-fc02-45ee-b050-c48dfb0926a0_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross&#160;Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_3a86de91-9bc2-45a3-ac95-d1641190e8a8_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc7838da-2bfe-4fe9-9943-2e5dad6b5ae6_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_b2709eb2-7246-43e8-a1b3-c9916b5a482d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_571703d5-6591-4b34-af2a-e0c698b66c4e_verboseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_19b6fffe-920c-4769-9692-347a2abfadb1_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2023IncentivePlanMember_8cfafbd4-be24-473a-9826-5fc819b74adb_terseLabel_en-US" xlink:label="lab_ino_A2023IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Incentive Plan</link:label>
    <link:label id="lab_ino_A2023IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2023IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2023IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2023IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2023IncentivePlanMember" xlink:href="ino-20231231.xsd#ino_A2023IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2023IncentivePlanMember" xlink:to="lab_ino_A2023IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_3e5d5938-43a1-4783-bc3d-6f7777b469c5_verboseLabel_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20231231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_59c1c3a6-64b8-447b-b580-60d166fd5648_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement amended amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAmendedAmount" xlink:to="lab_ino_CollaborativeAgreementAmendedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3ec4e601-7a96-4138-a06d-864825b8bb6b_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3b7f7cab-038f-4d05-b526-54442f5f41de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_8a089663-bed2-4e41-94d7-22864bf7f7b5_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_2b67519a-7571-46a3-b548-f089120473df_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funding received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingReceived" xlink:to="lab_ino_CollaborativeAgreementFundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_5f2a90d6-552c-411e-a7be-a2cf021a7a26_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_95cd1ef0-f945-49ba-8f33-0bf01ac374ee_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b416a7c6-4dac-4bb1-b968-8f29a44e3838_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementTerm_16da0bf8-9bf5-4825-ba38-8bf2a9dc0c26_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm" xlink:href="ino-20231231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm" xlink:to="lab_ino_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a4fb444e-965b-4c18-87f5-64e57d962716_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_34427be3-d782-4716-a8cf-807bba2204bd_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of common stock shares outstanding under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2dd5b513-3d07-4c8c-b0eb-5a8bdbf294f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_790c057a-6ab8-4247-a4a1-07c7fb6565f7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_99e841f5-211b-47db-883c-1bd2fbf1d65e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_f19f060c-423a-4cbd-9959-fc602de2b6e8_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Definite lived:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_d21312c1-8010-4fb2-b009-43a897ab2e4b_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_294ab974-6886-432d-a209-f3195057ea43_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AuditInformationAbstract_label_en-US" xlink:label="lab_ino_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ino_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ino_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AuditInformationAbstract" xlink:href="ino-20231231.xsd#ino_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AuditInformationAbstract" xlink:to="lab_ino_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1ddf93eb-e6a2-4cfb-aa4f-603f7bbee3a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_36067554-3093-455e-ae97-103f12436a38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d0793ce9-36d2-4a35-8c08-62a954690570_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_fcb30930-ec76-4715-99f2-9314d5c3d364_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_473408c3-5365-4fcd-a684-7fc7e8c631ae_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_38bcb08b-b4df-4853-a5b8-a07b53018365_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_a58a555b-ebc9-4c0b-b88e-c4552962926f_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_be6d4184-e16d-4ad8-9048-65cbe09178db_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, net of financing costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_ca89f317-2638-4030-8bb2-a3d1662ddf7a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6b07639-0816-4a8c-829f-4ebb34f0efa2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative arrangements and other contracts, including affiliated entity</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d2f2121e-c4f5-4e90-8eab-0a5417e27610_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f7cea78d-8dfd-413d-bc78-cf9d878bf9d5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3962e73e-258a-4dd8-b2b6-3edf2af74a5e_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_4e1b31df-4754-48d1-a4f3-e470f4f9b323_terseLabel_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_label_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_documentation_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:href="ino-20231231.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:to="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9b798321-ec97-4e1c-b872-07013bc7d57f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_114294d6-7eca-40db-8cf3-56ed152d84ef_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b46dad1e-1bd9-476b-aa17-a6985cc7fef0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6d505b14-7f25-49f1-aa88-9d2162d165f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for legal settlement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_19bafa39-5237-4f28-9302-07cd47611604_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_7d61a95a-bcbe-4569-ae67-c03346cd0f11_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_fbc594c0-02e3-46c8-a410-47f55cc878a3_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Four Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_14996212-1307-4885-83e1-f47865a95198_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_de341e96-995a-4279-a20f-bde0dd83fe2f_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_bfc2a5d9-b673-4a99-8eea-6966c28056e9_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:href="ino-20231231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale_28a8ab43-6ef8-43b0-b779-8b41080396ff_terseLabel_en-US" xlink:label="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment sold</link:label>
    <link:label id="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale_label_en-US" xlink:label="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Disposed Of By Sale</link:label>
    <link:label id="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale_documentation_en-US" xlink:label="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Disposed Of By Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PropertyPlantAndEquipmentDisposedOfBySale" xlink:href="ino-20231231.xsd#ino_PropertyPlantAndEquipmentDisposedOfBySale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PropertyPlantAndEquipmentDisposedOfBySale" xlink:to="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_304a5935-378b-4648-8fa1-50d1779906b3_terseLabel_en-US" xlink:label="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in prepaid expenses and other current assets related to fixed assets</link:label>
    <link:label id="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_label_en-US" xlink:label="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Prepaid Expenses And Other Current Assets, Fixed Assets</link:label>
    <link:label id="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_documentation_en-US" xlink:label="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Prepaid Expenses And Other Current Assets, Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:href="ino-20231231.xsd#ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:to="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7bfd67dd-801b-4047-8833-4750d566bf4d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_752239a5-96e8-427f-b26e-67bbb8816b2b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c7b45285-d787-47cf-b3d6-531dde70b671_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_91021737-6947-4c47-a6cd-bd9cd72db023_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual life (in Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_d9b04389-33a4-44f2-b2d5-6eee33cb02af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b7a792f4-3dcd-40f5-a7eb-72be80566c04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, expirations in period, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_fcb82f60-ad2f-4657-95b1-b34d27067c83_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:href="ino-20231231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2def5171-300e-4e49-a197-0ee8d3d35655_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2016IncentivePlanMember_336e269c-006b-4241-a95f-51f05072fa93_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember" xlink:href="ino-20231231.xsd#ino_A2016IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember" xlink:to="lab_ino_A2016IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2e66b75f-9e08-406a-8f20-095400a9e0e9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_3a585888-6ebf-4f51-bcdb-cb36c97a3f3a_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligation period to pay royalties</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:href="ino-20231231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_8a6a0418-ad9a-4d91-addb-7eea28edf3b8_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember" xlink:href="ino-20231231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember" xlink:to="lab_ino_PlumblineLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_a2fb9ae4-1dac-464f-b680-48823f888dec_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards settled in cash, percentage</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:href="ino-20231231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfLeasesAmended_e35cae34-090c-4f86-bde7-9a362f284888_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfLeasesAmended" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of leases amended</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfLeasesAmended_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfLeasesAmended" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Leases, Amended</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfLeasesAmended_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfLeasesAmended" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Leases, Amended</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfLeasesAmended" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseNumberOfLeasesAmended"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseNumberOfLeasesAmended" xlink:to="lab_ino_LesseeOperatingLeaseNumberOfLeasesAmended" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90ed19f7-4b2c-4b32-b3d0-0621f6aa76bf_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d721a1c7-30cd-42ff-a0ff-c04d426ff354_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_0c272250-8f81-4b66-b37d-d2b5de71e197_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase of base rent percentage</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:to="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_871c5fe3-ce42-435f-ae79-c4a95e1cb254_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible asset impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_1ad96bdd-e8f6-4e2b-a5c8-929a48754140_terseLabel_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Operating Loss And Tax Credit Carryforward Expirations</link:label>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:href="ino-20231231.xsd#ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:to="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c8c59177-edd9-427d-b1ef-152bdaee582f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_65918de9-97a4-404a-9c99-37a3b2e773f7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_365e580f-c510-43ab-9d16-28b350782dc9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1a51d7ec-7bac-431f-ac70-c95f304363f2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_e837849e-2c0b-4e3d-b0b8-fe29ad17e4aa_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_c64ae4e4-6267-4b26-80bd-95fa6922ce92_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_d0d5da0b-943c-4ce7-96e2-2ed632320ecb_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_59d9c7ad-b576-4f6b-9c09-172e900621ce_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of unvested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_b84dc217-0191-4247-8f23-b0b4fbfef45d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expirations of Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_21624196-d591-4ca6-89c9-cef750dde690_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0cdbb12a-2966-4a1b-b2f0-99c7ad3a355d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock/senior notes to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_ad392cfc-aba0-424b-9990-1c31bf44ff89_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Agreements To Sublease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Agreements To Sublease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:to="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6c90aa30-c4be-4874-aa8f-c9e44e606089_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7dbb0617-0714-4d66-9a87-745d803d1a88_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_bd012c04-eec5-4c0f-9bff-c20a8fd031c7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>ino-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b4fcd846-7e1f-480b-911d-4744cd39f89e,g:4f8a585f-cb3c-4f96-86ae-b643b290a1f2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d0dab36a-0b64-40fa-9f6a-8ebb767a0c06" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_DocumentType_d0dab36a-0b64-40fa-9f6a-8ebb767a0c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_5202d373-a396-4310-a900-3547344aa3a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_DocumentAnnualReport_5202d373-a396-4310-a900-3547344aa3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d4ec04c8-fdb7-4d8b-a53b-5805b61a14e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_DocumentPeriodEndDate_d4ec04c8-fdb7-4d8b-a53b-5805b61a14e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_bb975a24-cb8e-4a09-90fd-a13ce13b3b5d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_CurrentFiscalYearEndDate_bb975a24-cb8e-4a09-90fd-a13ce13b3b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7164401e-62d4-43dd-b362-e6ee4d196f98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_DocumentTransitionReport_7164401e-62d4-43dd-b362-e6ee4d196f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f9851ff3-23ea-49e5-9469-5b89e4b0b596" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityFileNumber_f9851ff3-23ea-49e5-9469-5b89e4b0b596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_660a3d14-9347-4cd6-9a65-9410d053832a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityRegistrantName_660a3d14-9347-4cd6-9a65-9410d053832a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_706dc4ba-1ff9-421b-b074-2f2bf211242a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityIncorporationStateCountryCode_706dc4ba-1ff9-421b-b074-2f2bf211242a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_457e20fb-ad0f-4192-90e0-4c383f6766e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityTaxIdentificationNumber_457e20fb-ad0f-4192-90e0-4c383f6766e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_648068f0-8a03-4414-80e5-b925ffd3a6aa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityAddressAddressLine1_648068f0-8a03-4414-80e5-b925ffd3a6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_10784a07-48a3-4a38-91f3-89a23b85ce78" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityAddressAddressLine2_10784a07-48a3-4a38-91f3-89a23b85ce78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6b917fe8-e3df-4ade-89fe-ae6d3a948884" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityAddressCityOrTown_6b917fe8-e3df-4ade-89fe-ae6d3a948884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_48a86978-fc34-4610-a6af-f90d40dc3d08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityAddressStateOrProvince_48a86978-fc34-4610-a6af-f90d40dc3d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bf056368-3f36-4d17-b50e-a24a98f1d5f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityAddressPostalZipCode_bf056368-3f36-4d17-b50e-a24a98f1d5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e60a16d8-b226-4204-af7f-1442e7b22793" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_CityAreaCode_e60a16d8-b226-4204-af7f-1442e7b22793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f991fb12-0e20-440a-bd4d-86854aeb3b1a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_LocalPhoneNumber_f991fb12-0e20-440a-bd4d-86854aeb3b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6f21a317-3e9e-4420-b140-15ce2bb16e27" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_Security12bTitle_6f21a317-3e9e-4420-b140-15ce2bb16e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6ee68b9b-e25e-427b-b25c-39106c1f89ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_TradingSymbol_6ee68b9b-e25e-427b-b25c-39106c1f89ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2fc04321-3d6f-455c-ad6a-8d3bf18e5b6d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_SecurityExchangeName_2fc04321-3d6f-455c-ad6a-8d3bf18e5b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_eda5a0d6-9b75-417e-a28a-fabf0ba11939" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_eda5a0d6-9b75-417e-a28a-fabf0ba11939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_a776683d-3303-438c-9307-f1b5ec8d3973" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityVoluntaryFilers_a776683d-3303-438c-9307-f1b5ec8d3973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ddc91d83-36cd-4936-bf1c-bce88a1b3469" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityCurrentReportingStatus_ddc91d83-36cd-4936-bf1c-bce88a1b3469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_47ab40aa-a151-4134-bdf2-6ce09dfe0a61" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityInteractiveDataCurrent_47ab40aa-a151-4134-bdf2-6ce09dfe0a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d2bc5e97-8f0a-4f00-866d-0c7f81db295f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityFilerCategory_d2bc5e97-8f0a-4f00-866d-0c7f81db295f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8e917db3-6e23-4dd6-bc57-a01a47ba39ee" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntitySmallBusiness_8e917db3-6e23-4dd6-bc57-a01a47ba39ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_82d02b1a-9e7f-4f25-b728-68d31febab1f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityEmergingGrowthCompany_82d02b1a-9e7f-4f25-b728-68d31febab1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_2c908533-599a-4bd0-86c8-0937eb53f1ad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_IcfrAuditorAttestationFlag_2c908533-599a-4bd0-86c8-0937eb53f1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_726fdf89-7559-49ab-bf4d-cce96ae039da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_726fdf89-7559-49ab-bf4d-cce96ae039da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_14ecccca-eaa8-47fc-88ff-43e35639c232" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityShellCompany_14ecccca-eaa8-47fc-88ff-43e35639c232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_c3fe0ff5-159b-4f81-bc92-42ab483519c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityPublicFloat_c3fe0ff5-159b-4f81-bc92-42ab483519c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_11047a6e-d399-4345-b5d1-840040042a9a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_11047a6e-d399-4345-b5d1-840040042a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_34164d2d-a189-4ccd-a6e1-1652ed0281d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_34164d2d-a189-4ccd-a6e1-1652ed0281d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4a73ad09-07a2-4e28-9939-25e68bac2167" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_AmendmentFlag_4a73ad09-07a2-4e28-9939-25e68bac2167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b0de5a30-6aea-460a-b453-676ec5204b79" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_DocumentFiscalYearFocus_b0de5a30-6aea-460a-b453-676ec5204b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bdb9b516-6f4e-4579-b93a-45459d96940f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bdb9b516-6f4e-4579-b93a-45459d96940f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_86736f96-085e-4a53-867a-7d2597c6d0ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0d73ccf5-b188-4031-9ef7-bc487a9e3486" xlink:to="loc_dei_EntityCentralIndexKey_86736f96-085e-4a53-867a-7d2597c6d0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AuditInformation" xlink:type="simple" xlink:href="ino-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_AuditInformationAbstract_d3036666-9d20-4661-96b8-68a79061ebb5" xlink:href="ino-20231231.xsd#ino_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_f0f119d4-f435-4fcd-8d8f-7a93b48371c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AuditInformationAbstract_d3036666-9d20-4661-96b8-68a79061ebb5" xlink:to="loc_dei_AuditorLocation_f0f119d4-f435-4fcd-8d8f-7a93b48371c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_42b0a822-dc7a-44b1-8b1e-52f6ea3076a9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AuditInformationAbstract_d3036666-9d20-4661-96b8-68a79061ebb5" xlink:to="loc_dei_AuditorName_42b0a822-dc7a-44b1-8b1e-52f6ea3076a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_1527fd0a-679a-480e-bd82-db8a19d4296c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AuditInformationAbstract_d3036666-9d20-4661-96b8-68a79061ebb5" xlink:to="loc_dei_AuditorFirmId_1527fd0a-679a-480e-bd82-db8a19d4296c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_79dc9439-cd21-487e-97eb-34580037bc67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c3adfda6-bfe2-4c3b-90d9-64b1c34cf5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79dc9439-cd21-487e-97eb-34580037bc67" xlink:to="loc_us-gaap_StatementTable_c3adfda6-bfe2-4c3b-90d9-64b1c34cf5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d9b407f-9302-400b-9afb-81cdd0b20b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c3adfda6-bfe2-4c3b-90d9-64b1c34cf5a7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d9b407f-9302-400b-9afb-81cdd0b20b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a08bba1a-aad3-44a4-9e3c-2913cd965481" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d9b407f-9302-400b-9afb-81cdd0b20b9b" xlink:to="loc_us-gaap_RelatedPartyDomain_a08bba1a-aad3-44a4-9e3c-2913cd965481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_e2b49688-f4a5-477d-9b6b-0ed1a0b44f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a08bba1a-aad3-44a4-9e3c-2913cd965481" xlink:to="loc_us-gaap_NonrelatedPartyMember_e2b49688-f4a5-477d-9b6b-0ed1a0b44f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_73637f10-8100-42fa-9100-e6c47639722e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a08bba1a-aad3-44a4-9e3c-2913cd965481" xlink:to="loc_us-gaap_RelatedPartyMember_73637f10-8100-42fa-9100-e6c47639722e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0b0564cb-5c13-4bb6-a5b2-337c6d45af67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c3adfda6-bfe2-4c3b-90d9-64b1c34cf5a7" xlink:to="loc_us-gaap_StatementLineItems_0b0564cb-5c13-4bb6-a5b2-337c6d45af67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0b0564cb-5c13-4bb6-a5b2-337c6d45af67" xlink:to="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8ff1d3a-d784-40a5-9ccd-f27539540103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8ff1d3a-d784-40a5-9ccd-f27539540103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_200e3213-52cc-4034-8f81-84fa1e412a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:to="loc_us-gaap_ShortTermInvestments_200e3213-52cc-4034-8f81-84fa1e412a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1cd3bb72-1ea1-4548-b608-b1f1985b679b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1cd3bb72-1ea1-4548-b608-b1f1985b679b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c39d738a-d3f7-448e-8db5-176818094df8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c39d738a-d3f7-448e-8db5-176818094df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_b3d820bb-1dad-4525-b793-8de51f7f44dc" xlink:href="ino-20231231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_b3d820bb-1dad-4525-b793-8de51f7f44dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cde72f21-bc08-4a1a-8c64-0130b8b61601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f566ac9e-03e2-48f1-9500-6a3795f85a67" xlink:to="loc_us-gaap_AssetsCurrent_cde72f21-bc08-4a1a-8c64-0130b8b61601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2d8adb22-0e20-4241-a70a-2bc7d0c9acf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2d8adb22-0e20-4241-a70a-2bc7d0c9acf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_1f00a2b4-5184-46c9-b529-1c9daa1b5422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_1f00a2b4-5184-46c9-b529-1c9daa1b5422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d53a076f-77b4-4455-a4e2-636f0b6a62ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d53a076f-77b4-4455-a4e2-636f0b6a62ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_35d21366-7422-44ae-b38e-d1e2927e48b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_Goodwill_35d21366-7422-44ae-b38e-d1e2927e48b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f3dc9ed1-c8d3-4f5b-a1be-007c59bf8991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f3dc9ed1-c8d3-4f5b-a1be-007c59bf8991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7b1b156b-05e7-4f9d-8be1-2c7081b02fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7b1b156b-05e7-4f9d-8be1-2c7081b02fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7bb684d6-02bb-4513-bda9-e694140aae99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac0a7aad-dd62-4ecd-88de-7a1fdf120474" xlink:to="loc_us-gaap_Assets_7bb684d6-02bb-4513-bda9-e694140aae99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0b0564cb-5c13-4bb6-a5b2-337c6d45af67" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f9ced94b-1250-41bb-b02b-34bf67a1c5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f9ced94b-1250-41bb-b02b-34bf67a1c5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_1c7264bf-ed99-48b1-a63a-b70f41ead4f7" xlink:href="ino-20231231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_1c7264bf-ed99-48b1-a63a-b70f41ead4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_82ad1672-d45f-42a3-b385-8f51d191f681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_82ad1672-d45f-42a3-b385-8f51d191f681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_e1114e43-d59f-4f18-b5bb-47fcf9909109" xlink:href="ino-20231231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_ino_DeferredGrantFundingCurrent_e1114e43-d59f-4f18-b5bb-47fcf9909109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4c0371e9-6446-4878-83e2-df84138908d7" xlink:href="ino-20231231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4c0371e9-6446-4878-83e2-df84138908d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_6aebe2a6-7155-4c9d-a8b9-66901cc48341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_6aebe2a6-7155-4c9d-a8b9-66901cc48341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7b20ef8b-6087-48ec-8e7c-f9e2cecb9187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40e0e486-f12c-455d-8722-bba31d7676c5" xlink:to="loc_us-gaap_LiabilitiesCurrent_7b20ef8b-6087-48ec-8e7c-f9e2cecb9187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_38bdd8db-12f5-42de-b4ff-29459e762e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_38bdd8db-12f5-42de-b4ff-29459e762e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_985be54c-98e5-49cb-bc64-a1f0dd7435fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_985be54c-98e5-49cb-bc64-a1f0dd7435fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6a73017a-cb8d-435e-8ed7-4b764d67dd87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6a73017a-cb8d-435e-8ed7-4b764d67dd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_eb19ec3a-2b16-41aa-aa85-e922e2bf597d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_Liabilities_eb19ec3a-2b16-41aa-aa85-e922e2bf597d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6c7b8786-16ed-4e9b-a1d3-8c2f38059507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6c7b8786-16ed-4e9b-a1d3-8c2f38059507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6fc2d67f-fb9a-4298-a059-c104cca972a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:to="loc_us-gaap_PreferredStockValue_6fc2d67f-fb9a-4298-a059-c104cca972a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2473eadd-64f6-4a08-ae32-d06c384ddf99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:to="loc_us-gaap_CommonStockValue_2473eadd-64f6-4a08-ae32-d06c384ddf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3c79a2fb-f5f5-401c-a444-706bd711e1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3c79a2fb-f5f5-401c-a444-706bd711e1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d6908a70-6c4d-4bd3-9c23-0428a6fb3afc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d6908a70-6c4d-4bd3-9c23-0428a6fb3afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9f122ee9-d6d9-4baf-8cc9-d399c0a078e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9f122ee9-d6d9-4baf-8cc9-d399c0a078e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d5a363d0-a020-42a5-8bea-36be3f6c5d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7280d531-89e4-4847-9a54-ffb6b6cbe158" xlink:to="loc_us-gaap_StockholdersEquity_d5a363d0-a020-42a5-8bea-36be3f6c5d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1970614b-24e1-4083-aeb2-13b709c5ecd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec075ad-a1c6-44d4-8a4a-783f0525f770" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1970614b-24e1-4083-aeb2-13b709c5ecd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2c730d8a-c474-410c-9dc9-835f9793663a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_56671e49-080a-413e-bb2c-83c95dfe6e75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2c730d8a-c474-410c-9dc9-835f9793663a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_56671e49-080a-413e-bb2c-83c95dfe6e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0d4285b9-9561-4436-a51b-7f18b7d23c58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2c730d8a-c474-410c-9dc9-835f9793663a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0d4285b9-9561-4436-a51b-7f18b7d23c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_41cd0e7f-53dd-4f2e-a16c-d028d1ef46b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2c730d8a-c474-410c-9dc9-835f9793663a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_41cd0e7f-53dd-4f2e-a16c-d028d1ef46b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_52f47bc2-99bc-434a-83c5-5424715807c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2c730d8a-c474-410c-9dc9-835f9793663a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_52f47bc2-99bc-434a-83c5-5424715807c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cfc1f9b6-a462-46a6-a8a2-c96f7e0f1bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2c730d8a-c474-410c-9dc9-835f9793663a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cfc1f9b6-a462-46a6-a8a2-c96f7e0f1bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fe4c2cd4-d228-4e73-ada6-68e0485b44b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2c730d8a-c474-410c-9dc9-835f9793663a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fe4c2cd4-d228-4e73-ada6-68e0485b44b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ae353380-86d8-4587-8815-afbdf63ff415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2c730d8a-c474-410c-9dc9-835f9793663a" xlink:to="loc_us-gaap_CommonStockSharesIssued_ae353380-86d8-4587-8815-afbdf63ff415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ea94020c-bb96-4dbf-add7-0202d7b187f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2c730d8a-c474-410c-9dc9-835f9793663a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ea94020c-bb96-4dbf-add7-0202d7b187f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3710d175-cc9e-4304-ad2e-d46f244af3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2c730d8a-c474-410c-9dc9-835f9793663a" xlink:to="loc_us-gaap_StatementTable_3710d175-cc9e-4304-ad2e-d46f244af3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_09c9fe06-3274-4c45-8104-ffa0610be15c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3710d175-cc9e-4304-ad2e-d46f244af3a7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_09c9fe06-3274-4c45-8104-ffa0610be15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1a352d45-9e41-45e1-a598-cc055e91b3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_09c9fe06-3274-4c45-8104-ffa0610be15c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1a352d45-9e41-45e1-a598-cc055e91b3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_841fa9d6-9e41-4cbb-80bc-d3b6979d1e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1a352d45-9e41-45e1-a598-cc055e91b3ae" xlink:to="loc_us-gaap_SubsequentEventMember_841fa9d6-9e41-4cbb-80bc-d3b6979d1e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fb4870bb-2318-4865-b881-821a374935fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3710d175-cc9e-4304-ad2e-d46f244af3a7" xlink:to="loc_us-gaap_StatementLineItems_fb4870bb-2318-4865-b881-821a374935fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3e32c3ed-706d-48f3-a4e5-13b9fd361d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fb4870bb-2318-4865-b881-821a374935fa" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3e32c3ed-706d-48f3-a4e5-13b9fd361d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6fc8da2a-a44d-4d4d-8e2e-d9d6ad888a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5a02ac7a-d870-41d1-984f-5f9a4be0f559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fc8da2a-a44d-4d4d-8e2e-d9d6ad888a18" xlink:to="loc_us-gaap_RevenuesAbstract_5a02ac7a-d870-41d1-984f-5f9a4be0f559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_449fde8e-d990-40a1-bc87-983a266d9155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5a02ac7a-d870-41d1-984f-5f9a4be0f559" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_449fde8e-d990-40a1-bc87-983a266d9155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_93fbbd86-7cd2-4295-b59a-bd8713867eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fc8da2a-a44d-4d4d-8e2e-d9d6ad888a18" xlink:to="loc_us-gaap_OperatingExpensesAbstract_93fbbd86-7cd2-4295-b59a-bd8713867eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_62f8d482-9fe7-4b92-a818-b7509e6ff4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_93fbbd86-7cd2-4295-b59a-bd8713867eb6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_62f8d482-9fe7-4b92-a818-b7509e6ff4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3b383924-be0e-4b20-b3e5-e9dd52b9cba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_93fbbd86-7cd2-4295-b59a-bd8713867eb6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3b383924-be0e-4b20-b3e5-e9dd52b9cba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d098d15e-d99c-4923-ace8-c030d4beaf38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_93fbbd86-7cd2-4295-b59a-bd8713867eb6" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d098d15e-d99c-4923-ace8-c030d4beaf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1bae721d-44bc-42a1-ad79-af6885f686a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_93fbbd86-7cd2-4295-b59a-bd8713867eb6" xlink:to="loc_us-gaap_OperatingExpenses_1bae721d-44bc-42a1-ad79-af6885f686a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_43634c0d-4764-475f-8483-c72995f3e244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fc8da2a-a44d-4d4d-8e2e-d9d6ad888a18" xlink:to="loc_us-gaap_OperatingIncomeLoss_43634c0d-4764-475f-8483-c72995f3e244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7e8deccf-7135-4001-8616-37817dfc9ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fc8da2a-a44d-4d4d-8e2e-d9d6ad888a18" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7e8deccf-7135-4001-8616-37817dfc9ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_d7c0a1e6-85ae-435b-8d15-28f0a0a45a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7e8deccf-7135-4001-8616-37817dfc9ab1" xlink:to="loc_us-gaap_InterestIncomeOperating_d7c0a1e6-85ae-435b-8d15-28f0a0a45a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b9805e8e-2846-4a76-8241-55d42bf2502a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7e8deccf-7135-4001-8616-37817dfc9ab1" xlink:to="loc_us-gaap_InterestExpense_b9805e8e-2846-4a76-8241-55d42bf2502a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0b5af3e6-4ec5-4bde-9afe-690ff8ce79ee" xlink:href="ino-20231231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7e8deccf-7135-4001-8616-37817dfc9ab1" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0b5af3e6-4ec5-4bde-9afe-690ff8ce79ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0c7b065e-c557-4f04-9c04-045e9a558387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7e8deccf-7135-4001-8616-37817dfc9ab1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0c7b065e-c557-4f04-9c04-045e9a558387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_00b6faa3-466e-43e9-8a75-c2a509fa27b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7e8deccf-7135-4001-8616-37817dfc9ab1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_00b6faa3-466e-43e9-8a75-c2a509fa27b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d7168c8b-22bb-4883-83de-02f9c42c7152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fc8da2a-a44d-4d4d-8e2e-d9d6ad888a18" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d7168c8b-22bb-4883-83de-02f9c42c7152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fe7803c4-4ca5-440f-955a-65069ccf6a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fc8da2a-a44d-4d4d-8e2e-d9d6ad888a18" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fe7803c4-4ca5-440f-955a-65069ccf6a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_649ebbfa-023c-4ed7-b136-576453d90c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fc8da2a-a44d-4d4d-8e2e-d9d6ad888a18" xlink:to="loc_us-gaap_NetIncomeLoss_649ebbfa-023c-4ed7-b136-576453d90c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cabbaca2-96bb-4313-992a-2757b5293d74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fc8da2a-a44d-4d4d-8e2e-d9d6ad888a18" xlink:to="loc_us-gaap_EarningsPerShareAbstract_cabbaca2-96bb-4313-992a-2757b5293d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b18cbea9-701f-4ca3-80a1-d02ca604747d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cabbaca2-96bb-4313-992a-2757b5293d74" xlink:to="loc_us-gaap_EarningsPerShareBasic_b18cbea9-701f-4ca3-80a1-d02ca604747d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5df28ef2-0f23-499a-8f62-c1e6f8b2c44d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cabbaca2-96bb-4313-992a-2757b5293d74" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5df28ef2-0f23-499a-8f62-c1e6f8b2c44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e9cb3c2a-e76f-4427-ac2e-6cb9cda26e10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fc8da2a-a44d-4d4d-8e2e-d9d6ad888a18" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e9cb3c2a-e76f-4427-ac2e-6cb9cda26e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6215d6ed-05dd-4df2-8c3a-31299130b351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e9cb3c2a-e76f-4427-ac2e-6cb9cda26e10" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6215d6ed-05dd-4df2-8c3a-31299130b351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_80454bec-ba4f-4981-aa61-766bf4340e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e9cb3c2a-e76f-4427-ac2e-6cb9cda26e10" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_80454bec-ba4f-4981-aa61-766bf4340e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedStatementsofOperationsParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_482d21a5-63e9-4d89-a30d-843109e5006d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ed4781e0-72e0-4634-9e75-213f4fb6f2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_482d21a5-63e9-4d89-a30d-843109e5006d" xlink:to="loc_us-gaap_StatementTable_ed4781e0-72e0-4634-9e75-213f4fb6f2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a322b629-cf00-483b-b8c2-e045e9842495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ed4781e0-72e0-4634-9e75-213f4fb6f2e8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a322b629-cf00-483b-b8c2-e045e9842495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80f4d591-c20a-4120-9084-bb7b08e11e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a322b629-cf00-483b-b8c2-e045e9842495" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_80f4d591-c20a-4120-9084-bb7b08e11e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f83e0bcd-9f61-4dd1-b0a8-3e3eb0043dda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_80f4d591-c20a-4120-9084-bb7b08e11e89" xlink:to="loc_us-gaap_SubsequentEventMember_f83e0bcd-9f61-4dd1-b0a8-3e3eb0043dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_14d3b701-d497-495a-a2a4-2c5d23d98984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ed4781e0-72e0-4634-9e75-213f4fb6f2e8" xlink:to="loc_us-gaap_StatementLineItems_14d3b701-d497-495a-a2a4-2c5d23d98984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f80c1ccd-4dda-4b2f-9ff3-604e384376da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_14d3b701-d497-495a-a2a4-2c5d23d98984" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f80c1ccd-4dda-4b2f-9ff3-604e384376da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2fd753d2-7758-49f7-b29c-da6151f8ce49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_71efc3db-74bc-479d-b2ea-35d6d17afc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2fd753d2-7758-49f7-b29c-da6151f8ce49" xlink:to="loc_us-gaap_NetIncomeLoss_71efc3db-74bc-479d-b2ea-35d6d17afc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f90551c2-adb7-4f88-9a15-e6a5d1264603" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2fd753d2-7758-49f7-b29c-da6151f8ce49" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f90551c2-adb7-4f88-9a15-e6a5d1264603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1881e7ee-694a-426e-b82d-1dae32315a73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f90551c2-adb7-4f88-9a15-e6a5d1264603" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1881e7ee-694a-426e-b82d-1dae32315a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fcbbecd9-39f2-45ca-a3f2-6ba21e5558d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f90551c2-adb7-4f88-9a15-e6a5d1264603" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fcbbecd9-39f2-45ca-a3f2-6ba21e5558d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0cb69ffb-ff75-4da4-bb20-24499b594781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2fd753d2-7758-49f7-b29c-da6151f8ce49" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0cb69ffb-ff75-4da4-bb20-24499b594781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7f51566f-b578-4874-9caa-4ae91584a61b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1a93a1d2-c062-4ee3-afdf-0f9728ea9a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7f51566f-b578-4874-9caa-4ae91584a61b" xlink:to="loc_us-gaap_StatementTable_1a93a1d2-c062-4ee3-afdf-0f9728ea9a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_75097bce-29f4-4627-855d-577f9a9c581f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1a93a1d2-c062-4ee3-afdf-0f9728ea9a35" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_75097bce-29f4-4627-855d-577f9a9c581f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_75097bce-29f4-4627-855d-577f9a9c581f" xlink:to="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_bd67a7b5-f4c0-4f8f-bb7d-9cd0ab3e9ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:to="loc_us-gaap_PreferredStockMember_bd67a7b5-f4c0-4f8f-bb7d-9cd0ab3e9ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ed4fb58f-f65a-4b4a-bba3-1839b38e2ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:to="loc_us-gaap_CommonStockMember_ed4fb58f-f65a-4b4a-bba3-1839b38e2ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f02f450d-a257-4282-b061-fb5d569ae809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f02f450d-a257-4282-b061-fb5d569ae809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_539cc2bc-7c5f-44bd-ad29-c3cae0b9babe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:to="loc_us-gaap_RetainedEarningsMember_539cc2bc-7c5f-44bd-ad29-c3cae0b9babe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cdf53ca4-ab0f-42bc-ab76-81f8e57f5bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56e0ea6f-5d78-45f6-846f-28fc27442431" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cdf53ca4-ab0f-42bc-ab76-81f8e57f5bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7e8db633-228d-4563-a063-fd475b2d070b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1a93a1d2-c062-4ee3-afdf-0f9728ea9a35" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7e8db633-228d-4563-a063-fd475b2d070b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ca437f10-df5a-4962-9bd5-410e78597773" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7e8db633-228d-4563-a063-fd475b2d070b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ca437f10-df5a-4962-9bd5-410e78597773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_35e2764a-08c2-45c9-b3ad-90d838f2cf66" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ca437f10-df5a-4962-9bd5-410e78597773" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_35e2764a-08c2-45c9-b3ad-90d838f2cf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6d342973-cdf5-4194-a548-b17930d28e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1a93a1d2-c062-4ee3-afdf-0f9728ea9a35" xlink:to="loc_us-gaap_StatementLineItems_6d342973-cdf5-4194-a548-b17930d28e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6d342973-cdf5-4194-a548-b17930d28e2e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_1bcd2b2c-54cd-40bd-8f68-7730f0105e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_SharesIssued_1bcd2b2c-54cd-40bd-8f68-7730f0105e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f81e720c-ab38-4b80-8dd0-25e649879811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockholdersEquity_f81e720c-ab38-4b80-8dd0-25e649879811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_85758cc2-348c-47b7-8ccd-b49517805809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_85758cc2-348c-47b7-8ccd-b49517805809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_71fafb5d-4e6b-46ff-b655-c5f597003146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_71fafb5d-4e6b-46ff-b655-c5f597003146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3bd6e642-f3a5-4420-8e22-cedd747aa370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3bd6e642-f3a5-4420-8e22-cedd747aa370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1b2386e9-d6ef-47b9-ad9c-d6361156287f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1b2386e9-d6ef-47b9-ad9c-d6361156287f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_12995edd-9cce-4be5-af6e-c0941d674e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_12995edd-9cce-4be5-af6e-c0941d674e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5c4f79ca-590d-48cc-89fc-beeccf113aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5c4f79ca-590d-48cc-89fc-beeccf113aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_da17277a-ceb5-4f58-a8a7-4647d248f7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_da17277a-ceb5-4f58-a8a7-4647d248f7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7c3a781a-1a89-446e-b6c4-0c99ef5e935b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7c3a781a-1a89-446e-b6c4-0c99ef5e935b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_99e0b531-9c03-4d57-aa22-6ff3f5d756c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_99e0b531-9c03-4d57-aa22-6ff3f5d756c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0409322d-8808-4e14-ac63-f26c69a4705f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_NetIncomeLoss_0409322d-8808-4e14-ac63-f26c69a4705f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7089ed2f-65ba-4a47-b8cc-2790d45b2afa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7089ed2f-65ba-4a47-b8cc-2790d45b2afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8e643646-4bfa-4386-a887-c5e916561db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8e643646-4bfa-4386-a887-c5e916561db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_05202114-49b2-4b8d-8e1e-8b464b361c60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_StockholdersEquity_05202114-49b2-4b8d-8e1e-8b464b361c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_3592308c-5e46-45a9-abd1-772c2ec3ffff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b11e9242-1b12-4829-bf80-546eaa989de8" xlink:to="loc_us-gaap_SharesIssued_3592308c-5e46-45a9-abd1-772c2ec3ffff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c8d86b70-1efc-4fee-8ead-703c022f230b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_9340b1c7-2d22-4c88-932f-eccbaa48a585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c8d86b70-1efc-4fee-8ead-703c022f230b" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_9340b1c7-2d22-4c88-932f-eccbaa48a585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6e69c686-3097-4348-9720-0a9994e7ff97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c8d86b70-1efc-4fee-8ead-703c022f230b" xlink:to="loc_us-gaap_StatementTable_6e69c686-3097-4348-9720-0a9994e7ff97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2ec10ca2-39ff-40db-a1f7-df21fd4c014e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6e69c686-3097-4348-9720-0a9994e7ff97" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2ec10ca2-39ff-40db-a1f7-df21fd4c014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_06631496-364e-4026-a843-64adab1b4bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2ec10ca2-39ff-40db-a1f7-df21fd4c014e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_06631496-364e-4026-a843-64adab1b4bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e588571c-39db-467e-ba4d-e6cfb5122a13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_06631496-364e-4026-a843-64adab1b4bcd" xlink:to="loc_us-gaap_SubsequentEventMember_e588571c-39db-467e-ba4d-e6cfb5122a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9737b866-7dc4-4123-91b4-906c0bd4d32d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6e69c686-3097-4348-9720-0a9994e7ff97" xlink:to="loc_us-gaap_StatementLineItems_9737b866-7dc4-4123-91b4-906c0bd4d32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1230c597-5b58-414a-93e4-313ea9b6e9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9737b866-7dc4-4123-91b4-906c0bd4d32d" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1230c597-5b58-414a-93e4-313ea9b6e9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_75b45dc1-97a9-4216-b934-6a470cc812e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2936ab07-02ba-4f84-befd-0ed832cdd416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b45dc1-97a9-4216-b934-6a470cc812e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2936ab07-02ba-4f84-befd-0ed832cdd416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2d35d877-e9c5-4be3-b16b-ae19a320bbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2936ab07-02ba-4f84-befd-0ed832cdd416" xlink:to="loc_us-gaap_NetIncomeLoss_2d35d877-e9c5-4be3-b16b-ae19a320bbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2936ab07-02ba-4f84-befd-0ed832cdd416" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9a6f203d-f774-4e2d-be70-679385c1eec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_Depreciation_9a6f203d-f774-4e2d-be70-679385c1eec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0ef0408d-766b-4049-a7d9-ed49f1dc81f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0ef0408d-766b-4049-a7d9-ed49f1dc81f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9749e0cc-f342-4027-8837-05fd8255be25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9749e0cc-f342-4027-8837-05fd8255be25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_bd1ffbc0-0c15-4ec0-9159-0f3b6ae69d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_bd1ffbc0-0c15-4ec0-9159-0f3b6ae69d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_b9fe4c56-6c7c-4c08-8e08-3f4165c4a7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_b9fe4c56-6c7c-4c08-8e08-3f4165c4a7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_90950cf0-76b7-47d1-b623-03776ff2df5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_90950cf0-76b7-47d1-b623-03776ff2df5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a61ee773-317e-494e-aba9-8ab5712fff65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_ShareBasedCompensation_a61ee773-317e-494e-aba9-8ab5712fff65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_52108883-561e-4446-a7a7-87745b92b8ac" xlink:href="ino-20231231.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_ino_NonCashInterestIncomeExpense_52108883-561e-4446-a7a7-87745b92b8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_dc6a8574-be9e-4da7-850a-31f0ea2e11ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_dc6a8574-be9e-4da7-850a-31f0ea2e11ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_94845a32-fd0f-4125-a7ce-af0bf0d37b42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_94845a32-fd0f-4125-a7ce-af0bf0d37b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_ebba3684-a3f4-4b41-aca6-003e53c4aa94" xlink:href="ino-20231231.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_ebba3684-a3f4-4b41-aca6-003e53c4aa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_85545810-85f0-42ab-9ad3-97f28828a8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_85545810-85f0-42ab-9ad3-97f28828a8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_a2554197-90fe-4ff6-8e0c-6f529acc76d3" xlink:href="ino-20231231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_a2554197-90fe-4ff6-8e0c-6f529acc76d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_2d6c7aa2-19dd-4db9-8817-eff8dcd48d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_2d6c7aa2-19dd-4db9-8817-eff8dcd48d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8d903575-fe1b-4786-87de-9b1b173537ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8d903575-fe1b-4786-87de-9b1b173537ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_39875f8e-3c94-4455-a687-a010c80a1bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a69b8ff4-67f0-463c-bf00-4b00b594e05c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_39875f8e-3c94-4455-a687-a010c80a1bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4bd66d3c-7e2e-4d93-b50c-4eeb7ffc1e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2936ab07-02ba-4f84-befd-0ed832cdd416" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4bd66d3c-7e2e-4d93-b50c-4eeb7ffc1e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2e7100dd-0d55-4ae6-9bb8-ec9fe80f20e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4bd66d3c-7e2e-4d93-b50c-4eeb7ffc1e7d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2e7100dd-0d55-4ae6-9bb8-ec9fe80f20e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b8610a03-d1c8-4718-aa11-86dc126d5a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4bd66d3c-7e2e-4d93-b50c-4eeb7ffc1e7d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b8610a03-d1c8-4718-aa11-86dc126d5a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b8fe55d7-cde9-4730-b2b6-28fa309724de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4bd66d3c-7e2e-4d93-b50c-4eeb7ffc1e7d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b8fe55d7-cde9-4730-b2b6-28fa309724de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7ed8ce78-428d-4023-8340-0552c75ca395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4bd66d3c-7e2e-4d93-b50c-4eeb7ffc1e7d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7ed8ce78-428d-4023-8340-0552c75ca395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_11b0a638-a7fd-46dd-9ee7-a073f5fb76c1" xlink:href="ino-20231231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4bd66d3c-7e2e-4d93-b50c-4eeb7ffc1e7d" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_11b0a638-a7fd-46dd-9ee7-a073f5fb76c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d9b9196-6bfb-4886-97c5-2623d499ded9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4bd66d3c-7e2e-4d93-b50c-4eeb7ffc1e7d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d9b9196-6bfb-4886-97c5-2623d499ded9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_70ea63bd-69bb-45d3-9d40-e575cde9e415" xlink:href="ino-20231231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4bd66d3c-7e2e-4d93-b50c-4eeb7ffc1e7d" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_70ea63bd-69bb-45d3-9d40-e575cde9e415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_3691c47a-bc78-4d07-a14b-09ee0e3163bd" xlink:href="ino-20231231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4bd66d3c-7e2e-4d93-b50c-4eeb7ffc1e7d" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_3691c47a-bc78-4d07-a14b-09ee0e3163bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d0506fbb-f7c6-4306-a81b-10da5c45e8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4bd66d3c-7e2e-4d93-b50c-4eeb7ffc1e7d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d0506fbb-f7c6-4306-a81b-10da5c45e8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b08985c8-c2e1-4452-a572-8f972039ae43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2936ab07-02ba-4f84-befd-0ed832cdd416" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b08985c8-c2e1-4452-a572-8f972039ae43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f8cc4dd-e161-4438-8fb6-cca5663f56d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b45dc1-97a9-4216-b934-6a470cc812e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f8cc4dd-e161-4438-8fb6-cca5663f56d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_b0732b66-32a9-4a4e-a7f0-e5332b4e0df3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f8cc4dd-e161-4438-8fb6-cca5663f56d5" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_b0732b66-32a9-4a4e-a7f0-e5332b4e0df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_7b9e8f9e-fa9e-445f-90ca-327ea01c795d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f8cc4dd-e161-4438-8fb6-cca5663f56d5" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_7b9e8f9e-fa9e-445f-90ca-327ea01c795d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_101fb53c-c081-4e19-bc8d-4286acc67bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f8cc4dd-e161-4438-8fb6-cca5663f56d5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_101fb53c-c081-4e19-bc8d-4286acc67bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2cb335b3-c87c-4912-8039-699524ef45d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f8cc4dd-e161-4438-8fb6-cca5663f56d5" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2cb335b3-c87c-4912-8039-699524ef45d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_2ab94029-bdf9-46ce-874e-7b6c2f6ee068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f8cc4dd-e161-4438-8fb6-cca5663f56d5" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_2ab94029-bdf9-46ce-874e-7b6c2f6ee068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6355bb6e-10d1-4094-9d76-c8717d7c5524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f8cc4dd-e161-4438-8fb6-cca5663f56d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6355bb6e-10d1-4094-9d76-c8717d7c5524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d93ac4c3-98cc-44dc-ba69-eba667f83bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b45dc1-97a9-4216-b934-6a470cc812e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d93ac4c3-98cc-44dc-ba69-eba667f83bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cb6d6ee6-35db-4601-a339-8959ffa12d51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d93ac4c3-98cc-44dc-ba69-eba667f83bd8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cb6d6ee6-35db-4601-a339-8959ffa12d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_38a98a4c-b8e5-4f84-8bb5-e207de720f5b" xlink:href="ino-20231231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d93ac4c3-98cc-44dc-ba69-eba667f83bd8" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_38a98a4c-b8e5-4f84-8bb5-e207de720f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_c80d9870-b15f-4175-b290-8a78c405e4ea" xlink:href="ino-20231231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d93ac4c3-98cc-44dc-ba69-eba667f83bd8" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_c80d9870-b15f-4175-b290-8a78c405e4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cbb3649e-7031-4144-9e92-67f858e17361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d93ac4c3-98cc-44dc-ba69-eba667f83bd8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cbb3649e-7031-4144-9e92-67f858e17361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d5f5b02d-a874-4518-b32d-f67b734cca91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b45dc1-97a9-4216-b934-6a470cc812e8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d5f5b02d-a874-4518-b32d-f67b734cca91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_30e24728-491c-4ffd-a29c-aefc44c94b09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b45dc1-97a9-4216-b934-6a470cc812e8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_30e24728-491c-4ffd-a29c-aefc44c94b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1472e74a-259d-431f-a76f-487323333855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b45dc1-97a9-4216-b934-6a470cc812e8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1472e74a-259d-431f-a76f-487323333855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4bac6dd9-28b6-4b5c-b772-3975fecbf0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b45dc1-97a9-4216-b934-6a470cc812e8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4bac6dd9-28b6-4b5c-b772-3975fecbf0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b987211f-cd09-4fb6-9c1b-ee3e31cf0f67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75b45dc1-97a9-4216-b934-6a470cc812e8" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b987211f-cd09-4fb6-9c1b-ee3e31cf0f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5fddf5a3-ffbd-4350-99c6-7444cc1ac21b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b987211f-cd09-4fb6-9c1b-ee3e31cf0f67" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5fddf5a3-ffbd-4350-99c6-7444cc1ac21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_d081396f-36a7-428b-86d6-6baba78c6091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b987211f-cd09-4fb6-9c1b-ee3e31cf0f67" xlink:to="loc_us-gaap_InterestPaidNet_d081396f-36a7-428b-86d6-6baba78c6091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_bf31c112-24c0-4f21-b3f7-8351a2488c93" xlink:href="ino-20231231.xsd#ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b987211f-cd09-4fb6-9c1b-ee3e31cf0f67" xlink:to="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_bf31c112-24c0-4f21-b3f7-8351a2488c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_ce57f5ee-d9b9-4911-8e6a-74740efb9d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b987211f-cd09-4fb6-9c1b-ee3e31cf0f67" xlink:to="loc_us-gaap_StockIssued1_ce57f5ee-d9b9-4911-8e6a-74740efb9d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/TheCompany" xlink:type="simple" xlink:href="ino-20231231.xsd#TheCompany"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/TheCompany" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_896af5ea-1e97-45ec-ab28-eeaf064671ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_689c4e3a-a6f8-45a2-bb07-00b5cb7b7bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_896af5ea-1e97-45ec-ab28-eeaf064671ee" xlink:to="loc_us-gaap_NatureOfOperations_689c4e3a-a6f8-45a2-bb07-00b5cb7b7bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ino-20231231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_054f44f1-3be3-4330-96d4-7ae82a5fa0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ba5b3bf3-993b-43f5-915e-126cb80dcad6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_054f44f1-3be3-4330-96d4-7ae82a5fa0a4" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ba5b3bf3-993b-43f5-915e-126cb80dcad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk" xlink:type="simple" xlink:href="ino-20231231.xsd#RevenueRecognitionandConcentrationofCreditRisk"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c059fe17-4780-42f4-82cf-30a3fd6f2434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_8498baf0-2883-4c27-aae1-7b62c06d4670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c059fe17-4780-42f4-82cf-30a3fd6f2434" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_8498baf0-2883-4c27-aae1-7b62c06d4670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20231231.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e61393c-84df-4457-ac14-08c4c6e6d9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_43a0647f-0089-45d6-8bab-55a11ef278c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e61393c-84df-4457-ac14-08c4c6e6d9f7" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_43a0647f-0089-45d6-8bab-55a11ef278c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="simple" xlink:href="ino-20231231.xsd#ShorttermInvestmentsandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_97661ce1-65c0-4f4e-85e1-f3d9bac1d841" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c7a940fe-185e-4faf-bf12-4ec661d0560b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_97661ce1-65c0-4f4e-85e1-f3d9bac1d841" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c7a940fe-185e-4faf-bf12-4ec661d0560b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f16f5f03-e56f-4d85-93e0-eadece7397b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_97661ce1-65c0-4f4e-85e1-f3d9bac1d841" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f16f5f03-e56f-4d85-93e0-eadece7397b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItems" xlink:type="simple" xlink:href="ino-20231231.xsd#CertainBalanceSheetItems"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_e790e08c-332b-4bef-811f-0ae83d03ef3e" xlink:href="ino-20231231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_188d3966-92b4-4974-990d-9db1839009b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_e790e08c-332b-4bef-811f-0ae83d03ef3e" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_188d3966-92b4-4974-990d-9db1839009b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssets" xlink:type="simple" xlink:href="ino-20231231.xsd#FixedAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8fec5fd1-aaaf-4a0e-ad27-5e0ed5004d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_29753031-0c6c-4405-b384-035cc029616f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8fec5fd1-aaaf-4a0e-ad27-5e0ed5004d3d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_29753031-0c6c-4405-b384-035cc029616f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20231231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d7388c68-9e95-452f-95c2-240498204efd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8d1a1844-6945-4cae-ab66-8571b292d60f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d7388c68-9e95-452f-95c2-240498204efd" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8d1a1844-6945-4cae-ab66-8571b292d60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20231231.xsd#ConvertibleDebt"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dc5ad8d6-85e5-4090-b5b3-a52da2134c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_288167af-9b3a-47cb-9386-03876e9729ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dc5ad8d6-85e5-4090-b5b3-a52da2134c74" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_288167af-9b3a-47cb-9386-03876e9729ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20231231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6567cb1d-acb7-49cf-b82b-c8531577a84d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8e8e094f-8960-4025-90e2-fc32093b4278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6567cb1d-acb7-49cf-b82b-c8531577a84d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8e8e094f-8960-4025-90e2-fc32093b4278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ino-20231231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ac8fc491-b0f4-49c1-b6cb-b7ec61687243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9bd38617-92d0-4875-98a3-d95521363171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac8fc491-b0f4-49c1-b6cb-b7ec61687243" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9bd38617-92d0-4875-98a3-d95521363171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c3d5be1b-4cb4-4195-b0d5-fa4c00abc40b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_6bdb6c06-8ee9-4b49-a0b7-33afeb152574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c3d5be1b-4cb4-4195-b0d5-fa4c00abc40b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_6bdb6c06-8ee9-4b49-a0b7-33afeb152574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlan" xlink:type="simple" xlink:href="ino-20231231.xsd#A401kPlan"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/A401kPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_85741686-d2f8-44c7-9eef-9ee553077539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_17141138-173b-42b4-aecd-a9f9d33f73ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_85741686-d2f8-44c7-9eef-9ee553077539" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_17141138-173b-42b4-aecd-a9f9d33f73ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20231231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_7228cb66-a3b0-499f-a178-af528d445805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5f881032-1712-4236-91eb-26db75ede8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_7228cb66-a3b0-499f-a178-af528d445805" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5f881032-1712-4236-91eb-26db75ede8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20231231.xsd#GeneosTherapeuticsInc"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_871d9ef0-b1a0-49c1-991a-87b56a23dbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d4da8221-e174-4064-84a8-01196a892603" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_871d9ef0-b1a0-49c1-991a-87b56a23dbc3" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d4da8221-e174-4064-84a8-01196a892603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ino-20231231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_c1e44dc2-e118-42de-8de4-91e339cd1aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ca793966-4ca6-4e69-89db-0bc149662821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_c1e44dc2-e118-42de-8de4-91e339cd1aaf" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ca793966-4ca6-4e69-89db-0bc149662821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ino-20231231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9c599248-22c3-4b6f-af7d-3d9ab17150ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9c599248-22c3-4b6f-af7d-3d9ab17150ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_089b93a9-3e63-4dd3-ab32-e0f3bea97db2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_089b93a9-3e63-4dd3-ab32-e0f3bea97db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3610d417-fbf1-4a33-a5b9-4debdd077466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3610d417-fbf1-4a33-a5b9-4debdd077466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_07f99908-a4ed-4092-bb08-89ccdc229cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_UseOfEstimates_07f99908-a4ed-4092-bb08-89ccdc229cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_b725d10b-d55b-4ec2-bef4-79dbdcf6e489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_b725d10b-d55b-4ec2-bef4-79dbdcf6e489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ccf08eae-1044-45f5-9ef7-5ab806ab19cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ccf08eae-1044-45f5-9ef7-5ab806ab19cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_953760b0-83e8-4ff8-8efe-5168ff679ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_953760b0-83e8-4ff8-8efe-5168ff679ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_589ecdf5-014d-45a5-9505-66f84716e9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_589ecdf5-014d-45a5-9505-66f84716e9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_df7afe2c-2154-48eb-b422-9dec18236ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_df7afe2c-2154-48eb-b422-9dec18236ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d9f4a802-9bb4-459d-8add-e1e55ee18808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d9f4a802-9bb4-459d-8add-e1e55ee18808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_6d94680a-8843-4ccf-a165-6bb5ac9ca0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_6d94680a-8843-4ccf-a165-6bb5ac9ca0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_311cadee-a31e-46b9-9e93-d50d33e2919c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_311cadee-a31e-46b9-9e93-d50d33e2919c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8ab0747d-4e69-4414-8ed9-8ada596a6515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8ab0747d-4e69-4414-8ed9-8ada596a6515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ddcaf3e7-b991-4995-ab9f-7fa8d7b381d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ddcaf3e7-b991-4995-ab9f-7fa8d7b381d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantRevenuePolicyTextBlock_bd598c2e-c003-4923-b10b-3d4dbab048ba" xlink:href="ino-20231231.xsd#ino_GrantRevenuePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_ino_GrantRevenuePolicyTextBlock_bd598c2e-c003-4923-b10b-3d4dbab048ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1592ae48-537e-4677-b640-d2ffa4e8d612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1592ae48-537e-4677-b640-d2ffa4e8d612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_689fc0fa-fd8f-4065-bd73-a68524d501c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_689fc0fa-fd8f-4065-bd73-a68524d501c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_4d6559d1-4592-4ca2-93bc-4fd22e7b521f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_4d6559d1-4592-4ca2-93bc-4fd22e7b521f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_756bc023-8505-40b8-8020-1da88e4779d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_756bc023-8505-40b8-8020-1da88e4779d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_f98d1881-0f50-42b0-b923-408ab5dbc9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_f98d1881-0f50-42b0-b923-408ab5dbc9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_20f256f0-2d8f-49c1-a19c-1bce1e643239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_20f256f0-2d8f-49c1-a19c-1bce1e643239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_f9c44784-4300-48a4-93fe-12011fff3851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_f9c44784-4300-48a4-93fe-12011fff3851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7763a5ea-b3c2-48ab-81b6-b0c635177d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e5c1d3a-b2c7-4db9-aa27-56118b1611a2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7763a5ea-b3c2-48ab-81b6-b0c635177d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ino-20231231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f01b433b-20b1-4d67-a719-1adb935dd5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3bfc99d2-a8be-4ba4-9f68-74fb9dfb4be7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f01b433b-20b1-4d67-a719-1adb935dd5ca" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3bfc99d2-a8be-4ba4-9f68-74fb9dfb4be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_29f89e12-7e2a-49fb-82d2-5892f1bbe4da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f01b433b-20b1-4d67-a719-1adb935dd5ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_29f89e12-7e2a-49fb-82d2-5892f1bbe4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables" xlink:type="simple" xlink:href="ino-20231231.xsd#RevenueRecognitionandConcentrationofCreditRiskTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_58ef785e-74d9-483e-a225-8f4bfae36775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ece975c4-63a6-442d-b8ea-8960fec62ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_58ef785e-74d9-483e-a225-8f4bfae36775" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ece975c4-63a6-442d-b8ea-8960fec62ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20231231.xsd#ShorttermInvestmentsandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dfd5e79a-9055-486c-837e-83e1b77b0b17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_003facba-a10b-46ea-bbba-9cc03c810cba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dfd5e79a-9055-486c-837e-83e1b77b0b17" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_003facba-a10b-46ea-bbba-9cc03c810cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_eaf3f1f7-7d6b-438d-aa9f-1571b01d7954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dfd5e79a-9055-486c-837e-83e1b77b0b17" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_eaf3f1f7-7d6b-438d-aa9f-1571b01d7954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="ino-20231231.xsd#CertainBalanceSheetItemsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_39522084-97c4-40c2-aa7e-9e9c937e1975" xlink:href="ino-20231231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_63c1bba7-7557-4f45-bb0e-b9f84c5ce0f4" xlink:href="ino-20231231.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_39522084-97c4-40c2-aa7e-9e9c937e1975" xlink:to="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_63c1bba7-7557-4f45-bb0e-b9f84c5ce0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_5908cf54-c6ae-4236-a0f7-a2e648775581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_39522084-97c4-40c2-aa7e-9e9c937e1975" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_5908cf54-c6ae-4236-a0f7-a2e648775581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsTables" xlink:type="simple" xlink:href="ino-20231231.xsd#FixedAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c70896a7-2d7f-482f-b652-6326d4b58848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7fd901d6-88a3-4296-8c4c-78920467a376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c70896a7-2d7f-482f-b652-6326d4b58848" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7fd901d6-88a3-4296-8c4c-78920467a376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20231231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cf0ca145-b373-4a8f-b18e-f52495a6e3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_0dec67d2-91ee-4e4a-98cf-4423ba5520fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cf0ca145-b373-4a8f-b18e-f52495a6e3b4" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_0dec67d2-91ee-4e4a-98cf-4423ba5520fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20231231.xsd#ConvertibleDebtTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_20411ba2-13e4-4b58-a2e2-b502356d78b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_c2e38363-b2b5-4e22-a1d1-972eb86eb2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_20411ba2-13e4-4b58-a2e2-b502356d78b6" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_c2e38363-b2b5-4e22-a1d1-972eb86eb2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20231231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8481005c-5cee-4f83-9ae0-7c66bf9bd84c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_b353a8a2-d66d-41c3-9637-7c0299d42cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8481005c-5cee-4f83-9ae0-7c66bf9bd84c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_b353a8a2-d66d-41c3-9637-7c0299d42cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_8f6c12f1-6b00-4f2d-ac30-cbf7ba705c86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8481005c-5cee-4f83-9ae0-7c66bf9bd84c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_8f6c12f1-6b00-4f2d-ac30-cbf7ba705c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7b3261db-e334-4e5b-ba61-94cf536beb67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8481005c-5cee-4f83-9ae0-7c66bf9bd84c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7b3261db-e334-4e5b-ba61-94cf536beb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_5f72f477-42ec-4636-8405-76e7ebf8267b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8481005c-5cee-4f83-9ae0-7c66bf9bd84c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_5f72f477-42ec-4636-8405-76e7ebf8267b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="ino-20231231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_db07230c-14c7-481e-aa12-bc2d470f5749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2f95a6a1-2190-4ce3-a0d0-d38ce59ef795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_db07230c-14c7-481e-aa12-bc2d470f5749" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2f95a6a1-2190-4ce3-a0d0-d38ce59ef795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e9825cb4-f9e4-4315-a81a-c19f6dd51aad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_fbecc885-4b13-4f6a-8ba0-f1adf2f14d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e9825cb4-f9e4-4315-a81a-c19f6dd51aad" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_fbecc885-4b13-4f6a-8ba0-f1adf2f14d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2077bbd0-89c4-427d-aa1f-5cf17dcc4be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e9825cb4-f9e4-4315-a81a-c19f6dd51aad" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2077bbd0-89c4-427d-aa1f-5cf17dcc4be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_77edd4e8-db6e-461a-ad1d-79a66a5d33b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e9825cb4-f9e4-4315-a81a-c19f6dd51aad" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_77edd4e8-db6e-461a-ad1d-79a66a5d33b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_99ca4db5-8626-4ab9-b593-300300178ef7" xlink:href="ino-20231231.xsd#ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e9825cb4-f9e4-4315-a81a-c19f6dd51aad" xlink:to="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_99ca4db5-8626-4ab9-b593-300300178ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_f0f05ec5-b15b-4f98-ab16-d93e40eaecf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e9825cb4-f9e4-4315-a81a-c19f6dd51aad" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_f0f05ec5-b15b-4f98-ab16-d93e40eaecf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_49ea6662-00c9-4998-99b7-53ba5a11e561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49ea6662-00c9-4998-99b7-53ba5a11e561" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_47335047-5a8c-41a9-a7d9-8ca35a914f67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:to="loc_us-gaap_StatementClassOfStockAxis_47335047-5a8c-41a9-a7d9-8ca35a914f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7fe6d15f-21b0-44fd-9ccc-078702d31ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47335047-5a8c-41a9-a7d9-8ca35a914f67" xlink:to="loc_us-gaap_ClassOfStockDomain_7fe6d15f-21b0-44fd-9ccc-078702d31ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9933f695-5675-4d4e-8dea-ffa356ca18a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7fe6d15f-21b0-44fd-9ccc-078702d31ca7" xlink:to="loc_us-gaap_CommonStockMember_9933f695-5675-4d4e-8dea-ffa356ca18a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1b546d3d-5895-42f2-a460-f2c8f0d3cc35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1b546d3d-5895-42f2-a460-f2c8f0d3cc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65548463-d92f-4ab1-b730-500feae59a25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1b546d3d-5895-42f2-a460-f2c8f0d3cc35" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65548463-d92f-4ab1-b730-500feae59a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_e6085923-4350-4d13-a689-874d93b0bc13" xlink:href="ino-20231231.xsd#ino_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65548463-d92f-4ab1-b730-500feae59a25" xlink:to="loc_ino_SalesAgreementMember_e6085923-4350-4d13-a689-874d93b0bc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_278f6aa5-96e1-4ed1-bf87-c01b6a7e1708" xlink:href="ino-20231231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65548463-d92f-4ab1-b730-500feae59a25" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_278f6aa5-96e1-4ed1-bf87-c01b6a7e1708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5f6952c4-4be9-4e98-869a-3a9cd2efe677" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:to="loc_srt_RangeAxis_5f6952c4-4be9-4e98-869a-3a9cd2efe677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b34b1cee-b897-48ff-882f-795507b55f37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5f6952c4-4be9-4e98-869a-3a9cd2efe677" xlink:to="loc_srt_RangeMember_b34b1cee-b897-48ff-882f-795507b55f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_73c992f8-cb7d-44ef-bd95-ce0edbb54588" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b34b1cee-b897-48ff-882f-795507b55f37" xlink:to="loc_srt_MinimumMember_73c992f8-cb7d-44ef-bd95-ce0edbb54588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_53895304-ede0-477d-9fe4-2a8939232ad2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b34b1cee-b897-48ff-882f-795507b55f37" xlink:to="loc_srt_MaximumMember_53895304-ede0-477d-9fe4-2a8939232ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9543ae8e-6e02-415d-9107-816bff813056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9543ae8e-6e02-415d-9107-816bff813056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_09512fed-ac62-4f04-ab3f-0601e102eabd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9543ae8e-6e02-415d-9107-816bff813056" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_09512fed-ac62-4f04-ab3f-0601e102eabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6454cef3-c914-4e6d-bd3f-7ead28493df9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_09512fed-ac62-4f04-ab3f-0601e102eabd" xlink:to="loc_us-gaap_SubsequentEventMember_6454cef3-c914-4e6d-bd3f-7ead28493df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1a32cefd-ee29-4616-a77a-578232742f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1a32cefd-ee29-4616-a77a-578232742f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0e684ba-eb62-44b2-90c4-400ce014fe12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1a32cefd-ee29-4616-a77a-578232742f42" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0e684ba-eb62-44b2-90c4-400ce014fe12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_2f030929-a036-4d7d-9c2a-702e3c328acd" xlink:href="ino-20231231.xsd#ino_BiojectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0e684ba-eb62-44b2-90c4-400ce014fe12" xlink:to="loc_ino_BiojectMember_2f030929-a036-4d7d-9c2a-702e3c328acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e98d1f0-6ebb-4ca4-b448-1aabade33b58" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_60f70b19-6fb6-437d-af3d-b8406452cccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_NetIncomeLoss_60f70b19-6fb6-437d-af3d-b8406452cccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_79195cac-5a2e-4570-b528-c9c3f53ec9c9" xlink:href="ino-20231231.xsd#ino_WorkingCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_ino_WorkingCapital_79195cac-5a2e-4570-b528-c9c3f53ec9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77059601-c822-4f89-ab25-07fea8859dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77059601-c822-4f89-ab25-07fea8859dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_537631ce-851f-4c35-929a-6d66913b4240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_537631ce-851f-4c35-929a-6d66913b4240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4351d5bc-a303-4633-adeb-e43a791b29ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4351d5bc-a303-4633-adeb-e43a791b29ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_5837555c-0fd7-4703-bff3-89a92b7beebe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_NumberOfOperatingSegments_5837555c-0fd7-4703-bff3-89a92b7beebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_231c1b0f-cb0d-4f20-9b92-e74def143ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_231c1b0f-cb0d-4f20-9b92-e74def143ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_05880153-3a98-48fa-89a0-53592766bdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_05880153-3a98-48fa-89a0-53592766bdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b515dc34-6a72-4376-a380-8cda7584b02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b515dc34-6a72-4376-a380-8cda7584b02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2c77a73e-5889-431c-8160-279d9a518f12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2c77a73e-5889-431c-8160-279d9a518f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a75b01d0-9ad8-4e3e-b6c0-0db76d2502fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a75b01d0-9ad8-4e3e-b6c0-0db76d2502fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_4f32f12a-6d95-4b4d-8617-c0f24a952be2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec518097-a548-43c2-877c-d97ff9c9baf6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_4f32f12a-6d95-4b4d-8617-c0f24a952be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_20351c4b-a03a-4a11-b904-a14ea0757ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0eba1e27-a4b6-4d91-8c16-67b7e116170f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_20351c4b-a03a-4a11-b904-a14ea0757ff1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0eba1e27-a4b6-4d91-8c16-67b7e116170f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_60adebc1-0865-48ef-9ba9-903a571d77b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0eba1e27-a4b6-4d91-8c16-67b7e116170f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_60adebc1-0865-48ef-9ba9-903a571d77b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_60adebc1-0865-48ef-9ba9-903a571d77b7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fc552a75-ef56-4f83-ba7a-9e2fc7f1dfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fc552a75-ef56-4f83-ba7a-9e2fc7f1dfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_19855e4a-59aa-49d2-927c-0daea1540ccd" xlink:href="ino-20231231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_19855e4a-59aa-49d2-927c-0daea1540ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a0465b1b-5262-4f1c-8603-627daa6ee847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a0465b1b-5262-4f1c-8603-627daa6ee847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_00ff4672-e51e-4a49-b5e3-383b3c5471e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_00ff4672-e51e-4a49-b5e3-383b3c5471e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_78e909f3-dece-4906-8ca5-61847d0871e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc8c29c5-658c-45bb-9821-fa8ecf966b32" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_78e909f3-dece-4906-8ca5-61847d0871e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7179d628-4c11-461d-9bb8-8a49145ee49b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0eba1e27-a4b6-4d91-8c16-67b7e116170f" xlink:to="loc_us-gaap_DebtInstrumentAxis_7179d628-4c11-461d-9bb8-8a49145ee49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52685b3a-1c60-483e-ae4e-2b85992a4667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7179d628-4c11-461d-9bb8-8a49145ee49b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_52685b3a-1c60-483e-ae4e-2b85992a4667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_94882005-b7b8-450a-bd03-0e0e1ebf392c" xlink:href="ino-20231231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52685b3a-1c60-483e-ae4e-2b85992a4667" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_94882005-b7b8-450a-bd03-0e0e1ebf392c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c11b787b-1d0b-487f-ae44-3ad667f1ad01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0eba1e27-a4b6-4d91-8c16-67b7e116170f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c11b787b-1d0b-487f-ae44-3ad667f1ad01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e96df88d-bf89-4f97-b84b-9d9f58bcad48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c11b787b-1d0b-487f-ae44-3ad667f1ad01" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e96df88d-bf89-4f97-b84b-9d9f58bcad48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d109d0fa-71ab-496a-8242-13a83cfe206e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2b5097d-1c55-4d6a-a0e6-d421d2931339" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d109d0fa-71ab-496a-8242-13a83cfe206e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2b5097d-1c55-4d6a-a0e6-d421d2931339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a8612def-6220-4f34-ad52-93a611084c09" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2b5097d-1c55-4d6a-a0e6-d421d2931339" xlink:to="loc_srt_TitleOfIndividualAxis_a8612def-6220-4f34-ad52-93a611084c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_202d88a4-a5b7-4cd2-836e-c186a7d72771" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_a8612def-6220-4f34-ad52-93a611084c09" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_202d88a4-a5b7-4cd2-836e-c186a7d72771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_48c008e1-ca88-42eb-b243-551a9363ab33" xlink:href="ino-20231231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_202d88a4-a5b7-4cd2-836e-c186a7d72771" xlink:to="loc_ino_EmployeesAndDirectorsMember_48c008e1-ca88-42eb-b243-551a9363ab33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_ff6904b6-fd1d-43b7-85d5-546cc3aa451d" xlink:href="ino-20231231.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_202d88a4-a5b7-4cd2-836e-c186a7d72771" xlink:to="loc_ino_NonEmployeeMember_ff6904b6-fd1d-43b7-85d5-546cc3aa451d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_324a88a4-0a3d-4413-b059-b4162470a0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2b5097d-1c55-4d6a-a0e6-d421d2931339" xlink:to="loc_us-gaap_AwardTypeAxis_324a88a4-0a3d-4413-b059-b4162470a0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0854d02-1b86-48da-8cdd-fd8332f6a6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_324a88a4-0a3d-4413-b059-b4162470a0c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0854d02-1b86-48da-8cdd-fd8332f6a6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_59843545-fd4a-40a1-b1d2-38503b2eece4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0854d02-1b86-48da-8cdd-fd8332f6a6ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_59843545-fd4a-40a1-b1d2-38503b2eece4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb9789-be41-4bcb-b58c-31b6b7325bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2b5097d-1c55-4d6a-a0e6-d421d2931339" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb9789-be41-4bcb-b58c-31b6b7325bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_c0362abf-616f-4398-882f-4f4d00f55c88" xlink:href="ino-20231231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bdb9789-be41-4bcb-b58c-31b6b7325bf7" xlink:to="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_c0362abf-616f-4398-882f-4f4d00f55c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8cf8c083-83e3-4303-ab90-d162947e1f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_c0362abf-616f-4398-882f-4f4d00f55c88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8cf8c083-83e3-4303-ab90-d162947e1f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c262b117-e917-4e01-a9ff-2cb9acb60c16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_c0362abf-616f-4398-882f-4f4d00f55c88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c262b117-e917-4e01-a9ff-2cb9acb60c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9de0189f-046c-45b5-b50f-a77679ef5843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_c0362abf-616f-4398-882f-4f4d00f55c88" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9de0189f-046c-45b5-b50f-a77679ef5843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_170fb50a-00c0-4014-bdb4-2340be2233b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_c0362abf-616f-4398-882f-4f4d00f55c88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_170fb50a-00c0-4014-bdb4-2340be2233b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8120373e-6784-46f6-94cd-7502f10db305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7b32ccf8-bae8-4b39-abe0-298d89fdeb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8120373e-6784-46f6-94cd-7502f10db305" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7b32ccf8-bae8-4b39-abe0-298d89fdeb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_11464c9e-4446-48d8-be24-ae3be69746e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b32ccf8-bae8-4b39-abe0-298d89fdeb3d" xlink:to="loc_srt_MajorCustomersAxis_11464c9e-4446-48d8-be24-ae3be69746e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0fea0970-6cd1-4eff-b3ab-2844385d4949" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_11464c9e-4446-48d8-be24-ae3be69746e9" xlink:to="loc_srt_NameOfMajorCustomerDomain_0fea0970-6cd1-4eff-b3ab-2844385d4949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioCorporationMember_cb83ca38-9cd2-4cc8-acbe-633f911dcddd" xlink:href="ino-20231231.xsd#ino_ApolloBioCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0fea0970-6cd1-4eff-b3ab-2844385d4949" xlink:to="loc_ino_ApolloBioCorporationMember_cb83ca38-9cd2-4cc8-acbe-633f911dcddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember_5aaa76bb-df63-4723-ad0a-af3cbd21c27e" xlink:href="ino-20231231.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0fea0970-6cd1-4eff-b3ab-2844385d4949" xlink:to="loc_ino_PlumblineLifeSciencesIncMember_5aaa76bb-df63-4723-ad0a-af3cbd21c27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember_3250a108-af13-4cab-90aa-afb07a071f09" xlink:href="ino-20231231.xsd#ino_DoDMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0fea0970-6cd1-4eff-b3ab-2844385d4949" xlink:to="loc_ino_DoDMember_3250a108-af13-4cab-90aa-afb07a071f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember_9422e395-6b08-42f0-b22b-4348b31b8daf" xlink:href="ino-20231231.xsd#ino_AllOtherCustomersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0fea0970-6cd1-4eff-b3ab-2844385d4949" xlink:to="loc_ino_AllOtherCustomersMember_9422e395-6b08-42f0-b22b-4348b31b8daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1c8e4dd-fa29-465c-8f37-1bbc9a8e0225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b32ccf8-bae8-4b39-abe0-298d89fdeb3d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1c8e4dd-fa29-465c-8f37-1bbc9a8e0225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2241fa8-0de4-4e1f-a790-8d44f4712653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1c8e4dd-fa29-465c-8f37-1bbc9a8e0225" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2241fa8-0de4-4e1f-a790-8d44f4712653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_80789964-4351-40d9-8bdc-e6379e9312b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2241fa8-0de4-4e1f-a790-8d44f4712653" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_80789964-4351-40d9-8bdc-e6379e9312b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_57fa0586-e23b-4928-8751-254a68501e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b32ccf8-bae8-4b39-abe0-298d89fdeb3d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_57fa0586-e23b-4928-8751-254a68501e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5451c609-7932-40c0-b42e-f4aedcbe8e87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_57fa0586-e23b-4928-8751-254a68501e93" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5451c609-7932-40c0-b42e-f4aedcbe8e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_53faa8b9-a4ab-4d38-9d20-322713a65f60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5451c609-7932-40c0-b42e-f4aedcbe8e87" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_53faa8b9-a4ab-4d38-9d20-322713a65f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ecf2d122-4e20-40ca-a83d-e99c3e41a614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7b32ccf8-bae8-4b39-abe0-298d89fdeb3d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ecf2d122-4e20-40ca-a83d-e99c3e41a614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_add4d82a-3dc7-4bf9-8232-8863030cd2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ecf2d122-4e20-40ca-a83d-e99c3e41a614" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_add4d82a-3dc7-4bf9-8232-8863030cd2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_02171c28-0183-41a2-a6d0-8203cd181b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ecf2d122-4e20-40ca-a83d-e99c3e41a614" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_02171c28-0183-41a2-a6d0-8203cd181b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ea928a6b-40b8-43b5-9187-0a2fb5f8a690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_be7dd5bd-15e8-42fc-ab71-3c316be2574e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ea928a6b-40b8-43b5-9187-0a2fb5f8a690" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_be7dd5bd-15e8-42fc-ab71-3c316be2574e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4363f9c3-e1d8-4b1f-9616-10800b439f04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4363f9c3-e1d8-4b1f-9616-10800b439f04" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_71d1eb4c-a8ef-4a2a-8b0e-9c29a0bdae33" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:to="loc_srt_CounterpartyNameAxis_71d1eb4c-a8ef-4a2a-8b0e-9c29a0bdae33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_71d1eb4c-a8ef-4a2a-8b0e-9c29a0bdae33" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_50467d8d-267c-44df-a5ad-3f4ead0146f0" xlink:href="ino-20231231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:to="loc_ino_AdvaccineMember_50467d8d-267c-44df-a5ad-3f4ead0146f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_0ae8cb9a-6673-4cd7-9a85-6b266e5571f0" xlink:href="ino-20231231.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:to="loc_ino_ApolloBioMember_0ae8cb9a-6673-4cd7-9a85-6b266e5571f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_e8415cad-0802-4680-bffb-c621c5735679" xlink:href="ino-20231231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_e8415cad-0802-4680-bffb-c621c5735679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_029f59d6-7b62-4111-9550-1bbaa85e9eb2" xlink:href="ino-20231231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_029f59d6-7b62-4111-9550-1bbaa85e9eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_4851f524-a831-4e40-8bf9-bcb2cff31529" xlink:href="ino-20231231.xsd#ino_DepartmentOfDefenceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06eb13f3-478f-47f8-969c-0502d3884042" xlink:to="loc_ino_DepartmentOfDefenceMember_4851f524-a831-4e40-8bf9-bcb2cff31529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1467ffec-efd7-4adf-8b5f-d695cde68516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1467ffec-efd7-4adf-8b5f-d695cde68516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e59e1f7a-8fe7-428d-aa2c-c7aedc696712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1467ffec-efd7-4adf-8b5f-d695cde68516" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e59e1f7a-8fe7-428d-aa2c-c7aedc696712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_7f63d5c7-94c4-4061-95ae-97b3f154a05c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e59e1f7a-8fe7-428d-aa2c-c7aedc696712" xlink:to="loc_us-gaap_CollaborativeArrangementMember_7f63d5c7-94c4-4061-95ae-97b3f154a05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_872fe268-457b-4660-8887-aa100e332fbe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:to="loc_srt_MajorCustomersAxis_872fe268-457b-4660-8887-aa100e332fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ea14a7a8-f170-457b-920d-343e6af6501e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_872fe268-457b-4660-8887-aa100e332fbe" xlink:to="loc_srt_NameOfMajorCustomerDomain_ea14a7a8-f170-457b-920d-343e6af6501e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_9023d832-05ef-41d0-9498-4b0ae7f63fcf" xlink:href="ino-20231231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ea14a7a8-f170-457b-920d-343e6af6501e" xlink:to="loc_ino_AdvaccineMember_9023d832-05ef-41d0-9498-4b0ae7f63fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1f10ec3a-0cf4-44f8-889e-e79dde20b861" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:to="loc_srt_ProductOrServiceAxis_1f10ec3a-0cf4-44f8-889e-e79dde20b861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1f10ec3a-0cf4-44f8-889e-e79dde20b861" xlink:to="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_da095a2f-aa4e-4233-a392-27b8519fe942" xlink:href="ino-20231231.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_da095a2f-aa4e-4233-a392-27b8519fe942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_7e625efe-6e4a-41f2-87af-90e209322da8" xlink:href="ino-20231231.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_7e625efe-6e4a-41f2-87af-90e209322da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_5ded3f14-86ab-44e4-8c8f-cd6f3f1fdc92" xlink:href="ino-20231231.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_5ded3f14-86ab-44e4-8c8f-cd6f3f1fdc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_dda590b1-f41d-435f-a0dc-3377f13e998a" xlink:href="ino-20231231.xsd#ino_INO4800Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:to="loc_ino_INO4800Member_dda590b1-f41d-435f-a0dc-3377f13e998a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_ce32b1a7-3569-4d5b-a384-100186680d41" xlink:href="ino-20231231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ed7b4d5-865b-4537-9593-9f61c5d49b2d" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_ce32b1a7-3569-4d5b-a384-100186680d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_232f8767-a27e-478a-8265-9d0a4e64f2b7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_4ec76d5c-e2d7-416a-a909-d83eae77eafc" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_4ec76d5c-e2d7-416a-a909-d83eae77eafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_28c295c0-08a5-4e58-bdbe-4790c4988e3b" xlink:href="ino-20231231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_28c295c0-08a5-4e58-bdbe-4790c4988e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_e5ab2ed5-b64f-4918-81c6-55a708a4c9dd" xlink:href="ino-20231231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_e5ab2ed5-b64f-4918-81c6-55a708a4c9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_8f3af8ce-7ddc-4e14-bc85-a23c13f10132" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_8f3af8ce-7ddc-4e14-bc85-a23c13f10132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aeb23078-2dc2-451b-a664-67696461118d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aeb23078-2dc2-451b-a664-67696461118d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_5e231836-4e59-4363-becc-a6b701e85d6b" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_5e231836-4e59-4363-becc-a6b701e85d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_eb82f339-93f9-4044-8b46-761842fa01e7" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_eb82f339-93f9-4044-8b46-761842fa01e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_de2ac6a9-f005-4b1f-8740-c6e8095a0347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_us-gaap_AccountsReceivableNet_de2ac6a9-f005-4b1f-8740-c6e8095a0347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_fbf5bb09-2431-4f3d-bcfb-f6283f2cb999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_fbf5bb09-2431-4f3d-bcfb-f6283f2cb999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_940bb2c6-b73b-4196-8ca6-502aa99ff6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_us-gaap_GrantsReceivable_940bb2c6-b73b-4196-8ca6-502aa99ff6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_cbd5ef95-50a2-405d-8a93-a8fc303f1a33" xlink:href="ino-20231231.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_GrantProceedsReceived_cbd5ef95-50a2-405d-8a93-a8fc303f1a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_c6efa5b7-f517-4cf1-816d-e0a632731af0" xlink:href="ino-20231231.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_c6efa5b7-f517-4cf1-816d-e0a632731af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_ada706fa-9009-4a04-a3aa-e51f87268f7a" xlink:href="ino-20231231.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_049867aa-fbad-4e3d-8449-76e815aed52d" xlink:to="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_ada706fa-9009-4a04-a3aa-e51f87268f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a5db2b7a-2a01-4c06-83ce-b87fb7ab64d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bd08181-fc47-43c2-8d20-87e71db59461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a5db2b7a-2a01-4c06-83ce-b87fb7ab64d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bd08181-fc47-43c2-8d20-87e71db59461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d96855d9-a076-4f56-90e3-ca5d5997d5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bd08181-fc47-43c2-8d20-87e71db59461" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d96855d9-a076-4f56-90e3-ca5d5997d5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d3c648b-76fb-4074-b446-393e2456b392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d96855d9-a076-4f56-90e3-ca5d5997d5c6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d3c648b-76fb-4074-b446-393e2456b392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_8b6e3f4e-f0e2-49ae-b616-58fa7dc055e8" xlink:href="ino-20231231.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d3c648b-76fb-4074-b446-393e2456b392" xlink:to="loc_ino_MutualFundsMember_8b6e3f4e-f0e2-49ae-b616-58fa7dc055e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_5859ba5c-7352-48fb-a005-57cb6b763120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d3c648b-76fb-4074-b446-393e2456b392" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_5859ba5c-7352-48fb-a005-57cb6b763120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_79bc0f70-b5e6-41e3-820c-d2ea06536f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d3c648b-76fb-4074-b446-393e2456b392" xlink:to="loc_us-gaap_CertificatesOfDepositMember_79bc0f70-b5e6-41e3-820c-d2ea06536f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_0af54d74-caa9-4fdc-8bdf-ffffd41d7fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9d3c648b-76fb-4074-b446-393e2456b392" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_0af54d74-caa9-4fdc-8bdf-ffffd41d7fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2dd73787-d860-41fc-8c61-c7869a8b7bb1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bd08181-fc47-43c2-8d20-87e71db59461" xlink:to="loc_srt_RangeAxis_2dd73787-d860-41fc-8c61-c7869a8b7bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_58087107-7c7d-4a91-be74-22637da9406a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2dd73787-d860-41fc-8c61-c7869a8b7bb1" xlink:to="loc_srt_RangeMember_58087107-7c7d-4a91-be74-22637da9406a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34c5e58e-eb38-4054-9f15-e6f0eb3a2c9c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_58087107-7c7d-4a91-be74-22637da9406a" xlink:to="loc_srt_MaximumMember_34c5e58e-eb38-4054-9f15-e6f0eb3a2c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8634422b-167c-4bf3-a8e8-aca3ca9449d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6bd08181-fc47-43c2-8d20-87e71db59461" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8634422b-167c-4bf3-a8e8-aca3ca9449d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_bf03e4ab-fae4-418b-9543-bce60f125346" xlink:href="ino-20231231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8634422b-167c-4bf3-a8e8-aca3ca9449d5" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_bf03e4ab-fae4-418b-9543-bce60f125346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7d2862a9-0732-4d26-9068-d981f46a646d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8634422b-167c-4bf3-a8e8-aca3ca9449d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7d2862a9-0732-4d26-9068-d981f46a646d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_08d24242-24bd-4635-96b0-72c8dad4e02d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7d2862a9-0732-4d26-9068-d981f46a646d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_08d24242-24bd-4635-96b0-72c8dad4e02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aa0cb515-25b7-4fc8-b8f4-76ee20148462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7d2862a9-0732-4d26-9068-d981f46a646d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aa0cb515-25b7-4fc8-b8f4-76ee20148462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_68436a28-d84c-4227-82af-d28796475449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7d2862a9-0732-4d26-9068-d981f46a646d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_68436a28-d84c-4227-82af-d28796475449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1ebacc1d-ce0a-4f9f-bd72-adf8b5b9d8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7d2862a9-0732-4d26-9068-d981f46a646d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1ebacc1d-ce0a-4f9f-bd72-adf8b5b9d8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b7f3f0a4-cb82-4dc7-8ef3-1a36d64ab6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94f45538-d84b-4bcd-885d-dfae8537e0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b7f3f0a4-cb82-4dc7-8ef3-1a36d64ab6f1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94f45538-d84b-4bcd-885d-dfae8537e0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_185dbe07-ca2b-458d-81e6-00432f70272b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94f45538-d84b-4bcd-885d-dfae8537e0e8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_185dbe07-ca2b-458d-81e6-00432f70272b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cd35da5d-01eb-4eea-8f26-a9fac4e99a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_185dbe07-ca2b-458d-81e6-00432f70272b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cd35da5d-01eb-4eea-8f26-a9fac4e99a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b7f3f0a4-cb82-4dc7-8ef3-1a36d64ab6f1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_bd557371-6e10-4089-9cd8-c519f7296d28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_bd557371-6e10-4089-9cd8-c519f7296d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_fa4bbe9d-7489-47fd-b563-cab755763e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_fa4bbe9d-7489-47fd-b563-cab755763e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f9c93b8b-da82-48fa-a341-2306d6347a17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f9c93b8b-da82-48fa-a341-2306d6347a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8fcfe4f9-7dd5-49df-86c8-b96d851e5af8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8fcfe4f9-7dd5-49df-86c8-b96d851e5af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_6218fdc5-6215-4705-837b-9b8d74312c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_6218fdc5-6215-4705-837b-9b8d74312c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_66ebbf05-42d4-47bf-ac64-f7f7281cec4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_66ebbf05-42d4-47bf-ac64-f7f7281cec4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_0830d3fb-efef-42ea-8116-c4230542768f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bc5de156-4156-4977-9346-b0ff2e98d6d3" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_0830d3fb-efef-42ea-8116-c4230542768f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_994f548d-8adf-4bef-a315-2aa89b40a5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2b5bd279-67e2-4b04-b452-0dbabb4df731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_994f548d-8adf-4bef-a315-2aa89b40a5ab" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2b5bd279-67e2-4b04-b452-0dbabb4df731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3bea6b06-fccf-472f-964b-74af89392658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2b5bd279-67e2-4b04-b452-0dbabb4df731" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3bea6b06-fccf-472f-964b-74af89392658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b82833fd-4622-411d-9a90-6209136a95bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3bea6b06-fccf-472f-964b-74af89392658" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b82833fd-4622-411d-9a90-6209136a95bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_eb3f7441-e6bd-4744-b1d7-1bad10e72a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b82833fd-4622-411d-9a90-6209136a95bb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_eb3f7441-e6bd-4744-b1d7-1bad10e72a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6b8d2528-813d-4d72-adeb-e4ba45fa6296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2b5bd279-67e2-4b04-b452-0dbabb4df731" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6b8d2528-813d-4d72-adeb-e4ba45fa6296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb5b1417-863c-4fcd-8e02-8e9fe1d2b57b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6b8d2528-813d-4d72-adeb-e4ba45fa6296" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb5b1417-863c-4fcd-8e02-8e9fe1d2b57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_5f6f25f7-5671-4b86-8a73-e229287c0c6e" xlink:href="ino-20231231.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb5b1417-863c-4fcd-8e02-8e9fe1d2b57b" xlink:to="loc_ino_MutualFundsMember_5f6f25f7-5671-4b86-8a73-e229287c0c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bbf7f6ec-5216-473b-9938-06bdbd0b552b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb5b1417-863c-4fcd-8e02-8e9fe1d2b57b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bbf7f6ec-5216-473b-9938-06bdbd0b552b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6707c453-e078-4d03-ad92-18b95b68fd01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb5b1417-863c-4fcd-8e02-8e9fe1d2b57b" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6707c453-e078-4d03-ad92-18b95b68fd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_4b7e5020-f311-47c3-8e3c-2e26b004b46b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb5b1417-863c-4fcd-8e02-8e9fe1d2b57b" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_4b7e5020-f311-47c3-8e3c-2e26b004b46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c601e05a-09aa-493d-b0ae-e354a8f5dc61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2b5bd279-67e2-4b04-b452-0dbabb4df731" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c601e05a-09aa-493d-b0ae-e354a8f5dc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d45c350-5894-4994-ae41-8e22f97c6ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c601e05a-09aa-493d-b0ae-e354a8f5dc61" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d45c350-5894-4994-ae41-8e22f97c6ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bbc06896-a70e-4811-86fc-9598e1243681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d45c350-5894-4994-ae41-8e22f97c6ca1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bbc06896-a70e-4811-86fc-9598e1243681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6d518342-d190-43f6-b507-b9b9095403f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d45c350-5894-4994-ae41-8e22f97c6ca1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6d518342-d190-43f6-b507-b9b9095403f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_60c70001-4170-45b7-bbdc-b0e49dd28fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d45c350-5894-4994-ae41-8e22f97c6ca1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_60c70001-4170-45b7-bbdc-b0e49dd28fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3362464a-8d38-48da-b963-b36bd4f1812b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2b5bd279-67e2-4b04-b452-0dbabb4df731" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3362464a-8d38-48da-b963-b36bd4f1812b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b7db71a3-5d21-4e30-a887-0849f3e4eb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3362464a-8d38-48da-b963-b36bd4f1812b" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b7db71a3-5d21-4e30-a887-0849f3e4eb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f552519-ac85-41bf-87c9-811f87dc8cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b7db71a3-5d21-4e30-a887-0849f3e4eb7d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f552519-ac85-41bf-87c9-811f87dc8cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_38b74338-b140-4d71-97f4-51ecf3910cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b7db71a3-5d21-4e30-a887-0849f3e4eb7d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_38b74338-b140-4d71-97f4-51ecf3910cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_66d18796-81db-4132-911d-3c270d1b5ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b7db71a3-5d21-4e30-a887-0849f3e4eb7d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_66d18796-81db-4132-911d-3c270d1b5ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_ddb6ebf9-e5ef-43e0-8e11-2f12a322b2bb" xlink:href="ino-20231231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_1391594c-c8ba-4327-8340-bc76ab43b9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_ddb6ebf9-e5ef-43e0-8e11-2f12a322b2bb" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_1391594c-c8ba-4327-8340-bc76ab43b9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent_c716c389-acc8-4956-8199-6b085298d9ff" xlink:href="ino-20231231.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_ddb6ebf9-e5ef-43e0-8e11-2f12a322b2bb" xlink:to="loc_ino_PrepaidManufacturingExpensesCurrent_c716c389-acc8-4956-8199-6b085298d9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_ed86fdba-ed9f-4531-a339-a64c7bce5c88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_ddb6ebf9-e5ef-43e0-8e11-2f12a322b2bb" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_ed86fdba-ed9f-4531-a339-a64c7bce5c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_23f68582-08cb-46bd-b70f-2313c1f2c43a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_ddb6ebf9-e5ef-43e0-8e11-2f12a322b2bb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_23f68582-08cb-46bd-b70f-2313c1f2c43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_c5e37f2c-c427-4f1d-aeaf-ce8f27ae7e18" xlink:href="ino-20231231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable_0117b889-2831-4e62-af68-855303d81b59" xlink:href="ino-20231231.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_c5e37f2c-c427-4f1d-aeaf-ce8f27ae7e18" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesTable_0117b889-2831-4e62-af68-855303d81b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_70a30d7a-bffd-4766-9c80-0dba371c56c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_0117b889-2831-4e62-af68-855303d81b59" xlink:to="loc_srt_LitigationCaseAxis_70a30d7a-bffd-4766-9c80-0dba371c56c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d592f799-4a12-41fa-90aa-3547ff192c9a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_70a30d7a-bffd-4766-9c80-0dba371c56c3" xlink:to="loc_srt_LitigationCaseTypeDomain_d592f799-4a12-41fa-90aa-3547ff192c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_423e1b10-35b5-420c-9609-31edf9426111" xlink:href="ino-20231231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d592f799-4a12-41fa-90aa-3547ff192c9a" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_423e1b10-35b5-420c-9609-31edf9426111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BehestiVKimEtAlMember_d2cad6f6-62ff-447e-bf0c-44bad69c40b5" xlink:href="ino-20231231.xsd#ino_BehestiVKimEtAlMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d592f799-4a12-41fa-90aa-3547ff192c9a" xlink:to="loc_ino_BehestiVKimEtAlMember_d2cad6f6-62ff-447e-bf0c-44bad69c40b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_17067513-051f-43bd-93cd-581b160b46a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_0117b889-2831-4e62-af68-855303d81b59" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_17067513-051f-43bd-93cd-581b160b46a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e0880f87-1f08-4a7f-963b-2ff1a9bb64f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_17067513-051f-43bd-93cd-581b160b46a5" xlink:to="loc_us-gaap_RelatedPartyDomain_e0880f87-1f08-4a7f-963b-2ff1a9bb64f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_ba57ca6f-c8ba-42cd-a532-e74d6a7f91da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e0880f87-1f08-4a7f-963b-2ff1a9bb64f2" xlink:to="loc_us-gaap_NonrelatedPartyMember_ba57ca6f-c8ba-42cd-a532-e74d6a7f91da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:href="ino-20231231.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_0117b889-2831-4e62-af68-855303d81b59" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_0dd83969-a0b4-4906-85ba-a1fdd3c105bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_0dd83969-a0b4-4906-85ba-a1fdd3c105bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_bea979e9-484a-43f8-b092-75e610a6500e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_AccruedSalariesCurrent_bea979e9-484a-43f8-b092-75e610a6500e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_9c0aa884-2155-406b-a528-bdae3baacb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_LitigationReserveCurrent_9c0aa884-2155-406b-a528-bdae3baacb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_bb2bdfa9-3c47-43e9-809c-e41535beb9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_bb2bdfa9-3c47-43e9-809c-e41535beb9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_06440877-98df-49f7-9c4e-21cd7f341248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_06440877-98df-49f7-9c4e-21cd7f341248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_f7a39d47-36f9-48fd-81c7-4b67e26130f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_f7a39d47-36f9-48fd-81c7-4b67e26130f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_b5cd9328-7f46-4e61-9814-4a0db3be731d" xlink:href="ino-20231231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_b5cd9328-7f46-4e61-9814-4a0db3be731d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e1f98def-fe04-4c3d-8d15-1142d5013a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e1f98def-fe04-4c3d-8d15-1142d5013a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_c3d8a724-a589-4d0c-8e85-33442efb8bc7" xlink:href="ino-20231231.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_c3d8a724-a589-4d0c-8e85-33442efb8bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_4a13d5e6-d087-452c-ac4f-22678adfb286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_4a13d5e6-d087-452c-ac4f-22678adfb286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantLiability_9317a4f7-6f4d-4388-8301-2f92a353185d" xlink:href="ino-20231231.xsd#ino_GrantLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_8fac1555-7c7c-4f95-9e18-1e6cbd4b7a95" xlink:to="loc_ino_GrantLiability_9317a4f7-6f4d-4388-8301-2f92a353185d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#FixedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_53dcb06e-89d9-4742-aa35-e26242d62bec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aa6c47c-5d18-4d87-b325-e7e73e9df56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_53dcb06e-89d9-4742-aa35-e26242d62bec" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aa6c47c-5d18-4d87-b325-e7e73e9df56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_38274497-4fa4-43b0-9656-a00b76370bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aa6c47c-5d18-4d87-b325-e7e73e9df56c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_38274497-4fa4-43b0-9656-a00b76370bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df20eeb-9285-45e0-bb3c-fc63f848b339" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_38274497-4fa4-43b0-9656-a00b76370bfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df20eeb-9285-45e0-bb3c-fc63f848b339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e865a3e6-aaee-484f-955e-b718e499e963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df20eeb-9285-45e0-bb3c-fc63f848b339" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e865a3e6-aaee-484f-955e-b718e499e963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_c06b11ea-4ab4-45af-88c5-5820c3d011e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df20eeb-9285-45e0-bb3c-fc63f848b339" xlink:to="loc_us-gaap_OfficeEquipmentMember_c06b11ea-4ab4-45af-88c5-5820c3d011e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_078935db-93b6-4f54-9848-0c787a637ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df20eeb-9285-45e0-bb3c-fc63f848b339" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_078935db-93b6-4f54-9848-0c787a637ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_5cae8e74-9481-4326-84bd-7db78eeb82ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df20eeb-9285-45e0-bb3c-fc63f848b339" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_5cae8e74-9481-4326-84bd-7db78eeb82ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aa6c47c-5d18-4d87-b325-e7e73e9df56c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c5210635-1fed-4ea1-a470-ba88a0de993f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c5210635-1fed-4ea1-a470-ba88a0de993f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_52d0388d-4209-4a3b-a7bb-d869f61842b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_52d0388d-4209-4a3b-a7bb-d869f61842b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2848f286-b79d-4881-b425-02ddf8779b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2848f286-b79d-4881-b425-02ddf8779b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_aa44c7af-cb8a-4aea-ba24-d1a1292b3b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_us-gaap_Depreciation_aa44c7af-cb8a-4aea-ba24-d1a1292b3b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PropertyPlantAndEquipmentDisposedOfBySale_58ac36d5-493b-49c7-b101-5a38167827e6" xlink:href="ino-20231231.xsd#ino_PropertyPlantAndEquipmentDisposedOfBySale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_ino_PropertyPlantAndEquipmentDisposedOfBySale_58ac36d5-493b-49c7-b101-5a38167827e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_b1e49e72-1e22-4c4f-bc9c-27dfa3ec7461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8876abf1-a7de-425a-8733-ee9e5b9e8ba7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_b1e49e72-1e22-4c4f-bc9c-27dfa3ec7461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d24f24ca-dd1a-476a-ba7a-463c5349ab96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_60735bf0-76d9-42d6-8ad2-3c0ce3435c75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d24f24ca-dd1a-476a-ba7a-463c5349ab96" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_60735bf0-76d9-42d6-8ad2-3c0ce3435c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a634c7c6-d31b-4bcf-a6e9-84e55989ab5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_60735bf0-76d9-42d6-8ad2-3c0ce3435c75" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a634c7c6-d31b-4bcf-a6e9-84e55989ab5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_377309eb-e909-4a0b-be1e-054098639154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a634c7c6-d31b-4bcf-a6e9-84e55989ab5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_377309eb-e909-4a0b-be1e-054098639154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_3d45359a-4cef-4ecb-bc48-712d2b7200f8" xlink:href="ino-20231231.xsd#ino_BiojectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_377309eb-e909-4a0b-be1e-054098639154" xlink:to="loc_ino_BiojectMember_3d45359a-4cef-4ecb-bc48-712d2b7200f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_11968745-fb8c-4bc9-abe5-a8a9576f602e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_60735bf0-76d9-42d6-8ad2-3c0ce3435c75" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_11968745-fb8c-4bc9-abe5-a8a9576f602e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_9dde90a9-2c86-40be-8600-a0a599ecf6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_11968745-fb8c-4bc9-abe5-a8a9576f602e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_9dde90a9-2c86-40be-8600-a0a599ecf6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_67d11a37-fe3e-49b3-9786-9449c085486a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_11968745-fb8c-4bc9-abe5-a8a9576f602e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_67d11a37-fe3e-49b3-9786-9449c085486a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_11f5a53d-7b82-4ef6-8fed-9bdf9059d0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_11968745-fb8c-4bc9-abe5-a8a9576f602e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_11f5a53d-7b82-4ef6-8fed-9bdf9059d0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_61e98f06-cce7-4eb8-9b64-3ac4b40e7097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_11968745-fb8c-4bc9-abe5-a8a9576f602e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_61e98f06-cce7-4eb8-9b64-3ac4b40e7097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fcc75f1c-9fa9-4400-9afd-cc73c45f18ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_2589fcb8-36a4-463f-9e3d-73d58aaa9a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fcc75f1c-9fa9-4400-9afd-cc73c45f18ad" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_2589fcb8-36a4-463f-9e3d-73d58aaa9a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a41f56a-e79e-4794-96a0-559eb0dc731b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_2589fcb8-36a4-463f-9e3d-73d58aaa9a3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a41f56a-e79e-4794-96a0-559eb0dc731b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_574e2756-b890-4615-b99a-01a6ea0c6d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a41f56a-e79e-4794-96a0-559eb0dc731b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_574e2756-b890-4615-b99a-01a6ea0c6d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_03288405-cfb0-44cd-a03b-f604df58fb51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_574e2756-b890-4615-b99a-01a6ea0c6d54" xlink:to="loc_us-gaap_LicensingAgreementsMember_03288405-cfb0-44cd-a03b-f604df58fb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_682f2a8c-5cbf-49f0-b20d-f3642f427263" xlink:href="ino-20231231.xsd#ino_BiojectMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_574e2756-b890-4615-b99a-01a6ea0c6d54" xlink:to="loc_ino_BiojectMember_682f2a8c-5cbf-49f0-b20d-f3642f427263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_6b378f1e-8d42-4ddc-b83f-f130abdd1afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_574e2756-b890-4615-b99a-01a6ea0c6d54" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_6b378f1e-8d42-4ddc-b83f-f130abdd1afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a0843680-4cb2-430e-9a67-a17e0018882c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_2589fcb8-36a4-463f-9e3d-73d58aaa9a3b" xlink:to="loc_srt_RangeAxis_a0843680-4cb2-430e-9a67-a17e0018882c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_172ae783-f0cd-4f22-8e8a-0f0469f8bc4e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a0843680-4cb2-430e-9a67-a17e0018882c" xlink:to="loc_srt_RangeMember_172ae783-f0cd-4f22-8e8a-0f0469f8bc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_0c56b348-ed60-4a18-95d3-44ca86285cfd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_172ae783-f0cd-4f22-8e8a-0f0469f8bc4e" xlink:to="loc_srt_WeightedAverageMember_0c56b348-ed60-4a18-95d3-44ca86285cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_83fd314b-7457-4629-aaa1-eee285836583" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_2589fcb8-36a4-463f-9e3d-73d58aaa9a3b" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_83fd314b-7457-4629-aaa1-eee285836583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91f3ab09-9aba-4d97-965b-c0c9a98e3559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_83fd314b-7457-4629-aaa1-eee285836583" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91f3ab09-9aba-4d97-965b-c0c9a98e3559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_357ce4a5-5714-412c-a4f1-ea97ee6502eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91f3ab09-9aba-4d97-965b-c0c9a98e3559" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_357ce4a5-5714-412c-a4f1-ea97ee6502eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_70cf3694-c161-4466-b29a-c01687cfce64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_357ce4a5-5714-412c-a4f1-ea97ee6502eb" xlink:to="loc_us-gaap_GoodwillGross_70cf3694-c161-4466-b29a-c01687cfce64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a9c3bd61-a6b4-4759-84a3-e31dc876ba62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_357ce4a5-5714-412c-a4f1-ea97ee6502eb" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a9c3bd61-a6b4-4759-84a3-e31dc876ba62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b8da5f18-3f30-466a-a87c-9fd81b254ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_357ce4a5-5714-412c-a4f1-ea97ee6502eb" xlink:to="loc_us-gaap_Goodwill_b8da5f18-3f30-466a-a87c-9fd81b254ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91f3ab09-9aba-4d97-965b-c0c9a98e3559" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9b4119d6-b828-44e2-89df-0af250d0e420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9b4119d6-b828-44e2-89df-0af250d0e420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50718209-fdb3-40c1-9cdb-741ce28c93bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50718209-fdb3-40c1-9cdb-741ce28c93bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d893ce9a-0934-4506-9f75-6370d51755ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d893ce9a-0934-4506-9f75-6370d51755ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_606e377b-a81d-4e6f-8a3e-ac59efb69b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_606e377b-a81d-4e6f-8a3e-ac59efb69b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a4048b7e-0b62-40de-b00a-03b8acaf37a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a4048b7e-0b62-40de-b00a-03b8acaf37a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_efe21c11-ea00-4755-8e6d-189ae4ae79cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2373ddc6-a052-4fe7-8a88-d728228803a6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_efe21c11-ea00-4755-8e6d-189ae4ae79cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_f3164bfd-0ce1-475f-b93a-cd5af8b0a275" xlink:href="ino-20231231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91f3ab09-9aba-4d97-965b-c0c9a98e3559" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_f3164bfd-0ce1-475f-b93a-cd5af8b0a275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_ae3bee4e-6fd8-437d-99ec-fde09bf11421" xlink:href="ino-20231231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91f3ab09-9aba-4d97-965b-c0c9a98e3559" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_ae3bee4e-6fd8-437d-99ec-fde09bf11421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0bb4e50a-b687-434e-b566-9c26db942201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0bb4e50a-b687-434e-b566-9c26db942201" xlink:to="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b7381e37-59f0-412d-bcd8-30e0d4cf83e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b7381e37-59f0-412d-bcd8-30e0d4cf83e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3a79cfd9-ccd1-4107-bbdd-4a6324d6fa43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b7381e37-59f0-412d-bcd8-30e0d4cf83e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3a79cfd9-ccd1-4107-bbdd-4a6324d6fa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_8e69dceb-ca1a-47d9-af36-ec0909eef2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3a79cfd9-ccd1-4107-bbdd-4a6324d6fa43" xlink:to="loc_us-gaap_ConvertibleDebtMember_8e69dceb-ca1a-47d9-af36-ec0909eef2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_59ca5364-caf0-4fa9-a737-50b6d19d81e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:to="loc_us-gaap_DebtInstrumentAxis_59ca5364-caf0-4fa9-a737-50b6d19d81e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_888b7a60-75d8-4918-b0f9-a68d241ddefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_59ca5364-caf0-4fa9-a737-50b6d19d81e6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_888b7a60-75d8-4918-b0f9-a68d241ddefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_67acd3d0-850f-4c55-a5ea-3a27e80c47df" xlink:href="ino-20231231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_888b7a60-75d8-4918-b0f9-a68d241ddefc" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_67acd3d0-850f-4c55-a5ea-3a27e80c47df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44073caf-9ee7-43ed-9853-4d21ea67a9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44073caf-9ee7-43ed-9853-4d21ea67a9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_b6fa879a-b4b3-4e99-a723-af1a19d313c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_44073caf-9ee7-43ed-9853-4d21ea67a9b1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_b6fa879a-b4b3-4e99-a723-af1a19d313c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_0a7ae9ba-8bfd-4448-bf55-f64029a58c10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_b6fa879a-b4b3-4e99-a723-af1a19d313c0" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_0a7ae9ba-8bfd-4448-bf55-f64029a58c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6ec0b2f9-ac5a-4a61-943c-3bde3de7274a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6ec0b2f9-ac5a-4a61-943c-3bde3de7274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_caa49bbf-deda-4e9a-8d67-8b85e609b707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6ec0b2f9-ac5a-4a61-943c-3bde3de7274a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_caa49bbf-deda-4e9a-8d67-8b85e609b707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d7a24827-dc4b-4857-bccb-85a48e7edba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_caa49bbf-deda-4e9a-8d67-8b85e609b707" xlink:to="loc_us-gaap_SubsequentEventMember_d7a24827-dc4b-4857-bccb-85a48e7edba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9087786d-f037-4ae7-bb46-13af8be932f0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_85772b90-3f83-4464-a5a8-863640e4c923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_85772b90-3f83-4464-a5a8-863640e4c923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4aa7128b-7f9b-404e-a86d-0a5b2bace9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4aa7128b-7f9b-404e-a86d-0a5b2bace9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_884ad500-f1f9-40ec-8b17-9dc4aebea69f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_884ad500-f1f9-40ec-8b17-9dc4aebea69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_77401d9b-0211-4a41-ab37-94123cb8f408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_77401d9b-0211-4a41-ab37-94123cb8f408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_118fa4c3-9dd8-4567-a1aa-aad4a3ad67af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_118fa4c3-9dd8-4567-a1aa-aad4a3ad67af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0287148e-1a5c-4e1c-902e-51872bd889e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0287148e-1a5c-4e1c-902e-51872bd889e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_839770fd-6fbf-483e-82fa-acb334f50995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_839770fd-6fbf-483e-82fa-acb334f50995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d89eec6d-ef79-4dfd-a029-32d6e449e2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d89eec6d-ef79-4dfd-a029-32d6e449e2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5a0798c6-245e-4bbe-bd7a-76a6c9c3c9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5a0798c6-245e-4bbe-bd7a-76a6c9c3c9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_2e921f14-25f2-45c7-83a2-07f409c5bdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_ConvertibleDebt_2e921f14-25f2-45c7-83a2-07f409c5bdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6313ae23-9f8f-47a9-9cd4-01984b406c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_InterestExpense_6313ae23-9f8f-47a9-9cd4-01984b406c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a308781b-daf4-4c9a-8ada-f6fd69ceb035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88f8d104-97f1-496c-9628-f4b2ef9c03fb" xlink:to="loc_us-gaap_InterestExpenseDebt_a308781b-daf4-4c9a-8ada-f6fd69ceb035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#ConvertibleDebtScheduleofConvertibleDebtDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a946639b-4cae-4238-b792-787fd5d72dea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_63ff2816-d572-4f49-ac88-6c34319f670a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a946639b-4cae-4238-b792-787fd5d72dea" xlink:to="loc_us-gaap_DebtInstrumentTable_63ff2816-d572-4f49-ac88-6c34319f670a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fcc16b2d-bcd9-4277-8932-2b0f02e115d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_63ff2816-d572-4f49-ac88-6c34319f670a" xlink:to="loc_us-gaap_DebtInstrumentAxis_fcc16b2d-bcd9-4277-8932-2b0f02e115d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_68f231cd-3593-477c-98c4-48acb28d3b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fcc16b2d-bcd9-4277-8932-2b0f02e115d8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_68f231cd-3593-477c-98c4-48acb28d3b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c887c3db-e55e-48b1-b72e-75b74edfc7e7" xlink:href="ino-20231231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_68f231cd-3593-477c-98c4-48acb28d3b6b" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c887c3db-e55e-48b1-b72e-75b74edfc7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_63ff2816-d572-4f49-ac88-6c34319f670a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5901f12d-2b93-4775-8ac9-e557528ccddc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5901f12d-2b93-4775-8ac9-e557528ccddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_4ec4792a-a142-49c8-83c6-0c7eef0cef5e" xlink:href="ino-20231231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_4ec4792a-a142-49c8-83c6-0c7eef0cef5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_646fc4f1-2528-4ffa-bc85-5b814589bcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_646fc4f1-2528-4ffa-bc85-5b814589bcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest_3dd1ebd2-6cda-4991-8162-a5e710aed063" xlink:href="ino-20231231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:to="loc_ino_DebtinstrumentAccruedInterest_3dd1ebd2-6cda-4991-8162-a5e710aed063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6ca65902-c898-493d-a0ba-9c02ccf0044e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7ed82886-4f9c-4669-801d-8ef0092dfce6" xlink:to="loc_us-gaap_LongTermDebt_6ca65902-c898-493d-a0ba-9c02ccf0044e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#StockholdersEquityScheduleofPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1d29ced0-9a17-4b25-a68d-4641466b1891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_77fee4f4-b84b-4b50-b76c-394708cef702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1d29ced0-9a17-4b25-a68d-4641466b1891" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_77fee4f4-b84b-4b50-b76c-394708cef702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9bcf3687-5ef6-4cd4-9e4b-9a99c33b3a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77fee4f4-b84b-4b50-b76c-394708cef702" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9bcf3687-5ef6-4cd4-9e4b-9a99c33b3a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_15f61872-0181-4d83-a68c-788da9995e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9bcf3687-5ef6-4cd4-9e4b-9a99c33b3a62" xlink:to="loc_us-gaap_ClassOfStockDomain_15f61872-0181-4d83-a68c-788da9995e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_29880e8d-70fd-416f-b103-9980c9829d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_15f61872-0181-4d83-a68c-788da9995e0d" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_29880e8d-70fd-416f-b103-9980c9829d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d4682da7-a379-420d-800b-3e81bd4d8fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77fee4f4-b84b-4b50-b76c-394708cef702" xlink:to="loc_us-gaap_ClassOfStockLineItems_d4682da7-a379-420d-800b-3e81bd4d8fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f4a2e85a-cdb9-4ca8-9c7a-222dd8b8178b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d4682da7-a379-420d-800b-3e81bd4d8fc3" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f4a2e85a-cdb9-4ca8-9c7a-222dd8b8178b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_914111f5-a5aa-42d3-90a5-9ff0571e6031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f4a2e85a-cdb9-4ca8-9c7a-222dd8b8178b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_914111f5-a5aa-42d3-90a5-9ff0571e6031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_30b078bd-0dfd-427f-a1ba-497365bd28eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f4a2e85a-cdb9-4ca8-9c7a-222dd8b8178b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_30b078bd-0dfd-427f-a1ba-497365bd28eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b773bd4a-b564-485f-9e83-29648b9782a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f4a2e85a-cdb9-4ca8-9c7a-222dd8b8178b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b773bd4a-b564-485f-9e83-29648b9782a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a8897e62-6e5b-43bb-9cfb-e1de97187470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f4a2e85a-cdb9-4ca8-9c7a-222dd8b8178b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a8897e62-6e5b-43bb-9cfb-e1de97187470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_2bf28063-080f-484b-8353-486f7824795d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_2bf28063-080f-484b-8353-486f7824795d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6d24a2cf-fffc-4f8e-b9d4-d0570c9860e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6d24a2cf-fffc-4f8e-b9d4-d0570c9860e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_be5541cf-a1a8-4dc8-99d2-755350b7ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6d24a2cf-fffc-4f8e-b9d4-d0570c9860e5" xlink:to="loc_us-gaap_ClassOfStockDomain_be5541cf-a1a8-4dc8-99d2-755350b7ee48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_c96df47a-68d1-4e52-bbb6-dca8d215233c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_be5541cf-a1a8-4dc8-99d2-755350b7ee48" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_c96df47a-68d1-4e52-bbb6-dca8d215233c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_446d6676-784d-44a9-8719-6ac2a27d8303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_be5541cf-a1a8-4dc8-99d2-755350b7ee48" xlink:to="loc_us-gaap_CommonStockMember_446d6676-784d-44a9-8719-6ac2a27d8303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_efc633c1-af70-4e86-b406-6a9d7b8379be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_efc633c1-af70-4e86-b406-6a9d7b8379be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbf1b6d4-80d7-40c6-ba90-f34806a646e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_efc633c1-af70-4e86-b406-6a9d7b8379be" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbf1b6d4-80d7-40c6-ba90-f34806a646e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember_87f983be-4145-439b-9bb1-cda34dc107bd" xlink:href="ino-20231231.xsd#ino_A2021SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbf1b6d4-80d7-40c6-ba90-f34806a646e7" xlink:to="loc_ino_A2021SalesAgreementMember_87f983be-4145-439b-9bb1-cda34dc107bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_f80dedc1-db94-443f-8811-47c3e79cb344" xlink:href="ino-20231231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbf1b6d4-80d7-40c6-ba90-f34806a646e7" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_f80dedc1-db94-443f-8811-47c3e79cb344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7de5e294-fdee-47c0-9221-b49cb1e01818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7de5e294-fdee-47c0-9221-b49cb1e01818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_82fd0d19-b252-4629-b50a-d5f1159dce4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7de5e294-fdee-47c0-9221-b49cb1e01818" xlink:to="loc_us-gaap_EquityComponentDomain_82fd0d19-b252-4629-b50a-d5f1159dce4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8b5a3d33-20da-4ff3-878b-d7f103aec82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_82fd0d19-b252-4629-b50a-d5f1159dce4e" xlink:to="loc_us-gaap_CommonStockMember_8b5a3d33-20da-4ff3-878b-d7f103aec82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ee876b74-a7f8-45b1-a0c1-a04072757cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_PlanNameAxis_ee876b74-a7f8-45b1-a0c1-a04072757cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c7f51974-1fc2-4924-b4ed-8e059fc68ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ee876b74-a7f8-45b1-a0c1-a04072757cfe" xlink:to="loc_us-gaap_PlanNameDomain_c7f51974-1fc2-4924-b4ed-8e059fc68ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_b45da787-32cb-42e9-b065-4d8d3ab2a3ec" xlink:href="ino-20231231.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c7f51974-1fc2-4924-b4ed-8e059fc68ed9" xlink:to="loc_ino_A2016IncentivePlanMember_b45da787-32cb-42e9-b065-4d8d3ab2a3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember_fc1008a1-4ae0-471e-acd5-f03f9c92d41d" xlink:href="ino-20231231.xsd#ino_A2022InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c7f51974-1fc2-4924-b4ed-8e059fc68ed9" xlink:to="loc_ino_A2022InducementPlanMember_fc1008a1-4ae0-471e-acd5-f03f9c92d41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_e1dc1117-ea54-400c-b237-9ca9683a8ef5" xlink:href="ino-20231231.xsd#ino_A2007IncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c7f51974-1fc2-4924-b4ed-8e059fc68ed9" xlink:to="loc_ino_A2007IncentivePlanMember_e1dc1117-ea54-400c-b237-9ca9683a8ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2023IncentivePlanMember_5e878588-025e-4a6e-94f1-3e090532cc4f" xlink:href="ino-20231231.xsd#ino_A2023IncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c7f51974-1fc2-4924-b4ed-8e059fc68ed9" xlink:to="loc_ino_A2023IncentivePlanMember_5e878588-025e-4a6e-94f1-3e090532cc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a3fd8b19-d9ef-42e8-9192-a8504bd663e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_AwardTypeAxis_a3fd8b19-d9ef-42e8-9192-a8504bd663e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_777dfab5-7fc8-433b-a3e8-efb541471464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a3fd8b19-d9ef-42e8-9192-a8504bd663e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_777dfab5-7fc8-433b-a3e8-efb541471464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_62c1e8d7-f62b-4509-be66-4170efc00b35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_777dfab5-7fc8-433b-a3e8-efb541471464" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_62c1e8d7-f62b-4509-be66-4170efc00b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0a626089-fced-42c3-b994-46d34a75b4af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0a626089-fced-42c3-b994-46d34a75b4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19113b04-521e-4d27-a21d-e3f6ce5a44d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0a626089-fced-42c3-b994-46d34a75b4af" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19113b04-521e-4d27-a21d-e3f6ce5a44d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e756c37-3966-4d2f-83a9-04e15d17aedb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19113b04-521e-4d27-a21d-e3f6ce5a44d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e756c37-3966-4d2f-83a9-04e15d17aedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8a8240c1-697e-439c-a44a-f668ff09b609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19113b04-521e-4d27-a21d-e3f6ce5a44d1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8a8240c1-697e-439c-a44a-f668ff09b609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0bb53da6-3b1f-460a-b02f-d1b8915de9c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_srt_TitleOfIndividualAxis_0bb53da6-3b1f-460a-b02f-d1b8915de9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_028ae6cc-af50-4ba0-96b7-60ac1a28e652" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_0bb53da6-3b1f-460a-b02f-d1b8915de9c0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_028ae6cc-af50-4ba0-96b7-60ac1a28e652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember_f6c09284-bd2c-49ed-931f-e6e65a09d979" xlink:href="ino-20231231.xsd#ino_FormerPresidentAndChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_028ae6cc-af50-4ba0-96b7-60ac1a28e652" xlink:to="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember_f6c09284-bd2c-49ed-931f-e6e65a09d979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_4d35bf91-3b9b-4693-b851-a743f3e53f83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_GranteeStatusAxis_4d35bf91-3b9b-4693-b851-a743f3e53f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_1b2bcc0c-cb65-481d-ad9b-4cd991aab96b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_4d35bf91-3b9b-4693-b851-a743f3e53f83" xlink:to="loc_us-gaap_GranteeStatusDomain_1b2bcc0c-cb65-481d-ad9b-4cd991aab96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_7fabf147-92c1-456e-88da-952d251dc067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_1b2bcc0c-cb65-481d-ad9b-4cd991aab96b" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_7fabf147-92c1-456e-88da-952d251dc067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_88cac831-b445-43d7-b024-6f97a3f682d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_srt_LitigationCaseAxis_88cac831-b445-43d7-b024-6f97a3f682d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7d3aeac0-56cc-4e6f-88d2-dbccc20d6f54" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_88cac831-b445-43d7-b024-6f97a3f682d7" xlink:to="loc_srt_LitigationCaseTypeDomain_7d3aeac0-56cc-4e6f-88d2-dbccc20d6f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_c907353e-8791-4abd-ba74-cf81f2946371" xlink:href="ino-20231231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7d3aeac0-56cc-4e6f-88d2-dbccc20d6f54" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_c907353e-8791-4abd-ba74-cf81f2946371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc280f71-2cf3-454b-85ff-0bbbe33dcbde" xlink:to="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_175d6c27-69c7-48ab-98b3-9ae34dedb1d0" xlink:href="ino-20231231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_175d6c27-69c7-48ab-98b3-9ae34dedb1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6dc543ff-9f78-44b2-9170-2bd125aae88a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6dc543ff-9f78-44b2-9170-2bd125aae88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_27d61f20-3323-42da-9340-cb13991cecb0" xlink:href="ino-20231231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_27d61f20-3323-42da-9340-cb13991cecb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_0957ed40-e7b8-4be7-a3bf-0a67acc7a147" xlink:href="ino-20231231.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_0957ed40-e7b8-4be7-a3bf-0a67acc7a147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_668f8bf9-79c9-4720-9904-c3268573f6be" xlink:href="ino-20231231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_668f8bf9-79c9-4720-9904-c3268573f6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_bf96de3c-7955-4c3e-a58e-33503202c30a" xlink:href="ino-20231231.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_bf96de3c-7955-4c3e-a58e-33503202c30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_c475fe7c-27fe-4099-b9af-a9fc33327f14" xlink:href="ino-20231231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_c475fe7c-27fe-4099-b9af-a9fc33327f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_28420a41-a1c4-422d-b64c-3ee2bd97ca96" xlink:href="ino-20231231.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_28420a41-a1c4-422d-b64c-3ee2bd97ca96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_16dfff8b-e0f2-4410-acf6-9ae5636ba228" xlink:href="ino-20231231.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_16dfff8b-e0f2-4410-acf6-9ae5636ba228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c4e47f78-649a-4df1-8004-547147052303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_CommonStockSharesIssued_c4e47f78-649a-4df1-8004-547147052303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7b3f03d9-1244-45b8-8b4d-622222b0a67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7b3f03d9-1244-45b8-8b4d-622222b0a67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_48e5eda0-8d9e-4b8b-b0b4-fe63b4e0f7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_48e5eda0-8d9e-4b8b-b0b4-fe63b4e0f7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_b2c52eb3-2acd-408e-b6e7-725ee358d894" xlink:href="ino-20231231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_b2c52eb3-2acd-408e-b6e7-725ee358d894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_1da1f0f7-1ae1-4ea3-af24-60fd978f8217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_1da1f0f7-1ae1-4ea3-af24-60fd978f8217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00a8bd40-ca9b-48e6-9c12-c89db3ebdd74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00a8bd40-ca9b-48e6-9c12-c89db3ebdd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db93f07a-fdfa-427f-b5f1-6f175b337764" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db93f07a-fdfa-427f-b5f1-6f175b337764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_82e0e1d7-9cf6-4793-9b3f-1be7e0104150" xlink:href="ino-20231231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_82e0e1d7-9cf6-4793-9b3f-1be7e0104150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2df5a3fc-75dd-44b6-a0f8-8e5898064bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2df5a3fc-75dd-44b6-a0f8-8e5898064bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_7d8abfec-a321-4a57-b8db-af49ea417d69" xlink:href="ino-20231231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_7d8abfec-a321-4a57-b8db-af49ea417d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_db728d48-b7d7-4f37-a44d-44579f1b03e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_db728d48-b7d7-4f37-a44d-44579f1b03e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4a17f4f-72e0-4dd4-87b7-5457cb763368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4a17f4f-72e0-4dd4-87b7-5457cb763368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52c9f615-dce1-449e-9614-083f79fc4191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52c9f615-dce1-449e-9614-083f79fc4191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_19463c90-b24e-4cdb-8f92-418828227e5a" xlink:href="ino-20231231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_19463c90-b24e-4cdb-8f92-418828227e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b728d759-8e78-4cc6-a20a-87caf6c530a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b728d759-8e78-4cc6-a20a-87caf6c530a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_2f5f3839-8bb2-4ce3-af01-fb279c3924ae" xlink:href="ino-20231231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_2f5f3839-8bb2-4ce3-af01-fb279c3924ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c7a603d4-7ed7-4f26-be27-46326a271f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c7a603d4-7ed7-4f26-be27-46326a271f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_30b7de6a-1d21-4b74-9da2-7a6717a1ff12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_30b7de6a-1d21-4b74-9da2-7a6717a1ff12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_68d2e806-6600-4c7e-9c85-9b39f41ec38b" xlink:href="ino-20231231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_68d2e806-6600-4c7e-9c85-9b39f41ec38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_6e86da4a-b991-4f4f-98f7-d50a692d22c5" xlink:href="ino-20231231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_6e86da4a-b991-4f4f-98f7-d50a692d22c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_33d4d971-fb28-4a47-a8c0-ab45c1f72780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_33d4d971-fb28-4a47-a8c0-ab45c1f72780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2ca339a4-7316-49d4-a11a-369e15b2ac6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2ca339a4-7316-49d4-a11a-369e15b2ac6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_329961b0-5f8c-4dea-8c97-5d74093599b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_329961b0-5f8c-4dea-8c97-5d74093599b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d05bbb08-797f-4627-8377-83a17dc12a73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d05bbb08-797f-4627-8377-83a17dc12a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e2e421d4-a486-4f32-baa4-2083c2a7d2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e2e421d4-a486-4f32-baa4-2083c2a7d2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e8c86cda-3577-4a07-823f-cd44f5744f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b830047a-5954-4f1b-955f-447f15a6c997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e8c86cda-3577-4a07-823f-cd44f5744f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#StockholdersEquityScheduleofStockOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a9a560de-00c0-4519-aeb2-0ace6e530084" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_fca76365-076e-482e-acdf-8c69db9556f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a9a560de-00c0-4519-aeb2-0ace6e530084" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_fca76365-076e-482e-acdf-8c69db9556f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c0a5fe3e-7f93-48ad-b074-1bb2b3a13120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_fca76365-076e-482e-acdf-8c69db9556f7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c0a5fe3e-7f93-48ad-b074-1bb2b3a13120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c0a5fe3e-7f93-48ad-b074-1bb2b3a13120" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember_157d7b9c-fc7d-47c9-bd84-3194bba26d46" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:to="loc_ino_RangeOfExercisePricesOneMember_157d7b9c-fc7d-47c9-bd84-3194bba26d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_1c92a1d7-6fab-49b4-bc3d-4aae2edd5308" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:to="loc_ino_RangeOfExercisePricesTwoMember_1c92a1d7-6fab-49b4-bc3d-4aae2edd5308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_5c876929-ea5c-42b7-9bd1-58419132303a" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:to="loc_ino_RangeOfExercisePricesThreeMember_5c876929-ea5c-42b7-9bd1-58419132303a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember_63a51e02-8cc8-4493-9c43-bf386a796c0b" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:to="loc_ino_RangeOfExercisePricesFourMember_63a51e02-8cc8-4493-9c43-bf386a796c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_1ad7389c-dda4-4a13-a8d1-a9805217722c" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:to="loc_ino_RangeOfExercisePricesFiveMember_1ad7389c-dda4-4a13-a8d1-a9805217722c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember_05d314ca-7747-4dbb-b383-4d1d8c72f16e" xlink:href="ino-20231231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0273fd92-fe1c-42f9-aa40-a6545f7299bc" xlink:to="loc_ino_RangeOfExercisePricesSixMember_05d314ca-7747-4dbb-b383-4d1d8c72f16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_fca76365-076e-482e-acdf-8c69db9556f7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8c065319-0641-43e9-876f-f614bcc0c378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8c065319-0641-43e9-876f-f614bcc0c378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_dc6fc474-5501-429f-872f-e12746257396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_dc6fc474-5501-429f-872f-e12746257396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_ea4f2606-b906-4a5e-8f05-db9de150102d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_ea4f2606-b906-4a5e-8f05-db9de150102d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_a88a845a-d7ad-4d0a-a5c3-54b1c651f527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_a88a845a-d7ad-4d0a-a5c3-54b1c651f527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_171d6740-ac87-44be-9f20-50d531b8e55c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_171d6740-ac87-44be-9f20-50d531b8e55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d29b9dac-9125-4cfe-8be8-cb10e738562e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d29b9dac-9125-4cfe-8be8-cb10e738562e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_bf5b9bbb-aa58-47eb-ab6e-0b6afb89e7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a2370f49-763e-4a41-9277-8d2d6d535d40" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_bf5b9bbb-aa58-47eb-ab6e-0b6afb89e7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_fbd3dc04-9be9-48bc-9eb3-1f8d4344316f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f67b2b75-c466-4e3e-929d-6a810fa0ed4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_fbd3dc04-9be9-48bc-9eb3-1f8d4344316f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f67b2b75-c466-4e3e-929d-6a810fa0ed4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_421110fb-ef63-4159-ae67-63bc6b563611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f67b2b75-c466-4e3e-929d-6a810fa0ed4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_421110fb-ef63-4159-ae67-63bc6b563611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_48d145b1-304c-45c6-a541-32e8b38efa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f67b2b75-c466-4e3e-929d-6a810fa0ed4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_48d145b1-304c-45c6-a541-32e8b38efa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_48a654a7-f4a7-4d3f-82ba-37dc9cd3ff2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f67b2b75-c466-4e3e-929d-6a810fa0ed4f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_48a654a7-f4a7-4d3f-82ba-37dc9cd3ff2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b5dd8a64-4e93-4d60-bbdb-fe3bf8d475c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f67b2b75-c466-4e3e-929d-6a810fa0ed4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b5dd8a64-4e93-4d60-bbdb-fe3bf8d475c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_45859166-9e92-48db-8dff-7964b7d0df2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f67b2b75-c466-4e3e-929d-6a810fa0ed4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_45859166-9e92-48db-8dff-7964b7d0df2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_affcb3df-58ce-4fa4-8586-98cddc48b6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_fbd3dc04-9be9-48bc-9eb3-1f8d4344316f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_affcb3df-58ce-4fa4-8586-98cddc48b6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_92d05cea-0682-4d2c-9270-865c25747906" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_affcb3df-58ce-4fa4-8586-98cddc48b6e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_92d05cea-0682-4d2c-9270-865c25747906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_beb5f1e9-4afb-481d-8492-2871cd7ede82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_affcb3df-58ce-4fa4-8586-98cddc48b6e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_beb5f1e9-4afb-481d-8492-2871cd7ede82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cc796378-2339-49cf-a4f9-1c0f152493cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_affcb3df-58ce-4fa4-8586-98cddc48b6e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cc796378-2339-49cf-a4f9-1c0f152493cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_4c7753d0-9a40-4431-ab6f-191480b63062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_affcb3df-58ce-4fa4-8586-98cddc48b6e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_4c7753d0-9a40-4431-ab6f-191480b63062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_218ec40c-a25b-4b4e-bfa8-74d73bef2b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_affcb3df-58ce-4fa4-8586-98cddc48b6e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_218ec40c-a25b-4b4e-bfa8-74d73bef2b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a10ea2d7-1442-42f5-8c5e-7c2aace35320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d30e0104-5c6a-404f-a921-8af8ce161f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a10ea2d7-1442-42f5-8c5e-7c2aace35320" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d30e0104-5c6a-404f-a921-8af8ce161f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e94cc68e-20a6-447a-8439-f4f3503c2728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d30e0104-5c6a-404f-a921-8af8ce161f80" xlink:to="loc_us-gaap_AwardTypeAxis_e94cc68e-20a6-447a-8439-f4f3503c2728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b89d2e76-b3f3-47c5-b679-034e64d49ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e94cc68e-20a6-447a-8439-f4f3503c2728" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b89d2e76-b3f3-47c5-b679-034e64d49ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_009e627b-db90-4866-be7c-ffba2428b639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b89d2e76-b3f3-47c5-b679-034e64d49ae2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_009e627b-db90-4866-be7c-ffba2428b639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36030180-2ae0-44a5-98d2-08b0d4f69016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d30e0104-5c6a-404f-a921-8af8ce161f80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36030180-2ae0-44a5-98d2-08b0d4f69016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36030180-2ae0-44a5-98d2-08b0d4f69016" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b17d63ab-1408-4045-a2e6-84a6ac235ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b17d63ab-1408-4045-a2e6-84a6ac235ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ca0d4b49-e1c0-443d-8be9-6a8a89a5f931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ca0d4b49-e1c0-443d-8be9-6a8a89a5f931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e76db63c-fe02-4b30-b19a-b203f44f27c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e76db63c-fe02-4b30-b19a-b203f44f27c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e32d1773-10cc-4804-8974-3dbb4ebeb599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e32d1773-10cc-4804-8974-3dbb4ebeb599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b7060891-cbc3-4517-a357-9b046bef3bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_48686a72-1475-4cde-be05-aaa39d4dc8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b7060891-cbc3-4517-a357-9b046bef3bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_44679e01-8bfb-4a09-bb09-e4fd0c84ce10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_056c6240-981c-4d79-94ed-610580efab0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_44679e01-8bfb-4a09-bb09-e4fd0c84ce10" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_056c6240-981c-4d79-94ed-610580efab0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d639db8-4287-40a2-a42a-88dc62412345" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_056c6240-981c-4d79-94ed-610580efab0e" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d639db8-4287-40a2-a42a-88dc62412345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_db42a96a-3b26-4c3e-8d41-fdecc1861fc3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d639db8-4287-40a2-a42a-88dc62412345" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_db42a96a-3b26-4c3e-8d41-fdecc1861fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_69ae823d-ad34-4ddc-820d-9218b75bbf03" xlink:href="ino-20231231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_db42a96a-3b26-4c3e-8d41-fdecc1861fc3" xlink:to="loc_ino_SanDiegoCaliforniaMember_69ae823d-ad34-4ddc-820d-9218b75bbf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_d82a1e89-acee-47c3-8b96-a5ca8b4f53c4" xlink:href="ino-20231231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_db42a96a-3b26-4c3e-8d41-fdecc1861fc3" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_d82a1e89-acee-47c3-8b96-a5ca8b4f53c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ace22682-3449-46b0-8730-8823c4664c37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_056c6240-981c-4d79-94ed-610580efab0e" xlink:to="loc_srt_RangeAxis_ace22682-3449-46b0-8730-8823c4664c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c19cbc1-f73f-42ba-b87f-2d6da97eeaa1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ace22682-3449-46b0-8730-8823c4664c37" xlink:to="loc_srt_RangeMember_9c19cbc1-f73f-42ba-b87f-2d6da97eeaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6851b6bd-8499-4054-8612-a6c463aa52d1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9c19cbc1-f73f-42ba-b87f-2d6da97eeaa1" xlink:to="loc_srt_MinimumMember_6851b6bd-8499-4054-8612-a6c463aa52d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4512a367-d85b-49cb-86df-6ae5046e78c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9c19cbc1-f73f-42ba-b87f-2d6da97eeaa1" xlink:to="loc_srt_MaximumMember_4512a367-d85b-49cb-86df-6ae5046e78c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_414310af-63c7-47df-af07-39542c92fe1e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_056c6240-981c-4d79-94ed-610580efab0e" xlink:to="loc_srt_LitigationCaseAxis_414310af-63c7-47df-af07-39542c92fe1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_39395e83-7b18-4346-86c3-94dda100493e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_414310af-63c7-47df-af07-39542c92fe1e" xlink:to="loc_srt_LitigationCaseTypeDomain_39395e83-7b18-4346-86c3-94dda100493e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_6ed31280-573d-4d11-b351-a20f827f9b99" xlink:href="ino-20231231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_39395e83-7b18-4346-86c3-94dda100493e" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_6ed31280-573d-4d11-b351-a20f827f9b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BehestiVKimEtAlMember_aa66b914-0b64-4831-84ba-b0f29dc3d6ec" xlink:href="ino-20231231.xsd#ino_BehestiVKimEtAlMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_39395e83-7b18-4346-86c3-94dda100493e" xlink:to="loc_ino_BehestiVKimEtAlMember_aa66b914-0b64-4831-84ba-b0f29dc3d6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_056c6240-981c-4d79-94ed-610580efab0e" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_19a91cab-7e3e-445c-89bc-2326060ddae2" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_19a91cab-7e3e-445c-89bc-2326060ddae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfLeasesAmended_2684a6e9-7d1f-4aac-989c-829aa1205eb1" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseNumberOfLeasesAmended"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LesseeOperatingLeaseNumberOfLeasesAmended_2684a6e9-7d1f-4aac-989c-829aa1205eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended_89f8ba96-2398-45e1-9dd2-0f2adefc80f1" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended_89f8ba96-2398-45e1-9dd2-0f2adefc80f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_6f219721-a330-4d11-ac1a-1ee734a5521a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_6f219721-a330-4d11-ac1a-1ee734a5521a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_27eac4bd-c1ba-41f4-828f-e32bb33c392a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_LeaseCost_27eac4bd-c1ba-41f4-828f-e32bb33c392a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3cdac115-ae32-4648-80f5-96b710dc4341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3cdac115-ae32-4648-80f5-96b710dc4341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_43567b2b-be3f-4b70-8b0d-5e6796638ea4" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_43567b2b-be3f-4b70-8b0d-5e6796638ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDeposits_6ec67c02-5425-420b-90b3-2a6e3db7c60f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDeposits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_PaymentsForDeposits_6ec67c02-5425-420b-90b3-2a6e3db7c60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_3bbf75b7-f4c3-4a25-af03-25079b175646" xlink:href="ino-20231231.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_3bbf75b7-f4c3-4a25-af03-25079b175646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_b2e2d066-1f71-428e-80d9-b8f640fc79d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_b2e2d066-1f71-428e-80d9-b8f640fc79d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_db53f64a-db97-4eef-bb4a-4a4b8c82ae37" xlink:href="ino-20231231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_db53f64a-db97-4eef-bb4a-4a4b8c82ae37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_38fc8147-483f-4fb1-ab41-571117961bd9" xlink:href="ino-20231231.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_38fc8147-483f-4fb1-ab41-571117961bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_5d324cf1-09c6-42db-8c71-b259d498137d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_5d324cf1-09c6-42db-8c71-b259d498137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_ac861f76-6507-42e4-a0d8-1c0800a56b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1c194327-19ae-49dc-b0ff-b622bf583995" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_ac861f76-6507-42e4-a0d8-1c0800a56b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_caa400a4-5d96-4a2a-972c-79083acfa792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_caa400a4-5d96-4a2a-972c-79083acfa792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_29a9a0ff-dced-4f51-b830-d2f91e67e739" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_29a9a0ff-dced-4f51-b830-d2f91e67e739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ece5d700-511e-48db-9cd5-a8ab3c6cb341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ece5d700-511e-48db-9cd5-a8ab3c6cb341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79091793-0ead-4d4d-883e-fa8af771b632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79091793-0ead-4d4d-883e-fa8af771b632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_05e8f701-7b01-49ad-91f8-2a553add9921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_05e8f701-7b01-49ad-91f8-2a553add9921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_33468634-e616-42fc-8a3d-e72007e6533f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_33468634-e616-42fc-8a3d-e72007e6533f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9fed2f9b-482f-488f-9552-b5ccc4bfc71f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9fed2f9b-482f-488f-9552-b5ccc4bfc71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d45f7985-f29f-48fa-81f9-1eaefe46ee07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d45f7985-f29f-48fa-81f9-1eaefe46ee07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e1158048-9289-4439-bddf-e8f58bb60da9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_OperatingLeaseLiability_e1158048-9289-4439-bddf-e8f58bb60da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_522e26dd-6a46-4817-827f-fcf9360cd5af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_522e26dd-6a46-4817-827f-fcf9360cd5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6cc497c4-6ee7-49a4-b433-328eeae723db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6cc497c4-6ee7-49a4-b433-328eeae723db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4d61807a-00b3-4c3b-b504-5a798d3e7852" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4d61807a-00b3-4c3b-b504-5a798d3e7852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_55907be7-a4cc-46ab-b086-e2cb44e1cf19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4d95424-72fe-447d-9f73-3f6daab4d07b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_55907be7-a4cc-46ab-b086-e2cb44e1cf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ino-20231231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesComponentsofPretaxLossfromOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_21372178-274e-4b8a-9e39-f8173146756b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c5f097e5-4853-49b5-a867-f7166a5709db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21372178-274e-4b8a-9e39-f8173146756b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c5f097e5-4853-49b5-a867-f7166a5709db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4f9b808c-7e73-4611-8d1e-5928e1652b18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21372178-274e-4b8a-9e39-f8173146756b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4f9b808c-7e73-4611-8d1e-5928e1652b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6ca36a58-2ad6-4f1c-878e-e837dc3de443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21372178-274e-4b8a-9e39-f8173146756b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6ca36a58-2ad6-4f1c-878e-e837dc3de443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesReconciliationofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0e2a33ba-489b-471b-8071-dce7cc4e268d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0e2a33ba-489b-471b-8071-dce7cc4e268d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_4058a747-ae4e-40c3-8d37-cf903225c589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_4058a747-ae4e-40c3-8d37-cf903225c589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_24c92a6b-dc35-4d55-8c01-3bba68a174aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_24c92a6b-dc35-4d55-8c01-3bba68a174aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_8283e7aa-e918-4467-8585-58455d046299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_8283e7aa-e918-4467-8585-58455d046299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations_46be3a03-944a-4d1b-8ab2-2e77a3915702" xlink:href="ino-20231231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_ino_IncomeTaxReconciliationStatuteLimitations_46be3a03-944a-4d1b-8ab2-2e77a3915702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_7ed4b20d-1329-4ce8-893f-830e3f77f6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_7ed4b20d-1329-4ce8-893f-830e3f77f6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_0386d9b2-3683-4c51-a3b9-a400439ab687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_0386d9b2-3683-4c51-a3b9-a400439ab687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_b02232a6-22bb-4df6-8580-5f31b3e063f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_b02232a6-22bb-4df6-8580-5f31b3e063f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_946e7e52-9c22-40e6-9936-8675e4a520b1" xlink:href="ino-20231231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_946e7e52-9c22-40e6-9936-8675e4a520b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_c8ecbfdc-ef80-44c9-8d21-270dcb7c7680" xlink:href="ino-20231231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_c8ecbfdc-ef80-44c9-8d21-270dcb7c7680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_ac58bb69-1492-47e9-9e9a-aa6d835786f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_ac58bb69-1492-47e9-9e9a-aa6d835786f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_3f26680a-4fc0-45f9-bb35-e5c63937fa35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_3f26680a-4fc0-45f9-bb35-e5c63937fa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_63311bc6-1d66-48ca-bad2-f8fbaef5e25b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_63311bc6-1d66-48ca-bad2-f8fbaef5e25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_8e60138c-4f83-4206-858c-289b41f03678" xlink:href="ino-20231231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ab43bca5-66bd-4a02-8fc6-5b1920b98267" xlink:to="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_8e60138c-4f83-4206-858c-289b41f03678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_399471f0-380e-4557-8b63-1837b49d602e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_86913ec2-7ee4-413c-90b8-58af0ba6183a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_399471f0-380e-4557-8b63-1837b49d602e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_86913ec2-7ee4-413c-90b8-58af0ba6183a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f12b69f0-d344-4171-86b0-135dcaa5c9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_86913ec2-7ee4-413c-90b8-58af0ba6183a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f12b69f0-d344-4171-86b0-135dcaa5c9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f12b69f0-d344-4171-86b0-135dcaa5c9c1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_cf506956-8ecf-46e6-8ac0-641c661ca8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_cf506956-8ecf-46e6-8ac0-641c661ca8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_38e8837c-c9b6-4bd8-84c4-d54a0b6d4c42" xlink:href="ino-20231231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:to="loc_ino_CaliforniaIncomeTaxAuthorityMember_38e8837c-c9b6-4bd8-84c4-d54a0b6d4c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_49f1989e-3922-4a70-8d4a-1f5143ab0c37" xlink:href="ino-20231231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:to="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_49f1989e-3922-4a70-8d4a-1f5143ab0c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_KoreanStateIncomeTaxAuthorityMember_85c41564-a5a3-4f7d-84aa-2abcd5d52d9f" xlink:href="ino-20231231.xsd#ino_KoreanStateIncomeTaxAuthorityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:to="loc_ino_KoreanStateIncomeTaxAuthorityMember_85c41564-a5a3-4f7d-84aa-2abcd5d52d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a08b2a3d-473d-411e-a02c-062a919493a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_15d2c576-51e3-4fe2-8d11-6c13224636ec" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a08b2a3d-473d-411e-a02c-062a919493a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1ab87b9e-bf48-442b-be70-b99abdabaf92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_86913ec2-7ee4-413c-90b8-58af0ba6183a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1ab87b9e-bf48-442b-be70-b99abdabaf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_deaf57f2-59ed-41b5-b380-da0502313f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1ab87b9e-bf48-442b-be70-b99abdabaf92" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_deaf57f2-59ed-41b5-b380-da0502313f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_42a2f793-cd19-404b-bc6d-b89f582a4784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_deaf57f2-59ed-41b5-b380-da0502313f4f" xlink:to="loc_us-gaap_ResearchMember_42a2f793-cd19-404b-bc6d-b89f582a4784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_86913ec2-7ee4-413c-90b8-58af0ba6183a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_47c7b031-2911-425c-8159-d20fc84c0d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_47c7b031-2911-425c-8159-d20fc84c0d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_d514857c-befb-49e9-a01c-7e72e481b4db" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_d514857c-befb-49e9-a01c-7e72e481b4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_b1d861bb-c796-4277-bc3b-a79b5a9abc22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_b1d861bb-c796-4277-bc3b-a79b5a9abc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_dbbba8d0-40cc-4ca9-b91c-8070107bdc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_dbbba8d0-40cc-4ca9-b91c-8070107bdc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired_0e31d6f2-2a0d-4b81-b3b9-4dc8c2deba1e" xlink:href="ino-20231231.xsd#ino_TaxBenefitsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_ino_TaxBenefitsExpired_0e31d6f2-2a0d-4b81-b3b9-4dc8c2deba1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_36872e05-9bec-4bd7-bfb0-d7ab0660ba1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_25e8ea45-53ac-4f14-b45b-4fc4a25e099a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_36872e05-9bec-4bd7-bfb0-d7ab0660ba1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c12c93c3-7f99-4fa2-94f6-8281842711cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c12c93c3-7f99-4fa2-94f6-8281842711cd" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c8a7f6e8-cc3c-4447-b9bf-f98912c3ffbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c8a7f6e8-cc3c-4447-b9bf-f98912c3ffbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e289888b-dd1d-4d64-a885-c6168a66a525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e289888b-dd1d-4d64-a885-c6168a66a525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_ab61736d-c024-4967-8919-204fe63a9468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_ab61736d-c024-4967-8919-204fe63a9468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e2dc2537-785e-4e6f-a759-1d14b04d47df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e2dc2537-785e-4e6f-a759-1d14b04d47df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5c1d1769-0168-4748-a0f0-6ef0443caeba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5c1d1769-0168-4748-a0f0-6ef0443caeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_99b0278e-c080-4589-8b94-d77c55240815" xlink:href="ino-20231231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_ino_DeferredTaxAssetsIntangibleAssets_99b0278e-c080-4589-8b94-d77c55240815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_f5ddf01a-f008-45ed-a312-56a262f6790b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_f5ddf01a-f008-45ed-a312-56a262f6790b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_0818998b-5049-47b5-991d-b4b5a94a6868" xlink:href="ino-20231231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_0818998b-5049-47b5-991d-b4b5a94a6868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_435c80f9-3841-4ad8-8dad-5cc31077135e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_435c80f9-3841-4ad8-8dad-5cc31077135e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_32b44c0f-80eb-47dc-9e1b-bc22c40070e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_32b44c0f-80eb-47dc-9e1b-bc22c40070e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_9870838d-6457-490a-a958-b2db987e3a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_9870838d-6457-490a-a958-b2db987e3a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d61dbb84-8637-45ad-88d2-b842f9f9f9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d61dbb84-8637-45ad-88d2-b842f9f9f9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_93d1792a-5f42-4868-a8f8-829e5c5490e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2c687a13-78ca-4dc6-9379-ed0b0c081561" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_93d1792a-5f42-4868-a8f8-829e5c5490e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_831073f5-dfee-4a5c-8cc7-46023a50e17f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c12c93c3-7f99-4fa2-94f6-8281842711cd" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_831073f5-dfee-4a5c-8cc7-46023a50e17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ce632a4d-976a-467c-a445-9be29fbbd13a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_831073f5-dfee-4a5c-8cc7-46023a50e17f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ce632a4d-976a-467c-a445-9be29fbbd13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_6ebb4273-2be2-4cdf-b35a-2d16662817e0" xlink:href="ino-20231231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_831073f5-dfee-4a5c-8cc7-46023a50e17f" xlink:to="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_6ebb4273-2be2-4cdf-b35a-2d16662817e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_316a251e-3b52-4dda-befb-16a160ba9066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_831073f5-dfee-4a5c-8cc7-46023a50e17f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_316a251e-3b52-4dda-befb-16a160ba9066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_04ad2e39-51c3-41af-b7f3-2a3d873fd91e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c12c93c3-7f99-4fa2-94f6-8281842711cd" xlink:to="loc_us-gaap_DeferredTaxLiabilities_04ad2e39-51c3-41af-b7f3-2a3d873fd91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b6567af9-73db-4861-b093-0aefffb15fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_08a2c490-e12d-4bd7-a239-5a93555fa930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b6567af9-73db-4861-b093-0aefffb15fb1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_08a2c490-e12d-4bd7-a239-5a93555fa930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_ac0370c0-7f3c-4cd0-821e-abcca1a26272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_08a2c490-e12d-4bd7-a239-5a93555fa930" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_ac0370c0-7f3c-4cd0-821e-abcca1a26272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3627c1bd-aee8-40b4-9154-6ac2b9dc07dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ac0370c0-7f3c-4cd0-821e-abcca1a26272" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3627c1bd-aee8-40b4-9154-6ac2b9dc07dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_c0540d13-3863-42d8-b533-0f240fa75290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3627c1bd-aee8-40b4-9154-6ac2b9dc07dc" xlink:to="loc_us-gaap_ResearchMember_c0540d13-3863-42d8-b533-0f240fa75290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_81fd636e-89fd-4647-8c06-30498cdd8298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_08a2c490-e12d-4bd7-a239-5a93555fa930" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_81fd636e-89fd-4647-8c06-30498cdd8298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_34953c5a-7d04-41ff-9ed4-6587f6d31166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_81fd636e-89fd-4647-8c06-30498cdd8298" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_34953c5a-7d04-41ff-9ed4-6587f6d31166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3543b9b9-824b-4ce8-bab7-a83362731860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_34953c5a-7d04-41ff-9ed4-6587f6d31166" xlink:to="loc_us-gaap_DomesticCountryMember_3543b9b9-824b-4ce8-bab7-a83362731860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_098795f4-8a1c-4e05-bf16-6d58368e0570" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_34953c5a-7d04-41ff-9ed4-6587f6d31166" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_098795f4-8a1c-4e05-bf16-6d58368e0570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_ceb992bf-dbd7-4ccb-a6fe-787bb8bf0598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_34953c5a-7d04-41ff-9ed4-6587f6d31166" xlink:to="loc_us-gaap_ForeignCountryMember_ceb992bf-dbd7-4ccb-a6fe-787bb8bf0598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_da7f38b7-c2c0-4ebe-97d3-203a9f1857b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_08a2c490-e12d-4bd7-a239-5a93555fa930" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_da7f38b7-c2c0-4ebe-97d3-203a9f1857b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da7f38b7-c2c0-4ebe-97d3-203a9f1857b4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_969e0f09-d959-4d05-a6b5-30fef742bd3b" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringInNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_969e0f09-d959-4d05-a6b5-30fef742bd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_6d653271-8868-4e48-b882-b80c98c81b76" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_6d653271-8868-4e48-b882-b80c98c81b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_83c145a8-0c4b-4e6b-ba6f-4f39244dcef9" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_83c145a8-0c4b-4e6b-ba6f-4f39244dcef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_1ef921db-2c22-4b25-8f8d-db349076ed25" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_1ef921db-2c22-4b25-8f8d-db349076ed25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_d894ea5c-7eb6-499a-85a5-543e4824bbae" xlink:href="ino-20231231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_d894ea5c-7eb6-499a-85a5-543e4824bbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_021ca779-d75d-49ae-9328-5537beaae1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_052d32c8-58ce-40d1-8588-77f45fa00c01" xlink:to="loc_us-gaap_OperatingLossCarryforwards_021ca779-d75d-49ae-9328-5537beaae1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da7f38b7-c2c0-4ebe-97d3-203a9f1857b4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_ebf90edc-aa32-4d98-93e6-bdd2a4d7b6ca" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringInNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_ebf90edc-aa32-4d98-93e6-bdd2a4d7b6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_dfbf4b60-6d8c-4708-b185-5e8aecb6eaa7" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_dfbf4b60-6d8c-4708-b185-5e8aecb6eaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_1bdce53f-cacb-4e78-8263-a4bfe5474214" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_1bdce53f-cacb-4e78-8263-a4bfe5474214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInFourYears_bb5dc694-d56f-4c8d-9f95-4fd0f581da57" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardExpiringInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInFourYears_bb5dc694-d56f-4c8d-9f95-4fd0f581da57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_d10bfd09-4e31-4734-985a-d1d43e835cab" xlink:href="ino-20231231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_d10bfd09-4e31-4734-985a-d1d43e835cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_e6b38260-3eef-4dc9-88ff-4353a7906a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_dd03ce07-2556-4d19-bcd8-eeb90248e8b6" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_e6b38260-3eef-4dc9-88ff-4353a7906a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_aef785f7-11d7-4c68-9c42-7600b12bc7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a10598ff-49a3-4e04-86ec-6441bf6d5b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aef785f7-11d7-4c68-9c42-7600b12bc7f6" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a10598ff-49a3-4e04-86ec-6441bf6d5b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_0a297a1d-60f3-49da-be78-00048dfbb56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a10598ff-49a3-4e04-86ec-6441bf6d5b0d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_0a297a1d-60f3-49da-be78-00048dfbb56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_8b9be790-66ce-4f77-b2b6-a2bc07a44ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a10598ff-49a3-4e04-86ec-6441bf6d5b0d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_8b9be790-66ce-4f77-b2b6-a2bc07a44ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_372053f8-bec8-44fd-bdea-9e277c174157" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a10598ff-49a3-4e04-86ec-6441bf6d5b0d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_372053f8-bec8-44fd-bdea-9e277c174157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_147b147d-9ecf-4043-bad2-c3dfaf11c660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a10598ff-49a3-4e04-86ec-6441bf6d5b0d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_147b147d-9ecf-4043-bad2-c3dfaf11c660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_cb656205-f8fa-49a0-8cd5-63da979d2962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a10598ff-49a3-4e04-86ec-6441bf6d5b0d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_cb656205-f8fa-49a0-8cd5-63da979d2962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#A401kPlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/A401kPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3fb22693-e4f9-48d7-96d1-048dd1b3f155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_71eaa736-fcbe-4b4d-9a51-752365bc9236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3fb22693-e4f9-48d7-96d1-048dd1b3f155" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_71eaa736-fcbe-4b4d-9a51-752365bc9236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_cbfe190c-4474-4fde-81a2-f3a1864fc8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3fb22693-e4f9-48d7-96d1-048dd1b3f155" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_cbfe190c-4474-4fde-81a2-f3a1864fc8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_f9d03182-f596-4d44-a914-5c8aa3f580e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3fb22693-e4f9-48d7-96d1-048dd1b3f155" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_f9d03182-f596-4d44-a914-5c8aa3f580e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_9a2ae724-8985-4b4d-8f29-caea0de31dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_9a2ae724-8985-4b4d-8f29-caea0de31dd6" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_707ead5d-c961-4f7e-9bb1-0ea3da46ad1e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:to="loc_srt_CounterpartyNameAxis_707ead5d-c961-4f7e-9bb1-0ea3da46ad1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac9941a7-db34-4b1b-86fb-86c9a1928d88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_707ead5d-c961-4f7e-9bb1-0ea3da46ad1e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac9941a7-db34-4b1b-86fb-86c9a1928d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_0b00409d-101b-4819-b763-f28747f9a7f6" xlink:href="ino-20231231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac9941a7-db34-4b1b-86fb-86c9a1928d88" xlink:to="loc_ino_PlumblineLifeSciencesMember_0b00409d-101b-4819-b763-f28747f9a7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_9b48d920-be98-4437-b054-e8d8bce3d855" xlink:href="ino-20231231.xsd#ino_TheWistarInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac9941a7-db34-4b1b-86fb-86c9a1928d88" xlink:to="loc_ino_TheWistarInstituteMember_9b48d920-be98-4437-b054-e8d8bce3d855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91239dc8-3b06-40f6-a126-76635ecb592f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91239dc8-3b06-40f6-a126-76635ecb592f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ec61d0cb-5e42-4840-9b0e-98fdcb135fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91239dc8-3b06-40f6-a126-76635ecb592f" xlink:to="loc_us-gaap_RelatedPartyDomain_ec61d0cb-5e42-4840-9b0e-98fdcb135fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_8472588a-eec2-4cb6-a538-da391abb0789" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ec61d0cb-5e42-4840-9b0e-98fdcb135fa1" xlink:to="loc_srt_AffiliatedEntityMember_8472588a-eec2-4cb6-a538-da391abb0789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_afa81257-6c8b-4b01-b571-b47b3b529f0b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:to="loc_srt_ProductOrServiceAxis_afa81257-6c8b-4b01-b571-b47b3b529f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c892bbba-6b8a-4d6b-8995-a88c5abdea5c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_afa81257-6c8b-4b01-b571-b47b3b529f0b" xlink:to="loc_srt_ProductsAndServicesDomain_c892bbba-6b8a-4d6b-8995-a88c5abdea5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_c6209655-6518-45a8-bccb-91753e52ec70" xlink:href="ino-20231231.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c892bbba-6b8a-4d6b-8995-a88c5abdea5c" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_c6209655-6518-45a8-bccb-91753e52ec70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5248a0a4-0aeb-4f56-8c4a-127ef6b467fa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:to="loc_srt_OwnershipAxis_5248a0a4-0aeb-4f56-8c4a-127ef6b467fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fe198437-f148-4a35-a8ab-38a386539459" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_5248a0a4-0aeb-4f56-8c4a-127ef6b467fa" xlink:to="loc_srt_OwnershipDomain_fe198437-f148-4a35-a8ab-38a386539459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_93bd32be-ef56-4b22-b8bd-48b9b9892f35" xlink:href="ino-20231231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_fe198437-f148-4a35-a8ab-38a386539459" xlink:to="loc_ino_PlumblineLifeSciencesMember_93bd32be-ef56-4b22-b8bd-48b9b9892f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d5e6f177-c3dd-44e6-bb5d-7f51de75143d" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_37021763-d59a-4aef-a365-aa93b2a8d723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_37021763-d59a-4aef-a365-aa93b2a8d723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_6e8f96d2-f8cc-431b-887d-2ee3fcc19a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_6e8f96d2-f8cc-431b-887d-2ee3fcc19a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d65e101f-32c0-4e60-b959-bb14de5607e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d65e101f-32c0-4e60-b959-bb14de5607e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_920aef48-4f8b-4a49-a6f3-4c2b19ab39a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_920aef48-4f8b-4a49-a6f3-4c2b19ab39a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_b728ccfc-7a20-44aa-a54d-4954836972a7" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_b728ccfc-7a20-44aa-a54d-4954836972a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_94d3ea4d-49bf-4654-b62b-68eba23e0023" xlink:href="ino-20231231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_CollaborativeArrangementTerm_94d3ea4d-49bf-4654-b62b-68eba23e0023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_9f867713-88e1-4317-a632-e244c595ae04" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_9f867713-88e1-4317-a632-e244c595ae04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_ef3276e3-acb2-4e1f-ac87-5362efe7030f" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_ef3276e3-acb2-4e1f-ac87-5362efe7030f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_03a16684-5e8c-4ea4-b313-898bb2fa4a54" xlink:href="ino-20231231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_03a16684-5e8c-4ea4-b313-898bb2fa4a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_9845ccbe-582d-46d2-a8fd-165f75d666db" xlink:href="ino-20231231.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_GrantProceedsReceived_9845ccbe-582d-46d2-a8fd-165f75d666db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9dd05262-51d3-4272-84bd-9d7918cce825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9dd05262-51d3-4272-84bd-9d7918cce825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_a1e89a4e-f314-4255-aa70-06cf10bb9184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_AccountsReceivableNet_a1e89a4e-f314-4255-aa70-06cf10bb9184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_93e02962-a7d7-4267-9504-9619a24c1d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_93e02962-a7d7-4267-9504-9619a24c1d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_a1403eec-0103-426e-895c-f572514176df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_a1403eec-0103-426e-895c-f572514176df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_74008b08-dd97-4f8d-8017-7d563980b16b" xlink:href="ino-20231231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9ea2b14f-981f-4124-bed3-a68f1cad0204" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_74008b08-dd97-4f8d-8017-7d563980b16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_dab03873-66bd-46dd-8d3d-0b509d4b1ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_fd5f64ad-02ff-460b-a87d-56a401b021df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_dab03873-66bd-46dd-8d3d-0b509d4b1ea5" xlink:to="loc_us-gaap_MinorityInterestTable_fd5f64ad-02ff-460b-a87d-56a401b021df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5600f6e3-3b60-479f-9282-48f74c33cc17" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_fd5f64ad-02ff-460b-a87d-56a401b021df" xlink:to="loc_srt_CounterpartyNameAxis_5600f6e3-3b60-479f-9282-48f74c33cc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc01d937-5441-4848-b4a8-177db520e302" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5600f6e3-3b60-479f-9282-48f74c33cc17" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc01d937-5441-4848-b4a8-177db520e302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_051ba087-62bc-4cee-bbde-7307623b826c" xlink:href="ino-20231231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc01d937-5441-4848-b4a8-177db520e302" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_051ba087-62bc-4cee-bbde-7307623b826c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3888b4ec-666e-4604-93e6-13addb4fe050" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_fd5f64ad-02ff-460b-a87d-56a401b021df" xlink:to="loc_srt_OwnershipAxis_3888b4ec-666e-4604-93e6-13addb4fe050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6e249bbc-7471-4037-9b14-67f08b0dd3f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_3888b4ec-666e-4604-93e6-13addb4fe050" xlink:to="loc_srt_OwnershipDomain_6e249bbc-7471-4037-9b14-67f08b0dd3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_250ff8cd-e511-4291-b97f-40e8a30613b9" xlink:href="ino-20231231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_6e249bbc-7471-4037-9b14-67f08b0dd3f9" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_250ff8cd-e511-4291-b97f-40e8a30613b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_92632736-6e3b-4ee0-a7d1-029ea4acaeec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_fd5f64ad-02ff-460b-a87d-56a401b021df" xlink:to="loc_us-gaap_StatementClassOfStockAxis_92632736-6e3b-4ee0-a7d1-029ea4acaeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bc929973-018a-4a47-ac8e-bf3718826c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_92632736-6e3b-4ee0-a7d1-029ea4acaeec" xlink:to="loc_us-gaap_ClassOfStockDomain_bc929973-018a-4a47-ac8e-bf3718826c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_214d23de-aebc-44c4-bcc3-84212347fa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bc929973-018a-4a47-ac8e-bf3718826c1e" xlink:to="loc_us-gaap_CommonStockMember_214d23de-aebc-44c4-bcc3-84212347fa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_51465b4b-2b66-41ec-9f0e-0ca3ecb93649" xlink:href="ino-20231231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bc929973-018a-4a47-ac8e-bf3718826c1e" xlink:to="loc_ino_SeriesAOnePreferredStockMember_51465b4b-2b66-41ec-9f0e-0ca3ecb93649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_016f7ef5-ff2f-4937-b997-859c7a3c6b33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bc929973-018a-4a47-ac8e-bf3718826c1e" xlink:to="loc_us-gaap_PreferredStockMember_016f7ef5-ff2f-4937-b997-859c7a3c6b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_46bca4de-248a-4b16-b9bb-a70132dd305f" xlink:href="ino-20231231.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bc929973-018a-4a47-ac8e-bf3718826c1e" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_46bca4de-248a-4b16-b9bb-a70132dd305f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_fd5f64ad-02ff-460b-a87d-56a401b021df" xlink:to="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_65d51f1d-5270-4a95-b901-bed17ca07239" xlink:href="ino-20231231.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_65d51f1d-5270-4a95-b901-bed17ca07239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d0452d11-9f65-4a47-b6cc-452939f934d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d0452d11-9f65-4a47-b6cc-452939f934d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_103db4cb-2d04-42e0-8717-d0055d3e9152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_us-gaap_EquityMethodInvestments_103db4cb-2d04-42e0-8717-d0055d3e9152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7c971b8d-42d3-4b64-b865-77521aef409a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7c971b8d-42d3-4b64-b865-77521aef409a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_6f2c71ad-f63e-494f-a59b-32d3f693d040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_6f2c71ad-f63e-494f-a59b-32d3f693d040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_f553581a-4b7d-4f4d-98d1-9352093baf52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9572f48-2631-4db3-9839-3707cbe631ab" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_f553581a-4b7d-4f4d-98d1-9352093baf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20231231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_227aafb2-2e1f-4391-893f-4670c4a7b2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_227aafb2-2e1f-4391-893f-4670c4a7b2f5" xlink:to="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_43641868-5bcf-4d8f-9691-635a70cf0e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:to="loc_us-gaap_DebtInstrumentAxis_43641868-5bcf-4d8f-9691-635a70cf0e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_15e27252-1dce-4516-8ed4-09db0407de5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_43641868-5bcf-4d8f-9691-635a70cf0e8d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_15e27252-1dce-4516-8ed4-09db0407de5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_e0a02946-fc7d-41a4-a208-83e4c75d7f9e" xlink:href="ino-20231231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_15e27252-1dce-4516-8ed4-09db0407de5e" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_e0a02946-fc7d-41a4-a208-83e4c75d7f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a7db1f1e-b0a4-4aba-b09f-51f15a594b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a7db1f1e-b0a4-4aba-b09f-51f15a594b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_857483b9-8f61-4ca2-8089-d76c12d5d183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a7db1f1e-b0a4-4aba-b09f-51f15a594b7f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_857483b9-8f61-4ca2-8089-d76c12d5d183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d19f7512-856e-4dfd-a6e7-d73f8d6897dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_857483b9-8f61-4ca2-8089-d76c12d5d183" xlink:to="loc_us-gaap_ConvertibleDebtMember_d19f7512-856e-4dfd-a6e7-d73f8d6897dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_668884d6-603f-452d-b0bb-2d221e1f81e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_668884d6-603f-452d-b0bb-2d221e1f81e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_935f6ad5-32aa-47a7-9a5c-32013f347563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_668884d6-603f-452d-b0bb-2d221e1f81e1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_935f6ad5-32aa-47a7-9a5c-32013f347563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f50955a6-297e-46d5-a997-6744d1c269ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_935f6ad5-32aa-47a7-9a5c-32013f347563" xlink:to="loc_us-gaap_SubsequentEventMember_f50955a6-297e-46d5-a997-6744d1c269ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_42929f50-8999-4fc9-a4a5-3499b84df5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_42929f50-8999-4fc9-a4a5-3499b84df5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2512e787-2fbc-4bbd-a9d6-08febeeb007e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_42929f50-8999-4fc9-a4a5-3499b84df5d3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2512e787-2fbc-4bbd-a9d6-08febeeb007e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember_8cd42c4e-3b4a-4278-b6b9-c984019fe831" xlink:href="ino-20231231.xsd#ino_A2021SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2512e787-2fbc-4bbd-a9d6-08febeeb007e" xlink:to="loc_ino_A2021SalesAgreementMember_8cd42c4e-3b4a-4278-b6b9-c984019fe831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1ff2b999-9f25-4881-83b2-68e2a791b031" xlink:to="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a0c1687d-6ce4-4225-a035-54e00bbd8034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a0c1687d-6ce4-4225-a035-54e00bbd8034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0b1363b0-f741-4d22-8033-ac8af2e0d513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0b1363b0-f741-4d22-8033-ac8af2e0d513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d02f9599-0d47-46fb-b2f3-858a094b02a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d02f9599-0d47-46fb-b2f3-858a094b02a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_f4bde965-f017-4de3-b119-a267ffc9004a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_f4bde965-f017-4de3-b119-a267ffc9004a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7213eea4-f47d-46f8-a917-b0f59cbbfcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_95c726b5-1d0f-49b7-a8d7-44ac893f6081" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7213eea4-f47d-46f8-a917-b0f59cbbfcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ino-20231231_g1.jpg
<TEXT>
begin 644 ino-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
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M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
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M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
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MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
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MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
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M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
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MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(BQ+[6?;0T3LYA?A+5%TI<A9CD?#Z>HO'+F,Q*'L]-> C$(*H&[-8OV2BJP-
MS[4DW1"8&3.H]2X[#T;63RUZGC,;2A.Q<OW[,-2G5@C;J.6Q8G,(HHQ9N7(S
M%F^JJX';>[[&29[FF=G6*&%Q."SKNW%Q,;NY ;:=QMB%V 6'@H\KD&ZW<G\#
M'BP!:.*GMC]OO7.\V0-LS:^"],0V!FQ>DL?(38VKX;.,4]Z3@9<KD/,C*S:Y
MCB,G:G6K W#X/H#ZV=S]_*W;.2REZYDLC=F.Q<OY"S-=NVYY"ZI)K-JR<D\\
MID[N4DAD3N_O7R41 $1$ 1$0!$1 $1=C;6[0ZHUODQPVDL#D]09(N'*OC:QS
MM !<\2VY^&KTH7Z29IK<L,;NW2Q.7#(#KE?M6K232!##')--(_3'##&<LLA/
MY,(1QL1F3OY,PL[_ %E8,[-_<09N[X&0W1U#!AJ[O'(^GM-2!>R;ARSG#>R\
M\#X^G+PSCTT(<I&W+&UKEGC4[FP/8QVSVQ@ -'Z4Q]"T(=,F7L-)DLW9=WZB
M.?+7SL7>#+VFABEBK0\^'7@AB$(Q J=[ =T[O)KP8;4F ^8_$RN+MD-7M/BY
MRC?S\2'#/$>7,>/,'GJU8Y6<2CD('ZE--L/W&.W6!&&SK;+Y/7%\>@I*P,6G
M\$)-YD U*=F?(3 _/01SY5VD86,88')P4X"(#J[;#9'1^BJ;4-):8P6G*OO*
M/#XRI1>8^GI>6S+!$$UJ<A;@[%F26:3]'(3KM#A>40!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'%]7Z'PNH*4N-SV'Q>;QTX]
M,]#+X^IDJ4P\L_3+5NPS02#RS/P<;MRS/QRRBTWP[EW9[5(SSX*K?T+D9&,H
MY=/S-+C!E=B<7DPMYYJS0=;LY0TI*#] ^'#) SL0RYH@*>&_/<J;L:3&:UIP
ML=K_ !T7),^(;X,S)1M[W+"WK$@O(S,Y/#2R=XR;I:/KD+PVB=U/I3*X2[-C
M<WB\EALC7(@GQ^6HVL;>A,?(AEJ7(H9XW%_>Q1M[V?W.RV.*ZBW<V%T9KV@>
M,UCIK%:@J$! +9"J!V(&)B9RJ78^B[2E%R<@FIV()HCXDC,3$28#7F(K.G:,
M[AW$6QL7MKM128>QR1Q:?U-+8O8M_+EH*^9BCFRE4>?(#N0Y4OT,A^;R# EO
MYV4=P=L;/J^M=,WL3$<GA09-F&WAK9.[L#5LM5>6F9GTNX0G+'8=O?"SL[,!
MCPB(@"(B (B( B(@/+.[.SL[L[.SB[.[.)"_+$+MYL3/YL[<.SLSL_+*9OL2
M=\-JS0/J>G]>O=UGI('&&*]-8>;4^$@9A$? M6')\S4A9N&I7I@LQQO^9KS!
M%'4DAC1 ;#O9O>W2VX&$KZBTAFJ6;Q5AF;QJDHE+5G86(Z=ZN[M/1NP\MXM6
MU'%,#.)=#@0D7:JU\_9[[2VL]KLY'G]&9B;&V7*)KU0F:?%Y>O&3OZIE:$GS
MJU"0D8#(WAVJW6\M*S6G891MS=AGO-M'[PQ0XBST:;US'#U6-/6I6]7R/0W,
MMG3]LW;UZ%OHI*DC!?K-SUPRPBUJ0"3)$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5%KO-OC[W-^SE7\
M!XE7I51:[S;X^]S?LY5_ >)0&"B(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]T
MK],7MG_;]7?P>ZN0%WM$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.
MDOQDQRIC*YSWT7Q ZD^S.DOQDQRIC( B(@"(B (BG$V^[L3'[@=G3":[T=!8
M'<0&RM^Q5*W+)6U%5I7KE<\9#7E)X*EYH(0.@<31C/9#U><NFQXL0$':+]K%
M:2&22&:,X9H9#BEBE HY8I8R<)(I8S9CCDC,2 P)F(29Q)F=G9?B@"(B (B(
M I+N[6[>MS9O4_J65DFLZ"U%9KQ9^IU&?P38Y:&+45"%NIO%K 3!DH(Q8[]&
M,&9SL5*@O&BB V/>#SE/)TJF1Q]F&[0O5X;=.W6D&6O9K6(QEAGAD!W$XY(R
M$@)GX=G9?555ONA.\1^9:Y4VKUK>Z=-Y&=PTGEK<PM'@<G9FZO@:Q))PT>)R
M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
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M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
M?"C\_,?#"07=O)VDD+W.W"H9QI@:IX@<;87#.B3K^E9^7/2M-G=+:C&IQJ[<
MC4-2MY=VZ<>BG)RY<JE9.$*JHQE-QB5\\6>+?HE-MD&W;+FHQHKJURINRU+]
MA;SWV[^6GTVV[APF+$1BKUX^>CPX8H8F8G^0(XQ >7<G?@1%FY=_)N>5=R[#
M_9R@VQV\PV >$0RUD/A;44WLO)/F;T<9V ,A\G"C$,..@9N6:&H#\F9'(=)+
M9C7<.WNO=-:NN8I\[B\-FZ&2R.'\7P?A"O4L#,SQF0F'K54V&W4:5O"EGA&O
M,0032&U^#:7=G :YT[BM5:8R,.4PF8K#9I6X'9_)W<98)PYZH+=683KVZTC#
M+7L1R0R"Q@[*R_"7L/9'A;K>=J.7J%>N49F/CXNE:E'%EB3J<H^9J561CRNR
M8T7V6QK5$HY%GF8L9-34IW55X'V?=+Q)69F=YT+LGRX5U0:VLKKL]Z^UI[[N
M<U"OF3<HJ,E+96+?L=$12X6A/#LJOG?0=A<\'D3WHTA2?X/R-@ U_1K"S-3R
M$SB%74P1,W] OGQ5S)"[N%XJMTA,;5V:&T(OA:GTQC\UCK^(RU.OD,7E*=C'
MY"C;C&:M<I6XB@LUIXBY$XIHC.,Q?WB3K<>!>,LC0]1ISJ=Y07U>33NU&_'D
MUSUO]I;*=<G]FR,)--)IZWQ9PS1JV%;AWI>^MZY[;NJU)\LU\NKC)?>@Y+=-
MIK7@Y*I%E*;GP)NX.,@OQP0NW#\MQYL[>3^7'U5:8[G+MWGKC %MKJNYUZQT
ME4C^"+5B1REU%IF 1ABE<SY>7)8;YW5O]1/)8JR5+@^(?KG@P/=MWLDY'8O<
M"?!<6;.D<QXF1TCE9F(QL8\C=IL59F=W8LCAC(:]AC?KGKG4O<?FDF#&S36L
MLQH_4&%UGI>X=#,X.]#DL?9C<N/$B?YY6L"+MXU.Y"4E2[6+F.U4GF@D8@D)
ME>/B[AW!XNT.$\>R,G96LG R?6J[EVY9[;N,9-.G(@]W%I^[YE<=J;\(ZWE\
M):W/$R8R5$K'5;7Z2KW^[V3<=U93+M*+V349/?8;,Z\K%7L;=JS";Q:%Q>K\
M3X=>U(+5,]AVE:2?!YN 6:Y0FY83>+JXL49R$6M49J\[,SF0!E4N>^H8%V+?
M;C9%<JKZ+)56URZ2A.#VDGZ/JNC6Z:V:;33+R8N57?57=5)3JMA&<)Q[2C);
MIK\O3NNSZA<2UYH?%ZFPV5T]FZD=_$9JA9QN1IR_T.>I;B*&8'=O:$N@N0D'
M@XS83 A,6=N6HO-79*$HS@W&46I1E%M2C*+W4DUU332::ZIG[2BI)Q:33333
M6Z:?1IKU371HH&=H/8/*[0;@9S0.9(YXJ<OK&&R!BPMEM/W#D?%Y%F;V?$.*
M,H+;#[,5^M;B'V09>UV:>T'DMG=QL)KK&M)/3KR^IY['QO\ \Z:<NG$V3ILS
MNPO.( %RCUNPC?JU7-V!C9[,??%=C,MQ=!MJ[!4WFUGH""SD*@01]5G+Z??H
MFS.(9A9BFEACB^$\=%P9O9KRUH!8[\G54GQUJ/)T>GGDA#D7]_+<>[G_ #^2
MZ%^'G$]'%&A.&5&-EOERPM1I>RYI.'*[$EMRQO@_,@UMRV<\8O>K<H[X@Z!=
MPSKE>;B<T,>RR-U4ENU%<W2+^+JEO"6^[E#E<NDC8;Z+UCC-0XC&9W#6XKV*
MR]&MD<=<A?F.S3MQ#/!*//#MU1F+N),Q@7(&S$+LW)U6Q[C;MA/&]S934-OV
MX?7<SH66S+[4E?J>SF=/0];OUE6)YLQ1A9^IJQ9(0'P*@-'9.5'N..$[M%U+
M(P+=W&N7/1:UMYV//=U6KTW:]V:6ZC9&<-_=+A\+<0U:I@T9E37UD4K()[^7
M:DO,@_P?6._5P<9>IQ/76B<9J3#933^9JQWL3F:%K&Y&I(WL6*ER$H)HW?WB
M3@;N!B[&!L)@[$+.U"K?38S)[2Z_U!M]F#.=L99YQMZ1F%\M@[?5)BLFS"PC
MUSUV8+# +!'=ALPA[,;+8 J#SOM>R&^KM%P;E8.F\NIM 0&^0&M%U6LEI"2;
MQ<A"3C[4C8*623,PBXGX5=\JT/!V"&21/ GCC]%ZHL.^?+AZDX4RW^S5E)M8
M]O7[*FY.FQ]%M.,Y/:I;:/XP<&1U;2YSA'?)Q(SMKV^U*O;>R"^+7*IQ]=XM
M1ZR97T[(W:/N;,;FX36,3R'A9)&Q.JJL74[V]-WYH6O$ -Y26,>X19.H+L_7
M/4&!G!IG,>V>]\W[JZRWJRLF-N17</@,-@L%B[,!]<$\?JGPS:G#CV7<KV7L
M0N?D11UXF+CH9FQFT/MI)JG$E:.<:L8,XPF\/K!V..>MQ'Q8>(P?RZ^HNHF=
MF'@7=8][F;:VM/O&9V/6H93>/Q&B*/PSXY "ZI).6(6?H?D?H''A^%63^Z5<
M8<-:KA+3M)UC&NX@TK4Z*M<TVJG,<WBPHNG!O)CC_079AWW5*ZKZ0[5S.N24
M\6=:K=H.J9LM(6F9,91I>5&^N4FO>\N-D'%);OELDX6)227-#>._-N^.4M43
MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
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M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
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M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
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MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
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MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
M$<9/YC*%&I,(NWSFZ?/6,Z.S'9^T;M[C6Q.CL!1PE1^GQB@$Y;ELQ%A:2]D+
M)SWKTO#-\\M6)B9^>'963X5Q?#WP^HEC<%Z!A1RW!UV9T(SMOL7JLC5LN5VH
M9-;DE)40M>/Z5RK22)KX/\%74HN5->!5LMVUYN7-?#>3DXI_YR:<7_BOA#'V
M0>YGK5"K9W=F:'(3\#+!HVA*3T8B9V=GS62B(2O%PSL]"ET568G::S:8GCCG
MMPV%IXZK7HX^I6HT:D005:=*"*K4K0QMTA#7KP"$,,0-Y!'& @+-PS,OI<?R
M_67E1[Q-Q?GZO=YV;>[-F_+IC[M%*?I54NBZ;)R?-9+9<\Y;%@]%X?Q=/K\O
M&J4=]N>Q^];8UZSGW?RBMHQ^[%((B+63-'\2"SBXDS$+L[$SMRSB_D[.WU';
MW\^7"J-=HK0Q:8UYJ[!.+B-#.7"@8AZ.:EYQR5$F%O(1.E<KF#,[LP$S,_#*
MW.Z@'[V';7U#56#U3"'$.>QQ8ZT;<,SWL03/&Y,WGUR4[0#U/]$-<19G:-U2
M'V\.#GG<*8VJUQ;MT34*YV->F%GI8EW_ ,5]!DWZ1C(H1_="/#G],<)86J5P
MYKM!U*%EDMMVL'48_1+TMNW]]_H^3?5*,)].NZBK8TZ_Y?)_YKU&/ZZ_KJ?^
M7_NN/G/\SBM9PG^S_ X%L!N*.@NTGH34<DK5Z=[*8NGD)B,8H@IYR"335DYI
M"?HBBC8HYIS-Q (A*0W9N368';%[0<F[.X=G(U)9#TS@FDP^FHG<FADJQS$]
MO+-&_##+EIQ:7K=FD*E!0B-V\%A:+3M28[\TXFVS<.4-F!R;W\@4<@>?_9ZS
M?]OW+*G1>0A# T\@/3U7*D4K?)PYQMXC-Q[N#ZF_6;Y%VZXZXJRL_P $_"+4
M<9N55^C3X9RY+=M6\-VRT[!JD^W*Z\7*GR]TZ(_JG8WP2X@OR.!.'<1SVQZ<
M:%=RWZR>F[X%4'^PHXT9;==Y*#Z<IV%@-'Y+5>>PVD,#%XN1R]R*A7;S\.)C
M?Y_<L.+/T5J<#26;!\.[0Q'PQ%P+VX]F-IL7H;3&(TMAHV"CB:HPM(XL,EJP
M9%+<O3\._-B[:DELS.[E\\E=NIV9E%QW4'9K>CC;.YN8A?U_/PG3TT$GOJX-
MI/S3?$7]TF6GC 8I.>IJ-<"C=H[DG7,LS+;O ;@%:7IJS;H;9>?",ES+WJ\9
M^]!?)W/:V77K'RD]G%HN%X8\.?1\=YUL=K\N*\M/O7BK9P7R=S2LE\8JKLTS
MRB+PZGDE$]#+9.M2K6+ER>*M4J0RV;-F<QBAKUX *2:>60W88XXHQ(S,G81%
MG=W\E2'[P3MB6]\]P3LTSECT/IB6WCM(U"(NBU"\K!<U'-%P+#8S7@12PB8O
M)5QP5:Y.TCV&*:'O;>U".1ADV=P-N1AN#7FUQ:IR=#^J$33U],-./MB]I@BM
M9@8NERIG7HO+TV;L#02ZUV^P^ TU<EJ56CM!$,S2O)))(  8N?M2F7 >'U=;
M-PW#=7GR[K8O";QYX/T3B3#TS.6?EZYJ.HXNCX7T7'HGA8$\VVO'=^3D795,
ME)SM54_(HOE5",X[-V24:V^,G%-^37?INGSBH4;O+L;:4[8=51#:+YO+:][J
MD[?=>W)UZ#Q>G<KG\KB]*Z:I29+,YBY#CL;2@;V[-N<ND6=^.(X@;JDGF+YW
M!!')-([!&[J[]V(^R/B-FM"8_2M!X;.4E)LEJ;,1Q.!YG.SQ1A9LNY\R^JP!
M''3Q\1NW@TX(FZ1,I.8R.Y>["I:>Q;;O:KI%'J/45.6'2E*RQ-+AM.6>GKR1
MPEPT.0SP@)1N0O-6P[Q@)1%D;L"GU9E,WCQXD?I'*>DXEF^%AV/SYQ?NY.5'
MW6MT]I58_6,?25KG+JHUR6Q>"_A['2\-9N1#^_,J*E'F7O54RZ[OX3M^U+UC
M#ECT;FF9>415W)P"Q1[8_:XTYLSHRYJO/FT]@G>E@<)%((7<]F#B.2O0K,7+
MC&S 4UVTX%'2J1R3FSNP1GW'O#N[@-!Z9S&KM3W@QV$P=.6[=L$SG(0QM[%>
MK #/+:NVI.BO3J0"<]JS)%!$!&;,J./:S[4VH=]=<V=49CQ:>%J>)4TKI\C%
MX,'B&<?(W#V)LE?,/6\G;=S(IC&M"34JM6*.6_";PTLU_,Y[HRAIN-)/)L6\
M7;+HXXM4OUYIIV27\E6]VU.52E'7B-Q[3HF'*?-%Y5D6J*WL^7NO-FOU4^D5
M]^?1)I3VZLW!W)U'N-JG*ZXUE=*[E\K-XLI/UM6I50Y:KC,="9'ZMCZ4;^#5
M@%^&;JD-SFEED/L'L\]GO4>\6LZ&B=+@\0EQ8S&6.(Y*. PT<@!:R=MPZ1(F
M8O"IUGDC.]<**L$@,1RQ]<:7TCF-59S$:-TI1/(YS.6QHXVG&_3XLS@<DLLQ
MNSM#5JUXI;5NP;=%>K#+.?L@ZNK]A'L683971L.%J/%>U#D6@N:LSS1],F5R
M@@_,</5R<6,H/))7QM=WY&)SGD;UBQ,3VH\3O$''X9T^&-B1K6;95Y6#CQ45
M"BN*Y//G6NBIJVY:X;;66+D2<(V.-:/#C@G)XDU&>I:@['BUV.<Y2;WG*3YO
M+BWWLGOO.2WY(/?=2E'F[Q[/FP>G-L])XK1^EJ8U<7C(GYD)A>UD+LK]=S)Y
M"9A9[%Z[,Y2SRE[O8AC8((HHPK%=OFNU7=/<4?)V;(G._2+,WYHQ52T[<>[J
M;Q79W\NHF<O+GA6WU49[R2SX.Y>Y\ON\(O$Y;W^QIN@7EQY\^7_LN"/]T/E/
M*X:T>ZZ4K<B[BK&Y[)MRG.5^#J4K)2;ZN4Y)-OON21[2<*Z-"P>2,:X4YJ4(
MQ6T85PP<M\J2V2BE!;+;IL5U9ZOL#Y?H6_T?R_67%[M7WKLZY5\N/+R;C^7\
MO_!<2N5F\U5_&R/XG+S1\_I'KV2+>OHX>Y[Y':S5VDY9>J;2>L'LP1>S\ZQN
MI*,=N!^.>IO$R5++^\6%^ANEW+K8;$2J)^C::G*OK7=+!L[,&3TQIW*D/U3P
M>5R-0'_78=02?7X?ZC*W8NFG@CJ<LKAC2YR>\JZ[<=OY49%M=:Z[]JHP7P79
M=-CKE[/VKRS.$M)G)[RJA?BOY1QLJZFI=?U:8UK\NG0(B*5R90B(@"(B (B(
M B(@"(B (B( B(@"(B */+O/NS5_-+VESE2G6>QG]."6J-/C'&\EF6[BZ\Y6
M:%<1Y,I<ECCMTXXA8O%GD@;AB82&0U>'9GY9VY9_)V?W.WZR UMPDQ,SL_+.
MS.SM[G9_-G9?TL^.\K[-[[9[M:@QE:OX."SA_--IYQY\+U#*22%9JA\@OC\F
M%VHT3/R-<*LG2 3QBV Z (B( B(@/UKV)(9(YH9#AFB,)89HR<)(I8R8XY(S
M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
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MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
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M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
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M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
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M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!46N\V^/O<W[.5?P'B5>E5%KO-OC[W-^SE7\!XE 8*(B( B(@"D5[I7Z8
MO;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0$5'?1?$#J3[,Z2_&3'*F,KG/?1?$#J3[,Z2_&3'*F,@"(B (B( KM/
M='?$)HK^['X9O*DLKM/='?$)HK^['X9O("2=$1 $1$ 1$0!$1 1.]Z'W?,.[
M6 ;4.FZT,.X.GX">D?E&VH<9&TDDF"M$[B'K'6_BXJU(_P XG8JQDU>T914V
M+-66"66">*6">"62">">,HIX)X3>.:":(V$XIHI!*.6(Q$XY!(2%B9V6R)5=
M;OA>[N*^%W=W1%$SO01#)K;"TXA=[E:/EGU/5A!FD*W6C<0S,8,?C4XH[X@$
ME:Y)8 K,(O#/_)EY0!$1 $1$ 4ZG=%=X>^CLC5VQUG>-]*YBVT>FLE9,7CTW
MEK+O^8)Y2=BCPV4F<1C=W./'Y&49.F*I:M3005KPXL_D[<L_D[?5;ZB V2**
M!3NAN\1^:FE6VMUK>YU)BZHQZ5RMJ3D]08NK'P^-L3&7)YC&PBS0D7MY"B'6
M[E9K3%-/6@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B B>[ZKXA
M,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$ 1$0!7ANZG^E^VX^Q^7_&3,
MJCRKPW=3_2_;<?8_+_C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( JDW?(Z&^!NT[H#48@31:RV[OXPI''@)+>GKD['&Q<\&45:[3,O+
MV6F!G;CAU;94"G?P[5^M:=VIW!AC=Y]";B5<9;F\N(,%KN&+"7R=O?Q\)UL$
M1G]"$02._P BA#VC]!>H\%<040CS61P+;ZULWUIBY2?3X5\[WVV7KLNJT+Q1
MP99/#NM506\WIN8ZTN[FJ)N*_?\ _0B"C#_W7N1C\J_@(_\ 3_X_^*]L&7 :
MN!_/KQKQ-NY^]\?4_NIMQ@=57L9A=2')6QE[(5ZDN2K]+6<0]PVJ!E('/V?S
M <P69XB]BQ7BEKGY2<MRG7^TF;VOSTVA]20"$E.$"HVHF_,F5QCD<57)TB?S
M\.?P3:2,OGE>P,L$K.<;N7'7CY%V;EN6=N6][<_*WU';WLK$5G:C!=H79W3L
MN1,:N=AH=-#-1 Q6L3G\=S1N!)UL9RT+<U?IO5B=O6:QA8A*.<:MB._'LM9V
M7Q'H>K\$69]W)@7?^DFBX-ETGCJ^R,<+4U"$GRU2DW@R@X;1C;;?-KZZV99[
MV#N)?TS/B/AM7+Z?BU4ZWI5<Y]+J.=8FJ8ZYGM!>9/3K*]MHQLLME-;62FJ]
MFEM6YO1>>Q^K-+72I9/'RM+#(/M0V("=O6*-V'GIL4K<7,-F$N'Z"\2(HYPC
ME"TIV3.U1A-U=-AE\>S4LK3<*V?PDAB5C&7N';J%A(GFQ]OI*;'VO+Q8>8YA
MBM0V((JNFK-'YO1N<R&D=5TCI9*A*\4@N[E!9A)R:O?HS<,-BE;!FE@F'CD7
M>.48IXY8H_=VRW.U!MMJ:IJ[2\PC9A%X;5:1R]3RV-E.*2SC+S!YO7G*&(F-
MFZZ]B*&S%\\A'F>/##Q&R^&LZ>FZBK?HLK'"VJ::E7.+Y7;"+ZJV&VUD.GF1
M23]Z,''H-PGQ5;I%\E.-CQ9SY<O%::G38GRRMA!]59#;:<=EYD5ROWHP:N2,
MZ+H3LY=HK3^YNFZ^HL!,WF[5\GC9#9[N&R(Q@<N/N@S#P8L8R03,+0VH#CGA
M=P/R[[97PQ,NK(JKNIG&VJV*G79![QG&2W337_[UV?4LWBY5=]<+J9QLJLBI
MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
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MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
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M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!03][WW>S:OQMC<_1U'G
M5>%I]6H\=6 GDU%AJH\M;AA!G:3,8F'K/D6:6_CP*NY235:413L+QP@-;>SL
M[,[>;/YL[>[A_<O*FH[WCL$?,!GCW"TM3)M&ZGOG\)U8 ;P=.:@L]4IQB ,S
MPXO+F,L]1W%XJMWQJ77$$^.@>%= $1$ 1$0'AVY\G]WRJVUW-/;5+6NESV[U
M#;<]3Z-J0-BIYS9Y,QI<&&O6X=WZY+>$(8Z5KJY(ZDM"9BD-[/A5)EVOL;O)
MF=OM6X+6.!E>/)8*]';CC<B&&Y7\X[N.M,)#UU<A4.6K./O89/$#B2,"$#8<
MHNH]B-Y\-N%I'!:RP$K2XS.T8[48N_,M6=G*&[0L-PW3:Q]R.>G8'AF:6$W'
MD7%W[<0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %1:[S
M;X^]S?LY5_ >)5Z546N\V^/O<W[.5?P'B4!@HB(@"(B *17NE?IB]L_[?J[^
M#W5RCJ4BO=*_3%[9_P!OU=_![JY 7>T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$
M5'?1?$#J3[,Z2_&3'*F,KG/?1?$#J3[,Z2_&3'*F,@"(B (B( KM/='?$)HK
M^['X9O*DLKM/='?$)HK^['X9O("2=$1 $1$ 1$0!$1 %^4T0R 49@)@8D!@;
M,0&!-TD)"[.Q"3.[$+^3L[L[.OU1 5!N]>[O,MMLR>N=)4S?0N?N&]RG7B=X
M]*9>R3F]9V!NF+#9"0B?&D[#'3GZL<[B)41DAH6QFUQHG%:DP^2P&<HP9+$9
M>G/0R%&R/7#8JV >.0";R<2X?JCD!QDBD898C"0!)J0O;[[$F5V6U?)C^+%S
M2>6*6UI7-2-U>L56?F7&W9!9A'*XUR:.=ND&M0/!=C%FF..(#!-$1 $1$ 1$
M0'U<'G+N,NU,EC;4]'(X^S#<HW:LI0V:ENM(,M>Q!*#L4<L,@B8$SMP[?4\G
MNG]VSV]J>\NE_5<H<%37>GXHXM04!>,!R,+<1PZ@QT(]+M4MNXC<A$!:A?>2
M#AZ\E26:DVNUMD=Z=0;>:GQ6KM+V_4\QB9G.)R8BKVJ\C=%K'WHA(?'HW8N8
MK$/4SNSC)&031Q2 !L.D6,/9([4^GMWM'4=58*1HIG$*N;Q)DSV\)F B K5"
MPS>9QLY>)3LLS1VZI13BPDYQ1Y/( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1 %>&[
MJ?Z7[;C['Y?\9,RJ/*O#=U/]+]MQ]C\O^,F90$A2(B (B( B(@"(B (B( B(
M@"(B (B( B(@"+QRNCMY^TKH3;VJ]K6.J,7@QZ/$CKV)WER%@?/CU3&51GR-
MHB=G86KUI')V?AGX?CTXF'=D61JHJLNMF]H5U0E99)_",()R;_!'X9.553"5
MMUD*JXK>5EDXPA%?&4I-12_%G>2*"+=OOQ=.0/+7T'I3(YR07(8\EGI!PU N
M'<6ECIQ>M9&6-_9,1G&C*3<A($1>8QZZ[[S[>?4Q'QJ&OIRJ;\M4TSCX:(@W
MG[KMLK^4=^'9BYO,#NW+1A[E+VA^ W$&8E.VFG K>W7,LY9M?Z&J-ML7\K(U
M_B1!Q'X[Z!I^\8VW9UB^[AUJ4-^W\M;*JIKYURG_ !1;=MW8:\92SRQ01 SD
M<DT@1Q@+>\B,W819OE=W9F^JL=-8=L?:G N8Y7</2-<XWXDACSE&W8C?AGZ9
M*]*6Q.!<.SL)1L3L_+-PZIF;B[EYS/$YYS-97,DQ=3?"F0MWF$W\^H LS2A'
M\O\ 0Q%F\^&9= 96ZS<\<,WUF9;_ $>SK14M\O5+)OUCCX\:TOPLLLLYO^CC
M^!&MGM)WWMK$TFNN/W9Y.3*QO\:ZJJE'\%;(N0:F[V[8;&.3%K([O3^BQF%S
M-X7\V;D7BH^U[^?)O<SO[F6 O;5[U/8_<;;36NAJTFJ)K>=P%Z'#W"TZ\=>I
MGZXO;P-J5[-J"8(X,M6I33%&#&T'B,SL?+-68OV^7?\ \5\$R7WRO ;0[:K<
M>Z6;=5=5.FV,[JXJ5=D7":]RB+6\6U]H_*[QFU>^$H.K!C"<91E%46R;C);-
M/GO?1I[?9,S*_:-PW1&\U;(M*X"\K!#7<&DZ6<V!WM"[@QN_2[LS\<<LWN7L
MMVE<"WOK93W_ -3UO_5K!\S_ )?47J2$JK0_N6OA/_\ RFN_A^FKMO\ =%-<
MWV9.%\IMVUYW5OI',E%=?1>X]DOZC/>#M+:;?CJ;(1^7+]=5B9G^H_A2R>?U
M..6^J[*4OL"]ZCMIM_C\]@]593*U\?8N097&RUL)EK[#:FA&M>@>.M5,HVZ*
M]67KXZ"+K87ZF=WK8F2]4R6R<$_W./@+AW5<?6=%RN),/,QU?",):EC9&-;7
M?5.F==]5VGRLG#::G%1N@U.NN3D]C8?"?V?-"X.XBQ.)M%MU2&?B0R:E3?EU
MW8=]673.BVK(J^C1MG#::L@H7UN-M=<VWR[.UMVNNVCV8]X<%&P:ZCP>K,96
MFFT]G,CIW4-48C)FD+$Y0FQS$6/NR (F+^))1E+URM&9#+#8AGT[O_I:8'JV
M\S3'AR%C+QNGD2=NL3*%NH2XY%_+J%V+CSX4:YEPO1,_[Z^WB?["%7$-BR*.
M(*\+)BMG9+1W:[=MN1VSKU.E.<$N5356[CLI=(Q2M/K/$"U"]9-N+75<X\MD
ML>3BKDDE%V1FI[RBERJ2<9<NT9-J,>6:GL^=L,=L-40:ATYG:-RE*XQ9K"/=
M:*IF<?R_5%*!N(QVX&)Y:%IQ\2O,W2_57EGBDM&;=]N?:74F(QN7J[@Z0I#D
MH(Y1Q^5U)A<;E:LIOT'4N4+5Z.Q#9BE8HW'H<9'9CA*2(XY"UX?KD@/R)DS_
M ">?/^GE?N&IKD?F,K/Q\A1QDWZS\B_/\N'6K\,^R+XA</TV8VG:OPMK&,WS
M55ZC;JVFRKENMY1ECX.I*/.M^:M;P<MI*46Y\V9X7XPR-,C955%743?.J;9-
M*NQ]Y5RBMTI_>BULW[RV?-S;(9NT7M\_NUWHU_UM3X1__P">7$=?[C;5:JPN
M1T_G-5Z*R.)RM:2I<JRZDPA"8'YB8%Z[U16()&&>M/&XS5[$<<\)A+&!-KMX
M=QLA%[@IGQ\AUW9O=\OAR1_YG9?7BWGO1^^G0+W>X)@_;X\8_+ZWR?*[^Y>/
M6/"'Q?@IUU\+<*9\))PE&KB:R,;(R6S369IN-O%I[-22W6_0V>[Q2S)QE#]&
MXUD)Q<91ED2Y91:V:DI5;--/9I]&NA-?O?MW6VZU7:PU3/XK4> L==G"9?'9
M2A?&?'D?#09!JD\K5LA4=_ L!)T--TC:@9XI6$.K(]6OALGC\_I_+-1R^-L1
MW*%JM*WC5[$;N[/[/D0&+E%-$7,<T)G%() 9"HMXNT+;C9N,94=_E?QI19_K
M\,+\?K<O]3E>S_/.7@9^,53]WRV)N.?UF#S_ %O+]I5+U/V+_&F6?+-T[A#2
M,'>WGA6N*-,MC#9\RY9_2:9^Y+K"3]^,=DVY)MP]DTYTISECXL*H>9SU0^D*
M3H>^Z4+-X2VB_L-^]%);MR7,[G>V'>X;?SZ8Q]O53Y''ZG&!HLIB\?C+-R":
M["/0=FA9%AKC4NNWCPQ6)XY*SR/7E(_"\>3K[6G?-X*/K#3>B\O?+Z$9\W?I
MXN-G9OHVKTFRTD@._N$I:Y.S]3]#MT/3KN=K+.@WSFAB ?CWR1W)F_7X&Y!Y
M<>7'/[;MY+@&8[5VL9&<8KM.HWU*N/KL_P"T5EK)C]7EB9_?Y\/PI=A[-GM*
M:E7"CZ1P-P]M'DEDV94LBYI+;GFZL/6JW9)==ZZH1W>^T.C6ZRXNXONKC7"[
M!QG&*B[57&5D]DDY2<XY$.9]VXPBM^R1:#W([TK=+/#+#C;&-TM6D9Q?X(IC
M-<8'Y9V:]D?6GC=V\FD@A@F!^2"0"Z>(L=Q-Z,%CKEW)ZEU#4^%;\TEJ_/<M
MM;R]ZP?!'-9%BFO3RR>7!S,[EPPL[\,S0MZIWDU/DF(;N>R<H$SL48VI((G9
M_P!"\==X@(?^R[.W^E=&WK+#R3\-[R(GX;Z[D[_7\W=W\_E=973?[D_Q!Q#=
M5D>(WB=GZE7"?.]-T7%GY,6]]WCY6H6+&QWL]O<T3JGMT2ZX"_@;4-3G&>KZ
MO?D)/=5Q<I0B_7R_,:KJ?I[F.OX(DWW+[P.G ,E?2N*DM2,SL.2RO,%=G_IH
M:,;O8E;Z]B6J[>[PG;@E_/8C[%6[':YUHU63)7JNC</;K%JK5=J$QPN"J3&4
MA8[!T@&*E>U!8KQ&-2E$[E!U0W<Q/' 8'9R+[L/N.M:;VV*&K-=1Y'1&UCOX
MX6S!JNI=61L[.,.GJEB(WI8V;S\34%V'PR!N,76O$96*M\O939+2VW6F<5H_
M1>%IX#3F%KA6H8ZD),(B+-USV)I".Q<N6"9Y;=ZW+-;MSD<UB:64B)[+<.>$
MWAKX35RQ>!M!P[.(^1U7<09K6J:EC-KDL;SLGG\JZ2Z2P]/AB8BE[U]+<?*G
M,'!?AI@X?+;#&4=O\;9O/(L_"<NM<9>OEJ"DNR[27%NS+V9=&[0Z-Q6A-"8>
M'#X'$QETB/MV\A<F?KN97*6R;Q;^3OS.\UJU,[D[N,4315XH88^_D1:!E95E
M]EEUTYVVVSE9999)RG.<GO*<I/=RE)MMMO=LF",5%)))))))=DEV2"(B_ ^P
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 73F^&
MQ&F=P\%9T]JC'1WJ4WMP3,S!=QUIF^=W<=:87DJ60XXZXWZ98W.O.$L$DD1]
MQHO%J.FX^91;BY5-61C7URJOHNA&RJVN:VE"R$TXRBUW31^&5BUWUSINKA;5
M9%PLKG%2A.,ELXRB]TTUZ,IK]MSL":HVMGDEL">:TC8G(<7J6M ;#7,G^<5L
MS"#&./NNQ>$Q$?JMQ^IZTK&3UXHQ9JI 11R,W4SN),_#B[?Z'8OV^6]_RLMB
M9F\%3R=.SC\C5KW:-R$Z]JG:B">M8@E'IDBFAD8@D Q=V<29V_O,J\';?[G"
M5O6M2;2Q^,#.<]G1MB=O&B%W<C^9^W8=FEB'GJ'&79FD >H:5F1_"IOY/9VS
M\CPQSLC3\>61G<!ZGD/(E@?69&=PMGVM*S,P8KGMSM)R$HK-Q(*>9CN$,O'C
MDS^DPOKMQ%X7W:=.R_3%/(P9MRGB=9Y&*_65/>613\8=;X[)I7>\RK'K'0Q5
M^NS5#KJOR\L7'4\'RN[-Y]4/^</<[=+=2Y'MGVA]>Z.,)-)ZTU3IWHZ6&/#Y
MW)4:[B+L[ =6&P-66+EN7BEA.(^.#!V\EW/E\-;Q]NS0OU9Z5ZI-)7MT[<,D
M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
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MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
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M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
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M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
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M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
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M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
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MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
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M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
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M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
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M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
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M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
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M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
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M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
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MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
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MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
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M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B ^=E\M7H5+
M5ZY*%>I3KS6K4\C\!#7KQE+-*;_(,<8$9/\ 494$NUYO[9W.W&U3K.8S>OD\
MC)%AX3\O5,#1_,F'K,/DPNU**.>PPLS27)[,[BQ2DS6=^^B[2?S';8%I2C9\
M'-;@2R8D6C-QFBP%;P9<],W2[/X=F*2#$R<^119&46\_-J>R (B( B(@"(N2
MZ-T?D=0Y?&8'#UWM97,WZN,Q]=O^MMW)@@A8GX?HC8S8I9']F.(3D+@1=T!8
MG[AWLV.P:CW4R-?CQ'/2^F2D9^7 /#L9Z]%Y\/&4OJF.BD;GDZ^0C]GI]JR(
MNG>S]LWC]OM&:<T;C."K8'%UJ)3L#1O<M #%=OR"WNDNVRFLFSN_2\G2S\"R
M[B0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %@5WH'Q![F?8.'\*X]9Z
MK KO0/B#W,^P</X5QZ HR(B( B(@"(B M_=QC\2EC[=]0?O3#J9)0V]QC\2E
MC[=]0?O3#J9) $1$ 1$0!$1 $1$ 1$0!$1 8E=NS=[YA=HM?:E$VCLU<!8I8
MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
M_FS_ "B8$Q1RQD<<@D!D+W<>[Z[<.+WITB%LRKT]886.O5U7AHNH!BM&'$>4
MH1R$9EB<FX225OGDSU91FHS3'+7\24#/M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$3W?5?$)G/L
M]I3\.55305R_OJOB$SGV>TI^'*JIH( B(@"(B *\-W4_TOVW'V/R_P",F95'
ME7ANZG^E^VX^Q^7_ !DS* D*1$0!$1 $1$ 1$0!$1 5F._TQ3CG]N+_#])XC
M/4V)W?CJCN4)G'CCCEFD9W\^>']WRJN;'I=[N0N6HG(9ZQ42CD G&2(Q#K"2
M,A=B Q*-B QX<2#D79V5I_O]M*E)H_;[/,/LT=4W\,9-QY/F,-->CZO+JX;X
M!DZ7YX9R=N.3;BJ+E=12XS)-*'/AV*L8FS?TT4DW#_4=V8F;]9_[]]O!#)C9
MP_I^^VU?TJJ2^#65<UO^4HOKZ,JUXJXV0L[-6-)1NFL>RMOINE"KF73;NHR2
M^9*-M3WJ_:#T;X4!ZLCU9CX6$6HZNQE7)2, ^_C,5@HYLY";R:2YD;@CQSX?
MO9Y*=K/2#*3/%#KW;C)U.7Z9<AI#(5<D#<\-U?!>9/%2"#>9&X9.:3CR"(R9
MF*M_C-S F<0)F,B=A$7%W(B)^EA9N.IW=^&%FY=_D^1<BKY_%W&\V'WNSN#L
M[,[>3L[/SYL_D[>]G\G;GR6S:SX3<.:AO*S3L>N;[V8N^++=_>:QW"$I/OO9
M"6[WWW(\T_Q1XET[:-KMM@O2S:];?+S4YI?*,EMV+KNT7>E[%:R\*.AKW&8N
MW,["-#4S2Z<M"?'+@[Y4*]8NE_9ZH[,D9%PT9FSB[Y\XW)5KD$5JI8@M59P&
M6"S6ECG@FC)N1DBFB(HY )O,3 G%V]SK743Z8H66?H,'ZOT),S<\_K^7UERC
M;W4FL=$3%:T7J?/::D(_$-L)E+-*O-(/FQV*D$C4[+L_N>S!+Q^V_,1:W[,E
M$MY:=J5M3^[5EU1NB_D[J?*E%?/R;"2-&]HZIN,<[$4'ZRKE*MKYJNU23_Z2
M)L.^5Y5-':[OFM^]+O%%EK&GM;40]F2+4&)>ID7C;WM7RN$L8[HF<N.9KU')
M-T=0M$S]!!);M1W_ -HBXT4.M]&:CTS.["TUK$G!J/' ;OPY,PMC\CX0MYNX
MT9)7;R"(GY9H@UOP+XBP]W'%AF07W\.V-C_Z&:JO;_FU27S):TCQ6T3,VY<M
M4R?W<A<G_73E6OSFBP"BP\V=[?\ LUKUHVTSN%I^U8D;EL??GEP66;Y/:Q.>
MAQN1'VO98GK=)/\ 0$7+<Y?QRB0L8NQ"3,0D+LXD+MRQ"3>3L[<.SMY.S^2B
MS/TW)Q9NK*Q[\:Q=Z[ZITS7XQLC&2_<;]C9E5T5.FVNV#[3JG&<7^$HMK^)^
MB+PSKRO$>@(B(#X6HM,8W,5):&6Q]+)T9Q<9J>0JP7*LHNW2XR5[ 21&SL[M
MP0.W#J*7?;N5]G-5^/:T_2NZ RLO6;3::G?X)\4N7%SP%QY\?#$Q=+/!C1QT
M;@Q,/29>(TNZ+.:)Q-J&FS\S S,C%DVG)562C">W965]:[%\K(R7R,7JFB8>
M;#DR\:G(CZ>9",G'^;+;F@_G%IE/+>SN:]Z=&O/9TW)B]PL5%R498B1\7GGC
M;CGQL+DC>'K9W=A&CEK[FP];C$Y>&T8>HBNX:_+A]38;(8/*P/Q-C\Q0LXR_
M'[1 Q/6MQ0RO&1"31RL#QR,W5&9CPZV)*ZVW-V=TKK2@6+U9I[#ZBH$Q,U?+
M4*]P8^KCJ*$I@*2 RZ1Y. XS=F9NKA3WPU[2>?3RUZGBU9L%LG=0UCW_ #E*
M&TJ+'^S"-"_:V(5XD]GW3,INS"LGAV]TGO97OZ)2WC;'\7*S\#7U2X3'W&YC
M(6=V^A+CS\O=Y?5_:7S\1H6M6M1V9  SKB[5O)B:'JZN2CYY8>&,V%FX9G,B
MXY4Y?>>=W]LOMCCJN9TSE<_I_4>8M].,T9!;#+8FU7B=GOW.+XED\33AY8?&
M^$K%=YY8:E.@(]95X']TMR(--8P[#]$EV5GBH5G\_%FX_HAMSY00\]<A?+[,
M;/U&RL?I'$V%Q!@U9&/CV2JLM3C#,H46K*)J49PC+S*Y.NQ)QNKE)0G!\LU.
M+Y8:CP#FZ9G/$R,B&0H\KA7"2L7,WO"4VTG'D2YDIQ4EO&;:BMY8Z=K3<U@A
MCTU3D]J3HLY4A?Z&-G$ZU1^//F0N9Y6?C@1A'A^M^FU)Z+SL\^*V?UAK.6,&
MDUCK6>K5E<7:0\?IFG#C^EBXX* <E-D6'I=^)AG9_-E2*SMNU?M33R/);NW)
MR-V;VI;%F<^& 6Y^CDD)@C!N&;D0'AN.-H1W<W9S':?8_;;03QL%O"Z;KSY?
MI;I8]09N:?/ZBE9G9B%I<YE,A((%R48$($1N/4\9^T-JL<30Z,&,OK<[+ANO
MUJ<>+MME\>ESQDEVV?RV++<!Z6J=DNOEP<IR_6LGLM_Z/,E\$D9KHB*DI)H1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!<1U]HJCJ/"9; 9*-I:
M&9QUS&6P=A=_ N0' 9"Q,[=8,?7&[M[)B)?(N7(OROHA;"=5D5.NR$JYPDMX
MSA-.,HR7JI1;37JF?2RN,XRA-*49Q<91?52C);-->J:>S* VX&ALCI;.YS2^
M6!PR>$R%[$W!82$3EJR'#XT3%P7@V08;%<G^C@EC-N>IG4<V,9H[0L7T,=D6
M+ZS!*S$WG];ZO]Y6HN^L[.1XC4^)W*QT'&.U'#%B,YX8/TP9V@!/3MR.+<,V
M2QPC [DS,T^-<G(SLL(U<<]2>ME+\+_H+DSCY</T2&\L1?MQF!-^NM*_N9NB
M2X7XQ\2^$[>;=TZ-J>!S;?78&/D9]2O2[2WAJ6'"<ETC9S5R>ZV*78&A2TO4
M]6TR>^U;A*EOO/';FZK-^SWKLAS;??YH]TT9/V<Y0I"[1B'(\^T7']_CW,WE
M\O\ H69.Q78"WJW/:"Q@]*V,-AI^EPSVJGEP.,>(G%O'KQS029*["PDQC)1Q
M]B.0/:B(_-FB)BU'D(;4-J&W/6MT[$5FK8KF\4U:S6E:6O8A,?,)H98PECD]
MXF(DWN9;!?NX>V-4WJVRQ&HSFA^:3'!'A=8TXQ:/U;4%2"-Y[ 0_H*F5B*+)
M4V#JC".P59C*2M*P]/?%WCO4M$PJLC QJ;(V6.JZ^WGDL:4EO4_*ARIJSWES
MRGR1FHQ<).<3)>'WA-IV5D2CGWVV6QCSPA'9>;L_?^LGS-<O1N,8)M-M22BS
M ;8#N'M&XQH+FY6H<AK.ZS"<N)Q96-/X #ZF)XGEKSOF;@"W,3S-<H/*S-(U
M>N[^&TT.U^S&D]$X\,5I'3F&TYCP;CU;$4*](9'?CJ.8X0&2>4G9BDFG.260
MO;,R)W=^S45)>(N-M5U:3>?FWWQWYE4Y<F/%_&&/7RTQ?S4.9^K9:31>&,#3
MHJ.'BTT=-G.,=[&OA*V6]DE\G+;X((B+5C/!$7SLEEJU*"2U<L05*T+=4MBU
M-'7@C'W=4DLI!&#<_*1,R^4FVDENWT27=OX(-GT449N]_>Z[%Z(.:J>K&U1E
MH7<7Q6CZDV<-C;WC-E(FCP-8@+AI(I\J%D>7Z8#<29HBMZ>_OUME/%J[<Z)Q
M.GX"Z@'+:HDES>2Z'\FDKXVC/C\?5G#CK K5C*POSTG5]E^J1>'_  FU_4N5
MTZ?;55+JKLM?1J^5_>CYNUED?G578:=K/'VD8"?GYM3DNGEU25L]UZ-0W47_
M #Y1+4I$S,[N_#-R[N_DS,WO=W^1F6!V^/>8[)Z \6+,ZYQE[(0]7.(TX[ZA
MR3R"[CX)18OUB&O+UMX9-;GKC&3_ #XHQ9R:GON_VA=UMR_$'6^ML[EJ,Q$1
MXGUIL=A'8O>!8C'C5H2 WFXC-!+T\OTNS.ZZ4IZ5QU(68R!NG] #"S<,W'EP
MW'][Y/<IQX?]F:*Y9ZIJ$I/[U&%!12__ .B]-OX/;'CMMTD_2&->]HK'@Y0T
M_%=LNRG:W+K_ **OHOSM:?P)^=Y/2 ;]KQ:VVVWQ5P?Q ARVM+<;S>;,T4K8
M3#3S1#TOR3@>;DZQ=F?PW9^8I-W>VKO?N,4HZEU[F8\?-Y? ^"(-.8>.-_?&
M5;$!5EMBS\NTF2LWIVZG'QNC@6QF+45.$XX:T7B32F,4,8B\LTTINS!'%&#.
M4DAN["( )&3NS"SOY+,?:/L![Z[@>">%T-?QN.FZ?^5]3R1:<QT8$_3XOAWR
M#*60;CVO@_&79!X\XV4O8?!?"W#]:NG1@8S759.=9"=K:[^7;E2DXR?ZM/*W
MV42,LCC7BO79.O&CD\C[PIA*,4G^M"A)-?.QO;NV87U='TJSD<I Y$_6;M[1
MD;OR1$3^\G=WZB)W=_?SRO8L9_&TQ=@$&X^4W;_SXY5B'9WN!H3\*QN-KZY8
M?D#EQ6CZT5.-_+EXBR^6@N2F'5[)%%C8#,'=P.$^DFEWV0[OS9_;WPI--Z'Q
M 7H>''+90),YEW-GY\3X1RYW+$9,7M#X)1#'R[1" \"VJZ_[0VAXF\<2-^H6
M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
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M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B Z*[2VQ.-W*T1G]&Y/B.++U.FK;Z&.3'Y*N8V
M,=D(>?/KJVXXI"%G9I8?%@/F*:02U[7:-VTR>D]69+"YFL=3*8ZU/C,C"8DW
M%S'2O 9BY-[<,T/@3UI6Y">J<,T1%'(#K9,NJ[??I=ADM08%]VM-U&/*Z>A%
MM75XA-Y+F%KAT0Y@! 28IL1'S#=9^GKQQ1V"-O@UHYOOP+".D<<</\3U;0VA
M=P_K.W1W:/JDH^39*791TS5(8F=.3V4<19G7FY8N)_$GA9W2HU6B.]^+"=&3
M%+K;A6;O?YO%MVN7^:=W>2@BH1=CZ9'?Y"9B;^\[/_G9_P!IU(SW8O;BM;'[
MAULC;.:71NHGK8G6-(")V"EXI-5S<$3<B=S!RSR66'IZYZ4EZF! =@#&/G(U
M^J(9&\^E^'_[I>Y_UF?C^^O0B9WX9F=W^HS?773K7-)HS\:_#R8<]&1!UV1]
M=GVE%_=G"24X2^[.,9+JB*\?-LQ[:[ZI<ME4E*+_  ]'\8M;J2]8MKU-H%@L
MY3R=*IDL=:@NT+]:&Y2N5I!FKVJMF,98+$$H.X2131&,D9B[L0DSLOK*F?W<
MG>^Y#:32%S16J\%EM6XG'LTNC&HVJM>QC/%E<[.'MSW"9PQ D9V:4D(6YJ<C
ME4"KZJ43UN0;S=];O7JKKK:4@PNWU"3D?%Q].+.9L@<GY9\AFH)Z,'7&_2[U
M\2%F(G\2"W&; 0TR?@#KL\V['IA3]&A9M7G76QKJLK?6$O+AYEZERM*<8U24
M9II2<=I.7K_%K2*,:%U]SC<X[SQH1<IQDNDES2Y*]M_LMS6\=GLGNE;JU9K/
M#X"E-DL[EL9A<=7%SGOY:]5QU*",>.HYK5R6&",1Y;DCD%FY;E_-E%SO9WTV
MR.DVFAQ67NZ\R$;N(UM(56MTY#;GW9JW)4Q!Q_0\RU[=@2%^8FD=G%5*M<Y?
M5&L;39#6>I,SJ*TTA2C+G,G9O-%(?#F5>&>0H:SEY,[5XHFX9FXX86;X4=#&
M4VY=V(F^I[O+Y//S_P S*6.'_9IPZ^6>I9MV3);-U8T5CT_S79+S+9KYQ5+]
M.A$FN^T7NY5Z;B)OLISWME\GM'EKB_DW-?B3 ;P]^INKJ)IJVB]-8/0]23J"
M*W8DDU/F6!V<6E:6Q5QV,AD?R,8_@RR,)/T/-89F-XN]R=Q]P-?3G:UUK/4>
MHWD)S&#*Y:T>-KD7D7J6'"2/$4@(>6**E2KQEYN[,[N[\5TU/?S=^/#Z9Q%[
M,Y6;^A8[#T;&2O$//#GZO4CFE&-N?GDI",4;<D9BS.[2/[.=T1OMK&2O9R6/
MQ6A\9(0R26-47NO(-&Q,WSG"8R*]8DF9GZVKWY<9%* N+VHR?E2E7IW"W#,.
M;DT_3Y);QG;)2RI)?JSME9EV;[=H.6_PW(_EJO%O$,MJUDRJ;V?+%JJ._P 8
MUJ%$'L_O-?CL1FQZ?QM+D3<'<'=G$6%F;I?CC_R9F\OKKV*67]8G"EBJ,]ZY
M([#%4HUIKMN4G=A$8Z]>.28R)^!$0!W=^&%G=^%:(V;[A[;;%M#/KC-Y_6]H
M>'EJ169M-88R^IX6)L#E^AN&<6;,#\K'UCP+2U[3]GO0^A:HU-'Z4P6G81'H
MYQF/KP3R-QPY3VV![=B0O?))//+)*3N<AD1.ZC[B#VD-*Q^:&GXV1G36^UDD
ML7'?P:E-3N?X.B'3M+X;=HWL\YN0U/5,R-:?5UQD[I_-.,>2I?CYD_P^-0#9
MSNP]^=>-%/\ ,J>D<9,S$-[6<QX67I<F%W;#%%+G(W;GE@LXZKUA[4;DW',K
M6RO<&Z9I/':W#UKEM43^1EB\#6;3N*!^/:AEMR6,CE+K"7T,\,V)8Q\BJM\E
M@E%!_$/CUK^=S1JNKT^J6ZY,2M*S;TWR+?,MC)>LJI5;OT2Z*9] \'-#P.5_
M1OI-D?O9#WCOZ_50Y:VO@IQGM\7W,:ME>QWMAMX+/H_1&GL/:\,8Y,I'CX;&
M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
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MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
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MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
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M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
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MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
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MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 5,[O9NU:^XNZ-K!XZP4FF= 2V\!0Z#ZH+>8&2,-09$&%^DA];KAC8)
M/:8X<?X\1/'8'FS#W@G:-;:W:75FJH#$<LU,<1I\7]\F=S)M1H&+>XAI>+)D
MIAY%RK4IF!^OI9Z(.)F.4WDE,I)9#>2261W(Y)#+J,S)^7(C,G(B?S<G=U:/
MV<>$E9;DZS=#=4;XF)OZ6R@I9%B]4X53A5%KHU=8N\>D">-_$#ACU:=7+;S=
MK\C;UKC)JF#^4K(RFUW3K@^S.W,%\G]_]KA=8[B[QN0GB\/)P/F%K( 7'UBB
MJ$WR>]CL"[<^Z+CCK?@VN]?F[%BZ!N(^87+ OPY?5KQ$WN;_ .*8^9/\[9^E
MCYEK[HKNP3W3R,6NM:U)8MN\-;%JE(W* ]892L?454';B3X#I2"#9.<'#UV0
MO@^M*_1=."S/%'$F+I.'=FYD^2JI+9+9SLL:?)55%M<UECZ16Z2ZRDXPC*2A
M+@SP[EFY-5MU?/.3YJ:9_8C%/?S[^C]V.^\8M-=MU*4HQ(Y,%V5=PQP6.UC/
MH#6%G2V2C*U2S%7 9*YC[$ 2&'K4TU2O.52F91D\5FX,$%L7&2O+)'(!F@U5
M2)VAEACC(69O"Z6B(6XX9O#X'I9N...GCRX\N%L8*=.*O#%7KQ1P001QPP00
M@,<4,,0L$<448,P1QQ@(@ "S"(LPBS,RZ4W1[,>WFMHSCU7HO3>>>1W<YLAB
M:<MIR?SZVM^$-H39_:$QF8Q+VA=B\U7+3/::Y9R65I2\MS;C/'R/?C7N^52A
M;7M.:CLI-65QD]VHQ3V4S<3^!4,_EG'4;(SA':$)P:K4MES.+KFG%2?QC.6V
MR;:BB@H5#%VF\G$.?JLSMY_77LX#&9'#3^N:=S.1PUIBZQLX?(V\798V]Q>+
M2F@E8F\N'ZN>.//A6M=TNXLV;S+RS:<FU/HJR;D0AC<O)EL:)F_+D]+/MD;#
M"S_00ULA6A 7< C8>AACDW2[B#<S%>)/HS5^FM3P [D-++C<T[D7!F\@BE"+
M*XZ>9W\_GTV.B9G?DV=FZI3TKQQX:SUY=F1+%<^CKSJ'"+^4K(>;CI?SK4B*
M<[P9XDP'SXEKO4>SIMYWT^$9>7=^Z+9B%MAWF_:%T9X<4>M9M3T8^EFIZPI0
M9TG'R8N<J0U\Y(9#Y=4^4G$2;K8.7-CD/VR]('R%<HH==[9O-&W2TV1TAEQ:
M;AN&)PPV9BBAD(FY+SSM<1=NGAV+J"*+<GL=[VZ(:0M1;=:C"O%SUW,95#/T
M>&^B+UG!RY"/H9O,B)V$1\RX;GC%Z'5].4SAGC!I8R*.6-_8EBD%^DPD!^'"
M07Y8A-F(7Y9VY60R?#[A36H.VO%P+D^KOT^R-?5_><\.<(RD^_O\V_JGU/)3
MQYQ;I$E7D+(:7W+X.3:7P61!M+;]62^78N3[5=\+L-JAXHY-6'IBV?#/5U90
ML8?H-_T!7G&?&/PWF\@WBBXY^><L[*131VOL%J*G'D-/YK$YVA+_ $*]A\E3
MR=21N&?YW9I33PGY.S^R;^3L_P JUYI4L799^. =W]S\.W\OVE^^G\5?PEOX
M2TYEK^&O^QQ=P^0M8RV3 [N(G/3E@E,6=W^=D1 [$3.+L3L\:ZS[,V%/>6!J
M&10^ZAD5UY,/YJE#R)Q7S?F/;T?IO&D^T>XM1S\%+T<H.=3_ !VDK8O\-XKY
MHV*_+)RJ16WG><]H;1S0M7UI\T-2-F'U#5V,JYN"1P^@8[@!1S+ P<#TP9B)
MR]IS?GPW"17:ST@2W$T<6O=N'<FX&7(:2R7(DWZ*0<7E^EP^5FB;*2?5>5O<
MHEUKV?\ B#%WE37CYT%O_P FN49[+XUY"I;?R@YDK:/XRZ'E[+Z1+'D_2Z/3
M^E6[$OQERHLPHHQ-I>^#V$U8\<+ZN/3%X^GFAJ_'6L(0$;\"'PBXV,'*;E[/
M17RTQ<\<MP0N\B^E]98C.5FNX7*8[+4RXXM8V[6O5WY;EF\6M)*'/'Z%R9_K
M**=5X?S\&7+FX>3BO?9>?194G_-E.*C)?!Q;3]&2+@ZKBY4>;&R*;U\:K(3V
M_%1;:?R>S, >]*[O_$]H?:S*Z5E"M6U9BPGS&@\W/&)%B]10P%X5>63RD#&9
M@!;&980+RK3-9$)):L(K6&ZPTAE-/Y;)X+-T9\;F<+D+>*RN/M \=BED:$YU
M;=:87XX.&>,PY;V39F,7<29WW"7*I#>DV]@R'3VHL/OQIVB\>/U?:KZ=UT-<
M.88=2UZ3C@\W.(MQ#\,8VB>+LS^S"5W'T&/BYD.JQ8'V>N/)49+T3)F_(RG*
MS";?2K*2YIU)OM#(@FXKLKHI1CO=)F-UW!4H^=%=8[*?SCV3_&+_ (?@BJ$L
MP>P%VG;NSN\>W^X-64HZF'U#1@U!$QN 6]*Y28,=J6O)YL)$.)L6;=1I'\(,
MC5I32,XQ.SX?(XL3.+LSL[.SL_'#L_D[/S\C^Y_K*WN;A5Y--V/=%3JOJLIM
MB^TJ[8N$U^<9-?(U2$W&2DNCBTT_FGNC<68[(06Z\%JM*$]:S#%8KSQ$QQ30
M3 ,D4L9MY$$D9"8$WD0NSLO<42G<>=HZ;<SLT[>9._,<^:TY6NZ'S<DI=<DE
MS2EL\=2LR2>3'+D<$.(R<SLS,$MTXN/8Y4M:Y?:[I,\#-R\*W^4Q,B['D_23
MILE#F7QC+EYHOLTTUT)(IM4X1FNTHJ2_-;A$18H_4(B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@*JW?I=FIL+JS$;F8^!PHZO"+#9PP!_#'46+I\49
MY#\Q&7(X6KX0CR/6V&DD82)YB4#"OS]M3LZP;I;;:ET@01E>M5'N8.61V#U;
M/8_FSBI6E)Q:(3L U6<W)A>K8G ^8S,2H/V:LT$LL%B*2"Q!+)!8@E HY8)X
M3*.6&6,F8@EBD$HY )F(#$A)F=N$!^"(B (B( L[N[?[2C[8;KZ>RUF8HL%F
M9H]-:C]MPB#&9:>&(+TWGTO'BKS5<A)U,[M7@L,#=;BL$5X=D!LD!)G9G;S9
M_-G;S9V^1V^LZ\J.7NM.TJ^Y.TF%FNSM+J#3/.F,]R_MR38X!;'7B;GE_A#%
M%3GE+@1]<:W&#=,3*1I $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$6!O>1]I?^9=M3G<Q5L/!G<OTZ;TVX.S2ME\I#/^:8_-G9\=
M0@NY'K_0O5%FY,@$@*N?>B]I-MRMV\S9IV'GP.F!?2N"Z).JO)%CK$Y9&_$S
M?.R*_DY+#^L"SO/4KT1ZSBAAXCM7\Q@PB(BW#"S"S?49FX9OVF7]( B(@"(B
M *<#N/>S8^H]>Y#7^0@8\3HFJ\&-ZQY&;4V3!@@D!W9Q)L9C/6Y3;R(;%RA(
M#_.S90AQ1'(81Q@4DDA#''&#<G)(9,( #?*1D["+?*3LRO?=@'LWCM;M9IK3
M,T8CF)(#S&HI.'ZI<WEG]:M1ESQR-",H,7#[(OZO1B<F>0I"(#,Y$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!8%=Z!\0>YGV#A
M_"N/6>JP*[T#X@]S/L'#^%<>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-
MO<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 5(;O9M-OC.T%N"S!TPWY=/
MY2#_ +0W-+83U@_<S>=^.XS<<MPS,[]3$S7>549[]G2;T]W</E6#I#,Z,QXN
M[-Y238S(Y."0^?E)H9ZT;\?H0#RY]X$*J(B (B( I!>ZMU$V,W_VXG(B$+%_
M,8TV;G@_A336:H0@3,[<BUFQ!)P_DQ@)<.XLRCZ7?W92U6V#W.V^RSDPM1UC
MIZ0B?W,)Y.O"3OQ\G3*_/R<<\^2 V"++RB( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
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M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
M(B( B(@"(B BH[Z+X@=2?9G27XR8Y4QE<Y[Z+X@=2?9G27XR8Y4QD 1$0!$1
M %=I[H[XA-%?W8_#-Y4EE=I[H[XA-%?W8_#-Y 23HB( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"KB=\-W
M=KSC?W?T31YFC"2UKS$50!O&AC%B/5%6(&%RFA%B?. +&<T3#D6%CBN'+8[7
MY3P!*!QR ,D<@$$D9BQ@8$SB0&!,XD)"[B0DSL3.[.W" UNB*8?O6.[T/;'-
M'K32E,OF U!=83IUH"\+265G%R?'F\?4,>(O2C))BYC&**M+(V)?VAI%9AX0
M!$1 $1$ 1_J(B M:]T5WB+:PH5ML-:7NK5F*JDVG,G9=V/46(J WYBGF)^F3
M-8N'R\^B3(8^-I^F6Q5O3R3MK7#8#4%_$WJ>3Q=RSCLEC[,-RA?IRE#:IVZY
MC)!8@E'S"2,Q$F?S9^.DF(7<7NM=W#V\:.\^EGCR#UJ6N,!'##J+&QD(#<!V
M8(<]CX7=B]1NDSM/&+$U"YU5C+PSK',!(^B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1
M$0!$1 %>&[J?Z7[;C['Y?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B
M( B(@"(O#H"M3Z2.#_,KM47#NS:HSPN7'LL18>%V%R]S.3"3LS^;L).WT+JJ
M-<EX"*-OT3N;M^LW#?6^7_,K=_I'>'(]K]OLBW4XUMRHJ)\<=+>OZ3U/.Q&W
M3RW#XWI$N6%NOI+DC#BG_,?,O'R"(LW[7+_Z7?W*_7@/8GPSB+]6[,B_Q>39
M+^J2( X]A_ZUFW^I7+_LXK^LLU^CH;)-9S&O]Q+4+/'BZF-TEAI2!G9[=]SR
MF<(2?V@DKU(<+&SC]%'?F%_H>%:V41_<B[<!@.SYIBWX;#/J>_F]0S%T=!R#
M/D9J-5SY9G)FJ4(?"-_)XG!Q=Q<5+@JE^+.LO-XAU*S?>%5[Q*UZ*&(E0]OE
M*<)V/YS?X$N\*8:HT_&CMUG#S9?%NWW^OX1:C^"01$4<FQ!$1 $1?$U!J7'8
MFI-D,K?I8RA6C*6S=R%J"E4KQ W)R36;,D4,48-YD<AB(MYN[+[1BY-**;;>
MR26[;?9)+JV?#:2W?1+NWT2/MKQRHHM\N^;V0T=XT&.SEC761BZQ&IHV&/(U
M3D%W;I^&YI:V%('?AVE@NV!('YC\1VZ7ATWG[]7=74?C5M$Z=PNA*A\@%N>0
MM3YIAXX\09[52ABX9'XZQC^"[#1<N#RV&9C4F</>#VOZCRRKP9XU+V^NS7]&
MAL^S4)KSYQ_:KIFOF:5K7B)I& GYV97.:_Q='ULOPWC]7%_*4XLMH9_4>/Q5
M66]E+U3'4H6ZIK=ZS#4K1,S._)SSG'&/DSOYDW/#\*+S>_OFMC=(%/4H9^UK
M7+0.0O0TC1GOU&-AY;KS\XUL 0]3>&;5,C;L0GRTE<>'XJ3:_P!:ZYUU8/(Z
MVU9J+4TYD?1\-9:W:J5^LNN4*>/.5L=CX.2;BM1K5:S=;L$3>;+B<&G\?4'F
M0X^6;W#Q\GU^?_-3OP[[-.+#:>IYUN1+HW5BQ5%2?JI66*RVR/\ -C1+YHA+
MB#VB8INO3\9.7;FLWMG\MH0Y8P?\Z5B)@M[>_9W1U 4M306GL)HK'GR(W[X'
MJ+4+MSRQQ%*5;"TG<7<3B/&Y,F^CBM1OPS16;G;@:ZW#L-:USJK.ZF()/%BA
MRM^66A7DYYZZN.9PQ]4F;RZX*L9](BSD["W'RL"]K*6@QVG<-D<WD#=ABHX?
M'6\M>D-V\ACIT()[!D[-Y"$3N_G\G"D9V<[I7?36HQ6<CC*6A,;,P$TVJ;)!
MD&B+SZAPE ;%V.1AY_,]]Z$S'TA*,7)&,K5:;POPS!3Y=/T]Q7NV62C+*GTZ
M\L['9E6;[]H.6WP2V(XLUGBSB*3A37DSKD^J2<:8K?IO&/+3#\9-?CON1EU]
M.4*C-XA@W'Z$?/ZGN\N&_O\ _@OI8JV]RW'CL+CK63R$O]!IT*D]^Y+P[#S'
M5JQR2DW+MR31\-SYNRM#;(=Q/MUAFBL:YSV:UW?'I*2 .K3>"ZF?GI"A2M6L
MB8\<B?K&9F8VX,8XG\FEMVHV!T1H6GZCHW2> TU6?I>5L/BZE*:R8CT--<LQ
M1-9NV'%NDK%N:><V^BD=1[Q#[2&E8_-#3L:_.FNBLE_>M#_:3LC*]K]ET5[]
MMUW-NT7V>L_(<;-4S54GLY50?FS7QBU!QJ7X^9-+X/L5$]G>ZOWYUR\<\^GJ
M^BL3(S$V0U;<CIS&#\<^!A*;W,QXC,3&/KM3'P2#RX67+R7L=M3L"P;&UM*1
M3ZJL:ES>I!RDEUFH14,;4@QKTQ'U.)YK%J0BDM^W)/,S<,(C$S\D5T#A58N^
MZUNU_<[ 8.,V./3^D:\DK,_/A7LUD;L\\3M[F)Z-+&2\LS.0RCSY"RU/@?Q9
MUK7];IQ[94X^%&N^ZW&QZME*,*I1KY[;79:]K9UM\LX1;^YMT-ZUWPST?1-,
MLMQZI3RG.JNN^V6\DY33GRQ@H06]<;%UBVEZ^I6I[7,XO4PE?Y3L7K'U^((J
M\?/UN?6?V_/R?A6;_1?-X'O;>;A:%EFZI-+ZJJ9RI#YOX=#5%%Q(N?T(R9##
M778&=VZF,^&<R<JLO:?R'K&9K5F?D:5$6=F]S26)"E/]9^AHF=O^RWUE+=Z-
M3N'+B-^\_IXCZ*>J]N<LSQ\NWBY7 9G!W\>_#/TEX6-LY_CJ'EFD=P(6ZQ.6
M/%S2%E<+Y\=O?HA#,AOZ.BV,YO\ Z!VI?SO@93@"WR7BQ?W^:+^?FN3C_%P9
M>Q1$7/HFX(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( NN-X-<CI
MC2FIM2&X\8' 9?+\'] 18ZA8M@!>;<]9Q,''+<N[-RW*['4>7>NZO^!>SUNC
M:8N@[&GGQ41=3"[2YBY5Q@<.[MR[O:X$6Y<G=F9G]SY;0<'Z5G86-MNLC+QZ
M'^%MT(/^$CR9]_E476_Y.JR?]"#E_8:_AYY9@!I#*223Y]8D-W*224_:(S)_
M-R,W(R=_>3\NN5Z9S4&.M#*;\2B/SOEGX%R\G=WX]DNGR;GW<\\KX=2!A%S+
MW"W+\_49O_9<?,GD(C?Y2YX^HWR-^LS<<+J%*?7=>GP_AL52R,6%E,Z)[\DX
MN,]GLWS=))OX->ZUZKH98T-?UIF%I?#/J]W/')=/'/#MYOT\LY?4Y;GCEE]:
M2GC+C>3L+O[^>';S_:_E_>5CWN.^SUI'56P.6BU?I;!:DI9;7^<F"#.8BGD8
M_#IXW"T(I('N5Y'CE@GAM/#9K$TD$CEX4D<P'QW;O=W%NU>?&:?1^1S6@,B;
MF4;5)2SN$$R^A:3$9*P%EX0]KIBIY>@3\MS([-P\-Y7CSI6+J.5IV=3D4?1K
MYT?2815],N39.4HPVNAL]TXPKM?3OUV7@L\!,JS&JS--R8[VUJQ4N7E26^[4
M5S;U2].LI5]_EUK#;::LUAH2V>0T)JC,Z;L&3'+\#9"6M7LDW#=5RBSO3MNS
M-PSVZ\SBWD/#.I1]F._&W<TY)'6UMA<#KG&B[,=J&$M.Z@ >&'EK5/Q<19$&
M'D8CP]>:0R)Y+_''3P3>'N<-\=(--8P<6*U[0A?D3P-IJ.5./S?K?#Y4X?;8
M6Y*&M>N&SNP1/.3MS&MJ1\O@;98W5.!R^!R .P24<_BKV'O 7GQS6R->M.W4
MW+B_1P0MU"[CYK9YXG"_$T'+;3]0DX[2G!QCEP6W3>4/+RZOES./;;;NC7(Y
MG%W#DDI+(C5%[J+W=4NO79/GHF^O7;X_'8ML[)]]7LEJLX*F8RF0T)DYN@6@
MU51DBQOB$_!"V?H^N8F$ ?CF7)6,<)<^PQ,SNTJ&F-78K-U([^'R5#*T9A$H
MK>.MP7:QB3,0N,U>22-^6?GZ+E:\,H<9<;RZ0=_^Z3>?]YV_]^%R+0^:U1I&
MV.1T7JG.Z;M@7/C:?R][&/(W/4\=B*I/%%:A)_.2O:CF@E]TD9L[LHMXA]FG
M"LWGIF;=C2ZOR<F*R*M_11G'R[81^<O/EZ_(W_0_:,E%JO4\-)]%SU[U2_%J
M7/7-_P UUHV':*H%L[WVN\NEO!@U9C<)N!2BZ ,[,?S.9F0!YZG^$L95GH-*
M?+<D>#D'R9N@7?J4N>R/?=;.:G&&#4,N5T!D#X"6+457Q\8,O#<M'F<;ZS7:
M%RY:*:Y%1(A9SDBA8288*XA\&.(-.WE+">74O\;@R^D+\?*2CD16W7>5*C\R
M;="\3=&U!+RLR%<VE]7?]4^OIS-NIOY*QOY$Q2+AVB=PL#J6C#E-.9O$9_&S
ML[PY#"Y*GE*4K"_#O%:HS3P&S/Y%TF_#^3\/[N8J+K*Y0DXSC*$HMJ49)QE%
MKNFGLTUZIF^0FI)2BU*+6Z::::^*:Z-!$1?0^P1$0'A8U;M]CC:W73R'JK0F
MF\M8E<G.])C8:^1<R;AY/A&HT%WQ&]XR>/U"_N=9+(O5AYU^/-68]UM%B[64
MV3JFOPE!QDOWGX9&-7;%PMKA9!]XV1C.+_%23132[[WL.:3V TGIO7VW53+Q
MTLGJ@<!FL/DLM-D,;3CM8ZY;HSXZQ9@FR<,\EBH<<@6\A<@.)V:&* @=RJ0:
MVUA:SV2LY.YTM+.XL,8<N$,,8L$40N_F70+>T3\=9N1,(L_2VPK])(TW'<[*
M.KL@;,Y:?U3MWDHW=F=QDOZUPNE^1=WY%WCU"8NXL3])$+LPN1#KJ%?;P-U_
M*U'05=EW69%U.;D8KNMDYV35<*+HJ<Y;RDXQR(K=MO9+=MD;YW#F#AYDK<;%
MJHG.I)NN/*N64GNHQ7NQ3E!-J*7;X$M_<5YSU#M4;4GXC1^LWLW0Y<7+K:YI
MO+1/&S,S]+G[F-^&'Y79O-;,E:R;N/,.5WM3[2"+2/ZOE\K==H@<W8:NGLM(
M3GPS],;-_1#\F ?-W9;-E0/[2BC^FL/;O^C*^;_\UE;&X\/?R,O](_\ NQ"(
MBKN9X(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"_B0&)G$F8A)G8A
M=F<29VX=B9_)V=O)V?R=E_:("BGWB_9N/;#=;4>&@B>/"92<M1:<+A^CX*RT
MLDSU!?C_ /-EWUK'-R[D\->"4WZI>&P;5NCOM>S5\U>W5;6V/@ZLQH&>2S9>
M.)CELZ:R#QQ9.(R'@W:A8"IDHR?Q AABO,P#ZS)(-1= $1$ 1$0!3Y]Q3VDV
MQ&I\YMED+##3U2!9O A(Y=(YW&U>G(UXGYZ1._B( G(7;VGQ(]+B9$TL!BYQ
MMGN%D=):BP>I\3(462P&4I9:F0FX=4M.<)O!,FY^=60$Z\XNQ#)!+)&8&!$+
M@;%A%UGLUNEC=;:4T]JW$2#)C]0XFGE*_!,11>LPB<M67I=V&Q3G\6K9C?VX
MK$,L1LQB3-V8@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(N
M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
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MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
M4#:IH^7@VNC,QKL:U?XN^N=<FOBE)+FB_24=XM=4VB9L+/HR8*S'NKNK?:=4
MXSC^&\6]G\4^J]4$1%C3UGCA<?U/I'$YNI+C\SC,?EZ$X%'-2R=*M?J31FW!
MA+7M1RPR 3>1"0.SMY.RY"B^T)N+4HMQDGNFFTTUV::ZIKXH^)13332:?1IK
M=-?!HB9WN[F'9/5GBV,5B+6A,A([DUC2-CU.B)/]3!V1LXB$&^2*G5J1LW+L
MS$[D\1.\G<;[K:<\6UHS4&$US2!G,:LHR:;SG#=3O&-:U->QEAQ9F891RM<Y
M3=^*L3<<VW$4G</>,7$&G<L89T\FI;?4YJ^DQV79*R;\^"7PKNBOET1HFN>&
MFBZ@GYV%7";_ ,90E3+KZN,5Y<G\Y0DS7N;D:$UKH6RU#7&DL]IN5R( +,XV
MQ7J67#GK>GD7 L?>$>/,Z=J<&;CEVY9<$&UC+C>T(BY<?0\.W][_ ,G6Q(S>
M"I9*K+2R-.KD*4X]$]2[7AM5I@?WA+7G"2*0?^R8.SJ,G?#N=MD=9^+8JX"Q
MHS*'U$V1T?;?&QE(_+\SXB<+>%E8CX*0QQ\5HVY$;4?/+3IP][2^+/EAJF#;
M0^SNQ9*^IOXNJSR[*XKX1G=+X)D*:[[.>SE9IF9ROJU79O5+\.>'-"3_ !A6
MM_@4^,)C[V(N!D].Y>_A\A&XE'>Q%ZSC;H./+ATV*DL,W(N[]/!NS.[\<._*
MD-V7[VW??0WA5<EEJNO<7#P+5=5UO$R(QC^A'/4FKY&4G\W*7)%DI7?CVV9F
M%9";T=Q5N5@VEMZ"U+AM8U@<G#%Y-_F=S1 SMX80S2%8PUF8F=W+UBYBXAX\
MC+EF45VZ.U>O] 2E7USH_.Z?$#:/UG(T)'QQD1< ,64A\;&R^([?.VBMEXGO
M!B]ZE:K5.%N)H*#GI^?*2V55T8QRX_S(6JO*K^'-6HI^DF1[/3N+N'9.4?I*
MJB]W*+E*EK]J5;G1+X[3_-'=O?'=Z,V^.SN'TM!I*_I>]CM74<[GFGR-3(8F
MQ5IT;E.DV/N"%.[):._?8BISXT(XH68QN3FQ,U7*&$Y#&.*,Y99"&.**,7*2
M64R8(XHQ;ERDD-V !9N2(F9O/A9<]JO=Z#-78<+C>EJ..)SN2ASQ9R/M!T!]
M6*I&[ASYL4QR\>48N>6W<@=E#^:OVB-%07*Y3X#0]R+<+.LS/X9?,Q;K7,'4
MF?AQ*&UJ/X):S!(!0VZ4=NI*S!.[K*X^GZ=PUI>2\:MTX6)'(S)0YYS;ER\[
MC&=DI3;FXQKK4I/JXQW+ <)YVHZABX]VHQ4,J_;:'*H2C4WM6[%':*E);V/9
M+:,DFN9-%[7NJNR8^RVQ&@]#VHA#.!CY,[JD^"8Y-2ZBGDR^4C-S83<<>5F/
M$5NL ,:6.K 8,0NI#T1<W]5U*W,R<C+O?-=DW6WVOXSMFYRV7HMY;)=DMDNB
M)FJK4(QA'HHI17X);((B+P'W"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"ZNWLVHQVN=):ATAE@8J&H,7:QTQ./4\)S!^9[0-RS^+4LC#:A=B
M$AEA A(79G;M%$!KG]PM"Y'2^>S6F\O"\&4P.4O8B_$[.W%FA9DK2&'+-UPR
MO'XT$K>Q-#)'*#N!B[\/4\??H=FU\+J["[D8^OQC]6P/BLV0-[,.H,7"/JDT
MK,S<?">*;H FZOGF*F\1Q>2)B@<9 $1$ 1$0!6^NY4[2CZNVTDTAD;'BYK0-
MD<?%UFQ36-.7.J?#S.SOU?F0FMXKW.+0TJI.;G*0C4%6>_=J]I$MLMVM/Y.S
M8>' YLWTUJ,2?YU\'Y0P"K;+WL!8W*!2N/+PY#6"W"Q $\A,!>91>&)G9G9V
M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
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M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
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M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
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MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
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MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
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M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
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MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
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MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
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M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 5=#OX.S6\]+3FZ>-KL\E OF:U,X#[15+)^-@KQ\-Y!5M>
MMT)R)R)_7Z3"PA";JQ>NJ=\MI,=KS1^H]'Y5OS%J'$W,;)(S<G6EGB?U6[#S
MY>/1M-#<@ZF<?&@#J$AY%P->*BY?N#H3):7SN8TYF(? RF"R5O%WXO/AK-.8
MX3(.>'>*7I:6)W9G*(P=V9WX7$$ 1$0!$1 9&=DK?NSMEN+I;6D!R-!BL@(9
M2&-_SWA+P%2RU4A]TG53FDEA$F)@MPUYQ9I(8W:_CA<Q6R%.I?IS!8IWJT%R
MI8C)CCGK68@F@EC(7<2"6(Q,"9W8A=G9W9:X)7 >Y7[2;:OVR?2-VQXF9V]D
M@Q; ;_/3T[;:8\#*W/T4588+6+#A_G<=&$2$1*)S F/1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 >K=NQ5H9K$\@0P5XI)II9'88XHH@<Y)#)_(0 !(B=_)A9W=4
M(NVMVAI]T=R]4:M*0RQT]^6AI^(W_.^GL<9U<4W2SNP26H!^$+(,1B-NY.(2
M'&(.K/\ WQO:2?0^U%K!8^SX.>UY,^ J.!<308ANB;4%H6;VFZZ'_)@2-TO%
M+D@F _$B$2IKL@"(B (B( B+[FF-,Y#-Y+'X;$UCNY3+7:V-QU2/Z.Q=NS!7
MK0L[^0L<T@"1O[(#R9.PB[L!8?[ASLW#+)J/=3(5V=H#DTIILY1=R:1XZ]K.
MWH&?AF'HEJ8V.<6)W)LC78@Z)1.RJND^SELI0VZT1IO1F.Z2@P.,AJRSB+#Z
MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
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M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
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M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
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M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
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M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
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M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
M %N&$1%F$19F9F9F7[(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( L"N] ^(/<S[!P_A7'K/58%=Z!\0>Y
MGV#A_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=
M3)( B(@"(B (B( B(@"(B (B( B(@"(B (B("F9WN79$;;;<23.XFL\6E=>2
MW<O1:,>*^/S?B#-F\4W2S#"!2V!R-*'R#U>U+#79XZ1A%%$K\?;2[,5#=O;[
M-Z1L^%#D)(2NZ?R$H,7P;GZD<A8ZR[\=30'([U;H@[')2L6 %V)Q=J'FK-*Y
M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
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MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
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MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
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MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
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MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
ME<$GY<A9N!\W=F4):CPIJF&W'*T[-QVO\KBW03^:DX*,D_1IM/NF;/7DUS^S
M.$OPDG_:9.JEMWKW;'/=O<;YGL%=\?0NAYIJ&/>O)UU<SGF(XLKG&('\.:&/
MAL;C"'J!J\%BU&;M?<0F9[V7O"\7H[07S,Z%S^.R.K];-8QL=O#9"K=^ <&T
M?1ELH<]2:1J]R8)(Z&,$G:3Q;$UP'_,+L54C2^)BQU1I'%@8!88Q9N&;AF9F
M9OD$69O]"LI[/?AZTY:YEUM-<].!"<=FN\+\G9K=/O34_P#3-K[#*[^.O'GT
M>E:9C2WMMV=_*^N[ZU5=/CTLG\/<_:1R"'%7+,V.P&'JRWLOE[E3&T*5<7.Q
M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
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MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
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M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
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M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
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M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $18[[P=KK:O;Z&6QKK<;1&D(8'XG/46J,-B/!=G$7:4
M;MR$H^"(6?K9N')F][H#(A%!MN)Z23V+--335I][<=E[,75\[TKI?7&JX)"!
MQ9QCR> TSD,/R_5U"YY$!,6=P(N%BCFO2XNR)5)Q@L[FY)F<68Z6W]R,79QZ
MG)FR-Z@? O[!<@Q=7F(D'M("SNBJPEZ7[V4?&$&QV[CPN!.4_P P]5NF1G9A
MC\%\_P"(3$/)>(WLB[,+^;^7W<5Z75V1K!]$Q;I41Z@;Q;6@)C!F)^'+BCD[
MDG3&WM'Q'U.W]#$W\D!:!10(:$])P[%6<*&(MWI<%8G+I&+4FA=PL1#'Y#P\
M^4ETN>%@%W+H9Y<F')"_Z'I)Y*]EN\)V*W&'JT+N_MSJEV:/KBP^K\):L1%*
M(&$4U4;C68)W&0.JO-$$X.3"<8EY(#,1%_(&)"Q"[$),Q"0NSL0NW+.SMY.S
MMYL[>3M[E_2 (B( B(@"(B (B( B(@"+PG* \HB( B(@"+PSKR@"(B (B( B
M(@"(B (B( M39VG>_$[7&'W-W*PV*WYUG0Q6&W#UQB,71A@TV4-/&XO5.5H4
M*L93X&:8@KU:\40E++(;L#.1.ZVR:TB_; ^-_=S[JNY'XZ9Q 9R_D\W;'_5"
M:W_Q;2W\74_)YNV/^J$UO_BVEOXNJ))$!+;^3S=L?]4)K?\ Q;2W\74_)YNV
M/^J$UO\ XMI;^+JB21 2V_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI
M;^+JB21 2V_D\W;'_5":W_Q;2W\74_)YNV/^J$UO_BVEOXNJ))$!+;^3S=L?
M]4)K?_%M+?Q=3\GF[8_ZH36_^+:6_BZHDD0$MOY/-VQ_U0FN/\6TM_%U<NQ'
MI#G;2I1Q11[]Z@FCA)G8;FF-O;AR-U=;C-8L:/.W*)>8OU6.M@]D#%F'B&1$
M!8^VO]*N[7V *(<GGM$ZPK@8/*&>T;6K6I@ >'#UO!7,4$3R/YF8TR9GYZ '
MRXE][-WIH(':K4]W]DRIU)#<;&H=NM2/D#KL_#"1:4U#2I221 _4<\L&J);#
M!Y08^>1F$Z(B(#<I=BKO:^S[V@6"OMIN1@LEGWKO:FT;DIQP>M*\ N RREIG
M*/7R<\$!20C8MT8;=. YH(Y; '-&)2/+1/XC+W,=<JY''7+F.R-"<+5#(X^U
M8HY"C:B?F*S2NU)(;56Q&_G'-!+'(+^XF5Q3N?\ TI_56C+>,T!VE[UO5^C9
M9(J>.W.:O#)JK2X$(10#JB"K' .H\'"8L\^6&(M04HI))[+Y>*(1C V)B+BV
MB-;X?4N'QFH-/Y.EF<)F:5;)8K*XVQ';H9"A;B&:M:J682*.:&:,A(# G9V?
MCR=G9N4H B(@"(B (B( OX.1A9R)V$19R(B=F$19N7<G?R9F;S=W\F91>]Y=
MWN^SW9;P W]>Y:3(:GR->:336@, \%O56?DCZ0&0:TDL4.*Q(3'&-K-926O3
MA%S:#UNT(5)-<_WE?I N_7:+L9##_#<^W.VE@WCKZ"TA:.H=VJW#,^J=2Q##
MF,[--TL4U.*6AA %V@;&3.TEJP!?$[=OI&79GV.*[BGU8.Y6L:9%#)I+;>6E
MGYZUL"Z"K9;.-:CT]B)8CZFLP6LD]^OX4L;TCL,$$E23M7>EU]H36@V:6VVG
MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
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MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
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M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
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M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
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M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
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M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
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M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
MMP(MU22R.$40'(8 7,+U^&K#-9LS15ZU>*2>Q8GD"*&""$'DEFFE-Q".**,2
M.20R80 2(G9FY6KP](6[[FYVC=6V-M]OLC+#L=H[*OZM8K3F#;D9^BSQ'J.Z
M,;B$FG:-@K$>F*4A3Q6P"+44HQSSTX*0'S^^[](+U9VDK^3T!M]-D-);%03-
M ]%QDI9_<0JM@C#)ZG<96*K@)2CKV,=I7H$A>(+.:DL6#"C0K<,S,S,S<,WD
MS-[F;ZC+RO8ITYK,\%6M#-:MVYX:M2I6ADL6K=JQ(,->K5K0B<UFS8F,(:]>
M$#EFE(8XP,R$4!ZZSV[$/=B;Y]HF_P"J[4Z#R.9QL4XU\AJW(F&$T9B2ZW&1
M[NHK_17GEAZ9'.AB(\IE'>*0 H&8D+6KNYW]%3&Y!B]Q^U'5D$)@BN8C9N.2
M:N0 3=<4VO\ (U9XI7F<7'G2] ABA]H<K>L&Y48+SF@MO<#I7#X_3NF,)B=.
M8#$U8:6*PF"QU3$XG&TZX#%!5HXZA#!4J5X8Q&..&"&., %A$69F0%,SL<^A
MN:*QPTLIOKN/G-5718);&D]!L&F=/>)RQ%6O9ZU!<U'?@9B>,WQ9Z<F(XPD"
MQX1G ]E3LZ]TUV;]J8H!T1LYH7&V:[ X92WA*N:S12 +"U@\OFAOY%[+L+=5
MAK#2GYN1NY%S(>B _@ 81819A$69A%F9F$6\F%F;R9F;R9F;R;W+^N%Y1 %X
MX7E$!^-BN$H'%* 2Q2 X21R")QR 3.)@8$SB0$+N)"3.SL[L[>:C;[2/<\]F
M;=B&<=:;-:)LV[ 2B68Q&)BTUG8SF+KEGAS.GO@S(!:,FY>SX[S\LSM)RS.T
ME2("C_VP_0U]-V@N9/8G<W+82T3R2U])[B1PYO#\NQF-2GJ3%5*69IPL31PQ
M'DJF>L #E)/9G(6$J=G;0[N#>WL^9-L=NSH#+:;@GG.#':AA>#+Z2S#B?1&6
M-U+BY+.-(YV<)(J%V6CEP"0!M8ZO-U1#NDUP3<O:_3>L\'D=,ZNP.(U-IW+U
MI*>4PF=Q]7*8N_6E%PDAM4KD4U>4'9_+J!W%^"%V)F=@-&4BNT]\KZ+%8TS5
MS&YO9CJW,GAJP6\EG=H9#L7LMCZ\8E/+/M_:D>>WE88V:1FTO=,[PQC%'A[=
MI^F@U)5BYY\B%Q(@(2%P,# G$XS F$PDC-B P,1,"%Q)F)G%@)U^YA[\C7'9
M4SE; W_6]5;*Y7(-)J'1CF4MO3Y63?UK4&B'DD&*C?$S:UD<,_3CLVP2>53)
M3>OOM.=@=_=([HZ.P&OM"9NGJ+2FIL?%D<1E:,G5'-#(SL<4P/Q+5NU)ADJW
MZ-@([5&Y#-5LQ13Q2 .CP5BST>WOF+G9MU_'HS6N3E+9/7-^.'-!:E,JVA<_
M:DBBK:SI,_7ZMCI/.MJBO&#12UBBR[O'-CIWL@;41%^%:S'-''-#($L4H#)%
M+&0G')&8L021F+N)@8NQ"0NXD+L[.[.SK]T 1$0!:@7O[_IQ^T!]N53\6, M
MOTM0+W]_TX_: ^W*I^+& 0$1*O!^A3?](^TA]A=I?W]N2J/BO!^A3?\ 2/M(
M?87:7]_;DH"_:B(@"X;N+_T>SOV&RG[QG7,EPW<7_H]G?L-E/WC.@-%AA_SI
M5_8\'[D*^BOG8?\ .E7]CP?N0KZ* (L[==]WQK;#[":$[1=07S6@-7YO46F\
MQ)2H3#+HC-87+R8O'QYN=IYPFQ^I/!E+'9,8:D%>\#8JT/K%FC):P20%J7T;
M3OL'V,U-6V5W(R!#M'K3,N^#R]J0BCV]U;E9!!C-S+IATKJ&XX#DQ!NC%Y>=
MLNXM7N92:/9CQ2B8B8$)@8L0&+L0D)-R)"3.[$),[.+L[L[.SLM$B8,0N),Q
M"3.)"[<L[.W#L[/Y.SMY.S^3_*M@5Z,)WWQZFJ8OLT;LY<Y-28JF]?:G565N
M-)-J3$TQ(FT1?GGXDDS>"IBSX"222>3*86M+4(ALXL/7 +M"(B (B( B(@"(
MB (B( B(@->CZ:1\9NP_VBZU_#^#5+U70O32/C-V'^T76OX?P:I>H";'T<GZ
M=G87[*ZX_@JUXMM^M2!Z.3].SL+]E=<?P5:\6V_0!$1 %JT/2NOIQ]0?<\V^
M_>V46TO6K0]*Z^G'U!]SS;[][91 5OE-WW!W=NZ#[46\>H-O]P\AJG&X7%[?
M9/55:?2.1QN,R19*EGM.XR**:?)X?-P'3>OE;)'$%6.5Y1A)IA$" X1%:\]#
MO^F<UC]QC/\ XWZ*0$_/Y3L[+GZ;-[_ONTA_P^3\IV=ES]-F]_WW:0_X?*UV
MB JB?E.SLN?ILWO^^[2'_#Y/RG9V7/TV;W_?=I#_ (?*UVB JB?E.SLN?ILW
MO^^[2'_#Y/RG9V7/TV;W_?=I#_A\K7:("J)^4[.RY^FS>_[[M(?\/D_*=G9<
M_39O?]]VD/\ A\K7:("J)^4[.RY^FS>_[[M(?\/D_*=G9<_39O?]]VD/^'RM
M=H@*HGY3L[+GZ;-[_ONTA_P^3\IV=ES]-F]_WW:0_P"'RM=H@*HGY3L[+GZ;
M-[_ONTA_P^3\IV=ES]-F]_WW:0_X?*UVB JA'Z'3V7"9Q?5F^'#L[/QJ[2+>
M3^7O_F?JRSV>=C\1MIH;2>W^ FR%C":.P6.T]BY\K-!8R4U+&5PK5Y+T]:M2
MKRV2C!GEDAJ5XR/EPA!N!;N1$ 1$0$-_?:]ZSBNRKM)9U!6:CD=Q]5>MX/;3
M3USQ#AMYMJ[%/G,G! 03%@-,Q2Q9#*,,M;UR0J6'BMUK63KRAJ6MT=T-1:WU
M)G-8:NR]S4&J-2Y&QEL[FLA(TMS(W[)<R32DS,(  L$->"(0@JUHH:U>.."&
M.,95._<[P"?M"]HK6&<IV3ET9HJY>T!H.%IO$K'A]/Y"Q5R&=KB)$ _-/EXK
M.5 AX,L=\%QSB,L! ,.'* +E6A="9S5.9QVG-,X;*:BU!E[ U,5A,)1L9+*Y
M"R;L+15*54))I79R9Y"8?#A#F28XXQ(VYMV?]AM5;I:WTQMUH?&'F-6ZORD>
M)PN/$GC YGBEM6;5N9@D]6QV-H5[62R=L@(:F/J6;)"31]!;7;NBNY:VV[*V
MF()*-2GJ3=++8^M'K#<2Y58KUB?HZK&)TV$[RG@--13&8QTJAQSY%@AM9B6W
M8CA]7 JD=@+T0C<#5U6GG]_]5R;98ZQT3#HS298K-ZT>N72[!E,S8#(Z:P=J
M0')WKUJVHBKNT33DTQ35J]M/LL]P[V5=HHJQ:>VEP&:RM=FYU%KB+YL\Y,?0
M G(5G.M:KP=9 TW@4JE2I%,[E7KPLPB,OO"\H#YV(Q%3'UH*5"K7I4ZT8Q5J
ME2"*M6KQ#]#%!!"(111BWD(1@(M\C+Z"\H@"\+RB \+$/M!=@'9+=6*Q'N'M
M7H75DEEW*:YE=.8V7)F;\^W\*A7CR+&+OUB36F<9&$V]L1=LO40%.SMH^A\;
M2ZECM979+5^?VSS)#UQ:=SDIZNT3-)R[N,;VW#5&)>3K=W>/-Y&E'X<4=;&5
MQ>0BI'=NGNU-Y^S?G PN[&CY\17MSR0X;5.-E^%M':A\-_HL/GH(PC\8P<9/
M@S*08S-1 7,V-C%NI]T(NH=]=A=&[FZ6R^B=?:<Q6JM+9RL=7)X;,58[568"
M;V)H^IO$JW*Y\3TK]62&[2LA':J3PV(@D$#1VK^3!B9Q)F(29V(29G9V?R=G
M9_)V=O)V?R=3X]^KW*.8[*6K:V;T])<S>S&L<C+6TIFK3R37]-Y8HI;?S&ZC
MLNW3-::O#9GP.4(F+,8^I8&P 7Z-@K,"" OG>C#=^%;R4N*[,V[N:>Q;CK04
M=G=49&8SLW(*D1!_,_RMN8R:>S3J1POI*<W::Q3AGQ$SG-6H%8O1+128'/W\
M3?Q^6Q-VQC,MB;]+*XK)4Y'AMX[)XVS%=Q]^K*/#QV*5R"&S ;?0R1"_R>>X
M7[G/M_P=I+8/1NXLK1P:F"*?3FN* ./YCU=@)/4<G* CY!4S #7SV.'WC0RE
M>*1@GCFC "41$1 %B]VW_B6W?^Y?K_\ %/++*%8O=M_XEMW_ +E^O_Q3RR B
M^[@OXO=9_;@'X'I*>)0.]P7\7NL_MP#\#TE/$@.D^TM\7&O_ +2=5?@*^H6?
M1]?^BFXWVPX3\$R*:;M+?%QK_P"TG57X"OJ%GT?7_HIN-]L.$_!,B Q>[0^)
MN=ESM+8W6^)K21Z)U=9LY*6L N-23%92P$6K</"T?LM-B+4\67Q\+-Q"QXT.
MDH'.,K4&%S-7(TZF0HSQV:5ZM!<J6(B8HIZUF(9H)HR;Z()8C$Q?Y6=E@3WF
MG9;;=/:W+TJ5<9M2:>&346FGZ6\66[1A,K6-C+]"^6H^/2#EV!K159)'Z(G6
M(_<E]JM]4:,M;<9:<GSFA(Q?&C.3M8M:7L3D$ ])\2/\!VS;&2"[?F:K+C(B
MXZA9 3?D3,SN[LS,SN[N_#,S>;N[O[F957=:36.U7VG*^*K.<^WF@[,D$L\3
M_.)=/8;( ^4LB[^3%JS*QA1K2BWB/C2K3.+%7< E?[V?M6EMIMA<IXNRT&I]
M9/)@<.8FS2TJ9BSYO*"/D3/5QY%6K2-PT=^[4E=C&,XRX]W/_93_ )GNVD.?
MR51X-3:^&GF[WC XV:N&&*0M/XV5B9CC*.M:GR$T1\2!9R,L<S"<70 '47?S
M5HX=G-+11 $<46Y&%CBC 6$(XPTGK(0  %F$0 681$69F%F9EGUW>GQ([8_:
MGC?]0E@9W]_Q0:9^Z7A_Q5UFL\^[T^)';'[4\;_J$@,R41$ 1$0!$1 $1$ 1
M$0!:1?M@?&_NY]U7<C\=,XMW0M(OVP/C?W<^ZKN1^.F<0&.ZV/?H:_Q ;D?=
M=O?BEI9:X1;'OT-?X@-R/NNWOQ2TL@+>J(B (B( B(@"(B (B( B(@.B^TUV
M>M.[L;?ZOVWU95]:T_K/ 9' 9(&Z?&ABOUSBCN53(2:*[0G>.[2FZ2\*U!%)
MTOT\/I6-]=E\UMQK;5NWVHA9LYHK466TUDS$'C"Q8Q-N2L-V*,O;C@R, PY"
MN!^V,%F)B\^5O&G6J2])\VDATIVR=P)JT(P5]88'1FM $69NNQ?P_P #9"8N
M/HBFR. MRN3LS\GT\.PL1 5_5:V]$([2%K2_:.U'M]+9Z<+N=M_?/U4G9A+4
M^B[U7)X:P)$_ \87(ZJK'&+.4YSU'ZF:NPG5)4GW<K;E'I/M9; Y<2(0EW#Q
MF"G$2D%I(=3UKFG&CD:/S,'GRD!]!,X,8 9,S!U,!N,67E$0!1C=[AWC^$[,
M&S.>W"O!!?U'8_Y"T)I^65HWSNK;\4C4(9.&(VQV. )<KEY0$BCQM.=@YFDA
M$I.5J??2*N\D+M![^Y2C@LB]O;C:J2_HS1XP67FQV3R=>T46K-5U^D0B-\MD
M:X8VG9#Q0FQ&'HSUIS@MN1@0H[L;JZBUUJC4&M-796QG-4:IRUS-YW+6B=YK
MF0O2O+*3,[NT5>(>BM3K _A4Z4%>I"PPP S=?HN<;9;:Y[6>H\#I#2N,L9K4
MNI\M1P>"Q547*>]D\C.->M"W#.T43$3RV;!\15*L<UJ<@@AD-@,NN[E[N_7W
M::W*QVW>A:S0QMX-_5FI[0.^(T=IOQO#LYC(.W!6+,C#)7PV*B?UC+9'H@8J
M]0+MZGMF.[Z[O3;CLU[?8_0&W6,\&&,8[&?U#=&&34.KLUT<6,WJ"]'''ZQ:
ME=R"M7C&.CBZ;18[&UZU*"*(>F>Z([L73/9:VEQFC,:%6]JW*A5R^XFJ(H6"
M;4.IRKL,PQR%U3MAL1XDM#!5))'&O48YN@+%RRYRF( B(@"(B (B( B(@"(B
M (B(#J3?38C1^YFE<QHC7FG\=J?2N>JG3RN&RD/C5K$1-Y&)"X35K,)<2U;E
M62&W4G$)ZTT4H";:JKOL.Y;U/V3M80V*$E_4FT&J+,@Z-U=88);F.M^W(>DM
M5G!'#'%FZL(M+1R+004L[2?Q*_1D*V0J0;;!8Y]K/LKZ-WKV]U+MGK[%QY73
M.IZ+U+41-TV*=F,PL8_*XZ=OGE/*8J]%!?Q]N)QD@LP1DSN/4) :1M>';W<.
M0NSB0D!.!@8$Q!)&8NQ!)&;"<<@.Q@8B8NQ,SMF=W@/8AU7V=]V-5;5ZM I;
M&$ME8P>8:-XZVIM*W99BP.H*C](A^;:D?AWX \J.5@OT7Y:N)GAD@-H_Z-WW
MNLG:'VSFT-K;(^L;N;84\?2S-F=A&;5VF)!*KA=6"XB 37^:TF.U$,8L89"*
M&](+1Y6 BLHK2R]W;VUL[V>MX]%;KX([!C@,B$&HL7!+)&&H-(9$HZ^I,'.(
M=33-9H\VJ(R1RC!F*6-NC&\M6/C<O;7;EX36>FL!J[3=^#*:?U/AL;G\)D:Q
MA+!>Q66IPWJ-J*2,B @FK3QFSB3MY\<OP@.>(B("C_Z9CV4VM:9VHWLH5.J?
M!YJUMWJ*S& \AB\_6M9G!367%NOP8,MB[5..4W>.*?*Q0,W7;%4#UN<N]*[)
ML6^'9_W2VT>!IKV?TO<EP?SOQ3BU)ARCS.G9X Y;F>+,T*91<.WM\-[N5IB(
M",@%Y(RBDX;Q(C9V**3W'$;$S$)QDS@3$+$SL[.S.SLP'Z.<H\'!(\4\;C)!
M*W#O%,#L<4K,_D[QR")M]<5NAN[+[5L&]VPFUVY\4S36-3:5I'E^#8RAU%C"
MDPVHZLI,S-X]7.X_(5YV9F898S%O<M+TM@[Z&MVJ1R>@-SMF;UWKMZ0U)!K7
M 5)#Y./ :M@&MDXZ_7([O!!J#&6;4D4(=$$V5>25P>U%X@%U-$1 $1$ 1$0!
M$1 ?G+(("1F[" "Y$3OPPB+<D3O\C,S<N_U%IK>]R[5A;U=I+=S<*.R5K%WM
M438/3A.3%%'IG2<$.FL.U7H(XFKVHL8>38HG8+$^0GN$+2V9.=G!WZ_:V?9K
MLM;L:FIWBQ^H,OIVSHK2EB*0HK4.HM9 6 HW*9QNTH6L6%V?*P2@Q##)1&68
M?!"0FU ,,0Q@,8-P("("W+OP(LS,W+\N_#,WF[\H#]%<=]#I[(AZ@W2W"WGR
M-/JQ>W^ KZ/T_9D;V)-4:L)KF5>#GJ8I,5I^A7&=W8'C^:"J\9ES,(TX#-A$
MB)V$19R(G?AF9O-W=W\F9F\W=;;7T>#LAGM!V4]MJ5^C)0U'K6@^XVI8;$+P
M7(KNKV#)8^G<CDCBL16,;@BQ-&:M9!IZD\$M<V%X^E@*67I6?9!/;OM-3:VH
MUGCT_O'I^IJB.46^=#JK"M'@M4U.>IW\0X8<%F'(N&,\O,$;=-=^*S*V@/I7
M'9!+</LQW-;8VGZQGMG<Y0UD+QQ]5@M,62^!-6@+LXOX5'&WPS\_41"U?"S.
M$4D[Q,M7\@.Y>SKO_FMJ-?:,W-TZ3MF=!ZCQ>IZ47B%"%QL98&6YC)I 8B"M
ME\>]O%6B$2(:UR4@;K87;=M;>:\QFJ<!A-2X6=K6(U#B<?FL799F;QZ&4J17
M:DCBSETD<$P.0<NX%R+^;.M& MHQZ*MVORW*[,%'2N1L-+G]GL_<T%9$Y1DG
MFT\5>MF])7W!O;"#X,R,F"C*1^N6UI^[(WL.'(%EA$1 $1$ 1$0!$1 <8UMK
M'':=PN7U!E[,=/$X+%W\QE+<K\15<=C*DMV[9D=F?B."M!+*;\/P(OY+27=J
M3M"Y#=K<K7>Y^48PNZ[U3EM2/%(0D=6G>L/\%43<.0<Z&*CI4B<'<"*NY"[L
M_+[-WTGKM9-MAV4M5XRK8>'-[J7Z6VF+&.0@G]6S,-J[J*<'C)C (--XW*"4
MKMX3RS5ZTCL5J)BU5+-Q[O)F\F0'E79_0UNR&]_5NZ&^>1K?F?3^*K[;Z5D/
MAQ/(YJ6IG=57  @Y8ZE&A@<?6L1R.SCD<O6,!=F<J2<\PQ@<AOP("1D_OX$6
MY?R][^3>YO-_<RV^O</]CR39+LM[7Z5R%<Z^H\OB3UOJP)08)HM0:SF+.V*$
MHB[MUX6I:I8-G8B8QQK2=1.9$X$P"(B +2M]X]],9VA/N[[Q_P (^I5NI%I6
M^\>^F,[0GW=]X_X1]2H##-;";T+7XL-\?NDX/\4J2U[*V$WH6OQ8;X_=)P?X
MI4D!=*1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!3L],Z^(W:/[L8?B'K):Z)
M;%WTSKXC=H_NQA^(>LEKHD!E'V&_CMV;^ZKMY^-N(6[-6DR[#?QV[-_=5V\_
M&W$+=FH B(@"(B (B( B(@"(B (B(#^3!B9Q)F(29V(79G9V?R=G9_)V=O)V
M?WLM0YW\_8<K[!=IK7>F,/3&GH_4_J>X.BHHW^=08;4_C%DL< LW$ XG5-34
M%"O68B\/&18V5FB"Q'#'MY50R]--VN@"UL)K<0%K$WS9Z1E(6!CDB:/$YN+Q
M'X\0VA**5HN7<0\:7AN3=T!1<6:/=Q]H:?:G?W9W<&*P5:#3NX>F2RQ@+&YZ
M<RN2APFIX>AW$7*;3V2R01.3],<_@S$Q-'TOA<OPM7#KQG8CX\2NSV(^?-O$
M@^>ARW+.[,0,[LSMRWRL@-[NBZJV)U#)EM$:-RLQ=4V3TKI[(2EQQU2W<13L
MR%QR_')2N_'+\<\<NNU4 59?TM?Z4#)_=&V]_"TJLT*LOZ6O]*!D_NC;>_A:
M5 :O=?.S'YTM?L>?]R)?17SLQ^=+7['G_<B0&][K_P!#C_[@_P"JR_9?C7_H
M<?\ W!_U67[( B(@-?%Z:9\86P7VFZ^_#>F%2L5U/TTSXPM@OM-U]^&],*E8
M@)L/1T/IS]D/LGJC\1]2JXQZ2%W(O\W73<F\&V>,!]X='XU@R.+K"$9[AZ6I
M"9EBR?@1DU)AXG.;3\\I,]J$9<++( STY:M.?T=#Z<_9#[)ZH_$?4JVX" T1
M_FSNQ"0$)$!A()1R1R 3A)')&;"<<D9B021F(G&8D!BQ"[,5W#TGGN/QT_9R
M_:9VDPXAA+LLM_=_2V+IQQQ8J]/,\EC</'PUA%O5<A+*<FL(GC;P+3/J!Y3:
MUD6CI'H">_N%.^0O]EG< L1J:Q8L[+ZYR4'S:T!&6<]-Y0J\=&KKC$UX^KF:
MM'#3JZAK #ED,+7"2/\ -6-JC+M8M*ZHQV<QF.S6'O5LGB<O1J9+%Y&E*%BG
M?Q]Z".S3N59XW()J]FO+'-#*#N)QF),[L[+17*Y9Z,7WW9:$RN/[..[.;8=$
M9NU#6VKU'D[#M%I+.W9Y&+1E^U.3A%I[.V9HBT\<A118;+E-CG(ZF5IAC@-B
M(B(@"(B (B( B(@"(B QV[7WQ2[H_<[UM^+636D'P_YTJ_L>#]R%;OCM??%+
MNC]SO6WXM9-:0?#_ )TJ_L>#]R% ?16V#]&)^D?V6_9&Z?\ #-N&M3XML'Z,
M3](_LM^R-T_X9MPT!/:B(@"(O@:JU1C\)B\EFLM;KX_%8>A<RF3OVI0@JT<?
MCZ\EN[;LS2$,<,%:M#+--+(0A'&!$1,S.[ 0+>D,][.79GVGCQFE+0#NQN0]
MS"Z-87$CT]CXH'^&]:3@3.W1B!DKU,9&_!6<U?I<-ZO6N2PZIR>Q++))--+-
M8GGEDGGL6)#FL6)YC*6>Q8FD(I)IYY2*6::0BDEE,I#(C)W>1#O6.WSDNTIO
MCK#<ZQ-.V GLMA-!XV5Y&##Z)Q#E!AX8HI!C.*;*EX^H,EXD<<SY'+6 ,(XX
M88(8ZD 5IKT=KN)Q[0.4@W?W3H&^R^G\G8KXG!RO)"^Y6>Q<SPV:TKCTG\R&
M(NQG7RY1DSYJ_!-AQ(:L&1\6)/NEN[ES/:@WGP&W50K5+35;HU!N!G:T9.6&
MT?1LPC>""1O8ARN;D,<-ASD=ABMV2NN,P4I()-P/MAME@-%Z=PFDM+8JG@].
M:<QE/#83$8^$:]/'XVA %>K5KQ S"(1Q +<^9&7)FY&1$X')\)A:>-I5,=CZ
MM>C0H5H*=*E4ACKU*E2M$,->M6KQ",4%>"$ BABC$0CC$0$6%F9?41$ 1$0!
M$1 $1$ 1$0!$1 %5K](M[CFGOQI>[NYMKC @WITABI)+%"F,, ;DZ?HL,TN&
MO,X-XNI,95CLEI:[XD1V))"PUZ26M/2DQ]I1$!HDY8CC,XY8Y(I8I#AFAFC.
M*:&:(RCEAFBD89(IH9!..:*01DBD$@,1(79OS5J'TJ'NS:^T6[-'=W2=!J>A
MMXK=LLE4JUVCH8/<2I7:UE(8O";PX(=4T@EST%<QCYR-7/20%)&3Q5:KR MG
M^BF=YQ+MMNC-L3JK)FVB=V+D/S)#:EXJX#<8!D&&"JYNS01ZUKN&/E@_H<V;
MHXAJXA;OV/6]E"M%'@\]?Q5^AEL5;EH97$WJ65Q=^ R">CDL;:BNX^Y"8N)#
M+5MP0SQNQ,['&WFMS5W8O;%K;^;#;:[JP^&%O4VGXQSU6-R=J&J</8GP>J*#
M=<<1N%7/8W(1P2O%&-FLT%N$? GB)P,\D1$ 1$0!$1 $1$ 1$0!$1 8W=LGX
MH-U?N;ZY_%C*+2'X?\Z5?V/!^Y"MWAVR?B@W5^YOKG\6,HM(?A_SI5_8\'[D
M* ^BMLQZ-)])-LG^Q]<?PD:P6IG6V8]&D^DFV3_8^N/X2-8("=A$1 $1$ 1$
M0!$1 $1$ 1$0'#-Q-N\%J[!973.IL31SNG\[1GQN7Q&2@"U1R%&R#QSU[,$C
M.)@8OY/Y&!,)@0F(DVJ@[]WN;+_92U]6NZ=]<R6SFN;=HM$9.U(=JWI_(1"5
MFUHC-6S;KFM4J[%9PF0F=Y<KB(S:>2;(X[(32[9)8=]OCL8:7[0.TVL=JM61
MB-'4N,EBQ^2&();6G\]79Y\'J+'];/T7,/D0@M@PN+3Q!-4E=X+$H$!I4U]_
M2FJ\I@<KC,YA+]G%9G#9"GE<3E*4GA6\?DL?8CM4KE8^'89:]B*.06(2C+IZ
M) .,C!^;;Z[+:@VWUIJK0&JZKTM1Z-SV1T]F(.DA#UO'SE$UB!C]IZEZ#P;]
M(W=WDIV8).?:752 W$/<W=XA3[3&Q.E-?22U&U=2ACTUN)CZ8O%%C];8FK6;
M+%#6(Y)*U'+#-!F\9#(<A1X_)5X_&G\/QY)3UK#?13>W7_,P[04FVV7O>KZ7
MWMIU\'&$\S!5@USA1N6]+S ,A!&%G+5Y\G@F)B\2W8L8NFP32M4&/9Y( B(@
M"U<GI97TX62^YEH#]TU MHVM7)Z65].%DON9: _=-0("M4K5GH?7TT.I_N.Z
MC_&?1ZJIJU9Z'U]-#J;[CNH_QGT>@)'O2@.Y#*T.8[3VT^*%[->&?(;QZ9HQ
M<%<K01L9[@XV&-F8[E.$)/FL@87ENTQCS$9/8IW([E#,29V9V=G9V9V=O-G9
M_<[/\K.M[7:JQ3Q20S1A-#,!Q2Q2@,D4L4@N$D<D9LXF!B[B8$SB0N[.SL_"
MUA_I&/<EGV?-52;I[;XPFV6UGE!"7&TJK!7VVU->=W^!'&!O"ATOEYQ.33TI
M!7CQ]F5M/^WTX\YP*PRMG^C3]]LVS>>I[$[GY48MJM4Y*1M(9NY(?AZ"U9EK
MC2/2GE?F.#2NH[MB:2P9^''B,U,UMR]4R%MZU3!?R8"0N),Q"3.Q"[,[.S^3
ML[/Y.SMRW" WN+$SLSMYL_FWU_UEY5+ST8OOOGUKCL=V<=V\X4NML/6.';#4
MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
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M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
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M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
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M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
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M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
M'$[%:KD)0R-Z(3A8Z%*RQ6*P\SQZ<:]D+-NQ8N7;,]V[<L3V[MVU*4]J[<M2
MG8MW+,QNYS6+5B22>>4W<Y)9#,G<B=W ]53Z^C<]@X=[^TM@+F6HE:T;M/%6
MW%U$\@2/4GR="]&.C,3.0N($5W.Q?"?JI2<6:>"O#+%/6:>$X"#-A%R)V$19
MR(G?AF9FY=W=_)F9O-W^1EM3/1E.P6>S/9NPV>S- Z.L]WI8=?Y^.Q&T=RIB
M;<'AZ.Q<X.WBP'5T\]:[/3D=CJW\G=CEBBL>.* L2LO*(@"U%??Z]A2'8'M+
MZQP&*IA2TAK4!W'T9!!&05*F*U'>O!D\37\F 1Q.H*>4A"M'PU2C/CXV 82@
M<]NHJO'I7'86_FF=GHMR<11*UJK9&W+J9G@&/UB;1.1*I4UQ"1$/457'4(:N
MJ)XQDC?HT^1BTT@!7F UBRGS]&[[>!;(]I;3M')W'KZ,W8"';W4T<AL-:'(W
M;+2Z.S!]3LS34<Z38SJ;EWIYV\/29^%T0&,Z_DQ=V=A(HR_0R1DXR1DWF,D9
M-YC(!,Q 3>8DS$WFS(#>Y(HCNX_[>P=HCLZZ)UE=N0VM7X:L.C-?C'P)QZPT
M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 5?STH?Z23=G[)[7_ ,+&B58#5?STH?Z23=G[)[7_ ,+&B4!JDE\W,_G2
MU^QYOW,E])?-S/YTM?L>;]S) ;QKLW_%WH+[2]+?@.BHGO2#.[L#M"=GG4=;
M$8X;NX.WT5O7.@7C;B[9R&,J2'EM/5I/_P#)L3'/CHX)/G$N2;&2R/$5>*S!
M+#V;_B[T%]I>EOP'17<[MSY(#1&12B8B8^8DS$W+.S\/Y^;.S.S_ %6=F=G\
MG9G9?HI_O2/.[GFV&[0>9S&(I>#M[NS-<UII,X@%H,;EISB+5^G#<.&$ZF9G
MDRM%B$'/%Y>M"+SRT+4Y0 H#9B^BD=XE%N=LI+L_G;SR:RV3@H8NE'.?SW(;
M=W'GATK9K=3\S!@?5)M.6A%R>G#5Q#S-$%^J)VJUIH^ZE[=]_LX[ZZ(W-A,R
MP5:^&#UQ2'EVO:'S<T%;4'2#.S';Q<+1YS',[MU7\9! 1-#/-SN0-,ZDH9G'
M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
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M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
M1$0!$1 %1:],D[%L)8_;7M 8FDWK-6\6VNL[$(^T=&_%<R^D;MOI%^8J=^KE
M\6,QF QS9FI S&5@>B]*HTN^([-8;M=F;>3130-8NVM%Y/+X<'%Y"'.::!M1
M88X@9GZK Y'&5WKMY?/O#X('9C8#3>+^H[$T)A-6F*O9@DCGK6 _HE>S 8RU
M[$?N^>03 $H/RW20,_++UJTS2QQRMRS21A(S/\C&+$W^9_Y?)^Z W./=9=K&
M/?#L][4[G,_YLU%I6M%FP<G)X-2X*>QIW4]?J)W.08=08K(A',?25B)HY_#C
M:5A'/]4\_0WM^RS&RFX>W=B82ET+KX\G0A=S>0,5K#'PWR+E_9&%\O3R?0 M
MPTCRD[D1NPW#$ 1$0%13TR7Z7G;S[L.+_%'5RUO2V0OIDOTO.WGW8<7^*.KE
MK>D!WYV3_C7VJ^Z?MY^..%6[T6D+[)_QK[5?=/V\_''"K=Z( B(@"HG>F.]N
M8XH] =G7#VC%[L5?<S7(Q%Q&5&"Y>QFC,7,0B_6<V3H9C,SU_$ H&QN*FEBD
MCO5S"]BM-'WM7:N;>SM&[L;AP6&M8F_J>UA=-S"_5')IC2_& PLT!](N5>[7
MH/DH'(1/P[S,3,3<,!'6N=;7;8YS6VI].Z,TS5:[J/5N<QFG,%5?J:.7*9BW
M%2J/.8B;Q5(9)FL7;'00UJ<4]DVZ(B7!5:.]$I[)[:Z[2>0U[D*?CX3:#2%O
M+P3%X3@&L=4SM@M.Q]!?/'<,.&K;WBP\>!-4J!([C9Z7 V(78N[*VGMDMK=%
M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
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M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
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MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
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M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
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M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
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MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
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M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
M?2W"R(#3FY/N4>US3&4Y^SON6P0MU2%#BZ5D6;AGY%ZV1E\3CGS\/JX\V?W/
MQB]N/V)-Y]'C*>J-H]RL'%!U>/8O:*U#ZG XD0%XU^"A/1CZ2$O,K#,[-U,[
MC[2W::_B2(3%Q,1,7]XDS$+_ *[/RSH#1%06XI6=XI(Y&;R?PS$^'^H_2[\/
M]9U[#K<X]J;NL>SUO.,Y[B[2:*SN2G P^:(,+4QNJ(NL.ABBU)C(ZF99X_(H
MP.X<0F('X;D+.U*CO4_1/]4;?8W,:\[/.4RVX&G*+'=N;:Y2 +&N<;28W*P>
MF\I7*&+5L%.)^L,38I5M0E7A(:UK4&0.."0"H=MYKG-Z0S%746D\SE=,9^B?
MB5,UI_(6L/E*Y<L[L%W'RP6/#-Q'Q(2,H9F9AFC,/95LCNQ_2P-RM"WJ.F>T
M,$VY6B#<(&UACZ-:#<# "Y</9NQUSJ8[5="-G(I(7JT\W&WG%<OMT50J)SP2
M1220S1R030RR03P3QG#/!/"91303PRB$L,\,H'%-#( R12B4<@B8NR_) ;Q_
M9?>O2FXNE\+K70^=Q^I=*ZAI19##9K&2O+4NU96?@AZA"6&6,F**Q6LQ0VJL
MX25[,,4\9QCVBM7_ .C.]['>V1W4H[3:JR;MM/NKF(:/3<LN-31^N[P#5Q&>
MJ#(7@UJFH; 4\%GA%X@.0\9DI'=Z$WB[/]OY?R_E_P"0'E$1 %67]+7^E R?
MW1MO?PM*K-"K+^EK_2@9/[HVWOX6E0&KW7SLQ^=+7['G_<B7T5\[,?G2U^QY
M_P!R) ;WNO\ T./_ +@_ZK+]E^-?^AQ_]P?]5E^R (B(#7Q>FF?&%L%]INOO
MPWIA4K%=3]-,^,+8+[3=??AO3"I6(";#T=#Z<_9#[)ZH_$?4JVX"U'_HZ'TY
M^R'V3U1^(^I5MP$ 1$0!$1 %Q/7FA,-JC"9;3FHL;3S.!SN/MXK,8G(0C8I9
M''7H3KVZEF$V<9(9X9#C-O?P_(NQ,SMRQ$!J3>_([G[,=E3<=WQ,-R_M!K*W
M:GV^STY-/)CY!%[5K1>9G9F=\IB(G(L?9D$2R^(B:U[5JK?Z805NSNV5V0-$
M[[;=:CVRU_CAOX#4-0HO& 8FR&'R,;.6.SN&L2QRM3S&)L]%JC:$"Z) >.09
M())8CU!_>%]@'7/9JW-R^V6N8GL351:_IW4D-4ZN,UEIN:0XZ6H,6!23C&TA
M@=;)4&L3R8G)PV*,TDC!%-,!ACB,O;Q]RGD<?:L4,ACK=6_C[U24H;=&_2GC
MM4[M68?:ALU;,45BO*/M1RQ@8^;+:5^CY=]/3[2^AVT9K>_5@WPT/C@^:. 8
MFIQZRP44S5:>M,3#UG&4A"=6KJ>G 0^H9HWLQUJN,RF-C;5B+NOLY=HG6.TN
MMM/;B: S$N#U9IBZ-W&W8^2AE'R&UC<E78@&]B,E!U5,E0E)H[%8R9BCF"*:
M,#>"HHT^ZJ[S#1_:DVLQVN].G!0SU-XL7KK23S^+=TIJ88 EL4Y!-@EFQEP2
M>WA<DP/!?I$[!(]FM<B@DL0!$1 8[=K[XI=T?N=ZV_%K)K2#X?\ .E7]CP?N
M0K=\=K[XI=T?N=ZV_%K)K2#X?\Z5?V/!^Y"@/HK;!^C$_2/[+?LC=/\ AFW#
M6I\6V#]&)^D?V6_9&Z?\,VX: GM1$0$-GI!VDGS78RW_ *@Q^(5;1D6:%G*4
M.E].9[#Z@:7F%G)_ ^#/&8";P9'C\.P[0%([:B);J;O$ML7UKL+O+I-N>=0[
M9:UQ3=).)/ZWI^_'PQ-YB3\\"[>;.[<+2GT)WE@AD=N'DBC-V;Y'(!)V_:=T
M![2V=WHBVKAR/9(]19XW/3NZ>O,1*( 8D!67Q&HP&4B(ADD*#/0R,<3 #121
M1D/BQRD6L16PS]"\W%:QM1O3I%Y ZL1N=CM2!$Y"QN.H]'X;%R2L//6X=6E8
MP<NGH8F9N>IW9 7/41$ 1$0!$1 $1$ 53/TQ/Z6O2'W7-/\ X U,K9BQJ[47
M8]VSWJP-72^ZFC\7K73]+)19BKB\N]KU6+)P06*T-QFJV:QE+'!;L1BQD0,T
MI/T\LSL!I)$6WD_*_'8R_4^:&_\ ER_^]$_*_'8R_4^:&_\ ER_^]$!J&T6W
MD_*_'8R_4^:&_P#ER_\ O1/ROQV,OU/FAO\ Y<O_ +T0&H;1;>3\K\=C+]3Y
MH;_Y<O\ [T3\K\=C+]3YH;_Y<O\ [T0&H;1;>3\K\=C+]3YH;_Y<O_O113=]
MYW5/9+V3[+F[6X&F=C=&XK55/#8_!Z6R-0LE'=Q^H-6Y[%:6QV3I/-E'![&&
MDR[YEFZ)':+'RFT4O0\9 :W1?.S'YTM?L>?]R)?17SLQ^=+7['G_ '(D!O@4
M1$ 1$0!$1 $1$ 1$0!$1 8W=LGXH-U?N;ZY_%C*+2'X?\Z5?V/!^Y"MWAVR?
MB@W5^YOKG\6,HM(?A_SI5_8\'[D* ^BMLQZ-)])-LG^Q]<?PD:P6IG6V8]&D
M^DFV3_8^N/X2-8("=A$1 $1$ 1$0!$1 $1$ 1$0!$1 >'6G3[[/4T>7[7':#
MO1=/0^XENJW1U./..Q6*QQ^9B+]774+K\N&/J8>19G6XL6D8[7VY46L]W-UM
M75Y?&J:FW+UWG*,OB-,)X[(ZIRMG&]$S"#2Q#CSK!#*PBTD0@3,S.R QW5C'
MT5'3Y7>V7I2R(=38G0FX>0,NHF\,9,74Q3'P/D7)Y,(^D^!^>=3>V(*N<K<'
MH;NW,U_M$;C:H>-BIZ9V>MXHC=G^=Y'5>L-,S4B$F-N']1TOF(W$@)B:7J9Q
M(&Y V2"(B +5R>EE?3A9+[F6@/W34"VC:U<GI97TX62^YEH#]TU @*U2M6>A
M]?30ZF^X[J/\9]'JJFK5GH?7TT.ION.ZC_&?1Z V8B(B (B( B(@.@NU!V9=
M&;Q:$U'MQK_$QYG2VIZ$E'(52=H[$!/[=;(8^STD=+*8ZP,=S'W8V<ZUJ&,^
M"%B M0YWGW=P:R[+VZ62V]U2TM[%V!ERNB-5^"T535FF"L%#!>'HZHH<I2-A
MIYS'B773N=$K"-2[2.3<P*,_O6>[-TEVI=JLIH+//%B\_68\IH;5XU([5W2F
MI80_,ML!)PDGQ=[AJ&>QT<\'PABYIHHYJ]H*MJN!IOUV3LYO#J?;W5>G]<Z+
MR]C :LTMDX<O@LQ68#EI786(.2BD$HK%:Q!)-4NU9A*&W3GGK2BX2DRY+VD>
MSIK#:376I-N->XB;"ZKTKD)*&2IRL3PS!SU4\ICIW$1NXC+57COXN_%S%:J3
M ;=)M( =(H#< =SGWKFE^U9M?6U)3]6Q6O=/!3Q6Y&DHW,7PV>.NQ^OXT)CD
MEL::SG1+<P=OQ9W")IL;;F^$L?=C"7!:6[N\^WWKCLV[G87<K1%@I"JR14]2
MZ>EF./&:OTS),)Y' Y(&)@8SCZIL5>=GEQ63&"Y'U1-9KV-O?V-.U_HG?;;K
M3NYN@,F&1T_J"KUO&[L-[$9*!_"R>"R]9^)*>5Q5L3K6J\HBY=(687DJ6*\T
MH&42(B *&+TAOZ2[M ?:?6_&+"*9U0Q>D-_27=H#[3ZWXQ81 :BQ>']SKRO#
M^YT!N<NZ=^E8[-/W -F_X.M.+/\ 6 '=._2L=FG[@&S?\'6G%G^@"(B (B^7
MG,W4QM*YD;]B*I1H5;%V[:G,8X*U2K"<]BQ-(;L$<4,,9R2&3L(@+D3LS.@*
M>_I?';V+2FV>F=AL#?>'-[G76S6K1@D(9HM!:>F\1J!E&8E$VH-1?!T,HR.X
M6L5CLK2.*2*W(4>NK4A/>J=MFUVA=_-P]T"GGDPV3R@XC1U:660X\?HO3\;8
MS 05@,G&".]'%/GK,<0Q!)D\S?LE$$L\C*/9 <[VLVQS6MM4::T7INJ=W4.K
ML_A],X.J L1397.7X,;2%V(@%HPGL#).9& 10!)+(81@1-NF.Q?V7<'LKM5H
M7:S3D8AB]%Z?IXD9!9N;E[VK67R<KL$;G8RN6L7LE9E(!.6Q:DDD]LB=:MON
M%>TWL9LOO<6ZF^&1R]2#2>G[0Z&JXK361U&\^I\PYX^WDIAQT,ST3Q&'>U'6
MEEZ'F/*FT75X,O3=U_+8/8X_3/KC_)SJC_TB LF(JV?Y;![''Z9]<?Y.=4?^
MC3\M@]CC],^N/\G.J/\ T: LF(JV?Y;![''Z9]<?Y.=4?^C3\M@]CC],^N/\
MG.J/_1H"R8BK9_EL'L<?IGUQ_DYU1_Z-/RV#V./TSZX_R<ZH_P#1H"R8H^N]
M+[$U#M"[$;@;76HX_A#,XE[VF+9](EC=7X64,KIJ]'(3CT"&4JP5[8]<86<?
M8N4YC:O9EYBX_+8/8X_3/KC_ "<ZH_\ 1I^6P>QQ^F?7'^3G5'_HT!JZ\MA[
MF.N7,=DJTE+)8VW:QV1I3,XS4\A0L25+U2479G:6M:AE@D9V;@XW7SU*+WQN
M[FS&X>_>K=Q-C+N0L:4UT\.I<Q4R.GKNFY*&L[QS?-(\-2[%"4\66L@&<GLQ
MQLTF1R-\Y#DF.0E%T@-@!Z'AV\_A/3&M>SOGL@\E_2UN;7>@HK!!UOI?,25Z
M^I,13]MCD@P^HC'+.#Q$4'S4&/K!5VK5ZMW!:5ON\^V!D=A-ZMO=V<>\Y1Z4
MS@'FJE=RZLEI?)PRXK4N.*,?SQXV'N69:\!>3WZ].4'CFABECW.^@==8C5&"
MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
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MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
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MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
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M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
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M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
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M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
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MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
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M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0%.STSKXC=H_NQA^(>LEKHEL7?3.OB-VC^[&'XAZR6N
MB0&4?8;^.W9O[JNWGXVXA;LU:3+L-_';LW]U7;S\;<0MV:@"(B (B( B(@"(
MB (B( B(@"UB_I>.)BK=K3'31]77?V8T/;GZGY9I0U+KZBW0W#=(^!2A=V?G
MV^LN>"9FV="UI?IA^'*'M-Z-OO&XC?V:P58)')G:5\;JW61R"(\^R\+9.-R?
MANKQAX=^E^ *H:L;^BGYH*G;'TW&;DWK^@-?4AZ69V(WK8RR+%S[A_,W/+<O
MU,+<<.ZKD*:[T=/5?P3VS=E'<PC'*9+4>%,CX9G:YI'.3Q@SO)&S%+8IP1A]
M&Y&0@T9$3.(&W!9>41 %67]+7^E R?W1MO?PM*K-"K+^EK_2@9/[HVWOX6E0
M&KW7SLQ^=+7['G_<B7T5\[,?G2U^QY_W(D!O>Z_]#C_[@_ZK+]E^-?\ H<?_
M '!_U67[( B(@-?%Z:9\86P7VFZ^_#>F%2L5U/TTSXPM@OM-U]^&],*E8@)L
M/1T/IS]D/LGJC\1]2K;@+4?^CH?3G[(?9/5'XCZE6W 0!$1 $1$ 1$0!$1 $
M1$!U3OCLEI?<C2&H="ZTP]3/:6U1C9\5F<3=B"6"U5G9G8F8Q+PK-:88K=*T
M'$U.Y!!;KF$\,9CJ0.]^[JW5/92W/L:7R!3Y;0VH);N2VWU<8.P9C"QRB1XG
M(GYA'J73X3P5,M%RPW0\#+UA&"X4%;<*K!/O%^[\T-VE=L<SMMKBJS#9$KVG
M,_!$!9726I8(90QNH,3*_#C-6*0HK=4B]7R6/EM8ZV)U[)L@-+VN<;8[FZ@T
M5J3!:OTGE;6#U-IG*T\U@<O2,H[-#)4)6FKS XD/7&3L\5FN;O#;JR3U9Q."
M:0"[B[8G9$UML3N-J/:_<&@-+46G; ,T\#2OC,WBK(O)C-082Q-'&=O$92!G
MD@E<6.">.U0L,%RE8B#&5 ;4_L)][AI[M6=EG<S*2%0Q.Y^EMM=6T-Q](UY"
M;U*\>F<N%3/XJ&9_'ETYJ 8)+5"7F9J5D;>'L3R6J!R2:I_#_G2K^QX/W(5D
MIV9^U'K7:+45K4^ALHV-R&1T_G=*9>":,K&.S.G=1T),?E,5E*;21-:@(3CM
MU7<Q.ID:M2W&3O"\<F.U:!HHXXAY<8P",7?CEV 6%G?AF;GAO/AF;GY$!^RV
MP?HQ/TC^RW[(W3_AFW#6I\6V#]&)^D?V6_9&Z?\ #-N&@)[41$ 1$0%5+TH7
MNF+.\^WE3=_0F+>WN5M;2LED:%.!Y+VK= <36\EBX0B%Y+.4P-E_AG#@3&YP
M/EZ$3#)?C(=9S'()B)"[$),Q"3>YQ=N6=OK.WFRWN:UM?I)/<93;19O*;\;4
M89FVGSUL;.M,#CH2Z=O-0Y&WX<F3AKQCX<&CLY<L0"#1,$>#R\Y5S <?=JE5
M J1JWQZ./W]];:&:CL1O1F8:FUMR:P^B=:Y6VX0;?Y*U-')\ 9>>;F*OHW(S
M26K%:_--%#IN^3PR,^*O=>+J#KP[,[.SMRS^3L_N=G]_+?*R WM-2W%8BBG@
MECF@FC"6&:(QDBFBD%CCEBD!R"2.0'8P,'<2%V(7=G9>PM7YW-?I(>MNSU%C
M]O\ <R'*[B;/PE!6QXQSA8UAH*HS]!!I^6W)&.:P<(.QAIZ_<A.F,;QX>Y!$
M0TBV-/92[8^V>]^EJVL=KM78G5N#G&-ICH3\7<99D#K>AF<9*T=_$9"+@AEI
M9"O!.) 7 D+=3@9-(B( B(@"(B (B( B+%[M9=M#;#8W2\^K]T]8XC26%B"=
MZ[WYNK(96>N F=+!XFNTN3S60+KC$*6-JV;#G+$S@WB"[@9/22" N9$PB+.1
M$3LPB(MR1$[NS,S,W+N_DS>;^2U^'I'W?_4-:5<UV>-C<W'=TO.UK%[I:[QD
MAO7SOAS/!:T5IB[&0QV<.?ARQ:ES$#S5<K#(V)Q\TE5[\LN%??%^DMZVWY@R
M&W^TL69VWVHL.<&2N2S!4USK:K[0>!DYZ,\PZ<P<[.QRXC'7)+UX>F+)WQKO
M8QTE7, 81819A$69A%F9F9F;AF9F\F9F\F9O<@/+,S,S,W#-Y,S>3,WN9F^1
MF_O,I1.[+[KK5W:.O:YO4?7\1H;;?2.=U)JG5$%09V+*T\1:O:?TCB_&"2*?
M,9NS",MGIBL_!F&BL7)H?&L8V.SCEV'.Q1KKM";DX3:_;VD$^:RO-K(9*TTG
MP3IC 02PQ9'4N<EB$SBQM#QXQ&,!*Q?N2UZ%0#L6 9MM-V6^[[T/L#L1;VCT
M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
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M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
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M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
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MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
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M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
MGWZU]*!1RZ^UW)&;<&$FM-3F!-]0A+*N)-Y-Y.SMY+B&3UOG;S.-[/9Z^+MP
MXW\WE;HNS,[,SC:MS,[,Q$S-QPS$3-]$7(&Z(W;[PC8K0413:RW@VWTV @1\
M976."K2$P-RXQPE=>:65_(0AB Y9#<0C C(6>'C?[TJ_LC:/CGCT]J74NY>2
MB&1@JZ.TEFX:)SASTQOG=35,#B9(Y&;V;5"?(5^29G/ECZ-6?%2AC)S"&(#?
MWD,8B3_+RY,W+OSY\N_O\U[* MW=LCTO[>;5K6L7L]H_3VUV'E:2(<[FO_LO
MUI)&3NS25A(JFFL*;QNX$!4-02L;!/7O5C;PVJR;U;XZRW(U#;U;N!JC.:RU
M+=<O'S.H+\V0ML!2'+ZO6\5_!H4ADD,HJ&/BJT8'(O!K1L[LNK%^<LH@+F9"
M CYN1.PBS?7=_)D!^BRS[%?8BW'[0.N\;M]MG@ILOEKDE>3)Y V>/"Z7P\DX
MPV=0:BODXQ4\=3#Q)1A8BO9*2)Z6+KVKAC$I1NZT]'AWH[1MBCG\S3O;6;6'
M+&<VL-1XF>/+YVJQ,\H:-T[<*G9R#2#UQQYR\T&$BE;JA?*/%-6;93=A?L ;
M7=G71E?1.U^G:^(I/X4^8RTK!9U!J;)1Q-$65U%ER ;.2N$+.,3&XUJ<3^KT
M:]:N(Q,!T!W3?=1Z%[*.WS:6TX3YK56:>"]KK6]NO%#D=2Y6,9/#CCCC;BC@
M\6TTM;"XP3D>O7=YK4UJ_/:M32F21"8D!LQ"3.)"3,XD)-P0NS^3L[<L[.WF
MSNWN7Z+P@-'!OE@BQ6NM=XLQ<"QNN-8X\@=F%P>EJ7*5G!Q$B$>GPNGI$B%N
M.&=V9G73V8_.EK]CS_N1+-_O(-.CB.T7V@<6 >'%0WQW:KP"PQBS5AU]J JK
ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
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MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
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MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
M*7)_$M49$0%YP?35,BY"W\[O5;J,!Y_FER>743#S_P!"_DYY5\/#WO6JE6UT
M]'K->"?HYYZ/&C&3IZN&YZ>KCGAN??PRT44?T<?]MB_=!6]-TC_S3C/L?2_>
MT2 Y"B(@-#YA?SG5_M$7^H*^FOF87\YU?[1%_J"OIH"R_P!TCZ1C;[*VTQ;7
M0;2P:V$]69_5#YJ361X%V^'&HMZEZ@VG,K^=O4_Z/ZW\]\1OG4?1[4GGY=5R
M/ZG:K_E+D_B6J,B("\W^75<C^IVJ_P"4N3^):?EU7(_J=JO^4N3^):HR(@+S
M?Y=5R/ZG:K_E+D_B6GY=5R/ZG:K_ )2Y/XEJC(B O-_EU7(_J=JO^4N3^):?
MEU7(_J=JO^4N3^):HR(@+S?Y=5R/ZG:K_E+D_B6N#ZH]-/UO+!*&%[/NE:5C
MJ/P;&5W$RV3A8>":-Y:=/2.*-RZNDC$+[-PQ1B?+M(U)Q$!9NW<]+8[6FHP.
M'"_S,-!PDYB)Z<T?D,C?:(F-F&2YJK46>KE,(DW%BMC:7M@!A$'M,4'':8[<
M6\6\LWB[I;EZOUO$QQR1XS,9:;X!@DA>3P9:^G:?JN"BL1-+((6QQWK?0XQE
M.01QL.+"(#P(LS,S,S,WDS,W#,WU&;Y%Y7]UXCFFAK0QR3V;!M'7JUXSGM69
M'XXCKUXA.:>1^69HXHS-W=F9GY96 ^[X]&T[16^94\KFL/-LYH>R_4^IM?8B
MY#F[,'_QL-H2:?%9R['(/MUK&4FP5"W&44]2Y8K2-.P$%FW.W.?UAG\1I32>
M&R6H]2Y^W'0PN"P]62[D\E;D?RBK5HVZG$!YEGGD<*U2 9+-J:&O')*&R"[A
MCT=G'[%-B]W-XX*F9WEEK')B,!'-6R&G]M@L.WM5)XXRCRNKR@^<W,S'+)1Q
MHRST<*TC/-E+LM?=L=SQLMV7\2\6A,$V2U;<KA!F]P]0QUKVK\JW2WC5X[S0
M@&'Q4LK/*^'PX5*+EX;V L20Q2#*@@"(B (B( B(@*BGIDOTO.WGW8<7^*.K
MEK>ELA?3)?I>=O/NPXO\4=7+6](#OSLG_&OM5]T_;S\<<*MWHM(7V3_C7VJ^
MZ?MY^..%6[T0!$1 $1$ 7#=P=O<'JS!Y336IL30SN S=*?'9?#Y.M'<Q^0I6
M0<)J]FO,)!)&8ORW+=0$PF#B8B3<R1 :Q'OK/1Q-7[!V,KN'M%4R^MMEVZ[E
MVHQ/D]6;>"<ID5?)011M;SFF*PN 5,[#%8R%&$6#4#'T%E[-7L#$A8A=B$F9
MQ(79V=G;EG9V\G9V]SLM[;-"$@''( R1R"0&!BQ 8$SB0&),XD)"[L0NSL[.
M[.W"J8]ZUZ+#M_NO8OZVV/MXO:G7=B6S>R6GGQY%H#5-B9CD-FHTI(#TCDYK
M+^*^2Q4%K'2N<L=O"')-'>I@:V)<\VMW3U/H;4%#5>B]0YG2>IL6;28_/:?R
M%C%Y.OP[$\7K-4XRGJR\=-FC9::E;C<H;=>>(B!^_>U[V#=W]ALW)@MV-!YW
M2<OC'#1R\]4[>E\V+%TA/@M3U&EPV2"5G$VKA:#(UV,8[U&G/U0CB,@+:78N
M]+MWOT6]3$[NZ;P.[.!BC"$LQ2'YE-=1,) WBS6H'GTYFG:(3;P9<1AK,DQ^
M--E9&;PGLJ=GGTJ[LD:SBK1:CU'J3;'*3C&)T]9Z6S$M".<^.8WU!IJMGL-%
M&#/[=O(6<?68F(6D?V.O5LH@-USM+V^=D->0-9T;NYMSJ6%Q8NK$:PP-MVYY
M;I...\\@2"[.)QF R1F) 8B0NS928O-TKP>+2MU;D?#/XE6Q%8#AW)F?KB,Q
MX=Q)F\_-Q)O>SK1,'1A(VD*&,I&X=I' 7-G9^6<3=NIG9_-N';A_<N;T-P=1
M5!Z*>I-1TPXXZ*>?S%0..7?CHKW8QX9W=V;CAG<G][OR!O0U\G*Y^C0#Q+UV
MI2CXYZ[=B&L''/'/5,8-QR[-SS[_ "]ZT?[]H#<%V=GW!U\[.W#L^MM4.SL_
MD[.WPK[OK+B&0U]J&VW3<U%J*Z''3T7<]E[8=///3T6;DH\<^?'''/G[V0&Z
M,W:[?FQ^@X?6-9;N;<Z:BX9V++ZPP51RYZF$0"2\QF9N),$8"YF3=("3NS*&
M;M"^E:]DK1L5F/36H-3;GY2$9ACIZ/TKF:N/DL1/PT3Y_5%7 XJ2*7CYU<Q\
MV1JEY/XG#\MJUXJ, $YA#$)OSR8Q@QOR_+\DS=3\OYOR_FZ]I 6O.VKZ7!OO
MKMK>)VHPF#V?P$S21CE7$=4Z[F F,1D'(W0CT_AWZ7 _!JX7(6(IAY#+'&[@
M56[7FN\YJK-9#4FI\SE-1:ARTWCY/.9N]8R>6OS=+"QVKUR26>1@ 1CAC<_"
M@B$(8 CB  'BB_B201;DG86Y9N2=F;DGX9O/Y7=V9F][N[,S<NW(']KL?:'9
M[5>X&I<3HW0^G\IJG56=L>JXG!8>N]F]<EXY,N'((:U: /;M7;<L%*I%S+:L
M11MU*8ONVO1[]_.T7)5RSXF?:[;V9XI'UUKC#9"N60K2.SE-I73$QXW)ZC9H
M^7CME/B\++(XQ1Y<B&=H-C)W;?=);.]E[ /CM 8,;>I+M>.+4&O\Y%5MZOS[
MCTD<4^1""/U#%^,SRP87&C6QL!.Q>#)*WBN!&?W%/H^F#[-]>MN3N,5/4^]F
M2QX1CX?@6L#MU6LQ%ZWB]-R>"QV\S.$SU,WJ(I""R$(U<1#4I/9ER%FI$0!$
M1 $1$ 6H%[^_Z<?M ?;E4_%C +;]+4"]_?\ 3C]H#[<JGXL8! 1$J\'Z%-_T
MC[2'V%VE_?VY*H^*\'Z%-_TC[2'V%VE_?VY* OVHB( N&[B_]'L[]ALI^\9U
MS)<-W%_Z/9W[#93]XSH#188?\Z5?V/!^Y"OHKYV'_.E7]CP?N0KZ* VH7HK7
MTFNB/MGU_P#C7D58N5='T5KZ371'VSZ__&O(JQ<@"(B (B( B(@"(B (B( O
M2R6-KW:UBG<@AM5+<$M:U5L1!-7LUYXRBG@GAD8HY89HB*.6*02"0"(29Q=V
M7NH@-6KZ0QW*EKLW:T/<#06-F/8[6V2Z<>T3^,V@=3W&DGFTI<X83BPMXPGL
MZ4M&+QQ0C)@IYGLU*1WZW*WB6_>P^D]SM'Y_0>N,-4S^EM38^;&9?%W 8XYJ
M\S>4D1<=5>W6D8+%.W"XSU+445B PEC$FU%W>T]UYJOLI[HV=%9<[F8TCEPF
MRFWNLYJSQQ:BP+3$#U+LL0-3CU/A7\.OG:,)#SUU<K#!!2R5:*,"+Y$1 38^
MCD_3L["_977'\%6O%MOUJ0/1R?IV=A?LKKC^"K7BVWZ (B( M6AZ5U]./J#[
MGFWW[VRBVEZU:'I77TX^H/N>;??O;*("M\I5>Z"[SJ;LG[EYC<6#1D>N#RVC
M;^D7Q,F<+ - U[+X7*^OM<'&9;Q'C?#M!ZOZN+$T[GXHO&PE%4B O-_EU7(_
MJ=JO^4N3^):?EU7(_J=JO^4N3^):HR(@+S?Y=5R/ZG:K_E+D_B6GY=5R/ZG:
MK_E+D_B6J,B("\W^75<C^IVJ_P"4N3^):?EU7(_J=JO^4N3^):HR(@+S?Y=5
MR/ZG:K_E+D_B6GY=5R/ZG:K_ )2Y/XEJC(B O-_EU7(_J=JO^4N3^):?EU7(
M_J=JO^4N3^):HR(@+S?Y=5R/ZG:K_E+D_B6GY=5R/ZG:K_E+D_B6J,B("\W^
M75<C^IVJ_P"4N3^):?EU7(_J=JO^4N3^):HR(@+S?Y=5R/ZG:K_E+D_B6K(7
M<K=Z[8[7&@M7:UL:'BT(6E]:R:1#'19\M0M="/3V"SGKY62Q&']7)RS)5O5F
MAF9AKC-X_,SQ1:B);&3T,?XB-V?NSV/Q!T0@+AB(B P([R+N\]$=IG:_+[;Z
MTB*N4W_*&FM158P+*:4U+6C-L=F\>Y\-*T1D\.0H2$,&3QTMFC,0-,,T6I([
M<_85W$[.^X.3VZW(Q$E#)52EL8?+0BQX75>">8@IZ@P-L))HIJEJ/PWLTRE>
M]A[1ECLG#!;B(7W5RPE[>'=[[6]H[1DNBMT-/196J#RSX7,U7&KJ/3&1EB>+
MX4T]EQC.>A:Z>!FBXDIW8Q&&_5LPBP,!I:5^4T(2"X2 )@_'(F+$+\/RW+.S
MMY.S.WUU/EWH/H\N]W9RGMYO&T+VZNV,9'(&MM+8><\AAJ[<N#:PTS5ER%W$
MLP\">7IE=PA2,_CV<<4L%>2 Z&8)!8XR$P?W$+L0OP_#\.WD_#L[/]1_)T!/
M+V#/2-.TKL57Q^"'/T]S-%4.F&/2^XC7<E:JTF(?S-A]5U[,6>QSQ!UA4:])
MFJ%9CZ/@V6&.&*.UQV9O3 NS]J2"M#N9IS6NV&4/PPLS18R;6VG@-Q'QIHKN
MG(9,T]8#)VCZ]/C9D$")ZX/P#ZV9$!N2]D^^&[+NXD->72>^FW5Z6R G'C[V
M?@P&: 2;EFLX'438K-4S;W%';H02 3$!B)B3-G7A]T--9'_F_4."O^_\YY?'
MVOH6Y?\ H%@_<WF_U&\W6C#GKQRMTR1A(/U#$3;^\3.R^GB<G:Q[.V/MW,>S
MN[O\'V[%'ER;@OSK+%]$WD7U6\GY;R0&]B9UY6C6H[S:UJEU5M;:UKET]'5!
MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
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M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
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MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
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M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ino-20231231_g2.jpg
<TEXT>
begin 644 ino-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ()!:(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'V4?WC4]% $'V4?WC14]% !1110(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHI,T +1244 +1244 +129HH 6BDS1F@!:*2B@!:*2B@!
M:*2B@!:*3-% "T4E&: %HHI* %HI,BC- "T4F:* %HI,T4 +1124 +129I:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML_PSX/\ C59Z_93:WX]T+4-)20&XMK?2?+>1>X#9X-<Q\"?^3D?C-_UUM?\
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M3=WY49- #J*;DTHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *R?$WA^#Q5H-]I-S+/!;W<9C>2UD,<BCU5AR#6M133<7
M=":4DTSXN^)7P,TWPO\ &CX;>&;+Q%XG73-<>=;Q7U>4LP1<K@YXKT/XFZ#;
M_L_?"G4],\+ZEJUWK7B6[BL+-K^]>XD21\*60MR,+D\5-\;6'_#37P6_ZZ77
M_H%<]\3X?$/QJ_:-L]#\):G;:;'X'MQ=SW=U!YT7VJ3HNWU"U]1&I.LJ+JR]
MU1<G?;23M?YV1\G*G3HNLJ4?><E&-M]8J]OE=G2_LOZKJ7A/5/%'PP\0:C<:
MCJN@RK<6UU=R%Y)[>0 @Y/7#9%<7H?PXLOBU\>OBE#KVOZW;0:;<PK:PV6IR
M6Z(&7)X!JMXPT/QK\&?C1X.^(WBSQ!8ZS:7TJZ'?2V5K]G$<;GY"_KSWIWA7
MX+^%OBY^T)\69/$$5U.;2Z@$)M;MX>&3/.TC-5:,74Q"G92BG>*Z\R3MM_3(
MO*:IX9PNXS:M)].5M7M?^D;6@Z?=?![]HSPSX5\,^)=2U[0=8LYI=1TW4+LW
M7V39]V4,>5S[U+HNFWO[4_CSQ7/JVKZAI_@/0+TZ;::;IUPT'VN51\\DCKR1
MGC%5_#W@72OV?_VF]!T;P^TD>B^*]-F6>&\D,SB:/[I5VY&?3-6/@CKEE\$_
M''CCX?\ BVXCTA;[4I-4TJ]NFV0W<,O+!7/&X'M45'>+JTM9\JL[:O5W=NZV
M]-32FO>5*MI#G=U?1:*ROV>_KI8WK#X-ZQ\)?'&A7OP^UF[N_#MQ/Y.KZ+J>
MHF5$C(XEC+DG<#VKC/B!X=M/'W[6M]H.N>(-3TO1H=#CN$CM-1:U7S-V.Q K
MB/C-H?PT\(^.O!\?@B]O+[Q#<ZY!)>2VNHRSPPQE^0_S%1D]!72?$KP_X'\2
M?MA7UMX]>T32ET")XOMEP85\S=Z@C)Q6U.,DU5E)W<):\MI:->>OJ8U)1:=*
M,593CIS7CJGIMIYK74]4\/?LX^";6^=K#Q7KMY.\+QF/^W7E^5A@D#=U'K7C
MWQ;^!^G>#_BI\-M T_Q'XG6PUVZEBO%?5Y68JJY&#GBO9_A?X+^"OA;Q=#=^
M#+C2AKTD;0QBWU RNRG[P"ECZ5@?M"M_Q?SX*?\ 7_/_ .@5RT,156(Y>>37
M*]U;H_4Z\1AZ3PW,X13YH_"[[R7H>J_#7X3:7\+8;V+3+[5;X73!G.IWCW!7
M']W=TKMZ*6OGISE4DY3=V?1TZ<:45""LD%%%%0:!1110 4444 %%%% !1110
M 4444 %%%% !7!V_PIMH/C!<>/A>RFZFT\6!M-HV!0<[L^M=Y16D*DJ=^5[J
MQG.G&I;F6SNO40\5Y_X#^$=KX$\:>+/$4%]-<S>(9UGDA=0%B*C&!7H-%$:D
MHJ48O1[A*G&<HRDM5L<'XF^%</B/XE>&O&(OY;6[T6.2$0*H*3*_4$]JX)?V
M;]<TGQ-XAU7P[\1M4\/QZU=M>3VL%O&Z[S[FO>:*WABJU-63TM;9/2]^OF<\
M\'1J/FDM;WW:UM;IY'G7@?X;Z]H/]H1^)/&=[XPL[N+ROLU] B*H/7[O7(KB
M+/\ 9MU_P7)<6W@3XB:CX;T.XD:3^RY8%N(X"QY\HMRHKWRBG'%U8MM-:]+*
MWW6L*6#HR233TV=W?[[W/*_!_P  -(\(^$_$.F+?75_JNOHPU'6KHAIYF88S
M[ 9X%4;C]FO1+[X6Z)X.GO[M9-%(DL=6@(2X@D!R&4_TKV*O/O%/Q^^'W@O7
M)M'USQ39:?J<(#26L@<NH/0G"FKA7Q527N-MWOI]W_ [$5*&$I0M422M;7[_
M /@]SAKW]GGQ;XHM/[)\5?$_4M7\.D@3645LD+W"C^%W')![UL_$C]GF'QE>
M^$[O1=>NO"ESX90I8R6<2OM!7;T/M79>"_BYX-^(DTL/AOQ#9:M-$,O%"Y#J
M/7:0#6IX>\::)XKN-1ATC48;^73YC;W:Q9S#(.JG/>KEB,5"5WIR^26^FJM;
M7S,XX;"5(V3OS?WF]M='>^GD>;:9\'/'5CJ-M<7'Q:UB\@BD#O;O:1!9%!Y4
MX[&LW4OV;]6C\?>(/%/A[X@:EX<N-:9&N8;>W1U.T8'6O=:YK1?B1X8\1^)-
M1T#3-:M;W6=._P"/JSB8EXOKQ41Q6(UE'MK[JV\].Y<L)AO=C/OI>3O?RUOL
M87@'X>^)/"UQ>-KGCG4/%,,\7EI#=P(@C/\ >&VI_@[\*;;X0^&KG1[6]EOX
MYKR:[,DR@$&1BQ''89KH_%7C+1/ ^DOJ>O:E;Z78H<&:X; SZ#N3]*Y3P?\
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M5L1+E3Y6O>?Q:16J_/?<T/'46H_&SXP:9\.;^^N;'P[IFEQZCK4-G*8VNI6
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M4<(?RT\SE]HW8]<<U)7RQ]:%%%% !1110 4444 %%%% !1110 4444 %%%%
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M23UKPKPCXD_X7=I_Q#^)+Q.ME:: ^D6*RKC:XC)F8#_>XKV_]F7GX$^#L?\
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M'8INY%>(^./A+;Z)I_[/7@GQ%;BY1KJ1;VWW$ LR[BN1Z$U]*^#_ -F_X?>
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M5V\5SX"_9OBFB26)KNV#(Z@J1Y?0@UOZ7X \1Q_!_P"-6GOH]TM[JFHW,EE
M4^:X5AP5]0:I>/O"_B72OAK\$+B#PUJ.IW6@3037UE:1@S1A4P01ZYKJ]I&=
M5OF5W)]?[G^9R>RE"DERNRBNG_3S_(]N^+GPC\+>+? 6LVUQHME#,EL\L%S#
M L<D,BC*LK 9!!%?.WV/Q;\2_@O\,/%,.E-XN7PY>.;_ $AG&^\1"5#@'AB
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MCQL5&G#=/7W6[VVU^?9G;@9.56>TEI[R5K[Z6\NZ-2BBBO(/9"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@""ZL;>]V?:+>*?8VY?,0-M;U&>AJ;%+13
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!6E_DW^-?.E%4\ER[_GRA?VUF/\ S^9]%?\ #<GC/_H%:7^3?XT?\-R>,_\
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MTC_OE_\ &OEM>E#4?ZOY7_SX7X_YB_M_-/\ G^_P_P CZC_X>&>/?^@/H_\
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M+_XT?\/$/'O_ $!M'_[Y?_&OEBBC_5[*O^?"_$/]8,T_Y_L^I_\ AX=X\_Z
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M^&?'&N:)<ZUJE[=2P?9$N#''+@]6/8 >E=1J/@_P1X-\=?"WQ5INAW']E^)
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MZV5M]U]UKWZ'A.A:-=^(M7L]+L(Q->W<HAAC)QN8]!FNJT;X+^+_ !%XRO\
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M"M*VT&23!E;8/1>M;D-K%;(%C0*/:GXK&55O8V5-=2I;Z7;V^-J9/JW)JUM
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M+<[?FF#8Y^E=<XX;"24<3*\GT7ZG-!XK&1<L-&T5U?Z'A6O^.-6\0,1/<&*
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M  B<O_/=?RII\(S'_ENOY5I'Q H_Y9'\Z3_A(5_YY'\Z/;3%[.D9O_"'R_\
M/=?RIO\ PALW_/=?RK3_ .$C7_GB?SI#XD7_ )XG\Z?MIBY*1F?\(9/_ ,_"
M?E3?^$)G_P"?A/R-:9\3J/\ E@?^^J3_ (2A?^>#?]]4>VJ!R43+;P3/_P _
M"?E2?\(//_S\)^5:A\4I_P ^[?\ ?5-/BQ1_R[G_ +ZI^WJ=Q>SHF8? L_\
MS\I^5-_X06X_Y^4_*M0^+D_Y]V_.F_\ "8)_S[M_WU1]8J=Q<E$R_P#A ;C_
M )^8_P C2'P#<?\ /S'^1K4_X3)/^?=O^^J0^-$_Y]F_[ZI_6*G</9T3+_X0
M"X_Y^8_R--/P]N/^?J/\C6K_ ,)JG_/LW_?5-/C>/_GU;_OJCZS5[B]G0,H_
M#NX/_+U'^1I/^%<W'_/U'_WR:U?^$X3_ )]6_P"^J;_PGD?_ #ZM_P!]4?6J
MO<7LZ!E_\*WN/^?N/_ODTP_#6Y_Y^X_^^36L?'D?_/HW_?5-_P"%@1=[1O\
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M?S?@A?4LL_ILYIOV1]5/_,;MO^_9J,_LAZN?^8Y:_P#?LUT__#65G_T )_\
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M:A^S?KAA(L]6LQ(>\J,0/PKB=6_8Y\9:XQ-UXPMMG:-(F51^ -:Q_;LT\?\
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M (4W_AX)IO\ T*5U_P"!*_X4_P#6C,OYU]R%_9V0?TY'+?\ #OW7O^AFLO\
MORU)_P ._=?_ .AFLO\ ORU=0?\ @H1IH./^$2NO_ E?\*3_ (>$:;_T*-U_
MX$K_ (4_]:<S_P"?B^Y$_P!G\/\ ].1RW_#OO7O^AGLO^_+?XTO_  [[U[_H
M9[+_ +\M73'_ (*&:8./^$1NO_ E?\*:?^"ANF*,_P#"(W7_ ($K_A1_K1F?
M\Z^Y"_L_A[O^,CF?^'?.O_\ 0SV/_?EJ3_AWSX@_Z&>Q_P"_+5TW_#P_3/\
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MN_7_ /H:+'_ORU(?^"=OB#_H:;'_ +\M6Y_P\JTO_H3+O_P*7_"C_AY5I?\
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MYEI7_0EWG_@4O_Q-'^M>;?\ /Q?<A_5>&/YOQD8G_#N?Q!_T-5C_ -^6I/\
MAW/XA_Z&JQ_[\M6Y_P /,M*_Z$N\_P# I?\ XF@_\%,]*'_,E7G_ (%K_P#$
MT?ZV9M_S\7_@*%]5X8_F_&1A?\.Y?$/_ $-5C_WY:E_X=S^(?^AIL?\ ORU;
M?_#S32O^A*O/_ M?_B:0_P#!372O^A*O/_ M?_B:/];,V_Y^+_P%?Y!]4X8_
MF_&1B_\ #N;Q!_T-5C_WY;_&C_AW-X@_Z&JQ_P"_+?XUM?\ #S;2O^A*O/\
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M?^AJL?\ ORU'_#N/Q#_T-5C_ -^6K9_X>=:5_P!"3>?^!:__ !-'_#SK2?\
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M0R_.(XV^=2W5,#^5>+^$/CW\2))I=(\(1,)[WY/)M8#*P)[C.=I]Z^@O@?\
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M7]H[PKXICU"6?0K;1$TZYN(X6W1.8]I^4\G!J3MHU,'3K)I17+*%GZKWNO\
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M[G]_<B/9GRXQW] *Q-5_9^\*^,O ^N:UX)@\1Z->Z'MDN+7Q%;E%GA)P9$;
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MS/$)/O&F5[?/^S7%>^&M<OM$\:Z9KFM:'$9M1TBWB93&@X)60G#8^E9G@_X
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MKEC@>IJI%,+:T5V^:20EMO<L3FGQVID8//\ .W9>RU)[L8J,4D*UY$W0,_\
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MGM<^[RG.Z6*?L,QITVXQ?)*45HTM$^C1ROQ.\8:-XNU:WET72CI=M;Q^4J\
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M5U!4@@]".E,;O2]G%*QE#+,-"#@TVFK:MO3LNQ\E6_[)/CCQ1?:3;>./'/\
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M;14E6,:#P=HUOC;81L?5\M_.L[08QX>UR^THXCMYR;BV]!GJOX5U#ML5F)X
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M8]1U"W659%+9"@L,#([^U=O\*=)TB#XX:IX@L_&__"6:U:VT\U['9:?Y<%P
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M/\0Y?B+ID>HV$DQ6V66U,X#Y&2!VXKZY^#_B+PCXD\%PS^"+9;/08Y&CCA6
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MP6,>R")8E[[1R?J>] $]%%% !1110 5EZ[X=M/$%KY5RGS+]R5>&0^H-:E%
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MTKZUA^&Z^%_C-X0L5\':[XWNX1;R-XMU.^?[-$F <HJ_+A>P)K(\90ZAX?\
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M2O# ODE%*44M.UT8OCC]JS1O&'P+U6?3Y18>(9T%K)8LWS(6X++ZBO*/V+?
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M**[W_A07Q(_Z$G6?_ 5J/^%!?$C_ *$G6?\ P%:J#ZK7_P"?;^YG -25WS_
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MIC7$W_/:3_OHT?6O(/K'D>X>:G]]?SH\Q/[R_G7AOVB;'^MD_P"^C3?M$O\
MSUD_[Z-+ZUY!]9\CW3S$_O+^='F)_>7\Z\)-Q-G_ %LG_?1IK7$V/]=)_P!]
M&E];\@^L^1[QYL?]Y?SI=R^HKP0W4RX(FD'_  (UT>CZPUY%L>1A*O7YCS[U
M4<4I.UBHXB^ECUC<OJ*/,7U'YUYNTTG_ #T;_OHTZ&\EMY X=CZ@D\UK[;R+
M]KY'H^X>HHW#U%<G:W@NHPRDY[C-3%CZG\ZT]I<TYSIMP]:9-''<1/'(JO&X
MVLK#((/4&N<W-_>/YTFYO[S?G1[0.8^>_BA^S;XG\#:U<^+_ (-:E)I5](2]
MUHJR!8I^YV@_+^!KYB^/'Q5^*/CVRLM%\;:5<:<MBY8QK;-&)&Z;F[&OT@+-
M_>/YU!=6L%\NVYACN%])4#?SKZG!<02H2C+$4E4<=I/27W]3Y''9%'$1E##U
M73C+>*UB_ET/S2\&_'?Q_P"$?!Z>%?"B-IENS%I)K.V)GE8]RV.M:G@7]F+X
MG?&+6?MM]975E;SMNGU766()SU(!^9C7Z)6^BZ?:-N@L+:!O6.%5/Z"KNYO[
MQQ]:[ZG%7)S/"T%&4MWN_P D>?3X7Y^6.+KRG&.R6B_4_/C]IK]ET? _2-$U
M'3KJ;4K&9?)N[AQ@+-V..P->_?L,_'.'Q-X7/@K5;@+JVF#-HSM_KH?0>ZU[
M9XV\(Z?X\\,WVAZK%Y]G=QE"#U4]F'N#7YQ?$#X?^*OV</B%#<0O+"(9?-L=
M2C!V2KGH3Z]B*]#!8J'$&#E@L3+]\M8OO_6S\CBQ>'EP]C8X["Q_<O22[?UN
MO,^N/^"A6J+:_"W2;4$9GO@=N>P4UVG[%6GBP^ >C,0%\]Y)?S:OC?\ :"_:
M"MOC5X)\,1&-K;5K1G-[#CY=V,!E/H:^SOV>[%M+^#/A.#E2;-7/_ N:X,PI
M5,#DU*A6C:3F[KTN>AE^*IX[.ZN(I.\5!6_ X_\ X*#:?]I^#ME=@!OLNH1D
M_1@16U^Q+K\,G[/EI+/(L<=C-,LC,>%4'-4_VN]/;5/@3KO5C T<WY,*^+?#
M?QPU#PK\&M0\$Z:)(I]0NB\MPIZ1$ %5]R:WR_"SS3)U0I[JI]RZO\3#,,=#
M+,Y>)J;.G][Z?D6/C/XHO/CK\=KU].5KG[5=+8V2KS\@. ?IU->D?$[]@[Q;
MX7LH[_PS,GB*$1*TUH"$G1L?-M!X89_&NS_8_P#V>Y]%$?C?Q# 8KJ5?] M9
M!\R*?^6A'8GM7UIYC?WF_.M,QXA>7UX8; V<*:L^S_X;\SGR[(8YA1GB<>GS
MU'==&O\ A_/H?F;X=^*7Q8^"<WV."^U?2HHS@V5]&S1#V"L./PJ7XJ?M'^)/
MC/X>M=+\1V%C/-:R>9#>0Q%)5/<?0U^D-_IMIJ:E+RUANU_NSQAQ^M9<?@7P
MW#)YB>'],23KN6T3/\JYX\385S5:>%7M%U3_ . ;RX<Q<:;H0Q3]F^C7_!/B
MK]G?XE?&;0_#[>%_!&A2:C:22F2*>[@/EV^>N&;  [U]+> ?V67U+Q''XR^*
M6ICQ3XG)#K;9_P!%M\<A0O?'Y5ZS!$EK&(X46%!T6,;1^E/W-_>;\Z\;&9[.
MO.4L/35/FW:^)_/_ "/;P630P\(QQ%1U5'9/X5\O\[G7H$C4*H5548 '  I=
MP]17'[V_O-^=&]O[S?G7SGM#Z;VGD=AN7U%&Y?45Q^]O[S?G6=J>L?8H]H<F
M4]%STI.I978>TMJST#S$]5'XT>8G]Y?SKQF2ZFD<LTKDGD_,::UQ+_SU?_OH
MUC]8\C/V_D>T>8G]Y?SH\Q/[R_G7B4MX\*EGG95'4EC7+ZQXXE7=%92N3T,I
M8X_"HEBE%7:)EB5'='TIYT0X+J/Q%'GQ?\]$_P"^A7R#)J5Y-(7>ZF9FY),A
MIGVVY_Y^9O\ OX:P^O\ ]TR^N?W3[!\^+_GHGYBD\^+_ )Z)_P!]"OCW[==?
M\_,W_?PTUKZZ_P"?F;_OX:/K_P#=%]<_NGV+]HB_YZ)_WT*/M$7_ #T3_OH5
M\<_;KK_GZF_[^'_&F_;KK_GZF_[^&E_:']T/KG]T^R/M$7_/1/\ OH4?:(O^
M>B?]]"OC5K^Z_P"?J;_OX:B:^NO^?J;_ +^&E_:']W\1?7?[I]G_ &B+_GJG
M_?0H^T1?\]4_[Z%?%S7]U_S]3?\ ?P_XTTZA=_\ /U-_W\-']H?W?Q%]=_NG
MVG]HB_YZI_WT*BN+J)8)3YJ<*3]X>E?%_P#:%W_S]3_]_#3)M0N_)?\ TJ8_
M*?\ EH?2C^T/[OXC^N_W2WIAW0S-UW7$K?\ CYJW65X5'_%/V9/4J3^IK5KT
M#V%L%%%% !1110!QOQ8;'@Z?_KHO\Z\>T]LXYKUGXQ3>7X2(_O2J*\ATUNE-
M"9T]KG JV*I69RHJZ*H0M%%% !2$9I:* (9(Q56:#KQ6A44D>: ,2:W]JI2P
MUO2PY[51FM_:@#T'X<>-OMZ+I=_)_I2#$4C'_6#T^M>@U\XE7AD62-BDB'<K
M*>0:]B\!^,5\1VOD3D)J$(^=?[X_O"I8SK****0PHHHH *3'K2T4 96G>'XM
M)U"XN+:1HX9^6MA]S=_>'I6G+_JW_P!TTZF3?ZE_]T_RH ]H_99=(_A#9;F4
M$W5P>3_TT:O6_M4/_/:/_OH5\:?"NXFC\'Q*LLBCSI?E5B!]\U<U[PZ^ILTL
M%[/:SG^[(VT_AFN.IC'!M*-[>9YM3$N+:4;GV!]JA_Y[1_\ ?0H^U0_\]H_^
M^A7P)JMGK>D,1/-=;>TBRL5/XYK.74[S_G\N/^_K?XUQ/-N5V=/\?^ <OU^V
M\3]#/M4/_/:/_OH4?:H?^>T?_?0K\\#JE[N/^FW'_?UO\:0ZI>_\_MQ_W];_
M !J?[8_N?C_P!?VA_=_$_1#[5#_SVC_[Z%'VJ#_GM'_WT*_.7_A(KEKE85OK
MEW.2=LK8&/7FIVU2]Q_Q^W'_ '];_&M*F9SI652DU=7U[?<9QS2$[\JO;S/T
M2^U0_P#/:/\ [Z%'VN#_ )[1_P#?0K\\1-JS6PN!/=F'./,$C$9_.J_]J7O_
M #^W'_?UO\:R_MC_ *=_C_P#3^T/[I^BWVN#_GM'_P!]"C[7!_SVC_[[%?G3
M_:E]_P _MS_W];_&C^U+['_'[<?]_6_QI?VROY/Q_P" +^T?[OXGZ+?;(/\
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M?_GO'_WV*_,YM7O_ /G^N?\ O\W^-)_:U_\ \_US_P!_F_QH_MQ?\^_Q_P"
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M_P"_S?XTW^V-0_Y_[K_O\W^-']O?]._Q_P" ']K?W/Q_X!^H/VRW_P">\?\
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M[K_O\W^-+^WE_P ^_P ?^ 1_:_\ <_$_4?[9;_\ />/_ +[%'VRW_P">\?\
MWV*_+C^V-0_Y_P"Z_P"_S?XT?VQJ'_/_ '7_ '^;_&G_ &]_T[_'_@!_:_\
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M"TLU;(@CRP'J:XS2YL%:9+.RLVX%:"UD6$G K5C;(J@'T444 %%%% !1110
MQTS5:2'/:KE,9?:@#(FM^M5X)I],O([JV<Q3QG*L/Y&MB2'K5.:WH ];\(>+
M8/%%CN!$=W'Q+#W!]1[5T%?/]G=7.CWD=W9R&*=#^!'H?:O6?"WCJR\0(D4C
M+:WV/FA8X#'_ &3WJ1G3T49Q12&%%%% !39!F-A[&G4V0@1L>P!- %+X8'_B
ME5']VXF'_CYKK*Y+X7J1X55CT>XF8?3>:ZZO$J_'(\*K\;&21K(A5E#*>H(S
M6#J7@K3=0W,J-;R?WHO\*Z!JR9O$VFVMU]G>Y4S%Q'L4$_,:B.'GB&U"#E;L
MKG+4J4J:O5:5^YQFH?#J]A9C;3)<#T/RFN2\06MWH6R.XB\EY#@;OYCUKL/&
MGBK4_#OB7:EPL5GY8D6*11A\'D XZU5\6:CIOB[0(III8],U&-/-1)OF++_=
M!'K7T> X=Y:N&Q>(CS4)M-VN_DUOZV/E<=F-*4*^'P\N6M"]KV5_--Z>ESAE
M:V6]MK>!RT\:EYF[<C[H]36@:\^\1S3?8;1(;9H2)"3=X/SG/3/H*ZO2?'L$
MVN3VVJ:1']A5@@GLV8,@'!;W!/-?3<5<-XW,<3];PEI)*UMFN7\]WITV/GLD
MS'#X:@J-9\MW>_37^M^NYZ]\/E5]!=64,#(<@BI=8\"V&IY>$?9)_P"]']T_
M45J:'I=MI-BJ6C,\,G[Q2QSP:T&^]7Y9&FN7DFC]+C%.*3/$O$FEWGAN[,,M
MNTJ_P2J0%?\ .N6T[Q0E])+'*RV\BL1Y>-V!ZYS7TA=V<-]"8IXDE0]F4&O/
MK[X"^&KNWN@GVJ&YG4C[0),E<^W3%?693/(*5-K'T&Y:*]VUZVNK?B?,X_!9
ME*I?"U5R]MGZ7UO^!YKH_B:SUB25+=V81MMW$=:UO\:2Q^"NI>#9)7CD6_ML
MYW1@AC]12L"K$,""#R".:^?XBI9=3QK_ +,=Z;5_)/LK]"LO>+='_;(\LE^7
M<.U,:E:14QD\GH.]-W!@"#D5\S*$E%3:T?4]!23ND]0I6/RTUB%4D\"LC6+Z
MXT^*6:>)8[5'5?F.&;<,@#^=>SE.2XK.JWLL.M%:[>R3=OZ1PXW&T\%#GGJ^
MB[FA<S.EO+)&K.L8R[+SL'J:S+7Q%:W)9'G\C:A/G,N1N[#CUK#U"\NYH[S3
MK:*1+F["893E1%UX(K1TVP^P/#+'$HDDB$5Q:R+E6['\QS7Z]A>%\FP-%4<=
M.,JD;R?O6NK=M^7]=SY"KFF,K3]I23C%V5K7L[_F=/' DWA]-2BND=@VR2(K
MTXZYS52-G= 778Q[9J*#3TMI&$1*0$Y6$<JM6:_+L^Q&4U*D:>54K16\M;OR
ML^W?J?28"EC8)RQD[OMI]_S"BBBOE&>N-HHHK,H:W6FM3FZTUJ"6-I.]+2=Z
M"!C4E*U)04A&Z4M(W2EH9(@[T-0.]#4NA(#[IJ.I!]TU'4B8A[4-TH/:ANE
MQC4?PT-1_#0P&T445("+2TBTM !39/NFG4V3[IH$,IU-IU!(M,I],H ****
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M;R945R%A<%<<UT=G/N IB-6BF1MTI], HHHH **** "BBB@!"N:ADCJ>@C-
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MEJ*OU ^^&-]ZFMUIS?>IK=:3)8UJ8U/:F-4DLCIK=:=36ZU)(QN],I[=Z94
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M9 6ZCYAD[@^GTKPUK>?3+R2VG0QS1MM96IDG26\FY:M*<BLBSF^4=ZTXFS5
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M&8>M>Z_\(/H7_0-A_7_&C_A!]"_Z!L/Z_P"-'U2?</JLNYX.3S4>X>M>^?\
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MU_QH_P"%:^&?^@/;_K_C2^HS[H/JD^Y\OL1N'--<C;7U#_PK3PQ_T!K?]?\
M&C_A6?AC_H#6_P"O^-'U&?="^IS[H^6\BDW#UKZD_P"%9>%_^@-;_D?\:/\
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MW^-']GU.Z%]2GW1\BLP]:8V",'!'>OKS_A4WA'_H!6W_ (]_C1_PJ;PC_P!
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M 'V__P 53Y6%SX3W#UHW#UK[K_X4#X _Z%JV_P"^W_\ BJ/^% ^ /^A:MO\
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M^"/^A<M/_'O\:3_A2O@C_H7+3_Q[_&E_9-7^9$_4*G='PX6&#S0&'J*^X_\
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M)_T+5G_X]_C7/2R[%4')TYI733]'OT+EE<JEN9K1WZ[H^#<C'6F,1ZU][?\
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M*_\ ,OQ)_LNK_,C\^0PVGD5'N'J*_0K_ (4'\/\ _H5[+_Q[_&D_X4#\/O\
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M^A4L?R;_ !H_X9[^'?\ T*EC^3?XT?V'7_F7X_Y"_LFK_,C\Z]P]117Z*?\
M#/OP[_Z%6Q_\>_QHH_L.O_,OQ_R*_LJK_,CT.BBBOM3Z@**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ino-20231231_g3.jpg
<TEXT>
begin 644 ino-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &-! (# 2(  A$! Q$!_\0
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MQ>/?^A'\.?\ ?^X_QKX>HH^H8;^0/K=?^8^X?^'L7CW_ *$?PY_W_N/\:/\
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M?^A'\.?]_P"X_P :/^'L7CW_ *$?PY_W_N/\:^'OPHH^H8;^07URM_,?</\
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M?#U%:_4,-_(1];K_ ,Q]P_\ #V+Q[_T(_AS_ +_W'^-'_#V+Q[_T(_AS_O\
MW'^-?#U%'U##?R!];K_S'W#_ ,/8O'O_ $(_AS_O_<?XT?\ #V+Q[_T(_AS_
M +_W'^-?#U%'U##?R!];K_S'W#_P]B\>_P#0C^'/^_\ <?XT?\/8O'O_ $(_
MAS_O_<?XU\/44?4,-_('UNO_ #'W#_P]B\>_]"/X<_[_ -Q_C1_P]B\>_P#0
MC^'/^_\ <?XU\/44?4,-_('UNO\ S'W#_P /8O'O_0C^'/\ O_<?XT?\/8O'
MO_0C^'/^_P#<?XU\/44?4,-_('UNO_,?</\ P]B\>_\ 0C^'/^_]Q_C1_P /
M8O'O_0C^'/\ O_<?XU\/44?4,-_('UNO_,?</_#V+Q[_ -"/X<_[_P!Q_C1_
MP]B\>_\ 0C^'/^_]Q_C7P]11]0PW\@?6Z_\ ,?</_#V+Q[_T(_AS_O\ W'^-
M'_#V+Q[_ -"/X<_[_P!Q_C7P]11]0PW\@?6Z_P#,?</_  ]B\>_]"/X<_P"_
M]Q_C1_P]B\>_]"/X<_[_ -Q_C7P]11]0PW\@?6Z_\Q]P_P##V+Q[_P!"/X<_
M[_W'^-'_  ]B\>_]"/X<_P"_]Q_C7P]11]0PW\@?6Z_\Q]P_\/8O'O\ T(_A
MS_O_ ''^-'_#V+Q[_P!"/X<_[_W'^-?#U%'U##?R!];K_P Q]P_\/8O'O_0C
M^'/^_P#<?XT?\/8O'O\ T(_AS_O_ ''^-?#U%'U##?R!];K_ ,Q]P_\ #V+Q
M[_T(_AS_ +_W'^-'_#V+Q[_T(_AS_O\ W'^-?#U!X[C\Z/J&&_D#ZW6_F/N'
M_A[%X]_Z$?PY_P!_[C_&C_A[%X]_Z$?PY_W_ +C_ !KX>H]/4TE@<*_L!];K
M_P Q]P_\/8O'O_0C^'/^_P#<?XT?\/8O'O\ T(_AS_O_ ''^-?#WXXH^HQ3^
MH8;^0/K=?^8^X?\ A[%X]_Z$?PY_W_N/\:/^'L7CW_H1_#G_ '_N/\:^'J*7
MU'"_R!];K?S'W#_P]B\>_P#0C^'/^_\ <?XT?\/8O'O_ $(_AS_O_<?XU\/?
MH:*?U##;<@?6Z_\ ,?</_#V+Q[_T(_AS_O\ W'^-'_#V+Q[_ -"/X<_[_P!Q
M_C7P]11]0PW\@?6Z_P#,?</_  ]B\>_]"/X<_P"_]Q_C1_P]B\>_]"/X<_[_
M -Q_C7P]11]0PW\@?6Z_\Q]P_P##V+Q[_P!"/X<_[_W'^-'_  ]B\>_]"/X<
M_P"_]Q_C7P]11]0PW\@?6Z_\Q]P_\/8O'O\ T(_AS_O_ ''^-'_#V+Q[_P!"
M/X<_[_W'^-?#U%'U##?R!];K_P Q]P_\/8O'O_0C^'/^_P#<?XT?\/8O'O\
MT(_AS_O_ ''^-?#U%'U##?R!];K_ ,Q]P_\ #V+Q[_T(_AS_ +_W'^-'_#V+
MQ[_T(_AS_O\ W'^-?#U%'U##?R!];K_S'W#_ ,/8O'O_ $(_AS_O_<?XT?\
M#V+Q[_T(_AS_ +_W'^-?#U%'U##?R!];K_S'W#_P]B\>_P#0C^'/^_\ <?XT
M?\/8O'O_ $(_AS_O_<?XU\/44?4,-_('UNO_ #'W#_P]B\>_]"/X<_[_ -Q_
MC1_P]B\>_P#0C^'/^_\ <?XU\/44?4,-_('UNO\ S'W#_P /8O'O_0C^'/\
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M/_Q='UBC_.OO#V%7^5G@E%>]_P##"?QT_P"A"N/_  *A_P#BZ/\ AA/XZ?\
M0A7'_@5#_P#%T?6*/\Z^\/85?Y6>"45[W_PPG\=/^A"N/_ J'_XNC_AA/XZ?
M]"%<?^!4/_Q='UBC_.OO#V%7^5G@E?H3_P $C_\ C\^)?^Y8_P YJ^<?^&$O
MCI_T(=Q_X%0__%U]G?\ !./X"^._@K=>.F\9Z!)HBZBMI]FWRH_F;/,W?=8_
MWA^=>;CJU.=!J,DV=F$I3C53E&Q]M4445\L?0&/K5U-:O"(G*;LDXK-_M:Z_
MY[-^0JYXB_UEO]#6/753BN6]C.3:9<_M:Z_Y[M^0H_M:Z_Y[M^0JG16O+'L%
MV7/[6NO^>[?D*/[6NO\ GNWY"J=%'+'L%V7/[6NO^>[?D*/[6NO^>[?D*IT4
M<L>P79<_M:Z_Y[M^0H_M:Z_Y[M^0JG11RQ[!=ES^UKK_ )[M^0H_M:Z_Y[M^
M0JG11RQ[!=ES^UKK_GNWY"C^UKK_ )[M^0JG11RQ[!=ES^UKK_GNWY"C^UKK
M_GNWY"J=%'+'L%V7/[6NO^>[?D*/[6NO^>[?D*IT4<L>P79<_M:Z_P">[?D*
M/[6NO^>[?D*IT4<L>P79<_M:Z_Y[M^0J:WU.YD:0-*QQ&Q' K-JQ9_>F_P"N
M34G&-M@NR0:M=XYG;/T%']K77_/9OR%4Z*%&-MA79<_M:Z_Y[M^0H_M:Z_Y[
MM^0JG13Y8]AW9<_M:Z_Y[M^0H_M:Z_Y[M^0JG11RQ[!=ES^UKK_GNWY"C^UK
MK_GNWY"J=%'+'L%V7/[6NO\ GNWY"C^UKK_GNWY"J=%'+'L%V7/[6NO^>[?D
M*/[6NO\ GNWY"J=%'+'L%V7/[6NO^>[?D*/[6NO^>[?D*IT4<L>P79<_M:Z_
MY[M^0H_M:Z_Y[M^0JG11RQ[!=ES^UKK_ )[M^0H_M:Z_Y[M^0JG11RQ[!=ES
M^UKK_GNWY"C^UKK_ )[M^0JG11RQ[!=ES^UKK_GNWY"C^UKK_GNWY"J=%'+'
ML%V7/[6NO^>[?D*/[6NO^>[?D*IT4<L>P79<_M:Z_P">[?D*/[6NO^>[?D*I
MT4<L>P79<_M:Z_Y[M^0H_M:Z_P">[?D*IT4<L>P79<_M:Z_Y[M^0H_M:Z_Y[
MM^0JG11RQ[!=ES^UKK_GNWY"C^UKK_GNWY"J=%'+'L%V7/[6NO\ GNWY"C^U
MKK_GNWY"J=%'+'L%V7/[6NO^>[?D*/[6NO\ GNWY"J=%'+'L%V7/[6NO^>[?
MD*/[6NO^>[?D*IT4<L>P79<_M:Z_Y[M^0H_M:Z_Y[-^0JG12Y8]A79HMJ5S]
MC#^:=QD*]NF*B_M:Z_Y[M^0J-O\ D'K_ -=?Z57I*,>P[LN?VM=?\]V_(4?V
MM=?\]V_(53HJN6/8+LN?VM=?\]V_(4?VM=?\]V_(53HHY8]@NRY_:UU_SW;\
MA1_:UU_SW;\A5.BCECV"[+G]K77_ #W;\A1_:UU_SW;\A5.BCECV"[+G]K77
M_/=OR%']K77_ #W;\A5.BCECV"[+G]K77_/=OR%']K77_/=OR%4Z*.6/8+LN
M?VM=?\]V_(4?VM=?\]V_(53HHY8]@NRY_:UU_P ]V_(4?VM=?\]V_(53HHY8
M]@NRY_:UU_SW;\A1_:UU_P ]V_(53HHY8]@NRY_:UU_SW;\A1_:UU_SW;\A5
M.BCECV"[+G]K77_/=OR%']K77_/=OR%4Z*.6/8+LN?VM=?\ /=OR%']K77_/
M=OR%4Z*.6/8+LN?VM=?\]V_(4?VM=?\ /=OR%4Z*.6/8+LN?VM=?\]V_(4?V
MM=?\]V_(53HHY8]@NRY_:UU_SW;\A1_:UU_SW;\A5.BCECV"[+G]K77_ #W;
M\A1_:UU_SW;\A5.BCECV"[+G]K77_/=OR%']K77_ #W;\A5.BCECV"[+G]K7
M7_/=OR%']K77_/=OR%4Z*.6/8+LN?VM=?\]V_(4?VM=?\]V_(53HHY8]@NRY
M_:UU_P ]V_(4?VM=?\]V_(53HHY8]@NRY_:UU_SW;\A1_:UU_P ]V_(53HHY
M8]@NRY_:UU_SW;\A1_:UU_SW;\A5.BCECV"[+G]K77_/=OR%']K77_/=OR%4
MZ*.6/8+LN?VM=?\ /=OR%']K77_/=OR%4Z*.6/8+LN?VM=?\]V_(4?VM=?\
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M4-^!-?+'[)&O6-I^SB/@]=^*4^'_ ,1/":W.CZAO>&.\M6%P[I=PI-\LB.K
MAL$8J9>0'L?P?^(WBOQ,WB71_'OA>/POXA\.RHLUY9R,^EZA"Z;UGMI7 .,
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M]TGI1X^_: \ ?#_6)_#VI^,-&L?%C6<ES:Z/=7&))&$99%;'";B /F(SGBO
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M&1L'[S[3YW.>I]<5ZY\,K>_B_:]N%UE%.M)\,M)^VL5&1<><1(<^N[/-*[T
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MHHHKD-#!\1?ZRW^AK'K8\1?ZRW^AK'KLI_"9RW"BBBM!!1110 4444 %%%%
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MG [BJN@.O\%_"_P?\-])GTKPIX7T?PYIUP=TUKIMHD22D\$M@?-Z<YK.\'_
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MC (Z ]A7G/@G]K7X:?$#Q/IVA:5J>HQ3ZHS)I5YJ6DW%I9:FPS\MM<2*$E)
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MP,WX>:E=ZU\/_#.H7^E#0KZ[TVWGGTM1@6<C1@M"!VVDXQZ#%;]+]>325KT
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M #ZK_P!_&HN^P%>BK'VB'_GU7_OXU'VB'_GU7_OXU%WV KT58^T0_P#/JO\
MW\:C[1#_ ,^J_P#?QJ+OL!7HJQ]HA_Y]5_[^-1]HA_Y]5_[^-1=]@*]%6/M$
M/_/JO_?QJ/M$/_/JO_?QJ+OL!7HJQ]HA_P"?5?\ OXU'VB'_ )]5_P"_C47?
M8"O15C[1#_SZK_W\:C[1#_SZK_W\:B[[ 04E6/M$/_/JO_?QJ/M$/_/JO_?Q
MJ+OL!7HJQ]HA_P"?5?\ OXU'VB'_ )]5_P"_C47?8"O15C[1#_SZK_W\:C[1
M#_SZK_W\:B[[ 5Z*L?:(?^?5?^_C4?:(?^?5?^_C47?8"O15C[1#_P ^J_\
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M+OL!7HJQ]HA_Y]5_[^-1]HA_Y]5_[^-1=]@*]%6/M$/_ #ZK_P!_&H^T0_\
M/JO_ '\:B[[ 5Z*L?:(?^?5?^_C4?:(?^?5?^_C47?8"O15C[1#_ ,^J_P#?
MQJ/M$/\ SZK_ -_&HN^P$%;/AO[T_P!%_K6;]HA_Y]5_[^-6MH,BR--MC$?3
MHQ.:SG\+&MS8HHHKE-#!\1?ZR#Z&N'\9_#WPO\1K:QMO%/A_3_$-O8W*W=K%
MJ$(D6"9>DB#LV*[CQ%_K+?Z&L>NRG\!G+1F!8?#_ ,,Z7XPU3Q99Z!86WB?5
M(1;W^L1Q 7-U&-N$=^X^1>/]D5BP_ GX<6_@6Z\%1^!]$C\'W4XNI]#6U M9
M9@0PD*9^]E5.?85W-%79".:A^&?A&'Q3IGB9/#>FKXBTRT&GV.JB ?:+:V (
M$4;?PJ 2,>YJM:_"#P-8VOB:VM_"6DP6WB=F;7(H[<!=2)SGS_[^=S9^IKKJ
M*+(#CM1^#/@+6/!-EX-O_!NBWGA2R %MHT]HKVT&"2-BG[N"3TQUJ+P_\#_A
MUX1U#[?H?@?0M'O?L!TKS[&R6)OLAZP<=4/<'K7;4460[G&P_!?P#;_#]_ L
M7@[1T\&.QD;0!;#[(6+;RVSUW8/UJWXD^%O@WQCX7M/#6O>%M)UCP]9HB6VF
M7MJLL,*H JJ@/W0  ..U=/1181R=KX#L? O@*^T/X=Z/H?AB58)/L%M]CQ9+
M.5PK2QH067/7G..]?&GB#]D#XE?%#2K#PQJOPW^%WPWLKG6(=0\0>*/"<Q\[
M4(XI"PCCM]NY,YS@N1GTK[WI<G^E+E0[G%^.O@OX ^*$EBWB_P &Z-XG>P01
M6TNJ6BS/$H_A#'M[=.:M^(_A;X-\8:9HVG:WX7TK4]/T:59]-M+BU4Q6<BC"
MM$HP%(' Q74TE.R"Y@7WP_\ #.J>,M/\77F@6%UXJT^ VUGK,D(-S;Q'=E$?
MLIWOQ_M&J_AOX7^#O!UCJ]CH?AC2]*L=8F:XU*WMK91'>2,,,\J]&)!.<UT]
M%%@N<3X%^!OPZ^&&I7&H^$/ V@^&M0N$,<UUIEDL4CH>J[AR!]*GTOX.^!=%
M\,ZMX<L?"&CVN@:O*T^HZ9':+]GNY& #O(G0D@#GVKKZ*+(+GS!^TK^SWXE\
M3?!__A4'PA\(^$_#G@G6&5]4OI9S;_V>PG5V,5N%/F%@H.[(/!%>_?#SP/I_
MPU\!^'?">EKC3]%L8K&$XP6"+@MCL2<G\:Z+T/<4E)12=PN%6+/[TW_7)JKU
M8L_O3?\ 7)J;V$5Z**X7Q9\</!7@?XD>%? >M:NUIXH\3ACI=H(&99,$CYW
MVID@@;NI&!1MJ!W5%+MZ\$_0&JVJ:C;:+IMYJ%],MM96<+W%Q-)]V.-%+,Q]
M@ 3^%%P+%%<C9?%3P]JD?@V6QEO+VV\71--I-U;V,LD+QK&)"\KA2(E*G(+X
MR>!S77JK-@XR,X]CZ &F E%'5B!^7?\ 'THYZ8R>O'\Z "BEVD*"01GIQUI/
M7U[4 %%*58<%2#_.C:<X[_Y[4 )12J"W09_"C!S@ D_RH 2BE"D\ $_04JJ2
MVW:<],=\T -HI<'IU_0TDC"&-I'!VJI8X!Z 9./4T %%8_@[Q59>.?#&G:]I
ML=VEC?Q^;"E]:26TX7<5^>)P&0_*>"*V&XXQSC(XY/X4 %%+M/7!QG XZ_0T
MG^>E !12D$<XXQQV^AHVGT/OQ^M "45B:AXVT32?%VA^%[N_2+7=;2>6QL]I
M+2)"H:9B0, *".2>I I?"'C#3_'&E2ZAIJ7L=O'<S6C"_LY+5_,C<HQ"2 $K
MD<,!@C!&<TKH#:HIVQO3!]#Q^/\ D5A^(?&&G^&=0T*RO8[UI]:O!8VIMK.2
M9%D*ELRLH(B7 ^\^!FF!M44NUCC"G/\ .A1N^Z,_3]* $HI>>P-<LOQ*\/O\
M3'^'XNI?^$I32UUAK;R&\L6I?RPWF?=SN!^7.:38'445SOBKX@:+X+U;POIN
MJSRPWGB74?[*TR..%I!)<^6TFQF ^4;48Y.!71XP<'CZ]*$P$HI64JN3Q[GI
M1CC.#TS3 2BEQVZGV]*1L[L=\],=* "BN7\0?$OP_P"&/'?A;P=J-S+%K_B9
M+J33+=8&=9%MU5IBSCA,!UQG&<\5U%3<"PW_ "#U_P"NO]*KU8;_ )!Z_P#7
M7^E5Z: ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[/\ 8YTW1/!O@VUTCQ+<V'CKPYK+Z]_PFCVBRW-_=3,3>>?'O&Z.8$*4W?*
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M9H#Y^\8>'=?_ &5O$_POUNQ^(/BKQA9>(/$MGX8\0:9XEOOMD-U]J#@7$"D
M0,CJ2%0X(.*YCX??#WQM\6/!WQ.\377Q9\7:3J6B^(=8@\-Q:;J)2VLQ!*S
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M;_0UCUL>(O\ 66_T-8]=E/X3.6X4445H(**** "BBB@ HHHH **** "BBB@
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M0%Z$Y'%</)^V5HVGZ=%KVK?#WX@Z)X(D(/\ PEU]HP6R2,_=E= YFCC/7<R
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M0YDMY"CL-I/RDCCOCK79,C(0"I&>G%?GYX2EO?$F@^!OANNJ7NC>'?&7Q/\
M$D.M7&GSM;RSV]N9)Q:K*OS*)& #8()'&:ZSQ]_QA_\ %'4--^&_VV#P]K?@
M76=8?0;FZEN[>ROK) 8;J,2,S)N)PPS@[:?,!]L>2_\ =--*E<9!!QGD=J_/
MWXQ? ?0_!G[*?A7XAZ?K^M7'C6_N-!NM6UI]7N'&M&YNH#(DB%RAC!8,H4#&
MP>^?0_&WQ"O/V9?'G[1.DQRRS#6K)/%OA6"5BVZ]N6%G-#&#][%P8G*CH#T[
MT<SO8#Z_(*D@C!'44E<;\&?A_P#\*J^$_A/PFTTES/I>GQQ7,\KEWEN"-TSL
MQY),A<Y],5V54!8;_CP7_KK_ $KYP_;[T.X\2?LOZWIMM87&IO<:IIB-:VL+
MRNZ?:X]_RH"<;<Y(Z5]'M_R#U_ZZ_P!*@5BC HQ0@8R/3TI6N@/&O!_['7P1
M\#:S9:WHGPUT2RU6T*RPW1669HG !#*)'90P/0XX->?V?C0?LS_M ?%:^\8Z
M%KUQX=\;75IJ^DZ[HFE3:BLDD<'E2VD@A5F1U893<,8/49Q7U(>F,4^.:2(D
MH[)GCY3BER@? EYX5\0^#_AGX<^(.O\ AW6-.M=0^+H\:7FD0V;W-WIFG.KH
MC20Q@L&/#,H!(+5/XE\)>'_ WQT^).O>/KCXGZ=H'BZZM];\/ZOX'GOE@NE,
M"*UO/%;*62=&'R[P/E.,BOO-9'1MRNP/U/\ .E6:2/<5D<%NOS$9^M+E ^*_
M"'@$^'D_9L;3/!/B#PM9OX\U+5;C3]>O&U"\A66SGVW%S)M'EF3Y6VM]TM@D
MFO1/%6A:E??M:^,9(-/N9(KGX62V4,PB;RWG:X?$0?&TOR/ESFOH_>PW88X;
MK[CT-)N?RP@=@O7&>_K1R@?"_P &YKC6K7]CBT@TG5HKKPK<ZMIFLQ7FGS6_
MV2X72F7:Y=!A2Q #]#V-<1X\\1>*OB5\-?B)I?C+4/BO=_$]TU*&W\$Z#I\M
MGHUO&ID$+"5(PDL/EX9MTA+[B ,D5^D+32/G=(S C!!)((]*/.D5-@D;:.@R
M3CWHY0/DK]G[2[Z'XY> ;N2PO(+2/X,Z7:/--;21HDZRQAHB64 .,'Y3SQTK
MN_VJ-.N]0U;X*&TM+B[%O\0-/FF-O$T@B0)+EWP#M4>IXKWEI'<89V*YSC<3
M_.@.R[L$C<,'!Q^%5R@?*GAWQ]'^RW\7_BY%XQ\/^()]*\7:_P#\)'H>KZ+I
M$VH1W8>%(VM"8E8HZ,F & 'S=:X7X?\ PW\3^&]1^!E]K6AWFG7>M?$77/$\
MVFM$9#I4-U%(\*3%05C8#&>@!..M?<T<SQYVNRY_NG&?K^E(KLN<$KGK@]:7
M*@*>K63:IH^H6:3&![NVEA69>J%D*AOP+9_"OS>\)^ ?#G@[X1I\-_%OA[XR
MZK\1[.)]);PAI&J7T>DZH-Y"R13!3;QV[J=QR>.>,U^E? X XJ032!-@=MO]
MW=Q]<4Y13 ^<?A5X5F\,?M8^*(8M-N;'2[;P#H5C!))NEC4Q/*#&)B )"HP"
M1R>I%>+7GAG6&\/ZI&='OV9OVEXK\(;20@VHF0F?&WF+_;^[[U]Z[CC;EB@Z
M#/\ GGWIPF?CYVX&.O;T^E'*!\W_ !LA\26O[4G@K5_#FE2:IJ-GX*\1_9 Z
M'[.]WMC,,3OC:-[ 8!/-?*'Q0U35OBA\#;>2\U7XN^+_ (BQ7.GW6N:5>:9-
M9:1H[+<1M< PK&J2QKAE0*7/(;L:_3S<VTKN;:<9&3V_R:>UQ*VW]ZYVG*_,
M>*GE \(^"NGW,7[5WQPOI+2>*RNH] -O<RP,D<P6U.[8Q&&P2,@=#UKP/P?X
M?\0>#_ _PZ\?GPWJFIV/@_XC^)+S5=.M+1GO$LKF>9!<Q0D;G"[E;"@DJ217
MWBS,P52Q*KR >@]:/,;>&W-N7HV>:.4#XZ^.VN>*?VNOA7X]T'P'X5U$>$K&
MWL+NQU+4K:;3KS6+V&Z2>6VMTEVL$$<9 8@?/C!-87@C0?A]\1/B/X"AT'1?
MC)XCU&QU*/4KX^+-6OH;+P](BD^;)]H39,X;*!(\[@3R!7W$TC2-N=BY[[N<
M_C2R322 !W9P/[QHY0/AG2_'-S\!_P!GWXC_  >UKP9XFU3QE'_;8TM--TB:
MZMM6M[LRO'<K.JE!M5\N&.[*' )(KZ?_ &7[.;3?V>/A-:7,4EO<6_AG2XY8
MID*.C+;1@AE.""#Q@\BO2%GD1=JR,J^@)Q]::6+-N)YSDGKGZ_C3LP/@KX?^
M&=6C\/\ P0672+Y3;_%[6[J97M),Q1,UULE8%?E0DKACQTYKW+P3I]Y'^WC\
M2M1>SN$T^7PCI$45V\3"%V61RRA\8)'&0#7T&97.?G;D8/)/'8?2D9F9=N3M
M&<*2>]'*!\)?#[PWJL.A_ U)M(OE:W^*VLW,JR6D@,49:X*2,"ORJ<C#' Z8
M->U^ M+O8?VZOBEJ#VES'83>$M)AANWB812.LK%E5R-I(] <U]"-*[;LLQW#
M!YZCM]?QINYO+"%B4'\.>/RHY0/@3P?I^L> O 'PE\9W_A[69M'\,?$7Q#<:
MO'9V$DMU;V]Q+.B7'DA=[1Y(R5!.""*O>*_$%S\5/B-^T-XETCPWXAM=&O\
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M/A'5+S6H+3Q'XLT+PEKERUYJO@W2M3\K2;V5VW2$Q[2Z*Y^\B,JGTKWRBBR
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M\I6E8[C^T-/_ .@A;_\ CW^%']H:?_T$+?\ \>_PKAZ*V]BNY/.=Q_:&G_\
M00M__'O\*/[0T_\ Z"%O_P"/?X5P]%'L5W#G.X_M#3_^@A;_ /CW^%']H:?_
M -!"W_\ 'O\ "N'HH]BNX<YW']H:?_T$+?\ \>_PH_M#3_\ H(6__CW^%</1
M1[%=PYSN/[0T_P#Z"%O_ ./?X4?VAI__ $$+?_Q[_"N'HH]BNX<YW']H:?\
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M_P >_P */[0T_P#Z"%O_ ./?X5P]%'L5W#G.X_M#3_\ H(6__CW^%']H:?\
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M#2]=8'[3::7<M<VZ'<0-DC*I8$ 'IP3BM>J6JN 4444Q!1110 4444 %%%%
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M.AVD=JUC93BRM;>,(D;*A,:HB@8&<  "G&;E>X,9_P )EX>_X2#^PO[>TO\
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MJ?B2;7+GPA ]U/="]GMEN)ELYI\Y\Q[8.(F?)SDK^M>KT4K+L',S@OB-\"?
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M;_ODT;&_NM^1HT$(.**78W]UOR-&QO[K?D:- L)[T4NQO[K?D:-C?W6_(TM
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MUO$WB"6_W27#QY:.4$D^8<?+M]"".2U?H)CJ0<@\BG2ES1"6@4445L0%%%%
M!1110 4444 %:GA^9X+B[DC8HZVLA##J.*RZT=$_UEY_UZR_RJ)_"P0W^WM1
M[WLW3^]1_;VH_P#/[-_WU5"BBR[%%_\ M_4?^?R;_OJC^W]1_P"?R;_OJJ%%
M59=A7+_]OZC_ ,_DW_?5']OZC_S^3?\ ?54**++L%R__ &_J/_/Y-_WU1_;^
MH_\ /Y-_WU5"BBR[!<O_ -OZC_S^3?\ ?5']OZC_ ,_DW_?54**++L%R_P#V
M_J/_ #^3?]]4?V_J/_/Y-_WU5"BBR[!<O_V_J/\ S^3?]]4?V_J/_/Y-_P!]
M50HHLNP7+_\ ;^H_\_DW_?5']OZC_P _DW_?54**++L%R_\ V_J/_/Y-_P!]
M4?V_J/\ S^3?]]50HHLNP7+_ /;^H_\ /Y-_WU1_;^H_\_DW_?54**++L%R_
M_;^H_P#/Y-_WU1_;^H_\_DW_ 'U5"BBR[!<O_P!OZC_S^3?]]4?V_J/_ #^3
M?]]50HHLNP7+_P#;^H_\_DW_ 'U1_;^H_P#/Y-_WU5"BBR[!<O\ ]OZC_P _
MDW_?5']OZC_S^3?]]50HHLNP7+_]OZC_ ,_DW_?5']OZC_S^3?\ ?54**++L
M%R__ &_J/_/Y-_WU1_;^H_\ /Y-_WU5"BBR[!<O_ -OZC_S^3?\ ?5']OZC_
M ,_DW_?54**++L%R_P#V_J/_ #^3?]]4?V_J/_/Y-_WU5"BBR[!<O_V_J/\
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M?_M_4?\ G\F_[ZH_M_4?^?R;_OJJ%%%EV"Y?_M_4?^?R;_OJC^W]1_Y_)O\
MOJJ%%%EV"Y?_ +?U'_G\F_[ZH_M_4?\ G\F_[ZJA119=@N7_ .W]1_Y_)O\
MOJC^W]1_Y_)O^^JH44678+E_^W]1_P"?R;_OJC^W]1_Y_)O^^JH44678+E_^
MW]1_Y_)O^^J/[?U'_G\F_P"^JH44678+E_\ M_4?^?R;_OJC^W]1_P"?R;_O
MJJ%%%EV"Y?\ [?U'_G\F_P"^J/[?U'_G\F_[ZJA119=@N7_[?U'_ )_)O^^J
M/[?U'_G\F_[ZJA119=@N7_[?U'_G\F_[ZH_M_4?^?R;_ +ZJA119=@N7_P"W
M]1_Y_)O^^J/[?U'_ )_)O^^JH44678+E_P#M_4?^?R;_ +ZH_M_4?^?R;_OJ
MJ%%%EV"Y?_M_4?\ G\F_[ZH_M_4?^?R;_OJJ%%%EV"Y?_M_4?^?R;_OJC^W]
M1_Y_)O\ OJJ%%%EV"Y?_ +?U'_G\F_[ZH_M_4?\ G\F_[ZJA119=@N7_ .W]
M1_Y_)O\ OJC^W]1_Y_)O^^JH44678+E_^W]1_P"?R;_OJC^W]1_Y_)O^^JH4
M4678+E_^W]1_Y_)O^^J/[?U'_G\F_P"^JH44678+E_\ M_4?^?R;_OJC^W]1
M_P"?R;_OJJ%%%EV"Y?\ [?U'_G\F_P"^J/[?U'_G\F_[ZJA119=@N7_[?U'_
M )_)O^^J/[?U'_G\F_[ZJA119=@N7_[?U'_G\F_[ZH_M_4?^?R;_ +ZJA119
M=@N7_P"W]1_Y_)O^^J/[>U'_ )_9O^^JH44678+E_P#M[4>?]-F_[ZKL?A[J
M%S>R7WVB=Y]NW:7.<9S7GS?=/TKN?AG_ *S4/HG]:Y\1%>S-([G=T445Y!T'
M ?$O_CXL?]UOYBO,/&?@G0/B)X=NM!\3:3:ZWH]SCS+.Z0,A(Y5AZ,#R".:]
M/^)?^OL?]QOYBO"/C5JGQ2TG2-,;X5>'-%\2:M+<LEW;ZY<^1''%M^4H?,3)
MW<'FO6HV]EJ<LOC,'X;_ +(/PA^$GB2+7_#'@RWL]8A8O!=W%Q+<O QR-T?F
M,VPX)Y%'B;]D3X1^,/%.I^(=6\'PW.HZF#]M"W,T<%PV/]8\*L$+\D[L9SSG
M/->'?!K]IS]HGXQ:]JMMIOP_\%M8:#JXTO69OMKQO P;$A3=/\^ "00""1WK
MZ^U#Q9H.DZG!IU]KFFV&H7!'DVEW>Q132 G VHQ#')Z8!JH^SFMM ]XX>X_9
MN^'MUX;\%Z#-HLTVE^#;H7FAPO?3EK24$$'=NRX^4<-D<5)\4/V=?A[\9-4M
MM3\6>'Q>ZI;QF!+ZUNI;2<Q'.8V>)E+)R?E;(YKFOVA/CMK'P?\ ''PGT/3=
M.L;R#Q?KJ:3>R7@?S((V>-=T>U@-V'/7(XKUO5/%&B:'?06>I:UING7=Q_J+
M>\O(X9)?]Q6(+'Z U?N-M"UZG+:Q\"O >O\ PR3X=W?AJT_X0U%54TN'=&D>
MUMP964[@V>=P.3FOGW]ISX#:[XO^'?AOX)?#[P)=?\(JM]!?2>*M0U(30V"[
MY#*G[QS,S_.3W&& %?5FI^(]'T66*'4M6L--EF5FBCO+N.)G4#+%0S M@=<=
M,\XJ"?QIX=MM)AU:;Q!I,.E3MMCU"34(5MW;NJRE@A/'8]J)1A+2X7:V)_#?
MA^S\)^'=*T/3D$>GZ;:Q6=NH&/D1 H/XXS]2:Y;XG_ _P1\9$L#XLT1;^YL"
M?LE[!/);7-N#R0DT;*X![C-<Q^TQ\<+GX-_ ?5/B!X8BTW7YK>:W2 32^9;2
M+)(%8[HV&2!Z&N]\&^.--\4Z;IH&IZ:^M36,-U<Z;;72/-$SHKD>7NW@<]Z=
MX:1#WMS@O#_[(/P>\+7VCWVF^![.'4-)NOMMM?/++)<&7^])(S%I.><-D9KV
M'^=>):U\6_&WAV3XR7M[I_AA]%\)Z1-J&B?9=16:\GD2,OMNX4D+1@X_NI_6
ML+P3\>O'WCSX?_!_Q-I^E^$X1XIE?^VXM0U'[*T$8D"C[(CR!I6(W':-YS@=
MZF,XIM(+-GT517D/AG]J7P)XJ^*7C'P7;ZO963>&8HC-JE_?00V]S(Y.Y(26
M^8(!\QSP2?2O3;CQ)H]IHZZO/J]A!I#(KKJ$EU&MN5;[I$I.T@]B#S5J2>S)
ML^IHT4V*:.XB26)UEBD4.DD;!E92,@@C@@CO3JI %%%%, HHHH *T=$_UEY_
MUZR?RK.K1T/_ %EY_P!>LG\JB?PL$9K-M5CZ G\AFOG/X9_'3XR_%[P?;^*/
M#?PW\('2;F::* 7WB6:*9O+D9#E?((&2I[U]%R?ZN3_=;_T$U\,_L_\ P>\>
M>*OV5QJO@?XJ>*?#^M/-J#V.B0S1+IS2+<./+_U>]=^",AN"<]*B;:>A4;6U
M/J'X,?&2/XJ>&];N]1TMO"^L^'M0GTO6].N)U=+2>+&\K+P&CP<AOSKJ?"_C
M[PQXWCN7\.>(])U];7BX.F7T5QY7<;MC';^-?$GBK6-%OOV,O#*>#=/31[74
M_&=G9>,;77+R5]ETTQ%TM_,/WAC:18\M_<*^N*]-TOX?^)_#GQ_^'VI:JWPQ
M\%7'V2]@_LKPBUS'=:S:&')7RVC5&6,A7#-C'.#S4>T8^4^AK/XH>"]2U*PT
MZU\7:'<ZC?J)+2TAU&%I;A"2 T:!LN#CL#T-6_%7CCPYX%M8;GQ+X@TOP];S
M-MBDU2\CMU<CJ%+D9_#U%?#W@WP-\/(_^";MWXB6RTY]?2RGO%U<*HOH]62=
MA"J2?>5P0@5 >AZ<UU%CIOCGQY^TUXM5]$\$Z[K5AX:TD6MIXY$[>7;R0!IY
M;>-$9?FF,@=CR, 9Q1[7R#E/L>;7--M]'.K2ZC9Q:4(O/-\\Z" 1D9#[\[=N
M.^:QM(^)_@[Q!HVH:OI7BO1=4TO3D,E[>6>H12Q6RC/,CJV%Z=Z^1])LM,\*
M_"RU\):Y;:%\2+C4OB%)'X=\+^'-6EBT>SNE42&TGFF3!BB<2-Y9# Y4 'MM
M>#-/U*V_;233=?\ #/@_P[+>^!;P7NC^&7\Z)X_/0H+M2BJ7],+]TBG[70.4
M^@/@/\:M(^//@&#Q-I;6T3--+%<6$-TL\EJ5D94$A7[K,JA@#V/>NE\5?$#P
MMX&\G_A(_$VD:!Y^3%_:E]%;;\=2N]@2.W%>4?L0:;:6?[-?A>6UM(+=[B2\
M,LD,2H9"+N8 L0!D@<<YP,5R_B*:V\8?'+XAIX1^'/A_Q5K>DP6MAKNO>-M1
M L[3$19(88"CLJ!22[+M!(ZFKYG&*86W/HRY\2:39Z&VM7&J6,&C+%YQU&2X
M06XC/1O,)V[??->=:9\?]+UKXR'PCITNEW_AW_A&CXA'B2UOUDBP)FC9,CY-
MJ[<EMW%?)?P@:VU[X>? +0]?2QF\"W7CW6X+JW5BU@\L89[& !C\T1D+[0W7
M S7I_B[PYX9\+?M0?$&'P]:V>G3R_#.\EU"SL8UCCCF+$*2B_*K,@&0 ,X&:
MGVG,U8?*?3-C\2O!^IZRFDVGBO1+G5'@%RME#J$33&(KN#A V2I'.X#&#FJW
M_"R-$UGPOKNJ>%]<T'7Y-+AD+E-3C^S1RJI(6:52PB7/5CTYKXV\5?"WPEIO
M[*_[/$D'A^RBO+_7='%W>K"%N+A;C(F5Y1\[!P2I!.,<5W?Q@\-Z1X-^-GQ'
ML] TNST2ROOA1>RW-KI\"P0RO',4C8H@ R%)&<5/M)6V"R/HZW^)6A6/A^QO
MO$.O:#HUW+I\>H3QG5(S!'&V!O61B-T6[@/T-0^*/B'!:^!XO$?AJ^\/ZS:S
MW$$<-U>:LEO92(\BHQ$XW*7 )VJ/O' KYQ^'O@[1/%WQM^#T>MZ;:ZM!9?"Z
M&Y@M[R(2Q"42( Y1@02,G&1QFN/\>:=:^'O!/Q]T33+>*QTBS^)FB26UC"H6
M&$O):LVQ1PH+$G XYJG4?8+(^T/$'Q$\*>$]4MM-UOQ1HVCZC=8-O::A?Q02
MRY.!M5F!//I7)^-/CYX=\$_%WPAX!OKRPBO/$$,\QN+B^CB%OM"B%"I.2TS,
M0G8[3C->(?$3X:W]UXX^+>N>&]/\#?%;1=0=1XBT/7I#;ZII;); &&&Y*D1K
MM&]<XP>14_A-O#'CKXN?LP:SI>B^7I=YX7U![:#556XN42-(1$))&!+LAR%<
MG/<8S4NH[;!9'TG:_$7PG?:Q!I%MXGT>XU:X>2.*PCOXC/(T9*R@)NR2A!!&
M,C'-1Z7\3?!VN:^^A:=XLT34-;0E6TVUU&&2X##J/+#;L_A7S/\ !_3/!7A;
MX.?'#QSXBTE9EA\2Z\U]?VD8%\(!(8]D$N-T9(8KP1]XDUP'Q.T_4?#O@_X-
MWL/P\\&_#S1QXDTDZ/)9ZE]IUID8Y!\Q$4,"G,F6;[PZFB51V"R/INQ_:1T3
M7O&GQ/\ "ND7.BR:MX/LTGMFN]7CBAU"0V[RRY;GRXX654D?G9DYZ5W3_$#2
M-#\&Z3KWBC6-&T"&\MH97N)=1C%GYCQJQ6*=RHD7D[6XW  XYKYJ\2Z'IEOX
MK_;1GATZSBFA\/6NR1($5XQ)I$QD (&1N/)YY(&<TSX1:+H_B_XX^!=.\6VE
MIJ<>G?"W1[CPW8Z@BR0EWC074T<;95I!A5)P2!FJ]H[L+(^J?^$NT'^P[;6A
MKFG?V-=%%M]1^U1_9Y2Y"H%DSM)9C@8/-0:#X\\,^*KZ\L=$\1:3J]]9'%U;
M6%[%/) <X.]58E>>.>]?#7Q0TNPM_#/Q_P#"VB)'%X#M_&?A^.WMK-R+>WN9
M9(C>10X.%!8Y(7&"3P*]X\?>"?#OP_\ VF/@K+X=T>R\/+);ZOI\[:7 MOOM
MEMP55]H^;:1D9R?SI\[[!9'M$/Q&\)W7B=_#</BC1IO$*$AM)CU")KH$=08@
MV[/MCBD^)'BQ_ ?P\\3^)H[5;V31]-N-06U=R@E,:%@A8 XSC&<<5\8'PC'\
M*/AGH>KZAH?A#XH?"NSUF*^LO&F@7)L=?1VN_EE=R/\ 2&WMM8*07 (.*^L_
MVAI"WP#^(\HZGP[?..,=86/2G&?,F)I718\ _%_PUXXT_1(DUS1X_$FH:=#?
MRZ##?QR7,'F1JY7R\[CC.,XK5\3?$CPEX*O(+7Q#XIT70[FX&8H=1OXK=Y!T
M#*'8$@GTKY;\7_#;PSX,_9S^!6K:%H=CINM6_B#PTR:E;0K'<DW#H)MTH&YM
MX)!R3Q6AKDUGXT\4?&:_\'_#?PMK-C:WLUEKWBKQYJ(V^=%  Z0PA&>.%5'&
M&4$\X[U'M&M&M1\I]2KXBTJ35(-+74[-M3N+8WD-DLZF:6 $!I47.60$@;AQ
MR.:3_A)M(^W:C9?VK8B]TV))KZW^T)OM(V!9'E7.4# '!;&?I7QC\-;AO"O[
M/'[/'Q5>3$7AFZ;2]5GSPND7<SP-DGDI&PA<#VK%^(T>J>(/@I=>.REFEO\
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M2@FU^PMX[NZT]"?-AA<X21AC&">!S28&K1110@"BBBF 4444 %%%% !1110
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MSI^W%))#^SMJ+Q6WVR5-8TIH[7<%\YA>QD)D\#<>,GCFOHM_^1=B_P"OMO\
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MNW@ <5Z0GP'^(OC"/PQX?^(?C;0];\%^'[NWO!%I6F207VJO;D& 73,Q10"
M6$?WL>]3>/O@[\5O$UMXL\.6GCGP]J/@KQ#-,ZCQ+I<EWJ&E1S</%;D-Y;*H
M)\O<,K^%3:70-#A_BS^T1<'XO3^"KKXAR_#72](T>VO+S4M TEM4GOKR==PC
MC)CD5857!R1EMPZ5G6_[1WCS7?@?J5YIUS>74VC>*%T;4?&&F:&[7#Z45W_V
MA#9NO^LP0K#:5!R<=!7I_P#PH/Q1\.O$FG:_\*?$^GZ7=+H=KH.I:?XEMI)[
M:_BMEQ#.6B(=95'''!''%:9^%OQ/3P-"$^*]Q+X]36/[8-_/;L=,8$%38^0&
MW"U Z '=GYJ.68:&9^S5X^NO&-_XBAMOB?9?$[PY!'"]G=75NMIK-I*V?,CN
MH%1 $Z;6QGJ*E_:!\0^.8OB-\+?"W@CQ OAT^([F^AO[R2U2X$4,<(<R!6ZL
MN#M[;F&<@8K0^&'P?\1Z1\4-8^(OC74]"N/$5[IL>DQ6GABQ>VM(X%?S&>0N
M2\DC-CEN@&!7(?M.:?KFI_&OX$6_AK5[?1-=^W:H]K=W<)GA#+:$E)(P061@
M"IP<C.1TJ]>34GJ8/BSXW^-?V>;[X@^&==UC_A8%Y8Z!;:[X=U*^MH[>=VGN
MOLGD7(B 4A92&!50< @]:V?$VJ_$KX /X+\4>)_B$_C?1]6U:UTK7M*N=-AM
MX[8W)VK+9M& P".0-KDY4]<UKO\ LRWOQ"M?'5_\3M>M=4\1^*M+BT9)- MV
M@MM*M8G\V,0"0EF;S0)&+=2,#C-.A^"/Q%\::IX3MOB5XQT'6O#/AJ]BU&*V
MT739+>XU2XA&(6NV=BJ@=2L8PQ_#"]XH\L\3?&KQG:>/?%.GZW\3S\,_%ECJ
M\D&B>&=>T=8M!OK-7 C9[TH2QD7/S!A@XP*Z7XY?%KQ%X=^+$VD^(/'NI_"7
MP<-+MIM(US2M%6_M-0O'!,XN)W1A&D;  +\N5Y)YKIO'WP0^*GC+1_%'A"3Q
MYH&J^!]?FF_?:_I<MSJVGP2YWQ0N&$9*@X1V (_"M_6OAG\2] U!$\!^+]%F
M\-OI=KICZ!XSLY;N" P1>6LT/E$8+  NK @D4O>MH&AA:/\ $KQ7-XV_9LM;
M[7='U,^)6U7^V+K0"DUE?^3:;XGBD9<J,X8[2.<@Y'%>.?!G1_BEH/[,6K^-
M_#OCX:5;Z'=ZQJ&F^&6TV&6UO88KR9Y5N9&&\N[>8%V%0!MSWKVOP'^S)-X
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M/_X$#_"C[1I?_/A/_P"! _PHYO(+&=16C]HTO_GQG_\  @?X4?:-+_Y\9_\
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M'^%'-Y!8SJ*T?M&E_P#/A/\ ^! _PH^T:7_SXS_^! _PHYO(+&=16C]HTO\
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M1^T:7_SX3_\ @0/\*/M&E_\ /A/_ .! _P *.;R%8SJ*T?M&E_\ /A/_ .!
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M_P#@0/\ "C[1I?\ SX3_ /@0/\*.;R"QG45H_:-+_P"?"?\ \"!_A1]HTO\
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MI2C5E1/@GXPTQ+RX\YKD!XHEQOAQEI!)EE &0>E??[<&H!8VJWGVL6EN+O\
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MJ8<B/*/^$.U?_GQ;_OI?\:/^$.U?_GQ;_OI?\:]7W4;J/K4PY$>4?\(=J_\
MSXM_WTO^-'_"':O_ ,^+?]]+_C7J^ZC=1]:F'(CRC_A#M7_Y\6_[Z7_&C_A#
MM7_Y\6_[Z7_&O5]U&ZCZU,.1'E'_  AVK_\ /BW_ 'TO^-'_  AVK_\ /BW_
M 'TO^->K[J-U'UJ8<B/*/^$.U?\ Y\6_[Z7_ !H_X0[5_P#GQ;_OI?\ &O5]
MU&ZCZU,.1'E'_"':O_SXM_WTO^-7=,\*ZI;M<F2T9-UO(B\@_,1QWKTK=1NI
M/$S:L'(CRA?!VL 8^PM_WTO^-+_PA^L?\^+?]]+_ (UZQ32U"Q4]@Y$>4_\
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MO_SXM_WTO^->K[J-U'UJ8<B/*?\ A#]7_P"?%O\ OI?\:/\ A#]7_P"?%O\
MOI?\:]6W4;J/K50/9H\I_P"$/UC_ )\6_P"^E_QH_P"$/U?_ )\6_P"^E_QK
MU;=1NH^M3#V:/*?^$/UC_GQ;_OI?\:3_ (0[5_\ GQ;_ +Z7_&O5]U&ZCZU4
M#V:/*?\ A#]8_P"?%O\ OI?\:3_A#]7_ .?%O^^E_P :]7W4;J/K4P]FCRG_
M (0_5_\ GQ;_ +Z7_&C_ (0_5_\ GQ;_ +Z7_&O5MU&ZCZU4#V:/*?\ A#]8
M_P"?%O\ OI?\:/\ A#]8_P"?%O\ OI?\:]6W4;J/K50/9H\I_P"$/U?_ )\6
M_P"^E_QI/^$/U?\ Y\6_[Z7_ !KU?=1NH^M3#V:/*?\ A#]8_P"?%O\ OI?\
M:/\ A#]8_P"?%O\ OI?\:]6W4;J/K50.1'E'_"':O_SXM_WTO^-'_"':Q_SX
MM_WTO^->K[J44OK4P]FCS-O"NJ'18X?LC&9;@OMR.FWKUJI_PA^L?\^+?]]+
M_C7K%-W4+%3#D1Y3_P (?K'_ #XM_P!]+_C1_P (?J__ #XM_P!]+_C7JVZC
M=3^M3#V:/*?^$/U?_GQ;_OI?\:/^$/U?_GQ;_OI?\:]6W4;J/K4P]FCRG_A#
M]8_Y\6_[Z7_&C_A#]8_Y\6_[Z7_&O5MU&ZCZU,/9H\I_X0_5_P#GQ;_OI?\
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MA^L?\^+?]]+_ (TG_"'ZO_SXM_WTO^->K[J-U'UJ8<B/*?\ A#]8_P"?%O\
MOI?\:/\ A#]7_P"?%O\ OI?\:]6W4;J/K50/9H\I_P"$/U?_ )\6_P"^E_QH
M_P"$/U?_ )\6_P"^E_QKU;=1NH^M3#V:/*?^$/UC_GQ;_OI?\:/^$/UC_GQ;
M_OI?\:]6W4;J/K50.1'E/_"'ZQ_SXM_WTO\ C1_PA^K_ //BW_?2_P"->K;J
M-U'UJH'LT>4_\(?K'_/BW_?2_P"-'_"'ZO\ \^+?]]+_ (UZMNHW4?6IA[-'
ME/\ PA^K_P#/BW_?2_XTG_"'ZO\ \^+?]]+_ (UZONHW4?6J@>S1Y3_PA^L?
M\^+?]]+_ (T?\(?J_P#SXM_WTO\ C7JVZC=1]:F'(CRG_A#]7_Y\6_[Z7_&C
M_A#]8_Y\6_[Z7_&O5MU&ZCZU,/9H\I_X0_6/^?%O^^E_QH_X0_5_^?%O^^E_
MQKU;=1NH^M3#V:/*?^$/UC_GQ;_OI?\ &C_A#]8_Y\6_[Z7_ !KU;=1NH^M5
M ]FCRG_A#]7_ .?%O^^E_P :/^$/UC_GQ;_OI?\ &O5MU&ZCZU4#V:/*?^$/
MUC_GQ;_OI?\ &C_A#]8_Y\6_[Z7_ !KU;=1NH^M5 Y$>4?\ "':O_P ^+?\
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'445SEG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ino-20231231_g4.jpg
<TEXT>
begin 644 ino-20231231_g4.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" -^!A\# 2(  A$! Q$!_\0
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M#Z44 ;O_  FNK?\ /=?^_8H_X375O^>Z_P#?L5A44 ;O_":ZM_SW7_OV*/\
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MK?\ /=?^_8K"HH W?^$UU;_GNO\ W[%'_":ZM_SW7_OV*PJ* -W_ (375O\
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MU_[]BL*B@#=_X375O^>Z_P#?L4?\)KJW_/=?^_8K"HH W?\ A-=6_P">Z_\
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M*B@#=_X375O^>Z_]^Q1_PFNK?\]U_P"_8K"HH W/^$VU;_GNO_?L5VQOYO\
MA&_M>[]_Y&_=COCTKRRO2V_Y$W_MU_I0!R7_  FNK?\ /=?^_8H_X375O^>Z
M_P#?L5A44 ;O_":ZM_SW7_OV*/\ A-=6_P">Z_\ ?L5A44 ;O_":ZM_SW7_O
MV*/^$UU;_GNO_?L5A44 ;O\ PFNK?\]U_P"_8H_X375O^>Z_]^Q6%10!N_\
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M*.O2@#1_X2+4_P#G]F_[ZH_X2+4_^?V;_OJL_:?0TF#Z4 :/_"1:G_S^S?\
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M<91CWO;U-HS2G)2?;\CR/X7_ !^\>>(M'_:#GU'7?M$OA5YAH[?985^S!6E
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M_%_XB6&E.D%U'I<\FBD#S(3G*N.WREL&NN^)'Q/\-_#?]O+2_%FO7[6N@?\
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M5  Z8SCFO%O$WQ*\=_&;X[>,_!T?Q.MOA/IF@3F&QM9@L<UXPX!W$J6SU/.
M.@-9GPNF\<? ;]K:RN/B-]BL%^("O'<OI[9MFES\C'T(8=/]JM'Q=X^^$OQ#
M^)GBS0OCEX/M_!GB'3)?)M=3A>4/=1#.&:1!R<8(R",'%4J:C4<HJZ:OIK;T
M0N9R@HMV:?4]@^$_B#XOZ'\,_'"?$*.WGN])LII]&\26LL$B7BJC$$JA/((!
MRRC(/.:\5^$7BG]H[XP>!;3Q/8?%OPWIEM<221"WU*WMTF!1MI) @/![<U4_
M9<O;A;7XYZ;X9O=2U'X76NF7)TR;4<\2%'QMXZE>H';!KRCX(:;^SO<?#JQD
M^(FN:S8^*3+*)X+-9_+$>[]V1M0CD>]:*FES::Z=+].Q'.WRZ]^MOQ/T4^"E
MCXTT_P $I'X\\1:?XHUTSR-_:&FJHA,>?E7Y449'TKC?VDOCUJ?PKL?[%\,:
M!>:WXKOK&6[MY4CS;6<2!M\TK?[."0#P:V?V9]0\!7/PO@L_AQ?76H>&["XD
MB66\5Q()"=S [P">OI73_%Y1_P *I\9M@;O[&NQG'/\ J6XKSM%5]Y=?0[=7
M3T?ZG%?LB_$'7OBA\"=&\1>);_\ M+5[F>X62Y\I(MRJY"_*@ ''M7LE?._[
M ?\ R:[X;_Z^+G_T8:^B*FLDJDDNY5)MPBWV"BBBL30**** "BBB@ HHHH *
M*** "DI:2@#T?6O^1+?_ *XI_,5YS7HVM?\ (EO_ -<4_F*\YH **** "BBB
M@ HHHH **** "BBB@ HHHH \"_:R^,WBWX16?@Z+P?%I\NHZYJ)L<:A&73)"
MA>A&.37F_BW]H3XY_ G5= O/B5X?\/W/AO4KM;5Y-*8B12>N,L><<],'&,U<
M_P""@EA)JT7PLL8;N2PFNM>\F.ZB.'A9M@#KR.1G(^E:NF_L-#4/$VDZGXY^
M)/B#QW::;*)HK#478H6&#@EG; R!D#&:]&G[*-.+G;6_34XI>TE-J/D=1%\<
MM?G_ &MHOAPB69\-2:2+X.8CY^XQAOO9QCGTJ/XS?'3Q'X!_: ^&_@S3([)M
M(\0LHO&GB+2C,A7Y"#QQ[5XC\7OAS+\4/VZG\/VVOWWAEWT:.07VFL5E4+']
MT8(X-8'BSX/W'P=_:M^$5A<^+=4\6->74<RSZJY9XL2$;5R3QWJXTJ;:[\NQ
M+J3U]=SZ>_:F^-FN?"31?#MAX1L[?4/%WB#45LK&WNE+)M_B; ([E1U_BSVJ
MU^RM\:[_ .-WP]GO-<MX;/Q+IM[)8ZC;PH456!RI"DDC@XZ]0:^;?BKXR\8?
M$7]L"35/!7AO_A,[7X?_ .C+8^:$B$Q#!G)SU#GM_P \Q4O[._BGQ)\,?VK-
M5T_QAH)\&Q>/D>YBTYY0T7V@$LA5L]SO4>[ 5/L5[&WVK7\_ZL/VK]I?IM_7
MS.PU#XW_ !@^+GQ2\7^&OAQ?>'O#EEX;O&LR-5*_:+IE)4D!@<@E3T'''->B
M?"'XQ?$#6_A_XY/CCPS)H7B?PS%*T5RUJ\=K?;4<ATSPP!3G:<8(]:\-UZU^
M"7Q]\?>+$\6-<?"/QOIMT8IKF34$A%TRD@O\PVDY';!/!JW^S7\0O$&K:+\9
M?"+^(KKQGX/T73+@Z=K=UN+?=<!0QYPP!."?X>*N5.+AI&UK?U?J*,WS:N][
M_P!6Z&C\)?C5^TE\:O"K>(?#=CX0?3EN'MB;E'C;>H!/&[IR*^G?A#)X]E\*
MLWQ%ATR'Q!]H;"Z228?*P-O4GG.:_.3X Z+X,U'P+)+KWQKU3P!??;)%&DV<
MKJA7"XDPIQD\C\*^_OV;9=!7X9Q6?A[QG/X\M+.YDBDU>Y9FD,APQ0D^@85&
M*@HWY5U[/\QX>3E:[_']#F?CW\9O'7ASQYX=\"?#GP];ZGX@U6)KB2^U$,+:
M!!G )! S\K'D]NAS47[.?QT\7>.O&GB[P-X]T>ST[Q/X="/)-IS$PR*V.,9.
M#R".>AZ<4O[5'[3ME\"=.M-*TY;>X\8ZJN+1;GB&U0G;Y\I] >@[X-9?[(=M
MX'M6UZ?3O&MOXY\?ZJ1?:YJ,>[IGA5!'" G'^167*O8\SC\_ZZ&G,_:V4CZ2
MHHHKB.H**** "BBB@ HHHH **** "BBB@!*]+;_D3?\ MU_I7FE>EM_R)O\
MVZ_TH \UHHHH **** "BBB@ HHHH **** "BBB@ KYH_;,^*'CGX?7'@#3_
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MV)V(YVCYF#,N3SD$&NJLE-2A'5Z=M#"E>+C*6B_,YS]H'XN?$+Q1\4/'.O\
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M4 %%%% !1110 4444 %%%% '>6G_ "(+_P#7$_SK@J[VT_Y$%_\ KB?YUP5
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MO[)Q?\OXH?\ K!E_\[^YGN__  KD_P#/_P#^0O\ Z]'_  KD_P#/_P#^0O\
MZ]>'+^UIKC?\P>S_ .^VJ=?VK=;;_F$6G_?;4O[+Q7\OXH/[?P'\[^YGM7_"
MN3_S_P#_ )"_^O1_PKD_\_\ _P"0O_KUXVO[4VM-_P PFT_[[:IU_:>UEO\
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M7_UZ/^%<G_G_ /\ R%_]>OC[_AO#Q[_T"]#_ ._,O_Q='_#>'CW_ *!>A_\
M?F7_ .+KF_M[!=W]QZG_ !#O/OY8_P#@2/L'_A7)_P"?_P#\A?\ UZ/^%<G_
M )__ /R%_P#7KY _X;N\>_\ 0+T/_OS+_P#%T?\ #=WCW_H%Z'_WYE_^+I?V
M_@N[^X7_ !#O/?Y8_P#@2/K_ /X5R?\ G_\ _(7_ ->C_A7)_P"?_P#\A?\
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M -^9/_BZG_63+^[^XG_B'^>?RQ_\"1]7_P#"N3_S_P#_ )"_^O1_PKD_\_\
M_P"0O_KU\IC]MOQP?^8;HW_?F3_XNG+^VQXW;_F':-_WYD_^+J?]9LO[O[A?
MZ@9W_+'_ ,"1]5?\*Y/_ #__ /D+_P"O1_PKD_\ /_\ ^0O_ *]?+"_MJ>-V
M_P"8=HW_ 'YD_P#BZD'[:/C8_P#,/T?_ +]2?_%U/^M&7+J_N(_U"SI?9C_X
M$CZC_P"%<G_G_P#_ "%_]>C_ (5R?^?_ /\ (7_UZ^8%_;-\:G_F'Z/_ -^I
M/_BZD7]LGQH<?Z!I'_?J3_XNH_UKRQ?:?W"_U$SK^6/_ ($CZ;_X5R?^?_\
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ME_W[;_&K$?QMUUAS!9_]\-_C63\2^'UO.7_@+,WPYCUT7WG??\*Y/_/_ /\
MD+_Z]'_"N3_S_P#_ )"_^O7%V_QFU@L#);VK+Z*I!_G7:Z!XZ_X2" M$1',H
M^>)@,C_$5[F3<:9+GM?ZMA*O[SI&2:;]+Z/TW/.Q658K!QYZL=.ZU.CO=)^V
M:*=/\W;E%3S-N>F.<?A7-_\ "N3_ ,__ /Y"_P#KUK_VQ<_WE_[YKA_B)\;;
M?P"@@(6]U-UW);+@!1ZL>U?8UZ]/#0=2K*R1X=6K"C!SJ.R.A_X5R?\ G_\
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M_P#?E_\ XNE7]I_Q;_SZZ7_WY?\ ^+H_U@P7=_<']L87N_N/=/\ A7)_Y_\
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M?C9KY_Y8V7_?MO\ XJM%B(,?]IX?N_N._P#^%<G_ )__ /R%_P#7H_X5R?\
MG_\ _(7_ ->N%7XS:\W_ "RL_P#OVW^-31?&36MV7AM"OH$(_K6BJ18_[2P_
M=_<=I_PKD_\ /_\ ^0O_ *]=-_9?_$E^P>9_RR\KS,>V,XKD_#GQ$_M]?+X@
MN@,F,C@^X/>MW^V+G^\O_?-:GHTZD:L>:#NC(_X5R?\ G_\ _(7_ ->C_A7)
M_P"?_P#\A?\ UZU_[8N?[R_]\T?VQ<_WE_[YH-#(_P"%<G_G_P#_ "%_]>C_
M (5R?^?_ /\ (7_UZU_[8N?[R_\ ?-']L7/]Y?\ OF@#(_X5R?\ G_\ _(7_
M ->C_A7)_P"?_P#\A?\ UZU_[8N?[R_]\T?VQ<_WE_[YH R/^%<G_G__ /(7
M_P!>C_A7)_Y__P#R%_\ 7K7_ +8N?[R_]\T?VQ<_WE_[YH R/^%<G_G_ /\
MR%_]>C_A7)_Y_P#_ ,A?_7K7_MBY_O+_ -\T?VQ<_P!Y?^^: ,C_ (5R?^?_
M /\ (7_UZ/\ A7)_Y_\ _P A?_7K7_MBY_O+_P!\T?VQ<_WE_P"^: ,C_A7)
M_P"?_P#\A?\ UZ/^%<G_ )__ /R%_P#7K7_MBY_O+_WS1_;%S_>7_OF@#(_X
M5R?^?_\ \A?_ %Z/^%<G_G__ /(7_P!>M?\ MBY_O+_WS1_;%S_>7_OF@#(_
MX5R?^?\ _P#(7_UZ/^%<G_G_ /\ R%_]>M?^V+G^\O\ WS1_;%S_ 'E_[YH
MR/\ A7)_Y_\ _P A?_7H_P"%<G_G_P#_ "%_]>M?^V+G^\O_ 'S1_;%S_>7_
M +YH R/^%<G_ )__ /R%_P#7H_X5R?\ G_\ _(7_ ->M?^V+G^\O_?-']L7/
M]Y?^^: ,C_A7)_Y__P#R%_\ 7H_X5R?^?_\ \A?_ %ZU_P"V+G^\O_?-']L7
M/]Y?^^: ,C_A7)_Y_P#_ ,A?_7H_X5R?^?\ _P#(7_UZU_[8N?[R_P#?-']L
M7/\ >7_OF@#(_P"%<G_G_P#_ "%_]>C_ (5R?^?_ /\ (7_UZU_[8N?[R_\
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M_GQT[_OAO_BJ=_PT[XF_Y\M/_P"^&_\ BJ?]NX+N_N#^U\+W?W'O'_"O=/\
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M^27^*_\ L'3?RKRKP;_R-&E_]=UKU7XM?\DO\5_]@Z;^5?(YYL_\+/U'@O\
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MM)@R)=2U"7RH%(ZC."3^ XJSXZ^"?B/X?Z7!JMS]DU31IB NI:7-YT&3TR<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC!VD=,BO0_BG+XG\2^)O >GV5C;7NG7$45[*U["?LQN!D@.P]N=HZU\VZO\
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M_F"7G_@?+_C3O^&#OA /^8+>?^!\O^-? B_M/?%;_H>]8_[_ -3+^TW\5?\
MH>]8_P"_]+^SLQ_Z"/Q8?VME7_0-^$3[W'["/PA'_,%O/_ ^7_&G?\,*_"(?
M\P6\_P# ^3_&O@I?VF?BI_T/6L?]_P"I5_:8^*?_ $/.K_\ ?^C^SLP_Y_\
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MQX^(/_0VZG_W^-2K\=?B ?\ F;-2_P"_QI?V?C_^?_XL/[6RK_H%_")]>_\
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M[[_OZ:CZCCO^?WXLK^U<J_Z!OPB?2R_L[>"5Z6$__@2_^-2+^SYX+7I83?\
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MG\-O^A1T_P#[X/\ C7YP+^U7\6?^AWU#_P <_P *E7]JGXL'_F=M0_\ '?\
M"C_5;RA]W_ #_7ZO_P _:O\ X$__ )(_1O\ X9S^&_\ T*.G_P#?!_QH_P"&
M=?AQ_P!"EI__ 'P?\:_.E/VIOBL?^9UU#_QW_"I5_:D^*I_YG34/_'?\*7^J
MR_EA]W_ #_7VO_S]J_\ @3_^2/T2_P"&=OAQ_P!"EI__ 'P?\:/^&=_AR/\
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M&J\_\=_PJ?\ 5.E_S[I_^ K_ "%_KU4_GJ?^!?\ !/ML?!+P..GARS_[Y/\
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M?[=<?\]F_.C[=<?\]F_.@#8_LFV_N'\S1_9-M_</YFL?[=<?\]F_.C[=<?\
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MX-_Z </_ 'TW^-'_  IKP;_T X?^^F_QK1^W7'_/9OSH^W7'_/9OSH^JT/\
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MS']JCQ9<^"?V??&VJVC-'<K8FWCD0X9#*RQ;@?4;\_A7XYIG'/)K];?VW_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2BM(QE=<JO:[5KOKW.8F_9YUFX\5>)[.PO+&'1M&O/LS:KJ%P(823@JN['+
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MI/B+_D6]5_Z\Y?\ T U^6S_ZR3_?;^=?@_$GQ4OG^A_=GA=_"Q?K#_VX<O\
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M(M/KZ?T_X/W?Q&_99\*+X<TFSEUTWSRS7+;(I&B#S @N>3U7C/:H/'7PEN_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z*P_X\X?I7.UT5A_QY
MP_2@"QG'7BDW+ZC\ZJ:M_P >3?45@YH Z;RX?[J?D*/+A_NQ_D*YG-&: .F\
MN'^['^0H\N'^['^0KF<T9H Z;RX?[J?D*/+A_NI^0KF<T9H Z;RX?[J?D*/+
MA_NI^0KF<T9H Z;RX?[J?D*/+A_NI^0KF<T9H Z;RX?[J?D*:]O;R8WQQ-_O
M*#7-YHS0!T7V*S_YX0?]\+1]BL_^>$'_ 'PM<[FC- '1?8[3_GA#_P!\"C['
M:?\ /"'_ +X%<[FC- '1?8[3_GA#_P!\"C[%:?\ /"'_ +X%<[FC- '1?8K3
M_GA#_P!\"C[%:?\ /"'_ +X%<[FC- '1?8K3_GA#_P!\"C[':?\ /"'_ +Y%
M<[FC- '1?8[3_GA#_P!\BC[':?\ /"'_ +Y%<[FC- '1?8[3_GA#_P!\BC['
M:?\ /"'_ +Y%<[FC- '1?8[3_GA#_P!\BC[':?\ /&'_ +Y%<[FC- '1?8[3
M_GC#_P!\BC[':?\ /&'_ +Y%<[FC- '1?8[3_GC#_P!\BE^R6O\ SQA_[Y%<
MYFC- '1_9+7_ )XP_P#?(H^R6O\ SQA_[Y%<YFC- '1_9+7_ )XP_P#?(H^R
MVW_/*(?\!%<YFC- '1_9;;_GG'^0H^RVW_/./\A7.9H+!02S!5 R6)P /4T
M=)]EM_\ GG&?P%5)-&TB1RSV-DS'J6B3/\J_.3]IK]LS7-=\0:AX9\#:@^E:
M%:LUO+J5JV)[M@<,4?JB9X&.3ZU\T-XR\032,\FNZD[L<EFNW)/ZU]-A\CK5
M8*<Y<M^A\?BN(Z%&HZ=.'/;K>R^6Y^V']AZ-_P ^%C_WY3_"E_L/1O\ GPL?
M^_*?X5^**>+=<_Z#6H?^!3_XU,OBS7/^@SJ'_@4_^-=7^K\_^?OX?\$X_P#6
MB'_/G\?^ ?M1_8>C_P#/A8_]^4_PH_L/1_\ GPL?^_*?X5^+J^*];_Z#.H?^
M!+_XU,OBK6_^@SJ'_@2_^-+^P)_\_?P_X(?ZT0_Y\_C_ , _9S^Q-'_Y\++_
M +\I_A2_V+I'_/C9?]^4_P *_&=?%6M_]!B__P# E_\ &IE\5:W_ -!B_P#_
M  )?_&C^P)_\_?P_X(?ZT0_Y\_C_ , _9+^Q=(_Y\;+_ +\I_A1_8ND?\^-E
M_P!^D_PK\<X_%6M?]!>^_P# E_\ &IU\4:U_T%[[_P "7_QI?V!/_G[^'_!#
M_6B'_/G\?^ ?L+_8ND?\^-E_WZ3_  H_L72/^?&S_P"_2?X5^/Z^*-9_Z"]]
M_P"!+_XU.OB?6?\ H+7W_@0_^-']@S_Y^_A_P0_UHA_SY_'_ (!^O/\ 8ND?
M\^-G_P!^D_PH_L72/^?&S_[])_A7Y%IXFUC_ *"U]_X$/_C4R^)M8_Z"U]_X
M$/\ XT?V#/\ Y^_A_P $/]:(?\^?Q_X!^MW]BZ1_SXV?_?I/\*/['TG_ )\K
M/_OTO^%?DPOB76./^)K>_P#@0_\ C4J^)-7_ .@K>_\ @0_^-']@S_Y^_A_P
M1?ZT0_Y\_C_P#]8_['TG_GRL_P#OTO\ A1_8^D_\^5G_ -^E_P *_*)?$FK_
M /05O?\ P(;_ !J5?$FK_P#04O/^_P"W^-+^PI_\_?P_X(?ZT0_Y\_C_ , _
M5C^Q]*_Y\K/_ +]+_A1_8^E?\^5I_P!^E_PK\K5\1ZM_T%+S_O\ M_C4J^(M
M6_Z"EY_W_;_&E_84_P#G[^'_  0_UHA_SY_'_@'ZF_V/I7_/E:?]^E_PI?['
MTK_GRM/^_2_X5^6Z^(M5_P"@G>?]_P!O\:F7Q#JO_03O/^_[?XT?V%/_ )^_
MA_P0_P!:(?\ /G\?^ ?J%_8^E_\ /G:?]^U_PH_LC2_^?.T_[]K_ (5^8:^(
M-4_Z"5Y_W_;_ !J9?$&J?]!*[_[_ +?XTO[#E_S]_#_@A_K1#_GS^/\ P#]-
MO[)TO_GSM/\ OVO^%']DZ7_SYVO_ '[7_"OS/37M4_Z"5W_W_;_&IDU[4_\
MH)7?_?\ ;_&C^PY_\_/P_P""'^M$/^?/X_\  /TK_LG3/^?2U_[]K1_96F?\
M^EK_ -^UK\WH]<U+_H(W?_?YO\:M1:YJ7_00NO\ O\W^-+^Q)?\ /S\/^"/_
M %HA_P ^?Q_X!^B_]EZ9_P ^EK_W[6E_LO3?^?2U_P"_:U^>4>M:CG_D(77_
M '^;_&K<>LZA_P _]U_W^;_&I_L67_/S\/\ @A_K/#_GS^/_  #] O[+T[_G
MUMO^_:T?V9IW_/K;?]^UKX(BUC4/^?ZY_P"_K?XU:CU>_P#^?ZY_[^M_C4_V
M-+_GY^'_  2O]9H?\^?Q_P" ?=W]FZ?_ ,^MM_WPM']FZ?\ \^UO_P!\+7P[
M'JU]_P _MQ_W];_&K<6J7O\ S^7'_?UO\:G^QY?\_/P_X(_]9H?\^?Q_X!]K
M_P!FZ?\ \^UO_P!\+2_V=8?\^UO_ -\+7QE#JE[_ ,_<_P#W\/\ C5N/4KSC
M_2Y_^_A_QJ/[)E_/^'_!'_K+#_GS^/\ P#[$6QLE.5@A4^RBG?9;;_GG'^0K
MY'M=8OX)%>.]N$<'@K(?\:]6^'OC^76)AIVHMNN2,Q38QOQV/O7)B,NJ48\Z
M=TCTL%GE'%5%2E'E;V['L7V6V_YYQ_D*7[+;]HX_R%<WS7R=^T=^TUJ>GZY=
M^%O"5R;);8F*\U!/]8S]TC/\./7KFOF\9C*6"I^TJ_\ #GZ-DF28O/L5]5PJ
MUW;>R7=GV;-IVF2-F6VM6;_;12:C_LK1_P#GTLO^_:5^3EQXGUFZE,D^K7TT
MC<EY+AR3^.::NO:G_P!!&[_[_M_C7R[XDA_SY_'_ (!^M+POK6UQG_DK_P#D
MC]9?[+T?_GTLO^_:4?V7H_\ SZ67_?M*_)K^WM3_ .@C=_\ ?]O\:<VO:G_T
M$;O_ +_M_C2_UDA_SY_'_@!_Q"^K_P!!O_DC_P#DC]8_[+T?_GTLO^_:4?V7
MH_\ SZ67_?M*_)W^WM3_ .@C=_\ ?]O\:=_;NI_]!&[_ ._[?XTO]9(?\^?Q
M_P" +_B%]7_H,_\ )'_\D?K!_9>C_P#/I9?]^TH_LO2/^?2R_P"_:5^47]N:
ME_T$;O\ [_M_C3O[<U+_ *"-W_W_ &_QJ?\ 6:'_ #Y_'_@"_P"(85?^@S_R
M3_[8_5S^R](_Y]++_OVG^%']EZ1_SZ67_?M/\*_*5=<U+_H(W7_?YO\ &GC7
M-2_Z"%U_W^;_ !J?]9X?\^?Q_P" 3_Q#&K_T&?\ DG_VQ^J_]EZ3_P ^EG_W
M[3_"C^R])_Y]+/\ []I_A7Y6)KFI?]!"Z_[_ #?XU(NN:E_T$+K_ +_-_C4/
MBF"_Y<?C_P  G_B&53_H,_\ )/\ [8_4_P#LO2?^?2S_ ._:?X4?V7I/_/I9
M_P#?M/\ "ORT76]1_P"@A=?]_F_QJ1=<U+C_ (F%U_W^;_&H?%</^?'X_P#
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M1]EMO^><?Y"N<S1F@#H_LMM_SSC_ "%'V6V_YYQ_D*YS-&: .C^RVW_/./\
M(4?9;;_GG'^0KG,T9H Z/[+;?\\X_P A1]EMO^><?Y"N<S1F@#H_LMM_SSC_
M "%'V6V_YYQ_D*YS-&: .C^RVW_/./\ (4?9;;_GG'^0KG,T9H Z/[+;?\\X
M_P A1]EMO^><?Y"N<S1F@#H_LMM_SSC_ "%'V6V_YYQ_D*YS-&: .C^RVW_/
M./\ (4?9;;_GG'^0KG,T9H Z/[+;?\\X_P A1]EMO^><?Y"N<S1F@#H_LMM_
MSSC_ "%'V6V_YYQ_D*YS-&: .C^RVW_/./\ (4?9;;_GG'^0KG,T9H Z/[+;
M?\\X_P A1]EMO^><?Y"N<S1F@#H_LMM_SSC_ "%'V6V_YYQ_D*YS-&: .C^R
MVW_/./\ (4?9;;_GG'^0KG,T9H Z/[+;?\\X_P A1]EMO^><?Y"N<S1F@#H_
MLMM_SSC_ "%'V6V_YYQ_D*YS-&: .C^RVW_/./\ (4?9;;_GG'^0KG,T9H Z
M/[+;?\\X_P A1]EMO^><?Y"N<S1F@#H_LMM_SSC_ "%'V6V_YYQ_D*YS-&:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1_\ D)6?_79/_0A65%VK5T?_ )"5G_UV3_T(5C/X6:T_CCZH][\1?\BWJO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<1\<O^2,^-O^P3/_Z#7;UQ'QR_Y(SXV_[!,_\
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MTG#,=KAEPZX/.W(-.^)_Q7\/ZS\/;C19-<_X3?6Y9D>#4VTP6AM4# D'@$G
M(XZYKYX3[M3Q]ZYZF=XB4:L6E^\O??KH]+V]+IVZ6,X\.82G.C)2E^ZM;;H[
MK7EOZI-)];GT1XU^+WA:Y\1^"O&>DW5Q=:SIJ1VUUI;Q% D(#;SN(P6RV!@F
MK=CXV^%_AOQ==^/M.O\ 4[S6[@RS1Z0\141RR [B6QC')[G&:^<UJ=.E82S[
M$<[J.$6[J2T>DDK<RUWTZW7D<SX<PL::I1J32LXO5:Q;ORO3;5[6?F>P:]\0
MM+USX*0Z2]VO]O2:P]]-:K&P"JS.20V,=QWS70^(OB1X=U'XF^ M6M]1\S3]
M+M88[N;RG'E,I.1@C)_#->#)4\=>;+.L3U2^QW^P[KKUZ_A8<LCPRO9O>;Z?
M\O%9].G3\;GT#H/CWP/)KWC.XO+K['=W]X9K+5_L0G(C_NJK*=I//4=_:LCX
MQ>/-$\:>'O#<>F:A-=7%EYB31W$6R3!QAC@!><=!TS7CT?>K,?05SXC/L36P
MT\*X149;V3O\7-WM>_6U[;W.2GD>'HXF&)C*3<=KM6^'E[7VZ7M?8LQ]!5F.
MJT?059CKXR9[$BW%VJS'VJM%VJS'VK@J''(M1]JN153C[5<BKSJAQS+<?:K<
M=5(^U6XZ\V9PS+D/2KL-4H>E78:\VH<4R]:_ZQ/K7MEO_J(_]T?RKQ.U_P!8
MGUKVRW_U$?\ NC^5?T%X._'CO^X?_MY^>\2_\NOG^A)1117]*GPX4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M &T4[RV_NG\J/+;^Z?RH ;13O+;^Z?RH\MO[I_*@!M%.\MO[I_*CRV_NG\J
M&URWQ5TF;7OACXKTZW7=/<Z;.B+ZG83_ $KJ_+;^Z?RH"NI!"G/TJHR<9*2Z
M$3BIQ<7U/Q%C1H_D<;77Y64]B.HJ=:^U_P!I;]B'5M6\17GBCX?01W O7::[
MT9F$;)(>2T1/!!/)!QS7S'/\!OB3:7#Q2> O$1=3@F/3977\"%P:_4</CJ&(
M@IQDEY=C\;Q66XG"U'"4&_-+1G%)4R5UZ_!#XC?]"#XE_P#!5/\ _$U,OP1^
M(O\ T(7B7_P53?\ Q-=/MJ7\R^]'']7K?R/[F<BM3+VKKE^"?Q$_Z$/Q)_X*
MIO\ XFI5^"OQ#_Z$3Q)_X*YO_B:7MJ7\R^]!]7K?R/[F<BO:IE[5UJ_!7XA?
M]"+XC_\ !7-_\34J_!?X@_\ 0C>(O_!7-_\ $TO;4OYE]X?5ZW\C^YG)QU.O
M:NKC^#'Q _Z$?Q%_X+)O_B:F7X,^/^/^*(\0_P#@LF_^)H]M2_F7WA]7K?R/
M[F<HM3I74K\&_'W_ $)/B'_P63?_ !-3+\'?'O\ T)/B#_P6S?\ Q-+VU/\
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MF#S'!?\ /^'_ ($O\SD*=77?\*;\>?\ 0G:W_P" ,G^%._X4[X[_ .A.UO\
M\ 9/\*AX>M_(_N8O[2P7_/\ A_X$O\SDJ?76#X.^._\ H3M:_P# &3_"G_\
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M^:YYCJ>*JQA2=U'KZC:*=Y;?W3^5'EM_=/Y5^S'S VBG>6W]T_E1Y;?W3^5
M#:*=Y;?W3^5'EM_=/Y4 -HIWEM_=/Y4>6W]T_E0 VBG>6W]T_E1Y;?W3^5 #
M:*=Y;?W3^5'EM_=/Y4 -HIWEM_=/Y4>6W]T_E0 VBG>6W]T_E1Y;?W3^5 #:
M*=Y;?W3^5'EM_=/Y4 -HIWEM_=/Y4>6W]T_E0 VBG>6W]T_E1Y;?W3^5 #:*
M=Y;?W3^5'EM_=/Y4 -HIWEM_=/Y4>6W]T_E0 VBG>6W]T_E1Y;?W3^5 #:*=
MY;?W3^5'EM_=/Y4 -HIWEM_=/Y4>6W]T_E0 VBG>6W]T_E1Y;?W3^5 #:*=Y
M;?W3^5'EM_=/Y4 -HIWEM_=/Y4>6W]T_E0 VBG>6W]T_E1Y;?W3^5 #:*=Y;
M?W3^5'EM_=/Y4 -HIWEM_=/Y4>6W]T_E0 VBG>6W]T_E1Y;?W3^5 #:*=Y;?
MW3^5'EM_=/Y4 -HIWEM_=/Y4>6W]T_E0 VBG>6W]T_E1Y;?W3^5 #:*=Y;?W
M3^5'EM_=/Y4 -HIWEM_=/Y4>6W]T_E0 VBG>6W]T_E1Y;?W3^5 #:*=Y;?W3
M^5'EM_=/Y4 -HIWEM_=/Y4>6W]T_E0 VBG>6W]T_E1Y;?W3^5 #:*=Y;?W3^
M5'EM_=/Y4 -HIWEM_=/Y4>6W]T_E0 VBG>6W]T_E1Y;?W3^5 #:*=Y;?W3^5
M'EM_=/Y4 -HIWEM_=/Y4>6W]T_E0 VBG>6W]T_E1Y;?W3^5 #:Z*P_X\X?I7
M/^6W]T_E706/%G#GCB@":21(UW.0J^IJ+[9;_P#/5*BU?_CR;ZBL&@#H_MEO
M_P ]4H^V6_\ SU2N<HH Z/[9;_\ /5*/MEO_ ,]4KG** .C^V6__ #U2C[9;
M_P#/5*YRB@#H_MEO_P ]4H^V6_\ SU2N<HH Z/[9;_\ /5*/MEO_ ,]4KG**
M .C^V6__ #U2C[9;_P#/5*YRB@#H_MEO_P ]4H^V6_\ SU2N<HH Z/[9;_\
M/5*/MEO_ ,]4KG** .C^V6__ #U2C[9;_P#/5*YRB@#H_MEO_P ]4H^V6_\
MSU2N<HH Z/[9;_\ /5*/MEO_ ,]4KG** .C^V6__ #U2C[9;_P#/5*YRB@#H
M_MEO_P ]4H^V6_\ SU2N<HH Z/[9;_\ /5*/MEO_ ,]4KG** .C^V6__ #U2
MC[9;_P#/5*YRB@#H_MEO_P ]4H^V6_\ SU2N<HH Z/[9;_\ /5*/MEO_ ,]4
MKG** .C^V6__ #U2C[9;_P#/5*YRB@#H_MEO_P ]4H^V6_\ SU2N<J.XN(K2
MWEGG<1P0HTDCGHJ@9)_(4 =+)J-I#&SO/'&BC+,S  #W-<7/\??AM;3/%+XZ
MT!9$.UE_M"/@CMUK\S?VE/VF-:^,WB:[L[&[FL?"-K(T=K9Q,4\\ X\R3'WB
M>P/05XDJC/2OKL/D+G!2K3LWT1\-BN)E3J.&'A=+J^I^SG_#0GPS_P"A[T#_
M ,#X_P#&E_X:"^&G_0]:#_X'Q_XU^-"*/05,BCT'Y5U?ZOTOYW^!Q?ZT5O\
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MQK\GD4>@J95'H*7]@TOYV'^M%?\ Y]K[V?JY_P +O^'_ /T.6B_^!B?XTO\
MPN[P!_T..C?^!B?XU^5*J..!4RJ/04?V#2_G8?ZT5_\ GVOO9^J/_"Z_ /\
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M-T\4:7_X%)_C3O\ A:W@W_H9]+_\"D_QK\ZXE'H*MPJ/2I_L.E_.Q_ZT5_\
MGVOQ/T*_X6IX//3Q+IG_ ($K_C3O^%H>$3T\2:;_ .!*_P"-?G_&HSTJY&!Z
M5/\ 8M/^=C_UHK_\^U^)][?\+-\)GIXBTT_]O"_XTO\ PLKPJ?\ F8=._P#
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M_P ]5_.C[;;_ //5?SKG** .C^VV_P#SU7\Z/MMO_P ]5_.N<HH Z/[;;_\
M/5?SH^VV_P#SU7\ZYRB@#H_MMO\ \]5_.C[;;_\ /5?SKG** .C^VV__ #U7
M\Z/MMO\ \]5_.N<HH Z/[;;_ //5?SH^VV__ #U7\ZYRB@#H_MMO_P ]5_.C
M[;;_ //5?SKG** .C^VV_P#SU7\Z/MMO_P ]5_.N<HH Z/[;;_\ /5?SH^VV
M_P#SU7\ZYRB@#H_MMO\ \]5_.C[;;_\ /5?SKG** .C^VV__ #U7\Z/MMO\
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M ,]4KG** .C^V6__ #U2C[9;_P#/5*YRB@#H_MEO_P ]4H^V6_\ SU2N<HH
MZ/[9;_\ /5*/MEO_ ,]4KG** .C^V6__ #U2C[9;_P#/5*YRB@#H_MEO_P ]
M4H^V6_\ SU2N<HH Z/[9;_\ /5*/MEO_ ,]4KG** .C^V6__ #U2C[9;_P#/
M5*YRB@#H_MEO_P ]4H^V6_\ SU2N<HH Z/[9;_\ /5*/MEO_ ,]4KG** .C^
MV6__ #U2C[9;_P#/5*YRB@#H_MEO_P ]4H^V6_\ SU2N<HH Z/[9;_\ /5*/
MMEO_ ,]4KG** .C^V6__ #U2C[9;_P#/5*YRB@#H_MEO_P ]4H^V6_\ SU2N
M<HH Z/[9;_\ /5*/MEO_ ,]4KG** .C^V6__ #U2C[9;_P#/5*YRB@#H_MEO
M_P ]4H^V6_\ SU2N<HH Z/[9;_\ /5*/MEO_ ,]4KG** .C^V6__ #U2C[9;
M_P#/5*YRB@#H_MEO_P ]4H^V6_\ SU2N<HH Z/[9;_\ /5*/MEO_ ,]4KG**
M .C^V6__ #U2IE97564Y4]"*Y:NBL/\ CSA^E $>K_\ 'DWU%8-;VK_\>3?4
M5@T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %<9\:+B2T^$/C.:)MLB:
M5.58=OEKLZXCXY?\D9\;?]@F?_T&MJ/\6'JOS,,1_!GZ/\C\?(/]6OTJRM5X
M?]6OTJPM?KI^%DR5,E0I4R4@)UJ9>U0K4R]J0$J]JF7M4*]JF7M2 FCJ=>U0
M1U.O:D!,M3I4"U.E("9*F6H4J9>E("=>U3+4"L..:G4]* )5J9:A3D@ 9/H*
MF7T/!J229:F6H5J52* )TJ=:@6IEI 3I4RU!&:F4CUJ0+"5,E0I4R4 6HZMP
MU4CJW#4#1;CZU<CJG'UJY'6;*+<-6XZJ0U;CK,M%R.KD-4XZN0UFRBW#5R+[
MHJG#5R+[HK-EHMQ=JUM$D:/5;)U.&69"/^^A63%VK5T?_D)6?_79/_0A6,_A
M9K3^./JCZ,]Z*!T'THKX _;0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KHK#_CSA^E<[716'_'G#]* (]7_X\F^H
MK!K>U?\ X\F^HK!H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %=%8?\></TKG:Z*P_X\X?I0!'J_\
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M,'0?2B@=!]**^ /VT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ>(BDGU1] ?VU!Z-^5']M0>C?E6)17SY]L;?]M0>C?E1_;4'HWY5B44 ;?\
M;4'HWY4?VU!Z-^58E% &W_;4'HWY4?VU!Z-^58E% &W_ &U!Z-^5']M0>C?E
M6)10!M_VU!Z-^5']M0>C?E6)10!M_P!M0>C?E1_;4'HWY5B44 ;?]M0>C?E1
M_;4'HWY5B44 ;?\ ;4'HWY4?VU!Z-^58E% &W_;4'HWY4?VU!Z-^58E% &W_
M &U!Z-^5']M0>C?E6)10!M_VU!Z-^5']M0>C?E6)10!M_P!M0>C?E1_;4'HW
MY5B44 ;?]M0>C?E1_;4'HWY5B44 ;?\ ;4'HWY4?VU!Z-^58E% &W_;4'HWY
M4?VU!Z-^58E% &W_ &U!Z-^5']M0>C?E6)10!M_VU!Z-^5']M0>C?E6)10!M
M_P!M0>C?E1_;4'HWY5B44 ;?]M0>C?E1_;4'HWY5B44 ;?\ ;4'HWY4?VU!Z
M-^58E% &W_;4'HWY4?VU!Z-^58E% &W_ &U!Z-^5']M0>C?E6)10!M_VU!Z-
M^5']M0>C?E6)10!M_P!M0>C?E1_;4'HWY5B44 ;?]M0>C?E1_;4'HWY5B44
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M58E% &W_ &U!Z-^57(I1-&CKT;D9KF*Z*P_X\X?I0!'J_P#QY-]16#6]J_\
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M*!T'THKX _;0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NBL/^
M/.'Z5SM=%8?\></TH CU?_CR;ZBL&M[5_P#CR;ZBL&@ HHHH **** "BBB@
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MUN&MI6-Q&FV1>H^8C/UKZ$\$>.%\:?M>7,=J5&E:1IUQIUG&A^4*@ )'U/\
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M -=D_P#0A6,_A9K3^./JCZ,'0?2B@=!]**^ /VT**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT/[%F_O)^9H_L6;^\GYF@#/KHK#_ (\X?I6;_8LW]Y/S-:MM$8;>-&Y*C'%
M$U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5T8,C#(93D$>M1F[@%P+<S1B<C(BW#=CUQUKC/@22?@C\/B3D_\ "/:?R?\
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M^+&21]&'84F@^&_&_B[_ ()PZ/9>"1=W5X;N1KZTLB3<7-J)GWHF.2>A('4
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M^;(P'+-M^7/TXKFJ4HPA&2DG?\#KI5I5)RC*#5NKZFA1117.=04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I#VI:0]J ,OQ+JDVD:6]Q %,@8#YQD<UR'_"?:E_<M_^
M^3_C72>.?^0!)_OK_.O-Z .D_P"$^U+^Y;_]\G_&C_A/M2_N6_\ WR?\:YNB
M@#I/^$^U+^Y;_P#?)_QH_P"$^U+^Y;_]\G_&N;HH Z3_ (3[4O[EO_WR?\:/
M^$^U+^Y;_P#?)_QKFZ* .D_X3[4O[EO_ -\G_&C_ (3[4O[EO_WR?\:YNB@#
MI/\ A/M2_N6__?)_QH_X3[4O[EO_ -\G_&N;HH Z3_A/M2_N6_\ WR?\:/\
MA/M2_N6__?)_QKFZ* .D_P"$^U+^Y;_]\G_&C_A/M2_N6_\ WR?\:YNB@#I/
M^$^U+^Y;_P#?)_QH_P"$^U+^Y;_]\G_&N;HH Z3_ (3[4O[EO_WR?\:/^$^U
M+^Y;_P#?)_QKFZ* .D_X3[4O[EO_ -\G_&C_ (3[4O[EO_WR?\:YNB@#I/\
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MU_W(_P"E &!_PGVI?W+?_OD_XT?\)]J7]RW_ .^3_C7-T4 =)_PGVI?W+?\
M[Y/^-'_"?:E_<M_^^3_C7-T4 =)_PGVI?W+?_OD_XT?\)]J7]RW_ .^3_C7-
MT4 =)_PGVI?W+?\ [Y/^-'_"?:E_<M_^^3_C7-T4 =)_PGVI?W+?_OD_XT?\
M)]J7]RW_ .^3_C7-T4 =)_PGVI?W+?\ [Y/^-'_"?:E_<M_^^3_C7-T4 =)_
MPGVI?W+?_OD_XT?\)]J7]RW_ .^3_C7-T4 =)_PGVI?W+?\ [Y/^-'_"?:E_
M<M_^^3_C7-T4 =)_PGVI?W+?_OD_XT?\)]J7]RW_ .^3_C7-T4 =)_PGVI?W
M+?\ [Y/^-'_"?:E_<M_^^3_C7-T4 =)_PGVI?W+?_OD_XT?\)]J7]RW_ .^3
M_C7-T4 =)_PGVI?W+?\ [Y/^-'_"?:E_<M_^^3_C7-T4 =)_PGVI?W+?_OD_
MXT?\)]J7]RW_ .^3_C7-T4 =)_PGVI?W+?\ [Y/^-'_"?:E_<M_^^3_C7-T4
M =)_PGVI?W+?_OD_XT?\)]J7]RW_ .^3_C7-T4 =)_PGVI?W+?\ [Y/^-'_"
M?:E_<M_^^3_C7-T4 =)_PGVI?W+?_OD_XT?\)]J7]RW_ .^3_C7-T4 =)_PG
MVI?W+?\ [Y/^-'_"?:E_<M_^^3_C7-T4 =)_PGVI?W+?_OD_XT?\)]J7]RW_
M .^3_C7-TE 'J>H:I-:^'6OD"F81J^".,DC_ !KD?^$^U+^Y;_\ ?)_QKHM:
M_P"1+?\ ZXI_,5YS0!TG_"?:E_<M_P#OD_XT?\)]J7]RW_[Y/^-<W10!TG_"
M?:E_<M_^^3_C1_PGVI?W+?\ [Y/^-<W10!TG_"?:E_<M_P#OD_XT?\)]J7]R
MW_[Y/^-<W10!TG_"?:E_<M_^^3_C1_PGVI?W+?\ [Y/^-<W10!TG_"?:E_<M
M_P#OD_XT?\)]J7]RW_[Y/^-<W10!TG_"?:E_<M_^^3_C1_PGVI?W+?\ [Y/^
M-<W10!TG_"?:E_<M_P#OD_XT?\)]J7]RW_[Y/^-<W10!TG_"?:E_<M_^^3_C
M1_PGVI?W+?\ [Y/^-<W10!TG_"?:E_<M_P#OD_XT?\)]J7]RW_[Y/^-<W10!
MTG_"?:E_<M_^^3_C1_PGVI?W+?\ [Y/^-<W10!TG_"?:E_<M_P#OD_XT?\)]
MJ7]RW_[Y/^-<W10!TG_"?:E_<M_^^3_C1_PGVI?W+?\ [Y/^-<W10!TG_"?:
ME_<M_P#OD_XT?\)]J7]RW_[Y/^-<W10!TG_"?:E_<M_^^3_C1_PGVI?W+?\
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M\:YNB@#I/^$^U+^Y;_\ ?)_QH_X3[4O[EO\ ]\G_ !KFZ* .D_X3[4O[EO\
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M* .F_P"%@ZC_ ,\;?_OEO\:/^%@ZC_SQM_\ OEO\:YFB@#IO^%@ZC_SQM_\
MOEO\:/\ A8.H_P#/&W_[Y;_&N9HH Z;_ (6#J/\ SQM_^^6_QH_X6#J/_/&W
M_P"^6_QKF:* .F_X6#J/_/&W_P"^6_QH_P"%@ZC_ ,\;?_OEO\:YFB@#IO\
MA8.H_P#/&W_[Y;_&C_A8.H_\\;?_ +Y;_&N9HH Z;_A8.H_\\;?_ +Y;_&C_
M (6#J/\ SQM_^^6_QKF:* .F_P"%@ZC_ ,\;?_OEO\:/^%@ZC_SQM_\ OEO\
M:YFB@#IO^%@ZC_SQM_\ OEO\:/\ A8.H_P#/&W_[Y;_&N9HH Z;_ (6#J/\
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M:1XETC5;PJ7%O97L<LFT=3M4DX%=#7G--;G;>^P4444AA1110 4444 %%%%
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MQM0D$Y;@9^E9\L/9<S6OYE\TO:63T/?J***Y#H"BBB@ HHHH **** "BBB@
MHHHH 2O2V_Y$W_MU_I7FE>EM_P B;_VZ_P!* /-:*** "BBB@ HHHH ****
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M]%3[2:O9[E<L=-#@_B;\#O!?QBFT^7Q;HRZM)IZNEL6E=-@<@L/E(SDJ/RK
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M'\C71?VU/_=3\J/[:G_NI^5 '._\*\N_^?J'\C1_PKR[_P"?J'\C71?VU/\
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MGY4 <[_PKR[_ .?J'\C1_P *\N_^?J'\C71?VU/_ '4_*C^VI_[J?E0!SO\
MPKR[_P"?J'\C1_PKR[_Y^H?R-=%_;4_]U/RH_MJ?^ZGY4 <[_P *\N_^?J'\
MC1_PKR[_ .?J'\C71?VU/_=3\J/[:G_NI^5 '._\*\N_^?J'\C1_PKR[_P"?
MJ'\C71?VU/\ W4_*C^VI_P"ZGY4 <[_PKR[_ .?J'\C1_P *\N_^?J'\C71?
MVU/_ '4_*C^VI_[J?E0!SO\ PKR[_P"?J'\C1_PKR[_Y^H?R-=%_;4_]U/RH
M_MJ?^ZGY4 <[_P *\N_^?J'\C1_PKR[_ .?J'\C71?VU/_=3\J/[:G_NI^5
M'._\*\N_^?J'\C1_PKR[_P"?J'\C71?VU/\ W4_*C^VI_P"ZGY4 <[_PKR[_
M .?J'\C73ZMH\FH:&+%75'VJ-QZ<5%_;4_\ =3\J/[:G_NI^5 '._P#"O+O_
M )^H?R-'_"O+O_GZA_(UT7]M3_W4_*C^VI_[J?E0!SO_  KR[_Y^H?R-'_"O
M+O\ Y^H?R-=%_;4_]U/RH_MJ?^ZGY4 <[_PKR[_Y^H?R-'_"O+O_ )^H?R-=
M%_;4_P#=3\J/[:G_ +J?E0!SO_"O+O\ Y^H?R-'_  KR[_Y^H?R-=%_;4_\
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MZGY4 <[_ ,*\N_\ GZA_(T?\*\N_^?J'\C71?VU/_=3\J/[:G_NI^5 '._\
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MS1Q[O]7"HS)(?0#^M>8W7[6422D6^@O+'V:28*?RP:\[$9CA<++EK32?;?\
M(XZV,H8=\M25F>D?\*\N_P#GZA_(T?\ "O+O_GZA_(UYE_PUHW_0N_\ DS_]
MC1_PUHW_ $+O_DS_ /8UQ_VYE_\ S]_!_P"1S?VI@_Y_P?\ D>F_\*\N_P#G
MZA_(T?\ "O+O_GZA_(UYE_PUH_\ T+G_ ),__8T?\-:/_P!"Y_Y,_P#V-/\
MMS+_ /G[^#_R#^U,'_/^#_R/3?\ A7EW_P _4/Y&C_A7EW_S]0_D:\S_ .&L
MG_Z%T?\ @3_]C1_PUD__ $+H_P# G_[&C^V\O_Y^?@_\A_VIA/Y_P?\ D>F?
M\*\N_P#GZA_(T?\ "O+O_GZA_(UYI_PUB_\ T+O_ ),__8T?\-8/_P!"Z/\
MP)_^QH_MO+_^?GX/_(7]J8/^?\'_ )'I?_"O+O\ Y^H?R-'_  KR[_Y^H?R-
M>:?\-8/_ -"[_P"3/_V-+_PU@_\ T+O_ ),__8T_[:P'_/S\'_D']J83^?\
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M_(/[3PG\_P"#_P CT+_A7EW_ ,_4/Y&C_A7EW_S]0_D:\_\ ^&HF_P"@ /\
MP(_^QIP_:@<_\P#_ ,F/_L:K^U<'_/\ @_\ (/[3PG\_X/\ R.^_X5Y=_P#/
MU#^1H_X5Y=_\_4/Y&N"_X:>?_H C_P "/_L:=_PTX_\ T A_X$?_ %J?]J83
M^?\ !_Y#_M+"?S_@_P#([O\ X5Y=_P#/U#^1H_X5Y=_\_4/Y&N%'[33G_F!#
M_P "/_K4X?M+.?\ F!C_ +__ /UJK^TL+_/^#_R#^TL)_/\ @_\ ([C_ (5Y
M=_\ /U#^1H_X5Y=_\_4/Y&N)'[2CG_F!C_O_ /\ UJ?_ ,-(/_T!!_W_ /\
MZU7_ &AAOY_P?^0?VEA?Y_P?^1V?_"O+O_GZA_(T?\*\N_\ GZA_(UQP_:-<
M_P#,%'_?_P#^M3U_:*=O^8,/^_W_ -:J6.P[^U^#'_:6%_G_  ?^1UW_  KR
M[_Y^H?R-'_"O+O\ Y^H?R-<F/VAI#_S!A_W^_P#K4]?V@I&_Y@X_[_?_ %JM
M8NB_M?F']HX7^?\ !_Y'4_\ "O+O_GZA_(T?\*\N_P#GZA_(US(^/TA_YA _
M[_?_ %J>OQZD/_,)'_?[_P"M5K$4GU'_ &AAOY_P?^1T?_"O+O\ Y^H?R-'_
M  KR[_Y^H?R-<^/CM(?^84O_ ']_^M3U^.$C?\PM?^_O_P!:K56#V8_[0PW\
M_P"#_P C=_X5Y=_\_4/Y&C_A7EW_ ,_4/Y&L>+XV,S#?INU>Y63)_E73Z+XZ
MBUV$M;LN]?O1L,,*M23V-J>*HUGRPE=FG'HDT/AE].#J\WEE0W0=:Y7_ (0'
M4_[T'_?1_P *ZK^VI_[J?E1_;4_]U/RJCJ.5_P"$!U/^]!_WT?\ "C_A =3_
M +T'_?1_PKJO[:G_ +J?E1_;4_\ =3\J .5_X0'4_P"]!_WT?\*/^$!U/^]!
M_P!]'_"NJ_MJ?^ZGY4?VU/\ W4_*@#E?^$!U/^]!_P!]'_"C_A =3_O0?]]'
M_"NJ_MJ?^ZGY4?VU/_=3\J .5_X0'4_[T'_?1_PH_P"$!U/^]!_WT?\ "NJ_
MMJ?^ZGY4?VU/_=3\J .5_P"$!U/^]!_WT?\ "C_A =3_ +T'_?1_PKJO[:G_
M +J?E1_;4_\ =3\J .5_X0'4_P"]!_WT?\*/^$!U/^]!_P!]'_"NJ_MJ?^ZG
MY4?VU/\ W4_*@#E?^$!U/^]!_P!]'_"C_A =3_O0?]]'_"NJ_MJ?^ZGY4?VU
M/_=3\J .5_X0'4_[T'_?1_PH_P"$!U/^]!_WT?\ "NJ_MJ?^ZGY4?VU/_=3\
MJ .5_P"$!U/^]!_WT?\ "C_A =3_ +T'_?1_PKJO[:G_ +J?E1_;4_\ =3\J
M .5_X0'4_P"]!_WT?\*/^$!U/^]!_P!]'_"NJ_MJ?^ZGY4?VU/\ W4_*@#E?
M^$!U/^]!_P!]'_"C_A =3_O0?]]'_"NJ_MJ?^ZGY4?VU/_=3\J .5_X0'4_[
MT'_?1_PH_P"$!U/^]!_WT?\ "NJ_MJ?^ZGY4?VU/_=3\J .5_P"$!U/^]!_W
MT?\ "C_A =3_ +T'_?1_PKJO[:G_ +J?E1_;4_\ =3\J .5_X0'4_P"]!_WT
M?\*/^$!U/^]!_P!]'_"NJ_MJ?^ZGY4?VU/\ W4_*@#E?^$!U/^]!_P!]'_"C
M_A =3_O0?]]'_"NJ_MJ?^ZGY4?VU/_=3\J .5_X0'4_[T'_?1_PH_P"$!U/^
M]!_WT?\ "NJ_MJ?^ZGY4?VU/_=3\J .5_P"$!U/^]!_WT?\ "C_A =3_ +T'
M_?1_PKJO[:G_ +J?E1_;4_\ =3\J .5_X0'4_P"]!_WT?\*/^$!U/^]!_P!]
M'_"NJ_MJ?^ZGY4?VU/\ W4_*@#E?^$!U/^]!_P!]'_"NUT2RDT[2;>WEV^9&
M,':<CK53^VI_[J?E6O&QDC1CU89/Y4 5M7_X\F^HK!K>U?\ X\F^HK!H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *"0H)/0#)HIEQ_Q[R_[C?R- 'R#\1/%%QXL\67UW-(6B61HH$[(BG  ^O7\
M:YNI;K_CZF_WV_G45?AM:I*K4E4F[ML_+:DW4FYRW84445B0.HHHJ@"BBBF
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M% !1110 4444 %=-;_ZB+_='\JYFNFM_]1%_NC^5 %?5_P#CR;ZBL&M[5_\
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M H]KT_\ X\;;_KFO\JL57T__ (\;;_KFO\JL5TGZ!'X4%%%%!04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !736_P#J(O\ ='\JYFNFM_\ 41?[H_E0!7U?_CR;
MZBL&M[5_^/)OJ*P: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_CHH T?[%@]7_.C^Q8/5_SK._M2Z_YZ?^.BC^U+K_GI_P".B@#1_L6#U?\
M.C^Q8/5_SK._M2Z_YZ?^.BC^U+K_ )Z?^.B@#1_L6#U?\Z/[%@]7_.L[^U+K
M_GI_XZ*/[4NO^>G_ (Z* -'^Q8/5_P Z/[%@]7_.L[^U+K_GI_XZ*/[4NO\
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M*/[4NO\ GI_XZ* -'^Q8/5_SH_L6#U?\ZSO[4NO^>G_CHH_M2Z_YZ?\ CHH
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M[_O\/_B:7_AGKPL/XK[_ +_#_P")KYT7]LCQN?\ EVTS_OR?\:D7]L3QL?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !71V?\ QZP_[M<Y71V?_'K#_NT ,U3_ (\9/P_G7/UT&J?\>,GX?SKG
MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'@ 9.>U=%*K"JW96DM[K4Y,10JX>,>:5XO5-.Z\S9U+Q+J^N0PPZEJM[J$4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5%>*6L[D#DF%P/^^34M% 'XI:M
M&T.L7\;J5=+B164]00Q!%1+7T;^V%^SKJ?P[\:ZCXJTJTENO"NJ3&X::-<_9
M)G/S(^.@+9(/OBOG%6'K7ZUAZ\,12C4@]&?A^*P]3"UI4JBLU_5RPM31U K#
MUJ9&'K70<A.M3+4"L/45,K#U%("=:E6H58>M2JP]:0$Z]JF6H%8<<U.K#UH
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M9V^BCFN87X_^"FZ:E)_X#O\ X5RSQ5"G+DG-)^ISSQ%&F^6<TGZG>?V?;?\
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ML^V_YY+1_9]M_P \EKS./]IOX?2_=U:4_P#;M)_A5F/]HOP++]W5)#_V[O\
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M:]^-K'_\<KT?[/Q;5_9L\IYK@4[.JOO/HS^S[;_GDM']GVW_ #R6O H?VX?
M,^-MCK@SZVT?_P <J_#^V1X(F^[9ZQ_X#I_\72_L_%?\^V3_ &M@/^?R/:[C
M1[*Z@>&>UCFAD&UXY%W*P]"#UKSW5?V9?A7K5QYUUX%T8R]VBMQ%GZ[<9K$A
M_:P\'S8VVFK?C G_ ,75Z']IGPK-C;;:F/K"G_Q=5'"XRE\,6C.>89;5TG.+
M]=0_X9.^$?\ T(VF?DW_ ,53O^&4?A*/^9&TW\F_^*KJ?"7Q4T#QE<"WLYY(
M;ILE8+A-K-CTY(/YUV%93K8JF^6<I)^K.FC1P5>//2A%KR2/)_\ AE/X3?\
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M_P :[VBCZQ6_G?WL/J>&_P"?4?N1PH^!W@5>GANS'_?7^-.'P3\#CIX<M/\
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M[;_GDM6:* *W]GVW_/):/[/MO^>2U9HH K?V?;?\\EJ=5$:JJC"C@"G4A[4
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MDA!.-'F"P3(0.JJ-A[XQFM'X 6^J>/M4^)/Q?M&M[F[\13/IWA=KPMY*Z?;
MI$20-RI)-O<@=1@]Z!'JGQP^(TWPD^$OB?QA;V2:C/H]FUREK(Y192"!@L!Q
MUKS&;XG_ ![LO"I\1/\ #KPC?V*6@OFM;3Q#*MP\>S?A=\ 7=CU.*X_X[O\
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M3XC6_A+3O#?B58_"FIR>&);AHD8DM;33B55"[6^7?Z''I7IG[8/_ "'?@?\
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M-['KVK?\%?M#7=OX7\;7'Q*\/2>#M3\&+OU.6(M+974>W<LMK(0-P;IM/()
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M^.&OV?Q$M/AM\/\ 0;77?&LEC_:-[<:C.8K#3+<G:KRE069F/1!@GUJKX/\
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MKG/ OBY;[XA?M1?$GP]HZ>-_#IATZSMK>&0"+5#:VKBZ2-]K!@ Q' ()X[T
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MBPFVDJ+B.3)V'!'F @ ]17@?P^\0>#;?]DCX%^'OB/X<%]X&UQIXKCQ#)=-
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MKI< *D="#MX-=I10!RNL?"GP7XAU&;4-4\):'J5],09;J[TZ*61\  99E)/
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M_P"*_$5QJVDZK-H!N7,D]LL(EB+DY)49&WZ<UBP?L.6\./\ BKI3_P!N(_\
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MII&+O))I<#,S$Y))*\DFNRHH R-(\'Z%X?TF72M,T73].TR4LTEE:VR1PN6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-6CE\'^&(K'3[V"S\&_$"]G;2KJ-9@C317>1EUVG83G*MZ5JZ/XLT[Q'\/\
MX#+HF@Q^&K+3OBA'IZVMG?O=V<K(')>"4_>A8MQVK[AUKX?^&/$FFVVGZMX>
MTS4["U_U%K=VD<L<7&/E5@0O'I5@>#M"6TTVU&CV(MM-D6:QA%NFRU=<[6C&
M,(1D\C'6@+GYZ:Q!\)Y_@?X[U[Q?J<$'Q[AO;]R]Q>,FLP:@L["V2WC+!M@
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ML6LELX5LVW;K<(/+.3DY7IR23^-0VOAO2;'37TZVTVUM["0$/:Q0JL3 ]05
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(NT=>?SH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ino-20231231_g5.jpg
<TEXT>
begin 644 ino-20231231_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX*M>*?!UC_P2K_:%\2:YJ5M)I%S\#/$PCG\Q6CG\[2KA(0C="7=T5<=2RXH
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M*\%>-[*'PW\=M:\5Z UF=<U.8%=5U JKL&DG0I?B,8S/:.>AX /UD_X+%_\
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MX!*D@$?0U% 'S/\ '#_@E)^S1^T=^R-H'[#'QCU_QIJ_PS\-06,&FZ#_ ,)
ML$AALHTCM(Y;F*)9Y5B5!MWN2QY<N0I'LO[/7P-\*_LT_!KP]\!_ 6KZM=>'
MO"FDV^E>'HM9NUN)K.QMX4A@MA*$5I%1$ #2%G]6/&.SJA/XI\-VWB>V\%7&
MO6B:Q>V$]]::6UPHGFMH7ACFF5,[BB/<0*S 8!E0'[PH X#X)?LK>#?@/\1O
M&_Q/\,>./%FI:C\0]675/%$?B#61=PS7B0Q6\<L:L@-N$@ACB6.(K&$4#9D
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M(J?LP_LS:7K'P_\ @%\7_C'X4^'FO:A->:C\+='^)%Q'HNZ7 E2([?MENK@
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M+VSBM799/D*^:""1QR,@'UE1110 4444 %%%% !1110 4444 %%%% !1110
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M%#X;?%"?P/X;U-M(BLK?59YDL3;W-W!:B.,>4;N9F6(1AU@1?E9B]>M^%_\
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M1Q\'_P#!([5OVX[&&Q\*>+7U=?&8^%QD>2W^TW-REHEL-23:1+=2$RM(Y88
M5<9K[)_:(_9+\:_M ?\ !/OQ+^Q/<_%S3-+U3Q3\.I?"=_XQ3PG)-!''+;?9
MI;B.Q-ZK!C&6*J;@A6()+ ;2 ?DAXA_X*\_\%;/AU^QG^QK^W5?_ +3_ (9U
MI_C9X\N/#OB;P#<_#FQ@T^ZA%]+!'/-<1C[0LN$;)MVA0#RQL8J[2_6W[&?[
M<'[;.B?\%Y_B[_P3"_:)^.]E\1O"&E?"^V\5^&]1/@^STF;2[IETUWMXQ:C+
MP'[;, )GED 2/]X2&+8?CK_@W0^(GC/]BC]G3]C5?VZ](M8/V>/&-SX@TSQ
M?A#*[ZS(]V]S#%+#_;($2H9'5BK,7&TC9@[O;O __!)7X@>%O^"O7B__ (*L
MZE^U3IUQ)XQ\"_\ "*W7@BP^'TELUK:BWM(UEBOFU*3$P>S1\M 5PS+M'#
M^$_VN_\ @LW_ ,%,_P!DGP-X+^+WQ=\>Z7H7Q+C_ &A#X9^(?P&TJWT;6_#M
MEX>FCFEM%DU&SMI+BQOGCA^6*6^\Z1=\X@6/")]<_M&_MV?M*?'3_@K-K_\
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MO_Y7&?V9?^S=;_\ ]$^+*SYO^#6+XFW7['^G_LH:E_P4YU&]M_#_ ,93X_\
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M?_!&/XL^*O\ @I%I?_!4O]B']L.W^$WQ*N]#BT;Q_:ZGX)&LZ9XAMDAC@WM
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MU2_\*>+K*&T\/> [RTTG?HUQ:Q16]_+=3VEK'(T\E[%<LB;PBP21L4#.$B]
M\>_LM?M!_$/X2:%\)/$W[46G:I;7FM17?Q5N=9\"/+_PE5EYBO-I=M%#?PQZ
M;9RHH@:/;<%H=RNTCR2R/\L_LG?\$4_B]_P3R^ 7[0_P>^%O_!20>&/ 'Q2A
MU34_#RZ;X!DL)OAQ>2HZK=V=VVJR%D2 11OE4=A;1LLD3 D@'Z0U^-OPTE_:
MB^)__!V7\6_AA/\ M>>(+&S\$?!6.XT,1Z%83PV^D7%QH-Y+I$<,T;)%&[W
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MBY\+/*%]<1FSMH?+C-FKK+*C0_9YE%NRW*-,S!3'*2?H7]OO_@BA\0/VNO\
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MI;^'?B,OB;P-'K%AXKMHX8H?/FAAGM0DA2"#=&FU"UO"R&(H=WV[\,/".O\
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M_F\!Z=K<FE1I:?:EDNY/[1DM4VQ[Q:VKC8 (_.*MMV9CJ']I_P"''QT^%_\
MP<H_L/\ AKX\?M$W7Q,U3_A"[^0^(=2\.V.G7(E-OJ8GC*6$4,#0^8"T6(E=
M4;:[RD;S[UI/_!MCX3O/^"/US_P2B^)O[4(UT:=XTE\5>"?B!8>!S82Z1J#%
M\&6U:^G%RNV:XC.)(R4F(&&4-74W7_!&C]K/XH?MV? O_@H%^T1^WOX>UCQ;
M\%M 72UTS1_A2]O9:LF)T=V+:DTD<LD<\C22;F4R,"D42KL(!XSXE_X*Y?MT
M?M+>*?VJO$/[%[^)GU;X"?$*R\,?"[X8>&OA;)K=GXO:UO6BU*75[M;.5X1.
MD<I@6*XLVC5 3YC9)Z/_ (*[?\%$?^"@W_!/C7O@'^W?:Z]XAL_V?O&EWI<'
MQC^&;>%=+?6/"US-"DS6\=Q/;>8-Z><A65@5FMV3S(Q-&(_4/ ?_  1C^/O[
M,'[?7Q/_ &L?V%_VZ(OA]X0^-FI?VE\1O >K_#Z+5RE\TLDSW5C,]PB12>9/
M<-&9(W2/SV#),H5!ZG^W?_P30\4_MZ^ -5^!'Q-^.VD/\.I/ -WI&@:!JG@N
MYOKZRUV2*..W\07%[_:<?VRXM@LACC,48W7$C,S-M( /9/V/],^+,'P&T+Q#
M\:?CF?'^N:]9QZI+JT%K81V<$4ZB2.WM6LK>%9H41E43L"TI!DP@<1IZ<Y8(
M2B@L!P"<9-?EU\?O^"8G[;W[/O\ P2 \.?L;?#O_ (*J>+X/%'PZU^*;X>^(
M/ /@BYTS6?$5O%!<FS\-,D.J.\@\UTV2B1(XHK93,ACB:1?T>^'6A>/U^"^A
M>&OBCXD,OBD>%[6U\1:OII5-^H?9E2XGB^7"YEWLO&!QQVH _&3]JO\ X+-?
M\%,?V4/"7P_^*OQ@\?:7HOQ*;]H%_#'Q+^ ^E6VC:UX=T_09A+):(^HV=L]Q
M97S11?+#+?&9QNG\E8R$7Z-_;N_;8_;O\!?\%Y?@?_P3R^ '[0UCX=\$?%CX
M>W6J:K!J_@VQU$Z?<10:OODMV*1RD[;&.1%DD91+RP:,F*O,+G_@U@^)E[^Q
MY:?LF:G_ ,%.M2O;71/C*?B!X>N[KX6VK1+=O$T,S7?^E?:;N=U*D2&Y5 0X
M,;;E9/JSXU?\$EOB3\8O^"JGP<_X*?W/[5^EVM[\(_"(T&/PG-\.&E&KK)#?
M1W,\ETFI1B)W-_,R!82L>U 0^#D ^3?V./\ @N+^U?X&_P"";_[8GQS_ &I=
M?TSXB>+OV;/'MSH'AG7I-#@TT:P\UR+*R%U!9K'&%6Y*LWEA&,;%<[AO/S=_
MP4[U_P#:Q^+'[+W_  3T_:<_:<_:5?QQ>?$_XH:)XDN-(E\*Z?80Z'-=_9;B
M*"S>RBB8P+!(J,+CSY#(FX2J"4K] OV;/^#??1?A=\!?VG/V<OCM^TO!XZ\.
M_M,:S)J^JMI/@5M'N-"OVFEG26!GO[I91'*\<B*RC#0C)8$BN \:?\&\_P"U
M5\7O@'\ ?V=_BO\ \%&M!ETC]G+Q''>>![K3/A"RRWEK 4-LEZ'U,^9*@CCB
M4QF-%C4AEE=O,4 _3_XDZ9X?UKX=Z_H_BS7/[,TJ[T6ZAU/4OM2P?9+=H662
M;S&XCVJ2VX\+C)Z5^!?A'X\_\%:O^#:;P_+^S+^UE^SU:_'3]D87]S9Z7XGT
MRWRMII]Y,Y>-9QN%J9#,[-:7B%'D=DBF"G>?WG^*?@74_B5\&O$?PSFU>"&\
MU_PQ>:8]^MLPB26>W>(RB/<2%!;=MW$XXR>M?+VO?\$_OVQO%W[#U[_P3T^(
M/[8'A7Q1X4U?P9_PBNI^/=9^'4O_  D/]E- ()%V"^-M-=>5N6.[8*8SL=HY
MG4NX!PW[4W[</[*'QF_9 ^''_!/K]FK5)]7\0_M;_!V]T/X1Z3+?&T&G:-/H
MTL;:CJ-PXD:WC@A#@J$EFEEB:-4<AROY_?\ !&']H/P9X:TG4_@_^WAJ8L_V
MC/V%?#?B:Q^#'@CQ2HAL7MIU"7+1"%?/OKXE([-%#.H@>V>"*1S(]?:O[>/_
M  ;K^'/C;<_ CXC?L/?M*ZE\&/'G[//AJQT#P1K4NF_VG%/86<AEMA,/,C(F
M65Y7:3YUE\Z17C((QRO[8G_!N-\8/VR_&&A?M>^-OV_HM"_:5\.3:=)IOQ"\
M%?#:#2=,<61+0O+:QW#7$EVK;,71N,!8D00A0  #V#_@K1KWQW\5_P#! /XR
M^*?VE?!NB>'/&>I_"XW6L^&] NY+B#29'>%C:F:3!FDC)*LX"J6!"@@!F_._
MX*_\$Y_VO?\ @L#_ ,$/?V2/V1_ASX%T/P7X"\,Z]>Z_XB^*/B;78999HUO-
M3@\JQL;?S)9#MN921,8 SQ(,A3O'ZG?&[_@G?^TI^T5_P39\3?L0?&#]N7^W
M_&'CS3OLOC/XGZU\/HI%=2804LM-M+JUBM4"0JH&]\LSR-N9S7;_ /!,']BC
MQ9_P3N_8S\)?L>>(?C)I_CFT\&0W$&DZ[:>$WTB22*6ZGN2)8FO+D,P,VT,K
M*,*.,F@#W7PUH<'ACPYI_ANVNYYX]/LHK:.>ZDWRR+&@0,[?Q,0,D]R35VBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#E/'?P)^"'Q1U2WUSXF_!OPIXBO;-0+2\UWP];7DL !R CRHQ7GG@UT
M]I:6EA:Q6-C;1P00QA(884"I&H& J@<  < "I** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH X_5/VAO@!HGQ*@^#&M?'+P?9^,;K;]F\)W7B:UCU.7<,KMM6D
M$K9'(PO(KJM.U'3]8T^#5M)OH;JUNH5FMKFVE#QS1L RNK+D,I!!!'!!K^?+
M]ES_ (*86?\ P2OUKXB?\$J_^"\7['][J.A>.?&^K:KJGQ6.C&]C\3+>SY>_
MN48;KZ')#)<V[M-"H2/R@\?R_?O[0G_!3+PU_P $J/@%^QU\)O@)X*TCXO?#
MSXD0:#X%\/>-(_%K6<@MHK>RMH+]42VF2=7A<.5WH0R[>^0 ?HM17Q9\!_\
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M^/O@KPE?7Z[K&R\3>*K.PEN!G&8TGD4N,\< U\"?&S_@LU^V]X2_8_\ B?\
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MA/QKX-\?:2-?\"^+=,UJQ9BJWNDW\=S"6'4;XV*YY'?O7XD_\%8=1\'>$/\
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M?$KC*>'FUB 7S?N_,X@W>8?W8W_=^[STYKX1^-G_  6P^++7WQ[U_P#8J_9
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M3F:6Q\/:/#90O(0 7*0JJEL #.,\"MZB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ I) 2C!>N#BEHH _.O7/@5^V=^T9_P2T@_8F_X*!?\
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MZ?Y\+P2O#!=3/#'*T$LL)F5!+Y<CIOVNP,/[&W[!_P"R_P#L"?#V;X6_LM>
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M_@I]X7N[7X3?"/4/#?B/X17UAJ7P,\0CQ!I,3ZMJDMXG]HW$\OV@S6<$=O!
MT"KAGDR\BY2-4^\OV1O$?[1?B?\ 9U\*WW[6WPZM_#'Q'BTJ*W\86%AJ5O=6
MLU[&@62YMW@9E$4K NJ'#)N*D':&;TBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\P/^"@/_!8;QQX(_X*(:[_
M ,$Y/!?Q@L/A->Z-I/A2YT#7+W1(;N]\7ZAJ>K6$<]M:O=!K:**&SN)25,;2
MRR))M=!$0WUAI(_X*9ZO\$_%GPUO=>^'=A\0K;QS-I'AKXEGP]/_ &8V@&TA
MN(M9;3#<LTUV&D>V-N)DB\]"^?*7:_R9_P %S/V??^">7_!1;PMXX^"OQ';2
M=&^./PJU3PM9Z/XC6XCBU:RTW6+^QC%RJ!U-W9J+NX!BDRJ2Q,P\LN&;D/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3X;E;B*Q\0:1#>PI,N=L@2964,,G#8R,UM6]O!:0):VL"111($CCC4*J*!@
M = !VI]% !1110 5X7X!_P"4@GC_ /[$32O_ $8U>Z5X7X!_Y2">/_\ L1-*
M_P#1C4 >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5X7X!_Y2">/_P#L1-*_]&-7NE>%^ ?^4@GC_P#[$32O
M_1C4 >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^W!XZUOQ/\,M4\+W$G@C3U?3M5=&EC"2X4DH<8;<2/\ =- 'T[1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?'O[:7[.'[?OBC6O&LWP&\3^
M"_%_@[QCK_A+5+;P9XGN;C3KS0+O3=0T][F6WNE\V*:"6*T61X62,J58H7=B
MK^:?"G_@E'^VU^Q%\%;B+_@GM^U/X"\/>/?%OQHU+X@?$^P\1^!B?#>MI>#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>%^ ?\ E()X_P#^Q$TK_P!&-7NE>%^ ?^4@GC__ +$32O\ T8U 'NE%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45^8'_!0'_@L-XX
M\$?\%$-=_P""<G@OXP6'PFO=&TGPI<Z!KE[HD-W>^+]0U/5K".>VM7N@UM%%
M#9W$I*F-I99$DVN@B(;Z:UJY_P""L6H? +Q3\,/#%Q\-8OB<GCV71O#7Q-N]
M*FM]'3PZ;.*YCUJ33S--))=[G>T^SJWE_:%WG]RI# 'U+17Y=_\ !&;]O/\
MX*7^(/\ @HO\=O\ @ES_ ,%(?%/A[QWK?PKT2#6;3XA^'=&@L8RDK6IBMW6W
MBBC99H+R*9 8UD0Q3*Q?C;XWX=_;W_X*T?\ !1#]JWQ/I_\ P3H_X*R_LI>&
MO"=YXIO8/"'PT\0S+-XF@TNVG> 3FW?2I#</+'$;K:DSA1,JEDQA0#]J**^
M/C'^W=\<?BI_P5_TG_@D=\"?B]=>#H?#OP@N?%?CKQW8:-I]UJ=UJ3(BVEHD
M=Y;S6T406:&XE(AW/Y@1#$%);L?^"#G_  4R\1_\%4_V M-^/_Q%T>PL?&>A
MZ]=>&_&D.EQE+:6^MTAE6XC0DE%E@N('*Y(5V<#@"@#[.HHHH *\+\ _\I!/
M'_\ V(FE?^C&KW2O"_ /_*03Q_\ ]B)I7_HQJ /=**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4445N9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5X7X!_Y2">/_ /L1-*_]&-7N
ME>%^ ?\ E()X_P#^Q$TK_P!&-0![I1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOQ53Z49?^!I_Y'N'ASQEX0\86_VOPEXKTW5(L9\W3KZ.=<>N4)%:5?'/B/\
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MVO.;;F_1RMY#888K>)8((E1$4*B(N H'0 #I3J**^J225D>-N%%%%, HHHH
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MKITEYQ?5>7YV9Z51117Z*>X%%%% !1110 4444 %%%% !1110 4444 %%%%
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M_:_+Y(\@^//BKQ!^WE^U#8? CX>:BX\)Z!<.;N_AYC.P@7%V>S8_U<?8D@Y
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M56G7C3DNJJ*__DK;^1ZXOPT^/?@88^'?Q@BUBT3_ %>F>,+4R,!Z?:(_G/Y
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MJ/\ X#'EC]R/E7_ALS_@H7J''A[_ ()-:S+G[O\ :7Q;TFT]^=R'''Z\4?\
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M_P 0V5N9!:^&M/A)/L0#M&>WIQ7U511_:V,Z<G_@NG_\B']IXKIR_P#@$/\
MY$^5?^'>?[0UQ\VH_P#!3_XQ,PX4VS6D(Q[@(<GWH_X=L_%";YKS_@IC\?V9
MO];Y/B>",'UV@0_+[>E?55%']KX_NO\ P&'_ ,B+^T\9T:_\!C_D?*O_  [!
M\03?N[S_ (*1_M,M&?O"'XDI&WX,+?BC_AU=9R_)??\ !0K]J2ZC[PW'Q=)4
M_E;"OJJBG_;&8_S_ (1_R'_:F._G_!?Y'RK_ ,.HO!S_ "7?[:_[2$\9^]#-
M\6)"K?7$(H_X=,?#'_HZ_P#: _\ #J3?_&Z^JJ*7]L9E_P _'^'^0O[4Q_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF$7N4U:_63WE)^<G=O[EH>C@,%1R_"1P]+:/XOJWZL****]T[ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGQCL)^/4K!'D?3MFC^R<6OB<%ZU*:_#FN']FXE;N*]9P_P#DCZJHKY5/B_\
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M7QG922#_ ( DA;]*XO0/^"2G_!.;PWC^SOV5= DV]/M]Q=7?_H^5\UW'A_\
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M!/K&HQ?RMVQ2C]A_XS^,SYGQK_;Y^)6J%N98/")M] A?_9*0*^5]J^C:*/\
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M'[ML<F%QC@X SO/W=5'Q'X:\/>,-$N/#?BK1;74;"[CV7-G>0B2.1?0J>/\
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M_P##%_[0>G?\B[_P4+^(D6/N_P!I6-I>?GN49[?KZTG_  S/^WCI_P#R!?\
M@H],Z#I%J/PKTV7/U?>#_C7T711_K?G+^-49?XL/AY?G28?ZFY*O@=:/^'$X
MB/Y54?.G_"IO^"E>G<V?[6O@?4<=!J'@(0Y^OE/^%']@_P#!5;3O^/+Q[\$-
M2QT_M#2]4AS]?*/X5]%T4?ZTXB7QX7#O_N!37_I*B+_5/#1^#%8A?]QZDO\
MTJ4CYT_MC_@JU8?\??@[X%:ACK]AU#5HL_3S!^%'_"R?^"FUE_Q\_LT_#F]Q
MU^Q^,I8]WT\Q>,>]?1=%'^LE"7QY?AW_ -NS7_I-1#_U9KQ^#,<0O^WJ;_\
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M_/.#X563+^;29KZ+HH_ULS!;4<.O^Y;#O\Z;#_5#+GO7Q#_[FL0ORJH^=/\
MAF?]OB;Y+O\ X*5R%#U6'X0:7&WX,)*/^&4_VSI_FOO^"D&N,PX4V_P]TZ(8
M]P&.?K7T711_K?FZVA07IA<,ORHB_P!3LGZSKOUQ6*?YUCYT_P"&.OVFY_EO
M_P#@HEXW96Y<6^@V41)]B =O/;\*^BZ**\S,LXQV;<GUCE]V]N6G3AO:]^2,
M;[+>]NF[/5RS)L#E'/\ 5N?WK7YJE2IM>UO:2E;=[6OUV04445Y9ZH4444 %
M%%% !1110 4444 %%%% !7A?@'_E()X__P"Q$TK_ -&-7NE>%^ ?^4@GC_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXNO]?USX;>.+SPO;ZSJEPTUS=:>MM:W5MYLC$L[(+EH03D[(4R30!^F=%%%
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MT8],H))#]3S3)?\ @G+_ ,%'?';^9X[^+OB^^63[]IXJ^.-Y+;#U'EV,"8_
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MWM^I]!2?:_\ @J]IG^OTGX"ZF@Z?9I]8A<_7?\OY>E?1=%'^M$Y?Q,'AY?\
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M %N+^R.)EMF7WT:?Z6/G3_AY+X!'$G[-WQJ1A]Y&^'4N5/H?GH_X>8?!_O\
M!SXK_P#AO[C_ !KZ+HH_M+A9[Y?+_P 'O_Y6Q_V9Q6MLPA\Z"_2HCYV?_@IK
M\!8CLN/ ?Q(B< ;HY/ 5V&7V/%)_P\Y_9_\ ^A*^(W_A!W?^%?15%']H<*?]
M %3_ ,'K_P"4A_9W%W_0?3_\)W_\N/G3_AYA\'Y?^0?\'?BO=Y_U?V;X?W!\
MSZ9(H_X>(P7_ ,GAK]C#X\ZBQ^XZ?#TQQ'T)=YA@'Z5]%T4?VGPQ'X<OD_\
M%6D_RA$/[+XIE\68Q7^&A%?^E3D?.G_#8W[3>N?+X%_X)V^-[AC]P:_KUEI8
M/U,F[%(?B3_P4Y\6<>'OV:OAQX2W=#XJ\8RWX3Z_8E&?PKZ,HH_M_+*7\'+*
M*?>3K3?W.KR_^2B_U>S2K_'S2NUVBJ$%]ZH\W_DQ\Y?\*7_X*.>-_P#D<_VP
MO"OA*)_];:^"O ZW61W59;Q@Z_[PYI#_ ,$X/"GB[Y_CM^T7\4O'8?\ U^GZ
MKXL>WL6]0L$ 7:#Z!J^CJ*?^N&=TO]V<*/\ UZI4Z;_\#C%3^^3#_4S(JO\
MO2G7_P"OM6I4C_X!*3A]T4>8_#3]B_\ 93^$+QS_  _^ OANSN(L>5>SV N;
ME,>DT^^0?]]5Z<  , 8 Z 445X6,Q^.S&K[7%U95)=Y2<G][;9[V"R_ 9;2]
MEA*,:<>T(J*^Y)(****Y#L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .)^-O[/?PL_: \/_V%\1?#J3R1J19ZE!A+JT)[QR8R!GDJ<J<<
M@U\CZS\//VJO^">&N3>*OAYJC^)? [S;[R(Q,T 7_IO$"3 ^./-0[3@9/.RO
MNZFR1QS1M#-&KHZD,K#((/4$5\'Q1P#EG$.(CC\/.6&QL/@KT])>DUHIQZ-2
MUMHFDV>/F&38?&S5:#=.JMIQW^?=>IY3^SA^V+\)_P!HZQ2ST6]_LS7DCW7/
MA^^D E&!RT3<"9.O(Y ^\JYKUBOES]H__@G/H7B>^?XC?L[WJ^&?$,,GGC3H
MI#%:S2 Y#1,O-L^>FWY,XX7EJYGX+?M]>/\ X1^(Q\'/VQ?#M[:W-JPB777M
MB)XQT#3(O$R'M+'DD#.'SNKY_ \=9OPQBX9;QE35/F=H8J"_<5.W/_S[GW3M
M'=^[&S?%2S?$Y?45#-(\M]%47P2]?Y7^'HC[)HJGX?\ $.A>*]&M_$7AG6+:
M_L+N,26UY:3"2.53W##@U<K]9A.%6"G!IIZIK5-/JF?2)J2NM@HHHJQA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\!_\%8_
MB%KOC/X;_$K]EK]I7]D;Q3X@^'&L>(/!LOA'Q9HGAU]3L=1MI=4TU+^QG%HS
MSVEPCBX"2,D8=9U5&# %LK_@A]^Q1\5_^"9O[$OQ2\._$3PCXHMM'\3?%/7-
M>^&WP]=?[2U?2M#ECCAL8+@6Y=$NY4A5Y%#;$+ NRL7"_HC10!^6'_!L3^QI
M\??V6_\ @GE\1/V/_P!M+X!>)/!FL>(OB#JNI_8]4M5:"\TJ[TO3K,E+B%GC
M#[X)E,;,'QA@",D?+\W_  1M_;.F_P""8<?_  1-_P"%7ZQ_;L7[4IUL?$7[
M#_Q3Y\(?9R?[9^UY\OS/FV?8L_:=_'E[?GK][Z* /S1^(?["_CK]BS_@M?HO
M_!2;X8?"?Q%XK^&_B#X'2>#->L?"6FOJ&HZ5JMG!!'9;K:/,CP3P6EO")54K
M'(K&4QH0U=[_ ,&Z'_!-_P")W_!,W_@G/9?"KXZ6$%EXZ\6^)[OQ1XITN"Y2
M<:;+/%!;Q6AD0E'=(+:(OM)42.X!8#<?O&B@ HHHH Q)?AI\.)Y6GG^'^B.[
ML6=WTJ$EB>I)V\FO&_A?H.AZ+^WSX_L-'T:TM(!X%TO$%M;+&GS2-NX4 <X&
M?7%>_P!>%^ ?^4@GC_\ [$32O_1C4 >@^+OV=/@/X[W/XK^$/AZ[D?[UP=+C
M28_]M$ ?]:\Q\6?\$S?V6_$>Y]*T;5]#9N<Z7JS, ?I.)!^%?0-%?-9EP;PG
MG%WC,#2FWU=./-_X%:_XG!7RO+<3_%HQ?R5_OW/CC7/^"3KZ;<_VG\-/CM=V
M<R?ZI+[3?F'_ &UBD4C\$JC_ ,,V?\%*OAA\W@;XV'6HD_U4"^(FEX]-EZH0
M?3.*^U:*^0GX.\&TYN>7^VPLGUHUIQ?XN2_ \Q\+Y7%WH\U-_P!V37YW/BK_
M (:'_P""F?PQX\:?!DZW''_K96\.F<8[G?8N%'UZ59TO_@JYKFAW0TSXF? "
M:UF'^L:UU)HF'_;*6+/_ (]7V95;5-'TC7+4V6M:5;7D)ZPW4"R*?P8$5/\
MJ)QE@/\ D6\05DETK4X5K^LG9_,/[(S2C_ QLO\ M]*?XNQ\\>&?^"I'[-FM
M;4UNT\0Z.Y^^UWIJR(/H87<D?\!%>@^&OVS_ -EOQ7M&E_&S18B_0:E*UG^?
MGJF*M^)OV2OV:?%VYM:^"?A\,_WY+.P6U=CZEH=AS[YKS[Q+_P $QOV7=<W'
M2M/US1B>G]G:N7 _[_K)1R^,V7[2P>)CYJI3F_N]P5N*:'6E47_;T7_D>Z:#
MXO\ "?BJ+S_#'BC3M23&=]A>QS#'U0FM&OCS7O\ @DEH2RFY\%?&Z_LW0YB6
M_P!)64Y_WXY(\?7%9Y_8B_;H\!?/\./VE/.AC^[;CQ#>P;O3]VRM&?Q-'^N?
M'^"_W_A^;7\U&M3J7](Z/[V/^U,YI?QL$_6,E+\-S[3HKXL,W_!67X?_ 'XF
MUJV3I\NG76[\L2FC_AN#]N?P-\GQ#_9J\V)/O3GP[?0;O^V@9D/X"C_B+>4X
M?_D88#%X;NZE"5OOBY77R#_67#0_CT:D/\4'^ES[3HKXWTG_ (*VV<$OV3QA
M\";JVD0XD-IK08Y_W'B7'YUV.A?\%4OV=-2PFK:%XGTUOXFFT^*1!^,<I)_[
MYKOPGBYX<XUVAF$(O^^IP_\ 2XQ-J?$N1U=JZ7JFOS2/I>BO&M$_X* ?LE:Y
MA8_BQ';.>L=]IEU%C_@31[?UKKM%_:6_9Y\0X72?C;X6D=ONQ-KD".?^ LP/
MZ5]/A.+.%L=_NV.HS_PU8/\ *1WT\RR^M_#K1?I)?YG;T53TKQ%X?UU/-T37
M;.\4CAK6Z20?^.DU<KWH3A4CS0=UY'8FI*Z"BBBJ&%%%% !1110 4444 %%-
MFFBMXFGGE5$12SN[8"@=22>@KP;X[_\ !0[X&_"**;2O#&HKXKUI 0MGI,P-
MO&W_ $TN.5'T3>V>"!UKQL[XBR3AO"/$YGB(TH?WGJ_**WD_**;.7%X["8&E
M[3$345Y_HMW\CVWQ+XG\/>#="N?$WBO6K;3]/LXS)<WEW*$CC7W)_(#J2<"O
MBWXU_M._%C]L_P 5R? ']E[1[N+0I3MU/5&!B:ZBSAGE;_EA;_[)^9^A'.RJ
MNB?"3]J_]O\ UVV\7_%[5)?#7@Q)?-L[;R3'&4_Z=X"<R,0?]=(<8)P2!MK[
M ^#_ ,%OAW\"_"4?@WX=:$EI;KAKB=OFGNI,?ZR5\9=OT'0 # K\PJ5^)_%'
M]SAXSP65OXIOW:^(CV@O^7=-_P SUDNZ;BOGY3S#B'W8)TL.]V])S79+HGWZ
M_>CE?V7?V4O O[,_A;[+I:+?Z[>1@:MKDL>'E/7RXQ_!$#T7J<9.3C'JE%%?
MJ^4Y3EV1Y?3P.!IJG2@K**_J[;W;>K>K=SZ/#8:AA**HT8\L5L@HHHKT3<**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KC/C3\ OA?\?O#A\._$;P\EQL4_8[^'"7-HQ_BCDQD=LJ<J<#(-=G17+CL#
M@\RPD\-BZ:J4YJSC))IKS3,ZM&E7ING4BG%[IZH^$=;^'7[4_P#P3PUV;Q;\
M.=4?Q)X'DFWWD31,T(7_ *>(@<P/CCSD.#@9/.ROI;]G#]L/X4?M'V"6FB7O
M]F:\D>ZZ\/WT@\T8'+1-P)D]QR!]Y5R*]6EBCFC:&:-71U*NC#(8'J".]?+O
M[1__  3GT7Q'?/\ $C]G2^7PUXAAD\]=-BE,5M-(#D-$R\VSYZ8^3..%Y:OR
M6?#7%/A]-XCAEO$X+>6$G)\T5U=";NU_@=[_ -YM6^;> S#)7SX#]Y2ZTV]5
M_@?Z/\6?4E%?&_P5_;]\>?"?Q&/@[^V)X=O;2ZM6$0UU[8B:,= TZ*,2H>TL
M>20,X;):OKSP_P"(=!\5Z-;^(O#.L6VH6%W&'MKRSF$D<B^H9>#7W/"W&>1<
M74)2P4VJD-)TIKEJ4WU4HO7?2ZNKZ7N>OE^:83,H-TG:2WB])+U7](N4445]
M6>B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK57_ +>U^!QOA;)+WA3<7Y2DOU/BT?LQ_P#!2WPS\FD?M!?;U7[O_%5W,O\
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M1110 5X7X!_Y2">/_P#L1-*_]&-7NE>%^ ?^4@GC_P#[$32O_1C4 >Z4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMTKXM:3^W!XZM?B]XLTO5]47P1IYGNM*L#;Q,IE_=@*2<$ -GUR/2OIVO"_
M/_*03Q__ -B)I7_HQJ /=**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#*\9>!O!WQ#T.3PUXY\,V6JV$OW[6
M^MUD7/\ >&?NL.S#!'8U\N_%C_@F%8VVH_\ "9?LV>/;KP_J4#^9;:?>W,GE
MHW;RKA/WD7_ M_7J*^MZ*^6XDX+X:XLII9EAU*2^&:]VI'MRS5I*SUM>W='G
M8[*L!F4?W\$VMGLUZ-:_H?$6C_MA_M=?LKZE%X5_:;^'=QK6G!_+AU*<!)7
M_P">=S&#%-QSA@7]6%?17P9_;,^ 'QP\JR\,^,X['4Y< :-K.+>X+'^%<G;(
M?9&:O2]6TC2=>TZ72-=TNWO;2=-L]K=P+)'(OHRL""/K7SM\9O\ @F9\$?B!
MYNJ_#R:?PEJ+Y8+:+YUF[>\+$%/^ ,H']TU\6LD\2.$=<IQ2S##K_EUB'RU4
MNT:RTD_\=DNB/+^J9[EO^[5%6@OLSTE\I=?F?2-%?#JV/_!13]CSY;%Y/&7A
MJVZ(H?4(%C'^SQ<0@#TP@]\5Z'\(O^"HOPA\6-'I/Q5T.\\*WQ.U[@ W-H6Z
M<LHWISV*$#NU=^7^*N02Q*P><PG@,0_LUX\L7YQJ? UYMQOT1M0XBP;J>RQ2
M=&?::LOE+:WGH?3]%9GA3QGX1\=:4FN^"_$]AJUF_P!VYTZ[29,^A*DX/L>:
MTZ_2J56E7IJI3DI1>J:=TUY-'NQE&<5*+NF%%%%:%!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>%^ ?\ E()X_P#^Q$TK_P!&-7NE>%^ ?^4@GC__ +$32O\
MT8U 'NE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7GGQ<_96^!'QM62?QUX M'OG'_(5LA]G
MN@?4R)@O]'W#VKT.BN',,LR[-L,\/C:,:M-[QG%27W-,RKT*&)IN%6*DNS5S
MXS\5_P#!-/XG?#;5F\6_LQ?&JZMKA.8[6^N'M;C:/X1/#\LF?1E4>IK/C_:Z
M_;E_9MD6R_:!^%+:UIT1"MJ%Q:B(D#LMU;AH2?\ >5F]:^W*22-)4:*5 RL"
M&5AD$>AK\WJ^%>$RZHZW#>-K8";UY82YZ3?=TIMI_>DNQX,N':="3G@:LJ+[
M)WC\XO\ S/GGX:?\%,OV<_&WEVGBFXU#PQ=O@$:G;&2 MZ"6+=Q[NJBO<_"G
MCCP9X[T\:KX*\6:;J]L0/W^FWJ3*,]B4)P?8UY_\2OV*_P!FKXI&2XUWX96=
MG=R9)O\ 1LV<NX_Q'R\*Y]W5J\-\5?\ !++6O#>H_P#"0_ /XWWFG7<9S;QZ
MH&BD7_MYM\$?A'4?VAXM</Z8K"T<PIK[5*7LJEN[C/W6_*(O;\28+^)3C6CW
MB^67W/3Y(^QJ*^)O[:_X*B?L_?\ '_ILWC#3H>A:%-3#@=3F,K<_]]8K6\*_
M\%61I5Y_8WQF^"=]I]Q$<7$FEW'S@_\ 7"<*5_%S6U'Q=X:H5%1S>E6P51Z6
MKTI)-^4HJ2MYNR*CQ+@(2Y<3&5)_WXM?BKGV'17C7@C]OS]E?QOLBC^)4>E3
MMU@UNV>VV_61AY?_ (_7JWA_Q3X8\6V0U+PKXCL-3MCTN-/O$F0_\"0D5]WE
M?$&19U'FR_%4ZO\ @G&3^:3NOF>QA\;@\6KT:D9>C3+]%%%>P=04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^S;_ -&]^!__  D[/_XW1_PS)^S;_P!&]^!__"3L_P#XW0!Y9_P]J_X)T_\
M1TFB?^ =W_\ &:/^'M7_  3I_P"CI-$_\ [O_P",UZG_ ,,R?LV_]&]^!_\
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MWX'_ /"3L_\ XW0!Y9_P]J_X)T_]'2:)_P" =W_\9H_X>U?\$Z?^CI-$_P#
M.[_^,UZG_P ,R?LV_P#1O?@?_P ).S_^-T?\,R?LV_\ 1O?@?_PD[/\ ^-T
M>6?\/:O^"=/_ $=)HG_@'=__ !FC_A[5_P $Z?\ HZ31/_ .[_\ C->I_P##
M,G[-O_1O?@?_ ,).S_\ C='_  S)^S;_ -&]^!__  D[/_XW0!Y9_P /:O\
M@G3_ -'2:)_X!W?_ ,9H_P"'M7_!.G_HZ31/_ .[_P#C->I_\,R?LV_]&]^!
M_P#PD[/_ .-T?\,R?LV_]&]^!_\ PD[/_P"-T >5#_@K?_P3G,AB'[4>C9 R
M2;"\Q^?DXIW_  ]J_P""=/\ T=)HG_@'=_\ QFLCP/\  +X$W'[=GCKP[<?!
M7PD^GV_@K3);>Q?PW:F&*1G;<ZH8]JL>Y R:]J_X9D_9M_Z-[\#_ /A)V?\
M\;H \L_X>U?\$Z?^CI-$_P# .[_^,T?\/:O^"=/_ $=)HG_@'=__ !FO4_\
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M-$_\ [O_ .,T?\/:O^"=/_1TFB?^ =W_ /&:]3_X9D_9M_Z-[\#_ /A)V?\
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M4 :__#VK_@G3_P!'2:)_X!W?_P 9H_X>U?\ !.G_ *.DT3_P#N__ (S7J?\
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M[/\ ^-T >6?\/:O^"=/_ $=)HG_@'=__ !FC_A[5_P $Z?\ HZ31/_ .[_\
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M[\#_ /A)V?\ \;H_X9D_9M_Z-[\#_P#A)V?_ ,;H \L_X>U?\$Z?^CI-$_\
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M-$_\ [O_ .,T?\/:O^"=/_1TFB?^ =W_ /&:]3_X9D_9M_Z-[\#_ /A)V?\
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M'=__ !FO4_\ AF3]FW_HWOP/_P"$G9__ !NC_AF3]FW_ *-[\#_^$G9__&Z
M/+/^'M7_  3I_P"CI-$_\ [O_P",T?\ #VK_ ()T_P#1TFB?^ =W_P#&:]3_
M .&9/V;?^C>_ _\ X2=G_P#&Z/\ AF3]FW_HWOP/_P"$G9__ !N@#RS_ (>U
M?\$Z?^CI-$_\ [O_ .,T?\/:O^"=/_1TFB?^ =W_ /&:]3_X9D_9M_Z-[\#_
M /A)V?\ \;H_X9D_9M_Z-[\#_P#A)V?_ ,;H \L_X>U?\$Z?^CI-$_\  .[_
M /C-'_#VK_@G3_T=)HG_ (!W?_QFO4_^&9/V;?\ HWOP/_X2=G_\;H_X9D_9
MM_Z-[\#_ /A)V?\ \;H \L_X>U?\$Z?^CI-$_P# .[_^,T?\/:O^"=/_ $=)
MHG_@'=__ !FO4_\ AF3]FW_HWOP/_P"$G9__ !NC_AF3]FW_ *-[\#_^$G9_
M_&Z /+/^'M7_  3I_P"CI-$_\ [O_P",U[=\.?B;X"^+GA>+QI\-_$]OJ^ES
M.R1WEKG:67J.0#D9]*Q/^&9/V;?^C>_ _P#X2=G_ /&ZX#_@GC!#;? W4[:V
MA6../QQK"QQHH"JHN2  !T% 'N]%%% !1110 4444 %%%% !1110 45XW^W9
M^VQ\/?V ?V=M>_:2^)O@+QCXBTCP_9/=7EEX,T!KV98U*@N[L4A@0%URTLB#
M&2,[3CF?V:/^"BO@KX_?\$Z=!_X**:K\-]9T?2->T*;4K;PGIH.J:E*PNY+:
MWLX%C1#<7,\BQI'&H&9)E0$_>(!]%5S>F?"GPCI'Q1U3XP6<,XUK5]-@L;UV
MG)C,,1)0!.QR>O>O@O\ 9+_X. +WXO\ _!0FS_X)S?M9?L"^._@-XQ\264MW
MX%?Q5JJ78U:)8I9E,J+!$(-\<$P5HWG0R1-&7#"OL#XF?M11>!/VJ/A_^RYH
MW@>36;WQ=X;U[Q%KM_;WC!M!TG35MHQ<&!(G:X::ZO+:!(P4)S(P+&/8P!ZQ
M17Q[^R__ ,%B?AC^U?\ \%)?'W_!.7P1\"_&FAZG\./!LVM>(-?\86HT]I)5
MN;&*.&&S8-*8WCO4E$LIC;"@>60P8.\1?\%67\7?ME_%+]A_]E'X'V7CKQ9\
M&O!JZ[XYN-?\:?V);&5T1X["R*VET]S/MD0,[K%%&S!3)F@#[ HKQC_@GU^W
M%\*O^"C7[)7A3]KSX-Z=J5AHWB>&=6TS5XU6YL;F"=X)X'VDJVV2-@&4X9=K
M<9P/9Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\;_ &[/
MVV/A[^P#^SMKW[27Q-\!>,?$6D>'[)[J\LO!F@->S+&I4%W=BD," NN6ED08
MR1G:< 'LE%?.O[-'_!17P5\?O^"=.@_\%%-5^&^LZ/I&O:%-J5MX3TT'5-2E
M87<EM;V<"QHAN+F>18TCC4#,DRH"?O'YQ_9+_P"#@"]^+_\ P4)L_P#@G-^U
ME^P+X[^ WC'Q)92W?@5_%6JI=C5HEBEF4RHL$0@WQP3!6C>=#)$T9<,* /O3
M3/A3X1TCXHZI\8+.&<:UJ^FP6-Z[3DQF&(DH G8Y/7O725Y/\3/VHHO G[5'
MP_\ V7-&\#R:S>^+O#>O>(M=O[>\8-H.DZ:MM&+@P)$[7#375Y;0)&"A.9&!
M8Q[&\5_9?_X+$_#']J__ (*2^/O^"<O@CX%^--#U/X<>#9M:\0:_XPM1I[22
MK<V,4<,-FP:4QO'>I*)93&V% \LA@P /L*BOB3X]_P#!973?!7QA^.?PA_9U
M_9_;XCS_ +-G@>/Q-\7+N;Q6-*6",QF=K/3U%K<?;;I+=)9&5S @:/RPY<D+
M]&_L:_M<?!W]NS]F?PG^U;\!M4GN?#'B_3S<6:WD0CN+61)&BFMID!8++%+'
M)&P!*[D)5F4@D ].HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HKQO]NS]MCX>_L _L[:]^TE\3? 7C'Q%I'A^R>ZO++P9H#7LRQJ5!=W8
MI# @+KEI9$&,D9VG',_LT?\ !17P5\?O^"=.@_\ !135?AOK.CZ1KVA3:E;>
M$]-!U34I6%W);6]G L:(;BYGD6-(XU S),J G[Q /HJN;\;_  I\(_$'Q%X<
M\4>(X9VN_"VI-?:289RBK,4*$L/XA@]*^"_V2_\ @X O?B__ ,%";/\ X)S?
MM9?L"^._@-XQ\264MWX%?Q5JJ78U:)8I9E,J+!$(-\<$P5HWG0R1-&7#"OJS
M]H+]M3PS\ /COX3^#.J>%GU"#5?!?B/Q?XMU>"[?=X>T32(K<-<_9TB=KEYK
MF[M[>.(%"2TC*7*;& /;**_-?X8?\'#U]+_P4"\)?L,?M:?\$ZOB5\$5^)-V
MEO\ #;Q-XRO8WDU1Y7,=O]HM%A46_F28B(CFG,<CHKA02P]E_:0_X*UZ1\+_
M -HCXF_LR_ OX,)X_P#$?P5^%$WC_P"*)N_%']E0Z?9)&DR6%LPMK@W-_) X
MF6)Q#"%9 TZEB% /L.BO.?V1_P!J7X3?MK_LV^$/VJ/@=J4]UX7\::2M]IIN
MX@D\)#-'+!*H)"RQ2I)$X!(#QM@D8)]&H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHK-\7^)[3P9X:O/%%[IFI7L=G%O-II&FRWES,<@!8X
M8E9W8DCH,#J2 "0 :5%?)7_!+_\ X*U_#?\ X*EZ_P#%FV^%WP<\3>%--^%O
MB2VT627Q<T<5]?3R+-YA>UCW"VV-"5VF1V.>0A&*^>OVOO\ @Y)M?V-/C%HL
MWQ-_X)V?%"/X$ZWKYTG3OCO<R"WMM1=2=UQ9V30'SX&57EB9IXGGB0R1HRT
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M9(!Z]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16;XO\
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MK6A-N3;R6S1^0D>+6W $:(4$8V%: /@3]NG]CG]HC_@EE\7?VSO^"CO@G4O
M7B;X.?'7X6:C#XGTOQ/XJN-*U31=7GB,40A5;.XCO1)<3R)%%NB+&Z5&:,1[
MW^G_ /@VH_9E^)7[+'_!('X;>$?BUI5SIVM^(9;_ ,22:3>(5DL;>]N&DMHV
M4\HS0>5(5(!5I2I&0:^D_BK^P_\  WX__$?2OB)^T/;ZKX\C\.ZDNH>%_"_B
M6_#Z'I-TN=DZZ?$L<%S,F3LFNEGDCR=C+FO8* "BBB@ HHHH **** "BBB@
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M+9;)YH _2:BO*OBU^VS^S-\#_$FI>$_B-\1)H+S0M.CO_$G]F^'[_48=!M9
MS1SZC-:02QZ=&RJS*]RT895+ D#-=[\//'_@[XK^ -#^*7P[UZ'5?#_B71[;
M5="U2W#".\L[B)9H9EW ':\;JPR <'I0!L45^7/_  <0IXM\'?%S]DO4?AS\
M7_'_ (3D\?\ [1>B^%/&">$?B!JNEQ:GI5S)$LD$D5K<(F=JX#A0XRV#R:^Z
MO'7[7/[''[,7CCPG^SA\1/V@O#>@^*?$D\=GX7\*:GKYGU.[+EMKF-F>;RR0
MV9I,(,<O0!ZY17B/[./_  4C_85_:[^)^O?!G]FK]IWPOXQ\3^&K;[3JVDZ1
M=,SBWWJAN(F90MS"&9 982Z NF6^9<ZWQT_;A_9<_9OU6\T'XM_%$6E_IFE#
M5-9L-*T:]U2?2K [L7EY'8PS-9VY\N3$TX2,^6^&.TX /6**P_AI\3/AY\9?
M 6D_%/X3>-M+\1^&]=LUN]'US1;U+BUO(6Z/'(A*L.HX/!!!Y!K<H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBOS<_X+[_ W]J"'1?A/\8?^">7QC\;^%OC/J'Q9AT_2=-L?B!?P:-KJ
MQZ1J6I?9+G3WE-G*7;34C7?&J-YC+(=C$@ _2.BOD[_@E3_P4H^&W_!5?]EV
MY\0:AH<GAKQ]X<E.A?%SX>S2RV]YH&JJ&21=I*RI#(4=HW)##:Z$^9$X'._L
M$?LV^$?B5\'/C;X/\<?$'XD:A'>_'/QIHEMJ$_Q3UPWVF:?;:I)#;6]G<F[\
MVU6)(U"^6P/'S%LG(!]IT5^3?_!&WQO\4_V$/^"COQ:_X)2?MU_&?QOXR\::
MJY\2_ _XA>.O&>H:@OBCPX4&ZUBCN9FBBGC$+2,(UW%TO%+%8DW?1^G_  1T
M[]N;_@HIKGQ_TOXF_$+3OAA\)[>3PO+IGAWXBZMIVE^,_%:./M<CV]M<I$]M
MIRJML2J@3737"/N%J0X!]JT5^7/[1G[4?P5\=?\ !<_5OV%_^"B7Q/U+PK\.
M+'X::3<_!?PU>>)+K1]"\4ZM=,3=W5Y+#)$+FX4AK:WCF<P@PRA5\YEW?3?P
M-_8=\7?LS_M[#QY\.?BOX\U3X1ZM\*=2L;7P5XF\8WNK6/A?6!J.FOFT:\ED
MDCCN80Y6+<RQFUD";5<( #ZKHK\G_AM\/)?B%_P<E_&7]E/Q9\7/BC-\.-+^
M 5CXDTKP?:?%_P 0VEG9:F]QI<3SQ+;WR%,K++\@.S,C'&<8^T/"G[''PO\
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M#6E\0:=\,-:U(EC#%9ZA(^EW 8Y;RHKR%E '_+%-@PN!7J?_  3._;!\0?\
M!4KX2? GX1_$:.;_ (2;X0.^J?M$Z==C,L'B#0YS8Z5:W2_PR7-ZAU88^ZVE
M8XS@_HE\-OAOX#^#W@#1OA7\+O"5CH/ASP]IL-AHFC:9 (H+.VB4)'$BCH H
M _4\UQG[/_['_P "/V8_''Q,^(GP?\)#3M4^+7C1O%'C*;<#Y]^UO%"VS !6
M,F-YBI)_>W,[9P^  ?&O[:5G:Q_\'''[%M]';H)I?AWX_220*-S*NG2%03W
M+L1_O'UJO_P2.^)>K>//^"MO[?MA\6G*^-M)\>^'['2X+SB6/PS!;W<>GK"#
M]V$IB9@O!:X#GEP3]/\ Q<_X)R_"'XS_ +8'@[]N/Q/\1O'-KX\^'UI<6G@N
M;3-8@BL]+M[B-H[F);<V[)*LJNX<R^8QW8! 5 J_&S_@G#\$/BU^TA8?MB>$
MO%WB_P"&WQ5M-&.CW?CGX=ZK#:W.K:;D$6E]!<P3VMY&I52IEA9UV)AAL3:
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MOQO\=_';X/\ @O5K:]^(91M=T&^\07%SHRR" P231V3L8C-*C2!YY!)*1-,
MZK+(K 'E7[,'P7_X)^?MT_\ !"GX2^ OC%X>T;5O@U'\)]#N];A;5Y;&'3Y]
M-MXVNGEN;>2-X9(;F"?S6#@EEDW$AFSYBGQ&D\>?\' VK_!;4?VB_%GPT>__
M &8]$F^#ZZ9I^EK+J-B;V:>_@1-8L+HK,SJC.B*DK+8'?N$ "^G?"7_@WB_X
M)T_!3XMW'Q"\"6/C^'PU/KBZS_PJ*7Q[=-X/%\KK(DS:;D"8*ZHPCF>2,;%&
MS: M>H_\%#/^"3G['O\ P4QL_#UW^T-X=UFQ\1^$9S+X5\<>#]8;3M9TK<P9
MDCG56#(64,%=7"L-R[222 >*^+OV O@%^R-;?M>?%CP9^T)X^\6?$?XP?!34
M]7\>Z+XCFTS[)LAL;N"VOA;Z=IUK'!)(WVA%+']Z5G*J2DA'SIKMQ;?\09R2
M/,FS_A1=LFXL,;O[210/KNXQZU^D'[)/[ 7[.O[&GPKU?X5_#;2]7UI?$TAD
M\8>(?&^M2ZOJOB%S%Y(^V7,Y+2JL7R+& L:J6VJ-S$^!:+_P;W_L*:-\"/$W
M[,,OC'XLZC\/==69=&\&ZQ\1[B[TSPFLL_G2_P!E6LJM%;NQW+YSK+,JRR[7
M4RN6 /"_^"CS*?@S_P $P'!!!_:,^&N#_P!N KT/_@OM9VK_ !:_85OVMT,\
M?[;/@^-)2HW*K/(64'T)521_LCTKZ#^,O_!)_P#9&^-W[+?@G]DCQ/!XSM?#
MOPWUO3M8\!:O8^/=1;6=!OK%#';3VU_/+),A2-F55R40$;%4JA6+X[_\$I/V
M<OVA--^&.B>,O&GQ!MK/X0^((/$/@B/3_%K&6#7(IFG&K7%Q.DD]Y=M([.TD
M\D@9BS%=SN6 /!OA[\8[-O\ @YK^(7PH^,&HK#?)^S=I<?P?@OFVK):->"XU
M,6P;@RR2J2Y7YF2R.<K%QV_[7WPD_P""4_[)'P:_:Q^)/Q7\'W>GVGQ(\'6^
MN?M!6_A[5+U[S5+><W5E9&-#-Y=M/<3-<QQB,Q"20NS_ "@L._\ V\/^"27[
M)G_!1-/"6O?'D>)['QIX'4#PS\2_!NN#2=?LQP6 GAC\LAG&_:8]J,6,83<V
M=/PC_P $L/V.?"_[)'BW]C#4O!FJ^(O"OC^%QX[U/Q5XAN;_ %GQ!.RHHNKJ
M_D<S/,@BB\M@5$7E)L50,4 ?G_\ M^:=\94TG_@G-XD\3>%_#'@GPA!^U!\/
M[#P-\/-)>?4=1T?3C#M@6\U6215N)/LZ1J\,4 5&W#S[@!7KW?\ ;W_Y6%OV
M!_\ L7OB9_Z837<WO_! G]AS7/A-X(^%7C+Q=\7-??X<>)+#6/!'BK6?BKJ$
MNL:%]B#"WM+*Y#K]@ME!'R6RQ-F*%MVZ&-D],^)?_!,+X$?$S]H_X=?M33^.
M?'&C^*/A'I<FG?#5=$UJ&.TT&UDMA;311PR0.LPEBRKF?S2P;&0H50 ?*'[4
MGAK_ (*1?L*_M4?&;]O7_@GYIOA?X]_"SQGJMM=_&;X(ZK.UOK6DZA8:9;VT
MTFG3@'S";6&%C&0[;655@D^5A]H_\$WOC=\"?VBOV#_A3\6OV9/#EWHO@*^\
M%V=KX8T._'[[2[:T7[)]C<Y;<T+0-%N!(;R\@D'-8VI_\$[/",7Q,^(/Q/\
MAS^T?\5_!4WQ3OUO/'>D^&O$-H;'4)1:Q6F^..[M)S92&"&-#-:M#,0BGS,J
MI7USX)?!7X7?LY?"3P]\"O@IX.M?#_A3PMI<>GZ%H]F6*6T"# &YB6=B<LSL
M2S,2S$DDD _.G_@X](_X6;^PUS_S=_X:_P#1R5M?\%T_!7A#QQ^V5^P;H/C+
MPS8ZK8WG[0LEM>6>H6JRQ7$#VL9>)U8$.C;%W(<JP4 @BOI3]M;_ ()>? ?]
MOKQGX2\9_'_Q_P"/BW@'7(]9\%6'A_Q#'I]OH^H)Y96ZC\J$/)*&C5@TKOM)
M8+M!Q4W[0_\ P35^%?[4OCGX:?$OXQ_&'XB7NN?"/5AJW@>_LM7L[3[)J(93
M]KD2&T6.>0A$4B163:I&SYWW 'SC^U)IFG:+_P '*'[*NJ:1916UQJ7P5\86
M5_+ @5I[>&*22*)L=51V9@#P">*C_P"""OQ*\/?'*#]K[P?\7'@O/B1_PU!X
MG@^(NF:B=UR=/=8K2PB8'YOLJPV\MO$OW5$$@ YR?ICXA?\ !-_X4?$[]KGP
M=^W!XJ^*OC]OB#X!TV;3_"E];:O:Q6ME:S(R7$1MEM?*E$H=]YD5F^88*[$V
M^=_M-_\ !"W]B']IK]IF?]KJ74OB'\/_ !SJMND'BK5?A7XYN-"_X2*)0HV7
M@A!+95%#-&8V;:-S$@$ 'M?[#_P-_96_9C^!$?[.W[&F@IIG@?P;KNHZ?!81
M:C=7D<%[]I>6\C6XN7D>4I<2RHV'8)(CQ\&-E7UZOGK]H[_@F#^R?^TK^QGI
M_P"P5KWA_5_#7PYTFXL)=,T[P;K#V,\!M)A-&/-(<R;G!9VDW,[,9"WF8<?0
M-I;165K%9P%]D,:HGF2%VP!@99B2Q]R230!)1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 >0?&;QG^VKHGC>2P^!OP7\'ZYH MHVCO\ 6O$;VTYE
M(^=2@4C .,'O7*?\+*_X*:_]&T?#G_PLY/\ XFOHJBOH</GN&H4(TY8"A-I6
MYI*I=^;M52OZ)>A\YB<@Q6(Q$JD<?7@F[\L72Y5Y*])NWJWZGSK_ ,+*_P""
MFO\ T;1\.?\ PLY/_B:/^%E?\%-?^C:/AS_X6<G_ ,37T516W^L6$_Z%V'^Z
MK_\ +3'_ %;Q?_0RQ'WTO_E)\Z_\+*_X*:_]&T?#G_PLY/\ XFC_ (65_P %
M-?\ HVCX<_\ A9R?_$U]%44?ZQ83_H78?[JO_P M#_5O%_\ 0RQ'WTO_ )2?
M.O\ PLK_ (*:_P#1M'PY_P#"SD_^)H_X65_P4U_Z-H^'/_A9R?\ Q-?15%'^
ML6$_Z%V'^ZK_ /+0_P!6\7_T,L1]]+_Y2?.O_"RO^"FO_1M'PY_\+.3_ .)H
M_P"%E?\ !37_ *-H^'/_ (6<G_Q-?15%'^L6$_Z%V'^ZK_\ +0_U;Q?_ $,L
M1]]+_P"4G*?!G5_C#K?@B._^.7A#2=#UXW,BR6&BZ@;F 1 _(P<@')&<CM7C
M'_!0 @?%3]EO)_YN2M__ %%_$=?25>.?M(?L7^$?VGO&W@WQQXU^+7CK2I?A
M_P"(HM?\)67AO5K>UM[/5(X9H!=,IMV,[>5/-&4F9X]LCC9\S9^>Q%6->O*I
M&"@F[\L;V7DKMNWJWZGT>&HRP]"-.4W-I6YI6N_-V25WY)+R/AK_ (*S?LA_
M&_\ 8-_:13_@N?\ \$X/"S7>O:-:^7^T/\,;+*6_C30!M,UZ$4'%S$B!G8 G
M]VDV"T4BS?0/_!#[X\^!_P!J3]DOQ5^T?\-!=C0/'/QL\8ZWI"7\'E3I!<ZI
M+*J2+DA74-@@$C(."1@U]@6-E);:9#IU]?2WS1P+'-<W2('N"%P7<(JIENI"
MJJY)P .*X']F/]E7X)?L>?#^]^%7[/OA)-!\.7GB34-;CT:!OW%I<7LYGF2!
M<?NH?,9BL8X0':N%  Q-C\\/^#L_P-I7A+]A7PG^V]X'O+O0?BG\(?B-ID_@
M3QEH]QY-Y8"YDV31;P/FC8I$^T_Q1+V+!OTH^!/P>\ _L_\ P=\-_!?X7Z/]
MAT'PYI,5GIT#2&21E4?-)([?-+*[%I))&RSN[,Q)8FO*_P!OW_@G!\#/^"E/
MP\M_@]^TQXI\7R^#[>\AO6\,^']8CL;>>[B\S9/(Z0F9R!(1L,GEC:I"!AN/
ML/PQ\"S_  U\%V7@J;QSKGB);")8H-2\130RW;1JH55>2**,2$ ??8%VY+,Q
MYH ^</VR_P!C#_@G_P#\%>(/&?[+G[27P[74]>^&5_;6PUFSE6VUC0VOK&&[
MAN;.X7<RQ2*Y4I(ICDDMG#1L$4U\=?\ !.W2_P!N+_@DA_P59\*_\$C?BA^T
M+J'QB^"/Q)\#ZEK?POU?75)U'PN+&.21K=V+,4B A,)C!,+&6%XQ$3)%7W7\
M0?\ @F=\#?&7[1/B']KOPG\0/B)X&^)_B:WM;34O&/@KQC+:L]E;V\<,5H]G
M*LMC<1+Y9D'GV\K!Y'(8#:%V?@'^P3\)?@;\7M8_:/U7QCXN\?\ Q-UO1TT>
MZ^(?Q!U6*\U&WTQ7\P6-K'!##:V5OYF9&CMX(P[_ #/N(& #\_M-^ WPV_:$
M_P"#J?XT^$/B?;:S+8VG[,VF7D*Z)XJU'2)1*+K2D&Z6PGAD9=LC?(S%2<'&
M5!'W!\&OV/\ ]F[]@?XY^,_CWX3\2ZMIMM\5;3PKX:ET_7O$FI:S-+J=M=ZA
M';F*6]FGF_>?VDBE%(CC$#RD*/,>N:N/^".GP%E_:IUW]MJV^/7QCLOBCXFT
M==)UOQ9I?CE;.2YL5\G;;>3! D*1 P0D(J 9C#8SS79>$_\ @G)\+]$^.?A+
M]H/QG\:OBMXXUOP++=3^%K/QOX\FOM/L+BXMI;62Y6TVK$9_)FE192"RB1L$
M9H ^@Z^(%NOVK?VDO^"@GC#]I#]G/0_AYJ7A/X0V-U\-?"\GCK5KZ!7U9WMK
MK7KVV6U@D!Q(EGIY9L%7T^Y49#M7V;XO\/S^*_#%]X;MO$NI:.][;M$-3TB1
M$NK;/\<32(ZJWH2IQU'.#7FG[&G[&?P\_8;^&,OP<^$OCCQ?J?AUM1N;^VLO
M%NM+J$EM<W-S-<W4JSM&)F,T\\DC^8[C<25VY;(!^<W[#EU\7_\ @F1_P7F\
M=_LQ_'_3O#6C^%?VO])E\;>$(?"E[<3:5;>)[5I6N[>)[F.-E>5?M,CKMZR6
MB#/&/4O^"@O@WPEXI_X.%_V&+?Q+X:L=0BD\+?$"22*]M4E5G@TOSH&(8$$Q
MR_.I/W6 88(S7T1^VA_P2A_9S_;R^,/@GXX_'3QM\0(M<^&MXUYX ?PSXH_L
MU-"N6>!WG@,,0<R,]M"Q9V8@Q@# XJ_\1_\ @FA\*_BK^TSX _:_\9?&7XC3
M>/\ X8:;-9>"M8AUFSC2PBG@,%T3;K:"&9IT9_,,B-G=@;55%4 ^8_$?P^\"
MWW_!UYI.I7WA#39[C_ABQ=7\Z:S1F%_'XFEMH[K)'^N6%1&'^\%  .*Y?X=Z
MGXO^'/\ P6-_X*0:Q\%[(PZ]'\#_  MJ^DVME%_Q\:M'H$K02; ,-(9".<9)
M8^IK[0N?^"<OPENOVX8_^"A<OQ-\>?\ "R(= _X1^*Y&L6_V)=#^T&X_LO[+
M]G\O[/YC$YQYN3N\S?\ /1\(O^"<OPB^#/[7WB[]N+PY\2?'5YX]\?64%GXR
MGU368);/5+:WC6.WB:V6W5(A$J)L,(C8;3DD,X8 ^,_^":?[*/PF_P""G/\
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M>\.W'PP\*:M--JWB6^LY-<1H;^[O#,(;%Y&EDE^S(MRVUU!G3YHA^J'[+?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 444V:&.XA>WE!*NI5L,0<$8ZCD4
M.HK\:?\ @H_\3_VQ/^"57_!3Z[_:Q_9/UCQ_XY^#'A7X8:)KOQT^$^L^.]0U
M:"'3]1U/4[.74-/@O)9!;&'^SHI"R$"-F)($#3!?O+]J/XP_!_\ ;#_X)/\
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MWCK2(V2#5;GP+XSBNOLS$[D5I[&8M"QVDC#*3M/O0!Z!17XW_P#!#']F*_\
MV[?V6?CUJGQI_:Q_: 7Q3X;_ &A?$?A/PAXQTOX^^)H;O1+"UM+![81Q"_\
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M+&_V69!*K),_#@\X(Y KK/VD_P!B;X?^%/\ @G_K/QQ^&_[4OQB^&/BWPO\
M#23Q#8>.HOCCXBNHK>Y@L?M&;NVO[Z:VNK=G0"2.2,Y4G:5;!H ^ZJ*^#_\
M@F_^W7IW[9/_  1'\/?M-_\ !2;QEHO@RS\6^&M6T/QMXFU/5$T.UO[=;BYT
M\W<<NZ,6\D\:;AY97]X6,0 V@>_?L/M^Q_\ !?\ 8*\$S_LR_$F"3X+^'/"9
ME\/>*M<UB0Q#3(C(SW$MQ=;2L8PY+-M55' 50  #W*BO%_ /_!0W]CCXD_$O
M1O@_X:^-5M%XB\2VKW/A2PUK2;W3!XBA0;FDTV6\ABCU% IW;K9I!M^;IS7C
M/[2?_!97]GWX"?\ !0_P)^PGJ6MR0R7NDZGJWCS79=&NI8-.BAMC]EM(FCC/
MFS23,&<H&$2Q!6PTGR@'V=17FWQ?_:Z_9Z^!5M82_$CQ^T%QJFFOJ-AI.EZ/
M>:EJ$UDFWS+H6=G#+<>0F]0\ICV(64,P)%:'P4_::_9]_:,^#T'[0'P/^,.@
M>)?!=Q#+*/$>FZ@C6T2Q9\T2L2/):/!WK)M9,'<!0!W-%>)>"/\ @HW^Q5\0
M_B;H/PA\,?'>Q.N>+8I9?!L=_IUW9VWB5(U#.VF7=Q"EOJ0"L&S;22Y4[AD<
MU\-_#;XC_!C]CS_@X+_:9^(/QA^+\^@^#['X!>'[ZYU'QCXINKR.TFN+R &*
M!KJ61QOD "6\7!9@L:<A: /U1HKQSX1?\%!_V)/CK^SY?_M6_#+]I[PA>_#K
M2+F2VUGQ==ZLME::;-'LW17+7/EFV<>9&=LH4D2(0"&4GA/%/_!:#_@EIX*\
M#>%/B3XH_;9\&6FB>-WG'AF_>XE(NXXKR6RDG*K&6AMQ<031B>0)$QC;#D#-
M 'T]17-_$'XP_"GX4?#JY^+OQ*^(NC:'X7M+>.:?7]2U&.*T"2%5C(D)VL79
MD5 ,EV=0H)(!XOX0_MP_LM_''XF7GP5\ ?%)5\9V.G+J,WA#7]'O='U5[(G
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M_A7IE%'^K&,_Z&F)^^C_ /*0_M>A_P! E+[I_P#RP\S_ .$H_:J_Z)9X9_\
M!XW^%'_"4?M5?]$L\,_^#QO\*],HH_U8QG_0TQ/WT?\ Y2']KT/^@2E]T_\
MY8>9_P#"4?M5?]$L\,_^#QO\*/\ A*/VJO\ HEGAG_P>-_A7IE%'^K&,_P"A
MIB?OH_\ RD/[7H?] E+[I_\ RP\S_P"$H_:J_P"B6>&?_!XW^%>CV3W<EG"]
M_$L<[1*9D1LJKXY /<9J6BO5RO*JV72DZF*JUKV_B.#M;MR0AOUO<X\7C*>*
M24:,*=OY>;7UO*1\RZ5I.E:__P %:/B-H6NZ;;WME>_LR^%8+RSNX5DBGB?7
MO$JO&Z,"&5E)!!!!!(-?F%^VIX2^)?\ P;OW7Q=^&GA'2-5US]CC]I#PIX@T
M_0K* /._PV\67FFSQQ0+G)^RS-M49Y:)<_-);'S_ -;M"_8F\,:!^U3?_MB0
M_&OX@3^+]5T.VT/48KG5+1M/GTJWN);B&Q^RBU$:1I)-,0Z!9OWKGS,L2>S_
M &C?V=_A!^UC\$/$G[.WQZ\'6^O>$_%>FO9:OIMP/O(<%9$8<QRHX61)%PR.
MBLI! ->N<)P7BS]H+1OV5_\ @GG;?'[6=,DU ^'/AOI\VG:1 ?WNJW[VT,-G
M8Q?]-;BYDA@0?WY5KY!^(_\ P3&_X*"?&3_@F!XH_8!^)FA? W4;CQI8WNJ>
M(O$\OB'5OMMQXEN[QM3DU(_Z&4\P7[;PN[:$58PVT5]=_M&?\$_/A5^TUX0\
M!^ O&_Q'\>:9I'PYU33-4\.V/AKQ$MDIU#3G1[*[GVQ$SO$\:.JN3'N4-LR
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MP^"?$7B/Q#X)T^P_L_2]&\;ZFFIBSL=A0V:N\89X-IVB.0NJKA5PHVT =O\
M"+XI^"_CC\*_#?QF^'&L1:AH'BO0[75M&O87#+-;7$2RQL"/56'T/%?F%X[\
M$:G^U1_P=L^#/B#\-$:YT;]F_P"!'V?X@ZG#S%;7]_%JZV]DSC@2M'JT4@CZ
ME8I3_"<>@?MP?\$P_P!OKX!?!>Z@_P""$O[5&H?#6S26>XO_ ((:I+:W&CW(
MD<R2#1[F^BE?1G9RY\F.2.W)DRI@P2_N/_!+?4_V<? WP<MOAQX4^ ^O?"#X
MAZS=2:CX^\&?$,7+:_JFMLNZ\O'U"[);70Q5F%[%)*A3 /EE3&@!Z-_P4;^"
M7BW]I/\ 8#^-'P"\ +NU[Q?\,=;TO1(M^T2WDUE*L,9/8/(54GL&-?+O_!KY
M\8_"GQ&_X(^_#_X<Z?,+?Q%\-=0U;PUXRT29=EQIE\FHW$ZI+&<,A:&:)^0.
M68=5-?H57RW\3/\ @D=^S7XI_:#U7]JWX,^-_B%\&/B'XBQ_PEGB/X0>*!IB
M^(2"2&OK.:*>SN7R68N\&\LQ8L3S0!]'^)/&WA7PA=Z5I_B+68K:YUS4ET_1
M[8@M)>7)1Y/+C1068B..21B!A$C=V(56(_/3_@W6^)6J_$^V_:UUSXL,?^%G
M_P##6'B%?&<-WS=6]ND%K!8P'/S"")89X8DZ*(G K[2^"W[*O@WX0:^WCS5O
M'/BWQUXM>S:S_P"$N\>ZW]MO(;9F5GAMXXTCMK-'9$9UMH8O-,<9DW^6FW@O
M&?\ P3-^"FI?M*:W^US\'_B)XZ^%7CSQ980V?C?5/ASK%O;P>)HXAB)KVUN[
M>XMY)D7*K.L:3 ,?GYH _.C]F;P+J?PZ_9P_X*X_ SP[8A/A/X>U'Q>W@C34
M3-GI]_/H6H3:C;0+TC6,&Q&Q<!>.YK8_: ^'W@6V_P"#.*SM[7PAIL22_ OP
MQJTHBLT7??&XL'-R<#F4L 2_WO>OT8U#_@GM^SX?V2_$'[%WA1==\.^#?%T>
MH)XQGTC5RVIZ^=0$G]H27=[<++---<F1S+,6\ULX#A?EKD?$7_!)W]G[Q7^P
MQ;?\$Y-=^(_Q"F^%%K9PV*:(->MUN&L(7CDALFNEMA,84>-6 W[C]UF9 $ !
M\??\%M?!WA/PC_P0]^"DGA;PU8Z<VB^.OA]?Z2;*U2+[)=22(9)TV@;9',LI
M9QRQD8DDDUV7[=/PX^'WQ!_X.-OV2-(\=^$-.U:U;X6>+;AK34+598I9;='G
M@9T88?RY?WJA@0K@,,$ U]*?M"?\$JO@5^U)^S5X6_9*^-?Q1^(NJ>"?",UG
M+IEE#X@@MKB1[1=MHTUQ#;++*85&%RW) 9][ ,/B_P#;^L_A/XC_ .#@7]DG
MX5>*_P!IJ_TS5- ^&/B=3XIM/$]I9ZM87YAE:V:1E00^9+L=?)EB,<RED:-P
MQ! .H^/OP3T[X1?\'.?P%^)O[.GA:VT[4/'?P5\5-\5K+2(E@CO[2TMY1:7-
MT$ !+W;6<7F-U-O$.JBNB_X-A?&\?QL_X)CZWXB^):)J'CC6?B[XK?XN)J,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS^Q-\%M,_9[_ &8/AE8^%/">DEWMM-LW>1I)7.7FFEE9I)Y6.,R2,S' &<
M>;_L'_\ !,/X"_\ !.6'7]*_9L\;>.8M(\4ZW+K/B'1/$&OIJ%O>ZC(BH]V6
MEA,J2E43)1U#;%W!L#'T;0!YE^TMK/[/VN67AW]FS]HSPGINO:-\7]6N/#5M
MHFM6<4]G?S)I]UJ#0RI(<',-E,5P"=ZKC!P1^1/[?W_!./XQ_P#!O-I&K?\
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M$ 8[2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *IS>'/#US<&[N-"LY)6;+2O:H6)]<D9JY10 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVFA#"&5D!9 V-P!ZC.!G'7%2444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388976378976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,370,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#8217;s 2024 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8217;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#8217;s fiscal year ended December&#160;31, 2023.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388976369360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young&#160;LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388974841152">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 14,310,862<span></span>
</td>
<td class="nump">$ 46,329,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">130,982,913<span></span>
</td>
<td class="nump">206,669,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,393,665<span></span>
</td>
<td class="nump">50,130,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,432<span></span>
</td>
<td class="nump">375,227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">153,113,100<span></span>
</td>
<td class="nump">315,242,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,960,986<span></span>
</td>
<td class="nump">7,727,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investments in affiliated entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,780,287<span></span>
</td>
<td class="nump">2,007,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,129,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,491,735<span></span>
</td>
<td class="nump">10,228,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">605,315<span></span>
</td>
<td class="nump">684,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">170,951,423<span></span>
</td>
<td class="nump">348,533,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,365,382<span></span>
</td>
<td class="nump">10,594,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,406,522<span></span>
</td>
<td class="nump">2,803,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87,489<span></span>
</td>
<td class="nump">2,475,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,918<span></span>
</td>
<td class="nump">87,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,770,654<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,570,228<span></span>
</td>
<td class="nump">96,868,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,614,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,032,066<span></span>
</td>
<td class="nump">12,655,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,046<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,602,294<span></span>
</td>
<td class="nump">126,170,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December&#160;31, 2023 and 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2023 and 2022, issued and outstanding: 22,793,075 at December 31, 2023 and 21,090,938 at December 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22,792<span></span>
</td>
<td class="nump">21,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,740,954,074<span></span>
</td>
<td class="nump">1,710,888,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,622,965,136)<span></span>
</td>
<td class="num">(1,487,847,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(662,601)<span></span>
</td>
<td class="num">(698,741)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">117,349,129<span></span>
</td>
<td class="nump">222,362,756<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">170,951,423<span></span>
</td>
<td class="nump">348,533,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,701,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,847,744<span></span>
</td>
<td class="nump">79,686,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,405,228<span></span>
</td>
<td class="nump">10,036,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,070,519<span></span>
</td>
<td class="nump">$ 1,220,439<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company effected a reverse stock split of its outstanding shares of common stock on January 24, 2024 where every twelve shares of its common stock issued and outstanding was converted into one share of common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any fractional post-split shares as a result of the reverse split were paid in cash. Shareholders of the Company authorized the Board of Directors to approve the reverse stock split at a special meeting of stockholders held on January 12, 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding share amounts have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388976142848">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22,793,075<span></span>
</td>
<td class="nump">21,090,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22,793,075<span></span>
</td>
<td class="nump">21,090,938<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company effected a reverse stock split of its outstanding shares of common stock on January 24, 2024 where every twelve shares of its common stock issued and outstanding was converted into one share of common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any fractional post-split shares as a result of the reverse split were paid in cash. Shareholders of the Company authorized the Board of Directors to approve the reverse stock split at a special meeting of stockholders held on January 12, 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding share amounts have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388977639536">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 832,010<span></span>
</td>
<td class="nump">$ 10,262,268<span></span>
</td>
<td class="nump">$ 1,774,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,676,563<span></span>
</td>
<td class="nump">187,650,503<span></span>
</td>
<td class="nump">249,240,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,582,104<span></span>
</td>
<td class="nump">90,185,285<span></span>
</td>
<td class="nump">53,752,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">144,772,038<span></span>
</td>
<td class="nump">277,835,788<span></span>
</td>
<td class="nump">302,992,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(143,940,028)<span></span>
</td>
<td class="num">(267,573,520)<span></span>
</td>
<td class="num">(301,217,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,133,290<span></span>
</td>
<td class="nump">4,782,030<span></span>
</td>
<td class="nump">3,363,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,222,789)<span></span>
</td>
<td class="num">(1,253,952)<span></span>
</td>
<td class="num">(1,936,447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">773,145<span></span>
</td>
<td class="num">(1,899,654)<span></span>
</td>
<td class="num">(553,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,850,626<span></span>
</td>
<td class="num">(7,846,172)<span></span>
</td>
<td class="num">(3,222,838)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,711,596)<span></span>
</td>
<td class="num">(3,861,584)<span></span>
</td>
<td class="nump">343,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before share in net loss of Geneos</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(135,117,352)<span></span>
</td>
<td class="num">(277,652,852)<span></span>
</td>
<td class="num">(303,224,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,165,213)<span></span>
</td>
<td class="num">(434,387)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (135,117,352)<span></span>
</td>
<td class="num">$ (279,818,065)<span></span>
</td>
<td class="num">$ (303,658,710)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (6.09)<span></span>
</td>
<td class="num">$ (14.07)<span></span>
</td>
<td class="num">$ (17.45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (6.09)<span></span>
</td>
<td class="num">$ (14.07)<span></span>
</td>
<td class="num">$ (17.45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22,173,662<span></span>
</td>
<td class="nump">19,885,182<span></span>
</td>
<td class="nump">17,402,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22,173,662<span></span>
</td>
<td class="nump">19,885,182<span></span>
</td>
<td class="nump">17,402,483<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480228/946-830-45-39<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388977967440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parenthetical)<br></strong></div></th>
<th class="th"><div>Jan. 24, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.083333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388976140448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (135,117,352)<span></span>
</td>
<td class="num">$ (279,818,065)<span></span>
</td>
<td class="num">$ (303,658,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(3,920)<span></span>
</td>
<td class="num">(25,556)<span></span>
</td>
<td class="num">(30,134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on short-term investments, net of tax</a></td>
<td class="nump">40,060<span></span>
</td>
<td class="num">(390,949)<span></span>
</td>
<td class="nump">4,048<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (135,081,212)<span></span>
</td>
<td class="num">$ (280,234,570)<span></span>
</td>
<td class="num">$ (303,684,796)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388969434400">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Adjustment</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th" colspan="2"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th">
<div>Accumulated deficit </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">15,570,957<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 461,140,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,571<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,367,578,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (906,196,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (256,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,275,861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">209,441,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,276<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">209,439,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock/senior notes to common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,120<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock/senior notes to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,377,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,377,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,299<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,057,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,057,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,336,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26,336,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(303,658,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(303,658,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(30,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,134)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">399,669,421<span></span>
</td>
<td class="num">$ (1,468,216)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,115<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,609,789,064<span></span>
</td>
<td class="num">$ (3,294,019)<span></span>
</td>
<td class="num">(1,209,855,522)<span></span>
</td>
<td class="nump">$ 1,825,803<span></span>
</td>
<td class="num">(282,236)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">18,115,237<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,870,478<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82,955,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">82,952,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,223<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,114,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,114,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,555,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,555,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(279,818,065)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(279,818,065)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(390,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(390,949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,556)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222,362,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,090<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,710,888,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,487,847,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(698,741)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">21,090,938<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for legal settlement (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,083<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for legal settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13,999,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,305<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,461,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 875<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,460,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,749<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(466,646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(466,713)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,072,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,072,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(135,117,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135,117,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,920)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 117,349,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,792<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,740,954,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,622,965,136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (662,601)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">22,793,075<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All share amounts in this column, including appropriate reclassifications between common stock and additional paid-in capital, have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388977967440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 72: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388969697344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (135,117,352)<span></span>
</td>
<td class="num">$ (279,818,065)<span></span>
</td>
<td class="num">$ (303,658,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,621,649<span></span>
</td>
<td class="nump">3,656,713<span></span>
</td>
<td class="nump">3,040,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">145,417<span></span>
</td>
<td class="nump">496,494<span></span>
</td>
<td class="nump">520,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">736,472<span></span>
</td>
<td class="nump">1,342,819<span></span>
</td>
<td class="nump">1,170,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">1,984,444<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes</a></td>
<td class="num">(32,046)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">11,072,486<span></span>
</td>
<td class="nump">22,555,419<span></span>
</td>
<td class="nump">26,336,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_NonCashInterestIncomeExpense', window );">Non-cash interest on senior convertible notes</a></td>
<td class="nump">155,814<span></span>
</td>
<td class="nump">186,977<span></span>
</td>
<td class="nump">858,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of (discounts) premiums on investments</a></td>
<td class="num">(4,686,144)<span></span>
</td>
<td class="num">(1,320,546)<span></span>
</td>
<td class="nump">1,633,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Realized loss on sales of short-term investments</a></td>
<td class="nump">4,805,804<span></span>
</td>
<td class="nump">4,029,961<span></span>
</td>
<td class="nump">5,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GainLossOnRemeasurementOfEquityMethodInvestment', window );">Gain on remeasurement of investment in Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(165,215)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Net loss on disposal of fixed assets</a></td>
<td class="nump">317,997<span></span>
</td>
<td class="nump">1,074,830<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">(Gain) loss on equity investment in affiliated entity</a></td>
<td class="num">(773,145)<span></span>
</td>
<td class="nump">1,899,654<span></span>
</td>
<td class="nump">553,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Share of net loss in Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,165,213<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gain) loss on available-for-sale equity securities</a></td>
<td class="num">(5,850,626)<span></span>
</td>
<td class="nump">7,846,172<span></span>
</td>
<td class="nump">3,222,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized transaction (gain) loss on foreign-currency denominated debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(176,927)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, including from affiliated entities</a></td>
<td class="nump">9,332,988<span></span>
</td>
<td class="num">(3,706,172)<span></span>
</td>
<td class="nump">11,031,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets, including from affiliated entities</a></td>
<td class="nump">39,020,611<span></span>
</td>
<td class="num">(5,336,525)<span></span>
</td>
<td class="num">(6,343,632)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">78,729<span></span>
</td>
<td class="nump">741,750<span></span>
</td>
<td class="nump">24,531,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses, including due to affiliated entities</a></td>
<td class="num">(45,989,061)<span></span>
</td>
<td class="nump">32,606,581<span></span>
</td>
<td class="nump">26,140,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="num">(8,228,691)<span></span>
</td>
<td class="nump">267,807<span></span>
</td>
<td class="nump">375,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue, including from affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(85,989)<span></span>
</td>
<td class="num">(39,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="num">(2,020,971)<span></span>
</td>
<td class="num">(2,603,956)<span></span>
</td>
<td class="num">(2,329,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability, including from affiliated entity</a></td>
<td class="num">(2,453,297)<span></span>
</td>
<td class="num">(2,034,517)<span></span>
</td>
<td class="num">(2,973,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,826)<span></span>
</td>
<td class="num">(42,837)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(124,365,551)<span></span>
</td>
<td class="num">(216,215,421)<span></span>
</td>
<td class="num">(215,708,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(203,475,052)<span></span>
</td>
<td class="num">(248,528,843)<span></span>
</td>
<td class="num">(348,953,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale or maturity of investments</a></td>
<td class="nump">284,932,562<span></span>
</td>
<td class="nump">361,083,850<span></span>
</td>
<td class="nump">174,839,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="num">(320,898)<span></span>
</td>
<td class="num">(969,153)<span></span>
</td>
<td class="num">(1,231,006)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of capital assets</a></td>
<td class="nump">6,219,263<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Investment in Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,999,998)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">87,355,875<span></span>
</td>
<td class="nump">109,585,856<span></span>
</td>
<td class="num">(175,344,484)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">5,461,745<span></span>
</td>
<td class="nump">82,955,311<span></span>
</td>
<td class="nump">209,441,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ProceedsfromStockOptionandWarrantExercises', window );">Proceeds from stock option exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">283,022<span></span>
</td>
<td class="nump">6,668,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(466,646)<span></span>
</td>
<td class="num">(1,397,631)<span></span>
</td>
<td class="num">(4,611,348)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,995,099<span></span>
</td>
<td class="nump">81,840,702<span></span>
</td>
<td class="nump">211,498,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(3,920)<span></span>
</td>
<td class="num">(25,556)<span></span>
</td>
<td class="num">(30,134)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Decrease in cash and cash equivalents</a></td>
<td class="num">(32,018,497)<span></span>
</td>
<td class="num">(24,814,419)<span></span>
</td>
<td class="num">(179,584,340)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">46,329,359<span></span>
</td>
<td class="nump">71,143,778<span></span>
</td>
<td class="nump">250,728,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">14,310,862<span></span>
</td>
<td class="nump">46,329,359<span></span>
</td>
<td class="nump">71,143,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for purchases of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">108,181<span></span>
</td>
<td class="nump">204,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,066,975<span></span>
</td>
<td class="nump">1,066,975<span></span>
</td>
<td class="nump">1,077,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets', window );">Change in prepaid expenses and other current assets related to fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,071,000<span></span>
</td>
<td class="nump">7,709,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock as part of litigation settlement</a></td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Prepaid Expenses And Other Current Assets, Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GainLossOnRemeasurementOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Remeasurement Of Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GainLossOnRemeasurementOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsfromStockOptionandWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Stock Option and Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsfromStockOptionandWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388977991920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company</a></td>
<td class="text">The Company<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA&#174; delivery devices help its DNA medicines enter the body&#8217;s cells for optimal effect. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related anal dysplasia and oropharyngeal squamous cell carcinoma (OPSCC); glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in August 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140389061235728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss of $135.1 million for the year ended December&#160;31, 2023. The Company had working capital of $110.5 million and an accumulated deficit of $1.6 billion as of December&#160;31, 2023. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $145.3 million as of December 31, 2023 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings, including under At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $5.5&#160;million, $83.0&#160;million and $47.7&#160;million from equity offerings under Sales Agreements during the years ending December 31, 2023, 2022 and 2021, respectively, and $162.1&#160;million from a January 2021 underwritten public offering of common stock. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, as previously amended, to effect a 1-for-12 reverse stock split of our common stock (the &#8220;Reverse Stock Split&#8221;).  As a result of the Reverse Stock Split, every 12 issued and outstanding shares of the Company's common stock were automatically combined into one issued and outstanding share of common stock. The reverse stock split was reflected on the Nasdaq Capital Market beginning with the opening of trading on January 25, 2024. Accordingly, an amount equal to the par value of the decreased shares resulting from the reverse stock split was reclassified from "Additional paid-in capital" to "Common stock" on the balance sheet and statement of changes in stockholders&#8217; equity. Any fractional post-split shares as a result of the reverse stock split were eliminated by the payment of cash for the value of such fractional share. As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding stock options and outstanding shares of Series C Cumulative Convertible Preferred Stock and to the number of shares of common stock issuable under the Company's equity incentive plans. The reverse stock split did not change the par value of the Company's common stock or the authorized number of shares of the Company's common stock. All share amounts and per share amounts disclosed in this Annual Report on Form 10-K have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash equivalents, short-term investments, investments in affiliated entity, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes for disclosure purposes only.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain mutual funds and U.S. treasury securities at December&#160;31, 2023 and 2022.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2023 and 2022. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. There was no allowance for doubtful accounts for potential credit losses as of December&#160;31, 2023 and 2022.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets include property and equipment and leasehold improvements. Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:f-447">three</span> to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of long-lived assets, which includes fixed assets and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. No impairment losses have been recognized related to long-lived assets for the year ended December 31, 2023 and 2022.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goodwill and Intangible Assets</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate the carrying amounts of the assets may not be recoverable. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company&#8217;s stock price. This sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of September 30, 2023. The Company first tested its long-lived assets for impairment. The Company determined that all of its long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, represented one asset group for purposes of its long-lived asset impairment assessment. The Company concluded that the long-lived assets were not impaired, as their carrying values were not in excess of their fair value. Next, the Company determined that the fair value of its reporting unit was less than its carrying value and the Company recorded a loss on impairment of goodwill of $10.5&#160;million. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2023, the Company also recorded an impairment charge of $2.0&#160;million to research and development expense for the remaining book value of intangible assets acquired in 2016 from Bioject Medical Technologies, as the Company had no plans to further develop or utilize this technology. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Refer to Note 8 for further information regarding Goodwill and Intangible Assets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $327.5 million and $299.1 million at December&#160;31, 2023 and 2022, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-research and development expense as opposed to revenue on the consolidated statement of operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.&#160;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2023, 2022 and 2021, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes would have been anti-dilutive. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658,098&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387,806&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements.  Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2023-07. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the Chief Operating Decision Maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and disclosures.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2023-09. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2023-09 requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978024272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition and Concentration of Credit Risk</a></td>
<td class="text">Revenue Recognition and Concentration of Credit Risk<div style="margin-bottom:3pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the years ended December&#160;31, 2023, 2022 and 2021, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloBio Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc. (affiliated entity)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Defense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,591,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,262,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No revenue recognized during the year ended December&#160;31, 2023 was in deferred revenue as of December 31, 2022. During the year ended December 31, 2022, the Company recognized revenue of $14,000 that was included in deferred revenue at December 31, 2021. Performance obligations are generally satisfied within 12 months of the initial contract date. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2023, the Company had no accounts receivable balance. As of December&#160;31, 2022, all of the Company's accounts receivable was attributable to the CEPI MERS grant. There is minimal credit risk with the Company's customers based upon the short-term nature of the accounts receivable, collection history, their size and financial condition. Accordingly, the Company does not record an allowance for potential credit losses against its accounts receivable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978050000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements <div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#8217;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. In the fourth quarter of 2022, the Company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine continues to develop INO-4800 with its own resources under the terms of the Advaccine Agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research and development expense on the consolidated statement of operations once earned and collectibility was assured.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023, 2022 and 2021, the Company received funding of $3.6&#160;million, $1.2&#160;million and $4.5 million, respectively, from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), which was amended on June 14, 2023. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company received funding of $245,000 from the ApolloBio Agreement that was recorded as revenue. For the years ended December 31,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">there were no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant reimbursable program costs under the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with CEPI, pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS.  As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56&#160;million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023, 2022 and 2021, the Company received funding of $1.8 million, $6.7 million and $10.0 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December&#160;31, 2023 and 2022, the Company had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an accounts receivable balance of $0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $1.7&#160;million, respectively, on the consolidated balance sheet related to these CEPI grants. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had $2.2&#160;million recorded as an accrued liability, and at December 31, 2022, had</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded as deferred grant funding on the consolidated balance sheet related to these CEPI grants.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $9.0&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $6.9&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.0&#160;million to accelerate development of the Company's next-generation intradermal electroporation device, known as CELLECTRA 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3&#160;million to support large-scale manufacturing of INO-4800. During the years ended December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received funding of $330,000, $1.1 million and $6.9 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December&#160;31, 2023, the Company had $2.1&#160;million recorded as an accrued liability, and at December 31, 2022, had</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $2.3&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Gates awarded and funded the Company a grant of $2.2&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1&#160;million for the project. During the years ended December&#160;31, 2023, 2022 and 2021, the Company recorded $70,000, $233,000 and $182,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December&#160;31, 2023 and 2022, the Company had $87,000 and $153,000, respectively, recorded as deferred grant funding on the consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. The total amount of funding provided to the Company under the OTA Agreement was $54.5&#160;million. The Company determined that the OTA Agreement should be considered under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which is outside the scope of Topic 606, as the government agency granting the Company funds was not receiving reciprocal value for their contributions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded contra-research and development expense on the consolidated statement of operations in the same period that the underlying expenses were incurred. During the years ended December&#160;31, 2023, 2022 and 2021, the Company recorded $0, $6.1 million and $27.1 million, respectively, as contra-research and development expense related to the OTA agreement.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The total purchase price under the Procurement Contract was $16.8&#160;million. The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Company determined that the Procurement Contract fell under the scope of ASC Topic 606 as the contract was with a customer and the Company was able to satisfy its obligations under the arrangement. Performance obligations under the Procurement Contract consisted of the delivery of a specified number of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. In 2021, the DoD announced that it would discontinue funding for the Phase 3 segment of the Company's clinical trials for INO-4800 and in January 2022, the total purchase price under the Procurement Contract was reduced to $10.7&#160;million. During the year ended December 31, 2022, all performance obligations under the Procurement Contract were satisfied. During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2023, 2022 and 2021</span>, the Company recorded revenue of $0, $9.6&#160;million and $755,000, respectively, from the Procurement Contract.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140389061217456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2023 and 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,389,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,522,888)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,164,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,873,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927,161)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,036,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,001,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,450,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,802,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $1,000 and $21,000, respectively, and gross realized loss on investments of $4.8 million and $4.1 million, respectively. During the years ended December&#160;31, 2023 and 2022, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $5.9&#160;million and $(7.8)&#160;million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2023,&#160;2022&#160;and&#160;2021. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2023, the Company had&#160;21&#160;available-for-sale securities in a gross unrealized loss position, of which 20 with an aggregate total unrealized loss of $3.9 million were in such position for longer than 12 months. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2023&#160;were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December&#160;31, 2023, the Company did not record an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:38.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,056,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,763,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,836,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,627,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,676,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,634,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2023 and 2022 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain or loss on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2023 and 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div>There were no Level 3 assets held as of December&#160;31, 2023 or 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2023 and 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,389,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,522,888)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,164,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,873,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927,161)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,036,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,001,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,450,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,802,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $1,000 and $21,000, respectively, and gross realized loss on investments of $4.8 million and $4.1 million, respectively. During the years ended December&#160;31, 2023 and 2022, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $5.9&#160;million and $(7.8)&#160;million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2023,&#160;2022&#160;and&#160;2021. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2023, the Company had&#160;21&#160;available-for-sale securities in a gross unrealized loss position, of which 20 with an aggregate total unrealized loss of $3.9 million were in such position for longer than 12 months. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2023&#160;were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December&#160;31, 2023, the Company did not record an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:38.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,056,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,763,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,836,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,627,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,676,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,634,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2023 and 2022 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain or loss on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2023 and 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div>There were no Level 3 assets held as of December&#160;31, 2023 or 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978107760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Certain Balance Sheet Items</a></td>
<td class="text">Certain Balance Sheet Items<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets at December&#160;31, 2023 and 2022 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance recovery (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,907,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,729,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,130,481&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2023 and 2022 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,862,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,574,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses (b) (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,432,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,847,744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,686,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:24.91pt">In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of class action securities litigation (see Note 11). The final judicial order for the settlement was issued in January 2023. The settlement consisted of $30.0&#160;million in cash and $14.0&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts were offset against the insurers' cash commitment as part of the settlement. During the three months ended March 31, 2023, the cash component of the settlement was released from escrow and the Company issued 760,083 shares of common stock pursuant to the securities class action settlement.</span></div><div style="padding-left:36pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)        In March 2023, the Company entered into a stipulation of settlement for the proposed settlement of shareholder derivative litigation (see Note 11). In June 2023, the court preliminarily approved the proposed settlement. As part of the settlement, in July 2023, the Company paid $1.2&#160;million to plaintiffs&#8217; counsel for their fees and expenses. This amount was accrued within &#8220;Other accrued expenses&#8221; as of December 31, 2022. On October 12, 2023, the court entered an order and final judgment approving the Settlement, which was effective on November 13, 2023.</span></div><div style="padding-left:36pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)       December 31, 2023 balance includes $4.3&#160;million liability for unused grant funding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388977982960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text">Fixed Assets<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2023 and 2022 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,917,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,753,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,164,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,538,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,078,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,816,577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,204,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,812,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,851,913)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,960,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,803,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,036,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,767,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,295,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,803,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,360,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,428,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,291,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,563,403)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,727,997&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Depreciation expense for the years ended December&#160;31, 2023, 2022 and 2021 was $2.6 million, $3.7 million and $3.0 million, respectively. The Company determined that the carrying value of its fixed assets was not impaired during the periods presented. During the year ended December 31, 2023, the Company sold fixed assets with no net book value for a gain of $148,000 and disposed of fixed assets with a net book value of $466,000. During the year ended December 31, 2022 the Company sold fixed assets with a net book value of $6.1&#160;million and disposed of fixed assets with a net book value of $1.1&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978023040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended September 30, 2023, as a result of the sustained decline in the Company&#8217;s stock price and related market capitalization, and a general decline in equity values in the biotechnology industry, the Company performed an impairment assessment of its goodwill and long-lived assets.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company operates as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company&#8217;s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company&#8217;s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represented a level 2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a non-cash, pre-tax goodwill impairment charge of $10.5&#160;million during the three months ended September 30, 2023. As a result, the goodwill was fully impaired as of September 30, 2023.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Before completing the goodwill impairment assessment, the Company first tested its long-lived assets for impairment. The Company held no indefinite-lived intangible assets as of Sep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">tember 30, 2023. The Company determined that all of its long-lived assets, which included property and equipment, leasehold improvements and right-of-use assets, represented one asset group for purposes of its long-lived asset impairment assessment. The Company concluded that the long-lived assets were not impaired, as their carrying values were not in excess of their fair value.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the quarter ended June 30, 2023, the Company recorded an impairment charge of $2.0&#160;million to research and development expense for the remaining book value of intangible assets acquired in 2016 from Bioject Medical Technologies, as the Company had no plans to further develop or utilize this technology. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.267%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,513,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,323,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bioject </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,115,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,984,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,988,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,111,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (a)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,050,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,031,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,150,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,165,556)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,984,444)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,129,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,663,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,165,556)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,497,815)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,643,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Other intangible assets represent the estimated fair value of acquired intellectual property. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to intangible assets was $145,000, $496,000 and $520,000 for the years ended December&#160;31, 2023, 2022 and 2021, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no impairment or impairment indicators present and no losses were recorded during the years ended December 31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978026272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Notes were senior unsecured obligations of the Company and accrued interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes matured on March 1, 2024 and the Company paid the then remaining $16.9&#160;million obligation in full, including accrued interest.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $16.3&#160;million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of 13.1%. In addition, the Company allocated $592,000 of debt issuance costs to the equity component and the remaining debt issuance costs of $2.2&#160;million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, the Company adopted ASU No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;). The ASU eliminated the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, the Company accounted for these securities as a single unit of account, unless the conversion feature met certain criteria. The Company adopted the new standard using the modified retrospective method and recorded a net reduction to accumulated deficit of $1.8&#160;million, a decrease to additional paid-in capital of $3.3&#160;million, and an increase to convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Notes were subsequently accounted for as a single liability measured at amortized cost, as no other embedded features required bifurcation and recognition as derivatives.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December&#160;31, 2023 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,770,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>For the years ended December&#160;31, 2023, 2022 and 2021,&#160;the Company recognized $1.2 million, $1.3&#160;million and $1.9&#160;million, respectively, of interest expense related to the Notes, of which $1.1 million related to the contractual interest coupon in each year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978091984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:47.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $0.001</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holder of a share or shares of Series C preferred stock has the right at any time, at such holder&#8217;s option, to convert all or any lesser portion of such holder&#8217;s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2021, the conversion value w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as $326.40 per share, such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that the outstanding shares of Series C preferred stock were convertible into an aggregate of 275 shares of common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the years ended December&#160;31, 2023 and 2022, the Company sold 875,305 and 2,870,478 shares, respectively, of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $6.33 and $29.34 per share, respectively, resulting in aggregate net proceeds of $5.5&#160;million and $83.0&#160;million, respectively. As of December&#160;31, 2023 there was $161.8&#160;million of remaining capacity under the 2021 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company issued 760,083 shares of common stock pursuant to the securities class action settlement, as described in Note 11.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors adopted the 2023 Omnibus Incentive Plan (the &#8220;2023 Plan&#8221;) on March 24, 2023, pursuant to which the Company may grant stock options, restricted stock awards, RSUs and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Plan was approved by stockholders on May 16, 2023. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2023 Plan will not exceed the sum of 1,166,666 shares plus any shares that may return from time to time from the 2016 Omnibus Incentive Plan (as amended, the &#8220;2016 Plan&#8221;) as a result of expirations, terminations or forfeitures of awards outstanding under the 2016 Plan as of May 16, 2023. At December&#160;31, 2023, the Company had 1,334,012 shares of common stock available for future grant under the 2023 Plan, 1,875 shares underlying outstanding but unvested RSUs and 3,150 shares underlying options outstanding to purchase common stock under the 2023 Plan. The awards granted and available for future grant under the 2023 Plan generally vest over three years and have a maximum contractual term of ten years. The 2023 Plan terminates by its terms on March&#160;24, 2033.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company had 262,641 shares underlying outstanding but unvested RSU and options outstanding to purchase 961,499 shares of common stock under the 2016 Plan. The outstanding awards granted under the 2016 Plan generally vest over three years and have a maximum contractual term of ten years. Following adoption of the 2023 Plan, no further awards may be made under the 2016 Plan, but outstanding awards continue to be governed by their existing terms. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2022 Inducement Plan will not exceed 166,666 shares. At December&#160;31, 2023 the Company had 125,575 shares of common stock available for future grant under the 2022 Inducement Plan, 10,278 shares underlying outstanding but unvested RSUs and options outstanding to purchase 27,759 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2023, the Company had options outstanding to purchase 136,456 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2023, 2022 and 2021 was $10.4 million, $22.2 million and $25.0 million, respectively, of which $4.5 million, $8.8 million and $13.4 million was included in research and development expenses and $5.9 million, $13.4 million and $11.6 million was included in general and administrative expenses, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023 and 2022, there was $4.3 million and $10.5 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.3 years and 1.6 years, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023 and 2022, there was $3.5 million and $7.2 million, respectively, of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.5 years and 1.7 years, respectively.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the years ended December&#160;31, 2023, 2022 and 2021 was $669,000, $1.3 million and $1.4 million, respectively. As of December&#160;31, 2023, options to purchase 61,808 shares of common stock granted to non-employees remained outstanding.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:26.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.32-$18.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18.01-$39.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$39.01-$52.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$52.01-$90.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$90.01-$130.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.01-$233.28</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the aggregate intrinsic value of options outstanding was $2,000, the aggregate intrinsic value of options exercisable was $1,000, and the weighted average remaining contractual term of options exercisable was 5.5 years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, the aggregate intrinsic value of unvested RSUs was $1.7 million and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2023 was $1.3 million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, options to purchase 1,128,864 shares of common stock and 274,794 RSUs were expected to vest.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2023 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:70.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2023 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price per share was $38.86 for the 9,357 options which expired during the year ended December&#160;31, 2023, $101.64 for the 6,437 options which expired during the year ended December&#160;31, 2022 and $54.72 for the 583 options which expired during the year ended December&#160;31, 2021.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $11.19, $28.08 and $91.32 for options granted during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value was $10.34, $37.44 and $124.44 per share for RSUs granted during the years ended December&#160;31, 2023, 2022 and 2021, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock options were exercised during the year ended December 31, 2023.  The Company received $283,000 and $6.7 million in proceeds from the exercise of stock options during the years ended December&#160;31, 2022 and 2021, respectively. The aggregate intrinsic value of options exercised was $81,000 and $7.0 million during the years ended December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388979123024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 56,600 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December&#160;31, 2023 of 3.4 years to 6.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company amended one of its leases representing 31,207 square feet of office and laboratory space with a lease term expiring in November 2023, to extend the term to February 29, 2024.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company entered into a lease agreement for research and development laboratory space in San Diego, California ("New San Diego Lease"). The total space under the New San Diego Lease is approximately 5,563 square feet.  The term of the New San Diego Lease commenced on February 10, 2024 and the initial term is 4.3 years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the New San Diego Lease.  Rent payments under the New San Diego Lease will include base rent with an annual increase of approximately three percent, and additional monthly fees to cover the Company's share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, the Company has paid a security deposit of $33,000. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,247,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,466,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,555,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,665,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,226,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,439,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,407,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,032,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2023, 2022 and 2021 were $3.5 million, $3.4 million and $3.4 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third and fourth quarters of 2023, the Company entered into agreements to sublease a total of approximately 4,400 and 7,000 square feet, respectively, in its Plymouth Meeting headquarters, in each case with sublease terms through December 31, 2026.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters, with one sublease term through March 31, 2025 and the other month-to-month.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. The plaintiffs&#8217; complaint was later amended to include certain of the Company&#8217;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, the Company agreed to pay $30.0&#160;million in cash and $14.0&#160;million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers paid the $30.0&#160;million cash component of the settlement. During the three months ended March 31, 2023, the Company issued 760,083 shares of common stock pursuant to the securities class action settlement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserted state and federal claims and was based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accused the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff sought unspecified </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monetary damages on behalf of the Company as well as governance reforms. Between June 2020 and August 2020, additional shareholder derivative complaints were filed and later consolidated by the court. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, an additional shareholder derivative complaint was filed in the Delaware Court of Chancery, asserting substantially similar claims as those in the consolidated derivative action. In May 2022, the Delaware Court of Chancery entered a stay of the litigation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the parties submitted a joint status report to the Court of Chancery reporting that the parties agreed to a settlement in principle, which also provided for the resolution of the consolidated derivative action and certain stockholder demands. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the plaintiffs in the consolidated derivative action filed a motion for preliminary approval of settlement with the United States District Court for the Eastern District of Pennsylvania. The proposed settlement provided for resolution of the consolidated derivative action, the derivative action pending in the Delaware Court of Chancery, and certain stockholder demands.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the court entered an order preliminarily approving the proposed settlement of the derivative claims, in accordance with a Stipulation of Settlement. The Stipulation of Settlement contemplated that, following the settlement hearing and the final approval of the settlement by the court, the Company would implement certain corporate governance reforms described in the Stipulation of Settlement. The preliminary order also approved the form and manner of the notice of the Settlement. As part of the Settlement, in July 2023 the Company paid $1.2&#160;million to plaintiffs&#8217; counsel for their fees and expenses. In October 2023, the court entered an order and final judgment approving the Settlement, which became effective in November 2023. The Company has implemented the corporate governance reforms in response to the provisions of the Stipulation of Settlement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an appeal by the Company, in July 2020, VGXI filed counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. The Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. In October 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. The Company filed preliminary objections to the complaint, which were overruled by the court. In September 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978082432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,979,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,440,803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,614,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,117,351)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,652,052)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303,224,323)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no provision for or benefit from income taxes for the years ended December 31, 2023, 2022 and 2021. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2023, 2022 and 2021, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,375,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,307,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,677,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,922,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,601,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,447,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,394,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,065,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,424,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,139,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,534,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,523,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,099,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,509,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,337,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,246,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,143,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,252,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,624,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,768,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,734,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,442,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,822,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,247,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,808,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,062,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,486,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,439,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,493,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,124,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,993,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,148,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,993,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,347,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company had federal, California and other state tax net operating loss (NOL) carryforwards of $1,013.3 million, $251.4 million and $102.6 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $719.3 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year. The federal NOL carryforward began to expire in 2023, and the California and other state NOL carryforwards will begin and have begun to expire in 2028 and 2023, respectively, unless previously utilized. </span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also had Korean NOL carryforwards of $1.1 million as of December 31, 2023. The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2035, unless previously utilized. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2023, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $41.6 million and $6.1 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;D credit carryforwards as of December&#160;31, 2023. As a result of the analysis, the Company estimates that approximately $7.3 million of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets accompanied by a corresponding reduction of the valuation </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes, may further limit the ability to use the NOL and R&amp;D carryforwards.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2023, 2022 and 2021, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,139,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,602,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(582,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,114,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,139,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $20.5 million, $19.7 million and $17.4 million as of December&#160;31, 2023, 2022 and 2021, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2020 and state and local income tax examinations before 2019. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not to its knowledge currently under Internal Revenue Service (&#8220;IRS&#8221;), state, local or foreign tax examination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978088544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text">401(k) Plan<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees&#8217; contributions, up to 6% of their annual compensation. The Company&#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $1.4 million, $1.8 million and $1.5 million for the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978091984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company owned 597,808 shares of common stock in PLS as of December 31, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, representing a 17.8% and 18.7% ownership interest, respectively. One </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December&#160;31, 2023,  2022 and 2021, the Company recognized revenue from PLS of $0, $34,000 and $245,000, respectively. At December 31, 2023 and 2022, the Company had an accounts receivable balance of $0 and $59,000, respectively, related to PLS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the exclusive right to in-license new intellectual property developed under this agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $13.6&#160;million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding extended through August 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The sub-grant also includes an option for an additional $1.6&#160;million in funding through September 2025. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company received a $1.2&#160;million sub-grant through Wistar with funding through November 2023, with an option for an additional $5.4&#160;million in funding through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched nanoparticles (dLNPs) for vaccination against HIV infection.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2023 and 2022, the Company recorded $1.0 million and $8.7 million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December&#160;31, 2023, 2022 and 2021 were $1.8 million, $1.4 million and $2.9&#160;million, respectively. At December&#160;31, 2023 and 2022, the Company had an accounts receivable balance of $2.4 million and $9.9 million, respectively, and an accounts payable and accrued liability balance of $1.1 million and $1.2 million, respectively, related to Wistar. As of December&#160;31, 2023 and 2022, the Company had a prepaid expense balance of $20,000 and $375,000, respectively, and recorded $22,000 and $88,000, respectively, as deferred grant funding on its consolidated balance sheet related to Wistar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388977982960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. <div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a series of financing transactions through June 2020, the Company less than a majority of the outstanding equity of Geneos on an as-converted to common stock basis, which triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance. Accordingly, the Company deconsolidated its investment in Geneos in 2020.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its investment at fair value. The Company determined that its investment in Geneos did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment is marked to fair value.&#160;There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 was allocated to the equity method investment, reducing the balance to $0 as of March 31, 2021. The remaining $4.2 million loss was allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, reducing the balance to $0 as of March 31, 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of its Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 28% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-2 preferred stock was based on the per share price paid by third-party investors. The Company concluded that its Series A-2 preferred stock investment was a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not made any further investment in Geneos subsequent to March 31, 2022. The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, Geneos completed the closing of its Series A-3 preferred stock financing, in which the Company did not participate. Following this transaction, the Company held approximately 23% of the outstanding equity of Geneos on an as-converted to common stock basis. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span>&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388977955776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2024, the Company implemented the 1-for-12  reverse stock split described in Note 2.  All share information contained within this report, including the accompanying consolidated financial statements and footnotes, have been retroactively adjusted to reflect the effects of the reverse split.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January 1, 2024 through the date of these financial statements, the Company sold 543,620 shares of common stock under the 2021 Sales Agreement for net proceeds of $5.2&#160;million.  The sales were made at a weighted average price of $9.76 per share.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, the Company's Convertible Senior Notes matured and the Company paid the $16.9&#160;million obligation in full.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388974666160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (135,117,352)<span></span>
</td>
<td class="num">$ (279,818,065)<span></span>
</td>
<td class="num">$ (303,658,710)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978496208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971786992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Liquidity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss of $135.1 million for the year ended December&#160;31, 2023. The Company had working capital of $110.5 million and an accumulated deficit of $1.6 billion as of December&#160;31, 2023. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $145.3 million as of December 31, 2023 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings, including under At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $5.5&#160;million, $83.0&#160;million and $47.7&#160;million from equity offerings under Sales Agreements during the years ending December 31, 2023, 2022 and 2021, respectively, and $162.1&#160;million from a January 2021 underwritten public offering of common stock. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, </span></div>occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></div>The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div>Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash equivalents, short-term investments, investments in affiliated entity, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes for disclosure purposes only.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain mutual funds and U.S. treasury securities at December&#160;31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short Term Investments</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2023 and 2022. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span>consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div>Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. There was<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets include property and equipment and leasehold improvements. Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:f-447">three</span> to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of long-lived assets, which includes fixed assets and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. No impairment losses have been recognized related to long-lived assets for the year ended December 31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goodwill and Intangible Assets</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate the carrying amounts of the assets may not be recoverable. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company&#8217;s stock price. This sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of September 30, 2023. The Company first tested its long-lived assets for impairment. The Company determined that all of its long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, represented one asset group for purposes of its long-lived asset impairment assessment. The Company concluded that the long-lived assets were not impaired, as their carrying values were not in excess of their fair value. Next, the Company determined that the fair value of its reporting unit was less than its carrying value and the Company recorded a loss on impairment of goodwill of $10.5&#160;million. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2023, the Company also recorded an impairment charge of $2.0&#160;million to research and development expense for the remaining book value of intangible assets acquired in 2016 from Bioject Medical Technologies, as the Company had no plans to further develop or utilize this technology. </span></div>Refer to Note 8 for further information regarding Goodwill and Intangible Assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $327.5 million and $299.1 million at December&#160;31, 2023 and 2022, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div>The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div>The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantRevenuePolicyTextBlock', window );">Grants</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span>, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-research and development expense as opposed to revenue on the consolidated statement of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities (VIE)</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span>For the years ended December 31, 2023, 2022 and 2021, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes would have been anti-dilutive.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span>The Company recognizes forfeitures as they occur.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements - Recently Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements.  Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2023-07. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the Chief Operating Decision Maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and disclosures.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2023-09. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2023-09 requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Revenue [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-5A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-2AA<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140389061552144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Shares That Were Excluded From The Diluted Net Loss Per Share Calculation Because of Their Anti-Dilutive Effect</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658,098&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387,806&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used To Estimate The Fair Value Of Stock Options</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978183328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Revenue From External Customers</a></td>
<td class="text">The following table indicates the percentage of total revenues in excess of 10% with any single customer:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloBio Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc. (affiliated entity)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Defense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,591,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,262,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971880224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2023 and 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,389,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,522,888)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,164,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,873,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927,161)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,036,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,001,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,450,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,802,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:38.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,056,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,763,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,836,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,627,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,676,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,634,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388975133872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses And Other Current Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets at December&#160;31, 2023 and 2022 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance recovery (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,907,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,729,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,130,481&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable And Accrued Expenses</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2023 and 2022 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,862,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,574,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses (b) (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,432,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,847,744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,686,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:24.91pt">In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of class action securities litigation (see Note 11). The final judicial order for the settlement was issued in January 2023. The settlement consisted of $30.0&#160;million in cash and $14.0&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts were offset against the insurers' cash commitment as part of the settlement. During the three months ended March 31, 2023, the cash component of the settlement was released from escrow and the Company issued 760,083 shares of common stock pursuant to the securities class action settlement.</span></div><div style="padding-left:36pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)        In March 2023, the Company entered into a stipulation of settlement for the proposed settlement of shareholder derivative litigation (see Note 11). In June 2023, the court preliminarily approved the proposed settlement. As part of the settlement, in July 2023, the Company paid $1.2&#160;million to plaintiffs&#8217; counsel for their fees and expenses. This amount was accrued within &#8220;Other accrued expenses&#8221; as of December 31, 2022. On October 12, 2023, the court entered an order and final judgment approving the Settlement, which was effective on November 13, 2023.</span></div><div style="padding-left:36pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)       December 31, 2023 balance includes $4.3&#160;million liability for unused grant funding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978235744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule Of Fixed Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2023 and 2022 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,917,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,753,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,164,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,538,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,078,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,816,577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,204,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,812,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,851,913)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,960,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,803,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,036,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,767,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,295,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,803,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,360,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,428,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,291,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,563,403)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,727,997&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978202784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Goodwill and Intangible Assets By Major Asset Class</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.267%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,513,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,323,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bioject </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,115,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,984,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,988,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,111,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (a)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,050,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,031,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,150,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,165,556)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,984,444)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,129,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,663,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,165,556)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,497,815)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,643,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span>Other intangible assets represent the estimated fair value of acquired intellectual property.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978207968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December&#160;31, 2023 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,770,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388969424704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Preferred Stock Authorized, Issued And Outstanding</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:47.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $0.001</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule Of Shares Authorized Under Stock Option Plans, By Exercise Price Range</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:26.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.32-$18.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18.01-$39.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$39.01-$52.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$52.01-$90.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$90.01-$130.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.01-$233.28</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule Of Stock Options, Activity</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2023 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:70.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule Of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2023 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978249328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule Of Maturities Of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,247,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,466,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,555,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,665,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,226,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,439,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,407,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,032,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978496208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule Of Components Of Pretax Loss From Operations</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,979,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,440,803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,614,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,117,351)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,652,052)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303,224,323)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule Of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2023, 2022 and 2021, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,375,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,307,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,677,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,922,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,601,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,447,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,394,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,065,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,424,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,139,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,534,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,523,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,099,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,509,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,337,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,246,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule Of Deferred Tax Assets And Liabilities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,143,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,252,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,624,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,768,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,734,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,442,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,822,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,247,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,808,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,062,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,486,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,439,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,493,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,124,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,993,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,148,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,993,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,347,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock', window );">Schedule Of Operating Loss And Tax Credit Carryforward Expirations</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule Of Unrecognized Tax Benefits Rollforward</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,139,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,602,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(582,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,114,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,139,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971109568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,117,352<span></span>
</td>
<td class="nump">$ 279,818,065<span></span>
</td>
<td class="nump">$ 303,658,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622,965,136<span></span>
</td>
<td class="nump">1,487,847,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,461,745<span></span>
</td>
<td class="nump">82,955,311<span></span>
</td>
<td class="nump">209,441,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327,493,000)<span></span>
</td>
<td class="num">(299,124,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,984,444<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.083333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="nump">$ 83,000,000<span></span>
</td>
<td class="nump">47,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount of current assets and current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971842672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Securities Table (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">1,658,098<span></span>
</td>
<td class="nump">1,494,827<span></span>
</td>
<td class="nump">1,387,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">1,128,864<span></span>
</td>
<td class="nump">1,018,095<span></span>
</td>
<td class="nump">874,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">274,794<span></span>
</td>
<td class="nump">212,964<span></span>
</td>
<td class="nump">204,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,328<span></span>
</td>
<td class="nump">55,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible notes | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">254,165<span></span>
</td>
<td class="nump">254,165<span></span>
</td>
<td class="nump">254,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388969791840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract', window );"><strong>Summary of assumptions used to estimate the fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
<td class="nump">0.91%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract', window );"><strong>Summary of assumptions used to estimate the fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">1.96%<span></span>
</td>
<td class="nump">1.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumptions used in estimation of fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971700224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 832,010<span></span>
</td>
<td class="nump">$ 10,262,268<span></span>
</td>
<td class="nump">$ 1,774,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_ApolloBioCorporationMember', window );">ApolloBio Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 245,056<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_ApolloBioCorporationMember', window );">ApolloBio Corporation | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember', window );">Plumbline Life Sciences, Inc. (affiliated entity)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 33,596<span></span>
</td>
<td class="nump">$ 245,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember', window );">Plumbline Life Sciences, Inc. (affiliated entity) | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DoDMember', window );">U.S. Department of Defense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,591,778<span></span>
</td>
<td class="nump">$ 754,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DoDMember', window );">U.S. Department of Defense | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All other, including affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 586,954<span></span>
</td>
<td class="nump">$ 636,894<span></span>
</td>
<td class="nump">$ 774,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All other, including affiliated entities | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_ApolloBioCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_ApolloBioCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AllOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388976249216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from deferred revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388970573088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 832,010<span></span>
</td>
<td class="nump">$ 10,262,268<span></span>
</td>
<td class="nump">$ 1,774,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">ApolloBio Corporation | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Obligation period to pay royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">6,700,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | Lassa Fever And MERS Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | COVID19 Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | IN O4800</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill And Melinda Gates Foundation | Collaborative Arrangement | D N A Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">233,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
<td class="nump">153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department Of Defence | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Grant proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="nump">27,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeArrangementRevenueFromTheProcurementContract', window );">Procurement contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="nump">$ 755,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department Of Defence | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded', window );">Purchase price, procurement contract</a></td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="nump">$ 16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementFixedPriceContractAmountAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementRevenueFromTheProcurementContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement , Revenue from the Procurement Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementRevenueFromTheProcurementContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_INO4800Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_INO4800Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971643696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Schedule of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 134,873,427<span></span>
</td>
<td class="nump">$ 216,450,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">36,647<span></span>
</td>
<td class="nump">21,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(3,927,161)<span></span>
</td>
<td class="num">(9,802,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">130,982,913<span></span>
</td>
<td class="nump">206,669,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">55,389,289<span></span>
</td>
<td class="nump">117,036,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(3,522,888)<span></span>
</td>
<td class="num">(9,373,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 51,866,401<span></span>
</td>
<td class="nump">107,662,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual maturity</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 75,164,782<span></span>
</td>
<td class="nump">95,001,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">24,938<span></span>
</td>
<td class="nump">7,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(44,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">75,189,720<span></span>
</td>
<td class="nump">94,964,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">2,978,917<span></span>
</td>
<td class="nump">2,977,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">11,709<span></span>
</td>
<td class="nump">13,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 2,990,326<span></span>
</td>
<td class="nump">$ 2,990,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual maturity</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 1,340,439<span></span>
</td>
<td class="nump">$ 1,435,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(403,973)<span></span>
</td>
<td class="num">(384,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 936,466<span></span>
</td>
<td class="nump">$ 1,051,261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388977773104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>position </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Debt securities, available-for-sale, realized gain</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Debt securities, available-for-sale, realized gain</a></td>
<td class="nump">4,800,000<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="nump">$ 5,850,626<span></span>
</td>
<td class="num">$ (7,846,172)<span></span>
</td>
<td class="num">$ (3,222,838)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | position</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in a gross unrealized loss position for more than twelve months | position</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (in shares) | shares</a></td>
<td class="nump">597,808<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388967807088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 130,982,913<span></span>
</td>
<td class="nump">$ 206,669,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">51,866,401<span></span>
</td>
<td class="nump">107,662,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,990,326<span></span>
</td>
<td class="nump">2,990,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">936,466<span></span>
</td>
<td class="nump">1,051,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">130,982,913<span></span>
</td>
<td class="nump">206,669,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">2,780,287<span></span>
</td>
<td class="nump">2,007,142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">133,763,200<span></span>
</td>
<td class="nump">208,676,539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">127,056,121<span></span>
</td>
<td class="nump">202,627,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">2,780,287<span></span>
</td>
<td class="nump">2,007,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">129,836,408<span></span>
</td>
<td class="nump">204,634,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">3,926,792<span></span>
</td>
<td class="nump">4,042,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">3,926,792<span></span>
</td>
<td class="nump">4,042,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">51,866,401<span></span>
</td>
<td class="nump">107,662,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">51,866,401<span></span>
</td>
<td class="nump">107,662,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">75,189,720<span></span>
</td>
<td class="nump">94,964,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">75,189,720<span></span>
</td>
<td class="nump">94,964,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,990,326<span></span>
</td>
<td class="nump">2,990,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,990,326<span></span>
</td>
<td class="nump">2,990,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">936,466<span></span>
</td>
<td class="nump">1,051,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">936,466<span></span>
</td>
<td class="nump">1,051,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971747600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Schedule of Prepaid and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EstimatedInsuranceRecoveries', window );">Insurance recovery</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PrepaidManufacturingExpensesCurrent', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">1,486,638<span></span>
</td>
<td class="nump">1,401,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">3,907,027<span></span>
</td>
<td class="nump">18,729,453<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 5,393,665<span></span>
</td>
<td class="nump">$ 50,130,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidManufacturingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Manufacturing Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidManufacturingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EstimatedInsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EstimatedInsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388976291504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantLiability', window );">Unused grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,577,826<span></span>
</td>
<td class="nump">$ 19,862,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,837,104<span></span>
</td>
<td class="nump">12,574,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,432,814<span></span>
</td>
<td class="nump">3,249,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,847,744<span></span>
</td>
<td class="nump">79,686,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember', window );">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of cash settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares', window );">Estimate of shares settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Amount paid to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares', window );">Shares issued in settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_BehestiVKimEtAlMember', window );">Behesti v. Kim, et al.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Damages paid</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccountsPayableAndAccruedExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable and Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccountsPayableAndAccruedExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Amount Awarded to Other Party, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LitigationSettlementAmountAwardedToOtherPartyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Possible Loss, Value of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LossContingencyEstimateOfPossibleLossValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_BehestiVKimEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_BehestiVKimEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388969723936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 25,812,899<span></span>
</td>
<td class="nump">$ 29,291,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(20,851,913)<span></span>
</td>
<td class="num">(21,563,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">4,960,986<span></span>
</td>
<td class="nump">7,727,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,621,649<span></span>
</td>
<td class="nump">3,656,713<span></span>
</td>
<td class="nump">$ 3,040,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PropertyPlantAndEquipmentDisposedOfBySale', window );">Property, plant and equipment sold</a></td>
<td class="nump">148,000<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, plant and equipment disposed of</a></td>
<td class="nump">466,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">15,917,596<span></span>
</td>
<td class="nump">15,803,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(11,753,081)<span></span>
</td>
<td class="num">(10,036,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">4,164,515<span></span>
</td>
<td class="nump">5,767,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Research and development equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">3,538,698<span></span>
</td>
<td class="nump">5,300,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(3,078,165)<span></span>
</td>
<td class="num">(4,295,217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">460,533<span></span>
</td>
<td class="nump">1,004,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">2,827,476<span></span>
</td>
<td class="nump">2,827,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(2,816,577)<span></span>
</td>
<td class="num">(2,803,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">10,899<span></span>
</td>
<td class="nump">23,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Computer equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">3,529,129<span></span>
</td>
<td class="nump">5,360,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(3,204,090)<span></span>
</td>
<td class="num">(4,428,306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">$ 325,039<span></span>
</td>
<td class="nump">$ 932,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PropertyPlantAndEquipmentDisposedOfBySale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Disposed Of By Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PropertyPlantAndEquipmentDisposedOfBySale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971781200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,984,444<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,417<span></span>
</td>
<td class="nump">496,494<span></span>
</td>
<td class="nump">520,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388969492384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Goodwill and Intangible Assets By Major Asset Class (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="num">$ (10,500,000)<span></span>
</td>
<td class="num">(10,513,371)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,150,000<span></span>
</td>
<td class="nump">10,473,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,165,556)<span></span>
</td>
<td class="num">(8,343,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,984,444)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,129,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and intangible asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,497,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsGross', window );">Total goodwill and intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,663,371<span></span>
</td>
<td class="nump">20,987,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsNet', window );">Total goodwill and intangible assets, net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">12,643,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,323,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,323,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses | Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,115,556)<span></span>
</td>
<td class="num">(2,988,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,984,444)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,050,000)<span></span>
</td>
<td class="num">(4,031,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other | Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388977715792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Feb. 19, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,622,965,136)<span></span>
</td>
<td class="num">$ (1,487,847,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,740,954,074)<span></span>
</td>
<td class="num">(1,710,888,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222,789<span></span>
</td>
<td class="nump">1,253,952<span></span>
</td>
<td class="nump">$ 1,936,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971818528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Convertible Debt (Details) - 6.50% Convertible Senior Notes Due 2024<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleDebtConvertedAmount', window );">Principal amount converted into common shares</a></td>
<td class="num">(62,085,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtinstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">355,654<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 16,770,654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleDebtConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Converted Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleDebtConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtinstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtinstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388969810640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series&#160;C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388968104272">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 16, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare', window );">Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,793,075<span></span>
</td>
<td class="nump">21,090,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="nump">$ 22,200,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding to purchase common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128,864<span></span>
</td>
<td class="nump">1,018,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value for options exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm', window );">Options exercisable, remaining contractual term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber', window );">Number of options expected to vest (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, expirations in period, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.86<span></span>
</td>
<td class="nump">$ 101.64<span></span>
</td>
<td class="nump">$ 54.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, expirations in period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,357<span></span>
</td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.19<span></span>
</td>
<td class="nump">$ 28.08<span></span>
</td>
<td class="nump">$ 91.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 283,000<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options, exercises in period, aggregate intrinsic value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember', window );">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares', window );">Shares issued in settlement (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Nonemployee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 669,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding to purchase common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="nump">13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,794<span></span>
</td>
<td class="nump">212,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value of unvested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value of vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber', window );">RSU's expected to vest (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.34<span></span>
</td>
<td class="nump">$ 37.44<span></span>
</td>
<td class="nump">$ 124.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Former President and Chief Executive Officer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash', window );">Awards settled in cash, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan', window );">Number of shares of vested restricted stock outstanding under the plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">961,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2022InducementPlanMember', window );">2022 Inducement Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Reserved number of shares under the Incentive Plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grants under the Incentive Plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2023IncentivePlanMember', window );">2023 Incentive Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Reserved number of shares under the Incentive Plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grants under the Incentive Plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,334,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | 2021 Sales Agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Common stock aggregate offering price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage', window );">Sales Agents will be entitled to compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Stock sale agreement, aggregate number of shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,305<span></span>
</td>
<td class="nump">2,870,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Sales made at a weighted average price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.33<span></span>
</td>
<td class="nump">$ 29.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Stock sale agreement, aggregate proceeds from issuance of stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="nump">$ 83,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company effected a reverse stock split of its outstanding shares of common stock on January 24, 2024 where every twelve shares of its common stock issued and outstanding was converted into one share of common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any fractional post-split shares as a result of the reverse split were paid in cash. Shareholders of the Company authorized the Board of Directors to approve the reverse stock split at a special meeting of stockholders held on January 12, 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding share amounts have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Amount Awarded to Other Party, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LitigationSettlementAmountAwardedToOtherPartyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of vested restricted stock outstanding under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_FormerPresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_FormerPresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2022InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2022InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2023IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2023IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_A2021SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_A2021SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388970432960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">1,128,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 58.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">746,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 72.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember', window );">$4.32-$18.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">4.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 18.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">283,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 14.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">66,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 14.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember', window );">$18.01-$39.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">18.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 39.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">264,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 35.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">141,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 34.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember', window );">$39.01-$52.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">39.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 52.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">156,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 44.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">156,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 44.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember', window );">$52.01-$90.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">52.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 90.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">129,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 76.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">121,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 77.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember', window );">$90.01-$130.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">90.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 130.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">136,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 100.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">131,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 100.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember', window );">$130.01-$233.28</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">130.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 233.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">158,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 140.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">129,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 141.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978648144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock Option Activity Under Equity Incentive Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">1,018,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">339,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(228,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">1,128,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 75.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">14.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">66.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 58.76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971856848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of RSU Activity Under Equity Incentive Plan (Details) - Performance-based restricted stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">212,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">194,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(99,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(33,497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">274,794<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388970259120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>lease</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>defendent</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178; </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseNumberOfLeasesAmended', window );">Number of leases amended | lease</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended', window );">Area under lease amended | ft&#178;</a></td>
<td class="nump">31,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease', window );">Number of agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember', window );">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of cash settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares', window );">Estimate of shares settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares', window );">Shares issued in settlement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_BehestiVKimEtAlMember', window );">Behesti v. Kim, et al.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendants | defendent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Damages paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease | ft&#178;</a></td>
<td class="nump">5,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of contract</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease', window );">Annual increase of base rent percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForDeposits', window );">Deposit payments</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">57,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease, Amended</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Agreements To Sublease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseNumberOfAgreementsToSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseNumberOfLeasesAmended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Leases, Amended</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseNumberOfLeasesAmended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Amount Awarded to Other Party, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LitigationSettlementAmountAwardedToOtherPartyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Possible Loss, Value of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LossContingencyEstimateOfPossibleLossValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for deposits on goods and services during the period; excludes time deposits and deposits with other institutions, which pertain to financial service entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_BehestiVKimEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_BehestiVKimEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388969811600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2024</a></td>
<td class="nump">$ 3,247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">3,466,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">3,555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">2,955,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">2,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">17,665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(4,226,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">13,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,406,522)<span></span>
</td>
<td class="num">$ (2,803,973)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 11,032,066<span></span>
</td>
<td class="nump">$ 12,655,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388976282432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Pretax Loss from Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. Domestic</a></td>
<td class="num">$ (134,979,579)<span></span>
</td>
<td class="num">$ (277,440,803)<span></span>
</td>
<td class="num">$ (302,614,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(137,772)<span></span>
</td>
<td class="num">(211,249)<span></span>
</td>
<td class="num">(610,320)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before share in net loss of Geneos</a></td>
<td class="num">$ (135,117,351)<span></span>
</td>
<td class="num">$ (277,652,052)<span></span>
</td>
<td class="num">$ (303,224,323)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971347744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Benefit from income taxes at statutory rates</a></td>
<td class="num">$ (28,375)<span></span>
</td>
<td class="num">$ (58,307)<span></span>
</td>
<td class="num">$ (63,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="num">(3,922)<span></span>
</td>
<td class="num">(3,601)<span></span>
</td>
<td class="num">(3,447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">28,394<span></span>
</td>
<td class="nump">61,065<span></span>
</td>
<td class="nump">77,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncomeTaxReconciliationStatuteLimitations', window );">Research and development tax credits</a></td>
<td class="num">(2,139)<span></span>
</td>
<td class="num">(7,534)<span></span>
</td>
<td class="num">(16,523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,099<span></span>
</td>
<td class="nump">2,913<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">2,291<span></span>
</td>
<td class="nump">6,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill Impairment</a></td>
<td class="nump">1,962<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits', window );">Expired NOLs and credits</a></td>
<td class="nump">1,352<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits', window );">Limited NOLs and credits</a></td>
<td class="num">(997)<span></span>
</td>
<td class="num">(1,337)<span></span>
</td>
<td class="num">(542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rates</a></td>
<td class="nump">365<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">3,246<span></span>
</td>
<td class="num">(819)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ComprehensiveIncomeLossTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ComprehensiveIncomeLossTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss), Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ComprehensiveIncomeLossTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeTaxReconciliationStatuteLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Statute Limitations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeTaxReconciliationStatuteLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971672560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxBenefitsExpired', window );">Tax benefits expired</a></td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">20,500,000<span></span>
</td>
<td class="nump">19,700,000<span></span>
</td>
<td class="nump">$ 17,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">1,013,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 719,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">41,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">251,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">102,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_KoreanStateIncomeTaxAuthorityMember', window );">Korean State Income Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">354,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxBenefitsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Benefits Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxBenefitsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_KoreanStateIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_KoreanStateIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971785168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expense</a></td>
<td class="nump">$ 50,143<span></span>
</td>
<td class="nump">$ 41,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">235,624<span></span>
</td>
<td class="nump">212,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards', window );">Research and development and other tax credits</a></td>
<td class="nump">27,734<span></span>
</td>
<td class="nump">26,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,683<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredTaxAssetsIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment in affiliated entity</a></td>
<td class="nump">1,406<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredTaxAssetsOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">2,822<span></span>
</td>
<td class="nump">3,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,808<span></span>
</td>
<td class="nump">11,062<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">329,486<span></span>
</td>
<td class="nump">301,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(327,493)<span></span>
</td>
<td class="num">(299,124)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">2,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(1,993)<span></span>
</td>
<td class="num">(2,148)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,993)<span></span>
</td>
<td class="num">(2,347)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherTaxCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388976162016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear', window );">2024</a></td>
<td class="nump">$ 18.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2025</a></td>
<td class="nump">13.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2026</a></td>
<td class="nump">12.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2027 and thereafter</a></td>
<td class="nump">249.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">719.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">1,013.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear', window );">2024</a></td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2025</a></td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2026</a></td>
<td class="nump">7.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2027 and thereafter</a></td>
<td class="nump">332.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">354.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2025</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2027 and thereafter</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract', window );"><strong>Expirations of Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInNextFiscalYear', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinTwoYears', window );">2025</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInThreeYears', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInFourYears', window );">2027 and thereafter</a></td>
<td class="nump">41.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total</a></td>
<td class="nump">41.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract', window );"><strong>Expirations of Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInNextFiscalYear', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinTwoYears', window );">2025</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInThreeYears', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInFourYears', window );">2027 and thereafter</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely', window );">Indefinite</a></td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total</a></td>
<td class="nump">$ 6.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Next Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringInNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Four Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Two Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Indefinitely Carryforward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsIndefinitelyCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Carryforward Indefinitely</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardCarryforwardIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Four Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringInNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Next Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringInNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Two Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388976176800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of the year</a></td>
<td class="nump">$ 21,139<span></span>
</td>
<td class="nump">$ 18,819<span></span>
</td>
<td class="nump">$ 12,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">2,902<span></span>
</td>
<td class="nump">6,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="num">(841)<span></span>
</td>
<td class="num">(582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of the year</a></td>
<td class="nump">$ 22,114<span></span>
</td>
<td class="nump">$ 21,139<span></span>
</td>
<td class="nump">$ 18,819<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388976305936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum annual contribution per employee, percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's contribution to 401(k) plan</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388977856816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 832,010<span></span>
</td>
<td class="nump">$ 10,262,268<span></span>
</td>
<td class="nump">$ 1,774,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,676,563<span></span>
</td>
<td class="nump">$ 187,650,503<span></span>
</td>
<td class="nump">249,240,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (in shares)</a></td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="nump">18.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.80%<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Grant proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Revenue under collaborative research and development arrangements from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAmendedAmount', window );">Agreement amended amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedOptionAmount', window );">Awarded option amount</a></td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expense</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding from affiliate</a></td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAmendedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Amended Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAmendedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Option Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_TheWistarInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_TheWistarInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388971699968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,165,213<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,999,998<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember', window );">Series A-2 One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Resulting in again on memeasurement</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment', window );">Loss from equity method investment, recorded and allocated to investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388978613504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 01, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th">
<div>Mar. 06, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.083333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">2021 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_A2021SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_A2021SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M(&V V=\+H8^&/:";W=E?4$L#!!0    ( #6 9ECPJ_W?)@D  (\H   8
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MHI)W*O]W-C.+ZTD\03,Y%ZO<?%&;?\AM0('UEZJ\JC_19FN+)RA=5485V\:
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M(-.KR/2N(U,N&KHQJ53L7YRPI(K1UF5>X/=K:85!\7>0_P6&#0IW%86[[Z+
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MMX(GHC0 N+^64C_],0]H3RSG_P-02P,$%     @ -8!F6([!X*7^ 0  ' 0
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M@BOL.LQGC8TD"&V _Y><J\>!7F!H3?-?4$L#!!0    ( #6 9EB/_=0BZ0P
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MUATE:BM/4(-B7J1<&4B_; :ES4G?CQ2G1DHV:01&#7%NY)EF'-(8LD(^E!9
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MVG?7)M3Q7.+JMB6*&.K50FD+*&T)I?E06C#BB(70R!&*UI5QZ]A2M6.+GJ!
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M6@'A5P:-+K.J!JOEDX948L*PK-J),>2N7RD5=8(0T:DPCB+;JZM34H5BRNF
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MLV55STPVVHUTH]--W>W%,.O,!9295)*$S%Y6$66D1$AM<ITC0LX84UQ-=,%
M/LQ//C\&^VV= "ST%3RK*Z #=/8(R^\&**E,7X.%+JLB*[OP7NB'%NV'HRAT
M=UPR1R0S&H4QFQK]@9D8\Q=K5@"NNK&VV5UF"I(2UJ$L>8 I/+GE9EXD>^N>
M^ZRMS<_5VKAK!U1C?E2[37M<,64.G3V92?0!^CG--PO3R5UMS$Z04[/)A:P8
M>"-6RHXE5SCC$<%F$\)WE, R0R:VLVP@-^8GMV^UALT1.'HQY*W[0*K:E09$
M[>9.NXVP/]T=+G_QF#"P:>\-$>5, HE+9J__F#*$!!MR-M$? ]0Q/]3]VEF?
M7NZ9BU>1BIA=?\%D@D;221:NC@G)Z>$Z.78R$!OS$]L^I-?):]+M=F%DDS2M
M-WH8[L-176RT*>F=.JX(K D9JYC82'J'2#D+20@[&;L[L/H6%22>P@$V\!T[
M4I+:.D_A@RP%MFOK#/[?=01JT26QF8)%+(P=AZZ2A9$B]@8,T?%(QHQ.N!L
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M%<1P:4Y0D+6V2U*"-1/^;F!3\?&8SW3T@(G!7M<E[1$,24OG= X@54#=LL
MS %$(;/QEI37<E.F.R"9",GP6VU&<@3+@0/Z#IO 4O23H=V0S+7",92BCYAA
MO& ENB)&V\3B$C*&WIVH\"'+%C#@I^ LPBLPV/:+WQD1=7*;DC#K6Y)C*YD>
M9,LD)S(\+3;8><$<KQ.1H"(^(*(@#4Z(!=R+GEXP[0"N%'H%JD4DVLI4K.89
M03A"&B*RTH"D,0\!L$A):X+Z 0!+&'Y .JH D;"2AR#>UD2%'>0H:>"FIY\$
M'N./1#59%#EKY'%I>T5JE0Y]PZ_PC!Y"02>FI&>ZXR]."4H582\[*(U09TKR
MTNX'@F9AB'.\V4([Q/3I!J80MHG?!!ZR+!80*VE+TGI!Q.L GB9OAH<52B-:
MJUBQPB*A7!/I5ZPC1$GJ$SE=4Q$>,^-4"'T_P9D269)X(.<#V\>2#3:;U2WD
M/)3$=A>9%9NT2D4/8!S11&;L AVQ2I*1<E*;H"GHT &[H7]%89&,J("^D)=H
M;=XK;9NH'_S&A[:S*(*)LJK9/".@B4OIW)C,8MA;(\2]3LE* $N,F!B6<B<Z
MCF5"H/,!MC]QZ 96H-/DO6&QDMQ ;"0W6\)[\FOE!>89R]RS6$@LBY+.W1E0
M-R9K3&>M8U"3W:'[Y06)DCN(GC3)3-,QSN5)2AC/-VJ[,.''SXDDZH8,&J6%
MM&5< B$0A1NVA"<8:T0LILG),2'VF(R91O?&(C%I>6] "YD'H8Q/'@!4U;8C
M^/ *]PHZ5@]&=SCR/A,#(8,@@,VD'$(./S&:Z(V6CM*T=@IOI$50W1F@JR<'
ME[9.4K.$I-HLZ)C!T+1A"-W[%MC791]8Q>\CY8ZP2LX^(@$F9\U$+[Y-VSS]
M([E6ST'-E@794E6%-=SQ(P"BJI.,+5Z_#BCH7"AHRKX29.Y*=+65%]!.I:7K
M+3D(9!_WCH)RT%;:FMPB3="/19R1>GA+)/E)X"X+R#N\?73E+<=M6N3'< ED
M@T< X>@ZP->1Q<0B+=EPE"@0F^U69#*.UQ#O[.6$RE=Y4ZT@8?QE(Q(*RY,@
M.A98=6?I/G6-[@QT84H603BNQ4XQMW, P=.P?I##9MN3S1T P*M^/4V3G(9;
M@;$=K)'?>^NL,$ ;,C/L(58]6VU84W;&%E>YHT.;.&UA/ILF@V%3@QLKK B#
MC>SJC%EC,N"-B+P9L'KK9=LX=]V0Y*1/U\FU^+9D)]*,6*MC+4P..IE]T&&R
M58;MP!X&S,2<QQI2C-H86+5\X>!6O.J6**@]S(#D/K)1)J0TS@D'Q(0>,PD*
M<B6+/VDO8Z ?GH HH%1B4(X4C)+N&'R;%VU&6MW:$V0E7%45>/>]88>39D0@
M,#F9'?\W*:M;(W8"0= QH1)F5<@<I&WX$O2@:VJ)1B*@6*C'6I;JL[(&0& %
M1L2ULVE /1^^SLIA*T/0G$H AY'TNJI)L23OH&C3S/0L=DFEOJZR*>,$ZNF.
MV+O<'==WD,-D@K9%7D#.Z>"KMDB3-V^NIT1\*V9(P0X(\U<7JVCEF5CC10XB
M82&5\MEL2;(K2"0FL=&&V (^P(+HG" HB)-;0Q3"'B@="Z$L=,F+2J+10 G,
M0.>; )$&5"7/5'1DZ\(L@T@*R=P"S'B\23\1%;#Y]"E\ -&Z2EF6.UL)!U1G
M/M8E5C/>H'D9'&*&V+"^10B9D3JP5,04DT?6LN$("&D\15T +N%F0[9]N6.5
MI+;NQZKHF*\E+/-1#/R7:GVV# >1$>,0((O'_$7"P4O8#+B;%>#'Z<TT^?GJ
MZATA@I@>[!88DD3RP*&S>EN+FGZCPDOLZ\"C8VH!*6P<70*5RI76#F>;4QFR
M=^))C?_NP A$>EQ01X7"ES=M!?889.#AJK=VLHW+!?Y\XXA?>!=60 >98<U4
M,7;S OZWU>@D8SS&F,4A1OU!79/$)F'QOF@_):\"HF^[IA>8&:O.M2+*<+YB
M0'X2H_)3"Q)E[@9S S?D50<$9I7KX=!=3.'0TIW0,6&'CXJ7E47812(>).60
ML6/:M7[Z,!S(E+8F7]^.A,D41')T]T77\SX(R<[,@:T5;AKN&P3RHBS(G,F3
M54_B!\'ND*?S@M4Q&^&*<XG7>I"4*HH&KA6=-].72";(M-S M1*AC]07>5"L
MVPG8K496-^EGPLZ?Y"G:J/A^1 LD#8M%40#7 !/9$ .G?PA2.6]6.41P5CE(
M.((>5:22OM_7@EW=,2$*";-K 8[J6U5Q;XE^DM-I\BJE7?[&JO@7,D7I# 4%
M !;H8]O0(V^)UT5S;\+7/=9A<77KQIACPEH3#B!!W" VNE-4$L9JX/9/Q!O6
MB"UMR=!)>H50YH\79202 V%JI^J>DK-]:\KD9,+!_4I43;U !D:#5CPQVXCT
MY(^^!@+5&"ML<I#.#$Z E5H-JT^C(0T5+L&>6= \TZ7GT=*Z'H>WY(B^>DE3
M\*"<9&V&8!D";)7_S>WIF:1<>/'3:/&^VM\Y+2@H)[[J2K9*JUH7QSY2B;!)
M:)K,F)HCV9#X'$1F-0V.Y*@0Q[1%L=U5H;@?SP\L1V68M5*&>8/) <DSB?@3
M"%R2GUZP8!?@)M[:X4#OK83_6 T6^2"OPD@6/1*,(R^#L<9J3*-+=IS8]EE@
M7Q,?%HQ(EQK)TJ;9,<:\$MG?X%\*9I)NR9?YS-I%=92DO3P/084Y;R; =B#J
M1)JT)CPRLOG&TSDI$PN\7Q!@%W*\6KP(I0$M;.]..(_.CCB'V#@XQ83H3+>!
MG@%:"XE0CB)?%LVL-UC"GNHK.H.F8Y>!,P00?NR1L_J!>P/!Q@$S@+(7E(S<
MXHD:R-8V%WD5;E0]T!!$@0U&J3=EDFW?D*8$BJN25,*U58C\X660/[O>2Z@U
M8L^01FN\8QRH^X5A+5KN5.=$AT3KDOO5VL 6R=T5!_F&AXX8KZ;)"'!&99PN
M0YQ7YPK WTO_*7_G3JMM>K:,-$Q/0]BV[!H6J&3"@$B<'3>2"92LR#RBPM?!
M!D."$6DX4.D,$RG4XUUA2G&E_9HL?WT\-R\X'L5G:0-2O$6?"POG#@(Q:>"0
M<*2N)81,(T@=:D*43 [B8Q+&#/F4<C([6T0M>$@J 7%0^XH^'R_2[!.<MP"A
MD@3? ]Q&SH<2>T2TOGMS,_F&@_DZ\?!UDN!C13@IF9%71$AJ]TLZO*X&5D\@
MSICKAX"8SXI[2>&E3>7R*-X#@ 7C'%#GL7)PE04ROFK,&BG66TT%H$H"UI8
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M#5Z@Y\NZ[NPO6,#]W:J?_A]02P,$%     @ -8!F6 ?[Q>*C!    @L  !D
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ME/PH"<<A36TA' #:FC-3>7D<1>G3)Z9B-#>V.ND)>F=<D6N7DE7Y-R"6NE#
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M9T#/2T5R[2]<@.'[:?D/4$L#!!0    ( #6 9EB&5;?9: ,  ( '   9
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M#/=M0,TPL@6T+*9FPXGF:4^=)PHH0T)M0R!IG"S$RII"/"CS&V[ XB/E*L.
M_-)-/T6N VM?KC)4:Z5!-NSEJK;8MIV# C[57H&&J6&._2AMV=UHW/+#E&H[
M S1^,"2/W<:4*>1OT-Q41J;Q]UK@UM=V07OS.UI)Q:_ARHV [Y\Q6H'S+XY
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M@/V5P<=*^\(&^I]J[OX#4$L#!!0    ( #6 9E@5<1OAW08  &80   9
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MM_P@2I!(6ERIJ+.1VHE':1KVUFL$!3-14$]3[;J&>@Z=W^\T EU8:AFQDX^
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M^DXTM!K<Z NKRM00+J_(*9==@Z<YZ+JSRZY.?U_712:;]COQPQ]]WMV_/NW
MF9Z?IIK+A>+B'>#B>N)=777K5OQ093*;,SB%2(-<GI'KPGN0X_<RM87O6L)S
M//\!?OZ@I\_\_"?H*7ZI.RG^>7[5=@VBXU_[]%9<@_U<*6->MILDE6\62(E6
M-K=R<?;M-V[HO'I YF"0.7B(^]&^.9[+M]_$GAN],OI_0 ;(II&9X$7B<IU
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M  G3J$Y ^?!=T@"*S-YSO^6J>$2A8SFQ?P!-Q*9O"$TZBDVB;F6*'3O"KK0
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M M,"/+^NZ\Y<T ;#;_[._@-02P,$%     @ -8!F6-/CE554$@  IC8  !D
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M%_,GER=RWC!=M*[A7R*M'."]XC_I!(KQ] *>%\ZUZ8(FZ'^:]O*?4$L#!!0
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M?FK-BEG:#32Z"*8&:9"3FH)RZRU6)>3\^0>AN!<9FW+KU^RCY=KQX"]WVO/
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MB?7:>W/?*!A5;MAKPU$RWF=#&^]X.S57D *[HC#6!TLJ7@JO#&%VXKDL\[K
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M!GO35'1&""1M71 =P*J VK#" ,P11+&P\9&LK!6Z4GL@F1A)\RB3DQ[!=I"
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MM9$+%'=8K@EL'WOV%=E7"!]K"ZK!2*@;E6VI5GS/-O3#*/73<4RM($S]8)I
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M.UOA(\H]P@H+M96\4TJ6L%2R0&DU:RVJ@J7&DEM8<?, '^[91J#Y. DL47!
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M<*!MEK-[5$ -+X >3L7L%NSO@7N-*.8!P0%/6RBO L)!/#]!*0?;H@@,I3S
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MSSA/+N'=++6[ .?S"C)XLW *VI?X^%]02P,$%     @ -8!F6*&N^[3 !0
M#0X  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULK5=M;]LV$/XK!S=H
M$T"P]6;+>3.0I!V6 FV#)ML^#/M 2R>+"T5J)!4W_WY'2E:<Q/&&81^<4-*]
M/'?WW)$\6RM];RI$"S]J(<WYJ+*V.9E,3%YAS<Q8-2CI2ZETS2P]ZM7$-!I9
MX95J,8G#<#:I&9>CQ9E_=Z,79ZJU@DN\T6#:NF;Z\1*%6I^/HM'FQ7>^JJQ[
M,5F<-6R%MVA_:6XT/4T&*P6O41JN)&@LST<7T<GEU,E[@5\YKLW6&EPD2Z7N
MW<-U<3X*'2 4F%MG@=&_![Q"(9PA@O%7;W,TN'2*V^N-]9]\[!3+DAF\4N(W
M7MCJ?#0?08$E:X7]KM8_8Q^/!Y@K8?Q?6'>RTW0$>6NLJGME0E!SV?UG/_H\
M;"G,PS<4XEXA]K@[1Q[E1V;9XDRK-6@G3=;<PH?JM0D<EZXHMU;35TYZ=G&%
MVE+IX)())G.$6\^$:XNU@<,[MA1HCLXFECPY^4G>6[WLK,9O6(UB^**DK0Q\
MD@46SPU,".* ,][@O(SW6OR(^1B2*( XC),]]I(A[L3;2_Y#W+]?+(W5Q)<_
M=D7>V4UWVW4]=&(:EN/YB)K$H'[ T>+]NV@6GNY!G0ZHTWW6%[?4DT4K$%0)
M-QH;Q@OX](,:U*"!"UG -UNAAJM6:Y06+HQ!:W8%L=?-[B V_ABY4=Y-WKMA
MW@TP"U0EK)?T:5,I+TV+&')%C6PL%@X[J4.I!$T$+E<GG:27NI:FU;X@&G/U
M@/H1#MD1',#[=_,XBD]IE81!&/K?D(*:R;:D>K6:S %N$A(%Z7P6S)*Y6X51
M$,;S/D%-KSB()L%QF)% !M$\R.+C()TFY&L:),=),)M-W3H,(O*=SB/84\GI
M4,GIOZ[D19ZK5E(&;]BCZSA?27JI6WPJ[ZXJ[G<QF&UZLZX6K#<[1/Y_5.U.
MLP*=Z>?^J%;!-,N">3RC=70<S&<QY2\;8LM5[5 P/Y_I<Y(%49A"%)-:&AS'
MT2 IN.6K3HZX9@76CGB.&AMBI.E BZ[&KR(]7![!87X$LR!-XF >I00O3JG4
M6=;#2[,@2U-ZR(Z#&5%G/I]Z']<2/K?BT0<;^#1<$7(F'X%0H"8G7%H%#&JL
M%=&W:&N7KY9FGS:6GATM:0/UJHU6C3*DLQ4(">>"VLAO4CY&ZBT*F5!O17YH
M$.&KL@A1=#2&.U<.+IF /]N"YYP62I/'P=.6@S4SP(UI/53X3/U".["O8&=G
M2_19R0^2<!S2OB.$ T"J.3.5I\=!E#[_8BI&LV+#DSY!'XPK<NU"LBJ_!\I2
MYPJ8(+BM'=)#\?/:C&EF.1,O*?D\[625#X,B9UISRC-4K #?U4[2XW3\4K)/
M\!NY#V!=\9QBJCORKJF>L$0'J4+ATX4FI^[N$K47@?=^$$]C3T/RV<W)@8&4
MAB563)0OLK03@RI+0@EL1=N4L5[<NR1''X;P:F[K;@23<SW$^13>&#YV4]&]
MMI4F!M7=SHQN9X8O3)/C3>,'>W+W@DV:#E;,I;+4JNY3Y(FQW1X]Y;(9->8\
MV:+(,U(TK38M([O$CL[3P/X77?$4E6MF:LL._A/T-_K26-ZTHNLB\KX5RC]T
MI4=<*>':BG[\@;E#Y)ZF]*-"XG8V54N%H1U'<#J_,<UID+"&_#U@\99KWP:[
M"QKX!NZGT8NH._Y%XWCH2XJ^H<:2EA.;_*C,3ATBHJ/8Q,YI8J#;">33L'1D
MYZ8GI*_W9IRNN:T(@;,5AZ>[1ZW_&)TZ5N[JY3%\D_ MM\J]I&'_*EF;ZC'9
M3S0';1AUJX[Q/H4;9M^^ZF>'&<L2_:G?==Y72KB'$25!/_G<;O!Z\UOV1T(N
M<]$6E)B#=)P,&16<+3G5_]&GKY6MJ]Q*._J6K1]EXUW'@\G6$;U&O?(7$>-+
M8;O3^O!VN.M<=$?\)_'NHD2<7]$D ($EJ8;CC(X!NKM\= ]6-?[ OU26K@]^
M6=%]#;43H.^E(KKV#\[!< -<_ U02P,$%     @ -8!F6%BRW&)Y P  B <
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M"I]*J9T#?B^5LJ^&2S _OIN_ 5!+ P04    "  U@&98G! 35G$#   1"
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MIBD:[T#W*TU5V!D^0#.?LS]02P,$%     @ -8!F6+B/R#&D!   (0P  !D
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MB'+7_G+^J12BS-NW6T9E26P:R,_792E>%IH.#@^06/P/4$L#!!0    ( #6
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MT1)S;:">KYA:&>H;_8+F0\SL/U!+ P04    "  U@&98JB-=0=H#   "$0
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M)ZN*XU7)$?5PA C<9*G<"?!'NF;K)L!$!5Q'C9ZBOD)6Q&NV.@,8O@/(0=A
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MN390]U>,R?V)#E#^BV+V'U!+ P04    "  U@&98U?SB6I,(  #\40  &0
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M_3K7Z-6\J1X >'S@X^W_ 5!+ P04    "  U@&98(FZ;M;$"  !&!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6RME=%NFS 4AE_%8M/42ELQ.)"T
M(TAMHFF]F!8UZG8Q[<*!0T %F]DF2=]^MB$H36A43<M%L.'\/]\YM@_1EHLG
MF0,HM*M*)J=.KE1]X[HRR:&B\HK7P/23C(N**CT5:U?6 FAJ157I^AB';D4+
MYL21O;<0<<0;518,%@+)IJJH>+Z#DF^GCN?L;SP4ZUR9&VX<U70-2U"/]4+H
MF=N[I$4%3!:<(0'9U+GU;F:AB;<!/PK8RH,Q,IFL.'\RD_MTZF #!"4DRCA0
M?=G #,K2&&F,/YVGT[_2" _'>_<O-G>=RXI*F/'R9Y&J?.I,')1"1IM2/?#M
M5^CR"8Q?PDMI_]&VB\4.2AJI>-6)-4%5L/9*=UT=#@3>Z!6!WPG\MPI()R V
MT9;,IC6GBL:1X%LD3+1V,P-;&ZO6V13,K.)2"?VTT#H5ST HO=;HCI:4)8"6
M=NO<*Z@D^H26>M.D30F(9V@AH*9%BBA+T7>5@T"S1@A@"MU*"4JBBSEHJU)>
M:N'C<HXNWE]&KM*,YDUNTO'<M3S^*SQS2*X0\3XB'_MD0#Y[N]Q_*7=U9?KR
M^'UY?.M'_J$\OVY74@F]#W\/I=GZCH9]S=F\D35-8.KHPR=!;,")/[SS0OQY
M*.G_9/:B!*0O 3GG'M\SV0B;O("$;T \#Z7;>HRMA^D<FQA'[N8PA],(@MM?
M'_B";]3SC<[R[?=E15F3Z=5H1,'6"':ZSTF00ZRM7WA XHTF84@F1\1#<=C#
M_F08..B!@[/ [>&I.^QSH,$) +G&8^R/CT!/X[S)V+\>!628-.Q)PS>5=L]H
MSSZW^$EW]JD]^T/PX<EZ!^2:A&%P!#\0ASV"1Q/O"-X]Z'+F"_.-BG7!)"HA
MTU)\-=9E$&W7;B>*U[;QK;C2;=0.<_VA V$"]/.,<[6?F%[:?SKCOU!+ P04
M    "  U@&98J@I0&\@%  !M*P  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6R]FN]OHS88Q_\5*YNF.^F68"! NC126W[L;NM677?;BVDO7' 2=(!S
MMM/>_?>S@9*04#>1'EU?-.#X^=CP_6*;)YX_,?Y9K"F5Z&M95.)RM)9R<S&9
MB'1-2R+&;$,K]<V2\9)(=<I7$['AE&1U4%E,;,OR)B7)J]%B7I?=\<6<;661
M5_2.([$M2\*_7=."/5V.\.BYX&.^6DM=,%G,-V1%[ZG\M+GCZFS24;*\I)7(
M684X75Z.KO!%8ELZH*[Q=TZ?Q-XQTI?RP-AG??(^NQQ9ND>TH*G4"*(^'ND-
M+0I-4OWXTD)'79LZ</_XF1[7%Z\NYH$(>L.*?_),KB]'P0AE=$FVA?S(GGZE
M[05--2]EA:C_HZ>VKC5"Z59(5K;!J@=E7C6?Y&M[(_8"%&<XP&X#[,, [X4
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MQ-ICD[8@:*.W^8]4"%KKRS6")6*J@;R_I%0\%U2 _O J_1=02P,$%     @
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M _G[(LO$XT7Y@.8@\O1_4$L#!!0    ( #6 9EC2:F!B? <  %1+   9
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M6[@]5]N)9+DYFMXPJ0ZZ9IBH;Q'@.D#=7S(F'R?ZM%M]W81_ 5!+ P04
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M77$J%N]";Q]PH8%W*"V$TB(H+8;2*)3&4#1=@2HZ[]JC\U]W=M8.'RS(23]
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MY8A[Y34F"+2K+1 T@^N;/YN\&7*1P\AU#!2TJZW]?VRC@L$6<6/K*"I$NSJ
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MA+8?1+ELCF'>E$*4>?-VP>.$5^H"^?MM68KU!^5@<S!W]C]02P,$%     @
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M:W0!LE1_RR\)CPZT-/-#FK'\F'].TQ7A74 6G#S8%VO7)C]44Z&:!M5TJ&9
M-1.J65#-AFH.5',KK7&A09(.KS1X9T=K9NY>?8Y\<>:67]F?RUVA=W7N(C45
MJFE038=J!E0SH9H%U6RHYD UM]+VDU+NM^3NN=&:N:O4N:L(<_>ES%<_33?\
MN-N/]C*7?,G?%I]_)7^=+L:9BINX.IV1F@K5-*BF0S4#JIE0S8)J-E1S*FW_
MJN5H*$GC7C,#76BK'DIKIGU=@28+JULF4[9B?*^=7XES_/"&L(S0X+8UN:%5
M9U!-A6H:5-.AF@'53*AF034;JCE0S85J'DIK=@%U!9K<_Y2+;C*R8&<&U52H
MID$U':H94,V$:A94LZ&: ]5<J.:AM&:'4)>OR>+ZM?HK]_('&+3\REWT:XRI
MF+RZ,X!6N<G'E77CYC&=!FU0AVH&5#.AF@75;*CF0#47JGDHK9GA=16;+"YC
M4VE(E_QL?TW]MM^D3<7A5V?S<?F3K!Q>V%"A;6I038=J!E0SH9H%U6RHYD U
M%ZIY**V9T'61G"RNDO/\R \WK>4QXLBK<QE:#@?5-*BF0S4#JIE0S8)J-E1S
MH)H+U3R4ULSYNHA.'G_.>3NT8 ZJJ5!-@VHZ5#.@F@G5+*AF0S4'JKE0S4-I
MS0ZA+IZ3A84Y>QU"4/Y,)6'Y[7!V TC&DO9#!&C]'%13H9IV9@GVR >C24KZ
M)"QONJ'TR8)^M'W9J4,GS(!J)FXV+>B$V5#-@6HN5/-06O,>+W41G2(NHO/H
MCU,G!.+(:[,=JJE038-J.E0SH)H)U2RH9D,U!ZJY4,U#:<V<K\OO%/E33@@4
M:!4>5%.AF@;5=*AF0#43JEE0S89J#E1SH9J'TIH=0EW3IXAK^O[V"8'8O;I'
M@!;R037MS!(<ED?*K=D/+=J#:N;?GBL+.ATV5'.@F@O5/)36S/2ZC$\1E_&]
MT(BH/EO&-V1& _\U3B*?MF8VM(H/JJE038-J.E0SH)H)U2RH9D,U!ZJY4,U#
M:<T>H*[B4_J?<_"/K%R:0345JFE038=J!E0SH9H%U6RHYD U%ZIY**W9(=15
M?(JXBL]EO /@Q_SQX4D S6]/E]]P,K^[QOYMZL2WIU..J^@&@^'!CR-FXHFZ
MN@. WJ .JNE0S8!J9MNZ&@Z/[ET%;=2&:@Y4<Z&:A]*:F5U7[RGBZCTK\C.?
M!L79>_$C^3C*$CIOK<L]0_6K;X)ZVV^"Y/&I;X)F8NKJU(:6^T$U':H94,V$
M:A94LZ&: ]5<J.:AM&8/4)?[*>)ROZ<HVO .P(_F2;'GYIU _D08DN2_UN7[
M^SG_3Y>M-X^N9%G9VS=(M]+1?AQ:YP?5-*BF0S4#JIE0S8)J-E1SH)H+U3R4
MUDSVNLY/$=\M3V7K./5Y7M./XNZ7K5E=$HT[>ARE-+12#ZII4$V':@94,Z&:
M!=5LJ.9 -1>J>2BMF=)UI9XB+L!Z#C[">).MB,=8?FI^0YY9%*4?P1L]==T>
M6J('U52HID$U':H94,V$:A94LZ&: ]5<J.:AM.83H.I"O9[T*=?M>] J/JBF
M0C4-JNE0S8!J)E2SH)H-U1RHYD(U#Z4U.X2ZBJ\GOHD>^KJ]N+FK.PIH=1]4
MTRJM<0.GHQNHZ2UC]8\>QF"TC"4?/_W!;!EM,.H-#R^T0^?3AFH.5'.AFH?2
MRE3L[CUZ-F3)LG@&<TKF\2;*\D;VANZ>\_Q4/.WV8/A4OE?EEN&:?&^T#3?E
M>[M\NG/=;/FP:8\F2S]*>2*_\DF0;D>##DG*YS>7;[)X73P0]WN<97%8O%PQ
MRG,_'X%__AK'V?9-WL#N*=J3_P-02P,$%     @ -8!F6-=U\D+  P  QPX
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M!>VEN5Q2 J<\+8#W<\[5[D9_H/DGQ.1_4$L#!!0    ( #6 9EB>@[>TGP4
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MK0Z46)7[4^^$4B(K/RXYBWEA&NCOYT*HIP-S@683]>1?4$L#!!0    ( #6
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MWR:J:!FZ]&S%]$^1D92GG.5;R0M1=!H:H_U)UFRZ?RFP9^^K""C-@])\*"U
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ML^9V!Q27(#T GV\X%H>JH2>H__58_ =02P,$%     @ -8!F6(-N- 10 P
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M&)#R0\+LAUD[]^IG"R>)F\V.7Q/*"@FS%:;R66R\F"K7_[QSU[7V96U]Z_
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M<KGV?*_Q^C])]7@^-U\O?UE^[YS<EPO.]6U%>?H+4$L#!!0    ( #6 9EA
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M&_^^>?X"4$L! A0#%     @ -8!F6 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  U@&98,@%!C^X
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ -8!F6/"K_=\F"0
MCR@  !@              ("!.!,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( #6 9EC =*2U8 0  *H.   8              " @90<
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  U@&98,RDG
M<?4&  "]'   &               @($J(0  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ -8!F6([!X*7^ 0  ' 0  !@
M ("!52@  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( #6
M9EB72E(T9P,  *8*   8              " @8DJ  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    "  U@&98C_W4(ND,  "??0  &
M        @($F+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( #6 9E@'^\7BHP0   (+   9              "
M@6]T  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ -8!F
M6(]4+X/Y#0  _"D  !D              ("!27D  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    "  U@&98MHWU,=H*  !B.0  &0
M        @(%YAP  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( #6 9EA=U3&&B 4  $L-   9              " @8J2  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ -8!F6(95M]EH P  @ <
M !D              ("!29@  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    "  U@&980FB6OA '  "V$0  &0              @('HFP
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( #6 9E@5<1OA
MW08  &80   9              " @2^C  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ -8!F6)<'Q =G#   _R<  !D
M ("!0ZH  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  U
M@&98T^.55502  "F-@  &0              @('AM@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #6 9E@X/=3D= T  .\C   9
M          " @6S)  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#
M%     @ -8!F6((AL:8( P  OP8  !D              ("!%]<  'AL+W=O
M<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  U@&98$5"))LD&  !8
M$@  &0              @(%6V@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;%!+ 0(4 Q0    ( #6 9EC^C] FE@D  &H<   9              " @5;A
M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ -8!F6+;[
MAD!? P  10<  !D              ("!(^L  'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6Q02P$"% ,4    "  U@&98<RUG*UH"  !\!@  &0
M    @(&Y[@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M #6 9EAD.J)K0P(  (H&   9              " @4KQ  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ -8!F6)1H:#C_'   FUT  !D
M             ("!Q/,  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    "  U@&98=N&TTU,$  !<"@  &0              @('Z$ $ >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( #6 9EBK(+0U2@,
M !<'   9              " @805 0!X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ -8!F6!C37SQA!0  E0\  !D              ("!
M!1D! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  U@&98
MH:[[M, %   -#@  &0              @(&='@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( #6 9EA8LMQB>0,  (@'   9
M      " @90D 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ -8!F6)P0$U9Q P  $0@  !D              ("!1"@! 'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  U@&98;B4QP: "  "K!0
M&0              @('L*P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( #6 9EBXC\@QI 0  "$,   9              " @<,N 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ -8!F6 ZKA"X/
M P  QP8  !D              ("!GC,! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    "  U@&98HPHB])@'  "B$P  &0
M@('D-@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( #6
M9EASLG5II <  $Q"   9              " @;,^ 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ -8!F6$-S<H=Z!   E!D  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( #6 9E@Y0=@(X04  *,?   9
M  " @?5C 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M-8!F6%7-#^3S P  KA   !D              ("!#6H! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    "  U@&98U?SB6I,(  #\40  &0
M            @($W;@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( #6 9E@B;INUL0(  $8'   9              " @0%W 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ -8!F6*H*4!O(!0
M;2L  !D              ("!Z7D! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    "  U@&98GX_:*I(%  "F(0  &0              @('H
M?P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( #6 9EB?
M%RZ3H0,  ,@2   9              " @;&% 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ -8!F6%@=3PP7!P  E#P  !D
M     ("!B8D! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #6 9EAE-8_%T 8  *0K   9              "
M@>JP 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ -8!F
M6&+@;^5% P  S0H  !D              ("!\;<! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    "  U@&98PP:G10(#  !X!P  &0
M        @(%MNP$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( #6 9ECELLMUY0D  %%[   9              " @::^ 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ -8!F6-=U\D+  P  QPX
M !D              ("!PL@! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    "  U@&9856#Q9?0"  !:"   &0              @(&YS $
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( #6 9EC3KKWI
MGP0  ) 0   9              " @>3/ 0!X;"]W;W)K<VAE971S+W-H965T
M-C0N>&UL4$L! A0#%     @ -8!F6)Z#M[2?!0  4"T  !D
M ("!NM0! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    "  U
M@&98_6NX,VX$  "1$   &0              @(&0V@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( #6 9EC@5($;C 0  , 7   9
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M970W,2YX;6Q02P$"% ,4    "  U@&98"%)+8-D#   !$0  &0
M    @(%$^0$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    (
M #6 9EB#;C0$4 ,  +(5   -              "  53] 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ -8!F6)>*NQS     $P(   L              ( !
MSP " %]R96QS+RYR96QS4$L! A0#%     @ -8!F6)3X5:=]!0  CR\   \
M             ( !N $" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #6
M9EBL;5!7/ (  *\J   :              "  6(' @!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #6 9EA :Q>Z  (  ,8I   3
M          "  =8) @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !0 %
*YQ4   <, @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>328</ContextCount>
  <ElementCount>434</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>99</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical</Role>
      <ShortName>Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/TheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Revenue Recognition and Concentration of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Short-term Investments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</Role>
      <ShortName>Short-term Investments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItems</Role>
      <ShortName>Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/A401kPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</Role>
      <ShortName>Short-term Investments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CertainBalanceSheetItems</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FixedAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Schedule of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Certain Balance Sheet Items - Schedule of Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Schedule of Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Certain Balance Sheet Items - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Fixed Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssetsDetails</Role>
      <ShortName>Fixed Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FixedAssetsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill and Intangible Assets By Major Asset Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Goodwill and Intangible Assets By Major Asset Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Convertible Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Convertible Debt - Schedule of Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails</Role>
      <ShortName>Convertible Debt - Schedule of Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Stockholders' Equity - Schedule of Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Stockholders' Equity - Schedule of Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity Under Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock Option Activity Under Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Stockholders' Equity - Schedule of RSU Activity Under Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of RSU Activity Under Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails</Role>
      <ShortName>Income Taxes - Components of Pretax Loss from Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails</Role>
      <ShortName>Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/A401kPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/A401kPlan</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ino-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SubsequentEvents</ParentRole>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ino-20231231.htm">ino-20231231.htm</File>
    <File>ino-20231231.xsd</File>
    <File>ino-20231231_cal.xml</File>
    <File>ino-20231231_def.xml</File>
    <File>ino-20231231_lab.xml</File>
    <File>ino-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ino-20231231_g1.jpg</File>
    <File>ino-20231231_g2.jpg</File>
    <File>ino-20231231_g3.jpg</File>
    <File>ino-20231231_g4.jpg</File>
    <File>ino-20231231_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1009">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>103
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ino-20231231.htm": {
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ino-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "ino-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ino-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 353,
   "keyCustom": 81,
   "axisStandard": 34,
   "axisCustom": 0,
   "memberStandard": 45,
   "memberCustom": 47,
   "hidden": {
    "total": 12,
    "http://fasb.org/us-gaap/2023": 7,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://www.inovio.com/20231231": 1
   },
   "contextCount": 328,
   "entityCount": 1,
   "segmentCount": 99,
   "elementCount": 771,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1009,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.inovio.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.inovio.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorLocation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorLocation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.inovio.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical",
     "longName": "0000006 - Statement - Consolidated Statements of Operations (Parenthetical)",
     "shortName": "Consolidated Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "longName": "0000007 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "0000008 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "longName": "0000009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000010 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.inovio.com/role/TheCompany",
     "longName": "0000011 - Disclosure - The Company",
     "shortName": "The Company",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000012 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk",
     "longName": "0000013 - Disclosure - Revenue Recognition and Concentration of Credit Risk",
     "shortName": "Revenue Recognition and Concentration of Credit Risk",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "longName": "0000014 - Disclosure - Collaborative Agreements",
     "shortName": "Collaborative Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements",
     "longName": "0000015 - Disclosure - Short-term Investments and Fair Value Measurements",
     "shortName": "Short-term Investments and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItems",
     "longName": "0000016 - Disclosure - Certain Balance Sheet Items",
     "shortName": "Certain Balance Sheet Items",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.inovio.com/role/FixedAssets",
     "longName": "0000017 - Disclosure - Fixed Assets",
     "shortName": "Fixed Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssets",
     "longName": "0000018 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "longName": "0000019 - Disclosure - Convertible Debt",
     "shortName": "Convertible Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "longName": "0000020 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.inovio.com/role/CommitmentsandContingencies",
     "longName": "0000021 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "longName": "0000022 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.inovio.com/role/A401kPlan",
     "longName": "0000023 - Disclosure - 401(k) Plan",
     "shortName": "401(k) Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "longName": "0000024 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "longName": "0000025 - Disclosure - Geneos Therapeutics, Inc.",
     "shortName": "Geneos Therapeutics, Inc.",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.inovio.com/role/SubsequentEvents",
     "longName": "0000026 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables",
     "longName": "9954473 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)",
     "shortName": "Revenue Recognition and Concentration of Credit Risk (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables",
     "longName": "9954474 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)",
     "shortName": "Short-term Investments and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsTables",
     "longName": "9954475 - Disclosure - Certain Balance Sheet Items (Tables)",
     "shortName": "Certain Balance Sheet Items (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.inovio.com/role/FixedAssetsTables",
     "longName": "9954476 - Disclosure - Fixed Assets (Tables)",
     "shortName": "Fixed Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables",
     "longName": "9954477 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.inovio.com/role/ConvertibleDebtTables",
     "longName": "9954478 - Disclosure - Convertible Debt (Tables)",
     "shortName": "Convertible Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "longName": "9954479 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesTables",
     "longName": "9954480 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.inovio.com/role/IncomeTaxesTables",
     "longName": "9954481 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ino:WorkingCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
     "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails",
     "longName": "9954484 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails",
     "longName": "9954485 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)",
     "shortName": "Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-104",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
     "longName": "9954486 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)",
     "shortName": "Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "longName": "9954487 - Disclosure - Collaborative Agreements (Details)",
     "shortName": "Collaborative Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-107",
      "name": "ino:CollaborativeAgreementsUpfrontPaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails",
     "longName": "9954488 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Available-for-sale Securities (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Schedule of Available-for-sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
     "longName": "9954489 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9954490 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-170",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails",
     "longName": "9954491 - Disclosure - Certain Balance Sheet Items - Schedule of Prepaid and Other Current Assets (Details)",
     "shortName": "Certain Balance Sheet Items - Schedule of Prepaid and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:EstimatedInsuranceRecoveries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:EstimatedInsuranceRecoveries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
     "longName": "9954492 - Disclosure - Certain Balance Sheet Items - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "shortName": "Certain Balance Sheet Items - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ino:GrantLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ino:GrantLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.inovio.com/role/FixedAssetsDetails",
     "longName": "9954493 - Disclosure - Fixed Assets (Details)",
     "shortName": "Fixed Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "longName": "9954494 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-57",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails",
     "longName": "9954495 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill and Intangible Assets By Major Asset Class (Details)",
     "shortName": "Goodwill and Intangible Assets - Schedule of Goodwill and Intangible Assets By Major Asset Class (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:GoodwillGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:GoodwillGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
     "longName": "9954496 - Disclosure - Convertible Debt - Narrative (Details)",
     "shortName": "Convertible Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-226",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails",
     "longName": "9954497 - Disclosure - Convertible Debt - Schedule of Convertible Debt (Details)",
     "shortName": "Convertible Debt - Schedule of Convertible Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-227",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-227",
      "name": "ino:DebtInstrumentConvertibleDebtConvertedAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails",
     "longName": "9954498 - Disclosure - Stockholders' Equity - Schedule of Preferred Stock (Details)",
     "shortName": "Stockholders' Equity - Schedule of Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-232",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9954499 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails",
     "longName": "9954500 - Disclosure - Stockholders' Equity - Schedule of Stock Options Outstanding (Details)",
     "shortName": "Stockholders' Equity - Schedule of Stock Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails",
     "longName": "9954501 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity Under Equity Incentive Plan (Details)",
     "shortName": "Stockholders' Equity - Schedule of Stock Option Activity Under Equity Incentive Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
     "longName": "9954502 - Disclosure - Stockholders' Equity - Schedule of RSU Activity Under Equity Incentive Plan (Details)",
     "shortName": "Stockholders' Equity - Schedule of RSU Activity Under Equity Incentive Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-254",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-255",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
     "longName": "9954503 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-277",
      "name": "ino:LesseeOperatingLeaseNumberOfLeasesAmended",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-277",
      "name": "ino:LesseeOperatingLeaseNumberOfLeasesAmended",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
     "longName": "9954504 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)",
     "shortName": "Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails",
     "longName": "9954505 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)",
     "shortName": "Income Taxes - Components of Pretax Loss from Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails",
     "longName": "9954506 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)",
     "shortName": "Income Taxes - Reconciliation of Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.inovio.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954507 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9954508 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
     "longName": "9954509 - Disclosure - Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)",
     "shortName": "Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-293",
      "name": "ino:OperatingLossCarryforwardsExpiringInNextFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-293",
      "name": "ino:OperatingLossCarryforwardsExpiringInNextFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails",
     "longName": "9954510 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)",
     "shortName": "Income Taxes - Unrecognized Tax Benefits Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.inovio.com/role/A401kPlanDetails",
     "longName": "9954511 - Disclosure - 401(k) Plan (Details)",
     "shortName": "401(k) Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
     "longName": "9954512 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-298",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:InvestmentOwnedBalanceShares",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
     "longName": "9954513 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)",
     "shortName": "Geneos Therapeutics, Inc. - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-324",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.inovio.com/role/SubsequentEventsDetails",
     "longName": "9954514 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-327",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-327",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ino_A2007IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "A2007IncentivePlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2007 Incentive Plan",
        "label": "2007 Incentive Plan [Member]",
        "documentation": "2007 Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2016IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "A2016IncentivePlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Incentive Plan",
        "label": "2016 Incentive Plan [Member]",
        "documentation": "2016 Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2021SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "A2021SalesAgreementMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Sales Agreement",
        "label": "2021 Sales Agreement [Member]",
        "documentation": "2021 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2022InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "A2022InducementPlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Inducement Plan",
        "label": "2022 Inducement Plan [Member]",
        "documentation": "2022 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2023IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "A2023IncentivePlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Incentive Plan",
        "label": "2023 Incentive Plan [Member]",
        "documentation": "2023 Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.50% Convertible Senior Notes Due 2024",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update 2020-06",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595"
     ]
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r257",
      "r258",
      "r259",
      "r313",
      "r314",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r384",
      "r522",
      "r523",
      "r524",
      "r553",
      "r554",
      "r564",
      "r565",
      "r566",
      "r572",
      "r573",
      "r574",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r605",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r626",
      "r627",
      "r630",
      "r631",
      "r632",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r1049"
     ]
    },
    "ino_AccountsPayableAndAccruedExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "AccountsPayableAndAccruedExpensesLineItems",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses [Line Items]",
        "label": "Accounts Payable and Accrued Expenses [Line Items]",
        "documentation": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ino_AccountsPayableAndAccruedExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "AccountsPayableAndAccruedExpensesTable",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses [Table]",
        "label": "Accounts Payable and Accrued Expenses [Table]",
        "documentation": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Accounts payable and accrued liabilities",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts payable",
        "label": "Accounts Payable, Trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r870",
      "r923",
      "r1136"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308"
     ]
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued clinical trial expenses",
        "label": "Accrued Clinical Trial Expense, Current",
        "documentation": "Accrued Clinical Trial Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r881"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated Depreciation and Amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r211",
      "r724"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r127",
      "r220",
      "r720",
      "r750",
      "r754"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r34",
      "r577",
      "r580",
      "r645",
      "r745",
      "r746",
      "r1032",
      "r1033",
      "r1034",
      "r1046",
      "r1047",
      "r1048"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "negatedTerseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r917",
      "r1140"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r523",
      "r524",
      "r772",
      "r1046",
      "r1047",
      "r1048",
      "r1115",
      "r1142"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]",
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r257",
      "r258",
      "r259",
      "r260",
      "r269",
      "r313",
      "r314",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r384",
      "r522",
      "r523",
      "r524",
      "r551",
      "r552",
      "r553",
      "r554",
      "r564",
      "r565",
      "r566",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r605",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r626",
      "r627",
      "r630",
      "r631",
      "r632",
      "r633",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r691",
      "r692",
      "r693",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r492"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_AdvaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "AdvaccineMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ApolloBio Corporation",
        "label": "Advaccine [Member]",
        "documentation": "Advaccine"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AffiliatedEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "AffiliatedEntityMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Affiliated Entity",
        "label": "Affiliated Entity [Member]"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r873",
      "r923",
      "r1083",
      "r1120",
      "r1121",
      "r1123"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r954",
      "r964",
      "r990"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r957",
      "r967",
      "r993"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r958",
      "r968",
      "r985",
      "r994",
      "r998",
      "r1006"
     ]
    },
    "ino_AllOtherCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "AllOtherCustomersMember",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All other, including affiliated entities",
        "label": "All Other Customers [Member]",
        "documentation": "All Other Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocated share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r525"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r311",
      "r362"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r55",
      "r59"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total antidilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ino_ApolloBioCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ApolloBioCorporationMember",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ApolloBio Corporation",
        "label": "ApolloBio Corporation [Member]",
        "documentation": "ApolloBio Corporation"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ApolloBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ApolloBioMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ApolloBio",
        "label": "ApolloBio [Member]",
        "documentation": "ApolloBio [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r215",
      "r245",
      "r283",
      "r298",
      "r302",
      "r351",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r568",
      "r570",
      "r608",
      "r715",
      "r810",
      "r917",
      "r931",
      "r1076",
      "r1077",
      "r1124"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r223",
      "r245",
      "r351",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r568",
      "r570",
      "r608",
      "r917",
      "r1076",
      "r1077",
      "r1124"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of assumptions used to estimate the fair value of stock options",
        "label": "Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract]",
        "documentation": "Assumptions used in estimation of fair value of stock options."
       }
      }
     },
     "auth_ref": []
    },
    "ino_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.inovio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r937",
      "r950"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.inovio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r937",
      "r950"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.inovio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r937",
      "r950"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross\u00a0Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross\u00a0Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r368",
      "r714"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale, Sale [Abstract]",
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair\u00a0Market\u00a0Value",
        "verboseLabel": "Short-term investments",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r368",
      "r708",
      "r1053"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Liquidity",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "ino_BehestiVKimEtAlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "BehestiVKimEtAlMember",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Behesti v. Kim, et al.",
        "label": "Behesti v. Kim, et al. [Member]",
        "documentation": "Behesti v. Kim, et al."
       }
      }
     },
     "auth_ref": []
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "BillAndMelindaGatesFoundationMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bill And Melinda Gates Foundation",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "documentation": "Bill And Melinda Gates Foundation"
       }
      }
     },
     "auth_ref": []
    },
    "ino_BiojectMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "BiojectMember",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bioject",
        "label": "Bioject [Member]",
        "documentation": "Bioject [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r910",
      "r911"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r563",
      "r910",
      "r911"
     ]
    },
    "ino_CELLECTRA3PSPProprietarySmartDeviceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CELLECTRA3PSPProprietarySmartDeviceMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CELLECTRA 3PSP Proprietary Smart Device",
        "label": "C E L L E C T R A3 P S P Proprietary Smart Device [Member]",
        "documentation": "C E L L E C T R A3 P S P Proprietary Smart Device"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CaliforniaIncomeTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CaliforniaIncomeTaxAuthorityMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "California Income Tax Authority [Member]",
        "documentation": "California Income Tax Authority [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts accrued for purchases of fixed assets",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r209",
      "r879"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r140",
      "r241"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r140"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CertainBalanceSheetItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CertainBalanceSheetItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Certain Balance Sheet Items [Abstract]",
        "documentation": "Certain Balance Sheet Items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in prepaid expenses and other current assets related to fixed assets",
        "label": "Change In Prepaid Expenses And Other Current Assets, Fixed Assets",
        "documentation": "Change In Prepaid Expenses And Other Current Assets, Fixed Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gain (loss) on investment in affiliated entity",
        "negatedLabel": "(Gain) loss on equity investment in affiliated entity",
        "label": "Change in Value of Investments in Affiliated Company",
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r217",
      "r218",
      "r219",
      "r245",
      "r272",
      "r273",
      "r275",
      "r277",
      "r281",
      "r282",
      "r351",
      "r394",
      "r396",
      "r397",
      "r398",
      "r401",
      "r402",
      "r434",
      "r435",
      "r438",
      "r441",
      "r449",
      "r608",
      "r763",
      "r764",
      "r765",
      "r766",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r796",
      "r819",
      "r844",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r1013",
      "r1040",
      "r1050"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r281",
      "r434",
      "r435",
      "r436",
      "r438",
      "r441",
      "r447",
      "r449",
      "r763",
      "r764",
      "r765",
      "r766",
      "r899",
      "r1013",
      "r1040"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coalition for Epidemic Preparedness Innovations",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional revenue to be achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obligation period to pay royalties",
        "label": "Collaboration Agreement, Royalty Period",
        "documentation": "Collaboration Agreement, Royalty Period"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementAmendedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborativeAgreementAmendedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement amended amount",
        "label": "Collaborative Agreement, Amended Amount",
        "documentation": "Collaborative Agreement, Amended Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborativeAgreementAwardedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "documentation": "Collaborative Agreement, Awarded Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementAwardedOptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborativeAgreementAwardedOptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded option amount",
        "label": "Collaborative Agreement, Awarded Option Amount",
        "documentation": "Collaborative Agreement, Awarded Option Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses to reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "documentation": "Collaborative Agreement, Expenses To Reimburse"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementFundingReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborativeAgreementFundingReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funding received",
        "label": "Collaborative Agreement, Funding Received",
        "documentation": "Collaborative Agreement, Funding Received"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, funding to be received",
        "label": "Collaborative Agreement, Funding To Be Received",
        "documentation": "Collaborative Agreement, Funding Received for Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, period to receive funding for research and development",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementsUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received",
        "label": "Collaborative Agreements, Upfront Payment Received",
        "documentation": "Collaborative Agreements, Upfront Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r185",
      "r198"
     ]
    },
    "ino_CollaborativeArrangementFixedPriceContractAmountAwarded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborativeArrangementFixedPriceContractAmountAwarded",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price, procurement contract",
        "label": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "documentation": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "ino_CollaborativeArrangementRevenueFromTheProcurementContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborativeArrangementRevenueFromTheProcurementContract",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Procurement contract",
        "label": "Collaborative Arrangement , Revenue from the Procurement Contract",
        "documentation": "Collaborative Arrangement , Revenue from the Procurement Contract"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeArrangementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "CollaborativeArrangementTerm",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term",
        "label": "Collaborative Arrangement, Term",
        "documentation": "Collaborative Arrangement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r111",
      "r717",
      "r795"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r386",
      "r387",
      "r872",
      "r1070"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r920",
      "r921",
      "r922",
      "r924",
      "r925",
      "r926",
      "r927",
      "r1046",
      "r1047",
      "r1115",
      "r1139",
      "r1142"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding",
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of common stock shares outstanding under the Incentive Plan (in shares)",
        "label": "Common Stock, Other Shares, Outstanding",
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r796"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r121",
      "r796",
      "r816",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock\u2014par value $0.001; Authorized shares: 600,000,000 at December 31, 2023 and 2022, issued and outstanding: 22,793,075 at December 31, 2023 and 21,090,938 at December 31, 2022",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r719",
      "r917"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ComprehensiveIncomeLossTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ComprehensiveIncomeLossTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense (benefit)",
        "label": "Comprehensive Income (Loss), Tax Expense (Benefit)",
        "documentation": "Comprehensive Income (Loss), Tax Expense (Benefit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r227",
      "r229",
      "r235",
      "r709",
      "r730"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r99",
      "r100",
      "r306",
      "r871"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r99",
      "r100",
      "r306",
      "r755",
      "r871"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r99",
      "r100",
      "r306",
      "r871",
      "r1015"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r188"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "%\u00a0of\u00a0Total Revenue",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r99",
      "r100",
      "r306"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r99",
      "r100",
      "r306",
      "r871"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r885"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entities (VIE)",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized from deferred revenue",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes",
        "label": "Convertible Debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r167",
      "r1135"
     ]
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes",
        "label": "Convertible Debt, Current",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r404",
      "r405",
      "r415",
      "r416",
      "r417",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes",
        "label": "Convertible Debt, Noncurrent",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible notes",
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Convertible Debt",
        "label": "Convertible Debt [Table Text Block]",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible preferred stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r438",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued upon conversion (in shares)",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r67",
      "r120",
      "r154",
      "r444"
     ]
    },
    "ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share)",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share",
        "documentation": "Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r407",
      "r436",
      "r652",
      "r882",
      "r884"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r256",
      "r263",
      "r269",
      "r355",
      "r361",
      "r522",
      "r523",
      "r524",
      "r553",
      "r554",
      "r575",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r588",
      "r591",
      "r593",
      "r594",
      "r643"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]",
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r256",
      "r263",
      "r269",
      "r355",
      "r361",
      "r522",
      "r523",
      "r524",
      "r553",
      "r554",
      "r575",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r588",
      "r591",
      "r593",
      "r594",
      "r643"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]",
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r256",
      "r263",
      "r269",
      "r355",
      "r361",
      "r522",
      "r523",
      "r524",
      "r553",
      "r554",
      "r575",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r588",
      "r591",
      "r593",
      "r594",
      "r643"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r306"
     ]
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "D N A Encoded Monoclonal Antibody Technology",
        "label": "D N A Encoded Monoclonal Antibody Technology [Member]",
        "documentation": "D N A Encoded Monoclonal Antibody Technology"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r243",
      "r403",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r419",
      "r426",
      "r427",
      "r429"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r116",
      "r117",
      "r165",
      "r167",
      "r252",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r629",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r1041"
     ]
    },
    "ino_DebtInstrumentConvertibleDebtConvertedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "DebtInstrumentConvertibleDebtConvertedAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal amount converted into common shares",
        "label": "Debt Instrument, Convertible Debt, Converted Amount",
        "documentation": "Debt Instrument, Convertible Debt, Converted Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "netLabel": "Principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r105",
      "r404",
      "r629",
      "r895",
      "r896"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, effective percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r103",
      "r431",
      "r629"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt interest based on the fixed rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r405"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r428",
      "r629",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r1041"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r252",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r629",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r1041"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r67",
      "r70",
      "r102",
      "r103",
      "r105",
      "r112",
      "r153",
      "r155",
      "r252",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r428",
      "r629",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r1041"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, unamortized discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r105",
      "r1079"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities in a gross unrealized loss position for more than twelve months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale, realized gain",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale, realized gain",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities in a gross unrealized loss position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r370"
     ]
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual maturity",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "documentation": "Debt Securities, Available-for-sale contractual maturity."
       }
      }
     },
     "auth_ref": []
    },
    "ino_DebtinstrumentAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "DebtinstrumentAccruedInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Debt instrument, Accrued Interest",
        "documentation": "Debt instrument, Accrued Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Resulting in again on memeasurement",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs, net",
        "negatedLabel": "Unamortized debt issuance cost",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r1079"
     ]
    },
    "ino_DeferredGrantFundingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "DeferredGrantFundingCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant funding liability",
        "label": "Deferred Grant Funding, Current",
        "documentation": "Deferred Grant Funding, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ino_DeferredGrantFundingFromAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "DeferredGrantFundingFromAffiliate",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred grant funding from affiliate",
        "label": "Deferred Grant Funding, From Affiliate",
        "documentation": "Deferred Grant Funding, From Affiliate"
       }
      }
     },
     "auth_ref": []
    },
    "ino_DeferredGrantFundingFromAffiliateCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "DeferredGrantFundingFromAffiliateCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant funding liability from affiliated entities",
        "label": "Deferred Grant Funding, From Affiliate, Current",
        "documentation": "Deferred Grant Funding, From Affiliate, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r161",
      "r194",
      "r557",
      "r558",
      "r1043"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r166",
      "r545"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535",
      "r716"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1114"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, gross",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research expense",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1114"
     ]
    },
    "ino_DeferredTaxAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "DeferredTaxAssetsIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired intangibles",
        "label": "Deferred Tax Assets, Intangible Assets",
        "documentation": "Deferred Tax Assets, Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in affiliated entity",
        "label": "Deferred Tax Assets, Investments",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "documentation": "Deferred Tax Assets, Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1114"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expirations of Operating Loss Carryforwards, Components [Abstract]",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1114"
     ]
    },
    "us-gaap_DeferredTaxAssetsOtherTaxCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOtherTaxCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development and other tax credits",
        "label": "Deferred Tax Assets, Other Tax Carryforwards",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1114"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAbstract",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expirations of Tax Credit Carryforwards [Abstract]",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1114"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r1113"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquired intangibles",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1114"
     ]
    },
    "ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right of use asset",
        "label": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "documentation": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's contribution to 401(k) plan",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum annual contribution per employee, percent",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer matching contribution, percent",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "ino_DepartmentOfDefenceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "DepartmentOfDefenceMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Department Of Defence",
        "label": "Department Of Defence [Member]",
        "documentation": "Department Of Defence"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation",
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r60"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "ino_DoDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "DoDMember",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Department of Defense",
        "label": "DoD [Member]",
        "documentation": "DoD [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r937",
      "r950"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r937",
      "r950",
      "r986"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r270",
      "r272",
      "r275",
      "r276",
      "r277",
      "r279",
      "r594",
      "r595",
      "r710",
      "r731",
      "r887"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r272",
      "r275",
      "r276",
      "r277",
      "r279",
      "r594",
      "r595",
      "r710",
      "r731",
      "r887"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired NOLs and credits",
        "label": "Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits",
        "documentation": "Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits"
       }
      }
     },
     "auth_ref": []
    },
    "ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Limited NOLs and credits",
        "label": "Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits",
        "documentation": "Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options to purchase common stock",
        "terseLabel": "Stock Options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "ino_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and Directors",
        "label": "Employees and Directors [Member]",
        "documentation": "Employees and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r203",
      "r231",
      "r232",
      "r233",
      "r253",
      "r254",
      "r255",
      "r258",
      "r266",
      "r268",
      "r280",
      "r355",
      "r361",
      "r450",
      "r522",
      "r523",
      "r524",
      "r553",
      "r554",
      "r575",
      "r577",
      "r578",
      "r579",
      "r580",
      "r582",
      "r593",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r645",
      "r745",
      "r746",
      "r747",
      "r772",
      "r844"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Geneos",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r349",
      "r1024",
      "r1062"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r101",
      "r350"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in affiliated entity",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r607",
      "r880"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in affiliated entity",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r607",
      "r713"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized gain (loss) on available-for-sale equity securities",
        "negatedTerseLabel": "Net unrealized (gain) loss on available-for-sale equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r1061"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r954",
      "r964",
      "r990"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r951",
      "r961",
      "r987"
     ]
    },
    "us-gaap_EstimatedInsuranceRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EstimatedInsuranceRecoveries",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance recovery",
        "label": "Estimated Insurance Recoveries",
        "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r599",
      "r660",
      "r661",
      "r662",
      "r895",
      "r896",
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r599",
      "r600",
      "r601",
      "r602"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Investments and Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r474",
      "r479",
      "r599",
      "r660",
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r474",
      "r479",
      "r599",
      "r661",
      "r895",
      "r896",
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r599",
      "r662",
      "r895",
      "r896",
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r660",
      "r661",
      "r662",
      "r895",
      "r896",
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r602"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r19"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Eligible Item or Group for Fair Value Option [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r371",
      "r372",
      "r428",
      "r447",
      "r583",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r729",
      "r892",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial assets and liabilities that are measured at fair value on recurring basis",
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Useful life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets, accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r381"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r690",
      "r694"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails": {
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r694"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails": {
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net book value",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r690"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Indefinite lived:",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized transaction (gain) loss on foreign-currency denominated debt",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r615",
      "r616",
      "r617",
      "r841"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Transactions",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r958",
      "r968",
      "r994"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r958",
      "r968",
      "r994"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r958",
      "r968",
      "r994"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r958",
      "r968",
      "r994"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r958",
      "r968",
      "r994"
     ]
    },
    "ino_FormerPresidentAndChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "FormerPresidentAndChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former President and Chief Executive Officer",
        "label": "Former President and Chief Executive Officer [Member]",
        "documentation": "Former President and Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share of net loss in Geneos",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ino_GainLossOnRemeasurementOfEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "GainLossOnRemeasurementOfEquityMethodInvestment",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on remeasurement of investment in Geneos",
        "label": "Gain (Loss) On Remeasurement Of Equity Method Investment",
        "documentation": "Gain (Loss) On Remeasurement Of Equity Method Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfOtherInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Realized loss on sales of short-term investments",
        "label": "Gain (Loss) on Sale of Other Investments",
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "GeneosTherapeuticsInc.Member",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geneos Therapeutics, Inc.",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "documentation": "Geneos Therapeutics, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r822"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails": {
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r373",
      "r707",
      "r893",
      "r917",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Goodwill and intangible asset impairment",
        "label": "Goodwill and Intangible Asset Impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ino_GoodwillAndIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "GoodwillAndIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total goodwill and intangible assets, gross",
        "label": "Goodwill and Intangible Assets Gross",
        "documentation": "Goodwill and intangible assets gross."
       }
      }
     },
     "auth_ref": []
    },
    "ino_GoodwillAndIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "GoodwillAndIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total goodwill and intangible assets, net book value",
        "label": "Goodwill and Intangible Assets Net",
        "documentation": "Goodwill and intangible assets net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53"
     ]
    },
    "us-gaap_GoodwillGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails": {
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, gross",
        "label": "Goodwill, Gross",
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r377",
      "r893"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of goodwill",
        "verboseLabel": "Impairment of goodwill",
        "negatedTerseLabel": "Impairment loss",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r374",
      "r376",
      "r378",
      "r893"
     ]
    },
    "ino_GrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "GrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused grant funding",
        "label": "Grant Liability",
        "documentation": "Grant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ino_GrantProceedsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "GrantProceedsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant proceeds received",
        "label": "Grant Proceeds Received",
        "documentation": "Grant Proceeds Received"
       }
      }
     },
     "auth_ref": []
    },
    "ino_GrantRevenuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "GrantRevenuePolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants",
        "label": "Grant Revenue [Policy Text Block]",
        "documentation": "Grant Revenue [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Axis]",
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Domain]",
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ]
    },
    "us-gaap_GrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants receivable",
        "label": "Grants Receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ino_INO4800Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "INO4800Member",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IN O4800",
        "label": "I N O4800 [Member]",
        "documentation": "I N O4800"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r937",
      "r950"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r18"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "negatedTerseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r1039",
      "r1068"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r559"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before share in net loss of Geneos",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r128",
      "r172",
      "r283",
      "r297",
      "r301",
      "r303",
      "r711",
      "r727",
      "r889"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r559"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before share in net loss of Geneos",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r297",
      "r301",
      "r303",
      "r734",
      "r889"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share in net loss of Geneos",
        "negatedLabel": "Share in net loss of Geneos",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r129",
      "r171",
      "r287",
      "r349",
      "r726"
     ]
    },
    "ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from equity method investment, recorded and allocated to investment",
        "label": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "documentation": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r385",
      "r827"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r827"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r529",
      "r538",
      "r543",
      "r549",
      "r555",
      "r560",
      "r561",
      "r562",
      "r768"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense (benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r195",
      "r267",
      "r268",
      "r288",
      "r536",
      "r556",
      "r735"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r532",
      "r533",
      "r543",
      "r544",
      "r548",
      "r550",
      "r762"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in tax rates",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r537"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign tax rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefit from income taxes at statutory rates",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill Impairment",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ino_IncomeTaxReconciliationStatuteLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "IncomeTaxReconciliationStatuteLimitations",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Income Tax Reconciliation, Statute Limitations",
        "documentation": "Income Tax Reconciliation, Statute Limitations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses, including due to affiliated entities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, including from affiliated entities",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical trial expenses",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue, including from affiliated entity",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r1038"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets and liabilities, net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets, including from affiliated entities",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant funding liability, including from affiliated entity",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Definite lived:",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r958",
      "r968",
      "r985",
      "r994",
      "r998",
      "r1006"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1010"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1010"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1010"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r57"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of intangible assets by major asset class",
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r174",
      "r234",
      "r286",
      "r628",
      "r828",
      "r929",
      "r1141"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, debt",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r423",
      "r432",
      "r897",
      "r898"
     ]
    },
    "us-gaap_InterestIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest income",
        "label": "Interest Income, Operating",
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r820",
      "r862",
      "r863",
      "r928",
      "r929",
      "r1144"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r239",
      "r240"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Internal Revenue Service (IRS) [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of (discounts) premiums on investments",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares owned (in shares)",
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r853",
      "r859",
      "r861",
      "r922"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r758",
      "r759",
      "r760",
      "r761",
      "r854",
      "r855"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term Investments and Fair Value Measurements",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r175",
      "r176",
      "r200",
      "r315",
      "r316",
      "r603",
      "r604"
     ]
    },
    "ino_KoreanStateIncomeTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "KoreanStateIncomeTaxAuthorityMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Korean State Income Tax Authority",
        "label": "Korean State Income Tax Authority [Member]",
        "documentation": "Korean State Income Tax Authority"
       }
      }
     },
     "auth_ref": []
    },
    "ino_LassaFeverAndMERSVaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "LassaFeverAndMERSVaccineMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lassa Fever And MERS Vaccine",
        "label": "Lassa Fever And MERS Vaccine [Member]",
        "documentation": "Lassa Fever And MERS Vaccine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r916"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "ino_LesseeOperatingLeaseAreaOfLandUnderLeaseAmended": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "LesseeOperatingLeaseAreaOfLandUnderLeaseAmended",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area under lease amended",
        "label": "Lessee, Operating Lease, Area of Land Under Lease, Amended",
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease, Amended"
       }
      }
     },
     "auth_ref": []
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, area of land under lease",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual increase of base rent percentage",
        "label": "Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)",
        "documentation": "Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Maturities Of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total remaining lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: present value adjustment",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ino_LesseeOperatingLeaseNumberOfAgreementsToSublease": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfAgreementsToSublease",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of agreements",
        "label": "Lessee, Operating Lease, Number Of Agreements To Sublease",
        "documentation": "Lessee, Operating Lease, Number Of Agreements To Sublease"
       }
      }
     },
     "auth_ref": []
    },
    "ino_LesseeOperatingLeaseNumberOfLeasesAmended": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfLeasesAmended",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of leases amended",
        "label": "Lessee, Operating Lease, Number Of Leases, Amended",
        "documentation": "Lessee, Operating Lease, Number Of Leases, Amended"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, remaining lease term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r245",
      "r351",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r569",
      "r570",
      "r571",
      "r608",
      "r794",
      "r888",
      "r931",
      "r1076",
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r168",
      "r722",
      "r917",
      "r1042",
      "r1063",
      "r1116"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r208",
      "r245",
      "r351",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r569",
      "r570",
      "r571",
      "r608",
      "r917",
      "r1076",
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_LicensewithAffiliatedEntitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "LicensewithAffiliatedEntitiesMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue under collaborative research and development arrangements from affiliated entities",
        "label": "License with Affiliated Entities [Member]",
        "documentation": "License with Affiliated Entities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Licenses",
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r528",
      "r1110"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued litigation settlement",
        "label": "Estimated Litigation Liability, Current",
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r1071"
     ]
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount paid to other party",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "ino_LitigationSettlementAmountAwardedToOtherPartyShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "LitigationSettlementAmountAwardedToOtherPartyShares",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in settlement (in shares)",
        "label": "Litigation Settlement, Amount Awarded to Other Party, Shares",
        "documentation": "Litigation Settlement, Amount Awarded to Other Party, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net carrying amount",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r167",
      "r416",
      "r430",
      "r895",
      "r896",
      "r1135"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r62"
     ]
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesPaidValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Damages paid",
        "label": "Loss Contingency, Damages Paid, Value",
        "documentation": "Amount of damages paid to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of cash settlement",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r392",
      "r393"
     ]
    },
    "ino_LossContingencyEstimateOfPossibleLossValueOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "LossContingencyEstimateOfPossibleLossValueOfShares",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of shares settlement",
        "label": "Loss Contingency, Estimate of Possible Loss, Value of Shares",
        "documentation": "Loss Contingency, Estimate of Possible Loss, Value of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyNumberOfDefendants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNumberOfDefendants",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of defendants",
        "label": "Loss Contingency, Number of Defendants",
        "documentation": "Number of defendants named in a legal action."
       }
      }
     },
     "auth_ref": [
      "r1072",
      "r1073"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major Customers [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r306",
      "r902",
      "r1081",
      "r1137",
      "r1138"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r490",
      "r687",
      "r742",
      "r786",
      "r787",
      "r852",
      "r856",
      "r857",
      "r858",
      "r860",
      "r875",
      "r876",
      "r891",
      "r899",
      "r912",
      "r919",
      "r1078",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "McDermidVInovioPharmaceuticalsIncAndJJosephKimMember",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim",
        "label": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim [Member]",
        "documentation": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r490",
      "r687",
      "r742",
      "r786",
      "r787",
      "r852",
      "r856",
      "r857",
      "r858",
      "r860",
      "r875",
      "r876",
      "r891",
      "r899",
      "r912",
      "r919",
      "r1078",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "us-gaap_MinorityInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestLineItems",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Line Items]",
        "label": "Noncontrolling Interest [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest, ownership percentage by parent",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestTable",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Table]",
        "label": "Noncontrolling Interest [Table]",
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r89",
      "r91",
      "r133"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. agency mortgage-backed securities",
        "label": "Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member]",
        "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1054",
      "r1055",
      "r1056",
      "r1082"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ino_MutualFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "MutualFundsMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual funds",
        "verboseLabel": "Mutual funds",
        "label": "Mutual Funds [Member]",
        "documentation": "Mutual funds."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Major Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r306",
      "r902",
      "r1081",
      "r1137",
      "r1138"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.inovio.com/role/TheCompany"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Company",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r196"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "negatedLabel": "Net loss from operations",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r142",
      "r173",
      "r206",
      "r226",
      "r228",
      "r233",
      "r245",
      "r257",
      "r261",
      "r262",
      "r263",
      "r264",
      "r267",
      "r268",
      "r274",
      "r283",
      "r297",
      "r301",
      "r303",
      "r351",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r595",
      "r608",
      "r728",
      "r818",
      "r842",
      "r843",
      "r889",
      "r929",
      "r1076"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements - Recently Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ino_NonCashInterestIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "NonCashInterestIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-cash interest on senior convertible notes",
        "label": "Non-Cash Interest Income (Expense)",
        "documentation": "Non-Cash Interest Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "ino_NonEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "NonEmployeeMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non Employee",
        "label": "Non Employee [Member]",
        "documentation": "Non employee."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r958",
      "r968",
      "r985",
      "r994"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares of vested restricted stock outstanding under the plan (in shares)",
        "label": "Number of Shares of Vested Restricted Stock Outstanding Under Plan",
        "documentation": "Number of shares of vested restricted stock outstanding under the plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r297",
      "r301",
      "r303",
      "r889"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liability",
        "negatedTerseLabel": "Less: current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liability, net of current portion",
        "netLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r916"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r916"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Total",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards that will expire due to IRC Section 382 limitations",
        "label": "Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net",
        "documentation": "Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net"
       }
      }
     },
     "auth_ref": []
    },
    "ino_OperatingLossCarryforwardsExpiringInNextFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "OperatingLossCarryforwardsExpiringInNextFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Operating Loss Carryforwards, Expiring in Next Fiscal Year",
        "documentation": "Operating Loss Carryforwards, Expiring in Next Fiscal Year"
       }
      }
     },
     "auth_ref": []
    },
    "ino_OperatingLossCarryforwardsExpiringinFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "OperatingLossCarryforwardsExpiringinFourYears",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027 and thereafter",
        "label": "Operating Loss Carryforwards, Expiring in Four Years",
        "documentation": "Operating Loss Carryforwards, Expiring in Four Years"
       }
      }
     },
     "auth_ref": []
    },
    "ino_OperatingLossCarryforwardsExpiringinThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "OperatingLossCarryforwardsExpiringinThreeYears",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Operating Loss Carryforwards, Expiring in Three Years",
        "documentation": "Operating Loss Carryforwards, Expiring in Three Years"
       }
      }
     },
     "auth_ref": []
    },
    "ino_OperatingLossCarryforwardsExpiringinTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "OperatingLossCarryforwardsExpiringinTwoYears",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Operating Loss Carryforwards, Expiring in Two Years",
        "documentation": "Operating Loss Carryforwards, Expiring in Two Years"
       }
      }
     },
     "auth_ref": []
    },
    "ino_OperatingLossCarryforwardsIndefinitelyCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "OperatingLossCarryforwardsIndefinitelyCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite",
        "label": "Operating Loss Carryforwards, Indefinitely Carryforward",
        "documentation": "Operating Loss Carryforwards, Indefinitely Carryforward"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geneos Therapeutics, Inc.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r162",
      "r756",
      "r757"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "verboseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (loss) gain on short-term investments, net of tax",
        "verboseLabel": "Unrealized gain (loss) on short-term investments, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r348"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItems"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain Balance Sheet Items",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other Intangible Assets [Member]",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other (expense) income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1065"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r956",
      "r966",
      "r992"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r959",
      "r969",
      "r995"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r959",
      "r969",
      "r995"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_PaymentsForDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForDeposits",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit payments",
        "label": "Payments for Deposits",
        "documentation": "The amount of cash paid for deposits on goods and services during the period; excludes time deposits and deposits with other institutions, which pertain to financial service entities."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Investment in Geneos",
        "terseLabel": "Payments to acquire additional interest in subsidiaries",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of capital assets",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ino_PennsylvaniaStateIncomeTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "PennsylvaniaStateIncomeTaxAuthorityMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pennsylvania",
        "label": "Pennsylvania State Income Tax Authority [Member]",
        "documentation": "Pennsylvania State Income Tax Authority [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/A401kPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "401(k) Plan",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r909"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "ino_PlumblineLifeSciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "PlumblineLifeSciencesIncMember",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plumbline Life Sciences, Inc. (affiliated entity)",
        "label": "Plumbline Life Sciences, Inc. [Member]",
        "documentation": "Plumbline Life Sciences, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_PlumblineLifeSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "PlumblineLifeSciencesMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plumbline Life Sciences",
        "label": "Plumbline Life Sciences [Member]",
        "documentation": "Plumbline Life Sciences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plymouth Meeting, Pennsylvania",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "documentation": "Plymouth Meeting, Pennsylvania [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r920",
      "r921",
      "r924",
      "r925",
      "r926",
      "r927",
      "r1139",
      "r1142"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r434"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r796"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r434"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r796",
      "r816",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock\u2014par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December\u00a031, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r718",
      "r917"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expense",
        "label": "Prepaid Expense",
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r222",
      "r809",
      "r1134"
     ]
    },
    "ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets from affiliated entities",
        "label": "Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "documentation": "The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event."
       }
      }
     },
     "auth_ref": []
    },
    "ino_PrepaidManufacturingExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "PrepaidManufacturingExpensesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid manufacturing expenses",
        "label": "Prepaid Manufacturing Expenses, Current",
        "documentation": "Prepaid Manufacturing Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of debt",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings",
        "documentation": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of capital assets",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sale or maturity of investments",
        "label": "Proceeds from Sale of Short-Term Investments",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from stock options exercised",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r17"
     ]
    },
    "ino_ProceedsfromStockOptionandWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ProceedsfromStockOptionandWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from stock option exercises",
        "label": "Proceeds from Stock Option and Warrant Exercises",
        "documentation": "Proceeds from Stock Option and Warrant Exercises"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r304",
      "r689",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r878",
      "r900",
      "r918",
      "r1016",
      "r1074",
      "r1075",
      "r1081",
      "r1137"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r304",
      "r689",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r878",
      "r900",
      "r918",
      "r1016",
      "r1074",
      "r1075",
      "r1081",
      "r1137"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/FixedAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Assets",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r189",
      "r192",
      "r193"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisposals",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment disposed of",
        "label": "Property, Plant and Equipment, Disposals",
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ino_PropertyPlantAndEquipmentDisposedOfBySale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "PropertyPlantAndEquipmentDisposedOfBySale",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment sold",
        "label": "Property, Plant and Equipment, Disposed Of By Sale",
        "documentation": "Property, Plant and Equipment, Disposed Of By Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r210",
      "r725"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixed assets, net",
        "totalLabel": "Net Book Value",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r712",
      "r725",
      "r917"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and other",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Assets",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r189",
      "r192",
      "r723"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Fixed Assets",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant, and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r472",
      "r490",
      "r516",
      "r517",
      "r518",
      "r663",
      "r687",
      "r742",
      "r786",
      "r787",
      "r852",
      "r856",
      "r857",
      "r858",
      "r860",
      "r875",
      "r876",
      "r891",
      "r899",
      "r912",
      "r919",
      "r922",
      "r1069",
      "r1078",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r472",
      "r490",
      "r516",
      "r517",
      "r518",
      "r663",
      "r687",
      "r742",
      "r786",
      "r787",
      "r852",
      "r856",
      "r857",
      "r858",
      "r860",
      "r875",
      "r876",
      "r891",
      "r899",
      "r912",
      "r919",
      "r922",
      "r1069",
      "r1078",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "ino_RangeOfExercisePricesFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "RangeOfExercisePricesFiveMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$90.01-$130.00",
        "label": "Range of Exercise Prices Five [Member]",
        "documentation": "Range of Exercise Prices Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RangeOfExercisePricesFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "RangeOfExercisePricesFourMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$52.01-$90.00",
        "label": "Range of Exercise Prices Four [Member]",
        "documentation": "Range of Exercise Prices Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RangeOfExercisePricesOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "RangeOfExercisePricesOneMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$4.32-$18.00",
        "label": "Range of Exercise Prices One [Member]",
        "documentation": "Range of Exercise Prices One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RangeOfExercisePricesSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "RangeOfExercisePricesSixMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$130.01-$233.28",
        "label": "Range of Exercise Prices Six [Member]",
        "documentation": "Range of Exercise Prices Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RangeOfExercisePricesThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "RangeOfExercisePricesThreeMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$39.01-$52.00",
        "label": "Range of Exercise Prices Three [Member]",
        "documentation": "Range of Exercise Prices Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RangeOfExercisePricesTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "RangeOfExercisePricesTwoMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$18.01-$39.00",
        "label": "Range of Exercise Prices Two [Member]",
        "documentation": "Range of Exercise Prices Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Axis]",
        "label": "Name of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Domain]",
        "label": "Name of Property [Domain]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r951",
      "r961",
      "r987"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r649",
      "r650",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r815",
      "r817",
      "r851"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r649",
      "r650",
      "r651",
      "r652",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r815",
      "r817",
      "r851"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r827"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r649",
      "r650",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r815",
      "r817",
      "r851",
      "r1123"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r647",
      "r648",
      "r650",
      "r653",
      "r769",
      "r770",
      "r771",
      "r825",
      "r826",
      "r827",
      "r848",
      "r850"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of convertible debt",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r407",
      "r436",
      "r652",
      "r883",
      "r884"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r527",
      "r1132"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r952",
      "r962",
      "r988"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r953",
      "r963",
      "r989"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r960",
      "r970",
      "r996"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance-based restricted stock units",
        "verboseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r156",
      "r721",
      "r749",
      "r754",
      "r767",
      "r797",
      "r917"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r253",
      "r254",
      "r255",
      "r258",
      "r266",
      "r268",
      "r355",
      "r361",
      "r522",
      "r523",
      "r524",
      "r553",
      "r554",
      "r575",
      "r578",
      "r579",
      "r582",
      "r593",
      "r745",
      "r747",
      "r772",
      "r1142"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from collaborative arrangements and other contracts, including affiliated entity",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r296",
      "r299",
      "r300",
      "r304",
      "r305",
      "r306",
      "r467",
      "r468",
      "r689"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r1014"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r877"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition and Concentration of Credit Risk",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r470"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues [Abstract]",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ino_SARSCoV2COVID19VaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "SARSCoV2COVID19VaccineMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COVID19 Vaccine",
        "label": "S A R S Co V2 C O V I D19 Vaccine [Member]",
        "documentation": "S A R S Co V2 C O V I D19 Vaccine"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "SaleOfStockSalesProceedsOfAnyCommonStockPercentage",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agents will be entitled to compensation",
        "label": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage",
        "documentation": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ino_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement",
        "label": "Sales Agreement [Member]",
        "documentation": "Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_SanDiegoCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "SanDiegoCaliforniaMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "San Diego, California",
        "label": "San Diego, California [Member]",
        "documentation": "San Diego, California [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable And Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Common Shares That Were Excluded From The Diluted Net Loss Per Share Calculation Because of Their Anti-Dilutive Effect",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Available-for-sale Securities",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Deferred Tax Assets And Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue From External Customers",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r599"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Components Of Pretax Loss From Operations",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Goodwill and Intangible Assets By Major Asset Class",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leased Assets [Table]",
        "label": "Schedule of Operating Leased Assets [Table]",
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses And Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]",
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r823",
      "r824",
      "r827"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Restricted Stock Unit Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Shares Authorized Under Stock Option Plans, By Exercise Price Range",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock Options, Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r73"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Assumptions Used To Estimate The Fair Value Of Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r153",
      "r155",
      "r156",
      "r217",
      "r218",
      "r219",
      "r281",
      "r434",
      "r435",
      "r436",
      "r438",
      "r441",
      "r447",
      "r449",
      "r763",
      "r764",
      "r765",
      "r766",
      "r899",
      "r1013",
      "r1040"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Preferred Stock Authorized, Issued And Outstanding",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r63",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r120",
      "r121",
      "r153",
      "r155",
      "r156"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Unrecognized Tax Benefits Rollforward",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r915",
      "r1112"
     ]
    },
    "ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Operating Loss And Tax Credit Carryforward Expirations",
        "label": "Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]",
        "documentation": "Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r305",
      "r890"
     ]
    },
    "ino_SeriesA2OnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "SeriesA2OnePreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-2 One Preferred Stock",
        "label": "Series A-2 One Preferred Stock [Member]",
        "documentation": "Series A-2 One Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ino_SeriesAOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "SeriesAOnePreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1 Preferred Stock",
        "label": "Series A One Preferred Stock [Member]",
        "documentation": "Series A One Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series\u00a0C Preferred Stock",
        "terseLabel": "Series C Preferred Stock",
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1027",
      "r1080"
     ]
    },
    "ino_ServiceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service-based restricted stock units",
        "label": "Service Based Restricted Stock Units [Member]",
        "documentation": "Service Based Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting period of incentive plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of unvested restricted stock units and options outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards settled in cash, percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contractual year term of incentive plan",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "documentation": "Share based compensation arrangement by share based payment award maximum contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reserved number of shares under the Incentive Plan (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares available for grants under the Incentive Plan (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, remaining contractual term",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term",
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, exercises in period, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, expirations in period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, grants in period, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of options outstanding to purchase common stock (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "verboseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, expirations in period, weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range [Axis]",
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range [Domain]",
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, lower range limit (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, upper range limit (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonemployee",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of unvested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected life in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value for options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options expected to vest (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number"
       }
      }
     },
     "auth_ref": []
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU's expected to vest (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise\u00a0price (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual life (in Years)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r1030"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r242"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r217",
      "r218",
      "r219",
      "r245",
      "r272",
      "r273",
      "r275",
      "r277",
      "r281",
      "r282",
      "r351",
      "r394",
      "r396",
      "r397",
      "r398",
      "r401",
      "r402",
      "r434",
      "r435",
      "r438",
      "r441",
      "r449",
      "r608",
      "r763",
      "r764",
      "r765",
      "r766",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r796",
      "r819",
      "r844",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r1013",
      "r1040",
      "r1050"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r31",
      "r203",
      "r231",
      "r232",
      "r233",
      "r253",
      "r254",
      "r255",
      "r258",
      "r266",
      "r268",
      "r280",
      "r355",
      "r361",
      "r450",
      "r522",
      "r523",
      "r524",
      "r553",
      "r554",
      "r575",
      "r577",
      "r578",
      "r579",
      "r580",
      "r582",
      "r593",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r645",
      "r745",
      "r746",
      "r747",
      "r772",
      "r844"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r280",
      "r689",
      "r758",
      "r783",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r796",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r805",
      "r806",
      "r807",
      "r808",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r817",
      "r821",
      "r822",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r844",
      "r923"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r280",
      "r689",
      "r758",
      "r783",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r796",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r805",
      "r806",
      "r807",
      "r808",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r817",
      "r821",
      "r822",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r844",
      "r923"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r955",
      "r965",
      "r991"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock as part of litigation settlement",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock/senior notes to common stock (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r30",
      "r67",
      "r156",
      "r420"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for legal settlement (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash, net of financing costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r120",
      "r121",
      "r156",
      "r763",
      "r844",
      "r865"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r120",
      "r121",
      "r156"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r120",
      "r121",
      "r156",
      "r502"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock/senior notes to common stock",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r31",
      "r156"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for legal settlement",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash, net of financing costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r120",
      "r121",
      "r156",
      "r772",
      "r844",
      "r865",
      "r930"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r120",
      "r121",
      "r156"
     ]
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock sale agreement, aggregate number of shares issued (in shares)",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock sale agreement, aggregate proceeds from issuance of stock",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSaleAgreementWeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "StockSaleAgreementWeightedAveragePricePerShare",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales made at a weighted average price (in dollars per share)",
        "label": "Stock Sale Agreement, Weighted Average Price Per Share",
        "documentation": "Stock Sale Agreement Weighted Average Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock aggregate offering price",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSalesAgreementRemainingAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "StockSalesAgreementRemainingAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining authorized amount",
        "label": "Stock Sales Agreement, Remaining Authorized Amount",
        "documentation": "Stock Sales Agreement, Remaining Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r124",
      "r125",
      "r144",
      "r798",
      "r816",
      "r845",
      "r846",
      "r917",
      "r931",
      "r1042",
      "r1063",
      "r1116",
      "r1142"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inovio Pharmaceuticals, Inc. stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r244",
      "r433",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r446",
      "r448",
      "r450",
      "r584",
      "r847",
      "r849",
      "r869"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split, conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r655"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r655"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r655"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r655"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r655"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r656"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ino_TaxBenefitsExpired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "TaxBenefitsExpired",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefits expired",
        "label": "Tax Benefits Expired",
        "documentation": "Tax Benefits Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward amount",
        "totalLabel": "Total",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ino_TaxCreditCarryforwardCarryforwardIndefinitely": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "TaxCreditCarryforwardCarryforwardIndefinitely",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite",
        "label": "Tax Credit Carryforward, Carryforward Indefinitely",
        "documentation": "Tax Credit Carryforward, Carryforward Indefinitely"
       }
      }
     },
     "auth_ref": []
    },
    "ino_TaxCreditCarryforwardExpiringInFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "TaxCreditCarryforwardExpiringInFourYears",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027 and thereafter",
        "label": "Tax Credit Carryforward, Expiring in Four Years",
        "documentation": "Tax Credit Carryforward, Expiring in Four Years"
       }
      }
     },
     "auth_ref": []
    },
    "ino_TaxCreditCarryforwardExpiringInNextFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "TaxCreditCarryforwardExpiringInNextFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Tax Credit Carryforward, Expiring in Next Fiscal Year",
        "documentation": "Tax Credit Carryforward, Expiring in Next Fiscal Year"
       }
      }
     },
     "auth_ref": []
    },
    "ino_TaxCreditCarryforwardExpiringInThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "TaxCreditCarryforwardExpiringInThreeYears",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Tax Credit Carryforward, Expiring in Three Years",
        "documentation": "Tax Credit Carryforward, Expiring in Three Years"
       }
      }
     },
     "auth_ref": []
    },
    "ino_TaxCreditCarryforwardExpiringinTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "TaxCreditCarryforwardExpiringinTwoYears",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Tax Credit Carryforward, Expiring in Two Years",
        "documentation": "Tax Credit Carryforward, Expiring in Two Years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ino_TheWistarInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "TheWistarInstituteMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Wistar Institute",
        "label": "The Wistar Institute [Member]",
        "documentation": "The Wistar Institute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1122"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Title of Individual with Relationship to Entity [Domain]",
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r309",
      "r310",
      "r312"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "verboseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r428",
      "r447",
      "r583",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r729",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Adoption [Domain]",
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r257",
      "r258",
      "r259",
      "r260",
      "r269",
      "r313",
      "r314",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r384",
      "r522",
      "r523",
      "r524",
      "r551",
      "r552",
      "r553",
      "r554",
      "r564",
      "r565",
      "r566",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r605",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r626",
      "r627",
      "r630",
      "r631",
      "r632",
      "r633",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r691",
      "r692",
      "r693",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasuryBillSecuritiesMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury securities",
        "label": "US Treasury Bill Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r907",
      "r909",
      "r1133"
     ]
    },
    "ino_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Public Offering",
        "label": "Underwritten Public Offering [Member]",
        "documentation": "Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized loss on investments",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of the year",
        "periodEndLabel": "Balance at end of the year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r539"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increases (decreases) related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases (decreases) related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r184",
      "r186",
      "r190",
      "r191"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillandIntangibleAssetsByMajorAssetClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Useful Life (Yrs)",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876",
      "r1126",
      "r1128",
      "r1131"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r277"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r277"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20231231",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Working capital",
        "label": "Working Capital",
        "documentation": "Net amount of current assets and current liabilities."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2AA",
   "Subparagraph": "a",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-2AA"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(1),(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>104
<FILENAME>0001055726-24-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-24-000011-xbrl.zip
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M;OG2YC',:M\]0]:^Q3RBQ!HNQ2G*'O.5[2&9I!3OIK"!EF%J5D]Y10_%XN]
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MP"<+5 4E>(0OKBU=,8F_# "GVP3@2,2CB30ULQ5%%[*,#DLF&!>_1O"AJ-B
M=^/C>O7'2,6&R)D^:LRQK</#8V^2&>1M;2 !G3V^Y1'CN33GQ0=Q#OB,"(%&
M [P L*EM EO#EC&:JZB@C7>CW+CD'NB>P(Z4PVV:UHZBOI0P[_176!_P#9U*
M8B\^Q2X^U9AIL=/=E<H90A:YZEZ]QDS<'@&?$)1WSX#VHB6Y]+>*@EB.(0Z*
MZ9^];ZAY)HR^!M,<%]RKGWS&A'P>H+=JQW7X$G9<?':HYLL@61 1\>(R+!><
M1/!Z@K!8D:AHET2!&JSSMUF<7V!G1:%# %C+]&.+"H%*E$:;N/DNPA:)U1-Q
MXU\2R//U!9]JC2;SBJI+/G#W>__?0#U;WCXW*+E0 O+/96@3;8)3#0B')@/?
M;F2F(*\II48)QDF5Q2.?8LX/>YX$LF;/$4\/UC"85-C0PRV!K0%D(S:Q,F(+
M-6$2,[K'=.[K I&!\\-N- EB[8'82\K66[BW.<>DG#FDB@0##DQM"!D^;FZP
ME<0LI\N)-1.@5%?*J^;4W#5L"$5E[ RP=)K;R'_R#G(1:9^9]5=_/_F39[&_
M40SC4=,F6#Q\X#?WP+NTIOX8EP6X%AIO9.5A./]R@NFC,G(VU"7;P(U.FM['
M-@1;\  32D,H69I!>+Q8W%QU.#YN]XZ.Z;9#</A?S0=N+D*T^2+$?E"K9820
MXP=+.^WN@V6_V^M1NSLX?)YNCS;J=I\G(DX&3K>O9/EVYV!GWJ!9)L->=2.Z
M=T/(]S[N3WF<[2_/*'R%Y1VNT;OYM_'^:8X1)6R57S](A[GG*.%[0\_HV^K*
M;=96)UX7^O*W&];/QS>O^H,3SY_B^_.+GWX=_?ORQQ'?"OAN=/XL266PH6%$
MAYM_WKMD]83UV!$LB;8>X4^9MPV0W20(2BCHDN!S9S$W[T^ _;,C_/BQZSL\
M'ZM771Y+L5]XH=ZZP1T.=<#!T@T<^^!0AY/R3,1%KB$3HQM(:SH!$^_COI$5
M\+MF^_70^MAG ; B?M9<7'RD;#XA]^Y%5M;SK\3#^"O(!%9N2BX &>=]T42.
M$95U6&WRR.7*YC->]=SG*Z;_ U!+ P04    "  V@&98(1-J!P (   R*P
M&0   &EN;RTQ,C,Q,C R,W@Q,&ME>#,Q,BYH=&WM6F%O&S</_KY?H:78F@"V
M8SM.LCAI@*Y-@:!XUZ(ML(\OY!,O)T0GW22='>_7OR1UCIW87IQM:=W@+5#'
M=Y(H4GSXD))U5L32G)\5(-7Y#V<_MMOBK<OJ$FP4F0<908DZ:'LE?E<0KD6[
MW?1ZXZJIUU=%%/UN?R!^=_Y:CV5JCSH:.)_).=M/SV?[/,G9R*GI^9G28Z'5
MJQW=[\G> ?3R_L&@.U"0C7()1Q)@ 'UU< +9?WL[.!2[IS$A3@V\VBFU;1=
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MU!S3I;#, ?F.^"C1IE? <#:%2=UWI?;E/>5&=Z\_0L@*T"T*8Q#4H&>L@Q#
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M-N)VI<JX-U&"OH6%=10RB;+CY)/TZ)%TU!1ICK6'9CR]AQ'EO,OIP@&XYFE
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M"LR3U0?\>1AVOP+RHT%\*7-<&N9DY^O(M[0E\C(.I3=2Q",93FAX'-$S"UI
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M2-!E.:2&EN^ _^0PJVK.6=*.0!/!-+(*QM)Y6#D1SWK&(8RS>=DJ^R=:[N%
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MK3)WE>>JGW8H2RVRDLH6Z=Y*;OG^],ZV]+HMO7Z7I=>AQ+<O-BF^_<MY)P-
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M2[_8FJN1,N8G7'C'J2[N6.&*C!]-(L'J3I(9@K:@Z3IUXEZGO3J?8%+"MAV
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M'2FLZQ1P+O_%>T4BY%O?^E[M<)\XSTL^U#^SU(8RC4?8-R$Z=>YEP7[EIJG
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M]AZ<7L+K84-TV!"]'$G?$;$/&R)RSA5U>(A8N<.^J'[8%QWV1:\!%+Y[7W3
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MKF&P9*<JNGL\XJ+[IFI^>KJE$M"81=/N;S<L!DDN8$*N>$R3W\J2)K(B0;#
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M:A\"$-&_'OC6:&RC,D"?#3W<75(N%YY\$X0VO2Y^AWBE[X8>_45*QP<!(=H
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M5I]U#(LY!O-W1Q%7S@6@#)C72LW*VOEM1I&8>]T+IEU/=WR=I*]_.4U^P_&
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M;-YIS6Y' SVFW6VTC_:>S9X4"Y73]7C#RH63D^=9XZI/JE8*9^>;,EXX?MY
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M@X!A01'""L!F!3X\R-$'%/T0Z>N^IOL^\&_\2(*2]?N,W)>.J+; .RWT23B
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M:,$=XKTBT>B>5AK-?A7/.2*KTTH0)2I1GB1+=+&YVKWN!7R)S6:3PP4L'IY
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M)[A-P/8QKN8%*%^@' %Q"GRR_'-@/A-0AN-?>A;*.\=39';W N:02[ASHGZ
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MDW0+>47$_0,3G Q+DBWH:Z511MYUJMOH%-_4S5M12<,:Q&0C*JWQ2V-XS6<
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M9J;=1;HK0ZBF23/QPEJ_-_B6J;==N5$Y4I% 'V\SBG1_TYYE;$4/7)5.,3<
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MXMV[J[(1[0:JP'\7!@X>2OH=/E=D,9=YLQ0*->6=<.<H&QXB0%WUR+NL/1F
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MP63O=E%U2_8L,!4]PW;Y(I@:/4\,+^Z1)42F@A:B5.MX(%IN!2?1H#:7*;2
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MQU'%IY'"KF;\DPEVY$*U*9&*6F-L;TRQ"HG2:$*I&#G%JJ%+(Q(<3K7;)>P
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MQ0AT,I(Z;!4'% YJTPNDN-X6D1"'B4K#W>#<+ED%[2UE!CPV#T4T"-Z3,SU
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M5J,_<%[.X('!E47LC-_:,774W@%-C /^[(25W"MMW\2*@ <(DKN%;TT<[O%
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M#.QWS0H$2D*QWAJ 7'L292=QYD2MA.RN1(T /\A&BRP62$O'^-V$2;C]TWU
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MDL2 &#PRCWG9QN2']I6!BJLEJJ4%L":4$PF[M34>HN/9+_8*"AD<3@DE@@&
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MX_QA/7+MN$OZ0_4Z5'(WY,SB/P_DS26ZIY;FFMILWRBR> )!X8_2<$$92L6
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M+R][(7*.XK"TX\N--5<..J&&-Z),9-NWU%#%#7?&9H.]V;?&=<-_N'CU%!#
MMBCV="&".#FX2=DD<8O+^8XH00 %H7_*XA[;@P.0(^@K?6*$W;5S7]?[:$GE
M2$*@":N)G<"</G6S1&.'K/8>_I$FW29JTN[S%Q]M#<N*4XFQ>VO(UFIRQT;.
M* <W;<VY]:"R)>*,!KZ$:H-ITCN31#B!^]7^6*O=5X2L:LGG%:P^Q[+W =''
MG'5-)N3+8.S I==SXS(;SG N^JENV .,&IB1GC+E(8ACBD[%4B7XG4R8UF^*
MZ&G<XBE8W!9Y553F[7UZI>]#.9L2YI0VO:'9--0QQ3#5E5:_#.#D4EVF?-V%
MT)0,XL#WVD35/ L71:HBQ &8%9&"R2#-LXZ"(VD__'[XV<!W)+-+U(PD72$B
M,]QM5TG4-07)@4D>LS4JN5+FEO5W0>3<&!F&$K%Q'%\IO62Y,+$4^A&H2-:+
MMW<]&9\-2/-GI^*W;S<BJSDGTYRP&)%Z'L=_"<&?2OO%,['>^5Z]Y%?^,4J!
M3TE$_V*D9V6E+@I8PP94]&#DV* ++F\65P)7-7REH!,M>%:JJ5OH.TA3EN*<
M7;:73T-H[K/9*?[SX9CKY(W%UX#,AG4%!CGEWXR)YM5^864 I*.>745\FEP:
MN@XN-DU/W"E$"QC+R%XH-U);.+:Y?9.FDA+.TR,;=C>LMI#?FQK1>[6C&?LI
MVU@_&Z:F;C@/H[L^Q?0KG>7^>1- JK/6Z%;8 Q-E'1YA?<]8 )>>,'FO30%Y
M)V3NCV?#K3PYPE58FJ5P5(?/&+4! 3<J<MEB4'Q3MI%-6?D^(SV)6XY%L/P-
M15]<E*8N#-U$6J^8I%3E/ITAK9H1EO$KJ6W)6#Z6A1)WV.Y+PJ+IVTSP-<QW
M>^*%S"V9SQ&YCA!&%:^#V0J/#@.7*=+\+,,H>*A9[!:)8B[\ [J?VAZ\BH[,
M%#I=IA6B##PE6P[5\;)76>^4XM,8X+9<P373>W@B(&G62+GNR.9$OIPP;00R
MU#AN\"'/!"T6BCF(-IN>"15)_F? KF<:A5VQN*J@D*,=:9+@(ML=S,]BU'WP
MODLQ+D9RP+?D >:+HN?*!&Q;5297LD,^+M9YN8FZ1C/1'FV)P6L;SG9.V#HS
MR) IERQO+"!6O_4-"SM;<63>4#?<,M^$:RSL_X):F=;AE9MKW&Z[MBLV\L]<
MY JC;3>JKA7+$3(\YMU<K7N6XA4VZ&2UW.#W+TYD]S5D?^P2@=I\^,U+NB,K
M4#:L78-/%G&&ZWQ>K!D![O(]$&RV[*VS!:E_J2T5KD_' '#V[0_U<3X'WQ#P
MA5^1*K\F)X8$RMY)$M;+:$8U<2$'3:PT.>OG+WZY>'9T\JVMI//:?V7G@WI)
MH"(#P3!N@8A/082FS710@N+214F5!8(QP;=H9_.:N ')-=^ [I;H,$F2ALXI
M;=1Y74/ 4L;!A*E<81 0,0E&$2<YTH'6JNYI_56>^C8.;"3"=13ZTKC.=032
ME2Z,JU'F)]PZSX-U(,& W>RO8?^?\<7S][1AE:[7@_*7L9F>4A]0)8FVTP>G
M#S(-R-^_J:9]@-MW5X9ZS*-O'CS /H-$FMO-#AV5BZ=\^L>ABZRU/WK*C+CA
MPD O?O[YQ2]G;YX?SY[F@DIVN\#4J+3KP%!R8;=$U2_R5H9#A\VEF3F=L<"!
M)F#X0?J[3GZ)]?4(9L+T"I?)54-[=S0]O#G--$T>D,AVYXF>A>^&&[[2W8U;
MR[Y3T2$*UYHN$F9!"J12(5]2<7VY;Q860NF?MF!3^]@:]Q8S?49C'8+^$N-$
MHT&T^+/5_\_>NS:Y;5WIPG^%-57G=5R%5BPY,YF,/LF2$RL31RK+L4^=;V@"
M;"(" 0:7;C&__MWK69>]-@"R6\JT9=;P5)V)U21QV9>UU^59SU,U82MK:VWP
MU"-7-'V)*J,W'3^UL5L224BL%K;XV=A$YJ8+OLWCVWY_!OBVSV?R3AT_O-N9
M,9 B'8+0=P,'>XLVP @N&*=)B5J60IU&H&:PL-=M?YUZF#,+ 9ZQ;\*N@^I!
M>H,>#M>< [D%<$@<'XA2,\7Z!Z[Q0E5W>.!!O\P9_F;2_+]Z4:CQA<-MC:HI
M.)LXBYY]]=658ZE:;=N=3A@]Z[/_^'WZ\8D9C;UQ#$Z"-\XLLR3325;ZA*N!
M(.K;O[W(&/MTI'2FU_8NOJ&DPH<O"!ZEB!EQY]/%N?0&3U;?J?PAS6//XN_K
MJH\BH*2<G!>(TFUP)T"4L"YNQAP"-.+*Q6G0S$]]$%Y&>E6'&A&0>CYQOM"?
M'!8'>/GQ\VSQRI25$.HC(1)AH)&_W)/5"[ZK9X@WT=!P'R?3D*QRT @0-R&#
M5SAXVI9Y'2Q(J1,*TZ+M<?U4#E;D3,N8_R!6WN%_T :0 Q0.UF"AKL0<;/#_
MGO^"(J'Y72[<^8X*<M$E,H_QB]ZU1="<RP;_N>W"@'W'@_RFNPD1.,^BR9^_
M:^MP!:05?X1W]I,Y1J^,"]C4$^QQ.%"G'[A4'FHCJIP<'3N*XT5?E]:-;JO9
M2RPJ*YQ0:GFR4I&?Z3Y(US]1)L>"C4@[L;XR+?J._BIO*"0[M)(7,Z_&N0&1
MJ+%B^ 7[;?1^EJ#0)V -J1#Q]<J@@9@P_-?:!X1E3  R S1R;SSK"\'G:XP&
M(;D6GT=X.\9&NVLXV_9;Y!E94(SS;5PLW 4#I?13=-U=YMQL>I(Y<;G:LEAI
MXMQ161!3^%%Z$2R0J.DETQ:>(JF;+\AJA1-I3"D>PI+MR_@.R6&5D"(?XABG
M&H03J_9Z?ITE0[ML8D^=-:?%AKAH.=4=F9M=X]).9<+XBTWZ79A[)<C.Q&I.
MIXK3?&'9V/N:37#)/]-8"FN2E&&6S- Y)8>8BR2I?=$IE8=SBIAT<=+D1+#7
M,NY1-Z3HK"'!PZC3S&K;+[_]RU^^??GC#R\>!2+Q'W1*?<)K+H1Q- ]7T,E]
M3M+<Y%Q**$9-R'0!0GL\_?WO'AOL\9'S%;/7C$$X/F<:]3-%D<TQSY5!.><9
M6RT49F*).!7?DF2>[ 41RZN:6\J;WFCW6%Q&=V5,7W!E1!]V/=E_CK#&[32K
M\(<_7X\]7;//F#AR74H(=>3>7(LYROQV7A5JA)]_;2<%ZE@T4&E&L<<+!7X*
M*.EXB5"Z)V3D7!%EJ6]4CKCC$]QVQWY&9U6OLX_V<CDDDCQ_]*!0PH+_6]%2
M<ZI;*.:R"S-[8)P451F6TJ2:[2"]=D/X9[1+L-:KV^@QRZ,-DQ&./07A( &%
M2<PDX=+-N*Y+ZM%85^'H1_[0O!W]Z>Z'<,F8)2"DCW9_T3/BWV51<7O1M.Y!
MT!SFQ]*WC<_NU:@Y)8U2871+@%[(',.6VP?]NAO#+0^9W4":)5CP^/H0 ?'S
M&O.$#0^R/2>W(ET"'0 N4R@2A0+F#3,CJ!-9,E+SK?:PP:?!"M,QTVJ1T!A(
MQS.E_N#%3HN'L30&9#I:KZ.?N*+MBIC=B&Q8A(!,C$!1[=)F3B/W/$ON]-F$
MHM#]2):S\T3CS^4SAFZQBIB JUP277C2//.5(BCN\=VC5YE<K3>(G-<OFU=%
MYX79DRO12^DYB\[)@[OP^.4$Q:;$/H  _^W)NR<9!\O8W0H'B1EBY,WBB38K
M1=+RBNN$6$3K\J;J:W,F/66@'_(E KJ($#EU L[44)',4JL<(0UR4F$-A,#C
MR*DUP62PAA!05\$0R+,]67W?0EZ02Z*@;@AC-@H(_J;"8G1I]:DZS70 R7S'
M9,UQ2;KTD([)>HLPLB1V-[1W)LZDXBR5VL?6-2VVJELJ1YX^G*;8'0L0%N>
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MIQO/J/6?OG^;=DF92^"*2,.V(SPA *U.2<NQN<B4:H-8<D5QJ3(AY>=:TT#
M_B7':>[S:$)#^!$B\S]MB287TJ^N)-8?:>IKUZ-)^L[#C\F83,4M)V<X)25F
MHX2^9V@4XFU 5774=9HR#R&&10TEO.E0E_KRK',Y<S.^F/EO@PQR+%0!AZ0)
MVW#(K1*VI.G[)*^2%L0VL6I2W0:?)FR>O&8;S91=JL#GHS3_21>)) R29I4K
M_4M?5O]$5 LTMB:!E#65FW2FOU9TGV+BVC3"KG@K=^VNHCJV^ ,TF$NNVQ=^
M@/)B*YZ@*Y76^5TO%48K\0I?=BI9/ $&+Z'*<8W.Y;S1K#1M*(^%0,>_0(PA
M)<J/VOXNQ4;NZ:2A9SB;)VLC*+)S9)7[@XT],P(JW\><*2-+( *FH]AGCC6Z
M73J6)QLK6]$.#$MH&^P5,(O]()ILNMA0+2RY5T>'T7<Y'Q\CJT7P25EM%KQS
M]<DEN2TY)E%Z=YD#+W0PSU,"MINS'J5XZH71)[K=AT+QLKL%9I&X;A)C \5Z
M5W),3!/6 5>?04_HFE?/4>\,)Y;KXD_"W0[.Q[5".&T,9#$"CD%Y?[2$TE1>
M5^C67BN'1+5.3:)$VV^Y@"U0[W><F5R]6'/T_4>.>T. TP9?Y%4WWO#N>]GV
MN^ &K>F+=*@=TXE<L ,+QZM+1"=&.UH;PB#)^_Q6WF5I-'Q>P?T:Z[*?B!P:
M:A4JJ?,GT=O,/8#==5M4"M N[426HF,RQA'W>Y1E3U"^1]IJQ Q;B[^:93$F
M1Q4ZL^E0SU$N>,(I,"@L70;NB.%Q0C1C*H7@.>(8R\ -7G\?&X7^S(Y(!<ZD
M!V)ZKID5S8)17\,W#=NY76L3.Q^-?3P;C]#?9@J? )!(@!YJC=8=Z*&8NBI$
M=0:RF %Z%C4#+7Z8XML==\H95<=\=QG'&R):U8?!J\LK;DW6MQ:A0-0_M-<U
M%B38]62(5K\"TT+5Q";4J#IK1TW$"65'!I.9$(YA6,[0R/]<.N8C'O'_^>$^
M)O>[,/!S"I]/G KRW,.7T5_8]%RY8F:.WK\0O8^<-.(S=+TVU5#<0I8HPJ00
M"KBDBV5ZX#,BQ%=/@1Z:VKR4$X7O+<Q'<A %CV6]S87HV5&!>4(:N)':2T($
M) >^F#O/D' (P\ '@32M"D3CKNW>L]D=Q8XK+\F1&:8 +;^+,YFY.<Y6[\M#
MG#^>W V:O\.];\+)W%,4W]+<<@9 LW1@=4]D-JM>4B2H)/'@94+MIHD+'COR
M*=0UU(H;$V>AU8Z#S5I99>".;L+F"):>-5)NT6372953I@D+F<BOJF$<_#K6
MP#BX;47;38-.D G1%,KPVE2+D!K[AS&;LY#8]9K3.6$HOZ6Z0RT-]"X?@F,%
M6JDH0:2;4&OP<6K<C+G:GF6.!D(X'2/\@CHL]M,R"7>ICWCDB4CN D-Q-(ZF
M,"?.>9QR[CM"K^GB@ES:H!-HK5Q(P *3!%ROVN"</F.>G/\A[.,9FGNNL<",
MT<@%PR!=)XL3FTE?7ZP2)$1,1UT.GH1C0$]KO;-Y4F7>AN4C"RZ/5>3H>P=H
M,>FL\_B)^\@1;WHL0^?VCQQEG_*NB'?UE,N2&&3-J2)83N$3TPX^M 9)K!$6
M9W%R=I8^F7<9Q[JCXG4U4YMP_2U@SF-*R$^%2T,)4QRV7SAUMU5-?"_<Z(X:
MDP"DK6Y2@9^P[6S@TYU_GTMQP0PDF($_7# #)X9G><]FDIES=1J?#9T4;!*S
MX$[9I<J:I!:/_$8..W%,HEM"\+HHRLM)*.Z-D0P7-UYKPY$@["?%:7WB4R#[
M\SJQ$ R^0:%0<NI<=O(.?#9WWZ<Q!YEZX>E3MS0A]X3@D.L?6:A/9KZ?D7W>
MN<M@SNU2_>2B-O%8+.KB]QF!=<3!1=(J=<?]IP\\PB^B X\G,>'MKT5FL<$4
MUG+7%BY_#U"YHV:*34)F$BR;&OWVRQP^\N9S)<3@?N\YGSR9R+%9MUW'39I%
M"8'%C"V[G&%./G%A-HG/VXAA\GC"7N;VL>8V(K2(_NB*,!FZ1_.N(WZ6G4EP
M45[(.3U<<!^[>$Y?INGQS.C<_[182^9KR9=DC.&1']P'2;M,YZ-95,V['205
M3D*5$]16C1J4\+IP:(^6O"3EF:0Y-*LL^W.^'BX3^E@3ZM#H<EI.!!'+V[P>
M(UK*6*V3T#.)')/Y%?D*.ENI_;[@*J-E<B3S<Q%\_R4\(6B#6(=F!#;99(D[
M0S$^&HA8C9BK.V,_M#MDO%&$4HC99<X>;\ZX'""3%,-])[_*GBHX0N)F%(0[
ME^T2+X?VXF6Z'DM7DEJ01PL";*--9T%WGJ.R5MP6 I%>("Q5-]EZYT4SI<IJ
M22L,9[,TXXCR.</YEC D!A#7%D5/FW<*[A9+.,J9>$88$R2&E7<S>:T3?,,9
M5^]!X3M0"1\-RE;U33N3O6*%:TTZK^QK,DP)'FR9C[EW?(WVA=Z-& .XIEH#
M$0T%2*?,Q1>T:POR6DJ0!T@>70E&F6:&KA8BTW:F'T+KU??_T@X@@8OP/U?V
MP"+6!<Q@GTJ50,*81D&+X4ES*S_R3)^8< A7S"K&A&&5(N<B,0VXCT6ZV4G'
MZ$L0@C]YD4C+2HZBBJ50L^WZ?7[#[85AE"$-@^KH0$2H-X!O[UJM9!/</D3H
MY=ZX60TKC+P;H[0CCS3&26@S*VHRV D\/VDNTY8#:U%4_&>O\"I^ O!C16D<
M&5%02#,G*E*M7JF%6*7BB&>NY\T54/GZ4CG&"C'"./J&[]S6)\UIY6YJ3D$I
M01M?.1*'ZN]TL)^LWCJ6$^E[X7':HBV&GHDTS====1TE]=AF;C97N X>\,GJ
M13ULT9YA3V1C[K<4T4A#QIKIT75<:1ST4>QYU]M6Q! !'C6E<QY@?<G9S\BX
M*+I.Q__O8W'#K>4P=45KVS.=S):$@"PCBR,U2B/9R<JLN^A0F6V5=%P<:%+U
MW*G0''>[Z92!PYWGG\P2Y0L+U](7GX)5CE:B*K%:5]UZW/4#:YWU6UHD0S<.
M6V), :]FN&;8$80H88T46_3"2N\[2-?AM8F@LQDB+^]T&6%RYTMI*OJ9-KM@
M!J>$BU7G&WGR+C$<F@4'SKPBT%.CT(EJ[;I^$E'FY47GZ'ZE7S]I9#$-D;:=
MX_F(86\MJ5M"*2?@:<=+G,^6^<&D%'VGZMA0 V(3>[T9-ZQC$XD>)Q2380S'
MAL!-(!$'&2!AQAB?MR'+R@3M#.]PEV8\\YJ=GSON,8FSNF+J:YVL(EM\$:PY
M/I2FQQK6D#W\!%,#B%.*:.8S@/XK!23[9\*^B[3;C$#T;3_)),DD9*=:# W9
MG4ZO6WWW]2@N]58O<QJF"C)'AO._'H1<_M6&4G"@/F\H!:JKQ:0QV<[5SSD[
M%W\IAT' L",UV)#24LU_>WZ9@T>; S86W)I EM,Z ;1-X3+XCS;X;"N+I5#F
M,NR//^S(64C4,\%(7T;_T48?K'W:/@OI9>WHEU,Z]HI1+JTTEM[DXTU5<UPU
M7N;JT4^'J2OIP>BN!8X3'$2S,.6MCG[6<YK8RWP]EF4KT?E,&#/$G)ZH.&7%
MJ$C04.)Y<>:Y??"L.O6T>RR/^4]P:$ESV!(,-66Y)4#E#99LL$'[<!((6+8,
M@6BA\LZJM!3S&A0GLWQ)'X6V!E4>4YH&(V0W!M,)GY!C73\9"VO&"4%_(;WI
M[H$7J5<\5Y1^1)7V,B=WFY(.TE[R:1GAWW]."K;.I/]$'EMZNRWGF:A88-XP
M9N@)KP],3J1IGUW.;4$\G4J\%!L2\Q"#[/8#4S\4'7$5(@]\L'^JJ@02\=H:
M1FDBI(A !5_.!!$<KZTNL E_8BK]W2>O0E89J]XM0VM"$T((2T/>Y=PBC1#7
MQ%SM2?#*-8^5U[#.+UT.?MU]_=6ER^'$\'#J-UVBNCKCGC#->C+1VXH*!]YF
M.9(<2L$,O>5A#_QCX8UUNRG:0<N]0S<DI4L@ VE*J?B>[-V)6>!2^X*=+DJJ
M&0G,122&9F0HD/$\VG.V>([80 GB(B9&X]_H[=$ZR1*0&6H7;5>*RX6<V;6\
MMA&B4&I2&;$G_/T3;?7I7"45EL7F%8AX?OWTJ]_3<<?,"')-J87\\,-;9-28
MIT.Z$UQ>?? VW&QUTS97_1C6,H^HC-*G\DA^OA-*"Y9ZOD,O%$UT#!%8,^%M
M.-VI0*Z*0M;179.L=HV!+A(IG>3X3HB%5-:#D[/EE3#.0&.6MP=WG!3E35=R
MZS6A3'J<+*X:BKYG)DJJ;MN!&Q<G<B^Z58TF4Q0JP_F;BOS0P^E><=5[*+LX
M=8!21HN4O]H3;Z+CQ6M2GH(+7\SUJ.VR9@?&)EPA[+Y!VZ9#L+)0-TGT.&5G
MA5>*G'"B:N9,C9SX> AF7T91@ZJJ#$NXH1U()86N0G#$ZR7*0"U<D^GG35E=
M/T@&2$?'S1X5@]-J-K^,9/SC96R(:<&$_^E;E6#I2YHFW'3V6).WPWNPU10Q
M*1:!C/Q;-R'PZ >0OS$.1+DNZ!HT7:@1#4XMSIY91I4*2F$C^[*P5MQ8<0F2
M[!C@C9"BP.]Z<\J'#M?^=NR"@5K4*C;Y#>6GH=U*+5.SLB$;RS@\9Q@MX2!5
MG,3J31?\S 9D1JM7..1R,]:.#N(8<3V=E'K,) I-JEMK=DJ%S)F2H7Q_\LZN
M(_AHI2CE/1N;5"2$7U##NR)>W]SWA%EK04TI6>13^/.1AY]2HD<2+F9UPX_@
M*I4?PO?ZZI9H9L_L?'OX&M+Z(.U]&@#S&Q9]H> U1+)#UJ2V5O&/6CT+DF*\
MXX^O)45%'%]01<NYA:/2O)6XM<2UUQ?5>I8AFY%:X>W8+&4B%\4O4F*-L,OH
M*$7Z'9%VJKS*OMU'<K#>+ZZP+?_6:*+ #]2+M4L[I#?,>5E"/3%9J*QY3D($
M\N]&Z!',V<^36)3Y1:PCE1T^0C=Q> J6C$WD()R_#4W9IKS#XX>'>/;55UE8
MS\!BW5;%**+VL\&4IJV%ZZFXW^1R"_-A97?3D'=-)RSOYQ 92FGK?&J30J"1
M4O)F0C^%P[T4[">C4I;N#W#&PHL=6^LE%TIY&#O&3,:VX+#PZ NW9526'/(/
M7LQ)5''"<1><PKN<D*P$%\/Y.C:QW@ZQT-5FY#S]T-[EW8+ 8S\X>>I$SGZ1
M7GSCU[C/90"Y$>Z > ;\8Z4T,>NVX'R?K-S"C(FLVO!&$Y1+Y3T43!UE9XZ-
M*M'3 *;!@#+ ,=GEV51=F.V(JQ&SC@>3Q1]CG(KO@J$O_ DQ07646NU&7^GB
M :&[B+S_/JX]W<0.:^:E3WV])&I0,R?JSH$XY WP1P$\JB'MX7L>RIQ:/,(#
ME7M$C);2\IBFLPO37CB;_W"?Z-XCC!T3Y[2+:W'RP+KOA,+A(C2B;I)F]+)Q
ME4:?)H+8?':/'=E3@@!Q2UVYS>96B$#<.84B.#=&B$V<)6<<TZ2FQUMNI*.6
M2<<F<"N#P!4E\W)/**=;?7FL8CH-[W5=97CZI?$1;8&Q/[H[)+\*OE>%M.H%
MC^[BY62*9^315 A!8&JV%$9O[BY% 4@?O@03.6'K210#5?!N45G(Y15"4$7W
MZ9ZLD+Q ZM*YT(Z Q_PC-0+"2C17NW?WG=AC?9/2C7U'.W/Y6)S=<6/D/HD=
MSAL_0]==FQ=ZZM^[EF-,4-.)[K(W-7P'6W?._@+,U[,%=18^G*2Q^Z'V[3NM
M2I>EV+NJ=X$(F,P3@C_/.)SB[[1% OD]XOE#V4!%$&."XYAWMIR%L5!H<17S
M2'LD(649W.>ZG#TU<_CV4*KZKP</ZH;'A)5,-DWM"B6 GGS:LPFQ/^Z[X-A4
M>TJMMG4)>#8%F]260RQ_FV"-P8@JLAJVI9*=[(; +?CH^;KS62\0'6>Z<N(D
MZ.%KEQ?W3\9?CMN'/?;R8_H%&?X(BGRW$F6-PCWOD34)4XKP)^:#L<+?PUG<
MY7_G96 29*@6BN?,ZIW'CJNFK'!005*H;/I%QA.GC,Q(2T[Z5#NI0^%)&_(L
MS;?BZ(-D=M4_55LPOU#;Q8TO'&D3"W.G%&!H_;@O7O0%XZ,AHAZT!.>U+IVI
M=W>&3+<O5BA7J6K#($+SWJ 1<CDGGZ(C,@;_B3N#V2Y@&M4$*#MBCI^7*??-
MXA)9F-E,22&%4*X=4E&1NGI?UM66,.&V'V+XI1,U/^3/J\_NF<N[R#L5]T]<
MXK!J*H59\5@A^(%YDQ,4MT>6#Z[NPGPN#XH3IRD$RKO(/9FPS"C,N1#H'X=K
M8G0@9#[S0$/9<C=E76W*J_ <%.PWPN^ZD)!@^LRR!M UK+Q8222L!)= N.NK
MGRPH3IA$[\KSF%8[' &\LLE"E!\J[J&/H 3:2>Z5O/OE51<UMQQ;#/R-8KC!
MIIW\6*(?HUJ/ZA[:*[G]QG4]/E$E!-9B[*7,[\O\3R]E_A,VR'G/!'"9;_V*
M>>_#F.1KXY-(^K7"HAON:-WY9B"X//NPM="R%JMK<+:V9;T':HUL<+4Y2)VN
M'[B&Q/F^?-BFB29_V+ _$.8C[/I_:I(N\N^9SPP>4\0TX<TWL>V>%7<(/A,N
M%ZS>*^RCAPQ&TO74B1IML#XWE6;&A(?!SL!JHS4N#G+C"^5#OA*#I+[4Q$&*
M797G=[QYKPQGQK&#16URU0<W0#/&,L;A0%I3KRG1N1Z2L(;ZW[BR3#%Q3 \<
M!VQ0;,7.J=7JIZ'>T>><I-FK/D?EG?GB@R^4%S&DA$^#N/G]W*-DQS;XQ>@O
M4[[=X #L663W84[ Q#&+U+F+KIEY7KPBL\0M0X>C$N9C&R@N42F4]9LLP1(^
MI2?GP:4!P=4+!#LSSTZB7^I5WZ$J81F90YSA;UU!'*'R<MV/Z$QK0BK3]K06
M\:7\ GJ."F6W[Y@!-=B3.^&58^=C4M?Q(N$SM2^D*C3W"D@AVJZ7R*,CE?=,
M.%,R$A;"MDVM\3=()V(*1O,823YPJB %Y;HH>)"VHJN<$]:?0U<(\'13=5S*
M,VLDI5'=1@74</STRZ:TA7==6BMA,TT(*1/"W $]OCV%=.K4.>3WH.9QUJPO
M(T;DV.6I]L-P*V\&U(OD,#VA-8(3.XB/F-X#MEKR>/0[;K&?Q3M>E4&BZU\#
MJ<5).,$/@'C\$,FD?G TN1!"6KUEU<[/_AX?"93@AF$H:=$D=1XL(,JG*=RI
MC:J[F63ZF/'LR)<4BI,SFZ&2WP6S*(S,G%JOM (<5MVVVO<JI)%FDZ?L'RGN
M('PK[%3-T&*=47ZQ[,Y1Q%*C8 0),'Y#FRWB!/ -^;P@W+,DNZA+_\JQ4^B,
MA.'-U DMP2\?(BJ*P PQ-..<=./NF^F9%8/JO)G//#CDT50.CYSE6T[R\G2S
MML=$Q<Z?#\JK0(F9NX4Q,;TH=L!U%>)FY(M88U64&SJM23A3Q3G=ATUY-0/O
M)26KB(@(=TM.5=/_DK-C4ATG*)H(AB!FH!#^AN4\C<8<_$O&BI7N/H"#P[HN
MP5%N=^(OPL4_QPT1Z9?P(D*2T)H>3#H&=%2NM\*2H1*W/9=P;%EDG/*K:I'0
M%<!S,J# &,=5NTCON2C([*DVC,2IH+ED)0I",]?M^CWK+IK<[L^E<U\YJ6=N
ML7#>[/.#/'X8YG"LDSNA?T.^L3WDA(&VO['7M_!><8/,S#A];C8\JD:R<I2]
MV'PX<(P,*_18O48:+#A@/:) (7[WTP0CS>1A<@I$F.VF78^J-5DFA(Q#N=XV
MVK<4S5/R':>XR9E\YI,A(K*[QE)QWEQ$5+['[4;_5"2 "7PRLC8-,+[B^!*6
MQO%JT%>.[,\$TD?S3#9-T>U6'UMS:,(U+Y4.%VP*FP@+W!M!D,"*VME<8;_
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MKZI+S&'5<&M36/J1_R]>0[BG=ONR**>%&["5M=%4XZ<W+?0S4Q:UA]#R1"H
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M$Z5\@Y(@L7@%<^OP->C')(<1^387;E;U1X"2?%U(.''VR NB'A,DLU+APIU
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M6#(W%=E*,8Z452CKS541;FR/R&-%"PM'KN(,]'Q<O*\5UI@D ,C:X//<T7[
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M(TD-!Z:63WEP=.6/A#_Z.3\C _<FF*1&>R#@YTN4Z^S-)#D]&LNJMC<M^4N
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MO).&0PZ7M_(,)0Z#QG_"I2:7W%H+]OL6*=EK'OYFLYW CEY:A2PCGP\IUF/
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M4X5[&EMSWI<S"E#K0+LXSJ;8Y@0XTI6:IX8E>;; MW6/TFHA@(:;0.BN5+:
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M2 X@1>-D!KL:P:G.X:A_L59Q]9_^;'Y\P>$^X#,86K4FX"!0_C+$I]D1EOF
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M)^&CMMOI=6H:WMG>5$].P/M$O0>#CML]>G"+V1?356K'NT9MBLTC;U<P^3P
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M>G47[MV%T/"U<\Y]\A,GF,W](*83 <2",/7#ZX":JB>) K# AZ]:C::9[&)
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MB?"87&_&?\58=\@2),+2P-%..[VJ:??W*/Z*R-%4BP<S]+Q_WH&-U'JF951
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ME^-QD, -7?P2A(0B^I&N0;"J$DKA;-HB?RT:_]%1HT-I./\+YT;G@[7%'F@
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MJ.;]**8<>K:B< >MS6W5BG._M$M7=<3=OE=>W^WUN@_0U*NI^-%$0.EU&XF
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M[B3ZXV8>&M:E[VD5!%&1940E1(\;>=1N\)E\@1K5D].AOW*?674S464ZMDM
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M0C3/II8PZ^ ;.VJ!XD/1EHZ>3\><Z /W!SU*/OF^DTE_@98J42(:P.,#._O
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M+'C:%+0GRH00EBBLS@W72:!WIC[@D100?3R#$> OSTZ?:5$^?SFGB);>L=:
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M$0=LJ*SVR>A%EG$0"TXN+L /*#3I&7OAQ<WGNS8PU- =#\.$7(LI$(-6I&+
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MI.X3L9>+S06;M:MZB)06M7,)93;*[!.4V:U49K=09I=ZB]>5V:TU9?97>QS
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M)?&0X4*T!M :J 2GF^EUY]CUV(Q=CXW&B5D%>8AQY*6<"E "K024'2M!,NN
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MEQ%[#XD]E#&0\_;&.Y -=P$JL@<5I)G@^V9'4::*1&6.DB#^>_%2N P?LJ7
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MP-W!W=E+9J:N;](4FTZ9?56XK*(.'6MDRU1DPRQ+O06$UC:/7>LWN%P?5*8
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M!1(SH7A4# Y]:CN,&ABC"HB?XL]3M%U6 8^#56ZX'%K]K]W]%5D8G,&.:XR
MG]D2D,Y^@Y.FJ^M2EX1A:8Z+=5#J0-?40:^JI) :J"$-ZA1JLA7BCH&="P;]
M <AJH\&=$\2=S8.&=\*='N).%YM:CD]L]F/]A>[YPH.%_(<.#M-L;#<TW7L;
M8_AF$+#PC4V'K'#$:@*PU[/+"*SG!-72-(+U%KV^VM.&NU)(#5L>-:BT63)7
MC$O8$7L\4'OCG6OO&ERJ(2YMEM05X]*P==;7N\"7=FZ<4*_&5<<GN6-/C,/,
M@"D$I[8W:Z^"G63YVU!O-_=^EZ#]AI#]CN^XGOT1<)I)GL.7GS@HO?3X\_&H
M=38T@",/J^IDT-A.=4*NS=)][]B%T5;5Z.GJ2&O\.J>(7YLE_I[QR^AV$;^T
M85?5AR<VE*+^6L#E8FG:/D9M4 >X]SSKT7:<QFA_F:#_5< OANH+0I=&5P."
MZ*I]S5"-8;:\NK&QCA^+-DOT;=!H4P=%HZM7UD&Q09\:HL]F@;T[^AAU0Y\W
M8Y6GY7$UWO2WH<1N)(D8K%F?U5<;'LL<^Z%TZT^C2\W(QJ.>VNM5U8BL,8WJ
MA%6;!?6+T&HSZ^U7W?NXP:<ZX=-FR;T'?!K4#9_>C&G]F<V8[V./$/,G>V-Q
M\'V4C$AX\IS@._.G\#=]8BZ;V6%IV3ULG1FZVNWMTGNPL8YJR&.?2U,K@4:;
M>>NH;F92@T>OF;)6&1Z-ZX9';\;<OO+<-M4C4)^N-G8ZPQTO\"2;1/(=#&X:
MJ/$)P7F1@&99&:UA:$A3NT-=[8WJDMO9&$2O)ZPK0B.-!CWT^Y@ V82P3Q&-
M-LOJBM ("UP&JF$,U.&@+NZ^-V-.1Z(:6SMB_TULFQDPU_9\1 9:)CK*J0WD
MV[*V*S2V;=?[ )#&_C*7 LY<P7UA<@<0YID&?'>D-<G"IXA-SS0WJ!R=,. R
M&JCC85/'<(KH]$QG@,K1J=\Z&_5'ZF#WZ%UC>>^6?O[.LH,I]?1^CXVN%_9J
M$:"$MT&RB[8";\L6W\F%OA96BF#(J>4JG;=Y/?LL8'_N6C<<]J4I"8N"U &P
M9BV'EHZQ_4R#75M'P5\!O8:4@ZYWU?Y.\9H&O8Y/Z+\FFHUH+)EAJ'IMW(W/
M: 0OGC94RZN:S=9I@<UF][/9TW'*?6>P@/\PBS?X0H<<<-0 ]?E@#JRY#3;:
M8F<5_FV8OML)P5]-V\5L[FOW%B!]/;L.Y\R/)6/I6A-MC'K[J-N'OW6Q@1N7
MRBMZZ/:%6'H7$:NKC]7QH*EA.D7$VE)MKQRQM-997S7&=7$ -XI-G19X4"WN
M6'VQ2**HO('1S,Q@Y;.X_DB2*?9J_96YS'MC7MC=G; 8LXAYX/<DB*]G? #K
M[RR<>U;,$TOD#NK557HVOK'C<;WNC%1;R%F,W _ZJI[3FJEQN-8-J2I(EMHS
MH^K5C5&]&2>-G,&#(AYU'"\P'93N=%Y-F\[].&9N?&RH%C[=.*8;(O4L7\2$
M^ZTS0QNJX]J8.XT-70/G3$7(-<!H5W?84T?&SHV7&O2J(7H]TR?D!5BU6<8/
MCZR0Z? ^AL9?\1(+"C'W?:33,-)-UYP5YFQF.[89@H8#G\#W;\MO44'V&-H#
M%W/3O6>7[I^FLV+8DR!RVUZZYQ&$L:C"=)]*RQ]L6SHT5*W76)CUQZBJT\+W
MBUK4LW0T'JN#?ETJ=1H,>^5,\;UBF-%MG?7[AMIO>I:^-IY0-1\Z,*+)<KL%
M)]Z&+;"E*?"9'$3V-NW]-]H"AE8W6Z Q+0_JN2B!6%MP7YHUQ\,3.\\+:_"K
MAOA5.KND6OPR6F<]HZ<:H[KX71M/1IT6V+AM7AB'6KF^3!E^=Y_RXI@/INV8
M0+%M(-4VYA%+QT[ IBN?)@,W/IP7ZG<\?'L; ?+KPY7]1W04DHF6YI(]3,4;
M];OJ0&^JLNJ/4/M0\/:$6?W6V5 =]0:JULPT.DGTVE*_VQ-Z#7!DK*[KZL@8
MU02]&IWG%'U5,:XJH0^/$:2QIOL ]L)-;ANPW&?N] E(P_46MDOA*XM-PL:O
M]3*]YRL'[(6 ZUU\!))U?&((_#OS9QG?5NWBW(WOX?5Z$NX)IYIFPL>&4^7L
ML\VY."]&JBV4'8R%#@?J6,_ZLEZ]TWE%SH[:RGL><Z2(5#Q0EZ?8*J9K*8YM
M3FR'5-D/A4)]5^OB+=[_9C3*\REODZ7X;,KL!_28J8!N4V>%^U!FOK?()#^]
MU'5VM*QY#PG>E^[4QP&HGQG__]*5)_$].HBRK+G7;9V-5</0U?%H9SNT$?MU
M%/O/M<[: U)IZ-P8=O-]9\ULD[KATWYZ9>T!KW3>C-_0 +FR&9M-6+1^7K-C
MC13>^&QIVJ"\\+:N7'7VL'&$PEUDH="I]Z;YO TG_$N9B3@?.0)'=-\]=RUJ
M[O&RE(N> 6)KK';UKCK0=NX8T\1\3D$9V@N>4= :ASCT]:;NX-0P;+.7[94P
MK-\Z&ZC T-2!L8L"W@06F\RQ)HJ*/("(L>E4L"]UCL![+=W5+V1Z@];9<*0.
M]9WG:S5^AQJBUI;98'O"K2'@5D]3A_VF3<$I(M>+G5J5(->H=:;WU+ZA55$K
M6J\P:?TE>Q3-6II/Z)0D3X\YG?HK%KM_DEX>:\64T&O\//N8L%[L-;[AIP-V
MT3D_FV]Q'+LTP6'+Z;XZ'HW5;DYKX,8"KQNJO4J\JTH,ZW=;9X:N#KH#M3]J
M7(FGB&9E_3Q[03.-YL%JO:XZ;KH '$!S("5A"E_A>I30M^%?J3.\+3=!E=H
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M]KWCXZF[M#B\M_GWRVS&IMRQ]7,Z-]U[IOAFR!3^<Z  QI$J@Y/>Z0?T?SW
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M\C7\A^_$\[@O)7H///-9U+)="]#J@ZYW7@.Z&0:DZ<_0B?(.&+J"6IS>_2C
M0;]I'Q7/EU]<7EW_>7DM/G^OV" >E"F\B)0P8/KW3)G8(#:F<Q?V=/^D"'$"
MNN1T%8"( +!9[($YWI)FJ& ["&^QP#E(0'O_P<\^7YTK"V;94UA^@%'2.7.6
M2@B<+:3KESX^/U26S%LZC(_M!26!44F&&00>/ J%T:,=SI7Y"H &(FMI.P[
M[\'V5X'R[K>;/]^KRA3=9KY*#[5=;$%F>_"M?%9'X9O]1Z"  A*B,JP X&!1
M^"($UM)[9#Z*0MM5'NP'CR^-@L&>M2+U5U5F##&4&F M0WL!IV4!!+#C&KW8
M8@Y(._\)'[.V\SEL.&3F=$XOFWC6$T(#]K.:@6X-6*_88:!XCZY<<GN&9XVO
M"CU0I#K%FDIM$90@KJP0P@#$I6^ST 3@)! *0"# A^""DPD6M@4X_#BW 5(T
MZ!&,&T>9VOYTY9@^AZKG,/A-0O71\W\HCOT#KO5FX2/>)$%,9LSP8Z!,F>,$
MB".*!2!V/),B]OQDX;XE&%$S8$_BR E18:GWC",IG80\EXZ28#'_2._,=A]8
M(+VSH#A=?/GV[<O%W?=SL)N&O8\Q?@#5V%/8 %$#'GP:6TAD%>T"RY8(^^ %
MC)KM'1=N<"$OJ=%A)C:1<2W2.I$'P5=M0^L.::,( ^(6<M2GSV0&AL^"I0UB
MP@-X1CPA!#T2>,+W[S? $TS%Y_HN4N;$=FS08Y&@Q$D*O3?UH! M75@/L;?)
MDP+,)6(G+C 1ETX+^:##D"_=8/&8HOVB1XP3'H$Z,SQ[\T;@R>T!K0U_TK1V
M@MO!\E5EI'6,OU,G'5@U*M^4C@*H!HS.PKTQP9:08^'CW=5BPEE8L()3Q[6@
MGN\_P,TH2^5U3PP(:>8!O!Z);5N@1]I!R"5N<N%(A\SE7-^73#AZ F ][LN+
MMW6,> B,V[+(],"MX.$*B4;G!/3E^? 9[3P&B^!L*#!Q/ MSGI)R$,L*'9/W
M220&1]^LD3A1,644 1C@K.B$5/A%M-0DK)#9128R$^L);>? -GDV$K =$&!/
M[CU#"^VOE;E >8<L M 7)+ +P%'>7=_<7ER\_ZC<.[8W@;M#_'2Q<D(;12!3
MWOWZZ7>B% OHT'DB+Q&BP,0WJ;$V"M6/]$(3)&2(F 2O>P#+$G8!W,D+B%-Y
MD2 W[^'&("0T^3+Q'%,A,9WBFLHCAK-\X(&P9 ?5"I=0&7:=IB*JRC13D$OP
MBD*RDF"#M3_0P^9PXFVP=RT60PI(PS?9$@X6F#)< _*$B.3=;[>7W]XKDQ7R
M?M=;$;4!+,Y7]RO8E][5#2YW[)#V,0560DPE@39\97:0.%M)?'^X-B[M%DUJ
M@,IOH'4\H-["V8KCF!./6)%ROD0*_00:WH7G+SU!G5(%)A$EX 80XFS(R&%"
MM(P$?W65BSD8]ESY BRE!P6,_0!^<@\BEKB@N<0I>?  W A=*8^>3BM6\;BH
M33V>8/-O4)("V#KGFD?'%=8DO.F'+O,#H>#&9Q0(<F7*N25) @YLF=;(E=O5
M?^;>"AZHYA\J?(S<]_]C+IN:*A'*)Y!FRO\Q%\N/RN^ GJYE*K\BPBA?T;W*
M4>$=?0+$>^&9#N=@>%Q?EK;%%J#,4'H L&W4<4%P@;7 F8SR[N++S27=!^P'
M* &6$TQ)K  #^LQFF$U .R+4_\Y 6/J@C=WXWK^!P@/E_!ZN?5+>?3[_?G/^
MGB_XC\YM!^Y%4$E*E$]Z]]G[#%?]=OFG\B<'4J#<$7I>L1"5-S19@(NX4FL2
M5\&GH$N%*T"K=Y=_XH+_:;KLAZE\6?G>/:I(4U6YBE0M8E7)>\#"?I^X(/J&
MF,IOP#6!I;^[NOPM]R*\YMQQF ]**A[[96Q2?);F"=Q\?HE;4VX<$+V(1LHW
M>\:4VPB:WQDLE/EP-!DS[3MHN+#K]F_,6> 1?/- 9 <$37_A*5_M (4#/2I$
MY525[ /818#3SF&%-\QU@R<'3LHV^??_@FW!;=\9G-RYOWA*[TB>)3>3\-S^
M!8+?3("MG(>E#K0J9#&R8J!&056<97\&.4#V /RL=[L:[7J.%X8H?^!R>XE*
M]$_0*5&, XAFI);#]3?.$X@)0)'?&4/)I*: O0:F7]:<">4<...D ^<PGAJE
M^=/\:?XT?YH_S9_F3_.G^=/\:?XT?][R'[UL^/K6OG?15#?=\'PZQ69S8#C>
M>(X-1GQP!S=^<KSICSBDW<\):?>S(>W;U6)A\J!BX@U*_ I%OF-SQ'MC.DBI
MC7XR SNXGJUM\HG_F[/10<Y&!]F-%L;D"2@YH-);^[69Z8D?L'V//=W"%4%@
M(;^,SP)LS$F;0*?#-_NOE6W9X=.+W"L]RNTYO"\4'2S4N$@Q%9>%BN,%M-V_
MO;B" ;O_%\PKNV+AI3OU%NP;O&6[8H9!C'%8/F_T.]GV80J R)&^TBB6Q0#2
MEO*931F&T'B6JZ&IY.U/AR[FID419PI6\-9.I4'07P=!7-OU+_YHT32J]+9'
ML&VMV\FVSXBV3:$<%U,#5XL5#Y-8##B*'>ZXC5'A27YGH0EH97TQ?8R)!>?Q
MNS_S5T=;&<=;P5D,G>R0:&4B-Q)P)_,V1Q;$F(LXRSU\E(Q!IQ_86'*%3D'\
M81E1+<9;T>'-0RW$?"A(B,^BS4I6G.X3P).7 #_$NR2FP?_ %A@FNRJS%<_Y
MH(B.R\/+<7S5ESYWGB+#HK .12#D+\F($^:MD%.3<E7BB$PZ\!9G$IC!7,W,
M;J''!W//#]LA\Q<BG8$2/ZO"\0TMR\]=ZQ;??0>OOHS?7)8&C"[6,?4[V:X9
M,0VD4$>16,/S35;H T:G.P7&5LLE+(D.)0X(>5%Z&@^0B5DW%*P,,:,A"!5-
M5Q8 D'G <YKP 3Q"%F+8V Z"%86'*>TV-]/V95&SX2$CZ=2@>YU:9BO,H.'H
MGL+K)/I2&-T.;8R9A,E ,<;!7,8;;%"44D;K34>R7\1P .G"! UIBI09SGUO
M=3]7**6!W8,Z8\*Y4UDEOA=D.1 K93[X/E;2+OC<HGL?2=F\]QG_!"_^!8Y7
MK'VYFL"=%-SW 67A*"TV"?%WI*#P29XB,+AD&!]V#S Y!XJ:L_;OIO\#Y.87
M?L/U;,8HE^S6Q&2F\_C-[T2"WOH7,E4OR]],!6! L5NJ'(WBZ;1&XF6;%LEY
MSI392^(D*-N!DTP![B\@_(R 3U/^C7CP5R +6>YZ/;N@8E>J6"E-\%KKK)\C
M\KA($#2OEMR$_MJ; %5V9'2*ZBZ3TKO<1HS7WHC1.NL-.T4%XY'VA4Q1X*0G
MZ" 0Q)(A!XNG7$IM#?/C"&TS')S^U0E*\ -\B*E=3*3HJ"^ 7N^UH=<#X370
M<_36'/"9RG^;8"D!S>-F.? >?3L,F1MQ*\EBUNK)$XDG"8&'K!HO1E;J>J$R
M 8;Y8-H.:2PB?X5S0Q7YGCV+OU;I)K@!\ZA @(O<S(22A#E2MD.!:)'Y]&B#
M[#,MC&=C!I5)N8R<%Z%<(=;#?@);PS71LN>> WO$9%YXM07H0VE L&I>V()K
M3JPH*4AH2T*.6,PQGU2>/\<36((IB'1\'76$#W$3^"KXGU:[ ,5-:EA)5>P7
M$@:Q=@8\$X3(8D.5C!#=HNP%I7==P^HILX]DH2HT&7@+9?W!_ZK 2O,IC1Z(
M",%J\F\Z3T]Y,'W*G'#8/8<2$@T1/-=G37N!!VB34!8/ ET"1)6/Z48KG^=J
M3E8!)H^LY9)APRU2L[G2@;DI-D^/LAAB(F9ED/;%D*%0/J7O34Q*!^6Y':0$
MT!>@K]N(ZV38TGB *.6-A@901J5(U7JN4DHY!Q,CP#3=4)@=B15RF(HY!&+'
MSSX2"8ZKCWP'#N-$9H)*(_>#NL"$,3=AJL,.\?$F33^0.:]\/8!6$Y3\9@ *
MU01H,%IP1_FV?EA)A2'N00%ZDP<4[)(:E\I_YJ?+7(#CE$5:'F4YPID"=0%S
M7CEXDX*OI(R@J1>@*O9<=L6ZFRM;AR;KH=Y(*=JXN!3M $5EQ6X\/=>-9^06
MW!0RR0-!N7!;Z,D\0]-C^93R"L ;36Y=(*H#&YLR21,A""EE"B:/,.E]&\".
MY,;@7VX&@71VD>*34@SS=I%6@%(Q?18>$G0X"SYWGR1IHYOAWB/_%! ;"$G*
M1<O0'$(!F3+FI1$_SW$32(ZKBOM()">L7UX<(3D5FAU$.9TLR6YKS>[O;$OZ
M<K\STDL44N.4VR5PO",SR*_=6#_LD6;<2^M$,]M))O7?LJG/RU@PT(!21V)4
M]$N44&=B;C6E)8IO0"UVK87PFI" 3'\?I^:1S$CG?]/-#!0,N)=7M, +M#8@
M<EO3 ?7X2?!&2 &>!*$A6/JI%DG)DK><TXMM9^4\H/()H@2QQ9P;B 0!&K $
MFYHH<._>*@2)S/7D &B'IY.F_4.I93TRA-<*$^\I]9-G4$_0(8HYZ!XIF9M>
MD-7=[\A<ST(%<R!]-G,8CODC31PNO#(#R_Q+$1YE1;@@)@PPEBH4HO,'NG:%
MJ1#Z)KW?2Z!0GZ-0A^).J)S=<Y-**A:HC3N2D2Q-'[0^9Q6AD(7(96)1C0 :
M!S^^)/*/%6\)5$30S&8V*D9X=>L\]@)A"[0VU2H(ESDLH761@%=+0F)B.N0$
M"N9,%'9%NA7!F-JJD6LX:6P(9BB,553K@'*$58:O!XVES=<J=F9FL2MW9X@7
MS"'&'_)B(PZYIVA!Z)Z5SN,(FL%J.D\N@-[:V1JGL5S-\^G>$*VO?Z^DAY<6
MM, :"7&(B7HBOC.R,)TGRH:5:B7[B;4  =E)P/$I.=G#HDE*I/5FZAIMI-";
M%N8M8V&23UVW6/44*!?*!8\;8*KN!;TK)'7]!I">D;++MTIK*]C#>F,UI#Q2
MI;GO(;U8X:# J(!+;Z6*B6("M&R+C%".2OF44, FQ#$#HYA[/M65YBV]^ $=
M3%<7#,.4@\XP>@"/2'\J9@5*PP/,B7/71=K]SLC7#4_\BE5 6K?]3] .'A@W
M*+"9M6QU+)A,(6ZCIPJ^"'V/UT<!Z6%DE)SECB/<Y20",$P*UL8.L>B+R&P"
M+"J*0!LYH78C)]1^!(I):K]90ZG +"KK9BCLY7-H;9M.C;P36]C+HCHG%+U0
M5B*0M;%RG@K(D1T"_W>>VMXC"NI@-0ELRT9!*&X^QT*\;]\NGM=URZ60L'M<
M.R?%9Q,KC,$6"+RM'?4:1UX2UP4TE @<SYH16WK6#II1<1T%B .^/^Z]M"U>
MZ4--Y*GH%C1#@;&P2'(P@%A%G^D$Y*2HD0^PYHJB4<#6@>4FHXFVR[W/1#Y!
MPI>+C)BA5.+?"=5C.K?9+!&^1C<U"O/VPOQ!=:J@'?Q(?H&JV;U)NF!DX2*#
M]Z9QY@MWS^$5\%Q:#@C3M ?OP6:/O"9GS;3D!C3_2IJB")M"%[Z Y\:4D\NK
MKYE4$Y*T4=L1]U[@73KV#,<]11?^(VB_(+9R.J<9P]89G%DV\"S6E8 M'"3@
M)^ 6Z=^YM:&;>7LIKO)'P*YG7X1O+^ZI8HR.4/[]P9W!T6Z.,Z.*)DS$%??;
MR#*\"-$1-5(RVJCF\M?S\QL@/E!4445,N)RHN\@/%KET TF.JX50N+GS.!%U
M(2Z+[&<1B4HQYH+'S;F3F;Q3\<!IH5(+SW98< <F1D0Y$$*1?7[3TLC(6QGJ
MG50(+3-U* $G$2KT(Z'!]4VT7$/4<Z4OBWO$+!MC9-(*!;TXAEB5) AJ&QH1
M_,B_V\&/"[!7@&W!3S$]CG.TU/&Q:JGQ=O&X^'85W&\E2NM!*;A0.<7#.ON:
M$, !G!C'9:*V9!U]%"!+B$*>.Q-#CA,7!QV(_A]$,S:.((SDAW04%.=NI:4M
M>AQ"+E.!:HB$Z;7\)107 GT #-TI1>/"('Y\,A^,-V0"F,@[T?V3R# 1N\>B
M8MP'$%_DLD&_47+3&+-"XW+B8,VSI=RO;&R4X[*D?F'QNN>9;*<@PK'))0EN
M8?L83P(^0'PG[B3$&PUQ W9AVNB#=Q-5P%SA^$E-G0!((E]W!U=VC?!U/5L(
M]X/*B3A&]-4B,&2(>X5M0K#A >$LN0" F4ICG8?#X2M7T;I_SWHE0B\D)LO9
M,_EZ45JL N%RN (:4(Q=3/ZOINW_B3Z5ZUE$:Y<QJ7%K*>*JO>X1\D_<HD)[
M5'YG)A(I;>TX40\)FCRO,3G/<'_<+[9(["_!!]"?&<Y]QMI QW[R!C!3?,PB
M?!+$38V(@-K_(SJYV>YR!8]:"7SCST^_E%@BB'I\=.0G^*!\PY1$15,I)=KE
MAI@W@9T_B!08>C!Y8.&;OU8>DH-P==JN: 8$7 1=[%*_\LGWP$1F@5"#$GLF
ME>BC>+6>>K5X'V\31 2W]2N933=9H!5.,?7&XWV&Y&_1GGAO'_YR(_7RE9O=
M.;R0@QPX?>B0S]?UQ,MQ'R;/U^%)G#[#2*3037E_0#1B448DNB+)KG<)Q?1E
M/2@.CN7KP=-9KAH@?5+KN==J@?!64R(.3WPV YV:=&8.337V;5$.YP//?MHP
MPXZKZ(G[EN83'3-9""(K1=ZGBK8WL;L=Q(!-)Q^EET]-WZ<FPPG]/+O!O2Z3
M]RSZ28J[4/]Y=4-,]&@=1,&-!+03VD+4"3EQ9!WE-C\EWB3LQF 84DR89%'"
M 8XI. @6<G^K^!^/R\D6=H)R(D_,FJJ&8+5Y9E,N\/E+IS(XY*![9 6B$LT>
MWIER0FT+"7Q<@Y/S92C1!I>2269*1<E$/\U0NNHY@TUN5 2DDDOD:T,?4VPE
M*LN5#\HF@MAUGBHUK #/SEUKK9B@R&/:RRDDZVG':6))M9Q^2.Q],W#S>]6\
MZ>PIK7LDZ5-&;OI4K]@@)=0^#A%ZD2E&\KF+"(Q!/XZ/)RSE"2,#U'D2YEJ*
M.0._F<Z)WY*) PKB/658K3-[S D5A3K L(B%I@MV,"]4/*NC1#27*9T2<MV*
MC*G%BIQ-(CL9;B%W'?8J!'X(UC\*A\@UEE_&)A/9]6?;397BF'%Q52&7S,G3
MZ^E'R243LCM15';4&J;0TM><'[S]V8*UGVSF\ 2*&,7(+HC3?2V;=]U$D2W3
MD BCXVJFY+,3Z3=F(HQ$"5H!X'\G"=J8$I(4H!:BOYI,%2.BM!@)$7&+R?.E
M4:FY)PYL3G]@1#9!/[RD-;-PF5B]KICG:- WWV[5)!TJ61+,24K>Q6U9Q+#U
MO%)W^%0_$-Z5UGVW4W/_< $3'-)2J6$LCQ?P>EG/7?,H)71U4FG7%\)^"HSC
M546BS)CG]D>1 _0G1,'2*+I*F81D;>!'/IMC:>"#R(_'W@;HR>(+[2C?"Y>,
M/ZXV;RE+-A)CDZA,-<%B-X"^@&'M.&@H^P4CF2OOA.7S7L!+HF>U2**7G**3
MD4QU<L]S,DI9.XE@4S:UF7N-?< '.-U QI6B;O$R8"\\T@L6SCV+VSVB\D3>
M@M:6=)0F3AN6856</W*'38[E)%C1GR/X'MG;ZZ[1'(6R9QREG)=[5>+-GFZ<
MB<XHWG+L3\GP96"5GCU-1$ZI\MH3Y7VFSSO$ S=->QY$K@8R+E%*P(,\<=)(
MD(D6R$39O(( &?ZS,>@4\FX;J'-$D08,$F"YIZ6X#)VEF&F%2Z7VN10NLSR
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MATSJ.NL/G0&?#)+-P:(9%='^,PXVZ5&, GSKAX5;<?$8>=S/C#)7T^9]E#E
M6HGH2!LUMJ710CQ4\9Q13(,ZHONCNKK\1:5[D"<<VJE(JAQ]DEIY6N-+Y7;R
MED[1&O( FHNH?RRI^D\BW?GM'Q&Z@:W>:W?':L1*:$F2UXJ>*A=1:G,:;P?=
M0=2)NF"RP<[% #A(\%><9B466,CRASDL?WB4+)^V^TSE<RE_6Q&/'.8Y].#3
M0]5GW14AOARZDAEK%C<ZIC9 ]H1W:(J[M(@I3*M)2!@[[H_:@VX_GLI1CQ._
M IT6*ZEN?&\&AN(7#%\!ZVYODN^UKD[B2!1%M'BK;-MB>=P?N$CD"TS,7S'E
M]!LZ=!EYC^)RJ4%)O&B$M^X$Z>9[Z&SDEKAP9=I^&D-XB^DTTO"GR-([6?"7
M':67*DOARCJRR_:S;E4,.2XCN2JZ2LD2P?Q2KG0E5\4%5E\]'P[3Y14+P%1A
MIX&8:W/N6O2KPU]<R'6/L>NFV+8B]ZTD-WXBXZZ /F13?3%W-1[B/)7[3OO>
MD$SQ5ZI4ME"M\3LIT !.8Q8(;_&/W7L23PJCMDYA^NW1)2FR$3B/L0[N)HSX
MF^PJQ7Z*QO-4XYK3<3.,5P;$3&EE.8]3L2$"GP12X%)<V]1,($=JW:$@!5[8
M0,MS:40JS=U=;\[):] +X5"X/Y/WSQ)MB.+Q &%,B(DA!S1Z-5%>2TIW8A)R
M7B6P++=%;^G[E/Z8Y#?)B1'_B&9%?)$+3GI]UVM\144&-R,LK!JEP:7X[JBY
M4=Z(L")^IUQAR^9G3E T($L4G1"J)3\NC5'5=DN-F]S_"9H,YCY=BE)%$O5/
MZ[Z4<86MT _'9^5>%;G92+%1WOUY^>5]1:SV<%.)"C*U>1<X()ZYO52C_I0K
M01:R\)V#A$_OEF")6MZA4I-JVI]*-;9EGFQT(]X#(.6I>)1H&7AJTH6PSN1Y
MSU6<<NG2V'(Q*@F_@N=@$XQ4X7?Y)YGX'&G5I]KGB7+9F/SE6]?B\LNE0UM+
M90-30J%)B:C(+N,TX$3Z-<T-1 _(.^V]R+5_Y#8Y;QHH6&7D.8GWS9^Z0!Z2
M+JS%G !Q(UP6^?JCO,ADVC/N^9W.W^Q-'#%!D$)"D\#S)U$?A9DJ:['$C%!2
M"DD'%= 4C@8UO3[>ZSG9?A='5":\-"1]X$(ZR2224D!'J(]\7%6<@6P'B>PN
M4LAE^0!.LI*C2WGR#IP=X#;%H$2&:)C4$S!M/A[.EF;VY&VA2%+Z(X$Q53)>
M/IKZ=ZHL3#1U66.V@V[6!AYTC])Q(&9Q%_8&VH<3@8,J!X"'<B+\P8>4WUX(
M\]+ V<GU,O>3'8;:<H+Z;=Q%:,^KW=S^)%7_ KJF5*_RFBF]P]3,92@<D\)E
M(ZH'8M>,N)&7^*KB8F)0,9/(< -N'N"K&&>I46-G(3^C5;Q?ZU?)O=,B_*:0
M+SF.WR6N*Z6'II)=L;3+X9/]DLUO30>DD2NJ5O*[3W&IQ5M6B%[4O(%5%"ZG
MD2:)-I^)'A<D!V=/47;6DD*;Z.I W=JR19NH&/5'>K=NJ)_?"UH]#J\6YVHD
M#T4T-HE/<6E[5&HHOHGGEKWS>-PI[K;W7@P]32!8<EC;GE GL\(<5"(4YOM<
MZW*-.UDWNE2>/TV*893>B,4GSHKT!%C@*E8IUB8F)KHS4[% DF+18>!CEDQ2
MPZ 0NFA91+?![X$-J&"F6$/4IPCT CZ7TL]QH?$#*)%"^$8SF_4CR6S."?[#
MIX/RN0?<G7ON6I]C9^X7[L985R*/45W\GO17)[:H?)&NFK9R ;?QU%V::7[.
M)\<?52TY91&DV6O"^"-6ZF":-V\CB1-)F+4Y(#P#]D,U)%$+!/&UK"_F16_<
M:05?(4>+LY4YN*_.@85:8"^[6(_G6J2 @*+Q%>NV)=!# GK<O?S?*TMF$,B)
M  D.;8K#P84]H8LUKA1$/DBC+'BO;-F>(\XVB!(#<'^N[SD.-P/1?^@PJ90%
MX<J2N09<#^/%YAV.&%BBEUXZ?]U:,@566O.1:QCUP>L(8O< <&HQ$GWK,Y&!
M;W$;E$=1TLF&:V6R4RDI[U$+HPESPA<KWPK&,CE!?[C>H]M1?H/S]GP^S%A-
M+(WP@L>64%2)\0NB^#!I&C\7]?FHS+U'+,Q745U,IHS$B6&A!W3 ;> U "(V
MH%?!<1)VLH1M>@BZ*<L5TLD'_Y#2-LC$DJJSM$6;RAOFWZ*>4Q0N&N3TXAT<
M9R_>*]"=L/!*N<'X,F[Z);9VKU/2VLYMJ3HX7$O53V8 Z('J)&5@QYJN*$A?
MB7'05/F<U(_I\E2?&-$4F[\.%4ML+G"_Q=CCY*#EQ,PT?&A'^6P[M(:")8K"
M;A'0HFG@Y,2+)HG'77[I78G&F.3?VS@!&AV\</C<L,0O,5<6K.;6]]L_@M9[
M<0V-'Q:^U*@IB(7+)K<A,K-'(G5J)$*^W;CM)JQ#!GIDR@X.K4=5-V=TNQQP
M;<43KD/ICET?RLY7\,"D[U.HTLD=7]%P!#'O?:VG^;OLG*3Q>^Z:Q3*!1,%O
M;#>U[%D[6E5+P+J3:\$>?*8OQ>AD6P#.F*UB5(N&&N)QJI)#1SES+$)V48+-
MK2 !\GA4N:2 N#YK+?*8;,4033-//4SB9X0X:\VGN40"@;&@@21R(+H8C;'6
MWC?"$=A0SJXC1P4MCK=%B..7R7M601S$3$*5&O'$00.?+;P'T;6&Q_+2+IV<
M94:)>BYR8C-$EW5J61WEF_V#\5X=F052B% &B#T_NY[D['#.1R*8\+/*Z7I1
M;Q\'R9*O"<8<%'7PHG]UF36O4;-LT2-B RE0/%W8Y%'>#[5Z2"$<(B;.94H%
MI27VJ@IRT!A?$Z&0-?#S*3'H(5@MJ4F42Z/W8A\CYV&<P<:-SC#CJ"T?5?58
M[.F<62N'7<_.X8GR);'[]XOH ,Z3WE&$TCNO9^M:5HY^96RI217J'0?+5_&P
ME(($ 9T6H /.A,2ZM%@H%LA_+B)9IGGZ!B1,\ABP!\Q5(!DD\)+4X8LZBP];
M6KP 0K$!Z?%!]U6;LH27 ?L@?_@(XG'IF$\?;)< 0C=]S :^:1 1K%:X@.C$
M^-?"83(>=T9] PDZ].&O)5\LW"D= / OV<_[XXZNZ[E?=3M:[N=%C]*TSL 8
MEGI4\>=]X\07U<O_2C[J%SI$?I" *HAR_T\+B#IRKEFH>'WH*AJ@VB_IR[1^
MYCI]^1.O_)AQ(J[C%4>IJNE_M$;^PW7R)V??_Z#R_R4C8B*""ZW=X!)?)H@1
M216N4RCLH\C]'17,4/RF +3#AM\2T/0&:!'0QML"32M#BEG#; HF"1AF&W;M
ML%E6TGG+UU=':,?7<J2\%PW+2ND;A2BD/P^$K?&BJ^3 B=*$7@<YMH1583$P
M5]4R5<WC9$%P-]-@?S=]^)S*[;>K&(Z[[P]ZK3--U?21.AKT"GJGK!]Y9<>,
MW])Q;WO,Q1SG.;K+Y5@-RCZ'LI@>5CN4[2/*=K61VAT7=?!J4/;MHJQ60Y0=
MM,Y&PY[:'>G'@+#/*#G2>(==L&+\/I:K2FMTPM5^-!K=+?,Q!M_FT>[\J,R+
MM+H<0)PH2]%KR%*&8)T 2QF.=U;;\A%Z;V)N[76EQ=S;03NCAF@W K33='6\
MN[70H%U-T:Y70[0;HR\&%*CNSAI_16AW\HZ@F[BHJWK5(0<8)TI,_=<FIHW#
M%H?=UAG5[^D?*S)$CLPX?@,8-Z@?^QYJK;.Q:NBC!NE.%.F&-40ZO776[ZOZ
M<%P3K#MY3\,%SUZT>263[ 3[\K#1VU&Y1Z]!/ED*,="'4!>-NC'DJL:J5XDW
M9K&JUV#5"6/5\%5"@EFLZM<)JT[>^D^*<A>3A!LS?R-1U##H.!P Q?1[JC:H
M*DK>F%UU0[L:!J:&PP;M3AWM:AB8&H[JAG9-%D6=%EC#E!'.&\9U5@/OL&W"
M+KX;D:<D:GJ,)3;Q6:%2*==>F,CT!OAH'97&,297#OJ87+FSM[Y:'#@"Z[_!
M]DW87D-E=82#@-7>N*>.]&&#[@VZ5XCN-5221QJBNS$:JJ/NX/C1G?2P7ZAX
M>$/CF>)6:J4*U[_A_"SV#0= %@Z$&.7.<ZU+TQZ^]A<U+SM<>?Q7T3,21Y^V
ML=5C<NPI;2C=.#LQ>A 6NW8M;S7=]F;M52"&-_-F_=DK98M]:B7&YV\E.J5.
M3(<:Y01SQD+1('7]/CN(.W1;LM6#G(05=>P0':3YS=%P*]X5QG03@P]]T:M?
M]DZ/AXU%_:UY9VSSB4:I>K[O/29:;8JA,1ZURL(Z_!!G%1"@Q'1:_C2^$BSY
MPR$'U( BGLN0 S^X,^JC1O=' .#-1$1#7#&-;&G:%N^ +:+#.&4FW6 VT=8\
M7@^=O%AA9FW8?4>VU$GV:X=GLT=L(Y;H2I2<RQI]3CUJS,##+J(T:(%Z>^*$
M"]&18WW&=OW)!K/ "+B9L>9Q9[1U2N(-7B+Z(53!"19TZ/@..;7X0?0VYO0X
M2YP3@GAM-$?\EF@(QL:A/^N=VI1HDL(:D?"7Q"2;\Z+U:46R]5^U$RX6^#9:
M[7?>!N<"&_\5"@DCV\-L9!QE&[A;3.UH?R+R3X*ADL;KT>#C@EX]'&8YD*S#
M #="M(#GOHCTV6D"0!%1)KIH1DU]4LU^.&],=WG*).*F18WH139U/)(BJ098
M,?&GFLCP5EHQ$[\R \O\2_G5\4#2*;>\W_?OO#N7N$3.CJ$)86D.'G?>##-K
M3_>)HYM37= ^.:!HMF^G<\]!1K'D@R5];!5ZCPTDF</?]?QURJ,9R):4LBL[
M;Z"9Z!J:72#P.YK1)'LM\?Z:HB&F@LV5^20(?@217*&.7RM'MFH&Z88LBT:)
MH);+IS&)9<8CE&FA45<MT?8=M'[>RXMZAM+<#VP0)1<4LSW>YPQ'-4>8P _[
MP</N/EP(NU9\C7B_8\]8^L3,!792^T_NB5&'*AIWNH5$H)T$-J"&A)3HS99Z
M4(>:[-*2$DM-:A+SJ#%IX@J^YF@WN TN*]+(5/"<U'U2G0E^M&<^8[%616K6
MNDY#0\'N9"_$)YLYO/LL-4>2:@G@U#I!4-]'')8E;EE[[(Q/58'[72^Z-D@T
MXB)M:9[HT4K'B6YHWAZ6#^F#CZ.]H>;'^'VBH1S.G@'#A?=')V5SVV9L!^\R
MN('SZVEV&VDMU!UPQFS<9R"4[B?>._+Y1F9-V_-LVW-C#41U;7M>NL%YW(B.
M'"JDQ-QPU?(<F13I-J(;RI^289_'C/@.*2I'N^MMK\<5Z#N'TETRO6<38B?5
MHS(M>[FP1?$JQ LQ0#XX:;%TO"<FIS'0_"G/YVJYL(117P$)_5C?%G.C3M\8
ME6XQIW?&W7XUC=.,SM 85-7-K5?NCJ-;U#./VK*5VI;Y>:_3SRO?'9WOK8WV
M=$+]\/A.7]@4[_A/\KCZJC4=_)H.?C4#VAOKX/<]WZC=!G.JZ#9T*'38-8K+
M!RUD4AU3S1!Z&2,B,AV2[L]SW\?V[&A*?'K*MRYP$AP-@DM8%'AP7^'<Y,#@
M[W!J41 7+-[(Q.BWSGJ=G$X(?]_EC+?E# V.9'"D7T,<P>3_!D?J@R.#&N+(
ML'76[8RU9W#DY,N6<WS1+R*2Y_=] GB<DH?Z7O%8GLN?T;$48O*H=0;;J8C9
M;9,=]^;QH%]+/!BWSG+ZX35H\#IBK2YH,.X"&AA5B[5CLP._I.*DMLO'&56A
M_AT5*N>'@X;Y*MCD>5R=E,'5.^8OM%26+NQF^L%:^7@8,<)JK;-^IY_)E#F@
MJGY*9]VOU5EC6Z+.L#GK_9SUH%9G;;3.!AM/^N2-J\^I%)C&KMK*KKJ\^OHJ
MJI0\'*Y(;=U%<MPK[B+9J-JO8G'5'4/Z#88<V!BK.X8,ML20M]=9(%W1MIX6
MF)LNEI<Q]W;3S@":[43J69-L=@)Y7;5<5)-LUB2;G=9)GF@*4)-LUB2;-<EF
M3;)9S0VX8?V21,;#UID!ZF632%03'!G5$$<P_:(SSG:4:7#D,#@RKB&.8&.Y
M3N^YA,23CX<TR68OE8<UR2[I=[NMLU%VIDR39/0Z(J\V:*#A3.<&#0XDU6J#
M!OH6:'#R9F"3:[8I)V58HYR4?M? 7.DF_6@_1SVJU5'WFJ/>WU&/:W74_6>/
M^N1-JR;5[ 565;W31/K=;=-$&DU[7P97W3%DV&#(@6VQNF/(J$RJV6OU$X>#
M.Y].L8L[8,F-[[GP(^]I+#K'%O2/[7?'=6XR_ITA=BOQUI3TWE[62/G@26H^
MWY89;VN9WA;EE2D+\XFW;S25 &C:G@%]8PMFWBA2M'V,>[#.;-=TI[;I*''W
MXXZB?'_N9=0S$O/:7 \;F ,7L9>RC2Q_O:O8\!+^3NR^#=>NW$2SV:)U -+*
M9J4^"U;.>C=F%9\FGV/9 3:9Y:T6Q6KPLU409%HLU^N@,^%[.NCSVS^4*Z^C
M8,)(NSN,^V0> NLN75C+ ^4DT8)XF_NOT4DE*.PV-%V+&K1^\N _Y=W7\]M/
M[Q4;."B<4NZ%?RRI?^\[V/)[N5]UW_LMR4INV3VU>/].S8EQ_>_NO"5P5GW4
M??]!N5P 53Q(BO#$992N*>_\'"/H(8^2-X-%[&(_X?4 _N5J C!08(TT]H.D
MT_"C$HAU)PEK\B3: R, XB^H0W""Q<A;H];G$8_PV?W*,7T'G_-@L\>X0_3%
MW&8SY3IJF_X9)'J TO]W\P=@W;N+Z\^_O^<MW64_]T<[G&/G6W,ZCYM&+Z@Q
M+E^26 8<S<P.D5G <H%K -!-&EG".T&"_/)MGK:+(PUHO,)"]D?E2;W4P5\^
MS@;F2$^Q>)Z)O4C!")YABN7P=%U^FP!KL+8:WJ\9AQ<$\<F (N/!/\#$J<5R
MU+19,DNY1P*KC>G'0<B'#@0AKA !P_L$_WI^?L.)-7U:\HE N^)A03'$XN.C
M#&AY8' @M#A8?$ MLZ.[F4_Z$ ZEX!">VM0C>@Y2*>0[FR+%PUN]E3]EL/5S
MQTDN432A%@,H@!_[!!C!'&@M!"1Q'>^HO8;(' PH_-Q[A^4<20QP@"$7B]C@
M&A\ULU%SXYYC$*<@(EP:@H$-9:/T3$7KJX(=)I&!-YD.)'J6>E1/Y7VM?1;Z
M7K 4*Z*^UBK?#R/J,2W991P;K8> ^.D>VK"A1$-FT>-;=.F6PAB;8-O8%I[S
MX=S9(GE*@>B?&F'\T0O7\<&%:X0&">$*8C.2FNGEUDTV7KK ,)ER9_Z$MPBQ
M..SEB<7XRJ0X[!P2^@F^,I;L)$#T-N_O05H1%=@NM^^0X,R)MPHC#D\#/I#?
M/$7\/68D(6S3YWP.B&IJ.[9X!/ &!OR.9H#$3T;ZX_ )"9+8.+V36EZ&3>5S
M/-== <%*-K0%R]D/8[E? 1-!&; M8WEF$,K&CNC9^I;M9N$4%2NA?6M/K=EH
M,K)&YL#4>L9$-[M&CQG]7J^K#ZV>;OVOUL/Y'D5\+QY#=B V9P!C*^4'^,X>
MF+MB?.*;&Z)CXE^ &Q>K #;"_*S]KV6GGL!GV?DQXL%H36)O?$X&+@YJ<=&\
M]$VI?EV , ?- S.Y"@,(&[JOBY?G+$G/;7X>']%&?#F4R:_I&$I8^9+"N!+!
M\HM$A/# 9'F"+2: %\XC\\6!S."HE0<36,4J4("7T" 8O)OKO";P0.D*>&E+
M^R_$'_]E6^PRYG8)3/OR$]@2:*(2RX)/3S>^9ZVF87#N6K?,?X!E!3FXI^<<
MM)[%/9I9XZ$V36 D#1 .UIY&4V& UR$68KT?,B^<,RP!%-!LC9^P %*0M>[?
M)9-]DHKE5*S[PV:$W<B^4MBF=[8NIGRC@R!Z1S (0C*=HF\14\7C7[>N$S;6
MZ?+-E2GL-/J=_KBBPDZXH3^LJH;2R'])V46-.II6[DG[7].XHX_JMJ91!]2?
MFJUIW.D/Z[:F(3RI=W(EN7FU9GQE%HXV)!;W@1PV>%7K3 KU+:*?-0E2CK>N
MXU2$$E-B;\\$<&L"@NT*#/_.-4]OQO^_0[6)9.2I@F5KS- ;S&@P([\BM\&,
M[3'C377;>0M7-0=Z8E>=?"W)^1(=1Y]L3[GP_*70;]=Y]W.[W;KXMZL<5-??
M$B9_V]_^D_OV\96UVGAA7N(JL-:3$D?=9%)BMZ2C_<M/,5;YG(+KS+HS?Z:3
M#-W5HFUY9'7A.W(R#34#-(Y>7^WVL[7P^8UW*CM'_+;4>;Z\>"-7.=(K+,C/
MI<DCPLW\G-F1MK%^,166P5C,3>0AU_(*#[4>X%JV#+EN:':8HZF\\40C;QIY
MDR%H?;_R9F-2N[:APV[=>$ C:EY;U!@[B)IG4# I@C849]4-!QLYU,BA4Y5#
MO4/*H0WE=W7C 8T<>FTYM'E*7&5R:$.!7]UPL YRZ.0[ =PX@([XL?(-^]'<
M3FT&F!:HF S=4=Z9LQDE!C-+)!*_+Q33FV@\!RK'3L9YTF5P2.DRKHRR\W%X
M;P)DFRKR-X9<!3)B<Y._JF2$WFTPZ60P*8]-C0[M_->UUIEAJ/V</K@-@AT9
M@A6PJLT=""MC57K#JDX&DW)8U?C@<4I=Q"D-+=O7O<&P(\.P?%XUKC;:J&,K
MP>QD]<,@R\FGP% ?@<]L:?HA5?=[,_AMAG5B+S)4<[9_[$B?QU8/&8[3*P_'
M'9FG\Y20JX"CODY03:\\J-9@4JW8U)ZC-5MH?\/6V1CL5$T=#D<-CAT[CA5P
MJUU"+SE<:00XL[/^UR#+H9$ECR'MV<&_!4,:M\Z&_9XZZAL-AAT[AA6PHUV\
M_%EV9'1;9[VZ(,O)AU.Q41SU)E%%(T#>V2@=1+59\;R/-^:1R6.R!P]/&%KK
MK#\:J.-^7=PXC<^O:B:[2WPBA\GJ():U!EF.'5ERV!'<<7!^9+3.!L9 '>UN
M5C0H=F@4R^='6K?:((31 Y1ID.78D267'^W9>;\%/^J#M!OVU/XX.Z.V0;$C
M0[$B?K2+"S^''PVJL$*;H.AVAWV7[!'YPH3NN/>H8GDK[  HU]T4SE0&H"/E
M&7EBZ>!":=@Z&QFZVMT]4:?R<SX"O^J>J?Z(D+M((/:J%8@CG$)Y JA:ARJ=
MUZL6;:1B(Q7+2,7#VVICY#.J/M#A;U4I#(UD;"1C0C)6FS_1ZS:2L9&,C60\
M<<EH'%HR]C3@,RKZ,8?]1C V@G$/@G%0K6#4&\%8;6.'[ #KRD?@;)K;E'S,
M*T*#QC:]V+>7,\$\CT-_L\V)[=CAD^#DWZ/A3B5*17I&Z^S*RR!\-!XJ,3'*
M2H^AVCB%2GFDV7:PJ1GS_<2X*3/@]4-B!)VX7N\HGS<^/;KPV7E6\/2_O=Q^
M;!M50GX+"4F5;&HWA^?PH:L<CF+>;2Y PPR0M(YRDYC ZDV ,_"!V30W]9ZY
MS#<=YTD)X--@9L>3=#5=6<!^YP&?X8=CLNQ03.(F*"@XO*]S7&/3B1C/4WBW
M/C(MB5-STU)<3\X[#VC8NOU  YHFIH,0[2@;G@88:F*&XFQMJGG>\_!PS3#T
M[<F*3X"2L]"_W%PJOW_Y?JO<^Z884PL'AX-^X4 6>!Y\2IX/(HV/(TN_3$XD
M"W!R+!SO:BFFO0=SSP_;(?,7@.:AF 6,7^0L3T55Q6&<A.8V/-%_(E#9OH*@
MIREQ.</:.S3DVT?AY3RE86MY<*(XF!T)U[=H$#/.92,\I7F6'LXOMN,=XOAA
M'.A^;]IN$-(8R9REY@R.S(B9:L8]]I/C'@\SU+%7=A+?!0X0FU#O\@=V[@-*
MW=-(OW@":W:V'FPT,UNOU\_.UDL]6SF/I@4J+QK>R-^0\][\X8U;B_S".'>%
M9T:OVGYF[KGU (B,7:$^V=YR;@*SGK(5J7*!<KOZS]Q; =ET5.5;:+V0X1X*
M$AOW?>UFY%4WS21H9@E).QP5KB0P3,P,_2:F5$;8QEE@.8B^P[)&O?LQNHM^
MUSZ^5Y7'N3V=<^:\X&H(OM5G-*B6QF3_]PK>,N3"5GE7<"'?U?IKXE7+%W:4
M/VB^.5Z-G#D2OCGWI"%%T@'>"G"*K\4+&!KO 5(D&0EX@07Z@N,M505.<#4#
M48[,'Y<[]19 H<C"D:<G'A\--)9/GL+E-+U7N;RZ;O=&W:[4&\32?1MDA,TG
MR5_ YZ:JW)DV<'=5^<T#Y>Z?^ ^^\W=S:JZ4=[Y49F!]4M; *I]02Q1P^]5G
M)@XMIL=)B-$S#",YQ)Y$ KT;EG,>V":?6DP'1:=$)T3(0J,Q^4M->FV,71,6
M/C+FIH",[TI UU/^[=DT_!@%WFJ*HZ#O'0]4 ^5F#L)6,>1T^34=( +G%(@"
MD5*!]9JD*43@C%2^)2@:KAR]C)7W--P9E0#Y=OIP:B_Y]&5Y!O1$7#%="XME
M?ZVXJC='U0^O$8L5^$ +G7H!<&R4O]%#DL45>9N(L0BOX ^ UP6KY1+>)C?4
M24".)LD2U"<@ZU>X** 44$P"&U4??+N J'PGWPUL+84$R97QJ=*!&$G/?BZ1
M+Y#"C".J 7R7'"XS;^4#AP!8^/@< 'G6EL"!]E+PT(-MEX^EA87.5D3=8-2#
M^A0DR"D^.F0"RL7UGY>?V]I8F3.X%SCJ/4[5G7BP1'BM@$02*/*-^<\DMH9+
M\1Y=!!;L8@J7KK9F%Q4*CM>2#W!B !17J)V1;IM#R&O'AQ ']1A1#*DH@>J2
M+CD^ ;\#I$O0IQF+$3K$:4;@H,9JQC80G_\;*=ET"18D,<".2)/&$>>"H/*8
M$#_#\]L+Y<Y;@@HWZHXZRG=F+R8K/Q J%(UFCD^52#IA\9J!6%(;4 -,YNF<
M5I(D;$$1BM#^4P/8H['K" =OR7QA(J++#&?!NT*<2<;,+5X.HP"51BO2NJO%
M$WTK/%'V\_+MD+1@(G?>D@ZN<*UK6\]." >;"I$75HQ[+.U/Z::**]M]:8W8
MKK=FB43&PA]+0'4WO#&?\-?O8@G;^5(&L<DRP('W12GY %D'?E/+[F9TJ-T,
M6V=:1]^\&SK$DAL:'VI#(S1=L^GL2G0RJ Y(%5!=YWZ1:L1=!\3_#LD"MN6]
M]13!98W5O"EHM=S8MK8G)R-]C,Q0&VXR0,&<2!AWWZ45*(U0_#!MHL9FZ3M\
M:BL&7O1-Z[WZ.KB;[T$ZJ.SDMGHN0KV+8=7*M<.EZ:WUN"@K-IVS,"\VG:-K
M-YO.66N9(]&?O_Z_;4/K=E52U3]?G2OV8K%RJ4;=7(*EYGMD)\;FL\4"^][E
M;P_1MN$/6OJL/457J!_P#\!(1N_MY$GY[>9/-6EL"V.*^W5CP[MS="1YES@3
M.^#%^PZ'C%!%8),*IT/S'G9]CP LK91HW:VDGN=&Z'(>^19$D.?.^\3.IW.;
MO43VC7'X;R<GR!,)/X<%*-O^6MF<]0"B,7[D<\_AFIC/^QXHH?D3V\='3GV3
MKTKJ\BA$;8KJP,.!78&Q$R2='G@+P'$%'WC^DV(N 4$?R!&1QF?^&R"<2>Y\
M\M%']E@.@476-L(K)(&=?B >,'^;,(X *7\P-/?3M/D(,$$G01XR^-Z3Z83H
M_GCB1A(/<* JI(0VL>UE%.-':)BNNX+-N2Q4 CB5@,-4"5; 6A)73ECL1N&K
M=KS'-O\I]*329;5#!EQ?Y;\'J\F_05_ARR/'!7JRDS" ]U.TC7STBR4+;7F-
M*1PX< I^1,%/G1BND:<E#M_ABV#? @;D$4)(21\"@71S9$#K/H_XWSF$;^!^
M+XWH0./3#];*1Y,G0NT^Y1*N>_N%663.0L&=9[8?A GN28=1# A =F"G,P61
M%GX">]IV!'M>VD):<%8O#LL,0F!N;?I:?+8T0^[<>F"1M>9PJ6U)IAS(\XJ)
M)G$8+^*FPX/QTNU"Z$;5!M\:;S6>MRB^\E>5LR3BH'E?$X--\Z+F9#84<*A<
M(T)&TCO*5^&O29KT2>C5TKP_J"ZWYDBH)8#(,\>=9^70^KF<G/WV<.WK)3.(
MTHDLK[]>HW7F9A.)L@1Z2'Q%M1NX/"C9& ;BSE9*O !Q !;!0@038@=[GII3
M1QV[I#U_X<&%A%*H,WQ9VA9;@+9PXV.79V:YJ(M>NBZHA=PGO$5ZA=R4>$]/
MIVR?CTLOH!=]( 44N/W'1]L*YS+=,W&C2)/LQK>8D\!S5F'Q+8EDR"D9[0<2
MO%_;6G\-1(E_Y[Y<SQ(TS?8$#+X?;=*,/IC.H_D48&)P$HT A]:@N Z XER6
MY](K]-ST"F/[](K#J3=)4Q%,Y0?;6P7.NK<F3D A-1\SJ51E"62^0IJ'*[A3
M(:D!89R/9'W"U,^$O.,4I&]F$)C*#"[DD1_,T^HHF!*&BFP45(K3;%)191'+
M57F.5QP31>VK&DLWE?7?'FRMC:%]^U+?;K_7.BN<,B]]U; 5SEX] MUSILH6
M>B2W44)/+%ML!);^73AEX7P^QR[97&/F$?3 @+GQ5OJMLQD\K(U:8,:L6=(;
M>:H:Z) RDA^$(#GQ5$V,TH--%H?P1?11(USA/^MK*0!P'X^*B_@W=_FLYR#$
M84G/EU:LU-E)Z26,BLSA',> C12\[AGHU%-KNW25*\ 34KVSL7J +*QM*F.]
M=LC=L B 1V_E6,E@/MV8=,QS"@U8UC$7*"%P/O)(Y)*Y"@>/Z8K2RI+9L:9K
M.D^!3=Y'>(X9&R$",3:?K,@N@&]P!_D'<N#(9E'B[%XCB5KO0*&J_@!C;]F*
M)>6%042M?ZB-#%MG@\ZP<",OB!]J@T/MA=HY;/2AI@.(:9<GT#OY_ .1HR?L
M_W#N(2>0WL3M<RHV)H$;DB;T;&YY+=FMZ6Y*>'\!Z18D 4A;]%R\['OTKBL6
MYEF5X]99]L0/&O=] <D4Y! \ XQRY#% /VP.J:]E/Z1))"\O2)YY,&<LS!(1
M"5E.2355'<J5>E2.USY85K) "$3_!68BNN&Y:UUY/"W1+7^VZ/!\-A<DZ=/D
M](Q+41Q9K*02ZN;4"P&3 D@<E*@J)ZBM3B'#;@;ZMNSFX%B>.NZH*HP(,]:X
M=B/OTRDZ &OBOTUW9?I/HMZ 6]^/IM !$OJX "%P$&Z-E\3,TME5%5C? Z-U
M-LY1C-+LX9#T+3+#/3],F<UDULI?UDRT1$X\8,[]/+*CYRM8C@+&6C+Q_0\X
M%#C)6\S-"2@0?;[T;6?[TZXGC9>L9-TNR:%BY,,VR)UQO9'OT?,3=9*7/+%?
M5([\*5Q]ERY@5+@*F?*N=?GG9>N]S.M6_NGYS%2NY WQA8"FOS'3@<>^:_WS
MZO(WN(<J67A=R)J3)X74@+:WW@INI&>KIX:(VB$0L=\ZZS_+!4.J[&4.IKOG
MN8421;0NBC5>+"VR-L NM)B/];<,4^)]+\I<@P?94Z8J/UPLU0")?/'EV[<O
M%W??SQ7CYO9&C6H!D@^QF ,;Q62'&#.$DA9+H9*0UP\!>7*7%+4>3D!>R@ '
MO6QM>LY:(5$"$IF6 ,_YHFH3"*\E"5?MG-.-%V9]E,>TA'X^Q*GVW=S,C[).
M.;VT=[$*4D$G5B<[QF0'AYQ>VKE8Q3[&^5)_8S(_J6%%7CEDD'$Q7=)%1ZEZ
MYH([IZIRT.WJ"- +W*#[=00,N^@(*)J"\_8< ?HS[IA?";=BOUII>)/CY1G)
M5DMVOP_W0-(YD/PJDM@5Y4O6L%O#)TRT_3_F8OE1^1VT-M<RE5\I8/@5ETDZ
MX!%M_CE?R?4T]'C@51NI8J/2?$X$+ O\)B5)N'2!707B:ZAOXU!%6\%Z('+(
MB2%;OY]/ GZ-Y6/"E!T$*]Y_P'9G5+^\"C 0S4R*-5-&N!3QHC8$Z_MM> B;
MSEVL%D=)%"AS. VD+_80]<41= HF!S4,@!<X*^;^QZ2'_7;YIWC0NLE"V?8F
MYKMX8@NQQ;'P7&_JD$4+!V=// I4\_#YPOS!1%%-M#(TFP)>JP]/<[Q'>O?"
MMBR'M7F]0MR%@;M@5O>K($0L&DLL$IB#4BGNW5 280[A8AL:^7I;&F'D20'0
ML3"@M 6S.9K.V7DY8!DOS<W>14L?]EIGPVJ4=$,[Q/K[P!T,(S^_O+R";A1T
MF-OO'M F'^D%AY!6SDLT$EA3"#A1(R>4G<I>&!0O"=$"VW,WM2\!/!QT,JSL
M_'M[7BW:E/U\=,WF1%2O%?*3/ZI@44GM[S.F18=2\'\&N"$MO/OL?7Y_&IVY
MM+X(DHE.)1L[<H%^2&6(=W#N@2" \U4X]WSL#X(R\,;W0B]\6K+U6FC1U.GZ
M[CS;!HOSBLA)#\"-\F+S&A#)7CS4$Y,85=2J2+I>7]<P&^"9/@OFG(1XQ)"V
M07>O-_,%S1$?T$(]8]C[6#=+D]!&\/B;VQOA!>?>A2#PIGP@-Z9"/P4BQ94*
MFA%'$JHH?T+L_.&)UOQ3V5&)=\(*:>H:]P4A*4J>A36EMI4P5 7BQH4<*92C
M$K"23/RE7K87:YSCUED_KU]&2N7D8-G4 RF]\6!.^CW/-0X 9$C6'$H'<OL0
M#MVN)B&U01KW1^U!M[]W9_[V H#6=P5'!<?7!L8VLT/EBQ@QWQ8E58IH !P6
M>(->"XRR90)F(J]"/%Z>A#SUEA2LY*VF!MT!Z7PDNS$7WR74,,%NG(K&"&M=
MWXC. J(:T;P54!JO@9]LH#T,<CZ8SBJR56V?:Y38V!8+B.J7*4;PNLLSL/;1
M4TL6&0/+D"4$$8$2]3E/",ZH@1U5*\9=[ YO1FY(^B7U%0ACRI@5Q-PNHZ:.
MNGFY5:4-P@W=I0I64H[OCC2,;%0:H3$VN+BJ63.ZLX8;%EV=Q8?BQ"PHA=Q8
M%[B-.EQ<MF;DEJWUZJ9"QTU#$,IVH4)-/6VD0U7A=;5+'W6GJ,E@4E]&_%CY
MG+'(TMVH%VI4:X(:<^2!6F'U4\#6LAHB[3F9AM#HRP?0EW5X24I?)N\J;^*3
M4'6C<^38$>NS>2BQ5[4VKF?\BNAZ@^N1+SXGA?R<(W1IYH6NU4%.M4U6T3VD
M;K51R<X]C1D6 L8G%FEA<=-/T,2D(C9-GF%!@]$T^Q".>#[#X8FWB4U,>HA?
MG"A%+1X,\0QFD;404/?K62:28":ZI_ Y/=0 >A-;.5;N<3 F$6SB$F'"$\,9
M!6&(XX!FGI#=(&Y!;;>P'=*R  U2Y:,)3 ?%UK5,QP-I!D!RN,UM)X)3A:N\
M=!-J*(JH;.UFMF0SJFL53]_<6?L?ZSVU<[))[%0&N/! OY3'4K<G#M>2[';K
MV-7^V&V/RNB>*10J,8\'IYT4H=-SL$0S)QI"4VCGU%*,/]=6-U*-,TKQ(?C)
M!M6ZEY,;R&W$%X]4ZFV=B!ZC>:([#3"V!+I(;,DS*?M5F)2]K;.52ZVV)%D.
ML(;CN18*Y6W/WM;!Q\HWESBG8>MLV,]OV)6;*5C$,3I9<MHV //,++EMY_^,
M#C__IU]V_L]7T_;_1/=<// GR$[\&8VS-O9HG)WX4^[=E^X#"RAT%ERZG]D$
M\Q]_I[:/J,!^^6MEAT^W# Z:'*KPY04H9:;MWH%Y*GI1A<&F046C4<ZR1]EE
MW\:3KQ)K(HI"^"@$(.5W9@8"Z8+L!*-G)AIM#Y7;Z1Q4"(==S\X?3-M!4'SU
M_%L@FQ@6Z%-VI[9C$Y[?X379W8^[V=V/N_F'EL?_^0'G'+N^X9Y1[CVC,D.:
M#C4++FHD%#?RP*:D2K!:+$QAS<@3(8\_M:D,HD-9FU]8D-_P(<-?*M[H>*M]
MKDTM+?#1Y7^2Q/.FN]?@&+I[$=7FT;*QD9;S[AEMNH?XRV9)RZ<91D=/4VZI
M?]$R8!_D#Q_!XELZYM,'VR6@TTT?Q;,$ON28Z806_&L!N?&X,^H;"#R<.!L/
MYA5P[0!<?\E^KO<[(V.<^U6WH^5^7O0HS>@8XUZI1Q5_WC?T:A:E=T;=<OMK
M%E6O16F;'T4#EL.(_T1,BY-@[J3RM:'2R7'2#IN]TC3IT5;#I/-G;F_84^Z0
M=;C,]Q[YS_IVMV#UZO/@XB+I, #+V 7=;-^3R"^1G<F=01E=>Z,H<Q3G*HW?
ME>F02O [#NX%LXGO]IWM\A_(8_9^B\V7F3I?=\@$854;+N(>)P>T7WTO$/-%
M_G!!6\5!)A8AUJ^8=]? LS)X?J/9U0U 2P(4W3$<GMQ1)(:(H'\F3Y85 B03
M(9A.&9O-UH&AT/_CYR4;@/;U+5""R.\K9/X\"V\;="K:>;4X<CAXM-OM7<"0
M1U&5@:ZK'%11VA*"?UN'7W7[3^Z;1FC5:N/E@B>I.J-NIL9_S7>+[NV$+WOA
MP;9!%J"6\LD,[*!LV&2LM<[Z?=48C55]5-1A:6\'*5GCU@=:+)H:0FP(\8"$
M.)VN%BO*8B5=+=;24.']1%.;R\TZ&>MH:XYT3?_84&5#E2=$E>_J0)9H-Q60
MY19"TVB=&6I?U]71*)M3FO&/-(39$.8Q$.8^Z3*FR32%EB8]G *CJ:/!0.UU
MBWIEU(H 2[L01)+A\;D0_NC<=FC6<+#RGQ()#2^RH_.AL#7CJ%>,G\#S#1OX
MA'-X\>9$GEXOF4"W)M D6<TX627\]M)E__PXU7&_=:9MSC3:Y:CR U[ECCI7
M4AP[Q^P?UM(?8(*DJ@UZZG!4U)9J:\ZY@4GM0SMI4.P54.PE-NP6>#?$2;KJ
MV"BJOFIPKL&Y4@;:9K_)J#*_28-O)X!OE1D>8RX^1V-UJ!=U@']MU'K&MI#)
MC[!05HR)S56[7?5V8L18-T&CK;$C'[8G991I746<]"W9=X/]VG>#;K=:^VZ#
M:W KP91SU"<IF(:'M.\&7>PCKHZ'(W6L%57>EG6,U<#YW&!851BV%_-NT-6!
MV6CJL%M5\D"#<S4+P.T'Z=;LNRQ>88PMIY:W='2MP:=CYF$5F6^#;H^DX[BK
M&GI1!?QK8]8;BPR)YH^HZ-Q3&2/L#]N^[#M.])K9QUO"X_]6L=7&053 84:'
MU<,QNJ8:O:[:,W;6B1H7Y.EA6-6I@H/NH'%Y'QN^E=3!]X-PNR3!#;K#UEFO
M:ZCC879VV?9*>H-P)\#@*E/21ZVSL3%0>X.=5?0FP'(Z5^T:8'FNJO$U[]\R
M%5&T)C$ 92UOA8U.D$,4)RJ^H33;W4!S.DSZH-ED@^X8K!RCIXZ&AMK3JXHW
M5''$]4Z2;PB[(>Q]$O9^@CQ:MW4&>MF@UQ!Z0^@-H5=EU[]ZYN06E*YA:=M8
M'ZK:(%M>\]+2MH;.&SH_+3K?'YE7Y4S1,#'#Z*KCD:Z.M:R/[K@$-_D ?J'V
MG3EMN/-2 )O^H/5H,%G+KI?-HK9=5-,?M.D/NFM_4+WI#]KT!SW13H)-?]"F
M/VB-X=GT!VWZ@YYP?]"#^@":%J%-JZ57R<89'S34J^'P7&VH=HV!JAL[=PYI
MFIXUE%BCC;\B)5:>^*OUFAZA#56>(E663(_>#UGN%DCMM\[&JC$TU+[6:WJ$
M-H1Y&H2Y3[JL+/(YP/'C0W4PT-6AMG/;L:9):-,DM'9-9/K=/3>1T89-D] #
ML,R^=EA;'RMP<(BZINJ[=_1HBKM.#\7VE&",W?74_F#G_.(&Y6IIH>T)YW:R
MT/1NZZS74_6<8L.F?K5V^+9/=*O*\- UD)X]=3SH@='?] AMKFIZA#8]0NMI
MWNEZTR/T$())/ZAYIQN\1RBJVEFG=-.O\<UCV'ZL.[V'I2CJH,&YH\&YDN;=
M?I#NN1ZA>K]U9N0TXV]ZA-8.G_:)3I69;P/9(W3<K2IJU 2&FAZA38_0^G&8
M@TY='^@87%-[1E_MCYM1; V&[3]54&_&8AT=OI74P>LW*'N@CT%!'_54P]BE
METB#<"? X*I2T@T<;J1V^YJJYS2HJ66(I6E0^:9R/)NV-YQ## ZJ8ALX#DL;
MJ+U^%Y3LIF]=0]@-8=>!L/<383!TI'95S]$S&T)O"+TA])<9E?NA])U,2L/
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MF;0"3SG"42Z3D*9=I@,48$Q)[()]0YA*+DSMJ5#SD[K[>W?S1[)(/%)?"O
M,[7Z ^V,NM-G*G6_RU3J3E]7ICEID/U'N9.]D.D0L#$KCDA]Z<$$?G+^A?%$
M*LCF'OS[IB8S!IZ3W6E*:ULZ^?Y(Q<.N[9>4%BM]FJ;0A7D+(MS%:]Y0MQ%X
M-&UIGVYZE6Y,]X.DXA;G/@J\)&Z_I;3KPYI9GP@'GVX4:8UDI9^/83:>E?-
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MJT<=NS69Z4KS 0U\%.4W/,\3"03@OQ ^D#EYNB<ATR6J+ J*I*CTIT(G"[_
MA\"M*^ _L%N]U^D9LMD/D$-$>,$?NR_>YZ^?^F20?_QS[B4H,IM[@6^.P-G]
M+)(JAQQQH(HTF?E!#6MU\+GY  2 8>DOP =8"G$ D,R4 N)NT&7*)E90X4NO
MCHV6(@^\'ON/2.E(> ^>"XQ$L1^2.1IW"V&1A+#>K=) 2 5!(0*F59YOM-DR
MIFYG^S9[#N?DSA=+Z]Y:6([AR)IZKSB2JA%5US1),1>:LO@?D%"3K4+GX +&
M;!0P]E38>!Y37@? !W(??W"C.2Q/$I(?<.4[+YC_7JRO6K-&X3-\#@$LK)#,
M84(FL_>!3XUMM OPF:TG,RG9FJVU],$-KP.0=97OYB%I3Y_XQHW!G9AW$/=E
MHMP1WP6)\S6(X8T[::Z#SJQM'K*"5?M\X1.Y#Q,G?!5D&UE2MBE+_N*$\T=!
M9I^(E(_?!R!*_%=8Q:>51]!H=$"@NL]H6ZX\!QB;RMYE/_-%4:0MD@Q!]]F/
M (WX@D_P(C!IDJ[;QD8!>*UG 0!%/M;(P TWK6E]*[LN; $#'@[<R<UZ6 )_
M[J[ <7'HRW$%7##>6Z<*XP$)O.]L/^-I=7"L?H4QW,7H0WPG(9YA=QY(/D7T
M>+,Y&ANHWS:D?M#H/22PPXUI0\6%V@=_P9'E#!\QAO<IPR_ E03]I0D_(8_@
MIJ8BO:6R@/XNO_UY*H!QF(H'JB2CP$.7L\0^P7))F+X,A#_ !W67+O5*P6^-
M$QP!K.Y]\DK0A$G"*''0L0V$7Q,8C:QIMT#)!6&V]QV9@^J-77C9[9R"0;95
ML+?!E0/2H1*>@O"(T<N=$[*(A&48/-$[\T'00?9DXJH#5:M]^3U]VR=XV><(
M)S GWY:X?+UY!1P04Y^:K:PQ/3,1O X.!JX$G'-82$!!<.^Y#U291KB:94F,
M@MJ9ST%-LQ &@E]8.:\8_$* S9WH$1[XY-XX/BADSWNEL M#:I'!FJ92GC[H
MCJQB9IO)^![BP#=HN@D.V,M"R& Z.JEBM[#P7X05S 2G_53F/P :(ZI?UG#
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MX:UX,A_&L<+S!UA29]GXC&)@^.[U,='C0EC.*2U=A9DHL)(W6,D[BMB^:OZ
M[%@1WCD5;NEGZY5997&]6  K1?22K6QYU5KSBX^UG-L*#K5YG]7"ODHY<[MT
M4*C=7OQM%?A%/8GBM^_ /AM=4SQ%KQA3K:'\#!8NHVLE4APTT?M89 4(..QX
M>U#:+.G (O2(>_G /\6G4ZY;N:G249N:VU:&>8<U:UH<<S)3S/KY_S8.ZEB9
M9C1Y(%D!1CJ3]VPF#1DAYU!V_9LO? V>F>"RRW(K2W^D,?3L."6,[_;'+UG-
MF6]IO<N#,)@QU3OUO*AE$2.-;]1I0P;+O1,1?,!D=O?+B80"I;EP!_P2";?
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M53N*#$4_4+&98Q #_1%SJC78F#M+$\4\D#@Y!CVPFC3P;Q-!"G6*,H?63CZ
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M7Z@5-0LHW?%KQOK3BA?PZ*"1-_<2U.+,](S!%$&\9S8@M4I=6-SR:@*&\&J
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M-KA-'I(HSN1_X?=L$_\5CXB5:H]9K=)2:<Z28S)&Y=\YK*&(U(?K3IVZ#OP
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M2;'UKV3Q0/%199@RT9E&NR=S]"KSWE.U5CSU5EDY^%(D;(0>/ [S9T ^YAO
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M)O/!P@.<8>(2ND&YSU7$(:CQ@/E2]QC*.L.V-^4%I0VF%C3ATWD /HPBIEP
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MC\("$R"8\%J:0@.#!YLACHH5R,<!;U\F=+\:B!@MT8[+LA582C@]DU+L3&!
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M[@)PMUNTY]"X4R<SS1H3ZBX^ /*;/X>A.-C:RODS[R1U;3&/PUL*\ $[:_]
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MS(_0P?SB,Y<^U$V/-UU@LU?WQ&UXVBGQ8/#!#;13S?Q8>\P@>.^LW!@&\6_
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M37\&LH*Y&%.1WD+@5I.'4HOQ<]C6_.2G7__3>5J]_?!SJ?G)WKB5-\MB;-E
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M5]?&BF>IU"\&(=W44>9C;O4PF&:E>@69;$B,-<#MM;NNV-B@JJ.S;5Q-EB!
M&Z>&!R][9,.CLSJ<:BY+5KR?04W6&*:E,U61XN;'-MS=L57VATLSK:AJ^,Z'
M2]?V MQ"PS4OU08][A"7E8?9 =%:D5MCJ[SRP,K*^9:#12.R0-0/QUUTC&0>
M8)7KB1$?A+26672*[>SFX,TU??@-#M[L;G[PA\:\-8UY5N<U-.9QUJ RF6!M
MCO2YK[W"G\4X2C'4QXU86?!R-O<%@X'&:$ZZ!F9Y*'G'0)0KQ#N+%->$DY0[
MPU6R!'K]LNU6>DP-0_^Y:5\J"*!(\7P>A3] ER0"K*B&:#[@8>FJR-P*S>?:
M+N!#:/@]IFD>G5G+AN!/]2'WUL:1]M>'AJ,W&9H5O$UQHIRM[9RIS7JF+L%&
M<PBP:=+>7%.V=VTOZ KZ%HX<.*9(C+) OV*-R^!6PS5O[#.8.!2HHB1XJ;B>
M$E\;T$7O./.Y"ANY#3S4+,XJ,W&*Y!2Z(L8L"AT]0@^.:/F34EK'($" #WEX
M]94F9PK(Q?K:<"%CL1_YF;@R0<.UP%,./H:)7M61Y5^?4\%:3ZM@>R V5=!N
MNU"P]:FN D_(O,[F:1V"-PMJ_2O9&,P10"L;FU!OM=,#Y=/ .D@E_K_^F++U
M^PIN"Y1!+3Z8B=:2>U.A!5%C%730'$<Z4*R*XW=40DB-*5[D'L\)"K:D%K6S
MICY%+2J\XLW:,9*/E@5%]1QVG$0IQVWC-<9;JQ0]QF QQ8S=8E8EHU'A>ECI
MZLDLUHJ]$*E:6IS80Y<0.Z60K-E25 -6PRMW3?7B13%J>B.R2317DQN1V'@5
MY<[AK_#S583N=I/F-MV1Q)C=275EX^N4G<I,B"S\5%77Z2SEPK[5<=S''NZC
MPR1-C2DJJE_3T5EHR2^'4C01*@1/5@J\%CPAB1TO=A4P63-CMDG I#+ 614P
M,9NQ/4<P</J+-UF\ E^[C.F!MM+,=@5ESR9IA"=8?7OG^3@\R1+-EKM;>386
ML($H9Q3' JRP%V2%82UZH;9P2C?2V":E(A1Q*E5%Q?PNRI\!=["'@'8ZG/JF
M]7F/X;'G13:QUGNTA;O>VDV@YCEM^9.GM>5/06M;36SY+>H3R_VEC:<W;,"#
M*P*75G7@LK<'=H):5RSAP1C="-A$81H1]RZP)/U)@H,G2+VU:ZZ(Q>/Q'%OT
M[?)@4W !\ %'>/,/>A^*\UA?!*NMB(9(G;A?OGPZ_W8S>JU$S>1I29)>@L"K
MA*]W)"W 1#C3 !9TM\#)5PE:E]0>G>6?Q\)(8X9H0LTS\5!Y@K+1:_1;RR7\
MZEPQ$L 5_&P/9)C>JBL;X<"PU(Y+).8APGRC:QB%"]L'O3:7\<929D^MAZ)L
M[([F5T[>6\ 50!FR9EZ]*=<!"\T(4#EU3U[7K$/3F&TB>7_)ZCIUC1-YTB1%
MTR ?U*37WY?9HF'ERX9W_B,[A1"6>U_GYYPT;2"ZS0S43_<4M5[N!+(Z%1>1
MU5GN!,J?9?##MFL HD>_ DBCJ\#XW0XX =<CD[Y7&A**IAW*IK3NNL<@P;!!
M@\#T(RP!)F,CGOL8_@5B1MZ8-0DA+8"'8(P0\X:L:2]@SQ9)A72CJ$8V%G9*
M=<,8D6Y)L"PER/6ST[1@=CY%C:>BA@G(-I9SYZ5MD4BBT)8M@G)X)TL]F*9^
M<<JU-I16;A2W^"8,>(P]9.?.GEPOZZ2A$KXL-2(0KJ2"QD4N@?-H/./',M?-
M^+D%D_EJ<HO\]94L=/B!'G6)A97@[FG#K!H'P"R0SW[/:IV8%3YAS0"=-$-5
MIB(^7!]X-MDEAW<;.HES"3VS11QI#52%1I%S/0^E0&ZNFI-$"R-9)@)>K0DC
M@3P3MAWMG8K'.8J0&+;!3(=9>Y 8')G)P>=U9 !_B<YUF1S#E0Z81HUK?%'^
MG(KCMA"^8; ,6I>'RM^$:%^IG'.W0IMC>R.[BQX6.=V* &<BHY[& N&$PNRJ
M#4&)-F4.\!?-!J68:W I;H2R^:XFVIHNQ+AY_:G5(ZMA#>:*'I0AT#;?/Y1(
MK2V1ZM:72/UG'+H+^-\TF?EG_P]02P,$%     @ -H!F6/Z**VB/%P  =PP!
M !    !I;F\M,C R,S$R,S$N>'-D[5U;<]LXLGZ?7\&CES-;M8HMVTELUR1;
M\BWE73M224ZRYVD*(D$)&PK0@*!M[:\_#9"4*/$"@K+&V*6GIBJ6A&XT\#4:
MC48#^.UOS_/ ><0\)(Q^ZO3>'78<3%WF$3K]U/GV<-,][?SM\R^__/8_W>X_
M+T9WSA5SHSFFPKGD& GL.4]$S!PQP\X/QG^21^0, R1\QN?=[F=%=LD62TZF
M,^$<'1Z=I,727_GYY,1WO=.3#]V/N.=W3TX/)]VS7L_KGGP\.7&]XS/_] S_
M=7I^XI^B]Z?O_:X[.7:[)_[9A^[I!X2[DP\GQY.CLT/4\X\4T^?P/'1G>(X<
M:!H-SY_#3YV9$(OS@X.GIZ=W3\?O&)\>'!T>]@[^>7\W5D4[2=F T)\;I9\G
M/$C+'Q_(GR<HQ&EQ0ME&:?C\2-@[E\VA_-%Q#_Y/BTI&I((UH:% U%VQ]@3O
MBN4"A[UB(OC]0/XN*SKL'O:Z1[T<J9[RJ'MXW-T4TA,KLJR$[P_B'SL.$H*3
M223P#8!\A7T4!4 2T3\B%!"?8 \T*,!21S8*9'X6B$^Q^(KF.%P@%VN[\/,O
MCB-A)?,%X\*A.4(?A1,E:,B%(NLXL0K<,1<)I=FR9)BV*5?^  <BE)^Z\M.[
MY]#K'-2O-0J[4X061C5G:>+:DV],),CH<^_L[.S@62IHL02%2J?*=^6?W=X1
MZ(%!M67:6[]N^-1-Z5Y"AO7@-),AI=M1AL(!6:8+.DKU.=Q5C-7H-A8CH302
MH]A:U,0B)9 @O#>I,,3NNRE[// PJ3/^MHO+/TQ&W 83['HF=:;%Y1\%=2)*
MF5#T\IODN\6"4)_%7\!74E?/4X4=83^UV[EYJ\ JJ'_.$7<Y"S0FY&#!V0)S
M07"8G?,4@QG'_J<.F.EN:I]_7W#\#@1)2^3X;PXZ^3-4@$.8(51S[];M25E(
MO?O4"0&& ,<]9''S/>R;-A](""7_#8T/T,2T\4""@__T=KLH,&TWD+A1T$3E
M)?D#_.X0[U/GDH&[/D13D$Y^_VUT6^9 J5K7Q5.>*=>U$GX^5/_UG.[:O^\Z
MBM*1I+\=;!-LL8I"[ WH9_7W]M!.B),B%81;_5.;;G,P%9(E7Z;]6-&[_<@C
MXI;*!8R2I%XGYZBT?7VTV=>*@9/AT*(NOV0T9 'QY'+R @72'QS/,!9A704O
M(]>"< P]/X9NPRN-7[-R$EY.S.P-#Q$.$8=6S; @(.>.X&SRTB)U4A\IY]<-
MWG]I*7*KW@J9/X")38G68$B5\-$B]KX*L353A_G.FNT;5ID^WG&XU6&J1?%#
M$Q3?1F .@$LVAX;-, W)([YCX8X#,<].B^3'^DAN<'<D^S<$_;%@[L\9"SS,
MP^L_(B*6NT%8P$^+X6E]#+/L_]>)*WA#L:#77]#*ZIAK\3W;#=\WNYLWE"B<
MW03L:5=[NV*CP[!W:&!G@:NCV+8(J8<9EO,+HC7M9Z:\MN]5 (.$;L#"B&/X
M ,1.0MVB+AY'\SGB2S!(9$J)#[: BK[KLH@*0J=#T$:7X)HCHB8O+31'V] D
MC)4M6[-VUKR=E'F+D!OA1TPC/,(NF\9,$?7 @KC0I-BY!EO$L4?$B(0_ZR%H
MR%.+Y/$VDDD%3J8&!ZIP-NI0]D[5XLAJ6H3I)0L"-&&R&QYQ?\IQ/ '4G9"*
MB;4HG6RCM,')6;-J$1+C&>-"8#Z_I8\X%*KYH*@WB/#O*(CP/4:RLPS@,>*H
MQ>Q]SD9*]EW)W\E4H :7K,)1=3C92EJ$YB7F A&:C2K>@G-5=V"546M1^I ;
M63&KS3"DH[BU"(X;\HR]?AC6CMMG";2=_G&[TQ6U$Y.WJ)>_,.8]$;#DU+N%
M1M IF038I->K&&A1.-U&(>6F3-*:7_MP 5_G46X>0^.O\$347FUN$&G[_RP_
MJ:\X.))%BWJ\:3RN0=SMZ# W,;<]NC:?DY6W THHUVN8UE]55C'0HI%;Y6>X
MI0N/-;\6P7)+H8/Q WJN"T.60-OMN15\3.TH\A;U<O_DL/=S"!-HS=2057%M
M#^=6UD#ZZ\^_R(SZ-N6#C' @@Z5#Q,7R@2,:(M=@[[J46MO]N25SPLI1O)PL
MLQ:A\053S,*'&>9H@2-!W!#&?4U?LY!4BT-N&1SS<;*,_BJMS[L6P3".)B'^
M(X(&7#\:Q">VJ;2=GUO=KEDX,8]6=7J=X/<^ NIU NMG9^]/3C[FO*'Z@77G
MU_2O-FT5U@/@ <&:ZD4A33AJ =UAI\3Y-:ZD37":;6^8P-J(LQ;>%]D^:2/0
M)K%VH]%KSE<+<LZ5-(_DMQ'BLJ"\"9P:'EKH<MYG17B_C1AEPO8FL.3)M$CD
M7-%LS+^-75\1NS>!0L]&"TUN.Z9Z(Z"-8&T%]XU,6"&I%I3<[LSV[D ;8<B'
M^XU\@S)J+1BYK9KBA,WV 5(1^C<;(SHV.HA.<[LZE?L(;<0JLS]@@DV>3(M%
M+HJ1W5QH8]?7BRE\13Q.Z+K"X*,&+QJOR/'6@KA+Y*+KK.IS?DUJ?,-[&Y,^
M?/)($,EN&F,WXD2D!F\/&E"C-JU.Y,(=1CJ1E<!9B^ H&=[TI!2Y=2GI=5P@
MJ$RFP6,:*O'!*X_F"[63M0>U,:]<JT7Y>(J)%F4+2Y&Z2B8G*Y23D:J5>F46
M[$Q*^YS-KY\%YA0%EU$H8,;F9AKU\M5J=2D7X&D2@%U326&<5!IG)<Z;$FG1
M['M>7";(W'NQ1^VIK$^K-KEH5*.X/4QI*RFRUWVT4EU*#C<8J8"&AQ;67"2K
M[)Q$*Q$RV1N1-VEZ48"9WW^$?I(>&JAWB(*,[VCF;>RI<JU.Y )I#79O@"@1
M29J E5!=D*HKQ<IZLV^:50UNPU7N+C5H=20?WVNB(RU?\S8;X&I+ <K=$30A
M@1I"24D/B14QS+ C.<0X+ ; WR=_BNW9432=UIWE$]%WMDSQ!HTDR B=4G@.
M$EE&TL5Q5K([2OA6JF[9+O-:%X8<+Q#QH&,'8H;Y)709-#?N;C,/YT6JTJI6
M/JN^8M][4X>2^I42*0F<1(35]M^;AA3 E@0KPB%:2M< >@^^X1'VKI]E7,+0
M6WK!^K2ZD@OTUM>55 @GD4(I32*'DPK22H7)9$@8 5] IP4P%Y7=3*UH8>]7
M)$4T<S]-&&KQRL4_-?D6;?<L*SI_;0\K"ETL[]&_&%<?+@,4FHW(O=6NU9/\
MT0F=GF1MLZ;PQ=)1<L6?'259*[5K*S^GF7W0,=%BG;^'8#O=I^U68*N+UV-O
MZX==<-,RU>)8$(',X9@=I?FLKA9"FT_,VE@.^1C6'YXJ9+;L-V:KA3<?3"Q*
M!,LMJ.*JXL)O"*M.:A@&U//18E@OF:_MYK9J\*C?!O'^^B 2\M4?^<38BPU.
M#7\-PN\/:]WPL#5*X[&95.ID:GU#OQR=O@OC W[\1J%@7.Y6[9?"J)'GW/>A
M$77KU&I)_JREF98XJ22.$B4E6 FC3OJ_:<\6DJ/QMS]-:PSJTFI+/AU2KRU0
M_YN2E"E)1<YWTS58?89:N',QM>IT\K9["Q5]OTH@O$<BV2-?/6% IW<8A7B(
MEDUR15ZR2JU"%%S!6:T0F3S%M1B9IQ7 LU"2.*DH;XJS*XJ_]UY!=7[OO2G/
MZY]HD>F_C&)UOSLLN 5ZEB]=R'3.]4LF1N:E(6^M*N2"NAMG8Y1F))4EL0.H
M3KW:$>>F9M]E:3?B,E,3ADM DM30S$]-@:[!4HMO+I"[A>]F'1+CS<-1[0:U
MF>=7Q4 +6"YBNP58NQV[3-=FCF9D+>)5$MV$,D494TV!W*TV+>JY0.X6ZMES
M*)LF.95 %BU+N&JYILC,#U>H5!22S%;,O\&P_I49)?%;+')*P\K]4@GUC?5D
ME[JT6I(+%6]I25JYDZE=ZDA2O](+)8$3BQ#[>K$0;5>2;Y3'9RW^K4;S!:90
MD0C3>$E3?:C)5@=]+Q=#WH(^6X\R!6E-ZXA/&P%>79!JA%^.2@M/+GB;N5VU
ME1U?=E.JX1&L:B9:6')1TO);5UN)4N$EJ@U3TFJQTB*6"W26WL_:>E]X^_Y5
MP]/6Q<1:@ I.2V_=X?K?#L9O!\_A.5HL"/69_";^3"F+95=?P3<XB%_IDU!!
M[_^>[L0,TI3Z-"&Y7Y1:KRXA>,#/XB)@[L^.@R:AX&"J/G5\%(2XXU TQZ #
M.S&E,D40OOK4$3P"GL\3'I#S!>:$>;*]GSI>%+N1'2<$F 41D?STA;-H\:D3
M%R<"SSN.B(L+WI5_A;USD58C$[4EL\Y!6<_<1R)"P4U$O? >SR>89YL;2Q:W
MMJ#@/IO@L3DB5"__'8;>Q9M1V:^1E&_@K\]X/C 8*8'\K11-<T8OWOSD&RKP
M%'-]TR^@?E"U>PSCQ$-?8&X-;QC@HZJL!K,6J0WP;IX"AAF'3E6!!\SGI5!6
M$^T)MI1(WZ9<W"+_X$])PVI0ZEM'J$QG$>E/D_AD![0:3X@P:O*<49AL^%+?
MY'X$R]S,J?A^TKXR_2POOR?T@#T,>E-]3,W"4%4OV B[&+Z71A*X@?0CF%81
M=V>PUK_"CSA@"UF\IN(VYO[J&KZVHBP,+\%17(*T3XA[H+#)S(^#9?:'TBYI
MPLK.,5 TP<C[:D9@?0%BF02"IAB\:RY_N<+QOT;S51UV^[/JDHFL5M\5(VF1
M!_[U,Q"0$ \Y<=4$Q*MG+2V9S3-6<JO(#6=S6$\-.7.3@[MROW?;%M::SFIP
M;#X27!69W--0R+0(;'MJYT9LB0*QC,U=G=XHIWUU"_@%4!(2$HR],#'<Y6TJ
M*6W2BC\3OM0-46(GTU&RUM&Z+H4TEJKI5T:OYXN +3&N-DP%!6TP1?T%C!5V
M05BU]+EB-LA>:.L?GC1-T5'9T+)B)Z\O71?L]>?R$+6A@[A%:ZO94%FR8Q3@
M<&VVL>PS, 7]2,P8EQLHFAXP8V*I82DRAG(:[_N^R@;!3:QI,0-;>X!=58_D
M3 $K!NWUW=WUY<.H?SP<#V&F7G"B6CJ>(RY@\05VIKH]!@QL:.\="D-T PXF
MEV&BZ]'X.W)=0C6-U%'9T++Q#'$\R=U=NG:K)\MUD22E4AE8%=)]@,5V<C H
MW? 7[#L.1>:44!PU++=@?YH !F/?)%0BA0OKA"?9OT ^72!RHY -"B*/WLI^
MX9'J^?@&DULJ,+2ZRB)74EEJAN-$!AE:D;-'?"#E'L,LZF4NG1IA%*A)E7I]
M<!1=N8G[P-8%2OODA;C;ZL^4AZ94"I",)]*O^%G<D-!%P?]A5&X3FK"R,\JE
MCC8]<2($IL-H$A!WX(.O BVH-@1Z.AMLP^5,&NE;JBY-&_@9-;ZE*]]+V75$
ME^5>O!D76_4_O56D7W 1#BZW"CHR._5:#<S5R8SE-=0P!Y0&_A!^D"V0!1)
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MJ#7'B+[:0+%,%J5L\LW3*?: UV1)O/7I-/)OLVDZET34V0J) 2C2B/5\H^;
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MYO$>C$/(@&K(GWLM9TN5]??B7'%(7X;Y_'N9S;^&>5Z,A-3%V\A KNJ-.$T
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ML#4DENJ"6FF60NV,BC8C>9ZR[I']-:*N<Q1R^T29*A0,PX5#NL#+B3(N)L"
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M-49:DPM8[E=\."O6N<S[RU$I[HTBD)4N62*"!&\\<<!S1)\IY5C;2]T(IO^
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M&+.U[U+_$,4P#JZZODCMQ=>^?%'*TGOULBC R<<*759=# B$%B1 C(@T&,K
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MT_.1GT/Z93J9S7X?3\&/R@!^05N_*%,L+*ZK>1J#PO66EU0WF:,EP699$IZ
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MJP6Z+2"CX[4/*S=A.?0>UKL&&2Z/M'1S!;P=SV$*L_DG=&+1IYU#^HC^%/[
M?X&!]-XP;@,QV:%6J03BBZM$O0H\^'+5I';7PN[HCE$EU=AHL&A@?!T!TNP-
MVN7M;';N,=3^D M^-(#T25%*,L.5$C4<<8)DACB<XSP$#+5=[3N(F]$<ARXJ
M6;O!,>@G./,7BSV6#_G.R?S &$E90G52SG#$7C+B X953C(N8K!94EM9" _
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M!&;^$A&^2E<HZE)]H%QD/09IO>6R/ ]I9Z#$9T:"$R\-Y;3-F;J@:>T'LT;
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ME2\5=F(S27CPD1)57" )NF24)TX2;GF1TZ2S:A3O<U(*?^::8 A]MY%IY<N
M?\0W,+L:IW^^6Y;<O<#CY\I'0(<T^LOYNTE$-_7O?Y_.X?KKOX^O[HJ.42.4
MP,/&N!(!'Q():/^0F"W+W$DMS,9[Y]8[@4/&'O9JH([&I@.*NW+.R(-.Q+MK
MI/]^C?)9_F)93?=?7<S&\;Y= S,JZ<@-T2Z:TA@]$&>#(,Z#D E28(DV($T]
M1*?2D>60^L)'U$TO501;SV2D4U3H<67BLK$HJ\")8X82'A+CRGNPUE=V10Z
M^9(Y-I1V*I]H*VB/JQ_Y/\=7-U?W+4#6C=2Y21IW4$J$X*)TD$'/24B*?AL3
MZ*E%B*')EM1\Q)=,AQYE6SFWZD'!I276B]DT B04PZO)]P>%$'#[*^E$_@N,
MJ%,&$L(#$Y"O 4I_K(#>FM?&QV@\.ME-F-!ZY!?/B'YE73%AZQ%_[^C[Z@M^
MA28>K#J'3/.CYB\EV,.&[(AQT1%ID,[.4;2\!-=6&;3U-XN;/K]!-!OVQ7.B
M1RE7K%"Q'>J_8/SEZP*W,3S*D*V/[20$J1.(B$@5>GX1;7*O+. >IZA M4=!
M_4%\>&[4\Z-#-1E73/+;0]S;?>U7%%:AK9_$VWUO%*51&4PDW&0@DCI'@O.9
M>)>CP.,/Q=.D<N%AHY\?.ZK+O&+BP XCZ",4R8TG7YZ:059RZB4CGD44"^?H
MNVL9B0! 6]B9DFE^F(FY<\RS841M^58,W"LX[R^'/L%BL6JTLT*US*^"]'FZ
M[#IVX6>+52+6?,1TRAD/.P(T<Y0$H\3'K(NCK;30P7-N&]#A@*%?.BOZEG8/
MP10/S-]']DZ4@)-%OUA+YXE,F946O)*HDEYGJ.*]MD@X%TNSII0KOIHUSL[<
ME9SYN(7A@[:E)HA,17*$<2E+*2E+;)"):%[^%XK[5+W30NU)G /ACJO9+;=E
MG>]?:\WHFQ]?EL?O7Z>S95S$2%I0D#PE-CFTT@)NQ8$&23)H$23NRL8/7AS@
MP+G\9&XE/6\A<*?[WL?8/N1_PAQ=RXU<] ==69<UTTO6^RCPJ#@$0;B/"7V(
MTI!+@R&&*P"A;+*NB=]V,("73*GA)+^%+YW[USRP&99&X]/6O2QYEI&WA'DH
M?;6\(#Z7-WZ:T:NPV7)6O<GK/E OF2_]2'X+-SH7]#IXDUP5;7XW0?K?+,MO
M+"?X^:N??+A>IA+\5M['RA)9+9P1I=Z&<A&.3FH@N(>B9Q(9)]&Z% 2$E,S)
MG(YM)W<.7#U-)FSA?.<BS0?/=/E'V?=QY5[ ;#Q-;)2"0W,619Y31L>+FTR"
M0N]+9V94$,*8X2M"M<#_0S.WJSZWD+/;C?RA$UD_2[^>3A8S'Q<W_O(SS*Y&
ME@,%EDJ)SZR)-$X0A\X780$,4$8E4XU>_.O">LF4.[:6MC"N<UF@5Y?+WT$+
M=NO$UI4"1CQEY46.Q*A4>G(&33S-Z+N#LLY2+4.N?8_7#-E+YE./.MA"E4X/
M !WM@TVCX#Y$8G7#G=Z5J-.O(Y.L#QDB\8*7\$]E2+ IH%4L'7C)3-)-,G"'
M0?N2J7>B.MU"V\Y/$V_7>42?8/9M'&'[K.^LU.4$YY^G"W_Y\.>OI_/%;]/%
M?\#B(\3IE\GR+C,%PVV2E@136MEE84KAE+(TE7&H!EJ_ G)ODWG)9#XM36_A
M<.<7EMYFMC)\?YW.UG]5?H^-@O3,9)F)X:7B?RK=&DTP1.%T8S!:"%V[6^&P
M,_S)]EXYL27(]7@/-^OCZ<&]V_HF0O'HLF:*I%ANW_ T(DXS2:@5&5=UE,S5
M+F58?1+G0.3C:G8+5[O%Y->;S5UTV#OT&<>3^3C^TU_>P(B5/*CH* E<0DFU
M#L1FQXEDUG++N0'5*#2S=Z0OF9TGJ,LM5.W\/+3$'_9/,>R8XML_T>P?S\L3
MZ>.9X8E1;":C'#JH)3$F1O17.?5X;$2?=52"^EXJ*/0RFY=,Y1/3]18:=\MT
MZ+9*'\QJ(UC[+A1S\]*.9Y6%%3C;$'"I1BCO=I21'+AQ43@N?:-<B:&!OV02
MG[ZFM_"ZSFO5(4MV[[O<C@/ISF$81>,U%6CF&UCZO%R3 !R_TH)KSPW+K)<8
MO*/,]B6OC.-+KQ57MBR3.NVJAISZ*OYG)&@P";0G+)6[S=+\U"7/"8K#,.-9
MSJQ1?=%37B/__+E !F3)EM71+8-GWYS#/IOO&DJ VV):)O/4U=8V<;!4$ZTI
MQ0/2H*L=K2J/F"Y+!E'8T-04Z@_F2V;OJ6EQ"T.[/RT>-+>-1;AWDF!U\M*7
M?ARX#,M=IK/9D*2HUXXGSF.3GK%#X?UQ.=NC7K>0M_,#XUZO9&=SLOL)CF>K
M$LSO)JO;]PW_9.VYK-*'1P(MK>3,T@M!9]M+0[R-E/@@5639<&,;]4>H>7%=
M>8XOF?PO@A=;%L+Q\L!VSW?$HQ?">?0L!--$.O0Q/&.>".V J<!]K%Z0MX=I
M_!!T[EF[6^JC'/U1<9D2M&MQ+G_X!IV"7_UXMKKM%]PYS0(E*MM(9 )/;'2&
MJ&0D=4(Y%T[MR;'E%'\RO5]6;%D%_3=+/CCXOZTD$E4A!&J)<::T).&&6&'*
M'YZ9%!GWIG:8Z<E,_H=>.4=ETI8UU?E=]6%!EU4*V*,W-$@CX" Y*R>>M+K$
ME'$2/!Z%G%H1$5[BOG95Q[V@SH&#=26_A1O'2[O;F,G=<EB&=6T$%H"-5L>$
MMI1"VDM/D?M<9!*3E%D9_$.<GN&\?U[GP-"3T_\6DJ]?+O_O7S?DC!+XS^4/
MEG]?Y/@1\K^5__[^\=V=S/_XXX^_C)=EG_\2IU=_78I[*<"OTTO\_/EJN[_M
M*3#-#]?I@PN>-[#PX\OY8YCS\=7UY;[G]0Z#_?5^>H^GO1[Q$;GZG"C\N8!)
MPDVYC]UFLS#',F'] ;J2NSY_=+WPL;#S?@%X+@S-TA&C!93+!D8<+P=LXDDG
M)522PUQ"=9U)Y]W\OC/&X?A^^?X4X6US#8\2UHI0HU'.E@/Q,67T$+1+ ?<<
MG:M'4?4ZHXH[N+^\W+UOGP#OGVS\IT.5;96H_ZT(.BW^3[R<(K#_][_1%H?[
MOYQ.%K@CO5V5(\-M&+Z4+_JQA0X6Q+)I1:1>94#MF.Q$*?&>2*!&$A8"#VC_
MXS%Q0EO3KFF<0*>?HY.TD>$T'%EZ;4I689=:=^QH,J6>NACV,)WC=$$\.M7J
M4;\J3U[($J#<B)P<)QE8)))G1]##I\1K)54VW+D0?U3J[^D#^2,POPT]*O?L
M6,+XD!]!FW^8W+8Y9,HD$UPD.9I$I(F.A&0E$<S)$#S7238IHOS\*,-?HAQ=
MB=->-%"Y!=569)__F-XBBX[[4BM$9Q^(=$&2$ 5B]!XX)'0^:).*RL^/\I,;
ME30PQ+[Q&=5\RUL5K=&..P)>E2D'0UQ(C"A;TAU%J0'<)"MPWS@_^5%-"Y5[
M 6W%]NOT9K:&IH57#"A'5RN61E6EU%"4@H0LK/;&Z4B;A.KN&>8G/VKIH')#
MH.W0QM_NSCV?C+!X[J7D)>YH3!!OD;G>6:HX,X;S># ][H;Y28]:.JC<'F@K
MM$_C/]?(J$J"R>B),=(0F4(@05BTY1-+-AJ>F6Z2\OC\*#_)44D#%9L%]7.=
M/OT#9NN+]:OQ8F0CU0H-;$*U9$0*< 2/T4RR9G+97UZ8V@5G^IS/"^=QI<>.
M4R%,#UU<J\[M]^OK1W-+4><HC21*49P;=QGGQC,!QHW47!FQV4?IM!;#QGQ^
M+H93(LRIW]_>%MI_$!RQ#I<8@2^)Q523X/ /Z140FZDB*;@$#*=.>3KE=;%[
M:C^7R(G2J**'_GP2\H'3?#J]AH4M^,A;ZZU4GB3C$QJ1U!.OHB!*!A:U8EGQ
M8:KS##[UGZOM='31BH85+T2.(X9'_^07^#*>%)G\XB]+NT\V8H8E;8JG&*TI
M!9Z!N-)67%%4)@L6E.KET?)$YO]S79Z80EH1LN)U5*\6P8,B4+<60>(.SWX?
MB6.\M&'.:!$$L"0&1L$(JS0?IMM@]:G]7%(G2J.^+NAJ[1Q/I_?<SL%&(:O@
M0@C$>V6)-(!?!0V$!NUSL [,0+4>AYGOSW7UD@BWLRGZ0-DM'S_]_BHNQM_P
M+Y?2N$UV+.T2QM^@2*2?3)<6 _>:]7*H 'K-@&F0;W6_3H2F@C)+"?>E^KGT
MBCA<(X3:0)/,VE$VS)UL&]1]9[8T*66R"OI.@BZ;&1$5M2>2RDR\XXQ8GRVN
M9LUR_8HUM< ?-U^E-Y:VS4WI1]FGDH:R@H^_O Q7!5<J&%M 5GE=4CH]L5(X
MDF46BHK(#:_]'/D(P*FF?O3$@<UV6 ?K8K#'C2:"N)_&))43[C=_=1LAT&1.
M@R9H=)O/<3(T.M"D6J&NRCI^*?Q%^SIQ,)H$D44)D58D:.,(%1*T3-)YZ*7L
M[8O@[9[TBA.G;1O5]D#7C8[JOZ-"YN@]W(9 40>:FU#>ZM"^L;J4F3:1Y!P\
ME]P&+5QEWCT+Z%2N 8;4^;0OA0T6IE.UJ_7'Z>7EK]-9^4<CG%\)XN6$25,N
M !/@;*DBWGOADDS1II,IN7+0#$^0[ST[1:=+H)>Y7-8E>T/I^BE\P(E26]P#
MG",'C6>?USYRH2 /$^_9P^1>T"(9@*7#+Z@#*'8,N[M2);Q1]+B+!>D(L%BV
M-Y'*JY,CVEMOG5?9B9,I*=IR;C]7TE%64@>"]14OU\L\5]TY[N:)!G!">Q2-
MTY*?)8.@)##G2>!49"DS-W%PI[;2W'XNI*,LI X$ZRO4K9=YHA8RC!]-5?#$
MC!&$T1C1[Z.26&<D$2D$"0&"<K4=]0&G]W,Y'64Y=:/98/%IO1BSAFIJ'2,Q
M1$&D8H9XH4IJ.94Z0!8AO)RS::N_5#$4 _%>C1?+H?TDE8CC,4*>Q#',?_.S
MTH+@&QP>;]'FTSL'51P\E4J1$Q^NH0PR^?(>BII?S>>PF-]?K;#(G!3<$#S&
MH+1OB"30G$G0G(>LK'!.5:;E\XCJ13QL'6?UMDF5CII+2IPM^;W)..(D)*(9
M599"]H%6#Q=M@&NH.(6*G-@=@U!)_,<.+YC/%J./X"_?SA=^46[>7\5X<W5S
MB=^D-W ]@SA>;JMO8!YGX^7V^"%?S*8X^\7WY0,13QJ/W&")Y"4$FWI.O.2>
M6)N*%'!;DHV6&")Y0#3\[IYDG4$>/URA%EVFQU!;Q=NGIL#+X\\]XO4S4!/,
M;:(2*E!N&\YAHPT&ID)+ E;3XZEP, 5$ZK0G(G"-GH< 8I-D)">(D5G-<FS4
M .9%<6]'Q, +I%X;]56NC_;)3]Z,X<OTM;\<Y^EL,O:W)9?0#K%<).*3D'@
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MAUAE+3$F2[27*?K2M9/8.P$^S>>]+O?@P^EOV*@T_,&[R6_PY^+7\1SWR_]
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M78V<3 +\$DC F6N%,]<\$&TA>"Z TDWKMX'R'X]QMOKN(,J*F5:[>?BJY/C
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M-T*0T:ADLMMG-K89;W@?HHYVICV+MH=K]??3R1=TFZZ* #[COUFU'3$IL,R
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MS[//JP L64D920 0"   7WX S^MHVC)B8D;*JDJ2,O(2?U&@2<M;@>UAL
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M\D=L_Z0+E;_$#(@_]->V?ZV??18 P'OUXINHO[:9) , =?X  .'\7]MHOP$
MF"]QJQW]F_7@_Y$OEDY.G_A96:%0*(N5&8CE#X?^L_Q/._P[Y&^>Q_+'=/_L
M'DIQ,W-C9ULGRC_\!K*WM7>&4#I^,@:943+_]TG\=P_\U^U@4C4S-X.8@5]&
M:+YDF178XB7<8%,K)RM[,*45^/\MB'_GL/]._LSK%\')>0+@&K$ L$9Q ;!'
M0P X'%0 K'[&BP;XSW&31]8$_+'SM"AV_LS[OPCP?YP5)O*/#T<KB[^,$U-5
MIP0Y0US^U/VQ+0'P !0 )@ 70 0@!]  W@"8 >P 'H  X#U  B +4 *H W0
MA@ 0P!)@!X  H !/P!=  " 4$ 6(!Z0 ,@$Y@$) &: 24 =H!K0#>@"#@%^
M*< "8!6P!3@ G *N ?= (! 1B [$ 1(!*8"O@8Q =B O4!@H 90'J@)U@!^!
M%D PT!GH"?0%A@)C@"G [\!"8 6P =@.[ >. >> :\ ]X#GP#@86!@T&%X8,
MA@Z&%887Y@.,'(PZC &,!8P#C#N,'TP$3!),%DP)3"U,.\P@S!3,*LP!S!4L
M !85%A^6"I89EA=6#%8)5A?6'!8"ZPT; IL FP5;!ML(VPL[ ;L*>PA["X<
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M+;+-,-,X:"Q.(OT E;Y/?P"HO"O5+.\82TL_L?4WWU]BVV_XH/NR01['*S^
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M#D,C#K6=80YZ!Y#TA&..N"4''KG$0?U2,S_0GJQ>]>>BW%$P7RC);M=+Z+#
MB>)[:DWYAPI,X3)8G!OJ(V,[1.(Z7KMHLRAQ\AQR4B\ZJ1<"@=QO#':V??6P
M$PBAV> *%>":3XRWK]?:V[CW:2@9-F7E+E +^JCU>A'P;A:>V+^""Q!KY7@X
MI36%\6<W4Z1%/!:81#F_,^4^.]8VHL^@5)Z8)GP2\ASWA[P$G@LBL.TR( B%
M24T_PE[('13G;0DL-O&M+=V04^^_UOE]7H.'L0%F+00XA"A88L:)7C>'O])8
M]5("GH1?=]O^N8-X;I,JLWXV.X_=1F#7/5\H4&,/38D*>5R$O?+],#K1HC$5
M'S;3[QJ8^>B84$?8N:Z4T+7'!3F;-,S9Q'3D",_(WH0X6Z79Q=YC*7"&*S#]
M_1*R4[1U#@^MV>R;1*M:2#J[;/A&Y+E?YV'NL=+GS@_1KRX<5N<(+W)Z,A:X
M#+T -DM5 VVL4M?%T<%1ZF-[8!WBF];\4<K=FC*_<T/=MTJC3L0["ZBT\N54
MZY*"[/9+4:?CN /KO()OFI>,O_,,ET$K3.3^[1-]?_GP"175W:(X3PA0%*1W
MB:K$P>1JK\=7C=SP!S;35=7/L9M54[X@ZB9@H@9+O/O+'I-]XH^/;STC?=QB
M2E/7 .2(VS0Z>L#ZQE7L.+2C%*I&.[G4IW4XCJTR#C&=PNB7H30(K?1#.#E;
ME%M-IUI;AFYJI6G;"TUG175VZ_<\!WF$D7,7MF;A09ELZSZ:H4VABS&I49+-
MU[R+@=N>QIZ("XBBPOA?3K/D%71ZW(X-#$J?_LMAT.V5<%/SFF.UR(DL!_[R
M>NXU9F,">8= O&3QZ(4,G,JIV'E%F+'[>Z(G4%$(?YM:LRU0(=I=$$O6RP72
MDH.CI9XD8:H?H67_X/%Y3*WRP"H'W1 7K?*U?SAOLOB;HU^(QY4[:"[IA]>K
M'6,H.AY:+B^M 4A:1N,5[&9\DC.Q <W(RHR6X\]:1K.A<2"8>N/WTLEI]U@,
ML*-9GQ=?%)(85OQAT'NLX9U;F]0VTX*"+T8*N+8 RX2+;=;U="^O\SN(>[=[
MMP_G)OH2+FL/2M=9.]M]/YH]+19/9<)G-*Z]5?]V#%.U%'V"GYTO2Z=!$U-S
MI \,XQ["5!O%<$^4[QXK"C-$4_"HDB^HTA6^MN660,)@F2TGJ+M"M_TV\SW1
MO2Y:BBG@'&;/T;@Q1^/SJOS'V%UL54TU,93UJ[#+65%UN*SGJ>]1BBTFK;?7
MC&4'I&TYN9/E)>IFC!K.E#?W$4K7?W&6ME@L!8:<]J(!T%FX93<ZC4,\?5I3
M3[PWODNY>Y2<.1R/U"DV:K68FG#0\J7/E@@<E2;2&E/TTO_7[YPEFIKAXKW/
ME"=]2\X4V24YA<**Z31<7.*_D'('MF\3<F#(F>CK C^J7#CZ8NLDU8C&MB;\
M>8W.BS!4[YIAS&&&+8LM*$EL\@I]:.E*-8L*S@[_H>@V5MG94/H%1MCKKYU>
MIE^\OC;S;#W*Z\\.+V_%V$ )2-Q]8S5NHZ9N5'MS1N2R<<*T?LG-C87VU:$Y
MJ:\S_[2->X=G^1#>L'K+<-5KE-B6K5@<8M>C8)E[:7__^SSW <TEFVI]FX=.
M<0SU\C2&%)N1.(YKDS?2[%NWHOGWV%7ZNRP]4VTFL2EG]UK"&^E"".9"*HW#
MH$V.CHGQ]<N7.*T]JHZOL,>-%*PL6%=2I^8>(;CJIJX@M-[5"I&%&=\# W'F
M'YH_O\>Z^*%XHV(&6&U)PXZ3/^=UW2C/([_&M>/[-K@::_YQ D-IG".M6+=A
M!2U":#45JYL)9#==_3$,8D!_R#R=E<P[,M'- CC+<ZO2"4B<554/@A8\Y2OM
M_6XOVD0#.!R_!HX'H"GVC+OB$93F @*9OX1'URVKM7F?^/ /6F8T^E+@IUVQ
M1D\S@VQ9CXJ#[-V$*KT%EAI[^S.F1(W@R@K=5+],^6<3%_,>HJPL<HO6MT:T
M^Q[=B!(P=L,XS\#[>8TRXA2QC752\EA'@&15:]N86GEJS(5W]+& K*.5LY%8
M\_#LB&%8C5'.O#I7T[FK)P"Y-71&B]S#=8Z)T-MX):\);=#R/XM3CUGKDE![
M?>VYUW?+,B([P<C;8%?H?=O?066K771TAB]?6S1:IEG.SE%/X]">D96L6?O1
M->XX5\@C/ZTY7K*!*Z717YI0)"2<CSZBA]@X,W*9DX\Z!>UJNB6OK[BQUSI4
M%5YCW*OLZ:&^I5BX6$\'1$NWY.,R<F-^4/8'$X0HRU :NGV^BO/GG"(43]>F
MTQ/RB=N30?2!UJTRB^AS/(!?+Y95UFBD8K451BJ%GV'VX<;G^0+I@L)Z9_7@
M720'>Q-OMJ]SDUT;5[[#15:: -^/FK#3\0,%F'7;KP')8M/$Y:70R:0_9_"2
MFP*&A9&?_]-P^@B=_8.<O84K?@\ZG8_!A5V[.P<I9%C;<1W?*Z=P[2%'P_SS
MMN4I#VV=(=#/CR@JH20]*;Y>N6?V=W9@E9QB=0(RZ=+,1J%<UT^[XAD_^9KE
MLL&YV7%O:W0(7Y%BDBO9/;TY'^'0)HK>:6S<8S4ML])Q_-/@R'2/U2K;D'XB
MC81Y<C31<I*V//'H4(IL_81W,O_JIVDB%& 5\EKC@S4(%$==G,=BY8975NW\
M7!TADAS%#XG":WN9[%.'UXS?P],=#3D>0U2NG>&@F:C*&Q>\M ??#J;'O>JV
M?PMDB)".)E]MW93H5$%$5EJO 5G>G.<+O;3<_L3__\G"\/]*E430;^U:F;0%
M:4S^3!NZXD','%+%H'ID,*JH)@3:]6B#M(S\MF)$#1>Y;EI-[>)R?99:",C/
M7T W3E_!XE@ZM:*FNWHYQ,-B,&>^+1F1CR-$?DW$1G5%BE6^YQ?X<D/T$30S
M6*7"%?UJ4/+O9MESG)P-F<\8,BQ-61Y!96F+,@F?,+*RGG@\7OFG"ZV+B%^\
M,YG?[0!#\> -<KP=;&SFW&O2N(,6(G@OAUO4MH:7PF<#LXW7T VRZ=WP2U1+
M>L!-T4W">#*NF#HV;7O^\<R!JW7!Y$-Z)8G_7>WV#$5"@F'Q%^ 'Z4<3B> 1
MY1KV2N()NN874+2\F>5^4=?_+0?2?UT?-.M;]>S@W44(8OR'RQU)_W>V@?\T
M2#>?N\;W%,<W![R_GL(O49(%_EOS?_4)!&HK8S$!9+ >;@+4?SUD0'[XH/$S
M,A+2EMS&SR_-/3K433L;T-YT;EM^CW4FEX09V9L@7#_MX"B9!2R>8AZ,DG>&
MQ929-&\B8E)7638<KGI@'W35T,%+^BW@5KVZ6713SN0K.D([1XFD?IQ(N>7"
MU;:Q=2L>=F$")H45JXP,?[&'LFOD1',+!QU6LI\M&\,F-,/;INLNZDB^06)\
MS:E$Q"-(ZUT3E1)3-.ZQ&H\TAY_BT44'UKU]GIJ')ELX=VG6.C*>]0V?V>GF
M&-3 ,_YFP.GGOH>C:A.8H;@.Y#%NWM4O.A^VU^#FS0?',Z/^NULGF_]IMWMI
M[/J[5Q.:W,YS^L;@"H)L9)U[ABE,T@=<FI>& X5! $^&:U$D30<E=#W-E)\T
MN5]I\J_:9M_V^Z,PV>IP=\^L7V9-$YDE*42FZ)7[I!#%_-6[6)S50? H,K.C
M[?"OMMTH^?/*#?>;$[#&W5#4,'.CN*1BJD?7W=9VFR.3W&VV*&PQD>4;9;)?
M-LOC8RU@8P"BC:,0QMCS^3GGK.4)%?1[NK1[K@AJ:V38<W%\ 8!+^"KPG4(X
MX&&B7T!#:Z6>RHI=@&#NM!;O6[J?\V X^1KK^I#/3A<3"7@4RO%*GFO8;0^R
M!?3+:UZ4^JEEER7FRW@^7'9"\D;$O9_&LZQ)>=WO\LR!C-I%M7>O?<IN*ARF
MV67&]OWKZ\]KX>1]; 4/G!\QQI"_PS(>#)7+! ]FIM=_J7)>NI*^A$J("@+6
MUMEO'T=KJUN@K:5JS<.2AC3B *LWP>/$MV;G%NO%)PH?SLG0N!)RQ^>-@.\)
MWEO]0]UQH3=YN65UC9\2H8$TK8X$U*Y;P^7Y'W ??U[:<PKO.FU7@_PTHE^=
MAP"#-#NU Z-C;D<2\$ZV?N+A2=,PC#",IK0Z  3"27FC"8L]]OG>;F\_(S?Q
MU*2-$Q/YS/&8AMI/PJ]#G0S @'WRC?[!IP<O"8\M2"U(@64C(R/+#<.G_]W[
M_V!U,8_UG)LJ>S%',AD[GOEK]\9#>=#;MICBSVIYH_-9?_?I)R>7^OP?<,EW
MN?=O$\9Y;^B;Q%35-0K!%/&.-,F!!E . ]E^N!NJ9=?'M]6'UM<4?B1KY,7H
MF*84>]38R)+#MY5?=WDM_"D^-^\*-F5=+"42*%IWQ;KC=0Q(GWZGMV5^)?T)
M3;]M.I!  \[8V>%\J=YW<_O4O,^XZA 2I#Z_BW_#[^$#%<+?)W!KNK @WRA5
M4=OQ#DG:PLYV3>W? .J-:G4/;=ZIOB?[]NOFT)IK^ISM VX[<FQOJL6(IX=+
MMZ"1&Y\\+P3J3@1<60TJ/RSB'8[SNO2F4K_QCR[LZ>D(@]]C&?[=?C<I<9HC
MN7O!VE4+YEE<CTNY1SG(3 ?J)CX.>))UR'?&VS<MF-]MKWL>H69^/0S^4^W7
M>ML-=D_RL9T4B]>RLQNN7B]U5KX*>45P$/>62G-N.,1]+W$TK>E6PH5&]=;5
M"=8^M#A<<J/T0[=.;#-!O%/$^-#J6)8*+WF0A5^0BUY*9)N\#-EN*7/\A"[E
MD5S!%N6Y8R-+:O..&/A!QM3953;E\SZQ68F1B#_A/(;?>%/[3\T(Z>C>K/SY
M5Q?=WFCIDI-^OEL^>)+B)BUO,"1"-\;CCGS^R7"919O!@G+Z[LFXKL,/#9/0
M2&4^2U @Y -.CCCC^<8ZL%V5!;W>3^38$ND92/M0XD/$S,]<8])^YBH@PPU)
MEEF;<75VT==L[@VBZV*,NK"P3(T^06"N-@6():OXBI2A66M$?1_I,OXT&S"B
MNG;+M,_$C=.%!W&(,Y2&IS>Q="Q(Q-?\073/50IT2\EB>ZLO8;.I<N*?NZ(Y
M)90U(?)GVZ-ZNT_ZNJV-W@(>WK$5=-?%^VY^1;*4AP^KT,;-UD?&_X13Y*WL
M9<-<@"'#Y/UF7:(NZ_%-F'IUYI&W1D]*4IC%4QZG_.^#+VG;:(?4N? >RORG
M=ZJOKES-"3"^??1:5/^0EOG!U\C_D&Z1?JO^=O2B-/JJ[4)R9D@LY;^8%TGS
MWY,:0<<#R'KPBZ[YBSHI>(<R!O[=P8J7ZQ2WN24 "B(K;T!=UD&SY<K04XU/
MB?S^:K,27UUL+7*+,ZXJ%ZM9>0UJF1+ (N :W$B\C3-&='3(4@"-^4>KA3>&
M67'$&&Z<$CN6GHUYBL&NO"CK?A-:VW[CUX L[A:UA5$'WOZ,G>#VQ#:=G1??
M9P4:U9^/V=_$FNS3;/RISNZA@(PK._N\S!*^F9 9I_%T^D+7^%2-N#D;SK7U
MTQD_HV<'R>]48^F&^>J=<T&Q,]HM^(W,TI:UUC<%J8M^MW_[*M@CL6_%^K'#
M_V\6HK5J!_K)_D%#?HZ684K<2LBHZ.@)X@+TCDF]=RB]A][/V-*[P*&?.13H
MGWBJ\40\<E.4?+#8W%R2,E_-!S<9OF'.&_3^L5W-:Z2)!W?@C6^6Z+DU*XXJ
MV6?V>_UIC>:]&586XO=/#S\TR4*RD?-2(5A[UR3?K.E64[,83X*\2E"8.[\P
MJJC'PNC!\1$30]),(6D:XF08S4;41T==)V)/0$;Y=F1FBWA=-DC[6U%R;*8S
MEXH7V>BSU]-;-,7L^D]EM*:]T[_M=JFW3D*8:Q*#+!OFE R;S;.^PAMG6DK
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M&C?> CD$4<M/X&!G9I,Y9?9+ ;E1>9(AU^@PO\&FRJ].QV-:9GM%GGD M?B
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M7=R;RI8*4J.GK%)H=-&(8@T58%MV<D!!C(=FLAW1X1.!,+M8EQCM\$2=BGG
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M58F.84D9QMKP5,8M;>';8IVZ_9EHWC2P[-2*87N;VYLUE\<?3'-NE;4=:3J
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M#@=)6Y)6BW:IT.N&AA6MH-WU3(R78MOE6DB4TQ/ZK9;Q9::3U,7:*DM>J,'
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MKYDV&Y]%D41;)2A_9JKU"3X'[)O_=KC] ]??;@S-%CHKX( O!,J\0R=3 @T
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M?1B68]I6Y.L,<;'GPG-.+96TNE/U"[7I7,7?+)/7#7#Y9V"X1Z,K:"@Q,_!
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M"*7]J6Q_/M\Y-M%6X)!+IY $H=2^=GW1]?"M>_@ 8 U1F"^D!^QD17K]>0#
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MYA33=H\X$_(+B:R2B18G@!C\D\@NU7"1C[Y:Y%"(GWW>52X6=5(WF)S77_M
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MV#BWF,N%"I<:]#<-_?K7]CM@[)Z?AWY+$V^V;Z<8WNHQG2H18<[X)6&$/P"
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MP,KB%&)/PRP5>1[:Q_ ^S)3'PUN,FU1T<3FZV%C,X-$TAMQONQ:W-EC"T2D
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M\:8$05Q8#:"1=_VWYLB*-FIE-.5EGGENG:!#M$]9M28_B[R$^P]K^AA'"_"
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M_\X/B9PN@-*\[K9NK=&RZ-$>QCSI_Y=8L@IIC2K!&U:=)S@(1I+PR!I<.%#
MX?\UY1)_N0__K7*)ROB_JM+_VG8,;[Z81OJ5Y1;+#EVI(I%E-?HLY+'/OU=;
M^)2>A-)1EG]#]ZY&^7(N?0?M4L]H[)L$^+<NDV>K9I4'RI53?+"H$E%+/'Q+
M,E-OT&-'>KD=HLB8S&7#C,,B"&;B +G2/:G$)TV]3KK";H3Y9E59,Z?W?9XB
M25MU@6<61-0=Z P75?6;I42:&14@1FPMFE5:!PYF:X>I_KT' A-4,0 <9L _
M.C@Q1E%YR5P8J5^4-[%L8OX2M7F&9?W4G@D*!5FF,_+S+5DM4]#OKJ)4]C+
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M&3FM!Y0IDX%,Z-*/MOB4V-=HWF</WPLN5^M[XR54GKGA:SBX<3-58N)Z9>0
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M.BZ_S$+U5*E&W><9(2^W.;'O04ML(_=N]ZTJM7X:YQ+<I*&_:9=07+$,BHF
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M2M8E&[HF&VI&)X$5"X1@W6+HEB!W<@5 ;.R[S!ME[)%@^$"/B%)=QJAA$#-
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MF#BS6+"T-+AM?08$ #$Y/H@WVKW== 92>#+L!;>I#@J#!]D1 HE#_B<-&(_
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MDR,K%@C3*4RW\I5-28T>",1ZSPH"/8$"S>[\H_P?-J\<O]93*,B/8U9,=V_
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M=#]P2QXN!$_I;N(P>ST">#$3M?2<-D!.D3[TF?9?>HO^31 Y,^:G"'0P#Z\
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M=?;SUOVLAKI1M3/\RX"1:7AYL^6YZ1+E2]M7.Z+4I;T:J79BZ?W;<*DO)CS
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MXYNY(7S_-,X'=H!1@#9@*+^66\O 6[E>W=*AGW5M:=E[8*)Q?<Y4O+=_F-'
M='O.@%)OIBIWR5&/8_(LC^I:*-4I49\/ZL,)*.*._P;I&$</3]A[;](BP\?V
M8?^3BY0;MZ@]&55ZQ'[7OO!TVH))<.F,ZKJSS+3(Y:IM1_&.OC:%B&!70;%6
MZ%(B/UB"Z)-^2!<MB-NE@C AO!XVIQ0[ON"2[Z C(;UJM?)V@Z1!(QN2R]A)
MSP%WFDV5%"$%:#%[V"W5<TSOC<CRA>7%AV;"[#>#EEY=*NE5N5.\[X*&7E%I
M.F#:Z.3G1<ZO5[6@,OU>;P-BNR96PT+S#@P5'(X+WM@;!B<+>M=UD<N"C^K
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MR#1(C\@)D;23.'WQ*-  P)H_U?HB-]KN(PX!6>VM^ZF/3\LJ-C330K[LZ/8
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M@IJ3ESV@J=]4WXW^>8-P#MU\D/Y)_?M?$XE% \M<<U6G&MMR1:P:AX<ZYXU
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M-X>A1X3A-(N(L%KL22VFU.NTE"+?<B#KKK:%U\FX:S&G$ZIX;_2)C%[I+/W
MW.O3H!X67'4\$E/NP@KPA1 <(93KK%M-\;>JP>9QD#P[;(%[GK(\;WY]))8;
M[TVE['*X*/G -Y".]!E_TK&F^N>JVNLXF\'$!S3LU^>&'@GO8+]9I6\I722/
MCYUV^'TE]AN\LSZUVUFTFSV7GDL][ J!MP K)LC)]>A$^]<1[7EV0SZJ,7*'
M,IAM%D]>0M9&=UE<\]YM"QUWD"GQ[ +&J*+J#2W-XS::E69K QX9/U?[AEW=
M9#\;UBFAU4C)P R0HRGXR5'Z,ER2^:GW9Q/CGHU+"7K1B*^$O-ZEB,TS0<0#
M&LEUN&^[TL19*><AE.75YG1+JPB33+\"6*[<G;_ME".HT="]]P.-,K3(,D6O
M*3%+OZ7"2I:!7)#O)$ U5F7\4^*PW53Y^<5OGTFJ%)[+ZT9;YK2*K#Y=B)"-
M68DU:E\^KPJ1*(BL2'Z=-S7*S/TT.@N/L^\9EU>?2),S7N"0\8$57()9 CTU
MUQ[7P<PQA$JQ]@684E3.KG]O5]T\P#W !  -7^@5XV[&5;0=N=@'3!E>*KS;
M2<\D#FU"(0+ .K_6*4H*T^B"H&L(VQA>$;YH-, O%I82G:^184@<>Y%Y^YNL
M^IF:?*15]413=<R7?J-:3'+(/=[93OL8)EQ.NF(EM_D+2H,ZC,?EZ;H58Y6&
M1'HQTY[LRD&HPVJ9SA+IVG-/%$H^T_=YJG).1E31H'OT<"++V'9[%IWY>&EO
MU!?Y)2\6[*8D>@E#2A<.<985.R"$*J,)_X6):9FL0KU">A6@O[_#U_O0V)<K
MP3Q"A%I@K8\:GLV^EW<S$>0:N9AED2%Z>^FXOG)R;+DGJ2<@>B5Z9N$KKB+@
MQU6QT4!\/SH[MIE#Y].Z+#,5<78?3'9U_( FD=5XJ4UXN$CRDWQ7A?*P?S&H
M,GF 7&":S@W,<NPGKGUE ?35=DBK:VM:8T[9^[8VG6&VE?3*YK MK&FO1&PJ
MP47C_=[K_>"<*&^$X(#C" G ;.*S[KY#B<S1<K1#_@XTU$7:_/-Z.L^4FS9V
MSQZKLM"7.2;&Z?'(Q.W]U%/N+/9J@N['JF;F;B#]Y!4\JM9;1QZ<DSY8WYY]
MOJY5<U#.M*<I1G&52!&1Z<EEL;;\$2P_/2]DV@@CL:6<7(.&I&:4R8-BH!O!
M3/?"!!BY&!7C1^_[9#G KU"T'K!<NE@B=\$% G?>J(MG)<JRG4+\&)2YZ=>#
M(3J20QWK]S,?Y^O=T6^[/^APKP;F>H:AHO?>]XJJ=#:=-=5!.?8,/TR_T3LN
M^)8_Q68E7,Z9,*97W-N5GWAT4@FP7F;39HK/,5O/QBBF[O+VBNMQV4G6DW6:
MY.4N+9\'Q-OTIN;/SS#I-7S_^4(U@9S(,5ZO=2O_FC/'LI7BIN(![4*C?:D[
MZ\ <-7X*>K[8:N-R24V1,W4*%7(:S=(,2P(B((((I$:BM''[_=LCE@<T2Z9+
MD]4'M+O GP0K8FRNO7<7^G\>\FS2Q(="B9%Q- ;.J6HD=!X,P<'_D-%DV*\\
MU,AML>OKX;X\M^[IX9M_X$.S=8@R$)T]UM;OFC3PCA>B>A^1HW^;DBY=^<H/
MWU+Z<G-DM7_DH#MRD5?E$1>>;(2>K,F\3IVBVUF1NM1MGI++@$2J5>9@@ZQ2
M(-Q$\WXB?6:C@(WEZJ=(W4&3%W0DF3:.IO;:=W),,-Z5-[.QT!8GXGA1(:W6
M/2OIFMG7LX$$H)UBX9HT=AE)I9KSK0=1>>I_'9P)B-+S464!@F1:/V:'904#
MD8&93]+6]:)(T@IW/5+ WBTMZ4G+WA%[C0]H\_(RH$CY8EUU=9>*;_:1$ONY
M[N9(0E/\=_\?(93#<^,?;W0"\-5'5JL\4A=%W@K)$X-EQ R45_A-$KYF71MM
M,[M:_&6:%>+9U\QNQ@N2-I7\E&\.:UPM6Z_L7C\8U21;2 C)U&Z7ZJJ/@T*;
MQ3U^#EI=;X!8;I-XV2GNGIQ//: YJHH*Z0#Y'M!@B#&W:YULB[NM:MJ3C(&;
M]Y:+)69\O4P9<[.L%MS0I_6 .XXK6Q)E63 _Z.-B:^)*(W(Y4&__S4+.([+:
MX*87;J L:GTA45NXTJB><<&*DQN>;.)W\K#9!E<+K+0ONF(&+#:'NIQJ3'O7
M^R02PR,OP"? %R/8XWE3*Q/W@_&DZSFL>5<$(*K.&R/CG@R54N:XT;C(M]V2
MMR=]U9Z>3A:KM\L]OH;#33ZP[?']YW-H@!(!OK)[/:K.7A5T B^)#\,[PB:Y
MD<Q+RJ,,<0)4CYD&1.=_7F6%7=_6+W_IU[VO2,*Z03R>6:?K$/[B9:Q^U=B^
MF\9NM\#0W&QZ'H+]K=\J2L32Q055V!?9;S!DQIFA4VLLQ,.ODQ5-3.0$T2JN
M&O@L$RR'8$T5$C:SQ2+5/EK2;ES&V_\RNY7O5)!7-56%3D348NSKR'XE],%C
M-2^NKT!'D^;GJT_0PW>HRL?X.P!,+V/WDJ0>;[=BP[@45W-/>4A(B$A90CFQ
MD;9-?R1EFFID+0745EZ$A9SS>M]/5!Q.*670W)?:W!M$]RW7<<O=ODSF#7("
M'O':]Z )GOJM,?;S#M(PB>1N*7.KG:/-IVD1VGY\;SB05,?4>7:LN5JBX\6;
M)OO</3=5&Z=?4O#;T, #FI8V_-XP1N/V&6?;3N'/Q@67:<G4HG* AJY=[*?R
M!FF7^$TAUD[VTC0Y%U;B5)?VC]^<.S6T[6+*B7N$Y&$L@(^2W+J-\I^MN>5
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M:EBI<P.Z/M>?W-LCRS+-$65Z*NNN53F!2R3)Z"YA]>KG %$WI],:HWJ?DNO
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M/J-K!8])+5O*'O4R(CGSRF,V33/T?G8XS7+A$&VL^^L[S9O(Z9R*VE6??Q*
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M-#2T=+% BZKEC1WHL\L08'9TJFCUJ:6;+8Q7[@\X)+K]$"@HV)$N3S-.O6"
MK'<TW\CBV[T7,JE BA:LP>.?E6-Z7EU3R08?%_WUI2G\N"*UG=GFY2A^5M?[
M:;JV:?_CK1&]Z@82# Z -_[N.#4@:U*[G_=%@&P;5?N;4SKO<$HLS5VGYBWS
M>ZW\9'>A8%-"^=BA%VK@M'5;%&@]1X@>=/)ZR"6V+BN52WB&6W@[QYA>_D'
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MAH6(J^"@&/,M25B9BC/;KR.40[379N0LF]&%;P)"?^/B85;WYPVZ:AHMFCR
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M0ZN]#$4C,3HZ.KQ_T/UW?.\6A?K+J6W-UH2UY2.ZKW/6-Q:Y:)6_2&XZ?MP
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M30QOA9X0.EAGW,IY>U(1/??;0/JG;]>\-?M^[(H@/],9ZD(<+\ON,*B\I<G
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M59![+H W[*=_#G!_#PV_2O;039PD1GCMIF]8]P-?JW+1X#92C=KON%[?"TT
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MGOL; _)7N%H4U]XA(J9F?XZ=]T96UW9R^DV"OOK..%X;@W=N=@M_R/ER.A[
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M7'VX:VD[)/R$4^J:2FY8^N'L8J1.WV(*/:X),+P](X+= UH.]1186EB>\%2
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M=PAV[#3*B'"Q<ZO4ON\9R<%<\:@4&,6U1.+19VA-_XI"-T#<C/CY>XN=?@-
MM[3LT2EXYJ;:0P)<J:4/4*!WXBB3 G P()Q:KGDC13]F$:W4>5O_@$(_.5D+
MDS7.X9TGT/$Z\9H169H2@>B8(0N8C@M+2P<O41&XD,,4I5[;2I"Y]6B!X?7H
MSZ[I^=("L:B+<0WSC$)Z&L9]=IF!U?@/Z:2EB/RC\8R."<&^IL>Z>A<OMM+'
M^>;OA87@^U\2\#J# 1>^PKX^L6>)0\ ;T GKQI;0E9/Y/K+8K((4V]-P;5&[
M8?AE+MCOR9@N?3DE^=/15M/V_A;GOI+$)L-Q2N[2*8]B:ZO*675PQ;FQ7+T.
MGCVOX-HW]K>XB\5]':,J9TZG+Z3HA76Z+ZQ,9W<7=UJ:S\=/SS263@+?;+*6
M>WS!?^C0!J*W"IKX)D"_/,/C_]XR+/(="\OC.S4::\_.#[[;X&K#A*U/NYU[
M -%&2LC=^/W5PD1+!-1#]/JQALZ^HM$('*G:M.$851_O[+T%GM-FH13<F$("
M :?O&B9\7M-U&+/ \DH=#U"XPV/\OW%6"",:=K3%90IG<6F#0!PA%F:$EI\"
M#"^G0!#:)D4;?L!;19VQ/OM;!97/'H<\9-JJJ3G-J&?Z%$2#'T7J0G*ZES8T
M0R7246 #A):^B\!O'-UU6]5W1M94J_"TC)PP[JB$%R->*M2:SF^&S78[5P?N
M\8NZM(('6NBX&MC.IR.VH[^(>J4E3R=>[NS^QNENV&(H/G_7YMDNMIE?D*R#
MC-2""VD"?(?#20[LL"?.AZD96Q!+N-*!0XCKMPOAL6F[3Z=Q?":B+Z9SIQOU
M%Z8S5U>,GZVV1N#63#Y5BXIBSST2ZML5T7)XMLM\XG62AJU=6"EE_,J$SI 7
M@GD7]:;P3=AGE6PJLWCS7;Z33!ZI?;Z4N_N(Q9;Z590&,5I8(X&W_(X0\IM1
MF^+]KWU\TF:]KU0QSZYVL,-1#PPMPMK!#U]3/=1=<4B^>3.$Y) 57->&4[\.
M'UA=D*!+ER-\6&Y@V/_=E_'48?3G:CH<IN(J4J6),C/WSDS-86,^W6.QU[^4
M3G%W0$>P ZV6\TT'<P]5^TO]#$\5NFZI8J\5?=@J+A7T8)GB>1TGY(/F8\(T
M499YH0>+;+5^RF,7^4E^[]J:>EMAV*"]!(RXY;Q6-VCU5[)NW8,-6XHV6N4<
MEHW]-E'"_J"S@Q:=6OW"_"29W@0KDN,0J,C3=W53Y ]"JHQ9]"F_SZ/N5]H]
M2&*L_7E42\?:^C[UAZ^-R<&1^V=S)JJ%7@1!&LMIU"\W:LG@B@.^LHJ?7;U-
M!&2A*])G==T6(UP*>BJ"+IU$X=Y(+M"P_JZ9M^]$N;/[.Q$AY(3?<$ES)LW'
MT3E@7^X$.>F>3-T& ANKZE8]&R!L9_1T&XN(Y;W OK6B8P$M;*L,'(IZUZ/Q
M@*)7-<G)M2N8'+\Z2U9=B8D7@H1X)W*YE1+(47)I=P@N^$-A\)?![G/'J%?$
M2'&NV8IG@^VI9 \77HV-Z'#9400(73I/-0C6IC;3V/)YEUS#GG?.FN_\XAA0
M;5N+RN+.M;/Q.<'Z="( 32V>^#RFTKL+@,T;^7 4_MMNU[CXC?6$+R'2H13*
M+3T\96V<4_NHUO5]N2"RC8D<*G2>,2R_VW[/QK.4R;FX:MA85DLC$,!2F16%
M>[.:GCAOB7M#N-BI-O6Q20 ]4B(3YL&51INH[KAQ6>:;@QTBU!J>^9_'1/[;
M$J;^P%7Q\Y,JE?#1+,JR/SR3XY'BH=@DRA[\W/*RF$Q!?6GKL"@HL["1V(;@
MPPYCK>=0[?00)D5XSR2YKWSX_GE1JH_J,:_<T_,*HH/5WSB/_($7*#&"'=[6
MP[$:%H/,YRY(6AK "2,RX5R@C7G &)Y)+L,T=F175R%R8*SHX?G,VQ29QH]F
MHW3SFQV)0&"@]F.49+V%<Q9SIL5QN\=(C8LR1.(.T.7*R)BMN:%^4+.P<!^C
M>.MJ:Y,*4CA#+(J.E"9_'6LR.3=;Q4G$^&5>DOOQ)_^P7%._^(TS)G_[P^G6
MC3K>[( "/;LV*N:CS<U]A/J-D^;35#.6V09K-TCV*90\=B#D1[XVJ:XUKS7"
M"J=F-1F5$&)=V09Q%!VR!T^\TY!__,#O7#E+DQ,MIJ:*&U#63Z%(4@Y[+D_R
M%4WU67GYS:=M*>7E/P+:IC#D0C%^-4<_J>>^K'._V.']#VW/@3'='!5" 4Z?
M$3$ V&.$*&J_@/<[ZH"_$<_^=5!4R\83 7Y9X@?&!+ QW2V$?A[PEVF^2@>'
MN&PIQXB\E$B>&)*/IX.T.H4G1QQRS_UX-O(7/*=.(ZYN2V?5.6YFI@V?3)$Z
M[SN4A7E_/RX=WX/$^Q@M'F*G]]PW* V#3;]>;QQ(:909T=4:"HS LWP\-=6X
M90*HZ>S9*#$H "HFL]L7R+^>\<$C+#V?SC;12K7@"$O5<$//A)L/@_E2$W:*
M3\_H7L_EV](,4>^C.+\K>/(?:=@:;',Y-3*\EP90+,9Y@.')R>;^>#HZF* W
M>-5<]R1U1J(_TCE,^(#V;8D2$B(*(Z?[I-/>C&B$ U]$?O#5C^TQ"AO-/[F'
MY)2C(#/EW8R\<FF3$;=C%@E!ZH>A? ,\=6MNC1GXED6,&HT_&$41YCAZB.VJ
MJ!-&1I+3VK(XIM9N7/0+Y4;KGD,WF0E!IE!? #:OD7I?+OCX9V$%^Z5%M,%P
MDWBGIAQX1ZW2:8D4ZQ%3H7;CI_YTW-MF_$18Q/4R1YKYPO1G>!9+DT/1EEW&
MD;#&S4=OK)P^YT\^(E"5BAE=2H_2[N$RD+S(G!-&*"R$7VT>W<J5![4R6P_Q
M.,7QZ1V-'1<(N>"!1?48  5I];L5(6UG;+L#)5;@+=%1@3-*H!Q+H<[^4<KG
M3$E!4_10)8F-XJ_%&[(*H]?2*L )7 ;6."S$:S<6DW;WER[LKAX:2'#_PL=\
MWV*N ^Q3PVMT7\@&R_4;1W3_8(^U[ L)FMT]<I&;\MQ/,0H693EB7^PLF_JX
M\R,:_$WT9L;MP:V-5M5E<&?4_'A30;?A3WT.F]6+[%U8^.S-;;Z#B]^&6,-O
M')V"\<Y3"RSG+Z$Y::OKA'>T#/L8.(Y0/0ZR\L8/SXCM)#?<P+ATC+&<FUZM
M\X&@D@40=6^& :^2'*FOH^AI;+[2;+4H4IE\LX)_,3TF=?+95T2I8.F@PC4&
M7[U3BJ^0ZMUCV7M4G^@H\![CX.$\#G.DI^=H;>U?[NOKZ]\%DV\6-I%XO=G2
MG?G5?GC<8^S LN4L[$M WU6<<AS/K\%TP&($V%>5'1FUL'#@&\/.Q-G,+19$
M^;5V3V8THV^BMDN1<(</-E9I+"'-803R4U_OEL,R>G-Z9O4V,#WZ? [TH@(K
M]&  %I.<Z+=?GQE0<<355:$U9Y^H+UB_7>U<T2T9GB>P/+?8#0[WW/Q:\E.J
M1B[;Q,#LL8PWB6FL<>SCD'KT-B%YL*_8S9SAG14RAKU@\$[6=*[0B1&J>:3Q
MSOBD30*:/4U@X5*H;7$*NP^@Q>#F?GVQ;2S'$T9<*;5GG'TO+*PSOWKJV2G(
M^$<8L*#8FSB*EF7Q0_LPI2YEQ.#=_7X7HFM)#84;<::Z_=\XP9[C^3W[Q]O?
M)K@F=$EE*#VKW ;J5I"M?'&-N C]L?,FI6;5#=VX"=:S8L7T_EL: ^'<1LK*
MQ([,3K&?>7L!._J?IV^"9RXS7@OUI)2*9A]ZVCX*L_TE8*3HF=#4/&C:P"M8
MP:12?%%ZOX-2E@ 'UE2;7G.%GA5LTO\Z\LY+UV D"7,=!L@*.-XVI%91(H@N
M9%\-\;XD*&09X;!KX4DZZN.$%",W#]71<6N@G6 X4TRZKH+70VF5Y^Y'[^48
M8Q4L0-8T[YR=UUF@SE"-N4=7(N8:OA)&><E*WF$%M8M+$^S>@UQ.&8D6XQY.
MH; HCCCV\M>7[R.TPR<]:IU&CB\M[78TU.N</VBV\L3E\3\^0@[9D[]Z-^ND
M["9! !VP.X ?(2"+EJ91SJ_C[OW:YNIWX33ZYK@[T-=/';M2<T2CGP!=J2[@
M5*6.LAD4.+)_K"V(ZY=2C843 V1OJ?3:GG(LC=+XSMQY*725;>K>BQ'4-QD'
M3H'Q-NH^7KHHDITW10[5<?KJ#^C[FL>T<6]N&U>17U2>W683$FHQ@/Y=*EB(
MGD-A"B><]+Q<R\M\K=K@UEB%^5GG):[^19,2.-!K??E9!U#0TB6*"0]0IAEN
MU!96!,VR.:A;DM_D9$AX*.;[H]VP8^ :&,<-(GILW]8K^C1%2XS=S0*T&=I.
MJ"#V'/B=?S9S=3H>>4'-\M/%TY*;L@/6O+QK6A(6YB\VNLJ:_H$<NBC<$>2>
M$6L9^@9";VGI2_3W(3X[WNYO)!>8,]J(L%4L"GL0&^GU 3TH< #[,MJKL9!6
MUV!);=HGQ;5SU'K7DHB0N>DV<30.(=0',:84TD-;6(UV?T!0'E&':A>B;8KF
M?^.P*M__\;*IA['7P!1)[BQHK34FZN'PSCBCD/L[*/1%ID7W'\&DA5C-2%1A
M,-T/$'O2Q7VJE'K>(;-UV^=A7_B[_MM+M1(08TZC0$7M$@7238U2_D*-KNO[
M_%N=ZOVOFKIX.^^;_\91B[^/,G+821N8L=<H6@5Z7HB%QY@L2')_;!ZZ[@XN
M:EMNW5%@72MK[1LV2._;Y5"'\:==K:/DK]'V7ZP5!+RIQN<5F1GU@$XI' \<
M'AH<]P]OWU(G9?L3LTC(D,FJ.4@*Y%7\JSAT[#J6-F94V!OTB,!PQ\)%<'.)
M]V3ZMAK;_?6Q3D;P>D3X9$[,3=(B<70-(?2-3D8-%&%69B,^VC6QU.XR?&F>
M;;G2+"8*V!KRV#^(:\R/#)5=@Y5&1V$V3HM"ZJ"(T_ZETRM9ZW[*\/G"3TYN
M/^.VGU+.5.)T0*Z_SFYP3;\J@HLV*78/#S97[/XSB8K_NTGV /K=^^VNY:20
MWY.E<<^B?Y1J_L[:]:\SC#QSBFK/B4+ZO+T:>98K_\[A+X?_KF.*^&D$M-$$
M$F9LHR80V6_P(%1G$;)VJ]E/Y6Z@S;GG9!<DA<J@,:,$'/9Q[4@)@ 'P1+^2
MO=ZF">B%X<T?"1=[H1[T&!S5<GE/T5IH>=%0\6?H]0$"1:C6K'U@G'#VG'^K
M,@V]S!O>L-B3_^<(V<7.'FR?3[38&D+%C"5ZS-DV"HB:NE7)G\_6#UT7#4^C
M#"P@AX*%E**HCA4==6;0W\2Z4;<(]CDH=(=XW2?IE] KAOT2"0 "0 8!20:X
M/?AVE- \-VMT/_E1(64B_.W]M\LO6YM!*?]'"+Y_:X;/GG'^N"B<O-%X_>$<
MZ5JH/19O& Q[7/YP)9[.S[UL8:6)SG%P=(C'P\UYV+SQ8<%(%8*B/H%^'K^*
M+X[+K%C6M)U("V6D,/(%#\6+*_,*EZ!GL/6>@3.7=<TE36?RJ#!6V$[);MX%
MP"'6S^#:M199RZ^2Y1 =D6D&N1!)Q/L3[6\0C3C307C)V*H,,J1%4/X\)#$E
M/V+N6+ET^8CMGLM@3ZAP6Z)U?&=$1\L, J1J"NW28B7]H2QJUO(Y)OX:&UFU
M.H]K3+L_<72PRU%<A<H[33@HJ1[*R5]?QY?_^L_2BX]Z>P+G5S-SB'B_.XN:
M&YK_"-#&/7SR]QGZ-^Q=UDUU=BS[<<=.QNF-X37-YO*#V7^.G,K(_06"[5D3
M/S9^+@+;'HB]-D>SF?UI@I(1+/4!;F83BC;(@4WQ'P':+ER6_Z) I;G7@BA*
MGYH)BQTBD;;2B=47V2+4(3CB3%:2/^%__R7D194_P[GCHS8K#C$/0L##CJ52
MT,JF4=:#G\S%((HB[7*2:)VO5ITZED$?6%>"=/I3&2/?=WUNQK2WI\JGI6'N
M%&^0%)_]@/JJ5J9\.7F65LP(]_II+_J!V8_P>%=%2]B\!>,+Z"Q*XU,,3H)_
M+6%2>/=JLS*!/N;/I&U9OF,R<.:]8<A[P_: 9$Q[ +P_Q# 9,QUL"=;%N$L_
MJ!/-1;7YI3"SB=\KXBJW3662\B3/$[#FEZ4I0PYBNV^]DM#HYF4<#W;^ &?\
MF:JF9S9DM>+417R>?NQ1 R;@P<A>T^(V+UK/\F-5K='[?Z0YMW^8B#6)F,2Y
M4X[JZQMS;BC-7LF,4,/&,)U=3X.X26!D@Z%V4-C/A^RR5')Q/Z@"0#JI\(!8
MK8OE02VUE/ 1JJIK^3>#_QQ=_W_3E#[["_O6H.DO>LE_WFU_%42.EXO_*SN7
M%??)7WI^ !*]X541OJEI:CM.9Q!7_H8]WXQ<P4UU7XK4S;;TDW#W@_84PFD2
MO6KQ$C*= 5ND1)%O6 #TO,_*8OG(3>\1183@NSN]7#9,B\^[NJG,E\\ZO1)K
MVQX:$]SO5$;#5GE&C*(*>PN#SA^J)*X%.4.68&"VL/A1]24^95:7A<E""KC@
M\9"\(,$)->8;_"3CZFRZ!3\)TW;I>V5O/%P0>\X?[Z)_JQZVM=Y3M5@B(#70
MKS.L5F=+TS.]4?>A,-EUNBX\]B(VHDI\\^;[L4/@G<VN$Y $&:&-" J@S<2
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MXAC\007TP[CX;QQA!4J%,-KMUM?<4Y.![C#,F5(/N(^=)=C!-?U4NRE3?58
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M?(8\?9]A*=93;<.,/)ZZF;O''2#D8HF;1OMCI7\*,Q1?)O[GLZDFTX%K5;+
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M*LUWE)RF7'#,J2MO2GO ,.L??(+/36[:_L9O6\W%_?UW+*[)LA[-P68FSSJ
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MZEG7MF;!==CBFR3Y&+&CA<AYQMJ?6J(6Y_EDES6-]%"LY6Y#1"\\,*M2N"K
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M,I7*N\T'#$=DOOH^5P;?QG+[/IT8!@F8D]:33@([2_#B]'%6D-),;H^&CR_
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M\HNP7?>,Z-B&!G:0[\>+,/V%(=%I3FD !1A'4\_U"\.RI=.^*"^%Q8A.0E_
M4OGK^J8U%W83P=3'CK-A,AF(VN92;[XVUO>K31I9'2QB E_KI^QG\/^FR3E,
M6=D"\G);E';F*EU'Q8DIR*D;:JE(DBSI+(>1TYSHT:8F,I[5LM2JE?&)#,',
MHGR\M,/I8=;MC\DJ>L:9=5/SCSFZ)ZB;HCA@9&;_6V 8XUSYF(_1LUDLL4WW
MGZ^9]Y?7D:I(T+605:,^VGWI,"<MP\T;MB7?C<4EFA/19(__<DF KYJH!XB,
MA;\0TFIB-NRR6XIF$'QU5U-QEIO_]7JXF=.G>'<A?"&.*&O4\&BK)B4L)NT0
M:%/W=:"+R6"W28N5S']S>BMI;>=1'0["2,9N7:#F(/A<\;WS5/7@YI"F[O;Z
MVV8S2F%B.RY]0?LWUO:4?'X3KDCW.B,M=([RS\Z IW@^071KQ>5;1SUM(W=6
MI3(\@=" 6X.FES7&9QXUQ3X700-\*8L3:;Y'=%]"$IP.JJG6K#U=:<! 6^:S
M-(%#D.$O'[1'N-FVE%%@"D((*'YG]MW6]> !8^WX 2,S^%) 3S1$=.WIQK9_
M:.:5*89--W<NT_ (0JSASG;M[KESA0%H,2:4__R>*A3U+OW0A^,:.:)ZV67,
MO5*70B!+:9%?-.U_7;ETY[C>#SY3[K7+(TY5S5 S;5<"^OFDTO6%S:4?]IFG
ML[ >NY,;[%(B>()QOQQ<F:>;)!"T\.'6R5JZ_M6>(L=GL(RVPRS[M?'Z\T8R
M+CW FDBLSW+X)U,P1T?MQ';R=DZ(A(0D[?[-/97WKC_T5$>TYDK0./2)()2K
M)HT+<>"U;VNVY%.RZ$RU$I\[[VRH1]%BMSW;CP"5CHE[P;=;?: $$1R#W82Q
M& U>L<^@.**":U"JP$,7GFT.0-*4[M?-X5[!7JPW+O-">)XD%G7?A@?W]PZ)
MI'2NJ'"\.#R[SC$7YCOS2BOX!=1HT?:QRXKZ;(4"3W!L>UR.1O!R?-2.0!6+
M%6]S S.F8AR;*A]U,W'29\3S[ZC3530.)I!5CF:!-#.N0-T!@6RQ+OE;LZK>
MKX!A4%GZE$]"&2G@[,V+S7GV2A6W-%$]]?EA,H4W439=]GNO-1'>:%W^J2'E
M7N72[;CD#D<@?S$Y,PC-5$SI:EV6ZK,@[%DV+KR']&M5O"2CF@M5HI*?MBN<
MO";_\+'(!Y#>^](I).!;RI7(6U7!-TL1XL?[O_L9&P)Y4@[?2)]W=_!9"+A&
M4NS!>K2:6'$GFG"%3B=+4M!1BF+:$3J)T)0T0R<Y$Y''D;1C11O=&?Z%_KAA
MF/$FUS!8ISEW^0-&Y?[? @:J*R<H8^J3G@B'>#Y@P%(-HQXP]N'P6O';XCVI
M/L;CS>N-A@V"(1$=@-F+O-NZ:K23T*6P.0Z'?1!IG5 (U1'8L-Z!? 5I;76^
MVPS6-H5HM+X6"1FH]@B^TE9K'W$</L5KF 7:I: =MJOD?5HU8\:O0]"!7U[?
M/3/JMZ9G*UO](1*,VY!I4-OEK%$%P@X2_>(#/<!$0KJ3 T43Z%\!:RS68?;M
MH=%/,4EV6Q29!/KRC"\BGF4<ZP\[XA^KO WHL'SY*V(,!%)UZ[YCY^,+["SD
MSF1%W';J)BV'XC8ND#N^B1T8W.FT.4H0U^^*F3KZ[G3N+&+(538S<*5G'.6W
MQ*YU03>Q]H"15*UI'[0+4I3L2%%A+VTK H?D[O"J:'A098H%$TGUGU&A7,O_
M:&Z+Z&/F._*=T-5.X.(!^HQ\&'1J7O6 $9/F&!RZMOSQ]>D#1H+LNO(?EN1.
M"M!:<S+)ZQ!-6V]RF1^=K-!K5)2(%712X9$V:^>I4^8?5[&@UE+@ EC3<Z!V
M$3N3A1)E*Q5Z[>=[ANFB9^63D:J"3M,96<*.R)IG.>,C_!$\,-QW'DK6]'_)
M[8ZXNVSA;PJ?GY6YZ&V\#^]MY\%Y&:@Y3>&D/^J>(46VVY):.U)63+)2%+<H
M_C9HOS6W*]FNJ5IPK5T""P^%ZE>9@<')R7A5YF.)38EW$"9"&G-&Z @CLU/T
M,TV7E06RW;D/[,;23GMU-3XM^P\80?EF!A<IE_(JJK4WV9 J3%NW[AKOJG<2
M0Q-^1PF3:I%:HRV.IGR=M.1DATL\]EFLPX; (HIXGM[QC I%R\"&DC\B,:AF
MRW,MVB^!76\0(L8;=&'*A?!^OMP)TY4'(TS=+RS!KNU%:!$5C9\?/R+C/K"5
M.5/4#&M.:8?4IVP_8'@H,R41D3T[_Z\Y1M;C[OP*F?^6MWYD_YQ#EP,G;]G*
M\7/0NKX[T<21 N;&B\%[6E=$QE!A'ZC>9]!ILP,W7;"C[62R"5?/83;2Z-QQ
M&F@3#O/_M9:%79 4Q11CT%>8S$=.@N7NXQ-"AOR58YI4L#&9K=@.:@WFW*/:
M3#$Y0RQ?L\D82ZHR4CJ-N?LY!\I72-%Z&8Y" UJKSZ93T,F7U1#EX,WF-E\C
M>+U?5Q4W==#NE1]B&PQ*><"8)0^5*I^7&H"^[EA:U/FZF+)0(SB-9I[(<FB<
M$CP1<HN!?B$:,%)\)<0R71')L2O<KSY4)\3L[A*?X_R9G>>70)]\7N:O5_*,
M7HG0/3'_0YD'C-?0O@>,IH-C_25%I'N3N$J#.X>>CI>O67*UZMZD=<A>8LAN
MX:4PF)Q2M*-R"V1I+LJ=P+'\@,&FN#_,/<5KJG.;-Z;./3J3&YW;:OO'OCS9
M.$\]OG"[&$'QLVN-4E5)#/;& Q6:V76 GF;#]K4>@/A..<R>?)XO4:;3^&]!
M; EQ$0R.3;VB9]]J*!6G;"@,VI26/CU@-#Y@T(/[$3?9Z W$4C<7 KY7*(3%
MC7<V$OF H0G=OO* 2EB%'WE7VJ^MZY7JN*:KVGCSS16G:;IZJ)X 01#A 4[8
M<ET+\I1S8'-^IZZZ:7?>^<^3 +?-8AHDW \:P*D*J$9 :/;FL(N^64FX&VL9
M)[]*I_9)JK)]/Y.J9@"+@;V]Y,IL(:'"5V147\B?0=^FFNP?%&$EY<-JP,:^
MU*%R/-9G:6-)V8N_&%=JQQ44AH?G>Z\R<CM*CNC2WY/BXU#I=A00KZ$ KK>A
MQ^8_;"OJ@/P[[6,IIW!JK=1QJMMPHEXFA0<,K0S3NYT/HQ+Y+:$D]BB%VZWJ
M*M0"0GMNQ?1Y,;A74*7G+L!+HJTTP:C3V.TG_$/IJ III^W]0OL#1B=1K%FN
M6N>"QJ'I#=**R5\],+E7*R- DZJ$X;/ZU*.-BN\E< QK&_Q2E'7>[;@0S1/&
MJ 1AZUDN\CQC4*G_GD8(9[8@,SM9I?(U&VN>(IM-TKU.8E\^VCO#6'7Z<Y#
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MF$<D]1%"Z_<4@#X<M2E1?>X1&K)(A-/SL9?:D3BD<5VK.W$F+BQQ)M[/5Q!
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M#AA(M8'+38\&_E+1E_\ZPPCTH_AY-3[1OMH^]LA3!IX;)TO+I1W^(_ZO46X
M@.<??)K92"LTE>?_R_'@X?Y&FL1GTT9GW,#XTHX&T)<Q>\;8^?4>GP+F?=)K
M^],BM*YE1)E98.I<*$J&]A2'H*;(-J;M^&#"J<D DE6O[D]RKS#TI#=[VV4K
MKDU$DC)PQ<K="2WUZFPC),!\(T:=$#,!=U#L;W]H&"]G YB_;F-[%!ZZ.0"L
MT00)7>AE(@R:*-0T2BD%LQ^)_ACM&QA<LP4!HJ "U^-V+4D_ERME(L9^\=N;
MIM1V<>;#WK([C!T@IE*6])1YOJ,[W;<I(,S/?NC%U[8-F9\=2]M4D$3@V\[A
M&+X>?.LH9KLBK#M@+,'LGG0K::=CZ8>5RL*R3>/J+OE/@/(_F3]JI_\4R75/
M5OKO-3_:H?]8Z_X=A?<_-N7_2Z"1"8G-]6&G=WP5ZIF1JI.>K8)7D]5F1GW.
M9A+J!J^_X0DBN_.+C?\%2('E#H,6WWMYH!5Q6AEN9&&\X2KHL%RRO^'2D(DV
M0^Z95/.U:_#QN&R.:GA*M+;$4.K]%8;,GC__T.(+'UD&6=F2DS 0 FX##H'<
M$=T(6"V)C!Y66;%10(A>:.A%X*,/3G)W&&33I1#R-<@)A\37<KSI/CP!V;VB
M_NN6NGL=/EGVB)-'N;'_N8S0/V[?R/G/4/2,BSR[PLM4UG)IHLF.,>@>NI&0
M[ES*!('=2=RW5S+TEDM]ISC.=U<7C#)[]=;B2BI^74NH<C*8!1G3^U6-">I(
M2?2K["%NA>_G6O]E)=J%@V.8+W.5;\[ )KFT OA@Z]%K-H@^">/AU'E=5&;-
M^C7JD),YQ^5&:11VO GCN]&"PW"\H7S4K=7I>H+LQM0171/N^#QGU=\%A)I;
M5!2&P\KJ@A#=0=T@$-D#]I'_WXTA?VPS,??2<\^@+5,371O]V*BVR5-<Q.,\
M_'@MLP\/!'ODE2<VXRHV/#SS77;<XZE]'H7D5W$7?YI!,EH\5.O'HHR-?1C;
M_XBR.@40VL<([#2E)11*H>"YQQ?*!W!N#S1'7#@>'.(>'MR&YNT1UBWLXFGZ
M!61>8FM,?C)8NOZTL1H=)62?)WN]SJS5^;_[1'@%?X"@O_2;YBB:F5W^R7;V
M5(PNM=7TDAM2!':>/&-*WN))+G2YX.Z?>VF4/"V6-D-G.Q.'M'.^PQ"<M5I9
MW/V#<]@G"N& 8K,Z5W /\8&;?UB,-'?-M S(9P@<T./9G;KPBCWY2-:.QVQ'
M]ABK(O:84[)*^< RBZV75N7IOV;FH_?^4Z6A2I-EK:,G&5=B!1+/M#3'_C8D
M8XKF[&V_Q>AJM'^OTF#>X)\+$24\#/QO'BP*8'^ZWP6'?SL?)?RY:=? HJ'Q
M1?Y[<Q>5,<O@V(Z5<X6S5XY]+U/!=I*295. ;DI49IA&J@IZ[[M)P[ECJV"M
MD 3Y)*:!YCJ#Q*>Z)=[OPZ87/';H!X[OLI@?8-F4 SSBY8?UBQ5X $'^0=0Y
M)WO^XX[(]-%3SN0ZJ/?2XE6;">>M4^JI80;"JJDI>!;UO:2[>5A2JX^ !S'K
M-+\X+N-;)'"F5>Q]X,W*Z1 F?_;CX YC"3=UZKTI/[_^F;4%N0WW0C+E)C/%
MRX</AUD4^X?Y%6-Y9-7'ZAB$JFL[M>E)4C\":50[I(4P=Q-2TQ1"TXM;;Z5N
M:%TW)T8W+UG<';65SCXO.V@T+H3-%$W/*_!Z*DH \+B>9I+G2JN-]4Z9T1;)
M8K'\6KE/S^*2U%VKXO+.%],?[;]:I?U,UKROD*RV4(_GBQY!7T2.YMXI2-UA
MKYEE@B<A/L'T49T6]TQ]*<JQ=BNVIER0!2G9FQDE'M5'G7E9S,*I5>.2D<RS
MG0V[LIN0\#I71=[4;].T6K#])8*$1O7:[WA<PN6$\5P0=5FV+.&R2AZNH=';
M-PU4=8J2Q#@KE)BA&8L61XD_:BL]GR0^4W"\E34A*%%YQQV>D+7("/$_NI&;
M)65,Z!3*$[:,Z15:#7FJP!@#_\00Q6W%%].?\N91QF]54 \^K^K_X6"MXFU9
M5E0QO,IPHMF^VWYVX@.+@:;E&HM59(VT$5.1+>F5W),^9MV>!=YP2I^TLDI7
M%Y2&ZHMZ>^6H4T_SK&J--'EVF=?,?3A=MBQ/9*TCI->$^D7Y@+1G\Z&Z<M#9
M":+I9KFID[9?CRH</D<7DC>'T6"X6;)>IJ8!"(8Y;%/[?QA="[0R&2",F&)2
M?%BE=(\>X)E</KC!W-$1=Q)V:M!)KC$P$_9]5]O.%Z_-F:5X+,!D3#16S5:M
M5_+R'9NCKER%FO?O.4.>YR>K@@%=I^=1R!&!2;NZ@\@N]<EF'=SH'Z8\1Q=N
M/(V#'?IU2G<8LHZT</51MBO7^93\:M$H]6'&.'S"X^F)1:(%"EE'8P(.J5R^
MD]J+6M 3BU)IXI<C;WI/75X4/:Y\7\=^.^WM+,7F? NK=8$6O(_8.0R<D6,6
MZ*-3,79I53 L7_;T#/.[PQ"_L1R>]4,&]B4Z/G<3$D'K,%0YJA@UNZ"N6J#@
MQ6_2,DB)#_]NS\ UNU:4]7J0=:=NP?TPW?Q[0NL1/3_6N)E!W#SN!/>M"*S
M8+"[I8'*T>V&M5./D[:#\C,1?462$P>AX.[*/48K<Z4' +=>E671R3V$Q=HO
M/>PCM;W\G&3(LG=;^B)+4\&)N>:TUX$ J[VW#'/V9%P,U#6A^N$G':?N:T(S
MF_YNFALH,._D(?0.(U@DJEHVARA?5EM/K.72$MI;DW^U?JH6P- .=3S*H%@@
MV$B:F!*::>5?&=1/6#,"+0]6^W-0D&\5&PBKJ#I^5^A5<.(?A&C&3J51L,CN
M);!KQPGG,5BY/H@P^):A6%4NG?=[3'$,^$F\CO&83 >K=05>E1,4KR<AV7IX
M-<\.[S"TN=9'[S <;JI*)D>Q6\[E7/F:^P!Q4\W)M)Y*"/T._?:/*U4FO2DW
M!_P[,H^L,?12)%GIHKB)@::.)/K93<;ZJ/($\Y&\)_S4'ITJ(/5%A%IZ!&5N
MU@Y')VY%>I@OD6;_5($@Z\QZ*7QO02UCK5WN=0$3\<QB+Z\->"/9?7L =;M\
M29(CV'J'X72'073XES:9%Z'W\MD=QI%Q&O1V;2/[XJ9O*!EY4W5-,I*,]O>=
M'?]K@W1T\]7:3S:!#5(SO,3K_NS13Q$&"WQ<,3*9MU6X&S4)%9=<%SN6(+/U
M-=(B9L0 $]3);X!S[[+Q6JOLK$PM3WMXL6$CK/[=QY])TU"PE?\S\M,R2:S7
MQX,6'90\]_HM]N@Y#SLAJFY.KEJ^+W1O>N!>;E5VF%N03Q/Q#\$V-I*7K$X6
MV:7R7+;/J*)84YXVD*:\8\@Z]JBWW89W(3PCYL5&HS4W7\O@*A=QO"&%$5[0
M,9=.U@_J>-:2V^H5/F5P7A/$3BA\SI:8]_04]3H3R49!>(;G7Q>U:6-H7#<V
M7YIZ T@)72_S*I&@H_5455G'[!)C.V7<H/A8WD<5AJH-_>H)F#VD]LC3[2@E
M]3C1B_P<3VW@NL(!1R6X)[U*\%JKB-]4MX6M-8=KL;W80#Q9T<^=1@-4+EI7
MI/9-.EU.,MJU.-:P9LO/0 >REDA\#93.__6MX3%I*+)J=)>R/U6)I<-L=?R\
MV#%B.KO3M.<MUJ(Y?,G\H)9TIGJ\(U&1&,,H ZU)WR[I%3^J/<5B/*U74 %L
M*5]C)*;E#;.V(%GI7HV1QVV3)'&*M0_4G#V,W)M8H'%CMWU*=$U)W!YEB 13
M^[#R@3S4;)^N(;L\9BS"6;NF;IAB8^Y](5TCOL_T5RW-@\[*ZH\"BO.+NQ+Q
M5:R?H/YN_C9.&]%UC69-EINCV[*X'!E'%KNU+]=V>WZYH9O.A@_7WK4$"Y^*
MSIA#IBQ9%;MC^$KMW87!\0YXS?6_2,I%A91_1.'@W*@@7G@V1NF]/MF$0? X
M4HMZ/@MRK5I\+6D6"7%\__\@;WZHH! 33@T&RL4N;BRDKNCB;.7M97O9]_U(
M<R&+5D()3KGPO%V]YT "DJP6.H;70%GALY*;98T%A5._#9E\:SU/[H7[+0F,
M$50M+]VH#I\9MHRLG5AJDVZ;!Y? II%!6\%2HWQ"SU>N'.\PM.!P^.T??M_V
M5OCU,N+OM"-X!ZQ1DJ1K$<@DR>=1K)_RD_1PY\S#6#LRUN.D0']8,EA,B5W
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M5'9-+X[,U(*5RR(//F%_CKQPI/:D2,*+GZ.V *.QLK0I=X857%G,^YK84GD
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M"97+,",+&!-0G(M6?M*Y+3":RL5*_=7S]4KNJ/W"94$?Q57H:>0[3W>!7.1
MM/95*6M$-I/=I!^JN@IB4< 9FM_<)W*'(7-YT.P.<!'RBVAT=P<1'],?HREV
M?:H.+G=C[?:]<6U4*N2>[/-!*8Z'W@/N,)3VUUT$3[Y<XR6;9-<T'DQI3Z)L
M<2Q;W8B_51=2PZ@-/QZ61 %[G$F8OV1 ^MDZ>6&3E)."FK%OU!,_>,X)G:ZO
M"+O.LXZH?4E L[W35DVN8B?>=N*$@2$.G)DS?9TMHD@C,%)%:&JXY^W<%"6Z
M8?[TBMNN2F"X\6 U[3Q)!BRY9U+I#A7P@'.]9UO=5L;8."4Z2^"^L"[XN<24
MQ$T/C?40CFOC;!]%;K!DE&K'S_0B6R.O'FXI)_5<D/ME5UE52-(E3^MAD/'.
MDYPGJ$G44P.HNX>.UK8]0)XX2=0]426C) #V\Y0SLX* GFTQ_HP2R)1UY_.I
MKAU1HZ%''ID7NTD^W>.*06G=-8",,WODX' J94%"Z%+HNZ#8V4:QMX:<'VJ%
M6H;U[D6PKQY.MS]YT(ZCS*%G24+BS^FYELVD?*VYQF'W2KT'@L6E,&G.D1-I
MJ:V)$M@7#3?4='2HM#0T*,5S0K+0\"RI8*[L<Y$WCE+OV4//=BTU J:]3VP;
M"Y$DM?,CQM?MEN):,#TA8S5)QBB?\H9GB1?7%-.OX,%9/FQN*[4T$N?,#V@D
M9G1K&\4^-YAH7@2F+XK1 6T\=R$F^)B\?W!2;_6;+61NH5%^YM^Y8'Q7\YDU
M^R10;,V!WF0! 9D+U(TM1TV)WR62V+/&>;O)!:ZEW7=J7TEHTJR02\U?!&KK
ML?""$6IHVGSUY[$'%O8O!Y@@-\2D/4LH3;)SR+J*@DS!Q""?-S.(Z!^"+ 7G
MLDN,0^O<.U02N&/T0#\&SZ/DZAY2?.=1EL\OL5V/F\1&+2P,>K-7E_'7' ;*
M+$:=E))Q6G^+Y7ALBSL,S])-#\]<"Z<-FSF8/TKMHW^3\\OS<D#<^2Z!.C4O
M(F3J>[5$P-SUZ0))A"?J91G0^>1E)Q#A>"_^._NM,</5S(.SKW,.L(5WB2A
M:,'!]I(R='S-#LBN_*Z7V3#@^X"HYHU70>K/*$^S(/,@X4&6U)S$7%>/X;3?
M")BS C&</&D06L"7QJ:S1CMD Y>25?)3"=@;X95V[*.L)JQM$2@=P=<OLA!*
MJB\VS:*W82"Q(9$ZBYDN:RC(5.%4D7BM-=)<H"W'8O.NH0+E.;&3NZN6M 3M
M\[/>:L[^U,PTGIQ,49(UFHP(6&G/M=4Z=KA%W&&$5IE0-;W>QWO_@O@!+"XB
M+[;E!C'E>'N',7L).QU1"(:I0227Z'\M57!X>OB1!;T'[3B:#'3 (VB20'16
M5B@KW:^(MW.$:F?.2V5>4@P<X8V*%>(:TK:.T?>.&_$HND@25\%1HFW<4:\\
M4^C!S[^KZ4?<KU@8^IXEYIY&:E$Y;W"(\TVM_Q%0:N>^XV.OB)#4S);L_'08
M#+Y>J9):.ID:K:+-'PNEOF![52-6\,0'6MC<JV;SCE ](B[.1D;/&$LR72./
M]^.\X:3QWK<5UM9)%6(%A<HH+HML%:@;(+MZTV9O8_A )78IXYZ\^\<9:>9Z
M=3*1!SS!M62:PRO(7><G= /FP&H<![Z0'JMIA]H^?NN":-LVF.,&H8D-AV!%
M'3RIZ?.TAY*C/Z%Y$.$K/9'JA0"6R(PL"NZ(+-S2]5LF;Q[8PW)>6:6%0#TC
MIW&O_0I.#:S2!D%AZW>^O%VE)V_?^8NF/XFK9?<*)Z(@@T)-49:J=!A?)32%
MFWH"&'+7W^/5"6*6MSRV/>FZ6E-=(-E'>(!5+2>AEV*3&@:^:7O-JOE>>F+8
M?$E]&G[[F>:H.).NCPW7FNH<S2%A">D>_S-V)0(#+@#\7C,2*@=9 IA'U8''
M_"49% MQ@4VB]D2K0$<)'D/OA$+!'>$'#&J9O2*EW;ME@E";HX5#>5LQJB2K
M4URY8&AXVEO3(SNB%'D[^.=^)=EA"G&BP<(W2L2T(4LF1<$/C DX+1N;L9@*
M7-&9_"GA'8,?7-QY=/+6@HZVAYQCOP*@%QK<=>. J]48&J0A_U][1G6',6_E
MR^%0^'/;P4%O'=1I$7#81?/LK)IX+2[*N.QK;42T@,AP4HA1$P4N3G6C(J7+
MH]O7!UY9.C1R+Z.S )J\FKLF>4 "PK!A0$Q@V&2WV6^%=ZR?X!YV8TP\ %!;
M 7J*$!MH+:#0=JA;X#S9TXML37K*_3G^(FZ[)3B:F?S-SC%M$2,)*(I^?4Q*
M^QM4EN!']\/1?R5)YJ1&[_$KG2QX*B;YM&E23VCDQ>-OGYXJ6 BB'S(0T%\.
M[7REJKYZ.[]TTS]-WJDA6.!.QV1(R=+E59G]348''^\!#"=.ZQ[$Z@NS=Y*]
M4+)4.'^V-_)*P:=GW_#2,3 ;2[@*R<XH]NA_D?>647$_6[HP"2&$$$(""2[!
M71O7X X!@KM[8\$M(7CC#HT$=P@TWD ']\:]<0O0N$-#WO^9<^9=<V;==^[<
MM>;>6>N^_:GJ2_6JJKWW;]=33SV[9WQMXV1[;)[ 9M\ZLTP.='"V=Z,P@E6$
M]GG'\A];34@UJ:]&DS.TZ>(=U>O,DMZN0QI;*:8F.@S!\#UM\?M*(468*'E%
M'1,EY?G6RY15!B&XT%2Q$^?AQKL4)LA3G2&(<9=;E%^;VXXKPB^GKMG7SW@I
MJ$ @2_C[9+BGSGXO9\R 2\KYBS9XHGG7HN9;GTZQYL5/4:CC"MU!(>MHIV&S
M^[QGH%&;:IK79@KB/\7H^QOUZ-^^D:R\_">MX8_J"?^*]3@?;5)&*E$"[[Y?
M%Y,K)X:M_%/WGP?&W>J,S#)!*"/_H%4>=E=YWO>"?(5@VIJ>FS,>8H'/;0*-
MPE@;?A)XK?D$I@*]K8&!LM=LD8K!1DT_39X[$^Q,[.W9>E1[?X/=IX#J]$/:
MMR_453'Z16[_^GW@<OT[4^WD&F/'GZUS]D(0=5]8/K^W);(2IL^U&PYLVKL\
M'H=B>_@IH^+>B!1=MZ!_:F [):DVY#.1W2=YROXHPPK8J M61C31<EF46%_?
MTP<:GB Q>O['ZBW_QYH234&R)EV+#P"U.XC>K)B %VHO:I"PO0U\QS$$/SYS
MW2FAT[&9Q(!#S*[F",>R6@R/Y&))<U@TRG1RO'?#_++\;@(-4@.)YU\._=UQ
M3M2ZA1]DMWV,*?"2=LTNW/R>' ?9/B2<.?.?>YXYBY=^A=F8OV+HA HWOFO5
M?=D1.D5#P_GSG,G</JOXKZ4Q3$P8<!X^LU0].D)5%AD%U<]_Z]]SXOV(^<-N
MC?-25V"]]T?_7%PXD#0<F,NW#M-+,_W_MB]F-B^P?\"1\\(0[.LI\T4YR&AG
ME=(/?.56LR:BB([Q]^G_,^"8[/'OGE8^/;;]'PY/7= !VL#4",B8-(E.WU:V
M<L^YXX@@5[BR40CDMDCA^L>381V[H]B;D F3Y;AN_A2ZE$6_@@XJ'IUKBY/1
MK6=)_RMQYN_-6V(4!FL5J3<B19?#XG@NLVC1LX"X8K%*X)VF!(\L'$^.UE)2
M4AF)/#C(?YH8L&7T'8B$EYV>)LPWY/$^FU(IJ4E/0)$"6A38<V#BM"N03Y3E
MR6?-[^]8^Y;=9YNF2!W,JF^1J;D(%;:T29+, H->JX-DC2\G?,RZE/;5DLG5
M\!/C(F&,J"F N/+7KK_.>'V?S0ZM%KP^.1'4PHH /S2D7VN[M)B]SFQI$P0W
M.)RX''72 +SY'80O/S?B23^HWV@,/.?YUSD)SBX M9WE;$[U<U5-TD@SNPVC
MMDD_06_)G ^[.=VZ196X+N=:M(U+G;13=>GP8B5MVG3,CA:(5'8G&L[K]87T
MAE3(1=6"3_45:O7X*&TW'\B:ET8P;$BM>G/DL392@J<)J&/#'>B%Z3V+IDFE
M*NWL1["\?XSPG'L7B&4NM D.X>GEB;<':[L0E^GMN9?9/I4UC]F._<AQ BIK
M%/>]N%K?BS:NFB*4/6)@05<@A:&;5VXBY_-\":A]K^V&9W B%%8+ETI?;#!N
MB?T'2M?_!J[^WR Q3$'N,'58T_$';93!JV&V,M:K5G+6S9?(3NBN\R3=S=&:
M<YW#Z[OYRU$WOO5F!S''WJ&V$L?E65'<!N'OY?D)&Y#PR9;(/7F.3KE Q42=
M'V:7\FRC6!%-X.83!)N'+Y ^FB;:X%NTQ1/K:P#NTY'5JJZ&E9%%5H/I2V(.
M7^8L(9,A@^6$VXN^)6?9 9T^LJOROCZU@MT.AYW&T* YYQ/A7(RSP+D[G:8*
M#X/9\&F'-'QE<3&^((%\CG'^:4'2JWF1ARTXPI_[NVJ+LC%P]!?NQ:2X*-L=
MXA;VD.H!]^,XQ GHGA/(HK#A55-;KU3V:J /HO)L>,'5K)BE$I_.:L 96C5,
M^=Y6YK!%/Y."AA/=RM;CU>+I7MT!:8R'-K*V<&N:BI"A7@.H4C3)XL50I]"H
M,XH?_IB17,)8)HD?[0!:8%J\]?%:+:$5FV[:ZUBZT)#>NO[@B4U6%+^BHB,3
M%2O4$V^KKYV_Y61)M2.LG[(I;IGW ZCE^NPC:@7K6'I-BUG1,WU;&EAP;(E<
M;VRN# 3_LBF$:W6IU\3VFUVHTL_JOV":C# -)CIS]\W!&4![IM0S[-WGGY4%
M3>AX!O0J)'8SP6/#:5P6J7W%WV"LLWR\EUS;_)6]^)S .Q _YN$/FMCFLGQS
M>.A-;A0O-D [(T6+VS^]=DB)H-4U?S6-Z(%:Z]P9FIU8I90SJ%($4= W9*>:
MX#&TG1!!>O$>&^ZG@5G8[-SY*G:7)KDT'%*9F:X<(6HL<?M&!E%=,ZE7%@QQ
M/9-?#7=:DJ#ZH;H2[;ML( V9=^8(<5KK$81X9A']EE>)9_C,"JV; ]'%LE[0
MO9K\1OGZYG.O<]-V84N B,L#&<'GI;!K#[?C$)+\' >-18>[7*[D,4,\:E*]
MMIC*Y(F6!\)@+VMP)U[0N-3XJQ7E%>7& ,J%7+&^',^\F#C"F7X2*+?-#;]X
M01?'U)>=M)')RUQ;<A9*#QEM([JED63FN(T6_P7>LT5A% A\E.MGW&5G0B#(
M.R-RF9[=N[^G>,6+G>"ZU6D?XF81H8#*E&U9A]QF0'Q*%Q%_T.1E2[BE\OC&
MZ.P>)K9X@=J- D09-[MKE0+;JK;#*^P^]HD \09\<>J9[7#ES8/36;/M,X#[
M'[1P[-[H1V:PVR-E6I)@/,C]C'_P.(A=_&ZZML!/Y#?1DDC$UJX2ZN'HS>JV
M,7?1HV;60+_FU;<9;M)8 J$R7Z&]G:"LHYVX7:*:2&K2[)7C15PMD03UL<T+
M#T'#I5]3 K[?K?+Y'L-NR7Y:'D;BIBE?OLSJ[J<V/_HI]WG[$EB>C=P?52MM
M( L_)-Y_M:+$-C.Q0WT87VLJ9!!F%I=70+"F*ZV7 0UW@@H"J^M/5A4.=XH'
M=-+"HS8WMOLW1[!C,TBI$NU37A)N=_@"WO!?K*@.BS=.M5#Z @KQ]AT;4R=2
M0+_S$[=:PUG95X*RN4R).M*NN5X[1N;FF*^#LS/VR1A^T*=DJKY:ORK0*-H6
M[> J4V-V\EPN$__V_?-I:N/4V=FR&Q+IR=P8A"FF2)W;R1,1^%UQO.;"AC!M
M@'6UJ9L_#7;K!E-P:VY%N/Q2&WNUM8& #7;[W=Z*Y.8>5\@XU;@T(J9.=F;N
M<C_O9X1^VZK2\+WS(Z?BY_@ UHAU3/KF\R)9CWDRHHD=J#8L_SA]]7KA$(\+
M!7<Z I?Q*(_P.TW>F%"C_**44TV/5Y+!*[UTP9Y![G63#7&V#P0QLW3$/A"C
MS!#7O:#S5!AOT*W7Z>KX L^JS:@.C9W-KF1ZQVGT]E]G^0+]3W_0&IGLFDC%
MFWU'ND1)?_"J?GG52K(CCNFU]I/O? \,$.'<<$BCV*GU9 ]4_?S-:<SM\=:>
M\J7R]**S[&Q""&A=)#E#>.*;^#,VN;?O(Q1-G<5?*YW(&A^3MVP;G F$//M(
M'/)15UHF75K:(.PMP7JZ7D9&1EL&.,PD/XHWUX[-^' S'!093KBHL3/8$-3
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M.A/"9U'(:00YU90A?$YV6R6H?Q0^.LCD,4@WRN1X.ETYR)!$UD+V9H/;71C
MJ?1E8W-^6TE_^PI:.(;.S_%R=9N+F[T_Z2*I>% JP]^"W=BV8Y1G3E*^>$9
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MWV#EF2,/8Q8T]F 9O(9"_A6*01VSDMJSU_A.L@SY3BJI,[Y#4P"/T(KQ]=H
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MZQ_ZU5Y9]*/?#L$GQQ_/;Q852TGNS.8KY7E&M#<>[/=<=72+"A]ZB\IB(EZ
M[QE=S!:\SXKE3@WI&_FEPE=6)Q%O"QHK=4E^WCN_9;9[+GJ=!Z"45^1RD^5N
MT'?&/AEY=_OE0;37KU&/<9@Y0.@,WF^M!3Y>?&W@CS<?RSKK#8DH7%?Q 52K
ME2OTI5?=.1.=3>'VJ00*'\D:!0A*%O!'F"("0_P?2Z##88]_T!ZQ]\RKVH==
M-W\V'^B)A,#&[<;+1.\33Y B_=J5;HHJPTVT$R>(6RB+E&.XJ]BR628+R:YH
MYIQ7?V'A5Z'Z%>RRW)SX/,69RL@XLLB[/FMKOK4^@=S!HB9[/DQI6_W @H(O
M.>@JVH%I*3]O6I.+Z\Q%<7B'N:1G@?.NP,1:H-TNWQT3N5R;U"%5D<6YE&H?
M3,@AO\YDI5Y\475@Z IF-6'\T&0T"I6Y\AT;<(5\'M5B@*1\"G2<ZV.3Z"NZ
MN4U26KM_C[^PLO]P.\=!=KZW?\>"3\/%)Z6-B,WJP^T7>XX'1HQX1_?TB4$U
M*9]]'PY-XZ!#>DXCL9_WS4XFJ)57VANN%)(5INF5RDB1:KQRF'I[*9#C0%!(
MG;C:1'L.<.FBP1>GU?FXK@7J.#!H>(#_,MWD$[AX3*BAK1P;"_7C38"*G K[
MI>?$L%JV00#Q0R*WV&QJWU!ZLPT/P"P_*U6Q=PX=!ZZU^PN*G.7J-3E+1JGM
M5=E.9_"WSD=.XRL-JZ\N O"5ZQ"^12(E0A75]U9M2<E3N:RF>1CMKK4>(#O?
MNY2R0W>!=F6ZH&2D<>WE33#SZ?EERV7NTOE9X'OP ^'HFM^23[,^@5YKX>1=
M>;%;H9CS^OC,.T/YEH<7@_'=1I[/O8#%@/6LP:'*]I(SBMJ,*KW<A")IO87V
M4;K(EYH/-K]M,Y8>AP.LV%9B5->'(U;;'G-H?I>47^VRCE&RK[#K/,GH7.V'
MO7J@6[=PW+W9I] K]'I*<("?*F(X2:"#O=OO'!@AQ4UZ)\06O?,'[3=Y69#P
MFI7 TU6ZC=Z'1UM8;N;6)LJ0V.^=M.$=_=I_Z7UUZZ8W[\!>#%-9 U7SZ;=?
M5F<HRO&W%J6ZC6C&3F-Z/9W];,-0?K8AI >%T4$K;,UXS*# #O0#:;?;*VVD
MS#ZYPZ[5A_GZ" %MKWYFD,;@:6US+68@T7FG[4G MU09W>9+N>XT_OT13R3C
M^O:SD?.M4&7NQ8?MAS!8>([>5Q(I)MJDW5E:?K=$!;5%&NX@?AI^&H8@'W'V
M%N.,48G8>F[P*6,<_-9FS; M>_GF2JEDL.7:?8QE??I;B.$P@FWX_)(8=F7H
M/[A%S7^KE"-6X!]S-X)P:0UENESV]1</Z]48Z U-AD<>#PHTC]E _)=IP3>\
M1PW[K<064B:S&:%%)V,5RV-D:6ID)X<[#R*0M.GMELU4$WU%[^&8+23[XZ.W
MY_E#S?;#ML7*9L>8OIR6XVM]-I.BG_J)J08FN_0O .E1/D0H(6\$VXO";T<Z
M"9NI6.OU)PN5*K1X@MX:<IR4Y$OMR[U0G5SBDHE;LMFO ^ ,V1DZUJ,WRAVA
MA3V6E1AI(:+5Z67;O_'/$ -(A A_RB8\!52Z;;<PO:5^X; K-VGV/H![:T%0
MD7/QM^.U*F?UW!3,*"UX[ EW95\%0&4P]FJV\G.+CX;!T;0.WZ725&6125":
M?K=3<>4L"=["%@]]Z<@>]+FR&PHG/K7!CQ;!KS7$>JRZ!.%_=74PLK$BU2V4
M')!^W+<\*DCKT=!(B%[MFH_LMR=24MU'HR#R<?B,,I1)>$XA2],]ERE%[<-Q
MVJ_V;(5B%^=T$H<WFDRWRD^2<$L-W:YT6U6<_\!?[//ZU;Q!8EC#01@<^59D
MZW#$P5YN>,TIE?_SFML-V5?A9\GN-Q7S?K^,_=T-:(SK#Z<1S3"Y9VS3[)L[
MC3X;+C!\B6$G\4])L9-99!9I&$TJV[@<[#5I@#BGQJ,8-\$LH^Y$125J7IFC
M_&L/I1JCI-U\YQJC#G%RD",R-\!XT!X27&S!%#^>(=B*\6/FLR6(= /_1'+A
M3JPE,N3)S8YA2K1+FE@W/@"J&)8^,U^Y+'^\?O:9N][Z+6/59E6G9VTDX$WS
MJ+$"3:#>[1V[=AMW.+%K6ZO$ZN,>?^YU-NQZW8T--W.&1'9^ZXMQ&7P/:FIX
MLQC$X4=TQB^J1AY1KO9..X_A/+&]="?8Y$L"6+@.Y!V^4/)R=+?8>CF&O69P
M,&J@(DB&N'^X\>WM\%A:S<#JA;CMH$SYI0A/KLR8\:72J;WAY>@?--[9F'#;
M<@Q(^Q7TKR,^$:\U/U;SN_S?Z,)<*+BUY9/=LD>\/JV<[XK^3;3>@IB#X!]&
M=\DMR+B 6;B]:QB.%+O.1TO<KZEL,CK]?:_:^-DH;$@/>!<)V?69JF6D(_3@
M\GEF]$0L$?Y$&SC"/DI8V].POK7A/>S3L\18:>UEKQ1F<6ZG\3:5B89G;94#
M.GQI,ZN7:C4E &#QHV+?HW0O]?HB@\M/H=1H015!<(_-*032)OB*73%'([F2
MH[M-NW14Y/G(H\RD<_>M..[1#C-[78ND*B ZC[&QB)B!6*9ZKP2BXEOL')^9
MJ '2 !D49]K51#D42+PE'+__Z_#@K3L##8CE:S(2"2^OIP</ZZ8,PB_2YQVV
M# >;?<3>EHX;G9*N<'L_2#[NZK&"9L*S T5FTJ\-9$ -R0M"Q3 LB3ZEZ]PP
M65[/WJ[%=4M*[P4B.,>IALJ[R>-VI&#A%;K"7GM DQ;WZ>3@_K=?UC]O6>L7
M7CD)'%I4&Q2("?6FTP]VBZ0RD[EAM(4.O&:P#F-\03Y42+*DJS]F6;EU]*4>
MTORSCZQ9ZI5YYSO)XQVCIRL3XN366\K48Y-++Q]H8_C)X4-"T ^.</V@SX<K
MBOR>-JZ)CPU=>X$RR[>$WI=8H.9:<84W4,Z6-P>E.DN_EH-8U,>U%KST$CP$
M6XBJ#RQW+6=<\G^7P0V&5+D&HI8;KY0\%TAW779>4UA6]?661\(+P=4B%:D:
M?J6]?K6JGU1*BY;6E()<C=VGA3\[*=S$4%:NC(YO]PY75=NUU:N1 @ 7+??I
MJV&4*0MMLR,IE>#F\]<Z?IJ''T#RCS5I0\N>$63+8=4YP_*J_H"+OM&'-ZAT
MS-'EU-$4]'M%QL?,[B78[Z%;&&I6NV^S>W5@^('F#QKT3404-.-_\O7AV/AH
M;H-G347O2>5I@V<#)(_,'5Q8&EQ 9:==1;QDN@9= 45_+CO)A04SQ&$E9S40
M9+%3%JQ5UM<I7V+<_$$[MUK5[^=GWSJ9"]8,+/-V)-7^?=R G#G7:=)J:!1[
M7=GW+4>)SU@@?1M27(=+IB<0'?[=,\^4V;* X?0ID7G;"/H!MSPOX3^.:FJY
MKFIV?#WV_CL+EJR<4S,?]-I>R&]/"B*<C+-BO'-S$H1O(IZZ$3K;G=),;EBJ
ML#YG=VWT"TV8U =AEIURO]-C?:Z1JI^!U>RAI.H"[N0&!GI8/CN L_=P2[ F
MI!.]Q?Y6:T:HAYS=L_!H3)Y:;'K[83!N6B#31Q&%_U;F@#-R6-LXS9/TW>ZI
M_4+,0W.E%*OLB+GR<OI_XJO,CM\B] >-O.C+HXW&]HXM5SJKTTC1@L*\=W 6
M Q=(^-8C5TJ.-#!BP&#[H_8?-%A0/1@Q;+=<W3>/&HV*VTG2B!#T/Z>R-"8C
MI]G\MI&M9MC.*![13[=(.T8\ZRET5CV\8C0U<!"C5]H0J(NH(P&QN3-QMKS%
M<:EEN:MBS,I>KMC<?_7. 1M6:]PF<?=^]E_%!7XAR1=&KI6^U,/3$O'2\&:Q
M.4ICP/'A&%%[M8Y6@8G6I%.^C<Q\>X'6,$)1JEF+\/UYH[X',*7:;\?4=<L*
M'A]1!ZNUGK:$4U9]&P(K,NY(_+/NI(&[Y3 S8 9SIZPGMYTW&@/]"TG.%YL$
M:$_>H!&L26.D2\MTR+ZUMG9.R @L_5](:OZ)] B9^2?\\8FL]+_>W<*@T8%T
MK '0?=R5= ]N15*_?]N5_W<25+CW@;\9IJ& YOG:YXDZ4\38)_QI;&+T?$/2
M4F-M(>5N;,=>9\YB!*8<4BS1P8<.[PYE =I-SV8<I4VD6/'[U%6(@Q8$1D(Z
M(#]X.T!G(W_0M#)\#',-;)>$W'G3I^:$<E8P61*Z%J@IT@1/=>@+F$Z/-J2^
MC1@:]?9D]"*,LF^Z_B$4"T$H-$LE+E;.HD7[!P#*C]#Z=V>G(>\=+$U3;KVL
MT>NO-^)B10YRTX;.@>5-",)F%26#@VQN-\ZP'U/-B*R/QSO:7PX/N%S0SP2U
MX?-,6-DMMA;FYGL48(W_/G76OYK=[">CG4Z NB50DIT(DYK*<N]<4,KN*.>&
MQ?.[6#77!=#*V,Z*/S,YQ&5D5=U $Q;D)H:S.$*0%:6:<2E;7;8IVS^U8<'Y
MY="R4ACD Y9+\N>H.YR$*P.1DJ\N6?\1#@S S14?_8GK,Y0GPO'VG0P2ZIX_
MB*II$FOGT+\!$N=VD[ZOEG]E"/O<IX)\4QXM?+I[^?[4K^WJ?L?&BF^51+W>
M?;CH=,%!:F(=K ?O/QDI8(0";B9$=\)4_>\*-K<^6IO__PY]I*9&CSA8QHR8
M(7),S1T;_\X0-CR3FBH9$^85U>LC%TSHZBHP8O(]RC::/DP=RXPS_EEF7'L;
M]+TUGXY.#K--YE7FT,WL1:-C>&J+,NYN,I H(L3'T>L31G-&1G%T7@NVM^9%
MOQ]&['*9,(_=X?S$+1M-J;EK[/C-/#+Z ZX73G)D]KYE&3'H8A +ICPA#C_4
M%JQ0'GM7^'7N!-3J)X%DSUM2T4N9),DLDXCO5S9^M4$[X_;E5>3>MJT\JK[^
MJ&?T@XNJR^#&S$^NA6#;[T7_6">C]I_WZZ5\NUKF'H$9C9=NZ65WK4II5;Y9
M63@C5K\?IC3:,3\#T)MTA4-.WFF;A=G>A;XA1"'S%H/4CE9B^NT16&W& -]&
M T(N]*5NJ[RWEVT!Q9B>GIB>J96'OY9*: EDPGN\N^G>OQ%^Y3D\XMA8"^)7
M+X)^'?1^UZ#Z-F:>FV@]8<!QCI ^VJUY%4^O]AS?Y<%].CX,6P-J3 /D)\6I
M<-%M5RBID4GLMF:6<PN=-XE/)19II@I\*6C!QU@2,F\99BI0^):3WE2P]3\6
M3&> [G=0 7)MZDO6A\HS7VX__%M!A6?_N&3Y)\&$<I&*;B_-!XXEURMQCIO!
MC(_R&O\T+M42S$1*S 8RZS:./LB7/4UB(8K_5QH281G^'JAJE-U;D)?:"#SL
M/A%E?Z!%7ICNWZ[#IH/\FJ8?_Z!->]0Q-%;/IT(657JGN+X/BNG([^17$(&(
MR0?L!JW3T8-4/7]$H($7\>BISJWUE];$.A3:^T25_Z#1U *@00'9N7_0K+X\
M@!OHK!/ 4:OM,5D[:5W$/'-#'0IPL,EFRZL;4,QPA@ILFZLE4&7.8@<U;8.[
MY@@\NID:!<U7Y93\Y=).U:!:$?\''.AB8.A!-$H8 JM:R+BU67] 0C L",W]
M3A<6L@L@A!SO8VK'-7NVEFE/1XM<N=&;'T/O%%ILKL43!Y2O\OLWR@>]&'QS
MA+)8M]F@LV9E^EQF;EZ"2#)7=$X0M 7?!P ;V,\_@+M/ [Q4X#X9;(5@H$:'
M7Q7T&%;BIC=UI7OA<:W%ZW&Q("GJA<*MBV+D[^YPL.3Y/F9"FE5;[>9RB?UY
M\GW. W^\43,A'*YU4LQQZ.?!OF3FZLI'N"ZU<G']&UB<SU3^._HYOK3%6"E-
MBUF<NLT >80NR@]=Y_VGR&Q0URNK@C!9(*@.6US[H'L%]^ N[5] 3#7GZM''
MJ[^#F#NY!=5E'!GE#H$TMC?_"F+B&'%T-G?(PY)+" PX1$L9S<M5@A@\BX5B
M/,UKW2[3F::_&LWK%M>:;H91>7E:NW/9>%GOIJD[P\C/_>CR5^SKN:\]X+HB
M$O8DDJ7+E7@@86R]48/45&H!E*QIVDP5HH'4S4)5E3BJ2#BA\K*ZO5F0W+D<
MT)K9C9_LG#Z@9EYEPY%O_\4P+/0MQP2.T#B6.!C2NC%N:JM%</HJ(#?>^VQS
M:_</6E7R<7?'*%'#V=AG.(3::%F@3/VO]*C\,%>T409E04)W\R85=DA(OFV<
M'=VT:B5,VA@454TJR18X74+9BW?9OGQG4%;:9M^*BQ4^7C^273"@%R6JD&-[
M>V5(<4$34AU$59\.11[N8!#[E%8AG)RJ+B]36ZH:5-TUAGHF,;MNB9':$>&_
M%5^J2LE"XD1POQFSIZ[)?;.V1GUI5UH ?X^>TC6,=:=6I>:I?<=F>0A-B_??
M*-0 <XDG"8.XQ''&V(<4^4Q:\?TNTT)M^-4H?W E^M1G!D][NO7B0_#)O T-
M&ZW"4[THL>EL*$UQAQ218O;:-9BA-^8-;/4/8O\/=V\=U/:W[OM3%ZRX0W$H
M[A*DQ9T"Q:T0"!X@E.#04HJ[.RU:O"%XD!:'(,4U! B!XNYVO_NWSYXY9^YO
M]KEG[IYS9NZ:R4P^_WR266O-L][/:Y[UO%7!)<!H.%O]54T6G!<=QTU;OU4+
M9<YPO#;NTG4O:RF=9M]/MH^SR.J12I9WC<XV/6&:P@<H%7@PAO'L6=UJWJ99
M!FD8P-/;Z9DUE_?6#FO$!'YWZ\(2F^6&!P]]ZU2P\=84;%O)GPKB4CT8744<
M8N)WQ>>&9'3,)J>/,J]>\K*\1:>[4]X3\/+:AXE/T^A^@A_W4=%6_A4CLH$1
MJ%EU)92+5L88Z1.JHA^4,;)O&KW*P[^9A"C)<?.P#%GP^V"7,W(=LK&\T@6>
M- <4M:E9RL+""^IPFP:U><M1>_1HE?WP1M$6E;ZZWX?$7; ).[P'+!^3606I
ME*DJ.ZL/$KZP?9Z/[M9:S!G??H< (;YY]1I)"6'+K6L)7FE)J=;AE\!2]J-2
MO:J#N_&#)13SAFECMM_N7X=4;6\7I8$0,:+ESP]FIT2/?'>7?C09PJ$]N,_'
MX(1LPFY37 LIZ;,+UG6)F4W/Q%7OQ>&-&R '@L6C>FY?3HA%(HU$9'(M\,P)
M78]W]?K0F+I2_]35^<Y;HC\F$+/TA+[,JPM3TSL<NUJ':Y3+]16=:_V5;-$'
M3X'>#4U Z'CMEW23-@8Z@X\D?C?MAN'T6N89J*%^U#7JPCP^/#^J.B<Q>3N[
M(COW,'L5RRD;7<0V'R3:S]:,>?J]0R#:NEXG4B=2?92U1GTUF.E@X#JN":O[
MH,%@+;82U>J5266B-I2516.@#-UP]%;!='5M[VPWNJM$1.2%46RN#TVV^1FX
MLI@\<16Q*.4$1@X#B%R7>N(_M3C7A0^T";XDAAZ8[ZH2)0/[I=XPP]V&=]ZX
M# VWXHDD'CS;GG4U"._+695@QQ:E]*-+^ZP/;"!>@=JQ_LCA(3^ /=C ;KUN
MPX*,#[RK:1YD.8LMN-0.[!);Z?$2^[V??SF@V^:TO%B692GC%$@#2:=KE!#K
MMZVA\+^T@W-UC[1^?;*_9'<9M_31TQT[B;PND_-+JJ.R!FCM%'X:6;LX:@S&
MQ/'W.5QG@T?Z"=-J1K 3UW  +H)C%V&*QEZWIYVE.GB9#&VV%IQ" L-$Z6QQ
M/C0DW=KWKG)Y[ 9]/6A&;_Y 0!9/[,4'ODC3Z%>#XS2&50,IZ[?;?95HWM3)
M7=LT<Z T#)='R&Z4^@TL#$,M# 54C_^E(I?CP][,A,#X]EE&(20: CH13>CY
MR;O:*YQRQ+^V&BJ3QUM2'@9CA%WQX4$:1C^41ND/'X=[9M6GS@<(L@R+B?"J
MO]5D^-,,H\QP3]%&'_/.;@7?:BW ?1J0+[T-OZP?$"013B!#E>]P4G3[MPXO
M*V.\HB!2E6*"EM2VEC=<^D&85\"T( *B.&S*'<ZUSC+Z^CIPFBNNAVO';B2+
M0);%FO'*=0=PV\XR=*4^%GM_.:_H/,CC8/4.QW#DPJ<J3$W1,2='%G-&$;7+
M7DP$_3">B L@RWE349R6ALWNU$%72(G],>VH)G%;U-K>VV/7(_B&;$QZ.7;J
M_:NS4VALHKD-@:#02^K/AOEDAX7N]V=B<'$1ATSL(_6#X]1-O2OT=S@E=3%W
M.%?J M6_T&(,EPB70^X1W/8;T\^WI<I[AYCV ]S/3BCX>'-Q J:.#9<DM^!E
M(YU&FTSE.:UE&'1_NYN+4$I,FGOXVF]:0O'[I/,W5G&UM]D6!\FFT?G3H,)Z
MA^I($,0M.BDZ,=EDMI1EW/)QGE*XS6(N)B=O@D^ZDO>B]5%\6I< K>)%#:4K
M9<LLFB0-X&+"Q@:B/I]_QX4C$?Z:;VR9:+YWH:'55P,+*R[N<%HP"U"DP?#X
MDV3_(5]?/_>O5C1D/WSA*!$UIG*=U/WB@BN4CV! ;WF/NO&S]IRLQJ6MNBW6
MCCUA],.M::8$KNTH'R!M]50AJ.K<--^N9,VJ(Z/UYMJF+"#(BEUO:[+!X@Y'
MIF+Z4^7W]>.B.YQ@D= GG"6',M.D1]X7!T=J+[786>U@M"Z.;+)V/160CMT%
M@>8+9GK1F78]X0 @=B2/K[.QL6'4O^WT<*GU&E#YQ1<IM^Q)1B60<:TE)!:;
M=<E#6TD]^SST&B @15Z0REML%YBTL?4D4'%V0M\U#P(>VJQ)722@;?O4G]54
M.^<X0R\\-'M=85638%Z^+"%K+/*@5T.[T[>3L*;$@OXTY5=#*G4N66.B'[LG
MOLUX^Y:XB/ED=;+^X46[BK;9J6=- Y?P8'>[I]E9<5#HQD!I>]9A@EXKG9-T
MT6Z]GHK=82/NMD9@74B_2>^@@M2'\[9*%A> &/[/P3'")%G"3DZ>V=@+U.X8
M'YFY^K[2$A#H1L'=^KI[K8,1G!M^V.A=_HOK^$K+ZR"-6YT9-Z>-MKF)[?B,
MU?5Q^H'SGZWS@)]%#"QD2[D\TMDOP=Y6)2FU,_WX&<WARORL:YV4?19J B*W
M:9.9@M/?G<SYLL93C5I$HR2BZU1L@NYPO&#"+A9]"( XG4/1LWM=/\.?Y:R>
MN.*Z"XNBM298IN;5$R7B37W9R@=+_:?9;F.V[:NDS#MK[G 6]77\=IMR!*^G
M9:30F&D,S#XF86]XCD[AX-WDVW71.QPF_V?T%B4=1H()Z%BF0>N ]\N/P2I%
M \ #&*Z8NHK-SF#=SNFZPY"Q L37#A Q@D&61'E'G53_Y)6?8&8T3%2*5*:P
MWE_=D)%:,&B=2J-R;YG]A-YTVUG'7C=ZW=CN. QD2)$M(1W\I[2?)$5=TLL_
M2:B+;.%!RLH;%0F3B%/@3]-D?8)_2(\_'!!980"URNPZ;#1Y+2.;RU9KOE\H
MBKW:#;X80.95+8;N?;M20)GJ;WH[G&JY+6;XSV](KMZJ&MX4=\OHZ*G;^:UX
M32L)ZQ^1K'B>2HH2<9R0R54F_Z$ F] .<Y33J*V@\'GF?(A J[G,8A!==(WY
ME:EQMOW25/KVVJ>6:[Q$HTK>KYW/VH_3#LB&CY3VQKBA B+SN26BT4]*EZH8
M]Y7#A6]68>0NZD$5O]*RT=>=;_MV]DN+#MA0N-V:%-*\&HWC8@U-"75!)V>>
M0=/H5<U#WA_S=%MCU%/Q-A]BBW]MJBDMG)\[YZBOT.\JZ51S]N-]W.UDT<-1
MI8(\OJ^QC9!6I!B5+'FU';*5;3$6LK(L7K?!T<^6UY__IFIF^-7;9%LJGHG\
MB?SI;I%FIWU&3/MPBR!4%;6<SLQO+^P</,;?6+N_2Y^0"8NB2(N@^QBI8MY:
MG/ZF=PYD,I[:(ZMRAR--!N[/7(QHA(%.Z.=_A^7E<W*"'V=/:(U>:>X(&TF8
M7T>MN[#?']D);9HR])AM+J[%BY"^N3%E+=H8@/$S#[93<2H>6P*GQ[57*$X.
M[G 4&:Y.29!_YO\D#4(+NXSM+S'CDC0FCJHYO=]?TPJ8V."FV8%$8:5+WC>]
M2 G">.*9PM+E/\7.G-VFGEZ2@[Q#$#.9L*X!N44=7>MA4.X#$+;'H7*YP]WK
M4)*_,<JGR4SZ]:W,9D+_"J#\,\H*@UFISU-FI?"_PRD +# ,<P_]\13'=+>W
M<ZH?7G&='>Y=A"B\A:7_I\>>C&C!^/'AS-5Y18Q;75S_>%U<JX'!&D!X]Z=G
MI6%"QNP"6[!\]&Q.:V(@W=LGM;<]IO/F :6UF@U"YR1,[F.YVH)UD3_NN9*X
M(#]M^E%>;&4D"0DA5\14$&[SCR8]$>=^HG71@;DHC8"@/* :'=_W87Y7J8#2
MHK1GD+_RC^(V.8<_WB%_S5Q")<F)'QV.@=4_;IK:Q:[0C^6VAHWL@)6"ABCE
MI)5+'J+_'!A6\(->]>S>7AIS?JW_.8@")L5_R<E/F>O$M2RQE;YJJ#?]5.Q9
M9%$319(04^.)"7R^1CZ]YMRJ=$3ND1B=1(JGU3$E1RQK8VZ)?I99FEBDQRCG
MO:/;:H*;O-UUHV-4#F+,?%80Q.Z6RDQ" ;5;RDJU>3+QG];FO:5!5\ZI+\5P
MA<Y+!83A-E<9'4G\?$+..'Z.,-=_F12\^:(/]/(!/57+F^X1!KW/2"IMZ:M]
M_6 G4=O8YY/YB7XD@T!:?OFG4HE([I!M1EKW"*H,P-/P)A*XX-=IY\7?-;NQ
M6,< ZU57I9WZTI#HRZR?/S%9D^[O?VKPT0P]E>[_7!@D/)<=T=R'^ME]_ ^W
M9O V_="JUQ/CC2&JJ%47NT///\DWTD"UK+2(P.O/J\.D]E^BM CD5TCE24A(
M@W=^""G:7P?F=J[L&V5B#*G"ONG1R#4>=.ES=I M/0FD^=[";R<49#_4ATQD
M]S376MX=,D-^;S!D?K"/XVNJ<1+U 9&@")2.)S!&5S9S8M['F]$^6>;H+W10
MSA]0^2^)L/]0=SJB_^^=N8X?4?UCULEO=P7.DV&G>]]E?:TF^CE<_L/C_PY2
MXLVW ) YUP#/PM=X+]9LOGW?@@O]:+0M[?&(/QS";OV8)P[R"F<;O!;BV#:@
MWKN>&\&5^.I9^_K:HAL]UA 79QM%8W]X7F\'NF2FS;6LSI-ACLGJSXL\_/IW
MOB8)J!-37E/W%[T\R/KB7.PH+> :-ZI8&O+C9";G.I2_W_B;<.&M)JW"7J=/
M^02/&Z5_R_E5"M\4.XTPCP'"[,N"BO.[=.[7<IIK+((]O,.+SMO#B]@?1_8G
M)P'Z1;5K165RGD<S&B 3IL=+9J[CD2/WT<Q"?9C>_HX'/_X'N^C>>\=[:S[B
M'+J\$<-%&ONF^'C9 D8#$/\R>%/"9H?Y8^OH?;DJ=QM("Z-H['YCC=1"717/
MC7M[X;[]=)ZR[<A%RDG1=WY-RO_>OK$AB]#<V1F2)83PKJ&"[&KM1=C_?>'6
M 5;?"B<ND[0W&D/"CV8K0,P?L1&?&2'48UGBAQH'W8S]?7 $_^'@+M):2XB!
M3&UR\^<#6I&OD2T"G_D_*N(!:=\S+?"'?X0_;?@K(@D6Q7W@G4DM0KOP<2H=
MOALG@S3G8ZX_;8K0I]S'7J=G\27V9A&V?&3!+*R*F?W3"?A_\';]WQL7+/LH
M//0ZBX22];HJ);N7D6ULF9'JC10+CHG)JRA(>UCQ]4D!,#4/<09!O9NB1CP*
M"[Y='KH>>AO1L22L?H1I14"ZY!Z3S%2Y+XV+7&0\TV*Q]K9/SEZ0^+Q ?(J*
M3DBX%R'3*_(D8*<5A183GSUC4-+9G/+V+=B?$OT!IR_NG'RRIO*KT4'(J,\T
M\]K_\(;?URQ[5.?A(XU1V?W#0/^\U#,X?'_[#D<_)V-^\Q^><>: "L"OU;F6
M/QO2.LYHU[I';;:I<EYT?*EYA4]X2$CV*;=8&.DM^-WM>TN8[NN^$88R\8B_
M=HZLMI8H>&;-G\KYVB96I4]+@EG4^L$#"G=^ 2@CHQ>QG9T=],BRIM++H]T[
M+/18-,C4_-1\N>0K!(ZX\!$/3:WC.AQ<E)MA9@>=K5QLGKS@XOCZWTMQ<4W%
MG%#IMW99I=7"[Q67)CL<I:+%?[]W(^HR3ME=>4AU@Z$7[39J#IMEBL[):!VJ
ML9H4OF%T24LC1$AZF'22U,L:;Q@Y#/LGM'<V6T],5GI><?.'S/B=BU8SZ"67
MZ!Y'+R(/WM]DG[0S&_9U)->'!G)A37>& KF@G0>.&3:93\*]94 LO.J+^</5
MR[C0Z'9_C$XG]*IU"^I.XUIP3!Y;&?)3OECXA$Y2,F33GR\-3B"*4V+B;=7"
M\&A"_&LD/U%BRG*@1$(_JK%CIVMJ#FT^RY4YK[]>QUUH'G0XK#:4.2K+JS&Y
M(1%#G1!!TJAH4"N@C#QWCX(T9P&=0)"J<S-R&M;L_NQ!SXV5/\9])FYIA1+[
MY<J<.,+9 FK. F&FGB]*76:KUF\.IK3)HB?-0!^[50:U9;[63M4,$XYD4TH9
M:W.0  "D/ES></*E$!8*6[O*,'Q[ A_1V]B?S;/#&[.R?!L&:I#DM>5V&?V(
M_OIONNZF.Y3=SI&=96VO)FM<NGJ,13'ZK.9@J46Y:EOL7@.K@",^.Q=U@/3:
MC?4M-YM,@0=C%"(PQ/L2;1CGQP<K 2+2$?1\FE80XX7DJAU\/%')-8/CZL-&
M_8)'$3E9J1"VN$*:.79R[-PX@'7!H<[H0>A:=5/V= /&72SX)*WK?:;2\C4L
MO29R*-YZTSKV5FW203XTL9K[&FF VM'*&!-6IBG:IXR15:!4++=V/_G>(T?[
M0RJWFE*JD'OOE\J:QDBO% <R/*#P>$XL-"LBT/G*)[4N2NDV%M"#+$[;'"AK
MV!ET;F:'MYGO&)>M?6>?G#:%(O<=><EZ#U/R/NG&Y.Q^1.,#E[4SJJ-^BV_0
M-6,GR"VF-("'J_F=U@/6G)+FV58-'O0CG1%(H@:UU)ND7?&Y05QYH"%J<&MK
M^3?DT>S(LR^<5*UMT2!>:,U^$_Q%IRN[:^@I"Z="3O)$_J?SJ)[=EQ,2^36W
M7_30FS^ J[*7T/6D^0(U+,5E(>JKM_JWC0UQJYZ+RM;KG,J=6U?[\3L<N^9C
M.XN=X;$-%T8E*7#*>*.FA)R ^_-T,ULI9YGQ$Y+X=Z%L\8,W301:!?$70DSL
M7N:?.PXC.9HO9CFU^@?Z^QLXA[5TDP(6BMCF72<;FIBGS:S(*)7^/YLYW6A=
M\T1UF\3SE^%1AS++1-[8>UA2\&G&GN$L"NZS83+!(#P7*A"8 RCL@DQUH5I3
M6[WQ!"A[[);[P.C8Z= ;-_V\V+2/5;]OCA&(R@'_P-C08M3[51\<FZ^="1-3
M3.Q0BCP!>_HZ!KNB&8$/[W.9-^]PDD$Q,R::R]I/ZX9,4SVM6YQ]G*>T[$3(
M&MM;S<S,ZTLV7FTET_Q9C6$.;Y$?J^WFDV43J@'<:/(8"T\79CJ^""*34-R9
M%1S+.I@K<:T?2#*?IBXG"08^D9S8-G* I!FGMXNO.)W/XKKT'4O\,L.0N),(
M0,#OE6LM@XKF78$TM<TJ7^/F8Z5URKMSY0)]E7PEH86%G0SXTZ09W!_[S#6$
M@%_= AN?PS\V)#8!>;):G9@3&UUX!F/5)J;Y3$1!Y)P[QA+.&BO<3'1*&CA,
M#WZ&P_V(;=PGC#]2Q2I#7[CZ)20=AX<W9! !]KD7;?8ZA9KA4IS;)X7+A[-Y
MG)N&/'D\$>-15/ZE(=D5L\>7\ZS/>*OJVKJ]5K09#@_-2L<V#E-W/-[XI+K,
M5R:J\9]?)>A:) 4,3TTAIJM/UM0TIEHF?7*4'19R:RDJ&H&EY[%=+G%=^O8"
M1OL@$#GUAV6[U;[LZ/ HW(:TM[Y3KQUZKCL5)-5'^BKZUYDO@O9[\T4OC-)O
ME6T3)*.D]P-EG!*%A#^1"+_?63W*2W;?7Y#%<]UQ[SR.JF"KM6/,3B1)R"#*
MD&V)SNF+N,,Q1]WA_"X:Y'9T]*_5-Q>>WITV?QOCV<-5@GC*2EJ_56-1DJ:<
MJQ@I9JME8"-^9,RI.FQVN,4Z..^:(&-^XY<-F9!J0 S9!7T8)MT^39J3"?4Z
M"5"5AH/3>)D_XR8S!=GFA8*-+_-F&?PJ7L:3MIR]L/="0N-_&;W?PI<M]C0(
M=&5?PGDUV:'(UW2^T91=-K@WOJ:Q<+@]$HNIJ#.(*)^Y$5Z8/&_"S#ZZ6DB\
MUKP*RQ.UX X4F[QFI[C)F[)\EI:RG)8RN-(=\B_MDOJN786+^VBKLJU70"A&
MDR^Y]LV(%-U"H4Z$^,'VE0C=EXM _YL%G[G1=_#VH<:%'=Z@,?O0H"D,3WS0
M-6GGTCN2%6[0[0X5Q#(JW_VV5$CY@-C% 7H[F5QRAZ-*<>- UE$;R#*6UUXF
M#[T!5_/)3F'B6!.-*CF5IF3R0G5@K2JTZ8W8P7P*L?6\Y!ST"7H!UD9Y@\RP
M%J&+['@YO,N\.C22)3;AFH3,8_6S[XNVN4"(U-]^>;=BAA<=;GCL9VY@*,:Z
MG^CDDGLC&WG"4E+3ZW(S,4L91U=X2%KED %6#^Q)'QR-G!)5]XA^8SWD]+:6
M2E)O\$47ZQ+*=Q@SI:^E#/%9VCY"-S0TK7QF:*3T3_W4GQ=*F #V, 'I!3Z,
MV9V*E4IYO+G:!P9:M.@TPM')%Z"R4 I3+;<AH4[NE+):1;#KP^'G!0+G.F09
M1A;BCXUEO*C4Y'K9<0BPG;SJ=(.>R^!Z(LB%*6K]).\.Y\E-4>&!]A=J\IKM
M^FU/ PUT:TH4JWZ5)ON0=$/9K/ X>&Z=IWZSF2$U;"7NA?U"G5FNDI2?DCM4
M/D6T%357@QMPJC^2%J3U9T;]JQB?MF.+LT2 4%:WW8'''8Y\>WB[*:,Q*B.[
M@--)]67(MQ%B>78-& 7\Y3,AN ?4LYI&#B3"%M?G+Y3O26"HM=J:6^[M-*XK
M$2+AAJNCI$G6^ NU8%U'.AIU\<-CK:C7"G#4P*!%^LZ+YE[<5.-28!H2>%^*
M/!]G [1FWYDM<F8'@OXIC9;-/V!-S\EV2B/UDW#T7IAR:)C^_J[!L70G+C'M
M%Z?J* @Y/52E>USM!0/L]\9>&KAR"[[[L>/'AI[2;Q^QJ0C=&^U0]47:-CDG
MZ]SAS(ZTK-N)"2R7AT^^71&"',,<4-H,/XT-XK,NZ;QJ+9^LYN3U(\D"]Z,:
M(QJI^#EQWHJ6%F"7YOX,]B"H)V]Y+]?-,L^+6)KR;UCI5J;?S;$Y<U\*OJ_H
M;4:4!Y2\PXC?TG2WYG7+E$\^5# :G_)>=K_1+G27:$[$'(D/!EJ$+.D,J;.K
MU5TF*;G\"JG;4>86O">6\.P!O"&I9I6C[7=6E&Z4>Z)?<9:FR&QQ<W$;QWFR
MGJ9P9@"UTX?I7_EL7HBF,)L3NR@@67C=-T%B0)+1F*BT5GC2C09= CP\A&8U
M,L<D 0[9'M1:/2!IR>FYJBR1,C41>FLE,O323J"<H[_X*%M,KP5H,C$-2Z4U
MS@C5&9B6T$1'PL1HY]U)<SH7!=P?YR I[;39BAHFUJH+>VUGN=BNSUGWJ_Y4
MIRG89ZZ'9O)^S<OY8L9VA]/S-D5P:Q-#ANV_QCX3LEA;M==T^N9<A^]>")\#
M&S+A< ^+=ONFFDEL^?I0W.]=),(,;LQE4S5BYU/-7K@ ><5JF7C- @@)T(MW
M./U37=&+SU/5*FIKA#=7.;6D2280%C3ZQ4_.0NK6GS'%!VVG R2C<_9WH;-T
M=BLSY1]A!8)A$YH)HZ=H&BJ5ZW:A%79<;V.CN.#X7@:R K""B_((CZ3;66T;
M]X55V?MY^>W=[L2VXEO><BD$5^2YDI?Z4L9SI[9A/PGC8A"DK=(0=**^OQXF
MS'*'0VG0<$YZW@'<L^9]K*V%W5L^)&I,]H)15&# G^-XZ41?J>,M1"&.]\&#
MN]=N>P/QJ+0]%W0 _K)^OVW9UH*9%*[^I&>+1GB/[#?:$[;JA.2\H0&S!)LB
M+\P\"$06GS6ZH-]D))JZ&#S1Z (THLT6\!&[R!EZ(=00^F*(T:C3.#T#A9SB
MM5ZAEXIN NF8-P,,JX\?%EF:_;G>S7LA&C<%$6;Q=T^@P!&P93R U9S'H@'V
ME6D1>X_Y?%/*)L5-([Y^72]9'U"WU1^-AF"N^TS*!ZJ7ATPB Q-M_*0!48U0
M+9U+M3(^+XXFM=1V1_VF4;[8\>M15.L!ZL]0&P 0-O;;@>O2XA1@J#.\GND?
MHQ'*UFWR :Q7.',53+K;;[^'MG[E@9$3_P82:)* ">D/4&K)4ZY$8U/E*%<B
M!2")QAKIS)$"8+/">-3'1UF)3"!7&7*STW+4'R%#JPZ,KTFL>/:N&NV!'?/.
MD]<!1F5*N[07, W( 9:R"=L >6)+N%8]QZSX!M*D_?'W&=,"]Y:0;*BE$/F6
MV:^)C'-W#A='V6"30>)[\N!DZ*;:( FBHDHFK\1M*BWQH/S#LK4RL^#;]>SY
M-#Y M)U-D>@:AGI+-VD30X>\U^$S%_LM*@Y:0(97?CI'6T8<H[EC"E.V+U5U
M!<[R%+!DKFE2U.V6;:=?\<"H">7GPN7%*2^$F@O/V21$>/-S-=ITA3RLQ&A]
MC..(3"MP>E(E?U *X)82*IBA)SVY/ 0A@GO^TS8HE]/VZ)VL['J+*!_G-)MZ
M]7PVQ_*WT5;TD9R*@<^<@YGX[IW]IZ +M[P![B@PMZ[J2,>8^O@5]6<*)SH!
M\1,I=OY NUI\I&R4;E^G(X4U,975?6(*$'2']+53W@(/;L+8Q?94%K)CWY9?
M0GTFZ@  < =]R>!2L4**F0FV! H3-\"$!94Y )^BV@GU>M'?9NOVFQ&X3927
MU\ 39\*_,@<Q.,'7[@Z94N&*P05_]DCP1[;-B[57KD3=JQ&13ZC^[0!WK<)J
MC<65UX]I,B; 5M9J\1-ZNZ><]8S&TR1+.@>W]R8OXC,7N196?H^5:8$A\3%O
M#/S.'$\3>&I0E;))<*OEGVM#QU,%Q$$Y_@S)_,_KD8L_C1:^ZC8>[J^*!"]P
MOR;ITWBTIN-M_5?$_VM@<UIF9V^&T<;3R?]475"$O59(\P]S,/A]92R:5P#H
MS9X^'/I4)9"G\6-9B2U)UOT<RH>_12L^PB>6Q$:O=1\\@7+]7NC1*E8+WU7:
M 45FC_ ^4"/:\&=0/Z(=DM-UKCRXH*O"2@,[1 \EW=[Q^27&"O_]ER@8QR0-
M3KUXHGZM+/M120TKI7(QX, 10UZ,(,D4((@<<KJ63#-K%R@]N-MXF+6(V1V*
M*179E;=<Y6I)'\(E_!S#S)"C7@J9Q(:*T7M3L?1@"+J#&5Q_IF*?Y7Q<?/#:
M. L>.X YW9)WR*&((3KQ)^!]GJC&TSG?$F @Z#6".IJ_H*HT2PH% ;/3%133
M31$Z_S7Q]>])Z4EN^7W$;YF79T+;M+)?W/\\%_S']N.Y60 >< )WT&\#CSM+
M$]_._X?'_^W%#]]Y(5V FSQQ0^A0/N+%Q#[K.EHS0K9)8#WE=0'\-H2QUQ(&
M,0QBCRUH>)6.M.Y9LX^<R]*RJ]WY15*>T[D*(W]X^VFY3R^S],1M9/N CV_U
MUI+Y*K5%6K.DPNK0F%OQU\N&R#[S'I/[X$1<86ZDKCO;!:UM2,;\:E#2YKW]
MO]--L[0F)VB;?;T>77BF8>IN--*6G]B3)#FW@"<)N=*T_@<8G*O@OH_K/DYV
M#RQC6#R6H[5\L^9OL;3)0V:M3-U<_?""^N4>=K\G+R4&<P_;6BZ>E584GY.'
MI*%LH&U_:7+P/^9!!IQVHIO%QZW/1!N0P%5#QS,X-V  _OZDU/OE$9_0J9@I
M0>BK-R.M+=IL7LMYC._(O?9<.5:@5UI_^FRMZLJ/;,%=SGM3YSGB_#/I>6'+
M(35B I]^^3#48V[P&N]_#V/,(.JS90G5@JBX]O<S A(RV@>4M%:U#Q&(:NS?
M_XFW%PB+_FM%D'<XE?=L8Y>D*ZQ*JT]J81=#=G1%&VH8;+>1*5?\"SX/63&!
M168QWIUEQ,'J"#"%P7S:],T158TD;S+,V\N###1QP6OZF4OB(O*8R=_'T[ W
MY97SSNK!U!,O+^SBF[?_M*?!OV>G^AOZY(BA-IDSL6VLY4_OY,?/_[YK$RPV
M+(OYG.]P&C;WELX,.39UN5!<Q]T[>:<WYM?TFZN/%O__,;BB<@!%%T'AE5!A
M.Y7 0/K NO1_8*O_%I7_/3U]I<Y5>Z;L+V=?O=N[G-7WC/W_<IWU\UJ/$/ U
MR&3KU"CE+3_%ND1=*%,V?0\%H[4RTXAA)-N*%$@.".W[C-.KM"$2:X$;(O*>
MSCE@R*K,QF&N%UV)/R!6KJF+52>*_F%<#A(,]3U2<,:PZ"G8TG[4V);3&EYX
M9>Z5?OH4#L_,J#'R7LUZ[0C0]7]@=2W/+3T=O9ZEA4INLA8/EBCI'E2>=@P!
ML8U(<Q%3$L7^XTRZ>9^K4AAK%+V2ROS,.I6) QMI%!$K >2'\B<*$?'S0U\R
M6E/8@3S= C>K]AO/Y)]* O3-'B_@/9(IR=2UDM8.JWKS FMM=\@=HY1("3G
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MXN4$7O7Z"<=-[%;_A3YYL?\Z?4Z(,)LDOB?D];2MC7,%3HNIN,< CZ7LNS!
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MP3(>H)VI$5@RBMU9=(+.2"_!P93"39V]"DOP_1A+0H8/TL0"#Z"HA^]B!L4
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M@DEM897[]_Q1GY<VQ:5\0!<W$CR&T.WW"7(?Y>:A;]#>;O >2%T_SPAJK?'
MWI$N 0W-[L@;DM$Y]!;/P<K+D)[!W>A RLD0,1\J\402A1>'I/(KS.#?,KLX
M5/]SG.A_5>7\O#!I:[>L8"JH;&S[2-/\H=5+0'PT6@[AZA@_*%1:#*+\Q-@L
MZYO71_(\GZL'2S,CW@1Q%UPH29.AE9YVD"R@7 _OLB84X1E>7I0_QNM" )QW
MK=4^>S.2?N3-C#[XO^B\\OU;G==G-C:>'E?__21U+LH]VAV:Z^&F+*VU"HVM
MB\ILHA+W33R(LFA,F\ [BF\&\]!DN@^.5O"!Z7:U[!]?(O/>Z,B)[8@IQU7,
M&;:R,9@7]VX\L0Y;##/NXRE"P!]""4L80._@'YXV!*R>8%//)2+%7=[*_(C'
M'UY8 SGM!>5=;5_^??&:(<@$Q#J3!<1@-_).?G^QT;1TFM.(M8@&>(#I6WW9
M:$\.ULQDIN>.=5_QQ4.SMRT47O >J])#J47JQ*TFAC5WYH.F-T^W;1HP-*^]
MJ6/?\I8?.4C_$C 9[C&NZ!)P&U+2>$8HF7'O=0OY0^;[ ?X#RO]%1_R?>N/>
MOSV.<)[$]_*EL,5]&U)2D,M+SZ7>C.N<'*B-S:&GEXT.R9[Y[L&M#;7EI*]D
M,F'(B.'UO'SM,_FTX>G$^=\?P?+B//(R6W"1%KAR#R)N?SE\S%_%NYJWRMV4
M5W.97X1VGIU?/[M1=,.*??JQB,-X+2%IO^,J=A<U0-62#>IAMF)E5'T,=3=8
M7W@P%<Y1/].R^03EI BRRNU/&5;:26F$%Q7WF2:&AKA^6VB*4S?(G ]ZBG58
M8*Y[]^5?+XHM"44:]\^5)<*G<U,O*3]"E3&V])P4CKH)H*^]I/$/2?O8<;\
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M%[7XA[53$]T!/!HWLD4COVC\VM_V/M[K3,7C<ED<K_91VKWQW;U1E2P47==
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MK)=/OX;935I<6I!,UI)9JX>]#LX%XEEV&7C8_YAG60:+W1T9(++^7U>M[%F
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M&3J).CXBS7T<>@X?ED0Z*CRNBO%>C!6<IK!0,P^@Q8B8% ?"Y(5BY1"EPI/
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M1]4\;!V:%LCZ/1L.=IQ37JW9>A%:FKOVX;SE*1/U5UY-X??E@+L[;S<&134
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M5Z#YF9FNCE=HUJ'RL44+9#0M2EY!/_DZ''S ,Q9NKHH2VDWDX[V:X<BN7B\
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M:P*Q'C2P8 KTK8YYS XG:_H,C>,5PEM>REIX(U#N5%P86<=MQ_Z):%@U&R\
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MF178)=#/XE*&^-Q9U?I! KN19(92X7L?D,\2&M$7,M^;ESZS8=#>[>,D+JP
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M%QI&&D\KH]]HQZ&?9\)+&]^#?HQL=A"L )#><\NG//'KO]'X128=%94SKP
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M"#58CR\F]GIE0!>W@@7V5^KK],&5.W?!WWN/' ,*7(E%ACHH51X-'.IN!]7
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M?W>.Q9+X_H>G?T1$^3=M=M;,RW&_=R@UJ(C2<0)%:=0_7FV+FKMG#V/$PUX
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MW'I$+^ DJH?,+K5,_"F73ZRH;T^291W7Q#;* "*GQ#@2)U9RN!=PL,FR=@_
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M*\:_CT?597U'W_*B@V=)O=)L_/"3Q,3G8#HKL^:H3.D9EG5?P*B6RZDV6(:
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M[AP-;MM;X7 W][0@@88G9-^^?K)(N*-,L8:E9XT^^\"J5SZ +?O_5=FM?ZE
M+%&T'FZ5@S3IYZ\H/2OMS\P1(<O=E;;MT28O*<2K\>UW^[MX:N3H_'P51:9)
M\>,OO>\!.=>!G#X=*DYXF=<=\^BNB3P\^HP;GY%,7U(V=G!/IFZ;H#B58U=R
MOP;0\A1$^C;%#MUC_O8;(M-XN-AX$(9190@0 /UM@?P>GOZ9#1Z@J #:  R5
M/7HU1) @ICHPJV8 O9J@(V(W'MA9-J"P/- ?>[1IP:$*.?Q>/'# (0GW!H%0
MB XH*A"!.M^QC)$Z?H'XPU;7J=(EM*EDX(FR=-(<50=ZGJXW[09"8L6,2.O"
M!M#X.5,88\ZI2XZB3KH&5T(EK#H^7RM3K,UE-M>KWYTY26=).&@5>H$]G:&%
M\I*+QE96WXL%9Q=?#(IE3?/,+S,&8EA<XX"Q=4.B^>[PDO2@VF;O!5JORT?V
MYN#*'.6SM>0XKM%\MAJ5^'23(\R^-("'1^<* U*966F['U=(%_O9.X5^VID9
MK0@['FL]<\<P2#"-,7\1VA25 H<TD4*_R/6%J)M>\2>X>R]D#T*^7$9<)FQY
M1HH8A4_L.(:&]&GE,GR)22<_UP*1O?-^T8/?.&=O"$ZVUO:,=IPS'= +3V5Z
MXH5@_/Y2<W#I'U5R[@$22[Y_!0_]XD?5DS8:-"6XI$2K(XL7$Z<(O@=\*CG;
M23P;: AP[T*U%S$7#V#>>Q7^E=-I'_O,Y!SVNN\8+>/2]'L ,=8R^II]YD35
M:?&9,E95;/\L>$7ZX/=DF5JY%%\&?WEJCU&%-8UIHAWAD F1JC2'%?6S9RCD
M2*-OE6_+NX5RV3VDKA&.?D)6\::@,&Y7@0N8DN[J57#5L.A@J( Y?.GIVU<N
MYTS/2F=/'-R![K.@79OB4L?*M=^FT]JY%*]5<*SE5A4_UQ#> X: [^(_R8C[
M$%[/91!NE$(^G"UE!S[TO5*]C%EA]^?6LKYQR%E)&8;PT. 7*F[<C!LD[<<]
M;;_F@"BY5NQ%@ARR7USIU=]LENQTJ0@AQC086L;).9(2_2L2 PX"85+G"P[%
MY)!D*=WAAZ14TRU5%$&P+1[=J(::IDPE5D%*L,16/IZ>ADTWB%VOAKD5U^4C
MKA5U4B<N3?/#TD"_'2>S:5T;D)/TBNNO=>1)9=4LR'G8LE21_D5VI*KG7GYH
MNC@I4T^/SA"NA_'7?C@_4.S16EN,Y^>RYUF;QJ@T(++-.H_=;6QMAWV*)6ZE
M5E7%^E3.SD^SM]Y&!X18FFUI+*4X.*BI K%NM8[<2(D=F6]N0HWM*2MO]Z]1
MW1>LU@?,8W'C<Q&4<Z;Y4[0<IE,J$ZO/+>6Y:L2II]6J2C=[8\HR)\^R4R=T
M13#&.#_K9P11@O#I)I<I&]CT2,8K'I3KV>EZEQY!XD@K_J^/>N3E\@<ODRJ)
M"24CBS8(JW,D.SE[WD<!QX7OLHVORU0])2Z>)TFN=Z9+5^=15_"Q&W'QL3UJ
MN[%3UB6#TW E9'0-(3(BCL["LWRR*Z268RIJ5CC8-BA?O!RG?FT7;.B!IE"!
MK58THCI]?!V8I=FOY_D]DYR\O<$R/@X]+<I69':NC;L*?ZKK1@=:G3RD%/+B
MW#,6APM%P8O(06QRY%Q<+<-;RS-1=CZI'W60VO$M/F5+)C]N^(YY\%-XS_3T
M^]_E!^<N'H6)$A7R KW1V\P_1;H^&5Q-G;.><G,,#=9JK?HGUB[2KZ@E+9\=
M)"+)?B:;)ILFRI'&83TOM[7+"V?9*WQ9V213;T9<>PW=6UR&MCHTSAD/BK]5
M[33T]L#S/T$W*CCR?K!>%K7.FTE'4?"N@PEW(=A%9$:4E;IPN4@*+;^/?9L"
M5$6)=EI?4XN%25M#SW!CU(4I'KT67DPP#7(ZF'URI/M7E9LV,2L;M;*#D3^]
MSV.TRBGM:JM\M14I<_I4ZK]TVKK:LF[?G%&3MILU?CR\V!3#>N+4][N%ROOD
MJC](1FB^?%$8EC)ZRW$R2) D)DRB-"56\GCF5R>0R&7-0H1^?Z8FW1-'2V$^
M>F0AM<V?Z<F0G?:1(G'I[%,2SZWM>-W5V ?--&M2RTTKJ3!8;.%$4WCU(US3
M)1X@7H_SRK:)HP#:4NO5H>R!J]:!WDJ6G&HF^8$9+Q%/V%^DHJ_/5ZR#W63)
M>5U%SCG.\T)9RY*<-<UX65\<*UC W]O&U72JI*_BH"@E173)N_&(U7Z[9;L#
M3IP8N<!,E(1%P1IU%;;B-! 3.UP(=:YLXAOW*XMC]RA:<7QN5!X1NV (=D1J
MF?9%MCNMD\LHF' K>>0?=\,O3EPZY-:H%$Y%!(?FA<X%:?G+B*BHB=H=3Z1/
M3E&LH,L]9'5##'9IG[AIK[<2T'G.?_L-.8N$!2I!^AH?N^-CK/8UN4:V;14Y
MD<69:L(C3%-2% ::P?DVS$]*5$6V!]Y08FCA")2C@[:4C);1U\IQ>+[P!P\R
MN_^1]9,J['_T>;"OPG4:NT]3!G11Z1R]2;2J/50PW+H_V>FV061W40":9B4^
M',^6A]KHA")8586C&RHUXZW*+&DNH^-5R!3(@4U=65E-1O.?.AG#_NI+!!K1
M5N(TV>+_VC]GV&J\*B(ZYAX@VBG:>"=^0\'DR^N$2_$-NB"L-VOR<JK%ESP9
M_$ZLILK5IVO_7.>N!:UU/%>.Z'$]$6[EN09Z,5&?!0*S3ELE4R:2!A!NDK9V
M?'D/09[V_#X,0YLQJV5@DK;K]!\B0$7W_C .XX@5@^7--Z1GH)*LD,;Q?(:!
M64RH2G;8]223.+SA-57N6;F(7^SA4![B[OQPKI.YY%UX_C"4T5MZU=Z!-(SK
M2YU>XX@GA#C_1$U:E_G:*4MW<.CPQ*2F\G#T LDSS.1Q$Z.?B--7TZ*<D)3E
MQ^7\IX[FENIW9=,AQM6IWH1X1CWI<] ^ T1]$0+1)!Y:+'J]'^<M=] AY]-X
M2P=U.).K$^,1;/': W-NL<_D2O^4$2V#6D56R%=+CZHIF?9N$?00X'A0)I)]
MA68D =._C<Z*HE^_E4^)EI[_C!>82E6\RD>'4IO@'6G+W*Q]F0+?CT(_^_QZ
MJL!1T35FHHO>P_>+9["CY<5RQC:$20?-S5.?BGX305/QO1!PM$Z<X,AFR0$<
M3VG+3'(?1FJ$9BI1<JU32/7C];<BG,KN 6%(?TV;)N O$3TBSIF*&Z7EM[^+
M,_/C](^&/<81M?.<.C/[%;RS?#6^"2\Z-S0R4KP4$D"G/Y/+ P5@1V2<F<D%
M=8;OX# DQ>*.QZ6:MX+6/F72!CQF<S(U@]"4=TM"98L^LHC-Q5A@,2&V3_5(
M+R:\3_ KW7L_8;MQ:7@WQ\&2<[<H^ZW!"<82<W-G)(ZXZTSBD"RJCXE.CGXI
MXA+7O)64+6:<^]**)K!B:U5S7L<0^"+:9U.:051#DRJA,G+3@'0,_)S5<[D=
MZM X3[2GMRJWFN3V)R,+/*3F&\ )PF!S=M&N@]TS_IB2W /:E(VW+=_.7F(6
M[HQ5=9URK1?O >V!@=.G'I<-'$EL[EGX[X=W^FE>4 66;QE (=,H [D-76PY
M&)*^3IQ2\>8PV*'BM%O!:]@2:AR<:'=)=3DBVG<I$KCV]S5\9S4WZ7>UT1_>
M"Q)BP@UT,Q [83O[UV[GD,T"7I"V:("(%@YIPH@%PVG4F_ "*UJ?CXBT =O)
M2)LV+D_'$A&Q;SN)#$Y\8)_]:JU]:U&@L8'=&T8SY2]6 QJP7[K"R68#PX['
M"NPN5QRLW"NQP&=TM(G6>8#UX';HKI&PAZ)>16E&55Z94V((GZZ#<^.\0FTE
M7HE2IU*2:&WIH+I'PS1S7[&\6J9=<NX+C154HK[,J?7>6H]Y4%$%Q>^$#$SY
M\U[SOW!CG$ 6?@^H%.%X\Z*CG.%D/E0'U["WQ;#P*>AF<T)YY-Q'9-Y3H_-4
MY:\9=<WRRS"Z->DBT  Y$S=S YZIAB9-I7IQ0UDT1[1R8R-MX#=Y00)<53;Y
MED])]IJDC@*\0;L])U!2FQMB8G/+LK;6<M2/XK T1C$YE;ID4PB;L=;%TJ\K
M)V5'J*,A^RRCI*L24BV:*%GM4GVUS-BC,\V@W%*OHG"[/;Q@<Z17KJ4?<^;4
M%;<??WP/H&W9TAPN"EO/V1<.Y#QE!8T?,AVLXN +:8OR!ATB!??]#2D[G+:6
M-.':$2WZ@YFF5J ;1L930]]V=-^B;WP?H<.%)///4X)^F//@EM,>KE2=E:=)
MBRZV/>*+F]7N>>0,W,SRU;F<840L%^SD]$-639#W&;-H%M1,JS1N5#DSJGSQ
MN 2YUTC7=@]X?IKENFQFU+@ZI*60=9<_ID'=>:MZ31S6&ZS>*7O+B*8]'L48
MYV(RXE(RQO;J.$R,\>X!5O_8-8^,:=T;%YGS&I3=9+?;GIWZ.-YNHFC5/+.?
MIN5%]O)H9W73)K9'3DI:-F=^'ER7IV+[/  C"[AR^&+*3AS[9O$/_7K:U?5K
M93'C6\75R[9K>H$-6^?&)B4Y91()GLH!T4T!91;51+M\M2AE=G>;H[E*2O5N
M;]Y6QJ@1>BRFQ4^=*96J#G(R 74(FQ*IVY/%(X_%]$WF82V=@RZVE/)/BJHJ
MCT,>CQ,Z'ZB.4 1_12)Z(GCJKO_"56:Z.8XS]O[?2#S%@J,,>Q'#1WL^0?"B
MQ%AJT);=SHU5&VQR(&(5-S[JY)= G$14E.Y1Y7"<[JCOW3U@[*Y9QS!0<;+A
M=9;@7#U"^T]%*"H6O0QB+R]5.2]+IC_E8W^D/>W,H;UN:1QA55:J)&W\Q,)!
MOM7LEE_"Y4\+J?+!R-\UYP04S2V*&0RE597EG"ZLX^[1I[%DGZ8U&ZOZ-?0U
M2A!CRI-J9B7X(R1XSLW#KO4Z#\Q,FTYN'FH=31]J_9,)$:DS&$X7^<%%8.NA
MY;OW("Z&?]2>T1@%O3_*&MEU+2N"BL^<<V2;1CZ_B23K5I(,"P/'M+L_V;1'
M,,E\IPV\-GCPTR6))@ /5)KILI94E$,KDUE9X<1LHD]W&+EZ)Y5%7.(CX:M;
M.Z\\+QKE\BM P'LI=6&*5BG.NI^_&*F8<WW3TI)Q7MN^MWP>PJ4/+I;J!EVZ
M./O4O500+T0EGPKX!2OQB81@A]JBPOYD@"_R$[DOZ(.TL',3(@4_X!I"^#4/
MAQ#8 J,<W%$NR>:9%N2,=4JBZ39G-A63;$H@:9?H=7JF069I55O59+UE@886
MF\J2RI@GD_X_+B%OH2V,&G8&^6$ENVU\\#1IJ_%]0DG"!GE3HWO *V1M:+D]
MF[0,4S5V1G6G*\O&C616;L>+"3UU^UWE32OUK0[K.E6LMNHY&I-<(Z.W0\*"
M:2:-;(J]:J;??F5*?]17>>2\/]U@ST;5!C'(&O&,%;69]S7&0DC(B]>/Q\SR
M$4=$^&.JOV^MS@SZ5AM/V 6"$3KGCM6#>P8SQI^W[>6<V#,'EH>WD++*4GP'
M,6GL<QS^W51T/[FD<;E@A(]5PZ4?LJ.DW_[5$C>0DT>X7]@P]P#O@%8HANKH
MM-+N:4IJ,=Y. !@"":<8F[,"F7+>+KFRHQF?C-4/YR[%#GJ[PYBTJ71@[/ED
M_>:-AHU_$A=KYXENM:9-R$MTQ30%41\'T<WM*[<WT+JDP"?3F2JY&:OW@-E;
M>??;T%N@5"GP+7/ET8R-2ZN__-O/@F:FH4IRF;'3/@4O21^ZF9U4K]3ZBUKH
M(%7C@Y];XWW(*E-^H6@T'"=RBG(Y"CQBW?&4 04X=,XAZ2F/O03]M74\LDW"
MO3+ZQWKP(M^/CO5$-W#AQ5;0?:+Y/$C>J[C]6 K?:[@7_Y%T8]-@W\$N^A6%
MNTNEW# U<M6)6;[H& 3+. H38IQH>'V0KMRF>1;!*2-P5A @9J;%&5D1#UM5
MFAL_TRH) [DCM>.4]W%.IJ8:RKJ13QDU*.E.MM[D6SUCV2-;XTF7)(BH^TB;
M'&+&^DQ$<.LC<C9VV9LN=.KQJWX1!E45W!J"3/4>-D=N*39I&I-W!*ED$5%U
M=4)S%&T9<L&S/L9\/SW>&!OT6!4/2Q\H]<CB^A%IV67476F5*G/IE0'EO+2H
MHV^,B\)R"P\/MMULSSO</MI*FS6'UV[BY6(]XVYJQ469U3;TMO513/N8>\T/
M3^_8[ NF_5+&Y#SPN@><Q>),H(HZC)ZX:#:++E_Y4V.=@L5;%>\!)I.</LH.
M=MF"SB(UW";E)OU@?J4A&-$L_:JM#7+7=<4%W<!7*^?D6+E?N?"H=3'PF45Y
MG\^J')Z!6&D$W,\W>)Q@\QPK9&N3Q):,+E&-Y#B,]LF5&8@L];5""JXO$RAE
MX*!C8\.C@"3=3^2G %(U-J2_C+'(0>FE0>Q[1NLA)#>@/<Z5VDFO\GURC13O
MS]F*B?2R-YFPS5.=#.=5&,)F9L#L\)?AYX4B1^KLMI/68S3W)U/%4;C2F!R/
ML#!?X$G.5W&)/<<%ZL:G;EE-MYR@#"'AF@[Y%_*:'%%#R:;-F72#T.Y*8&Q=
MX2SSH$BY5U_K#-J\I5C_:I"A"./*[4O/E!GBLJS_LR;MP/".PS+%#\S*K.8C
M^)HDW\9NL<02&.E%'X/>^**\!'W,V?4H@D?8E>[S'</&5-Z2!4D!N53]QN0R
M[ZS&Y%[Z7AJC/'-ANA+OI))CNO]KNVEQ#57"QB)S>';OX>,%5XDZ-T4+ $I/
MAD> ,&9)5_XC@UCOG8A52D^.DMWZ] :EFGJ':K!VGL7$:W'];=[0W!X[0W8?
M19 5EKTK4;GDF!REA H]Q8<EWBG7EX+CK0]0A!HU3(3B+ ?^S;[4&] ,":-)
MDI77:9&PXVP(/-/>(GQ4F_28CG_]3A[X<316N34BNGY'$/!ZBK@@,AY\DJ8$
M3!W9%961F>+1\;UP$;2MK>&:@>K)Q*I&A9'%8@N0EXY1.I*P#!/])NQA$NH,
M('1!^TD6CI'R@+WKM;<LM?E(:EDRO4ED: TJ2?J]#(G2M=R<R+J')@L"6)V5
M6DARC4J^C3QG%.>FS*CB4(7PE'E,R^/;:*PL]DPW#9:-@\21"M^7T7B1,V16
M9!:9\H5V1"BNN6[+?6=@3:/^0,;/K*(2YF<-I3Q:]52]W;7?5'>JQ>T5?,FK
M@M#-]B.Y#3@]DEJ;ZZ0I>=]+T@M_E.'XJG@2?)(V>\MH]X:]980R250F\M#+
M'F80(@3],Q>YS-JP!E6>>LK]T;(BM<_V@CK>L$^V,+Q;%F[8&YR:L5*:$[GR
M5N7#E,4S9A%<B/#[<M_VO/2=_LP<7Z9M!?_%+-?*_ADUU=H5RI-VO97''&IQ
M$ZRJH8HDPRN+!0E&\766LWN#\J*)3KMY-%$Q=]\<+P\/\Z:3[1T;0W[\-6*;
MY%T52FJ(6-J2]MJD9'O3E[V^.)'X81B>Q77%,FW7I!1=AS]4^*SZL-R(XTQ0
M:(2\J?GLE@,3$. 'W!>_!,.@&.-;M(6&T67LD=HXN;!^0^Z?^%W[AC%";5/F
M;R(^GLPVBV4\1B^MO*J;A2G;NTB/:ZXI<%6#-<K#IQLPC[U*H)!<6Q+W@,,L
MOX7=XY[,G/Y[ ,CA+/!SB[>J9D]?#BY8D;YT71)\@[X+_^CA&Q@7:0S);.4[
MCSN"]K<6WG:9+]K#*<PJ.&1O:(7]^Q\D0X6O]!2XG)ML^]3%";YP-PJ8O:2.
M>I.4ACSC)>48)F[\E3:?U00"(;+:YN?1HV.'(- EN_O,N^_LJG<A(]_FY^\!
MGU9975#7OI@RU_*$I>L5>@93ED7Q*LX$*Y?I!7;"M&9&5<N3AH_]:Q1N:5Q4
M^A2 ;V9;8K4#GV-EM^(=-/#UT6V>QU6!/(:397M0</XG4O?6;0G6Z< C%M;:
MTU6[GW>8YU<9.])"8KD<^ON77$7 5<<I_MLB#'WG66!Q%':ILH^N^%FK*6;F
MDN(X.T+;%*$:-U$[AMM:TI#:%R ?NFKAE.1JP&-Q3CY+N@O:=2SJAG!P3OVU
MGGL>^\%6'G1U,'8'Q!<)J1Q[:<]T1H]_\8"BD>)];[M= N<T\V$<$"K#D+LE
MW>60Y?;1S3,.)$J<$CK0S!_1"Y;DB?A).W51R[N^:XE84O[%51=XF:4061Y_
M4%2X@JG-Y<)_O['>$ \!!PCUO:K2;79RX<MXJ<B&N0C&Y'7RJX"Y Y]U[NW>
MR>Z+W0-8HLJ1@P:(Z^(.S2MHK7&"Q\HZ'*CEZ5KU'JK$)I;R<ZS'=?69P2B\
M>VQZ[,5<AURJ7%:OX8 7B3!],<<ARP2^L?2^WR[^$_!4?<T)9,CC>&X\V3BG
M>(9[YEO&E@OCM<:?2D^OKN2*#?:/E:7X5 57LU&*#)V[1"/Y/7MO?*1I_+<J
MZE!9%_+BYY02-$SPI>[_13IB2X8_*.Y-E7M WOB\R:O\8BX0D^PGW( JKCA#
MA:^<A^DQ VO-#W!J'O]^\.U!>!)HZ!W?R/X(<?RD+GPT:UA"$^7%5G G=15M
M0.E@5CZH9442Z*=&9$3'C4_-QDA9DR!MJM([A?3< 3E<X>B:0"G>Z!>]*?_"
MYFB^Z63Z1BHRE+^"K@+19<&EN$((U6:,J-V90+PU>/7/:'%/6<@E)PCL;]'(
M65#+3W::_G1@PTM09Z>AZ  K+J1Q [-*_'>%FZH,I&6\Q2WTU])YFEWZ\;9&
M6!:\<+CR$%&&_^*1ZEMX7RXIZ'BA43:5ZQ([!TS:;Y&>\CTAHZ+D9NLCFGS^
M5YL\)^X]0'WY')+\WV,KA.CCY0)]"0>E<G96*A)/XZP80=D/-PQQQ&LU>Q1!
M<+01D;M%%)4T&YK'@K6NZ;R&CR?C;DA!>%98OG'C<,:(1?UJ#N\U:M=>."I"
M2F2JB&'$.*8GX7U#,GEND!:MS>YDV?NDQ]&/7O]S$C@^_CQK/]A6IPB!_=)R
MU?4]YZIG_2Y(-,NI3%S6!V?;0JL-L-WQM (YX'<<8H63S?AU.GO^OUJKN(D7
M%(V^AX2&A8O .'X.=?'R1:2AD]A H@<+FV%>;"K2@>9]-!]TR^J,!GXO9N$4
M\AJ)AFQTF9;-U A$/5H>2+VZ%@D.&C60\Z5FS_BT_*EKX^H+^B%;Z^#_=+SP
M/RC+NGO5K.V/-O#=Q+IZKK2ION;3_*O2X>IRG_@KL-CR.=:1HE :/5[[OW?I
M_N^^\47&*\Q,R'<PE]WLRS/JZ503".U/%'<44&K]I?>)V\ 2P3A<BD(C[=JE
M2KQTQ0OA$T.4[#.R=FC&L=2W93LF0QW78)JRIV7&5*X!U5(/&K'9Y#>-U;%\
M& U;!%.#]-\2NPKOW#ZY.AEK$Y*/OSH.;VS--S#,MCWY"C-6DR*KBQK4^6"'
MN#)A9KTBE5O>GZ-]6#_PS]6$#3B\1(XESSMH3<I?<%HO355WE1S_,D=3#\M0
MV;TA[ R>EP?<G?RZ0:NRJ W@KRD]F:\7@_;N*8H!Q8/:C1G#AB=#+X30ZC;O
MZK2<S6(_,)Q:G;HD<ILD,C_>2);X0.W@QJ(G7'/;5^' H.'>5Y3MJ^\!J8/G
M=9_*%: (<Z"0GP\YF<>SEG/8I<6*0"3M:ORUA#!WG&2:ZSF_=H,0^=GBN5 $
M:[R494$IZO'TP6SF4UFK4)WE;MF"Z.!?L"59PZR<D+//_QO/-)">T 4]W%+N
MIAG]].F@FV9D.$'XFH<'R'&T-;*]?ZM9=61UQ+U_I6 +.GVGR':Z>=Z85^K'
M!<0EW%V22AV#7 Z^L%WSQJDQ^P'DU'_WZ&WKW&W_6R.C&J@0PWY'%&R!9,2B
M5&>;73>A\@!I]"HN-.E);%8S?C:EKG!-3&6<=IF:7.X#+TM+E).;-W!J<Q\X
MT/9/AG?LG2]ZH&"L);#:]S"T^+ILROWFC"$9BILD!527*G9+$!C3?D6SY#5E
MZTQ2>P<)_7)>3#9$<L#[01[BYF1B.C['N9U6RM2F5Z2N[G6L@>R:-'M2Q.C,
ME=8GO1^$<?G*F) JH<,U8O20@94_EWS8>. 1SONH]^%U[Z. N/"1'AX>[W_<
MP"1@(B;^?W \__]V^N EP=M'FC;V("<*7WQ(T5-)\L0R/M:S"NF)V0:M7R)N
MDDSB21'?A%V7"#H?<_3"D7)4QZ,]Y.S@Z;@G+@V>4MN1"J_-N#C'*,G#(^W?
M7.N'V8-Y?=[\Y")I5UQO(,_L<16ZC#&D7F"LN\A:0M(GC]^DEZE(TE*(\#\(
MJ=CD[$:[H]SI0=L4'@QK,-B<90RB3%A.SSOO/=\1S<"+2?],OA?3MG?@^"GG
M$U%)9I?93=)SQ5$6.5P;"^:D>\#TZ*/>ZM:K%#;<AH*+C:T:]#]/P\P+?VS5
M7<8N<1&J4S)@$<QD!]=I:>UY%9"^BH4)NV#CEZNU/AC46W8%V>3&AX$Y$JD:
M/SVY]"6_:/QU1!535.+"^<8^6.F-DE3PB9_<<1HH)M*V[[!;33-CU,^_Z &%
MIJS"UV2&2+8Z#>H#FX55X;KTH<H"F!>X9K)-DX^*$':<.V+JIYS_'4+XK')F
M3[!F)A-[?VY++A*[*/J(M5Z_X=NLD!MQ:?WT'Q29/<SD[U[DLH^%Z/9I-#/E
M?(B0"Y6?V4\Z[S)EIN7,1?PZ2/XO5;E\;DR0-E:WH'Z,T%1ZXHJYJ0I7W)E'
M,E^YEA8&_;/0[_'RU#U X6+)/VX8PVVI2:6YWEJ"@2";;M]"[LSA/^B8_Y\D
M 2O,$O37K/UO.=;G,3(655'0CO[A1M_AROK^X!.S53XKX#=$5O"QX#4^<^RS
M9D_7U^RFBJH4QSOLV/BQV. NA-X]0%:AC@U2G:X/XG+F&2DJ$.4K%7GOF:BH
MK/P%@N,C0W*#ZRA7KIXPF#7 \Y*PJ5]760QP(M0U,\.>B"A2J_J#]F4+!UKR
MW%EP^-"T6[BN;N2OOG(W+M@]'*C8B>+DLX<Z-C8[& <9-(JG6-A77^-[YD P
M@6B[;:MO[=9C]X#P;C],4YWX];Q+IICD\LY=)^1ZEKG%@3$T4#73\!Z@>^UT
MUM(.1.?TE&A7,Z%<+P^*L"5O"CL/#]R6N3WV?I_G[YX(<JUC)$AW2NX!-C"5
M2W>H)UW:H@YZ=8GEJ< >JJ$=OZCJDZ@@^9/4']/DKU$\25/!R\-8>M+X.F#^
MP4'R&5LL_B>>\B#ER8R:)E#)7BO76.A$TY\&HA;GU.NIL/T:]6>,H/4.["*1
M^&PUL4)63M,LY<0@7SI2D[]S^%#@JUDL%T'L>Q) -$#G ^!)ZJ?'NJF?=(-U
M_U&R6RN'LDVM[A7^IRZWREN6J)&!^?[APKFS0LBD]R)6.Y@C_OM6E%MR6[-P
M#SXN"]CB9M1R5F8LHZ>D@2[3HE-D-J_4D!IK>M!MT+7X-& @O&3>0H*F+WNF
MO?B]L&0>=\N8"(9I"E^[=_/AQ]@9)SZ!MUU7Z96*:,8OOV*]6^ALZS?J[+]V
M8[TZ_[*NG^2A<Z;-ZMCB4EFZ!DW>X<\GJX)U'.4=+LAL)B4]M\MJ')1HV=@1
M',Z+-H4Z8'#N ;E!_L@W:W@-0H;UA9#FMZ>?IE-BA51>NG%D=@_LX%5\I,6I
MZ[=>,B\+>46]U[QAL"%;+$>40CZIXU+Q4K=Z2VK;W)4P08Y:..'E2]]/GY2W
MS.^:"5$8Q^;8MB7#CTT+55P5YX:=^O#M\O8,1B0O\9<'UGMFN]^$KWBMM<CV
M-4,Z0IGFHM)P!UI/:YTL<?O.[$I?BQ/)J.-K][27\CSD6(_HZF>*[J5TI8]O
M[YGJZS7 GN=\I?PNR(SJ^S$0>_TX.\8BC2?87A/-J#KDG[E)>O@1.<*RMSS[
M26V[5FE02GDF4K*_3072>]/@1:::494S6-J$GA/T2&XY*+)<FA'[':G?H>-H
M]=9]UN3[DK\<U>9>B[\>H^*R58]&#071ZZ3/4\FR0OD)F?2]ZUMO7\W2J,YW
M<&E<Y ?]+K/CX2!L7'0+G1"@5$Z;G#+M6W>NS\V-*\!Q)NC"\1W$1,H5  7+
ME1U1.MERC,F1<L]R,EG4-Q@I5ZOV^"WF1YY3MWNY ^]BL,^6.;(=<ASG.5!^
M)2AI;'UEK+4;7L7G-<QR8Q9L46K[#JT>=G5;<?,5/C)EEP4, ^'UDLY"JYZ7
M^CBY9WUNVK:L9@HX12>36U7*1A;KW6*]!(]<U?6@//U:!<ZFX)&2W"!J9KJ7
M/B1.EF>64#MCJX9#[P&K8=V-&" CDPN9[>C)QHGFM:=)9($CE?;;/Y=T#=8=
MWB*QJ/Y5NT7V<ZV\,&O>Y<HVAK0:O&4S4VRAO %;$I!/4]B?+7E< @*=ABFC
M&;5?W:K?-E,+0H8?"^S9 SA.9>$T@-'M0X/W@"B@ZLO6NO=0#N4#^.A1=^O*
M V>LW^^SRY+P:D]_M!70SV0"ZW]TJ W8Z'.>VJ8<=KCOJ<1FNK$>A29%<%A@
MHT;ZCXRG%0*C;95@ 8LY'D/F<1:Q(]=O-I?8Q$+[KXY-Y]&!:EMK6""8S4WP
MF*NGF)#$2-V[_M]6IZR-&QPYSP7#.>7R>0. *J8NJ6Q\LL6FSF>VFRY3:R1D
M9>I%SSX:$9!</WQ'XAIHG9/(Z.KI&3NZ+P8[JF\!L&W;A>\[Z!TCSBF#<2?-
M<KVN^W9/:+:"7>(I4AI1)]P@]J2[@W=D6X@/*[PG]X#="KG)3Y>3QP:E_?.W
M4/V.6?.[J87/)1>HO)^)(!7ON&['I[%1A3WPV'EO%GYS_O8_#- 0_3NS3MY[
MP*A<92D7K4Q[E3W&^L(8:"IPIR!D3!T]=7X/.. 3I,OWPE2!6>D#!YM/-X?C
M^/,ZR@K6S1W#[@%MLL:5?6B_>\#5L'GE@8V\[C)7L7,SLTE0J#I.4KXC+ @0
M6D_"/$($+N ! 9[#C8336I]Y^2L?C S-DE>:.!F2ZQ?TP?0FZ^)2(9_=SWGN
MR@]?'-P#6%WZV^4P8RUEV3D9D3?E]L6Z;VZ9$%JS+(',FZ/Z?E:=):57#>%E
MPWT#^O[^W-\Q'J\,C3<I3*'HG(19>GP4QLCNV LRZ]5I$R#UNEJU/G+31D@L
MKG+/[V7+0IC\(.OCUZT*@[SOI"88XR=GI*<D'AT*MLL??@AIQY#)(P_7#_FE
MX:.'!W#XX>$_6*T9K:VW:4VG-S%'>D>MSQWA>OA>C?N:\[5$?S8]^ 1<&RW$
M7Y"]O_X"P4O--@W ZJZ*&=#+;+EKCLA) )G:4!Y)'J6T5OWL_ %J1+0IA\=*
M5J1.Q9-/#^YMFS@GMG,[9I A13X=C>$3'U1]:!LSBGBCSP?MS<%S/0^@+O2J
MV2IB?%6"L% 29TE39U:[1/O2:]AHSI*. %O]JJ,/HB>[_(RE&5),._1',W9>
ME\0MUO)+Z31>22G-CS >PAR6FV [0&]2_Q0_7,@9 URO)'GT>Y9B7[,5CE<F
M7= G$I8O4O-K0PA:%Z^M#@R'4$0SKHGC0&?9=!1[/#2YTY,=W&['#A[4!6_+
MT"=DZVMSZ&=F(FI,O:.WTG6QK]WB!^_2,D(M+=?B]5Y:_N.R-/E'MJW+OS "
M[SRMZ29'%Z0,GB!!J2;#S8P 5%6OI%W=-K=B^=<'V]JW/HBKKBX5=A"LM1G2
MQ.7;G#L(%NQLR3$F)-#O6V01?<F9+Z5LD P8559+MH$MF8!4^*ZU69BB%@B4
M4#V>M7+T(\SBADG)[?[+B=?XI#/&&?U_U3=&X6;@^W1FKMO^+IH0J,)^#_"$
M;"[]%29,RYW$IGAGW.(]8%^?*)^I0ZNE,J[J+E"W0D*I@.XR.M'FX*9HOPZS
MG+:6=S/<S#\JGHNY!V!8Y^;:@Z9O4]+QQ/.JM=W22$D2^\NPE!3]'0M)FY/:
M&94,_#]Z6IZ4#U%1"TL]&V8&B,=44@L$?3Y]&%>N$.;XZ7M)3MCZ7^/H;CZK
M(V_0NOE]5N-,$:F%:J66UL_,=0KO.ZA 49O&73/*C7YDD!V*L.SL8W&9+&(D
M9U)6BZ:;5,T(NIS2UU=(RA99!&WK7\HX(_'-T79MZ<7U,^']LU#'>K'61"@(
MZ2-PIR6Z_?S(YZ V">YR-?'8X<GK6?8!Y67B)3(X&^M\_OC=[R;I[[3-NL,W
MDW0TO3KV+E2D2A\YU<7'GC/Z]<G!TM(R#U5+)5QQZQDV!"ERA8-<.AB:EO;+
MQV#^PM_*IM=1(_O>PJ<\7AUKB.+.E_> &1[!P.DRJ=*Z3:<(H4K^BH1"4W-_
MDLBR_'1W#OUM9!Y)^Z'#$+8;\BWC\.Y%9A3V.NDS$]V?)HA5[2S[Z0SI_G;5
MS[6?];42U58AGMMNYTBH9 6HT_*L,**_D55V=XD_L[^N+L5 3*R!(#FM14_A
MR6-3D(7)A9_-J)QA6MIPJ*4J^^KT"6?,K<^O@(LAYKK/:?_698KK42BR>F7#
M4^N:B<A23]YA9)9KO'1-SG"X6UQ*%!A]&1M7+,VE&MG;P 2C2T0<)/Z!K&DJ
MW@.VXQ8#SX1:[P&@SEZQ&73)^#U 3U/VT3T@7=SA'O![[PB]< \@N-6_*))!
MVVC&7Z3= Y[LKNZOWK7#0!>N]P#P7@X\\.B'U4,:%@-]M7C#70%PT8*,LT*L
M:("2J#<F:F%_TBN][?K:MY3'5VP,,KVGXZ9.;+HBW\$1HJ_MN$3SVH/E(WL9
M/ZZ98*3 CV!SL 19?J+R8YRYAX&_6Q*4;]BL2B]"H3S 1[YRNQ'W@$]WF0X^
M-9WU2\#D=_#NK17E0_CAP57SO"?G,0CE8+$=D!UC5Y2_MY9U#;45\G/F&-O9
M1!MS^MZ*U/[9>6X1B*GXEIA79/&:CR?(R='&;(-#A[^=(D@E?R[_3H%Y&M:X
MR4K)/ 3/9(_S0CJ,K]ARYB5K9*CM+EI-YL9-G#=URK0WK^<,GR_NB\_<M $3
M-T#<RJ,'=W5U)_VM84X)&$V'T57#J;EV^UD^QY4N%>RRU=ZZ0()EOIK78!E/
M03I'\/%)<YI@0 8-GMI!%JV[2?SH\;2;,1(C21YPR,,H/<K#$YVM!RDV#-^?
M#^I5Z?H+;LC#Z1Q%OX-VN5RH::*_@EM[**W"*C>%JW<&_6W\:5\Y>$\#]VMO
MG9T.%HF'Q<82>]=J#:S6T7.D@LHX-HWK]J33QGL+:'W0OH!85=EEB[RA%?U.
M8(J/E'#G4+M$ ,0%!&) @0(9K9Q\A<5;0ZZ)<M *G'7^E[RRFP6[M_"^@XA%
M-WW[4>M:(=M)/9B^P"I/H=,PZSKJUPOX]AK'D<P[+A2!^3Y^#(5 ],GB5W^#
M2IMYTD;'Z!4#K)[71CMAH#(9*CN5I7>X':\&PUN?I.K'4?V,/=IK?GW@CG1/
M??Q=A/]=Z%=.1A1&N15H!:Q2=\#DYI:Z@[7\I*VH_%65<,XE35^ATK/V8'"@
M]?P+L^SZC0^*:+-Q)IEW,I1NZY5B5=CZQAQB/D:(05^H?6,T]ZM;A3S5!B<!
M]HXE;6I&9^#;K5UNC?F1 )R <_;;:<=+MWX')&FKHR9T$-@YE^3&SXTJQEZ!
M=AQ57>[HFYM53VZ^)Z&>('-,VH]FMEEG8KMRZN&)B9YJMHL;=N4TZ_$$Q63I
MZEO=KO%VE"\8.I0X--@S=(SK"3-#V@MW<@IQ"_:F"IYK5;L.3M)G^B_EE$FR
M42V7Z^I%LG*^$]$J^HEWT'8ZS'91*(C4 2N0E,NBU50LW9CME6COBM@*U2CN
M?BKO&Q]S?D>]=STWR!RR4)H["<63MSLRF)[5Q9J68]DO [OXRO.?^?(K4'KW
MNENL;Y0K:#:L+"^-GZD:1'(;;M(AQ*SE&,D_,M:)U4,#6LMSQYN?(=5>]R(G
MQJ.PQ+;7O!S%QS$>(:B5F_WZBT7-)KFU!/'/[DW7)P.G]X"MVYQ]85;A0CYR
M7@S*N&?R%-/=?F(4QA8MO=F2I0*/78GQP8C/F1?VV^/J3;J?<236NL!D/MM&
M&XG3H)JB+3X>U,_2!!21N&;7<\\"K/9YDC^0C\!R3#WTUG%=>@BJ90@>NWRM
M>Q_\A0W -K(%IV&#K]+RL(.T+6I@!I5"O?4HHO^#MK>,BJO;MD4A!@D6/ 1W
M".Y22(([P:60A,*E\,(AP=T*UP0-+H6[>^$.A;N[R_N^??9N[^[[[FOWGG;N
MF>M/K3^KUFICK#7'G'WTWLU\$4#GL,X*U4V+-Y;3WWDW.[1-D:+11OP(7,QL
M:5U8C\'34]=A8 Y=7_%@'@)^<;2B@IXUD;+,_%<&%4;\2<%K!7'AV7T3N-M9
M3%@H>@'(Q-,C%C8HM,488EBIF"WNS+[*>^#J JF9>SXI[#*76N:B4$0C58AA
M&R9=WIV#/?.U(]4Z?>.^X+X2*].V7L[F>?CU?4ERS^^@%OD*@2.R"%+'? N\
MNQDQC13[P#I',[X\3^F*V!XNK&JAFR?309 16"&'N-HJ;-"K*\_-AX[Y7Q)M
MBS!8+>8_""?+:OV:D1_72"*8 ,2B1(=@X5"]LH,YE*,Y]:O[A/8!G(5"583U
MN*7G=%6HXRFXJP4PXT1B:+-VWV._?"P&E!/EF<G;F1$/:"232Y4XZE(@\;N_
MW6Q>\G[RF;C;:Q?N\ZI<RJD\R,BI;KO4[]]AXJ6]KJ5U9,G["4<@V@=Z@!_)
M%#@\*?7X/Q3VE*LU,U5L>(C6^6"L62J2A<YHEFS84^OY,WT_.U@7 ;YZ: -]
M<(U-$"? M)E2DBWJ(.7?E<V^/-<ZG>%H@"HOI)(F="Z4Q?0@_).W"]R+([BY
M:BO;Z6O0>XF"@ICU.AE(C!6NC[7;.M8QR0V >LD:3*<EB3H@$\V<;'C-H5R1
MP&X#T^&7N0_-.<FR%T/%&5AK*&A\9Z09^N6&I@-;$YZ-!S650C6:RQ9_:O<B
M@JV;BD4/!.8[29L\O$*FXG4_WK+;^O&P<G+M>1K\*B#Q;D21OP?I=I*X_(FI
M51F'O6RL=P:8OMC.R\W7#XF!L$J0NJS/"9;X-_;8>?"<Z_,I.L7.Y4TH-+FZ
MQ6]HZ%_T*Q5])Z:DG5>)18@^S#C=B?S^;.:%\FUB\B8?T4RM$*:ZFR(QGQ>A
MG90SO-O0N>9)T48N!*7.7R?"2/H0.<PINPZARE=7ORT;EO'O\N^2D4U3D$WR
M]T\-PC';3-//##+;3&]*3S#TO\FFEQ[)%L6_OQA<]O,0V\L='S!;1J2YV\+L
M8B-BYNW"M!]]Q+-5NAIQJ0 =LP>9Q70M7>OG8?NU%BQKC]-CI:G$ELRYO!&+
M,@UN*&?>P"A'[U810_K,&4WD(]W#2?6M*.-+K^GOU"GZS:V68F;>K[9K<^7$
MO3.0?8&SFBZ$JX>CA"(I'+S8+OE79%"SZFS+"(!:YP+B.T0\FP0;*I[/5?EV
MMMY71"!2,$%7H&RUJ?=<M$3EO6DO.K27)\1LKR"A1SLA0\K_1+\ 7!6 'YKX
MJ0]WNOI5=F<O-ZX4IY3-%@Z:8,M\WIOT'D%T-YIT-Y[;NJNJ]*3DKXJL)KN"
M^7"-4>5EOS002SY17)'RP-#*H5N'Q2WFL#SEE):)FL=]V:5UY$1)*XR'='JW
M:S9K<""2]5!D$;\V4;S'[2UE$'#W5TGD5-7K63*+--1/9E:2@U#5(7].Q4X^
M1:O?X%2 /T<_362IY[ZNB%1FHC>!^E\!G]VO%$DM+53Q<<<-4_-/E!53B=T9
M;,_;X]X<TU3$5<O;8>R07WDD[U#QZ)%OB+6X_.(9?O4F036^"2Q53/C'L(Q'
MONI0@DNS6K,-3^V+D%07CB2S\6<CA8,UI>'!_:P>*47N"8N\%(N#"?T4*YA!
M^%55RES)Q,[$P4Q;CIFKS_>TP*Z]E8K0R*GFQDFN0=;T?MFALK#*#0?EO$HN
MM\1B]8@4!>>0!D-*<7@D4(/-Z=ME=-Q C1:Q4#4GGO472&YAI1"OI5X1A;+N
ME,67V;64M^MOOT>3A@J\DC%,,/%1O)N%"]1_5&/+KE:D; P>;%_M@Q_,%IAR
M6E@:,PPM37E,6J-JE[![H?\<M[8GB4DGOI>%.$UZL)2R[< E:+G1-ZU>)G_H
M8]Q#IXE]/]W\,I&*RX_K2^R?+A.Y'5E"]1@A7+C[PX=3,<%AOIV'W?P_ZYVF
MF[77AV]IMTKN%_ K6P >"!9@@:)8^DW[:G<*1&RJ:J=N@M&6H=-Y ]Z,L 47
MUCL[BS8\]M:,;54M0[!<66Q6)WQ>6+[]5E(W[X!,,O5E-]C1Z7,* P^!")M)
M _T6_UE\MMDE\<8#EV:%>NAOLEBR=>FT0ZZXWW@ES.Y F=UP8IC#$GXR=7TR
M#!<&\\+JB"%D&10U;';0QZ@C.L3Z<_IQ67I)"&*%85(\G23 L(D"3N5F[1KN
M- K8(=G7*P9W<K]Y<$I%#O]ZM;48OE2#\+(OA4WYEL!!&;6IH1_"\WR;<<SW
MUO^(<_S :WT#VE?_);7R2ADE>(6%FNN^SJS#_2*#IF_RM%[S]:S+IX+EI=[^
MFOGZ_=!G),K-(EHU95>Z_=AYCK@<[]>G=(+#F>@>&7.3=45\.T?^5#. 9R3^
MC('N_:L9-X8UVW?2]P2[A&6A_::YF- ^'<OX](6=PG&P<4SK07H!3=C&>:F!
M'D P"EV*U6.Z:**(>-!H\E3+E_<1#T:,Q-7:AU#NQ[U%A4%;T?<\/42L)Y.)
M[^3%C)*7K",633%QD<_=6$9(>%DN;AT.MEFR]LY7,PL>]]2G'$ :JG$;V:]R
M!?JOPBGJ<^G/9&UOZ#Q/(6KJ,Q&8-<;#C)(N]N&)BBV<F50&44N2@_>EO(<7
M1WT[%=%D K!X:TL=G;GD/JX$S$VN[25%.OZ"/M8G:QKX"/K EYFV\11P*3%A
M1)=*^/?<T-_*Q$KOP=&A)1]/I\H^8.U(4 8C 3=,30V]'(GU)C-,P0; 9<^T
MU+*Y:[E!6N[6.46VOM2+(9ZH"$FT!T6>J8;+#=\PGU2@OX1V]N)_':HQT@*S
M#H\=!<[NI3-08$%3_!-/<(CYWF^?=FA6>"9BKN*G(DT6)\&BIV!<80+LA?CS
M!3QN)F5&U+ZNM+%O5^+<:0-=%;)3B"2? F5R<%Z21P<L; "I-#@!*XT\(OZ(
ML/I"=E=M#-?7?QBJOD]@Z/VYL=O>Y:J%]2/6&5X,"U-"3SY_Y"=:1,W[#WQE
M)34!<M<ZV+_PUU+<<,- !=GUZ6!XW ?.9E'U> _Q @G_#.8>SJ(2*=CH6_L5
MRE"F/)(9$I=U:=NGW(DW,=2&H!H:?U%PN%@_+UL%V2:+:P5U=![A\9Q^Z]&3
M),C*.1_TCTE>SJ&IFUCH<;,[AYOF&'>==G7:_;-S@."]2]!5K$WI?(EL9AG%
M&_ &AM]$#+15Q=1A<2:T#>86#;)J#B\NZ>,(H _(>4N+HM-2"%AVF5>HYEV=
M&*UB=OY>Q6(+__7Z0'OREL("3%0K)-H^>YVO1*83*;#=SW6)W'/PBC$Y!C<Y
MA@A:3Y1:3Y0LJD*$>QN##8C!O6UL;'A2^6=DSF^)^I^^$#A0^41+2*;WI3\D
M)Z<C'E+A!ON-VS"0#7C: B' 389I.JF<,9E6?A.5,="+GI 5WYT<O/.%5$^[
M504F*<6!2X'MK&6P>P3/A.-"3E472]:_<9N_*1B,\]U$'E&U0Z=]X2UH -3A
M0Q,GXJ^8ZM6G<W%M>'> ^E_P]_QO- ?^CY^7;&.!D[B:,'1-)NU0&>8O['\;
MB/Y2&42O^-M ])<$CI31VC<EFN'AYJK/JK"F]7*;B%]3AF]7K0;I?DXZ]K,2
M>),L8+DF;5;DEY"3C?@/.:YML!IT$[@N9EA"!:1P9FU:@/3YU[CRFTZ1>7E\
M' +F0@+$_?E%1GP6GY;SF6!-A!9*E,(604/&;XR,PL/?A3T6>[#N861-\U5E
MN))])632UBN7^J+%%R2@P&3,5.'0YCT2 ($1-0.^,V,ZO)1F_@&2^U<+A?E]
M&6 H?R$LGINNKD'U\'%NR'SC *]R,(=%<8N5[3#F&WWJ^23Z(DA)K![EO7N7
M,O@3X4KU*UXK1?S0::-(]RN*:)- 5SKD6,;?<22^?[<!K$>_;>M*"D"DIUNY
MJPDC,I?\'&V*I\9T]Q!-@3\K[;]$-E.2I@H*BKD0N ;-)^@AUW/-YI%*1D(\
M\-9=E\Q1T=RH;ET5$$+Q@O7H7G]8QQI?:18L%C$HZ\(MVO[!L!X0,$K@Q'WY
MPIX2 G&^_&\237#==--8/A8ZUK,&;D"VK<Y>N"EAYF5-X^7A1A%/#G.ME:MU
M;=#'F/I@;LEQ[?8FJN,WE'+TJV,Y-LLWXPA)Z A7+(2MTQF9#R<43%[D>;.W
M@==!&"$9]*;,53&P;O<-XR^1H6J^.#?2Q;N:6+> QK.C9R3])P-#..)A)M'E
M_QWT]!MIZ;<.]/\Z]]9W_=>].AR^_ 7[F,T3,3'[#G?C7,!#9;QWO%2HG_NL
M-9'M@J/S0X6\T-8AR7M_J(P8DE*;BZ%QQF#](6(ZZ9 ^X"U5H)B5P%!KT(PA
M2E#(PK2MPO&!4.ZF03C6X%P]LPJ,VX8[9BG?]"KH]:^+87+9W08_>>R  E+=
ML=JT2B@?UT(U?8RRP\8PQ$;)>Q+69_K@,#2[.2M>X4UN4N6D;7G\^E RUK5T
M+VU%ZD '/4RB@Z<(+WSB#3W)\%?0?J*XJ/JUTH=#?=BPS7]"'3]KQJVV=VGK
M,:WH!@NG3.Y/]9+-Z75]J]FGIY==O]A5_A$YO-!KN4<.#[/'5BT?E(9Z:=7_
MJ7V!@O7J?WG]%Y\ .RT4SO1SZ;0W_9'J/5H"QUDW/R<S39T2U^D$U(C^B;=#
M,G:.@Q7Q'V<?N-Q4=?3S&P!KN)(^$%'TI<^R@O\=\OXO7P.\('1=MDK1B20V
M^,(:P9'P9OID$>DIVS30E-@N*E$"/=VI.,;*=\Z0'J;H,+CVJUVT4B<1H,*6
M@ZZ/L)0UV P+K"OPD8 H17?:"+*AWQO-SFZ70 2B"G6EB30/SHZ6O>+\8W4,
M/#JU&>Q,J!GG]MNZ?PT\E]2F(H!JK#']!(S2D_E"V62\FM1[ME2[.$$DACV%
MSC_^?&3;:?L1C"Z#COJC;:[K[ZX?]+\63UW)7?[)P;+IZ<ES<S[_]/%EE/F'
M_ '([)*\[78?1[ZV(;#M@8T0A7JE\DT[GJYO$A;;*!4RIBX2H=L>^^P;M]T>
MG.X&"MXO( >>(ZTR<,ZI3I'EA^+I"N3P<NTR?O1H./JOH[]K>GHBO[HD**XH
MYN"2AN>1SS&.-4NHAV(I)\E?:WGVG6+XW VZ27_(K--F@8GWFXA=&2"FA!$/
MF'AT=:U:IT@7Z^\Y%EOXW[35M=C^S6SXG['X=S=AE<U_EUY_(1;SO^U6TK$5
MF31RGH9.Z@($B&1#)F<]9JW@Q.5P$JU?_+K=CA"ZR"DU"IBF >EJ!9XJEP-S
M(X^K\]V8YUX:<ZD2@1;#,&[8_->TCW$FA#MKXQ9WW%YFKQGJ^NF)_CJFN*?A
M/"=6V3Q%MN"1+=X9H*4P1@8*>D9J_Z"4FKT=L?.B6(\HY?O;AW7:J)3J'5<'
M6\RV,&RGLQ8ID84/)T_/2 ^M5K=V);++C;-*^EKYWQ (-HG\R12I7U.3EY9=
MW2"FG+:-^-+@'H3C_ 1,GC:(##6*4'@IT[*80U:UF%<:L?W04EOOY-(YS%&F
M/[X[H/3IIK=_J,3I[.P[_O"MEN7!KHUW&E1E.85SOO@T$5/^)4M.)E5BLD*K
M;LVUO(\6:1KM.?"P*N',$9'>(EY[#\^NK*$[X4@&1N1Q;BEW?9<74IF(U#%,
MP YM$9^T[J<$H*MT.1!&.\S4F90X-%ZB?6@E@0%P/>86X.F9>[#[S$QZK;D#
ME'E.X='Y9HZ"G"3C@5[@BHT8J9>#>'HWNU;]>N.)@@OUI6>:E\*PQG$[/7K/
M0.N]Y,FZ:L?4=T*8,AIE[EP^D_W&,Q+>D9]M?N-K1);L2:VFHF$0_4E?@:>:
M'$'NC9=>[&.!2-]0E9)6D(93X@@T<T2M>ZP^MF\N,$&47-.CME2;-_)=-9.$
MFG8%1V*T--YG52+1.DF$RG;3RQI3<:_+7=UB-?'?%QO3!>8';A529VVFR&;"
M#JRN5K<^[[B0Z?;R)8NFSJ#3[V0QC[,/]W06)JQ+(QMZP_)II,L<G.E<K!)7
MXW.#Y*54;O'=I4DT860+X=,9[UXQ3Y7X1UNABH<53#^\K7/CNN6'\34_Y8O>
M/THZ-KT^&=F)E]8=+K-.77D*T)O1Y=AJ6)PX!$L8C.VD,7A=UZA$:)\V=IDN
M[Z0QGHN @8N&"]6B&W=> YDZHCJE2VNV,=^KII79HGLLO !R>@F.7&!T;Y$(
MB"T!O'\PCW\V?184[CEL80P)_> KFTL9CIIRH.\/(#&J,930;)MQ+=D^$\&4
MUC3]['GFYAOBWX%#281"'&7VJ6Y6-KF'0&!(MSL54^5V\726^:*4F4]+>Y2A
M&O*[$)3/<4VYY@7(+P[C*XF6[6]/&!9[5 6@.VIT]^'+SI8@0O+UXQS7RT(R
M<QS(H &F-_Q0'YDT\L9X*,H<S[CZ>G45[[69+4_&!4@]8J3=!U,S,11VEMT"
M47=+Y+PN*+3R,:BH[)Z6;_H^B!D!)U/!UG)P>B=RWP\P;:^\=[%E45^':IJA
MGS2(Q:#V3\6E4#,ZJ'4==XYW3H/J.3[$J6I;QO6GE?B)N&[!>#@F#S?89@/3
MW^'G-T(VD]]\O+34",Z'F;HISE(%HG[>2!"'O ^7"9E+1OS)7 BJ5D2<+@[>
MA=.D.;6PE6%G_R'_BO[!U?CJ.$VR5W)H<NWZH!Y-!EM8-V#SJUO" ]D*8:FE
MO<N7)G1ZXLI4@\,RG\*>9Z2,.&!F1Y+.E&ROZW57!F=@5/YP-TTEJVH FG.3
MN\?5X9.-J$MKR^I8R1!P0L/$H2*VF;O&1B?! W*HS9?07:2IL 4S<L-8S,GH
M&I=EKL3]J^XG^JOXR&.KOZ\42@THH5W$^"*!)6ON89?!8.K+A]Y3\I(87\(]
M8$!W]L,LFS8].+&159!A\0% C6=D,SQKRK/T9^(.3:'K;--Q)CL7NQPO9BH@
M8+,YMI*RLUK(AC^_T3@M(.7#VX:D8+=F'[/T\ Z;FLAV\V910BG1MS(4;L&2
M^:W6];%7<@M18PNMUKDP 5$ADG3DKF\O> &]8&%=@XRJ18NSK>WV[KJ+^ _I
M(),P6QB3^YC6(#Q.-][*_7(E$T59?1BF,Q06CZ>\%W=7Q'K_-7*D(4C>[/QL
M B&;/AS95/JV_CXF>.S.A:_0<;HC@5AYG=7$@5?Q&>GW5.[;(9L/M=7,9Q?<
M&K\B0H$$F Q4+Q,^O\A6GV*B_[A**#"LXD^)MYC+R)W](7>JGC=6OLC6:&W8
MDL,!JA*N%I>SU$]3:U,[1M-0NQ-L<MQZZ$<''9OB'7EIX:>R/RH:,,SG0TR<
MG>T8N8H65AL$XK$&]8A/=HU(..0-X?B_F1*:YD:U BDN[%!^&GY&TN9G6+A,
M;KC1OVXF[D] >+5/ G^F6%"G"KB4YG)%YZ!K4OW!T-/D?.-BA[JG&LJ&G[5"
M5P<I@>)-FT;?#6I(TNXERKT[EWW#-F6<X;H:*V/%?1;OFN+VF83"K2^L\U1&
M2#I\5C!-/C+@1/J5N,3H7F]LU+C)8$RR2,:59 &C>.HT7JGN=]B\7EH_/:]J
M"_NZVU[*9G21&VA*/[J$Y2K ^7XL%<B2"PK/9;EGM%Y04=C9CKJU:\4)N_4Y
M:$GU>U3>O!L\LWO,38@(\N7-9%[;WG^(>FA-1,NS5CJ5I['=6*5$(3OB=S%9
M*B.??CK;80$OO9$SW0Z,!L6G;ES]3&I]L*-_K#[J]H27)2HOUUXE'W[4.X\3
MX=@RA,H_(Q&>B&R12:5TJ8BRTAG8C#0GIV5>I2=/6UK\^-8K<[C993T$OUM2
M[+U-0-_1\=0+I[[\,'C9U.#VC'3::F%F@Y6^%C'WN,;RC+36>K9J+>AEP2AJ
M>+#PC+1DD4'CT2I5=)F/F1D^<T6-?QGX)?!B$<J%"FMLA'%Y(!"(1WAO:N-]
MW(B+^S7O/L:$I7LV\.XH?%152&UF+]QH,B6V'@LH\JGX-!7T1P;!<I)[XQ:M
M7!@!H!X:ZR-W,G0&AP]\9V^<* 5AR$</R8*G4R>T]M!6V<= #IKVH\:E,ZG%
M#K=H]%^.)MRR/_)0I*"@TI<O54Z#L/\E)]8\!#_CFS2])=+PP?,T=3(VWKU3
MG=\KJ0D/[^^]!3!!_5<CWK*D9=.L':78(T0_L2&J*CRQ5S>8>WOZX?MOU=3W
M>\/N5>+PLIER&@XF%,581&>LBM'UVZU;HN85:^%K508X&6BXP1-S'O[OZ[FO
M<@O"*QCU^XUI&5GU:ND#-WD6U.3Y6(\GAX98Q%A*@K+B%)96BUF.[F*XF&XA
M70/"++F+]V)']&^6K7##D[33C&\S^KB5QY^4X-1AK2)Z'@L!7PY?DDMR^A1@
M83QNF:1<F:<G:!1O  7F;.;XFZZ4E!S3?NN?.<3E+#B $0NVWGDQAR2_#41>
M\_2P^W^W]*>* ^$S3N'%J<ZQN63)GS"+[MRN(PZ/2<?)S=+?JE(9W4I6.TV$
M!4V#B@^4%MVBPUI?%6<5;>X\&,U5U6QMN.MD])3U?-T[N7&Q_"!37-ZTG/W]
M1J4_ZQFIT)'Z&:E,$^.K8826XZG(GR?<GJ!',@)N\M,P.A\TBXU1[MEGI)1*
MP_&6.1_S?P/H_R>\GEDK8/E>//L9J73JT7K0OO6&6N492:/V:5>#Z_\'>Z?
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MVK+?PL79HVKV_A9<.\XCFV+X8]%I/B$LF:6XI']=0+CA.EW>1_:RDKPJKW&
M(5W"@&@F_FN8B-/5DS7DI?U%@I74GN42+ 2NX4ICOVN%3__"PM*8L4_, &.>
M5PS DVOJG0PRI:.@(LP*/+<N];&XK &)6=J9U48F%N:VH7R<"Y?8\$'9W'-V
MNR&D0G&,2G2?SJY0[XM\03]+ML?2..'QMK?I(T>EMN I9NOXU]GZ?-/OV% 6
MC;G<YKSMU!CO,#BQ;!0CR7I)['LZ\W68<8;-";#+)=OTD9#.PV(.%EK1?U\W
MTPHA0AL3TV?J.SQBF%TXB]/36*M%%M=ICRL*O$TZ@1:9' ,QC\K2$G4T[CUZ
M\P&61<T9@"]F$ ]]H^JM]-L;<;C",,=(%LGTFZ$8_ ?C)C=T_[& 4$< 0+/U
MM<6= E(V8-P&\^#;Y7!*IR6"S\[VNV-<=J-<)Y]L.;2N_]7IV3%&(0P]ON2S
MP20O52RGB_WFY<6J35PVJ\B&JE8%<K^!.3.RI+#5^V1);EQ):O08>3Q?E4%L
M&)XIZZLAQ8[XIUWO193JAMJMEVJZ)Q>L92U+199=PSP7TSEI4@PLGJ=W5+VF
MJ%3Y'KGK'VSB@?EM[F--Q^N)06CJ78^, 1CG%4Q@>]\E'>V*)=4HY6H;8>LB
M,"PLW4).J>JWX>NZ*W=OA2H;,3"/DH>:0$O\_./DW55 .K6H3+^4K<D0HG7,
MU6PS>6'QR;JID!=X4IY9ZV)T0'=EWE_.E\9H9K\D?,B8OK,'Q4UP;= VV077
M<R3>49=!BT7'*+\EB#!KE7Y/16V^,\CW)I 4T)Z62PNE*R[LNPY//+&WJ!M@
M<QU@Z9'MKG)SM-OK*QQ@]:TL,EKEEX>%/>4UYM786W!/R*8<7V+&PW<>GH#2
M>PTX($=7H+0TK9STWK<X;3F!7]! B[TY_W68:A\71NAX-SN,PVZV;-[E\^1?
M2X9&"BSNWQ[.>=?\LM,O.M@NZ3:S**]%U=R<T02AX*>E!4'PM?FG>2LTJ? 8
M<^M7VL):?RRJS-R/O#>>D5 ]/YCA>C[5)!?:S4!BQ>+8-BKC&R@O69G%MBH1
M: L11I&Q[=W,_+U)S!ME"JP]*F)KQY12RZ-%7R[$:)0@Q4W474;HVQ.8.-/@
MD?$3F$/!'<_<A]$69]N&*$Z$G/!\0,S\K)3B,'M*>//&@!=T==H@N:SG0.#0
M#ZUIX8QF\OM'BMN\W)H%1*6S0[?'X;GU[T:#3&/A:@^"K<D:OVWNNWU0\N,X
MD'?- V/0"\,U?0WK:9]1%-HU=%5SI'+P</OHYF&@]W.0-,NR_XU0?PO$/8A#
M4S?K<*325AZ?IY^$-+,S 2$[U]7!YRH\>B=DV1[1MEHPR,'5+DXN5R7)DJII
M%I\=RK 6D;9=[3 4_D@U0@,;>#JC]0!WZ:=\GT]OZ+  4S%G5VPZXR<UZ)=L
ME_DK.]WUWE%H1GZZN=L>/%>->S'2R1GLZ;"V&9 [0H:S0*VBVE/*>#_6,^=%
MY^/GIR$:UNA\93 >]79M4'TJ0V_M*2IXW5CM("?UC/)AF^;(PTF)!6(^Z"2A
M[IKA^W]CU_P=-V"FD=N'VR9O@)1!2.\I*KI:$[\]M2N^0"M%J!K3:Y-T2"\!
MU6C3OW0ZE^GL)+@IL6PC(/T?.]9_=SO//:2G9_;//0[_F%ZA'>2JK5](>#2[
M9F/B\6B_Y_7AA$],?G2HPL(D6(WT481)K>)^YZP<^CKC=T%+(#BI>0H:/^Y4
M [LZ!\C\QTW=?0AO3O,:2'ZG&N]1Q3+=K-0&J&@'IYW.%?$# /QI7-TDO@H'
M:V)_-YH5W4)DE^=3TVO=#74U["PX9Z](PE]V"BMT,V)&&A2\]'HI'EWV/6LS
M.1(E\.N6 %*FX5ZYF3V]A6GO-M<","8SJ]2!T9DL_90&0C"H&LE0.4F%<G8*
M7@]D:NN 'ZP="@A@OV0G\/_'EC0I\;R:QY_#GL#)A@G*495OIU!M7UP7T]IH
M:#!'55.:[-+FKM7,%7E!BK3]N4G9OLH>8"X\XJ%%M7VA?Q,\W[?!0DX* 2/2
M#N:3DNM,3^FB!W-T_'5F)9-TDHLYEKOG%<Q@^9 B4I,TQCC=?%5_5:XG<WZS
M$M_?WX/@#10ITS+[?0^ _HA*E3.>#8WA?R%M+NOPA^3FXTO"^(3'P$9!Q09@
M9AYW48]DF$?%)@^)[V*5NP\A#<2!H][#5WZ%.KS4=FIU!")@("!%A?)B5'^4
M-&7PRZ$P2:D4K#USAK,FJX5.2-[PH[7*-\9,D=%&D"?@K$?L-4::_R@QH'/R
MK+39/9[*EV$ED#WT P@U*Y3C6R1#-@'J>OCKI,](K_TE=)(DDY/K3 [^"]GX
MWVN^_<__X#ELG5U_VW0GZ(EQ_<ZMD$48SI'ZU[<9/XX_22?']&JS5]]U+8A6
M6S_#_#,-)K/6CT[.&.320>>K(D 6#X&6W)XN#@BF[4&KNPE:^?F0M K35;EB
MGJA^^^K2NNN89#0INE4(YKS6<.UZ[#+,YU:.X4$P53%_CX:<0$CW&9E,M:Z"
MZ)M#)8P#7Z>_KT"'RJ%GD2ZYH4@>3%3@4\A=HXP2TQ@T-%H;-K!N+:M&&=G\
M]@LX/2DS3\8TN*DKX&$V-3J:Q#A\F!/'3N3=OR XS<:&>S@7L3B85.!/QC (
M7#Q@2\L_F]]GT;\=C7KVP3MK2RZM*5:_B\MIR/2*,4Y3]VN]G=?KLI.&;"QQ
MT?Q*#8=9SS1DTTBQM P:W"X?)H<A^[Y7(R3E Y3<."'=W/8#KS!*W<S,C,B6
M/\),'![54<_N5"]_0@5RK;792T QYAO-X=%)O<2)YEU$):],2'\',K#V,G\G
MDGB]B^U$:"8R/B_N=''Q,4K&>*U9.XFZ66%1G#:X[G./ND/<789<PNO,F#VS
MT"Y/15W9[Y0Q]Y?_U]%H;UYF:3PSYCQLR?=XL;*4J-(DWUBE3(T/*)"8-R3^
MYL(?'0S5M33.S.JSA32G3PH(NGJ*\+ZL<*'T_N[;A/T2T$JCW-\'1KSO)":9
M&%C'X^AG#!:6!73>3YX39[AP9X0S)9$B]:YJIQ;O;UY^]3O;C#Y9E(ND&(S"
MPJ$S,7^=TY?,W9*MAPX]9CRV$8(9<[^9W'@GI,-]X8Q94;Q-,K.0^<X3DIZ<
M)O=)\KROQ*0[Z1"%,I*RU*"6QXTH.370EBW&;;4U\>S)<.=?69QY<_LW/>DA
MHG?F5J3HED(X17T+QLU3U$USQ0S'MSP1>TTS,9OQ)125,EQG0#8OKH,_F\"!
MBQ+;S,54"_.HZN@DS+*\LXA'47O$[GQRD2X\C8Z4*S1I_G/7M B_U142!91+
MR!.FP")&1%.FLP6+\IH@G??ALO^*8/&2CA"W_%!B(?2ZCRA*>3J#M7QH.5+:
M 1WQQ\2T2%-F#8I%J*,PXNV=@GLS]./L/_/V_QLB731>R.*2ZNEU9#LWT/KC
ME $=[S\@9*KF\58%@[EG)-NIY?:C4I7)'*T&K=VP!='#N\8;X:D^M.:L_^7U
M0R/OV())9:_,9+TY0?$<\<,>_P98_S-+_D=(6CU!R^(H\L9_S! 1U<D7C:/T
MWV1!_P)&>H)8PI X!E^%YE#*W!5;%4O:0RS/L6$B^?GOT<K;Z;6(ZGI_!L\Z
M* R]=NII&#06;HC1#M6F#Z?S=1TF^AWW468S](M=K !2<E=;>Y^";)J,_E^3
M\8WZPK'4T7VJ136RI2*?I@7O]=<%OKRU(5!>I>.EG"OCD$Y( 7%5['?3:#?W
MC@N3!"N>)BLDB;5_ >=W+^TAE"XXA$8XA/:4=-X2?S?V$IK:0[QUYC(S-&H]
M<AL[6U,P/[$T3Q/**=K[YFQ&]NLPS%9+?:RMI)- B-"9$6%)N"1W=C6J@_HN
M%0&&#'N?ZS%CIY*9,=7(4SKU,TD3NH%_JVR =C)*&K9Z\<82ZV\@*S^2LF/Y
M&')PPOOT,")VLN\;%VKIN-R=H#KQ*[G%[-D8-BI!$7<ZN?9KS-5(] Y"!I*S
MH2(DH;D_$])&^B1IQE_\"#GZ-\9[O<^_R?__LPWAW^7]/T5]^G=&_%<<O/^#
M\&%U3)EO1\J8AM,&?N7/#?U*1)W ^+I'9B,\^1]X_C^C@(@G:)P%-!=;9\ \
MES+R#(>6-8$IUMA2VS3N'C1>CO,3O*CU#+\C&O(ZT@)M> @^/9H("[B7:3<D
M>D*4E<"L"4/F"*W/#OQ""-422S:*%-S-R.9Y1Z<8S58Y^T@X@ +Q=>0#^2MF
M,56VP#0?R,^,TNOBSM:$IGG<>^>\6VM?&S;!A,4B6YN)=)MN[8WJ8?K5'4O^
MH]HJF\"SO-YKDWW"_7[AV 1$@RQX+:;42G[9XLN:RSFYM7==*TGM(:#V&J$T
MXI!O&96,X2;B-S#K>J)[V&6!%\F"(:RF2G])Y>W]PZ$:)&3/WUBOAV[.?R$@
M2V)P-7D +.3%TLW 91Y?:D,(6%OH2XV5S\!!$JF%C'>O0'YL"C)&_6JF!""[
M:J1FG77[/3TEB77!JUTX#6<GC::5MO_B7UD=_K>(IBO#5N!7W/#>(73MY%M3
M+4?]B9,Z/]E*_ 4T>YYW @4M(M<T3U.:M&,%4Y9*7Q.9X[(_;4&W)-TZ6ZGE
MX/YI)FCVQ=<K=X[B5:LGFVG$LB73<#F1\+D7 PR :8 G[^@N18?%;O<UFF8G
MCR>#7X^);Z^=RN)DPN=;VS2 L)X>F'9]PYA(T. =),VUI?.Z9->*F-+'P'(A
MAC=_;(II[?Q&F\2H,65$\6UOH*<QS0._I0XE]=O72\V,XI3K>':JT3U%C:D-
M1(=#TP+-+H5Y%ISUC1@"/[";];SXO_S.#LOB!#2I5US^H/ G#HI.D>?DT*[@
MB >=E+4?A)=H7A=^70W)7>ZWIB4<3(PAS7V7W;(XZ<"_+'"I5JK13E<"YF0+
M(:-7R=^MR& IU"&*=U2?T)N<OE9--4API-<#C?58*C?Q>N(JK3U0Q!["!$RB
MARU,4L3^-A@XIJD<I(G<9J[\ZUVI)*Y/QL8&0!L2,O; G28-#;F7/06Y:^:D
M].Y\)080NB#5O4];7.*R/Y,#K0UHNYA-M ?;*SBF>NN4T1,#T1D/NN=J^9H:
MUHFSRFUXK#T P$F=7T@,=OS\8>>*$VX"X8>S$$OM^4<<O.O\D(VH*:IJ(<+H
M^8C2#O,2@<#Q%$C2:,?*GTZQ@._>^>998#F='!]+*TT31QBX_9PVC'-0*/),
M1NGL.E*$EH6-\,( /]5L4^L2ZC>OG32^Q HLK6@X*B]PLBM+679N2 WV_'#R
MY)X@/UV-RB?I>!=Z "RR!G+7>.V7'#+>R7F6[\6-'R 3V+I N>R&EA3@E\3[
M__"74;>K^X(-XK,:GM#VRAH5@-LF0A)7;L1:F,A'<#;/7=#:NM<I"58R>\O%
M(,;DGZJ,JAVD/UCU@?;:.VKI]BIV_(L;[BDU-+IM&>>,XT#X-S6)[>Z9D4H*
MC*60.=IW^^'Y B*A'*%+BD]OWR\OQRS(G-[<+7#D'9S&C&BAS2]UT2'43^C$
M]_A%=&Y/8:;TPF.LF5A$!OQIQB2)[#.\X1SKC$(Y0S3K;>=G?/7+#XM<STB;
MVX?&/*Q S3V2Z;))B-P62#2V-JE_GL^;#%XOIQ6)[>WY:<HOJT1P_4"S !U_
M#3N4 GM8Y)BU'\=6:>.+&J6NV-A'_:R!O>2;-30J'+[V>5?9IU#KI@YE?BZ[
M#P,SX<'&G];9Q.NLI#M629$;-_$J]A*4;/JMC_IB]19##C86ZSE.UZYL/DU<
MIX(C[$T+XKO=#]A/)YP;J?6HE]@+V;*@P(.:K9J9G?J6H[[DH\W2'NG<B\G&
M[#][Y7N*%MK$R'B_GECI93*#N''L;,X;=78ERV3$CWH"!7DIJ<MI!0X6V0::
ML+L_2+Y_92_UDL2^AQF[]P,7*A(2#!4)C3TXC N-ZZ_!-O<U@WE-+\+P:]](
MG_?C^1+[LNN4NM=\0=#!S*OLEO[^8P&/<1L$&=EHP83=3N=O&WUVE66;M*V[
MX7[/;9;E?AO\,8HBRN6R^8W#^1[KEA<SP]GN<W GNT0A:).CQ0-1(U_T+8'!
MA>?YH%%O?X:*V]*AS;PX;M7\RZ_[X;"0R$_EO9$Y1T]T:EQV/:7T1*A!(Z@E
M^K%T<4&!9>K6P+CU,@,+T.]ULTKW*+ZD*;?[URYLZ7V+0R8E<D=/PHWGI"%)
MP RQ]]3F11*LU :H:X%TJ&O(1/ESYS^]4U-9@%3$Z]_D$TEE/6JV^(]2EK/O
MN&F*;X&"QID-8P0W4ST5$^5D+([S#W]:P%K'4NE7"^O-E4IHZ_@\>U%M0QQ5
M(CF!(GH>L][YY!I/E=ONT-J,'Z.I*K'SZ3RA09J6CQWUH?U@NJKH.[L[RW3Y
M4>T>BPA>^P$"SF1F$U=,A?BEI+_JN@&]4 "1/4J!-,K]5W!9^X5!KAM_K=L
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M8A6D1C!<F$*THSE[%I$*5!?-"LM^%<U1==_B_9-)G$F>N8C(&\<:\$KU1!F
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M73(%TF7:_?W?%?EX6Z5-$M<P.I4^-(;2R Q9/KYYPC(6)E!6_U53*I?&9+5
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MILW$P98^1U)1VW**!2ZD WE<NETC*:I4:H/E>70;^!&AO),W&,0&AY!/GX_
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M&A1-002E6J=!$_IUG/W*IR43 LBSQE[J[F#9/Z[HK>YV@7>&%):8[K9F?MH
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M%NP2T!VJXVE>(LGB@[U9&2AE(IR972X_WY>CI)5QD]U#@9#U%<BSL]0Q6G1
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M.'I9Q9.%"--;'-=RZ:=7[ASK6HE"7NE^008A0I/GN5=:F^O O;"EOUS$WAO
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MHT":D6M0-B.9DSA\(YAI>7*\2K>WI5A:HF-F]EW'+_6K*A7*"YYCT=FKC,Y
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ML9"@"EV7^+8^O%&$T;;?B LJX1S:K6+B_=S58=1_[5'Q_D3M*7&EK'A4,\V
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MZ57:U+D\;A_W:.Z:4 ZYKSU>/0=KR_K]\4/0CV"9O.Z[W[ZV@X^W<B,]C6\
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M'1(1PU$OT@QQJYET.;=\<7&!;J.3'VP]Y45D>XKW\SW/;R*>?1#OO3'_ZXW
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M;>'+5G2G9*>T)*W G_&&5JVYO%>LN1IING=?3!"+JV<I?#*7-L?B'^RGN!X
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MSR*!_*WL#X_ A*;6D+_] 9B7<X(PY9R5,Q\REYRUW%&]J%=^+Z#5]/B2$<C
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M1$/ZC$ )\-17 @/1JF5DW-BL^(#':RLTW:;#IH.(N*-U6#2Y.$3X22[?!;%
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M;^KD&./KK.-D8XMSTLLGFW657?6K*:_[!(GZZ-H;(&9ZC;]0)G-F3/B7!61
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MJ86B"*7J_<BR%.;+?Z&DLAU6W.<(!/O=VMTIZ9GO%KZU<B&==VN[$RE\QD%
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M.40"0CR,0<9:[FL>&,MV_0%+.Y<!J@<MH>7\$[9@0W>>"&QSY575BO)RTHP
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M^J%7U/Z V((7#8,&+]"^ZD\W.$UF>0CG=0@DRDUQ2F.M#X[R=R1_8G_Q#EY
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M@_J=?C_.H$XRSL?58=5D:E0A_$I,MBQ$BB[=Z.C<:S*R![*R1TRCHV-=%41
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M6#)0)U R-5 G-46R-47G#Y7DSZMMY'[#4P+>X_<;\I9IHQPR_C?</BI>6;(
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M@:F7NCGZO5#%&08[6SO13 E%&7RY'9F;$'Q.PPUZFW]#)M4[*N:2P(N'70.
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MAI(F7_,PLG]23)AJ]J)^YS*@WN""?SRH[_KHJMIR/G(^0=8,4X?7-)J:O__
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M2=WN$ Q4OZJHQ=87-)DB>^':?X'N:LZ2.B"/%5(NN7WCYIFNSHYO9DF3M+-
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MHN<"1J^%<P_.'INS!;#)&9;T-K>,GO(/JSJU9ICNA3HNU5S:%YRS \S5FIK
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M?GR2%E9HJ>6IV."&^+!?R11V+4/K[PN=";=^9(S&[W*V_L1+ +XDF_$$NZ#
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M1,G]93"QFM*](F>;W00+(&P8&4JY/=O.J6_1)?IU=>3BIVL%Z7M9GO'[ID>
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M\.:CK0]WA32$<Q-*'#?/P"45SP9BQ]-"OS"L]H/,-OH*#=Q+D_N(N37_H''
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M(,1_,K@VYZ7UE4D\*0L')?->2FYR>#DV0P/=P%RGO>")5JIQQ+OW3QOP"/#
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MUXY:YFDW5XXP!<J:&Z;6@6_Z..;)2_<6''4Z?=DL4NCX@W,@,DJ"+:!_&:/
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M9P R"S9F*IL^$KBBQ7\L$/O4O[/QOL+XZZEQ+%NR,9V\7S(5<Y+.."X;./E
MIV9A,-2+>=?F*'Z6 ]\$7Y"T:[H>_$&6A& X[!LKPELLB_5+A&7V33EA01'6
MSQR)%%#8^;BQ'W.'"NL+\TNF)77U9';D/9(+=4V3HB 3;VHQ)MM$>XJ(=,H
MACT>;5:C?8N,OISVA8>=.'#>A!W'O/K,RI$:4J\,)2.S[4S68+J1+@PNK;)J
M4+-6M'?%"]2>HI1KL\K'23\</XDTG?6EDGE"&WW764+:QN0W%Y]ZK>,LY!.-
MD="_;C[!".U>5\TIL6&1VP7PDL.QF<$Z6A.E;JC(K,J1]; DC>2#(Y6$7$=&
M\^X?E5B$8F L[6LB&,31&(28Z$+"2Q^/M"5!7+[E(U7[H#N/X\2E&I'LJS G
MYQXWTN0B8Y<"]U.X/I)[XN8Z^[XN%-;K>(P\]Y>[9F OQ>W+<5BA9J5=(+A_
M8@A6<-70Q4O>6G*^2VJU7($, FSQ@02A(OLUM$LI V0ZPF(P'8_I%CAWLX[4
M\$*9.J$"!$5K9G[4C7F<7&:RVN90:*GBW'T/DYKV<#")(M]A=)^P*K?8*!(A
M_[L6<81AM+#S9D\V2ZD@8ATI@\/A%"3A++;"-I*^OE$!1^)#)D'-(!KPI6YQ
M3=[(B/('(,J($&CYC"E@Z1IZN>#*05,*&2>*-6:[]8_7FE]EB.[6X'B OMFF
M=PN@8:MM\6(V0: 8^6X]KXUW 1O_M@N$Q6.CSI986X2Z6JNM#"9+_),@1X>%
M#!^#CQ_WLZ1! <*V-N)F/?9[W^H576K+0BS*)H>V3S@;$"<\[K.TOIL$A@RO
M!9P5N \94)EX:UJ/"!5=GTJ:0]<\_5U];W7O-,IIOQ36]RD-U[@W-D0*O%4?
M-^-Z'&JI!NC6KXJD3,:2"O:5CS>'7R)O#G921<^2,5V'A>\L601/:183# LE
M](%.&F7'%WM-3[FM-AP:7\36LVGE>^3%SE3#1YR_ZB+_X'[R*!?WG[^X^AN_
MS7;G5YVG$%17<8WP<X,[2!V&9YV5[I[ [/P#;]F/Y-;!QJ#LN"'.JVH=')*T
MR5G*7-(2O3)"4=QRK91&1.;&J%CP:L +WIR%@1N#R%Z#+S_$?,]^/J/+GWX-
M0]#$S.O.?#36(4E[7F,K]XV^5SF_1G#*\TPM60G7!Z:W61P_]V?,!@\[OX5^
M4UQA=K2;/D "G\)AM">8P:0G&(_?8S).M(J-B+3E@Y7R>Z96V)T', #/R'8T
M%2\&#-[BAW G924G*G2G[5575]]E9"19F!]M+@^XT2-H$Z=?>N4]VWLVL&.-
MZ]"1LC37M=J4@O *ST<X)?G#G*Y>DT0W&O]K;H6-"^*Q7HLA?245DWQ;XSZ+
M>Y?%9>&%1)+L_##_I222',P]\R:/$*E,F90MVFJ6W(7Y=>?"TNO#+XVYI[@2
M$1<DZQMO+!C?82:-2;^3K[ ,0S68&)M,["?.*##/L(D>2U/+/Z\5SBYP7H93
M5(FXB4Q$P8CL?A?Q6*31-UN!U)YV$\+=ZK3Q7 @([T%!J)&SW;>'=C*5Q&W,
MJRY[F2:G$G+^N")EQ'[J!9R&WQRQI!.>9W6S,RDV9D:2G74 =!I/?ZX[BAQ/
MC@"&Y7[L,*8SM)_[MJI!'-8SY1\IF/!^N^!U+0.\O1@AL-&Y]]F(N/A]#+"=
MYL_&[]C#EQK//2;(HHT@6TU/^IA'.SIK,V%-1=SDS6L%PAI??C!W5OZ\D WT
MFM0J< 5ENE6KP-]<[]K"*);6MV@"+EAH6]C\4[<0)X.W1@5*^WZ+\=83C-[L
MF%Y%NXZM-K>^50:9\&E=PHQ'H6(O,P8IS@ETX?JVO./^!%&[19*4\@-*/>/!
M\302RO$MCG97=\=EX.2(XK&4T&? $C'9$'EJCR6J>98.=\B1:2&5;:PKK#FT
MRY\79T.]?E3,$_P1ISTM+G<KG1+-N([-A$'\^'"N?^=!0CD7QI8T,QV<,_!-
MJ;^R1M=>46&R"NW?,$;5.L_+.)/7[EY;O6:AA-L3,*R[-L0S7]JBXTQD46ZQ
MF5F2/^!YE93<$!>RE+6M1"D0E<#U !"8?:'#6_N:CNK3YI1.$@W8G"^MUW+>
M3,%T%3G90[>%ICH-:> VP$L4W2-=(AD-;!XV6P^4P(X%.H[W.@*]U6$=GV Z
M8>L^CA=-;(<>:%5C2A-C@ M*AE&$=(!]F3/S46P$0@99U,3CM+LW*RP_*C+.
MO\RI/,$LJ=0ZFF<.IQ'F;^$20(#&>11I'\)U\[,PM!>#; @;W(+>-GX[.#JF
MC$NJ.<J#_=,;6-L3>'Q'6S=TF;/D3:U=,OUUXX<OUZTU04:.%TV-T5!(QR&1
MRK6:XX0I9)V(<E7C@K:<Y4<YH7U.+FV!(92,IM=&_5:Y>!D246ML??'S*N$Z
M]6[H;WG*)7QI:NJG-Z4<GOU"*A8BDUIY9*V*U(#]1EW\7 /X-G$97-QKT>Q*
M@DIS:)%>'EJKVW^/[#05RB11P.2,4LE9I$2<V"?"&#7&"K*%8Y.CXE<_=")N
M6FR9"9OB03,M9/0H_SRA5:J?_U5SE\+\K %8:5)T[8=(( ,[JDD!P<*_GA[1
MU$TV<16V$Y*86D!KT<SX.JZMI/<^C\#^MEW)R 67QU\E):A..Y[[&6T\0<#&
MQQXW:@>0W2MV6\+%9E,8<5U?M3T/37E].4!<)E_#H@1*"G]@BCQE:.T;G(U:
M2W=T4:0."G]Z*D!T![S$8HA6QAP:V"?9SJKH@OEXQR:]3\O"TB;QF8)85C@2
MD>'4[<R;L_$2%KF+VM0F4)E<(';9!$ZUBVE QG:\9)853;/Y94QM"["QD3#?
M>H-BEJ^=):.(O;&Q,R065/+ARR1E8R_VB8M#+67@RC8LS-?%2O;>=_!-5]A@
M :;]0ZG:><<A%N:L2:UD;CPU1S*5@:!QW.(M\CY9=F1)!U"UPYH#;H[/)Q1B
MV_MH_%$DOH7++[P[5I=B<3BYKD O=K5;DQEW/CX\V93N->. "<>%ZB)F,89V
M1%PE98.@#\%R;HX6F06N%BWEO7]+)1@;@9_^?#$="EU(_&.Z^\>0]PSL4N#;
MZ@M9MQ8RUQM9T)[.+,<BS$QBR5O;2!>3WA-TO,:G<'2D#2/5'C 2#DD?@#Q(
M' JA.+W*KBAX.S<>-#)W_,A>DQY/73O_57H]YKNYJ'6DKY1^>D\+OBD*5RTZ
MZT;<]I7V%A])713I2QYL+76:<WU/'5\ R;0F$?%^9EGAE1EB[!@OT@:%.2G'
M*(F3K+;#AK'%6K]QZ=I:JJAA).I2)X@RFJ"DJNTQ;H9  9C8O<=([%^8/@G5
MM?5%L=9*+P:QUK\?,#H($Z(XUK_0I%Z%SC5YZ#7\?'94)**(8YO%UKFMK)U)
M-E>3I4C+SNM(5<20"/NG3?LG(ZV<]:5>GJ(']F7&9$E?$,'+#PV2C\%+7&M5
M$[$-<!2P];PDBB40>H;IUTB =1].,?*'N0L[G %W@=)\BV/3NM6E>D00'4<!
MS<BJ)9((=(Z]Z<.A(<>]*D]<?1@Z<X%1I[@1NP3.[43]R"$@@V'&V34-G/UH
M0_RYWLY)U# SLF &#PZ%3A[0K>T*JU^>/)D/W_'UU6P22F NQRN8RG1'R)VB
MHJG_#C+94?!!K,[*O)@EUZ/VMC$:5T%AT84."C!DEXF6T7UQ4;4A.AI!^HU8
M@,7SQ>PX!J(E>$Q2PCAH2DM* ^@,9$=SN[+\CNX<<$?5 D6#KC FJ)\4=T4N
MV% S0E :E<BY7#5U_48$Q84)%=9S,ELB>WU1U)+R5QT8#OZ^ :DINXKR9LO(
M%CRZZ[NGW%-KBK'0.2:Y-0:*>B]=15U+316A C16SH%UKM*6$;7+*1?,"9,>
MH1YIGP+]2Z%#)"Q,G.8HLE/1V?XZ%]9$;-@!JOP.T1]3,,\OL)K'/ORJ6>57
MI_2CP,;@$K#P!-,RS/MXJ+0M/]]^8%;_!..>ZO0P7_7\)?[#_6Z:QD/XY1/,
M,4#1M_GMS217Q1W!S\IC&93^! ,N_2".(.3+!YI^@C$6:+\;FLPZFGIT'BYY
M[/7TO4HI%%HJ(5.!C5H92:GUG1NU>_S!L7U7*Y0!L'R"@62N/&Q9C%Y9]F,+
M&U_]CZSCZ[GBPNX20%\[U0XN</*"-JDOM1P+3PI'WV)1G-_",!L><X!%.,0M
MB-F;@G*Z"\!L_L<->9:1F3+;;3O^,-=UBJ'%Y"QG=%S@<OHSB8-9[\5FY/1>
MP1U;Z+'$C)BR-<@+\%;Q>HV(9C+@1)5_O60QJ<*E_"*9CFH"\T.KFD.YN_<]
M,TA G&FP)K/=P=5::.JT@?0^F>5JHMOG-\>SR<F;YTN53S!O>[_[GKUO7Y'Y
M-92SKR+C.'\4^>LY?'Z)%AE#T 2$HO46,"[X;1&?8&A0'LZS?@WK42C@E)0V
M\,!=#TJ$'YY@!OR?8+QI?XN9OO;[3:;%':D<.LF;\MX!CW3@F:;)Q<+R3;0:
MS#;TZR0-L"*][@7+^:$/H[TLMD)&"MOCZ_1[$;F+I43*+FZ7+.9E8GOV/#&P
M;K/?LP7P;Z7EADH!0.ZWP*B:>HN*->F GNYN>8-EJB'1GZ7LZ" ?G/@[W+6$
MC+587H*6K"XV0=(](;EVC(L,3_1ZGLN"(\C!1<LZ[Q'SA'GID:P]ZTT.*I.\
M;5%8*1]^SE1R_QY(:_V,KN.(2-0(<;41!:B:VZHT+C1-Z!TQ9#4RRBM?]]WB
M&Z.KK4VY*@RDW*$F>;&4).V;!IW1=.7;3[==6$8)-J)JJ^1E5LHFZ#Q4S[(7
MW,N=/,38-%0L^$<TY,UVLCZ]Y2P\PZV\D=T<!%;J]0T^CT)=E.H.",].20DR
M'Q)(L(X\\)6#<ZQAVN,SJV%5:-0F6R2S,8S*U4;KZ$!)P@ =N(P4 -7&(M)#
MI?7+^!=MMG$&#\??O:'E?R5!%3U,%*V 6B7"C]5K/PI_DB+!@=5%%U YBOK9
M00'5CUV"+MX1*;F990"VQ=?TJD+6ECGIZ[X>1D;?GAY#D85$=!<($MM2RSR=
MD.5/DHULF,AN%-ICQ29F6;I*[<G:PV^&?QGZ\S]C9^0*L@PEGLJMF2^A.:RY
M*TD.BE(89.;D\&EN@=/ S"QBQ_NH79!=B7VBM8H7@B[6:Y+GZH'EUBRT<./+
M\K,PB2;YWUW!ZX_-=_?%5D"793B-CJ(EHPW_""(PJCYTR,CQ942H%I'+CF)K
M4Z(AET,LP6KT.M?5R7T8! !T[!:V5#CN/_(9 K];=/62YV8Y1*BJM_1N&U54
MX$^^@=>?+L-+R4C).$L.20\C!8F\&ERCL-*?+JZ_-7QN.W*8 (43/ZY;LA2H
MFKU>;?>;XGS!@H] TV]XQE:=" 0&01@=:_E[:48EBKD"4'*$W38(R&(UHY1]
MW0S>$SM!2YP<[TS+C3RQU'#;"UVH.!7+ 5H6C7D\NY:HFMAQX3;D'V8&E*VP
M!CX-=!F%3TAW8D_"!O&$M[9X?W,G\B[!9L??=[%;/WX7GUTO^4"_7JMXJ!4\
M'S2LPR9AU))[*,7XWGAKT,(@=W-%2:FF+=B&H.QX^J,7AR"/H/EW_-1TC\'G
MV,/JF37=73,.\0&TZN6%A; 81:"(@S[M<@!]1$2M$?/^P>8\K>8A<]WDPJ?/
M@%??+T#)3=P.]<8;V?%>03/<U'HA")>4U(AJ\@G(,KD0S8'DW&2*5%9N_YP(
MP;WR'VBD\W%6;//'BNG8@*EE1OVF"26A,%=92T,_:HBB"!<RJ%?WE:>;;AQ<
MIT\,$#X*5-O_.;;[O]FQ#A8M,QH<ZS5KS/0$4\1V':@C*9&*ZQC/9Z!H5GG[
MX6<=X.@+]WV4P"^M,V;]Y  HK JTI-#YTMQ=UW-1_O68.<[6?0IH6N:@,*%(
M]5A?>-S7A>7^28@?I3X-6(\BZXV\K$D>LQ <2S<,;9,B>P5^*'1&K*ES]:"8
M;W 4B!60R.06 #9Y_,"D\\./QDGJMF0ED X)DGF!>L[.UMV!AATC*;;61X\+
MP:D<'6M95(?4$D[FZ0OO==N"@:KPBJ*]ZT7G/H1X5*7\%PTN%IJ=@X79GU(:
M]UQ-GH^J_+,$PY%_8!/*KY#VGN5X@OF.)E^6#"FIQ3->JEXN1=-C:4H5PBMS
M?F",UPIM:&F>O]"LLA<QJN$F*(:6FC+:ZT#P(3%P''D/_-5 V+P8W&6E;_=@
M]@>E5,(GF"26Q_/?0F%+0HGZN+-VXO#VMUM!3S";@T\PK5B_Q2]?!XW;;-Q7
M]!FS3-UDM]_\+-6.Q7\+$;)K=-R%&$[G!B\$S>T>==OOQB6XO;==E$Q:XPX:
MFW4^%("Y)==JU?BYA!#SJSA1J(D7?3Y/-QZH)_:9[/)#I1 A07',-XFVGXAS
M^K[98+=B$,"6C?];*+K&_MVS)&+I7W/;&%R#K;-"T:;OTO:S>L)S)DC_ZI%2
M31)!.Z%0Y0NYZ#N)*<4M</E-N^P9^%^\=$5";#%Y7#TUOGFG"_[8BJ<D=D3=
M5#8^M3X"Q GM(TT):=?0$]T_6XWZ$AP#<FF 6. ?>C>J6 DL+MGHZ1N\+BA8
M;'5-SV4)F41>K^(K9# C' <@<4#0^??AV2O#9%Y^  " 9&Q+FGWC*I.;KG7Z
M\57D4W,9R WN<,PY=J@F/5,];">"$@,;7P7COONX3RW/^9<[UB-F-]<## XQ
M&^:SUXT*"\ >RW01T$?7F&F/+OEAZ8#DA> +8I;DB&Z_Y%3] @<R6V$HV7^1
M;]Q_=-SX4&H107H$+=I8*H>][=U]*1/SF0'QCC@R\\"76'<N5?AW E3.5<G[
M<,1#WG/0D=HB8T$D3;]:=-<L5WLKYL&%_-B%)=6)Y9XY L<F2K5K)AP%K8(7
MG6+/5W?V0HGR*0T+T_L^N4PVCC,@335+;RQVY JUFC5SRX#SYTL+_$?Y-5L>
M0/P%0=/KJD -YX+\ "'V!5A:9-J>Y=4B,\CX*.)7_,:"4-Z2^1=U)1\*'L"*
M(W;HA0M+&H47(V&#<QV6PTQQP2S^0^KO>2WT D-XZ?)>_4R_+V4XY6I!KX*6
M>+?+Z!IDY1M9+$A&4KLL.&?R%B(\0])0BL_+164)WCA"^ &( N_.DG<7Q6W7
MV*?U@=?-ITXXQ7&P]3(U?L04?HNPB]O+C?EWZC;>-C)*TQ#M*Z7G_.H;%G2+
M/2?0]?*^_>NQY(W$WM019SDG1+N>C*\T:82V=@&0*V-D>VV=YI8[[_W(X>:,
MP,4RS/=Y;ZHDE%1W=T$\IZGM\@.LF5)PL0@T"("H8FNU;;,DG#A\9JEI+*T*
M8SM?8\796UKONGW%(UN_@2 II;T7K7:$S6@'DK*()U5NC*UF:[+NNFH0OIF2
M;Q2;$[B&[F\T*S@^F[ZB('N!WTK>GM=<@SCO;=?+2)$R_:MF&6P1Q,W7J8*A
MZRX#MG&PR757\V#R"@;:_GU?D?$)1A/V-]6R/]E0+$GIPU.]$XTQ[49OXLW5
M(.##+T/&_K6RE>F7C KDS? .8JAF5$&*7\F8Q0^&=EYXWAH0MX;)VF2FS%FC
M705S-\[J<)9((B.!PD0L=ELD/YL2?!*?_ZCB18R:2]F@W6-<51-)3U%/+E5>
M)JWD46B3II?M^L/^2K@P4YY+B8XG@EA;RX3G])9%J7=N"![';Z 7Z5@*^V:?
MK9L-/H5_^([ZI1Q_>"X4=N2RVMI)>^&=11E>P5[&DEA)];4WX&/QL^ZWIDY)
MWWLG\(S(<,-I*]D53=YC"K^2(P]X+[Y0 ,2[U.L\*)\VURN=C DQ.M?/*OQ$
M\#PM+:FU1,LKO;R3,".\7+OG("%%&GX38BE#==F?8;EPA'/(#4EC:>UI2EN-
M&9SZ*+-[)Y9=O%8S(Z72<IO%NAU5'YOL,#9TKH09[*DRDZ@?G'Q6,.[BQGZ^
M-'LV)Q I)'^[?I^^%_5 \6P@I,3LQIJDC[3 V^%1T47J,4*(Z>/<^OEHN=#
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M4S'>VS.\O$D:3DG7&?3WY7SV0AFXSXW+I#8_ZEMUL7'*P+5JT/U5@4&6\H>
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M81Q/;UKFF:RAKJK(ZIYWD.]FW.J:7(/X0];L.$37LAYY'T)D(MI,+3?WDV^
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MC"T]C'96#<2.>T#1BG._<0J!^F?[]")/W2P ^*[@.J>7FI6S$2$.91Z:^+L
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M1LBJ[/5H8_/L-"GNIIWD'>1Y9)LB"VAIU"-"AM1/D"8\MUG%&0>WUWRW2T/
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MW']>N9S4@MH$,3<[B7;+T++ZLXO<M'IA=-DTAH)CKF]?.*5'6G0R/S9 VYV
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M68,\?Y:>Q&/Q<TW"T)19C*C/XNX%(=WWXLJ?,B0" WQM(/K^Z2#)<&^M9.9
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M)OZ32G.Z; R!A^G?Z!\=L,Z6C[..3IB E<UY&WD*[>MBIT9L+CN5C&GXR-&
M':L6C6EU5 QJS:99>*LR8TCG%PS&TP<HU(-_K#(,=OR:L$-[%A;+*2U@3_9M
M5$:?!L"ZMR3H<W2WB!//VL&VS0N.S)"Q]^0I8VC4YK3OX3W38),S"\*,N3R6
M,^77CU0Z60)<.DFS"40?L'10_Q$!?L6"P84-"P=ZBTNBYH$K ],7 E0A;P2
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M18RG86K.^YQLD2@3.A/VY*JY'$C#['\P+TARI'<P]UR=48C;I]*SYA[%C*=
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M@]?Q5HSSF/?J0\'8#SR]S-V?J')=G#EUL;Q:\]^R>/HXFA,/_1RG$:<5N_,
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M+Y;+W=YN<M/I'YY?*&.>^2Q)VA,U)Y)\?.LW&S)7_?+;5\/C5ZON?(:Z2U4
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M7]>+-A);HA7R810SSGHHI$!JY,U("62[GQ106WU:4P;%'N!3>Z-DH#2X1S?
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M* _EH3R4A_+_2YI]9/P=4$L#!!0    ( #: 9EC'.."L>Z,! $3$ 0 3
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M(42&.0X5#Z/E/MK^^-H4K-X8V]M#&>Z-2&Z(C=)R[D:>"KQ#8E\,H8K"GE[
M0>M]95UXJ*B]R <*GS04K6K[14>19?R]U(9<6B3:D,39RGF:4D9XT33#&7[
MF^0"?7G.[O*JJ7'IUDU1!4NW*,XGKMD;RE?;#PRAV,9=>V0<UQYA5@ID!2O;
MXXW%;HM3W(E-5A1OTN41!//J $24'0T=7[=(\@_%&95C-LKO?WH@AE9F9-5
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MMF8Q%@1:I.(/PQ7AE  ZX)Y;-!WP.IS&,]EO*5@A1NQ$?_V6-YC4QDW3?9&
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MC[WS_M]FE\@;1Z>V87_+)I[B9Q;/: /0^%=8G2N/@XBP,2Z[$QG!W!SH4=$
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MT/.-_T)+STLOVUM*'AYK06[VA)<9V(,:Y.("8JV@8O( .9>Z9G/,<,FM$QO
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MK ,,")%6>*)78O[D!;A0:/YJ\7K0<HLL121_@O*HNY/&BG65 5[N\Q$MOUS
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M#+P >.)GPA]ER?Z<^BL@Y<@]*]0\)YC$WC,'_LLN,MF%WV@2>LBB%MF1.-P
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M5I)ZQ"2!AL=SB+,_9GM,' A\<Z$..JO;2FGVEVSOXU;O%^S%A4(H&_SFZD]
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MSKXNQB5TI;WV=] 5TQ,]-3L'!5Q]-XR:@N&3P$ST,=6/B;W?U;M)N\%I@9
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M7=/FND$%541@<+C]V_6%,K&".)&43T4TKQ^W^ *-$11%/O>6I>MC?<E QN&
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M5$:I'Z +'A?</:'C2-]F2+;^X!OGAX)%=*9,1)2'H)'%<]O(>\_9&W[4D\R
MLG(OQ+'FK7E]A5LM+&,53L\&"5^AR;%6%1+K570*8QD:&5HF]^,M2<[<9L^4
M^Z):&[HK,Y/V?OB8[9[LN.B"P?BDY3V@"I2WN\/W5WE*NP,B?"WAN9\5*(H4
M43@]-6>L$.!*4S;2CRG]PI[K;3F?)NJ'0Z6^HS4@TS"2R?%>R^ 6/_7V&$)
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M3@II5IZ"^&S<-JFB_#<:P6!,>^<\UZB)%LH?5+0MIB;L++"7'(^16,]*4?W
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M\02E-99RW/#%C-A?2[1+:!ZC@Y+)E$O1\1=@948;WH \STPMP'SOZ&+G[Q7
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MKK\[W9(3"L3Q6SS,/./T/?)@:'ZH"4I'*9G?Y]%*8*DK4?R2RGY]=@X/VVA
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M'#(5.8C<8,7V9S*'QMHL=\Z&2<O?<WX@2K8$\GWB%$ [LRO++(D?EHQ"?D!
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MTDEQ,Y! 3W[3949I%N)?^<)^"S(C]'TIJ<,R)7ATW@M-/@,&UYXF*4"V;B-
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MU#'<JEVPI=OW8ESABXRW%N"TYG1:&U,&=TCF2#YJT.5/X;?!S;9D<W6[R>/
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M7QZ>!?(1JMT!5PXDK&L;H6ZK,@\2+%?E+1VS_'J935!Y<_US5JA^'K3!S^A
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M9.;J!VG$N9&&<?#K^B[W5^=VD^HSH/<=E%""USPZID3';Y5_ZQ7UEN%3]9?
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MP>8H3*G+ZL$&:T?4+O?#%R%2I(*S >8]7J[;Q3K<W;X@CY(;E)SG^*#K/2>
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M="K;=D_V)9R6<@4WER]-!3%;3A_K<O#*:MN2<2PR3@ASS5]S]DO547JG%__
MV*)]2/@6WPLUVPJ7U0R\#CP\@QZ (HLWTALQ*WO.FQBY_A2UHS)4'2;?>-/
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M&3, ,7\%J"Q)AA F" G0%N'ZG^&2=4+8-NCJ61%;J.+LKJO*:<3#1/IA'@I
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M?:-3+E9^[PQ!!"Q=00^?,LN!SUA$;B"H9:.[X&($QOT/<!3PCHAAST,M%E/
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M-)#Q[O&1"^KC:V>!\T192O.G;/FOC-9;L(7S,A%[C)4X&P"NRH4$6:P9X9E
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MIL+YJ( (*#/0ZY'_(=Y/41J0Y/STC!PX,^6P-]UZY?Y:CK;\#XN_)\2QXX^
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M]/,DOE\MOW-<O)!4BADPP*9OWX-:^+QO#X3:0?V\BF6O9!KLLKMT[HYX[D&
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M_<QFF1X967B1Z/!5S2>L87<S6:+F;IRG9*6^,@=4XF%T'F$*QC+;G;)^&)A
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MY4QNUO+Y11NWUWWB[8Q,JT8]A<:JU@U! 5Z^GQQCHU OC3@YBXZ,>:OA[43
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MP2 [DG!\9S]4(SJN@$QH;M"/2&S1')')'W1!-O=")B1G]VS1"%<94>=?BI>
M:^7-C]C6+6MY%:MS+8J\%/XH39NQ]]GA3C*$"_:.2@;_"\>:R)T9-9*L^I52
M7OV+Y+75MDM \.\.P7$B,UX+W4A@SL.4%\76B8#HS2UAWE3?ZCOB=.@^#4)Y
M_T2&=INM8>[[<L\-G['U!M$,7@+(!G&Y"783>[]Q 9$QMQMJ9PNN5Y3?L8QZ
MKD6=8_M"V?YYL$?.M_2Z/]1\59R1,77Z=XYW#X[+Y7IPM^5I7;U\F8W*U,O"
MS4,H0>UQ_C/FP""4F>>BE2:8V=%]:\[ MK'-U8"$YJ=2B>I%64#(W0XVG'R8
M)S0&TCC7S<7':J96:3:&/5OY_7L6[YNT5-//3W(_A]MNP^F'4+FO0S"1&G_W
ML"NH 80D*-K[\$6(5S"IZZ2\V\K=L?1J&N5_4T)3J?!4Z=E&0.C MOY!E$RV
MW#9B]M"XNK:ETS7M[0LK+>YTL0$&X5O-ZV^;MX6Y^OP>;=<Z.9A,(;[30!S3
M^I:U-@;8"$>.ATT2YX]M.F7%Z\=$U"Y"@&H5*WOU$0=V9ZD[A&)6Q] (C\VO
M6D)XE_%R@DX^+)=X0P5G@=&:%O/2=B7R+"$'5<IB[U"9,"^%1)+%!;NO)DRW
M?]D-J.ND;[N[8S.,+J=*(Z36\C\/CDV^21F[\7<4]M=CQ-GY;#0;=<XA46_U
M:$JW)B[XU'2.BDPO)\/G%MUHIV";"#:LA_$2T'W?"\(S\A4)1N./=7A7+9(\
M/-XP[ME2,1UK( (-NT5UR.;J8,U'!__<**VM2,2]-H.J\B[A.:E;*;U\Z>:A
M]9K!;H=A] F+#6ORD(\^W<Y/M#9YTTO,=M(DK;<:&Y"I'WLEE\U_UC[&S%CI
M4&!EDX3Z()2])[G2_9DT0?8?U%7W3)9\I7BO@<;^5'>O'?8'PA:MG57I<&Q[
MB05P[J1OV)M97\H:WF[^M!B=Q.?;K%NDHLR$FU!*UWE#VTXQ_U17Y@-[013'
M0;2%<1U*K:VU3ONBV9QGVX^T6\Z?4KC?6):/(ZVC<?BX[:C,5YJY&E,'HBEO
MGO5JE]=BHWA#\;0]9G5$-;H] G/TW8N.WLE"R4+U:XG9O.!Z+$NME946?9/W
M>2F'C7SU+IO W._*/F57T_Z@!GF$")39D?<:CH;3+?R-S'!0-&=<0Y6%$_%1
M6N:/^W(;@P)5?S\>*8ZX!ZI.'HOIG=S#4Q6Z<!(L+C[FTEO,&4R+6J_9C-24
M%$\-<$>^$O^" 9"$:=5U_! -+-]2O3=^O+-8JB]O,>6E7*H>F^7/]>-WVDWW
MR.<VICF*_6\AI'!W#!^G!:P"S('$OYZHVS/1LV3%KN2GQ\P.27&NE27^&ARX
M[XT9-QVQB.Q=I87S726##+CP%)#I&Q(& 4_#Q=[--60Z^QHN59T_BO#BEG[%
M).HK^,ZW\K/HL1A4YR+^$N#$-K[>U!@#B=:[62KV]?9D_^=H1>N'0HZJ?5/O
M7MD>^ZOCO,/0KYNMV%Y,'J<WHHVG#KXU2<J[GK/O;<QV!.6>5+7A3;&0_D!E
M?+TK:M-^ZMBT:DKF@,*YVKK]#S<9V=\RUB<I30Z_#).OO\0+]8!JH:%$$?C]
M-JP]@5,HWHN6>Z#0#*\?'?8\N#?=!<4HE7*:L'7C<P(>@^%*O&GN? G @OGB
ME<*V9N?DSZ!]SV3KIWH*+=].]M5(R4DU6]]42E!ZWOR@^JQV;36Z@P.WG!VV
M97UKXJ"R8H_Q<)?5+T[Z9TP7TY]2UIZ44'=+DS-BNE?IBZVWSFG2VVDEO&B$
M\D>7J.<8&EQ8L]J/]9!ITQX(EXS$#>*8.^$Z_G M6T*_9AP.$E4RC7Z%/9(4
M?6>QU"??2HF@CG"@ /4-K[0S$:G.O[R U?2B)1 7%MS.G?3U"X7U/H_*TNB;
MM3\Z5"MB"AF<IRMV1?@L9V)![?(7[Z!;QMLC8=>3C32U/BXY<&R9G#!8Q%2?
M1'5NS 0=-.3MT5\"QDHN :N(@K<B$R:J$W2$L\H+@O._#?%S$NM_C@_ZYWB,
MX;\-G_D;1\:)=>J7 -72*[+,^5_,V(XNTV]E =_X_AY#SO'3_S:L3JZUL]C^
MYXC_9?!O!U4LFZ5\CI'$ %,B4?;?!EM <*6&V?ECT.%VYRFN^-]&Z^YUO_L#
MR-N7@%SC2T!GO-9_FAJK+_^O'+DN^/]85_]?FI,.9&P5^7_*=FU? I!W6!]>
M9+O_MG4[W)K]\J\>OEN%_'=N/?O__PS];T?^MR/_DR/T)F,1Q*-+@ :Q/NM?
MHY@TA-WY,>4:IS65QY0Y&D3-N33_+4;DXW\L5[["QDU!' 05;&>?BPL7E!D?
M!,;1ML</+2/[BQ\)F-VU3KZU.U^!Z8/LB!$CJG=J<KL<Q#A"7F$O ;U*D#A9
M,*OY)BOKBM#,;=;3LSYW$@\O]L7W/ONJ&IB+)+,J A7>';IF67E=:RV $42Q
M;"!>-#X[36W^FNS!A\+ $V.#@' ?&>,%RM]?\0XH=OBS0E@&4+ZP,JIN6*UH
M?OL;R4FLRTM*!LW5GB^,DOO.]94]=*1F2'PF<K7'XLG5H*]=W]W;Z[+2_KPQ
M1B3ZR 46MFS?JR%-F ZDP5.;8?73PZ $KF\K,*,?)*YY8,=*5W(J?IO<UE#P
M$Z_B-A 6A)I[[T77N!E(,5[GOUK%(S)676.6M1M9QNVEOL1;OVBH\6'?O8K
MAJ7M[#W%BEK?G)CJ3D!HCE^O.K]MLSC\YG@Y[+@T4 !ON;;*CK>>ZK4X#:_+
MMNV==8QV+;1&EE7U%%\K^0+R!  P]9Y'AJ^XLRN#=^'4:R)[=*B5Q*]X&^-0
M<)5E0"*KGN(+$3U.>G./N<^8=K@3FFZ!%&W:3WN_MY>SLC<H?)5VM\(KZ@J'
MP?)Z//B4GR8(4U-B&A>;I3^O-7,<5;9OO0LJ$'^N_!F2T$&-)T6_3Q-#7P+(
M-U>$_,D8+/5*+$3'&!-1-/[^GK_+\8DH:!C\5:$CTKL1%2#R;.K(R21 ;A(]
M\\3DW;V>.MT'S"%=_5XR'W=#?U\_[;T$T&SG2$T1K'R_F%G!2L'!B^8[4H]H
M1]JTO WY:K(/!LXU2_%05%!8&X]MZ?QF(/OD42F/S>NFZ?*]\H]:OOPTTD/M
M[!\,/*Q4F,W$W56OX[FP.ZB( O=BO'H7DBZBGOJ]Y(A7H;FHD1)O:=,[BLFB
M2>)-/)L&=K0<-<Q'Z7C20EXI B[>2D)*+.ROOR1MBQY/!FP@6\[NU5#G/@B<
M[*Q=C8;K8X.(+!0]?)1X<&\.U2P'Y'E'F@?T(J?'RUO2,ESUU<LO^S^ #-87
MV,.NLZ!>" G>I\?/ @.>>&-3_1YS/52<VK9:2 A7$3M^ROSQHY$/=?C_M @_
M:U[#[UX%6W\N-Y!E+2B:EP7+6U]:7Q0#-&#?\@XEMT\A2\SN0F;<"FG]SL[L
M6LPSP]SJAP6/<Y:7.,LAQ;-\BR%/&F9-WK;W]TT&S&,T1'\&!),1F5]0,YOR
MV^.>]2+S VG3$);#BU"VQU-.\B8G4H/4B.IHZB&4=K3NYU#\X)J'E5^IW$TI
MZ43;39+":X9:)K<"K2X!?+J*6W$Y;4%*@'L%R$>A:AQ; Q9@B/4TP%#7./*Z
M-F@TODCA@.C_])JA[I=&M=R>..ZU:^ _7\B^?10& L#C1B7)B]Z?CP;@XZ2.
M!=U;<T<RR0\BY)*ZD25F:[S!=ICI<1(-6[QROXFU(A:17>E4O5P03PA\(QS@
M)%B'\F'YBW[+03<$N]/ E2 Y*J6P3F0&&.K5'7<CWBKL',GD;A0 F(T^:"E@
MN+W/..5RU0\&=AY2:=@X\\I-R.2R.0:RM79JUR^["J4AQIS$[CSZ6FCSL.L&
MY7I._@T():P7C$.DBG\M+-CUQBV-./801_5,#_G?Q3W2)A%)ZB4)?:#IH;M)
M6R*\R#5%,8[#7P*2S )OXR)R4=GJCVK:$XZ+9BNOQW]OJ$VV,[^1]K/L2U0Z
MZ8$JN5-(O8;XK$+/YTN $K/;>1X(/!G,&&/M3_JBAJ"+/2<\"8I$;T/PNL_T
MK%Z5MT7\Z?\>)"J?<>K1Q)>NF#_/H\$RBB]%D\>NM5OVG+F5 JM68.F&Q*$I
M_@36#SH>O^JR.(+_:D[;IH18\3YX"SL[^OJ ,<;$J#1EH'E+4V&4[LD4R;V"
M ;>BQ<FDVE:>PRF>>X!OS4'T<+VK-!H!]$%!*9SEI?HK\1GB^5-BL^1>2:XS
M%C:C"D\H7CAPC+%,/U_Z+Q7,TIF(_R)F^N7&O6^?_F^WEOPO:M26JESG4P%L
M9[.R_R[:C*%L+;,^&FJ\RV17O7,),(<>R29:\O[+LOI(9%)T8S;4<+SUWSVU
M[K^V4M8@/^C9^HSU_[B=:N1/<JWBA/JS'48U]>]7G BZZ'V'L#7\+<ZS):*
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MG\$GNB(]QP>+%-UGD% "!3I ^<DL0<T>PZ-I=7=T#MS(YQ+Z1\9F7(>)7OW
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M56YI$6"-0M2YN7V1$HAZ\36.E>;K0T3W0:XZKK%/9&PA?2"WSB"%N^:G;*D
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M]K]<#^A?FHD(:6]NO_MKX[^>+<\YN%@OF"RC;NSC?N7;C^MQ5]4]H9"N$V9
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M(2]PW#MWO)]R9*2+?1(W+_>=**3B(4P3E=,I23>B]^,N,W);EA3FBMN9<#R
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MB2.]S:(ZFBB5Q?-3$1+DR5XG\8B:78Q=\Z&CUYU/'R^,-^4=;HW'(.U?9:R
M\7XG>K6 &W9PRYI2#S^;[>K,4CSI5W#UCW@.(?<C\PBV0KZLB ;+-@+Q#X#)
M=0%QQ0E,[P&W/LTOFG5IXL84N]M:W@L95@UOH&MYTWDD (JXV/2^P+:QJC8+
MQEL;X;SUPQR78.P8E?2&BRR5W^MNW(CG*FO9[X17N<3'  N!LYWG1AV^9*5]
M0Y?5W$R[H!=;02,K4Y?#$."U?)M=/?F(7!*9GB"/D7;$JW<2UDA7,;[<-*@H
M7V3,09/XN-04NXGQ\/,T.7W_VNL2:I-<*.^.X&>'XT,SJBZ'>C='>RR$_5(?
M)E\8_;HB0@GWR:EIJD(G7UZIC:#,)-88.+/0E)R.D1.[?AGMGD_D6UALR^38
MX986%L6HDM][*]P#RZVE^T&//$!_6HO?X8;BB@A+%(IJA$A-D.\Z@./%7^7B
M3:._5. 'J@BP1(WAG05T/49$2Z-GW%ODE<2VPS25@2?49@;6U58ERZCBC1/E
MF80-8"*"'S'[*(=KV8-+K#@ZLX8F-:2I[W)/3#T_ SEI5R U!D*\-^\:;N+:
MWB/YX J 7)$SA-NC03>;>+L9+QXAWL!0N"81V]M1VY"VU<,BJ]X77#QO^TA7
MYX7K5T 6W]9APT.@W"0H9W^>,>_ #EYTX3 I'J 0V4;V3##]/DP87^MBV6L8
MZ7"E2=$5>:'*D1[@\*0@AD*3'P_B[K_:R]VN*2+)/R0?H<GWI*?GD0KY"Q6>
MMT&"TW+OE\!T\)LESI!*RHY3KT.=C*E'XTR:',$;=KUUNY]\4QSECG0N_-B9
MK?&8XL3ZQRD^AXL6 *PZR6<@P_?N#;)?C_B%U?-LA*+Y^9/"']V?,Q!>4T;3
M-BZA5]X?!+US5\R7T%S\@2KK,G[.P^;9LESY0O>1$EKYR7 3.2Q2^Q15(L8[
MD@L-3[L%86CQWXUJKASO,X_ZL:YYA8M@C6Q-) ,B5? >G5K6JH]KT?7COC,V
M*SJ:$G7KMVVGF/*5V/"2:D&I/*.-']7ZX*GST,@F10!BA__0615"VT2@[8A\
MA6E3YL7/%)=U%4QEXAZF7=]DZ?DFU%OS(G#<OUWW]2P$R#P/U&*5I6OQX>,I
M)4"RDH#V$%'2(4&KHQ)=J\EC7E7U?=/+;R4TOR0X?N=X2&OBH5QB,NDFG!H]
M'"(/R^_DP+0<*8L!WNWCX\/JIUG=!UMBV_R_5O47[]N]N#!-U<)UB+(_S6Q@
M]9P?C-Q5]9]O9,7N'5:/6,=3J_DEV<9_*SL:,'^EC7Z$HY,/-"W0UY$:M>X*
M0BJUT<<WD1/-@)=?UVPNC"D&8Q/9;-2*IJI>B=S #> ?\B7+I9E"DZK"N)CB
M>.0QO-C$E\J2/R%8,Q>.B+1;X^XAO-8P%+2Z[(T673HSX?%%UA_33%Z%MJ,9
MQP,Q2AG364\6XGR^Q C]#(L1S/L/[U4-+3]GJS4OVL22FJ;.0/=9NH#?7?*R
M;;J4ZTT"A$M#E<-2J_")'/W:Q'N78\<RWX6RCM<=G+O:P']QM:8#R*JQXD&\
MG#0#TZ!MCNND37Y!9_8]=,S2'\7J+[)3MLS=KG4JZ '[!#XU_ E0;0A(>[O-
M_UHX,5I6<KDM#1/%T[\;#Y)XDW^3;)M->@.!1\*\Q*^LS?+7C1?[S##I1<AM
M[4@+OT;'CXU*QM6R/>?)&FT2!%Z>SR$=[-I))R8CM0;?+I-W!CIY(&O(V1'?
M^VV%1A=$M_@2J@1K;I]D[6B.)ET-)L.^S5(BV,&L?6%[.TS6ZLYV.;^F-<.3
MYGU?.#YC4S!Z4[.2D>4JVAG,U20T9#]<LF\T[K,F53AS(^;4?>'.X[XI8_U#
MMZ>:(%  OUV&-KACDC6J5*RD,M/UC]%M-TZW=AG9L@$\>+NN\*;N>#.D=&^N
MBL@+#&)[I[B%'Y=!8SA$:X>)<EZ#MB[V:0Q"W]MOD_&O@$ 3WUGV=&-(8, #
MF[]EB/=M$/AB!O/?&@_LS/2K>TY]<;J-Z\*"N4SBQPC0MIRT4!'K[:U> EEK
MWGK/+UBVFJQL[8D(9/+.43H;/UC4GS@==H_R,]?3THU9P:$& 9=J^>VR_-6T
M[2E&M\?K"O:BJ]3?R#%M6=R +I8:]8NU@\2'5"E#MCN>Z!Q)^T=QUMA'[+<_
MDO.LO1A.1CW%5XO2Q_.\S($;G^8W/,R2_U9!H.U,Q])>TZ;6'>.SC'IMV-GO
M*_]PPL3K1%5&\F["W1B4TVRX5U8S(7TAY!7>^_L+(&_;,NC$]<.'(%>-X6TI
M5@IS%MDBIM]"$;.>R+<<>]0*4]:/QSF+. L\BI?U\--3/\K5A;+BBG,B*$<]
MH1> +K7A=*QX)^W%SH'9C58>,)"8-^5T^;LV"^J#%-@UC-$;399<0\G&;SJ3
ML5\/0[0>%\MSY_B5V#G<*T=7Q]UXU/.Z\WPAI'@!NOCQV5+0*_;SG"@]LAE[
MG=1*FAT^ U7+GX$<3NO$T3X#BB53I\>&TH-<,(_60Y.#.DS47OR-]85WMJ/B
M7UXNKK ;^UV*@'U'I3==(T* 1W/ECJ^)CK@-)Q/S2>[')QUW"DEC;MJE<NWK
M-$V.[\-_*7C&&7%T-*42*/6 ZB*8*=8D'%<DB')_OH]DA?TVO!_K3<YKGW"9
M6)4LF,W6>25L1B@X6\L@P#W8\U:9[:6MW(_5XT.S-L)*Z(84P61?/6HVC-SS
MBU1=?PRKESB/0&<F;GUV.:QR*I^QR%EWJ'Y$7J3Q?CIT?KZ:DC(#Z)VWWL,<
M@LLO=2SFF2-5QI]H.L@]NR%]I58@Y>7^]2 39)Q4IG@GF!7A8GWM=\>U)M:J
M^I]2"K?1T3D7A<WIWUWL46$S\"NB2>!D#C+-??7VN%Z5D/ 2EU=C36\]O)]7
M?>^]S]2O4L7LU18V7 0A/3*]G4Q%_B!-NFU$2W8H.#\/,>8^-S+99##TW!?R
MNIF1* &.:F(#$&TV$HU#:$YZ>E<263V#V3HM=^&[W/Y"8[M6"E.Y"W6F[\YU
MA(I6-#X1_+5Q!OK53./SKO0SQ]MF!FE1FV51BW&@OS8_PY9J0A"1WDL;Q_4T
M?S*U)R2Z/L"SGB<FMYG7BOZ[>$S^@G_KJ4#'3AXM.RJ_]O5$<>>3,,YHWIEF
MEQ5EF\TG=O>6ZVG%M*(5%9P.DSL\?<9=GJ4QPJL1XFG0IU[J?^QWP"-/P,2;
M!/\8Y8NK'%DIA/0.&Z:RC$/]W;UXF9X!C>L=FSU3%@]%_*^:+>[?0K_-<&E5
MHK<Y+2[U08:3Y G/>1@3EA?:;(1YV&)U@^]W5C^WUVC/TXYT%/_1LC:>B=.=
MY,0YMG&+^IZ!HB"7W:02+[>). <7.LW>2B"Y2OM=N7DG"B-(M9)QU&4PXN'3
M/"&+(V5-5M:EY=)WL-G*YV[:P8=CHT!I#ZUH4L+N?]^:;7I#4/\.B8&P2.7\
M>8<;')-A? 9Z?2OMMC2MK I^M2R+<#6"@=WBT>3KEQ]IQJU&4LHL>%[B=W X
M8*YK5@F?.?ZQSN8S]OW6)(5EXAWHA"X;S-U42&;EC?IUGKL&701C%$ENFJCX
M;7@<IP11T[8T'%/<I%9/?O#M/M]4[[U+NQI'P:ZO@)*#\TGF:>(FJEXW7Y7/
MH9_?<E=I[7P=4*73=9INHD(ZE/8X,"RKP2C*X2#1@7%N//D+6Q;:!M*^O-G?
M=&?,NS85T3,)4_T6*1/)@[IC#>K^^4!7V^0?,N.,YBZW7XQ,6[G<INVSL=B&
M"DW'CX2%$ QD0JDV=*!1/"S)NSUCBKI?&L<.9=[0/N8^O,X(\:LOGPY3AJK:
M&!+,54X+E2]_]#Y0\G$DS9@2A5<&Z8D"^#@D7K?Y*I"F?:4'P<@07"!6/D2/
M[I(R+>6[+3Y[_^LGT&6VP1(Z=\EO7M/'JEW02M,#\<Y^,!89L;?%9S7N+IKV
M6^\\^+&*Z7Z^</<R,<> /:>FJ^_&?-*KD8Q]]@8[[*^&AW5,KL<6KL]?U-G9
M=(I]B$N<<9\[NG+4(65YN]G5R3=JSY5SRX/$\GB]K.>@8%@)7W\EQ1&\04_F
M;\7ER((ET0*^.%W.D%YZ')44),*O");BP@J]*AUOL2QJTP/\T3XH\H71+HGK
MPE)$)XCM/,Q*!M\^OH #7W,*8:R."?:W'/&YY^"6U%]HW>5>.C=SZ1<%WV3-
M()CHC\>TS;'!..\W-97/X8HB-;;MFV($M^:-1&X]_YCZC),Y[F(0)H4HA<]+
M)R@<Q #AK.V<HG<[ZM+B/ZV^6/-TN1H;:^<FFG?R(<KNC9UK_\?NT. .;V^8
M.C;W#!3?!/H%R QP>[>9S-X<V]M+,8B:]N;R4O@>?V/I<X+!%.4,VWQ6I7</
MAB6Q "Z.<VU\!F5 .+7D3:CD0:4K#2U</&<\HO4DDI^ =L$INQ+S3\:V*#LF
MZ6-O9%E36XY(%WQ6<$C1:4S /E6.TT^@Q[ 0P'$6<EM$YYQU)G3^ZWU4_+7
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M SW+%+X_YC!BB/N#XPQ$O/F[$1<;*QROU2\RI!T7&3_BPF7O^=&O%-FJ?(E
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M#?AE]*?^+Q[#Z$PKU^J?P7G0V=E(4\;MF=0EUB4VGK%5[L@19GWU3^\'X2I
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M'6FL.+IS?Q.UNJX:9CO7I@HW-;VR4#;::E:W#R[2W^$T6GZ:1T__!K)>C]5
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M.H=&Z@2E2VEG09K&14Y-FV>.2&^"XT\6_4]L4>*LCR%;'9&P7W36UX"JAFO
M=P(?>20I:E@/TX6J.>\Q$<AQ*/@)]G'P(1B]D/[*>#O93$+KTT:E/./ ?O6I
M'.0J&VJ^;DDQ#]' 45D&U4(?H692PO;! E@S0:3H;9&KA.A6@T62]!]APYD
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MU'AT9PW8,Y;,&<?Z!53V332:44WP]?<\ZB;:29L1"PF&KGX>L+PC.0E$L"N
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M;@BM":E<=8I7Y7@R]BY.XFM5=7!T<3UM[N2226 @>*,JF:APQ.:D)"($G\9
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MP)::&U_9OD0]4E5)74=02)(,X/&@*0-(F6<  <TW#/X+EWHT^%\'DI\S^W]
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M=R\&," W@%&NV^_']+E./: G5:#(?53;M/=F[])TRI&>'/-7+SNU]KVIT/3
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M\%ZG&CLD/I88\+JSV!_G IQPNJENWK(MR?/]-0_%5,I9+_ RL76! 1!6FAD
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MYCXISY3GV]BAZK)H+4;TQ7W"\,+OYA)H%1A_7+R_D#(K*:'9]DHIK?OA:<7
MB:Y'ZS VT!$*@8"Z3+^J^6"\P:>RN9*K$TV/G:[%M/J\[<D96FHOE<U:6QO9
M]"7ED+^6^(EW^YVY@=M_QO]\\]B!/M./+6.S>D>P$W>VG8D5 </5"@87BHDE
M# #OV?AU2;'=ZPY5+V>LS29ON"&(SUPX?Y>.V*-GM1JHQ  I<GL+C N\LU-1
MG]7+F<YS!A'" &;:;:8>/[EX?OM]US[E10:@VJQ'.4/.;4KE !T[S/2)P0_]
M]@M$1GV_V9MRI=L_C?N#2=G(DL'W]\84O@4G4C$(GVLDH880.=C!3PN*G!$,
M8)^ZK)\A$0RN$T9X^3;&6>^O0<HK&F+LJVP/ZS %?CBLK]$J/)CA=Y#<3&2V
M)(/X&'PD1UNZ5VKC"=WN:^C"5J0_6CCD(N$][[1#RXXUU.[!XH"=?O[$]7">
MY@@70F3+IE-W&/*5(LMC*_EH=FJC@[+(:_WMQ?0.<&^-1J$]1M#O$/U0%3'U
MT:J5_/CLT.C !-;]_976I.,LXZFXB1+C"5R6$Q(TFY/L6'%<\F4 IC/VU,/D
M?HJ.GR.AT"NDT4-]K[_R7=$OB2^\AGT>Z.^ONB\]BWTL[T5"["KSTPRY&-($
ML[\C&ZT3\O']<%^*:P)UDLR<03YI0#@6/8\56M,'$/YO-(4N)97DF;&''L\5
M5(ULJ*/3$FT_F^&23 -$B4ETU?*R=]%'%7WC;C__<*]YIWI@D);4+J5O5K[P
M3U[>RA9+1-H>.SRVQ5G$R[4U180@T9C*:3D7<*#_)C)4#KVW88A%\+WXWI/+
MI9.D&5>#@$Y01-4*CQ+RJGX_IM:]L+K$0W83:SN5U-1XJ.)TRV7. \]\1),,
MZ?VP\L7X]\DJO;J]<6/X%I6"B>Z[7L'].X>G/_HSS9P9'T LA#B-^YH.YO;6
M()WQJ;"Y+ 0RX:EOE5W0%>T=.ULW^.*E2*J=</A\>NY)4H6A>G1&F/23N7^5
MY=RU,IA)2"=4(F:M':SCL,M'&, P:C6-4S$C3!+X5Q<J 7ZG*TQ4F>SO,KX;
M_GYHTD=DJCI/,>E-N[-PWGWU:TNF[]EZZN)1SQC >%K5,77Q?G7N627.8Z;K
M0XV6;>(2>PK>;S/&/[(Z[99LO"42E&SVMV!Y M3IG:)BA-K!"*I5FE?CA7[G
M@;:%.Q,1XM/Y&S9:PFZJ3P<S+?P<B8<"AM;KMM<,X!_51\UNGSUV.TR<72[V
M+>QXQ->N._U=K/1Z<+<JUP32RG9JH.:\B]V!Z!WHQ*SHP_>\SI@(G%:O,8OP
M6L%9AQ)C2-1^JO($ERLM8?/L6[CMBQ9*]"&SJ=4.]US=;&K, #:]L_^"9;\[
M3=^47$JL;DJ06+Q**&L0VE/+2143ZI6:._6\E3?C6NF^,0U;_.>P/EIQG:Q7
M93U("/'2PRTV#'MU-55F'XS-U.&XES;]S5ULZK2@6!@!L=>/B[!4#QO6'A^(
MP45YDRS;\Z9C%F,$+0,F3JL%Z15?HUX@8RFF7I'-V-WQ^E4(UM2%=AU%K4,[
MNJ2:->B'AC%+"8Y)<H(RT768H*9I:1VU8?5P6B1=SA$C$" \@@HMB9MNMI!-
M/Y*<?T',O/VX#3HL#[C%_-D#Q9PZ(='$&0D34+7)D&A&R@7%)>S&#SML6MX\
M6J(;S:1\X/7IMDD\W".=S"<77K>-/L#C8*T>W'4YOO6S:C@M!3L3X9J4+A)L
M^6@V(<::.%B?&B9ZFG@[E8AJ>$W>W^SCU'LV/JY8JK8/^5SXS1[+?6)BSQWR
M)/M>9)0D5%54;+"=?,%]M\/S\QH#8",WXCE# IC)I)76SY;#\T-J6=&S0FOE
MSW4KG[#M,=AY15OD[ ?5L&7]H( #M"QU:?)^?:+:5C@<!@83*X8=^4FS\HNG
MSSQXP !4&LA,>7,\$#NMW\@:=?0):41:"L9KI1JR>4QXLZ]97Q =G>]2WSV;
M6A;1VE@KJP]#5O7'AUU>0FLXEFT@N]HC\K3U?="79)T4,9H!R55<G5C9VC/#
M^9MR!*B!B5-G+@UO&?H6_X1Z_MV0E;:^R=X/6=1JCX)G;&COR-9:&[SF]#,W
M&AMNLD*4_S-KYK41<J:QL;U??=O3N-UEHO-M2U;8A76H$68 ./5(V -G63FJ
MG&U=SQ RV_UY[)W79]Y+Q,V'K<"&Q/!Q(3BXJ.8X/-1:&)+\_0L#SHLO:UI6
M#@N__)A[FDUDC_?LM;WZ0]5:#$"N=U5E<K#,@@%8YU0N^!(3FQB  %4,A0K#
M!_N?/]^W^T%_L?$QI?=VQ]* TV)YXY-NJ !4#.:&R$V*H;/H^:Q&4*!QGQP1
MU]_'^_WL92N32(/%X4-UI?E-FEJ9.N8%,F^/0&U$B>OU?Y'WS#50LQ?%R@#F
M0^GN]6:^#I"(8(=$! ]U_F$:ZS\_O#),T4.0@R@:?B;=:+EG N >A0Z8T?.K
MAYO'Q*+THKZE.>S=G;;GU;Q5ZT([D;W90G_Q:*'?&74UYU Z'V7G.Y5WZC>;
M#YC I;^5MDEI3>PY7>*,<ZZ78_=SI&71X0YTZ5[KN=-RUX8N%WWX?.;C>!57
MO>J>=[-6<@O%_A(+L\28JV3E":M38X)RDR=G-JD><Q%>2;':]^3?/\5+/-R!
MNID9_C0#[6%QU6-DY4: K01ZG<8I0];WGN ,2P@)MQT$[<]@@&2X4?38V !I
MG7;_5G)[E<FX&UY->@:[$RDQ#JM'B) ;P-#6B1'3)^(/G154&F6W';O*#3>]
M?N$#7I'8U8 1\#M(*"G$[ZN3()\T)1Y>&"HJMI5YJLRE_?9AKKR$\G2MO_*X
M MF5<H[*1HX8AP?5B?352 6+)^5D[[NRSA)\#E-SM_I4$EXPUUIEKG941=J?
M$O:BO'L>97K3[PP9AD<]2V&M)(?CX>$)+8&>1>E5KRM>QW^LK-"2N'%]'X>H
MND%DL>?8'@PY'N?\%3LADOIT+=&79GGA37)Y[>V/1/'DB1T>92^4.7:,IR";
M5S'/Z%P]=+9&@B=>(L1/)VM.2"AKNYJZ3+&*EGX\.G3?:2KGM3ZPK/+AF@P,
MI]_:X>VFIJ]-J"C.C.W&E*],Z0AMY K3%K8C7G((O=(R]1NVLM17?YK79G6?
M-(CX-$R4:.Z".8"O*Q\ICL)-ZY TK=7AN002*7IJAV?%'I^5IW85)\;2":*!
M^<GZ#9OK#;"('J\&6JYIWZK<7L2&C!01PZ7<J?*4:T:CF)/-:[@%NX<!W&0
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MKHOB?IU23R*'[*"YBW_.S<<2>D6EML)TDDZ#2(%/G^+*MK5WJ*V]&_X%$9E
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M!Y6SZW1&5K*/V^9AL)8!O)>P[I<WEA[*T=W,G B-R]4-='3+WV:;;YIA$>O
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M\'[=L$8SMO=WK@KH');2SWJX%YDU,.N?E9YF?R1E:<'DR?'-8SZ7=U8$Z_^
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M]X+K?$W[DR&'96*+-[CF7=?L-2I4'_Y,:M;U7K6IE<8<P\:!Y+?ALU*0$%*
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MN%PIE&&B=WC2LMVC8I7Z.6'A9V*Y=:EP1FT8Z=N*Y5D5]5%9,0O]L(2^1I<
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M'(3U"";(>!K15HJ@LK$.<L.90-*WQ>[>NA?(1;X\36J"; .3I(G  07:RYR
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M4N(R$R2Y+2N)P:/Q#/%+5JTD311U -&^MXU!#Z?>"VX''P;4=_K=F EB!VI
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M#LN(A7#T]M^6Q @/'^S006OET#(;Q9,\R:J;7#OH'#8W^O /$!L'S)D@HAW
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M":S.\5_IW61;6B \S2[W<*UN7G;L_4XXV/_V<[XA.:=>I^R+[6OKA<8+59.
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M[T#E><>6.Z89CCJ&CI8RY%5VVZZQ&)EB3:PWHH'.1M ,M%M#ADFLRGR!^>T
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MF@E(GPE0[M35,I!8X3Q+)5O\ROS@L5@8/M &68Y&!.G\S*\#G$+CFD6ZOQV
M@#.=7:K/$M%>/+J]C*L)2RE:.F>8=^<6+V:'F$"GE9(,6[*&=TN7 )'DO%&T
M).MDDV&I"K0&(./LJ2(VG\H!8AUQJ_W FQ)238DG1&PRS'E1.]M >]1:3E3#
M+-U_9K?NQ0I6DSX.P(X7CVBG4EH!BEMOE\@K(]):&" X3T+*M/]S)\_41RZ(
MV1$H9:PKSQY@BNHZ,) /,!E7PW1Z-&*]P!NK\K0UIRYC+[[?+752^XD7F&'[
M4B+QB)UQ2:!TRABP&MH/058#[P[PHQXZ,%?T#J+M&:!D*<3H 70C3)Y*B*:3
M9*,=BE$/O9F''J[S%P\%S.A2IKK+E@%TD_41HQ<^SJ4#I<RVE<;KLS1#U'93
MWMM!X)W**/H.T!8HK0-<H1=7?1"ST0">%XK%/ :_-,FI.8MA4!79.C8#MPQN
M-NC^&8';UX G9=T^+/7G5_H?5?*3_.\JXFI<N0:^9LS$W4HRTGQ2"L'G4J^N
MB<5SN*YV'6FT$/*'?_*='?D2I_Z66^@NX9-(<^W9YV.!RZ$[MUW.26.XU:P,
M-O-1^_6#3^KEYL^2'*T) F# ,P_]A-T,6;Y"$5S$L5&U_- D<]T$XS7L5(14
MHU/0U&>AJ;2+LZZI_'FSDA?N#>6IG_N<R'[1_5C ZY Z@[IOAIDK'W8RA8^8
M'-+#Y^;W3LZI /X77IX^R:0L\^8H!0DP.WY.48NY<?PD8+@!W;,:;2!2"A9D
MUD@_Q(F]795[7G-R"D&9ZFKA_5WAVLE& XQ3L QB19ZV[N0)%+M2IO!_&.7@
M4PU_Y7EHTB<!;K\YF7$;>Q* Y8;;!;O-2]^1>?8!</GTF.\ :F0:N3(;.)PX
MU]6BE[M;058D#<&LKW_.*"?VH^%NN9.M!GTQ0.,Y,X3K84&$)T[0 *ALSH06
M(V*;_=:<@F92\L$(5S'Z-N</FYRHC^JN*Z5 0QMC^B+PGF=BC<;CN85Y0-/5
M:.-48R:TE'1SYL:_7(TL" #01)"9:93 [<13RF\4I+MMOB[K(@L9AL38 3:E
MR=G<MSGT>6KNE+8_V[3IY["[W=^KYW+?Y&Q"8BQ>WV%A6<_O=\!R.O7]?.BX
MY<?UTS;>8R^=S!X#.QI],X?/53 Y-%=+=@''"C^BDE3C%!]N=T&/\MX<0VG$
ME[D9I6DDN/LF)^]E,> TN_("3Z[^OHH-,ZGL6%U.F]%RGHH(R+C)OF/OQJOV
M1-GE<,7-YNM<W_;U+E3!_2@W UK)&=55?A.H(P,JM(A![H*E5.XH;K816[UN
M72LED\ER^LD,7[<\'6CL]J;]%@,48MK&*UEG7//0)FW9V8Y848VZ.C\_ \<S
MEY'FT?;8#Q/QAQ[$L'+S'Q1<N,1N3HE@LI6Z20].T+%D-7MC\+>LMT:XLM'M
MII2-7-;3T^F'1X> $= 9P_NKD$TN92NK\X;\;G?3T#3 ;:K6T9KI$BC>FM<Q
MVNT7Q_'?7::)NNM.S)+45C?>'44 ##"S\Z_/,(-6HF69';K=E/6[LP4\K[?H
MGN[>[;UD]MTBYE9(,\\SOWHY";N;EZ,\$)AK-*\7!+QJRLEHMWI@:_;%++2,
M*'/LZ#)QF')07@B,33=[R!P3@OK X#1?ET'*I4QGB9_;S;JS6\M1P/.&MOMF
M^F$$,+*R?M42>-2(T7;?RLPM464BDLLL2O?!LJ 5'7.S*.@='E\F !$VI91I
M>LSY*P -PRK'M)BX[58S#+L]P&R2D_+"=.K>Y.NIIPJ'<[68Q!%S;<I>&]H4
M98.3_+_898B-Z5\VEF599Q]#L%2SC;3F#"[Z#I>78)]7?A?/X/+A\A!ZNG<4
M[;\?FK:VPEH@\&ZARW@&&Q>UX"]A$))T43N]N_Q%Z$4,1F7M?_IHS'_JN,P1
M[D:K2_*2V=0%9I@Z 9TM]L!XT'QE&:("]2:M)8122+]1GMCQ*^L+>.KB^CA]
M"?&FP%[&[IF2JP1X)6LW:R'@[[5^-\S9.3SS1,-A;^:O8N1N7=$/K=PIK F_
MBF&#@TT1A+K1U8NRK3/A/UG4B:*0G7$6VEJQ?V@[W?LZ,%#%GY2GR>SI\(_L
MI'NK >G#JHV.P*S!/!^Z_]\5U?]S4>A_IN@O@.K_!##TOU+TX)^*:O\?BJ"?
MS8!YE@NQ^M9BQJ$5Y(&PP0)SYV5@/CB'_-\5#2+:+X90]YDHQDM?XP?W.^-F
M$Q%OTI9*1C?:(-^!W"/[]Q7MORMU+Q&DH@/R0-F6 DW=4%^-M&2<SVF*$>5N
M-^8X1$.:<8H01\R@M$4O_'JVM_W7@<!Y,_8\V<J*F+R'?B4L1_7('^V?1^JB
MX3]'I C[\-)-!0MWEMQ-"X:BR;V=#]:5NN]G*;J/IA)(!8*I&FE9=_B(BWZ2
ML;/+(40!0#6I<@"6':0FCL*F 5@X1\"4==0X-/32Q/ 3>J!9"'T_A-35,M$*
M))1V$[TF9!QDAT)"?%-@@'I>(=I1C?0]%#U:"#!3M@<A:3NZ:VD4-LV_@PK+
MFZARW6W-#%#7,H'^*X&G?T51:53(6 BY@QGFA 'Z"K&'%,H@=M8^ Y;4)?II
M7%^%)I74CQA]QUSHL8>RPQ";7#B@7AP#Q/,!;@3(Q,^'S%!>?T"I#O\"F@VN
MT .Y0_@-#?%P'KPQR0QV$DT5);1!V&'03<[JW]"2X'IHQ$\KRBXL1\1]77H
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M'-: B"B;]Y44]BT+D=ZG(TU>]OU%C@,V$1^<T::X0?4+:?3F#D 0\"UT6D;
M'0MOE&G%NR95M+],1)./!%\T:2:^@@@P]SHOCD(?G81*D*+^IEZ**R71SFZH
M'5%F(+\>Z%(5F.XOAEL=T*/%,75T1AR-HDV-IX]T =I T L8$8-4QU:,$V+S
MQ!>@8Y>!L=5S<U?N0(@Z20#3Z[@=P5U0D'\-*NG?@AH=K$#1]KD 6@200<FM
MOZ$E20K:0LQ),T!"S#"3W_X! .3S)G)GDZFC':'OH(/Q<7^UODIYH@](3L0O
MR<EA@$Q3?XWT/QB@5P],Z(&0=5UZ'\V"W@)H4":GLD@ 9H ^9,+57<,T&_7*
M2I(/#B-& 5>7QWLW8?DK@=I*_HV8+E6-![?)S0!%(8B-"X $13,E"+&]# '4
M0Y4P0#" S  B*,#X0GD.XN>-14 AR).ZPOY!&F790N_CIAN9DH,B!1M!=LED
M@):1 %_^$02XWU>72F:JU&*F2BVV=-4#R OJI=$!ZC@MNLH8H->_4MEP$[8=
M G/8"M+/9NB2CS! 30B*]98@19ZIXLTA%.([0*(@&XO,202/D^@U[T+,_4V^
M;7NPX!T&Z#=R"1-SDCMN3%AG23! *S% ZU" :ZKT'WC$; \P[V0 (FY")3,C
M=Q5C?@"-!2"=*[C5#43$[8I_4!1%<.O]#!!@V>S(4_^ 3/ "Q*7@J( R+8'<
M9H ^;Z)VMIBZ'J9)M(L!6%@"L!"VH>69I.9*10 BNLOV>!7KN[,TI5DZO934
MHQMQ!C<#9H N +U@1U5$T?8CIG"T0K(N[0.@[=$H&L4,4B2#^0T6FK"8-PJ,
MF:WV73W1:0+8 :A!)(4\.FFJJ@!0]=Z5FD#?D["V#J,_Q.V2R V0B-LE$=!B
MO@") TPMUM;5C<'-$B>9.'2__/O_'DDD@ _O+C[+MU$A&]"-4\"H8("(C7-0
MHAUSUB@!9@T' "@@F#W !(0."+B0!\RGD+A=19:OF6M%H']P SK!G KC]GY^
MD 'Z(4G788 &/JC^ 0!ZC]IEERKE'T  O(?N(G8$>J!Q5YU-_59GID@#P%)
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M^4\2:/"K@'9BTQF]Q\?MI\1[!?K1F%#4@2W(*3CT)UPVTVRNYY2%HY;[:N8
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MYYSW/=_[>YY[?_?<][WWO?X1GKV']5EK9LW:,VOV7K.FM]2&*5BCCPRR[Q_
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MPU"?1)3E1"^]<64>CWY#OT$Q*Q<Y1"U,=H]U#=5K)]*D#MKF?K-*;+Y7_Z#
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M&9!A%>WDN37K\=W($^7O0YX&D@JSMAM*)!Q5=2#JR]2A!E$7*7;')CO;[!Z
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MVQH+7SQHHOO_%=+SZQ7X?U!(S\]G)'-@YLC2C)M.BZB3<*]YC<.^18MI?G@
M:HH(I3H.("IP:$M!LO6[J'2@'&$E[Q!'Q+P<>55=@SK(W"WW;;L3<K]QKTYJ
MKUF/V9>;!?GAUD'GVDRNG*-_PB5+P5%U<EFV90?+J&XIO>[O>PS/X &5]"\/
MK4:$KX"^+>J54618JNF[%RUV1!M[3V21:GU>GDAHC^$+'/\#W)L>::(]0I?,
M^6R$[/BL3'E*EZ_/)KWJ8*_LJ=FK?4D*V'["U@HR, @-6EK\;:=[L!$^N_G#
MZ5T-M'91M5=!JWD(M*5K3&4=,*U#(,=ICSK0C.@>BT.S=(9JNILI(VT.3T-"
M*IR2'WJ?5''CE?U.\?SR2$/8%]%>4GL=E3>=&Q79_<:0KJ^1O;V.FV_O2(89
M2J/X!;@JBLAE6C0.591M8D&>M"Q_HNC4+S<XIXZO1"#K7]^2.RIBRM &)/JH
M5:^I\8-NGX49-I6FOZU9$E[;R1+W.6ODU^?>_L0=5F#N>[$DB+8<$J<-W<<C
MJ1&IV::BZRY]J]6JI*[[=;6H^5'5HF'7"0.FD+=ON[>P!S;4<<92LGF)^R(^
MKGJ6\G",ZK>SHS^Q+;U\T"S4(&J@SIJDCHLN8M0H5?<W1_&+VX7IE,65RN,7
M/WJZV:1KI%$UM!FQWMRN@S-*"T9XL]A->Q]$K'IU1-?>7MR(_>XM0.;UODAV
M_=I;>V, NLL8_]V0Y'SWQE&.NV;$LYUK%'-,( MRQUY&ARP2.;!?X]-R46^X
MM>276C>7^Y^R)7-G5B\URC7:O<NAG3.?ZE5LP0=C=MC>'U_S*<S-^S8:HG*R
MVG,!7<IL/U8#?1:24N?J)IV>U6XAD!KT^>O.,3O#JTCN(CS.K<U,VY=3AQ(_
M$(H.\):4ZB$\Q/-L='> 6)SG7BK.=2^R?GK&?+G?*$#*,_5IF;*I.16F2\8%
MJ$C! G)[-%<L9DLCQO,//(]G]O??D_S:7KKOL%TUS[5>%H1DM)HH?4."]WW*
MN0G[NQFX%8WYGP.FD>WHKP^'OT;-_]E1,ROF$Y.#5'9H2C+%W4LG1J^TNS1"
M!1+,&+7Z!#,=C2B+IPJ1/('I8LI%VCD9D:(C!A$HQZ6)O4TKE\8$Q%-+[]]$
M:86JW9GM0GIE]_@E[5.W-)F.=.@>Q]WR((;!;0 1^IFF;L/V7(NX^_LTG>QE
M+V>S(*6YKZ#.5^FJ5.$AQ+-V6<MQ(65SX^INGM;F#-WH_6>/7W2:T:<KM*D=
M4O3SMN+TCS;KX<G,MZL[H;EKY]AQ#A9DUUQ^W)),E^SD@CI5CIQ_I2EVID1&
M]:&'T/<HS=M=.P3"2C7'2N]KE;K7ZI:8Q^-IMC[75F:P/=M/"=V+%HW6.FF4
M%U?<K6GFL';'0R:TC,>=,% U$E5&>(M_6?I<W5'I"XX[^\"&DGT<1,\&2NHC
M5UR@:<VR)<%V69)X[#;7?O,]JENM#PLMSVWJM40!V7.AU87R+::=/4G-*04W
MM0HDRWD[=@-R%CK$)^B9@_UH_Z*UBM$^4XNLR S9[<P)C\-A=?.@V;3%D&QT
MF,OM.N](*:15S[B2O(0[S$%Z<U $ C_=WB=/$SEH1895DTB>JAFF6O$)IITX
MJ8.HIQ4J6AN.GW.,29NZ0D9\ZA.DG_U85/QM,:7X<?M 9HJ5DY!]N"?Z90@#
M-8[8Y#[@;4NS-*^Q,[ UO9C@E&I2'3C"]7"C1BL+(C%"E_1014]74:2];(?S
M8UUC3]7R\MV@58VKWZ)$S=R.<(QA0<0<Z]NLJ6:%8M^-X-=PARPMS&S0[MT#
MT."R?17[>@\TO?N8%YXG5?ZQ5F1.Y^NE+877<&]\^2:-U XQXM2.X)Y*CQ5G
MYUE[V3H8%X8N^\WS,MN5/$D8;3)PE=P78%]B<BK]=6_W^4/%2IX]@5'5_0_V
MU/1KO$-E14N:G$\WK^V^4B3FT4:6^(8-1$3KCI)<TRTMPAR@'*C[[FK(/<%[
MA?8X!SN[U$.DO2!7$*V&?7Z^.Z@5-7'.?>-QQ_,?:%U:Z(Q6N*GD?_SBT"+.
ME**(QD.?8G)$LM.0%?9VV9.4BLV9K\Z?3@IQN<8!:A(=XJV<09<BA\7C>J=Z
M^>,U7P6;N'28JZ=EW_#?OH7;92KD%DD^^]JJL&Z;5H]%+OU*0?^]LO:3SMY9
M7!:B;EX.LS'UY/W:VB7?E@2G%;AMI62DNF]]^%IP2^V)@:UE'<WT+<?@6\3.
M0R;R5-.K?5ZGA]2H5>[-1DF!Z3/8B\F&12HA%IL#<$K'^J(Z?@^.RKQB\"M6
M\5>LXO]HK.(T4Y"N1X&6^SCA$=">X[):C\_TQ[I5*0&NI (&*D0KUN[(UM;@
MD*@6^50]E[>IG+?12$K,S+%!M("[I>..SU;)5-3%@@=>\18[6K[P;WJ5T"F.
M'1X2G-/S5F8DX9%;J-;>)]^/KSD&>\NB1S52)YL<YQ$TS@_$M-,SEA?9Z6J
M]]^&E[V+'!=F71A>O#.J..72S/D9^PQ/=&4?6HA8&2I-^BWL*[&B5PBOG-0L
M7]FY5^-\[UM?CJYX,F&(\*R,=[RH+.8-(W;&]6 ,[7SV':1##^5Y!:=(X;AD
M@^$[4[5,C4Z:--(%G753%9<_YMW36#> J<S4'P""6)"! RV'\HO+YM\^#6Z[
MK4^8XWV\ Q":5.&AT(S):H^PX]GC16*X5#M%'3<5I91BK927PR$.'#!=2T.\
M;).*JD2,<^B<8\5-V\'T)DW]J$R@!BA9).SS=J5PAI7 =SQN+W+P3[K8S8+D
MY'HY'MI[=^SP+::%Y",]'W:ZP:R$TWKF'PPONJ(,<-*>$<5*-,33HJC\BF+<
MEN-[:[0+BO@=3QHN^(5]&A.@2[XC0VL(N]PYSZ$U\O$MKMH"UC3UCW:&H_KV
MXBO)!T+V1:Z27H)+X!<?%M^]LMXO3*AO%GB_.)RR+;<YORZ[<!"QQ\Y2EB3M
MZF,YDC4W*RQSL']#QX8.J-9K=LB8V44)B3JK1#UG!SVWN[^/(=C=OP(L_P4!
MEB0-'P>2X:C"@=T:IO7,JGA:[6H<A/@F%YY]FSGO>QL];4(HP<2^WKXF>8&V
MUW%.?/3.+Z+_2:(,M, =CBI+WG870_ODJ[G1'2>G32[!LB13?U+\9!'G("5_
M^<W;5Y;U=&V*>( K=#/5[^HWO-F#O-;C1^X<":W><:[:]\E]-;PF:@D8BID.
M',"$'>CM!2I3*X^)?%DR.ZMX2FD;/^PT[-$*+H%]!J(5]='A&_RAN2OH'-5D
M+#Q Q]<_L/%#VX$$HSKIU)&.+%A5<UJ;P()&<@M%[:16K.2T/PBZ30T'1IU;
M +(0@H+E9VY+'CS)@LA%Q[._KEC NPID5E=769#P&D;P2X"(JP)B*<VM=5UE
MY4BJ&.YI#;W1U)')H7J)0-;![$*OOG+IHV_Q1'85P-=1SX&;H["%*0IRU-N;
M/24@+=%4L;FG@?1&(1 %I[8&LR";^BD[69!8 GM7MELR39^=@P<.GX=.FU<P
M?7PEZ<1P=FRMCP.!? 6Y$T=O6'-C<I2"\JY@=J)7XW/GZ)R@O)?_1=X+O))1
MNR3(?H8" =GG(]CLV>T;&MP MN\V!FS?G/9_1]R+W>],U_! ?V+9 >1JO#P[
M+XVG)POR6<V5 N(L09RO"'KF,HQ.I[,@7^#9SM#51>82T^9K71<(3 #Z,5WL
M@+IT4" !BD!V<%K"%A2,@;[ /]O&ORQ]@P51(_ Q;>JT]:5\?B-\D"Z!C]I^
M^ D1MX MR+,A6&;K9Q:$2"32_1G/?JI_86-K'?(*;EHX"[T:=QR8JV@A+>\B
M<=+KE^$K ^-_ /QHO"=8$ P2G''D1@VP[671R XC<]B"G#$+ C+F7Q9D8_+@
M*R,3@-UU%F1L;(QY[D\AI@9UR$OH#C<SY&KL76"NKM5O^6![#;T^>AU@.P#_
M"WV002WRHLRT=B;N)\T4;<_4!>9M91G:_"(AEXQ96%A@00XP*^OA8Z1!0OWJ
MI%(^C]>:;[52,PM27W4+F ENG:()3W&#U=V,8:S986:.BR\PK?X D"^MM7V9
MZC%:AK?S,ZV6@96)]ZZ,\"57%N3E#)L^,/8&@%F _:G9P N&0[B[B$YE0^1J
M&/NTV7?8F.5K;49,*_:IU^_AN2<(Q-481C#Z=RU56Z4_)WV0F2Y^CZ-79P)S
MW083--E)T$)/!B-IRVW0$Q4 ?!0^;0[0U^A&JXD:Z]\$EVXQXET5V%]K<0QR
MFZQO8UP<V![3;B;5#HT;(& 6CMT"K6%UB8I;4"F2;FNAPBY%&E-XWMJ]K1%^
M=NONO3W[2"@43;7W>/"8W;=IHK+H&=PY,FB:U\EMV,<-!@XCPU;1SK-.YJ=?
ME4?X&21TJU[>HO$TRKAN9^%-PFZMOPX]J\Z+^FI!W_YYF'DH-YX)_3%:)?\D
MY_A%](OH%]'_BT13/_?G1\4S@A57(A<4TNUW!?3*.VB%.)WE_7?GT_WUVP/1
M$VG-#<1#I&PF>P\V+_(9MBY)ZJB:S<9CVU48BKOT4$*!RX;A/E[Y0.=KC[RU
M&3VG-:-/?3G(3\'0[MV(W=[ZU'0OKTSAT/-FPOMEE:.#CHJ>A0I?.L!#Y=HZ
MKMF(^A@JT"B+U3,,6BV]LOWB(9<Q(8-D#RU:L:3HW)1RM\_Y'G%\HO)+X:@(
M_AVIX^K'%9^;YV3(:4A>O#>P;W?JMZ$4;S@Y_UPI(XH%N>NC/!#]+-VRC\I;
M92AK47'#0YH%^?AU5[?H=X'L\)  P4;)),;CA/B:/I$+<B=$Q+P=#@^M1!JV
MG;#;&77IZ\1A4D)/V<4]V8UOAZ[HYMBG9C5(TF=]/!UGHC6O?C\O<K!(O5?6
MKS6L#;H\"[JBY[B1Z\EW!-U%RY?+E!EY\#M0GDG9*T6^V*0:6\5(,=)6RJ=M
M^HT[H"D>XE6.G?R??;D9[YA"5 Y$27M8X*! PIP0ZD/+1NX-V7G]+OO3+UV?
M^&H>D9" RX^BO6RMEZA6(;^+&QWIRYPN@KT[M7+54J-L6W*"7&C3AQN8*\=L
M"H+:Y0XW']8-RQ3=S$%1& 6XR@3=Y9:MR:@[AD+%G1,QBH[W#[?C])TO?7W]
ML%)&0+?*@S0SD&YJ!VH$&92U.-7A*!4[4TY$'74YG;"AXEC64=UK$FGJXSTX
MJV]8BY9DB4C+>2,\\6U3^V]&%[>'R I>.2>"%RQ^:,[M+'_SONRA[XI6I/VH
M$.IN3:HHF1H9R8)L7<;4LB"X.U-C\-W?A0'J,<,G(_%U"*XO(^?Z!\^@M5S&
MG;\Z$<KC:?Y&O-,#5QY0XY >2V7I.-NB/9+2*6FF$Y3L3U[8Z!/ WD.I^++\
MLGRS8-O!@D<!AL:O9,,GMPX2X+X;Z H?& 4E7D.X_?1+A:TRBYEJM&E3R^#]
MW1I[=B540F/"'_*_D]44*QWKQTRWI#.)IJ20H6:Z";@2J:!-V8H0+Q1]G^_6
MSO7N7@/<[YT1(![*3P](O4A^P5AJ[O(T'TT*2;=L$T6L."R[D=JR^N3&969Z
M%)F/]Q)6&$!UBL65AIDNU^)'K_4#GE\J/K=R!E<#?72*L'&N1,:=!=F#!WA-
M46]FGFQ[ZW G1-AH$SWUU2Q#<H(H= > NB [H#6*R.USKB@"M-=NYY?FR<IG
M)4TJ$I_NG3BQV?5:7=29-&=54Z.1%J3R*Q=G&]/=V*^Y.MWQ%BH9/N3\7?)J
M][^\.^ZPP,%3L-1PV.UJ S1A7U/):>++#"[*'!(#ST%42]F<HR(&B4\L%6T/
MM,941-HEBA2\?&5NJKD!D#*C9D=H- 7>T'Q-=:QF@L_$XWOCRY;;^-V, F8O
MEN5^//S=O.L9QE/LC'C2 5=(&.K8]7U';+6^3B!3,/KNHW9.HT^D5\WRS=)M
MJ1BO":9DDP(J-2^[;=I1FC<@H'=D?TTK1URQ<YIIIVQP\,OK4E]V7^*')_B:
MC)LB/C48(K=7#82Z52*WE(G:YNL*2B\M1O\6?2ZT^^G=8^))JSY5GH'T/3OO
M[/:^3KT "YES:*E 6\.70ZMC,2<C/:V?;U]2<)2Q;)=O\>QSS<(H*Z_%9C1;
M5E\S-XSN,D7U::=[),\]74I0L^43+<MSL_*_%JLI_FU[DW3VC4VA^V+:FXI>
M\=D:[%H2Q#V$VQ X?1N$QJH1VS7Z2QVK^=7$\84TUQ=&J\:"25LNE+S8=P,A
M.)JC(D>&5A!R969B*9&7**J-*7SO$OOL FEJ0U^5ZRZ6#(N<T-'^?%XVXD6<
M)M)XJC2O4/L$]FA5^;9"94FM*=2<U:*=X%!!B(K>\31/V1.B"WM4*#6'1+^\
MGUNY]G)CW[G>LKU4H[>3L(\Q,\]2O66:E^H89I]ZQ;(5KW;9[9Y#>7#E"5S?
M4.SB_H7CP$)S,0+=M\WW)#5PB"_UJ??!=(M3H6\_FIMF9#J.7ES8L*?V[M8A
M.^L<<>>JF^1P?=TQ0[N)TAW^89'O1J:[(Q[8HAAW?%!'*N]]E/R2UKSO4 [$
M> UJ&E%VCKI*]AKB?UIVX(YIC+]"^E0FO()\SF-[#,Y^5+5VX[%-<&F.Z>-C
M]:N:*D9MO; <S)5OTU)96:EEA4&;-*6E\U8_GMB78P_Z](.%[_5"#@H>$P<^
M3:687A,_^I7'+'WRCJXZ7Z/KO_U-TW_:[^",]B6OJYL4VYTF]SIWU2M>4+'G
M15^[X;<F1$5^+MM/;0(7MG'+D0-]FS4I<@.S20](#X*MI+N?6A0(0N2.?;KJ
MJ[=#=BNN>#SKO4+/X<%F)Z]W3H,GON:$M+ZRWA^WL*1VELI/]AM$5"+1=934
MP7?QG(%'<G)1]J(7GLU3)(]=-=[HY.]&^Q[AN=U(W"J%CF1$,&6H-/UO:B*U
M%&BYB&2K)1,^W<E5QYNC?%3Y E]WB5_4YT^?^58L^ BD6\.K;UZ9XHM,[CH#
M-E7J]QNP8GVG8HI[&=!(PBWD$\S.Z]2$(4PP;-==JV]+R-UOJK9$9 @VJV#K
MKB<4< 5M&,MR,H,)JNUVSZF"X?/+,0*V<9I%Y-%@WDS&7(+04TTI](L/5JTN
M6\IBW^2X%Q:%I42WKYI69W]J"3UR<4[#:\EAA4Y4H=:28>4P$?E2.(+B\VHE
M.D].L-]86FCWOJQF37TBWPA!!&XC9T43M^OC\16:X+6 R2KB/T8,[SV3< M(
M/,^)'28UYQJZ4/B.S7=.\'NY*&#]4XQB\39';J]U4#'E:DJ,#&_A 57^LWCJ
MA:0&^Q23"U9[(OHT2B,.&VS.=@IYGJS084J7HK1GTZS<]0=%L*^E\H+*^,TL
MSKLDRC[OD=?C?"H]6+GE[JV-JE.309*V-[N+0W87H;275E]1/KU]DZ*GI_D.
MYX 1'90$_.!"@#7QJ8A$"?5<DJV:-!G]-$NMC9'@(5N]'++MH*_-E2VC')LH
M(20OFBK]"#6M5X(26 E_MA;8Z9KI\*VKB^K0..:*+WKT\-)V_=-7MVR;U#R#
M2SOZQKVV4>IT>JEP7L:Q_F,M$797Z@QP;PI72\ER WTSO&3Q\A7/(^C/"9R6
M08,S6:'5.-62"*Q$>NZN$T,C#!W/E= 2.0IZB'^Z< C'@^J#RA-XJ$&HX!OO
M;#TO-QVZ\MC 0P!S(DW4\;[DM)*DYM#(F?=AW'$3?988.0F/N[:?6ZX=J;N=
MF8H,IXS5.';"3:FA-%7JP<5@?6N*3/F:P5[*Q<CW\N]%KT5_+WNPQ,EYNM'C
M<P:#OU^\B@%;AI.K'PUDGI\K5U-MDCE2[,7M-1)B46V!?M$L:C^\\^*5TY]Q
MN>-IQI/O)78TB -4D0"T])O1T:QXPY817%;@&*8J'AW*@N#% Z9+-ON0+>$[
M[+3E;:Y2CHSR;:D>>7.;X\[L^9QAEZSNY5 JC,(^YW<+'L%!=8 )$_SD<1_-
MA5??&+\+_\U.,;TH0MA6Q:BK]1K#4]=I^+$F4L=S?"V6!;E=K679;)]O[S(^
M6V2\"OWD*\EX8U0==[1-;9N[D7IS[X1H2>OQWEW'=T8&6E=6#DM["0V*DV5J
MB$]8D-S42D#877B D4BX,;C-.RVEK.290=6+ZY\\WG\:\2+UNAADV$C:ZQO:
M-:"8UG4R>II*$45N".WE:>]@LE$_NI(H[/N-FQ(X.!(5$.AUX_;=Q9Z]U;H'
M+F,M:K9_@@BB>\7%RHK>!(UDFEY[&V^8]TPZ\#8,ND_%'+2^8L<'Y4%',W8\
M_W>'C?PG_MZJ8FVA=I ZBC3V5'A*:>6&RX\>KE9K*'P!RGVPP/T^YBI\R$(\
M#!C>($Z;HD\UC'.\94&>T/28(P3&/%"-IB+P,K-F+$B?.!T5_^:A$N(?"N[\
M(V5AT=%?T/\7H$4-5H9Q%>?XL_UE9_0#]CE;(BT#!QU7>4F,+RQ("N3Z/QB6
M!EV\*V9%B@69BV0J-#2=W2_^#P7R_T!HWK-G0_,OX'\XL/DJ)W92Z&U[V7[4
M,-?M7>G]8;*76!"A86! K950Z,B">&,H6<&F+$@XB)@* DY:.O_?T[A?P'\!
M4*&#!;'59D&VLB#=]\K<(D>M]MGPC2A,V+,@AQP912R(%F3T'ZTIF<D[HTV+
M9D%6:D%#&QU_O2/RGTK@_VAY#D&0"?@O\"\P]')^>VID^9BN-4+EH'V!LB=)
MC@7AYM1E01)/@51U0"C*%/CRF 59JF1!E/K3.%)9$'_VJ2]$88 V0@ G5V,E
M-)V2SX*4F=%1L>#LZOB/)7?^F;HP[BC'NU\,?C'XKPR*5?>NZ6AK/1Z]^GY^
M^_-2)5*D41K5B*D^!5\!L*^Y>L^P(,\W8>9P"SA%W"4*D?[P, OB R1XE/Z7
M;-%<LF=QD<F,;+HKSKVX2DG&7VT7<?#6-YG$KU[!9@N=L0;A(Y1BV]/+N(R8
M.2XZA2I#)M8 .\LDZ+<<-U.9CINDLHK*)VX\)71I:YYJ^2S0'4"?PD$%-#6)
MJ;AQ9\,7D4%H_7'8!B8IL*J7DQJ<AJ3JV4,K>[ES(F:GU LP:K?;Q(67'Y\1
M4'$*-P_T9T'N8IXE*I#IGJ.!Y/-S!LV'OQO.]ET]'IH?4#-+N]Y&0W=^A3]B
M02#,DY,Q:XR:(!6=K#LQ"!^LN5A#1V@8I%85<3C1":GD+C. JSH-6!>#"]<+
M-7&X9?G;5LX#\6=$8-*;[Q]VN=YAU1J>ZZO0QN5B_2"SR+0O^TFJX2E$?OB2
M=#C-VA35ES/WE"EJZO[@TMRB\ M\<5.6>)=BSM%-FOFIXGGW>9S7.&?L*<@J
M4ZEWN+?>VTH)+0XM]8]'A>?UU!MEH3$SYINK,(\.LB"/?:B)8Y]FG [U:&^/
M>UGZ7+6\QP-;:/YP"Z3ZQ(ESQ$QK;QAY2^I[[Y/DI59X[CSU_!G[?.G L:,T
M6+WO94'2U#?7U&GL$7&'O'86Y+675HP60\EL22V>ZD^[A/:';W5![*'&5,3L
M33S<]O(<9X#>Y;JQ"-_S'>.0VM-SEB8>-&-O"ZKS\!0+LJN,3RR^/[YVEVA!
M=HSBWJ27$.O5>/'$)V*H6 ;N^$C3$%5XR*@M,-A;X?5W;B_&38[1C%D1N=%7
M>V&*T?3AA2HOFVIH5_= GY\*K^U[D]X)IF)AZY&GIG?:C;8=CACV*PP0OJ%+
MK%<*<<U(WII6_6VTM.Z^??'7=GFUP[Y-V>[B-1AN>2FXEHYE38WL3>6%,^@O
MYYO\KQ=?F7XF%Q(6-3W](!UV%C$L.83LBC?W8_+'3'=F(-^,1U<_*(R5[KQJ
MBHW8>"'1S_'"(@Y[7$V<JFA:;":E7!5WA#'].5K2"T5]&]X(W7#A%DE5R_:\
M%.@,U'?QEKR-9V:XCSV!HX[1=<E]@S%!B(#D?,?-VH>U[:3KN$N+5Z7RAQO[
M+K07(1["<]_%4OH&>K&X;A,>9</F2HQ]<YS%R(F4<+_KUL8["B9YO'/(KUB0
MZC/,5MC2DA,+@K=+(00LR72N_#?VWCNLJ:W;%PZBHBA@H0@(40&1+EUJ1*2)
M@'2D15&D1$ 4I"=*[Q$04 2"]")$A- A=%!$.J'W7A-*")!RX][[W7N_]^SW
M^\[WW7//.?<^^X_U/)E9:_[6;XPYYIACS+76G/6IM(2F:1^[#ZJ#4JXYGDF-
M,OMF%;;W74<57PR]7H$4&0G4V1=R[1R6R668>\NB4(==F5)=(W5.JGC; 65A
M!$.ZMNVS;@:A]<<A3?F+WT?;)G8*J(T%<NQ4F-YL1)ST3'#B0Q)59CP?^2G<
M+$\47:L_O_U(0>62'9<FRS8\^)TL\;Q><[.;[!:0&!G/WR(#.]YY>)U  1B6
MQ;K0+YN4X29T"RH?/LUXKJ1YE *HM\=+[1<Z([$63"-="7M+:,F>3-(GJ)"O
M)/ISO[(@41RN@4W(DE!C6$B:ST*->6ZK+WS%*S#XG<6ISB3$8[NFH06SD/?G
M9EH'^RTMBM;3Y]\QB="T'0L#N$[4K,[RKSM,,1VUES<<TGDTNTK27> MZW4;
M#7P?R@O%%5<[<+UFYX\6:@<Y;P(=N?EKL*"F6J!*W<!FD0PD*3K*CE-Q01KP
MB<\(B ^[<6/TOCH"]=:%&TPX'@W](5%:Y$.WUG>H)]M6O>YSM]]7T5?\DX-K
MRS/AD=E."=5+1T&"F8RFY3CZ8<3LV!MR'^O/Q4V+C5J4DPY"\,@1.4[]#W:)
MY:1D.Z75.19"4X&G!CX9BVRV D^W%F.[5&LU2RT(2)ZXK^]EUDYGMKX7K(9:
M0Y>0IC@9=!;!@TPODNW(493ED#TD%O+X^,J&;;1PJ<2Q_; VI?SY6X(ZH]JR
MVU>D+<(QR"F_*+47(V+->O2$!,)]!VZ^7FF+QJR6VOBUYU]+W16,XEY;,7AU
M2E>.^JQ1G>[EH#_/J7L#P]!S>N ]'G+\8OP2]"HURU&"C<$/[M&E_LNM=;LH
M@%*/=:4\7T9<8E"-7):G-OE<Q+CW\5AFBXQ3+N>>GCC>EXSI9L%BUD>S)U=!
MI6P-APQB]^1-LEZ<:G'QS;A*)XDE;(8O-[5*YCDXY04YW&C$*=%ID[XHJJ43
M5IL.Z)I!P;(3]&6#.:R#>[V6[X]O/5.V"N#AI0UHA?02I7'?7,Y N\G7"#8C
M$O5)(DGC,(>3>^Q:9*X/G@<+-5VW2=&^6I\\]V[CZ)J18:90Z9#;R7H.-MW,
MX.L7_;4>O7[#1)OLCI3!T35-GB'JDLK)EX8\/5K+4X_71C<*S*&_A+9OB=*U
MWW2?19LOS64H;.U8OYS<%%\HX 2C8W:0H75R'6GD;O)%PB-2Y)>V@B'4='\D
M0?P12+2S9F<UJ9.4A;;'88]WJ43_W,LH,.[^P'S,P[[!%YPG>IYW-:;*X]<@
MBYNGB K4V[N,!M0GV876.'C,?A@N_9JM?3CTW87C 5SXR'H;%!4PJQ<QDAB&
MAJ08MG*(-9$,9YRCIC4_:)6B/IN*:UR]WBLI[-*?,!7]0E?JREQA/HJD)OAE
MWJ-GHFUX\JBRL!G1D6"7Y5G5*UW*=J?CQ=.+Z.$LU9!;SR3AEJ9=:.P@C$69
M'\(Q2N0EN$(^$6"JE1"?CD+UAPO?3!6O;%J>._Y,ECO^&YFJ(3%%-IQ0Z\2Q
MP9U3%,!IAKO*E=E+>SU?.EDES*]?$)"S=*I?B&N$GB1 <!9&.-DP,@=1<X!\
MSG'5<V9/IS+E8=3C+@DOG]9[VT1+'[><M8^ZSZOZ<HR1:3Y:NN(EF+PU:TY2
MT4,<_]K^# 40&D-XJ>UDT<0>?7@[U2:C\W3!JT-OKN'E49:OGB[X*D+>+,,Y
MC%E/W;$)1WG;WDW_%:Z;;]]X!\QC:![A7C3#SH$>@Z/-34,WIS&VV*W"3([Y
MFH<F6R 9Q7/JM-S[.])A6.UZ\X1"+/)F50#^/?B8FO#1HH"?PQW_?$,*M/:8
M08:NH*XV\L/RG$;I!P?^O@[T^SV])L191[(PUOI#_NH(<RK'0-&9T@-+9&V:
MW)+N<9C@%,@>-.+32 '02'F9+)CM@L]_$1JU=U7F?0:+:J>SF:U<':FEG6YJ
MH2:&HA',UE<B6K(GQIWF!M/?W*B.\;3C%5]4\I*> Z'V7M4HL34@0NN$.'2*
M<1</'C]3SERMTN>H.F;,OQ'I_4BZ14=EH#0A47YA+F]"(16)1;0QX"2G$<&^
M9OA'>DXV+6(,^74XULWI\=>((J$"I! I'C8WJLP)&V)E6K7.NV]T1]*!0VU"
MX'-ZN"#]O_G&Y([Y'<".'X1\FQK^%0D06[PZO650U,35@@+ ,)-M:A;^Y><I
MBA_P_J2T0BB-PP%79VN(!U*KP!+U20;_E'83<.:Z!N_B!99%#MCZ0/:(9YQV
MGZ+5E-A9@BB#NOYITY'D8X^.)C_VIVG5_,K>"N$DTY\H7V=K'.A-DNK_41MA
MDKAQ$JH35%L2GC7#--PUZ]$FXJ)23LB8\6,5.[V<*.36[>!*Q@UY^V;$WOAZ
M@WW9.DK>K3;I[<$D<L[UA[O<"#QFX]'L0("O'S@H0SMY @4?#4[GY389KRXN
M+]3 L>%?%1,\<!8-$\<K>IW%1&LT;X9OR $TGX]"'WA);\NVU)YOK<I9;W\*
MY8+(I )Q]$O%H4BQ-XJ0"_"%H\S.FOA/8BP$V(SSZT-C(D_$C$>8% 5P;D7"
M2GTPS@$G#+D(??CM#8_NBS6'UD"NE /K\=NK6E86>7A@&SK:V[0>=-)B53XJ
M^2!YSU3; ?+0\6:LW:6X2#P V.U1 *.M$W> <2G2.LWXB9X4'ICWO%KR_K4G
MKV'D.25UIEDP/[D/=,%)# UA.GU_W,$[NG(:2?NYHAK5^W [RR>;\W4;+2"T
MC;_$"%$,;SGE!)Q=C"0*.#WRRUCBYHO5,=0NZ9\^T\D<KLU\JB]^O)L:R.8=
MH#>\"HNH#;T <CH<!>O 37$AZV%>+K-.+YJ@QPE>!9XK3HR&QS^Z.[;P1+6J
M7FLL>Z9R<?:&]!"1CY0MI1=A?03'C7;(L7+ D+E,Y:-C7KP6OIO__;@?XR#P
M'J2IU.5( XYNAC^J1AO+,Q.$"=Q%EY6LC*AG/34YZ2RAY83\,3Y:$G^#=V#3
M?Y(5!3KG0 %<(++/6 FIP9L/U%.>[<G_"*+G]1@R-9%@N2 2]\:OBY9Y_L[%
MNI4!"\PBE;Y^GJB3]=Z.M!1PM'>VQ>3JGAI!8Z;0^KM<Y)A9ZQ/XLQ59P9A4
M#>[=3=@)*,\X-1C+@,BFLO?7\%^KL%=NR&\UL&&F11]E9(3=(4#P!MU0F17P
MJ?G$Z;UF$=K& R9\8-K0BA;[VXZ@,0I ZNXS=04\LI+,-$(H:ZO'?_:<M2[&
M\8?V:FQO[DRE7[6<OTF?+W%<P6A&H#&EWVFO.E[]14HR6O4M8?[PSA+ZZ*X(
MC[H?OSZUQNX]<XQ6[^SX9?W6V5U% (TB1]R4WOKE=%^W1+//Y7UB.PP>6@_$
MI&JU9-I?X2J@BF>>J0&YH)<]@5,4P)#B_4\.)E6(2*:#JU%']0NL?ZR=.!&2
MG\,OTFW7CU$XE":*#93"SGH6S+!%%#UMB_0U^K;M4"8AU/;H1&L_[_F$*;OE
M^UM-PR^DD0M@J=JLN.Z]E6OIE8RO_N()#8U0[RCY]N2A.SE^(?[/$UG;YO_J
M8[7O./5:MJ :V7R(9.NV2LZH4D<;MZQ$[E=:I57=2J9(X)86\1$%\*  3@(,
M:)B\R4I_BK4 CVYK5'0;6H,8?6T4E;V<](4'"@=>^'LLN@#-=\8M\.^PM6\G
M&74"/3AJ$='\6U*'!<^.-/OLOP[EH;OT>ADLZDN'S6D3 T([Y6'!1$F/Z0C@
M,<=[VD_Y:QB=!V5<$(IG5T=*ZV[X\E43J.[L].84C!$"?C)0Z,[.$V"6<&9:
M],+<U_ED?QHE!F^##&U$8E&M;U6R8):NM8OJ"BP*R.F&]G<EV.XJG"K (1T?
MW0U9JX:]G/=P?AK3UEM('6(;,H@,V-MU?(./DA8N2UBT0)P"A+?$ZXWIMI%O
M8(Y,QXDZV);))H$:#]QQ)G:SCAG[V;*RD+OAW4VB8XG"KYR_X0*HK% :S1#D
M66@/F;E[!WG2$:K0YWO&U+"_M%:4-=%WLS%XI/#5<9KV#:$;W1'SJ[5DM6\E
MEN,RRFD$)1Q,@] Y=:'&-"MST.3#7+2G*):WW)Z,]?5FA+1M4CNT0,; KA+M
M]%Z8K\:TDZA'\*QU:>@)QJ9@VUW:L?!MIF&QF=MU3(0"W/E&ZRO=[J!3]E5K
MAJN#2>H%M)]P@,QO^=4J#XS*57X<4Z&:WK$5>;T %(R9>))0;L<4D)G@M8C%
MA*:K12MG=8?\D+C!;LSKD8^_'IF96=H[CMJ^A?_RUKC.K@<J0<KS%9@&!\B#
MFZOMG7<+3^DGW;@2W7\LWBJ:_K/-=2,L)*$/]M0BZLY,KQ1!;;8E?+['Y&6?
M7@)+:%,<:>SB8F\-<):_^2%.%<_2LPM?@R@=-\(=??G%8AD;6AB1\> K1W2;
M])HU76^=0!,P)+N2E.8F4(J*'D;HD#M1)O9ER(UR=SJ@J'<OE9H+7^$DK%LI
M,TN(OP=FCKB[XHW*CL@<6S'=+LR*^G35:^'-E/JKQW'6=-/ T1<-J4(XZ\2L
MNIBB98XG2 6+Y:2%CPY?>K=N/CM2YD,!'."LQV=U('>PU"!OU\_T?L2/GD*G
M$4ANL_5+&RZHKH>?T,PF7/DZ%E^0ZRM&"$OW#-#!L?D_Z!>9[5.D.R=2/:K9
M!KE[A&OTRW.CU]%*$'KF627>*,?.-J.NJE!!3<6S:E?:GQB_\3_U:L@Y@T>Q
M%R/0_:\VW/)(0&Q=0I-<03\J!#>=0',JL(,96,HS(T#I_W2AKX/8^C'<:"OB
M0@UL6@RP1 ;VB]1(^U(ER!9+F!%IN1?[&)#*=&<->HS<8ZTX4"<)]A4EI$Q3
M0_=F 0B^@K^/4Z#<_JGL]_JYB_Y,_::!GH93K1]Q'_#1A&VG+,\2 VQVQD,8
M[V>M1P*WWX^HT]@V'"W2<'Y?U(?G*.E1!.&T6[SY(]*JP1&#MM.00O6ICL51
M?UFO^YM]BLF1-K6.;W*^"O&E6]?EI)S4>V^U05;U/79X&]H#8A-3O.7+^='3
MD=RE5><CQ^&^]>Z,[F3MI:X+R];+4\!0X%E?GBDQ5L^X665$UA)V60L? 5LK
M.\U]O28@V.5=,< /0@TM7W$?Q[9%(&M>B*)Q3V:GOW]>/<=KTKT2,W(JGC=V
M3I)A2/%)71BFCM,A*7$-A>-LA-(3 JEC.HHNTOH]I[YVI2%$R.MQWHVC/&<4
M8NZ47LKJ>)R0 M+O>UO8"27!5&6;0.?1#F+1\E9M$34L.?;*G-@F5B?YKGM-
M.MYI,:^:+Z;*I_A74\<K:+>U,(Z_?I)]=60O&-Q4=QT[4#/QV(-UHPQS[LHY
M+LF!YR<NB1]@$+[\A)QTSUF\?C=1+,-7LX^:;11H! LI?(A83A"PV=JN"+*1
M/<[5UE?H"CL&Y?',:)T D-+6W-&L5IY-VKT[ 5S!'Z]=D9-[RW;3VQG@NI,E
MZ+!M+7"?C Z=5; PV8"K8T 0]%E/&-X8BX0_[ELK\KT_PYE0$O12POQV0^A$
MD\<#.O85O_P+T*O0'C"#N][I%:A@[P[RHB?8+/[8-T_G\>RDS@N,SU\]8O_Q
MK'XJ$L,R30%P>E*U4 QJBI)L2^6HP=0H?!K7.IHHD^,X]/GMC ')^!5OI'L#
MRU>B0=\.:!BITUVC@87-C$\4NRNM7/%T%TN8YPN-)+:'O$X^<F+1XV)X15_4
MF)&'RP'ZEN6\K= .&/-^ U;*W^("!YT6]56;X6*[W0VNY_!N$S9-!$L=<MKO
MO]5D])"1-YH$*//[^A#@?M.=/N >J1,UQW*;MSN\(%M=\VLV@0)O8K:/K5O!
MUKU<12;7$+.GPF:V^#_HEL=J4@ 5K69AP/>%>L/:9!U$_22>'MB.D97RB]HW
MWG2I'^D:&7T_@E&DG4:W40 CVK/'/^2N0,]W*TKZY9A;:SWINK85/:]TO3=Z
M:*$V O^ E.:K@GM" ;18L^.B(UPR".5-AONF$4^T@KXT/V*_<2F/+I;!-PH+
MFJ(+(U_UY<:%A-;PS#*8:@Y^<M?J%;DZ\C)Z8M5^3..;"J-*O7*]*8K<IBR/
M!;XFGR1T@<-'9OI:DFXIDGFTE[7'=*X$?,Y38OD0^9)W<;!*R#!$^*U!U7IW
MZ]M%SVUQ:I;.M@Z?08; 6-VY.!N3_*)SII%,A6C\>$=CK]3=]>UK#^H%@!XQ
M_:;=H/.*&K-*JM-9"<78_%&]06F?07]/UOU7087C6D^^VBYN["&#Z]BH0>]>
MI/)%SXEM;8*=TXR2P@SS%QWE0A^WF(Y7S44M=G3T^P\TY[9[Z]Z2_,F7+#T#
MII7: MV-/*6[3HR5(:0D2!2 &&^VQM/G:"Q'>/_LB1SFVG$*8(K8D6-@$)\Y
M@<;,>:4F'MZ"]B9AF@M-ZU^F K'-J7Q]E]C89.8>&I\X>H;LS#3!)=0OJGS#
M5P6[V<H46'<"L[93#4&<O:]8]=WU\J.+]5K-=R^\4M9?M=QL N]KBC4C#X^J
M40!I:@9$)Q N&7P,O3KH,B_"H&XP/P]FH/9)RV^R"SZC.'[<Y/I)'-L,6\NZ
MWO1D0RU(3RP]-JFH.B^RY7R /T )\#0Z4I>1CGGS&+0;<89\D6C66P?T?=*W
M,TTJ;9!"GW$(.7MG;NJ(@O^0=;@*#T_2#,@.R.8 /@*SWPPG,^-0:^9\@\6>
MHD]=D,D:I]NY-8Y63CF;'GU\$(T"KHO/%(K-EJ^?PB(:K4_4AEC5](K5#?AX
MV,QH/KR%JR1-3:V;?;VAI,GE6)OL58L0JW8B6XQ9_AC;&SSD"LX[?#1)D,47
M]"L#"=&<%VIXKVK?<&&YHWTT.M]X/*S!,I:)MLC'-'T5P2X]KH#/Q^XUY1IT
MUH!R'?1\A(,EGDS0GD651/IFH#SY]AI("K,>ZSRXQ2;9.O.QVJC2!%G=RNN6
M@E'12M5 &T@<*9EH-0,Z"QV<.-M;<_^4!M+3Y6Y%3X['C^7;=P[-%NM.+-9)
MJF8=+TKHP6R,W<GL*UFA *S@/7>NI==D=/]3H+@+I*< VFOMR)N[TO,#*\HL
M%$",=Q=I<L7^2/D?K_RL]BJ^H  NG01-@A>M7?[MVZ#/4T\1+*81(56IU;GV
M\HY#5JMQ$2FW;JY-N+TJ'O\ZF^B<BAKHT5T7HN]XH=!L?@P>7LJEJC9PZ5#W
M0^Y-/.9ZK#IAZ&$B3TS,??))+&, =K,12_"X^=E"A(/K4,2##?PN=M)'[H>.
MFY2^!\3ME-#8-J?8,')Z\$/:Z@%?3DCLJ";&ZC'Z2[2=6::MT[=;BZ<"EN%W
M%BB Z3 R ZP; 20?[: Z --*?7-!%&OO8Y\;2CT=RZ#3->(9!$:QXRH9HU^G
M0V?L374JN)_ZL$><\;!3C(6\P2+7D%AD _12@$6O+]#N>(;SX72"NM=1)]*\
M">\1!>Z!E1VC0ZV"X0U38;?N*?)5(B,6W"I0NN]KD2%:>#6U**$ERVWHHG_3
M/(^<($BP'HM8R\)6UY.O?,&X@4]KV.7?KR/PGV]OX;SPXY1-K7.X8V;OO,Z0
M98SSNN,S#G ]C':ICALG$V*7+BP/#F-'& 5TOL#[#W_E38;7>'L/]OK*85<\
MF<AGFK+5^(/KOC\E-UP6KC/=>^Y%],9HJ_'+*0WMVY1IT$*P_ VL,(8-Q6.,
MX7G3%B$26@\7ZMC#Z!1*4M,\"K^2N0G/MQMB/'57-<MKL&OW1*J&+)'O7C,_
MU%!J>S18)7AM(?'9O!5<&&NWAL8V39-K65'IGG=Z1PT"%]CG1 1"#W)M;BJ3
M(+GEU,;_X!(:1YB7ZO8UE +:0? Q$2=P46GG7[>E;5I9,<M]71FZUF(?\YUX
MF^ TW14^PF%/%NA+-/X<;5NA.?[^CJ;\]4O^#,^5)4COH)R^-_O3^J4I ,:B
MCUX,I2_#A,8T3X2+!UIS)C/NKKS59_^F<-TULESC'1%$^J#,113!T:^FLF.W
M'*K26[O#!ATNKC_TO]X<OK-R+4O@CNZ6QXD6M?N7TL,%[_R3W>^ SL/:4]$;
M&B2A+J%NH@XUJ?*F "J!.VE,BO]R&2>%ELD3-0*S2&;[U"N#.UFU@U+63T5/
M1V8#/WC<?.:U6]0:[E"Q$MCK\YHOC#^OR%2'\&BZEK\M*3%RW6T^HCDI\LJI
M#^-K=T/E&2KKB<?<C>Y]L#@6-S8OK1<TP3&H^,)VEK/VAM:,@M!+5'GM]@7F
MJ-=' 8P*?77<1'$LIK'ZU"KHU')!MHK?,^>B6]7B"88#8;Q)*_8YG4+F,_.F
MM=%Z9M162/%H2]*+W)2:Y@]S*]U:=QE4-U%;]*=I8M0S_[EN$)!X#;<8*BI=
M:-@D6!74L1^GY>#*>XK'@^_>ZSCK3C6#O!MKS=/LSM%,>@3.*3_^Z8&]UT]W
M+HC4B/N>J"J)>L?^1:5#V>/\&[DNQQG8O^E=.D9)(W>YJ)WK]13XB#V,P5?2
MA1J-, XS@+3*[3S7!SJ."3]OXXW[FD>TFE82:K/FK.MVK];WR0+S)[HZF^6Z
MM]]H7\QE*5:S^[[ILV(<_\F6 &Z2]PA05,BQ-U>J*.TM)9A,C !: EVC _CC
MS-_JJQ\4!S'K:QX)OY;V3T=L0NPK)> _O2-D'54(:T^@ '9;0.^0<FG_ILIO
M!^/Y&5A#+>W,0%M(-H9['7RKE@V/L'US2>((4^>;YS=8QGO43"4=^+M-M,:F
M0--:!!\RVQE"8MTV^9S8%Q+<)4DQZL-+TIC=C;U<(@0KVY2J2 B:1K"OZ'E6
MM86TR]B<O-72Y+P?++<X4<L8#NVU&$LU6W_4I<Q!35P7&R?/>"9:]G%O;1KC
M3E, ]G65Z+>:+>62#STOL#\Z,/3UPO(TP<[4N$\CV2:U_&R+"'Y-YI9F=WG&
M:(_3S]+QR,WV1'F+,),RD9U^JK$R*#BBC@_:#&*LXR/D;S9+?"U8XHB??2_Z
M0;W2+-9.Z7Y\?+">KTW59C"LQ,Z_[CQ!^WZWFQ D*JE9AV%WM_GCQA.#$_/%
MKU^U76!9<3-TSY?^-N%O-(60,$>(M?U<*X!@Q3$MIG@[0*YQ\AKPX)B/6,-D
M@#=;/36K'[.' A/P$+F-I/4DLHOT7KSQI8N,U].KJP2^H;0*M,9X=,]ZA"O:
MS;*MY4QM1EM?+</X:KD71%3[N#J=?NEQY4:/"O\E)\58;Y(@I@$Q#&\$']F-
M(.DUE<MG8M@^G_(Z1FJ/OQ7,4%_?T(ZT3$]$(<3X=ICL&)TACM2LZK']7^5D
M?-X6L/8/%( SNK>FMU8$/4?MZN7@Y9O<D'^U%*RQM)\@QJH7*34Z5+.J4)'$
MGO&5,R;X1'N!V[WC3*^)3.E$.6QG3@A1Z;$4Z2I&6:>J^$&EG&*LGGGA##)X
M@@M7A$I;.?B1*B;-P @K7=YFL]UZ3,;3+.**4L.+['PF]>^;MXG-(H.A%PEO
MJS1QW,E5H;U%+;NIB[9;V;2<%3R*WKT$NVEDB"]P1L<#W/M)N;-@-9JW7S0R
MLE.<2SZ5[C,51RX+ K[YL]-K-X/H:\1F$!SV=2+]I2V(9HX;+?%++TTB[6Y<
MNG@=+X=4PH!LJ'FQ]:5!46DA^.D+=A5O.H1?EALTG2^6X[?Y?!'AB#\0S#!P
M'8[]I=];4/L][(PG8U>#!Q183JWXI'-0TXV@K1[>T?,E\QPLQ?4SN15(M[X0
M;4:\6L#[E$MO)'LJX UT+Q?IG!YD '&X[C:U=_O)Q-7R0P5U)(V><.NLH.F%
M!KK<%J_@@$,QHBBV*_Q\,[57KSWHGWW3<3[E>XP<F>_6R[R=^IE:W?!X 8TG
MLLQ[*FK,1F__EY/LYV1.JB+A)PAQ%KCC\,R61Y\@+@N.;)K?S:>_Z&KR<VDM
MZSL"3Q+Y\CU7NEH].(3Y6UC#6;ETV&/O 2[1^M,^<^UR7+7/7XC??.YE,J@(
M7<6K$E3\W$6:R2>^Q#I897I(:'6<CX7N%;I/,I(9";+3-^JXSW6G]4!'R]>Y
MM<6W91;9ORI)0+ZDY_4GQW^PN1?NH;D%8X5^0]/70(KT"E;JF$KB[J64=PKS
MI6]S5C[(/*)7^)(#W 2DMX>>K<#6I:0-#]FSB4M)#ENH\]PW#N9TO1BK\:+3
MG=G _>K !T:S'+?H.Y/3H$ 1XG%%YBJ& D\S 95LS:Q90#(N.7DQ>?%*)8B>
M_ U&7\->I%*P#&4JB2:/ES?Q?M\*'2T!-$?"S7>3KAE?+8H;D[MRP*XLA"V*
MFX4S32QYKR<Y<AC/!*:.W+K53G.:IJ'K'DC0(Y@HGD70:,)[<\/MR^2-DZ%W
M6=NUC/144B$&X1^JS0J$QA:(I["+3;#3.Z,13*<=])=E/,ZCOA??_JZJZ5W.
MNVVY47BH0%081.E ]*NQG=43$.UR?<^YF&/M8Q<VZ>NYC8"%WM(LEENZRQ$)
M,JAP#L:0A]-^K&V:O86Q'3I?PAZ4E\,W6L.O,YN 0J <GG:-4-Y!7Y5,!W$S
MQX,F%W1EV ?2Y2^Z9G94A5=C]-3T)#'ZPQ=_(+"8)G-P%)((AF2V,(6)S9P9
M6Z'YX!L* )Q-?LE5;4"-B1F(LDA/M!9.AQS/\@.=): MM/"$X81<.^ B[.R*
M C624K8;DS-]%$J(PIHV %D#Z5J@W*B![%<V0B'';%5(W:L!\*<S\!#04>)9
M;&*7,C-V/3M.:O;<V"4Q(2:=]3CJR6IO@>UO8^7=EL5H:91<)__T9(@;B'6E
MCO]S[VPY!J5F5%MKXM0GN'/T//Q; 2((RJRLS"U#;BGG%CR[#Q[1CKEL5?U,
M_9GG[(VBHG#+W@UEXZ%KZ>$Q__S8&!X$F[,NH0 \#I*V5OX4T$O1\(>ZE0]*
M#99%#<H(,RXLMU"S/:0H!;"X0LVH(7[/!@<7U !O?BYP-((XS-N_1Z=  =!O
M;9*A'XE1P#^N5".A0'N&/S<$@6WDS-^\N$D4ZD#O'X1L2<$::ZHI $0NC,>*
M#=]/ 8SK?8.OYU$ 58AXP(L_[M7S!ZP;>-20 G '"8+*<L@K4".:'Q3 [R :
M_P"6[H$YZ9'ZB;E_$_N;V+^/&$:OP'[+D>-"L:F17[XL=[+1?RMV_VW5]C>Q
M_[.)Z<$ROWJD?3CF?O^TXP>XKCB9I>/_2#G^)O8WL?\78N[4A) 4@.=:7?!2
MMMX8;C,O^'?0,_0LF;&%^Z\I#^1U7O1!#S1F2&CZ <BH!5DPZJV6 .O!J0[@
MD]@'.5L-2(6S[Z:??9DOE$(X40 \T642P5Q;_?'OEX%_)8Y7(E$Z ]9-O4L<
MB$35V6 4!7!KDWR7 L!+MY$J$RF KLD&"B"FDY070(;]_+7\EVKY!8<"Z*[\
M'0A.!5K\!4B*FJE*4 #[AP30%M/Z7> VF8D(IZ:O05X>% #H'ED=3C!-A&WO
M,LU!OE, TY\0Y" J\NM?8?2H,$L40#V"W I?KT&3H5 F8@@I+_ W,HB_))-#
ME(Z@DOE#*J:_0 GZ0R38OT()^ -%[)]*H/5/=$0B$;A/A\\^OT\!T)$ULF!_
M80<+3?@BV $;;,N. BC.H@""?Y;0OY0R#B$T/U<(I".KDOL;8: I:KR[\[LJ
M[/^DGYI),@>* EBR!A+.4P!#O11 DS&:=&IR7Y):ZB,/U\.ZNAI^KH?H^!"$
MP,+FO$%_84'6+ZAY@A$%L",&)YZD -8<--;O_:E$ 3Q] %M<_$D"5(I%=%';
M2HF-S#(_222I[G. IJVMJ*;0#XI!*E*%R*8*T48^"L-+%1P:R%$ [P!4W<+)
MK0A\W:E?=!MPJ'>22 %0%<;3C?Z];L;O>-L4 ,'Q*@60]EO%9) C'6B;6OA*
M+10<FM+]6OD2N>\WQ6S^%<H4>CH'07[%0P$< 1UR>!"E9JD-= (VI4$!F"/^
MT2ZJY-[?,#:HQO5O0:8UUJ46R0]4?X(<]$\?:O^4YP(%@*8 2([(=6&QG^8:
M<*C]#WDJ_M)PPX"E&8C]U_!#"E6(P1QJ"VF"2#1TI)_%56,*P/XA^F?+ $?,
MP(M4J^%"_$4+63XC95A2 -^989,4:M=6@MGGN.P',!U200;SS=84#L$!0'P"
MVZ_69O67GNXJR-Z!B=@00B)3;VN(P?O'H!<809M[5(44VBRA4?LA^.C?  S_
M$D!"&:0)6SCS:Y54-'<F:/LD<(\J5:%),3-"_W=!W/ZRR[R8G2T-(3_4I@!@
ML(/^7<(T#^R["&QS\^?MC0.&X8>J#+]IT>,O3.N39YV,Y/7)['7K^<=?R<9]
M2W7R$5:!J&K1W<.>STWT*%Z\3$YXQOVM1M,GR=Z\W03;G:F5;2];53<N2#P%
M$$AG2-X![OUDLX+^U3?_ZH/SHS/^^31HFH;JZFOI2#NPQBKD;^X>^)M;!\S#
M_G0:3KCI#MI4H0#\@-BB@E\=M,9O \4K.?"?SF:0SW#I'7;#)JE]/_]7KZ__
MJU]/8S3]X]RU_P>BN;1_\_R;Y_\FGD68VU_B='N=UN='%]2OOTR.1AG^>KDY
MKCA6ZM% L-[\31;4_[Z]0_X['VEOTN*Z3R<)) )QFV*'4<0H@&\ [GP+&[<P
MSG9WK)<U[+%]FFY[^#/ P2X1\B'/&3V[XK(WNM]O3'!RC"TP,+ZZ,0H2R9,U
M<'X^'L2L;_9&/OQ:/A58X-7!M?2D<RS>?7D%@RE&P8*]O2(BYC2.:KDK:H5G
M6G+Z!';3+ZP\-W3X:M[\:,4X-]^X,%U*SF&U]UWI[K)%\^,P Q'U^"N8VW=N
M%Q@@S<,<C5>MQ-D%\7F/<A-1VESN-].-UPWY;M7F/R[*90Y+R#8/<K0M&F*]
M6YO?[+=2A2\XNU?4SAP66UJ:<LM*](#SW0<'U:Z*#2%I0=<]2-6Q5ET1+6>X
M:U1@3$%T)"W4)L5XASHF__Q>KPA"S&]Q0Z3QNS^C*N?"?\0JAZ8Z+N1TL3V-
MK:(G51#8[EE8%2@>8/H/(X/X_&.[@W_Y1.O_JN.]*P7 O44!5$RV]RW_;G/\
MGU/;FDW!N%W9PW7BBF#"*EDYF]IST2EJX,".EU"3/?IKZ6\8T\,%7UU+#W^@
M''XM.S#(NG3%<3?'^'(XJGMY@FY VN74I*?_@$U"X]>R'T<#ONOYU25C%%$K
M(!KI4+I0,:*"-ZP;U?$R@"[M#6TY;D4(3:?+4B#HSH7,Z<J9<9O.:RPTUO6#
M*2/"6@G@!G-$1$8_WV=-XH<3-<OS[_&"\+L'AR;H0"CS*OEZG^Y'R$76*NAZ
MP0NO:U$7#[TQCV:B),"!%,#)JSU\?E5UY2_)3R9K\6Z\ITGJH,U\6&LDTVE/
M1@5^\2411QK[%Y]!'7%MOLXDR,!!BN!UYWQG?2V4C^-$Q+>.%^B5TN66JD1G
M 9F:T;X-BV3^B#K.5>N3/H9Y:L#A(EV>JJ"]9KWLC<FHJY78;4LL"?\!HO3E
MQT'H\8%U,\TOBY]Y5JW0X36@H\"3'*M:.,N#P1"7E[D)V^9>#^04I\H[6Z'Q
MDT3.0ROD:[?^P4R41>5CV!I?E64[6F 9L3Q2)3"_LV+BAC+5RG'#3)2C]23-
M'DP;($L&K*ZB]+8F2$P(HO&TQ22=8XAN_VD0Y 17+!M3N1(-3ZT%%O9J%\&I
M=:-W?6 V@/MI;\5MRQUVI95=9*"+K]:LB'F'Y8"36Y2ZC ,_0C_.IMHNC7\'
M7S"KT:\H6/Y,RT.F<&H^17E4.>Z2^+>)U]7<\5_I3Z7\T/=-]'/?QV^_O#&K
M]D+N1IV.'Q16%"(YHW=JQ?I<_TB38;G,'N#X1?]/3,\T]$UVF8X[CFB$/-TM
MZ("5#%O5M9<GR\W*M7U$WB24YUF9KUB?Q8GD1NLH6H@-.3FG[V?4'PVC <DZ
M^^42@HJL/>%3DR&[#+? \@L0C.A0_=(8S9#IX\^E'P6+=0[S5_MTT9)>#_/4
M!K30[E90X,+S$6"CRSE"@(:5[H^OYB,WS2]M"=:DN0N>7"CQE9T:MV@Q?UO&
MX9?G-7VT<X$KX@(=4%Q)#OD0)VG9@J.=3C=GLW IN<JJN+XDV1?]MJ.^> G(
M,M(4ICSL;[/"9O]#G(!QZ7?@=_(;)Y(FG!2@_-H-!KHCRVA$M1^U$$-(;)3/
M"=A,P!B6;UEA?)TS)>0/_.4'#3"9!$*)KQ!6Z*Y617-R^<1HM%!G0L6J893
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M,[^M\.B=BGKR4](HE*M6SP0KVSRNVE(G7=GMJR$_MNR=:>" :SVK_V!N;03
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M$QA5;3#OO=^$] :/'+86#D[J4-'YB8Z-4 RWI,N^1Q]L\Y<UY <JQ?8]SE(
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ML36D-0_T2G93NLC],'$@[ZN&%DB("X,7YD;N]Y BZ K([BFD/'<*0 F$Z]'
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M;TF;S66=SNHBXRTG!5#-H=E\Q9UX8]Y/^_,YGME%M4[Y^P@Y:L1TT@DY3(@
MX[AKZKBQP5$>?!G@4I_,5+7G%6K$6B\E(6L*8 H87*,WS65H07"9J534D'F;
MZC21XO[4YH/=2[ US?I(U:K5D<49>#T3LZ=+4XLSBL3?G"@;N_RM7DOXB8&*
M?JI?;8O.H2Q!UHP RB*,MDR(ER!4J*%AB<XG5VO1MO?;R<<4$2J[1>]G',W=
ME7)J4MZZ85Q2<[@4N?@%W6KCIZ^5+1;!K<N_E#_QK69O/^J&?$!@PQX_G*4;
MW;Q:Z22F5G(K>_/)K'#%CV8NW!@^7YD+>%+45XAF$-$L0^9] [PQ*LAI/U2\
M/$D#648')V%>22,Y[.5A@34VO6;+'(^QHTL..1T7GAN>T]VZ3O/AXDXAKJ+J
M[3)*5T3)O2P)]KXM84K N(#-W!6B(Q?K3 &\'$^H94JFQG@^NH.*"H4$1',2
M!8!G"MX9;;)=;*-)NO]X/)K9C0LDCRKRI4&7X/9":I0R',4=!ZN(1U:^'3Z\
M>9E\U7W]M776E)4@D(&HA-O=?!U.()-V54[V.4^),"56G.<?[N)[S9]**(J>
M.>B[3=C'+IH.VG)8%^0NBQT;3.I](B1'_RH\@WS?_T4;ZGD'N[%17$0=WCK\
MT&5;(2/QX?@U@0*960^/01TE*-L2RF*,FCNP^Q[KDT+2KW*@@Q5-F<(>=\]M
MH2S< C^&[O#IZMX$?4/Y@@YEAL:7#Z3+"F?:I9#,$*HI.W[N_<X7("I!*^.-
MV$Y:VMD\[H@^Y7L*YW_8G#"K%Z(?,_WE]!0ILZ3DR+N5ZVKN'JE,_<2'.,EI
MO0BIW(3%)KRWK]X+[R(9U6*HK2(6(F>3S]N;EXZNS:Y;>;E>F7F=V9:/7V/B
MY9Y[CYS4Q-[H?/^^JDFOLQN7^;9.#?Q;=6G\QWB_"Q>-M*U +84VHV "8L;O
M5F? 2)?O@JQUY/'C,''+1DRW8=Q;'@'GGBV6C M&;VTVXFQ#5\:L\C/=G44'
MU/__NGHGZ/*!L>:O[GU8H^? CAC@!%H-AUTV<2Q[3P%<&M4[F$&T&R<13OK>
M)94AZFN/A%_+$_Z/&&J%,JBY'-P,-E[TO$H!1-@-(8T _@=[[QW59-"MCT91
MD"Y*;T$!0:I(4UI !$2D]R[2B8 T:8%0!)06BH""@!3I17H1"!"*B(!T"#4)
M4@TD2(D0PHW?=[YSOG/7_>.N=7_KMG7^>%FL>>>=V;-GS[.?/9GB\E]T8U-6
MGX!/QY$"QG[\'YZ#]/^WQV"9[.229L]\TL\!:K*R_TX])JW?_ H7]0#N,W><
M VKVS@$%G,\F#_\=YL%'+'4$I1:G'6,M S+-N)0N_J2)9FKX$77FI[\[3,@
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M0Z=V0?S=7??NCJ'W: BNIHTY9B87Q?7F\X -BP7L?^(O=#QUB/S(:-I$IJU
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MVM<X^%TX]A>$N.*>4*AR-9J*:UE/-H::ML/AS?7-SP#9:.<D:N4[VOU.!-B
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MTB\HD&.E=@\V"]OZV!02Y8&3]SB<^;".+V!&2PI97$84]G1 6E$3!AFO+KT
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MZ(#ADQH]OF0YR4.N\1XUH^@"F=V&.>N@R69K61^.AW5T'+]?S-/X4XV^8HB
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M&C@[E^T35XKX\1^R#L>'1JB0_>ZV\XJ\>G*0E^J\_826/4)HU]ZFDG;R5G7
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M4EL_MA/.%'Y!#MY^23LJ3-3.PP8A!$.-8O[XE2W53#=9)>P54@@XRU5\4L;
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M4OV.G:317S%2Z>A:*K(]8;!);!T+(4!9+U3^8*52.^-,9M-BY/=GCU9>>2;
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M90J3/?M^7K&%?6B@J6@OE5E;U=>GMSO^)H+/7<<M'M/A*A#HFUP9,78:L!G
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ME?&,J]_UI@UD+AE>4N+$'&5/-S?/%6*AKE\FK4RJ(TJ$[OLZY<+W';^3<*=
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M,B/\4]2NQITU2[*HWGD&-[Q&8B((TMQ3O':K$_^[H5+.#:(5;RH#PCTQ7:H
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ML038;?_+1C$%O_.P*KRZ&W5)R\9 0#A**-&%:YI_,=SMB$X>TNB[RTNO-(V
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M!D!8M[P3V&22O(&C+)N3&:[,+4CJKX6P:$<].TK:X.$JP/N<TI7_7KWL$Q1
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MK*+%4G[--UJ\(GGQS:,SV;I1!DFG)VHGD"C01H_SS4&WT 3?\*4:9Q":W7M
M.TLA236?.&C/]:6=L#M7.,% 7RWU4#N3?*4C<O2 S-,\>X?[_BLZG\?),GR1
M15;5MD&E!A.8KH1Y$GL*D4*0#F16D%)P&L9I'>)J];[T]F!:.A06[%LZK9FT
M/^%&2+.85^_P-=V8.^W,OMYC6Y"XCMU50-  SHK$@KW8>7S],K]"V4YKM3][
MTIYNMN-:3M2]7&.I)Z<%D]Y"N.&S\-7H3AW^VWS\NJEY#%X*'D$!]((R2-37
M()G,V1!B5K-;&YGC"7QYKFSQ($Z.U G$5B(I'N?"S&*;D[5-GA[Q1"\?FGI%
M:164"[$8[?JS7<OH&E"_O=.81P2G0JIB)#W1K@JO*#D,WTE(<E6)"KXQ6[]_
M"1^VZ^>AS\Y\'].X1CE]?(\23.OD__(TM\\J92>W(*@:>?WQ;*38]PYIOAR!
MEMAPYNEB9TE2D\+.R&J]-[F[2L2.+"B_[;*VZGAQ7B(W6@(XXLZN9VY?$J8A
M%A?[)8-O$P;Q<A@^>L<:^>.CBR$A[(J\[PB&DJ%K6.Q 377671$NO888Z/<<
M#\;Z%*@J3 %4WSLX.._D+BO<A"52QAP!G-K\!%.?[CCN5W4ES;FK4B>S(O%\
M]X>_=YL\TKQ=6MK?V?[<O(S@JOC1CH\#&K_'N=(9=#3CE/E$%682*8?1H0NE
MQ(TEMMD^&6 &-*/6!MXQ'M%-TS2TM/?[WC>/MD0R;7/(X_04Q@(3Y )"G-.X
M9;[:K)47T\O:V_#&&)3FN+@0^C9M8BDCU%GSO[?[?ICE100</J0G>[9=1#@3
M*.*+KG)NX":7]7@O.VPX"J0T@ANPFR4ZT@<5ZU+$H&AACY8(&>39WT^G*V:^
MS[YW3SR7^^ZJ1ZT!V=P:\6!!!P2!\>WXGM-XZA,*$Y$52X4R**@Z3/(X&\>J
M6"X2'H0GA].\#7_GB%T9$W6:97U$A'\67_NB[NDA]V@I?S3363%GVDH8U+<?
MP.$<PE&0(/M"0>>1[*\9M#^),(M0)!DIU2%<S85EN.MA)]^:+GF,_A')=?B,
MN#[Q4.-&SOC5MX>33J[CB2"FL!F $^ONFB/CH#*XXR$2S'4$9&E->5?<2XS1
MYW__1KSS=%>(+*&!3?9C?-B;%C'U;%-9O^C^S-&QIKL2_KR<7^,9A["[/G38
ML*I6'K+XK76>0R\=JT^B?%4?2YU[:L]@7'ZW+/=(UO:2S&M#O5U.^R.5;T<5
MBIS5-1"&//:?6YT;V@2T=1B='-AVPH[548X*=CMDOL1T2<ABC\W1BVF;J58"
MU(P24T^67,?Y*\5P\<,V+X\/6\TYYZ5)'WG:XGI8D1ZB\"N6-INT\ALP+L.@
MZ#EI>[KTU!2:FUGR=94%SO]2%@J,=#)6>S][;W1<C1P*A7#]>2^WFQ4@F:[0
M!9M>I 3_(/<JBUWTE'L631;BFK",J;""\'*4C^K4+Z7$ALL:ZQ8WQR,#L!-G
M?O09LAX.KG$+,A.1Y?B(S44_]B9H^0I%5/SV;I(P0]R/1A'$>@"QT2]#7X?R
MQ>NGSQ$B996[_AK./_LOOV7PJ)1_[GW'D5V9#ZI'C?#468FT(E+]:M7&PQ?@
M_,\UZR]ZRZSH 7&T;^UU22TUTDL=SGO&8O@%[.+6I;.YZJT7!8^8M*SZ_VM<
M<>=*>]$1@\; P:J><4"/-\Y 5I"7N1K,U ]^S,>4O<HNU:_N4>RBK(H<7M@>
MB+'\>5@H\57L>4G@*.2O)?L(*&,Z?X:_"_Q%\^<)^[8@H=YX)R"-OKG0.$0\
M)IP<O69VQ&SBE=7<@7?#WB<#ZP?E(LXVWO)5'!R(>H.&6^)[SOW>KF],']K8
MON[TBU<%#QDG7^)&WF+!Z<EI=,>L TC1-;;DURAO7B%=UV#YG>Z#[M?VSWM7
MQN\-%R>^W'V6MY-7#*=2[BC08KJ1Y"CV?P"#X]BS4K>7/Z4\^JCK)1D1YV7W
MYD,=.23(X6H0J<WS]'\=_QUHR#33T(H[\$9"&=_3 3I*]X'-NW@(/@B?#K)W
MEYI=WAKL_UC[8DJ%VZ9@D@TCMU [;,**RGZ;?CX;?X3NJI0E;ZY>Z(XVL88C
M^)IKI=#9+M5O_^ 9YN,;8P<WS[2EN$YW3;^^D[=4%I"'-GF3$YJWF".665H
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MQ-K,=+B'WXX^@3I?.+D\JQ3F8C,@B6H\XFG1FK[DE*%R3OH8E!EFN4&A(I1
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M0&321PE(A\Z>]J[+FX2"<:FG;MSABN9L!483-TT<%T%.X DJ0)><0I)64<9
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M*^7'M@"TJSYR1>4M?94!48OT?')5>OWH;:F_LO;#?!K,K,5P_]M3E[ZYN;E
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M8/(09QNR64JTBFH_[;X\_)74$S 69SX<B.EZZWJTNY:;@5ANELY&X6=G"J@
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M\T \A;M#,GYV.BX^Z-8?J^SV5VY?8VR-'4SO>PSKK\WDLA,MW9=,!MC\.*F
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M]"UFKA< O879^GH;<8[@/JH7%(6]0(%<V-J VZIM:!70)%]VDY7KF 3KCY#
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MZHV#)2WVEGFEH)T W"4-RM</D;GWFQIVB]P.WN3\])Y^*28*VK91R1BJ>ND
M4N@)E0SCEY-M?36^^2;&*_N])26&WH>;&R*'3N<.%"I/S:_9H,O]]R;=_JI
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M"]#VKM%-^V;VLPSC8L&CL_#J&;$G+J_^F.+F1O,\CP$W)CWO#E:TR?IT/C*
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MW4&N4]*''(8IT"9X:2?\885Q1X.JVT> VA,/5M&[ TB0-DQT9+B2NM#S^5R
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MCKG]43ZCDLY25?0:ZX%O##AN>Y_B(^9?G!YOT!/&X&YC>0WOD;U&)XA,&](
MVDZ>+ _:,]SBSG*(S#BN#CD9Z&JUF0;HXY2=N+--5!)XD-+$F>,C"A(=F=EV
MU[WUSYNJ^R[$+*/!D.0Y& 8;[:>W<R 8]I@AF2Q4?R*4<)Y*7.7!"IQ*6@%.
M$*A)5@ CWHB/R*Y3 HIPXLBHG8;K?8^YZ1@]='D35Y)0CPO1AK:[::2;_1@.
M263TIFT5O%N7AT43)"G,-'AZ+C6F;4^9Z!&CR." O8JL(^_#*F;99S1!Z_<
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M*L^N3!S2*2+96QB20'$\^$Q\N;Y6E.6H!2@!Q+L3B7<Y?,<V_+H9N!;+I,&
MNRH;!80^+ 1\?M=3SK%$7G)A+7I TWG"7LSX#G#(_V4:^Q(_53DSV3RS=$^8
M=AS3+FZ=#S1HJOXUE<GT5<<YZA9+@N\1C;_A_).W _.[('D&F&,#C0YR85%0
MJ/8PBZ4UT8[;85$K"\RYH7=GM1OD,#3%PD)L<Q"<7>]?>P:>O@!FT;;Z.$1O
MM-=\SU:&,SY?KN+"DNV'TYTN]:PDWOD^[.-H6_-3Y97^1?4X8,<VR%.]?.9V
MGPM+0>^Q,[U7;B&.GU/Q^"TTG]";3-.JY,)J>W'4>0R=@@,/FLP/E_N9W^QK
M/6: (PR&>'\,G[X6J @TG@T1BB+Z<F'#Z+90XTQZU=D8XLF2\P, +K<DKI:*
M'E9C>-$#?@T0^$",-GM=?5ZB?V@C(_I:-\&GN]X,4M9V=J9_5\?YOM6NO;FX
MX9'WMY!+&Y],$ G#V-XFJNNO4INGS(8FISA/_T(K8+0'^!E:%$[EPOC 4@2R
M15ZUKT:Q/7#(I>-01S]?N33X&]*#AZ:>9@?>T^S;YYCZIY] )-;4P0(@)9VC
MK[9YX(;B&=,TR6[:!./Q[Q?)BZ/)>\:;ZOK6?,NE6.;P.1R<3"2!6#] 5_K[
M+*KW&+(AF6ESM)#E*[J:\)@HV%T]C8\7(-'L4-!J8)4'RM.*.XNOW&15',CG
MR(0SIFCZG^A"#._?URT;CM(65F2("\_=3X.[D%2-R2/ ^MZK6D$W%POYG);B
MTP<_(@><=9#)Q@7(-MX-9Z9%'$C:+'_U=K@),6QXC:8\.W+FR*,1GY-)P(^@
M3'A.P#%)EK@9X][W-]EO(ZEANL38HCYJ"N^$; &.^:N.EJL9=#<Q(.K:3N)2
M20L79I9@7D+7-+'WG@DI(NHD%T[CI7N0Y.?P2KOWD<G4UH"O(1UA15?.)H.B
M)K6KK^O.L@N)'K@]E'NX1()$RNABZ\C/G5.<K5^$9E"6$=2O$AU G>O+;I;N
M52[L@-S*;W5"+6WN[(8ID#7:<VD%+QP$7+'4/S/HNR26)#TPHP@'9W3O-$Q;
MB"MT\?K_#( @_&&<:NG>_\=&#?-LSW*JUU2ZE;"90=U5U<T;>O [P"6(5>\&
M96AQ!ZKQ MYJU :O+?P>!5\$Z_TV"R@?M5HQ7\C=*>?3_A6,5Z34*[3^"HKI
MC5[+Q7]6"T:J%GUU=C'@>U"XH"5JY0+DC;&2_>B(6-9Q\MBNJ=9QM8'R:K;1
M5VVEKLD?+Q02PSZQ[L^:-N+CL;J</J($$E)?\4\T7H9+SR+U6Z&!_W&K![&O
M\[Y*3:+7KZ$YG]9Q+V3G2S^H-%M"\1?$6_SJ4?302YDM+@*FF%$#M&*'E.5&
MX/UG'UOAJ[VR5Y^)[!AA\I A2$1' UM92O!PK)RGJ=?-=SZQH[]R9R\ K]+I
MF>AO]V "NUC-A5@5NLG:D:#N[>G$./08/B;9$[$>"!F^]H#9AYMJ4Y.&+3%A
M0RIFN]?0IET!9GEA&^SI2<"--&S62*Q"1A(Z"_-(<[4I#\I\4CNB'Z\N3\";
M]AR7+&FWL-":?6R%*IL\:G$E97*%=D3:.T=5314_N] P&E);%FB4+!CU(B+O
M94^RNMU'U;RX%?/F?\.-JO_F]JX[$0DC2+*P- IMJ14MI-3>AG0E1O/=]>P
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M?FJI=_G=,PKP0&D>$ ^LOX,>45OE84"*]=".M0N4H_I94E&M<)$YH@C&"X!
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M#_C^O]W 9O^)1+N"7C\]M2 ,B;OC(A?V[6R8JXL?TY[3"0@!OOB'V=WSO^G
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M#GP^MR_1P=B]/C'UT)R,Q\_N"$=D;+WNII @69>.!(TI.7TB[/"NS6B^>F?
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MO"\._\HB8_9YJ"/&#\4+=,\.R*LP7OZNUXLG0K;YG>Z$FKTL'ZL_>-T4/H]
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M.:7^'9J#(3NP0$LRZ]';G7C4DM(0&?YQ<1 CN/?6S(,L@?9?7[%I?W;PW[#
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MRNI7.>?5T 7(ZQ%L=Z?-E [%M,%(FC1-.K*-<F(S03O?!YBL#[90[%K8)AE
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MPK1K@04*P4* _-'H:"_+EJYI<1)AX6=$8&AD@YRM?35_@;GPJ,ZM M/ZA$Q
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M2:-X*\(;^L7;A/?MH8(V:*7NN1=I?#5IG[TKVL='Y29[S)MY<A'SW(G&Z'C
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M'C8.(S652;^+'&<_O:T>RGN6;7GYM(=UU?2)7AX4WE9+CWF9PASCO1^%ZT4
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MQX4@LN,EV7S$ME<W6(=RI&S3MG"W2X"O9?;5.VH?=?I30>-N*'B0R)9\SWP
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M^7-!+.BWDFV]JN;> _]ZF%^VKP[@>*.R7BF#(HQ,G&@]  R^!BHORY)%FVV
M]:N1^RX!OX/2%$Q</>62CUWQY#=C?'\U4GRF(KQM"P)8(;_&4.KIB"!6R'()
M[9F]S'*^#,%VPL@.V;,YZKZRO'?N'CFPW+2X5C@N-*TS1W>E?)>NE.&1:@BV
M9PNRF\G> >Z?Q\<3:P=Z4G&2F'"72$=F(V,BJD3$QBHY])GM)=_VOL=C!/6C
MY['-028?!))Y6"[&RQ1:RM;D/&TU81\<J:CP!?1B$8%HV1]DD:(/C_,N/ Z>
M&.8N)_U]:9 D:NFJ<.UOY79HEIUL'4"=SE>,&W<;ZL#/2';#9<9J\=.EW9:.
MHW 8^/)C14GAB5H4JDIZH*7#/?ZHK0QSM/<Q(#N /KP#]X:]&Q0!LIA>H.4+
MMA H2VE"0T'WCKIXLO4(W?7K 6V/V=E^TVJ3]TV]:X,_US[;'%'=2;4'3Y*Y
M%U,8)MP.G.(69'2@&+TMU7Z6.*7.?,=)H,-AJV0)G#J(<Z3N<Q] .(UQCV(2
MG$9O!GO56WEE1R(NMS949\]Z\^4>2\2^B*[V4_EAOZUE1@?\N$+&0#U7"DW?
M1QN2A>VVNLT_L!3??*JTQXO_._ !\SW[7.QGUI5HR<^_?B7/A$-0#QGV; EW
M2GTG(OXUI;(+,:T^3TIBRQHE3R$Q[@Y@$UZZ]L\;/MR0B=N3XFSE0I2*5;R
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MVKUU]W"S+\"CW9N'IV9-?WE,6X9,='O'!ZB'WX*=H+HZY5W=24$GDF5,S8M
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MK&$ CX(QBQ]_LS',SKXHN?"RUWG*)0R&"C-& FCC-:=RW* +K!J1RM7#WF)
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M(5;PMR\;9AJ*)N1^,)"Z/K-[2U$5ZY*UYYYD09WY+5?_MB4.6NJ@)0_^4 R
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MD5FFMC,$K=*MSYA//TH.3%-MAH'3TY_.P#!UZ@V@,$TC@'$QW?4%&* U=YN
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M0.YS[@5FR2<&U"=/,>EX 0TS_=$IAAT-3!#5==U.@I*I%_8</'OE3Y-TNK0
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M%1=\S9HA75TMR?N'1Y*7B@%UEQ75@N PY&'DPR1,,XC2B$*<>D1-%!;(HUZ
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M/'0D34H'3+$<-^HF1<B]&[</X*\S &A2A#$AD+;5&.-Q W;B&^G(!K5&9+!
MPW3-&2LU+,7=+]FP7<2\U+W+,&S2L#1+V7N/3*PI.TI_U2\^[XLSK/<ND,1,
MHW5$G*6'G6'<JNB[O\YL1=TGF.\7;9_ZM?GW^F9=5S5IJITVY=_O5_PC>= *
M^PZO,+4SA^B. !@1='P#N)'1;#_T:&X;*EP!239_RKDZ@0;E-]HFX^)9[9J!
M96?;1..B]?>4QJ=M._\W:1VJH'!S+OTMK^\WLQ@/@X(^C=6(#FG,DR" *,0!
MQ!3)OQ'/\S@.!4>&4P%,R$^\;S=)1PKANU73J\9T7( 1F'I^C.D@,MOV&W2:
M$O,-)^"K9 5L)ZM.&F*U \+9= (CXC-/+K !YGBJ@=4J]NG8K"@?BW;*JRJ9
MD7;Q6I)]?EUPL8BC, U\02'%H=>.!DKC,("I$*E(<8@$U6K9H$EOGO#K'@M7
MH&%"H@8Z1H#BQ#Q1>PC&80TS 3AF*L4%+E8IW!K27I3)/;3^[ G=&L*>RNO6
M><R^:<LM^=:F<IQIU+L@//(Q"F*8H"R&R M]B#'+8!!D/DZ". SU+ T3HA.K
M@8;8KEF+>;>14=!T/(7NH3!U$';=150CIDV*UD$[[UTW[PE ,F_)XA*L"UNR
M7 ::54<67>DU.K*,+C5[1Q9=X4YU9-%^UNYJ]O;O:[G(SH_X[NECWM777,N[
MGY2QJ\J*A1]P&@?0"Z6"1 D3D(0TABR(0B]-4618$:-+>&)U^7[U)*JZ:=>N
M!OP>=K725 W&:.K=RJ; R-!X:CC8BPR\^QU^?._NPF4JHZ.KEC;962]9IF <
M7J^,G[=,AV'W@J^7XB8[TE*23&\@<I.=W\N>9P'V>4!AZ!$DS2V$(4Y(  G"
MJ>>G891B(QUBR<?4B2\=5^ F R>.5"!9TYH5[A1Z/84S Z!F^F>+97$:2[*/
M95>[,XUKZ$)P7"6K6'(Q;X;*95 =I:5<N)Q%:P]U#Q7EHYJ^J1S@3:@PQ C%
MU/.@($U1,/(@]E &,\22A!.?4Z;5I.X<@<DS2G8DF_")>9N.4Z@,:Q87LIJI
M#&,QS5IN#,AR28N-4\O.UU)C0*B]%AI#G[,S):ZEE<WSY5K5]N_LEK??V'+-
M!6_]Q ^/Z[HK$'Y+RI6\ E6?1-DDHGW8YFN&(:<BPARR*&00I9S#E.!(_BTC
M:>Q'.#:;>^2*L8DW=9_-GID.-HQN(BE;5ILV]!VSJC]-F_YY0:ZMLS>H9Z*\
MQ'LQ4T"SOA)C*\8U?H[,&F=LS6KGN ;ST/!QOOZE][W^5/+;DJPJU96E6%6O
MGO=^T[0#"-*08Q*D,/*0@(@2*F][40"]@/ 0$TR8I]4M\"(NYKKK->U$&MJ@
M(0[Z?%VI-/O]7ULU8;![#Z97OXG0M;_X.07V@FN?!3#.+WTF/+S0E<\"IO,7
M/IO%[)2<U*0/*@HI+XZ-\JQZZ5"+R!->&(4)%)QYROL=RZM?Y,,TQCSF-/8#
MHE7VJ4-L\FN@(@TJ1?L*5 UU4/32[7[,5]V/_V*FG@81U--"KG QO3(VD'QI
M(6D)7X$>:7?:1$= 1TICD-2LND%'Z$,5H/6,><;O)U%T=;Z:";[;!R;>EI_>
MWNBG\^ZD&-Y6U@*8[1_)N\/9AR>9MDK!W:TR6\;M$>/]!-OC7YKGMK3-2^5]
M8#N)5F62KE@3MI0GX]MOCWDI^$=1[P+&156)2FZ=U_(7>5TM/$%)ZGD(,I_Z
M$ GA2<L\%#!&B'LX2SRFU\7($3]3)\:U'("/-Q_:@ %KR>IG?;C ?'BCO@"2
MAH'@#7.@-Y%ZG[\KL$5:U/V\D8;)!OG7+X&\?BK.S&_ +DMGGC=AE,3C$+>!
M_!X75&9+_7$(23\KR.6RED-2Y'(J=5NN+%;L^6U5YP_R'G:3?9*_4,VSU <6
MU LP"C,&$\%3B'@8MR=,$/M^E,91&H5:\RR-J$Y]CG1$E4N"D>H>5**NETU9
MO.&P%2T(]2Y,SH$Q.Q;4ZJ!'7VJ>'DH;'AK%XW"(BXG,K@:\:-&<=_B+"0Q'
M@V&,'K;UJ$@Y5)&'TDR?\^K/5@.IORVR,.(H1B%,$S^$B,H_:!)%D%+NI4&<
ML- SJO$:H#6Y/Z5'67WK6\I D3;UGYS'2]=]X@0%4^])'P!%ZZJ/P3RM,34D
M=^96.4]I9J_*J,C'3I7Q1\QKK:[7<HVB_%"T,W<7(>(\#9 /(^;[:I@CAAA1
M#B.>TI0E/N,\UJVK.EA[ZFAZ2PULR.D72AUB,+Q?+Y3,;']J"V54Y72&?:N*
MIL.U9JM>.B-$OU+IW$?LCL1/8E6ICDHK?E/?JWK'JBY%G;?#NUZ)E<BDA?XF
MK]BR4.T-=OF;22RHYTF#FG(L(!),GIR"(<B0X$3(_V=<:XS4I8Q,O &1Y__X
MYU_ )_E#L[/3&EB]@W4.N,QV]><M>;"A#_Z8Y&B]5'9'YZXU&[,>RI>"=7AB
M7[R>G9XZXUYH:C15RJW\TBRWGQ'5(HHSYB=)!M-(9!"13*HGQ!CT69;Z ?*4
M)6"BG@SI3YWET10+YZV[K2;?KL!*U,K4SX2$E"P!;5^$F<HRQ5A/4TV(G N/
ML0+RT%G9PMND\BON>I]O.I$]J*Q3=^K,$B!'6LR4^JS*RQ*:0YUEN\S%>1N?
M2'E3-F3X[V2Y%IL\N$7H!?+;B#U(0\0@"E(!29 )Z"4L)%GD^]BS3=\X1W/6
M+(Y'4H(G1;U)WOCMRQOP*,HVB<,^A^,LFKJ^"*<8F?HD^AD=DKYJ]=!R !H6
M=GFVD^1VC$GL/L7C+,67RO08@V @X6/T4<LTUC6M<IZ3\EEU2+S)&EI-#4N"
MDRS*X@#BV$\@PH3*>Q8)Y1\HY6'JQ9E9<?-92E,;*J3-F&SH&97WC&.DM^N=
M2&ZVUXV$-D__'!/(58KG63KSIG&.B7N4JCGZ@&6<,:_S=BS@9U&)\DELQL.F
M480\S\>0840@0@Q#FH89Y,3'?NP%C%.MIL]CA*9V-3)6KN5IM-R2MX\GGH-*
M,X3H  ##JT$7;5*UNUOIMQTMKMQ-U-45T560\!R9>>."(\(>A0+'/F^W@3^*
M^C6I[C^5Q5/.!7_U_%LE^/M5VW C7]U=J\MA4\^R"*F@A$8(IK'<S4A-UB'(
M5Q.P?$H)PPG[?]2]>9/;N)(O^E40<>?=VQU1Z. ";O?^5=[Z^8;;=MCN,S&O
M_U!@+7..2JH15=6N^?0/X")1&XF$0)9/S!QWN2PB,W]4)H!<([;8KK=T::?2
M]J1!2KYCP/J+;M)OZE2!AY854Z_PRZ.9M%"N?M7_:QE"=,<13/4!(-L9@VF@
M@YD'@YIA GWNH_9GA]J.%W0[CAK85, !\&0\ (1G-2=P0(X-C,,*_IH9+41&
MLRA5 O.")YCH0P+.8T9QE(H\,M.\<@H:V7F.R,1GA>F;%%W1D&C"8\*%YD,3
M'!"&!)NPX]#+=Q>ZI+.#GYUB(O>?JXVDR_*_I3"91Y_75=T:^>.C29>OLY+J
MOU<+$4HN<\%P03.)21Q&F)$\PRI*J&)AKB@'7=6]<#6Q_C?TS!VWVI>3&T.
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M(7AJ.O&%42 "(51N<V>$$)WXMMC6+F_I#^/<-W31+ZRA#.K89(G@>'1T"ER
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M*WW.(J(R2"J(/>D9$D.X";8\M*P@]HQ4QP:B.SY@2@^ ULX(3 ,8S"@8K.K
MU.<>5K\81I#Q;^QX0;?CJ($-!1P 3X8#0'A60P('Y-BP.*S@.2'O35D]K"NZ
MK/25/(^+-%282].[T=@6&JI,G^1I+DW+ZJP 7<G'24Y\>-@G7SWLDJ]DQP02
M-1=:<=;*4S+:'DH[@^(7()@A&4E,VW$P0WK:B;13)ZGM"?X<J6HG %@GK)T^
MZ=X HJPGEE9Z^=?KU5;;'JDMD*SV\:%]:"M5@O$BSW&0I9$^BBB!F4E-E4)D
ME*<R5B&'=H>P)S^QU>@Q4VO% 3OP7A( 6.VLQG1@P2S(($[3A16O@\%C"PL
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M_1Q#,\9*FNP?=#,*?V@KM-%'N/<KK5^RVG[0M\OW6WEO!G71),M8H;6?:A/
MBP+G19'A.!%*$4XHB1*(,;A(:6(C8/HBK5=;_?BR:8+7D$=_&090S0'0 %S&
MS$[QO2 !4_BK0  K^ZB GI3\,IU9E7M4W&.E'G_ P8^W7)J&8&;8UCZ/MINR
M8.O.&UAC:J_><HE:VOT$=D"YTB  %JX]3[(#/7P7Q/8X;\)6.#='W]#"\_G[
M+,0[</O9?-Y)!>L^^":I':QX1T_.H&[[.0J5&:303\4':=VQS%:Z=H6X< T;
MD-2_HEV0S%6]CI>;4ZDNB'*D2I<^=45:RO?U4C]1F</N]OGC>BOKWWY]6.J+
M<IT07IG0EWF!X2+F:4%4'F%.B&DTE.:8$I[B)"1Q1H(D3F)XXC: @8DUM4FS
MJ SE&\1WM)'IQ+9V2$:!0&MWG)T2,)BN]SGY7ZCA!1EF;MKB_:\-C'N.T)=!
M&-V24ARP\)F7 B$_?VJ* SAGLU-<UH%OZ9\>M]66KLQ1X8OD:[WL<UWQ?+^U
MW=HOKS"QX3BL";TWC5'LM_4!N<>W=S\BPU2_1Q-U1!$$ M V/RZATW8_L.QL
MV_ZX:/WMW^+3\$#@&ZGD9B/%[_ILOGWW6*_>]KE>!+R(91XSG$9%9N+I$K-(
M)%@F&6-183+0K=L*#M"96#=KBD@U)'<-HI_M(UA#$ TKJ$?!81K:$46-\"U9
MO1DWA/W(;A^K\X2!6V3.%0M0#,Y"PH&(V]#3L\77+$3H1]-L/NYV*^E6;B9S
M?*,_VN$<K^1*JG*[D")4YJZ! \5-O$P)G$O&,$T"204+J+Z;0"XA(_0F-D^[
MK^>6_H .BQY#RNY.X5%^1RO5#LLQ,?26-OJEI7ZY2S/XOF IIZ?KP1BU66\#
MEJ(?'_YM'X,?._;MS==5U8_'5Q=30R@CJ>2284;,:&="%"ZDBK%(@C24/!&9
MLNH#X4;^I\I$<D!O_* R+2; &\9^X(%FYB"CIO*5F.0 HOV)9UHPW0Y"$X *
M.B.Y8S)P=')8=+83E;O _8/6%:M<7W7<F["XZP0D%GF>FXS0 (L\UJ8XBU-]
M^$HSG)"(JSC)21%;50Q94YP^=ZE7@MO4(ZX;%G;]V2PK'NQ!M#N<>84&9H0/
M46F<NBWU71,SCSU K"6=H$SY/+T7JU8>%'^H:'GX0=<@$=W60=M/JCD'WJ[J
M5F(;^5V?!<LGV?ZV2\CC^F06<9G@5$4%)DR?TU@F8LS#0.;$]'H,K;Q&CO0G
M#Q&UW#0MO'IL=+<8UU1'*,ZV :/)T(/&BSP YQ C<A+?6X@(1GWF")$3-*<!
M(K=E'(W1(ZOD?SUJ<F^?3&VF7N7V1UDM9"*27 F.BSCCF$1*8*HHQRS/DB07
M1:CL*E1&Z$QM7'9444T6&;I:+S1EJ#&Y@).ET;A>>J!Q<!$<;@R&Q?*E]!>H
MS*O<PZ*>*/'(QQV5M>UV^4F=;T)J-=/]U?/I5/>Z,^$BE%&4I*3 4F81)@&5
MN!!"X$S?0E@0I@5)"$CG)V5W:M-1=QYFAYV']PEW7?_A??MA5/.':@;;#IQ0
M&S/MZ[4T53_-2P-:O'.=HKV]+[AIG 5&7Q9V6F;G-=2S ']B[^>AZI*.P+;O
M5_JH6/LWCQK2MG^5HDDO6<BBB+65SW 8!$IO #S!N3GTY81%8< 2EHMXL:K[
MZ(MOMFD*]O2MC$/1&(<3+@!>F'+%RP>Z1+2FVN8EZL7,;(#UKHE6_<8@@7T
MT./! ^^X.084V1;MV;@YZ;&]^XU&#Y*F!48,DALQ#7*NR1+^$ 0F4,!A&,RH
M "PW8XH%7,C#G N'YUV["2_U7]<F\O D>P>3H[%OSXLL5#S**,62Z;,W81G5
MEVX>8$XB:L8N"BI!S0IM"4]\GNZQ8?(9[S824B,%1M'NL#L%-C +>\#!X8'U
M>#;CY/V)85AXZU5L27;FOL4P,$Y[& .?]S+HHZUAHDEH)E3G^O::ZV,<H2$N
M\CS$F1D^G]"8D!Q4_'R6RN3FPN,P#ZO:+F_20@W \? .;S5=5A)-,ZICSGHO
M*S%'1G-<5?W5;V[XKEQ]W=YOS42_S>OU9B/K<8YUA[XPI2H488992$QC D%Q
M'D<""UGD01Q3&=F-#+ C-W669=<O4W- ]7U*7Z?V :F:';3G!]XS= #&82WV
M#P[PQ@3!Q5LC1)C45_4:'5A^]JZCXZ*>ZS]J\13<S_)5;LS$YNC32G[>M%F>
MM7^GW7L2FB09B6),@H!A(M(0LRQ+<1'F<9@Q423":D^VH#6U8[RFCFYQA#0#
M:,=!D]!B?_T?0VS<1^(1!Z"O>1""\1T<C(6]]\,C)FX.#\>O!\BW82GD@#MC
M;(79/!B6HO2=%K:/S#R_MBEFW7M3JD_;[W+S[3M=M?E3[]8;)<NMR7YO.K(O
M2*QD&"IM!3.3@1[D!#,6*!SSE"@EC5E4 '_S"X@PC\OZM1GPL%QJ)?JE[#S3
ME^LX7ORU6@8:?[*W]%)S;-M*_YX\J!8(;;5$^RFW.Z'V4VY_@J&V[N_BI6?;
M.G#^KS'BUOV5>)MT>P4+;IM60_ /N?V^UDL^R;9?3NL+ID*0D.<%IG%] .<I
MIB),S+!,&H>!2L,@@/C#!JE-?/INK45#'/6HP[:#8<#L#+@W&& F]R("T[K'
MK:3U9-2&:<UJAJS$/C8<=@\Y%S.;&1*O34/(DCUVR1-O[Q^6ZV>Y^8-N^7=3
M.=W_=ZF_2:OM0A5YIF)]\XXI8\8!QS&E48J5E&G$<A6R C3XVIV5B8W$'_1'
M>?]XC^AJ]4B7B/<80 _Z9"$;#N6-^1NW[E_@X178699Y@ 4Z]AJ>4)]HW8!8
MG^!:OE#'V,&';E#+F\G3;S\JJ_^%?M^8HD&];7HMR+X2-W^UVJZ,S%W&?25@
M9RJ\KUWQVMS@]ZNM_N*:R,9M5<EM=;L2OZ_7XN]RN3R::B]XG*6Y*G!$(M./
M)J.8YH+A@-)<982$,A:+)[EA:WC*KS47$)7M\V)_1VMY,OK7L5 W#=^SB!H>
MT2M]KJ#_N=XT?T>OE[0"'JQ<7H/E?7E::('WWAZFIS :<'=(-ZFUTQS*KL#$
M>^JL/0<OE \+ANARDBM\*3>C5M\;VR8X#:6]UM PCD28"9PEH33-M#+,9$%Q
MD?(@SF44" FZU0W0FCK706ZVM%RA5W193W+]^EUJXU/WU(89GR&X[(R,)Q!@
MQJ1Q=[54.QORUR0&PT(^3X9AB-*L!L!"Y&-%MWGD&D?-5\D?-^6VE-6[IX_E
MGZN-I$N3%?^[U@+3E&%1Q"J1(DAQQHH<DTQF.!=9C%G,:)+P(J4*E -I1W9B
M-?^HE?IQ1Q3=&97_9:GI_HKT58(^T7)I;"=6ZPVNJ-XR9>/IJ'9LN_AX1K&F
MC*K %'P5(HTP2:G)&Q,2%XJ+*.*YHF'H$(3Q"/G5\9,CY'\QT/^*#/0OBCS$
MS>;SN^OD;]LS<(/>_0-_?'^#]ER@W^LOLV'$8W\QF.1>?6^C1%_ "6<+Q'EO
MG/73/L/&5F5/IT5/?SX\R$W]TX?ROMPN:$[R@"?4-$C7)JJ@!2X*R7&>QWHG
MR&68):"$UBF9G=K_WU4O/A@&;M"CH8[JB Q:&OIUB%B8].--53O[ZG"QEVBQ
MI[=Y37AX_G?D'@\&5Z%JBUJ_S:8DM>9TZA"O7SPGC>EZ8O4G".+Z!=TN:NN9
MIH=&:-0X$BY.B%MD:1RF"0LQC^($$RK-L91'.$@X"5+]+O($= 4 T)[8A!\U
M1Z.-%XW3AW)KBE+K^]85O=%&<+6SOA.A!3.F1_W26J".QC_>',Y_G*A]FAT$
M4S12&Z'\<BW5[" 9;*YFN81[-49E>B5M'DP=EA2OGK^8;$FI1=V[Q524$\)X
M@HLH,3U/",=,)AG. IYI$R28# MH4<8HU8D-S(X/U&?$I*'M6(%79(Q#.6Q9
M)@,(&,8=Q\:SZ]%)\*M*-,:IS%ZI82WXN8(-^X?=+463AO9V)=YH(HLL+DS7
M>S.,*]=6@:8QIB*.<$XD"7F4J%B K<(!A9DL0)LHBC159,C"U?X0%WL5=Y;6
M39VM!752V[/"7*6BARO.KHYG!3JG>N<_"!]%]6TC]#7X5C1-@.OODN4(JM,G
M)]:=CA1 82Y(.*PMUPL'4Y4SDUJ1G:R@Z5*717*:*G5FN=FF25T6I3]%:N!3
M\#+"IK>G\<>: _*%/,HOK>M6'Y9OE_7;D.+;>O^!14Q8R,*(X)Q3CDD6A)@%
M>C=3F9)1JG>OA.6VQ89>.)I89>OV^_4EL0W<W#?)P>6.@1NTD=R\!%%?%VG'
MI)FHNO^4?<&>G_<T;"!>!'V836D;#3>!'V181!?3LV]0QR?2C*+;_BMX_V*O
MP+ZR<O97X59_.>,K =5L>H5OH++3#YW9ZC^]PM*O$O6[L)N_]XM\DJM':1BH
M$UXIW_Y[N?W^^K'::MXV;7&SF7VH(AEBP@HSARC.,#-9J"*-1":H3 H&:CMK
M177B':GEH=F4.B[0WYH-U/&!7ND[[/=[NK&LF8>!:N?F]0X5;/L H31!8QR0
M^)Z<NW8T9W7K@F X=NC"'G:-&\D'6HIV6%J7F+82'[5\[>S,6+ X2DF(4Q7H
M(Z^, EPDII-II%3!PIC$J55S'7N2DT>):@:0;#B !H1& ;.- _F$ 1K^:1!X
M.X* 0V3'5BAO 9U1@C/'<6P!. W?6#_IINI=.M*GU9GHT#Z*&06$4L((#@*5
M8L(YUW?=5&%]M2THR7B6*MXE+=HIO!UAAWQ%F-J;5,4N,5&4U<.ZHDL3]53E
M#W-W=0@.6R)J9P\\HN1D$WIYA@:A-S5"9>W"ZH6&F\CP%$%AF/R>S(<ET5E-
M" R(8S,"?-K-E%P<=QSKVP7)<ISP(L D3W+,DC#',B6D*(0*A 2-MGF9,<?M
M/7]+?W1'!/0+&QOQ"\+)SB+,/N1XGMG&\\PT_BEF&0-G&/N?7>S<9Z2M<^_N
M'8]T^4UN[A?Z\)_F>4 P39@^',1QBEF@,BR*4&NXI%&:6I:U3L =1#&<REU[
M]-"SI!NDC<N]V1W+E2DS-FVF'_0#@.9TGE_/N-?[!2&'V:*:"\2&VS^]:ML_
M(7;:_@EUK1KZ;\WP_'*O!]!K\.5>DV-OPMYKX/W710^[=56]SSVTKXO6K^N^
M?5V\][J,?OWFJ;'A-(@.-4+T3'&^QHG30'70:'$B$F['V7>TW/R#+A^EOO1P
M?45\U%_T??(=%QD-,ZYP$0F"29@'>O?C!"L5!K$(9)X3 3G4#E*;^&C[]?MZ
ML\7UMM5O[V0"MX8M5/.%_I#4<.70_&H82;MCKS=\8!M.3_X>X8F*I:UD]'02
M'J8UZWG82NSC4['=0VZ:__'1^- _J=W@^J_RKO[:+V*91468,IP6*L*$2X'U
M#59B%F52_T^%- 3-C;](:6*-;^B:0^JZHXRJEC1,MR]C9:?77A" Z?1>^!U1
M]'5,>+ RCPKF29$OTYE5B4?%/5;@\0?\.+3KW@J];6W!E5*IH 7.(L+TSIUI
M]661Q&F0Q3S(4D$BE_K[,;H.GFR'ROM=?DGGTS;E3I7YKE?[37Z?@'6E:_L$
M6S>GMA-4/MS978E3TQ#%IKGGU0[L2[).Y+H^(?>B3NM+PH^YJR\^=VWKMMNN
M%<6[]<:0VA?M?RA7LNX(M. 953)5#(>")IB8<9TT#/1/61BKC$4B8J#"2!#U
MB<\!]0"D?J>)V]/>''\99IKN2,[SE6UPMK,=DZ$',R0CP'VU!NZ*%FP  +PW
M7[.A_4)MUP"P7&ZX!EG$L=5:=^[YH._5\M]E>??=C+Y\TK^]DU_DO3:!W3\:
M9T:X"*,BC9. 85;(3)];4HX9U<>8($FB(!6Y8$4*:QX)96%R5WK' J8-#VC3
M,8&6AHO:]0=LT0:%V<X,30D=S!+M[S UM1O4,8-:;M".G>83P^YN>(<W1R1\
MM7V#DI^W%YPC."<-XES7@0<'/R^?[]>/V^]_2%F/S92K5?6\?**KDK:IKBG/
MPR!56DOC.,0DSREFA!>89TK&>9:R2&6VU2ZCU*;.^FOIHY8!TSQZSX)]4&@<
MM?$HG%<L8$9D& :' 5OC>-B'O;SBXA;(NA8?4%#*6MZ!,-/X&K,%CJS%Z8>"
M[!^"U\::X-)M'25:/G^FI?A']7K]52XEUR:U#7+LHQ.65;.0-2<V:8=Q\98G
M9)A"3]5O==B<KDQ_P8:[+JYC7WD+PF_8[$T)'<P".J+F.1+DBH=3J2^(T&Q%
MP"[B]\N#G9[WFO!HPM#EZE&;K?;8MEY5NX]^D0:#<EDVL6U6U1'K11RJ(,F3
M A=F0C$IXA@77.28\Z0H5"Q#PD$U6?Y8FR>M\FQVX0W:\XOV#-^@WD.'3*._
M.K:!KBJ/K]+N ODR+PAF$X??S5NES"3?)WGP.NA6'KV3&W2KM_+5UN;=^$H;
MO0+&:3--71C[&9)3KP#4,I_U&@INYENO^WHCA29--YMGM=Z85*+FN[K@2A(F
MF, L8_J.:R8>Y(D(<:3"D+&"J)2#<M8':$UL8(U6\IHTXCW:B-;$859R$+%0
M%#R)&<[RL-"()1EF<9%AR<.<29$V.]AZ2Y?S(K:C:(^8><0?,';[@2=Q80;>
M?#<:JJA/MK/8_LRTA72>[.X0I5D-J87(QY;1YA''@MXF6=+, 7TCZPJN:L$8
MD5$:Q#BF681)E":82D)PE 0)#[.8BMBJY]H C<FCES69+F48VL3U#"9VNGJE
MI$#77$L,Z>\#ZLAYK,V]+(NO8MPS%.:MOKTLXDFY[<!'W33O-:V^WZZ$^8^I
MLWNB2[/^;:/B^K!3YS N BIR6B2!WBUCBHD^?."<<HG#.%4)-V<0GL!B>U9T
M)P_H&?)U'C$W/\@](S!5M0/13GF] P/T,W6(U#_T.+A!M-V%S6VWYL*?EH.$
M]J3W=C1GM00@&(YM ^QA>.#M0\G-=<AT8[E5JK[K2/%67XI,UD$;- EE&D4Y
M,[6S4:+MA)G!%F?2=$S-TSP@0<BL\H\MZ4V\?W?M:!Y-;WS$S0P-9IK.&I^"
M?DQJ^!I=$?J#R_5#4Q>T+P=I>]#1'?=(MNS;!ZIL4!\/W7G&$F926N)-'Y\]
M>=31=PC?V:!B'\#SC(Y;".]ZE$!!/(#, V$\FU5F"^0!1.J'\B"/.8^Y.-_1
M_L]*JL?EAU+I$U9*64[C&.=QQ##)E+:<+%8X*7C"991%*<S!;D%SZM2%W5R&
MA_U<!MFQ<8,>:T;04G,"GFXQ"J?E1<DO2,"+T^'<BL.Q%3>H80%]&(+'98:%
MK<#^9E>,4IQ[9H4M!&=F55@_ZB/L7Z>5^XOXGUWN98/]36&#APC_>:B&K<!$
M* 'O6P" 9@GF#\KO*8Y_GL8+AO 'A1Z.W@\_ZG#-6E=5$VNZDRO^_+;:EO?Z
M1/))?=;_8"9LFP_4=[E/JAGBM2BB(@])*'&4,(5)&)FS@PSTV2%7O A40:55
MKT,W\A-;D(Z#ID;,$$25W&Z7$M8=V@%6BVO5I& !;UFFH*['S WJ(]<QA,S'
M;MJ*<?W[AJM)803<PR:%T_%:-@6LL)N:,RI#%S?XHO/=XYP%/KC6N:_B=LN[
MY7SS*,6'DC)]B327Q[-]5E62J5RQ%(N(Q:93)<4L4N;*)Z,B9B),4ZM9##"R
M$QOIE@G4XP)VI[,$S^Y:YQ\2F"F&H &^PL&$\W2+LR0ZZT4.!L3Q70[XM&L"
MYE9_+XRQN:T;M7Z4V[<_^/+1S-WY?;T6?Y?+Y2XO+RNB)!$YP2(-3-T_*7"1
MQP6.:%0PD:HLY99=ZES(3QYJZVH7F\YS'6-M!UO39.N>_N=ZT_P=\:7^+S1#
M$H"UG1V9"C^8-=ES@1HV;I!I"OS+CA74\?+K1"F,<!2\)2D"2,^<A@@'Y331
MT&$-^(7RM=QL:;EZ1?6WBLNOWZ7<UO7!ELI@L\2$[I&&,FI)HYIV4[,.SJ6V
M L/^MN(3%+>[R0 X?JX>MB(.7#1&EYCM6F$K3/\28?T,7"W?F*FE&RF^T1^-
M^A^;@P6+8\4%,_-&8].7.BTP)8G"B0PR0F(11:E5"S\K:I-?$/[KL=3T>UL_
MP.LPCM6X#?.* ,R(=:3K"H1N#S_9UGW"86_%O,+B9L:NA =DT:S%'3!IXVO,
M9M.LQ>D;-?N')IGRU9NU'N2,,I)BFN0"$YD)G&=!A@.6T(#$A9 4U+G(EO!,
M:4.F*.1NU0RCJ#/JUG7#[:9VQ%R#VM3V+V7E=^07M'?I%+C!+*3-X*]I>II"
M99]GZM<+=3J%@@&<_>6KKO56B%JKZ-*$X-ZO7M.'<DN7;=Z7Y$F:QF&N02?:
MJ@@1X"(E,68J4BHF*DA@_= &J4U];-K11F;,$M:'?=Z0![I7!Q&S]*KZP@'H
M3-U#\+F%H*4\P0! *QE]^50':<WK2K41^\2#:O403,/[H^9O5ZM'NOPB']:;
M[8*DDHF"I_KRHWC7SESF.!4RDY+H_\NIC5)?(C"Q'G<D44,3-43M=/@B)L-J
MZT-2X#4')J2U<HY),I"4HA]M5%'_L-? BPO.HG1CXG1Z-OJY:YI"C,P!7H1Q
MK!(6!%C$BIIF?A(7*DMQ($211%D4YQQ4?&=%=6(E;*9]Z/UCM9NII]#O<B77
MX%"##81I0F@>1@4N,J9-%A4,%_IB@WFD,J$$C6)&82,)_8%XS43"F6&T#=5X
M_GY!8S3](>MJ<,BZ[^82ED)[[1LQ1O,%6D)8PG"^VX/MP_#3S.OUD]Q8AEI.
M/C]A7,60\1HNO,B\T_9\N-)L^_)9 ?H;\OD/.+;Y?F25_*]'_05[^V2^97NW
M3:%DK(^U"JO0%(/HBRQFDF<X#\*,1+G,26QUVAVE-/6.NZ.+&L+ _MP7 ;+;
M%+R(#=.K$XDG<EN-BN:KH_9%.O-VSQX3]Z13]N@#CEVQ3;;WV:'7BR@/I8HC
MBB,>I)C(4&(6ZLMJQHS&1GE1P%KR7"8UL=8V-0</A_/F@:H[@).=[OJ1'J:\
MC>!'8^9O4$O78TOJ4=E\-9^^3&C>-M.C I\TE!Y_PF-3K8_T7KY9FR[5BTSD
M/$VR".LM.,)F/"RF09YAF4A1$"&3E(.VWA%Z$ZORQ09*A@/T5\,#L!7A&()V
M^NT1%YB27PF)G]92IX).V5ZJ1^WE6TR=BF[59NK,8U>.S>S/B_QBQF=LRM5=
M&Q&)XT+F <VPF1R-2< ISA4KL(B2D(LBB)1=Z@V$Z,2F8#\I\N9@5.8-VO'A
M.#5S"$@[8^ ;'IA%Z".S(SI!< DBI>\IFD,D7V:8I@4(%V=JVCSK9AT^R*J2
M\G"<15<C\-QUWWKS*!=<TB#.*=='!*'_*/05O9"IQ*&L6]WD!3%19OMVDK:$
M05;"L;?DR5@;MP9VUEC:&8DI$((9BH:#&W0RTF;'Q@W:KA&3=:3:G^& 2N[)
M>%B3G=6 0,$X-B+@YQV=>ZZSPC\]U*V%WZTW2I9;,S;8=)KX\5#N>@Y_EIMR
M+1:$%B&+@QA3:J;])5F.61%0K(*,**%")0H%BR]-SO/DL:G7)DU[N90"_5*N
MVG+Q7X%.Q\E?G*7S\J=X&6Y.4,,7KAE#A_TM]MR;BJ_^YUH)T&US&6N%N$$]
M,9H..7M!3 RR$<6C7W4NU'WY9R?G=UX_[USPG_B+9R/LNIVL-ULS.JT?&D](
M$%%>Y)BGL3Z#QDF"\UA%."M(&@DF)&,$5C%ZC@S$3KA5AGJ8_'P6'UM#>YW,
M4-MHA#7DILD)&)+&F\TY0V)F,W%9R%/-'OBL0]G6^DWKVDBBO!"F*SE/4J*U
M+Q.8JHAA,P8U"S/%HB2V+L_J5IW8"?3G;U]_,TVZZ:8&PF3NF&J05679?.L0
M@6']<I8+IE":A$,#T;T0@%(I%V$<2Z)LA((5/ATS/U3@M/OL?(5,Q^P=%"R=
M_"-<;[]NU_R?9E+R[=U&UCOZT932SYN22[U7U]O\HB LS_(TP'EHW#L12YI)
M*UFB8A%'22*551@(3GKJE S-1X7NJ9"FGS=%?W?3>+N1Q@^&F?KZ)$S#XTV%
M]%6YN4I9WJ0<X!ZW)-.!"-R_#1^HGI^^X^3,3..:&W,[:2XYDP%G;[VF ]#-
MQ)T#TAU'D"UT@V+ 8 (7G,VJN@G:-[V.*\#M\^V#MC;K5^6ZW9:#@N1AW3I>
MF.+WU)RN1))BDJ@BCHJ"$&%=_'ZT]L06=D?-7NF/A1\WAU>(!+-W.T(.AZQC
ML>R-U17BN5DC@)@@4W-!D %;<OS$;,;B JM]:W#I(XZY=)T/ODWPJ18J2+@H
M3)^+PN2])J'"A;Y&Z3^*5.KCF% J@@353BC,$CU;[\)#CKES)[C8.3*NDA9F
M%?81L+=C(L*SXRZ)X2LI[F3]>7/A+HEWD@)W\8/NDYZ.AL-\D=56[]]Z-V^'
MQQS^HO?)QHGY?L4W)E[V1C;_U7]OVE6]_<&_&T^I&:_:S%U=Z$M2'"J:8$(3
M_0?+<YS+),<L$#3*1<BR,('H\KSL3VPH.@Y07=#M;0;5C*_7SB3]O"\-9N\,
M9S=G1F+M>4?-1\Q[//KEX1.-4*B3"OW2R?5K/3:Z[>C7R=;,*VZD\SMM:_ZW
MXG%LUXS,SS[_:_X7<VZ0V MPX;:K-15[)FBW7FGZ;0XR)05-(A%@GI%07R%3
MA?-4)9A%D8S3/&=2@IHLGZ4R\3VR+2#=$75,USX/D)WYOEILF)6%2PPV?8,2
M>;)0YVG,:D@&Q3S6]^$/NZGE&S,0O5HO2U'?P[](;1X>ZQ\_J2_2]%24O0+;
MW_7?/VU,$6X[DYK(/"H24> X-#Z?F&C5E46 @US?E6-":): JC"N8V=B1=>V
M]'%97Z;T:9#>F8Z>ZQ6ZE_?[+%>8RE\)OIUMF ]28#SPD"]S1MMQ9N*='6^]
M\/L-,NRUU?O^AXO[0<J3<;J2F5FMF!_@CLV=IU4=\WBV^N"CST\?]+=F^7\?
M-V4E]"E*TVY=I/I(E)(BB;'*J#ZXY%& *<\H#J(@+Z)$D22R&N5C26_J8*.A
M#DSD&0'(SCAY%!L:'C07-G,+K$FC/NT)2DHLY?25^#-";=X<(#O13]*!+!^#
MS^_[N%[]KBFTM2EO9,4W99T<"![=-[[2Q'JK&<"_W]Y^W@V>Z_%@/Z7/ I!A
M;?:/!4R9AV"88!:?O:A.8_@LEI]M I^]J/WA>X"GX(UZWIJ)O\]MD7G3:4T?
MR8VY>*P61<;S(& ,BR#)3*:M,M-Y<RP30F5.2)R3R+;]X!"AJ5T*->FNH0':
M$4<-=?M^A(-@#2NU3PB [@5'Z4$MD&Q$<^J(-+CP; V2;,3K]TNR^KQC/*O?
M3MOTT/ZFUVG=6U*%F2P8P9D(""8%T?HJPP('.4EX+K*X4!QRC!Z@-;'*'C8-
M-Z21H>WH#!S"S#*BXP<)8/C%%01X:&1</%]QC %*\P8=QD4^B1!8/')E3LB^
M+]]"!E%8R#0Q(Q+UYAN0'!>A_JND41 709XR*IVR0O8T)@[WUD-$ZZZ0;6[(
M>N6:$]+#Q4YAKY06IJC[O)"#CI@3)(><2N,[/:1'X6421$Y%O)@B<N:C+A.)
MF%ZKVFZ:EL/-@,3W*[UIR6J[J&M="I%BGJ9";ZD1Q05G$@N2Q6E1L#@, OMI
M1 .4)MY0N^&<94L.,G9G")]A;?0J-=0ASK9H3_<&=0B\]XP 9.B0)R1<!PZY
M(@*<-60AY>"<H:'G9YPQ9"'&X7PAFP<<SP=*E5R:B.6#6;P;^1$JFC(2X221
M^KB?Y0DN"A%B(15) L:I/O&#6B^>HS)]%%!J.)I4,"&?Y')=$Z\SPA[@0<#S
M2%F>&:Z5'WAJJ,FA';T)'.6#$ODZ.9RE,>_984C,D]/#X(==X_[-;+'F0/*-
M_N@-6%Z0).=)KBA.>6"&"@0<%T$8X2C.F&!IQ/4IO^M8\LW^/#]$T^I+>]AQ
MY)MKWK?HYMAMZ0^T=)V$/HB@G?I>#<CU4PY[%&_0[YOUP#1GAWCZN'C>HN4#
MI&:.A8\+?1KIMGC&,8XM-V9D^N=-2Z*N$VOW&,8DS5,S-H1+A0G+.,YYGN,T
M# LNLB1(8@5L2W&9&N3[[-:=HJ;]/_]'F ;_YS7:L8!J'H"Q[2'0@I2&5.28
MI6F,22X%+B3G..&Q#(J09T5@%6'P#)E+T+^FC";$RLX*>D( 9@0O"3]%[']<
M/E]Q_P%*\\;\QT4^B?=;/ )WE7S0-O2NOG1^E=OMLL[1:_*#ZJ9 YA#1=+"F
MFVW3.*A:Q%$@!<GTU<0,)R1!J$\_2<RQ2G*9\2PJ1&PU4LF1_M1:7Q-!954U
MSA54[1B#]V)SA7C<!S,Q<#!CL6<&[;GI\@]1RY#I*-DVIC<\W32%\(!IT2Y
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MJD"Z4Y\Z=UP8*U'N^$#489R-+90IB5E!*,,A#0I,PI!@1@C!N1**A(4D8:
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M<6MM,1:*S@JD8@#\U++RLYFAV'(#_M#L@):?&=AS%%2M^$ 13M,X49]:^?A
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MF,E8.Y!)1(EM]/DBE9%50D.WV@/MY 2W4Z1^C*Y'F(-([K;KO81V"A9?%6I
M5/CRVI.%?Z^*UXWS7K_8O5=&E=9S)]>J:2?JT"7CS*TC[[&*HCFL4*OU8^7/
M-Z1GUQI&6,G=O\4"B.RVN?RE=6J/T2.35V.,<^M-UA*C1YAN,XR^R]S+7C[H
MYZ.7TX^R%&8,@/Z&?BNE>O^GY#MS*O-9*;U7U\U1(2\HB5"L[6'$,$0R2R$6
M&8(YIGG!I21ICFT+89PHC[PY:U[ GIG:&C3L@#T_H&'(OH3$#=O^'3PJ8HZ!
M2P>P/&KYW%"S+\49#3V_XIP@KYQ3G8X7 #V5.V[K35;+XR5FM[K';P&_,,0G
MN34^B[:.OFMBXLWS;QLI;I=UU]9R^7##-<4Z#;D]]\@+5JA$:UY.C X640PQ
M+1*HG9 D)GDLA"S<#JO<F1C]>*KRQ-5B]<>F[D14MKP NF?FW]P"%AY0VT4O
MQH7/33>;W@P5=BTW9H+43X8A#>'/8,\3.# URCF2/R:! AP>#$P:[? 'Z#3T
M,6 E=W/1E.QL;A[64G82R"0G1!9(&CW$(4JR'!*2%9"E,5&Y$J1(4UNK\!R!
ML4]R#$FPIVEOJ9P%X[H9-U1$-XUP(IV'07963'N[:ZBX?N:5L]A.IE2?3#T6
MT]G;)C.,^ICNVC^]UWF.F=#/II-2'N$D+TC$H4(FWP8S,W W05#0G!&LBB(M
MD,NQRO'R8P=+];^&)-J?8&%G8_A+Z!@4M1?.?=##61E"370X7GS:T0UG!7LQ
MH^'\50-&6NOO^_L_S5PQ.1>%$"1#$4Q$H7=4$:>F0PF&/,$YPPD56;J?T'+O
M.,GZ0,;JO3MN2GKOD[U:$P6RINHQR;J#C':5<HD8ATF!%422)Q"CA,.LR&B6
M%#R+:.P\W-L1DB&9O"&QL-,U R1T4S9[X=Y?$<YO//=+$4*.X^ZL/OWX[9>B
MG1VW?>8RWVR)IW)+%]5BHMSN],JW=8V>>+/;?EIM_TMN37+./$6(J(1I/21Q
M"A%!!&*.!>1<9E$11UD>674O=24\\C:LSRPV@'*^WFE?6JW6X*D[/$J5?YH,
MV2H7SS6/PA):N\T[!F!NN[KA '19 "T/@.VV0',!GN6V2N<*F4;A)GFP3 I+
MLA,G4[B!\3*?PO'^D..A+295?]H9K^2S.AVF.B^*@M-"IC MXEB[%K%60&E*
M(4MQDG&&(X2P6W0T.(^C!T^_R(U<?]>;;5EQ8/13U3MY W9F8 '8?I-F0YJ6
M[M\EJ$S^G\IE<\W/(>9'#WF"=GKN59^*8P3&4((5(Z#++.AP:\*TW>L:CD'%
M\@Q\VC_(FFUPX'OLX=,!(!UU]/00_GZ P=,!X+4;.QV"D'N\^&:QJ)OO[#;;
MU:,VO)KP881()A''4)AL I01I#5T(:'D"J>"*9$F5A&@'AICFX2+!5@9LMVI
M&=X#,_JPNAY1#H" FTHSPM<I/GN2'H'E2P+;QY8#".X77O8"P"G$?$6TGBCS
MI3LG"S1?8;T;:[YVJ:=9:;J1F^;B>L'WU80(;;'*_;$NSE6,LUAHR[#(H?98
MD<GJ)Y!D/.4HHSD23EG]_>3&/KWJ$/^_H"9O/"QI<Z[K@YZE?18,$T=C:P@<
M[B:3E92A[)]^8M,:,U:"O[!,[.YRSP2^7U/S_=4V3M65P#()^/BND?=I0ZQK
M]%LFL)P1L'\/#I/-;;^=$2M8?X7+<G@E]YXL-5E>[WD1NBF]%ZX8VE5RM=F\
MI>OULUJMJ_E(50'=G&5F4C55,"EX 5'$%*0RPC!&22&C)$]49)7#:TEOY&W5
M*1K5Y,$1_:9 U/'S=PT_N^]?0%3<-N0@0 9T/NP5,WC?P_/47JGK8:_HEWL>
M]M_F.9W;C-IYO]F6C]H)W<Q9D9&<\03R5'*(N"*0,95!:AJ%IP7CA!1.<[:/
MEA]Y:VMB)N*U)^<X"/L8";M=ZR^?VR8]%6V:0M/STH6:(GV\^+3SH,\*]F*R
M\_FK/)MBK)8/IN^N:8!XKY=HLGFD0(IQ6L LS6.SX6)(<%S *%8(%XJ1##DU
M%CU/9N2-=V@J;,C.@"'LF>QT 2:[W3A<>+==6<E][RJW>VN)7K%"=8\X3V3:
M!A&]@K[H =%_M=\VW0\<,#/JZ$)VVKJW\0R.F*0\3F N1 H1,F.>6$1AG$4%
M+3CG@CE](Z^3''G[7IFZL*FF+AC.O"-$%JC:[?"P6+GM=HOA%*/$C.QE#J0*
M+ A.JA;L 3A5$0YWNJD+(<OY>W-@\_RA7,CZ'&PN<T(S)0JH1$(@TIXQ))(2
M*#!'!.,\P\(J<_#<XB.K@)H<,/2:LV.[#7X6A_ZM/%0ZMTWK()CUQNR3H"?0
MI&^K=Y_^X;#ISBXVR?;J$Z/=2+W7A.BQ_]N2/IJI'?\KQ;MR4PU;GQ,9H8*F
M"@ISR()HCB%-!()I*K$VB&/!^8!F^V<H3O%]+3N-YW<'%H!H>!C2?/\<B';?
MTZ#0>'Q.N^WX.]3!NVNH#.S*WR/I*.WYS]%[Q3[]/>+W-^SONW&$9I'MP.AW
M.WEC1GC]EZ3K#^5W.=>.<:%(CF"193E$A"%(\@C# A6\$)RR*.?!VD5>XF+L
M Z!O<BVKR64!NT!>1-32PQX;)T<'W+$39#T'SO %#&,3=7^\ALL4_1\O\O#C
M=("\!I-3#\BKBWDFBC1-7)N<MQ=)<U^DUI0EWTI1'5W_MBRWFRI5KBFJ/NV^
M2EF!6<HCJ&*"(4I1 0F1.:0B*M)$(IZXQ1("\S=V*DJG)>Z!,U"Q!@QO;=>!
M9\>$E,!/R4XWOB+V;EKS;-[PX3A^=OY9S/8/8]0^NB.A&"JE)C!WT^;@C /M
MBZ2=D<AX'G NUY*O'I;&9+VG?[Z12ZDTP7>2K\T'8Z.YV2W,]^.#QNMN7:[6
M]409?>W=:E,:AC=S3'E&J4AARC,$4129D"_G4& 5150A&B'L42T;@C<K-1&@
MQ+9A"?PD6NY^!FNYJ%*7M8GU9+@#S\:RVM(_P5/+GN,9;(B'9:>M)\/>[[RW
MPYV96PQ:_LR,Y)I#L.>P[GA4\=@.MS*WW%U]!NX'P@%!"W6,'(*E:0^? X+X
MXL@ZY-KN(?&;G2CU&_2A7#_>BGF>QBBCD8)QG*0084$@SK2M&T=QC/,<,Z68
M;3S\:.61S=*&%C#$P.T[^TCXL?C7P^#>0KDI$UMYG +@9WGWBGX?KS19Z/NL
M -VX]_D+/(^5ZZA99?]\5K?+K7X^I;9RZF$L<YD(QD7*89;( B)41) @_5-$
M1"%YBA(61VY%J/T$7=XUKXK2+GF3N%3N&?"J>;\"'Y9)@7*L8)%%&429(I#P
M0MMHD@F$9:$2Z32(+QQX?JT#)H3.SE@*!XBCYCK!XD"Y&785\)3=2L10)^S]
MQ*8]7;<2_,7)NMU=OJ?J7[_)Q<(XC73Y/$\*EI*T*"#/(W.N3@3$<4XAYBRG
M7/)(9<+M7+V[_#0GZQ5%T)!T/5L_0N.Z63%,1K<=ZB2>QPG[.2D&G+$?+3?Q
M*?LY45Z>LY^]RL_H>+/;E$NYV=SP?^S*VKBO?ES+?5\]*EBDXAQ*H4QA(TXA
MIDD.!6$Y3F*,,7,Z1KM*<>3-UM(''09FH&7!,R7U.HQV']&@X+CMTJ&X.']-
MK64-]$&]3F_2;ZJU^*>?5?L;W6L>3=RUF:7[3IK$V7)9?;[?Z5_:5D#VK3'R
MWNZ0!D>T@2%N7QG9"T/_3@Z)@-L&]A3>J7+21C*O.LK>A2>KJK01KUMC:75]
MT#.)?9#]*$KWUC316F[/!+I5Q#*J8@[S0E#]]8YR2"B.89$D-,WC'*/,J5-E
M&+9&5@.'DXC.Z0.OF1GK_,'UP0PZ@1@1[F!G$"V/IV<0#9>O<PKA"=RXYQ"N
M3/T()Q&>0%J>1?BN[MOWN*;6GH#<+JOV,8>LH<.LY;E^IGEF"GL83F.(B!*0
M%(1 BE+!.4FB'%F=5WC0'EEIUIV'%KYSI5U M--](T'CIN#V6NRGEHV?0;EL
MVC1U4@HM8/-H..P,0+!FQ/:4)VY4[ S)RR;&[DMX.%*[A8RU[16;_AMB]:2-
MD \+^F#M0YV_?6SWR>39&;(P/NJ]TG#@X#]=D-["=1HNN*/7U"\S^-V0#]1W
MYHIP?H[3A36G\YGZA3IREZY<.CC?UN2*O7E^NZ";S2$S,Y((B]PTZZ=%!I&D
M4G^R<P59I!VAE-*"%L*Q>V\_Q=%/3O<YL2ME9OTI677!KM,P#QTVM0F^V9C&
MXC=+ 3[OMMI579J.0-YYLF?1M?N6!T3,;7MWH:H!8L^@(CY5AFJ?O.$S3L]2
M>ZT,TC[1>S)">V_SG36P^78RQ_V08MK,>3_^1>?*><+S5"A*(4<9,Y5$$K)$
M(AC)6%O]*8ZE2N=/E5OR=4O76SLM,H@GEQUSRIGUYJF&_ID1HMS\( _49X#)
MAW*Y-*:OWE@U =<1!4.>2"0QD3(U\RIY A'F#&*B_P])05 F1:94TCR1]TOQ
M0SZ/EJ\03T/JW[[*<[#3_I,AZ_9M,(1F]63+]UTT.Z4-]24&])-?=N\(.6XB
M %#!9E ,X67BP10!8'LYK2+$HIZI@+PJF]W<T6=CHVA*-_60F(YSVD3#]-\^
MK99-<'N>4HDECQDD@J00L332/V48)BQ" DF,&'$:E>/+R-CY;PU;X*GFJ]JA
M[1R=9JJ5:PZ<+^1V*G *(-VTWQ[#NPZ&#5/CQ+.&8A JL<Z7C6E3[@:"]2(9
M;^AZGH;WZO%QM:Q,^GH"1.V3SG$4TSQE!=1/AT*4Q032J(A@1B*4H@2Q(G<Z
ME[Q 9V0]5%,%&T-VUL[#*6NOVWOZS27(+&VMX4 X6E$U!E]K#&J:;>@AH&74
M+U8HF^<"E6FMF7Y17]@I5RZ?>(A6W8+]T UD4T77[[_1Y>>GZK#N;]IF,K/$
MZV.\>8+C+$EX 7F!(Y->6$#"(P:ES),"DSP1*O<HFYR*?ZM]-;BTLJ;Y"@.U
M7)^F933P1WHXKS5^JQDCT1&F.57<:G% (\\,-(]>/_F[?N]^NM%<GD_AM2=V
MN;+]SS'(R_-A!)OOY4O??>S7VV^&E]OEW^AB)TT]R7>]<D7R=GFSGY'5ED"H
MB">4T02RJ(K9YBED@F-8\"3E7+O"-,_M3GV<:8]^_O,KU>K@I\5JL_D9:)U3
M[KDQ:N)T7)AE)8D[PC@JF(P5@1A1"9'I>D!(EFB$)4^+C"E5Q.V7^S40/O[J
MNB'\DX'X9V @-@C+6E>_$M#]']517T]'5Z!BPV!3,5)7X^U9,;\_,.-6Y^0.
MFOV\M]' \YL"=_]-@J7<@G65^E9-A3:S5>O8OH'4_(OOD5:T7(/O+=SF;U?>
MTE_ _;=R<W35!CQ*NMF90V2Z/5I1WZ\9,:$ <]3#Z*;<_!)F%)T7ZCT#ZMS6
MFVQLG9>8W6%V?@OXSQ^X;[JES[&B*#:9XR(AVC'3?AC$)JB<I"(F1131@F3S
M[6I+%W8>67=QI[#,GH3U%OJDMP\W4U"J\9F/[JU3CX"P\VE\Q7/3L,?3!,*.
M#SCE/N#0@/W2DX\*.!7JW(" %]>XVZ9_Y>],]8?XV^UR];U<W6E3^9%RN=N6
MG"Y,.O/-4OS'?VA#[^G;?Y:/S4A2'LN$9"*!/!;:1!5F>*2@.22QRA#*F4B0
M];Q:'P9&#HZV+('OOX":*W#"5E4D\$MU\/ ?OX":.Z#9L[<)O'"_;D^-C:;;
MIO<'TF-^KA>B]L;6V,CZV5PCO*I.QM 05'IL(J]E)S.-A@C=M9 &K>-Y/E]U
ML/B@#>7*+#-MKK6KJ WH.2[2),+(Y(8A;+H II#%*(>Y4+% N<0(2Q>KZ2*E
MD4VH>W-+TTSF@G?@>+Y^$3++ _000#B>D%<D9\ 0;3S: ]F Q^+7) MU[GV1
MSK0'V]?$?7%R??4&SR,NNL\V?;M:;DI1%8"8WJ-<EM^E^+R\7]/EAO+JHX8E
MP2PO*.11D4+$<0)IQC&4F&E_*):(XMRI"[,+]=&/L3L,&'^_XL#QB,D)3<MS
MHK$P<CSLH9W\\1DX1JOEQ<1*.MP$/*;Q 2'468L3[6D/3'Q@>7'JX;6([TP;
M52Y-I&:Y79=L9U:\TZ_9^\>GQ>I9KO]*M_Q;N7PX^KO4+^1R^UE5?YPCA%F:
MRQCFE"*(,I%!G,8Y5)AF21'%A<A2MYDW SD:62VUC(#'AA/ .ZS,3$C4,.,Z
M%6?H8[#379."ZZ;/&M9 ES8PS,W 'O*6OZ.+9J!AT6C#ZHJ0LW<"X15L-L]0
M?B:>W1,(OI>S?4(M[*<V&T+RJUQ_+[D\?T[]:56%Q:6XJ8=>&^>E^_>WJ\WV
MTVK[7W+[9=]NH#Z/_K!:-[\RU\5S*C*2DJR "J411"Q3D!*<PA0KD:,<89H[
M#;*?EOUI%+($FUJ:.AD)LBJ]A7<8GH%E*Q*@E4QFQH[Q*+M7Z7]LMOI*TY/%
MG'>UHLW:PRYS]K4^B.>FZ"=^<>R^"C_NZ^!H$E\;#[*7H4UW,DSKW];/^DOG
M6=\=GO47BV?M_&%Y'<@#?84F9G[23];K/)C3[]LK<>%^Q'2WV#TR_3?YL53R
M*R^E!ME$-YL0?$0RG!<%@@41!42\8)#0@D"&(X8*GN11:M7![SJID3\R>^+
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MO#-UE!/,$2L8C!,20Y1A :G "G*:"9ICE*38*:?K(J61%6&'+MC(9;E:FX9
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M.'6+M16WIS?LU24FZP1K*TRW[ZOU/4$#"%6VX?G\;ZU=248XCV&2(^,%:.W
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ME"!50^O,/&B6$08QH5I#I!F#1*8IC%3&<JTF:)XY:8CNXB.K 4,*5'5S/A,
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M$3@*'D@UV%*=5%DX0G&J/EQO]RK-O5V*\GLI=G3A7I+[XMZQO^:+!>C0=*K
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MV/>P>.KTL!@V)-T)7)Y*(64*I4"IUN**0X)->X TQ3CF0N8BFV]-D\M7A?;
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M>9%2R+L](+K7R>N5\I167J^6=]<5(3A'5#_^<X^L65SH"F%0Q'@=.!.1I.'
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MI(+.!1ZE,BU,QOVK[X:-[G.0#43;!41>S^G32!S3K_AK6(=SMB;*AD@Q48#
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MXTQF.5JCLK&TKUJ??$^0U$W(-AS.6BJE"Y1=HW^"D7M,LI9A<A(,KT,&@].
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M6,CTB\-JV^@,"]DY%WCKC,@#I!Q?3T['\!E>]1G6@8F0;(!,6XOBS\S!.U6
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M8W%UP5DF9B^^?EO.V5Z1#MZ6C^%;+3FJ,YU([*M)<BQ[9QE$KFMK&*LA"L_
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MLYJ_-4R"$3:'8!"=:NTB/DK0N"6"@QJD=HKH %77)I:_NR#A>E- QDI1Q@I
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MV7O3[;9R9%WP5?H%XE[,PUK]QV.VZSAM+SLSS^I?6A@"-L^12!^2<J7OTW>
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M$L]&HFM][S*<NF-Z+-P_$C?65P=(O%O^^?;'A\GMZ_H+KGSR,KH(.;A5<G^
M(!4'(1F=*5+9P%L[@<,HZV5$[[X1N <]=8"^I_?5[4OV3S7?G_3ZX;PZP1_+
M^L^+$U=2055\[3ZL2:YU8KNI;TED]IWFJ$,Y[&$]D/!>QGZ.:SWWH>7NH5T3
MG";3\]GYXF'VN?B=?N/;XN/\_6SZ%>?WQ6$$=R4G#?0-B<,R#4[6V;W19:LD
M%VG8Z.IFH-^9I5Y&[HR['0Z+C XVROU3[./TQHO(B3$88ZD-/T56Q$XL$))1
M4"PY]HXG3*IUEM(S)(W;Y/IP0&VIF5T?N_]HAK=K#C[^>XKY93@-TX1?OI'P
M:X:59%F6"$1B(;[JU1KG!I(B#THK88TKC<'V%#WC-JD^'-*:Z>3X'[9O=)A:
M+'#U>S=:SU[^9@[+JW]Y-@V?JSKFD^G759K@P9MT[4CG>"V\6@KX\ V^O%=%
MJ_JH$,@75I$V1Y UF2X$YZ-B08?63X*':_!UXT7ORAH@+G^;S\Z_USD*%S,-
MHXY96 _&UKX7D=7B6RV Y1AB5+E8V3H980A=1]/B:Q,$/?$HWT9!';BB-WBZ
M83'>SO%_SG&:?J[>D&7$8"(S4%(BF5E1P!L5P2J*/[WTPN@]YH \1E8GSZ+-
ML/ XV)HHIB>L/<30Y0-R=,))66JJOR"1<9[!!\\HL&.>2Q.\CH=(^KA#5C=8
M:P.% 7D>N^BE4Z@MKER:RZ0"C+)8I3B@J;4E]"U$GBWP&#)G:$70K</L(71U
M K968!B25+2+9GI VR-]]4QT66A1YT]*8N,B-1DIJE,Q*%V"$;ZG1IE[>[7<
M_V'90 %=5-LT;=232*)<<0O.R%1KC<CK12;HBR_(,PG<MCY+?_U>F1M!:I^]
M,C?1[JC8?KB!HRZF"%TL:&,Y;7=G*"2S$E (+YQ-+)GG[FY^]6Z9&VGXR6Z9
MFPB["SMXW7CQ7M/%&(LM!A-HP0WY!C*"]](!(U<A9A:U;IX6_C@UOU"?S&W0
MUEA=';AR3[5<-);9I#1MFSHS5V4FR?1[ =Q%\GB-*YFUOGO[9_3(W 5ZK136
M ?8:-4=4T:)F@D&1G(R]39($27(5*$QD3$5U=P#R_]\CLR=$CP"##L _L)XI
M&<:1Z0#,AP#*UYF3+""@U"JXHG-J/N&D83WBWLSQ(:^C6ZFG)] -*FX26>DD
M-0/MO"+FZ$M Q6E;"5&\32:%O6'OERE(W @A.Q4D;J*NGK#X0/E;C(D9YPT$
MRQ"4(X/N3$G@M7?(A9+&[0UYQUV0N!$(-BA(W$0C7434#S$CUGYRUMQ))2!S
MST#)8B!J9B'ZZ)G7BLF[(T7W B_10TP]+KRVT4BW\))K9EBRC-6):MP2,[7Q
M58PYD=U'Y7,6KF#K#,,GR.G$41L%7MMHI"]X/>3=7L5A7TB/%_-,P_<[HU2E
M-$(9%<#EVC[:Y5"K*"1$:6)6A3N^OV826](\;CA\P(CB "KMP;][X+;@ZN\N
M\C(?DL1UZEJT.5H>).@L>)T&S" X9X$YY8M$A?0+^W]-WHCF3CS%@R#L^2?I
M_:F["QL]N&V;+5H+S3V$Y#0=0;& L\G7%/?B;$XN->]WT;2OWB'?G/>(F6V[
M[FVBOBZ ^5 A\8ETT2I)VSIRQ>H[/@=OBP+-,17I.4NI-0@?HF/D8&=,P.VL
ME@X.]0L971TTKR>+=#JK?OV),9G7!JBT+7*D72(%^)HH)Y.P+/.H,;4>Z?$H
M,2.'/*-:M28*:M99O&F-57WZK,VE;PAOY;=<E_M\FN/W,,EAFC\NO^'\U?F\
M*NQ")MO73+59MT$-U!X$L&--4TV_>8RJ*SSG' W&X@%UK>Z3R"B@YQQ$X2)(
M(:*XF^/^8.K3<^OL?&PNEI.S6HA*^_9\7M?XC*F^/*Y:[Y(MUEXE2"X&XJ%V
M?99DL6.R)D0EHP^MKPR?HF<<OZVYMN\=D:U4,/(@HLMM^'N8GI<ZXZ:F>K_Y
M^SM.%[BXW),GR7*3I*MN9:)@R^MJF;T'$YG3PKOL2QFP*P8L-8[/M3>P[$/
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M]!U1?M%&*+G[^KDOE761=?2$^(C1*[ZDM@E5T*!MG7G!:Y-N54B P5M$HYG
M ]Z@WZ!L7!#N#QO#+R:W55,7\%L+Z:(/B66I2.,5)&XXN1B&HEY!L6YBW#B;
M2D+3^AK\%@'=WCQNK>-'<B4W%W<'9^<CB9[!)QDS,1!,[2AH=:V0"!)0\IR<
M-3&8UHEI.^3;CG%)V1H].RB@GR8K5_E*T>50W]5!%EDOV$R 0.@'7^J\;*%5
M2*V?/C;*'QOC)K(U8C82<@>FYMTT8WE</(^?\4)2A)-3[>&L!07?:,$%YR!;
MX81PCLG0N@9Z6UK'-5<'\YP.HLHN?*G']_.?"RSGI^\G!4]\5)S[7)\3A*,S
M'T6=KE" A2(TRPR58 =SY*_I&MN-/P1&!KOT6ZJK<Q N+IQ.S2QWM1M;R5&"
M8HF#3[E&YCQ1,)Z\C*T;/SY'T]B6L"OP;:&FWH%WHYW@S6J*D^R\3%C?4KVL
MO<B9(7_$:JBC%[+F5NO8NI)J<RK']1%[ V<+5>X:@QRVVH\9E-9&<I=Y;<UJ
M"LE1(H2D/99HZ(#HN=IO;\4OHP!S'TKK)R)^.AX\"8HI%RT"BX8$QS)"9(QV
MG(PNI%"D;1[:/$W1N&T!>[.,FZJH@RC[\<J(ZXUV0J0)GGB];V"LWBYI<&@R
M<.<#JH#6I];#S(;0-6ZGP%' UUQ=XYN^U4C2Q^MS+ESA(KE1L61@"7EEJ4#T
M,D#*.A0761!W.[<]/.;UF77&=O3V?!_37-0C]E1^AI>5*489$16"*9D"=VDS
MU*X3%$XA\['42>U\-] ,/0'WZ(*-"YE-Q=P,,$V+C5_-IA0&+RM;KS$N&S0I
M?>X3&Y3^;D1THPK>NM #!9,L1H6:G)QHZOAP25B(VE#XEX3)T2LA6.OGFX<I
MV;U!>UR^F])GG5^/E/',6>OH^"Q,VMH^W *Q:X#+:@[12U%:W]8^0,:XE[,-
M]'Z_1?MNHN[ =WX_FWZE3SNKK%P-%(U6.DZ1)^A:+:*XR! 3V47)D&65BI/-
M1](]1,?X>-E)N7>+M':5=(=H6;<5#.2.E^PAI4SN%F=5+#F3@(P4*IL25/.I
MJ@]2,BYB=M?P,Y#90MP=@.;.(7^9$$[1G,\)R7,+JU[+Q$XHT@ FYIE'+"*T
M/I(>)*0OR&RCX5EK<7> F=O&=[61M$]!2Z.(@[J1:EN+8.N^8M%D[C/MLM:'
MTGTJQGWB:WTD[2CE[G!RH]S1.1=M, RLK@&=YPXB*\2,<5DHGC.6UM=]C]'2
MDQNSN8Z?A,R6 A^Y#_0+\[\TNV$FO^!T,IM_F"UQ\?H<2:]J7=MJ0\HR,W":
M%5!):P@: \@@+#J6R(S>R3%X\/)EZ'H] 65;S<[V+.8.;,Z+_%_GB^6JR\);
MX@?__2*EV?ET.9E^_32?3>G;=-&#8;79E&)6TD8#.F1K?%E[*CHM067!,1#K
M/K:^5]B(P'&OBUN?:/O330? JP[BQ_(BS[Y7]5QNGDC.H+,^0%0UP09]->9"
MDG?' ]ERR65J[4<_1,?(15S[4_NLL0XZP-&U<+XLPS2'>5[\^3V'9;7)C)EU
MQ6ZP 7T,X.I#BE**S'XATUR,8L('[1)O#:Q!A(V+M-WU?W]&;6-E=("P+^=Q
M@?]S3O)\\Z/:]?5EB*%P,XKJ.R1=QU@:#E[)!#)FE!FML,VSD!XA9=PGK];'
M7@MY]PF;2Q\TA:!\C 4RYE!W&.V$;"QM!Z?1,!\M:]W!^5%B1NZSV$+5S\-G
M"[GW!Z!+XYEM$,H)"SFI",IIVEDI10HW@G)H,=\8=KD?\/1P<C52\M/0V4+B
M'<#FMCE^?V-*:G&9,P7>%DZ1KTG@C7!05!18?&*RM*Y6?X24<7,4]WOON)V\
MNX/-VY#PQ5GUY4X([U9$ST 65UO<& 5!!P?.2/+74"4O6K^'/49+3W=*6RKZ
M2?!L*?7NT/-N2I^,B^5G\OPI$%AB_H3S5'7U%4]4")8+%\$63^:4*810MQX+
M.HH8:L%"ZS;RPZGKZ4ED'PAKIID.,/=I/DN(>?&6Y/ANL3@/TT31;.67!*9"
MUHQ!X>1$TGY)=/YS"YZ.\( 1@_&MZ^D>IZ:G2\DVF&HD^0XP]!F_AY^KR[2/
MY<Y;\XFUBO%,.X$)3A(*BD.(Y!YXQ85,T17%7&,0/4%.3S%^&Q2UDGT',+HM
MGC^GX:(,#W/-T5N=YYR[$E22M!'JNY->M: , 4+(*LA $4IH;9&>):HG/WP?
MA]VN>N@.6#=/[S>E8*KIQ3<.<":<Y123 @\Z4>Q;)Z8P@:"Y(V<R.^>QM<7:
MB,!QZX,.ZUWMJI\NP'>Q[-O)M)[PKV:+B_H")[VUK&0PI39A=Q+!B4)[*$4I
M5=',^];#7!\A91"@['$!:G>9=P"=S[7F88KY39A/)].O-TO4B<-)FBQK=3IB
MHO "BR5/,9<ZS4%XD"(;5,JC:#X[\WFJ!@'*'1.@&FNBB[86+W)>#80/IY_"
M)+^;O@K?)\MP>J(#L]XE T)I!!4C0LPV@#7!))]D\J5Y[^*'21F$(W],.&HA
M\_%K6Q_)*SX1Z 4O7('019!;F"PX&00P2Y&&3SKFYAF6V\1WU^_BQP"9783<
MP1FV]N;>_/T=IPL\,9++@()"A^+H"+;!U^X_"ACWK@YQ-4FV'MARAX1A&#FJ
M"_!=A-P?1E8P#Y(YZWB$'(H"E>H+9,@!BBG9^(21R=;N\0-D#,/*45UE[RKL
M/@<KW[&2UU."[_R@6>WSLRNTKX7>C*G]UD8'KXR1]8$C!7)8A'00K1=@G2U9
M9RLRMD[;.EQMM)&E",<-9&UK*Q-54VB< S*;2G)?C&7[8.X8:J,WT?N0VNA-
M1-W!2?5 Z4Q)B9MX4<-)<9^PY(]Y*4!$5IA SG7>[W5AGW71&RGV^2*T3:3<
M'4YN5,X85^A 21FD]I(\L]JHVB4Z<UU(4;@LH]EO_E#'16@;Z7AH$=HF C^6
M(C3:1S;)' %UO2UPD9,1%@A61ZN0XC^+]AEOYA<H0MM(L]L4H6TBYNYLSG6P
M8#$[X9PA(^Q3;9#OP3&>P6%AS(M<AW%TE+)XT%+I=J?4=O+N#C8WDN>T9[S4
MYA0B7NPO34%A\G4W6"U<2CGOMUZZ]Y3%C10]-&5Q$ZGO<!.\W/FTNLW!G8CT
M\H^K5LJ5*X5)49@0(/ Z$M@G!TXF XQL*$DK8='/Q=^;KMF3L=D-,WN5=C^O
M"8\]VAIE2JIC882N@PI*">0@.@TZ.JZT\S'%UK,*=WDH/W@.XFYF:'>9C]KT
M?+TW)M>A1$KS\U7CVM4UYXG,F6/,@L[T6LKB/0<Z\$7M)V Y"YB9D0--SZ.+
M])E6N(NM:2//#MR;VD[IC\MV2B<F!4,'K(#D?.U;(>L;?0S@$Q,ID534L.G=
M&YB2F^OWF2JXB_W86KI]=DS]LIRE__XV.R5%+-[\S_ED^?/ZSOW3FLS5+VW_
MCK#Y&@U>$G9DK-%;PGTJ:M1]=;?,L_")[ ?XP"VH*/2JH0Q!4G&"9>3.M^Z+
M\C1%.]>>7@VZ7JWS\N>-,=;6%D0*."&Z6@\9-8-H30+IE66.7#3+6B=N/4'.
MR'6H[7!QKQBUD0HZ.,E6E48K[[^R<,G0ZN*4W+$B:Z]:C87,>'WI]T@L^>!]
MDC+*]G-*'R5F9"2U4O==&#61?0<@NDG_Y3TJU\74U&E@W'%0V<FZO1)8YS(Q
MX36RUJ6$]ZD8VP U4>_=S*W=9-T!6K[@?(*+5[<]A,O;<>&=8TAF>)50K;@I
M$#F3X+UCR3OALVU=B_,$.>/B9U=-W[4VC<3>19KQ3=E<!QU9&2=RL!!DS986
MC.(-QB)(=#QF$E=)K9.,'R1DW%O"?1U7N\N\ ^/S:G9V-INN>/AP7K%/#'TC
ML2X^A?E?X?0<7TSSQ^4WG%^GJ2RN?,:B@D"GZWR7Z&NRBJ,PU 800N3LHN/6
MM7YGWX7>?LS7EG"YE[1\(-UU8>)N&VIB\>/\HBW BM5/.%_Q?N*YXIR7VLHT
M!!)H)JO-@@9?"M.6HV&R=7P[C+*1T7<PK-PKP&^NM@[,YFVN+B3YXGSY;3:O
M);PGDD5&,LG :H62$K9 X'5NDK?2Z)B%P]:&\6F*QCV!.P'?3FKJ%'2UIP5Q
M$JV5=%R$.D.G)N?HVF25O&'AC7+16R="Z^>[QZD9]P6O*[!MH9Y.@?;Q?+FH
MC5(GTZ\GP3EOT0@PJ,EKEI%"]50B(,_H+05DY#P? &TW2!KW;; KR&VKJ#Y+
M3AZXM=Y]PMZ #]W+<]!!YNP]<\\O8A&.&0G,U:;_->QULC;A=J:0'5+6Z]87
MD>.]_Y1$O!;+0:1"+.K*K"X%6(P1I<PIYM9/T<?Z_K,)+C9Y_]E$!1T<?8]?
M4ILLR%*G J64!*HXA.BS@DSQ2;T4- Q;UTH>X?O/1NH>_/ZSB>P[ -$#-]41
MM58\U0"##GB5$YWR/@NP6DO-HD54K0N8CN?]9R/U/O_^LXFL.T#+4P\1R9M<
M%'F#QM6!=*@%T$8RD,E-S()K(67K]/!C>O_92-,;O/]L(O8.$'0C_KAD0"F3
MC;$&K%-U;D7PX"SW8$(20=CL)&O^\G.7B)'OG-JB93<1=X"1VC!^DB=A_O-+
MN#JZ5]872S*$9PZA6$9@=P9J]PIBQ&<;G;0^-G>2'R.FWY?"G1R;)K+O 437
MY-<:P8_ECWF8+BA\( 6MAQK$PJ.AP]NQ;$&Q1!P%SZ!(1>%%,,K<+9O<'4W/
M4C7^!(@&ZK\+JK:Z&+LLE[3**TN+%U_GN'(3UQ-T;?%.1@3%E095VR+X&#FD
M'"39<,YLO'-A\7 =[F,+C(R-QEJ<M1;IR+CX<TKR__=\LESB]--Y/)VDCX6(
MF$R_7O)22"I(-$..7M$Q+ LX5QLQVR31^A2E4@/@\=PZ(Q],^T-)4P'W<$2M
MH\R+.R[RV[[/IK@>06@S:A3$1\F(E04&7@A.5I<8X5C3R%J'X4\2-.Y3V=XO
M<G;600> NL/#>CBO*)EE<O>CH.!0&4'?:18@Z\*YKB/?FQ<Y/4A()U<ZNRMZ
MUEKJ'4#G?M#HH@XR2TG:K75]A;:6LRY"MH4S&3 YT;YYYS9Q^=X@TT"QSX;F
MFTBY YA\.@W3>JQ?A 3HK(E60;"E=OTGMRRP&B$PQ:RPVJ;2VK#<7'_<A_1]
M'4A;2[@C=*S]/%LT]T0])X& \D*1/<5:2,JTIW#286Z>Z7.+@G'-Q_::? 02
M6XAU_%"9FW?3.JFASFP@/M;CD)7.P3H+4J0(2B 9469TK8O(,D01)-XY7!Z+
ME!_\_#X4OXV^9HV%-SX A'@WS><7P]5O,%$H=F<NU#%$R,CCX@@A95UG11:?
MO,B*#[TK>7"!<:/@=A!H(+[Q,<#L0SA&3K$ZYQ8P: K7&4OD4]5Q5"EXXV1P
M6/0P"#SX^>,&K.T0L+OPQ@> D _QH.E0=-HY8*(VU L&P=<F,Q*99YJL6U)E
MH UXZ//'=1 ;FH"=A=>!;_CBWV&>KT:1!UFRBQ1$98^E'F$.//<"@M-,Q6R,
M1-78-;Q%P+B=5_85.VPOXPX LDH)?AD6F&O$C=/%I3KF8?IU=?HM7OZ\_IU/
M%T,.5QQ?LSW-=W:=M3:7$#78DLCMEC(">4<.L$2M.!V;RK3&V3[X&->?W0%6
M=V];Q]9Q!SC_C(OE?)*6EVD\?TXGR\7G+W]>6G4C$D>7+10CR+?7C'Q[- 84
MMPQ+8BPV'W/Q)$$C7]J.CI=[<[]:*:^+0E7R*V9G>'4U_K[^"U7 =9^S8(1A
MSD-)6"O.DH3HZ[.:R5(%JZ-J/EOU"7+&'7*YKP.[E?P[,&N/L++N?N$YEY$I
MT((B596%A2!X!I3%)-1!J=RZU/E)@L8U:\W4/@Q.6^B@ T"1J44BX!L9\-?X
M T]GWU>O=Q=3BJYB(*M-HJA7^FIFLRAU]ID'II#KS&W W+IX>0!978)K&Q#<
M/_R::J0#D/V&4YR'4^+H13Z;3">UPJC&V;>9<L$)56_KC;=8DY 2D*#J."SC
M2F$^&M;Z(6,08>/><>X/:.VU,B+4%O/ER1^3974>WDWSY,<DGQ-K*U,?HY8Y
M&)"14R1E6(#(:,-D'IVGW8(^#:I-IA5N0(K^= VG1Q<?=\9S:W^JC8Q[ \E_
M3I;?/N/I2BN+;Y/O?\S>3)>3Y<_+'<:$"V@2H;YH!BH&!MY$"\1CXD$X-'I0
ME\=-X?,T6>,<?HT \!2<&FICY/OXM[/Y&<X_D6HFN<;+T_SJVP3+F[\QG5<S
M^[&42<+Y^J7)).:%4Q"S2* \>:5>DBC1$$N!^>SMG</OP4OZC1;M"$0MU3X[
MA YZ\*KF8;K$E6MP?I%?I[+4L7A.N[#."C2>HAJG.02K9)&H97&MB[SN$3'N
M%/I]72'L)NO>P+)V'J.(*;$$*=:\!D=^8\BK(9/9>QY"],VGXCU QKAQW(Z*
M?0HF6TBY Z#<O^B]O@?^,)OBV??3V4]<1P>VA%BXLN %A0A*&X3::16\%EEH
MGA,SS8N[-B&P(W!M X=''W9:ZV9DI_S]9#GYNE++*^)NM0V=2R$Y69/#5R5)
MV5:/4H$IW@:*;IW(@Y#UC-]]?^5!D/''<H UD&Y7V*B/3>L7IBP#AL1 5\]0
MH:EU2%E IOV5!,NFZ$&OSALAY'K]\;SG7?7Y*#2V%.[(@=;OZ37.SR;YKW>K
M?EN?R$B>A83DX*=PNG@W3>3V_^M?LP5^__8?D[.KA@[,2BW))%I?T_MBAD@G
M/*3B>!%>&6GO/)4\&&]MLW8OP-E6V[,#BKX#A^CA-LW12<9J0Q#M:V)@X9'.
M55U *5NX#B9YW]KQV;Z3.F?'<ERU$_K(1NG&K,C'VX#^^9UVXNH7%Y.;WWV:
M3])U)V1N=39)6# ^V3IGF;AV48(/*%7&''EF TQ5.XKZZ?JS)31FH^NI![NV
M.><G)B=-47 !7ZPCV48!GEL&(F8N= CH7&AM]38GLY\^0[OA\U":&ME47K!R
MNRU%^'MR=GYVW9G[<L2NL-F0C\! 2B%K4WB*9J5B%$MS2=%SPA2'F,+A*X[<
MN;JIJ=N3G,=&SW4GC!5OG^:SA)A);"^F/V]4 I.9KMG]X2N>,*\M9F(';:2]
M$;$.VXCDF 1C0THV<&6'H&CCE4=N2MT63?N5^]BH6O-UM55>?*7OZN3DBX;>
MLW*KGWM-AG"Q>+ ^>5"6MH[WC&(:*8S3EB+PNRW3GC9,PY8=M[YB3]9I#Q+O
M#DS_B9.OW^KD>#JN:6?<]B.)*9-1)N),:U")(N6@'9(MUDP29))D82LL/;7J
MN)F_^X92,WEWAZ2K3;*VOV])N'6+U,'REQ(]2<KJ@C:!L 5!,>\A^E @^)(D
M'?$DSB$ML;9;?=P<J(,9J5;R[P5AUT[B9ZQWA)/IU_MNHE."!<4A\$1B%")#
M-"J!1*0XP]M:)+N=._[HFN.F%^S=(6\CZY$Q='W-_ 67R].+?;+B8E4OA/F/
MV6KXR:<P7UX4%BU.N,FET($.R(H@R7$&(153+T^TD28&(=P *&VQ]+CO?6T1
MM6_)=W%M=15:W/('DT(2CG5@E ^@<N%U;J("74O-+--BKPVN-_;*]W<EOX_[
MI]U%W@%RGBUS?*S*\?8(IQOCXFR4A<GL@0NE:KLA!RZJ#$;4?V*-:YLWRF[-
MQ#"T'L%M?A]J[J+@M)4(?H3):7W*>SN;KU*93I1#C3DP<-F3(QOIU(@L*BAH
M9%1T@-AP\$+_+7D9AOLC>B7H0NFCPK]Z0+>9^5C^P@7%_7<*RF],Q%MU.ZZE
MZR=1)"TP2A A90K2ZLP9@Q:LT(A2N^S\D"!Y:P*& ?)(WAH.HX8NC.T-[VCE
M6]\?NLASX(6V"?" =7A,D!!*3<YBA0(W5YS@S7-%GB-J&-J.X"UB/VKH EE;
M6_2+EKKOIK3;SE?].U82^>-;F'[\OJJP^5 ?BNN.O-BG)XP%%^O+3 HU%=DA
MA7^)"TC.YR@QYFR[.=<W96X8TH_@E:1O6!QS@+?Z4H\H,A.?<#Z997Z2HR>O
MGS14<@D7H\"CI@C7%&YUE-+:P_>TVH#^8:@_@@>=T94[NDN[->>7V1VO9M/5
M1-?S</H'SL].G$"&/-<FEL6 LEZ"IP@7>$2+C#/%]: DFK9D#0/LL;P3C:BR
M+ER7%Z>KWR%'_T%)7+:8.!&YZ"!+ JMS'9D7#016'%#$Z;QC1L72^M)V&&7#
MT'@$[TQ[5,C8+Y6[N4%W?9_K/*6+IY/\KA9)?#NQV858,$&0HE8K: O1Y4BA
M@_(8%+?9#"G,/PRUPV![)(]9'2JX R?WS661YQ><_Y@D?%A(5X[\2AZ+/V;+
M<'KSYZ]FB^6'V?+_Q>5G3+.OT]4U=XY6N*P<1%L'AA5I:Z>?:@6T]:0UUKY;
M\-Z8&98"?D1O<'VH_5?&_T5L\'8VO_RK^GO\)*K ;5$%K*@3 '*=IV>C!4W2
M2=$:*4WK^7"'Y7#83CFB][^. =+!]MGZ4+T\16]<J%Y>$FF1?#%<0T[U6I4.
M3?"&*V!.%C(@27'?NNEH<R:&;8)_PF-@$S4?[Y7)??:O$CS?44@^F2XFZ:]P
M>HXGO!8J)\\@"H6U>T<$5[P Q9T33@B+>E"6]MXI'8;M(WE7[$RQO1CT^+Q$
MXB,2>?,WQ46317WQORT(.MJJ8VBUI^B_UA"F9" (%NA\2Z&8I"4+>VGNLQ=N
MAFV#(WKP[$3QQWH+="&%&T*X4R-RE8E]]RY6%%VDDR2<&,DJ)*S/R(Q#B<+Z
M)+U085"IUZ$)'[8!CN =M'^U'_.Q\.PC\2/GYE5$=9)L,$Q2'&1Q=:$@#$04
M])V1P@1A>>%[R8H=A=MAN^K8WEG[!\X_<8M=)-&=2!9M1A. YWIA7<?=^AP$
MD/0LMX&7<IVV>JS[ZZ\--M<1O D?$V1Z<.B>$E%\SJW]CC7#=#FKO-^_QS N
M"W3,@#&,T3EN$7QRNKZG^Z(X)NGB4/=M?V0.0_X1O#_WIM*C1?>=_?ZL3-"9
M'%2H8XUHQ]<+:N^*A:Q9,%YD(=*0J;^'HG<8WH_IX;HW)??B,&TU9_!:'I/Y
MQ8R =].+YY@[X=ME8'?1X>%$DC.9O5T%:0Y44!:"2PQ"5#KQ8H5U@T:_M'R:
M:,SCL 951_30W35(CF$3;2Z>$Y&"E#Y0X"6Y >4I! N<!Y#&(]=1A-1\$, >
MV!BV%8[H)7ML5?\":%]5,#YF!U8_?$TQT]LPF5\\_DCAO>&1@2XN@<H8P"5O
M06>KF)?:^]C;8_:&+ [;)?^@I^Y]0N28=]"S5PZ;"BXS'6-D#JRW=4:8L."D
MK5\"MSEQ$6SK9.]NF!^VZX[@$;X[R6X$JRYJ(VYV"KNH5[WU((OY! 4JP>O1
MK)RI*9D"8J S6S G$_&316C=9OE9HH8A^(C>S]NJX9@M_1W&K_;>*BOR3G8,
MNN1,RN0P:MIC*C#::$(62%FIHBU]D?V%"L_S-0S=1_ XWBT8FFV0__M_W],1
MB>R_5S]:_:3^6Y^Q_%_U___\_.[6YT]6<TK^5YJ=77SX2N+?9J>DW\7%R;2>
M:#$K-XW"C;NWU[@,D]/%;;X6D[/OI\^E?>RPV/^^9N\NXY=KWL/COEC%OY<X
MS70@[&BM[I'S8;;$%W&QRKHX"3YHPS("8XF!TMQ#P"B A80&-6T,U[S\^DF*
M=K;.UY-2'MR:=[M.K3JBW-!+;8ZR>/GSUMW5Y[J9U\-6@C72:&#6("@G$$+*
MA4(3XW,DLV%*\UR]O7(T[I"1ANB\9YG[ 4*W3LO6,E@-0TLLZ((2P18OZR"6
M#)%9!3Q&$2DJ((M\F&O_G=@8>0-TA-)!KLWA('/<N^:^ *YF;%M9LA=0D"=0
MHI!-"XI!,%KI8H7W,?6S:QYC8^1=,S8TVVV5)C@9.=MB1?;'<HN5Q<?I>D N
MUS;;Z!.49#,HFSS$[!1([E6,09BLAK0O?WJ5HP5D&P#,]J*-'G'UQ[]G:TZ2
M%Z%V:S$E1% ^*HA)$D\AH,"<R3\<TLO\Z57&'7+6/:ZVTT:7N"*(K/>(3LX:
M+SQ@T%5$T8*/F8-VM?Q2UH;;0XH.GUMGW*EG_6-K2XWTB*ZWL_/Y)2M&!LV1
M"7+"4QT96)M,)24A%NE,L-XD-B0S]IEEQIV!UCVVMM1'E]":_+@ZVT.VTM'9
MGG-09'FYA.!HEP3OF!;<6B'2UM"Z6F;<<6C]0VL[??0(K2^3OR\Y83I+KE(
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MDV/N]+Q]4CHID?,MK0,A)8G(IP)!%0\\L<*U4%ZFP]2 [(O#7^8"\2CVY?[
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M97@Q,#$Q+FAT;5!+ 0(4 Q0    ( #: 9EB21KO0U0(  +D,   9
M      "  2H-  !I;F\M,3(S,3(P,C-X,3!K97@R,3$N:'1M4$L! A0#%
M  @ -H!F6.'WY)NG P  P1(  !D              ( !-A   &EN;RTQ,C,Q
M,C R,W@Q,&ME>#(S,2YH=&U02P$"% ,4    "  V@&98]XKXEQ4(  !I*@
M&0              @ $4%   :6YO+3$R,S$R,#(S>#$P:V5X,S$Q+FAT;5!+
M 0(4 Q0    ( #: 9E@A$VH'  @  #(K   9              "  6 <  !I
M;F\M,3(S,3(P,C-X,3!K97@S,3(N:'1M4$L! A0#%     @ -H!F6%^/NH@J
M!0   AX  !D              ( !ER0  &EN;RTQ,C,Q,C R,W@Q,&ME>#,R
M,2YH=&U02P$"% ,4    "  V@&98L7GTXPL:  "UK0  &0
M@ 'X*0  :6YO+3$R,S$R,#(S>#$P:V5X.3<Q+FAT;5!+ 0(4 Q0    ( #:
M9ECS:_TW.#\  #GV 0 8              "  3I$  !I;F\M,3(S,3(S>#$P
M:V5X,3 Q-RYH=&U02P$"% ,4    "  V@&98UJ%X-PH*   )2P  &
M        @ &H@P  :6YO+3$R,S$R,W@Q,&ME>#$P,3@N:'1M4$L! A0#%
M  @ -H!F6+F&"DOU"0  BTL  !@              ( !Z(T  &EN;RTQ,C,Q
M,C-X,3!K97@Q,#$Y+FAT;5!+ 0(4 Q0    ( #: 9E@(VI!!Y@D  %U+   8
M              "  1.8  !I;F\M,3(S,3(S>#$P:V5X,3 R,"YH=&U02P$"
M% ,4    "  V@&98Z7>L\7PZ P E/2  $               @ $OH@  :6YO
M+3(P,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( #: 9EC^BBMHCQ<  '<, 0 0
M          "  =G< P!I;F\M,C R,S$R,S$N>'-D4$L! A0#%     @ -H!F
M6&=8O\%0*0  &YT! !0              ( !EO0# &EN;RTR,#(S,3(S,5]C
M86PN>&UL4$L! A0#%     @ -H!F6$Z=2U-D@P  BKP% !0
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M;RTR,#(S,3(S,5]G-"YJ<&=02P$"% ,4    "  V@&98[,]H7?>L 0#E\0$
M$P              @ %*0P\ :6YO+3(P,C,Q,C,Q7V<U+FIP9U!+ 0(4 Q0
M   ( #: 9EC3CC+>MEL! *&(#0 4              "  7+P$ !I;F\M,C R
M,S$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( #: 9EC>[OV.%=   %!]"0 4
M          "  5I,$@!I;F\M,C R,S$R,S%?<')E+GAM;%!+!08     %@ 6
+ -,%  "A'!,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>ino-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:ino="http://www.inovio.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ino-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-24</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:BehestiVKimEtAlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-19</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-03-01</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-24</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:FormerPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:BehestiVKimEtAlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:CaliforniaIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:PennsylvaniaStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:KoreanStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-06</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>ino:segment</measure>
    </unit>
    <unit id="position">
        <measure>ino:position</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="lease">
        <measure>ino:lease</measure>
    </unit>
    <unit id="agreement">
        <measure>ino:agreement</measure>
    </unit>
    <unit id="defendent">
        <measure>ino:defendent</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-36">0001055726</dei:EntityCentralIndexKey>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-11" decimals="6" id="f-128" unitRef="number">0.083333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-11" decimals="6" id="f-183" unitRef="number">0.083333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:AccountingStandardsUpdateExtensibleList contextRef="c-13" id="f-232">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-11" decimals="6" id="f-288" unitRef="number">0.083333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-55" id="f-447">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-11" decimals="6" id="f-510" unitRef="number">0.083333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash
      contextRef="c-274"
      decimals="INF"
      id="f-995"
      unitRef="number">0.50</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-11" decimals="6" id="f-1235" unitRef="number">0.083333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-30" unitRef="usd">119700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">23370365</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#x2019;s 2024 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x2019;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#x2019;s fiscal year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-37">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-4" id="f-38">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-39">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-40">false</ecd:Rule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-41">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-42">Ernst&#160;&amp; Young&#160;LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-43">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="0" id="f-44" unitRef="usd">14310862</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="0" id="f-45" unitRef="usd">46329359</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-5" decimals="0" id="f-46" unitRef="usd">130982913</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-6" decimals="0" id="f-47" unitRef="usd">206669397</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-7" decimals="0" id="f-48" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-8" decimals="0" id="f-49" unitRef="usd">1701726</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-9" decimals="0" id="f-50" unitRef="usd">2405228</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-10" decimals="0" id="f-51" unitRef="usd">10036490</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="0" id="f-52" unitRef="usd">5393665</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="0" id="f-53" unitRef="usd">50130481</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity contextRef="c-5" decimals="0" id="f-54" unitRef="usd">20432</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity contextRef="c-6" decimals="0" id="f-55" unitRef="usd">375227</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="0" id="f-56" unitRef="usd">153113100</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="0" id="f-57" unitRef="usd">315242680</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="0" id="f-58" unitRef="usd">4960986</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="0" id="f-59" unitRef="usd">7727997</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-5" decimals="0" id="f-60" unitRef="usd">2780287</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-6" decimals="0" id="f-61" unitRef="usd">2007142</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="0" id="f-62" unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="0" id="f-63" unitRef="usd">2129861</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="0" id="f-64" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="0" id="f-65" unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="0" id="f-66" unitRef="usd">9491735</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="0" id="f-67" unitRef="usd">10228207</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="0" id="f-68" unitRef="usd">605315</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="0" id="f-69" unitRef="usd">684044</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-5" decimals="0" id="f-70" unitRef="usd">170951423</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-6" decimals="0" id="f-71" unitRef="usd">348533302</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-7" decimals="0" id="f-72" unitRef="usd">19847744</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-8" decimals="0" id="f-73" unitRef="usd">79686885</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-9" decimals="0" id="f-74" unitRef="usd">1070519</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-10" decimals="0" id="f-75" unitRef="usd">1220439</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent contextRef="c-5" decimals="0" id="f-76" unitRef="usd">2365382</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent contextRef="c-6" decimals="0" id="f-77" unitRef="usd">10594073</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="0" id="f-78" unitRef="usd">2406522</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="0" id="f-79" unitRef="usd">2803973</us-gaap:OperatingLeaseLiabilityCurrent>
    <ino:DeferredGrantFundingCurrent contextRef="c-5" decimals="0" id="f-80" unitRef="usd">87489</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingCurrent contextRef="c-6" decimals="0" id="f-81" unitRef="usd">2475031</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent contextRef="c-5" decimals="0" id="f-82" unitRef="usd">21918</ino:DeferredGrantFundingFromAffiliateCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent contextRef="c-6" decimals="0" id="f-83" unitRef="usd">87673</ino:DeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="c-5" decimals="0" id="f-84" unitRef="usd">16770654</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="c-6" decimals="0" id="f-85" unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="0" id="f-86" unitRef="usd">42570228</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="0" id="f-87" unitRef="usd">96868074</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="c-5" decimals="0" id="f-88" unitRef="usd">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="c-6" decimals="0" id="f-89" unitRef="usd">16614840</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="0" id="f-90" unitRef="usd">11032066</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="0" id="f-91" unitRef="usd">12655586</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-5" decimals="0" id="f-92" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-6" decimals="0" id="f-93" unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="c-5" decimals="0" id="f-94" unitRef="usd">53602294</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-6" decimals="0" id="f-95" unitRef="usd">126170546</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-96" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-97" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-98"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-99"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-100" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-101" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-102" unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-103" unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-104" unitRef="shares">9</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-105" unitRef="shares">9</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="0" id="f-106" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="0" id="f-107" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-108"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-109"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-110" unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-111" unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-112" unitRef="shares">22793075</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-113" unitRef="shares">22793075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-114" unitRef="shares">21090938</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-115" unitRef="shares">21090938</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="0" id="f-116" unitRef="usd">22792</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="0" id="f-117" unitRef="usd">21090</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="0" id="f-118" unitRef="usd">1740954074</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="0" id="f-119" unitRef="usd">1710888191</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="0" id="f-120" unitRef="usd">-1622965136</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="0" id="f-121" unitRef="usd">-1487847784</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="0" id="f-122" unitRef="usd">-662601</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="0" id="f-123" unitRef="usd">-698741</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="0" id="f-124" unitRef="usd">117349129</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="0" id="f-125" unitRef="usd">222362756</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="0" id="f-126" unitRef="usd">170951423</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="0" id="f-127" unitRef="usd">348533302</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="0" id="f-129" unitRef="usd">832010</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="0" id="f-130" unitRef="usd">10262268</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="0" id="f-131" unitRef="usd">1774758</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="0" id="f-132" unitRef="usd">86676563</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-12" decimals="0" id="f-133" unitRef="usd">187650503</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-13" decimals="0" id="f-134" unitRef="usd">249240324</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="0" id="f-135" unitRef="usd">47582104</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-12" decimals="0" id="f-136" unitRef="usd">90185285</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-13" decimals="0" id="f-137" unitRef="usd">53752353</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="0" id="f-138" unitRef="usd">10513371</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-12" decimals="0" id="f-139" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-13" decimals="0" id="f-140" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="0" id="f-141" unitRef="usd">144772038</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-12" decimals="0" id="f-142" unitRef="usd">277835788</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-13" decimals="0" id="f-143" unitRef="usd">302992677</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="0" id="f-144" unitRef="usd">-143940028</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-12" decimals="0" id="f-145" unitRef="usd">-267573520</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="0" id="f-146" unitRef="usd">-301217919</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating contextRef="c-1" decimals="0" id="f-147" unitRef="usd">8133290</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating contextRef="c-12" decimals="0" id="f-148" unitRef="usd">4782030</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating contextRef="c-13" decimals="0" id="f-149" unitRef="usd">3363080</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense contextRef="c-1" decimals="0" id="f-150" unitRef="usd">1222789</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-12" decimals="0" id="f-151" unitRef="usd">1253952</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-13" decimals="0" id="f-152" unitRef="usd">1936447</us-gaap:InterestExpense>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-1" decimals="0" id="f-153" unitRef="usd">773145</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-12" decimals="0" id="f-154" unitRef="usd">-1899654</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-13" decimals="0" id="f-155" unitRef="usd">-553570</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="0" id="f-156" unitRef="usd">5850626</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-12" decimals="0" id="f-157" unitRef="usd">-7846172</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-13" decimals="0" id="f-158" unitRef="usd">-3222838</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="0" id="f-159" unitRef="usd">-4711596</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-12" decimals="0" id="f-160" unitRef="usd">-3861584</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="0" id="f-161" unitRef="usd">343371</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="0" id="f-162" unitRef="usd">-135117352</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-12" decimals="0" id="f-163" unitRef="usd">-277652852</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-13" decimals="0" id="f-164" unitRef="usd">-303224323</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="0" id="f-165" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-12" decimals="0" id="f-166" unitRef="usd">-2165213</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-13" decimals="0" id="f-167" unitRef="usd">-434387</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-168" unitRef="usd">-135117352</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="0" id="f-169" unitRef="usd">-279818065</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="0" id="f-170" unitRef="usd">-303658710</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">-6.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-172"
      unitRef="usdPerShare">-6.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-173"
      unitRef="usdPerShare">-14.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-174"
      unitRef="usdPerShare">-14.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-175"
      unitRef="usdPerShare">-17.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-176"
      unitRef="usdPerShare">-17.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-177" unitRef="shares">22173662</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-178" unitRef="shares">22173662</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="0" id="f-179" unitRef="shares">19885182</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="0" id="f-180" unitRef="shares">19885182</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="0" id="f-181" unitRef="shares">17402483</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="0" id="f-182" unitRef="shares">17402483</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-184" unitRef="usd">-135117352</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="0" id="f-185" unitRef="usd">-279818065</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="0" id="f-186" unitRef="usd">-303658710</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="0" id="f-187" unitRef="usd">-3920</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-12" decimals="0" id="f-188" unitRef="usd">-25556</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-13" decimals="0" id="f-189" unitRef="usd">-30134</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="0" id="f-190" unitRef="usd">40060</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-12" decimals="0" id="f-191" unitRef="usd">-390949</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-13" decimals="0" id="f-192" unitRef="usd">4048</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="0" id="f-193" unitRef="usd">-135081212</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-12" decimals="0" id="f-194" unitRef="usd">-280234570</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="0" id="f-195" unitRef="usd">-303684796</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-14"
      decimals="INF"
      id="f-196"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="0" id="f-197" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-15"
      decimals="INF"
      id="f-198"
      unitRef="shares">15570957</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="0" id="f-199" unitRef="usd">15571</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="0" id="f-200" unitRef="usd">1367578149</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="0" id="f-201" unitRef="usd">-906196812</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="0" id="f-202" unitRef="usd">-256150</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="0" id="f-203" unitRef="usd">461140758</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-20"
      decimals="INF"
      id="f-204"
      unitRef="shares">2275861</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-20" decimals="0" id="f-205" unitRef="usd">2276</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-21" decimals="0" id="f-206" unitRef="usd">209439134</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-13" decimals="0" id="f-207" unitRef="usd">209441410</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-20"
      decimals="INF"
      id="f-208"
      unitRef="shares">84120</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-20" decimals="0" id="f-209" unitRef="usd">84</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-21" decimals="0" id="f-210" unitRef="usd">4377808</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-13" decimals="0" id="f-211" unitRef="usd">4377892</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-20"
      decimals="INF"
      id="f-212"
      unitRef="shares">184299</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-20" decimals="0" id="f-213" unitRef="usd">184</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-21" decimals="0" id="f-214" unitRef="usd">2057209</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-13" decimals="0" id="f-215" unitRef="usd">2057393</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-21" decimals="0" id="f-216" unitRef="usd">26336764</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="0" id="f-217" unitRef="usd">26336764</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="0" id="f-218" unitRef="usd">-303658710</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="0" id="f-219" unitRef="usd">-303658710</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-23" decimals="0" id="f-220" unitRef="usd">4048</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-13" decimals="0" id="f-221" unitRef="usd">4048</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-23" decimals="0" id="f-222" unitRef="usd">-30134</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-13" decimals="0" id="f-223" unitRef="usd">-30134</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-24"
      decimals="INF"
      id="f-224"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="0" id="f-225" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-25"
      decimals="INF"
      id="f-226"
      unitRef="shares">18115237</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="0" id="f-227" unitRef="usd">18115</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="0" id="f-228" unitRef="usd">1609789064</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="0" id="f-229" unitRef="usd">-1209855522</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="0" id="f-230" unitRef="usd">-282236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="0" id="f-231" unitRef="usd">399669421</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="0" id="f-233" unitRef="usd">-3294019</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="0" id="f-234" unitRef="usd">1825803</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="0" id="f-235" unitRef="usd">-1468216</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-33"
      decimals="INF"
      id="f-236"
      unitRef="shares">2870478</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-33" decimals="0" id="f-237" unitRef="usd">2870</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-34" decimals="0" id="f-238" unitRef="usd">82952441</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-12" decimals="0" id="f-239" unitRef="usd">82955311</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-33"
      decimals="INF"
      id="f-240"
      unitRef="shares">105223</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-33" decimals="0" id="f-241" unitRef="usd">105</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-34" decimals="0" id="f-242" unitRef="usd">-1114714</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-12" decimals="0" id="f-243" unitRef="usd">-1114609</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="0" id="f-244" unitRef="usd">22555419</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="0" id="f-245" unitRef="usd">22555419</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-35" decimals="0" id="f-246" unitRef="usd">-279818065</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="0" id="f-247" unitRef="usd">-279818065</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-36" decimals="0" id="f-248" unitRef="usd">-390949</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-12" decimals="0" id="f-249" unitRef="usd">-390949</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-36" decimals="0" id="f-250" unitRef="usd">-25556</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-12" decimals="0" id="f-251" unitRef="usd">-25556</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-37"
      decimals="INF"
      id="f-252"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="0" id="f-253" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-38"
      decimals="INF"
      id="f-254"
      unitRef="shares">21090938</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="0" id="f-255" unitRef="usd">21090</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="0" id="f-256" unitRef="usd">1710888191</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="0" id="f-257" unitRef="usd">-1487847784</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="0" id="f-258" unitRef="usd">-698741</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="0" id="f-259" unitRef="usd">222362756</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-42"
      decimals="INF"
      id="f-260"
      unitRef="shares">760083</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-42" decimals="0" id="f-261" unitRef="usd">760</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-43" decimals="0" id="f-262" unitRef="usd">13999240</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-1" decimals="0" id="f-263" unitRef="usd">14000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-42"
      decimals="INF"
      id="f-264"
      unitRef="shares">875305</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-42" decimals="0" id="f-265" unitRef="usd">875</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-43" decimals="0" id="f-266" unitRef="usd">5460870</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="0" id="f-267" unitRef="usd">5461745</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-42"
      decimals="INF"
      id="f-268"
      unitRef="shares">66749</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-42" decimals="0" id="f-269" unitRef="usd">67</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-43" decimals="0" id="f-270" unitRef="usd">-466713</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="0" id="f-271" unitRef="usd">-466646</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-43" decimals="0" id="f-272" unitRef="usd">11072486</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="0" id="f-273" unitRef="usd">11072486</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-44" decimals="0" id="f-274" unitRef="usd">-135117352</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-275" unitRef="usd">-135117352</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-45" decimals="0" id="f-276" unitRef="usd">40060</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="0" id="f-277" unitRef="usd">40060</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-45" decimals="0" id="f-278" unitRef="usd">-3920</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="0" id="f-279" unitRef="usd">-3920</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-46"
      decimals="INF"
      id="f-280"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="0" id="f-281" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-47"
      decimals="INF"
      id="f-282"
      unitRef="shares">22793075</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="0" id="f-283" unitRef="usd">22792</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="0" id="f-284" unitRef="usd">1740954074</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="0" id="f-285" unitRef="usd">-1622965136</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="0" id="f-286" unitRef="usd">-662601</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="0" id="f-287" unitRef="usd">117349129</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-289" unitRef="usd">-135117352</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="0" id="f-290" unitRef="usd">-279818065</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="0" id="f-291" unitRef="usd">-303658710</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="0" id="f-292" unitRef="usd">2621649</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-12" decimals="0" id="f-293" unitRef="usd">3656713</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="0" id="f-294" unitRef="usd">3040096</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="0" id="f-295" unitRef="usd">145417</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-12" decimals="0" id="f-296" unitRef="usd">496494</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="0" id="f-297" unitRef="usd">520415</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="0" id="f-298" unitRef="usd">736472</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-12" decimals="0" id="f-299" unitRef="usd">1342819</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-13" decimals="0" id="f-300" unitRef="usd">1170270</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="0" id="f-301" unitRef="usd">10513371</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-12" decimals="0" id="f-302" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-13" decimals="0" id="f-303" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="0" id="f-304" unitRef="usd">1984444</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-12" decimals="0" id="f-305" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-13" decimals="0" id="f-306" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-307" unitRef="usd">-32046</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-12" decimals="0" id="f-308" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-13" decimals="0" id="f-309" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="0" id="f-310" unitRef="usd">11072486</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-12" decimals="0" id="f-311" unitRef="usd">22555419</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="0" id="f-312" unitRef="usd">26336764</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestIncomeExpense contextRef="c-1" decimals="0" id="f-313" unitRef="usd">-155814</ino:NonCashInterestIncomeExpense>
    <ino:NonCashInterestIncomeExpense contextRef="c-12" decimals="0" id="f-314" unitRef="usd">-186977</ino:NonCashInterestIncomeExpense>
    <ino:NonCashInterestIncomeExpense contextRef="c-13" decimals="0" id="f-315" unitRef="usd">-858644</ino:NonCashInterestIncomeExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="0" id="f-316" unitRef="usd">4686144</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-12" decimals="0" id="f-317" unitRef="usd">1320546</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-13" decimals="0" id="f-318" unitRef="usd">-1633286</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="c-1" decimals="0" id="f-319" unitRef="usd">-4805804</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="c-12" decimals="0" id="f-320" unitRef="usd">-4029961</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="c-13" decimals="0" id="f-321" unitRef="usd">-5397</us-gaap:GainLossOnSaleOfOtherInvestments>
    <ino:GainLossOnRemeasurementOfEquityMethodInvestment contextRef="c-1" decimals="0" id="f-322" unitRef="usd">0</ino:GainLossOnRemeasurementOfEquityMethodInvestment>
    <ino:GainLossOnRemeasurementOfEquityMethodInvestment contextRef="c-12" decimals="0" id="f-323" unitRef="usd">165215</ino:GainLossOnRemeasurementOfEquityMethodInvestment>
    <ino:GainLossOnRemeasurementOfEquityMethodInvestment contextRef="c-13" decimals="0" id="f-324" unitRef="usd">0</ino:GainLossOnRemeasurementOfEquityMethodInvestment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="0" id="f-325" unitRef="usd">-317997</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-12" decimals="0" id="f-326" unitRef="usd">-1074830</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-13" decimals="0" id="f-327" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-1" decimals="0" id="f-328" unitRef="usd">773145</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-12" decimals="0" id="f-329" unitRef="usd">-1899654</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-13" decimals="0" id="f-330" unitRef="usd">-553570</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-1" decimals="0" id="f-331" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-12" decimals="0" id="f-332" unitRef="usd">-2165213</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-13" decimals="0" id="f-333" unitRef="usd">-434387</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="0" id="f-334" unitRef="usd">5850626</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-12" decimals="0" id="f-335" unitRef="usd">-7846172</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-13" decimals="0" id="f-336" unitRef="usd">-3222838</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="0" id="f-337" unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-12" decimals="0" id="f-338" unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-13" decimals="0" id="f-339" unitRef="usd">176927</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="0" id="f-340" unitRef="usd">-9332988</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-12" decimals="0" id="f-341" unitRef="usd">3706172</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-13" decimals="0" id="f-342" unitRef="usd">-11031705</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="0" id="f-343" unitRef="usd">-39020611</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-12" decimals="0" id="f-344" unitRef="usd">5336525</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-13" decimals="0" id="f-345" unitRef="usd">6343632</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="0" id="f-346" unitRef="usd">-78729</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-12" decimals="0" id="f-347" unitRef="usd">-741750</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-13" decimals="0" id="f-348" unitRef="usd">-24531654</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="0" id="f-349" unitRef="usd">-45989061</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-12" decimals="0" id="f-350" unitRef="usd">32606581</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-13" decimals="0" id="f-351" unitRef="usd">26140970</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense contextRef="c-1" decimals="0" id="f-352" unitRef="usd">-8228691</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense contextRef="c-12" decimals="0" id="f-353" unitRef="usd">267807</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense contextRef="c-13" decimals="0" id="f-354" unitRef="usd">375921</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="0" id="f-355" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-12" decimals="0" id="f-356" unitRef="usd">-85989</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-13" decimals="0" id="f-357" unitRef="usd">-39853</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet contextRef="c-1" decimals="0" id="f-358" unitRef="usd">-2020971</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet contextRef="c-12" decimals="0" id="f-359" unitRef="usd">-2603956</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet contextRef="c-13" decimals="0" id="f-360" unitRef="usd">-2329394</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent contextRef="c-1" decimals="0" id="f-361" unitRef="usd">-2453297</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent contextRef="c-12" decimals="0" id="f-362" unitRef="usd">-2034517</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent contextRef="c-13" decimals="0" id="f-363" unitRef="usd">-2973089</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="0" id="f-364" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-12" decimals="0" id="f-365" unitRef="usd">-14826</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-13" decimals="0" id="f-366" unitRef="usd">-42837</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="0" id="f-367" unitRef="usd">-124365551</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-12" decimals="0" id="f-368" unitRef="usd">-216215421</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="0" id="f-369" unitRef="usd">-215708525</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-1" decimals="0" id="f-370" unitRef="usd">203475052</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-12" decimals="0" id="f-371" unitRef="usd">248528843</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-13" decimals="0" id="f-372" unitRef="usd">348953236</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-1" decimals="0" id="f-373" unitRef="usd">284932562</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-12" decimals="0" id="f-374" unitRef="usd">361083850</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-13" decimals="0" id="f-375" unitRef="usd">174839758</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="0" id="f-376" unitRef="usd">320898</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-12" decimals="0" id="f-377" unitRef="usd">969153</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-13" decimals="0" id="f-378" unitRef="usd">1231006</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="0" id="f-379" unitRef="usd">6219263</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-12" decimals="0" id="f-380" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-13" decimals="0" id="f-381" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries contextRef="c-1" decimals="0" id="f-382" unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries contextRef="c-12" decimals="0" id="f-383" unitRef="usd">1999998</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries contextRef="c-13" decimals="0" id="f-384" unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="0" id="f-385" unitRef="usd">87355875</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-12" decimals="0" id="f-386" unitRef="usd">109585856</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="0" id="f-387" unitRef="usd">-175344484</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="0" id="f-388" unitRef="usd">5461745</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-12" decimals="0" id="f-389" unitRef="usd">82955311</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-13" decimals="0" id="f-390" unitRef="usd">209441410</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ino:ProceedsfromStockOptionandWarrantExercises contextRef="c-1" decimals="0" id="f-391" unitRef="usd">0</ino:ProceedsfromStockOptionandWarrantExercises>
    <ino:ProceedsfromStockOptionandWarrantExercises contextRef="c-12" decimals="0" id="f-392" unitRef="usd">283022</ino:ProceedsfromStockOptionandWarrantExercises>
    <ino:ProceedsfromStockOptionandWarrantExercises contextRef="c-13" decimals="0" id="f-393" unitRef="usd">6668741</ino:ProceedsfromStockOptionandWarrantExercises>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings contextRef="c-1" decimals="0" id="f-394" unitRef="usd">-466646</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings contextRef="c-12" decimals="0" id="f-395" unitRef="usd">-1397631</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings contextRef="c-13" decimals="0" id="f-396" unitRef="usd">-4611348</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="0" id="f-397" unitRef="usd">4995099</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-12" decimals="0" id="f-398" unitRef="usd">81840702</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="0" id="f-399" unitRef="usd">211498803</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="0" id="f-400" unitRef="usd">-3920</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="0" id="f-401" unitRef="usd">-25556</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="0" id="f-402" unitRef="usd">-30134</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="0" id="f-403" unitRef="usd">-32018497</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-12" decimals="0" id="f-404" unitRef="usd">-24814419</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="0" id="f-405" unitRef="usd">-179584340</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="0" id="f-406" unitRef="usd">46329359</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="0" id="f-407" unitRef="usd">71143778</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="0" id="f-408" unitRef="usd">250728118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="0" id="f-409" unitRef="usd">14310862</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="0" id="f-410" unitRef="usd">46329359</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="0" id="f-411" unitRef="usd">71143778</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="0" id="f-412" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-12" decimals="0" id="f-413" unitRef="usd">108181</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-13" decimals="0" id="f-414" unitRef="usd">204815</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="0" id="f-415" unitRef="usd">1066975</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-12" decimals="0" id="f-416" unitRef="usd">1066975</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-13" decimals="0" id="f-417" unitRef="usd">1077803</us-gaap:InterestPaidNet>
    <ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets contextRef="c-1" decimals="0" id="f-418" unitRef="usd">0</ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets>
    <ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets contextRef="c-12" decimals="0" id="f-419" unitRef="usd">6071000</ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets>
    <ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets contextRef="c-13" decimals="0" id="f-420" unitRef="usd">7709337</ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets>
    <us-gaap:StockIssued1 contextRef="c-1" decimals="0" id="f-421" unitRef="usd">14000000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-12" decimals="0" id="f-422" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-13" decimals="0" id="f-423" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-424">The Company&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;INOVIO&#x201d;) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#x2019;s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA&#xae; delivery devices help its DNA medicines enter the body&#x2019;s cells for optimal effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related anal dysplasia and oropharyngeal squamous cell carcinoma (OPSCC); glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in August 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp;amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO was incorporated in Delaware in 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-425">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss of $135.1 million for the year ended December&#160;31, 2023. The Company had working capital of $110.5 million and an accumulated deficit of $1.6 billion as of December&#160;31, 2023. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $145.3 million as of December 31, 2023 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings, including under At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $5.5&#160;million, $83.0&#160;million and $47.7&#160;million from equity offerings under Sales Agreements during the years ending December 31, 2023, 2022 and 2021, respectively, and $162.1&#160;million from a January 2021 underwritten public offering of common stock. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 24, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, as previously amended, to effect a 1-for-12 reverse stock split of our common stock (the &#x201c;Reverse Stock Split&#x201d;).  As a result of the Reverse Stock Split, every 12 issued and outstanding shares of the Company's common stock were automatically combined into one issued and outstanding share of common stock. The reverse stock split was reflected on the Nasdaq Capital Market beginning with the opening of trading on January 25, 2024. Accordingly, an amount equal to the par value of the decreased shares resulting from the reverse stock split was reclassified from "Additional paid-in capital" to "Common stock" on the balance sheet and statement of changes in stockholders&#x2019; equity. Any fractional post-split shares as a result of the reverse stock split were eliminated by the payment of cash for the value of such fractional share. As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding stock options and outstanding shares of Series C Cumulative Convertible Preferred Stock and to the number of shares of common stock issuable under the Company's equity incentive plans. The reverse stock split did not change the par value of the Company's common stock or the authorized number of shares of the Company's common stock. All share amounts and per share amounts disclosed in this Annual Report on Form 10-K have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash equivalents, short-term investments, investments in affiliated entity, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes for disclosure purposes only.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain mutual funds and U.S. treasury securities at December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#x2019;s affiliated entity, PLS, at December 31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#x2019; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. There was no allowance for doubtful accounts for potential credit losses as of December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets include property and equipment and leasehold improvements. Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally &lt;span style="-sec-ix-hidden:f-447"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of long-lived assets, which includes fixed assets and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. No impairment losses have been recognized related to long-lived assets for the year ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate the carrying amounts of the assets may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company&#x2019;s stock price. This sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of September 30, 2023. The Company first tested its long-lived assets for impairment. The Company determined that all of its long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, represented one asset group for purposes of its long-lived asset impairment assessment. The Company concluded that the long-lived assets were not impaired, as their carrying values were not in excess of their fair value. Next, the Company determined that the fair value of its reporting unit was less than its carrying value and the Company recorded a loss on impairment of goodwill of $10.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During 2023, the Company also recorded an impairment charge of $2.0&#160;million to research and development expense for the remaining book value of intangible assets acquired in 2016 from Bioject Medical Technologies, as the Company had no plans to further develop or utilize this technology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Refer to Note 8 for further information regarding Goodwill and Intangible Assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances against the Company&#x2019;s deferred tax assets were $327.5 million and $299.1 million at December&#160;31, 2023 and 2022, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements and Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-research and development expense as opposed to revenue on the consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses - Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2023, 2022 and 2021, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes would have been anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements.  Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ASU No. 2023-07. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU expands public entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the Chief Operating Decision Maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ASU No. 2023-09. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ASU 2023-09 requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-426">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss of $135.1 million for the year ended December&#160;31, 2023. The Company had working capital of $110.5 million and an accumulated deficit of $1.6 billion as of December&#160;31, 2023. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $145.3 million as of December 31, 2023 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings, including under At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $5.5&#160;million, $83.0&#160;million and $47.7&#160;million from equity offerings under Sales Agreements during the years ending December 31, 2023, 2022 and 2021, respectively, and $162.1&#160;million from a January 2021 underwritten public offering of common stock. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, &lt;/span&gt;&lt;/div&gt;occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-427" unitRef="usd">-135100000</us-gaap:NetIncomeLoss>
    <ino:WorkingCapital contextRef="c-5" decimals="-5" id="f-428" unitRef="usd">110500000</ino:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-8" id="f-429" unitRef="usd">-1600000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-5" decimals="-5" id="f-430" unitRef="usd">145300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-51" decimals="-5" id="f-431" unitRef="usd">5500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-52" decimals="-5" id="f-432" unitRef="usd">83000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-53" decimals="-5" id="f-433" unitRef="usd">47700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-54" decimals="-5" id="f-434" unitRef="usd">162100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-435">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-436">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-437"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-438">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-439">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-440">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash equivalents, short-term investments, investments in affiliated entity, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes for disclosure purposes only.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-441">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain mutual funds and U.S. treasury securities at December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-442">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#x2019;s affiliated entity, PLS, at December 31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-443">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#x2019; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. There was</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-6" decimals="INF" id="f-444" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="INF" id="f-445" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-446">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets include property and equipment and leasehold improvements. Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally &lt;span style="-sec-ix-hidden:f-447"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of long-lived assets, which includes fixed assets and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. No impairment losses have been recognized related to long-lived assets for the year ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-56" id="f-448">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-449">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate the carrying amounts of the assets may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company&#x2019;s stock price. This sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of September 30, 2023. The Company first tested its long-lived assets for impairment. The Company determined that all of its long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, represented one asset group for purposes of its long-lived asset impairment assessment. The Company concluded that the long-lived assets were not impaired, as their carrying values were not in excess of their fair value. Next, the Company determined that the fair value of its reporting unit was less than its carrying value and the Company recorded a loss on impairment of goodwill of $10.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During 2023, the Company also recorded an impairment charge of $2.0&#160;million to research and development expense for the remaining book value of intangible assets acquired in 2016 from Bioject Medical Technologies, as the Company had no plans to further develop or utilize this technology. &lt;/span&gt;&lt;/div&gt;Refer to Note 8 for further information regarding Goodwill and Intangible Assets</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-57" decimals="-5" id="f-450" unitRef="usd">10500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-58" decimals="-5" id="f-451" unitRef="usd">2000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-452">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances against the Company&#x2019;s deferred tax assets were $327.5 million and $299.1 million at December&#160;31, 2023 and 2022, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-5" id="f-453" unitRef="usd">327500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-5" id="f-454" unitRef="usd">299100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-456">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements and Revenue Recognition&lt;/span&gt;&lt;/div&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;).</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-455">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements and Revenue Recognition&lt;/span&gt;&lt;/div&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;).</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ino:GrantRevenuePolicyTextBlock contextRef="c-1" id="f-457">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-research and development expense as opposed to revenue on the consolidated statement of operations.</ino:GrantRevenuePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-458">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="c-1" id="f-459">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-460">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-461">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses - Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-462">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. &lt;/span&gt;For the years ended December 31, 2023, 2022 and 2021, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes would have been anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-463">&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-59" decimals="0" id="f-464" unitRef="shares">1128864</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-60" decimals="0" id="f-465" unitRef="shares">1018095</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-61" decimals="0" id="f-466" unitRef="shares">874082</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-62" decimals="0" id="f-467" unitRef="shares">274794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-63" decimals="0" id="f-468" unitRef="shares">212964</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-64" decimals="0" id="f-469" unitRef="shares">204005</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-65" decimals="0" id="f-470" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-66" decimals="0" id="f-471" unitRef="shares">9328</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-67" decimals="0" id="f-472" unitRef="shares">55279</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-68" decimals="0" id="f-473" unitRef="shares">275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-69" decimals="0" id="f-474" unitRef="shares">275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-70" decimals="0" id="f-475" unitRef="shares">275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-71" decimals="0" id="f-476" unitRef="shares">254165</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-72" decimals="0" id="f-477" unitRef="shares">254165</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-73" decimals="0" id="f-478" unitRef="shares">254165</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-479" unitRef="shares">1658098</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-12" decimals="0" id="f-480" unitRef="shares">1494827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-13" decimals="0" id="f-481" unitRef="shares">1387806</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-482">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c-1" id="f-483">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. &lt;/span&gt;The Company recognizes forfeitures as they occur.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-484">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-74" decimals="4" id="f-485" unitRef="number">0.0405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-75" decimals="4" id="f-486" unitRef="number">0.0205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-76" decimals="4" id="f-487" unitRef="number">0.0091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-74" decimals="2" id="f-488" unitRef="number">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-75" decimals="2" id="f-489" unitRef="number">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-76" decimals="2" id="f-490" unitRef="number">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-74" id="f-491">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-75" id="f-492">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-76" id="f-493">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-74"
      decimals="INF"
      id="f-494"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-75"
      decimals="INF"
      id="f-495"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-76"
      decimals="INF"
      id="f-496"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-77" decimals="4" id="f-497" unitRef="number">0.0390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-78" decimals="4" id="f-498" unitRef="number">0.0196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-79" decimals="4" id="f-499" unitRef="number">0.0145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-77" decimals="2" id="f-500" unitRef="number">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-78" decimals="2" id="f-501" unitRef="number">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-79" decimals="2" id="f-502" unitRef="number">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-77" id="f-503">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-78" id="f-504">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-79" id="f-505">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-77"
      decimals="INF"
      id="f-506"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-78"
      decimals="INF"
      id="f-507"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-79"
      decimals="INF"
      id="f-508"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-509">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements.  Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ASU No. 2023-07. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU expands public entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the Chief Operating Decision Maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ASU No. 2023-09. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ASU 2023-09 requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-511">Revenue Recognition and Concentration of Credit Risk&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the years ended December&#160;31, 2023, 2022 and 2021, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ApolloBio Corporation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plumbline Life Sciences, Inc. (affiliated entity)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Department of Defense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,591,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other, including affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,262,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;No revenue recognized during the year ended December&#160;31, 2023 was in deferred revenue as of December 31, 2022. During the year ended December 31, 2022, the Company recognized revenue of $14,000 that was included in deferred revenue at December 31, 2021. Performance obligations are generally satisfied within 12 months of the initial contract date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December&#160;31, 2023, the Company had no accounts receivable balance. As of December&#160;31, 2022, all of the Company's accounts receivable was attributable to the CEPI MERS grant. There is minimal credit risk with the Company's customers based upon the short-term nature of the accounts receivable, collection history, their size and financial condition. Accordingly, the Company does not record an allowance for potential credit losses against its accounts receivable.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-512">The following table indicates the percentage of total revenues in excess of 10% with any single customer:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ApolloBio Corporation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plumbline Life Sciences, Inc. (affiliated entity)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Department of Defense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,591,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other, including affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,262,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="0" id="f-513" unitRef="usd">245056</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-81" decimals="2" id="f-514" unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="0" id="f-515" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-83" decimals="2" id="f-516" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-84" decimals="0" id="f-517" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-85" decimals="2" id="f-518" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-86" decimals="0" id="f-519" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-87" decimals="2" id="f-520" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-88" decimals="0" id="f-521" unitRef="usd">33596</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-89" decimals="2" id="f-522" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-90" decimals="0" id="f-523" unitRef="usd">245310</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-91" decimals="2" id="f-524" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-92" decimals="0" id="f-525" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-93" decimals="2" id="f-526" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="0" id="f-527" unitRef="usd">9591778</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-95" decimals="2" id="f-528" unitRef="number">0.94</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="0" id="f-529" unitRef="usd">754853</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-97" decimals="2" id="f-530" unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="0" id="f-531" unitRef="usd">586954</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-99" decimals="2" id="f-532" unitRef="number">0.71</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="0" id="f-533" unitRef="usd">636894</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-101" decimals="2" id="f-534" unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="0" id="f-535" unitRef="usd">774595</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-103" decimals="2" id="f-536" unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="0" id="f-537" unitRef="usd">832010</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-104" decimals="2" id="f-538" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="0" id="f-539" unitRef="usd">10262268</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-105" decimals="2" id="f-540" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="0" id="f-541" unitRef="usd">1774758</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-106" decimals="2" id="f-542" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="INF" id="f-543" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-12" decimals="-3" id="f-544" unitRef="usd">14000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-545">Collaborative Agreements &lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advaccine Biopharmaceuticals Suzhou Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#x201c;Advaccine&#x201d;), which was amended and restated on June 7, 2021 (as amended and restated, the &#x201c;Advaccine Agreement&#x201d;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#x2019;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#x201c;Greater China&#x201d;) and 33 additional countries in Asia. The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#x2019;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#x2019;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. In the fourth quarter of 2022, the Company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine continues to develop INO-4800 with its own resources under the terms of the Advaccine Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research and development expense on the consolidated statement of operations once earned and collectibility was assured.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2023, 2022 and 2021, the Company received funding of $3.6&#160;million, $1.2&#160;million and $4.5 million, respectively, from Advaccine that was recorded as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contra-research and development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with ApolloBio Corporation ("ApolloBio"), which was amended on June 14, 2023. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company received funding of $245,000 from the ApolloBio Agreement that was recorded as revenue. For the years ended December 31,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 and 2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;there were no &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant reimbursable program costs under the ApolloBio Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously entered into agreements with CEPI, pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS.  As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56&#160;million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023, 2022 and 2021, the Company received funding of $1.8 million, $6.7 million and $10.0 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December&#160;31, 2023 and 2022, the Company had &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an accounts receivable balance of $0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $1.7&#160;million, respectively, on the consolidated balance sheet related to these CEPI grants. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company had $2.2&#160;million recorded as an accrued liability, and at December 31, 2022, had&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $0&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recorded as deferred grant funding on the consolidated balance sheet related to these CEPI grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, CEPI awarded the Company a grant of up to $9.0&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $6.9&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $5.0&#160;million to accelerate development of the Company's next-generation intradermal electroporation device, known as CELLECTRA 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3&#160;million to support large-scale manufacturing of INO-4800. During the years ended December&#160;31, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 and 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company received funding of $330,000, $1.1 million and $6.9 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December&#160;31, 2023, the Company had $2.1&#160;million recorded as an accrued liability, and at December 31, 2022, had&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $2.3&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Gates awarded and funded the Company a grant of $2.2&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1&#160;million for the project. During the years ended December&#160;31, 2023, 2022 and 2021, the Company recorded $70,000, $233,000 and $182,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December&#160;31, 2023 and 2022, the Company had $87,000 and $153,000, respectively, recorded as deferred grant funding on the consolidated balance sheet related to the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Defense (DoD) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#x201c;OTA Agreement&#x201d;)&#160;with the DoD to fund the Company&#x2019;s efforts in developing the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. The total amount of funding provided to the Company under the OTA Agreement was $54.5&#160;million. The Company determined that the OTA Agreement should be considered under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which is outside the scope of Topic 606, as the government agency granting the Company funds was not receiving reciprocal value for their contributions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recorded contra-research and development expense on the consolidated statement of operations in the same period that the underlying expenses were incurred. During the years ended December&#160;31, 2023, 2022 and 2021, the Company recorded $0, $6.1 million and $27.1 million, respectively, as contra-research and development expense related to the OTA agreement.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#x201c;Procurement Contract&#x201d;) from the DoD for the purchase of the Company&#x2019;s intradermal CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 device and accessories. The total purchase price under the Procurement Contract was $16.8&#160;million. The&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Company determined that the Procurement Contract fell under the scope of ASC Topic 606 as the contract was with a customer and the Company was able to satisfy its obligations under the arrangement. Performance obligations under the Procurement Contract consisted of the delivery of a specified number of CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. In 2021, the DoD announced that it would discontinue funding for the Phase 3 segment of the Company's clinical trials for INO-4800 and in January 2022, the total purchase price under the Procurement Contract was reduced to $10.7&#160;million. During the year ended December 31, 2022, all performance obligations under the Procurement Contract were satisfied. During the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2023, 2022 and 2021&lt;/span&gt;, the Company recorded revenue of $0, $9.6&#160;million and $755,000, respectively, from the Procurement Contract.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-107" decimals="-5" id="f-546" unitRef="usd">3600000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-108" decimals="-5" id="f-547" unitRef="usd">1200000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-109" decimals="-5" id="f-548" unitRef="usd">4500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved contextRef="c-110" decimals="-5" id="f-549" unitRef="usd">20000000</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod contextRef="c-110" id="f-550">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-110" decimals="-3" id="f-551" unitRef="usd">245000</ino:CollaborativeAgreementFundingReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-111" decimals="INF" id="f-552" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-112" decimals="INF" id="f-553" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-113" decimals="-6" id="f-554" unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment contextRef="c-113" id="f-555">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-114" decimals="-5" id="f-556" unitRef="usd">1800000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-115" decimals="-5" id="f-557" unitRef="usd">6700000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-116" decimals="-5" id="f-558" unitRef="usd">10000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <us-gaap:AccountsReceivableNet contextRef="c-117" decimals="-5" id="f-559" unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-118" decimals="-5" id="f-560" unitRef="usd">1700000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c-117" decimals="-5" id="f-561" unitRef="usd">2200000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c-118" decimals="-5" id="f-562" unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-119" decimals="-5" id="f-563" unitRef="usd">9000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-120" decimals="-5" id="f-564" unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-121" decimals="-5" id="f-565" unitRef="usd">5000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-122" decimals="-5" id="f-566" unitRef="usd">1300000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-123" decimals="-3" id="f-567" unitRef="usd">330000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-124" decimals="-5" id="f-568" unitRef="usd">1100000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-125" decimals="-5" id="f-569" unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c-126" decimals="-5" id="f-570" unitRef="usd">2100000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:GrantsReceivable contextRef="c-127" decimals="-5" id="f-571" unitRef="usd">2300000</us-gaap:GrantsReceivable>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-128" decimals="-5" id="f-572" unitRef="usd">2200000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-129" decimals="-5" id="f-573" unitRef="usd">1100000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-130" decimals="-3" id="f-574" unitRef="usd">70000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-131" decimals="-3" id="f-575" unitRef="usd">233000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-132" decimals="-3" id="f-576" unitRef="usd">182000</ino:CollaborativeAgreementFundingToBeReceived>
    <us-gaap:GrantsReceivable contextRef="c-133" decimals="-3" id="f-577" unitRef="usd">87000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable contextRef="c-134" decimals="-3" id="f-578" unitRef="usd">153000</us-gaap:GrantsReceivable>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-135" decimals="-5" id="f-579" unitRef="usd">54500000</ino:CollaborativeAgreementFundingReceived>
    <ino:GrantProceedsReceived contextRef="c-136" decimals="-5" id="f-580" unitRef="usd">0</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived contextRef="c-137" decimals="-5" id="f-581" unitRef="usd">6100000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived contextRef="c-138" decimals="-5" id="f-582" unitRef="usd">27100000</ino:GrantProceedsReceived>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded contextRef="c-135" decimals="-5" id="f-583" unitRef="usd">16800000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded contextRef="c-139" decimals="-5" id="f-584" unitRef="usd">10700000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:CollaborativeArrangementRevenueFromTheProcurementContract contextRef="c-140" decimals="-5" id="f-585" unitRef="usd">0</ino:CollaborativeArrangementRevenueFromTheProcurementContract>
    <ino:CollaborativeArrangementRevenueFromTheProcurementContract contextRef="c-141" decimals="-5" id="f-586" unitRef="usd">9600000</ino:CollaborativeArrangementRevenueFromTheProcurementContract>
    <ino:CollaborativeArrangementRevenueFromTheProcurementContract contextRef="c-142" decimals="-3" id="f-587" unitRef="usd">755000</ino:CollaborativeArrangementRevenueFromTheProcurementContract>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-589">Short-term Investments and Fair Value Measurements&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,389,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,522,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,164,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,873,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,036,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,373,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,001,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,450,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,802,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023 and 2022, the Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gross realized ga&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in on investments of $1,000 and $21,000, respectively, and gross realized loss on investments of $4.8 million and $4.1 million, respectively. During the years ended December&#160;31, 2023 and 2022, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $5.9&#160;million and $(7.8)&#160;million, respectively. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2023,&#160;2022&#160;and&#160;2021. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2023, the Company had&#160;21&#160;available-for-sale securities in a gross unrealized loss position, of which 20 with an aggregate total unrealized loss of $3.9 million were in such position for longer than 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2023&#160;were primarily due to changes in interest rates, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accordingly, at December&#160;31, 2023, the Company did not record an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.652%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,056,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,763,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,836,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,627,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,676,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,634,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 assets at December&#160;31, 2023 and 2022 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rations as unrealized gain or loss on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or as a gain or loss on investment in affiliated entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at December&#160;31, 2023 and 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;There were no Level 3 assets held as of December&#160;31, 2023 or 2022.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-588">Short-term Investments and Fair Value Measurements&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,389,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,522,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,164,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,873,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,036,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,373,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,001,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,450,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,802,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023 and 2022, the Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gross realized ga&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in on investments of $1,000 and $21,000, respectively, and gross realized loss on investments of $4.8 million and $4.1 million, respectively. During the years ended December&#160;31, 2023 and 2022, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $5.9&#160;million and $(7.8)&#160;million, respectively. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2023,&#160;2022&#160;and&#160;2021. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2023, the Company had&#160;21&#160;available-for-sale securities in a gross unrealized loss position, of which 20 with an aggregate total unrealized loss of $3.9 million were in such position for longer than 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2023&#160;were primarily due to changes in interest rates, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accordingly, at December&#160;31, 2023, the Company did not record an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.652%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,056,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,763,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,836,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,627,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,676,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,634,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 assets at December&#160;31, 2023 and 2022 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rations as unrealized gain or loss on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or as a gain or loss on investment in affiliated entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at December&#160;31, 2023 and 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;There were no Level 3 assets held as of December&#160;31, 2023 or 2022.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-590">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,389,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,522,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,164,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,873,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,036,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,373,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,001,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,450,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,802,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-143" decimals="0" id="f-591" unitRef="usd">55389289</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-143" decimals="0" id="f-592" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-143" decimals="0" id="f-593" unitRef="usd">3522888</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-143" decimals="0" id="f-594" unitRef="usd">51866401</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-144" id="f-595">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-145" decimals="0" id="f-596" unitRef="usd">75164782</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-145" decimals="0" id="f-597" unitRef="usd">24938</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-145" decimals="0" id="f-598" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-145" decimals="0" id="f-599" unitRef="usd">75189720</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-146" id="f-600">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-147" decimals="0" id="f-601" unitRef="usd">2978917</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-147" decimals="0" id="f-602" unitRef="usd">11709</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-147" decimals="0" id="f-603" unitRef="usd">300</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-147" decimals="0" id="f-604" unitRef="usd">2990326</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-148" decimals="0" id="f-605" unitRef="usd">1340439</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-148" decimals="0" id="f-606" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-148" decimals="0" id="f-607" unitRef="usd">403973</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-148" decimals="0" id="f-608" unitRef="usd">936466</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-5" decimals="0" id="f-609" unitRef="usd">134873427</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-5" decimals="0" id="f-610" unitRef="usd">36647</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-5" decimals="0" id="f-611" unitRef="usd">3927161</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-5" decimals="0" id="f-612" unitRef="usd">130982913</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-149" decimals="0" id="f-613" unitRef="usd">117036232</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-149" decimals="0" id="f-614" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-149" decimals="0" id="f-615" unitRef="usd">9373514</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-149" decimals="0" id="f-616" unitRef="usd">107662718</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-150" id="f-617">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-151" decimals="0" id="f-618" unitRef="usd">95001209</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-151" decimals="0" id="f-619" unitRef="usd">7567</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-151" decimals="0" id="f-620" unitRef="usd">44266</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-151" decimals="0" id="f-621" unitRef="usd">94964510</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-150" id="f-622">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-152" decimals="0" id="f-623" unitRef="usd">2977564</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-152" decimals="0" id="f-624" unitRef="usd">13664</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-152" decimals="0" id="f-625" unitRef="usd">320</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-152" decimals="0" id="f-626" unitRef="usd">2990908</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-153" decimals="0" id="f-627" unitRef="usd">1435592</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-153" decimals="0" id="f-628" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-153" decimals="0" id="f-629" unitRef="usd">384331</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-153" decimals="0" id="f-630" unitRef="usd">1051261</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-6" decimals="0" id="f-631" unitRef="usd">216450597</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-6" decimals="0" id="f-632" unitRef="usd">21231</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-6" decimals="0" id="f-633" unitRef="usd">9802431</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-6" decimals="0" id="f-634" unitRef="usd">206669397</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-1" decimals="-3" id="f-635" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-12" decimals="-3" id="f-636" unitRef="usd">21000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-1" decimals="-5" id="f-637" unitRef="usd">4800000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-12" decimals="-5" id="f-638" unitRef="usd">4100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-5" id="f-639" unitRef="usd">5900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-12" decimals="-5" id="f-640" unitRef="usd">-7800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-5"
      decimals="INF"
      id="f-641"
      unitRef="position">21</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="c-5"
      decimals="INF"
      id="f-642"
      unitRef="position">20</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-5" id="f-643" unitRef="usd">-3900000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-644">&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.652%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,056,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,763,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,836,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,627,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,676,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,634,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-154" decimals="0" id="f-645" unitRef="usd">51866401</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-155" decimals="0" id="f-646" unitRef="usd">51866401</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-156" decimals="0" id="f-647" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-157" decimals="0" id="f-648" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-158" decimals="0" id="f-649" unitRef="usd">75189720</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-159" decimals="0" id="f-650" unitRef="usd">75189720</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-160" decimals="0" id="f-651" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-161" decimals="0" id="f-652" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-162" decimals="0" id="f-653" unitRef="usd">2990326</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-163" decimals="0" id="f-654" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-164" decimals="0" id="f-655" unitRef="usd">2990326</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-165" decimals="0" id="f-656" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-166" decimals="0" id="f-657" unitRef="usd">936466</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-167" decimals="0" id="f-658" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-168" decimals="0" id="f-659" unitRef="usd">936466</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-169" decimals="0" id="f-660" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-170" decimals="0" id="f-661" unitRef="usd">130982913</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-171" decimals="0" id="f-662" unitRef="usd">127056121</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-172" decimals="0" id="f-663" unitRef="usd">3926792</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-173" decimals="0" id="f-664" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-170" decimals="0" id="f-665" unitRef="usd">2780287</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-171" decimals="0" id="f-666" unitRef="usd">2780287</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-172" decimals="0" id="f-667" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-173" decimals="0" id="f-668" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-170" decimals="0" id="f-669" unitRef="usd">133763200</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-171" decimals="0" id="f-670" unitRef="usd">129836408</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-172" decimals="0" id="f-671" unitRef="usd">3926792</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-173" decimals="0" id="f-672" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-174" decimals="0" id="f-673" unitRef="usd">107662718</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-175" decimals="0" id="f-674" unitRef="usd">107662718</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-176" decimals="0" id="f-675" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-177" decimals="0" id="f-676" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-178" decimals="0" id="f-677" unitRef="usd">94964510</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-179" decimals="0" id="f-678" unitRef="usd">94964510</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-180" decimals="0" id="f-679" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-181" decimals="0" id="f-680" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-182" decimals="0" id="f-681" unitRef="usd">2990908</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-183" decimals="0" id="f-682" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-184" decimals="0" id="f-683" unitRef="usd">2990908</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-185" decimals="0" id="f-684" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-186" decimals="0" id="f-685" unitRef="usd">1051261</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-187" decimals="0" id="f-686" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-188" decimals="0" id="f-687" unitRef="usd">1051261</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-189" decimals="0" id="f-688" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-190" decimals="0" id="f-689" unitRef="usd">206669397</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-191" decimals="0" id="f-690" unitRef="usd">202627228</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-192" decimals="0" id="f-691" unitRef="usd">4042169</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-193" decimals="0" id="f-692" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-190" decimals="0" id="f-693" unitRef="usd">2007142</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-191" decimals="0" id="f-694" unitRef="usd">2007142</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-192" decimals="0" id="f-695" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-193" decimals="0" id="f-696" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-190" decimals="0" id="f-697" unitRef="usd">208676539</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-191" decimals="0" id="f-698" unitRef="usd">204634370</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-192" decimals="0" id="f-699" unitRef="usd">4042169</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-193" decimals="0" id="f-700" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-194"
      decimals="INF"
      id="f-701"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-195"
      decimals="INF"
      id="f-702"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c-1" id="f-703">Certain Balance Sheet Items&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets at December&#160;31, 2023 and 2022 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance recovery (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,486,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,907,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,729,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,393,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,130,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses at December&#160;31, 2023 and 2022 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,862,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,574,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued litigation settlement (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses (b) (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,432,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,847,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,686,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:24.91pt"&gt;In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of class action securities litigation (see Note 11). The final judicial order for the settlement was issued in January 2023. The settlement consisted of $30.0&#160;million in cash and $14.0&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts were offset against the insurers' cash commitment as part of the settlement. During the three months ended March 31, 2023, the cash component of the settlement was released from escrow and the Company issued 760,083 shares of common stock pursuant to the securities class action settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)        In March 2023, the Company entered into a stipulation of settlement for the proposed settlement of shareholder derivative litigation (see Note 11). In June 2023, the court preliminarily approved the proposed settlement. As part of the settlement, in July 2023, the Company paid $1.2&#160;million to plaintiffs&#x2019; counsel for their fees and expenses. This amount was accrued within &#x201c;Other accrued expenses&#x201d; as of December 31, 2022. On October 12, 2023, the court entered an order and final judgment approving the Settlement, which was effective on November 13, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)       December 31, 2023 balance includes $4.3&#160;million liability for unused grant funding.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-704">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets at December&#160;31, 2023 and 2022 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance recovery (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,486,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,907,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,729,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,393,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,130,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:EstimatedInsuranceRecoveries contextRef="c-5" decimals="0" id="f-705" unitRef="usd">0</us-gaap:EstimatedInsuranceRecoveries>
    <us-gaap:EstimatedInsuranceRecoveries contextRef="c-6" decimals="0" id="f-706" unitRef="usd">30000000</us-gaap:EstimatedInsuranceRecoveries>
    <ino:PrepaidManufacturingExpensesCurrent contextRef="c-5" decimals="0" id="f-707" unitRef="usd">1486638</ino:PrepaidManufacturingExpensesCurrent>
    <ino:PrepaidManufacturingExpensesCurrent contextRef="c-6" decimals="0" id="f-708" unitRef="usd">1401028</ino:PrepaidManufacturingExpensesCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-5" decimals="0" id="f-709" unitRef="usd">3907027</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-6" decimals="0" id="f-710" unitRef="usd">18729453</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="0" id="f-711" unitRef="usd">5393665</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="0" id="f-712" unitRef="usd">50130481</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-713">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses at December&#160;31, 2023 and 2022 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,862,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,574,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued litigation settlement (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses (b) (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,432,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,847,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,686,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:24.91pt"&gt;In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of class action securities litigation (see Note 11). The final judicial order for the settlement was issued in January 2023. The settlement consisted of $30.0&#160;million in cash and $14.0&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts were offset against the insurers' cash commitment as part of the settlement. During the three months ended March 31, 2023, the cash component of the settlement was released from escrow and the Company issued 760,083 shares of common stock pursuant to the securities class action settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)        In March 2023, the Company entered into a stipulation of settlement for the proposed settlement of shareholder derivative litigation (see Note 11). In June 2023, the court preliminarily approved the proposed settlement. As part of the settlement, in July 2023, the Company paid $1.2&#160;million to plaintiffs&#x2019; counsel for their fees and expenses. This amount was accrued within &#x201c;Other accrued expenses&#x201d; as of December 31, 2022. On October 12, 2023, the court entered an order and final judgment approving the Settlement, which was effective on November 13, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)       December 31, 2023 balance includes $4.3&#160;million liability for unused grant funding.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent contextRef="c-7" decimals="0" id="f-714" unitRef="usd">3577826</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent contextRef="c-8" decimals="0" id="f-715" unitRef="usd">19862487</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-7" decimals="0" id="f-716" unitRef="usd">9837104</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-8" decimals="0" id="f-717" unitRef="usd">12574921</us-gaap:AccruedSalariesCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c-7" decimals="0" id="f-718" unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c-8" decimals="0" id="f-719" unitRef="usd">44000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-7" decimals="0" id="f-720" unitRef="usd">6432814</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-8" decimals="0" id="f-721" unitRef="usd">3249477</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-7" decimals="0" id="f-722" unitRef="usd">19847744</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-8" decimals="0" id="f-723" unitRef="usd">79686885</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-196" decimals="-5" id="f-724" unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <ino:LossContingencyEstimateOfPossibleLossValueOfShares contextRef="c-196" decimals="-5" id="f-725" unitRef="usd">14000000</ino:LossContingencyEstimateOfPossibleLossValueOfShares>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-197" decimals="-3" id="f-726" unitRef="usd">252000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <ino:LitigationSettlementAmountAwardedToOtherPartyShares
      contextRef="c-198"
      decimals="INF"
      id="f-727"
      unitRef="shares">760083</ino:LitigationSettlementAmountAwardedToOtherPartyShares>
    <us-gaap:LossContingencyDamagesPaidValue contextRef="c-199" decimals="-5" id="f-728" unitRef="usd">1200000</us-gaap:LossContingencyDamagesPaidValue>
    <ino:GrantLiability contextRef="c-1" decimals="-5" id="f-729" unitRef="usd">4300000</ino:GrantLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-730">Fixed Assets&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets at December&#160;31, 2023 and 2022 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;br/&gt;and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,917,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,753,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,164,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,538,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,078,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,816,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,204,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,812,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,851,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,960,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,803,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,036,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,767,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,300,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,295,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,803,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,360,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,428,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,291,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,563,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,727,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation expense for the years ended December&#160;31, 2023, 2022 and 2021 was $2.6 million, $3.7 million and $3.0 million, respectively. The Company determined that the carrying value of its fixed assets was not impaired during the periods presented. During the year ended December 31, 2023, the Company sold fixed assets with no net book value for a gain of $148,000 and disposed of fixed assets with a net book value of $466,000. During the year ended December 31, 2022 the Company sold fixed assets with a net book value of $6.1&#160;million and disposed of fixed assets with a net book value of $1.1&#160;million.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-731">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets at December&#160;31, 2023 and 2022 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;br/&gt;and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,917,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,753,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,164,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,538,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,078,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,816,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,204,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,812,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,851,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,960,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,803,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,036,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,767,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,300,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,295,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,803,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,360,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,428,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,291,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,563,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,727,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-200" decimals="0" id="f-732" unitRef="usd">15917596</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-200" decimals="0" id="f-733" unitRef="usd">11753081</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-200" decimals="0" id="f-734" unitRef="usd">4164515</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-201" decimals="0" id="f-735" unitRef="usd">3538698</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-201" decimals="0" id="f-736" unitRef="usd">3078165</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-201" decimals="0" id="f-737" unitRef="usd">460533</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-202" decimals="0" id="f-738" unitRef="usd">2827476</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-202" decimals="0" id="f-739" unitRef="usd">2816577</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-202" decimals="0" id="f-740" unitRef="usd">10899</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-203" decimals="0" id="f-741" unitRef="usd">3529129</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-203" decimals="0" id="f-742" unitRef="usd">3204090</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-203" decimals="0" id="f-743" unitRef="usd">325039</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="0" id="f-744" unitRef="usd">25812899</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="0" id="f-745" unitRef="usd">20851913</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="0" id="f-746" unitRef="usd">4960986</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-204" decimals="0" id="f-747" unitRef="usd">15803108</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-204" decimals="0" id="f-748" unitRef="usd">10036080</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-204" decimals="0" id="f-749" unitRef="usd">5767028</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-205" decimals="0" id="f-750" unitRef="usd">5300104</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-205" decimals="0" id="f-751" unitRef="usd">4295217</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-205" decimals="0" id="f-752" unitRef="usd">1004887</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-206" decimals="0" id="f-753" unitRef="usd">2827476</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-206" decimals="0" id="f-754" unitRef="usd">2803800</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-206" decimals="0" id="f-755" unitRef="usd">23676</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-207" decimals="0" id="f-756" unitRef="usd">5360712</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-207" decimals="0" id="f-757" unitRef="usd">4428306</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-207" decimals="0" id="f-758" unitRef="usd">932406</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-6" decimals="0" id="f-759" unitRef="usd">29291400</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="0" id="f-760" unitRef="usd">21563403</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="0" id="f-761" unitRef="usd">7727997</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-762" unitRef="usd">2600000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-12" decimals="-5" id="f-763" unitRef="usd">3700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="-5" id="f-764" unitRef="usd">3000000</us-gaap:Depreciation>
    <ino:PropertyPlantAndEquipmentDisposedOfBySale contextRef="c-1" decimals="-3" id="f-765" unitRef="usd">148000</ino:PropertyPlantAndEquipmentDisposedOfBySale>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="c-1" decimals="-3" id="f-766" unitRef="usd">466000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <ino:PropertyPlantAndEquipmentDisposedOfBySale contextRef="c-12" decimals="-5" id="f-767" unitRef="usd">6100000</ino:PropertyPlantAndEquipmentDisposedOfBySale>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="c-12" decimals="-5" id="f-768" unitRef="usd">1100000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-769">Goodwill and Intangible Assets&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three months ended September 30, 2023, as a result of the sustained decline in the Company&#x2019;s stock price and related market capitalization, and a general decline in equity values in the biotechnology industry, the Company performed an impairment assessment of its goodwill and long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company operates as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company&#x2019;s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company&#x2019;s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represented a level 2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a non-cash, pre-tax goodwill impairment charge of $10.5&#160;million during the three months ended September 30, 2023. As a result, the goodwill was fully impaired as of September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Before completing the goodwill impairment assessment, the Company first tested its long-lived assets for impairment. The Company held no indefinite-lived intangible assets as of Sep&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;tember 30, 2023. The Company determined that all of its long-lived assets, which included property and equipment, leasehold improvements and right-of-use assets, represented one asset group for purposes of its long-lived asset impairment assessment. The Company concluded that the long-lived assets were not impaired, as their carrying values were not in excess of their fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the quarter ended June 30, 2023, the Company recorded an impairment charge of $2.0&#160;million to research and development expense for the remaining book value of intangible assets acquired in 2016 from Bioject Medical Technologies, as the Company had no plans to further develop or utilize this technology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.267%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,513,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,323,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Bioject &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,115,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,984,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,988,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,111,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,050,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,031,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,165,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,984,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,343,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,129,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,663,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,165,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,497,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,343,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,643,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense related to intangible assets was $145,000, $496,000 and $520,000 for the years ended December&#160;31, 2023, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no impairment or impairment indicators present and no losses were recorded during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-57" decimals="-5" id="f-770" unitRef="usd">10500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-58" decimals="-5" id="f-771" unitRef="usd">2000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-772">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.267%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,513,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,323,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Bioject &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,115,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,984,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,988,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,111,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,050,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,031,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,165,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,984,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,343,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,129,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,663,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,165,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,497,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,343,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,643,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;Other intangible assets represent the estimated fair value of acquired intellectual property.</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:GoodwillGross contextRef="c-5" decimals="0" id="f-773" unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="0" id="f-774" unitRef="usd">10513371</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill contextRef="c-5" decimals="0" id="f-775" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:GoodwillGross contextRef="c-6" decimals="0" id="f-776" unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill contextRef="c-6" decimals="0" id="f-777" unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-208" id="f-778">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-209" decimals="0" id="f-779" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-209" decimals="0" id="f-780" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-210" decimals="0" id="f-781" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-209" decimals="0" id="f-782" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-211" decimals="0" id="f-783" unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-211" decimals="0" id="f-784" unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-211" decimals="0" id="f-785" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-212" decimals="0" id="f-786" unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-212" decimals="0" id="f-787" unitRef="usd">3115556</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-213" decimals="0" id="f-788" unitRef="usd">1984444</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-212" decimals="0" id="f-789" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-214" decimals="0" id="f-790" unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-214" decimals="0" id="f-791" unitRef="usd">2988889</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-214" decimals="0" id="f-792" unitRef="usd">2111111</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-215" id="f-793">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-216" decimals="0" id="f-794" unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-216" decimals="0" id="f-795" unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-217" decimals="0" id="f-796" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-216" decimals="0" id="f-797" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-218" decimals="0" id="f-798" unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-218" decimals="0" id="f-799" unitRef="usd">4031250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-218" decimals="0" id="f-800" unitRef="usd">18750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-219" id="f-801">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-5" decimals="0" id="f-802" unitRef="usd">9150000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="0" id="f-803" unitRef="usd">7165556</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="0" id="f-804" unitRef="usd">1984444</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="0" id="f-805" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-6" decimals="0" id="f-806" unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-6" decimals="0" id="f-807" unitRef="usd">8343900</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-6" decimals="0" id="f-808" unitRef="usd">2129861</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross contextRef="c-5" decimals="0" id="f-809" unitRef="usd">19663371</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="0" id="f-810" unitRef="usd">7165556</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="0" id="f-811" unitRef="usd">12497815</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <ino:GoodwillAndIntangibleAssetsNet contextRef="c-5" decimals="0" id="f-812" unitRef="usd">0</ino:GoodwillAndIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross contextRef="c-6" decimals="0" id="f-813" unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-6" decimals="0" id="f-814" unitRef="usd">8343900</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet contextRef="c-6" decimals="0" id="f-815" unitRef="usd">12643232</ino:GoodwillAndIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-816" unitRef="usd">145000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-12" decimals="-3" id="f-817" unitRef="usd">496000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-3" id="f-818" unitRef="usd">520000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-13" decimals="INF" id="f-819" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-12" decimals="INF" id="f-820" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-13" decimals="INF" id="f-821" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-12" decimals="INF" id="f-822" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-823">Convertible Debt&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Notes were senior unsecured obligations of the Company and accrued interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes matured on March 1, 2024 and the Company paid the then remaining $16.9&#160;million obligation in full, including accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $16.3&#160;million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of 13.1%. In addition, the Company allocated $592,000 of debt issuance costs to the equity component and the remaining debt issuance costs of $2.2&#160;million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, the Company adopted ASU No. 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;). The ASU eliminated the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, the Company accounted for these securities as a single unit of account, unless the conversion feature met certain criteria. The Company adopted the new standard using the modified retrospective method and recorded a net reduction to accumulated deficit of $1.8&#160;million, a decrease to additional paid-in capital of $3.3&#160;million, and an increase to convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Notes were subsequently accounted for as a single liability measured at amortized cost, as no other embedded features required bifurcation and recognition as derivatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at December&#160;31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.327%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,770,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;For the years ended December&#160;31, 2023, 2022 and 2021,&#160;the Company recognized $1.2 million, $1.3&#160;million and $1.9&#160;million, respectively, of interest expense related to the Notes, of which $1.1 million related to the contractual interest coupon in each year.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-220" decimals="INF" id="f-824" unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-221" decimals="INF" id="f-825" unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-221"
      decimals="INF"
      id="f-826"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-220"
      decimals="INF"
      id="f-827"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-222" decimals="-5" id="f-828" unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-221"
      decimals="INF"
      id="f-829"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-223" decimals="-5" id="f-830" unitRef="usd">16900000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-221" decimals="-5" id="f-831" unitRef="usd">16300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-224" decimals="3" id="f-832" unitRef="number">0.131</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-224" decimals="-3" id="f-833" unitRef="usd">592000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-225" decimals="-5" id="f-834" unitRef="usd">2200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-226" decimals="-5" id="f-835" unitRef="usd">1800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="c-226" decimals="-5" id="f-836" unitRef="usd">-3300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ConvertibleDebt contextRef="c-226" decimals="-5" id="f-837" unitRef="usd">1500000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="c-1" id="f-838">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at December&#160;31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.327%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,770,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-227" decimals="0" id="f-839" unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <ino:DebtInstrumentConvertibleDebtConvertedAmount contextRef="c-227" decimals="0" id="f-840" unitRef="usd">62085000</ino:DebtInstrumentConvertibleDebtConvertedAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-227" decimals="0" id="f-841" unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtinstrumentAccruedInterest contextRef="c-227" decimals="0" id="f-842" unitRef="usd">355654</ino:DebtinstrumentAccruedInterest>
    <us-gaap:LongTermDebt contextRef="c-227" decimals="0" id="f-843" unitRef="usd">16770654</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense contextRef="c-228" decimals="-5" id="f-844" unitRef="usd">1200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-229" decimals="-5" id="f-845" unitRef="usd">1300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-230" decimals="-5" id="f-846" unitRef="usd">1900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt contextRef="c-228" decimals="-5" id="f-847" unitRef="usd">1100000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-848">Stockholders&#x2019; Equity&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Outstanding as of&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par $0.001&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The holder of a share or shares of Series C preferred stock has the right at any time, at such holder&#x2019;s option, to convert all or any lesser portion of such holder&#x2019;s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2021, the conversion value w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;as $326.40 per share, such&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; that the outstanding shares of Series C preferred stock were convertible into an aggregate of 275 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuances of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2021, the Company entered into an ATM Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with outside sales agents (collectively, the &#x201c;Sales Agents&#x201d;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the years ended December&#160;31, 2023 and 2022, the Company sold 875,305 and 2,870,478 shares, respectively, of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $6.33 and $29.34 per share, respectively, resulting in aggregate net proceeds of $5.5&#160;million and $83.0&#160;million, respectively. As of December&#160;31, 2023 there was $161.8&#160;million of remaining capacity under the 2021 Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, the Company issued 760,083 shares of common stock pursuant to the securities class action settlement, as described in Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Board of Directors adopted the 2023 Omnibus Incentive Plan (the &#x201c;2023 Plan&#x201d;) on March 24, 2023, pursuant to which the Company may grant stock options, restricted stock awards, RSUs and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Plan was approved by stockholders on May 16, 2023. The aggregate number of shares of the Company&#x2019;s common stock that may be issued under the 2023 Plan will not exceed the sum of 1,166,666 shares plus any shares that may return from time to time from the 2016 Omnibus Incentive Plan (as amended, the &#x201c;2016 Plan&#x201d;) as a result of expirations, terminations or forfeitures of awards outstanding under the 2016 Plan as of May 16, 2023. At December&#160;31, 2023, the Company had 1,334,012 shares of common stock available for future grant under the 2023 Plan, 1,875 shares underlying outstanding but unvested RSUs and 3,150 shares underlying options outstanding to purchase common stock under the 2023 Plan. The awards granted and available for future grant under the 2023 Plan generally vest over three years and have a maximum contractual term of ten years. The 2023 Plan terminates by its terms on March&#160;24, 2033.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, the Company had 262,641 shares underlying outstanding but unvested RSU and options outstanding to purchase 961,499 shares of common stock under the 2016 Plan. The outstanding awards granted under the 2016 Plan generally vest over three years and have a maximum contractual term of ten years. Following adoption of the 2023 Plan, no further awards may be made under the 2016 Plan, but outstanding awards continue to be governed by their existing terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#x2019;s common stock that may be issued under the 2022 Inducement Plan will not exceed 166,666 shares. At December&#160;31, 2023 the Company had 125,575 shares of common stock available for future grant under the 2022 Inducement Plan, 10,278 shares underlying outstanding but unvested RSUs and options outstanding to purchase 27,759 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2023, the Company had options outstanding to purchase 136,456 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2023, 2022 and 2021 was $10.4 million, $22.2 million and $25.0 million, respectively, of which $4.5 million, $8.8 million and $13.4 million was included in research and development expenses and $5.9 million, $13.4 million and $11.6 million was included in general and administrative expenses, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023 and 2022, there was $4.3 million and $10.5 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.3 years and 1.6 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2023 and 2022, there was $3.5 million and $7.2 million, respectively, of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.5 years and 1.7 years, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the years ended December&#160;31, 2023, 2022 and 2021 was $669,000, $1.3 million and $1.4 million, respectively. As of December&#160;31, 2023, options to purchase 61,808 shares of common stock granted to non-employees remained outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock options outstanding at December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted    Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.32-$18.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$18.01-$39.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$39.01-$52.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$52.01-$90.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$90.01-$130.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.01-$233.28&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, the aggregate intrinsic value of options outstanding was $2,000, the aggregate intrinsic value of options exercisable was $1,000, and the weighted average remaining contractual term of options exercisable was 5.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2023, the aggregate intrinsic value of unvested RSUs was $1.7 million and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2023 was $1.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2023, options to purchase 1,128,864 shares of common stock and 274,794 RSUs were expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2023 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average exercise price per share was $38.86 for the 9,357 options which expired during the year ended December&#160;31, 2023, $101.64 for the 6,437 options which expired during the year ended December&#160;31, 2022 and $54.72 for the 583 options which expired during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share was $11.19, $28.08 and $91.32 for options granted during the years ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value was $10.34, $37.44 and $124.44 per share for RSUs granted during the years ended December&#160;31, 2023, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No stock options were exercised during the year ended December 31, 2023.  The Company received $283,000 and $6.7 million in proceeds from the exercise of stock options during the years ended December&#160;31, 2022 and 2021, respectively. The aggregate intrinsic value of options exercised was $81,000 and $7.0 million during the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-849">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Outstanding as of&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par $0.001&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-231"
      decimals="INF"
      id="f-850"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-232"
      decimals="INF"
      id="f-851"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-232"
      decimals="INF"
      id="f-852"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-232"
      decimals="INF"
      id="f-853"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-232"
      decimals="INF"
      id="f-854"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-231"
      decimals="INF"
      id="f-855"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare
      contextRef="c-13"
      decimals="2"
      id="f-856"
      unitRef="usdPerShare">326.40</ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c-233"
      decimals="INF"
      id="f-857"
      unitRef="shares">275</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <ino:StockSalesAgreementMaximumAuthorizedAmount contextRef="c-234" decimals="INF" id="f-858" unitRef="usd">300000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage
      contextRef="c-234"
      decimals="INF"
      id="f-859"
      unitRef="number">0.030</ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="c-235"
      decimals="INF"
      id="f-860"
      unitRef="shares">875305</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="c-236"
      decimals="INF"
      id="f-861"
      unitRef="shares">2870478</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="c-235"
      decimals="2"
      id="f-862"
      unitRef="usdPerShare">6.33</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="c-236"
      decimals="2"
      id="f-863"
      unitRef="usdPerShare">29.34</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="c-235" decimals="-5" id="f-864" unitRef="usd">5500000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="c-236" decimals="-5" id="f-865" unitRef="usd">83000000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount contextRef="c-237" decimals="-5" id="f-866" unitRef="usd">161800000</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <ino:LitigationSettlementAmountAwardedToOtherPartyShares
      contextRef="c-198"
      decimals="INF"
      id="f-867"
      unitRef="shares">760083</ino:LitigationSettlementAmountAwardedToOtherPartyShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-238"
      decimals="INF"
      id="f-868"
      unitRef="shares">1166666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-239"
      decimals="INF"
      id="f-869"
      unitRef="shares">1334012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-239"
      decimals="INF"
      id="f-870"
      unitRef="shares">1875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-239"
      decimals="INF"
      id="f-871"
      unitRef="shares">3150</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-240" id="f-872">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="c-240" id="f-873">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan
      contextRef="c-241"
      decimals="INF"
      id="f-874"
      unitRef="shares">262641</ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-242"
      decimals="INF"
      id="f-875"
      unitRef="shares">961499</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-241" id="f-876">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="c-241" id="f-877">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-243"
      decimals="INF"
      id="f-878"
      unitRef="shares">166666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-244"
      decimals="INF"
      id="f-879"
      unitRef="shares">125575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-244"
      decimals="INF"
      id="f-880"
      unitRef="shares">10278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-244"
      decimals="INF"
      id="f-881"
      unitRef="shares">27759</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-245"
      decimals="INF"
      id="f-882"
      unitRef="shares">136456</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-246" id="f-883">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="c-246" id="f-884">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-885" unitRef="usd">10400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-5" id="f-886" unitRef="usd">22200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-5" id="f-887" unitRef="usd">25000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-247" decimals="-5" id="f-888" unitRef="usd">4500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-248" decimals="-5" id="f-889" unitRef="usd">8800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-249" decimals="-5" id="f-890" unitRef="usd">13400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-250" decimals="-5" id="f-891" unitRef="usd">5900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-251" decimals="-5" id="f-892" unitRef="usd">13400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-252" decimals="-5" id="f-893" unitRef="usd">11600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-5" decimals="-5" id="f-894" unitRef="usd">4300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-6" decimals="-5" id="f-895" unitRef="usd">10500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-896">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-12" id="f-897">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-253" decimals="-5" id="f-898" unitRef="usd">3500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-254" decimals="-5" id="f-899" unitRef="usd">7200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-255" id="f-900">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-256" id="f-901">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-257" decimals="-3" id="f-902" unitRef="usd">669000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-258" decimals="-5" id="f-903" unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-259" decimals="-5" id="f-904" unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-260"
      decimals="INF"
      id="f-905"
      unitRef="shares">61808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c-1" id="f-906">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock options outstanding at December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted    Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.32-$18.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$18.01-$39.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$39.01-$52.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$52.01-$90.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$90.01-$130.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.01-$233.28&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-261"
      decimals="INF"
      id="f-907"
      unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-261"
      decimals="INF"
      id="f-908"
      unitRef="usdPerShare">18.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-262"
      decimals="INF"
      id="f-909"
      unitRef="shares">283472</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-261" id="f-910">P9Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-262"
      decimals="2"
      id="f-911"
      unitRef="usdPerShare">14.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-262"
      decimals="INF"
      id="f-912"
      unitRef="shares">66918</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-262"
      decimals="2"
      id="f-913"
      unitRef="usdPerShare">14.45</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-263"
      decimals="INF"
      id="f-914"
      unitRef="usdPerShare">18.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-263"
      decimals="INF"
      id="f-915"
      unitRef="usdPerShare">39.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-264"
      decimals="INF"
      id="f-916"
      unitRef="shares">264108</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-263" id="f-917">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-264"
      decimals="2"
      id="f-918"
      unitRef="usdPerShare">35.69</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-264"
      decimals="INF"
      id="f-919"
      unitRef="shares">141600</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-264"
      decimals="2"
      id="f-920"
      unitRef="usdPerShare">34.99</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-265"
      decimals="INF"
      id="f-921"
      unitRef="usdPerShare">39.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-265"
      decimals="INF"
      id="f-922"
      unitRef="usdPerShare">52.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-266"
      decimals="INF"
      id="f-923"
      unitRef="shares">156505</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-265" id="f-924">P4Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-266"
      decimals="2"
      id="f-925"
      unitRef="usdPerShare">44.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-266"
      decimals="INF"
      id="f-926"
      unitRef="shares">156271</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-266"
      decimals="2"
      id="f-927"
      unitRef="usdPerShare">44.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-267"
      decimals="INF"
      id="f-928"
      unitRef="usdPerShare">52.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-267"
      decimals="INF"
      id="f-929"
      unitRef="usdPerShare">90.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-268"
      decimals="INF"
      id="f-930"
      unitRef="shares">129681</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-267" id="f-931">P4Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-268"
      decimals="2"
      id="f-932"
      unitRef="usdPerShare">76.82</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-268"
      decimals="INF"
      id="f-933"
      unitRef="shares">121124</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-268"
      decimals="2"
      id="f-934"
      unitRef="usdPerShare">77.75</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-269"
      decimals="INF"
      id="f-935"
      unitRef="usdPerShare">90.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-269"
      decimals="INF"
      id="f-936"
      unitRef="usdPerShare">130.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-270"
      decimals="INF"
      id="f-937"
      unitRef="shares">136716</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-269" id="f-938">P4Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-270"
      decimals="2"
      id="f-939"
      unitRef="usdPerShare">100.15</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-270"
      decimals="INF"
      id="f-940"
      unitRef="shares">131640</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-270"
      decimals="2"
      id="f-941"
      unitRef="usdPerShare">100.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-271"
      decimals="INF"
      id="f-942"
      unitRef="usdPerShare">130.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-271"
      decimals="INF"
      id="f-943"
      unitRef="usdPerShare">233.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-272"
      decimals="INF"
      id="f-944"
      unitRef="shares">158382</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-271" id="f-945">P5Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-272"
      decimals="2"
      id="f-946"
      unitRef="usdPerShare">140.27</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-272"
      decimals="INF"
      id="f-947"
      unitRef="shares">129250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-272"
      decimals="2"
      id="f-948"
      unitRef="usdPerShare">141.78</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c-5" decimals="INF" id="f-949" unitRef="shares">1128864</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-950">P6Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-5"
      decimals="2"
      id="f-951"
      unitRef="usdPerShare">58.76</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c-5" decimals="INF" id="f-952" unitRef="shares">746803</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-5"
      decimals="2"
      id="f-953"
      unitRef="usdPerShare">72.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue contextRef="c-1" decimals="-3" id="f-954" unitRef="usd">2000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-5" decimals="-3" id="f-955" unitRef="usd">1000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm contextRef="c-1" id="f-956">P5Y6M</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested contextRef="c-253" decimals="-5" id="f-957" unitRef="usd">1700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-255" decimals="-5" id="f-958" unitRef="usd">1300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber contextRef="c-5" decimals="INF" id="f-959" unitRef="shares">1128864</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber
      contextRef="c-253"
      decimals="INF"
      id="f-960"
      unitRef="shares">274794</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-961">&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2023 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="INF" id="f-962" unitRef="shares">1018095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-963"
      unitRef="usdPerShare">75.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-964" unitRef="shares">339019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-965"
      unitRef="usdPerShare">14.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-966" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-967"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-968" unitRef="shares">228250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-969"
      unitRef="usdPerShare">66.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-970" unitRef="shares">1128864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-971"
      unitRef="usdPerShare">58.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-972">&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-254"
      decimals="INF"
      id="f-973"
      unitRef="shares">212964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-255"
      decimals="INF"
      id="f-974"
      unitRef="shares">194747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-255"
      decimals="INF"
      id="f-975"
      unitRef="shares">99420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-255"
      decimals="INF"
      id="f-976"
      unitRef="shares">33497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-253"
      decimals="INF"
      id="f-977"
      unitRef="shares">274794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-978"
      unitRef="usdPerShare">38.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-979" unitRef="shares">9357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-12"
      decimals="2"
      id="f-980"
      unitRef="usdPerShare">101.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-12"
      decimals="INF"
      id="f-981"
      unitRef="shares">6437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-13"
      decimals="2"
      id="f-982"
      unitRef="usdPerShare">54.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-13"
      decimals="INF"
      id="f-983"
      unitRef="shares">583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-984"
      unitRef="usdPerShare">11.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-12"
      decimals="2"
      id="f-985"
      unitRef="usdPerShare">28.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-13"
      decimals="2"
      id="f-986"
      unitRef="usdPerShare">91.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-255"
      decimals="2"
      id="f-987"
      unitRef="usdPerShare">10.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-256"
      decimals="2"
      id="f-988"
      unitRef="usdPerShare">37.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-273"
      decimals="2"
      id="f-989"
      unitRef="usdPerShare">124.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-990" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-12" decimals="-3" id="f-991" unitRef="usd">283000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-13" decimals="-3" id="f-992" unitRef="usd">6700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-12" decimals="-3" id="f-993" unitRef="usd">81000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-13" decimals="-3" id="f-994" unitRef="usd">7000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-996">Commitments and Contingencies&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 56,600 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December&#160;31, 2023 of 3.4 years to 6.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Company amended one of its leases representing 31,207 square feet of office and laboratory space with a lease term expiring in November 2023, to extend the term to February 29, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Company entered into a lease agreement for research and development laboratory space in San Diego, California ("New San Diego Lease"). The total space under the New San Diego Lease is approximately 5,563 square feet.  The term of the New San Diego Lease commenced on February 10, 2024 and the initial term is 4.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The base rent adjusts periodically throughout the term of the New San Diego Lease.  Rent payments under the New San Diego Lease will include base rent with an annual increase of approximately three percent, and additional monthly fees to cover the Company's share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, the Company has paid a security deposit of $33,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.351%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,247,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,466,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,555,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,310,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,665,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,226,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,439,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,407,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,032,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2023, 2022 and 2021 were $3.5 million, $3.4 million and $3.4 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the third and fourth quarters of 2023, the Company entered into agreements to sublease a total of approximately 4,400 and 7,000 square feet, respectively, in its Plymouth Meeting headquarters, in each case with sublease terms through December 31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters, with one sublease term through March 31, 2025 and the other month-to-month.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#x2019; fees. The plaintiffs&#x2019; complaint was later amended to include certain of the Company&#x2019;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, the Company agreed to pay $30.0&#160;million in cash and $14.0&#160;million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers paid the $30.0&#160;million cash component of the settlement. During the three months ended March 31, 2023, the Company issued 760,083 shares of common stock pursuant to the securities class action settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholder Derivative Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserted state and federal claims and was based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accused the Company&#x2019;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#x2019;s management, policies, practices, and internal controls. The plaintiff sought unspecified &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;monetary damages on behalf of the Company as well as governance reforms. Between June 2020 and August 2020, additional shareholder derivative complaints were filed and later consolidated by the court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, an additional shareholder derivative complaint was filed in the Delaware Court of Chancery, asserting substantially similar claims as those in the consolidated derivative action. In May 2022, the Delaware Court of Chancery entered a stay of the litigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the parties submitted a joint status report to the Court of Chancery reporting that the parties agreed to a settlement in principle, which also provided for the resolution of the consolidated derivative action and certain stockholder demands. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, the plaintiffs in the consolidated derivative action filed a motion for preliminary approval of settlement with the United States District Court for the Eastern District of Pennsylvania. The proposed settlement provided for resolution of the consolidated derivative action, the derivative action pending in the Delaware Court of Chancery, and certain stockholder demands.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, the court entered an order preliminarily approving the proposed settlement of the derivative claims, in accordance with a Stipulation of Settlement. The Stipulation of Settlement contemplated that, following the settlement hearing and the final approval of the settlement by the court, the Company would implement certain corporate governance reforms described in the Stipulation of Settlement. The preliminary order also approved the form and manner of the notice of the Settlement. As part of the Settlement, in July 2023 the Company paid $1.2&#160;million to plaintiffs&#x2019; counsel for their fees and expenses. In October 2023, the court entered an order and final judgment approving the Settlement, which became effective in November 2023. The Company has implemented the corporate governance reforms in response to the provisions of the Stipulation of Settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VGXI Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#x2019;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#x2019; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following an appeal by the Company, in July 2020, VGXI filed counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#x2019; fees, interest, costs and other relief from the Company. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. The Company filed an answer to VGXI&#x2019;s counterclaims, disputing the allegations and the claims raised in VGXI&#x2019;s filing. In October 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#x2019;s counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GeneOne Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#x2019; fees, interest, and other relief from the Company. The Company filed preliminary objections to the complaint, which were overruled by the court. In September 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#x2019;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The counterclaims seek damages, interest, expenses, attorney&#x2019;s fees, and costs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A trial date for this litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#x2019;s complaint. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#x2019;s consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-275" decimals="0" id="f-997" unitRef="sqft">56600</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-276" decimals="0" id="f-998" unitRef="sqft">57360</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-55" id="f-999">P3Y4M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-56" id="f-1000">P6Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <ino:LesseeOperatingLeaseNumberOfLeasesAmended
      contextRef="c-277"
      decimals="INF"
      id="f-1001"
      unitRef="lease">1</ino:LesseeOperatingLeaseNumberOfLeasesAmended>
    <ino:LesseeOperatingLeaseAreaOfLandUnderLeaseAmended contextRef="c-277" decimals="0" id="f-1002" unitRef="sqft">31207</ino:LesseeOperatingLeaseAreaOfLandUnderLeaseAmended>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-278" decimals="0" id="f-1003" unitRef="sqft">5563</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-279" id="f-1004">P4Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease
      contextRef="c-278"
      decimals="2"
      id="f-1005"
      unitRef="number">0.03</ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease>
    <us-gaap:PaymentsForDeposits contextRef="c-278" decimals="-3" id="f-1006" unitRef="usd">33000</us-gaap:PaymentsForDeposits>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1007">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.351%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,247,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,466,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,555,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,310,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,665,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,226,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,439,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,407,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,032,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths contextRef="c-5" decimals="-3" id="f-1008" unitRef="usd">3247000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-1009" unitRef="usd">3466000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-1010" unitRef="usd">3555000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-5" decimals="-3" id="f-1011" unitRef="usd">2955000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-5" decimals="-3" id="f-1012" unitRef="usd">2310000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-5" decimals="-3" id="f-1013" unitRef="usd">2132000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-1014" unitRef="usd">17665000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-1015" unitRef="usd">4226000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-1016" unitRef="usd">13439000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-1017" unitRef="usd">2407000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-1018" unitRef="usd">11032000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1019">P5Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-1020" unitRef="number">0.089</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-5" id="f-1021" unitRef="usd">3500000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-12" decimals="-5" id="f-1022" unitRef="usd">3400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-13" decimals="-5" id="f-1023" unitRef="usd">3400000</us-gaap:LeaseCost>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-280" decimals="-2" id="f-1024" unitRef="sqft">4400</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-281" decimals="-3" id="f-1025" unitRef="sqft">7000</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseNumberOfAgreementsToSublease
      contextRef="c-282"
      decimals="INF"
      id="f-1026"
      unitRef="agreement">2</ino:LesseeOperatingLeaseNumberOfAgreementsToSublease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-283" decimals="-2" id="f-1027" unitRef="sqft">13500</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-284" decimals="-5" id="f-1028" unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <ino:LossContingencyEstimateOfPossibleLossValueOfShares contextRef="c-284" decimals="-5" id="f-1029" unitRef="usd">14000000</ino:LossContingencyEstimateOfPossibleLossValueOfShares>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-284" decimals="-5" id="f-1030" unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <ino:LitigationSettlementAmountAwardedToOtherPartyShares
      contextRef="c-198"
      decimals="INF"
      id="f-1031"
      unitRef="shares">760083</ino:LitigationSettlementAmountAwardedToOtherPartyShares>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="c-285"
      decimals="INF"
      id="f-1032"
      unitRef="defendent">8</us-gaap:LossContingencyNumberOfDefendants>
    <us-gaap:LossContingencyDamagesPaidValue contextRef="c-199" decimals="-5" id="f-1033" unitRef="usd">1200000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1034">Income Taxes &lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of pretax loss from operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134,979,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,440,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302,614,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(610,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,117,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,652,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303,224,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no provision for or benefit from income taxes for the years ended December 31, 2023, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2023, 2022 and 2021, is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes at statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,375,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,307,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,677,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,922,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,601,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,447,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,394,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,065,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,424,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,139,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,534,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,523,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,099,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,913,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,509,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(997,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,337,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(542,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,246,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,143,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,252,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,768,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,734,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,442,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,683,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,822,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,247,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,808,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,062,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,486,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,439,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(327,493,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(299,124,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,993,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,315,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,993,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,148,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,993,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,347,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, the Company had federal, California and other state tax net operating loss (NOL) carryforwards of $1,013.3 million, $251.4 million and $102.6 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $719.3 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year. The federal NOL carryforward began to expire in 2023, and the California and other state NOL carryforwards will begin and have begun to expire in 2028 and 2023, respectively, unless previously utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also had Korean NOL carryforwards of $1.1 million as of December 31, 2023. The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2035, unless previously utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as of December 31, 2023, the Company had federal and state research and development (R&amp;amp;D) tax credit carryforwards of $41.6 million and $6.1 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#x2019;s NOL and R&amp;amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;amp;D credit carryforwards as of December&#160;31, 2023. As a result of the analysis, the Company estimates that approximately $7.3 million of tax benefits related to NOL and R&amp;amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;amp;D credit carryforwards have been removed from deferred tax assets accompanied by a corresponding reduction of the valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes, may further limit the ability to use the NOL and R&amp;amp;D carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2023, 2022 and 2021, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company's unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,816,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,602,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(841,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(582,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $20.5 million, $19.7 million and $17.4 million as of December&#160;31, 2023, 2022 and 2021, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2020 and state and local income tax examinations before 2019. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not to its knowledge currently under Internal Revenue Service (&#x201c;IRS&#x201d;), state, local or foreign tax examination.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-1035">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of pretax loss from operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134,979,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,440,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302,614,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(610,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,117,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,652,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303,224,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="0" id="f-1036" unitRef="usd">-134979579</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-12" decimals="0" id="f-1037" unitRef="usd">-277440803</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-13" decimals="0" id="f-1038" unitRef="usd">-302614003</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="0" id="f-1039" unitRef="usd">-137772</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-12" decimals="0" id="f-1040" unitRef="usd">-211249</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-13" decimals="0" id="f-1041" unitRef="usd">-610320</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="0" id="f-1042" unitRef="usd">-135117351</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="0" id="f-1043" unitRef="usd">-277652052</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="0" id="f-1044" unitRef="usd">-303224323</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="INF" id="f-1045" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="INF" id="f-1046" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="INF" id="f-1047" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1048">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2023, 2022 and 2021, is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes at statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,375,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,307,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,677,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,922,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,601,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,447,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,394,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,065,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,424,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,139,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,534,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,523,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,099,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,913,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,509,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(997,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,337,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(542,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,246,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-1049" unitRef="usd">-28375000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-12" decimals="-3" id="f-1050" unitRef="usd">-58307000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-13" decimals="-3" id="f-1051" unitRef="usd">-63677000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-1052" unitRef="usd">-3922000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-12" decimals="-3" id="f-1053" unitRef="usd">-3601000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-13" decimals="-3" id="f-1054" unitRef="usd">-3447000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-1055" unitRef="usd">28394000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="-3" id="f-1056" unitRef="usd">61065000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="-3" id="f-1057" unitRef="usd">77424000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <ino:IncomeTaxReconciliationStatuteLimitations contextRef="c-1" decimals="-3" id="f-1058" unitRef="usd">-2139000</ino:IncomeTaxReconciliationStatuteLimitations>
    <ino:IncomeTaxReconciliationStatuteLimitations contextRef="c-12" decimals="-3" id="f-1059" unitRef="usd">-7534000</ino:IncomeTaxReconciliationStatuteLimitations>
    <ino:IncomeTaxReconciliationStatuteLimitations contextRef="c-13" decimals="-3" id="f-1060" unitRef="usd">-16523000</ino:IncomeTaxReconciliationStatuteLimitations>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-1061" unitRef="usd">2099000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-12" decimals="-3" id="f-1062" unitRef="usd">2913000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-13" decimals="-3" id="f-1063" unitRef="usd">483000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-1" decimals="-3" id="f-1064" unitRef="usd">861000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-12" decimals="-3" id="f-1065" unitRef="usd">2291000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-13" decimals="-3" id="f-1066" unitRef="usd">6509000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-1" decimals="-3" id="f-1067" unitRef="usd">1962000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-12" decimals="-3" id="f-1068" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-13" decimals="-3" id="f-1069" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits contextRef="c-1" decimals="-3" id="f-1070" unitRef="usd">1352000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits contextRef="c-12" decimals="-3" id="f-1071" unitRef="usd">1459000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits contextRef="c-13" decimals="-3" id="f-1072" unitRef="usd">616000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits contextRef="c-1" decimals="-3" id="f-1073" unitRef="usd">-997000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits contextRef="c-12" decimals="-3" id="f-1074" unitRef="usd">-1337000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits contextRef="c-13" decimals="-3" id="f-1075" unitRef="usd">-542000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="-3" id="f-1076" unitRef="usd">365000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-12" decimals="-3" id="f-1077" unitRef="usd">-187000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-13" decimals="-3" id="f-1078" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-1079" unitRef="usd">-4000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-12" decimals="-3" id="f-1080" unitRef="usd">-8000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-13" decimals="-3" id="f-1081" unitRef="usd">-24000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-1082" unitRef="usd">404000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-12" decimals="-3" id="f-1083" unitRef="usd">3246000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-13" decimals="-3" id="f-1084" unitRef="usd">-819000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <ino:ComprehensiveIncomeLossTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1085" unitRef="usd">0</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
    <ino:ComprehensiveIncomeLossTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1086" unitRef="usd">0</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
    <ino:ComprehensiveIncomeLossTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1087" unitRef="usd">0</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1088">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,143,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,252,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,768,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,734,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,442,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,683,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,822,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,247,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,808,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,062,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,486,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,439,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(327,493,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(299,124,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,993,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,315,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,993,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,148,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,993,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,347,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-1089" unitRef="usd">50143000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-6" decimals="-3" id="f-1090" unitRef="usd">41252000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-1091" unitRef="usd">235624000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-1092" unitRef="usd">212768000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="c-5" decimals="-3" id="f-1093" unitRef="usd">27734000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="c-6" decimals="-3" id="f-1094" unitRef="usd">26442000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-5" decimals="-3" id="f-1095" unitRef="usd">22000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-6" decimals="-3" id="f-1096" unitRef="usd">538000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-1097" unitRef="usd">3683000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-1098" unitRef="usd">3945000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ino:DeferredTaxAssetsIntangibleAssets contextRef="c-5" decimals="-3" id="f-1099" unitRef="usd">907000</ino:DeferredTaxAssetsIntangibleAssets>
    <ino:DeferredTaxAssetsIntangibleAssets contextRef="c-6" decimals="-3" id="f-1100" unitRef="usd">559000</ino:DeferredTaxAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="c-5" decimals="-3" id="f-1101" unitRef="usd">1406000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="c-6" decimals="-3" id="f-1102" unitRef="usd">1569000</us-gaap:DeferredTaxAssetsInvestments>
    <ino:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-1103" unitRef="usd">2822000</ino:DeferredTaxAssetsOperatingLeaseLiability>
    <ino:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-1104" unitRef="usd">3247000</ino:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-1105" unitRef="usd">337000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-1106" unitRef="usd">57000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-1107" unitRef="usd">6808000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-3" id="f-1108" unitRef="usd">11062000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-1109" unitRef="usd">329486000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-1110" unitRef="usd">301439000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-1111" unitRef="usd">327493000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-1112" unitRef="usd">299124000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-1113" unitRef="usd">1993000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-6" decimals="-3" id="f-1114" unitRef="usd">2315000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-5" decimals="-3" id="f-1115" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-6" decimals="-3" id="f-1116" unitRef="usd">199000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-1117" unitRef="usd">1993000</ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-1118" unitRef="usd">2148000</ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-1119" unitRef="usd">1993000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-3" id="f-1120" unitRef="usd">2347000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-5" decimals="-3" id="f-1121" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-6" decimals="-3" id="f-1122" unitRef="usd">32000</us-gaap:DeferredTaxLiabilities>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet contextRef="c-286" decimals="-5" id="f-1123" unitRef="usd">1013300000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet contextRef="c-287" decimals="-5" id="f-1124" unitRef="usd">251400000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet contextRef="c-288" decimals="-5" id="f-1125" unitRef="usd">102600000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c-289" decimals="-5" id="f-1126" unitRef="usd">719300000</us-gaap:OperatingLossCarryforwards>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet contextRef="c-290" decimals="-5" id="f-1127" unitRef="usd">1100000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-291" decimals="-5" id="f-1128" unitRef="usd">41600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-292" decimals="-5" id="f-1129" unitRef="usd">6100000</us-gaap:TaxCreditCarryforwardAmount>
    <ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock contextRef="c-1" id="f-1130">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock>
    <ino:OperatingLossCarryforwardsExpiringInNextFiscalYear contextRef="c-293" decimals="-5" id="f-1131" unitRef="usd">18900000</ino:OperatingLossCarryforwardsExpiringInNextFiscalYear>
    <ino:OperatingLossCarryforwardsExpiringInNextFiscalYear contextRef="c-294" decimals="-5" id="f-1132" unitRef="usd">9100000</ino:OperatingLossCarryforwardsExpiringInNextFiscalYear>
    <ino:OperatingLossCarryforwardsExpiringInNextFiscalYear contextRef="c-295" decimals="-5" id="f-1133" unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringInNextFiscalYear>
    <ino:TaxCreditCarryforwardExpiringInNextFiscalYear contextRef="c-296" decimals="-5" id="f-1134" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInNextFiscalYear>
    <ino:TaxCreditCarryforwardExpiringInNextFiscalYear contextRef="c-292" decimals="-5" id="f-1135" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInNextFiscalYear>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears contextRef="c-293" decimals="-5" id="f-1136" unitRef="usd">13700000</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears contextRef="c-294" decimals="-5" id="f-1137" unitRef="usd">5200000</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears contextRef="c-295" decimals="-5" id="f-1138" unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:TaxCreditCarryforwardExpiringinTwoYears contextRef="c-296" decimals="-5" id="f-1139" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinTwoYears>
    <ino:TaxCreditCarryforwardExpiringinTwoYears contextRef="c-292" decimals="-5" id="f-1140" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears contextRef="c-293" decimals="-5" id="f-1141" unitRef="usd">12200000</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears contextRef="c-294" decimals="-5" id="f-1142" unitRef="usd">7100000</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears contextRef="c-295" decimals="-5" id="f-1143" unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:TaxCreditCarryforwardExpiringInThreeYears contextRef="c-296" decimals="-5" id="f-1144" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInThreeYears>
    <ino:TaxCreditCarryforwardExpiringInThreeYears contextRef="c-292" decimals="-5" id="f-1145" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInThreeYears>
    <ino:OperatingLossCarryforwardsExpiringinFourYears contextRef="c-293" decimals="-5" id="f-1146" unitRef="usd">249200000</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:OperatingLossCarryforwardsExpiringinFourYears contextRef="c-294" decimals="-5" id="f-1147" unitRef="usd">332000000.0</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:OperatingLossCarryforwardsExpiringinFourYears contextRef="c-295" decimals="-5" id="f-1148" unitRef="usd">1100000</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:TaxCreditCarryforwardExpiringInFourYears contextRef="c-296" decimals="-5" id="f-1149" unitRef="usd">41600000</ino:TaxCreditCarryforwardExpiringInFourYears>
    <ino:TaxCreditCarryforwardExpiringInFourYears contextRef="c-292" decimals="-5" id="f-1150" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInFourYears>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward contextRef="c-293" decimals="-5" id="f-1151" unitRef="usd">719300000</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward contextRef="c-294" decimals="-5" id="f-1152" unitRef="usd">600000</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward contextRef="c-295" decimals="-5" id="f-1153" unitRef="usd">0</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:TaxCreditCarryforwardCarryforwardIndefinitely contextRef="c-296" decimals="-5" id="f-1154" unitRef="usd">0</ino:TaxCreditCarryforwardCarryforwardIndefinitely>
    <ino:TaxCreditCarryforwardCarryforwardIndefinitely contextRef="c-292" decimals="-5" id="f-1155" unitRef="usd">6100000</ino:TaxCreditCarryforwardCarryforwardIndefinitely>
    <us-gaap:OperatingLossCarryforwards contextRef="c-293" decimals="-5" id="f-1156" unitRef="usd">1013300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-294" decimals="-5" id="f-1157" unitRef="usd">354000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-295" decimals="-5" id="f-1158" unitRef="usd">1100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-296" decimals="-5" id="f-1159" unitRef="usd">41600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-292" decimals="-5" id="f-1160" unitRef="usd">6100000</us-gaap:TaxCreditCarryforwardAmount>
    <ino:TaxBenefitsExpired contextRef="c-5" decimals="-5" id="f-1161" unitRef="usd">7300000</ino:TaxBenefitsExpired>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1162">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company's unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,816,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,602,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(841,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(582,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-1163" unitRef="usd">21139000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-29" decimals="-3" id="f-1164" unitRef="usd">18819000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-19" decimals="-3" id="f-1165" unitRef="usd">12210000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1166" unitRef="usd">1816000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-12" decimals="-3" id="f-1167" unitRef="usd">2902000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-13" decimals="-3" id="f-1168" unitRef="usd">6602000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1169" unitRef="usd">841000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-12" decimals="-3" id="f-1170" unitRef="usd">582000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-13" decimals="-3" id="f-1171" unitRef="usd">7000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-1172" unitRef="usd">22114000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-1173" unitRef="usd">21139000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-29" decimals="-3" id="f-1174" unitRef="usd">18819000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-5" decimals="-5" id="f-1175" unitRef="usd">20500000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-6" decimals="-5" id="f-1176" unitRef="usd">19700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-29" decimals="-5" id="f-1177" unitRef="usd">17400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1178">401(k) Plan&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees&#x2019; contributions, up to 6% of their annual compensation. The Company&#x2019;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $1.4 million, $1.8 million and $1.5 million for the years ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c-1"
      decimals="INF"
      id="f-1179"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c-1"
      decimals="INF"
      id="f-1180"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-5" id="f-1181" unitRef="usd">1400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-12" decimals="-5" id="f-1182" unitRef="usd">1800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-13" decimals="-5" id="f-1183" unitRef="usd">1500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-1184">Related Party Transactions&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;T&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company owned 597,808 shares of common stock in PLS as of December 31, 2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, representing a 17.8% and 18.7% ownership interest, respectively. One &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December&#160;31, 2023,  2022 and 2021, the Company recognized revenue from PLS of $0, $34,000 and $245,000, respectively. At December 31, 2023 and 2022, the Company had an accounts receivable balance of $0 and $59,000, respectively, related to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company entered into collaborative &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has the exclusive right to in-license new intellectual property developed under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $13.6&#160;million,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding extended through August 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The sub-grant also includes an option for an additional $1.6&#160;million in funding through September 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company received a $1.2&#160;million sub-grant through Wistar with funding through November 2023, with an option for an additional $5.4&#160;million in funding through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched nanoparticles (dLNPs) for vaccination against HIV infection.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2023 and 2022, the Company recorded $1.0 million and $8.7 million, respectively, as contra-research and development expense from Wistar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December&#160;31, 2023, 2022 and 2021 were $1.8 million, $1.4 million and $2.9&#160;million, respectively. At December&#160;31, 2023 and 2022, the Company had an accounts receivable balance of $2.4 million and $9.9 million, respectively, and an accounts payable and accrued liability balance of $1.1 million and $1.2 million, respectively, related to Wistar. As of December&#160;31, 2023 and 2022, the Company had a prepaid expense balance of $20,000 and $375,000, respectively, and recorded $22,000 and $88,000, respectively, as deferred grant funding on its consolidated balance sheet related to Wistar.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-297"
      decimals="INF"
      id="f-1185"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-298"
      decimals="INF"
      id="f-1186"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c-298"
      decimals="3"
      id="f-1187"
      unitRef="number">0.178</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c-297"
      decimals="3"
      id="f-1188"
      unitRef="number">0.187</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-299" decimals="-3" id="f-1189" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-300" decimals="-3" id="f-1190" unitRef="usd">34000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-301" decimals="-3" id="f-1191" unitRef="usd">245000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-302" decimals="-3" id="f-1192" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-303" decimals="-3" id="f-1193" unitRef="usd">59000</us-gaap:AccountsReceivableNetCurrent>
    <ino:CollaborativeAgreementExpensesToReimburse contextRef="c-304" decimals="-5" id="f-1194" unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm contextRef="c-304" id="f-1195">P5Y</ino:CollaborativeArrangementTerm>
    <ino:CollaborativeAgreementAwardedAmount contextRef="c-305" decimals="-5" id="f-1196" unitRef="usd">10700000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAmendedAmount contextRef="c-306" decimals="-5" id="f-1197" unitRef="usd">13600000</ino:CollaborativeAgreementAmendedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount contextRef="c-307" decimals="-5" id="f-1198" unitRef="usd">1600000</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:CollaborativeAgreementAwardedAmount contextRef="c-308" decimals="-5" id="f-1199" unitRef="usd">1200000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount contextRef="c-308" decimals="-5" id="f-1200" unitRef="usd">5400000</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:GrantProceedsReceived contextRef="c-309" decimals="-5" id="f-1201" unitRef="usd">1000000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived contextRef="c-310" decimals="-5" id="f-1202" unitRef="usd">8700000</ino:GrantProceedsReceived>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-311" decimals="-5" id="f-1203" unitRef="usd">1800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-312" decimals="-5" id="f-1204" unitRef="usd">1400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-307" decimals="-5" id="f-1205" unitRef="usd">2900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNet contextRef="c-313" decimals="-5" id="f-1206" unitRef="usd">2400000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-314" decimals="-5" id="f-1207" unitRef="usd">9900000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-313" decimals="-5" id="f-1208" unitRef="usd">1100000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-314" decimals="-5" id="f-1209" unitRef="usd">1200000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c-313" decimals="-3" id="f-1210" unitRef="usd">20000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c-314" decimals="-3" id="f-1211" unitRef="usd">375000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <ino:DeferredGrantFundingFromAffiliate contextRef="c-313" decimals="-3" id="f-1212" unitRef="usd">22000</ino:DeferredGrantFundingFromAffiliate>
    <ino:DeferredGrantFundingFromAffiliate contextRef="c-314" decimals="-3" id="f-1213" unitRef="usd">88000</ino:DeferredGrantFundingFromAffiliate>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-1214">Geneos Therapeutics, Inc. &lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following a series of financing transactions through June 2020, the Company less than a majority of the outstanding equity of Geneos on an as-converted to common stock basis, which triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019; economic performance. Accordingly, the Company deconsolidated its investment in Geneos in 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#x2019;s investment and the amount of underlying equity in Geneos&#x2019; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon deconsolidation, the Company recorded its investment at fair value. The Company determined that its investment in Geneos did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#x2019;s investment is marked to fair value.&#160;There have been no observable price changes or impairments identified since the deconsolidation date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s share of net losses of Geneos for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 was allocated to the equity method investment, reducing the balance to $0 as of March 31, 2021. The remaining $4.2 million loss was allocated to the Company&#x2019;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, reducing the balance to $0 as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Geneos completed a second closing of its Series A-1 preferred stock financing, in which the Company did not participate. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 28% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos&#x2019;s Series A-2 preferred stock was based on the per share price paid by third-party investors. The Company concluded that its Series A-2 preferred stock investment was a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not made any further investment in Geneos subsequent to March 31, 2022. The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, Geneos completed the closing of its Series A-3 preferred stock financing, in which the Company did not participate. Following this transaction, the Company held approximately 23% of the outstanding equity of Geneos on an as-converted to common stock basis. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to exclusively license its SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immunotherapy and CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment contextRef="c-315" decimals="-5" id="f-1215" unitRef="usd">-1500000</ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-315" decimals="-3" id="f-1216" unitRef="usd">-434000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-316" decimals="-3" id="f-1217" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-317" decimals="-3" id="f-1218" unitRef="usd">-819000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-318" decimals="-3" id="f-1219" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-319" decimals="-5" id="f-1220" unitRef="usd">-4200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-320" decimals="-3" id="f-1221" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c-321"
      decimals="2"
      id="f-1222"
      unitRef="number">0.35</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries contextRef="c-322" decimals="-5" id="f-1223" unitRef="usd">2000000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c-323"
      decimals="2"
      id="f-1224"
      unitRef="number">0.28</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount contextRef="c-324" decimals="-3" id="f-1225" unitRef="usd">165000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-324" decimals="-5" id="f-1226" unitRef="usd">-2200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-325" decimals="-3" id="f-1227" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-325" decimals="-3" id="f-1228" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c-326"
      decimals="2"
      id="f-1229"
      unitRef="number">0.23</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1230">Subsequent Events&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 24, 2024, the Company implemented the 1-for-12  reverse stock split described in Note 2.  All share information contained within this report, including the accompanying consolidated financial statements and footnotes, have been retroactively adjusted to reflect the effects of the reverse split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From January 1, 2024 through the date of these financial statements, the Company sold 543,620 shares of common stock under the 2021 Sales Agreement for net proceeds of $5.2&#160;million.  The sales were made at a weighted average price of $9.76 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2024, the Company's Convertible Senior Notes matured and the Company paid the $16.9&#160;million obligation in full.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-327"
      decimals="INF"
      id="f-1231"
      unitRef="shares">543620</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-327" decimals="-5" id="f-1232" unitRef="usd">5200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-328"
      decimals="2"
      id="f-1233"
      unitRef="usdPerShare">9.76</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-223" decimals="-5" id="f-1234" unitRef="usd">16900000</us-gaap:RepaymentsOfConvertibleDebt>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-114"
          xlink:label="f-114"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-116"
          xlink:label="f-116"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-113"
          xlink:label="f-113"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-110"
          xlink:label="f-110"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-117"
          xlink:label="f-117"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-108"
          xlink:label="f-108"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-112"
          xlink:label="f-112"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-109"
          xlink:label="f-109"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-115"
          xlink:label="f-115"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-111"
          xlink:label="f-111"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company effected a reverse stock split of its outstanding shares of common stock on January 24, 2024 where every twelve shares of its common stock issued and outstanding was converted into one share of common stock.</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any fractional post-split shares as a result of the reverse split were paid in cash. Shareholders of the Company authorized the Board of Directors to approve the reverse stock split at a special meeting of stockholders held on January 12, 2024.</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding share amounts have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-114"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-116"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-113"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-110"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-117"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-108"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-112"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-109"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-115"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-111"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-171"
          xlink:label="f-171"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-172"
          xlink:label="f-172"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-178"
          xlink:label="f-178"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-182"
          xlink:label="f-182"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-176"
          xlink:label="f-176"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-177"
          xlink:label="f-177"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-174"
          xlink:label="f-174"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-175"
          xlink:label="f-175"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-179"
          xlink:label="f-179"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-180"
          xlink:label="f-180"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-181"
          xlink:label="f-181"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-173"
          xlink:label="f-173"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-171"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-172"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-178"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-182"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-176"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-177"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-174"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-175"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-179"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-180"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-181"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-173"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-283"
          xlink:label="f-283"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-268"
          xlink:label="f-268"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-241"
          xlink:label="f-241"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-265"
          xlink:label="f-265"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-255"
          xlink:label="f-255"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-261"
          xlink:label="f-261"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-264"
          xlink:label="f-264"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-226"
          xlink:label="f-226"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-212"
          xlink:label="f-212"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-205"
          xlink:label="f-205"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-208"
          xlink:label="f-208"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-260"
          xlink:label="f-260"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-198"
          xlink:label="f-198"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-237"
          xlink:label="f-237"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-209"
          xlink:label="f-209"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-240"
          xlink:label="f-240"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-213"
          xlink:label="f-213"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-282"
          xlink:label="f-282"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-236"
          xlink:label="f-236"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-254"
          xlink:label="f-254"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-204"
          xlink:label="f-204"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-269"
          xlink:label="f-269"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-227"
          xlink:label="f-227"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-199"
          xlink:label="f-199"
          xlink:type="locator"/>
        <link:footnote id="fn-3" xlink:label="fn-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All share amounts in this column, including appropriate reclassifications between common stock and additional paid-in capital, have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-283"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-268"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-241"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-265"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-255"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-261"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-264"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-226"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-212"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-205"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-208"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-260"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-198"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-237"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-209"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-240"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-213"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-282"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-236"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-254"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-204"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-269"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-227"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-199"
          xlink:to="fn-3"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
